(function(){const s=document.createElement("link").relList;if(s&&s.supports&&s.supports("modulepreload"))return;for(const d of document.querySelectorAll('link[rel="modulepreload"]'))c(d);new MutationObserver(d=>{for(const m of d)if(m.type==="childList")for(const _ of m.addedNodes)_.tagName==="LINK"&&_.rel==="modulepreload"&&c(_)}).observe(document,{childList:!0,subtree:!0});function l(d){const m={};return d.integrity&&(m.integrity=d.integrity),d.referrerPolicy&&(m.referrerPolicy=d.referrerPolicy),d.crossOrigin==="use-credentials"?m.credentials="include":d.crossOrigin==="anonymous"?m.credentials="omit":m.credentials="same-origin",m}function c(d){if(d.ep)return;d.ep=!0;const m=l(d);fetch(d.href,m)}})();var El={exports:{}},co={};/**
 * @license React
 * react-jsx-runtime.production.js
 *
 * Copyright (c) Meta Platforms, Inc. and affiliates.
 *
 * This source code is licensed under the MIT license found in the
 * LICENSE file in the root directory of this source tree.
 */var Tu;function ff(){if(Tu)return co;Tu=1;var g=Symbol.for("react.transitional.element"),s=Symbol.for("react.fragment");function l(c,d,m){var _=null;if(m!==void 0&&(_=""+m),d.key!==void 0&&(_=""+d.key),"key"in d){m={};for(var h in d)h!=="key"&&(m[h]=d[h])}else m=d;return d=m.ref,{$$typeof:g,type:c,key:_,ref:d!==void 0?d:null,props:m}}return co.Fragment=s,co.jsx=l,co.jsxs=l,co}var Eu;function _f(){return Eu||(Eu=1,El.exports=ff()),El.exports}var a=_f(),Pl={exports:{}},be={};/**
 * @license React
 * react.production.js
 *
 * Copyright (c) Meta Platforms, Inc. and affiliates.
 *
 * This source code is licensed under the MIT license found in the
 * LICENSE file in the root directory of this source tree.
 */var Pu;function hf(){if(Pu)return be;Pu=1;var g=Symbol.for("react.transitional.element"),s=Symbol.for("react.portal"),l=Symbol.for("react.fragment"),c=Symbol.for("react.strict_mode"),d=Symbol.for("react.profiler"),m=Symbol.for("react.consumer"),_=Symbol.for("react.context"),h=Symbol.for("react.forward_ref"),v=Symbol.for("react.suspense"),y=Symbol.for("react.memo"),D=Symbol.for("react.lazy"),L=Symbol.iterator;function W(p){return p===null||typeof p!="object"?null:(p=L&&p[L]||p["@@iterator"],typeof p=="function"?p:null)}var se={isMounted:function(){return!1},enqueueForceUpdate:function(){},enqueueReplaceState:function(){},enqueueSetState:function(){}},ie=Object.assign,$={};function ne(p,A,J){this.props=p,this.context=A,this.refs=$,this.updater=J||se}ne.prototype.isReactComponent={},ne.prototype.setState=function(p,A){if(typeof p!="object"&&typeof p!="function"&&p!=null)throw Error("takes an object of state variables to update or a function which returns an object of state variables.");this.updater.enqueueSetState(this,p,A,"setState")},ne.prototype.forceUpdate=function(p){this.updater.enqueueForceUpdate(this,p,"forceUpdate")};function w(){}w.prototype=ne.prototype;function O(p,A,J){this.props=p,this.context=A,this.refs=$,this.updater=J||se}var U=O.prototype=new w;U.constructor=O,ie(U,ne.prototype),U.isPureReactComponent=!0;var Z=Array.isArray,X={H:null,A:null,T:null,S:null,V:null},T=Object.prototype.hasOwnProperty;function q(p,A,J,P,V,te){return J=te.ref,{$$typeof:g,type:p,key:A,ref:J!==void 0?J:null,props:te}}function C(p,A){return q(p.type,A,void 0,void 0,void 0,p.props)}function E(p){return typeof p=="object"&&p!==null&&p.$$typeof===g}function z(p){var A={"=":"=0",":":"=2"};return"$"+p.replace(/[=:]/g,function(J){return A[J]})}var H=/\/+/g;function Y(p,A){return typeof p=="object"&&p!==null&&p.key!=null?z(""+p.key):A.toString(36)}function ee(){}function le(p){switch(p.status){case"fulfilled":return p.value;case"rejected":throw p.reason;default:switch(typeof p.status=="string"?p.then(ee,ee):(p.status="pending",p.then(function(A){p.status==="pending"&&(p.status="fulfilled",p.value=A)},function(A){p.status==="pending"&&(p.status="rejected",p.reason=A)})),p.status){case"fulfilled":return p.value;case"rejected":throw p.reason}}throw p}function Q(p,A,J,P,V){var te=typeof p;(te==="undefined"||te==="boolean")&&(p=null);var re=!1;if(p===null)re=!0;else switch(te){case"bigint":case"string":case"number":re=!0;break;case"object":switch(p.$$typeof){case g:case s:re=!0;break;case D:return re=p._init,Q(re(p._payload),A,J,P,V)}}if(re)return V=V(p),re=P===""?"."+Y(p,0):P,Z(V)?(J="",re!=null&&(J=re.replace(H,"$&/")+"/"),Q(V,A,J,"",function(Te){return Te})):V!=null&&(E(V)&&(V=C(V,J+(V.key==null||p&&p.key===V.key?"":(""+V.key).replace(H,"$&/")+"/")+re)),A.push(V)),1;re=0;var ue=P===""?".":P+":";if(Z(p))for(var he=0;he<p.length;he++)P=p[he],te=ue+Y(P,he),re+=Q(P,A,J,te,V);else if(he=W(p),typeof he=="function")for(p=he.call(p),he=0;!(P=p.next()).done;)P=P.value,te=ue+Y(P,he++),re+=Q(P,A,J,te,V);else if(te==="object"){if(typeof p.then=="function")return Q(le(p),A,J,P,V);throw A=String(p),Error("Objects are not valid as a React child (found: "+(A==="[object Object]"?"object with keys {"+Object.keys(p).join(", ")+"}":A)+"). If you meant to render a collection of children, use an array instead.")}return re}function k(p,A,J){if(p==null)return p;var P=[],V=0;return Q(p,P,"","",function(te){return A.call(J,te,V++)}),P}function G(p){if(p._status===-1){var A=p._result;A=A(),A.then(function(J){(p._status===0||p._status===-1)&&(p._status=1,p._result=J)},function(J){(p._status===0||p._status===-1)&&(p._status=2,p._result=J)}),p._status===-1&&(p._status=0,p._result=A)}if(p._status===1)return p._result.default;throw p._result}var ae=typeof reportError=="function"?reportError:function(p){if(typeof window=="object"&&typeof window.ErrorEvent=="function"){var A=new window.ErrorEvent("error",{bubbles:!0,cancelable:!0,message:typeof p=="object"&&p!==null&&typeof p.message=="string"?String(p.message):String(p),error:p});if(!window.dispatchEvent(A))return}else if(typeof process=="object"&&typeof process.emit=="function"){process.emit("uncaughtException",p);return}console.error(p)};function N(){}return be.Children={map:k,forEach:function(p,A,J){k(p,function(){A.apply(this,arguments)},J)},count:function(p){var A=0;return k(p,function(){A++}),A},toArray:function(p){return k(p,function(A){return A})||[]},only:function(p){if(!E(p))throw Error("React.Children.only expected to receive a single React element child.");return p}},be.Component=ne,be.Fragment=l,be.Profiler=d,be.PureComponent=O,be.StrictMode=c,be.Suspense=v,be.__CLIENT_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE=X,be.__COMPILER_RUNTIME={__proto__:null,c:function(p){return X.H.useMemoCache(p)}},be.cache=function(p){return function(){return p.apply(null,arguments)}},be.cloneElement=function(p,A,J){if(p==null)throw Error("The argument must be a React element, but you passed "+p+".");var P=ie({},p.props),V=p.key,te=void 0;if(A!=null)for(re in A.ref!==void 0&&(te=void 0),A.key!==void 0&&(V=""+A.key),A)!T.call(A,re)||re==="key"||re==="__self"||re==="__source"||re==="ref"&&A.ref===void 0||(P[re]=A[re]);var re=arguments.length-2;if(re===1)P.children=J;else if(1<re){for(var ue=Array(re),he=0;he<re;he++)ue[he]=arguments[he+2];P.children=ue}return q(p.type,V,void 0,void 0,te,P)},be.createContext=function(p){return p={$$typeof:_,_currentValue:p,_currentValue2:p,_threadCount:0,Provider:null,Consumer:null},p.Provider=p,p.Consumer={$$typeof:m,_context:p},p},be.createElement=function(p,A,J){var P,V={},te=null;if(A!=null)for(P in A.key!==void 0&&(te=""+A.key),A)T.call(A,P)&&P!=="key"&&P!=="__self"&&P!=="__source"&&(V[P]=A[P]);var re=arguments.length-2;if(re===1)V.children=J;else if(1<re){for(var ue=Array(re),he=0;he<re;he++)ue[he]=arguments[he+2];V.children=ue}if(p&&p.defaultProps)for(P in re=p.defaultProps,re)V[P]===void 0&&(V[P]=re[P]);return q(p,te,void 0,void 0,null,V)},be.createRef=function(){return{current:null}},be.forwardRef=function(p){return{$$typeof:h,render:p}},be.isValidElement=E,be.lazy=function(p){return{$$typeof:D,_payload:{_status:-1,_result:p},_init:G}},be.memo=function(p,A){return{$$typeof:y,type:p,compare:A===void 0?null:A}},be.startTransition=function(p){var A=X.T,J={};X.T=J;try{var P=p(),V=X.S;V!==null&&V(J,P),typeof P=="object"&&P!==null&&typeof P.then=="function"&&P.then(N,ae)}catch(te){ae(te)}finally{X.T=A}},be.unstable_useCacheRefresh=function(){return X.H.useCacheRefresh()},be.use=function(p){return X.H.use(p)},be.useActionState=function(p,A,J){return X.H.useActionState(p,A,J)},be.useCallback=function(p,A){return X.H.useCallback(p,A)},be.useContext=function(p){return X.H.useContext(p)},be.useDebugValue=function(){},be.useDeferredValue=function(p,A){return X.H.useDeferredValue(p,A)},be.useEffect=function(p,A,J){var P=X.H;if(typeof J=="function")throw Error("useEffect CRUD overload is not enabled in this build of React.");return P.useEffect(p,A)},be.useId=function(){return X.H.useId()},be.useImperativeHandle=function(p,A,J){return X.H.useImperativeHandle(p,A,J)},be.useInsertionEffect=function(p,A){return X.H.useInsertionEffect(p,A)},be.useLayoutEffect=function(p,A){return X.H.useLayoutEffect(p,A)},be.useMemo=function(p,A){return X.H.useMemo(p,A)},be.useOptimistic=function(p,A){return X.H.useOptimistic(p,A)},be.useReducer=function(p,A,J){return X.H.useReducer(p,A,J)},be.useRef=function(p){return X.H.useRef(p)},be.useState=function(p){return X.H.useState(p)},be.useSyncExternalStore=function(p,A,J){return X.H.useSyncExternalStore(p,A,J)},be.useTransition=function(){return X.H.useTransition()},be.version="19.1.0",be}var Lu;function Yl(){return Lu||(Lu=1,Pl.exports=hf()),Pl.exports}var oe=Yl(),Ll={exports:{}},mo={},zl={exports:{}},Vl={};/**
 * @license React
 * scheduler.production.js
 *
 * Copyright (c) Meta Platforms, Inc. and affiliates.
 *
 * This source code is licensed under the MIT license found in the
 * LICENSE file in the root directory of this source tree.
 */var zu;function bf(){return zu||(zu=1,function(g){function s(k,G){var ae=k.length;k.push(G);e:for(;0<ae;){var N=ae-1>>>1,p=k[N];if(0<d(p,G))k[N]=G,k[ae]=p,ae=N;else break e}}function l(k){return k.length===0?null:k[0]}function c(k){if(k.length===0)return null;var G=k[0],ae=k.pop();if(ae!==G){k[0]=ae;e:for(var N=0,p=k.length,A=p>>>1;N<A;){var J=2*(N+1)-1,P=k[J],V=J+1,te=k[V];if(0>d(P,ae))V<p&&0>d(te,P)?(k[N]=te,k[V]=ae,N=V):(k[N]=P,k[J]=ae,N=J);else if(V<p&&0>d(te,ae))k[N]=te,k[V]=ae,N=V;else break e}}return G}function d(k,G){var ae=k.sortIndex-G.sortIndex;return ae!==0?ae:k.id-G.id}if(g.unstable_now=void 0,typeof performance=="object"&&typeof performance.now=="function"){var m=performance;g.unstable_now=function(){return m.now()}}else{var _=Date,h=_.now();g.unstable_now=function(){return _.now()-h}}var v=[],y=[],D=1,L=null,W=3,se=!1,ie=!1,$=!1,ne=!1,w=typeof setTimeout=="function"?setTimeout:null,O=typeof clearTimeout=="function"?clearTimeout:null,U=typeof setImmediate<"u"?setImmediate:null;function Z(k){for(var G=l(y);G!==null;){if(G.callback===null)c(y);else if(G.startTime<=k)c(y),G.sortIndex=G.expirationTime,s(v,G);else break;G=l(y)}}function X(k){if($=!1,Z(k),!ie)if(l(v)!==null)ie=!0,T||(T=!0,Y());else{var G=l(y);G!==null&&Q(X,G.startTime-k)}}var T=!1,q=-1,C=5,E=-1;function z(){return ne?!0:!(g.unstable_now()-E<C)}function H(){if(ne=!1,T){var k=g.unstable_now();E=k;var G=!0;try{e:{ie=!1,$&&($=!1,O(q),q=-1),se=!0;var ae=W;try{i:{for(Z(k),L=l(v);L!==null&&!(L.expirationTime>k&&z());){var N=L.callback;if(typeof N=="function"){L.callback=null,W=L.priorityLevel;var p=N(L.expirationTime<=k);if(k=g.unstable_now(),typeof p=="function"){L.callback=p,Z(k),G=!0;break i}L===l(v)&&c(v),Z(k)}else c(v);L=l(v)}if(L!==null)G=!0;else{var A=l(y);A!==null&&Q(X,A.startTime-k),G=!1}}break e}finally{L=null,W=ae,se=!1}G=void 0}}finally{G?Y():T=!1}}}var Y;if(typeof U=="function")Y=function(){U(H)};else if(typeof MessageChannel<"u"){var ee=new MessageChannel,le=ee.port2;ee.port1.onmessage=H,Y=function(){le.postMessage(null)}}else Y=function(){w(H,0)};function Q(k,G){q=w(function(){k(g.unstable_now())},G)}g.unstable_IdlePriority=5,g.unstable_ImmediatePriority=1,g.unstable_LowPriority=4,g.unstable_NormalPriority=3,g.unstable_Profiling=null,g.unstable_UserBlockingPriority=2,g.unstable_cancelCallback=function(k){k.callback=null},g.unstable_forceFrameRate=function(k){0>k||125<k?console.error("forceFrameRate takes a positive int between 0 and 125, forcing frame rates higher than 125 fps is not supported"):C=0<k?Math.floor(1e3/k):5},g.unstable_getCurrentPriorityLevel=function(){return W},g.unstable_next=function(k){switch(W){case 1:case 2:case 3:var G=3;break;default:G=W}var ae=W;W=G;try{return k()}finally{W=ae}},g.unstable_requestPaint=function(){ne=!0},g.unstable_runWithPriority=function(k,G){switch(k){case 1:case 2:case 3:case 4:case 5:break;default:k=3}var ae=W;W=k;try{return G()}finally{W=ae}},g.unstable_scheduleCallback=function(k,G,ae){var N=g.unstable_now();switch(typeof ae=="object"&&ae!==null?(ae=ae.delay,ae=typeof ae=="number"&&0<ae?N+ae:N):ae=N,k){case 1:var p=-1;break;case 2:p=250;break;case 5:p=1073741823;break;case 4:p=1e4;break;default:p=5e3}return p=ae+p,k={id:D++,callback:G,priorityLevel:k,startTime:ae,expirationTime:p,sortIndex:-1},ae>N?(k.sortIndex=ae,s(y,k),l(v)===null&&k===l(y)&&($?(O(q),q=-1):$=!0,Q(X,ae-N))):(k.sortIndex=p,s(v,k),ie||se||(ie=!0,T||(T=!0,Y()))),k},g.unstable_shouldYield=z,g.unstable_wrapCallback=function(k){var G=W;return function(){var ae=W;W=G;try{return k.apply(this,arguments)}finally{W=ae}}}}(Vl)),Vl}var Vu;function yf(){return Vu||(Vu=1,zl.exports=bf()),zl.exports}var Ol={exports:{}},di={};/**
 * @license React
 * react-dom.production.js
 *
 * Copyright (c) Meta Platforms, Inc. and affiliates.
 *
 * This source code is licensed under the MIT license found in the
 * LICENSE file in the root directory of this source tree.
 */var Ou;function vf(){if(Ou)return di;Ou=1;var g=Yl();function s(v){var y="https://react.dev/errors/"+v;if(1<arguments.length){y+="?args[]="+encodeURIComponent(arguments[1]);for(var D=2;D<arguments.length;D++)y+="&args[]="+encodeURIComponent(arguments[D])}return"Minified React error #"+v+"; visit "+y+" for the full message or use the non-minified dev environment for full errors and additional helpful warnings."}function l(){}var c={d:{f:l,r:function(){throw Error(s(522))},D:l,C:l,L:l,m:l,X:l,S:l,M:l},p:0,findDOMNode:null},d=Symbol.for("react.portal");function m(v,y,D){var L=3<arguments.length&&arguments[3]!==void 0?arguments[3]:null;return{$$typeof:d,key:L==null?null:""+L,children:v,containerInfo:y,implementation:D}}var _=g.__CLIENT_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE;function h(v,y){if(v==="font")return"";if(typeof y=="string")return y==="use-credentials"?y:""}return di.__DOM_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE=c,di.createPortal=function(v,y){var D=2<arguments.length&&arguments[2]!==void 0?arguments[2]:null;if(!y||y.nodeType!==1&&y.nodeType!==9&&y.nodeType!==11)throw Error(s(299));return m(v,y,null,D)},di.flushSync=function(v){var y=_.T,D=c.p;try{if(_.T=null,c.p=2,v)return v()}finally{_.T=y,c.p=D,c.d.f()}},di.preconnect=function(v,y){typeof v=="string"&&(y?(y=y.crossOrigin,y=typeof y=="string"?y==="use-credentials"?y:"":void 0):y=null,c.d.C(v,y))},di.prefetchDNS=function(v){typeof v=="string"&&c.d.D(v)},di.preinit=function(v,y){if(typeof v=="string"&&y&&typeof y.as=="string"){var D=y.as,L=h(D,y.crossOrigin),W=typeof y.integrity=="string"?y.integrity:void 0,se=typeof y.fetchPriority=="string"?y.fetchPriority:void 0;D==="style"?c.d.S(v,typeof y.precedence=="string"?y.precedence:void 0,{crossOrigin:L,integrity:W,fetchPriority:se}):D==="script"&&c.d.X(v,{crossOrigin:L,integrity:W,fetchPriority:se,nonce:typeof y.nonce=="string"?y.nonce:void 0})}},di.preinitModule=function(v,y){if(typeof v=="string")if(typeof y=="object"&&y!==null){if(y.as==null||y.as==="script"){var D=h(y.as,y.crossOrigin);c.d.M(v,{crossOrigin:D,integrity:typeof y.integrity=="string"?y.integrity:void 0,nonce:typeof y.nonce=="string"?y.nonce:void 0})}}else y==null&&c.d.M(v)},di.preload=function(v,y){if(typeof v=="string"&&typeof y=="object"&&y!==null&&typeof y.as=="string"){var D=y.as,L=h(D,y.crossOrigin);c.d.L(v,D,{crossOrigin:L,integrity:typeof y.integrity=="string"?y.integrity:void 0,nonce:typeof y.nonce=="string"?y.nonce:void 0,type:typeof y.type=="string"?y.type:void 0,fetchPriority:typeof y.fetchPriority=="string"?y.fetchPriority:void 0,referrerPolicy:typeof y.referrerPolicy=="string"?y.referrerPolicy:void 0,imageSrcSet:typeof y.imageSrcSet=="string"?y.imageSrcSet:void 0,imageSizes:typeof y.imageSizes=="string"?y.imageSizes:void 0,media:typeof y.media=="string"?y.media:void 0})}},di.preloadModule=function(v,y){if(typeof v=="string")if(y){var D=h(y.as,y.crossOrigin);c.d.m(v,{as:typeof y.as=="string"&&y.as!=="script"?y.as:void 0,crossOrigin:D,integrity:typeof y.integrity=="string"?y.integrity:void 0})}else c.d.m(v)},di.requestFormReset=function(v){c.d.r(v)},di.unstable_batchedUpdates=function(v,y){return v(y)},di.useFormState=function(v,y,D){return _.H.useFormState(v,y,D)},di.useFormStatus=function(){return _.H.useHostTransitionStatus()},di.version="19.1.0",di}var Bu;function kf(){if(Bu)return Ol.exports;Bu=1;function g(){if(!(typeof __REACT_DEVTOOLS_GLOBAL_HOOK__>"u"||typeof __REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE!="function"))try{__REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE(g)}catch(s){console.error(s)}}return g(),Ol.exports=vf(),Ol.exports}/**
 * @license React
 * react-dom-client.production.js
 *
 * Copyright (c) Meta Platforms, Inc. and affiliates.
 *
 * This source code is licensed under the MIT license found in the
 * LICENSE file in the root directory of this source tree.
 */var Uu;function xf(){if(Uu)return mo;Uu=1;var g=yf(),s=Yl(),l=kf();function c(e){var i="https://react.dev/errors/"+e;if(1<arguments.length){i+="?args[]="+encodeURIComponent(arguments[1]);for(var t=2;t<arguments.length;t++)i+="&args[]="+encodeURIComponent(arguments[t])}return"Minified React error #"+e+"; visit "+i+" for the full message or use the non-minified dev environment for full errors and additional helpful warnings."}function d(e){return!(!e||e.nodeType!==1&&e.nodeType!==9&&e.nodeType!==11)}function m(e){var i=e,t=e;if(e.alternate)for(;i.return;)i=i.return;else{e=i;do i=e,(i.flags&4098)!==0&&(t=i.return),e=i.return;while(e)}return i.tag===3?t:null}function _(e){if(e.tag===13){var i=e.memoizedState;if(i===null&&(e=e.alternate,e!==null&&(i=e.memoizedState)),i!==null)return i.dehydrated}return null}function h(e){if(m(e)!==e)throw Error(c(188))}function v(e){var i=e.alternate;if(!i){if(i=m(e),i===null)throw Error(c(188));return i!==e?null:e}for(var t=e,n=i;;){var o=t.return;if(o===null)break;var r=o.alternate;if(r===null){if(n=o.return,n!==null){t=n;continue}break}if(o.child===r.child){for(r=o.child;r;){if(r===t)return h(o),e;if(r===n)return h(o),i;r=r.sibling}throw Error(c(188))}if(t.return!==n.return)t=o,n=r;else{for(var u=!1,f=o.child;f;){if(f===t){u=!0,t=o,n=r;break}if(f===n){u=!0,n=o,t=r;break}f=f.sibling}if(!u){for(f=r.child;f;){if(f===t){u=!0,t=r,n=o;break}if(f===n){u=!0,n=r,t=o;break}f=f.sibling}if(!u)throw Error(c(189))}}if(t.alternate!==n)throw Error(c(190))}if(t.tag!==3)throw Error(c(188));return t.stateNode.current===t?e:i}function y(e){var i=e.tag;if(i===5||i===26||i===27||i===6)return e;for(e=e.child;e!==null;){if(i=y(e),i!==null)return i;e=e.sibling}return null}var D=Object.assign,L=Symbol.for("react.element"),W=Symbol.for("react.transitional.element"),se=Symbol.for("react.portal"),ie=Symbol.for("react.fragment"),$=Symbol.for("react.strict_mode"),ne=Symbol.for("react.profiler"),w=Symbol.for("react.provider"),O=Symbol.for("react.consumer"),U=Symbol.for("react.context"),Z=Symbol.for("react.forward_ref"),X=Symbol.for("react.suspense"),T=Symbol.for("react.suspense_list"),q=Symbol.for("react.memo"),C=Symbol.for("react.lazy"),E=Symbol.for("react.activity"),z=Symbol.for("react.memo_cache_sentinel"),H=Symbol.iterator;function Y(e){return e===null||typeof e!="object"?null:(e=H&&e[H]||e["@@iterator"],typeof e=="function"?e:null)}var ee=Symbol.for("react.client.reference");function le(e){if(e==null)return null;if(typeof e=="function")return e.$$typeof===ee?null:e.displayName||e.name||null;if(typeof e=="string")return e;switch(e){case ie:return"Fragment";case ne:return"Profiler";case $:return"StrictMode";case X:return"Suspense";case T:return"SuspenseList";case E:return"Activity"}if(typeof e=="object")switch(e.$$typeof){case se:return"Portal";case U:return(e.displayName||"Context")+".Provider";case O:return(e._context.displayName||"Context")+".Consumer";case Z:var i=e.render;return e=e.displayName,e||(e=i.displayName||i.name||"",e=e!==""?"ForwardRef("+e+")":"ForwardRef"),e;case q:return i=e.displayName||null,i!==null?i:le(e.type)||"Memo";case C:i=e._payload,e=e._init;try{return le(e(i))}catch{}}return null}var Q=Array.isArray,k=s.__CLIENT_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE,G=l.__DOM_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE,ae={pending:!1,data:null,method:null,action:null},N=[],p=-1;function A(e){return{current:e}}function J(e){0>p||(e.current=N[p],N[p]=null,p--)}function P(e,i){p++,N[p]=e.current,e.current=i}var V=A(null),te=A(null),re=A(null),ue=A(null);function he(e,i){switch(P(re,i),P(te,e),P(V,null),i.nodeType){case 9:case 11:e=(e=i.documentElement)&&(e=e.namespaceURI)?lu(e):0;break;default:if(e=i.tagName,i=i.namespaceURI)i=lu(i),e=cu(i,e);else switch(e){case"svg":e=1;break;case"math":e=2;break;default:e=0}}J(V),P(V,e)}function Te(){J(V),J(te),J(re)}function li(e){e.memoizedState!==null&&P(ue,e);var i=V.current,t=cu(i,e.type);i!==t&&(P(te,e),P(V,t))}function mi(e){te.current===e&&(J(V),J(te)),ue.current===e&&(J(ue),no._currentValue=ae)}var Ai=Object.prototype.hasOwnProperty,wi=g.unstable_scheduleCallback,Ri=g.unstable_cancelCallback,Ji=g.unstable_shouldYield,Qi=g.unstable_requestPaint,Xe=g.unstable_now,Wi=g.unstable_getCurrentPriorityLevel,Bi=g.unstable_ImmediatePriority,Ui=g.unstable_UserBlockingPriority,bi=g.unstable_NormalPriority,Zi=g.unstable_LowPriority,Fi=g.unstable_IdlePriority,et=g.log,it=g.unstable_setDisableYieldValue,pi=null,Ve=null;function Ce(e){if(typeof et=="function"&&it(e),Ve&&typeof Ve.setStrictMode=="function")try{Ve.setStrictMode(pi,e)}catch{}}var $e=Math.clz32?Math.clz32:ca,sa=Math.log,la=Math.LN2;function ca(e){return e>>>=0,e===0?32:31-(sa(e)/la|0)|0}var tt=256,at=4194304;function yi(e){var i=e&42;if(i!==0)return i;switch(e&-e){case 1:return 1;case 2:return 2;case 4:return 4;case 8:return 8;case 16:return 16;case 32:return 32;case 64:return 64;case 128:return 128;case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return e&4194048;case 4194304:case 8388608:case 16777216:case 33554432:return e&62914560;case 67108864:return 67108864;case 134217728:return 134217728;case 268435456:return 268435456;case 536870912:return 536870912;case 1073741824:return 0;default:return e}}function nt(e,i,t){var n=e.pendingLanes;if(n===0)return 0;var o=0,r=e.suspendedLanes,u=e.pingedLanes;e=e.warmLanes;var f=n&134217727;return f!==0?(n=f&~r,n!==0?o=yi(n):(u&=f,u!==0?o=yi(u):t||(t=f&~e,t!==0&&(o=yi(t))))):(f=n&~r,f!==0?o=yi(f):u!==0?o=yi(u):t||(t=n&~e,t!==0&&(o=yi(t)))),o===0?0:i!==0&&i!==o&&(i&r)===0&&(r=o&-o,t=i&-i,r>=t||r===32&&(t&4194048)!==0)?i:o}function Gi(e,i){return(e.pendingLanes&~(e.suspendedLanes&~e.pingedLanes)&i)===0}function da(e,i){switch(e){case 1:case 2:case 4:case 8:case 64:return i+250;case 16:case 32:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return i+5e3;case 4194304:case 8388608:case 16777216:case 33554432:return-1;case 67108864:case 134217728:case 268435456:case 536870912:case 1073741824:return-1;default:return-1}}function Et(){var e=tt;return tt<<=1,(tt&4194048)===0&&(tt=256),e}function Ze(){var e=at;return at<<=1,(at&62914560)===0&&(at=4194304),e}function Je(e){for(var i=[],t=0;31>t;t++)i.push(e);return i}function vi(e,i){e.pendingLanes|=i,i!==268435456&&(e.suspendedLanes=0,e.pingedLanes=0,e.warmLanes=0)}function ma(e,i,t,n,o,r){var u=e.pendingLanes;e.pendingLanes=t,e.suspendedLanes=0,e.pingedLanes=0,e.warmLanes=0,e.expiredLanes&=t,e.entangledLanes&=t,e.errorRecoveryDisabledLanes&=t,e.shellSuspendCounter=0;var f=e.entanglements,b=e.expirationTimes,j=e.hiddenUpdates;for(t=u&~t;0<t;){var B=31-$e(t),K=1<<B;f[B]=0,b[B]=-1;var R=j[B];if(R!==null)for(j[B]=null,B=0;B<R.length;B++){var M=R[B];M!==null&&(M.lane&=-536870913)}t&=~K}n!==0&&Pt(e,n,0),r!==0&&o===0&&e.tag!==0&&(e.suspendedLanes|=r&~(u&~i))}function Pt(e,i,t){e.pendingLanes|=i,e.suspendedLanes&=~i;var n=31-$e(i);e.entangledLanes|=i,e.entanglements[n]=e.entanglements[n]|1073741824|t&4194090}function ot(e,i){var t=e.entangledLanes|=i;for(e=e.entanglements;t;){var n=31-$e(t),o=1<<n;o&i|e[n]&i&&(e[n]|=i),t&=~o}}function rt(e){switch(e){case 2:e=1;break;case 8:e=4;break;case 32:e=16;break;case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:case 4194304:case 8388608:case 16777216:case 33554432:e=128;break;case 268435456:e=134217728;break;default:e=0}return e}function ht(e){return e&=-e,2<e?8<e?(e&134217727)!==0?32:268435456:8:2}function st(){var e=G.p;return e!==0?e:(e=window.event,e===void 0?32:Au(e.type))}function Lt(e,i){var t=G.p;try{return G.p=e,i()}finally{G.p=t}}var ni=Math.random().toString(36).slice(2),pe="__reactFiber$"+ni,Ue="__reactProps$"+ni,bt="__reactContainer$"+ni,lt="__reactEvents$"+ni,Ar="__reactListeners$"+ni,ua="__reactHandles$"+ni,de="__reactResources$"+ni,je="__reactMarker$"+ni;function fn(e){delete e[pe],delete e[Ue],delete e[lt],delete e[Ar],delete e[ua]}function zt(e){var i=e[pe];if(i)return i;for(var t=e.parentNode;t;){if(i=t[bt]||t[pe]){if(t=i.alternate,i.child!==null||t!==null&&t.child!==null)for(e=pu(e);e!==null;){if(t=e[pe])return t;e=pu(e)}return i}e=t,t=e.parentNode}return null}function Ra(e){if(e=e[pe]||e[bt]){var i=e.tag;if(i===5||i===6||i===13||i===26||i===27||i===3)return e}return null}function _n(e){var i=e.tag;if(i===5||i===26||i===27||i===6)return e.stateNode;throw Error(c(33))}function Ma(e){var i=e[de];return i||(i=e[de]={hoistableStyles:new Map,hoistableScripts:new Map}),i}function ei(e){e[je]=!0}var Ql=new Set,Wl={};function pa(e,i){Da(e,i),Da(e+"Capture",i)}function Da(e,i){for(Wl[e]=i,e=0;e<i.length;e++)Ql.add(i[e])}var rp=RegExp("^[:A-Z_a-z\\u00C0-\\u00D6\\u00D8-\\u00F6\\u00F8-\\u02FF\\u0370-\\u037D\\u037F-\\u1FFF\\u200C-\\u200D\\u2070-\\u218F\\u2C00-\\u2FEF\\u3001-\\uD7FF\\uF900-\\uFDCF\\uFDF0-\\uFFFD][:A-Z_a-z\\u00C0-\\u00D6\\u00D8-\\u00F6\\u00F8-\\u02FF\\u0370-\\u037D\\u037F-\\u1FFF\\u200C-\\u200D\\u2070-\\u218F\\u2C00-\\u2FEF\\u3001-\\uD7FF\\uF900-\\uFDCF\\uFDF0-\\uFFFD\\-.0-9\\u00B7\\u0300-\\u036F\\u203F-\\u2040]*$"),Zl={},ec={};function sp(e){return Ai.call(ec,e)?!0:Ai.call(Zl,e)?!1:rp.test(e)?ec[e]=!0:(Zl[e]=!0,!1)}function go(e,i,t){if(sp(i))if(t===null)e.removeAttribute(i);else{switch(typeof t){case"undefined":case"function":case"symbol":e.removeAttribute(i);return;case"boolean":var n=i.toLowerCase().slice(0,5);if(n!=="data-"&&n!=="aria-"){e.removeAttribute(i);return}}e.setAttribute(i,""+t)}}function fo(e,i,t){if(t===null)e.removeAttribute(i);else{switch(typeof t){case"undefined":case"function":case"symbol":case"boolean":e.removeAttribute(i);return}e.setAttribute(i,""+t)}}function yt(e,i,t,n){if(n===null)e.removeAttribute(t);else{switch(typeof n){case"undefined":case"function":case"symbol":case"boolean":e.removeAttribute(t);return}e.setAttributeNS(i,t,""+n)}}var wr,ic;function qa(e){if(wr===void 0)try{throw Error()}catch(t){var i=t.stack.trim().match(/\n( *(at )?)/);wr=i&&i[1]||"",ic=-1<t.stack.indexOf(`
    at`)?" (<anonymous>)":-1<t.stack.indexOf("@")?"@unknown:0:0":""}return`
`+wr+e+ic}var Rr=!1;function Mr(e,i){if(!e||Rr)return"";Rr=!0;var t=Error.prepareStackTrace;Error.prepareStackTrace=void 0;try{var n={DetermineComponentFrameRoot:function(){try{if(i){var K=function(){throw Error()};if(Object.defineProperty(K.prototype,"props",{set:function(){throw Error()}}),typeof Reflect=="object"&&Reflect.construct){try{Reflect.construct(K,[])}catch(M){var R=M}Reflect.construct(e,[],K)}else{try{K.call()}catch(M){R=M}e.call(K.prototype)}}else{try{throw Error()}catch(M){R=M}(K=e())&&typeof K.catch=="function"&&K.catch(function(){})}}catch(M){if(M&&R&&typeof M.stack=="string")return[M.stack,R.stack]}return[null,null]}};n.DetermineComponentFrameRoot.displayName="DetermineComponentFrameRoot";var o=Object.getOwnPropertyDescriptor(n.DetermineComponentFrameRoot,"name");o&&o.configurable&&Object.defineProperty(n.DetermineComponentFrameRoot,"name",{value:"DetermineComponentFrameRoot"});var r=n.DetermineComponentFrameRoot(),u=r[0],f=r[1];if(u&&f){var b=u.split(`
`),j=f.split(`
`);for(o=n=0;n<b.length&&!b[n].includes("DetermineComponentFrameRoot");)n++;for(;o<j.length&&!j[o].includes("DetermineComponentFrameRoot");)o++;if(n===b.length||o===j.length)for(n=b.length-1,o=j.length-1;1<=n&&0<=o&&b[n]!==j[o];)o--;for(;1<=n&&0<=o;n--,o--)if(b[n]!==j[o]){if(n!==1||o!==1)do if(n--,o--,0>o||b[n]!==j[o]){var B=`
`+b[n].replace(" at new "," at ");return e.displayName&&B.includes("<anonymous>")&&(B=B.replace("<anonymous>",e.displayName)),B}while(1<=n&&0<=o);break}}}finally{Rr=!1,Error.prepareStackTrace=t}return(t=e?e.displayName||e.name:"")?qa(t):""}function lp(e){switch(e.tag){case 26:case 27:case 5:return qa(e.type);case 16:return qa("Lazy");case 13:return qa("Suspense");case 19:return qa("SuspenseList");case 0:case 15:return Mr(e.type,!1);case 11:return Mr(e.type.render,!1);case 1:return Mr(e.type,!0);case 31:return qa("Activity");default:return""}}function tc(e){try{var i="";do i+=lp(e),e=e.return;while(e);return i}catch(t){return`
Error generating stack: `+t.message+`
`+t.stack}}function Mi(e){switch(typeof e){case"bigint":case"boolean":case"number":case"string":case"undefined":return e;case"object":return e;default:return""}}function ac(e){var i=e.type;return(e=e.nodeName)&&e.toLowerCase()==="input"&&(i==="checkbox"||i==="radio")}function cp(e){var i=ac(e)?"checked":"value",t=Object.getOwnPropertyDescriptor(e.constructor.prototype,i),n=""+e[i];if(!e.hasOwnProperty(i)&&typeof t<"u"&&typeof t.get=="function"&&typeof t.set=="function"){var o=t.get,r=t.set;return Object.defineProperty(e,i,{configurable:!0,get:function(){return o.call(this)},set:function(u){n=""+u,r.call(this,u)}}),Object.defineProperty(e,i,{enumerable:t.enumerable}),{getValue:function(){return n},setValue:function(u){n=""+u},stopTracking:function(){e._valueTracker=null,delete e[i]}}}}function _o(e){e._valueTracker||(e._valueTracker=cp(e))}function nc(e){if(!e)return!1;var i=e._valueTracker;if(!i)return!0;var t=i.getValue(),n="";return e&&(n=ac(e)?e.checked?"true":"false":e.value),e=n,e!==t?(i.setValue(e),!0):!1}function ho(e){if(e=e||(typeof document<"u"?document:void 0),typeof e>"u")return null;try{return e.activeElement||e.body}catch{return e.body}}var dp=/[\n"\\]/g;function Di(e){return e.replace(dp,function(i){return"\\"+i.charCodeAt(0).toString(16)+" "})}function Dr(e,i,t,n,o,r,u,f){e.name="",u!=null&&typeof u!="function"&&typeof u!="symbol"&&typeof u!="boolean"?e.type=u:e.removeAttribute("type"),i!=null?u==="number"?(i===0&&e.value===""||e.value!=i)&&(e.value=""+Mi(i)):e.value!==""+Mi(i)&&(e.value=""+Mi(i)):u!=="submit"&&u!=="reset"||e.removeAttribute("value"),i!=null?qr(e,u,Mi(i)):t!=null?qr(e,u,Mi(t)):n!=null&&e.removeAttribute("value"),o==null&&r!=null&&(e.defaultChecked=!!r),o!=null&&(e.checked=o&&typeof o!="function"&&typeof o!="symbol"),f!=null&&typeof f!="function"&&typeof f!="symbol"&&typeof f!="boolean"?e.name=""+Mi(f):e.removeAttribute("name")}function oc(e,i,t,n,o,r,u,f){if(r!=null&&typeof r!="function"&&typeof r!="symbol"&&typeof r!="boolean"&&(e.type=r),i!=null||t!=null){if(!(r!=="submit"&&r!=="reset"||i!=null))return;t=t!=null?""+Mi(t):"",i=i!=null?""+Mi(i):t,f||i===e.value||(e.value=i),e.defaultValue=i}n=n??o,n=typeof n!="function"&&typeof n!="symbol"&&!!n,e.checked=f?e.checked:!!n,e.defaultChecked=!!n,u!=null&&typeof u!="function"&&typeof u!="symbol"&&typeof u!="boolean"&&(e.name=u)}function qr(e,i,t){i==="number"&&ho(e.ownerDocument)===e||e.defaultValue===""+t||(e.defaultValue=""+t)}function Ta(e,i,t,n){if(e=e.options,i){i={};for(var o=0;o<t.length;o++)i["$"+t[o]]=!0;for(t=0;t<e.length;t++)o=i.hasOwnProperty("$"+e[t].value),e[t].selected!==o&&(e[t].selected=o),o&&n&&(e[t].defaultSelected=!0)}else{for(t=""+Mi(t),i=null,o=0;o<e.length;o++){if(e[o].value===t){e[o].selected=!0,n&&(e[o].defaultSelected=!0);return}i!==null||e[o].disabled||(i=e[o])}i!==null&&(i.selected=!0)}}function rc(e,i,t){if(i!=null&&(i=""+Mi(i),i!==e.value&&(e.value=i),t==null)){e.defaultValue!==i&&(e.defaultValue=i);return}e.defaultValue=t!=null?""+Mi(t):""}function sc(e,i,t,n){if(i==null){if(n!=null){if(t!=null)throw Error(c(92));if(Q(n)){if(1<n.length)throw Error(c(93));n=n[0]}t=n}t==null&&(t=""),i=t}t=Mi(i),e.defaultValue=t,n=e.textContent,n===t&&n!==""&&n!==null&&(e.value=n)}function Ea(e,i){if(i){var t=e.firstChild;if(t&&t===e.lastChild&&t.nodeType===3){t.nodeValue=i;return}}e.textContent=i}var mp=new Set("animationIterationCount aspectRatio borderImageOutset borderImageSlice borderImageWidth boxFlex boxFlexGroup boxOrdinalGroup columnCount columns flex flexGrow flexPositive flexShrink flexNegative flexOrder gridArea gridRow gridRowEnd gridRowSpan gridRowStart gridColumn gridColumnEnd gridColumnSpan gridColumnStart fontWeight lineClamp lineHeight opacity order orphans scale tabSize widows zIndex zoom fillOpacity floodOpacity stopOpacity strokeDasharray strokeDashoffset strokeMiterlimit strokeOpacity strokeWidth MozAnimationIterationCount MozBoxFlex MozBoxFlexGroup MozLineClamp msAnimationIterationCount msFlex msZoom msFlexGrow msFlexNegative msFlexOrder msFlexPositive msFlexShrink msGridColumn msGridColumnSpan msGridRow msGridRowSpan WebkitAnimationIterationCount WebkitBoxFlex WebKitBoxFlexGroup WebkitBoxOrdinalGroup WebkitColumnCount WebkitColumns WebkitFlex WebkitFlexGrow WebkitFlexPositive WebkitFlexShrink WebkitLineClamp".split(" "));function lc(e,i,t){var n=i.indexOf("--")===0;t==null||typeof t=="boolean"||t===""?n?e.setProperty(i,""):i==="float"?e.cssFloat="":e[i]="":n?e.setProperty(i,t):typeof t!="number"||t===0||mp.has(i)?i==="float"?e.cssFloat=t:e[i]=(""+t).trim():e[i]=t+"px"}function cc(e,i,t){if(i!=null&&typeof i!="object")throw Error(c(62));if(e=e.style,t!=null){for(var n in t)!t.hasOwnProperty(n)||i!=null&&i.hasOwnProperty(n)||(n.indexOf("--")===0?e.setProperty(n,""):n==="float"?e.cssFloat="":e[n]="");for(var o in i)n=i[o],i.hasOwnProperty(o)&&t[o]!==n&&lc(e,o,n)}else for(var r in i)i.hasOwnProperty(r)&&lc(e,r,i[r])}function Tr(e){if(e.indexOf("-")===-1)return!1;switch(e){case"annotation-xml":case"color-profile":case"font-face":case"font-face-src":case"font-face-uri":case"font-face-format":case"font-face-name":case"missing-glyph":return!1;default:return!0}}var up=new Map([["acceptCharset","accept-charset"],["htmlFor","for"],["httpEquiv","http-equiv"],["crossOrigin","crossorigin"],["accentHeight","accent-height"],["alignmentBaseline","alignment-baseline"],["arabicForm","arabic-form"],["baselineShift","baseline-shift"],["capHeight","cap-height"],["clipPath","clip-path"],["clipRule","clip-rule"],["colorInterpolation","color-interpolation"],["colorInterpolationFilters","color-interpolation-filters"],["colorProfile","color-profile"],["colorRendering","color-rendering"],["dominantBaseline","dominant-baseline"],["enableBackground","enable-background"],["fillOpacity","fill-opacity"],["fillRule","fill-rule"],["floodColor","flood-color"],["floodOpacity","flood-opacity"],["fontFamily","font-family"],["fontSize","font-size"],["fontSizeAdjust","font-size-adjust"],["fontStretch","font-stretch"],["fontStyle","font-style"],["fontVariant","font-variant"],["fontWeight","font-weight"],["glyphName","glyph-name"],["glyphOrientationHorizontal","glyph-orientation-horizontal"],["glyphOrientationVertical","glyph-orientation-vertical"],["horizAdvX","horiz-adv-x"],["horizOriginX","horiz-origin-x"],["imageRendering","image-rendering"],["letterSpacing","letter-spacing"],["lightingColor","lighting-color"],["markerEnd","marker-end"],["markerMid","marker-mid"],["markerStart","marker-start"],["overlinePosition","overline-position"],["overlineThickness","overline-thickness"],["paintOrder","paint-order"],["panose-1","panose-1"],["pointerEvents","pointer-events"],["renderingIntent","rendering-intent"],["shapeRendering","shape-rendering"],["stopColor","stop-color"],["stopOpacity","stop-opacity"],["strikethroughPosition","strikethrough-position"],["strikethroughThickness","strikethrough-thickness"],["strokeDasharray","stroke-dasharray"],["strokeDashoffset","stroke-dashoffset"],["strokeLinecap","stroke-linecap"],["strokeLinejoin","stroke-linejoin"],["strokeMiterlimit","stroke-miterlimit"],["strokeOpacity","stroke-opacity"],["strokeWidth","stroke-width"],["textAnchor","text-anchor"],["textDecoration","text-decoration"],["textRendering","text-rendering"],["transformOrigin","transform-origin"],["underlinePosition","underline-position"],["underlineThickness","underline-thickness"],["unicodeBidi","unicode-bidi"],["unicodeRange","unicode-range"],["unitsPerEm","units-per-em"],["vAlphabetic","v-alphabetic"],["vHanging","v-hanging"],["vIdeographic","v-ideographic"],["vMathematical","v-mathematical"],["vectorEffect","vector-effect"],["vertAdvY","vert-adv-y"],["vertOriginX","vert-origin-x"],["vertOriginY","vert-origin-y"],["wordSpacing","word-spacing"],["writingMode","writing-mode"],["xmlnsXlink","xmlns:xlink"],["xHeight","x-height"]]),pp=/^[\u0000-\u001F ]*j[\r\n\t]*a[\r\n\t]*v[\r\n\t]*a[\r\n\t]*s[\r\n\t]*c[\r\n\t]*r[\r\n\t]*i[\r\n\t]*p[\r\n\t]*t[\r\n\t]*:/i;function bo(e){return pp.test(""+e)?"javascript:throw new Error('React has blocked a javascript: URL as a security precaution.')":e}var Er=null;function Pr(e){return e=e.target||e.srcElement||window,e.correspondingUseElement&&(e=e.correspondingUseElement),e.nodeType===3?e.parentNode:e}var Pa=null,La=null;function dc(e){var i=Ra(e);if(i&&(e=i.stateNode)){var t=e[Ue]||null;e:switch(e=i.stateNode,i.type){case"input":if(Dr(e,t.value,t.defaultValue,t.defaultValue,t.checked,t.defaultChecked,t.type,t.name),i=t.name,t.type==="radio"&&i!=null){for(t=e;t.parentNode;)t=t.parentNode;for(t=t.querySelectorAll('input[name="'+Di(""+i)+'"][type="radio"]'),i=0;i<t.length;i++){var n=t[i];if(n!==e&&n.form===e.form){var o=n[Ue]||null;if(!o)throw Error(c(90));Dr(n,o.value,o.defaultValue,o.defaultValue,o.checked,o.defaultChecked,o.type,o.name)}}for(i=0;i<t.length;i++)n=t[i],n.form===e.form&&nc(n)}break e;case"textarea":rc(e,t.value,t.defaultValue);break e;case"select":i=t.value,i!=null&&Ta(e,!!t.multiple,i,!1)}}}var Lr=!1;function mc(e,i,t){if(Lr)return e(i,t);Lr=!0;try{var n=e(i);return n}finally{if(Lr=!1,(Pa!==null||La!==null)&&(ar(),Pa&&(i=Pa,e=La,La=Pa=null,dc(i),e)))for(i=0;i<e.length;i++)dc(e[i])}}function hn(e,i){var t=e.stateNode;if(t===null)return null;var n=t[Ue]||null;if(n===null)return null;t=n[i];e:switch(i){case"onClick":case"onClickCapture":case"onDoubleClick":case"onDoubleClickCapture":case"onMouseDown":case"onMouseDownCapture":case"onMouseMove":case"onMouseMoveCapture":case"onMouseUp":case"onMouseUpCapture":case"onMouseEnter":(n=!n.disabled)||(e=e.type,n=!(e==="button"||e==="input"||e==="select"||e==="textarea")),e=!n;break e;default:e=!1}if(e)return null;if(t&&typeof t!="function")throw Error(c(231,i,typeof t));return t}var vt=!(typeof window>"u"||typeof window.document>"u"||typeof window.document.createElement>"u"),zr=!1;if(vt)try{var bn={};Object.defineProperty(bn,"passive",{get:function(){zr=!0}}),window.addEventListener("test",bn,bn),window.removeEventListener("test",bn,bn)}catch{zr=!1}var Vt=null,Vr=null,yo=null;function uc(){if(yo)return yo;var e,i=Vr,t=i.length,n,o="value"in Vt?Vt.value:Vt.textContent,r=o.length;for(e=0;e<t&&i[e]===o[e];e++);var u=t-e;for(n=1;n<=u&&i[t-n]===o[r-n];n++);return yo=o.slice(e,1<n?1-n:void 0)}function vo(e){var i=e.keyCode;return"charCode"in e?(e=e.charCode,e===0&&i===13&&(e=13)):e=i,e===10&&(e=13),32<=e||e===13?e:0}function ko(){return!0}function pc(){return!1}function gi(e){function i(t,n,o,r,u){this._reactName=t,this._targetInst=o,this.type=n,this.nativeEvent=r,this.target=u,this.currentTarget=null;for(var f in e)e.hasOwnProperty(f)&&(t=e[f],this[f]=t?t(r):r[f]);return this.isDefaultPrevented=(r.defaultPrevented!=null?r.defaultPrevented:r.returnValue===!1)?ko:pc,this.isPropagationStopped=pc,this}return D(i.prototype,{preventDefault:function(){this.defaultPrevented=!0;var t=this.nativeEvent;t&&(t.preventDefault?t.preventDefault():typeof t.returnValue!="unknown"&&(t.returnValue=!1),this.isDefaultPrevented=ko)},stopPropagation:function(){var t=this.nativeEvent;t&&(t.stopPropagation?t.stopPropagation():typeof t.cancelBubble!="unknown"&&(t.cancelBubble=!0),this.isPropagationStopped=ko)},persist:function(){},isPersistent:ko}),i}var ga={eventPhase:0,bubbles:0,cancelable:0,timeStamp:function(e){return e.timeStamp||Date.now()},defaultPrevented:0,isTrusted:0},xo=gi(ga),yn=D({},ga,{view:0,detail:0}),gp=gi(yn),Or,Br,vn,Co=D({},yn,{screenX:0,screenY:0,clientX:0,clientY:0,pageX:0,pageY:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,getModifierState:Fr,button:0,buttons:0,relatedTarget:function(e){return e.relatedTarget===void 0?e.fromElement===e.srcElement?e.toElement:e.fromElement:e.relatedTarget},movementX:function(e){return"movementX"in e?e.movementX:(e!==vn&&(vn&&e.type==="mousemove"?(Or=e.screenX-vn.screenX,Br=e.screenY-vn.screenY):Br=Or=0,vn=e),Or)},movementY:function(e){return"movementY"in e?e.movementY:Br}}),gc=gi(Co),fp=D({},Co,{dataTransfer:0}),_p=gi(fp),hp=D({},yn,{relatedTarget:0}),Ur=gi(hp),bp=D({},ga,{animationName:0,elapsedTime:0,pseudoElement:0}),yp=gi(bp),vp=D({},ga,{clipboardData:function(e){return"clipboardData"in e?e.clipboardData:window.clipboardData}}),kp=gi(vp),xp=D({},ga,{data:0}),fc=gi(xp),Cp={Esc:"Escape",Spacebar:" ",Left:"ArrowLeft",Up:"ArrowUp",Right:"ArrowRight",Down:"ArrowDown",Del:"Delete",Win:"OS",Menu:"ContextMenu",Apps:"ContextMenu",Scroll:"ScrollLock",MozPrintableKey:"Unidentified"},Sp={8:"Backspace",9:"Tab",12:"Clear",13:"Enter",16:"Shift",17:"Control",18:"Alt",19:"Pause",20:"CapsLock",27:"Escape",32:" ",33:"PageUp",34:"PageDown",35:"End",36:"Home",37:"ArrowLeft",38:"ArrowUp",39:"ArrowRight",40:"ArrowDown",45:"Insert",46:"Delete",112:"F1",113:"F2",114:"F3",115:"F4",116:"F5",117:"F6",118:"F7",119:"F8",120:"F9",121:"F10",122:"F11",123:"F12",144:"NumLock",145:"ScrollLock",224:"Meta"},Np={Alt:"altKey",Control:"ctrlKey",Meta:"metaKey",Shift:"shiftKey"};function Ip(e){var i=this.nativeEvent;return i.getModifierState?i.getModifierState(e):(e=Np[e])?!!i[e]:!1}function Fr(){return Ip}var jp=D({},yn,{key:function(e){if(e.key){var i=Cp[e.key]||e.key;if(i!=="Unidentified")return i}return e.type==="keypress"?(e=vo(e),e===13?"Enter":String.fromCharCode(e)):e.type==="keydown"||e.type==="keyup"?Sp[e.keyCode]||"Unidentified":""},code:0,location:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,repeat:0,locale:0,getModifierState:Fr,charCode:function(e){return e.type==="keypress"?vo(e):0},keyCode:function(e){return e.type==="keydown"||e.type==="keyup"?e.keyCode:0},which:function(e){return e.type==="keypress"?vo(e):e.type==="keydown"||e.type==="keyup"?e.keyCode:0}}),Ap=gi(jp),wp=D({},Co,{pointerId:0,width:0,height:0,pressure:0,tangentialPressure:0,tiltX:0,tiltY:0,twist:0,pointerType:0,isPrimary:0}),_c=gi(wp),Rp=D({},yn,{touches:0,targetTouches:0,changedTouches:0,altKey:0,metaKey:0,ctrlKey:0,shiftKey:0,getModifierState:Fr}),Mp=gi(Rp),Dp=D({},ga,{propertyName:0,elapsedTime:0,pseudoElement:0}),qp=gi(Dp),Tp=D({},Co,{deltaX:function(e){return"deltaX"in e?e.deltaX:"wheelDeltaX"in e?-e.wheelDeltaX:0},deltaY:function(e){return"deltaY"in e?e.deltaY:"wheelDeltaY"in e?-e.wheelDeltaY:"wheelDelta"in e?-e.wheelDelta:0},deltaZ:0,deltaMode:0}),Ep=gi(Tp),Pp=D({},ga,{newState:0,oldState:0}),Lp=gi(Pp),zp=[9,13,27,32],Gr=vt&&"CompositionEvent"in window,kn=null;vt&&"documentMode"in document&&(kn=document.documentMode);var Vp=vt&&"TextEvent"in window&&!kn,hc=vt&&(!Gr||kn&&8<kn&&11>=kn),bc=" ",yc=!1;function vc(e,i){switch(e){case"keyup":return zp.indexOf(i.keyCode)!==-1;case"keydown":return i.keyCode!==229;case"keypress":case"mousedown":case"focusout":return!0;default:return!1}}function kc(e){return e=e.detail,typeof e=="object"&&"data"in e?e.data:null}var za=!1;function Op(e,i){switch(e){case"compositionend":return kc(i);case"keypress":return i.which!==32?null:(yc=!0,bc);case"textInput":return e=i.data,e===bc&&yc?null:e;default:return null}}function Bp(e,i){if(za)return e==="compositionend"||!Gr&&vc(e,i)?(e=uc(),yo=Vr=Vt=null,za=!1,e):null;switch(e){case"paste":return null;case"keypress":if(!(i.ctrlKey||i.altKey||i.metaKey)||i.ctrlKey&&i.altKey){if(i.char&&1<i.char.length)return i.char;if(i.which)return String.fromCharCode(i.which)}return null;case"compositionend":return hc&&i.locale!=="ko"?null:i.data;default:return null}}var Up={color:!0,date:!0,datetime:!0,"datetime-local":!0,email:!0,month:!0,number:!0,password:!0,range:!0,search:!0,tel:!0,text:!0,time:!0,url:!0,week:!0};function xc(e){var i=e&&e.nodeName&&e.nodeName.toLowerCase();return i==="input"?!!Up[e.type]:i==="textarea"}function Cc(e,i,t,n){Pa?La?La.push(n):La=[n]:Pa=n,i=cr(i,"onChange"),0<i.length&&(t=new xo("onChange","change",null,t,n),e.push({event:t,listeners:i}))}var xn=null,Cn=null;function Fp(e){au(e,0)}function So(e){var i=_n(e);if(nc(i))return e}function Sc(e,i){if(e==="change")return i}var Nc=!1;if(vt){var Hr;if(vt){var Kr="oninput"in document;if(!Kr){var Ic=document.createElement("div");Ic.setAttribute("oninput","return;"),Kr=typeof Ic.oninput=="function"}Hr=Kr}else Hr=!1;Nc=Hr&&(!document.documentMode||9<document.documentMode)}function jc(){xn&&(xn.detachEvent("onpropertychange",Ac),Cn=xn=null)}function Ac(e){if(e.propertyName==="value"&&So(Cn)){var i=[];Cc(i,Cn,e,Pr(e)),mc(Fp,i)}}function Gp(e,i,t){e==="focusin"?(jc(),xn=i,Cn=t,xn.attachEvent("onpropertychange",Ac)):e==="focusout"&&jc()}function Hp(e){if(e==="selectionchange"||e==="keyup"||e==="keydown")return So(Cn)}function Kp(e,i){if(e==="click")return So(i)}function Yp(e,i){if(e==="input"||e==="change")return So(i)}function Xp(e,i){return e===i&&(e!==0||1/e===1/i)||e!==e&&i!==i}var ki=typeof Object.is=="function"?Object.is:Xp;function Sn(e,i){if(ki(e,i))return!0;if(typeof e!="object"||e===null||typeof i!="object"||i===null)return!1;var t=Object.keys(e),n=Object.keys(i);if(t.length!==n.length)return!1;for(n=0;n<t.length;n++){var o=t[n];if(!Ai.call(i,o)||!ki(e[o],i[o]))return!1}return!0}function wc(e){for(;e&&e.firstChild;)e=e.firstChild;return e}function Rc(e,i){var t=wc(e);e=0;for(var n;t;){if(t.nodeType===3){if(n=e+t.textContent.length,e<=i&&n>=i)return{node:t,offset:i-e};e=n}e:{for(;t;){if(t.nextSibling){t=t.nextSibling;break e}t=t.parentNode}t=void 0}t=wc(t)}}function Mc(e,i){return e&&i?e===i?!0:e&&e.nodeType===3?!1:i&&i.nodeType===3?Mc(e,i.parentNode):"contains"in e?e.contains(i):e.compareDocumentPosition?!!(e.compareDocumentPosition(i)&16):!1:!1}function Dc(e){e=e!=null&&e.ownerDocument!=null&&e.ownerDocument.defaultView!=null?e.ownerDocument.defaultView:window;for(var i=ho(e.document);i instanceof e.HTMLIFrameElement;){try{var t=typeof i.contentWindow.location.href=="string"}catch{t=!1}if(t)e=i.contentWindow;else break;i=ho(e.document)}return i}function Yr(e){var i=e&&e.nodeName&&e.nodeName.toLowerCase();return i&&(i==="input"&&(e.type==="text"||e.type==="search"||e.type==="tel"||e.type==="url"||e.type==="password")||i==="textarea"||e.contentEditable==="true")}var $p=vt&&"documentMode"in document&&11>=document.documentMode,Va=null,Xr=null,Nn=null,$r=!1;function qc(e,i,t){var n=t.window===t?t.document:t.nodeType===9?t:t.ownerDocument;$r||Va==null||Va!==ho(n)||(n=Va,"selectionStart"in n&&Yr(n)?n={start:n.selectionStart,end:n.selectionEnd}:(n=(n.ownerDocument&&n.ownerDocument.defaultView||window).getSelection(),n={anchorNode:n.anchorNode,anchorOffset:n.anchorOffset,focusNode:n.focusNode,focusOffset:n.focusOffset}),Nn&&Sn(Nn,n)||(Nn=n,n=cr(Xr,"onSelect"),0<n.length&&(i=new xo("onSelect","select",null,i,t),e.push({event:i,listeners:n}),i.target=Va)))}function fa(e,i){var t={};return t[e.toLowerCase()]=i.toLowerCase(),t["Webkit"+e]="webkit"+i,t["Moz"+e]="moz"+i,t}var Oa={animationend:fa("Animation","AnimationEnd"),animationiteration:fa("Animation","AnimationIteration"),animationstart:fa("Animation","AnimationStart"),transitionrun:fa("Transition","TransitionRun"),transitionstart:fa("Transition","TransitionStart"),transitioncancel:fa("Transition","TransitionCancel"),transitionend:fa("Transition","TransitionEnd")},Jr={},Tc={};vt&&(Tc=document.createElement("div").style,"AnimationEvent"in window||(delete Oa.animationend.animation,delete Oa.animationiteration.animation,delete Oa.animationstart.animation),"TransitionEvent"in window||delete Oa.transitionend.transition);function _a(e){if(Jr[e])return Jr[e];if(!Oa[e])return e;var i=Oa[e],t;for(t in i)if(i.hasOwnProperty(t)&&t in Tc)return Jr[e]=i[t];return e}var Ec=_a("animationend"),Pc=_a("animationiteration"),Lc=_a("animationstart"),Jp=_a("transitionrun"),Qp=_a("transitionstart"),Wp=_a("transitioncancel"),zc=_a("transitionend"),Vc=new Map,Qr="abort auxClick beforeToggle cancel canPlay canPlayThrough click close contextMenu copy cut drag dragEnd dragEnter dragExit dragLeave dragOver dragStart drop durationChange emptied encrypted ended error gotPointerCapture input invalid keyDown keyPress keyUp load loadedData loadedMetadata loadStart lostPointerCapture mouseDown mouseMove mouseOut mouseOver mouseUp paste pause play playing pointerCancel pointerDown pointerMove pointerOut pointerOver pointerUp progress rateChange reset resize seeked seeking stalled submit suspend timeUpdate touchCancel touchEnd touchStart volumeChange scroll toggle touchMove waiting wheel".split(" ");Qr.push("scrollEnd");function Hi(e,i){Vc.set(e,i),pa(i,[e])}var Oc=new WeakMap;function qi(e,i){if(typeof e=="object"&&e!==null){var t=Oc.get(e);return t!==void 0?t:(i={value:e,source:i,stack:tc(i)},Oc.set(e,i),i)}return{value:e,source:i,stack:tc(i)}}var Ti=[],Ba=0,Wr=0;function No(){for(var e=Ba,i=Wr=Ba=0;i<e;){var t=Ti[i];Ti[i++]=null;var n=Ti[i];Ti[i++]=null;var o=Ti[i];Ti[i++]=null;var r=Ti[i];if(Ti[i++]=null,n!==null&&o!==null){var u=n.pending;u===null?o.next=o:(o.next=u.next,u.next=o),n.pending=o}r!==0&&Bc(t,o,r)}}function Io(e,i,t,n){Ti[Ba++]=e,Ti[Ba++]=i,Ti[Ba++]=t,Ti[Ba++]=n,Wr|=n,e.lanes|=n,e=e.alternate,e!==null&&(e.lanes|=n)}function Zr(e,i,t,n){return Io(e,i,t,n),jo(e)}function Ua(e,i){return Io(e,null,null,i),jo(e)}function Bc(e,i,t){e.lanes|=t;var n=e.alternate;n!==null&&(n.lanes|=t);for(var o=!1,r=e.return;r!==null;)r.childLanes|=t,n=r.alternate,n!==null&&(n.childLanes|=t),r.tag===22&&(e=r.stateNode,e===null||e._visibility&1||(o=!0)),e=r,r=r.return;return e.tag===3?(r=e.stateNode,o&&i!==null&&(o=31-$e(t),e=r.hiddenUpdates,n=e[o],n===null?e[o]=[i]:n.push(i),i.lane=t|536870912),r):null}function jo(e){if(50<Jn)throw Jn=0,ol=null,Error(c(185));for(var i=e.return;i!==null;)e=i,i=e.return;return e.tag===3?e.stateNode:null}var Fa={};function Zp(e,i,t,n){this.tag=e,this.key=t,this.sibling=this.child=this.return=this.stateNode=this.type=this.elementType=null,this.index=0,this.refCleanup=this.ref=null,this.pendingProps=i,this.dependencies=this.memoizedState=this.updateQueue=this.memoizedProps=null,this.mode=n,this.subtreeFlags=this.flags=0,this.deletions=null,this.childLanes=this.lanes=0,this.alternate=null}function xi(e,i,t,n){return new Zp(e,i,t,n)}function es(e){return e=e.prototype,!(!e||!e.isReactComponent)}function kt(e,i){var t=e.alternate;return t===null?(t=xi(e.tag,i,e.key,e.mode),t.elementType=e.elementType,t.type=e.type,t.stateNode=e.stateNode,t.alternate=e,e.alternate=t):(t.pendingProps=i,t.type=e.type,t.flags=0,t.subtreeFlags=0,t.deletions=null),t.flags=e.flags&65011712,t.childLanes=e.childLanes,t.lanes=e.lanes,t.child=e.child,t.memoizedProps=e.memoizedProps,t.memoizedState=e.memoizedState,t.updateQueue=e.updateQueue,i=e.dependencies,t.dependencies=i===null?null:{lanes:i.lanes,firstContext:i.firstContext},t.sibling=e.sibling,t.index=e.index,t.ref=e.ref,t.refCleanup=e.refCleanup,t}function Uc(e,i){e.flags&=65011714;var t=e.alternate;return t===null?(e.childLanes=0,e.lanes=i,e.child=null,e.subtreeFlags=0,e.memoizedProps=null,e.memoizedState=null,e.updateQueue=null,e.dependencies=null,e.stateNode=null):(e.childLanes=t.childLanes,e.lanes=t.lanes,e.child=t.child,e.subtreeFlags=0,e.deletions=null,e.memoizedProps=t.memoizedProps,e.memoizedState=t.memoizedState,e.updateQueue=t.updateQueue,e.type=t.type,i=t.dependencies,e.dependencies=i===null?null:{lanes:i.lanes,firstContext:i.firstContext}),e}function Ao(e,i,t,n,o,r){var u=0;if(n=e,typeof e=="function")es(e)&&(u=1);else if(typeof e=="string")u=tf(e,t,V.current)?26:e==="html"||e==="head"||e==="body"?27:5;else e:switch(e){case E:return e=xi(31,t,i,o),e.elementType=E,e.lanes=r,e;case ie:return ha(t.children,o,r,i);case $:u=8,o|=24;break;case ne:return e=xi(12,t,i,o|2),e.elementType=ne,e.lanes=r,e;case X:return e=xi(13,t,i,o),e.elementType=X,e.lanes=r,e;case T:return e=xi(19,t,i,o),e.elementType=T,e.lanes=r,e;default:if(typeof e=="object"&&e!==null)switch(e.$$typeof){case w:case U:u=10;break e;case O:u=9;break e;case Z:u=11;break e;case q:u=14;break e;case C:u=16,n=null;break e}u=29,t=Error(c(130,e===null?"null":typeof e,"")),n=null}return i=xi(u,t,i,o),i.elementType=e,i.type=n,i.lanes=r,i}function ha(e,i,t,n){return e=xi(7,e,n,i),e.lanes=t,e}function is(e,i,t){return e=xi(6,e,null,i),e.lanes=t,e}function ts(e,i,t){return i=xi(4,e.children!==null?e.children:[],e.key,i),i.lanes=t,i.stateNode={containerInfo:e.containerInfo,pendingChildren:null,implementation:e.implementation},i}var Ga=[],Ha=0,wo=null,Ro=0,Ei=[],Pi=0,ba=null,xt=1,Ct="";function ya(e,i){Ga[Ha++]=Ro,Ga[Ha++]=wo,wo=e,Ro=i}function Fc(e,i,t){Ei[Pi++]=xt,Ei[Pi++]=Ct,Ei[Pi++]=ba,ba=e;var n=xt;e=Ct;var o=32-$e(n)-1;n&=~(1<<o),t+=1;var r=32-$e(i)+o;if(30<r){var u=o-o%5;r=(n&(1<<u)-1).toString(32),n>>=u,o-=u,xt=1<<32-$e(i)+o|t<<o|n,Ct=r+e}else xt=1<<r|t<<o|n,Ct=e}function as(e){e.return!==null&&(ya(e,1),Fc(e,1,0))}function ns(e){for(;e===wo;)wo=Ga[--Ha],Ga[Ha]=null,Ro=Ga[--Ha],Ga[Ha]=null;for(;e===ba;)ba=Ei[--Pi],Ei[Pi]=null,Ct=Ei[--Pi],Ei[Pi]=null,xt=Ei[--Pi],Ei[Pi]=null}var ui=null,Oe=null,Ie=!1,va=null,ct=!1,os=Error(c(519));function ka(e){var i=Error(c(418,""));throw An(qi(i,e)),os}function Gc(e){var i=e.stateNode,t=e.type,n=e.memoizedProps;switch(i[pe]=e,i[Ue]=n,t){case"dialog":xe("cancel",i),xe("close",i);break;case"iframe":case"object":case"embed":xe("load",i);break;case"video":case"audio":for(t=0;t<Wn.length;t++)xe(Wn[t],i);break;case"source":xe("error",i);break;case"img":case"image":case"link":xe("error",i),xe("load",i);break;case"details":xe("toggle",i);break;case"input":xe("invalid",i),oc(i,n.value,n.defaultValue,n.checked,n.defaultChecked,n.type,n.name,!0),_o(i);break;case"select":xe("invalid",i);break;case"textarea":xe("invalid",i),sc(i,n.value,n.defaultValue,n.children),_o(i)}t=n.children,typeof t!="string"&&typeof t!="number"&&typeof t!="bigint"||i.textContent===""+t||n.suppressHydrationWarning===!0||su(i.textContent,t)?(n.popover!=null&&(xe("beforetoggle",i),xe("toggle",i)),n.onScroll!=null&&xe("scroll",i),n.onScrollEnd!=null&&xe("scrollend",i),n.onClick!=null&&(i.onclick=dr),i=!0):i=!1,i||ka(e)}function Hc(e){for(ui=e.return;ui;)switch(ui.tag){case 5:case 13:ct=!1;return;case 27:case 3:ct=!0;return;default:ui=ui.return}}function In(e){if(e!==ui)return!1;if(!Ie)return Hc(e),Ie=!0,!1;var i=e.tag,t;if((t=i!==3&&i!==27)&&((t=i===5)&&(t=e.type,t=!(t!=="form"&&t!=="button")||kl(e.type,e.memoizedProps)),t=!t),t&&Oe&&ka(e),Hc(e),i===13){if(e=e.memoizedState,e=e!==null?e.dehydrated:null,!e)throw Error(c(317));e:{for(e=e.nextSibling,i=0;e;){if(e.nodeType===8)if(t=e.data,t==="/$"){if(i===0){Oe=Yi(e.nextSibling);break e}i--}else t!=="$"&&t!=="$!"&&t!=="$?"||i++;e=e.nextSibling}Oe=null}}else i===27?(i=Oe,ia(e.type)?(e=Nl,Nl=null,Oe=e):Oe=i):Oe=ui?Yi(e.stateNode.nextSibling):null;return!0}function jn(){Oe=ui=null,Ie=!1}function Kc(){var e=va;return e!==null&&(hi===null?hi=e:hi.push.apply(hi,e),va=null),e}function An(e){va===null?va=[e]:va.push(e)}var rs=A(null),xa=null,St=null;function Ot(e,i,t){P(rs,i._currentValue),i._currentValue=t}function Nt(e){e._currentValue=rs.current,J(rs)}function ss(e,i,t){for(;e!==null;){var n=e.alternate;if((e.childLanes&i)!==i?(e.childLanes|=i,n!==null&&(n.childLanes|=i)):n!==null&&(n.childLanes&i)!==i&&(n.childLanes|=i),e===t)break;e=e.return}}function ls(e,i,t,n){var o=e.child;for(o!==null&&(o.return=e);o!==null;){var r=o.dependencies;if(r!==null){var u=o.child;r=r.firstContext;e:for(;r!==null;){var f=r;r=o;for(var b=0;b<i.length;b++)if(f.context===i[b]){r.lanes|=t,f=r.alternate,f!==null&&(f.lanes|=t),ss(r.return,t,e),n||(u=null);break e}r=f.next}}else if(o.tag===18){if(u=o.return,u===null)throw Error(c(341));u.lanes|=t,r=u.alternate,r!==null&&(r.lanes|=t),ss(u,t,e),u=null}else u=o.child;if(u!==null)u.return=o;else for(u=o;u!==null;){if(u===e){u=null;break}if(o=u.sibling,o!==null){o.return=u.return,u=o;break}u=u.return}o=u}}function wn(e,i,t,n){e=null;for(var o=i,r=!1;o!==null;){if(!r){if((o.flags&524288)!==0)r=!0;else if((o.flags&262144)!==0)break}if(o.tag===10){var u=o.alternate;if(u===null)throw Error(c(387));if(u=u.memoizedProps,u!==null){var f=o.type;ki(o.pendingProps.value,u.value)||(e!==null?e.push(f):e=[f])}}else if(o===ue.current){if(u=o.alternate,u===null)throw Error(c(387));u.memoizedState.memoizedState!==o.memoizedState.memoizedState&&(e!==null?e.push(no):e=[no])}o=o.return}e!==null&&ls(i,e,t,n),i.flags|=262144}function Mo(e){for(e=e.firstContext;e!==null;){if(!ki(e.context._currentValue,e.memoizedValue))return!0;e=e.next}return!1}function Ca(e){xa=e,St=null,e=e.dependencies,e!==null&&(e.firstContext=null)}function ci(e){return Yc(xa,e)}function Do(e,i){return xa===null&&Ca(e),Yc(e,i)}function Yc(e,i){var t=i._currentValue;if(i={context:i,memoizedValue:t,next:null},St===null){if(e===null)throw Error(c(308));St=i,e.dependencies={lanes:0,firstContext:i},e.flags|=524288}else St=St.next=i;return t}var eg=typeof AbortController<"u"?AbortController:function(){var e=[],i=this.signal={aborted:!1,addEventListener:function(t,n){e.push(n)}};this.abort=function(){i.aborted=!0,e.forEach(function(t){return t()})}},ig=g.unstable_scheduleCallback,tg=g.unstable_NormalPriority,Qe={$$typeof:U,Consumer:null,Provider:null,_currentValue:null,_currentValue2:null,_threadCount:0};function cs(){return{controller:new eg,data:new Map,refCount:0}}function Rn(e){e.refCount--,e.refCount===0&&ig(tg,function(){e.controller.abort()})}var Mn=null,ds=0,Ka=0,Ya=null;function ag(e,i){if(Mn===null){var t=Mn=[];ds=0,Ka=ul(),Ya={status:"pending",value:void 0,then:function(n){t.push(n)}}}return ds++,i.then(Xc,Xc),i}function Xc(){if(--ds===0&&Mn!==null){Ya!==null&&(Ya.status="fulfilled");var e=Mn;Mn=null,Ka=0,Ya=null;for(var i=0;i<e.length;i++)(0,e[i])()}}function ng(e,i){var t=[],n={status:"pending",value:null,reason:null,then:function(o){t.push(o)}};return e.then(function(){n.status="fulfilled",n.value=i;for(var o=0;o<t.length;o++)(0,t[o])(i)},function(o){for(n.status="rejected",n.reason=o,o=0;o<t.length;o++)(0,t[o])(void 0)}),n}var $c=k.S;k.S=function(e,i){typeof i=="object"&&i!==null&&typeof i.then=="function"&&ag(e,i),$c!==null&&$c(e,i)};var Sa=A(null);function ms(){var e=Sa.current;return e!==null?e:Ee.pooledCache}function qo(e,i){i===null?P(Sa,Sa.current):P(Sa,i.pool)}function Jc(){var e=ms();return e===null?null:{parent:Qe._currentValue,pool:e}}var Dn=Error(c(460)),Qc=Error(c(474)),To=Error(c(542)),us={then:function(){}};function Wc(e){return e=e.status,e==="fulfilled"||e==="rejected"}function Eo(){}function Zc(e,i,t){switch(t=e[t],t===void 0?e.push(i):t!==i&&(i.then(Eo,Eo),i=t),i.status){case"fulfilled":return i.value;case"rejected":throw e=i.reason,id(e),e;default:if(typeof i.status=="string")i.then(Eo,Eo);else{if(e=Ee,e!==null&&100<e.shellSuspendCounter)throw Error(c(482));e=i,e.status="pending",e.then(function(n){if(i.status==="pending"){var o=i;o.status="fulfilled",o.value=n}},function(n){if(i.status==="pending"){var o=i;o.status="rejected",o.reason=n}})}switch(i.status){case"fulfilled":return i.value;case"rejected":throw e=i.reason,id(e),e}throw qn=i,Dn}}var qn=null;function ed(){if(qn===null)throw Error(c(459));var e=qn;return qn=null,e}function id(e){if(e===Dn||e===To)throw Error(c(483))}var Bt=!1;function ps(e){e.updateQueue={baseState:e.memoizedState,firstBaseUpdate:null,lastBaseUpdate:null,shared:{pending:null,lanes:0,hiddenCallbacks:null},callbacks:null}}function gs(e,i){e=e.updateQueue,i.updateQueue===e&&(i.updateQueue={baseState:e.baseState,firstBaseUpdate:e.firstBaseUpdate,lastBaseUpdate:e.lastBaseUpdate,shared:e.shared,callbacks:null})}function Ut(e){return{lane:e,tag:0,payload:null,callback:null,next:null}}function Ft(e,i,t){var n=e.updateQueue;if(n===null)return null;if(n=n.shared,(Ae&2)!==0){var o=n.pending;return o===null?i.next=i:(i.next=o.next,o.next=i),n.pending=i,i=jo(e),Bc(e,null,t),i}return Io(e,n,i,t),jo(e)}function Tn(e,i,t){if(i=i.updateQueue,i!==null&&(i=i.shared,(t&4194048)!==0)){var n=i.lanes;n&=e.pendingLanes,t|=n,i.lanes=t,ot(e,t)}}function fs(e,i){var t=e.updateQueue,n=e.alternate;if(n!==null&&(n=n.updateQueue,t===n)){var o=null,r=null;if(t=t.firstBaseUpdate,t!==null){do{var u={lane:t.lane,tag:t.tag,payload:t.payload,callback:null,next:null};r===null?o=r=u:r=r.next=u,t=t.next}while(t!==null);r===null?o=r=i:r=r.next=i}else o=r=i;t={baseState:n.baseState,firstBaseUpdate:o,lastBaseUpdate:r,shared:n.shared,callbacks:n.callbacks},e.updateQueue=t;return}e=t.lastBaseUpdate,e===null?t.firstBaseUpdate=i:e.next=i,t.lastBaseUpdate=i}var _s=!1;function En(){if(_s){var e=Ya;if(e!==null)throw e}}function Pn(e,i,t,n){_s=!1;var o=e.updateQueue;Bt=!1;var r=o.firstBaseUpdate,u=o.lastBaseUpdate,f=o.shared.pending;if(f!==null){o.shared.pending=null;var b=f,j=b.next;b.next=null,u===null?r=j:u.next=j,u=b;var B=e.alternate;B!==null&&(B=B.updateQueue,f=B.lastBaseUpdate,f!==u&&(f===null?B.firstBaseUpdate=j:f.next=j,B.lastBaseUpdate=b))}if(r!==null){var K=o.baseState;u=0,B=j=b=null,f=r;do{var R=f.lane&-536870913,M=R!==f.lane;if(M?(Se&R)===R:(n&R)===R){R!==0&&R===Ka&&(_s=!0),B!==null&&(B=B.next={lane:0,tag:f.tag,payload:f.payload,callback:null,next:null});e:{var _e=e,ge=f;R=i;var De=t;switch(ge.tag){case 1:if(_e=ge.payload,typeof _e=="function"){K=_e.call(De,K,R);break e}K=_e;break e;case 3:_e.flags=_e.flags&-65537|128;case 0:if(_e=ge.payload,R=typeof _e=="function"?_e.call(De,K,R):_e,R==null)break e;K=D({},K,R);break e;case 2:Bt=!0}}R=f.callback,R!==null&&(e.flags|=64,M&&(e.flags|=8192),M=o.callbacks,M===null?o.callbacks=[R]:M.push(R))}else M={lane:R,tag:f.tag,payload:f.payload,callback:f.callback,next:null},B===null?(j=B=M,b=K):B=B.next=M,u|=R;if(f=f.next,f===null){if(f=o.shared.pending,f===null)break;M=f,f=M.next,M.next=null,o.lastBaseUpdate=M,o.shared.pending=null}}while(!0);B===null&&(b=K),o.baseState=b,o.firstBaseUpdate=j,o.lastBaseUpdate=B,r===null&&(o.shared.lanes=0),Qt|=u,e.lanes=u,e.memoizedState=K}}function td(e,i){if(typeof e!="function")throw Error(c(191,e));e.call(i)}function ad(e,i){var t=e.callbacks;if(t!==null)for(e.callbacks=null,e=0;e<t.length;e++)td(t[e],i)}var Xa=A(null),Po=A(0);function nd(e,i){e=Dt,P(Po,e),P(Xa,i),Dt=e|i.baseLanes}function hs(){P(Po,Dt),P(Xa,Xa.current)}function bs(){Dt=Po.current,J(Xa),J(Po)}var Gt=0,ye=null,Re=null,He=null,Lo=!1,$a=!1,Na=!1,zo=0,Ln=0,Ja=null,og=0;function Fe(){throw Error(c(321))}function ys(e,i){if(i===null)return!1;for(var t=0;t<i.length&&t<e.length;t++)if(!ki(e[t],i[t]))return!1;return!0}function vs(e,i,t,n,o,r){return Gt=r,ye=i,i.memoizedState=null,i.updateQueue=null,i.lanes=0,k.H=e===null||e.memoizedState===null?Bd:Ud,Na=!1,r=t(n,o),Na=!1,$a&&(r=rd(i,t,n,o)),od(e),r}function od(e){k.H=Go;var i=Re!==null&&Re.next!==null;if(Gt=0,He=Re=ye=null,Lo=!1,Ln=0,Ja=null,i)throw Error(c(300));e===null||ii||(e=e.dependencies,e!==null&&Mo(e)&&(ii=!0))}function rd(e,i,t,n){ye=e;var o=0;do{if($a&&(Ja=null),Ln=0,$a=!1,25<=o)throw Error(c(301));if(o+=1,He=Re=null,e.updateQueue!=null){var r=e.updateQueue;r.lastEffect=null,r.events=null,r.stores=null,r.memoCache!=null&&(r.memoCache.index=0)}k.H=ug,r=i(t,n)}while($a);return r}function rg(){var e=k.H,i=e.useState()[0];return i=typeof i.then=="function"?zn(i):i,e=e.useState()[0],(Re!==null?Re.memoizedState:null)!==e&&(ye.flags|=1024),i}function ks(){var e=zo!==0;return zo=0,e}function xs(e,i,t){i.updateQueue=e.updateQueue,i.flags&=-2053,e.lanes&=~t}function Cs(e){if(Lo){for(e=e.memoizedState;e!==null;){var i=e.queue;i!==null&&(i.pending=null),e=e.next}Lo=!1}Gt=0,He=Re=ye=null,$a=!1,Ln=zo=0,Ja=null}function fi(){var e={memoizedState:null,baseState:null,baseQueue:null,queue:null,next:null};return He===null?ye.memoizedState=He=e:He=He.next=e,He}function Ke(){if(Re===null){var e=ye.alternate;e=e!==null?e.memoizedState:null}else e=Re.next;var i=He===null?ye.memoizedState:He.next;if(i!==null)He=i,Re=e;else{if(e===null)throw ye.alternate===null?Error(c(467)):Error(c(310));Re=e,e={memoizedState:Re.memoizedState,baseState:Re.baseState,baseQueue:Re.baseQueue,queue:Re.queue,next:null},He===null?ye.memoizedState=He=e:He=He.next=e}return He}function Ss(){return{lastEffect:null,events:null,stores:null,memoCache:null}}function zn(e){var i=Ln;return Ln+=1,Ja===null&&(Ja=[]),e=Zc(Ja,e,i),i=ye,(He===null?i.memoizedState:He.next)===null&&(i=i.alternate,k.H=i===null||i.memoizedState===null?Bd:Ud),e}function Vo(e){if(e!==null&&typeof e=="object"){if(typeof e.then=="function")return zn(e);if(e.$$typeof===U)return ci(e)}throw Error(c(438,String(e)))}function Ns(e){var i=null,t=ye.updateQueue;if(t!==null&&(i=t.memoCache),i==null){var n=ye.alternate;n!==null&&(n=n.updateQueue,n!==null&&(n=n.memoCache,n!=null&&(i={data:n.data.map(function(o){return o.slice()}),index:0})))}if(i==null&&(i={data:[],index:0}),t===null&&(t=Ss(),ye.updateQueue=t),t.memoCache=i,t=i.data[i.index],t===void 0)for(t=i.data[i.index]=Array(e),n=0;n<e;n++)t[n]=z;return i.index++,t}function It(e,i){return typeof i=="function"?i(e):i}function Oo(e){var i=Ke();return Is(i,Re,e)}function Is(e,i,t){var n=e.queue;if(n===null)throw Error(c(311));n.lastRenderedReducer=t;var o=e.baseQueue,r=n.pending;if(r!==null){if(o!==null){var u=o.next;o.next=r.next,r.next=u}i.baseQueue=o=r,n.pending=null}if(r=e.baseState,o===null)e.memoizedState=r;else{i=o.next;var f=u=null,b=null,j=i,B=!1;do{var K=j.lane&-536870913;if(K!==j.lane?(Se&K)===K:(Gt&K)===K){var R=j.revertLane;if(R===0)b!==null&&(b=b.next={lane:0,revertLane:0,action:j.action,hasEagerState:j.hasEagerState,eagerState:j.eagerState,next:null}),K===Ka&&(B=!0);else if((Gt&R)===R){j=j.next,R===Ka&&(B=!0);continue}else K={lane:0,revertLane:j.revertLane,action:j.action,hasEagerState:j.hasEagerState,eagerState:j.eagerState,next:null},b===null?(f=b=K,u=r):b=b.next=K,ye.lanes|=R,Qt|=R;K=j.action,Na&&t(r,K),r=j.hasEagerState?j.eagerState:t(r,K)}else R={lane:K,revertLane:j.revertLane,action:j.action,hasEagerState:j.hasEagerState,eagerState:j.eagerState,next:null},b===null?(f=b=R,u=r):b=b.next=R,ye.lanes|=K,Qt|=K;j=j.next}while(j!==null&&j!==i);if(b===null?u=r:b.next=f,!ki(r,e.memoizedState)&&(ii=!0,B&&(t=Ya,t!==null)))throw t;e.memoizedState=r,e.baseState=u,e.baseQueue=b,n.lastRenderedState=r}return o===null&&(n.lanes=0),[e.memoizedState,n.dispatch]}function js(e){var i=Ke(),t=i.queue;if(t===null)throw Error(c(311));t.lastRenderedReducer=e;var n=t.dispatch,o=t.pending,r=i.memoizedState;if(o!==null){t.pending=null;var u=o=o.next;do r=e(r,u.action),u=u.next;while(u!==o);ki(r,i.memoizedState)||(ii=!0),i.memoizedState=r,i.baseQueue===null&&(i.baseState=r),t.lastRenderedState=r}return[r,n]}function sd(e,i,t){var n=ye,o=Ke(),r=Ie;if(r){if(t===void 0)throw Error(c(407));t=t()}else t=i();var u=!ki((Re||o).memoizedState,t);u&&(o.memoizedState=t,ii=!0),o=o.queue;var f=dd.bind(null,n,o,e);if(Vn(2048,8,f,[e]),o.getSnapshot!==i||u||He!==null&&He.memoizedState.tag&1){if(n.flags|=2048,Qa(9,Bo(),cd.bind(null,n,o,t,i),null),Ee===null)throw Error(c(349));r||(Gt&124)!==0||ld(n,i,t)}return t}function ld(e,i,t){e.flags|=16384,e={getSnapshot:i,value:t},i=ye.updateQueue,i===null?(i=Ss(),ye.updateQueue=i,i.stores=[e]):(t=i.stores,t===null?i.stores=[e]:t.push(e))}function cd(e,i,t,n){i.value=t,i.getSnapshot=n,md(i)&&ud(e)}function dd(e,i,t){return t(function(){md(i)&&ud(e)})}function md(e){var i=e.getSnapshot;e=e.value;try{var t=i();return!ki(e,t)}catch{return!0}}function ud(e){var i=Ua(e,2);i!==null&&ji(i,e,2)}function As(e){var i=fi();if(typeof e=="function"){var t=e;if(e=t(),Na){Ce(!0);try{t()}finally{Ce(!1)}}}return i.memoizedState=i.baseState=e,i.queue={pending:null,lanes:0,dispatch:null,lastRenderedReducer:It,lastRenderedState:e},i}function pd(e,i,t,n){return e.baseState=t,Is(e,Re,typeof n=="function"?n:It)}function sg(e,i,t,n,o){if(Fo(e))throw Error(c(485));if(e=i.action,e!==null){var r={payload:o,action:e,next:null,isTransition:!0,status:"pending",value:null,reason:null,listeners:[],then:function(u){r.listeners.push(u)}};k.T!==null?t(!0):r.isTransition=!1,n(r),t=i.pending,t===null?(r.next=i.pending=r,gd(i,r)):(r.next=t.next,i.pending=t.next=r)}}function gd(e,i){var t=i.action,n=i.payload,o=e.state;if(i.isTransition){var r=k.T,u={};k.T=u;try{var f=t(o,n),b=k.S;b!==null&&b(u,f),fd(e,i,f)}catch(j){ws(e,i,j)}finally{k.T=r}}else try{r=t(o,n),fd(e,i,r)}catch(j){ws(e,i,j)}}function fd(e,i,t){t!==null&&typeof t=="object"&&typeof t.then=="function"?t.then(function(n){_d(e,i,n)},function(n){return ws(e,i,n)}):_d(e,i,t)}function _d(e,i,t){i.status="fulfilled",i.value=t,hd(i),e.state=t,i=e.pending,i!==null&&(t=i.next,t===i?e.pending=null:(t=t.next,i.next=t,gd(e,t)))}function ws(e,i,t){var n=e.pending;if(e.pending=null,n!==null){n=n.next;do i.status="rejected",i.reason=t,hd(i),i=i.next;while(i!==n)}e.action=null}function hd(e){e=e.listeners;for(var i=0;i<e.length;i++)(0,e[i])()}function bd(e,i){return i}function yd(e,i){if(Ie){var t=Ee.formState;if(t!==null){e:{var n=ye;if(Ie){if(Oe){i:{for(var o=Oe,r=ct;o.nodeType!==8;){if(!r){o=null;break i}if(o=Yi(o.nextSibling),o===null){o=null;break i}}r=o.data,o=r==="F!"||r==="F"?o:null}if(o){Oe=Yi(o.nextSibling),n=o.data==="F!";break e}}ka(n)}n=!1}n&&(i=t[0])}}return t=fi(),t.memoizedState=t.baseState=i,n={pending:null,lanes:0,dispatch:null,lastRenderedReducer:bd,lastRenderedState:i},t.queue=n,t=zd.bind(null,ye,n),n.dispatch=t,n=As(!1),r=Ts.bind(null,ye,!1,n.queue),n=fi(),o={state:i,dispatch:null,action:e,pending:null},n.queue=o,t=sg.bind(null,ye,o,r,t),o.dispatch=t,n.memoizedState=e,[i,t,!1]}function vd(e){var i=Ke();return kd(i,Re,e)}function kd(e,i,t){if(i=Is(e,i,bd)[0],e=Oo(It)[0],typeof i=="object"&&i!==null&&typeof i.then=="function")try{var n=zn(i)}catch(u){throw u===Dn?To:u}else n=i;i=Ke();var o=i.queue,r=o.dispatch;return t!==i.memoizedState&&(ye.flags|=2048,Qa(9,Bo(),lg.bind(null,o,t),null)),[n,r,e]}function lg(e,i){e.action=i}function xd(e){var i=Ke(),t=Re;if(t!==null)return kd(i,t,e);Ke(),i=i.memoizedState,t=Ke();var n=t.queue.dispatch;return t.memoizedState=e,[i,n,!1]}function Qa(e,i,t,n){return e={tag:e,create:t,deps:n,inst:i,next:null},i=ye.updateQueue,i===null&&(i=Ss(),ye.updateQueue=i),t=i.lastEffect,t===null?i.lastEffect=e.next=e:(n=t.next,t.next=e,e.next=n,i.lastEffect=e),e}function Bo(){return{destroy:void 0,resource:void 0}}function Cd(){return Ke().memoizedState}function Uo(e,i,t,n){var o=fi();n=n===void 0?null:n,ye.flags|=e,o.memoizedState=Qa(1|i,Bo(),t,n)}function Vn(e,i,t,n){var o=Ke();n=n===void 0?null:n;var r=o.memoizedState.inst;Re!==null&&n!==null&&ys(n,Re.memoizedState.deps)?o.memoizedState=Qa(i,r,t,n):(ye.flags|=e,o.memoizedState=Qa(1|i,r,t,n))}function Sd(e,i){Uo(8390656,8,e,i)}function Nd(e,i){Vn(2048,8,e,i)}function Id(e,i){return Vn(4,2,e,i)}function jd(e,i){return Vn(4,4,e,i)}function Ad(e,i){if(typeof i=="function"){e=e();var t=i(e);return function(){typeof t=="function"?t():i(null)}}if(i!=null)return e=e(),i.current=e,function(){i.current=null}}function wd(e,i,t){t=t!=null?t.concat([e]):null,Vn(4,4,Ad.bind(null,i,e),t)}function Rs(){}function Rd(e,i){var t=Ke();i=i===void 0?null:i;var n=t.memoizedState;return i!==null&&ys(i,n[1])?n[0]:(t.memoizedState=[e,i],e)}function Md(e,i){var t=Ke();i=i===void 0?null:i;var n=t.memoizedState;if(i!==null&&ys(i,n[1]))return n[0];if(n=e(),Na){Ce(!0);try{e()}finally{Ce(!1)}}return t.memoizedState=[n,i],n}function Ms(e,i,t){return t===void 0||(Gt&1073741824)!==0?e.memoizedState=i:(e.memoizedState=t,e=Tm(),ye.lanes|=e,Qt|=e,t)}function Dd(e,i,t,n){return ki(t,i)?t:Xa.current!==null?(e=Ms(e,t,n),ki(e,i)||(ii=!0),e):(Gt&42)===0?(ii=!0,e.memoizedState=t):(e=Tm(),ye.lanes|=e,Qt|=e,i)}function qd(e,i,t,n,o){var r=G.p;G.p=r!==0&&8>r?r:8;var u=k.T,f={};k.T=f,Ts(e,!1,i,t);try{var b=o(),j=k.S;if(j!==null&&j(f,b),b!==null&&typeof b=="object"&&typeof b.then=="function"){var B=ng(b,n);On(e,i,B,Ii(e))}else On(e,i,n,Ii(e))}catch(K){On(e,i,{then:function(){},status:"rejected",reason:K},Ii())}finally{G.p=r,k.T=u}}function cg(){}function Ds(e,i,t,n){if(e.tag!==5)throw Error(c(476));var o=Td(e).queue;qd(e,o,i,ae,t===null?cg:function(){return Ed(e),t(n)})}function Td(e){var i=e.memoizedState;if(i!==null)return i;i={memoizedState:ae,baseState:ae,baseQueue:null,queue:{pending:null,lanes:0,dispatch:null,lastRenderedReducer:It,lastRenderedState:ae},next:null};var t={};return i.next={memoizedState:t,baseState:t,baseQueue:null,queue:{pending:null,lanes:0,dispatch:null,lastRenderedReducer:It,lastRenderedState:t},next:null},e.memoizedState=i,e=e.alternate,e!==null&&(e.memoizedState=i),i}function Ed(e){var i=Td(e).next.queue;On(e,i,{},Ii())}function qs(){return ci(no)}function Pd(){return Ke().memoizedState}function Ld(){return Ke().memoizedState}function dg(e){for(var i=e.return;i!==null;){switch(i.tag){case 24:case 3:var t=Ii();e=Ut(t);var n=Ft(i,e,t);n!==null&&(ji(n,i,t),Tn(n,i,t)),i={cache:cs()},e.payload=i;return}i=i.return}}function mg(e,i,t){var n=Ii();t={lane:n,revertLane:0,action:t,hasEagerState:!1,eagerState:null,next:null},Fo(e)?Vd(i,t):(t=Zr(e,i,t,n),t!==null&&(ji(t,e,n),Od(t,i,n)))}function zd(e,i,t){var n=Ii();On(e,i,t,n)}function On(e,i,t,n){var o={lane:n,revertLane:0,action:t,hasEagerState:!1,eagerState:null,next:null};if(Fo(e))Vd(i,o);else{var r=e.alternate;if(e.lanes===0&&(r===null||r.lanes===0)&&(r=i.lastRenderedReducer,r!==null))try{var u=i.lastRenderedState,f=r(u,t);if(o.hasEagerState=!0,o.eagerState=f,ki(f,u))return Io(e,i,o,0),Ee===null&&No(),!1}catch{}finally{}if(t=Zr(e,i,o,n),t!==null)return ji(t,e,n),Od(t,i,n),!0}return!1}function Ts(e,i,t,n){if(n={lane:2,revertLane:ul(),action:n,hasEagerState:!1,eagerState:null,next:null},Fo(e)){if(i)throw Error(c(479))}else i=Zr(e,t,n,2),i!==null&&ji(i,e,2)}function Fo(e){var i=e.alternate;return e===ye||i!==null&&i===ye}function Vd(e,i){$a=Lo=!0;var t=e.pending;t===null?i.next=i:(i.next=t.next,t.next=i),e.pending=i}function Od(e,i,t){if((t&4194048)!==0){var n=i.lanes;n&=e.pendingLanes,t|=n,i.lanes=t,ot(e,t)}}var Go={readContext:ci,use:Vo,useCallback:Fe,useContext:Fe,useEffect:Fe,useImperativeHandle:Fe,useLayoutEffect:Fe,useInsertionEffect:Fe,useMemo:Fe,useReducer:Fe,useRef:Fe,useState:Fe,useDebugValue:Fe,useDeferredValue:Fe,useTransition:Fe,useSyncExternalStore:Fe,useId:Fe,useHostTransitionStatus:Fe,useFormState:Fe,useActionState:Fe,useOptimistic:Fe,useMemoCache:Fe,useCacheRefresh:Fe},Bd={readContext:ci,use:Vo,useCallback:function(e,i){return fi().memoizedState=[e,i===void 0?null:i],e},useContext:ci,useEffect:Sd,useImperativeHandle:function(e,i,t){t=t!=null?t.concat([e]):null,Uo(4194308,4,Ad.bind(null,i,e),t)},useLayoutEffect:function(e,i){return Uo(4194308,4,e,i)},useInsertionEffect:function(e,i){Uo(4,2,e,i)},useMemo:function(e,i){var t=fi();i=i===void 0?null:i;var n=e();if(Na){Ce(!0);try{e()}finally{Ce(!1)}}return t.memoizedState=[n,i],n},useReducer:function(e,i,t){var n=fi();if(t!==void 0){var o=t(i);if(Na){Ce(!0);try{t(i)}finally{Ce(!1)}}}else o=i;return n.memoizedState=n.baseState=o,e={pending:null,lanes:0,dispatch:null,lastRenderedReducer:e,lastRenderedState:o},n.queue=e,e=e.dispatch=mg.bind(null,ye,e),[n.memoizedState,e]},useRef:function(e){var i=fi();return e={current:e},i.memoizedState=e},useState:function(e){e=As(e);var i=e.queue,t=zd.bind(null,ye,i);return i.dispatch=t,[e.memoizedState,t]},useDebugValue:Rs,useDeferredValue:function(e,i){var t=fi();return Ms(t,e,i)},useTransition:function(){var e=As(!1);return e=qd.bind(null,ye,e.queue,!0,!1),fi().memoizedState=e,[!1,e]},useSyncExternalStore:function(e,i,t){var n=ye,o=fi();if(Ie){if(t===void 0)throw Error(c(407));t=t()}else{if(t=i(),Ee===null)throw Error(c(349));(Se&124)!==0||ld(n,i,t)}o.memoizedState=t;var r={value:t,getSnapshot:i};return o.queue=r,Sd(dd.bind(null,n,r,e),[e]),n.flags|=2048,Qa(9,Bo(),cd.bind(null,n,r,t,i),null),t},useId:function(){var e=fi(),i=Ee.identifierPrefix;if(Ie){var t=Ct,n=xt;t=(n&~(1<<32-$e(n)-1)).toString(32)+t,i="«"+i+"R"+t,t=zo++,0<t&&(i+="H"+t.toString(32)),i+="»"}else t=og++,i="«"+i+"r"+t.toString(32)+"»";return e.memoizedState=i},useHostTransitionStatus:qs,useFormState:yd,useActionState:yd,useOptimistic:function(e){var i=fi();i.memoizedState=i.baseState=e;var t={pending:null,lanes:0,dispatch:null,lastRenderedReducer:null,lastRenderedState:null};return i.queue=t,i=Ts.bind(null,ye,!0,t),t.dispatch=i,[e,i]},useMemoCache:Ns,useCacheRefresh:function(){return fi().memoizedState=dg.bind(null,ye)}},Ud={readContext:ci,use:Vo,useCallback:Rd,useContext:ci,useEffect:Nd,useImperativeHandle:wd,useInsertionEffect:Id,useLayoutEffect:jd,useMemo:Md,useReducer:Oo,useRef:Cd,useState:function(){return Oo(It)},useDebugValue:Rs,useDeferredValue:function(e,i){var t=Ke();return Dd(t,Re.memoizedState,e,i)},useTransition:function(){var e=Oo(It)[0],i=Ke().memoizedState;return[typeof e=="boolean"?e:zn(e),i]},useSyncExternalStore:sd,useId:Pd,useHostTransitionStatus:qs,useFormState:vd,useActionState:vd,useOptimistic:function(e,i){var t=Ke();return pd(t,Re,e,i)},useMemoCache:Ns,useCacheRefresh:Ld},ug={readContext:ci,use:Vo,useCallback:Rd,useContext:ci,useEffect:Nd,useImperativeHandle:wd,useInsertionEffect:Id,useLayoutEffect:jd,useMemo:Md,useReducer:js,useRef:Cd,useState:function(){return js(It)},useDebugValue:Rs,useDeferredValue:function(e,i){var t=Ke();return Re===null?Ms(t,e,i):Dd(t,Re.memoizedState,e,i)},useTransition:function(){var e=js(It)[0],i=Ke().memoizedState;return[typeof e=="boolean"?e:zn(e),i]},useSyncExternalStore:sd,useId:Pd,useHostTransitionStatus:qs,useFormState:xd,useActionState:xd,useOptimistic:function(e,i){var t=Ke();return Re!==null?pd(t,Re,e,i):(t.baseState=e,[e,t.queue.dispatch])},useMemoCache:Ns,useCacheRefresh:Ld},Wa=null,Bn=0;function Ho(e){var i=Bn;return Bn+=1,Wa===null&&(Wa=[]),Zc(Wa,e,i)}function Un(e,i){i=i.props.ref,e.ref=i!==void 0?i:null}function Ko(e,i){throw i.$$typeof===L?Error(c(525)):(e=Object.prototype.toString.call(i),Error(c(31,e==="[object Object]"?"object with keys {"+Object.keys(i).join(", ")+"}":e)))}function Fd(e){var i=e._init;return i(e._payload)}function Gd(e){function i(S,x){if(e){var I=S.deletions;I===null?(S.deletions=[x],S.flags|=16):I.push(x)}}function t(S,x){if(!e)return null;for(;x!==null;)i(S,x),x=x.sibling;return null}function n(S){for(var x=new Map;S!==null;)S.key!==null?x.set(S.key,S):x.set(S.index,S),S=S.sibling;return x}function o(S,x){return S=kt(S,x),S.index=0,S.sibling=null,S}function r(S,x,I){return S.index=I,e?(I=S.alternate,I!==null?(I=I.index,I<x?(S.flags|=67108866,x):I):(S.flags|=67108866,x)):(S.flags|=1048576,x)}function u(S){return e&&S.alternate===null&&(S.flags|=67108866),S}function f(S,x,I,F){return x===null||x.tag!==6?(x=is(I,S.mode,F),x.return=S,x):(x=o(x,I),x.return=S,x)}function b(S,x,I,F){var ce=I.type;return ce===ie?B(S,x,I.props.children,F,I.key):x!==null&&(x.elementType===ce||typeof ce=="object"&&ce!==null&&ce.$$typeof===C&&Fd(ce)===x.type)?(x=o(x,I.props),Un(x,I),x.return=S,x):(x=Ao(I.type,I.key,I.props,null,S.mode,F),Un(x,I),x.return=S,x)}function j(S,x,I,F){return x===null||x.tag!==4||x.stateNode.containerInfo!==I.containerInfo||x.stateNode.implementation!==I.implementation?(x=ts(I,S.mode,F),x.return=S,x):(x=o(x,I.children||[]),x.return=S,x)}function B(S,x,I,F,ce){return x===null||x.tag!==7?(x=ha(I,S.mode,F,ce),x.return=S,x):(x=o(x,I),x.return=S,x)}function K(S,x,I){if(typeof x=="string"&&x!==""||typeof x=="number"||typeof x=="bigint")return x=is(""+x,S.mode,I),x.return=S,x;if(typeof x=="object"&&x!==null){switch(x.$$typeof){case W:return I=Ao(x.type,x.key,x.props,null,S.mode,I),Un(I,x),I.return=S,I;case se:return x=ts(x,S.mode,I),x.return=S,x;case C:var F=x._init;return x=F(x._payload),K(S,x,I)}if(Q(x)||Y(x))return x=ha(x,S.mode,I,null),x.return=S,x;if(typeof x.then=="function")return K(S,Ho(x),I);if(x.$$typeof===U)return K(S,Do(S,x),I);Ko(S,x)}return null}function R(S,x,I,F){var ce=x!==null?x.key:null;if(typeof I=="string"&&I!==""||typeof I=="number"||typeof I=="bigint")return ce!==null?null:f(S,x,""+I,F);if(typeof I=="object"&&I!==null){switch(I.$$typeof){case W:return I.key===ce?b(S,x,I,F):null;case se:return I.key===ce?j(S,x,I,F):null;case C:return ce=I._init,I=ce(I._payload),R(S,x,I,F)}if(Q(I)||Y(I))return ce!==null?null:B(S,x,I,F,null);if(typeof I.then=="function")return R(S,x,Ho(I),F);if(I.$$typeof===U)return R(S,x,Do(S,I),F);Ko(S,I)}return null}function M(S,x,I,F,ce){if(typeof F=="string"&&F!==""||typeof F=="number"||typeof F=="bigint")return S=S.get(I)||null,f(x,S,""+F,ce);if(typeof F=="object"&&F!==null){switch(F.$$typeof){case W:return S=S.get(F.key===null?I:F.key)||null,b(x,S,F,ce);case se:return S=S.get(F.key===null?I:F.key)||null,j(x,S,F,ce);case C:var ve=F._init;return F=ve(F._payload),M(S,x,I,F,ce)}if(Q(F)||Y(F))return S=S.get(I)||null,B(x,S,F,ce,null);if(typeof F.then=="function")return M(S,x,I,Ho(F),ce);if(F.$$typeof===U)return M(S,x,I,Do(x,F),ce);Ko(x,F)}return null}function _e(S,x,I,F){for(var ce=null,ve=null,me=x,fe=x=0,ai=null;me!==null&&fe<I.length;fe++){me.index>fe?(ai=me,me=null):ai=me.sibling;var Ne=R(S,me,I[fe],F);if(Ne===null){me===null&&(me=ai);break}e&&me&&Ne.alternate===null&&i(S,me),x=r(Ne,x,fe),ve===null?ce=Ne:ve.sibling=Ne,ve=Ne,me=ai}if(fe===I.length)return t(S,me),Ie&&ya(S,fe),ce;if(me===null){for(;fe<I.length;fe++)me=K(S,I[fe],F),me!==null&&(x=r(me,x,fe),ve===null?ce=me:ve.sibling=me,ve=me);return Ie&&ya(S,fe),ce}for(me=n(me);fe<I.length;fe++)ai=M(me,S,fe,I[fe],F),ai!==null&&(e&&ai.alternate!==null&&me.delete(ai.key===null?fe:ai.key),x=r(ai,x,fe),ve===null?ce=ai:ve.sibling=ai,ve=ai);return e&&me.forEach(function(ra){return i(S,ra)}),Ie&&ya(S,fe),ce}function ge(S,x,I,F){if(I==null)throw Error(c(151));for(var ce=null,ve=null,me=x,fe=x=0,ai=null,Ne=I.next();me!==null&&!Ne.done;fe++,Ne=I.next()){me.index>fe?(ai=me,me=null):ai=me.sibling;var ra=R(S,me,Ne.value,F);if(ra===null){me===null&&(me=ai);break}e&&me&&ra.alternate===null&&i(S,me),x=r(ra,x,fe),ve===null?ce=ra:ve.sibling=ra,ve=ra,me=ai}if(Ne.done)return t(S,me),Ie&&ya(S,fe),ce;if(me===null){for(;!Ne.done;fe++,Ne=I.next())Ne=K(S,Ne.value,F),Ne!==null&&(x=r(Ne,x,fe),ve===null?ce=Ne:ve.sibling=Ne,ve=Ne);return Ie&&ya(S,fe),ce}for(me=n(me);!Ne.done;fe++,Ne=I.next())Ne=M(me,S,fe,Ne.value,F),Ne!==null&&(e&&Ne.alternate!==null&&me.delete(Ne.key===null?fe:Ne.key),x=r(Ne,x,fe),ve===null?ce=Ne:ve.sibling=Ne,ve=Ne);return e&&me.forEach(function(gf){return i(S,gf)}),Ie&&ya(S,fe),ce}function De(S,x,I,F){if(typeof I=="object"&&I!==null&&I.type===ie&&I.key===null&&(I=I.props.children),typeof I=="object"&&I!==null){switch(I.$$typeof){case W:e:{for(var ce=I.key;x!==null;){if(x.key===ce){if(ce=I.type,ce===ie){if(x.tag===7){t(S,x.sibling),F=o(x,I.props.children),F.return=S,S=F;break e}}else if(x.elementType===ce||typeof ce=="object"&&ce!==null&&ce.$$typeof===C&&Fd(ce)===x.type){t(S,x.sibling),F=o(x,I.props),Un(F,I),F.return=S,S=F;break e}t(S,x);break}else i(S,x);x=x.sibling}I.type===ie?(F=ha(I.props.children,S.mode,F,I.key),F.return=S,S=F):(F=Ao(I.type,I.key,I.props,null,S.mode,F),Un(F,I),F.return=S,S=F)}return u(S);case se:e:{for(ce=I.key;x!==null;){if(x.key===ce)if(x.tag===4&&x.stateNode.containerInfo===I.containerInfo&&x.stateNode.implementation===I.implementation){t(S,x.sibling),F=o(x,I.children||[]),F.return=S,S=F;break e}else{t(S,x);break}else i(S,x);x=x.sibling}F=ts(I,S.mode,F),F.return=S,S=F}return u(S);case C:return ce=I._init,I=ce(I._payload),De(S,x,I,F)}if(Q(I))return _e(S,x,I,F);if(Y(I)){if(ce=Y(I),typeof ce!="function")throw Error(c(150));return I=ce.call(I),ge(S,x,I,F)}if(typeof I.then=="function")return De(S,x,Ho(I),F);if(I.$$typeof===U)return De(S,x,Do(S,I),F);Ko(S,I)}return typeof I=="string"&&I!==""||typeof I=="number"||typeof I=="bigint"?(I=""+I,x!==null&&x.tag===6?(t(S,x.sibling),F=o(x,I),F.return=S,S=F):(t(S,x),F=is(I,S.mode,F),F.return=S,S=F),u(S)):t(S,x)}return function(S,x,I,F){try{Bn=0;var ce=De(S,x,I,F);return Wa=null,ce}catch(me){if(me===Dn||me===To)throw me;var ve=xi(29,me,null,S.mode);return ve.lanes=F,ve.return=S,ve}finally{}}}var Za=Gd(!0),Hd=Gd(!1),Li=A(null),dt=null;function Ht(e){var i=e.alternate;P(We,We.current&1),P(Li,e),dt===null&&(i===null||Xa.current!==null||i.memoizedState!==null)&&(dt=e)}function Kd(e){if(e.tag===22){if(P(We,We.current),P(Li,e),dt===null){var i=e.alternate;i!==null&&i.memoizedState!==null&&(dt=e)}}else Kt()}function Kt(){P(We,We.current),P(Li,Li.current)}function jt(e){J(Li),dt===e&&(dt=null),J(We)}var We=A(0);function Yo(e){for(var i=e;i!==null;){if(i.tag===13){var t=i.memoizedState;if(t!==null&&(t=t.dehydrated,t===null||t.data==="$?"||Sl(t)))return i}else if(i.tag===19&&i.memoizedProps.revealOrder!==void 0){if((i.flags&128)!==0)return i}else if(i.child!==null){i.child.return=i,i=i.child;continue}if(i===e)break;for(;i.sibling===null;){if(i.return===null||i.return===e)return null;i=i.return}i.sibling.return=i.return,i=i.sibling}return null}function Es(e,i,t,n){i=e.memoizedState,t=t(n,i),t=t==null?i:D({},i,t),e.memoizedState=t,e.lanes===0&&(e.updateQueue.baseState=t)}var Ps={enqueueSetState:function(e,i,t){e=e._reactInternals;var n=Ii(),o=Ut(n);o.payload=i,t!=null&&(o.callback=t),i=Ft(e,o,n),i!==null&&(ji(i,e,n),Tn(i,e,n))},enqueueReplaceState:function(e,i,t){e=e._reactInternals;var n=Ii(),o=Ut(n);o.tag=1,o.payload=i,t!=null&&(o.callback=t),i=Ft(e,o,n),i!==null&&(ji(i,e,n),Tn(i,e,n))},enqueueForceUpdate:function(e,i){e=e._reactInternals;var t=Ii(),n=Ut(t);n.tag=2,i!=null&&(n.callback=i),i=Ft(e,n,t),i!==null&&(ji(i,e,t),Tn(i,e,t))}};function Yd(e,i,t,n,o,r,u){return e=e.stateNode,typeof e.shouldComponentUpdate=="function"?e.shouldComponentUpdate(n,r,u):i.prototype&&i.prototype.isPureReactComponent?!Sn(t,n)||!Sn(o,r):!0}function Xd(e,i,t,n){e=i.state,typeof i.componentWillReceiveProps=="function"&&i.componentWillReceiveProps(t,n),typeof i.UNSAFE_componentWillReceiveProps=="function"&&i.UNSAFE_componentWillReceiveProps(t,n),i.state!==e&&Ps.enqueueReplaceState(i,i.state,null)}function Ia(e,i){var t=i;if("ref"in i){t={};for(var n in i)n!=="ref"&&(t[n]=i[n])}if(e=e.defaultProps){t===i&&(t=D({},t));for(var o in e)t[o]===void 0&&(t[o]=e[o])}return t}var Xo=typeof reportError=="function"?reportError:function(e){if(typeof window=="object"&&typeof window.ErrorEvent=="function"){var i=new window.ErrorEvent("error",{bubbles:!0,cancelable:!0,message:typeof e=="object"&&e!==null&&typeof e.message=="string"?String(e.message):String(e),error:e});if(!window.dispatchEvent(i))return}else if(typeof process=="object"&&typeof process.emit=="function"){process.emit("uncaughtException",e);return}console.error(e)};function $d(e){Xo(e)}function Jd(e){console.error(e)}function Qd(e){Xo(e)}function $o(e,i){try{var t=e.onUncaughtError;t(i.value,{componentStack:i.stack})}catch(n){setTimeout(function(){throw n})}}function Wd(e,i,t){try{var n=e.onCaughtError;n(t.value,{componentStack:t.stack,errorBoundary:i.tag===1?i.stateNode:null})}catch(o){setTimeout(function(){throw o})}}function Ls(e,i,t){return t=Ut(t),t.tag=3,t.payload={element:null},t.callback=function(){$o(e,i)},t}function Zd(e){return e=Ut(e),e.tag=3,e}function em(e,i,t,n){var o=t.type.getDerivedStateFromError;if(typeof o=="function"){var r=n.value;e.payload=function(){return o(r)},e.callback=function(){Wd(i,t,n)}}var u=t.stateNode;u!==null&&typeof u.componentDidCatch=="function"&&(e.callback=function(){Wd(i,t,n),typeof o!="function"&&(Wt===null?Wt=new Set([this]):Wt.add(this));var f=n.stack;this.componentDidCatch(n.value,{componentStack:f!==null?f:""})})}function pg(e,i,t,n,o){if(t.flags|=32768,n!==null&&typeof n=="object"&&typeof n.then=="function"){if(i=t.alternate,i!==null&&wn(i,t,o,!0),t=Li.current,t!==null){switch(t.tag){case 13:return dt===null?sl():t.alternate===null&&Be===0&&(Be=3),t.flags&=-257,t.flags|=65536,t.lanes=o,n===us?t.flags|=16384:(i=t.updateQueue,i===null?t.updateQueue=new Set([n]):i.add(n),cl(e,n,o)),!1;case 22:return t.flags|=65536,n===us?t.flags|=16384:(i=t.updateQueue,i===null?(i={transitions:null,markerInstances:null,retryQueue:new Set([n])},t.updateQueue=i):(t=i.retryQueue,t===null?i.retryQueue=new Set([n]):t.add(n)),cl(e,n,o)),!1}throw Error(c(435,t.tag))}return cl(e,n,o),sl(),!1}if(Ie)return i=Li.current,i!==null?((i.flags&65536)===0&&(i.flags|=256),i.flags|=65536,i.lanes=o,n!==os&&(e=Error(c(422),{cause:n}),An(qi(e,t)))):(n!==os&&(i=Error(c(423),{cause:n}),An(qi(i,t))),e=e.current.alternate,e.flags|=65536,o&=-o,e.lanes|=o,n=qi(n,t),o=Ls(e.stateNode,n,o),fs(e,o),Be!==4&&(Be=2)),!1;var r=Error(c(520),{cause:n});if(r=qi(r,t),$n===null?$n=[r]:$n.push(r),Be!==4&&(Be=2),i===null)return!0;n=qi(n,t),t=i;do{switch(t.tag){case 3:return t.flags|=65536,e=o&-o,t.lanes|=e,e=Ls(t.stateNode,n,e),fs(t,e),!1;case 1:if(i=t.type,r=t.stateNode,(t.flags&128)===0&&(typeof i.getDerivedStateFromError=="function"||r!==null&&typeof r.componentDidCatch=="function"&&(Wt===null||!Wt.has(r))))return t.flags|=65536,o&=-o,t.lanes|=o,o=Zd(o),em(o,e,t,n),fs(t,o),!1}t=t.return}while(t!==null);return!1}var im=Error(c(461)),ii=!1;function oi(e,i,t,n){i.child=e===null?Hd(i,null,t,n):Za(i,e.child,t,n)}function tm(e,i,t,n,o){t=t.render;var r=i.ref;if("ref"in n){var u={};for(var f in n)f!=="ref"&&(u[f]=n[f])}else u=n;return Ca(i),n=vs(e,i,t,u,r,o),f=ks(),e!==null&&!ii?(xs(e,i,o),At(e,i,o)):(Ie&&f&&as(i),i.flags|=1,oi(e,i,n,o),i.child)}function am(e,i,t,n,o){if(e===null){var r=t.type;return typeof r=="function"&&!es(r)&&r.defaultProps===void 0&&t.compare===null?(i.tag=15,i.type=r,nm(e,i,r,n,o)):(e=Ao(t.type,null,n,i,i.mode,o),e.ref=i.ref,e.return=i,i.child=e)}if(r=e.child,!Hs(e,o)){var u=r.memoizedProps;if(t=t.compare,t=t!==null?t:Sn,t(u,n)&&e.ref===i.ref)return At(e,i,o)}return i.flags|=1,e=kt(r,n),e.ref=i.ref,e.return=i,i.child=e}function nm(e,i,t,n,o){if(e!==null){var r=e.memoizedProps;if(Sn(r,n)&&e.ref===i.ref)if(ii=!1,i.pendingProps=n=r,Hs(e,o))(e.flags&131072)!==0&&(ii=!0);else return i.lanes=e.lanes,At(e,i,o)}return zs(e,i,t,n,o)}function om(e,i,t){var n=i.pendingProps,o=n.children,r=e!==null?e.memoizedState:null;if(n.mode==="hidden"){if((i.flags&128)!==0){if(n=r!==null?r.baseLanes|t:t,e!==null){for(o=i.child=e.child,r=0;o!==null;)r=r|o.lanes|o.childLanes,o=o.sibling;i.childLanes=r&~n}else i.childLanes=0,i.child=null;return rm(e,i,n,t)}if((t&536870912)!==0)i.memoizedState={baseLanes:0,cachePool:null},e!==null&&qo(i,r!==null?r.cachePool:null),r!==null?nd(i,r):hs(),Kd(i);else return i.lanes=i.childLanes=536870912,rm(e,i,r!==null?r.baseLanes|t:t,t)}else r!==null?(qo(i,r.cachePool),nd(i,r),Kt(),i.memoizedState=null):(e!==null&&qo(i,null),hs(),Kt());return oi(e,i,o,t),i.child}function rm(e,i,t,n){var o=ms();return o=o===null?null:{parent:Qe._currentValue,pool:o},i.memoizedState={baseLanes:t,cachePool:o},e!==null&&qo(i,null),hs(),Kd(i),e!==null&&wn(e,i,n,!0),null}function Jo(e,i){var t=i.ref;if(t===null)e!==null&&e.ref!==null&&(i.flags|=4194816);else{if(typeof t!="function"&&typeof t!="object")throw Error(c(284));(e===null||e.ref!==t)&&(i.flags|=4194816)}}function zs(e,i,t,n,o){return Ca(i),t=vs(e,i,t,n,void 0,o),n=ks(),e!==null&&!ii?(xs(e,i,o),At(e,i,o)):(Ie&&n&&as(i),i.flags|=1,oi(e,i,t,o),i.child)}function sm(e,i,t,n,o,r){return Ca(i),i.updateQueue=null,t=rd(i,n,t,o),od(e),n=ks(),e!==null&&!ii?(xs(e,i,r),At(e,i,r)):(Ie&&n&&as(i),i.flags|=1,oi(e,i,t,r),i.child)}function lm(e,i,t,n,o){if(Ca(i),i.stateNode===null){var r=Fa,u=t.contextType;typeof u=="object"&&u!==null&&(r=ci(u)),r=new t(n,r),i.memoizedState=r.state!==null&&r.state!==void 0?r.state:null,r.updater=Ps,i.stateNode=r,r._reactInternals=i,r=i.stateNode,r.props=n,r.state=i.memoizedState,r.refs={},ps(i),u=t.contextType,r.context=typeof u=="object"&&u!==null?ci(u):Fa,r.state=i.memoizedState,u=t.getDerivedStateFromProps,typeof u=="function"&&(Es(i,t,u,n),r.state=i.memoizedState),typeof t.getDerivedStateFromProps=="function"||typeof r.getSnapshotBeforeUpdate=="function"||typeof r.UNSAFE_componentWillMount!="function"&&typeof r.componentWillMount!="function"||(u=r.state,typeof r.componentWillMount=="function"&&r.componentWillMount(),typeof r.UNSAFE_componentWillMount=="function"&&r.UNSAFE_componentWillMount(),u!==r.state&&Ps.enqueueReplaceState(r,r.state,null),Pn(i,n,r,o),En(),r.state=i.memoizedState),typeof r.componentDidMount=="function"&&(i.flags|=4194308),n=!0}else if(e===null){r=i.stateNode;var f=i.memoizedProps,b=Ia(t,f);r.props=b;var j=r.context,B=t.contextType;u=Fa,typeof B=="object"&&B!==null&&(u=ci(B));var K=t.getDerivedStateFromProps;B=typeof K=="function"||typeof r.getSnapshotBeforeUpdate=="function",f=i.pendingProps!==f,B||typeof r.UNSAFE_componentWillReceiveProps!="function"&&typeof r.componentWillReceiveProps!="function"||(f||j!==u)&&Xd(i,r,n,u),Bt=!1;var R=i.memoizedState;r.state=R,Pn(i,n,r,o),En(),j=i.memoizedState,f||R!==j||Bt?(typeof K=="function"&&(Es(i,t,K,n),j=i.memoizedState),(b=Bt||Yd(i,t,b,n,R,j,u))?(B||typeof r.UNSAFE_componentWillMount!="function"&&typeof r.componentWillMount!="function"||(typeof r.componentWillMount=="function"&&r.componentWillMount(),typeof r.UNSAFE_componentWillMount=="function"&&r.UNSAFE_componentWillMount()),typeof r.componentDidMount=="function"&&(i.flags|=4194308)):(typeof r.componentDidMount=="function"&&(i.flags|=4194308),i.memoizedProps=n,i.memoizedState=j),r.props=n,r.state=j,r.context=u,n=b):(typeof r.componentDidMount=="function"&&(i.flags|=4194308),n=!1)}else{r=i.stateNode,gs(e,i),u=i.memoizedProps,B=Ia(t,u),r.props=B,K=i.pendingProps,R=r.context,j=t.contextType,b=Fa,typeof j=="object"&&j!==null&&(b=ci(j)),f=t.getDerivedStateFromProps,(j=typeof f=="function"||typeof r.getSnapshotBeforeUpdate=="function")||typeof r.UNSAFE_componentWillReceiveProps!="function"&&typeof r.componentWillReceiveProps!="function"||(u!==K||R!==b)&&Xd(i,r,n,b),Bt=!1,R=i.memoizedState,r.state=R,Pn(i,n,r,o),En();var M=i.memoizedState;u!==K||R!==M||Bt||e!==null&&e.dependencies!==null&&Mo(e.dependencies)?(typeof f=="function"&&(Es(i,t,f,n),M=i.memoizedState),(B=Bt||Yd(i,t,B,n,R,M,b)||e!==null&&e.dependencies!==null&&Mo(e.dependencies))?(j||typeof r.UNSAFE_componentWillUpdate!="function"&&typeof r.componentWillUpdate!="function"||(typeof r.componentWillUpdate=="function"&&r.componentWillUpdate(n,M,b),typeof r.UNSAFE_componentWillUpdate=="function"&&r.UNSAFE_componentWillUpdate(n,M,b)),typeof r.componentDidUpdate=="function"&&(i.flags|=4),typeof r.getSnapshotBeforeUpdate=="function"&&(i.flags|=1024)):(typeof r.componentDidUpdate!="function"||u===e.memoizedProps&&R===e.memoizedState||(i.flags|=4),typeof r.getSnapshotBeforeUpdate!="function"||u===e.memoizedProps&&R===e.memoizedState||(i.flags|=1024),i.memoizedProps=n,i.memoizedState=M),r.props=n,r.state=M,r.context=b,n=B):(typeof r.componentDidUpdate!="function"||u===e.memoizedProps&&R===e.memoizedState||(i.flags|=4),typeof r.getSnapshotBeforeUpdate!="function"||u===e.memoizedProps&&R===e.memoizedState||(i.flags|=1024),n=!1)}return r=n,Jo(e,i),n=(i.flags&128)!==0,r||n?(r=i.stateNode,t=n&&typeof t.getDerivedStateFromError!="function"?null:r.render(),i.flags|=1,e!==null&&n?(i.child=Za(i,e.child,null,o),i.child=Za(i,null,t,o)):oi(e,i,t,o),i.memoizedState=r.state,e=i.child):e=At(e,i,o),e}function cm(e,i,t,n){return jn(),i.flags|=256,oi(e,i,t,n),i.child}var Vs={dehydrated:null,treeContext:null,retryLane:0,hydrationErrors:null};function Os(e){return{baseLanes:e,cachePool:Jc()}}function Bs(e,i,t){return e=e!==null?e.childLanes&~t:0,i&&(e|=zi),e}function dm(e,i,t){var n=i.pendingProps,o=!1,r=(i.flags&128)!==0,u;if((u=r)||(u=e!==null&&e.memoizedState===null?!1:(We.current&2)!==0),u&&(o=!0,i.flags&=-129),u=(i.flags&32)!==0,i.flags&=-33,e===null){if(Ie){if(o?Ht(i):Kt(),Ie){var f=Oe,b;if(b=f){e:{for(b=f,f=ct;b.nodeType!==8;){if(!f){f=null;break e}if(b=Yi(b.nextSibling),b===null){f=null;break e}}f=b}f!==null?(i.memoizedState={dehydrated:f,treeContext:ba!==null?{id:xt,overflow:Ct}:null,retryLane:536870912,hydrationErrors:null},b=xi(18,null,null,0),b.stateNode=f,b.return=i,i.child=b,ui=i,Oe=null,b=!0):b=!1}b||ka(i)}if(f=i.memoizedState,f!==null&&(f=f.dehydrated,f!==null))return Sl(f)?i.lanes=32:i.lanes=536870912,null;jt(i)}return f=n.children,n=n.fallback,o?(Kt(),o=i.mode,f=Qo({mode:"hidden",children:f},o),n=ha(n,o,t,null),f.return=i,n.return=i,f.sibling=n,i.child=f,o=i.child,o.memoizedState=Os(t),o.childLanes=Bs(e,u,t),i.memoizedState=Vs,n):(Ht(i),Us(i,f))}if(b=e.memoizedState,b!==null&&(f=b.dehydrated,f!==null)){if(r)i.flags&256?(Ht(i),i.flags&=-257,i=Fs(e,i,t)):i.memoizedState!==null?(Kt(),i.child=e.child,i.flags|=128,i=null):(Kt(),o=n.fallback,f=i.mode,n=Qo({mode:"visible",children:n.children},f),o=ha(o,f,t,null),o.flags|=2,n.return=i,o.return=i,n.sibling=o,i.child=n,Za(i,e.child,null,t),n=i.child,n.memoizedState=Os(t),n.childLanes=Bs(e,u,t),i.memoizedState=Vs,i=o);else if(Ht(i),Sl(f)){if(u=f.nextSibling&&f.nextSibling.dataset,u)var j=u.dgst;u=j,n=Error(c(419)),n.stack="",n.digest=u,An({value:n,source:null,stack:null}),i=Fs(e,i,t)}else if(ii||wn(e,i,t,!1),u=(t&e.childLanes)!==0,ii||u){if(u=Ee,u!==null&&(n=t&-t,n=(n&42)!==0?1:rt(n),n=(n&(u.suspendedLanes|t))!==0?0:n,n!==0&&n!==b.retryLane))throw b.retryLane=n,Ua(e,n),ji(u,e,n),im;f.data==="$?"||sl(),i=Fs(e,i,t)}else f.data==="$?"?(i.flags|=192,i.child=e.child,i=null):(e=b.treeContext,Oe=Yi(f.nextSibling),ui=i,Ie=!0,va=null,ct=!1,e!==null&&(Ei[Pi++]=xt,Ei[Pi++]=Ct,Ei[Pi++]=ba,xt=e.id,Ct=e.overflow,ba=i),i=Us(i,n.children),i.flags|=4096);return i}return o?(Kt(),o=n.fallback,f=i.mode,b=e.child,j=b.sibling,n=kt(b,{mode:"hidden",children:n.children}),n.subtreeFlags=b.subtreeFlags&65011712,j!==null?o=kt(j,o):(o=ha(o,f,t,null),o.flags|=2),o.return=i,n.return=i,n.sibling=o,i.child=n,n=o,o=i.child,f=e.child.memoizedState,f===null?f=Os(t):(b=f.cachePool,b!==null?(j=Qe._currentValue,b=b.parent!==j?{parent:j,pool:j}:b):b=Jc(),f={baseLanes:f.baseLanes|t,cachePool:b}),o.memoizedState=f,o.childLanes=Bs(e,u,t),i.memoizedState=Vs,n):(Ht(i),t=e.child,e=t.sibling,t=kt(t,{mode:"visible",children:n.children}),t.return=i,t.sibling=null,e!==null&&(u=i.deletions,u===null?(i.deletions=[e],i.flags|=16):u.push(e)),i.child=t,i.memoizedState=null,t)}function Us(e,i){return i=Qo({mode:"visible",children:i},e.mode),i.return=e,e.child=i}function Qo(e,i){return e=xi(22,e,null,i),e.lanes=0,e.stateNode={_visibility:1,_pendingMarkers:null,_retryCache:null,_transitions:null},e}function Fs(e,i,t){return Za(i,e.child,null,t),e=Us(i,i.pendingProps.children),e.flags|=2,i.memoizedState=null,e}function mm(e,i,t){e.lanes|=i;var n=e.alternate;n!==null&&(n.lanes|=i),ss(e.return,i,t)}function Gs(e,i,t,n,o){var r=e.memoizedState;r===null?e.memoizedState={isBackwards:i,rendering:null,renderingStartTime:0,last:n,tail:t,tailMode:o}:(r.isBackwards=i,r.rendering=null,r.renderingStartTime=0,r.last=n,r.tail=t,r.tailMode=o)}function um(e,i,t){var n=i.pendingProps,o=n.revealOrder,r=n.tail;if(oi(e,i,n.children,t),n=We.current,(n&2)!==0)n=n&1|2,i.flags|=128;else{if(e!==null&&(e.flags&128)!==0)e:for(e=i.child;e!==null;){if(e.tag===13)e.memoizedState!==null&&mm(e,t,i);else if(e.tag===19)mm(e,t,i);else if(e.child!==null){e.child.return=e,e=e.child;continue}if(e===i)break e;for(;e.sibling===null;){if(e.return===null||e.return===i)break e;e=e.return}e.sibling.return=e.return,e=e.sibling}n&=1}switch(P(We,n),o){case"forwards":for(t=i.child,o=null;t!==null;)e=t.alternate,e!==null&&Yo(e)===null&&(o=t),t=t.sibling;t=o,t===null?(o=i.child,i.child=null):(o=t.sibling,t.sibling=null),Gs(i,!1,o,t,r);break;case"backwards":for(t=null,o=i.child,i.child=null;o!==null;){if(e=o.alternate,e!==null&&Yo(e)===null){i.child=o;break}e=o.sibling,o.sibling=t,t=o,o=e}Gs(i,!0,t,null,r);break;case"together":Gs(i,!1,null,null,void 0);break;default:i.memoizedState=null}return i.child}function At(e,i,t){if(e!==null&&(i.dependencies=e.dependencies),Qt|=i.lanes,(t&i.childLanes)===0)if(e!==null){if(wn(e,i,t,!1),(t&i.childLanes)===0)return null}else return null;if(e!==null&&i.child!==e.child)throw Error(c(153));if(i.child!==null){for(e=i.child,t=kt(e,e.pendingProps),i.child=t,t.return=i;e.sibling!==null;)e=e.sibling,t=t.sibling=kt(e,e.pendingProps),t.return=i;t.sibling=null}return i.child}function Hs(e,i){return(e.lanes&i)!==0?!0:(e=e.dependencies,!!(e!==null&&Mo(e)))}function gg(e,i,t){switch(i.tag){case 3:he(i,i.stateNode.containerInfo),Ot(i,Qe,e.memoizedState.cache),jn();break;case 27:case 5:li(i);break;case 4:he(i,i.stateNode.containerInfo);break;case 10:Ot(i,i.type,i.memoizedProps.value);break;case 13:var n=i.memoizedState;if(n!==null)return n.dehydrated!==null?(Ht(i),i.flags|=128,null):(t&i.child.childLanes)!==0?dm(e,i,t):(Ht(i),e=At(e,i,t),e!==null?e.sibling:null);Ht(i);break;case 19:var o=(e.flags&128)!==0;if(n=(t&i.childLanes)!==0,n||(wn(e,i,t,!1),n=(t&i.childLanes)!==0),o){if(n)return um(e,i,t);i.flags|=128}if(o=i.memoizedState,o!==null&&(o.rendering=null,o.tail=null,o.lastEffect=null),P(We,We.current),n)break;return null;case 22:case 23:return i.lanes=0,om(e,i,t);case 24:Ot(i,Qe,e.memoizedState.cache)}return At(e,i,t)}function pm(e,i,t){if(e!==null)if(e.memoizedProps!==i.pendingProps)ii=!0;else{if(!Hs(e,t)&&(i.flags&128)===0)return ii=!1,gg(e,i,t);ii=(e.flags&131072)!==0}else ii=!1,Ie&&(i.flags&1048576)!==0&&Fc(i,Ro,i.index);switch(i.lanes=0,i.tag){case 16:e:{e=i.pendingProps;var n=i.elementType,o=n._init;if(n=o(n._payload),i.type=n,typeof n=="function")es(n)?(e=Ia(n,e),i.tag=1,i=lm(null,i,n,e,t)):(i.tag=0,i=zs(null,i,n,e,t));else{if(n!=null){if(o=n.$$typeof,o===Z){i.tag=11,i=tm(null,i,n,e,t);break e}else if(o===q){i.tag=14,i=am(null,i,n,e,t);break e}}throw i=le(n)||n,Error(c(306,i,""))}}return i;case 0:return zs(e,i,i.type,i.pendingProps,t);case 1:return n=i.type,o=Ia(n,i.pendingProps),lm(e,i,n,o,t);case 3:e:{if(he(i,i.stateNode.containerInfo),e===null)throw Error(c(387));n=i.pendingProps;var r=i.memoizedState;o=r.element,gs(e,i),Pn(i,n,null,t);var u=i.memoizedState;if(n=u.cache,Ot(i,Qe,n),n!==r.cache&&ls(i,[Qe],t,!0),En(),n=u.element,r.isDehydrated)if(r={element:n,isDehydrated:!1,cache:u.cache},i.updateQueue.baseState=r,i.memoizedState=r,i.flags&256){i=cm(e,i,n,t);break e}else if(n!==o){o=qi(Error(c(424)),i),An(o),i=cm(e,i,n,t);break e}else{switch(e=i.stateNode.containerInfo,e.nodeType){case 9:e=e.body;break;default:e=e.nodeName==="HTML"?e.ownerDocument.body:e}for(Oe=Yi(e.firstChild),ui=i,Ie=!0,va=null,ct=!0,t=Hd(i,null,n,t),i.child=t;t;)t.flags=t.flags&-3|4096,t=t.sibling}else{if(jn(),n===o){i=At(e,i,t);break e}oi(e,i,n,t)}i=i.child}return i;case 26:return Jo(e,i),e===null?(t=hu(i.type,null,i.pendingProps,null))?i.memoizedState=t:Ie||(t=i.type,e=i.pendingProps,n=mr(re.current).createElement(t),n[pe]=i,n[Ue]=e,si(n,t,e),ei(n),i.stateNode=n):i.memoizedState=hu(i.type,e.memoizedProps,i.pendingProps,e.memoizedState),null;case 27:return li(i),e===null&&Ie&&(n=i.stateNode=gu(i.type,i.pendingProps,re.current),ui=i,ct=!0,o=Oe,ia(i.type)?(Nl=o,Oe=Yi(n.firstChild)):Oe=o),oi(e,i,i.pendingProps.children,t),Jo(e,i),e===null&&(i.flags|=4194304),i.child;case 5:return e===null&&Ie&&((o=n=Oe)&&(n=Ug(n,i.type,i.pendingProps,ct),n!==null?(i.stateNode=n,ui=i,Oe=Yi(n.firstChild),ct=!1,o=!0):o=!1),o||ka(i)),li(i),o=i.type,r=i.pendingProps,u=e!==null?e.memoizedProps:null,n=r.children,kl(o,r)?n=null:u!==null&&kl(o,u)&&(i.flags|=32),i.memoizedState!==null&&(o=vs(e,i,rg,null,null,t),no._currentValue=o),Jo(e,i),oi(e,i,n,t),i.child;case 6:return e===null&&Ie&&((e=t=Oe)&&(t=Fg(t,i.pendingProps,ct),t!==null?(i.stateNode=t,ui=i,Oe=null,e=!0):e=!1),e||ka(i)),null;case 13:return dm(e,i,t);case 4:return he(i,i.stateNode.containerInfo),n=i.pendingProps,e===null?i.child=Za(i,null,n,t):oi(e,i,n,t),i.child;case 11:return tm(e,i,i.type,i.pendingProps,t);case 7:return oi(e,i,i.pendingProps,t),i.child;case 8:return oi(e,i,i.pendingProps.children,t),i.child;case 12:return oi(e,i,i.pendingProps.children,t),i.child;case 10:return n=i.pendingProps,Ot(i,i.type,n.value),oi(e,i,n.children,t),i.child;case 9:return o=i.type._context,n=i.pendingProps.children,Ca(i),o=ci(o),n=n(o),i.flags|=1,oi(e,i,n,t),i.child;case 14:return am(e,i,i.type,i.pendingProps,t);case 15:return nm(e,i,i.type,i.pendingProps,t);case 19:return um(e,i,t);case 31:return n=i.pendingProps,t=i.mode,n={mode:n.mode,children:n.children},e===null?(t=Qo(n,t),t.ref=i.ref,i.child=t,t.return=i,i=t):(t=kt(e.child,n),t.ref=i.ref,i.child=t,t.return=i,i=t),i;case 22:return om(e,i,t);case 24:return Ca(i),n=ci(Qe),e===null?(o=ms(),o===null&&(o=Ee,r=cs(),o.pooledCache=r,r.refCount++,r!==null&&(o.pooledCacheLanes|=t),o=r),i.memoizedState={parent:n,cache:o},ps(i),Ot(i,Qe,o)):((e.lanes&t)!==0&&(gs(e,i),Pn(i,null,null,t),En()),o=e.memoizedState,r=i.memoizedState,o.parent!==n?(o={parent:n,cache:n},i.memoizedState=o,i.lanes===0&&(i.memoizedState=i.updateQueue.baseState=o),Ot(i,Qe,n)):(n=r.cache,Ot(i,Qe,n),n!==o.cache&&ls(i,[Qe],t,!0))),oi(e,i,i.pendingProps.children,t),i.child;case 29:throw i.pendingProps}throw Error(c(156,i.tag))}function wt(e){e.flags|=4}function gm(e,i){if(i.type!=="stylesheet"||(i.state.loading&4)!==0)e.flags&=-16777217;else if(e.flags|=16777216,!xu(i)){if(i=Li.current,i!==null&&((Se&4194048)===Se?dt!==null:(Se&62914560)!==Se&&(Se&536870912)===0||i!==dt))throw qn=us,Qc;e.flags|=8192}}function Wo(e,i){i!==null&&(e.flags|=4),e.flags&16384&&(i=e.tag!==22?Ze():536870912,e.lanes|=i,nn|=i)}function Fn(e,i){if(!Ie)switch(e.tailMode){case"hidden":i=e.tail;for(var t=null;i!==null;)i.alternate!==null&&(t=i),i=i.sibling;t===null?e.tail=null:t.sibling=null;break;case"collapsed":t=e.tail;for(var n=null;t!==null;)t.alternate!==null&&(n=t),t=t.sibling;n===null?i||e.tail===null?e.tail=null:e.tail.sibling=null:n.sibling=null}}function Le(e){var i=e.alternate!==null&&e.alternate.child===e.child,t=0,n=0;if(i)for(var o=e.child;o!==null;)t|=o.lanes|o.childLanes,n|=o.subtreeFlags&65011712,n|=o.flags&65011712,o.return=e,o=o.sibling;else for(o=e.child;o!==null;)t|=o.lanes|o.childLanes,n|=o.subtreeFlags,n|=o.flags,o.return=e,o=o.sibling;return e.subtreeFlags|=n,e.childLanes=t,i}function fg(e,i,t){var n=i.pendingProps;switch(ns(i),i.tag){case 31:case 16:case 15:case 0:case 11:case 7:case 8:case 12:case 9:case 14:return Le(i),null;case 1:return Le(i),null;case 3:return t=i.stateNode,n=null,e!==null&&(n=e.memoizedState.cache),i.memoizedState.cache!==n&&(i.flags|=2048),Nt(Qe),Te(),t.pendingContext&&(t.context=t.pendingContext,t.pendingContext=null),(e===null||e.child===null)&&(In(i)?wt(i):e===null||e.memoizedState.isDehydrated&&(i.flags&256)===0||(i.flags|=1024,Kc())),Le(i),null;case 26:return t=i.memoizedState,e===null?(wt(i),t!==null?(Le(i),gm(i,t)):(Le(i),i.flags&=-16777217)):t?t!==e.memoizedState?(wt(i),Le(i),gm(i,t)):(Le(i),i.flags&=-16777217):(e.memoizedProps!==n&&wt(i),Le(i),i.flags&=-16777217),null;case 27:mi(i),t=re.current;var o=i.type;if(e!==null&&i.stateNode!=null)e.memoizedProps!==n&&wt(i);else{if(!n){if(i.stateNode===null)throw Error(c(166));return Le(i),null}e=V.current,In(i)?Gc(i):(e=gu(o,n,t),i.stateNode=e,wt(i))}return Le(i),null;case 5:if(mi(i),t=i.type,e!==null&&i.stateNode!=null)e.memoizedProps!==n&&wt(i);else{if(!n){if(i.stateNode===null)throw Error(c(166));return Le(i),null}if(e=V.current,In(i))Gc(i);else{switch(o=mr(re.current),e){case 1:e=o.createElementNS("http://www.w3.org/2000/svg",t);break;case 2:e=o.createElementNS("http://www.w3.org/1998/Math/MathML",t);break;default:switch(t){case"svg":e=o.createElementNS("http://www.w3.org/2000/svg",t);break;case"math":e=o.createElementNS("http://www.w3.org/1998/Math/MathML",t);break;case"script":e=o.createElement("div"),e.innerHTML="<script><\/script>",e=e.removeChild(e.firstChild);break;case"select":e=typeof n.is=="string"?o.createElement("select",{is:n.is}):o.createElement("select"),n.multiple?e.multiple=!0:n.size&&(e.size=n.size);break;default:e=typeof n.is=="string"?o.createElement(t,{is:n.is}):o.createElement(t)}}e[pe]=i,e[Ue]=n;e:for(o=i.child;o!==null;){if(o.tag===5||o.tag===6)e.appendChild(o.stateNode);else if(o.tag!==4&&o.tag!==27&&o.child!==null){o.child.return=o,o=o.child;continue}if(o===i)break e;for(;o.sibling===null;){if(o.return===null||o.return===i)break e;o=o.return}o.sibling.return=o.return,o=o.sibling}i.stateNode=e;e:switch(si(e,t,n),t){case"button":case"input":case"select":case"textarea":e=!!n.autoFocus;break e;case"img":e=!0;break e;default:e=!1}e&&wt(i)}}return Le(i),i.flags&=-16777217,null;case 6:if(e&&i.stateNode!=null)e.memoizedProps!==n&&wt(i);else{if(typeof n!="string"&&i.stateNode===null)throw Error(c(166));if(e=re.current,In(i)){if(e=i.stateNode,t=i.memoizedProps,n=null,o=ui,o!==null)switch(o.tag){case 27:case 5:n=o.memoizedProps}e[pe]=i,e=!!(e.nodeValue===t||n!==null&&n.suppressHydrationWarning===!0||su(e.nodeValue,t)),e||ka(i)}else e=mr(e).createTextNode(n),e[pe]=i,i.stateNode=e}return Le(i),null;case 13:if(n=i.memoizedState,e===null||e.memoizedState!==null&&e.memoizedState.dehydrated!==null){if(o=In(i),n!==null&&n.dehydrated!==null){if(e===null){if(!o)throw Error(c(318));if(o=i.memoizedState,o=o!==null?o.dehydrated:null,!o)throw Error(c(317));o[pe]=i}else jn(),(i.flags&128)===0&&(i.memoizedState=null),i.flags|=4;Le(i),o=!1}else o=Kc(),e!==null&&e.memoizedState!==null&&(e.memoizedState.hydrationErrors=o),o=!0;if(!o)return i.flags&256?(jt(i),i):(jt(i),null)}if(jt(i),(i.flags&128)!==0)return i.lanes=t,i;if(t=n!==null,e=e!==null&&e.memoizedState!==null,t){n=i.child,o=null,n.alternate!==null&&n.alternate.memoizedState!==null&&n.alternate.memoizedState.cachePool!==null&&(o=n.alternate.memoizedState.cachePool.pool);var r=null;n.memoizedState!==null&&n.memoizedState.cachePool!==null&&(r=n.memoizedState.cachePool.pool),r!==o&&(n.flags|=2048)}return t!==e&&t&&(i.child.flags|=8192),Wo(i,i.updateQueue),Le(i),null;case 4:return Te(),e===null&&_l(i.stateNode.containerInfo),Le(i),null;case 10:return Nt(i.type),Le(i),null;case 19:if(J(We),o=i.memoizedState,o===null)return Le(i),null;if(n=(i.flags&128)!==0,r=o.rendering,r===null)if(n)Fn(o,!1);else{if(Be!==0||e!==null&&(e.flags&128)!==0)for(e=i.child;e!==null;){if(r=Yo(e),r!==null){for(i.flags|=128,Fn(o,!1),e=r.updateQueue,i.updateQueue=e,Wo(i,e),i.subtreeFlags=0,e=t,t=i.child;t!==null;)Uc(t,e),t=t.sibling;return P(We,We.current&1|2),i.child}e=e.sibling}o.tail!==null&&Xe()>ir&&(i.flags|=128,n=!0,Fn(o,!1),i.lanes=4194304)}else{if(!n)if(e=Yo(r),e!==null){if(i.flags|=128,n=!0,e=e.updateQueue,i.updateQueue=e,Wo(i,e),Fn(o,!0),o.tail===null&&o.tailMode==="hidden"&&!r.alternate&&!Ie)return Le(i),null}else 2*Xe()-o.renderingStartTime>ir&&t!==536870912&&(i.flags|=128,n=!0,Fn(o,!1),i.lanes=4194304);o.isBackwards?(r.sibling=i.child,i.child=r):(e=o.last,e!==null?e.sibling=r:i.child=r,o.last=r)}return o.tail!==null?(i=o.tail,o.rendering=i,o.tail=i.sibling,o.renderingStartTime=Xe(),i.sibling=null,e=We.current,P(We,n?e&1|2:e&1),i):(Le(i),null);case 22:case 23:return jt(i),bs(),n=i.memoizedState!==null,e!==null?e.memoizedState!==null!==n&&(i.flags|=8192):n&&(i.flags|=8192),n?(t&536870912)!==0&&(i.flags&128)===0&&(Le(i),i.subtreeFlags&6&&(i.flags|=8192)):Le(i),t=i.updateQueue,t!==null&&Wo(i,t.retryQueue),t=null,e!==null&&e.memoizedState!==null&&e.memoizedState.cachePool!==null&&(t=e.memoizedState.cachePool.pool),n=null,i.memoizedState!==null&&i.memoizedState.cachePool!==null&&(n=i.memoizedState.cachePool.pool),n!==t&&(i.flags|=2048),e!==null&&J(Sa),null;case 24:return t=null,e!==null&&(t=e.memoizedState.cache),i.memoizedState.cache!==t&&(i.flags|=2048),Nt(Qe),Le(i),null;case 25:return null;case 30:return null}throw Error(c(156,i.tag))}function _g(e,i){switch(ns(i),i.tag){case 1:return e=i.flags,e&65536?(i.flags=e&-65537|128,i):null;case 3:return Nt(Qe),Te(),e=i.flags,(e&65536)!==0&&(e&128)===0?(i.flags=e&-65537|128,i):null;case 26:case 27:case 5:return mi(i),null;case 13:if(jt(i),e=i.memoizedState,e!==null&&e.dehydrated!==null){if(i.alternate===null)throw Error(c(340));jn()}return e=i.flags,e&65536?(i.flags=e&-65537|128,i):null;case 19:return J(We),null;case 4:return Te(),null;case 10:return Nt(i.type),null;case 22:case 23:return jt(i),bs(),e!==null&&J(Sa),e=i.flags,e&65536?(i.flags=e&-65537|128,i):null;case 24:return Nt(Qe),null;case 25:return null;default:return null}}function fm(e,i){switch(ns(i),i.tag){case 3:Nt(Qe),Te();break;case 26:case 27:case 5:mi(i);break;case 4:Te();break;case 13:jt(i);break;case 19:J(We);break;case 10:Nt(i.type);break;case 22:case 23:jt(i),bs(),e!==null&&J(Sa);break;case 24:Nt(Qe)}}function Gn(e,i){try{var t=i.updateQueue,n=t!==null?t.lastEffect:null;if(n!==null){var o=n.next;t=o;do{if((t.tag&e)===e){n=void 0;var r=t.create,u=t.inst;n=r(),u.destroy=n}t=t.next}while(t!==o)}}catch(f){qe(i,i.return,f)}}function Yt(e,i,t){try{var n=i.updateQueue,o=n!==null?n.lastEffect:null;if(o!==null){var r=o.next;n=r;do{if((n.tag&e)===e){var u=n.inst,f=u.destroy;if(f!==void 0){u.destroy=void 0,o=i;var b=t,j=f;try{j()}catch(B){qe(o,b,B)}}}n=n.next}while(n!==r)}}catch(B){qe(i,i.return,B)}}function _m(e){var i=e.updateQueue;if(i!==null){var t=e.stateNode;try{ad(i,t)}catch(n){qe(e,e.return,n)}}}function hm(e,i,t){t.props=Ia(e.type,e.memoizedProps),t.state=e.memoizedState;try{t.componentWillUnmount()}catch(n){qe(e,i,n)}}function Hn(e,i){try{var t=e.ref;if(t!==null){switch(e.tag){case 26:case 27:case 5:var n=e.stateNode;break;case 30:n=e.stateNode;break;default:n=e.stateNode}typeof t=="function"?e.refCleanup=t(n):t.current=n}}catch(o){qe(e,i,o)}}function mt(e,i){var t=e.ref,n=e.refCleanup;if(t!==null)if(typeof n=="function")try{n()}catch(o){qe(e,i,o)}finally{e.refCleanup=null,e=e.alternate,e!=null&&(e.refCleanup=null)}else if(typeof t=="function")try{t(null)}catch(o){qe(e,i,o)}else t.current=null}function bm(e){var i=e.type,t=e.memoizedProps,n=e.stateNode;try{e:switch(i){case"button":case"input":case"select":case"textarea":t.autoFocus&&n.focus();break e;case"img":t.src?n.src=t.src:t.srcSet&&(n.srcset=t.srcSet)}}catch(o){qe(e,e.return,o)}}function Ks(e,i,t){try{var n=e.stateNode;Lg(n,e.type,t,i),n[Ue]=i}catch(o){qe(e,e.return,o)}}function ym(e){return e.tag===5||e.tag===3||e.tag===26||e.tag===27&&ia(e.type)||e.tag===4}function Ys(e){e:for(;;){for(;e.sibling===null;){if(e.return===null||ym(e.return))return null;e=e.return}for(e.sibling.return=e.return,e=e.sibling;e.tag!==5&&e.tag!==6&&e.tag!==18;){if(e.tag===27&&ia(e.type)||e.flags&2||e.child===null||e.tag===4)continue e;e.child.return=e,e=e.child}if(!(e.flags&2))return e.stateNode}}function Xs(e,i,t){var n=e.tag;if(n===5||n===6)e=e.stateNode,i?(t.nodeType===9?t.body:t.nodeName==="HTML"?t.ownerDocument.body:t).insertBefore(e,i):(i=t.nodeType===9?t.body:t.nodeName==="HTML"?t.ownerDocument.body:t,i.appendChild(e),t=t._reactRootContainer,t!=null||i.onclick!==null||(i.onclick=dr));else if(n!==4&&(n===27&&ia(e.type)&&(t=e.stateNode,i=null),e=e.child,e!==null))for(Xs(e,i,t),e=e.sibling;e!==null;)Xs(e,i,t),e=e.sibling}function Zo(e,i,t){var n=e.tag;if(n===5||n===6)e=e.stateNode,i?t.insertBefore(e,i):t.appendChild(e);else if(n!==4&&(n===27&&ia(e.type)&&(t=e.stateNode),e=e.child,e!==null))for(Zo(e,i,t),e=e.sibling;e!==null;)Zo(e,i,t),e=e.sibling}function vm(e){var i=e.stateNode,t=e.memoizedProps;try{for(var n=e.type,o=i.attributes;o.length;)i.removeAttributeNode(o[0]);si(i,n,t),i[pe]=e,i[Ue]=t}catch(r){qe(e,e.return,r)}}var Rt=!1,Ge=!1,$s=!1,km=typeof WeakSet=="function"?WeakSet:Set,ti=null;function hg(e,i){if(e=e.containerInfo,yl=hr,e=Dc(e),Yr(e)){if("selectionStart"in e)var t={start:e.selectionStart,end:e.selectionEnd};else e:{t=(t=e.ownerDocument)&&t.defaultView||window;var n=t.getSelection&&t.getSelection();if(n&&n.rangeCount!==0){t=n.anchorNode;var o=n.anchorOffset,r=n.focusNode;n=n.focusOffset;try{t.nodeType,r.nodeType}catch{t=null;break e}var u=0,f=-1,b=-1,j=0,B=0,K=e,R=null;i:for(;;){for(var M;K!==t||o!==0&&K.nodeType!==3||(f=u+o),K!==r||n!==0&&K.nodeType!==3||(b=u+n),K.nodeType===3&&(u+=K.nodeValue.length),(M=K.firstChild)!==null;)R=K,K=M;for(;;){if(K===e)break i;if(R===t&&++j===o&&(f=u),R===r&&++B===n&&(b=u),(M=K.nextSibling)!==null)break;K=R,R=K.parentNode}K=M}t=f===-1||b===-1?null:{start:f,end:b}}else t=null}t=t||{start:0,end:0}}else t=null;for(vl={focusedElem:e,selectionRange:t},hr=!1,ti=i;ti!==null;)if(i=ti,e=i.child,(i.subtreeFlags&1024)!==0&&e!==null)e.return=i,ti=e;else for(;ti!==null;){switch(i=ti,r=i.alternate,e=i.flags,i.tag){case 0:break;case 11:case 15:break;case 1:if((e&1024)!==0&&r!==null){e=void 0,t=i,o=r.memoizedProps,r=r.memoizedState,n=t.stateNode;try{var _e=Ia(t.type,o,t.elementType===t.type);e=n.getSnapshotBeforeUpdate(_e,r),n.__reactInternalSnapshotBeforeUpdate=e}catch(ge){qe(t,t.return,ge)}}break;case 3:if((e&1024)!==0){if(e=i.stateNode.containerInfo,t=e.nodeType,t===9)Cl(e);else if(t===1)switch(e.nodeName){case"HEAD":case"HTML":case"BODY":Cl(e);break;default:e.textContent=""}}break;case 5:case 26:case 27:case 6:case 4:case 17:break;default:if((e&1024)!==0)throw Error(c(163))}if(e=i.sibling,e!==null){e.return=i.return,ti=e;break}ti=i.return}}function xm(e,i,t){var n=t.flags;switch(t.tag){case 0:case 11:case 15:Xt(e,t),n&4&&Gn(5,t);break;case 1:if(Xt(e,t),n&4)if(e=t.stateNode,i===null)try{e.componentDidMount()}catch(u){qe(t,t.return,u)}else{var o=Ia(t.type,i.memoizedProps);i=i.memoizedState;try{e.componentDidUpdate(o,i,e.__reactInternalSnapshotBeforeUpdate)}catch(u){qe(t,t.return,u)}}n&64&&_m(t),n&512&&Hn(t,t.return);break;case 3:if(Xt(e,t),n&64&&(e=t.updateQueue,e!==null)){if(i=null,t.child!==null)switch(t.child.tag){case 27:case 5:i=t.child.stateNode;break;case 1:i=t.child.stateNode}try{ad(e,i)}catch(u){qe(t,t.return,u)}}break;case 27:i===null&&n&4&&vm(t);case 26:case 5:Xt(e,t),i===null&&n&4&&bm(t),n&512&&Hn(t,t.return);break;case 12:Xt(e,t);break;case 13:Xt(e,t),n&4&&Nm(e,t),n&64&&(e=t.memoizedState,e!==null&&(e=e.dehydrated,e!==null&&(t=Ig.bind(null,t),Gg(e,t))));break;case 22:if(n=t.memoizedState!==null||Rt,!n){i=i!==null&&i.memoizedState!==null||Ge,o=Rt;var r=Ge;Rt=n,(Ge=i)&&!r?$t(e,t,(t.subtreeFlags&8772)!==0):Xt(e,t),Rt=o,Ge=r}break;case 30:break;default:Xt(e,t)}}function Cm(e){var i=e.alternate;i!==null&&(e.alternate=null,Cm(i)),e.child=null,e.deletions=null,e.sibling=null,e.tag===5&&(i=e.stateNode,i!==null&&fn(i)),e.stateNode=null,e.return=null,e.dependencies=null,e.memoizedProps=null,e.memoizedState=null,e.pendingProps=null,e.stateNode=null,e.updateQueue=null}var Pe=null,_i=!1;function Mt(e,i,t){for(t=t.child;t!==null;)Sm(e,i,t),t=t.sibling}function Sm(e,i,t){if(Ve&&typeof Ve.onCommitFiberUnmount=="function")try{Ve.onCommitFiberUnmount(pi,t)}catch{}switch(t.tag){case 26:Ge||mt(t,i),Mt(e,i,t),t.memoizedState?t.memoizedState.count--:t.stateNode&&(t=t.stateNode,t.parentNode.removeChild(t));break;case 27:Ge||mt(t,i);var n=Pe,o=_i;ia(t.type)&&(Pe=t.stateNode,_i=!1),Mt(e,i,t),eo(t.stateNode),Pe=n,_i=o;break;case 5:Ge||mt(t,i);case 6:if(n=Pe,o=_i,Pe=null,Mt(e,i,t),Pe=n,_i=o,Pe!==null)if(_i)try{(Pe.nodeType===9?Pe.body:Pe.nodeName==="HTML"?Pe.ownerDocument.body:Pe).removeChild(t.stateNode)}catch(r){qe(t,i,r)}else try{Pe.removeChild(t.stateNode)}catch(r){qe(t,i,r)}break;case 18:Pe!==null&&(_i?(e=Pe,uu(e.nodeType===9?e.body:e.nodeName==="HTML"?e.ownerDocument.body:e,t.stateNode),lo(e)):uu(Pe,t.stateNode));break;case 4:n=Pe,o=_i,Pe=t.stateNode.containerInfo,_i=!0,Mt(e,i,t),Pe=n,_i=o;break;case 0:case 11:case 14:case 15:Ge||Yt(2,t,i),Ge||Yt(4,t,i),Mt(e,i,t);break;case 1:Ge||(mt(t,i),n=t.stateNode,typeof n.componentWillUnmount=="function"&&hm(t,i,n)),Mt(e,i,t);break;case 21:Mt(e,i,t);break;case 22:Ge=(n=Ge)||t.memoizedState!==null,Mt(e,i,t),Ge=n;break;default:Mt(e,i,t)}}function Nm(e,i){if(i.memoizedState===null&&(e=i.alternate,e!==null&&(e=e.memoizedState,e!==null&&(e=e.dehydrated,e!==null))))try{lo(e)}catch(t){qe(i,i.return,t)}}function bg(e){switch(e.tag){case 13:case 19:var i=e.stateNode;return i===null&&(i=e.stateNode=new km),i;case 22:return e=e.stateNode,i=e._retryCache,i===null&&(i=e._retryCache=new km),i;default:throw Error(c(435,e.tag))}}function Js(e,i){var t=bg(e);i.forEach(function(n){var o=jg.bind(null,e,n);t.has(n)||(t.add(n),n.then(o,o))})}function Ci(e,i){var t=i.deletions;if(t!==null)for(var n=0;n<t.length;n++){var o=t[n],r=e,u=i,f=u;e:for(;f!==null;){switch(f.tag){case 27:if(ia(f.type)){Pe=f.stateNode,_i=!1;break e}break;case 5:Pe=f.stateNode,_i=!1;break e;case 3:case 4:Pe=f.stateNode.containerInfo,_i=!0;break e}f=f.return}if(Pe===null)throw Error(c(160));Sm(r,u,o),Pe=null,_i=!1,r=o.alternate,r!==null&&(r.return=null),o.return=null}if(i.subtreeFlags&13878)for(i=i.child;i!==null;)Im(i,e),i=i.sibling}var Ki=null;function Im(e,i){var t=e.alternate,n=e.flags;switch(e.tag){case 0:case 11:case 14:case 15:Ci(i,e),Si(e),n&4&&(Yt(3,e,e.return),Gn(3,e),Yt(5,e,e.return));break;case 1:Ci(i,e),Si(e),n&512&&(Ge||t===null||mt(t,t.return)),n&64&&Rt&&(e=e.updateQueue,e!==null&&(n=e.callbacks,n!==null&&(t=e.shared.hiddenCallbacks,e.shared.hiddenCallbacks=t===null?n:t.concat(n))));break;case 26:var o=Ki;if(Ci(i,e),Si(e),n&512&&(Ge||t===null||mt(t,t.return)),n&4){var r=t!==null?t.memoizedState:null;if(n=e.memoizedState,t===null)if(n===null)if(e.stateNode===null){e:{n=e.type,t=e.memoizedProps,o=o.ownerDocument||o;i:switch(n){case"title":r=o.getElementsByTagName("title")[0],(!r||r[je]||r[pe]||r.namespaceURI==="http://www.w3.org/2000/svg"||r.hasAttribute("itemprop"))&&(r=o.createElement(n),o.head.insertBefore(r,o.querySelector("head > title"))),si(r,n,t),r[pe]=e,ei(r),n=r;break e;case"link":var u=vu("link","href",o).get(n+(t.href||""));if(u){for(var f=0;f<u.length;f++)if(r=u[f],r.getAttribute("href")===(t.href==null||t.href===""?null:t.href)&&r.getAttribute("rel")===(t.rel==null?null:t.rel)&&r.getAttribute("title")===(t.title==null?null:t.title)&&r.getAttribute("crossorigin")===(t.crossOrigin==null?null:t.crossOrigin)){u.splice(f,1);break i}}r=o.createElement(n),si(r,n,t),o.head.appendChild(r);break;case"meta":if(u=vu("meta","content",o).get(n+(t.content||""))){for(f=0;f<u.length;f++)if(r=u[f],r.getAttribute("content")===(t.content==null?null:""+t.content)&&r.getAttribute("name")===(t.name==null?null:t.name)&&r.getAttribute("property")===(t.property==null?null:t.property)&&r.getAttribute("http-equiv")===(t.httpEquiv==null?null:t.httpEquiv)&&r.getAttribute("charset")===(t.charSet==null?null:t.charSet)){u.splice(f,1);break i}}r=o.createElement(n),si(r,n,t),o.head.appendChild(r);break;default:throw Error(c(468,n))}r[pe]=e,ei(r),n=r}e.stateNode=n}else ku(o,e.type,e.stateNode);else e.stateNode=yu(o,n,e.memoizedProps);else r!==n?(r===null?t.stateNode!==null&&(t=t.stateNode,t.parentNode.removeChild(t)):r.count--,n===null?ku(o,e.type,e.stateNode):yu(o,n,e.memoizedProps)):n===null&&e.stateNode!==null&&Ks(e,e.memoizedProps,t.memoizedProps)}break;case 27:Ci(i,e),Si(e),n&512&&(Ge||t===null||mt(t,t.return)),t!==null&&n&4&&Ks(e,e.memoizedProps,t.memoizedProps);break;case 5:if(Ci(i,e),Si(e),n&512&&(Ge||t===null||mt(t,t.return)),e.flags&32){o=e.stateNode;try{Ea(o,"")}catch(M){qe(e,e.return,M)}}n&4&&e.stateNode!=null&&(o=e.memoizedProps,Ks(e,o,t!==null?t.memoizedProps:o)),n&1024&&($s=!0);break;case 6:if(Ci(i,e),Si(e),n&4){if(e.stateNode===null)throw Error(c(162));n=e.memoizedProps,t=e.stateNode;try{t.nodeValue=n}catch(M){qe(e,e.return,M)}}break;case 3:if(gr=null,o=Ki,Ki=ur(i.containerInfo),Ci(i,e),Ki=o,Si(e),n&4&&t!==null&&t.memoizedState.isDehydrated)try{lo(i.containerInfo)}catch(M){qe(e,e.return,M)}$s&&($s=!1,jm(e));break;case 4:n=Ki,Ki=ur(e.stateNode.containerInfo),Ci(i,e),Si(e),Ki=n;break;case 12:Ci(i,e),Si(e);break;case 13:Ci(i,e),Si(e),e.child.flags&8192&&e.memoizedState!==null!=(t!==null&&t.memoizedState!==null)&&(tl=Xe()),n&4&&(n=e.updateQueue,n!==null&&(e.updateQueue=null,Js(e,n)));break;case 22:o=e.memoizedState!==null;var b=t!==null&&t.memoizedState!==null,j=Rt,B=Ge;if(Rt=j||o,Ge=B||b,Ci(i,e),Ge=B,Rt=j,Si(e),n&8192)e:for(i=e.stateNode,i._visibility=o?i._visibility&-2:i._visibility|1,o&&(t===null||b||Rt||Ge||ja(e)),t=null,i=e;;){if(i.tag===5||i.tag===26){if(t===null){b=t=i;try{if(r=b.stateNode,o)u=r.style,typeof u.setProperty=="function"?u.setProperty("display","none","important"):u.display="none";else{f=b.stateNode;var K=b.memoizedProps.style,R=K!=null&&K.hasOwnProperty("display")?K.display:null;f.style.display=R==null||typeof R=="boolean"?"":(""+R).trim()}}catch(M){qe(b,b.return,M)}}}else if(i.tag===6){if(t===null){b=i;try{b.stateNode.nodeValue=o?"":b.memoizedProps}catch(M){qe(b,b.return,M)}}}else if((i.tag!==22&&i.tag!==23||i.memoizedState===null||i===e)&&i.child!==null){i.child.return=i,i=i.child;continue}if(i===e)break e;for(;i.sibling===null;){if(i.return===null||i.return===e)break e;t===i&&(t=null),i=i.return}t===i&&(t=null),i.sibling.return=i.return,i=i.sibling}n&4&&(n=e.updateQueue,n!==null&&(t=n.retryQueue,t!==null&&(n.retryQueue=null,Js(e,t))));break;case 19:Ci(i,e),Si(e),n&4&&(n=e.updateQueue,n!==null&&(e.updateQueue=null,Js(e,n)));break;case 30:break;case 21:break;default:Ci(i,e),Si(e)}}function Si(e){var i=e.flags;if(i&2){try{for(var t,n=e.return;n!==null;){if(ym(n)){t=n;break}n=n.return}if(t==null)throw Error(c(160));switch(t.tag){case 27:var o=t.stateNode,r=Ys(e);Zo(e,r,o);break;case 5:var u=t.stateNode;t.flags&32&&(Ea(u,""),t.flags&=-33);var f=Ys(e);Zo(e,f,u);break;case 3:case 4:var b=t.stateNode.containerInfo,j=Ys(e);Xs(e,j,b);break;default:throw Error(c(161))}}catch(B){qe(e,e.return,B)}e.flags&=-3}i&4096&&(e.flags&=-4097)}function jm(e){if(e.subtreeFlags&1024)for(e=e.child;e!==null;){var i=e;jm(i),i.tag===5&&i.flags&1024&&i.stateNode.reset(),e=e.sibling}}function Xt(e,i){if(i.subtreeFlags&8772)for(i=i.child;i!==null;)xm(e,i.alternate,i),i=i.sibling}function ja(e){for(e=e.child;e!==null;){var i=e;switch(i.tag){case 0:case 11:case 14:case 15:Yt(4,i,i.return),ja(i);break;case 1:mt(i,i.return);var t=i.stateNode;typeof t.componentWillUnmount=="function"&&hm(i,i.return,t),ja(i);break;case 27:eo(i.stateNode);case 26:case 5:mt(i,i.return),ja(i);break;case 22:i.memoizedState===null&&ja(i);break;case 30:ja(i);break;default:ja(i)}e=e.sibling}}function $t(e,i,t){for(t=t&&(i.subtreeFlags&8772)!==0,i=i.child;i!==null;){var n=i.alternate,o=e,r=i,u=r.flags;switch(r.tag){case 0:case 11:case 15:$t(o,r,t),Gn(4,r);break;case 1:if($t(o,r,t),n=r,o=n.stateNode,typeof o.componentDidMount=="function")try{o.componentDidMount()}catch(j){qe(n,n.return,j)}if(n=r,o=n.updateQueue,o!==null){var f=n.stateNode;try{var b=o.shared.hiddenCallbacks;if(b!==null)for(o.shared.hiddenCallbacks=null,o=0;o<b.length;o++)td(b[o],f)}catch(j){qe(n,n.return,j)}}t&&u&64&&_m(r),Hn(r,r.return);break;case 27:vm(r);case 26:case 5:$t(o,r,t),t&&n===null&&u&4&&bm(r),Hn(r,r.return);break;case 12:$t(o,r,t);break;case 13:$t(o,r,t),t&&u&4&&Nm(o,r);break;case 22:r.memoizedState===null&&$t(o,r,t),Hn(r,r.return);break;case 30:break;default:$t(o,r,t)}i=i.sibling}}function Qs(e,i){var t=null;e!==null&&e.memoizedState!==null&&e.memoizedState.cachePool!==null&&(t=e.memoizedState.cachePool.pool),e=null,i.memoizedState!==null&&i.memoizedState.cachePool!==null&&(e=i.memoizedState.cachePool.pool),e!==t&&(e!=null&&e.refCount++,t!=null&&Rn(t))}function Ws(e,i){e=null,i.alternate!==null&&(e=i.alternate.memoizedState.cache),i=i.memoizedState.cache,i!==e&&(i.refCount++,e!=null&&Rn(e))}function ut(e,i,t,n){if(i.subtreeFlags&10256)for(i=i.child;i!==null;)Am(e,i,t,n),i=i.sibling}function Am(e,i,t,n){var o=i.flags;switch(i.tag){case 0:case 11:case 15:ut(e,i,t,n),o&2048&&Gn(9,i);break;case 1:ut(e,i,t,n);break;case 3:ut(e,i,t,n),o&2048&&(e=null,i.alternate!==null&&(e=i.alternate.memoizedState.cache),i=i.memoizedState.cache,i!==e&&(i.refCount++,e!=null&&Rn(e)));break;case 12:if(o&2048){ut(e,i,t,n),e=i.stateNode;try{var r=i.memoizedProps,u=r.id,f=r.onPostCommit;typeof f=="function"&&f(u,i.alternate===null?"mount":"update",e.passiveEffectDuration,-0)}catch(b){qe(i,i.return,b)}}else ut(e,i,t,n);break;case 13:ut(e,i,t,n);break;case 23:break;case 22:r=i.stateNode,u=i.alternate,i.memoizedState!==null?r._visibility&2?ut(e,i,t,n):Kn(e,i):r._visibility&2?ut(e,i,t,n):(r._visibility|=2,en(e,i,t,n,(i.subtreeFlags&10256)!==0)),o&2048&&Qs(u,i);break;case 24:ut(e,i,t,n),o&2048&&Ws(i.alternate,i);break;default:ut(e,i,t,n)}}function en(e,i,t,n,o){for(o=o&&(i.subtreeFlags&10256)!==0,i=i.child;i!==null;){var r=e,u=i,f=t,b=n,j=u.flags;switch(u.tag){case 0:case 11:case 15:en(r,u,f,b,o),Gn(8,u);break;case 23:break;case 22:var B=u.stateNode;u.memoizedState!==null?B._visibility&2?en(r,u,f,b,o):Kn(r,u):(B._visibility|=2,en(r,u,f,b,o)),o&&j&2048&&Qs(u.alternate,u);break;case 24:en(r,u,f,b,o),o&&j&2048&&Ws(u.alternate,u);break;default:en(r,u,f,b,o)}i=i.sibling}}function Kn(e,i){if(i.subtreeFlags&10256)for(i=i.child;i!==null;){var t=e,n=i,o=n.flags;switch(n.tag){case 22:Kn(t,n),o&2048&&Qs(n.alternate,n);break;case 24:Kn(t,n),o&2048&&Ws(n.alternate,n);break;default:Kn(t,n)}i=i.sibling}}var Yn=8192;function tn(e){if(e.subtreeFlags&Yn)for(e=e.child;e!==null;)wm(e),e=e.sibling}function wm(e){switch(e.tag){case 26:tn(e),e.flags&Yn&&e.memoizedState!==null&&nf(Ki,e.memoizedState,e.memoizedProps);break;case 5:tn(e);break;case 3:case 4:var i=Ki;Ki=ur(e.stateNode.containerInfo),tn(e),Ki=i;break;case 22:e.memoizedState===null&&(i=e.alternate,i!==null&&i.memoizedState!==null?(i=Yn,Yn=16777216,tn(e),Yn=i):tn(e));break;default:tn(e)}}function Rm(e){var i=e.alternate;if(i!==null&&(e=i.child,e!==null)){i.child=null;do i=e.sibling,e.sibling=null,e=i;while(e!==null)}}function Xn(e){var i=e.deletions;if((e.flags&16)!==0){if(i!==null)for(var t=0;t<i.length;t++){var n=i[t];ti=n,Dm(n,e)}Rm(e)}if(e.subtreeFlags&10256)for(e=e.child;e!==null;)Mm(e),e=e.sibling}function Mm(e){switch(e.tag){case 0:case 11:case 15:Xn(e),e.flags&2048&&Yt(9,e,e.return);break;case 3:Xn(e);break;case 12:Xn(e);break;case 22:var i=e.stateNode;e.memoizedState!==null&&i._visibility&2&&(e.return===null||e.return.tag!==13)?(i._visibility&=-3,er(e)):Xn(e);break;default:Xn(e)}}function er(e){var i=e.deletions;if((e.flags&16)!==0){if(i!==null)for(var t=0;t<i.length;t++){var n=i[t];ti=n,Dm(n,e)}Rm(e)}for(e=e.child;e!==null;){switch(i=e,i.tag){case 0:case 11:case 15:Yt(8,i,i.return),er(i);break;case 22:t=i.stateNode,t._visibility&2&&(t._visibility&=-3,er(i));break;default:er(i)}e=e.sibling}}function Dm(e,i){for(;ti!==null;){var t=ti;switch(t.tag){case 0:case 11:case 15:Yt(8,t,i);break;case 23:case 22:if(t.memoizedState!==null&&t.memoizedState.cachePool!==null){var n=t.memoizedState.cachePool.pool;n!=null&&n.refCount++}break;case 24:Rn(t.memoizedState.cache)}if(n=t.child,n!==null)n.return=t,ti=n;else e:for(t=e;ti!==null;){n=ti;var o=n.sibling,r=n.return;if(Cm(n),n===t){ti=null;break e}if(o!==null){o.return=r,ti=o;break e}ti=r}}}var yg={getCacheForType:function(e){var i=ci(Qe),t=i.data.get(e);return t===void 0&&(t=e(),i.data.set(e,t)),t}},vg=typeof WeakMap=="function"?WeakMap:Map,Ae=0,Ee=null,ke=null,Se=0,we=0,Ni=null,Jt=!1,an=!1,Zs=!1,Dt=0,Be=0,Qt=0,Aa=0,el=0,zi=0,nn=0,$n=null,hi=null,il=!1,tl=0,ir=1/0,tr=null,Wt=null,ri=0,Zt=null,on=null,rn=0,al=0,nl=null,qm=null,Jn=0,ol=null;function Ii(){if((Ae&2)!==0&&Se!==0)return Se&-Se;if(k.T!==null){var e=Ka;return e!==0?e:ul()}return st()}function Tm(){zi===0&&(zi=(Se&536870912)===0||Ie?Et():536870912);var e=Li.current;return e!==null&&(e.flags|=32),zi}function ji(e,i,t){(e===Ee&&(we===2||we===9)||e.cancelPendingCommit!==null)&&(sn(e,0),ea(e,Se,zi,!1)),vi(e,t),((Ae&2)===0||e!==Ee)&&(e===Ee&&((Ae&2)===0&&(Aa|=t),Be===4&&ea(e,Se,zi,!1)),pt(e))}function Em(e,i,t){if((Ae&6)!==0)throw Error(c(327));var n=!t&&(i&124)===0&&(i&e.expiredLanes)===0||Gi(e,i),o=n?Cg(e,i):ll(e,i,!0),r=n;do{if(o===0){an&&!n&&ea(e,i,0,!1);break}else{if(t=e.current.alternate,r&&!kg(t)){o=ll(e,i,!1),r=!1;continue}if(o===2){if(r=i,e.errorRecoveryDisabledLanes&r)var u=0;else u=e.pendingLanes&-536870913,u=u!==0?u:u&536870912?536870912:0;if(u!==0){i=u;e:{var f=e;o=$n;var b=f.current.memoizedState.isDehydrated;if(b&&(sn(f,u).flags|=256),u=ll(f,u,!1),u!==2){if(Zs&&!b){f.errorRecoveryDisabledLanes|=r,Aa|=r,o=4;break e}r=hi,hi=o,r!==null&&(hi===null?hi=r:hi.push.apply(hi,r))}o=u}if(r=!1,o!==2)continue}}if(o===1){sn(e,0),ea(e,i,0,!0);break}e:{switch(n=e,r=o,r){case 0:case 1:throw Error(c(345));case 4:if((i&4194048)!==i)break;case 6:ea(n,i,zi,!Jt);break e;case 2:hi=null;break;case 3:case 5:break;default:throw Error(c(329))}if((i&62914560)===i&&(o=tl+300-Xe(),10<o)){if(ea(n,i,zi,!Jt),nt(n,0,!0)!==0)break e;n.timeoutHandle=du(Pm.bind(null,n,t,hi,tr,il,i,zi,Aa,nn,Jt,r,2,-0,0),o);break e}Pm(n,t,hi,tr,il,i,zi,Aa,nn,Jt,r,0,-0,0)}}break}while(!0);pt(e)}function Pm(e,i,t,n,o,r,u,f,b,j,B,K,R,M){if(e.timeoutHandle=-1,K=i.subtreeFlags,(K&8192||(K&16785408)===16785408)&&(ao={stylesheets:null,count:0,unsuspend:af},wm(i),K=of(),K!==null)){e.cancelPendingCommit=K(Fm.bind(null,e,i,r,t,n,o,u,f,b,B,1,R,M)),ea(e,r,u,!j);return}Fm(e,i,r,t,n,o,u,f,b)}function kg(e){for(var i=e;;){var t=i.tag;if((t===0||t===11||t===15)&&i.flags&16384&&(t=i.updateQueue,t!==null&&(t=t.stores,t!==null)))for(var n=0;n<t.length;n++){var o=t[n],r=o.getSnapshot;o=o.value;try{if(!ki(r(),o))return!1}catch{return!1}}if(t=i.child,i.subtreeFlags&16384&&t!==null)t.return=i,i=t;else{if(i===e)break;for(;i.sibling===null;){if(i.return===null||i.return===e)return!0;i=i.return}i.sibling.return=i.return,i=i.sibling}}return!0}function ea(e,i,t,n){i&=~el,i&=~Aa,e.suspendedLanes|=i,e.pingedLanes&=~i,n&&(e.warmLanes|=i),n=e.expirationTimes;for(var o=i;0<o;){var r=31-$e(o),u=1<<r;n[r]=-1,o&=~u}t!==0&&Pt(e,t,i)}function ar(){return(Ae&6)===0?(Qn(0),!1):!0}function rl(){if(ke!==null){if(we===0)var e=ke.return;else e=ke,St=xa=null,Cs(e),Wa=null,Bn=0,e=ke;for(;e!==null;)fm(e.alternate,e),e=e.return;ke=null}}function sn(e,i){var t=e.timeoutHandle;t!==-1&&(e.timeoutHandle=-1,Vg(t)),t=e.cancelPendingCommit,t!==null&&(e.cancelPendingCommit=null,t()),rl(),Ee=e,ke=t=kt(e.current,null),Se=i,we=0,Ni=null,Jt=!1,an=Gi(e,i),Zs=!1,nn=zi=el=Aa=Qt=Be=0,hi=$n=null,il=!1,(i&8)!==0&&(i|=i&32);var n=e.entangledLanes;if(n!==0)for(e=e.entanglements,n&=i;0<n;){var o=31-$e(n),r=1<<o;i|=e[o],n&=~r}return Dt=i,No(),t}function Lm(e,i){ye=null,k.H=Go,i===Dn||i===To?(i=ed(),we=3):i===Qc?(i=ed(),we=4):we=i===im?8:i!==null&&typeof i=="object"&&typeof i.then=="function"?6:1,Ni=i,ke===null&&(Be=1,$o(e,qi(i,e.current)))}function zm(){var e=k.H;return k.H=Go,e===null?Go:e}function Vm(){var e=k.A;return k.A=yg,e}function sl(){Be=4,Jt||(Se&4194048)!==Se&&Li.current!==null||(an=!0),(Qt&134217727)===0&&(Aa&134217727)===0||Ee===null||ea(Ee,Se,zi,!1)}function ll(e,i,t){var n=Ae;Ae|=2;var o=zm(),r=Vm();(Ee!==e||Se!==i)&&(tr=null,sn(e,i)),i=!1;var u=Be;e:do try{if(we!==0&&ke!==null){var f=ke,b=Ni;switch(we){case 8:rl(),u=6;break e;case 3:case 2:case 9:case 6:Li.current===null&&(i=!0);var j=we;if(we=0,Ni=null,ln(e,f,b,j),t&&an){u=0;break e}break;default:j=we,we=0,Ni=null,ln(e,f,b,j)}}xg(),u=Be;break}catch(B){Lm(e,B)}while(!0);return i&&e.shellSuspendCounter++,St=xa=null,Ae=n,k.H=o,k.A=r,ke===null&&(Ee=null,Se=0,No()),u}function xg(){for(;ke!==null;)Om(ke)}function Cg(e,i){var t=Ae;Ae|=2;var n=zm(),o=Vm();Ee!==e||Se!==i?(tr=null,ir=Xe()+500,sn(e,i)):an=Gi(e,i);e:do try{if(we!==0&&ke!==null){i=ke;var r=Ni;i:switch(we){case 1:we=0,Ni=null,ln(e,i,r,1);break;case 2:case 9:if(Wc(r)){we=0,Ni=null,Bm(i);break}i=function(){we!==2&&we!==9||Ee!==e||(we=7),pt(e)},r.then(i,i);break e;case 3:we=7;break e;case 4:we=5;break e;case 7:Wc(r)?(we=0,Ni=null,Bm(i)):(we=0,Ni=null,ln(e,i,r,7));break;case 5:var u=null;switch(ke.tag){case 26:u=ke.memoizedState;case 5:case 27:var f=ke;if(!u||xu(u)){we=0,Ni=null;var b=f.sibling;if(b!==null)ke=b;else{var j=f.return;j!==null?(ke=j,nr(j)):ke=null}break i}}we=0,Ni=null,ln(e,i,r,5);break;case 6:we=0,Ni=null,ln(e,i,r,6);break;case 8:rl(),Be=6;break e;default:throw Error(c(462))}}Sg();break}catch(B){Lm(e,B)}while(!0);return St=xa=null,k.H=n,k.A=o,Ae=t,ke!==null?0:(Ee=null,Se=0,No(),Be)}function Sg(){for(;ke!==null&&!Ji();)Om(ke)}function Om(e){var i=pm(e.alternate,e,Dt);e.memoizedProps=e.pendingProps,i===null?nr(e):ke=i}function Bm(e){var i=e,t=i.alternate;switch(i.tag){case 15:case 0:i=sm(t,i,i.pendingProps,i.type,void 0,Se);break;case 11:i=sm(t,i,i.pendingProps,i.type.render,i.ref,Se);break;case 5:Cs(i);default:fm(t,i),i=ke=Uc(i,Dt),i=pm(t,i,Dt)}e.memoizedProps=e.pendingProps,i===null?nr(e):ke=i}function ln(e,i,t,n){St=xa=null,Cs(i),Wa=null,Bn=0;var o=i.return;try{if(pg(e,o,i,t,Se)){Be=1,$o(e,qi(t,e.current)),ke=null;return}}catch(r){if(o!==null)throw ke=o,r;Be=1,$o(e,qi(t,e.current)),ke=null;return}i.flags&32768?(Ie||n===1?e=!0:an||(Se&536870912)!==0?e=!1:(Jt=e=!0,(n===2||n===9||n===3||n===6)&&(n=Li.current,n!==null&&n.tag===13&&(n.flags|=16384))),Um(i,e)):nr(i)}function nr(e){var i=e;do{if((i.flags&32768)!==0){Um(i,Jt);return}e=i.return;var t=fg(i.alternate,i,Dt);if(t!==null){ke=t;return}if(i=i.sibling,i!==null){ke=i;return}ke=i=e}while(i!==null);Be===0&&(Be=5)}function Um(e,i){do{var t=_g(e.alternate,e);if(t!==null){t.flags&=32767,ke=t;return}if(t=e.return,t!==null&&(t.flags|=32768,t.subtreeFlags=0,t.deletions=null),!i&&(e=e.sibling,e!==null)){ke=e;return}ke=e=t}while(e!==null);Be=6,ke=null}function Fm(e,i,t,n,o,r,u,f,b){e.cancelPendingCommit=null;do or();while(ri!==0);if((Ae&6)!==0)throw Error(c(327));if(i!==null){if(i===e.current)throw Error(c(177));if(r=i.lanes|i.childLanes,r|=Wr,ma(e,t,r,u,f,b),e===Ee&&(ke=Ee=null,Se=0),on=i,Zt=e,rn=t,al=r,nl=o,qm=n,(i.subtreeFlags&10256)!==0||(i.flags&10256)!==0?(e.callbackNode=null,e.callbackPriority=0,Ag(bi,function(){return Xm(),null})):(e.callbackNode=null,e.callbackPriority=0),n=(i.flags&13878)!==0,(i.subtreeFlags&13878)!==0||n){n=k.T,k.T=null,o=G.p,G.p=2,u=Ae,Ae|=4;try{hg(e,i,t)}finally{Ae=u,G.p=o,k.T=n}}ri=1,Gm(),Hm(),Km()}}function Gm(){if(ri===1){ri=0;var e=Zt,i=on,t=(i.flags&13878)!==0;if((i.subtreeFlags&13878)!==0||t){t=k.T,k.T=null;var n=G.p;G.p=2;var o=Ae;Ae|=4;try{Im(i,e);var r=vl,u=Dc(e.containerInfo),f=r.focusedElem,b=r.selectionRange;if(u!==f&&f&&f.ownerDocument&&Mc(f.ownerDocument.documentElement,f)){if(b!==null&&Yr(f)){var j=b.start,B=b.end;if(B===void 0&&(B=j),"selectionStart"in f)f.selectionStart=j,f.selectionEnd=Math.min(B,f.value.length);else{var K=f.ownerDocument||document,R=K&&K.defaultView||window;if(R.getSelection){var M=R.getSelection(),_e=f.textContent.length,ge=Math.min(b.start,_e),De=b.end===void 0?ge:Math.min(b.end,_e);!M.extend&&ge>De&&(u=De,De=ge,ge=u);var S=Rc(f,ge),x=Rc(f,De);if(S&&x&&(M.rangeCount!==1||M.anchorNode!==S.node||M.anchorOffset!==S.offset||M.focusNode!==x.node||M.focusOffset!==x.offset)){var I=K.createRange();I.setStart(S.node,S.offset),M.removeAllRanges(),ge>De?(M.addRange(I),M.extend(x.node,x.offset)):(I.setEnd(x.node,x.offset),M.addRange(I))}}}}for(K=[],M=f;M=M.parentNode;)M.nodeType===1&&K.push({element:M,left:M.scrollLeft,top:M.scrollTop});for(typeof f.focus=="function"&&f.focus(),f=0;f<K.length;f++){var F=K[f];F.element.scrollLeft=F.left,F.element.scrollTop=F.top}}hr=!!yl,vl=yl=null}finally{Ae=o,G.p=n,k.T=t}}e.current=i,ri=2}}function Hm(){if(ri===2){ri=0;var e=Zt,i=on,t=(i.flags&8772)!==0;if((i.subtreeFlags&8772)!==0||t){t=k.T,k.T=null;var n=G.p;G.p=2;var o=Ae;Ae|=4;try{xm(e,i.alternate,i)}finally{Ae=o,G.p=n,k.T=t}}ri=3}}function Km(){if(ri===4||ri===3){ri=0,Qi();var e=Zt,i=on,t=rn,n=qm;(i.subtreeFlags&10256)!==0||(i.flags&10256)!==0?ri=5:(ri=0,on=Zt=null,Ym(e,e.pendingLanes));var o=e.pendingLanes;if(o===0&&(Wt=null),ht(t),i=i.stateNode,Ve&&typeof Ve.onCommitFiberRoot=="function")try{Ve.onCommitFiberRoot(pi,i,void 0,(i.current.flags&128)===128)}catch{}if(n!==null){i=k.T,o=G.p,G.p=2,k.T=null;try{for(var r=e.onRecoverableError,u=0;u<n.length;u++){var f=n[u];r(f.value,{componentStack:f.stack})}}finally{k.T=i,G.p=o}}(rn&3)!==0&&or(),pt(e),o=e.pendingLanes,(t&4194090)!==0&&(o&42)!==0?e===ol?Jn++:(Jn=0,ol=e):Jn=0,Qn(0)}}function Ym(e,i){(e.pooledCacheLanes&=i)===0&&(i=e.pooledCache,i!=null&&(e.pooledCache=null,Rn(i)))}function or(e){return Gm(),Hm(),Km(),Xm()}function Xm(){if(ri!==5)return!1;var e=Zt,i=al;al=0;var t=ht(rn),n=k.T,o=G.p;try{G.p=32>t?32:t,k.T=null,t=nl,nl=null;var r=Zt,u=rn;if(ri=0,on=Zt=null,rn=0,(Ae&6)!==0)throw Error(c(331));var f=Ae;if(Ae|=4,Mm(r.current),Am(r,r.current,u,t),Ae=f,Qn(0,!1),Ve&&typeof Ve.onPostCommitFiberRoot=="function")try{Ve.onPostCommitFiberRoot(pi,r)}catch{}return!0}finally{G.p=o,k.T=n,Ym(e,i)}}function $m(e,i,t){i=qi(t,i),i=Ls(e.stateNode,i,2),e=Ft(e,i,2),e!==null&&(vi(e,2),pt(e))}function qe(e,i,t){if(e.tag===3)$m(e,e,t);else for(;i!==null;){if(i.tag===3){$m(i,e,t);break}else if(i.tag===1){var n=i.stateNode;if(typeof i.type.getDerivedStateFromError=="function"||typeof n.componentDidCatch=="function"&&(Wt===null||!Wt.has(n))){e=qi(t,e),t=Zd(2),n=Ft(i,t,2),n!==null&&(em(t,n,i,e),vi(n,2),pt(n));break}}i=i.return}}function cl(e,i,t){var n=e.pingCache;if(n===null){n=e.pingCache=new vg;var o=new Set;n.set(i,o)}else o=n.get(i),o===void 0&&(o=new Set,n.set(i,o));o.has(t)||(Zs=!0,o.add(t),e=Ng.bind(null,e,i,t),i.then(e,e))}function Ng(e,i,t){var n=e.pingCache;n!==null&&n.delete(i),e.pingedLanes|=e.suspendedLanes&t,e.warmLanes&=~t,Ee===e&&(Se&t)===t&&(Be===4||Be===3&&(Se&62914560)===Se&&300>Xe()-tl?(Ae&2)===0&&sn(e,0):el|=t,nn===Se&&(nn=0)),pt(e)}function Jm(e,i){i===0&&(i=Ze()),e=Ua(e,i),e!==null&&(vi(e,i),pt(e))}function Ig(e){var i=e.memoizedState,t=0;i!==null&&(t=i.retryLane),Jm(e,t)}function jg(e,i){var t=0;switch(e.tag){case 13:var n=e.stateNode,o=e.memoizedState;o!==null&&(t=o.retryLane);break;case 19:n=e.stateNode;break;case 22:n=e.stateNode._retryCache;break;default:throw Error(c(314))}n!==null&&n.delete(i),Jm(e,t)}function Ag(e,i){return wi(e,i)}var rr=null,cn=null,dl=!1,sr=!1,ml=!1,wa=0;function pt(e){e!==cn&&e.next===null&&(cn===null?rr=cn=e:cn=cn.next=e),sr=!0,dl||(dl=!0,Rg())}function Qn(e,i){if(!ml&&sr){ml=!0;do for(var t=!1,n=rr;n!==null;){if(e!==0){var o=n.pendingLanes;if(o===0)var r=0;else{var u=n.suspendedLanes,f=n.pingedLanes;r=(1<<31-$e(42|e)+1)-1,r&=o&~(u&~f),r=r&201326741?r&201326741|1:r?r|2:0}r!==0&&(t=!0,eu(n,r))}else r=Se,r=nt(n,n===Ee?r:0,n.cancelPendingCommit!==null||n.timeoutHandle!==-1),(r&3)===0||Gi(n,r)||(t=!0,eu(n,r));n=n.next}while(t);ml=!1}}function wg(){Qm()}function Qm(){sr=dl=!1;var e=0;wa!==0&&(zg()&&(e=wa),wa=0);for(var i=Xe(),t=null,n=rr;n!==null;){var o=n.next,r=Wm(n,i);r===0?(n.next=null,t===null?rr=o:t.next=o,o===null&&(cn=t)):(t=n,(e!==0||(r&3)!==0)&&(sr=!0)),n=o}Qn(e)}function Wm(e,i){for(var t=e.suspendedLanes,n=e.pingedLanes,o=e.expirationTimes,r=e.pendingLanes&-62914561;0<r;){var u=31-$e(r),f=1<<u,b=o[u];b===-1?((f&t)===0||(f&n)!==0)&&(o[u]=da(f,i)):b<=i&&(e.expiredLanes|=f),r&=~f}if(i=Ee,t=Se,t=nt(e,e===i?t:0,e.cancelPendingCommit!==null||e.timeoutHandle!==-1),n=e.callbackNode,t===0||e===i&&(we===2||we===9)||e.cancelPendingCommit!==null)return n!==null&&n!==null&&Ri(n),e.callbackNode=null,e.callbackPriority=0;if((t&3)===0||Gi(e,t)){if(i=t&-t,i===e.callbackPriority)return i;switch(n!==null&&Ri(n),ht(t)){case 2:case 8:t=Ui;break;case 32:t=bi;break;case 268435456:t=Fi;break;default:t=bi}return n=Zm.bind(null,e),t=wi(t,n),e.callbackPriority=i,e.callbackNode=t,i}return n!==null&&n!==null&&Ri(n),e.callbackPriority=2,e.callbackNode=null,2}function Zm(e,i){if(ri!==0&&ri!==5)return e.callbackNode=null,e.callbackPriority=0,null;var t=e.callbackNode;if(or()&&e.callbackNode!==t)return null;var n=Se;return n=nt(e,e===Ee?n:0,e.cancelPendingCommit!==null||e.timeoutHandle!==-1),n===0?null:(Em(e,n,i),Wm(e,Xe()),e.callbackNode!=null&&e.callbackNode===t?Zm.bind(null,e):null)}function eu(e,i){if(or())return null;Em(e,i,!0)}function Rg(){Og(function(){(Ae&6)!==0?wi(Bi,wg):Qm()})}function ul(){return wa===0&&(wa=Et()),wa}function iu(e){return e==null||typeof e=="symbol"||typeof e=="boolean"?null:typeof e=="function"?e:bo(""+e)}function tu(e,i){var t=i.ownerDocument.createElement("input");return t.name=i.name,t.value=i.value,e.id&&t.setAttribute("form",e.id),i.parentNode.insertBefore(t,i),e=new FormData(e),t.parentNode.removeChild(t),e}function Mg(e,i,t,n,o){if(i==="submit"&&t&&t.stateNode===o){var r=iu((o[Ue]||null).action),u=n.submitter;u&&(i=(i=u[Ue]||null)?iu(i.formAction):u.getAttribute("formAction"),i!==null&&(r=i,u=null));var f=new xo("action","action",null,n,o);e.push({event:f,listeners:[{instance:null,listener:function(){if(n.defaultPrevented){if(wa!==0){var b=u?tu(o,u):new FormData(o);Ds(t,{pending:!0,data:b,method:o.method,action:r},null,b)}}else typeof r=="function"&&(f.preventDefault(),b=u?tu(o,u):new FormData(o),Ds(t,{pending:!0,data:b,method:o.method,action:r},r,b))},currentTarget:o}]})}}for(var pl=0;pl<Qr.length;pl++){var gl=Qr[pl],Dg=gl.toLowerCase(),qg=gl[0].toUpperCase()+gl.slice(1);Hi(Dg,"on"+qg)}Hi(Ec,"onAnimationEnd"),Hi(Pc,"onAnimationIteration"),Hi(Lc,"onAnimationStart"),Hi("dblclick","onDoubleClick"),Hi("focusin","onFocus"),Hi("focusout","onBlur"),Hi(Jp,"onTransitionRun"),Hi(Qp,"onTransitionStart"),Hi(Wp,"onTransitionCancel"),Hi(zc,"onTransitionEnd"),Da("onMouseEnter",["mouseout","mouseover"]),Da("onMouseLeave",["mouseout","mouseover"]),Da("onPointerEnter",["pointerout","pointerover"]),Da("onPointerLeave",["pointerout","pointerover"]),pa("onChange","change click focusin focusout input keydown keyup selectionchange".split(" ")),pa("onSelect","focusout contextmenu dragend focusin keydown keyup mousedown mouseup selectionchange".split(" ")),pa("onBeforeInput",["compositionend","keypress","textInput","paste"]),pa("onCompositionEnd","compositionend focusout keydown keypress keyup mousedown".split(" ")),pa("onCompositionStart","compositionstart focusout keydown keypress keyup mousedown".split(" ")),pa("onCompositionUpdate","compositionupdate focusout keydown keypress keyup mousedown".split(" "));var Wn="abort canplay canplaythrough durationchange emptied encrypted ended error loadeddata loadedmetadata loadstart pause play playing progress ratechange resize seeked seeking stalled suspend timeupdate volumechange waiting".split(" "),Tg=new Set("beforetoggle cancel close invalid load scroll scrollend toggle".split(" ").concat(Wn));function au(e,i){i=(i&4)!==0;for(var t=0;t<e.length;t++){var n=e[t],o=n.event;n=n.listeners;e:{var r=void 0;if(i)for(var u=n.length-1;0<=u;u--){var f=n[u],b=f.instance,j=f.currentTarget;if(f=f.listener,b!==r&&o.isPropagationStopped())break e;r=f,o.currentTarget=j;try{r(o)}catch(B){Xo(B)}o.currentTarget=null,r=b}else for(u=0;u<n.length;u++){if(f=n[u],b=f.instance,j=f.currentTarget,f=f.listener,b!==r&&o.isPropagationStopped())break e;r=f,o.currentTarget=j;try{r(o)}catch(B){Xo(B)}o.currentTarget=null,r=b}}}}function xe(e,i){var t=i[lt];t===void 0&&(t=i[lt]=new Set);var n=e+"__bubble";t.has(n)||(nu(i,e,2,!1),t.add(n))}function fl(e,i,t){var n=0;i&&(n|=4),nu(t,e,n,i)}var lr="_reactListening"+Math.random().toString(36).slice(2);function _l(e){if(!e[lr]){e[lr]=!0,Ql.forEach(function(t){t!=="selectionchange"&&(Tg.has(t)||fl(t,!1,e),fl(t,!0,e))});var i=e.nodeType===9?e:e.ownerDocument;i===null||i[lr]||(i[lr]=!0,fl("selectionchange",!1,i))}}function nu(e,i,t,n){switch(Au(i)){case 2:var o=lf;break;case 8:o=cf;break;default:o=Rl}t=o.bind(null,i,t,e),o=void 0,!zr||i!=="touchstart"&&i!=="touchmove"&&i!=="wheel"||(o=!0),n?o!==void 0?e.addEventListener(i,t,{capture:!0,passive:o}):e.addEventListener(i,t,!0):o!==void 0?e.addEventListener(i,t,{passive:o}):e.addEventListener(i,t,!1)}function hl(e,i,t,n,o){var r=n;if((i&1)===0&&(i&2)===0&&n!==null)e:for(;;){if(n===null)return;var u=n.tag;if(u===3||u===4){var f=n.stateNode.containerInfo;if(f===o)break;if(u===4)for(u=n.return;u!==null;){var b=u.tag;if((b===3||b===4)&&u.stateNode.containerInfo===o)return;u=u.return}for(;f!==null;){if(u=zt(f),u===null)return;if(b=u.tag,b===5||b===6||b===26||b===27){n=r=u;continue e}f=f.parentNode}}n=n.return}mc(function(){var j=r,B=Pr(t),K=[];e:{var R=Vc.get(e);if(R!==void 0){var M=xo,_e=e;switch(e){case"keypress":if(vo(t)===0)break e;case"keydown":case"keyup":M=Ap;break;case"focusin":_e="focus",M=Ur;break;case"focusout":_e="blur",M=Ur;break;case"beforeblur":case"afterblur":M=Ur;break;case"click":if(t.button===2)break e;case"auxclick":case"dblclick":case"mousedown":case"mousemove":case"mouseup":case"mouseout":case"mouseover":case"contextmenu":M=gc;break;case"drag":case"dragend":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"dragstart":case"drop":M=_p;break;case"touchcancel":case"touchend":case"touchmove":case"touchstart":M=Mp;break;case Ec:case Pc:case Lc:M=yp;break;case zc:M=qp;break;case"scroll":case"scrollend":M=gp;break;case"wheel":M=Ep;break;case"copy":case"cut":case"paste":M=kp;break;case"gotpointercapture":case"lostpointercapture":case"pointercancel":case"pointerdown":case"pointermove":case"pointerout":case"pointerover":case"pointerup":M=_c;break;case"toggle":case"beforetoggle":M=Lp}var ge=(i&4)!==0,De=!ge&&(e==="scroll"||e==="scrollend"),S=ge?R!==null?R+"Capture":null:R;ge=[];for(var x=j,I;x!==null;){var F=x;if(I=F.stateNode,F=F.tag,F!==5&&F!==26&&F!==27||I===null||S===null||(F=hn(x,S),F!=null&&ge.push(Zn(x,F,I))),De)break;x=x.return}0<ge.length&&(R=new M(R,_e,null,t,B),K.push({event:R,listeners:ge}))}}if((i&7)===0){e:{if(R=e==="mouseover"||e==="pointerover",M=e==="mouseout"||e==="pointerout",R&&t!==Er&&(_e=t.relatedTarget||t.fromElement)&&(zt(_e)||_e[bt]))break e;if((M||R)&&(R=B.window===B?B:(R=B.ownerDocument)?R.defaultView||R.parentWindow:window,M?(_e=t.relatedTarget||t.toElement,M=j,_e=_e?zt(_e):null,_e!==null&&(De=m(_e),ge=_e.tag,_e!==De||ge!==5&&ge!==27&&ge!==6)&&(_e=null)):(M=null,_e=j),M!==_e)){if(ge=gc,F="onMouseLeave",S="onMouseEnter",x="mouse",(e==="pointerout"||e==="pointerover")&&(ge=_c,F="onPointerLeave",S="onPointerEnter",x="pointer"),De=M==null?R:_n(M),I=_e==null?R:_n(_e),R=new ge(F,x+"leave",M,t,B),R.target=De,R.relatedTarget=I,F=null,zt(B)===j&&(ge=new ge(S,x+"enter",_e,t,B),ge.target=I,ge.relatedTarget=De,F=ge),De=F,M&&_e)i:{for(ge=M,S=_e,x=0,I=ge;I;I=dn(I))x++;for(I=0,F=S;F;F=dn(F))I++;for(;0<x-I;)ge=dn(ge),x--;for(;0<I-x;)S=dn(S),I--;for(;x--;){if(ge===S||S!==null&&ge===S.alternate)break i;ge=dn(ge),S=dn(S)}ge=null}else ge=null;M!==null&&ou(K,R,M,ge,!1),_e!==null&&De!==null&&ou(K,De,_e,ge,!0)}}e:{if(R=j?_n(j):window,M=R.nodeName&&R.nodeName.toLowerCase(),M==="select"||M==="input"&&R.type==="file")var ce=Sc;else if(xc(R))if(Nc)ce=Yp;else{ce=Hp;var ve=Gp}else M=R.nodeName,!M||M.toLowerCase()!=="input"||R.type!=="checkbox"&&R.type!=="radio"?j&&Tr(j.elementType)&&(ce=Sc):ce=Kp;if(ce&&(ce=ce(e,j))){Cc(K,ce,t,B);break e}ve&&ve(e,R,j),e==="focusout"&&j&&R.type==="number"&&j.memoizedProps.value!=null&&qr(R,"number",R.value)}switch(ve=j?_n(j):window,e){case"focusin":(xc(ve)||ve.contentEditable==="true")&&(Va=ve,Xr=j,Nn=null);break;case"focusout":Nn=Xr=Va=null;break;case"mousedown":$r=!0;break;case"contextmenu":case"mouseup":case"dragend":$r=!1,qc(K,t,B);break;case"selectionchange":if($p)break;case"keydown":case"keyup":qc(K,t,B)}var me;if(Gr)e:{switch(e){case"compositionstart":var fe="onCompositionStart";break e;case"compositionend":fe="onCompositionEnd";break e;case"compositionupdate":fe="onCompositionUpdate";break e}fe=void 0}else za?vc(e,t)&&(fe="onCompositionEnd"):e==="keydown"&&t.keyCode===229&&(fe="onCompositionStart");fe&&(hc&&t.locale!=="ko"&&(za||fe!=="onCompositionStart"?fe==="onCompositionEnd"&&za&&(me=uc()):(Vt=B,Vr="value"in Vt?Vt.value:Vt.textContent,za=!0)),ve=cr(j,fe),0<ve.length&&(fe=new fc(fe,e,null,t,B),K.push({event:fe,listeners:ve}),me?fe.data=me:(me=kc(t),me!==null&&(fe.data=me)))),(me=Vp?Op(e,t):Bp(e,t))&&(fe=cr(j,"onBeforeInput"),0<fe.length&&(ve=new fc("onBeforeInput","beforeinput",null,t,B),K.push({event:ve,listeners:fe}),ve.data=me)),Mg(K,e,j,t,B)}au(K,i)})}function Zn(e,i,t){return{instance:e,listener:i,currentTarget:t}}function cr(e,i){for(var t=i+"Capture",n=[];e!==null;){var o=e,r=o.stateNode;if(o=o.tag,o!==5&&o!==26&&o!==27||r===null||(o=hn(e,t),o!=null&&n.unshift(Zn(e,o,r)),o=hn(e,i),o!=null&&n.push(Zn(e,o,r))),e.tag===3)return n;e=e.return}return[]}function dn(e){if(e===null)return null;do e=e.return;while(e&&e.tag!==5&&e.tag!==27);return e||null}function ou(e,i,t,n,o){for(var r=i._reactName,u=[];t!==null&&t!==n;){var f=t,b=f.alternate,j=f.stateNode;if(f=f.tag,b!==null&&b===n)break;f!==5&&f!==26&&f!==27||j===null||(b=j,o?(j=hn(t,r),j!=null&&u.unshift(Zn(t,j,b))):o||(j=hn(t,r),j!=null&&u.push(Zn(t,j,b)))),t=t.return}u.length!==0&&e.push({event:i,listeners:u})}var Eg=/\r\n?/g,Pg=/\u0000|\uFFFD/g;function ru(e){return(typeof e=="string"?e:""+e).replace(Eg,`
`).replace(Pg,"")}function su(e,i){return i=ru(i),ru(e)===i}function dr(){}function Me(e,i,t,n,o,r){switch(t){case"children":typeof n=="string"?i==="body"||i==="textarea"&&n===""||Ea(e,n):(typeof n=="number"||typeof n=="bigint")&&i!=="body"&&Ea(e,""+n);break;case"className":fo(e,"class",n);break;case"tabIndex":fo(e,"tabindex",n);break;case"dir":case"role":case"viewBox":case"width":case"height":fo(e,t,n);break;case"style":cc(e,n,r);break;case"data":if(i!=="object"){fo(e,"data",n);break}case"src":case"href":if(n===""&&(i!=="a"||t!=="href")){e.removeAttribute(t);break}if(n==null||typeof n=="function"||typeof n=="symbol"||typeof n=="boolean"){e.removeAttribute(t);break}n=bo(""+n),e.setAttribute(t,n);break;case"action":case"formAction":if(typeof n=="function"){e.setAttribute(t,"javascript:throw new Error('A React form was unexpectedly submitted. If you called form.submit() manually, consider using form.requestSubmit() instead. If you\\'re trying to use event.stopPropagation() in a submit event handler, consider also calling event.preventDefault().')");break}else typeof r=="function"&&(t==="formAction"?(i!=="input"&&Me(e,i,"name",o.name,o,null),Me(e,i,"formEncType",o.formEncType,o,null),Me(e,i,"formMethod",o.formMethod,o,null),Me(e,i,"formTarget",o.formTarget,o,null)):(Me(e,i,"encType",o.encType,o,null),Me(e,i,"method",o.method,o,null),Me(e,i,"target",o.target,o,null)));if(n==null||typeof n=="symbol"||typeof n=="boolean"){e.removeAttribute(t);break}n=bo(""+n),e.setAttribute(t,n);break;case"onClick":n!=null&&(e.onclick=dr);break;case"onScroll":n!=null&&xe("scroll",e);break;case"onScrollEnd":n!=null&&xe("scrollend",e);break;case"dangerouslySetInnerHTML":if(n!=null){if(typeof n!="object"||!("__html"in n))throw Error(c(61));if(t=n.__html,t!=null){if(o.children!=null)throw Error(c(60));e.innerHTML=t}}break;case"multiple":e.multiple=n&&typeof n!="function"&&typeof n!="symbol";break;case"muted":e.muted=n&&typeof n!="function"&&typeof n!="symbol";break;case"suppressContentEditableWarning":case"suppressHydrationWarning":case"defaultValue":case"defaultChecked":case"innerHTML":case"ref":break;case"autoFocus":break;case"xlinkHref":if(n==null||typeof n=="function"||typeof n=="boolean"||typeof n=="symbol"){e.removeAttribute("xlink:href");break}t=bo(""+n),e.setAttributeNS("http://www.w3.org/1999/xlink","xlink:href",t);break;case"contentEditable":case"spellCheck":case"draggable":case"value":case"autoReverse":case"externalResourcesRequired":case"focusable":case"preserveAlpha":n!=null&&typeof n!="function"&&typeof n!="symbol"?e.setAttribute(t,""+n):e.removeAttribute(t);break;case"inert":case"allowFullScreen":case"async":case"autoPlay":case"controls":case"default":case"defer":case"disabled":case"disablePictureInPicture":case"disableRemotePlayback":case"formNoValidate":case"hidden":case"loop":case"noModule":case"noValidate":case"open":case"playsInline":case"readOnly":case"required":case"reversed":case"scoped":case"seamless":case"itemScope":n&&typeof n!="function"&&typeof n!="symbol"?e.setAttribute(t,""):e.removeAttribute(t);break;case"capture":case"download":n===!0?e.setAttribute(t,""):n!==!1&&n!=null&&typeof n!="function"&&typeof n!="symbol"?e.setAttribute(t,n):e.removeAttribute(t);break;case"cols":case"rows":case"size":case"span":n!=null&&typeof n!="function"&&typeof n!="symbol"&&!isNaN(n)&&1<=n?e.setAttribute(t,n):e.removeAttribute(t);break;case"rowSpan":case"start":n==null||typeof n=="function"||typeof n=="symbol"||isNaN(n)?e.removeAttribute(t):e.setAttribute(t,n);break;case"popover":xe("beforetoggle",e),xe("toggle",e),go(e,"popover",n);break;case"xlinkActuate":yt(e,"http://www.w3.org/1999/xlink","xlink:actuate",n);break;case"xlinkArcrole":yt(e,"http://www.w3.org/1999/xlink","xlink:arcrole",n);break;case"xlinkRole":yt(e,"http://www.w3.org/1999/xlink","xlink:role",n);break;case"xlinkShow":yt(e,"http://www.w3.org/1999/xlink","xlink:show",n);break;case"xlinkTitle":yt(e,"http://www.w3.org/1999/xlink","xlink:title",n);break;case"xlinkType":yt(e,"http://www.w3.org/1999/xlink","xlink:type",n);break;case"xmlBase":yt(e,"http://www.w3.org/XML/1998/namespace","xml:base",n);break;case"xmlLang":yt(e,"http://www.w3.org/XML/1998/namespace","xml:lang",n);break;case"xmlSpace":yt(e,"http://www.w3.org/XML/1998/namespace","xml:space",n);break;case"is":go(e,"is",n);break;case"innerText":case"textContent":break;default:(!(2<t.length)||t[0]!=="o"&&t[0]!=="O"||t[1]!=="n"&&t[1]!=="N")&&(t=up.get(t)||t,go(e,t,n))}}function bl(e,i,t,n,o,r){switch(t){case"style":cc(e,n,r);break;case"dangerouslySetInnerHTML":if(n!=null){if(typeof n!="object"||!("__html"in n))throw Error(c(61));if(t=n.__html,t!=null){if(o.children!=null)throw Error(c(60));e.innerHTML=t}}break;case"children":typeof n=="string"?Ea(e,n):(typeof n=="number"||typeof n=="bigint")&&Ea(e,""+n);break;case"onScroll":n!=null&&xe("scroll",e);break;case"onScrollEnd":n!=null&&xe("scrollend",e);break;case"onClick":n!=null&&(e.onclick=dr);break;case"suppressContentEditableWarning":case"suppressHydrationWarning":case"innerHTML":case"ref":break;case"innerText":case"textContent":break;default:if(!Wl.hasOwnProperty(t))e:{if(t[0]==="o"&&t[1]==="n"&&(o=t.endsWith("Capture"),i=t.slice(2,o?t.length-7:void 0),r=e[Ue]||null,r=r!=null?r[t]:null,typeof r=="function"&&e.removeEventListener(i,r,o),typeof n=="function")){typeof r!="function"&&r!==null&&(t in e?e[t]=null:e.hasAttribute(t)&&e.removeAttribute(t)),e.addEventListener(i,n,o);break e}t in e?e[t]=n:n===!0?e.setAttribute(t,""):go(e,t,n)}}}function si(e,i,t){switch(i){case"div":case"span":case"svg":case"path":case"a":case"g":case"p":case"li":break;case"img":xe("error",e),xe("load",e);var n=!1,o=!1,r;for(r in t)if(t.hasOwnProperty(r)){var u=t[r];if(u!=null)switch(r){case"src":n=!0;break;case"srcSet":o=!0;break;case"children":case"dangerouslySetInnerHTML":throw Error(c(137,i));default:Me(e,i,r,u,t,null)}}o&&Me(e,i,"srcSet",t.srcSet,t,null),n&&Me(e,i,"src",t.src,t,null);return;case"input":xe("invalid",e);var f=r=u=o=null,b=null,j=null;for(n in t)if(t.hasOwnProperty(n)){var B=t[n];if(B!=null)switch(n){case"name":o=B;break;case"type":u=B;break;case"checked":b=B;break;case"defaultChecked":j=B;break;case"value":r=B;break;case"defaultValue":f=B;break;case"children":case"dangerouslySetInnerHTML":if(B!=null)throw Error(c(137,i));break;default:Me(e,i,n,B,t,null)}}oc(e,r,f,b,j,u,o,!1),_o(e);return;case"select":xe("invalid",e),n=u=r=null;for(o in t)if(t.hasOwnProperty(o)&&(f=t[o],f!=null))switch(o){case"value":r=f;break;case"defaultValue":u=f;break;case"multiple":n=f;default:Me(e,i,o,f,t,null)}i=r,t=u,e.multiple=!!n,i!=null?Ta(e,!!n,i,!1):t!=null&&Ta(e,!!n,t,!0);return;case"textarea":xe("invalid",e),r=o=n=null;for(u in t)if(t.hasOwnProperty(u)&&(f=t[u],f!=null))switch(u){case"value":n=f;break;case"defaultValue":o=f;break;case"children":r=f;break;case"dangerouslySetInnerHTML":if(f!=null)throw Error(c(91));break;default:Me(e,i,u,f,t,null)}sc(e,n,o,r),_o(e);return;case"option":for(b in t)if(t.hasOwnProperty(b)&&(n=t[b],n!=null))switch(b){case"selected":e.selected=n&&typeof n!="function"&&typeof n!="symbol";break;default:Me(e,i,b,n,t,null)}return;case"dialog":xe("beforetoggle",e),xe("toggle",e),xe("cancel",e),xe("close",e);break;case"iframe":case"object":xe("load",e);break;case"video":case"audio":for(n=0;n<Wn.length;n++)xe(Wn[n],e);break;case"image":xe("error",e),xe("load",e);break;case"details":xe("toggle",e);break;case"embed":case"source":case"link":xe("error",e),xe("load",e);case"area":case"base":case"br":case"col":case"hr":case"keygen":case"meta":case"param":case"track":case"wbr":case"menuitem":for(j in t)if(t.hasOwnProperty(j)&&(n=t[j],n!=null))switch(j){case"children":case"dangerouslySetInnerHTML":throw Error(c(137,i));default:Me(e,i,j,n,t,null)}return;default:if(Tr(i)){for(B in t)t.hasOwnProperty(B)&&(n=t[B],n!==void 0&&bl(e,i,B,n,t,void 0));return}}for(f in t)t.hasOwnProperty(f)&&(n=t[f],n!=null&&Me(e,i,f,n,t,null))}function Lg(e,i,t,n){switch(i){case"div":case"span":case"svg":case"path":case"a":case"g":case"p":case"li":break;case"input":var o=null,r=null,u=null,f=null,b=null,j=null,B=null;for(M in t){var K=t[M];if(t.hasOwnProperty(M)&&K!=null)switch(M){case"checked":break;case"value":break;case"defaultValue":b=K;default:n.hasOwnProperty(M)||Me(e,i,M,null,n,K)}}for(var R in n){var M=n[R];if(K=t[R],n.hasOwnProperty(R)&&(M!=null||K!=null))switch(R){case"type":r=M;break;case"name":o=M;break;case"checked":j=M;break;case"defaultChecked":B=M;break;case"value":u=M;break;case"defaultValue":f=M;break;case"children":case"dangerouslySetInnerHTML":if(M!=null)throw Error(c(137,i));break;default:M!==K&&Me(e,i,R,M,n,K)}}Dr(e,u,f,b,j,B,r,o);return;case"select":M=u=f=R=null;for(r in t)if(b=t[r],t.hasOwnProperty(r)&&b!=null)switch(r){case"value":break;case"multiple":M=b;default:n.hasOwnProperty(r)||Me(e,i,r,null,n,b)}for(o in n)if(r=n[o],b=t[o],n.hasOwnProperty(o)&&(r!=null||b!=null))switch(o){case"value":R=r;break;case"defaultValue":f=r;break;case"multiple":u=r;default:r!==b&&Me(e,i,o,r,n,b)}i=f,t=u,n=M,R!=null?Ta(e,!!t,R,!1):!!n!=!!t&&(i!=null?Ta(e,!!t,i,!0):Ta(e,!!t,t?[]:"",!1));return;case"textarea":M=R=null;for(f in t)if(o=t[f],t.hasOwnProperty(f)&&o!=null&&!n.hasOwnProperty(f))switch(f){case"value":break;case"children":break;default:Me(e,i,f,null,n,o)}for(u in n)if(o=n[u],r=t[u],n.hasOwnProperty(u)&&(o!=null||r!=null))switch(u){case"value":R=o;break;case"defaultValue":M=o;break;case"children":break;case"dangerouslySetInnerHTML":if(o!=null)throw Error(c(91));break;default:o!==r&&Me(e,i,u,o,n,r)}rc(e,R,M);return;case"option":for(var _e in t)if(R=t[_e],t.hasOwnProperty(_e)&&R!=null&&!n.hasOwnProperty(_e))switch(_e){case"selected":e.selected=!1;break;default:Me(e,i,_e,null,n,R)}for(b in n)if(R=n[b],M=t[b],n.hasOwnProperty(b)&&R!==M&&(R!=null||M!=null))switch(b){case"selected":e.selected=R&&typeof R!="function"&&typeof R!="symbol";break;default:Me(e,i,b,R,n,M)}return;case"img":case"link":case"area":case"base":case"br":case"col":case"embed":case"hr":case"keygen":case"meta":case"param":case"source":case"track":case"wbr":case"menuitem":for(var ge in t)R=t[ge],t.hasOwnProperty(ge)&&R!=null&&!n.hasOwnProperty(ge)&&Me(e,i,ge,null,n,R);for(j in n)if(R=n[j],M=t[j],n.hasOwnProperty(j)&&R!==M&&(R!=null||M!=null))switch(j){case"children":case"dangerouslySetInnerHTML":if(R!=null)throw Error(c(137,i));break;default:Me(e,i,j,R,n,M)}return;default:if(Tr(i)){for(var De in t)R=t[De],t.hasOwnProperty(De)&&R!==void 0&&!n.hasOwnProperty(De)&&bl(e,i,De,void 0,n,R);for(B in n)R=n[B],M=t[B],!n.hasOwnProperty(B)||R===M||R===void 0&&M===void 0||bl(e,i,B,R,n,M);return}}for(var S in t)R=t[S],t.hasOwnProperty(S)&&R!=null&&!n.hasOwnProperty(S)&&Me(e,i,S,null,n,R);for(K in n)R=n[K],M=t[K],!n.hasOwnProperty(K)||R===M||R==null&&M==null||Me(e,i,K,R,n,M)}var yl=null,vl=null;function mr(e){return e.nodeType===9?e:e.ownerDocument}function lu(e){switch(e){case"http://www.w3.org/2000/svg":return 1;case"http://www.w3.org/1998/Math/MathML":return 2;default:return 0}}function cu(e,i){if(e===0)switch(i){case"svg":return 1;case"math":return 2;default:return 0}return e===1&&i==="foreignObject"?0:e}function kl(e,i){return e==="textarea"||e==="noscript"||typeof i.children=="string"||typeof i.children=="number"||typeof i.children=="bigint"||typeof i.dangerouslySetInnerHTML=="object"&&i.dangerouslySetInnerHTML!==null&&i.dangerouslySetInnerHTML.__html!=null}var xl=null;function zg(){var e=window.event;return e&&e.type==="popstate"?e===xl?!1:(xl=e,!0):(xl=null,!1)}var du=typeof setTimeout=="function"?setTimeout:void 0,Vg=typeof clearTimeout=="function"?clearTimeout:void 0,mu=typeof Promise=="function"?Promise:void 0,Og=typeof queueMicrotask=="function"?queueMicrotask:typeof mu<"u"?function(e){return mu.resolve(null).then(e).catch(Bg)}:du;function Bg(e){setTimeout(function(){throw e})}function ia(e){return e==="head"}function uu(e,i){var t=i,n=0,o=0;do{var r=t.nextSibling;if(e.removeChild(t),r&&r.nodeType===8)if(t=r.data,t==="/$"){if(0<n&&8>n){t=n;var u=e.ownerDocument;if(t&1&&eo(u.documentElement),t&2&&eo(u.body),t&4)for(t=u.head,eo(t),u=t.firstChild;u;){var f=u.nextSibling,b=u.nodeName;u[je]||b==="SCRIPT"||b==="STYLE"||b==="LINK"&&u.rel.toLowerCase()==="stylesheet"||t.removeChild(u),u=f}}if(o===0){e.removeChild(r),lo(i);return}o--}else t==="$"||t==="$?"||t==="$!"?o++:n=t.charCodeAt(0)-48;else n=0;t=r}while(t);lo(i)}function Cl(e){var i=e.firstChild;for(i&&i.nodeType===10&&(i=i.nextSibling);i;){var t=i;switch(i=i.nextSibling,t.nodeName){case"HTML":case"HEAD":case"BODY":Cl(t),fn(t);continue;case"SCRIPT":case"STYLE":continue;case"LINK":if(t.rel.toLowerCase()==="stylesheet")continue}e.removeChild(t)}}function Ug(e,i,t,n){for(;e.nodeType===1;){var o=t;if(e.nodeName.toLowerCase()!==i.toLowerCase()){if(!n&&(e.nodeName!=="INPUT"||e.type!=="hidden"))break}else if(n){if(!e[je])switch(i){case"meta":if(!e.hasAttribute("itemprop"))break;return e;case"link":if(r=e.getAttribute("rel"),r==="stylesheet"&&e.hasAttribute("data-precedence"))break;if(r!==o.rel||e.getAttribute("href")!==(o.href==null||o.href===""?null:o.href)||e.getAttribute("crossorigin")!==(o.crossOrigin==null?null:o.crossOrigin)||e.getAttribute("title")!==(o.title==null?null:o.title))break;return e;case"style":if(e.hasAttribute("data-precedence"))break;return e;case"script":if(r=e.getAttribute("src"),(r!==(o.src==null?null:o.src)||e.getAttribute("type")!==(o.type==null?null:o.type)||e.getAttribute("crossorigin")!==(o.crossOrigin==null?null:o.crossOrigin))&&r&&e.hasAttribute("async")&&!e.hasAttribute("itemprop"))break;return e;default:return e}}else if(i==="input"&&e.type==="hidden"){var r=o.name==null?null:""+o.name;if(o.type==="hidden"&&e.getAttribute("name")===r)return e}else return e;if(e=Yi(e.nextSibling),e===null)break}return null}function Fg(e,i,t){if(i==="")return null;for(;e.nodeType!==3;)if((e.nodeType!==1||e.nodeName!=="INPUT"||e.type!=="hidden")&&!t||(e=Yi(e.nextSibling),e===null))return null;return e}function Sl(e){return e.data==="$!"||e.data==="$?"&&e.ownerDocument.readyState==="complete"}function Gg(e,i){var t=e.ownerDocument;if(e.data!=="$?"||t.readyState==="complete")i();else{var n=function(){i(),t.removeEventListener("DOMContentLoaded",n)};t.addEventListener("DOMContentLoaded",n),e._reactRetry=n}}function Yi(e){for(;e!=null;e=e.nextSibling){var i=e.nodeType;if(i===1||i===3)break;if(i===8){if(i=e.data,i==="$"||i==="$!"||i==="$?"||i==="F!"||i==="F")break;if(i==="/$")return null}}return e}var Nl=null;function pu(e){e=e.previousSibling;for(var i=0;e;){if(e.nodeType===8){var t=e.data;if(t==="$"||t==="$!"||t==="$?"){if(i===0)return e;i--}else t==="/$"&&i++}e=e.previousSibling}return null}function gu(e,i,t){switch(i=mr(t),e){case"html":if(e=i.documentElement,!e)throw Error(c(452));return e;case"head":if(e=i.head,!e)throw Error(c(453));return e;case"body":if(e=i.body,!e)throw Error(c(454));return e;default:throw Error(c(451))}}function eo(e){for(var i=e.attributes;i.length;)e.removeAttributeNode(i[0]);fn(e)}var Vi=new Map,fu=new Set;function ur(e){return typeof e.getRootNode=="function"?e.getRootNode():e.nodeType===9?e:e.ownerDocument}var qt=G.d;G.d={f:Hg,r:Kg,D:Yg,C:Xg,L:$g,m:Jg,X:Wg,S:Qg,M:Zg};function Hg(){var e=qt.f(),i=ar();return e||i}function Kg(e){var i=Ra(e);i!==null&&i.tag===5&&i.type==="form"?Ed(i):qt.r(e)}var mn=typeof document>"u"?null:document;function _u(e,i,t){var n=mn;if(n&&typeof i=="string"&&i){var o=Di(i);o='link[rel="'+e+'"][href="'+o+'"]',typeof t=="string"&&(o+='[crossorigin="'+t+'"]'),fu.has(o)||(fu.add(o),e={rel:e,crossOrigin:t,href:i},n.querySelector(o)===null&&(i=n.createElement("link"),si(i,"link",e),ei(i),n.head.appendChild(i)))}}function Yg(e){qt.D(e),_u("dns-prefetch",e,null)}function Xg(e,i){qt.C(e,i),_u("preconnect",e,i)}function $g(e,i,t){qt.L(e,i,t);var n=mn;if(n&&e&&i){var o='link[rel="preload"][as="'+Di(i)+'"]';i==="image"&&t&&t.imageSrcSet?(o+='[imagesrcset="'+Di(t.imageSrcSet)+'"]',typeof t.imageSizes=="string"&&(o+='[imagesizes="'+Di(t.imageSizes)+'"]')):o+='[href="'+Di(e)+'"]';var r=o;switch(i){case"style":r=un(e);break;case"script":r=pn(e)}Vi.has(r)||(e=D({rel:"preload",href:i==="image"&&t&&t.imageSrcSet?void 0:e,as:i},t),Vi.set(r,e),n.querySelector(o)!==null||i==="style"&&n.querySelector(io(r))||i==="script"&&n.querySelector(to(r))||(i=n.createElement("link"),si(i,"link",e),ei(i),n.head.appendChild(i)))}}function Jg(e,i){qt.m(e,i);var t=mn;if(t&&e){var n=i&&typeof i.as=="string"?i.as:"script",o='link[rel="modulepreload"][as="'+Di(n)+'"][href="'+Di(e)+'"]',r=o;switch(n){case"audioworklet":case"paintworklet":case"serviceworker":case"sharedworker":case"worker":case"script":r=pn(e)}if(!Vi.has(r)&&(e=D({rel:"modulepreload",href:e},i),Vi.set(r,e),t.querySelector(o)===null)){switch(n){case"audioworklet":case"paintworklet":case"serviceworker":case"sharedworker":case"worker":case"script":if(t.querySelector(to(r)))return}n=t.createElement("link"),si(n,"link",e),ei(n),t.head.appendChild(n)}}}function Qg(e,i,t){qt.S(e,i,t);var n=mn;if(n&&e){var o=Ma(n).hoistableStyles,r=un(e);i=i||"default";var u=o.get(r);if(!u){var f={loading:0,preload:null};if(u=n.querySelector(io(r)))f.loading=5;else{e=D({rel:"stylesheet",href:e,"data-precedence":i},t),(t=Vi.get(r))&&Il(e,t);var b=u=n.createElement("link");ei(b),si(b,"link",e),b._p=new Promise(function(j,B){b.onload=j,b.onerror=B}),b.addEventListener("load",function(){f.loading|=1}),b.addEventListener("error",function(){f.loading|=2}),f.loading|=4,pr(u,i,n)}u={type:"stylesheet",instance:u,count:1,state:f},o.set(r,u)}}}function Wg(e,i){qt.X(e,i);var t=mn;if(t&&e){var n=Ma(t).hoistableScripts,o=pn(e),r=n.get(o);r||(r=t.querySelector(to(o)),r||(e=D({src:e,async:!0},i),(i=Vi.get(o))&&jl(e,i),r=t.createElement("script"),ei(r),si(r,"link",e),t.head.appendChild(r)),r={type:"script",instance:r,count:1,state:null},n.set(o,r))}}function Zg(e,i){qt.M(e,i);var t=mn;if(t&&e){var n=Ma(t).hoistableScripts,o=pn(e),r=n.get(o);r||(r=t.querySelector(to(o)),r||(e=D({src:e,async:!0,type:"module"},i),(i=Vi.get(o))&&jl(e,i),r=t.createElement("script"),ei(r),si(r,"link",e),t.head.appendChild(r)),r={type:"script",instance:r,count:1,state:null},n.set(o,r))}}function hu(e,i,t,n){var o=(o=re.current)?ur(o):null;if(!o)throw Error(c(446));switch(e){case"meta":case"title":return null;case"style":return typeof t.precedence=="string"&&typeof t.href=="string"?(i=un(t.href),t=Ma(o).hoistableStyles,n=t.get(i),n||(n={type:"style",instance:null,count:0,state:null},t.set(i,n)),n):{type:"void",instance:null,count:0,state:null};case"link":if(t.rel==="stylesheet"&&typeof t.href=="string"&&typeof t.precedence=="string"){e=un(t.href);var r=Ma(o).hoistableStyles,u=r.get(e);if(u||(o=o.ownerDocument||o,u={type:"stylesheet",instance:null,count:0,state:{loading:0,preload:null}},r.set(e,u),(r=o.querySelector(io(e)))&&!r._p&&(u.instance=r,u.state.loading=5),Vi.has(e)||(t={rel:"preload",as:"style",href:t.href,crossOrigin:t.crossOrigin,integrity:t.integrity,media:t.media,hrefLang:t.hrefLang,referrerPolicy:t.referrerPolicy},Vi.set(e,t),r||ef(o,e,t,u.state))),i&&n===null)throw Error(c(528,""));return u}if(i&&n!==null)throw Error(c(529,""));return null;case"script":return i=t.async,t=t.src,typeof t=="string"&&i&&typeof i!="function"&&typeof i!="symbol"?(i=pn(t),t=Ma(o).hoistableScripts,n=t.get(i),n||(n={type:"script",instance:null,count:0,state:null},t.set(i,n)),n):{type:"void",instance:null,count:0,state:null};default:throw Error(c(444,e))}}function un(e){return'href="'+Di(e)+'"'}function io(e){return'link[rel="stylesheet"]['+e+"]"}function bu(e){return D({},e,{"data-precedence":e.precedence,precedence:null})}function ef(e,i,t,n){e.querySelector('link[rel="preload"][as="style"]['+i+"]")?n.loading=1:(i=e.createElement("link"),n.preload=i,i.addEventListener("load",function(){return n.loading|=1}),i.addEventListener("error",function(){return n.loading|=2}),si(i,"link",t),ei(i),e.head.appendChild(i))}function pn(e){return'[src="'+Di(e)+'"]'}function to(e){return"script[async]"+e}function yu(e,i,t){if(i.count++,i.instance===null)switch(i.type){case"style":var n=e.querySelector('style[data-href~="'+Di(t.href)+'"]');if(n)return i.instance=n,ei(n),n;var o=D({},t,{"data-href":t.href,"data-precedence":t.precedence,href:null,precedence:null});return n=(e.ownerDocument||e).createElement("style"),ei(n),si(n,"style",o),pr(n,t.precedence,e),i.instance=n;case"stylesheet":o=un(t.href);var r=e.querySelector(io(o));if(r)return i.state.loading|=4,i.instance=r,ei(r),r;n=bu(t),(o=Vi.get(o))&&Il(n,o),r=(e.ownerDocument||e).createElement("link"),ei(r);var u=r;return u._p=new Promise(function(f,b){u.onload=f,u.onerror=b}),si(r,"link",n),i.state.loading|=4,pr(r,t.precedence,e),i.instance=r;case"script":return r=pn(t.src),(o=e.querySelector(to(r)))?(i.instance=o,ei(o),o):(n=t,(o=Vi.get(r))&&(n=D({},t),jl(n,o)),e=e.ownerDocument||e,o=e.createElement("script"),ei(o),si(o,"link",n),e.head.appendChild(o),i.instance=o);case"void":return null;default:throw Error(c(443,i.type))}else i.type==="stylesheet"&&(i.state.loading&4)===0&&(n=i.instance,i.state.loading|=4,pr(n,t.precedence,e));return i.instance}function pr(e,i,t){for(var n=t.querySelectorAll('link[rel="stylesheet"][data-precedence],style[data-precedence]'),o=n.length?n[n.length-1]:null,r=o,u=0;u<n.length;u++){var f=n[u];if(f.dataset.precedence===i)r=f;else if(r!==o)break}r?r.parentNode.insertBefore(e,r.nextSibling):(i=t.nodeType===9?t.head:t,i.insertBefore(e,i.firstChild))}function Il(e,i){e.crossOrigin==null&&(e.crossOrigin=i.crossOrigin),e.referrerPolicy==null&&(e.referrerPolicy=i.referrerPolicy),e.title==null&&(e.title=i.title)}function jl(e,i){e.crossOrigin==null&&(e.crossOrigin=i.crossOrigin),e.referrerPolicy==null&&(e.referrerPolicy=i.referrerPolicy),e.integrity==null&&(e.integrity=i.integrity)}var gr=null;function vu(e,i,t){if(gr===null){var n=new Map,o=gr=new Map;o.set(t,n)}else o=gr,n=o.get(t),n||(n=new Map,o.set(t,n));if(n.has(e))return n;for(n.set(e,null),t=t.getElementsByTagName(e),o=0;o<t.length;o++){var r=t[o];if(!(r[je]||r[pe]||e==="link"&&r.getAttribute("rel")==="stylesheet")&&r.namespaceURI!=="http://www.w3.org/2000/svg"){var u=r.getAttribute(i)||"";u=e+u;var f=n.get(u);f?f.push(r):n.set(u,[r])}}return n}function ku(e,i,t){e=e.ownerDocument||e,e.head.insertBefore(t,i==="title"?e.querySelector("head > title"):null)}function tf(e,i,t){if(t===1||i.itemProp!=null)return!1;switch(e){case"meta":case"title":return!0;case"style":if(typeof i.precedence!="string"||typeof i.href!="string"||i.href==="")break;return!0;case"link":if(typeof i.rel!="string"||typeof i.href!="string"||i.href===""||i.onLoad||i.onError)break;switch(i.rel){case"stylesheet":return e=i.disabled,typeof i.precedence=="string"&&e==null;default:return!0}case"script":if(i.async&&typeof i.async!="function"&&typeof i.async!="symbol"&&!i.onLoad&&!i.onError&&i.src&&typeof i.src=="string")return!0}return!1}function xu(e){return!(e.type==="stylesheet"&&(e.state.loading&3)===0)}var ao=null;function af(){}function nf(e,i,t){if(ao===null)throw Error(c(475));var n=ao;if(i.type==="stylesheet"&&(typeof t.media!="string"||matchMedia(t.media).matches!==!1)&&(i.state.loading&4)===0){if(i.instance===null){var o=un(t.href),r=e.querySelector(io(o));if(r){e=r._p,e!==null&&typeof e=="object"&&typeof e.then=="function"&&(n.count++,n=fr.bind(n),e.then(n,n)),i.state.loading|=4,i.instance=r,ei(r);return}r=e.ownerDocument||e,t=bu(t),(o=Vi.get(o))&&Il(t,o),r=r.createElement("link"),ei(r);var u=r;u._p=new Promise(function(f,b){u.onload=f,u.onerror=b}),si(r,"link",t),i.instance=r}n.stylesheets===null&&(n.stylesheets=new Map),n.stylesheets.set(i,e),(e=i.state.preload)&&(i.state.loading&3)===0&&(n.count++,i=fr.bind(n),e.addEventListener("load",i),e.addEventListener("error",i))}}function of(){if(ao===null)throw Error(c(475));var e=ao;return e.stylesheets&&e.count===0&&Al(e,e.stylesheets),0<e.count?function(i){var t=setTimeout(function(){if(e.stylesheets&&Al(e,e.stylesheets),e.unsuspend){var n=e.unsuspend;e.unsuspend=null,n()}},6e4);return e.unsuspend=i,function(){e.unsuspend=null,clearTimeout(t)}}:null}function fr(){if(this.count--,this.count===0){if(this.stylesheets)Al(this,this.stylesheets);else if(this.unsuspend){var e=this.unsuspend;this.unsuspend=null,e()}}}var _r=null;function Al(e,i){e.stylesheets=null,e.unsuspend!==null&&(e.count++,_r=new Map,i.forEach(rf,e),_r=null,fr.call(e))}function rf(e,i){if(!(i.state.loading&4)){var t=_r.get(e);if(t)var n=t.get(null);else{t=new Map,_r.set(e,t);for(var o=e.querySelectorAll("link[data-precedence],style[data-precedence]"),r=0;r<o.length;r++){var u=o[r];(u.nodeName==="LINK"||u.getAttribute("media")!=="not all")&&(t.set(u.dataset.precedence,u),n=u)}n&&t.set(null,n)}o=i.instance,u=o.getAttribute("data-precedence"),r=t.get(u)||n,r===n&&t.set(null,o),t.set(u,o),this.count++,n=fr.bind(this),o.addEventListener("load",n),o.addEventListener("error",n),r?r.parentNode.insertBefore(o,r.nextSibling):(e=e.nodeType===9?e.head:e,e.insertBefore(o,e.firstChild)),i.state.loading|=4}}var no={$$typeof:U,Provider:null,Consumer:null,_currentValue:ae,_currentValue2:ae,_threadCount:0};function sf(e,i,t,n,o,r,u,f){this.tag=1,this.containerInfo=e,this.pingCache=this.current=this.pendingChildren=null,this.timeoutHandle=-1,this.callbackNode=this.next=this.pendingContext=this.context=this.cancelPendingCommit=null,this.callbackPriority=0,this.expirationTimes=Je(-1),this.entangledLanes=this.shellSuspendCounter=this.errorRecoveryDisabledLanes=this.expiredLanes=this.warmLanes=this.pingedLanes=this.suspendedLanes=this.pendingLanes=0,this.entanglements=Je(0),this.hiddenUpdates=Je(null),this.identifierPrefix=n,this.onUncaughtError=o,this.onCaughtError=r,this.onRecoverableError=u,this.pooledCache=null,this.pooledCacheLanes=0,this.formState=f,this.incompleteTransitions=new Map}function Cu(e,i,t,n,o,r,u,f,b,j,B,K){return e=new sf(e,i,t,u,f,b,j,K),i=1,r===!0&&(i|=24),r=xi(3,null,null,i),e.current=r,r.stateNode=e,i=cs(),i.refCount++,e.pooledCache=i,i.refCount++,r.memoizedState={element:n,isDehydrated:t,cache:i},ps(r),e}function Su(e){return e?(e=Fa,e):Fa}function Nu(e,i,t,n,o,r){o=Su(o),n.context===null?n.context=o:n.pendingContext=o,n=Ut(i),n.payload={element:t},r=r===void 0?null:r,r!==null&&(n.callback=r),t=Ft(e,n,i),t!==null&&(ji(t,e,i),Tn(t,e,i))}function Iu(e,i){if(e=e.memoizedState,e!==null&&e.dehydrated!==null){var t=e.retryLane;e.retryLane=t!==0&&t<i?t:i}}function wl(e,i){Iu(e,i),(e=e.alternate)&&Iu(e,i)}function ju(e){if(e.tag===13){var i=Ua(e,67108864);i!==null&&ji(i,e,67108864),wl(e,67108864)}}var hr=!0;function lf(e,i,t,n){var o=k.T;k.T=null;var r=G.p;try{G.p=2,Rl(e,i,t,n)}finally{G.p=r,k.T=o}}function cf(e,i,t,n){var o=k.T;k.T=null;var r=G.p;try{G.p=8,Rl(e,i,t,n)}finally{G.p=r,k.T=o}}function Rl(e,i,t,n){if(hr){var o=Ml(n);if(o===null)hl(e,i,n,br,t),wu(e,n);else if(mf(o,e,i,t,n))n.stopPropagation();else if(wu(e,n),i&4&&-1<df.indexOf(e)){for(;o!==null;){var r=Ra(o);if(r!==null)switch(r.tag){case 3:if(r=r.stateNode,r.current.memoizedState.isDehydrated){var u=yi(r.pendingLanes);if(u!==0){var f=r;for(f.pendingLanes|=2,f.entangledLanes|=2;u;){var b=1<<31-$e(u);f.entanglements[1]|=b,u&=~b}pt(r),(Ae&6)===0&&(ir=Xe()+500,Qn(0))}}break;case 13:f=Ua(r,2),f!==null&&ji(f,r,2),ar(),wl(r,2)}if(r=Ml(n),r===null&&hl(e,i,n,br,t),r===o)break;o=r}o!==null&&n.stopPropagation()}else hl(e,i,n,null,t)}}function Ml(e){return e=Pr(e),Dl(e)}var br=null;function Dl(e){if(br=null,e=zt(e),e!==null){var i=m(e);if(i===null)e=null;else{var t=i.tag;if(t===13){if(e=_(i),e!==null)return e;e=null}else if(t===3){if(i.stateNode.current.memoizedState.isDehydrated)return i.tag===3?i.stateNode.containerInfo:null;e=null}else i!==e&&(e=null)}}return br=e,null}function Au(e){switch(e){case"beforetoggle":case"cancel":case"click":case"close":case"contextmenu":case"copy":case"cut":case"auxclick":case"dblclick":case"dragend":case"dragstart":case"drop":case"focusin":case"focusout":case"input":case"invalid":case"keydown":case"keypress":case"keyup":case"mousedown":case"mouseup":case"paste":case"pause":case"play":case"pointercancel":case"pointerdown":case"pointerup":case"ratechange":case"reset":case"resize":case"seeked":case"submit":case"toggle":case"touchcancel":case"touchend":case"touchstart":case"volumechange":case"change":case"selectionchange":case"textInput":case"compositionstart":case"compositionend":case"compositionupdate":case"beforeblur":case"afterblur":case"beforeinput":case"blur":case"fullscreenchange":case"focus":case"hashchange":case"popstate":case"select":case"selectstart":return 2;case"drag":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"mousemove":case"mouseout":case"mouseover":case"pointermove":case"pointerout":case"pointerover":case"scroll":case"touchmove":case"wheel":case"mouseenter":case"mouseleave":case"pointerenter":case"pointerleave":return 8;case"message":switch(Wi()){case Bi:return 2;case Ui:return 8;case bi:case Zi:return 32;case Fi:return 268435456;default:return 32}default:return 32}}var ql=!1,ta=null,aa=null,na=null,oo=new Map,ro=new Map,oa=[],df="mousedown mouseup touchcancel touchend touchstart auxclick dblclick pointercancel pointerdown pointerup dragend dragstart drop compositionend compositionstart keydown keypress keyup input textInput copy cut paste click change contextmenu reset".split(" ");function wu(e,i){switch(e){case"focusin":case"focusout":ta=null;break;case"dragenter":case"dragleave":aa=null;break;case"mouseover":case"mouseout":na=null;break;case"pointerover":case"pointerout":oo.delete(i.pointerId);break;case"gotpointercapture":case"lostpointercapture":ro.delete(i.pointerId)}}function so(e,i,t,n,o,r){return e===null||e.nativeEvent!==r?(e={blockedOn:i,domEventName:t,eventSystemFlags:n,nativeEvent:r,targetContainers:[o]},i!==null&&(i=Ra(i),i!==null&&ju(i)),e):(e.eventSystemFlags|=n,i=e.targetContainers,o!==null&&i.indexOf(o)===-1&&i.push(o),e)}function mf(e,i,t,n,o){switch(i){case"focusin":return ta=so(ta,e,i,t,n,o),!0;case"dragenter":return aa=so(aa,e,i,t,n,o),!0;case"mouseover":return na=so(na,e,i,t,n,o),!0;case"pointerover":var r=o.pointerId;return oo.set(r,so(oo.get(r)||null,e,i,t,n,o)),!0;case"gotpointercapture":return r=o.pointerId,ro.set(r,so(ro.get(r)||null,e,i,t,n,o)),!0}return!1}function Ru(e){var i=zt(e.target);if(i!==null){var t=m(i);if(t!==null){if(i=t.tag,i===13){if(i=_(t),i!==null){e.blockedOn=i,Lt(e.priority,function(){if(t.tag===13){var n=Ii();n=rt(n);var o=Ua(t,n);o!==null&&ji(o,t,n),wl(t,n)}});return}}else if(i===3&&t.stateNode.current.memoizedState.isDehydrated){e.blockedOn=t.tag===3?t.stateNode.containerInfo:null;return}}}e.blockedOn=null}function yr(e){if(e.blockedOn!==null)return!1;for(var i=e.targetContainers;0<i.length;){var t=Ml(e.nativeEvent);if(t===null){t=e.nativeEvent;var n=new t.constructor(t.type,t);Er=n,t.target.dispatchEvent(n),Er=null}else return i=Ra(t),i!==null&&ju(i),e.blockedOn=t,!1;i.shift()}return!0}function Mu(e,i,t){yr(e)&&t.delete(i)}function uf(){ql=!1,ta!==null&&yr(ta)&&(ta=null),aa!==null&&yr(aa)&&(aa=null),na!==null&&yr(na)&&(na=null),oo.forEach(Mu),ro.forEach(Mu)}function vr(e,i){e.blockedOn===i&&(e.blockedOn=null,ql||(ql=!0,g.unstable_scheduleCallback(g.unstable_NormalPriority,uf)))}var kr=null;function Du(e){kr!==e&&(kr=e,g.unstable_scheduleCallback(g.unstable_NormalPriority,function(){kr===e&&(kr=null);for(var i=0;i<e.length;i+=3){var t=e[i],n=e[i+1],o=e[i+2];if(typeof n!="function"){if(Dl(n||t)===null)continue;break}var r=Ra(t);r!==null&&(e.splice(i,3),i-=3,Ds(r,{pending:!0,data:o,method:t.method,action:n},n,o))}}))}function lo(e){function i(b){return vr(b,e)}ta!==null&&vr(ta,e),aa!==null&&vr(aa,e),na!==null&&vr(na,e),oo.forEach(i),ro.forEach(i);for(var t=0;t<oa.length;t++){var n=oa[t];n.blockedOn===e&&(n.blockedOn=null)}for(;0<oa.length&&(t=oa[0],t.blockedOn===null);)Ru(t),t.blockedOn===null&&oa.shift();if(t=(e.ownerDocument||e).$$reactFormReplay,t!=null)for(n=0;n<t.length;n+=3){var o=t[n],r=t[n+1],u=o[Ue]||null;if(typeof r=="function")u||Du(t);else if(u){var f=null;if(r&&r.hasAttribute("formAction")){if(o=r,u=r[Ue]||null)f=u.formAction;else if(Dl(o)!==null)continue}else f=u.action;typeof f=="function"?t[n+1]=f:(t.splice(n,3),n-=3),Du(t)}}}function Tl(e){this._internalRoot=e}xr.prototype.render=Tl.prototype.render=function(e){var i=this._internalRoot;if(i===null)throw Error(c(409));var t=i.current,n=Ii();Nu(t,n,e,i,null,null)},xr.prototype.unmount=Tl.prototype.unmount=function(){var e=this._internalRoot;if(e!==null){this._internalRoot=null;var i=e.containerInfo;Nu(e.current,2,null,e,null,null),ar(),i[bt]=null}};function xr(e){this._internalRoot=e}xr.prototype.unstable_scheduleHydration=function(e){if(e){var i=st();e={blockedOn:null,target:e,priority:i};for(var t=0;t<oa.length&&i!==0&&i<oa[t].priority;t++);oa.splice(t,0,e),t===0&&Ru(e)}};var qu=s.version;if(qu!=="19.1.0")throw Error(c(527,qu,"19.1.0"));G.findDOMNode=function(e){var i=e._reactInternals;if(i===void 0)throw typeof e.render=="function"?Error(c(188)):(e=Object.keys(e).join(","),Error(c(268,e)));return e=v(i),e=e!==null?y(e):null,e=e===null?null:e.stateNode,e};var pf={bundleType:0,version:"19.1.0",rendererPackageName:"react-dom",currentDispatcherRef:k,reconcilerVersion:"19.1.0"};if(typeof __REACT_DEVTOOLS_GLOBAL_HOOK__<"u"){var Cr=__REACT_DEVTOOLS_GLOBAL_HOOK__;if(!Cr.isDisabled&&Cr.supportsFiber)try{pi=Cr.inject(pf),Ve=Cr}catch{}}return mo.createRoot=function(e,i){if(!d(e))throw Error(c(299));var t=!1,n="",o=$d,r=Jd,u=Qd,f=null;return i!=null&&(i.unstable_strictMode===!0&&(t=!0),i.identifierPrefix!==void 0&&(n=i.identifierPrefix),i.onUncaughtError!==void 0&&(o=i.onUncaughtError),i.onCaughtError!==void 0&&(r=i.onCaughtError),i.onRecoverableError!==void 0&&(u=i.onRecoverableError),i.unstable_transitionCallbacks!==void 0&&(f=i.unstable_transitionCallbacks)),i=Cu(e,1,!1,null,null,t,n,o,r,u,f,null),e[bt]=i.current,_l(e),new Tl(i)},mo.hydrateRoot=function(e,i,t){if(!d(e))throw Error(c(299));var n=!1,o="",r=$d,u=Jd,f=Qd,b=null,j=null;return t!=null&&(t.unstable_strictMode===!0&&(n=!0),t.identifierPrefix!==void 0&&(o=t.identifierPrefix),t.onUncaughtError!==void 0&&(r=t.onUncaughtError),t.onCaughtError!==void 0&&(u=t.onCaughtError),t.onRecoverableError!==void 0&&(f=t.onRecoverableError),t.unstable_transitionCallbacks!==void 0&&(b=t.unstable_transitionCallbacks),t.formState!==void 0&&(j=t.formState)),i=Cu(e,1,!0,i,t??null,n,o,r,u,f,b,j),i.context=Su(null),t=i.current,n=Ii(),n=rt(n),o=Ut(n),o.callback=null,Ft(t,o,n),t=n,i.current.lanes=t,vi(i,t),pt(i),e[bt]=i.current,_l(e),new xr(i)},mo.version="19.1.0",mo}var Fu;function Cf(){if(Fu)return Ll.exports;Fu=1;function g(){if(!(typeof __REACT_DEVTOOLS_GLOBAL_HOOK__>"u"||typeof __REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE!="function"))try{__REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE(g)}catch(s){console.error(s)}}return g(),Ll.exports=xf(),Ll.exports}var Sf=Cf();const Nf=({title:g,content:s})=>{const[l,c]=oe.useState(!1),d=()=>{c(!l)};return a.jsxs("div",{className:"border border-slate-200 rounded-lg",children:[a.jsxs("button",{onClick:d,className:"w-full text-left p-4 bg-slate-100 hover:bg-slate-200 rounded-lg font-semibold flex justify-between items-center",children:[a.jsx("span",{children:g}),a.jsx("span",{className:`transform transition-transform duration-300 ${l?"rotate-180":""}`,children:"▼"})]}),l&&a.jsx("div",{className:"bg-white border-t border-slate-200 rounded-b-lg p-4",children:a.jsx("div",{className:"text-sm text-slate-700",children:s})})]})},If=({onSelectSection:g})=>{var W,se,ie,$,ne;const[s,l]=oe.useState("resumen"),[c,d]=oe.useState("p_aeruginosa"),[m,_]=oe.useState(null),[h,v]=oe.useState(null),y={topPathogens:{labels:["E. coli","S. aureus","K. pneumoniae","P. aeruginosa","A. baumannii"],data:[4e3,3100,2600,2e3,1500]},pathogens:{p_aeruginosa:{name:"Pseudomonas aeruginosa",burden:"4ta causa de muerte por RAM en Colombia (2,000 muertes en 2019). Prevalencia en UCI aumentó de 8% a 11% (2018-2021). 2do agente en Neumonía Asociada a Ventilador (20.7%) y Bacteriemia (10.5%) en UCI de adultos (2023).",resistance:{labels:["Pip-Tazo","Ceftazidima","Cefepime","Imipenem","Meropenem","Ciprofloxacina","Amikacina"],datasets:[{label:"% Resistencia",data:[35,30,30,28,28,30,30],backgroundColor:"rgba(13, 148, 136, 0.6)",borderColor:"rgba(13, 148, 136, 1)",borderWidth:1,sources:["GREBO 2018-21","GREBO 2001-03","GREBO 2001-03","INS 2022","INS 2022","GREBO 2001-03","GREBO 2001-03"]}]},intrinsic:["Ampicilina","Amoxi-Clav","Cefalosp. 1ra-2da gen","Tetraciclinas","TMP-SMX","Cloranfenicol"],considerations:"TENDENCIA CRÍTICA: Se ha demostrado un aumento estadísticamente significativo en la resistencia a Piperacilina-Tazobactam y Carbapenems a nivel nacional (2018-2021). La eficacia de estas terapias clave está disminuyendo activamente."},e_coli:{name:"Escherichia coli",burden:"1ra causa de muerte por RAM en Colombia (4,000 muertes en 2019). Constituye 26-28% de todos los aislados bacterianos. Principal agente en ITU asociada a catéter en UCI (25.6% en 2023).",resistance:{labels:["Cefalosp. 3ra Gen","Ciprofloxacina"],datasets:[{label:"% Resistencia",data:[28.6,25],backgroundColor:"rgba(13, 148, 136, 0.6)",borderColor:"rgba(13, 148, 136, 1)",borderWidth:1,sources:["INS 2022","GREBO 2001-03"]}]},intrinsic:[],considerations:"La resistencia a Cefalosporinas de 3ra Gen es un marcador de producción de BLEE. Datos de diferentes fuentes muestran tasas entre 20-28.6%, indicando una alta prevalencia de BLEE."},k_pneumoniae:{name:"Klebsiella pneumoniae",burden:"3ra causa de muerte por RAM en Colombia (2,600 muertes en 2019). Prevalencia en UCI aumentó de 15% a 18% (2018-2021). Agente predominante en Bacteriemia (19.9%) y NAV (29.8%) en UCI de adultos (2023).",resistance:{labels:["Ceftriaxona","Carbapenems"],datasets:[{label:"% Resistencia",data:[31,15],backgroundColor:"rgba(13, 148, 136, 0.6)",borderColor:"rgba(13, 148, 136, 1)",borderWidth:1,sources:["Expertos 2022","INS-GREBO"]}]},intrinsic:["Ampicilina"],considerations:"La resistencia a carbapenems es una amenaza crítica y creciente a nivel nacional, a menudo mediada por carbapenemasas como KPC, cuya diseminación en Bogotá fue documentada desde 2008."},s_aureus:{name:"Staphylococcus aureus",burden:"2da causa de muerte por RAM en Colombia (3,100 muertes en 2019). Constituye 10-11% de todos los aislados bacterianos.",resistance:{labels:["Infección Clínica","UCI Bogotá","Portadores Sanos"],datasets:[{label:"% Resistencia SARM",data:[43,62,20],backgroundColor:"rgba(13, 148, 136, 0.6)",borderColor:"rgba(13, 148, 136, 1)",borderWidth:1,sources:["Expertos 2022","GREBO 2001-03","Expertos 2022"]}]},intrinsic:["Aztreonam","Polimixinas"],considerations:"La prevalencia de SARM es alta y depende del contexto: 43% en infecciones clínicas, pero puede superar el 60% en UCI. Esto requiere el uso empírico de terapias alternativas como vancomicina en pacientes críticos."},a_baumannii:{name:"Acinetobacter baumannii",burden:"5ta causa de muerte por RAM en Colombia (1,500 muertes en 2019). Patógeno formidable casi exclusivo de entornos de UCI.",resistance:{labels:["Carbapenems"],datasets:[{label:"% Resistencia",data:[45],backgroundColor:"rgba(13, 148, 136, 0.6)",borderColor:"rgba(13, 148, 136, 1)",borderWidth:1,sources:["INS 2022"]}]},intrinsic:["Ampicilina","Cefalosp. 1ra-2da gen","Ertapenem"],considerations:"Patógeno nosocomial con tasas de resistencia a carbapenémicos extremadamente altas (>45%), lo que limita severamente las opciones terapéuticas y lo convierte en una amenaza crítica."}},crossResistanceData:[{title:"Producción de BLEE (ESBL)",content:"En E. coli, K. pneumoniae, P. mirabilis. Implica resistencia a todas las penicilinas, todas las cefalosporinas (1ra-4ta gen), y aztreonam, sin importar el resultado in vitro. Los carbapenems permanecen activos."},{title:"Producción de Carbapenemasa (ej. KPC)",content:"En Enterobacterales, P. aeruginosa, A. baumannii. Implica resistencia a todos los beta-lactámicos (penicilinas, cefalosporinas, carbapenems). El tratamiento requiere agentes noveles o terapia combinada."},{title:"S. aureus Meticilino-Resistente (SARM)",content:"En S. aureus. Implica resistencia a todos los beta-lactámicos (excepto ceftarolina). Usar Cefoxitin como marcador. Opciones terapéuticas incluyen vancomicina, daptomicina, linezolid."},{title:"Resistencia a Fluoroquinolonas de Alto Nivel",content:"En Enterobacterales, P. aeruginosa. Implica alta probabilidad de resistencia a todas las fluoroquinolonas (ciprofloxacina, levofloxacina, etc.). No se recomienda probar una segunda fluoroquinolona."}]};oe.useEffect(()=>(typeof window<"u"&&window.Chart&&setTimeout(()=>{D()},100),()=>{h&&(h.destroy(),v(null)),m&&(m.destroy(),_(null))}),[s]);const D=()=>{if(h&&(h.destroy(),v(null)),m&&(m.destroy(),_(null)),s==="resumen"){const w=document.getElementById("topPathogensChart");if(w){const O=window.Chart.getChart(w);O&&O.destroy();const U=new window.Chart(w,{type:"bar",data:{labels:y.topPathogens.labels,datasets:[{label:"Muertes Asociadas",data:y.topPathogens.data,backgroundColor:"rgba(13, 148, 136, 0.6)",borderColor:"rgba(13, 148, 136, 1)",borderWidth:1}]},options:{indexAxis:"y",responsive:!0,maintainAspectRatio:!1,plugins:{legend:{display:!1},tooltip:{callbacks:{label:Z=>` ${Z.raw.toLocaleString()} muertes`}}},scales:{x:{beginAtZero:!0,title:{display:!0,text:"Número de Muertes (Estimado 2019)"}}}}});v(U)}}s==="patogenos"&&L()},L=()=>{const w=y.pathogens[c];if(!w)return;const O=document.getElementById("resistanceChart");if(O){const U=window.Chart.getChart(O);U&&U.destroy();const Z=new window.Chart(O,{type:"bar",data:w.resistance,options:{responsive:!0,maintainAspectRatio:!1,scales:{y:{beginAtZero:!0,max:100,title:{display:!0,text:"% Resistencia"}}},plugins:{legend:{display:w.resistance.datasets.length>1},tooltip:{callbacks:{label:X=>` ${X.dataset.label||""}: ${X.raw}%`,afterLabel:X=>`Fuente: ${X.dataset.sources?X.dataset.sources[X.dataIndex]:""}`}}}}});_(Z)}};return oe.useEffect(()=>{s==="patogenos"&&c&&L()},[c,s]),a.jsxs("div",{className:"min-h-full bg-slate-50 text-slate-800",children:[a.jsx("header",{className:"bg-white shadow-sm border-b border-slate-200",children:a.jsx("div",{className:"max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 py-6",children:a.jsxs("div",{className:"text-center",children:[a.jsx("h1",{className:"text-4xl font-bold text-teal-700 mb-2",children:"Guía Interactiva de Resistencia Antimicrobiana"}),a.jsx("p",{className:"text-xl text-slate-600 mb-1",children:"Colombia - Versión Alpha"}),a.jsx("p",{className:"text-sm text-slate-500",children:"Sistema integrado de apoyo clínico y vigilancia epidemiológica"})]})})}),a.jsxs("main",{className:"max-w-6xl mx-auto px-4 sm:px-6 lg:px-8 py-12",children:[a.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-8 mb-16",children:[a.jsx("div",{onClick:()=>g("antibiogram"),className:"bg-white rounded-2xl shadow-lg border border-slate-200 p-8 hover:shadow-xl transition-all duration-300 cursor-pointer group",children:a.jsxs("div",{className:"text-center",children:[a.jsx("div",{className:"w-20 h-20 bg-indigo-100 rounded-full flex items-center justify-center mx-auto mb-6 group-hover:bg-indigo-200 transition-colors",children:a.jsx("span",{className:"text-4xl",children:"🧬"})}),a.jsx("h2",{className:"text-2xl font-bold text-slate-900 mb-4",children:"Antibiograma Inteligente"}),a.jsx("p",{className:"text-slate-600 mb-6",children:"Sistema de apoyo para la toma de decisiones clínicas en el tratamiento de infecciones. Interpretación avanzada de antibiogramas con algoritmos de detección de resistencia."}),a.jsxs("div",{className:"space-y-2 text-sm text-slate-500 text-left",children:[a.jsxs("div",{className:"flex items-center",children:[a.jsx("span",{className:"w-2 h-2 bg-green-500 rounded-full mr-3"}),a.jsx("span",{children:"Interpretación CLSI automatizada"})]}),a.jsxs("div",{className:"flex items-center",children:[a.jsx("span",{className:"w-2 h-2 bg-green-500 rounded-full mr-3"}),a.jsx("span",{children:"Detección de patrones de resistencia"})]}),a.jsxs("div",{className:"flex items-center",children:[a.jsx("span",{className:"w-2 h-2 bg-green-500 rounded-full mr-3"}),a.jsx("span",{children:"Recomendaciones terapéuticas inteligentes"})]}),a.jsxs("div",{className:"flex items-center",children:[a.jsx("span",{className:"w-2 h-2 bg-green-500 rounded-full mr-3"}),a.jsx("span",{children:"Ajustes por función renal/hepática"})]})]}),a.jsx("button",{className:"mt-6 w-full bg-indigo-600 text-white py-3 px-6 rounded-lg font-semibold hover:bg-indigo-700 transition-colors",children:"Acceder al Antibiograma"})]})}),a.jsx("div",{onClick:()=>g("syndromes"),className:"bg-white rounded-2xl shadow-lg border border-slate-200 p-8 hover:shadow-xl transition-all duration-300 cursor-pointer group",children:a.jsxs("div",{className:"text-center",children:[a.jsx("div",{className:"w-20 h-20 bg-blue-100 rounded-full flex items-center justify-center mx-auto mb-6 group-hover:bg-blue-200 transition-colors",children:a.jsx("span",{className:"text-4xl",children:"📋"})}),a.jsx("h2",{className:"text-2xl font-bold text-slate-900 mb-4",children:"Guía Clínica de Síndromes"}),a.jsx("p",{className:"text-slate-600 mb-6",children:"Base de datos integral de síndromes infecciosos con protocolos de tratamiento basados en evidencia. Más de 450 síndromes clínicos con regímenes detallados y recomendaciones de stewardship."}),a.jsxs("div",{className:"space-y-2 text-sm text-slate-500 text-left",children:[a.jsxs("div",{className:"flex items-center",children:[a.jsx("span",{className:"w-2 h-2 bg-green-500 rounded-full mr-3"}),a.jsx("span",{children:"453 síndromes infecciosos categorizados"})]}),a.jsxs("div",{className:"flex items-center",children:[a.jsx("span",{className:"w-2 h-2 bg-green-500 rounded-full mr-3"}),a.jsx("span",{children:"Protocolos de tratamiento detallados"})]}),a.jsxs("div",{className:"flex items-center",children:[a.jsx("span",{className:"w-2 h-2 bg-green-500 rounded-full mr-3"}),a.jsx("span",{children:"Búsqueda avanzada por categoría y patógeno"})]}),a.jsxs("div",{className:"flex items-center",children:[a.jsx("span",{className:"w-2 h-2 bg-green-500 rounded-full mr-3"}),a.jsx("span",{children:"Dosificación y duración basada en evidencia"})]})]}),a.jsx("button",{className:"mt-6 w-full bg-blue-600 text-white py-3 px-6 rounded-lg font-semibold hover:bg-blue-700 transition-colors",children:"Explorar Guía de Síndromes"})]})})]}),a.jsxs("div",{className:"mb-8",children:[a.jsx("h3",{className:"text-2xl font-bold text-slate-900 mb-6 text-center",children:"Atlas Epidemiológico Nacional"}),a.jsxs("div",{className:"flex flex-wrap justify-center gap-4 mb-8",children:[a.jsx("button",{onClick:()=>l("resumen"),className:`px-6 py-3 rounded-lg font-medium transition-all ${s==="resumen"?"bg-teal-600 text-white":"bg-white text-slate-600 hover:bg-slate-100 border border-slate-200"}`,children:"🏠 Resumen Nacional"}),a.jsx("button",{onClick:()=>l("patogenos"),className:`px-6 py-3 rounded-lg font-medium transition-all ${s==="patogenos"?"bg-teal-600 text-white":"bg-white text-slate-600 hover:bg-slate-100 border border-slate-200"}`,children:"🦠 Perfiles de Patógenos"}),a.jsx("button",{onClick:()=>l("principios"),className:`px-6 py-3 rounded-lg font-medium transition-all ${s==="principios"?"bg-teal-600 text-white":"bg-white text-slate-600 hover:bg-slate-100 border border-slate-200"}`,children:"🔬 Principios Clave"})]})]}),s==="resumen"&&a.jsxs("div",{className:"space-y-8",children:[a.jsxs("header",{className:"mb-8",children:[a.jsx("h2",{className:"text-3xl font-bold text-slate-900",children:"Panorama de la Resistencia Antimicrobiana en Colombia"}),a.jsx("p",{className:"mt-2 text-slate-600",children:"Un resumen del impacto, los patógenos clave y los sistemas de vigilancia que definen el desafío de la RAM en el país."})]}),a.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[a.jsx("h3",{className:"text-xl font-semibold text-slate-900 mb-4",children:"Carga de Mortalidad por RAM en Colombia (Datos 2019)"}),a.jsx("p",{className:"text-slate-600 mb-6",children:"La resistencia antimicrobiana es una de las principales causas de muerte en Colombia, superando la mortalidad combinada de varias enfermedades crónicas. Los datos del IHME de 2019 revelan la escala del problema."}),a.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[a.jsxs("div",{className:"bg-red-50 p-6 rounded-lg border border-red-200",children:[a.jsx("h4",{className:"font-semibold text-red-800 mb-2",children:"Mortalidad Asociada a la RAM"}),a.jsx("p",{className:"text-4xl font-bold text-red-600",children:"18,200"}),a.jsx("p",{className:"text-red-700",children:"muertes en las que una infección resistente fue un factor contribuyente."})]}),a.jsxs("div",{className:"bg-red-50 p-6 rounded-lg border border-red-200",children:[a.jsx("h4",{className:"font-semibold text-red-800 mb-2",children:"Mortalidad Atribuible a la RAM"}),a.jsx("p",{className:"text-4xl font-bold text-red-700",children:"4,700"}),a.jsx("p",{className:"text-red-700",children:"muertes directamente causadas por la infección resistente."})]})]})]}),a.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[a.jsx("h3",{className:"text-xl font-semibold text-slate-900 mb-4",children:"Patógenos con Mayor Mortalidad Asociada en Colombia (2019)"}),a.jsx("div",{className:"chart-container",style:{position:"relative",height:"350px",maxHeight:"40vh"},children:a.jsx("canvas",{id:"topPathogensChart"})}),a.jsx("p",{className:"text-xs text-center text-slate-500 mt-2",children:"Fuente: IHME 2019. Pase el cursor sobre las barras para ver el número de muertes."})]}),a.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[a.jsx("h3",{className:"text-xl font-semibold text-slate-900 mb-4",children:"Arquitectura de la Vigilancia de la RAM en Colombia"}),a.jsx("p",{className:"text-slate-600 mb-6",children:'Colombia utiliza un enfoque de "Una Salud" y triangulación de datos, integrando información de múltiples niveles. Para un antibiograma local, es crucial priorizar datos locales, contextualizarlos con datos nacionales y compararlos con benchmarks regionales.'}),a.jsxs("div",{className:"grid grid-cols-1 sm:grid-cols-2 lg:grid-cols-3 gap-4 text-center",children:[a.jsxs("div",{className:"p-4 bg-teal-50 border border-teal-200 rounded-lg",children:[a.jsx("h4",{className:"font-semibold text-teal-800",children:"Local (GREBO)"}),a.jsx("p",{className:"text-sm text-teal-700",children:"Red de hospitales en Bogotá. Provee datos de alta granularidad, especialmente de UCI, que suelen mostrar tasas de resistencia más altas que el promedio nacional."})]}),a.jsxs("div",{className:"p-4 bg-blue-50 border border-blue-200 rounded-lg",children:[a.jsx("h4",{className:"font-semibold text-blue-800",children:"Nacional (INS/SIVIGILA)"}),a.jsx("p",{className:"text-sm text-blue-700",children:"Sistema de reporte obligatorio nacional. Provee la data oficial del país. Nota: Sufrió una brecha de reportes en 2020 durante la pandemia."})]}),a.jsxs("div",{className:"p-4 bg-indigo-50 border border-indigo-200 rounded-lg",children:[a.jsx("h4",{className:"font-semibold text-indigo-800",children:"Regional (PAHO/ReLAVRA+)"}),a.jsx("p",{className:"text-sm text-indigo-700",children:"Red latinoamericana que agrega datos de 20 países. Permite la comparación y el benchmarking regional. Usa CLSI como estándar."})]})]})]})]}),s==="patogenos"&&a.jsxs("div",{className:"space-y-6",children:[a.jsxs("header",{className:"mb-8",children:[a.jsx("h2",{className:"text-3xl font-bold text-slate-900",children:"Perfiles de Resistencia por Patógeno"}),a.jsx("p",{className:"mt-2 text-slate-600",children:"Seleccione un patógeno para visualizar su perfil de resistencia, carga epidemiológica y consideraciones clave, basado en la triangulación de datos de vigilancia colombianos."})]}),a.jsxs("div",{className:"mb-6 bg-white p-4 rounded-lg shadow-sm border border-slate-200",children:[a.jsx("label",{htmlFor:"pathogen-select",className:"block text-sm font-medium text-slate-700 mb-2",children:"Seleccionar Patógeno:"}),a.jsxs("select",{id:"pathogen-select",value:c,onChange:w=>d(w.target.value),className:"w-full md:w-1/2 p-2 border border-slate-300 rounded-md shadow-sm focus:ring-teal-500 focus:border-teal-500",children:[a.jsx("option",{value:"p_aeruginosa",children:"Pseudomonas aeruginosa"}),a.jsx("option",{value:"e_coli",children:"Escherichia coli"}),a.jsx("option",{value:"k_pneumoniae",children:"Klebsiella pneumoniae"}),a.jsx("option",{value:"s_aureus",children:"Staphylococcus aureus"}),a.jsx("option",{value:"a_baumannii",children:"Acinetobacter baumannii"})]})]}),a.jsxs("div",{className:"grid grid-cols-1 lg:grid-cols-3 gap-6",children:[a.jsxs("div",{className:"lg:col-span-2 bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[a.jsxs("h3",{className:"text-xl font-semibold text-slate-900 mb-4",children:["Perfil de Resistencia para ",(W=y.pathogens[c])==null?void 0:W.name]}),a.jsx("div",{className:"chart-container",style:{position:"relative",height:"400px"},children:a.jsx("canvas",{id:"resistanceChart"})}),a.jsx("p",{className:"text-xs text-center text-slate-500 mt-2",children:"Pase el cursor sobre las barras para ver el porcentaje y la fuente del dato."})]}),a.jsxs("div",{className:"space-y-6",children:[a.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[a.jsx("h4",{className:"font-semibold text-slate-900 mb-2",children:"Carga Epidemiológica"}),a.jsx("p",{className:"text-sm text-slate-600",children:(se=y.pathogens[c])==null?void 0:se.burden})]}),a.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[a.jsx("h4",{className:"font-semibold text-slate-900 mb-2",children:"Consideraciones Clave y Tendencias"}),a.jsx("p",{className:"text-sm text-slate-600",children:(ie=y.pathogens[c])==null?void 0:ie.considerations})]}),a.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[a.jsx("h4",{className:"font-semibold text-slate-900 mb-2",children:"Resistencia Intrínseca"}),a.jsx("p",{className:"text-sm text-slate-600 mb-2",children:"Este patógeno es naturalmente resistente a los siguientes agentes. No deben ser usados."}),a.jsx("ul",{className:"list-disc list-inside text-sm text-slate-600 space-y-1",children:((ne=($=y.pathogens[c])==null?void 0:$.intrinsic)==null?void 0:ne.length)>0?y.pathogens[c].intrinsic.map((w,O)=>a.jsx("li",{children:w},O)):a.jsx("li",{children:"Ninguna resistencia intrínseca común a destacar."})})]})]})]})]}),s==="principios"&&a.jsxs("div",{className:"space-y-8",children:[a.jsxs("header",{className:"mb-8",children:[a.jsx("h2",{className:"text-3xl font-bold text-slate-900",children:"Principios Clave y Hallazgos del Informe"}),a.jsx("p",{className:"mt-2 text-slate-600",children:"Conceptos y conclusiones fundamentales del análisis de la resistencia en Colombia para la interpretación y uso adecuado de los datos."})]}),a.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[a.jsx("h3",{className:"text-xl font-semibold text-slate-900 mb-4",children:"Hallazgos y Tendencias Críticas del Informe"}),a.jsx("p",{className:"text-slate-600 mb-6",children:"El análisis de los datos de vigilancia colombianos revela varias tendencias y conclusiones que son cruciales para la práctica clínica y la salud pública."}),a.jsxs("div",{className:"space-y-4",children:[a.jsxs("div",{className:"flex items-start gap-4 p-4 bg-amber-50 border-l-4 border-amber-500 rounded-r-lg",children:[a.jsx("span",{className:"text-2xl mt-1",children:"📈"}),a.jsxs("div",{children:[a.jsx("h4",{className:"font-bold text-amber-800",children:"Tendencia de Alarma: Resistencia Creciente en P. aeruginosa"}),a.jsx("p",{className:"text-sm text-amber-700",children:"El hallazgo más consistente y estadísticamente significativo del período 2018-2021 fue el aumento de la resistencia de P. aeruginosa a Piperacilina-Tazobactam y Carbapenems. La eficacia de estas terapias de primera línea está disminuyendo activamente a nivel nacional."})]})]}),a.jsxs("div",{className:"flex items-start gap-4 p-4 bg-sky-50 border-l-4 border-sky-500 rounded-r-lg",children:[a.jsx("span",{className:"text-2xl mt-1",children:"💉"}),a.jsxs("div",{children:[a.jsx("h4",{className:"font-bold text-sky-800",children:"Impacto de la Vigilancia en Políticas Públicas: Caso S. pneumoniae"}),a.jsx("p",{className:"text-sm text-sky-700",children:"La vigilancia demostró que la alta resistencia a penicilina y ceftriaxona en niños estaba ligada al serotipo 19A, no cubierto por la vacuna PCV10. Este dato fue fundamental para impulsar el cambio de la política nacional de vacunación a la PCV13."})]})]}),a.jsxs("div",{className:"flex items-start gap-4 p-4 bg-violet-50 border-l-4 border-violet-500 rounded-r-lg",children:[a.jsx("span",{className:"text-2xl mt-1",children:"🧩"}),a.jsxs("div",{children:[a.jsx("h4",{className:"font-bold text-violet-800",children:"El Imperativo de la Triangulación de Datos"}),a.jsx("p",{className:"text-sm text-violet-700",children:"Un antibiograma local preciso no puede basarse en una sola fuente. Es esencial triangular la información: priorizar los datos locales, contextualizarlos con los datos nacionales, y compararlos con los benchmarks regionales."})]})]})]})]}),a.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[a.jsx("h3",{className:"text-xl font-semibold text-slate-900 mb-4",children:"Resistencia Cruzada: Interpretando Fenotipos Complejos"}),a.jsx("p",{className:"text-slate-600 mb-4",children:"Un único mecanismo de resistencia puede conferir insensibilidad a múltiples fármacos. Reconocer estos fenotipos es clave para la interpretación. Haga clic en cada fenotipo para ver los detalles."}),a.jsx("div",{className:"space-y-2",children:y.crossResistanceData.map((w,O)=>a.jsx(Nf,{title:w.title,content:w.content},O))})]}),a.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[a.jsx("h3",{className:"text-xl font-semibold text-slate-900 mb-4",children:"Estrategias de Reporte Avanzadas (Stewardship)"}),a.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[a.jsxs("div",{children:[a.jsx("h4",{className:"font-semibold text-slate-800",children:"Reporte en Cascada"}),a.jsx("p",{className:"text-slate-600 text-sm",children:"Práctica de suprimir los resultados de antibióticos de amplio espectro cuando un aislado es susceptible a un agente de espectro más estrecho y terapéuticamente equivalente. Esto guía al clínico a usar el fármaco más dirigido, preservando los de amplio espectro."})]}),a.jsxs("div",{children:[a.jsx("h4",{className:"font-semibold text-slate-800",children:"Reporte Selectivo"}),a.jsx("p",{className:"text-slate-600 text-sm",children:"Consiste en suprimir el resultado de un antibiótico que es clínicamente ineficaz para un tipo de infección específico, sin importar el resultado in vitro. Ejemplo: suprimir el resultado de daptomicina para un S. aureus de origen respiratorio, ya que es inactivado por el surfactante pulmonar."})]})]})]})]})]})]})},jf="modulepreload",Af=function(g,s){return new URL(g,s).href},Gu={},wf=function(s,l,c){let d=Promise.resolve();if(l&&l.length>0){let _=function(D){return Promise.all(D.map(L=>Promise.resolve(L).then(W=>({status:"fulfilled",value:W}),W=>({status:"rejected",reason:W}))))};const h=document.getElementsByTagName("link"),v=document.querySelector("meta[property=csp-nonce]"),y=(v==null?void 0:v.nonce)||(v==null?void 0:v.getAttribute("nonce"));d=_(l.map(D=>{if(D=Af(D,c),D in Gu)return;Gu[D]=!0;const L=D.endsWith(".css"),W=L?'[rel="stylesheet"]':"";if(!!c)for(let $=h.length-1;$>=0;$--){const ne=h[$];if(ne.href===D&&(!L||ne.rel==="stylesheet"))return}else if(document.querySelector(`link[href="${D}"]${W}`))return;const ie=document.createElement("link");if(ie.rel=L?"stylesheet":jf,L||(ie.as="script"),ie.crossOrigin="",ie.href=D,y&&ie.setAttribute("nonce",y),document.head.appendChild(ie),L)return new Promise(($,ne)=>{ie.addEventListener("load",$),ie.addEventListener("error",()=>ne(new Error(`Unable to preload CSS for ${D}`)))})}))}function m(_){const h=new Event("vite:preloadError",{cancelable:!0});if(h.payload=_,window.dispatchEvent(h),!h.defaultPrevented)throw _}return d.then(_=>{for(const h of _||[])h.status==="rejected"&&m(h.reason);return s().catch(m)})},Xi={MILD:1,MODERATE:2,SEVERE:3,CRITICAL:4},Bl={HIGH_ESBL_RATE:"high_esbl",ICU_ADMISSION:"icu",IMMUNOCOMPROMISED:"immunocompromised"},Ul={LOW_ESBL_RATE:.15,HIGH_ESBL_RATE:.3},Hu={esblRate:{enterobacterales:.12,klebsiella:.18,escherichia:.08,enterobacter:.25},carbapenemResistance:{enterobacterales:.03,klebsiella:.05,acinetobacter:.25,pseudomonas:.15},mrsaRate:.35,vreRate:.15},Rf={"Skin and soft tissues":Xi.MILD,Genitourinary:Xi.MILD,Respiratory:Xi.MODERATE,Gastrointestinal:Xi.MODERATE,"Bone tissue":Xi.MODERATE,Cardiovascular:Xi.SEVERE,"Central nervous system":Xi.SEVERE,"Bacteremia/Sepsis":Xi.SEVERE},Ye={CNS_CRITICAL:{type:"CNS_critical",description:"Blood-brain barrier penetration essential",excellent:["Ceftriaxone","Ceftazidime","Meropenem","Metronidazole","Linezolid"],good:["Ciprofloxacin","Levofloxacin","Penicillin G"],moderate:["Vancomycin"],poor:["Cefazolin","Oxacillin","Gentamicin","Tobramycin","Amikacin"],avoid:["First-generation cephalosporins","Most aminoglycosides"]},BONE_SPECIFIC:{type:"bone_specific",description:"Bone tissue penetration essential",excellent:["Ciprofloxacin","Levofloxacin","Clindamycin","Rifampin"],good:["Linezolid","Doxycycline","Minocycline"],moderate:["Vancomycin","Ceftriaxone"],poor:["Gentamicin","Tobramycin","Amikacin"],avoid:["Aminoglycosides for oral sequential therapy"]},URINARY_SPECIFIC:{type:"urinary_specific",description:"Urinary concentration more important than serum",excellent:["Nitrofurantoin","Fosfomycin","Ciprofloxacin"],good:["Levofloxacin","Ceftriaxone","Ceftazidime"],moderate:["Ampicillin","Cefazolin"],poor:["Clindamycin","Vancomycin"],avoid:["Antibiotics without urinary concentration"]},PROSTATE_SPECIFIC:{type:"prostate_specific",description:"Prostate tissue penetration essential",excellent:["Ciprofloxacin","Levofloxacin","Trimethoprim-sulfamethoxazole"],good:["Doxycycline","Minocycline"],moderate:["Ceftriaxone"],poor:["Vancomycin","Gentamicin","Cefazolin"],avoid:["Most beta-lactams","Aminoglycosides"]},SYSTEMIC:{type:"systemic",description:"Good systemic distribution required",excellent:["Most IV antibiotics with good tissue distribution"],good:["Standard parenteral antibiotics"],moderate:[],poor:[],avoid:["Topical-only agents"]},GOOD:{type:"good",description:"Standard tissue penetration adequate",excellent:["Most antibiotics"],good:[],moderate:[],poor:[],avoid:[]}},Sr={ANAEROBIC_ESSENTIAL:{required:["Metronidazole","Clindamycin","Piperacillin-tazobactam","Meropenem"]},ATYPICAL_COVERAGE:{required:["Azithromycin","Clarithromycin","Doxycycline","Levofloxacin","Moxifloxacin"]},ANTI_PSEUDOMONAS:{required:["Piperacillin-tazobactam","Ceftazidime","Cefepime","Meropenem","Ciprofloxacin"]},BIOFILM_ACTIVITY:{required:["Rifampin","Daptomycin","Linezolid"]}},Mf=JSON.parse('{"identity":{"bacteriumName":"Citrobacter freundii","aliases":["Citrobacter freundii"],"lastUpdated":"2024-07-30","clsiCategory":"Enterobacterales (excluding Salmonella/Shigella)","classification":{"gramStain":"Gram negative","morphology":"Bacilli","respiration":"Facultative anaerobe","notes":["Grows aerobically and anaerobically."]},"strainDetails":[],"biochemicalTests":"Gram-negative rod, motile, lactose fermenter (variable/slow), H2S +, indole variable, citrate +, urease variable, lysine decarboxylase –."},"clinicalProfile":{"summary":"Citrobacter species cause a variety of infections ranging from uncomplicated urinary tract infections to life-threatening infections of the abdomen, skin and soft tissue, lung, CNS and other sites in both normal and immuno-compromised hosts.","pathophysiologyPearls":["Citrobacter freundii predicably encodes an inducible ampC chromosomal gene that is de-repressed during clinical therapy with Ceftriaxone, Cefotaxime, Ceftazidime, Aztreonam, or Piperacillin-tazobactam.","Hence, initial in vitro susceptibility may indicate susceptibility to extended spectrum cephalosporins as the ampC gene is repressed.","With treatment, the ampC gene is de-repressed and patients may fail to respond clinically.","With de-repression, in vitro susceptibility now indicates resistance to beta lactams."],"keySignsAndSymptoms":[],"clinicalSyndromes":[{"syndromeName":"Urinary Tract Infections (UTI)","description":"Can range from uncomplicated cystitis to complicated pyelonephritis."},{"syndromeName":"Intra-abdominal Infections","description":"Infections within the abdominal cavity, often polymicrobial."},{"syndromeName":"Skin and Soft Tissue Infections","description":"Infections of the skin, subcutaneous tissue, fascia, or muscle."},{"syndromeName":"Pneumonia","description":"Infection of the lungs, often seen in hospitalized or immunocompromised patients."},{"syndromeName":"Central Nervous System (CNS) Infections","description":"Life-threatening infections such as meningitis or brain abscesses."}],"stagesOfIllness":[],"highRiskPopulations":["Immuno-compromised hosts"],"transmissionVectors":[],"prognosisNotes":["It is best to avoid extended spectrum cephalosporins (cefepime is the exception), aztreonam, and piperacillin-tazobactam therapy for Citrobacter freundii regardless of the results of in vitro susceptibility due to risk of AmpC de-repression.","Citrobacter strains can also produce extended-spectrum beta-lactamases (ESBLs), which destroy the antibacterial activity of most extended-spectrum cephalosporins, penicillins, and aztreonam.","Strains often exhibit concomitant resistance to fluoroquinolones, aminoglycosides, and TMP/SMX."]},"resistanceProfile":{"groupIntrinsicResistance":[],"intrinsicResistance":[{"drugOrClass":"Multiple Beta-Lactams","notes":"Citrobacter freundii predicably encodes an inducible ampC chromosomal gene. It is de-repressed during clinical therapy with Ceftriaxone, Cefotaxime, Ceftazidime, Aztreonam, or Piperacillin-tazobactam, leading to clinical failure."}],"majorMechanisms":[{"mechanismName":"AmpC Beta-Lactamase Production","mechanismType":"Enzymatic Inactivation","description":"A chromosomal ampC gene may be present but repressed. Administration of a cephalosporin or other beta-lactams can derepress the gene, leading to the production of AmpC enzymes that hydrolyze the antibiotic."},{"mechanismName":"Extended-Spectrum Beta-Lactamase (ESBL) Production","mechanismType":"Enzymatic Inactivation","description":"ESBLs destroy the antibacterial activity of most extended-spectrum cephalosporins, penicillins, and aztreonam. Cefepime may be an exception."},{"mechanismName":"Carbapenemase Production (e.g., KPC)","mechanismType":"Enzymatic Inactivation","description":"Enzymes like Klebsiella pneumoniae carbapenemases (KPC) hydrolyze carbapenems and most other beta-lactams."},{"mechanismName":"Metallo-beta-lactamase (MBL) Production","mechanismType":"Enzymatic Inactivation","description":"Enzymes that require zinc for activity and hydrolyze a broad range of beta-lactams including carbapenems. They are not inhibited by avibactam."},{"mechanismName":"Porin Closure","mechanismType":"Reduced Permeability","description":"Reduced permeability of the outer cell wall, preventing antibiotics from reaching their target."},{"mechanismName":"Efflux Pumps","mechanismType":"Antibiotic Efflux","description":"Active transport systems that pump antibiotics out of the bacterial cell."}],"clinicalAlerts":[{"alertTitle":"Inducible AmpC Resistance","details":"Until a Citrobacter isolate is speciated, assume it could be C. freundii. Avoid empiric third-generation cephalosporin, aztreonam, or piperacillin-tazobactam therapy regardless of initial in vitro susceptibility results due to the risk of de-repression of the AmpC gene and subsequent clinical failure."}]},"treatment":{"generalNotes":["Choice of empiric regimen depends on local resistance patterns, fragility of the patient, and the severity of the infection. Specific therapy is directed by the results of in vitro susceptibility testing.","For uncomplicated cystitis, see Cystitis, adult female guidelines.","For further discussion on resistance, see Gram-Negative Bacilli, Beta-lactam Resistance, Overview."],"drugsToAvoid":[{"drugOrClass":"Ceftriaxone, Cefotaxime, Ceftazidime, Aztreonam, Piperacillin-tazobactam","condition":"All serious infections","reason":"Risk of inducing AmpC beta-lactamase expression, leading to resistance and clinical failure, even if the initial isolate appears susceptible. Cefepime is a notable exception due to its stability."}],"adjunctiveTherapies":[],"regimens":[{"context":{"type":"Empiric","condition":"Suspected Citrobacter freundii infection, susceptibility pending","patientPopulation":["Patients in regions with local rate of ESBL <10-15%"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Cefepime","dose":"2 gm","route":"IV","frequency":"q8-12h","comments":"Infuse over 3 hours. Cefepime is the most stable cephalosporin in the presence of AmpC."}]}]}]},{"context":{"type":"Empiric","condition":"Suspected Citrobacter freundii infection, susceptibility pending","patientPopulation":["Patients in regions with local rate of ESBL >15%"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Meropenem","dose":"1-2 gm","route":"IV","frequency":"q8h","comments":null}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ertapenem","dose":"1 gm","route":"IV","frequency":"q24h","comments":null}]}]}]},{"context":{"type":"Directed","condition":"Infection with C. freundii, IV therapy indicated","patientPopulation":["Isolates with no in vitro resistance detected"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Cefepime","dose":"2 gm","route":"IV","frequency":"q8h","comments":"Preferred beta-lactam due to stability against AmpC."}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ciprofloxacin","dose":"400 mg","route":"IV","frequency":"q12h","comments":null},{"drugName":"Levofloxacin","dose":"750 mg","route":"IV","frequency":"once daily","comments":null}]}]}]},{"context":{"type":"Directed","condition":"Uncomplicated UTI (Cystitis), PO therapy","patientPopulation":["Isolates with no in vitro resistance detected"],"isolateSource":"Urine"},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Cefixime","dose":"Varies by formulation","route":"PO","frequency":"Varies","comments":"Dose depends on specific product and indication."},{"drugName":"Cefdinir","dose":"Varies by formulation","route":"PO","frequency":"Varies","comments":"Dose depends on specific product and indication."},{"drugName":"Fosfomycin","dose":"3 gm","route":"PO","frequency":"x 1 dose","comments":"Activity against Citrobacter can be variable; check susceptibility."}]}]}]},{"context":{"type":"Directed","condition":"ESBL producer or derepressed AmpC","patientPopulation":["Isolates with resistance to aztreonam, ceftriaxone, cefotaxime"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Meropenem","dose":"1-2 gm","route":"IV","frequency":"q8h","comments":null}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ertapenem","dose":"1 gm","route":"IV","frequency":"q24h","comments":null}]}]}]},{"context":{"type":"Directed","condition":"Klebsiella pneumoniae carbapenemase (KPC) producer","patientPopulation":["Isolates resistant to carbapenems, cephalosporins, penicillins, fluoroquinolones, and aminoglycosides"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Meropenem-vaborbactam","dose":"4 gm","route":"IV","frequency":"q8h","comments":"Infused over 3 hours."}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"q8h","comments":"Infused over 2 hours."},{"drugName":"Imipenem-cilastatin-relebactam","dose":"1.25 gm","route":"IV","frequency":"q6h","comments":"Infused over 30 min. For patients with CrCl > 90 mL/min."}]}]}]},{"context":{"type":"Directed","condition":"Metallo-beta-lactamase (MBL) producer","patientPopulation":["Isolates resistant to meropenem-vaborbactam, ceftazidime-avibactam, carbapenems, and other beta-lactams"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"q8h","comments":"Infused over 2 hours."},{"drugName":"Aztreonam","dose":"2 gm","route":"IV","frequency":"q8h","comments":"Infused over 2 hours. Must be given with Ceftazidime-avibactam."}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Cefiderocol","dose":"2 gm","route":"IV","frequency":"q8h","comments":"Infused over 3 hours."}]}]}]},{"context":{"type":"Directed","condition":"Pan-resistant infection","patientPopulation":["Isolates resistant to all tested classes of FDA approved anti-infectives"],"isolateSource":null},"recommendations":[{"preference":"Salvage","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Cefiderocol","dose":"2 gm","route":"IV","frequency":"q8h","comments":"Infused over 3 hours, if susceptible."},{"drugName":"Fosfomycin","dose":"Varies","route":"IV/PO","frequency":"Varies","comments":"Use where available and based on susceptibility. IV formulation may be required for systemic infections."}]}]}]},{"context":{"type":"Alternative","condition":"Complicated UTI","patientPopulation":["ESBL Producers"],"isolateSource":"Urine"},"recommendations":[{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Cefepime-enmetazobactam","dose":"2.5 g","route":"IV","frequency":"q8h","comments":"Recently FDA approved for complicated UTIs, including ESBL producers."}]}]}]},{"context":{"type":"Alternative","condition":"Infection with AmpC and/or ESBL producer","patientPopulation":[],"isolateSource":null},"recommendations":[{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftolozane-tazobactam","dose":"1.5 gm","route":"IV","frequency":"q8h","comments":"Infused over 1h. De-repressed AmpC producers may be resistant."},{"drugName":"Temocillin","dose":"2 gm","route":"IV","frequency":"q12h","comments":"Availability limited (e.g., Belgium, UK)."}]}]}]}]},"laboratoryProfile":{"testingIndications":["Until a Citrobacter isolate is speciated, it should be assumed it could be C. freundii, which warrants avoidance of empiric third-generation cephalosporins, piperacillin-tazobactam, or aztreonam due to the high risk of inducible AmpC-mediated resistance."],"methodologyNotes":["Breakpoints for Fosfomycin apply only to E. coli urinary tract isolates and should not be extrapolated to Citrobacter freundii.","Disk diffusion and gradient diffusion methods should not be performed for Colistin or Polymyxin B; MIC testing is required."],"recommendedPanel":[],"specialTests":[{"testName":"Carbapenemase Production Test (e.g., mCIM, CarbaNP)","trigger":"Resistance to one or more carbapenems (ertapenem, imipenem, meropenem).","purpose":"To detect the presence of carbapenemase enzymes, which has significant therapeutic and infection control implications."}],"reportingRules":[{"ruleType":"Conditional","drug":"Cefepime","condition":"Isolate demonstrates carbapenemase production.","details":"Cefepime S/SDD results should be suppressed or edited and reported as Resistant."},{"ruleType":"Conditional","drug":"Meropenem-vaborbactam","condition":"An OXA-48-like gene or enzyme is detected.","details":"Results for meropenem-vaborbactam should be suppressed or reported as Resistant."}],"antimicrobialBreakpoints":[{"tier":1,"tierDescription":"Appropriate for routine, primary testing and reporting.","agents":[{"agentName":"Cefepime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"19–24 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":["Due to the concern for inducible AmpC, Cefepime should be considered a Tier 1 agent for testing and reporting of C. freundii complex.","Cefepime S/SDD results should be reported as resistant if the isolate has a carbapenemase."]}]},{"agentName":"Ampicillin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"14–16 mm","r_breakpoint":"≤ 13 mm"},"mic":{"s_breakpoint":"≤ 8 µg/mL","i_breakpoint":"16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":["Results can predict susceptibility to amoxicillin."]}]},{"agentName":"Piperacillin-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"100/10 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"21–24 mm","r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/4 µg/mL"},"comments":[]}]},{"agentName":"Ceftriaxone","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Ciprofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"22–25 mm","r_breakpoint":"≤ 21 mm"},"mic":{"s_breakpoint":"≤ 0.25 µg/mL","i_breakpoint":"0.5 µg/mL","r_breakpoint":"≥ 1 µg/mL"},"comments":[]}]},{"agentName":"Levofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"17–20 mm","r_breakpoint":"≤ 16 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Tobramycin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"13–16 mm","r_breakpoint":"≤ 12 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Gentamicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Amikacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 19 mm","i_breakpoint":"17–19 mm","r_breakpoint":"≤ 16 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Trimethoprim-sulfamethoxazole","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"1.25/23.75 µg","s_breakpoint":"≥ 16 mm","i_breakpoint":"11–15 mm","r_breakpoint":"≤ 10 mm"},"mic":{"s_breakpoint":"≤ 2/38 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4/76 µg/mL"},"comments":[]}]}]},{"tier":2,"tierDescription":"Appropriate for routine, primary testing, may be reported following cascade reporting rules.","agents":[{"agentName":"Ertapenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"19–21 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Imipenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Meropenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]}]},{"tier":3,"tierDescription":"Appropriate for high-risk MDRO patients, subject to cascade reporting.","agents":[{"agentName":"Ceftazidime-avibactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/20 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"—","r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"—","r_breakpoint":"≥ 16/4 µg/mL"},"comments":["Confirmatory MIC testing is indicated for isolates with disk diffusion zones of 20–22 mm."]}]},{"agentName":"Meropenem-vaborbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4/8 µg/mL","i_breakpoint":"8/8 µg/mL","r_breakpoint":"≥ 16/8 µg/mL"},"comments":["If an OXA-48-like gene or enzyme is detected, results for meropenem-vaborbactam should be suppressed or reported as resistant."]}]},{"agentName":"Imipenem-relebactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10/25 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"21–24 mm","r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 1/4 µg/mL","i_breakpoint":"2/4 µg/mL","r_breakpoint":"≥ 4/4 µg/mL"},"comments":[]}]},{"agentName":"Cefiderocol","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 16 mm","i_breakpoint":"9–15 mm","r_breakpoint":"≤ 8 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Plazomicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 2 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]}]},{"tier":4,"tierDescription":"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.","agents":[{"agentName":"Aztreonam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"18–20 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":[]}]},{"agentName":"Ceftazidime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"18–20 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 8 µg/mL","i_breakpoint":"16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Ceftolozane-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"19–21 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 2/4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4/4 µg/mL"},"comments":[]}]},{"agentName":"Colistin or Polymyxin B","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":null,"s_breakpoint":null,"i_breakpoint":null,"r_breakpoint":null},"mic":{"s_breakpoint":"≤ 2 µg/mL","i_breakpoint":"—","r_breakpoint":"≥ 4 µg/mL"},"comments":["Disk diffusion and gradient diffusion methods should not be performed for these agents."]}]}]},{"tier":9,"tierDescription":"Urine Only Tier: Designated for reporting only on organisms isolated from the urinary tract.","agents":[{"agentName":"Cefazolin","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 15 mm","i_breakpoint":"—","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":"—","r_breakpoint":"≥ 32 µg/mL"},"comments":["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},{"agentName":"Nitrofurantoin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"300 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"15–16 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 32 µg/mL","i_breakpoint":"64 µg/mL","r_breakpoint":"≥ 128 µg/mL"},"comments":[]}]}]}]},"additionalInformation":{"diagnosticNotes":{"summary":"","biosafetyWarning":"","methods":[]},"preventionAndScreening":[],"treatmentLifecycle":[],"antimicrobialStewardship":["Reserve carbapenems for Citrobacter infections that in addition need anaerobic coverage or for treatment of ESBL producing strains.","Reserve Meropenem-vaborbactam and Ceftazidime-avibactam for patients with documented KPC infections."],"drugSpecificPearls":[{"drugName":"Cefepime","pearl":"Cefepime is a weak inducer of AmpC and is the most stable cephalosporin in its presence. However, strains with Cefepime MICs of 4-8 mcg/ml have dose-dependent susceptibility and may co-produce ESBL; caution is advised. Use higher doses (e.g., 2 gm IV over 3h q8-12h) for strains with MICs in this range."},{"drugName":"Ceftazidime-avibactam + Aztreonam","pearl":"This combination is used for metallo-beta-lactamase (MBL) producers. Aztreonam is stable against MBLs, while avibactam inhibits other co-produced beta-lactamases (like ESBLs, KPC, AmpC) that would otherwise inactivate aztreonam. This combination has been shown to reduce mortality in MBL infections."},{"drugName":"Cefiderocol","pearl":"FDA-approved for patients with complicated UTI with limited or no alternative treatment options. An open-label randomized trial comparing it to best available therapy for severe infections showed a non-statistically significant trend towards higher all-cause mortality with cefiderocol (24.8% vs 18.4%)."},{"drugName":"Plazomicin","pearl":"Approved for complicated UTI. There is limited observational experience for its use in combination with Tigecycline or Meropenem for MDR bacteremia or ventilator-associated pneumonia."}],"guidelineReferences":[{"source":"IDSA","citation":"Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin Infect Dis. Published online July 13, 2023:ciad428.","summaryOrNote":"Provides an updated framework for treating infections caused by multidrug-resistant Enterobacterales, including those producing ESBL, AmpC, and carbapenemases."},{"source":"Clinical Infectious Diseases","citation":"Karaiskos I, et al. Ceftazidime-avibactam plus Aztreonam for Metallo-β-lactamase-producing Enterobacterales: A Prospective, Observational, Multicenter Study (REJUVENATE). Clin Infect Dis. 2024; 78:1111.","summaryOrNote":"Presents prospective observational trial data showing reduced 30-day mortality with ceftazidime-avibactam plus aztreonam versus colistin-based regimens for infections due to metallo-beta-lactamase-producing Enterobacterales."},{"source":"Antimicrobial Agents and Chemotherapy","citation":"Marshall S, Hujer AM, Rojas LJ, et al. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae? Antimicrob Agents Chemother. 2017;61(4):e02243-16.","summaryOrNote":"Details the in-vitro and in-vivo rationale for combining ceftazidime-avibactam with aztreonam to treat infections caused by MBL-producing bacteria."},{"source":"New England Journal of Medicine","citation":"De la Torre A, et al. Plazomicin for Ventilator-Associated Pneumonia. N Engl J Med 2019; 380: 791","summaryOrNote":"Provides limited observational experience on Plazomicin for MDR bacteremia or ventilator-associated pneumonia."}]}}'),Df={originalKeys:["identity","clinicalProfile","resistanceProfile","treatment","laboratoryProfile","additionalInformation"],conversionTimestamp:"2025-07-15T03:16:49.265Z",sourceFormat:"modern"},qf={bacteriumName:{sources:["identity.bacteriumName"],value:"Citrobacter freundii"},aliases:{sources:["identity.aliases"],value:["Citrobacter freundii"]},lastUpdated:{sources:["identity.lastUpdated"],value:"2024-07-30"},classification:{sources:["identity.classification"],value:{gramStain:"Gram negative",morphology:"Bacilli",respiration:"Facultative anaerobe",notes:["Grows aerobically and anaerobically."]}}},Tf={sources:["clinicalProfile"],value:{summary:"Citrobacter species cause a variety of infections ranging from uncomplicated urinary tract infections to life-threatening infections of the abdomen, skin and soft tissue, lung, CNS and other sites in both normal and immuno-compromised hosts.",pathophysiologyPearls:["Citrobacter freundii predicably encodes an inducible ampC chromosomal gene that is de-repressed during clinical therapy with Ceftriaxone, Cefotaxime, Ceftazidime, Aztreonam, or Piperacillin-tazobactam.","Hence, initial in vitro susceptibility may indicate susceptibility to extended spectrum cephalosporins as the ampC gene is repressed.","With treatment, the ampC gene is de-repressed and patients may fail to respond clinically.","With de-repression, in vitro susceptibility now indicates resistance to beta lactams."],keySignsAndSymptoms:[],clinicalSyndromes:[{syndromeName:"Urinary Tract Infections (UTI)",description:"Can range from uncomplicated cystitis to complicated pyelonephritis."},{syndromeName:"Intra-abdominal Infections",description:"Infections within the abdominal cavity, often polymicrobial."},{syndromeName:"Skin and Soft Tissue Infections",description:"Infections of the skin, subcutaneous tissue, fascia, or muscle."},{syndromeName:"Pneumonia",description:"Infection of the lungs, often seen in hospitalized or immunocompromised patients."},{syndromeName:"Central Nervous System (CNS) Infections",description:"Life-threatening infections such as meningitis or brain abscesses."}],stagesOfIllness:[],highRiskPopulations:["Immuno-compromised hosts"],transmissionVectors:[],prognosisNotes:["It is best to avoid extended spectrum cephalosporins (cefepime is the exception), aztreonam, and piperacillin-tazobactam therapy for Citrobacter freundii regardless of the results of in vitro susceptibility due to risk of AmpC de-repression.","Citrobacter strains can also produce extended-spectrum beta-lactamases (ESBLs), which destroy the antibacterial activity of most extended-spectrum cephalosporins, penicillins, and aztreonam.","Strains often exhibit concomitant resistance to fluoroquinolones, aminoglycosides, and TMP/SMX."]}},Ef={sources:["resistanceProfile"],value:{groupIntrinsicResistance:[],intrinsicResistance:[{drugOrClass:"Multiple Beta-Lactams",notes:"Citrobacter freundii predicably encodes an inducible ampC chromosomal gene. It is de-repressed during clinical therapy with Ceftriaxone, Cefotaxime, Ceftazidime, Aztreonam, or Piperacillin-tazobactam, leading to clinical failure."}],majorMechanisms:[{mechanismName:"AmpC Beta-Lactamase Production",mechanismType:"Enzymatic Inactivation",description:"A chromosomal ampC gene may be present but repressed. Administration of a cephalosporin or other beta-lactams can derepress the gene, leading to the production of AmpC enzymes that hydrolyze the antibiotic."},{mechanismName:"Extended-Spectrum Beta-Lactamase (ESBL) Production",mechanismType:"Enzymatic Inactivation",description:"ESBLs destroy the antibacterial activity of most extended-spectrum cephalosporins, penicillins, and aztreonam. Cefepime may be an exception."},{mechanismName:"Carbapenemase Production (e.g., KPC)",mechanismType:"Enzymatic Inactivation",description:"Enzymes like Klebsiella pneumoniae carbapenemases (KPC) hydrolyze carbapenems and most other beta-lactams."},{mechanismName:"Metallo-beta-lactamase (MBL) Production",mechanismType:"Enzymatic Inactivation",description:"Enzymes that require zinc for activity and hydrolyze a broad range of beta-lactams including carbapenems. They are not inhibited by avibactam."},{mechanismName:"Porin Closure",mechanismType:"Reduced Permeability",description:"Reduced permeability of the outer cell wall, preventing antibiotics from reaching their target."},{mechanismName:"Efflux Pumps",mechanismType:"Antibiotic Efflux",description:"Active transport systems that pump antibiotics out of the bacterial cell."}],clinicalAlerts:[{alertTitle:"Inducible AmpC Resistance",details:"Until a Citrobacter isolate is speciated, assume it could be C. freundii. Avoid empiric third-generation cephalosporin, aztreonam, or piperacillin-tazobactam therapy regardless of initial in vitro susceptibility results due to the risk of de-repression of the AmpC gene and subsequent clinical failure."}]}},Pf={treatmentData:{_treatmentMetadata:{originalFormat:"modern"},standardizedRegimens:[{regimenId:"modern-0-0-0",extractedFrom:"treatment.regimens[0].recommendations[0].steps[0]",context:{type:"empiric",condition:"Suspected Citrobacter freundii infection, susceptibility pending",severity:"unknown",patientFactors:{population:["Patients in regions with local rate of ESBL <10-15%"],labFindings:null}},preference:"primary",drugs:[{drugName:"Cefepime",dose:"2 gm",route:"IV",frequency:"q8-12h",duration:"Variable",comments:"Infuse over 3 hours. Cefepime is the most stable cephalosporin in the presence of AmpC.",originalText:"Cefepime 2 gm IV q8-12h"}]},{regimenId:"modern-1-0-0",extractedFrom:"treatment.regimens[1].recommendations[0].steps[0]",context:{type:"empiric",condition:"Suspected Citrobacter freundii infection, susceptibility pending",severity:"unknown",patientFactors:{population:["Patients in regions with local rate of ESBL >15%"],labFindings:null}},preference:"primary",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:null,originalText:"Meropenem 1-2 gm IV q8h"}]},{regimenId:"modern-1-1-0",extractedFrom:"treatment.regimens[1].recommendations[1].steps[0]",context:{type:"empiric",condition:"Suspected Citrobacter freundii infection, susceptibility pending",severity:"unknown",patientFactors:{population:["Patients in regions with local rate of ESBL >15%"],labFindings:null}},preference:"alternative",drugs:[{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",duration:"Variable",comments:null,originalText:"Ertapenem 1 gm IV q24h"}]},{regimenId:"modern-2-0-0",extractedFrom:"treatment.regimens[2].recommendations[0].steps[0]",context:{type:"directed",condition:"Infection with C. freundii, IV therapy indicated",severity:"unknown",patientFactors:{population:["Isolates with no in vitro resistance detected"],labFindings:null}},preference:"primary",drugs:[{drugName:"Cefepime",dose:"2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Preferred beta-lactam due to stability against AmpC.",originalText:"Cefepime 2 gm IV q8h"}]},{regimenId:"modern-2-1-0",extractedFrom:"treatment.regimens[2].recommendations[1].steps[0]",context:{type:"directed",condition:"Infection with C. freundii, IV therapy indicated",severity:"unknown",patientFactors:{population:["Isolates with no in vitro resistance detected"],labFindings:null}},preference:"alternative",drugs:[{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"q12h",duration:"Variable",comments:null,originalText:"Ciprofloxacin 400 mg IV q12h"},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"once daily",duration:"Variable",comments:null,originalText:"Levofloxacin 750 mg IV once daily"}]},{regimenId:"modern-3-0-0",extractedFrom:"treatment.regimens[3].recommendations[0].steps[0]",context:{type:"directed",condition:"Uncomplicated UTI (Cystitis), PO therapy",severity:"unknown",patientFactors:{population:["Isolates with no in vitro resistance detected"],labFindings:"Urine"}},preference:"primary",drugs:[{drugName:"Cefixime",dose:"Varies by formulation",route:"PO",frequency:"Varies",duration:"Variable",comments:"Dose depends on specific product and indication.",originalText:"Cefixime Varies by formulation PO Varies"},{drugName:"Cefdinir",dose:"Varies by formulation",route:"PO",frequency:"Varies",duration:"Variable",comments:"Dose depends on specific product and indication.",originalText:"Cefdinir Varies by formulation PO Varies"},{drugName:"Fosfomycin",dose:"3 gm",route:"PO",frequency:"x 1 dose",duration:"Variable",comments:"Activity against Citrobacter can be variable; check susceptibility.",originalText:"Fosfomycin 3 gm PO x 1 dose"}]},{regimenId:"modern-4-0-0",extractedFrom:"treatment.regimens[4].recommendations[0].steps[0]",context:{type:"directed",condition:"ESBL producer or derepressed AmpC",severity:"unknown",patientFactors:{population:["Isolates with resistance to aztreonam, ceftriaxone, cefotaxime"],labFindings:null}},preference:"primary",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:null,originalText:"Meropenem 1-2 gm IV q8h"}]},{regimenId:"modern-4-1-0",extractedFrom:"treatment.regimens[4].recommendations[1].steps[0]",context:{type:"directed",condition:"ESBL producer or derepressed AmpC",severity:"unknown",patientFactors:{population:["Isolates with resistance to aztreonam, ceftriaxone, cefotaxime"],labFindings:null}},preference:"alternative",drugs:[{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",duration:"Variable",comments:null,originalText:"Ertapenem 1 gm IV q24h"}]},{regimenId:"modern-5-0-0",extractedFrom:"treatment.regimens[5].recommendations[0].steps[0]",context:{type:"directed",condition:"Klebsiella pneumoniae carbapenemase (KPC) producer",severity:"unknown",patientFactors:{population:["Isolates resistant to carbapenems, cephalosporins, penicillins, fluoroquinolones, and aminoglycosides"],labFindings:null}},preference:"primary",drugs:[{drugName:"Meropenem-vaborbactam",dose:"4 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infused over 3 hours.",originalText:"Meropenem-vaborbactam 4 gm IV q8h"}]},{regimenId:"modern-5-1-0",extractedFrom:"treatment.regimens[5].recommendations[1].steps[0]",context:{type:"directed",condition:"Klebsiella pneumoniae carbapenemase (KPC) producer",severity:"unknown",patientFactors:{population:["Isolates resistant to carbapenems, cephalosporins, penicillins, fluoroquinolones, and aminoglycosides"],labFindings:null}},preference:"alternative",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infused over 2 hours.",originalText:"Ceftazidime-avibactam 2.5 gm IV q8h"},{drugName:"Imipenem-cilastatin-relebactam",dose:"1.25 gm",route:"IV",frequency:"q6h",duration:"Variable",comments:"Infused over 30 min. For patients with CrCl > 90 mL/min.",originalText:"Imipenem-cilastatin-relebactam 1.25 gm IV q6h"}]},{regimenId:"modern-6-0-0",extractedFrom:"treatment.regimens[6].recommendations[0].steps[0]",context:{type:"directed",condition:"Metallo-beta-lactamase (MBL) producer",severity:"unknown",patientFactors:{population:["Isolates resistant to meropenem-vaborbactam, ceftazidime-avibactam, carbapenems, and other beta-lactams"],labFindings:null}},preference:"primary",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infused over 2 hours.",originalText:"Ceftazidime-avibactam 2.5 gm IV q8h"},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infused over 2 hours. Must be given with Ceftazidime-avibactam.",originalText:"Aztreonam 2 gm IV q8h"}]},{regimenId:"modern-6-1-0",extractedFrom:"treatment.regimens[6].recommendations[1].steps[0]",context:{type:"directed",condition:"Metallo-beta-lactamase (MBL) producer",severity:"unknown",patientFactors:{population:["Isolates resistant to meropenem-vaborbactam, ceftazidime-avibactam, carbapenems, and other beta-lactams"],labFindings:null}},preference:"alternative",drugs:[{drugName:"Cefiderocol",dose:"2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infused over 3 hours.",originalText:"Cefiderocol 2 gm IV q8h"}]},{regimenId:"modern-7-0-0",extractedFrom:"treatment.regimens[7].recommendations[0].steps[0]",context:{type:"directed",condition:"Pan-resistant infection",severity:"unknown",patientFactors:{population:["Isolates resistant to all tested classes of FDA approved anti-infectives"],labFindings:null}},preference:"salvage",drugs:[{drugName:"Cefiderocol",dose:"2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infused over 3 hours, if susceptible.",originalText:"Cefiderocol 2 gm IV q8h"},{drugName:"Fosfomycin",dose:"Varies",route:"IV/PO",frequency:"Varies",duration:"Variable",comments:"Use where available and based on susceptibility. IV formulation may be required for systemic infections.",originalText:"Fosfomycin Varies IV/PO Varies"}]},{regimenId:"modern-8-0-0",extractedFrom:"treatment.regimens[8].recommendations[0].steps[0]",context:{type:"alternative",condition:"Complicated UTI",severity:"unknown",patientFactors:{population:["ESBL Producers"],labFindings:"Urine"}},preference:"alternative",drugs:[{drugName:"Cefepime-enmetazobactam",dose:"2.5 g",route:"IV",frequency:"q8h",duration:"Variable",comments:"Recently FDA approved for complicated UTIs, including ESBL producers.",originalText:"Cefepime-enmetazobactam 2.5 g IV q8h"}]},{regimenId:"modern-9-0-0",extractedFrom:"treatment.regimens[9].recommendations[0].steps[0]",context:{type:"alternative",condition:"Infection with AmpC and/or ESBL producer",severity:"unknown",patientFactors:{population:[],labFindings:null}},preference:"alternative",drugs:[{drugName:"Ceftolozane-tazobactam",dose:"1.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infused over 1h. De-repressed AmpC producers may be resistant.",originalText:"Ceftolozane-tazobactam 1.5 gm IV q8h"},{drugName:"Temocillin",dose:"2 gm",route:"IV",frequency:"q12h",duration:"Variable",comments:"Availability limited (e.g., Belgium, UK).",originalText:"Temocillin 2 gm IV q12h"}]}]}},Lf={sources:["laboratoryProfile"],value:{testingIndications:["Until a Citrobacter isolate is speciated, it should be assumed it could be C. freundii, which warrants avoidance of empiric third-generation cephalosporins, piperacillin-tazobactam, or aztreonam due to the high risk of inducible AmpC-mediated resistance."],methodologyNotes:["Breakpoints for Fosfomycin apply only to E. coli urinary tract isolates and should not be extrapolated to Citrobacter freundii.","Disk diffusion and gradient diffusion methods should not be performed for Colistin or Polymyxin B; MIC testing is required."],recommendedPanel:[],specialTests:[{testName:"Carbapenemase Production Test (e.g., mCIM, CarbaNP)",trigger:"Resistance to one or more carbapenems (ertapenem, imipenem, meropenem).",purpose:"To detect the presence of carbapenemase enzymes, which has significant therapeutic and infection control implications."}],reportingRules:[{ruleType:"Conditional",drug:"Cefepime",condition:"Isolate demonstrates carbapenemase production.",details:"Cefepime S/SDD results should be suppressed or edited and reported as Resistant."},{ruleType:"Conditional",drug:"Meropenem-vaborbactam",condition:"An OXA-48-like gene or enzyme is detected.",details:"Results for meropenem-vaborbactam should be suppressed or reported as Resistant."}],antimicrobialBreakpoints:[{tier:1,tierDescription:"Appropriate for routine, primary testing and reporting.",agents:[{agentName:"Cefepime",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 25 mm",i_breakpoint:"19–24 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"8 µg/mL",r_breakpoint:"≥ 16 µg/mL"},comments:["Due to the concern for inducible AmpC, Cefepime should be considered a Tier 1 agent for testing and reporting of C. freundii complex.","Cefepime S/SDD results should be reported as resistant if the isolate has a carbapenemase."]}]},{agentName:"Ampicillin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 17 mm",i_breakpoint:"14–16 mm",r_breakpoint:"≤ 13 mm"},mic:{s_breakpoint:"≤ 8 µg/mL",i_breakpoint:"16 µg/mL",r_breakpoint:"≥ 32 µg/mL"},comments:["Results can predict susceptibility to amoxicillin."]}]},{agentName:"Piperacillin-tazobactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"100/10 µg",s_breakpoint:"≥ 25 mm",i_breakpoint:"21–24 mm",r_breakpoint:"≤ 20 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:"16/4 µg/mL",r_breakpoint:"≥ 32/4 µg/mL"},comments:[]}]},{agentName:"Ceftriaxone",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 26 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]},{agentName:"Ciprofloxacin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"5 µg",s_breakpoint:"≥ 26 mm",i_breakpoint:"22–25 mm",r_breakpoint:"≤ 21 mm"},mic:{s_breakpoint:"≤ 0.25 µg/mL",i_breakpoint:"0.5 µg/mL",r_breakpoint:"≥ 1 µg/mL"},comments:[]}]},{agentName:"Levofloxacin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"5 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"17–20 mm",r_breakpoint:"≤ 16 mm"},mic:{s_breakpoint:"≤ 0.5 µg/mL",i_breakpoint:"1 µg/mL",r_breakpoint:"≥ 2 µg/mL"},comments:[]}]},{agentName:"Tobramycin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 17 mm",i_breakpoint:"13–16 mm",r_breakpoint:"≤ 12 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 8 µg/mL"},comments:[]}]},{agentName:"Gentamicin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:"15–17 mm",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 8 µg/mL"},comments:[]}]},{agentName:"Amikacin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 19 mm",i_breakpoint:"17–19 mm",r_breakpoint:"≤ 16 mm"},mic:{s_breakpoint:"≤ 16 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 32 µg/mL"},comments:[]}]},{agentName:"Trimethoprim-sulfamethoxazole",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"1.25/23.75 µg",s_breakpoint:"≥ 16 mm",i_breakpoint:"11–15 mm",r_breakpoint:"≤ 10 mm"},mic:{s_breakpoint:"≤ 2/38 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 4/76 µg/mL"},comments:[]}]}]},{tier:2,tierDescription:"Appropriate for routine, primary testing, may be reported following cascade reporting rules.",agents:[{agentName:"Ertapenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 22 mm",i_breakpoint:"19–21 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 0.5 µg/mL",i_breakpoint:"1 µg/mL",r_breakpoint:"≥ 2 µg/mL"},comments:[]}]},{agentName:"Imipenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 23 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]},{agentName:"Meropenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 23 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]}]},{tier:3,tierDescription:"Appropriate for high-risk MDRO patients, subject to cascade reporting.",agents:[{agentName:"Ceftazidime-avibactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30/20 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"—",r_breakpoint:"≤ 20 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 16/4 µg/mL"},comments:["Confirmatory MIC testing is indicated for isolates with disk diffusion zones of 20–22 mm."]}]},{agentName:"Meropenem-vaborbactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:"15–17 mm",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 4/8 µg/mL",i_breakpoint:"8/8 µg/mL",r_breakpoint:"≥ 16/8 µg/mL"},comments:["If an OXA-48-like gene or enzyme is detected, results for meropenem-vaborbactam should be suppressed or reported as resistant."]}]},{agentName:"Imipenem-relebactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10/25 µg",s_breakpoint:"≥ 25 mm",i_breakpoint:"21–24 mm",r_breakpoint:"≤ 20 mm"},mic:{s_breakpoint:"≤ 1/4 µg/mL",i_breakpoint:"2/4 µg/mL",r_breakpoint:"≥ 4/4 µg/mL"},comments:[]}]},{agentName:"Cefiderocol",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 16 mm",i_breakpoint:"9–15 mm",r_breakpoint:"≤ 8 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 8 µg/mL"},comments:[]}]},{agentName:"Plazomicin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:"15–17 mm",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 2 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 4 µg/mL"},comments:[]}]}]},{tier:4,tierDescription:"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.",agents:[{agentName:"Aztreonam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"18–20 mm",r_breakpoint:"≤ 17 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"8 µg/mL",r_breakpoint:"≥ 16 µg/mL"},comments:[]}]},{agentName:"Ceftazidime",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"18–20 mm",r_breakpoint:"≤ 17 mm"},mic:{s_breakpoint:"≤ 8 µg/mL",i_breakpoint:"16 µg/mL",r_breakpoint:"≥ 32 µg/mL"},comments:[]}]},{agentName:"Ceftolozane-tazobactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30/10 µg",s_breakpoint:"≥ 22 mm",i_breakpoint:"19–21 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 2/4 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 4/4 µg/mL"},comments:[]}]},{agentName:"Colistin or Polymyxin B",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:null,s_breakpoint:null,i_breakpoint:null,r_breakpoint:null},mic:{s_breakpoint:"≤ 2 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 4 µg/mL"},comments:["Disk diffusion and gradient diffusion methods should not be performed for these agents."]}]}]},{tier:9,tierDescription:"Urine Only Tier: Designated for reporting only on organisms isolated from the urinary tract.",agents:[{agentName:"Cefazolin",breakpointSets:[{condition:"Uncomplicated UTI only",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 15 mm",i_breakpoint:"—",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 16 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 32 µg/mL"},comments:["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},{agentName:"Nitrofurantoin",breakpointSets:[{condition:"Urine Only",diskDiffusion:{diskContent:"300 µg",s_breakpoint:"≥ 17 mm",i_breakpoint:"15–16 mm",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 32 µg/mL",i_breakpoint:"64 µg/mL",r_breakpoint:"≥ 128 µg/mL"},comments:[]}]}]}]}},zf={antimicrobialStewardship:{sources:["antimicrobial_stewardship","antimicrobialStewardship"],value:[]},comments:{preservedStructure:{originalFormat:"object"}},diagnosis:{sources:["diagnosis"],value:[]},allOtherKeys:{}},Vf={_originalData:Mf,_metadata:Df,identity:qf,clinicalInformation:Tf,resistanceInformation:Ef,treatmentData:Pf,laboratoryData:Lf,additionalData:zf},Of=JSON.parse(`{"identity":{"bacteriumName":"Citrobacter koseri","aliases":["Citrobacter diversus"],"lastUpdated":"2025-01-17","clsiCategory":"Enterobacterales (excluding Salmonella/Shigella)","classification":{"gramStain":"Gram negative","morphology":"Bacilli","respiration":"Facultative anaerobe","notes":["Grows aerobically and anaerobically."]},"strainDetails":[],"biochemicalTests":"Gram-negative rod, motile, lactose fermenter, H2S –, indole +, citrate +, lysine decarboxylase +, ornithine decarboxylase +."},"clinicalProfile":{"summary":"Citrobacter species cause a variety of infections ranging from uncomplicated urinary tract infections to life-threatening infections of the abdomen, skin and soft tissue, lung, CNS and other sites in both normal and immuno-compromised hosts.","pathophysiologyPearls":["Unlike Citrobacter freundii, Citrobacter koseri does not have repressed chromosomal ampC genes. Hence it is safe to use ceftriaxone if the isolate is both speciated as C. koseri and is susceptible in vitro."],"keySignsAndSymptoms":[],"clinicalSyndromes":[{"syndromeName":"Urinary Tract Infections (UTI)","description":"Can range from uncomplicated cystitis to complicated infections."},{"syndromeName":"Intra-abdominal Infections","description":"Infections within the abdominal cavity."},{"syndromeName":"Skin and Soft Tissue Infections","description":"Infections involving the skin and underlying structures."},{"syndromeName":"Pneumonia","description":"Infection of the lungs."},{"syndromeName":"Central Nervous System (CNS) Infections","description":"Life-threatening infections of the central nervous system, particularly in neonates."}],"stagesOfIllness":[],"highRiskPopulations":["Immuno-compromised hosts","Neonates"],"transmissionVectors":[],"prognosisNotes":[]},"resistanceProfile":{"groupIntrinsicResistance":[],"intrinsicResistance":[],"majorMechanisms":[{"mechanismName":"Extended-Spectrum Beta-Lactamases (ESBLs)","mechanismType":"Enzymatic Inactivation","description":"Citrobacter strains can produce ESBLs, which destroy the antibacterial activity of most extended-spectrum cephalosporins, penicillins, and aztreonam, though Cefepime may be an exception."},{"mechanismName":"Serine Carbapenemases (KPC)","mechanismType":"Enzymatic Inactivation","description":"Resistance to all carbapenems, cephalosporins, penicillins, fluoroquinolones, and aminoglycosides can be consistent with the production of Klebsiella-producing serine based carbapenemases (KPCs)."},{"mechanismName":"Metallo-Carbapenemase (MBL)","mechanismType":"Enzymatic Inactivation","description":"Resistance to meropenem-vaborbactam, ceftazidime-avibactam, all carbapenems, and other beta-lactams is consistent with production of metallo-carbapenemase."}],"clinicalAlerts":[{"alertTitle":"Absence of Inducible AmpC","details":"A critical distinction is that C. koseri does not house the inducible ampC gene, unlike C. freundii. Therefore, third-generation cephalosporins (e.g., ceftriaxone) are safe and effective if the isolate is confirmed as C. koseri and tests susceptible in vitro. If the lab report only specifies 'Citrobacter species,' cephalosporins should be avoided regardless of susceptibility results due to the risk of AmpC induction with C. freundii."},{"alertTitle":"Co-resistance","details":"Strains often exhibit concomitant resistance to fluoroquinolones, aminoglycosides, and TMP/SMX."}]},"treatment":{"generalNotes":["Choice of empiric regimen depends on local resistance patterns, the fragility of the patient, and the severity of the infection.","Specific therapy is directed by the results of in vitro susceptibility testing.","For uncomplicated cystitis, see Cystitis, adult female guidelines."],"drugsToAvoid":[],"adjunctiveTherapies":[],"regimens":[{"context":{"type":"Empiric","condition":"Citrobacter koseri identified, susceptibility pending","patientPopulation":["Local rate of ESBL <10-15%"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Piperacillin-tazobactam","dose":"4.5 gm","route":"IV","frequency":"q6h","comments":"Infused over 4 hr."},{"drugName":"Ceftriaxone","dose":"2 gm","route":"IV","frequency":"daily","comments":"Safe to use as C. koseri does not have inducible ampC genes."}]}]}]},{"context":{"type":"Empiric","condition":"Citrobacter koseri identified, susceptibility pending","patientPopulation":["Local rate of ESBL >15%"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Meropenem","dose":"1-2 gm","route":"IV","frequency":"q8h","comments":""},{"drugName":"Ertapenem","dose":"1 gm","route":"IV","frequency":"q24h","comments":""}]}]}]},{"context":{"type":"Directed","condition":"No in vitro resistance detected","patientPopulation":[],"isolateSource":"Systemic (IV therapy)"},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Piperacillin-tazobactam","dose":"4.5 gm (infused over 4 hr)","route":"IV","frequency":"q6h","comments":""},{"drugName":"Ciprofloxacin","dose":"400 mg","route":"IV","frequency":"q12h","comments":""},{"drugName":"Levofloxacin","dose":"750 mg","route":"IV","frequency":"once daily","comments":""},{"drugName":"Ceftriaxone","dose":"2 gms","route":"IV","frequency":"daily","comments":""}]}]}]},{"context":{"type":"Directed","condition":"No in vitro resistance detected","patientPopulation":[],"isolateSource":"Urine (PO therapy)"},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Cefixime","dose":"Varies","route":"PO","frequency":"Varies","comments":""},{"drugName":"Cefdinir","dose":"Varies","route":"PO","frequency":"Varies","comments":""},{"drugName":"Fosfomycin","dose":"3 gm po x 1 dose","route":"PO","frequency":"Single dose","comments":"For uncomplicated cystitis. Note: CLSI breakpoints are only validated for E. coli."}]}]}]},{"context":{"type":"Directed","condition":"ESBL Producer","patientPopulation":["Resistance to aztreonam, ceftriaxone, cefotaxime"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Meropenem","dose":"1-2 gm","route":"IV","frequency":"q8h","comments":""},{"drugName":"Ertapenem","dose":"1 gm","route":"IV","frequency":"q24h","comments":""}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftolozane-tazobactam","dose":"1.5 gm","route":"IV","frequency":"q8h","comments":"Infuse over 3h."},{"drugName":"Temocillin","dose":"2 gm","route":"IV","frequency":"q12h","comments":"Availability is limited."}]}]}]},{"context":{"type":"Directed","condition":"Serine Carbapenemase (KPC) Producer","patientPopulation":["Resistant to carbapenems but susceptible to newer beta-lactamase inhibitor combinations"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Meropenem-vaborbactam","dose":"4 gm","route":"IV","frequency":"q8h","comments":"Infused over 3h."},{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"q8h","comments":"Infused over 2 hrs."},{"drugName":"Imipenem-cilastatin-relebactam","dose":"1.25 gm","route":"IV","frequency":"q6h","comments":"Infused over 30 min (for CrCl > 90 mL/min)."}]}]}]},{"context":{"type":"Directed","condition":"Metallo-Carbapenemase (MBL) Producer","patientPopulation":["Resistant to meropenem-vaborbactam, ceftazidime-avibactam, and all carbapenems"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"q8h","comments":"Infused over 3 hrs. Must be given with Aztreonam."},{"drugName":"Aztreonam","dose":"2 gm","route":"IV","frequency":"q8h","comments":"Infused over 3h. Must be given with Ceftazidime-avibactam."}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Cefiderocol","dose":"2 gm","route":"IV","frequency":"q8h","comments":"Infuse over 3h."}]}]}]},{"context":{"type":"Directed","condition":"Pan-resistant infection","patientPopulation":["Resistant to all normally tested classes of FDA approved anti-infectives"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Fosfomycin","dose":"Varies","route":"IV","frequency":"Varies","comments":"IV formulation availability is limited."},{"drugName":"Cefiderocol","dose":"2 gm","route":"IV","frequency":"q8h","comments":"Infused over 3h."}]}]}]}]},"laboratoryProfile":{"clsiCategory":"Enterobacterales (excluding Salmonella/Shigella)","testingIndications":[],"methodologyNotes":["For Citrobacter freundii complex, Enterobacter cloacae complex, Klebsiella aerogenes, Morganella morganii, Providencia spp., and Serratia marcescens, isolates that initially test susceptible to third-generation cephalosporins may develop resistance during therapy due to derepression of inducible AmpC β-lactamase. While C. koseri is not typically listed in this high-risk group, speciation is crucial to differentiate it from C. freundii."],"recommendedPanel":[],"specialTests":[],"reportingRules":[{"ruleType":"Surrogate","drug":"Cefazolin","condition":"Uncomplicated UTI","details":"For isolates from uncomplicated UTIs, cefazolin susceptibility can be used as a surrogate marker to predict susceptibility to oral cephalosporins like cephalexin, cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime axetil, and loracarbef. This rule specifically applies to E. coli, K. pneumoniae, and P. mirabilis."},{"ruleType":"Conditional","drug":"Fosfomycin","condition":"Isolate is not E. coli from a urinary tract source.","details":"Fosfomycin breakpoints (MIC and disk) are for E. coli from urinary tract isolates only and should not be used for other genera, including Citrobacter."},{"ruleType":"Conditional","drug":"Colistin/Polymyxin B","condition":"Any isolate","details":"Disk diffusion and gradient diffusion methods are unreliable and should not be performed. Broth microdilution is the recommended method."}],"antimicrobialBreakpoints":[{"tier":1,"tierDescription":"Appropriate for routine, primary testing and reporting.","agents":[{"agentName":"Ampicillin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"14–16 mm","r_breakpoint":"≤ 13 mm"},"mic":{"s_breakpoint":"≤ 8 µg/mL","i_breakpoint":"16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":["Results can predict amoxicillin results."]}]},{"agentName":"Amoxicillin-clavulanate","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"—","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/4 µg/mL"},"comments":["Breakpoints apply for therapy of uncomplicated UTIs or for completion of therapy for systemic infection."]}]},{"agentName":"Piperacillin-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"100/10 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"21–24 mm","r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/4 µg/mL"},"comments":[]}]},{"agentName":"Ciprofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"22–25 mm","r_breakpoint":"≤ 21 mm"},"mic":{"s_breakpoint":"≤ 0.25 µg/mL","i_breakpoint":"0.5 µg/mL","r_breakpoint":"≥ 1 µg/mL"},"comments":[]}]},{"agentName":"Levofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"17–20 mm","r_breakpoint":"≤ 16 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Trimethoprim-sulfamethoxazole","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"1.25/23.75 µg","s_breakpoint":"≥ 16 mm","i_breakpoint":"11–15 mm","r_breakpoint":"≤ 10 mm"},"mic":{"s_breakpoint":"≤ 2/38 µg/mL","i_breakpoint":"—","r_breakpoint":"≥ 4/76 µg/mL"},"comments":[]}]}]},{"tier":2,"tierDescription":"Appropriate for routine, primary testing, may be reported following cascade reporting rules.","agents":[{"agentName":"Cefepime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"19–24 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":["Cefepime S/SDD results should be suppressed or reported as resistant for isolates demonstrating carbapenemase production."]}]},{"agentName":"Ertapenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"19–21 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Meropenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]}]},{"tier":3,"tierDescription":"Appropriate for high-risk MDRO patients, subject to cascade reporting.","agents":[{"agentName":"Ceftazidime-avibactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/20 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"—","r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"—","r_breakpoint":"≥ 16/4 µg/mL"},"comments":["Confirmatory MIC testing is indicated for isolates with disk diffusion zones of 20–22 mm."]}]},{"agentName":"Meropenem-vaborbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4/8 µg/mL","i_breakpoint":"8/8 µg/mL","r_breakpoint":"≥ 16/8 µg/mL"},"comments":["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]},{"agentName":"Imipenem-relebactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10/25 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"21–24 mm","r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 1/4 µg/mL","i_breakpoint":"2/4 µg/mL","r_breakpoint":"≥ 4/4 µg/mL"},"comments":["Breakpoints do not apply to the family Morganellaceae (Morganella, Proteus, and Providencia)."]}]}]},{"tier":4,"tierDescription":"May warrant testing and reporting by clinician request.","agents":[{"agentName":"Ceftriaxone","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Aztreonam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"18–20 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":[]}]}]},{"tier":0,"tierDescription":"Urine Only Tier","agents":[{"agentName":"Nitrofurantoin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"300 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"15–16 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 32 µg/mL","i_breakpoint":"64 µg/mL","r_breakpoint":"≥ 128 µg/mL"},"comments":[]}]},{"agentName":"Cefazolin","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 15 mm","i_breakpoint":"—","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":"—","r_breakpoint":"≥ 32 µg/mL"},"comments":["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},{"agentName":"Fosfomycin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"200 µg","s_breakpoint":"≥ 16 mm","i_breakpoint":"13–15 mm","r_breakpoint":"≤ 12 mm"},"mic":{"s_breakpoint":"≤ 64 µg/mL","i_breakpoint":"128 µg/mL","r_breakpoint":"≥ 256 µg/mL"},"comments":["Applies only to E. coli urinary tract isolates and should not be extrapolated to other Enterobacterales species. The 200 µg fosfomycin disk contains 50 µg glucose-6-phosphate."]}]}]}]},"additionalInformation":{"diagnosticNotes":{"summary":"","biosafetyWarning":"","methods":[]},"preventionAndScreening":[],"treatmentLifecycle":[],"antimicrobialStewardship":["Reserve carbapenems for Citrobacter infections that in addition need anaerobic coverage or for treatment of ESBL producing strains.","Reserve Meropenem-vaborbactam, Imipenem-cilastatin-relebactam, and Ceftazidime-avibactam for patients with documented KPC infections."],"drugSpecificPearls":[{"drugName":"Cephalosporins","pearl":"C. koseri does not house the ampC gene, making third-generation cephalosporins safe and effective if the isolate is susceptible in vitro. This is a key difference from C. freundii, where cephalosporins should be avoided due to risk of inducible resistance."},{"drugName":"Cefiderocol","pearl":"FDA-approved for patients with complicated UTI with limited or no alternative treatment options. In a trial comparing Cefiderocol to the Best Available Therapy (BAT) for serious infections, 28-day mortality was 24.8% for cefiderocol versus 18.4% for BAT (not statistically significant)."},{"drugName":"Plazomicin","pearl":"Approved for complicated UTI. There is limited observational experience using it in combination with Tigecycline or Meropenem for MDR bacteremia or ventilator-associated pneumonia."}],"guidelineReferences":[{"source":"IDSA","citation":"IDSA 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.","summaryOrNote":"Provides a framework for managing infections caused by resistant gram-negative organisms, including Citrobacter spp."},{"source":"Antimicrobial Agents and Chemotherapy","citation":"Antimicrob Agents Chemother 2017 Mar 24; 61(4). pii:e02243-16.","summaryOrNote":"Discusses the rationale for combining Ceftazidime-avibactam with Aztreonam for treating MBL-producing bacteria."},{"source":"New England Journal of Medicine","citation":"N Engl J Med 2019; 380: 791.","summaryOrNote":"Presents observational data on Plazomicin for MDR infections."}]}}`),Bf={originalKeys:["identity","clinicalProfile","resistanceProfile","treatment","laboratoryProfile","additionalInformation"],conversionTimestamp:"2025-07-15T03:16:49.270Z",sourceFormat:"modern"},Uf={bacteriumName:{sources:["identity.bacteriumName"],value:"Citrobacter koseri"},aliases:{sources:["identity.aliases"],value:["Citrobacter diversus"]},lastUpdated:{sources:["identity.lastUpdated"],value:"2025-01-17"},classification:{sources:["identity.classification"],value:{gramStain:"Gram negative",morphology:"Bacilli",respiration:"Facultative anaerobe",notes:["Grows aerobically and anaerobically."]}}},Ff={sources:["clinicalProfile"],value:{summary:"Citrobacter species cause a variety of infections ranging from uncomplicated urinary tract infections to life-threatening infections of the abdomen, skin and soft tissue, lung, CNS and other sites in both normal and immuno-compromised hosts.",pathophysiologyPearls:["Unlike Citrobacter freundii, Citrobacter koseri does not have repressed chromosomal ampC genes. Hence it is safe to use ceftriaxone if the isolate is both speciated as C. koseri and is susceptible in vitro."],keySignsAndSymptoms:[],clinicalSyndromes:[{syndromeName:"Urinary Tract Infections (UTI)",description:"Can range from uncomplicated cystitis to complicated infections."},{syndromeName:"Intra-abdominal Infections",description:"Infections within the abdominal cavity."},{syndromeName:"Skin and Soft Tissue Infections",description:"Infections involving the skin and underlying structures."},{syndromeName:"Pneumonia",description:"Infection of the lungs."},{syndromeName:"Central Nervous System (CNS) Infections",description:"Life-threatening infections of the central nervous system, particularly in neonates."}],stagesOfIllness:[],highRiskPopulations:["Immuno-compromised hosts","Neonates"],transmissionVectors:[],prognosisNotes:[]}},Gf={sources:["resistanceProfile"],value:{groupIntrinsicResistance:[],intrinsicResistance:[],majorMechanisms:[{mechanismName:"Extended-Spectrum Beta-Lactamases (ESBLs)",mechanismType:"Enzymatic Inactivation",description:"Citrobacter strains can produce ESBLs, which destroy the antibacterial activity of most extended-spectrum cephalosporins, penicillins, and aztreonam, though Cefepime may be an exception."},{mechanismName:"Serine Carbapenemases (KPC)",mechanismType:"Enzymatic Inactivation",description:"Resistance to all carbapenems, cephalosporins, penicillins, fluoroquinolones, and aminoglycosides can be consistent with the production of Klebsiella-producing serine based carbapenemases (KPCs)."},{mechanismName:"Metallo-Carbapenemase (MBL)",mechanismType:"Enzymatic Inactivation",description:"Resistance to meropenem-vaborbactam, ceftazidime-avibactam, all carbapenems, and other beta-lactams is consistent with production of metallo-carbapenemase."}],clinicalAlerts:[{alertTitle:"Absence of Inducible AmpC",details:"A critical distinction is that C. koseri does not house the inducible ampC gene, unlike C. freundii. Therefore, third-generation cephalosporins (e.g., ceftriaxone) are safe and effective if the isolate is confirmed as C. koseri and tests susceptible in vitro. If the lab report only specifies 'Citrobacter species,' cephalosporins should be avoided regardless of susceptibility results due to the risk of AmpC induction with C. freundii."},{alertTitle:"Co-resistance",details:"Strains often exhibit concomitant resistance to fluoroquinolones, aminoglycosides, and TMP/SMX."}]}},Hf={treatmentData:{_treatmentMetadata:{originalFormat:"modern"},standardizedRegimens:[{regimenId:"modern-0-0-0",extractedFrom:"treatment.regimens[0].recommendations[0].steps[0]",context:{type:"empiric",condition:"Citrobacter koseri identified, susceptibility pending",severity:"unknown",patientFactors:{population:["Local rate of ESBL <10-15%"],labFindings:null}},preference:"primary",drugs:[{drugName:"Piperacillin-tazobactam",dose:"4.5 gm",route:"IV",frequency:"q6h",duration:"Variable",comments:"Infused over 4 hr.",originalText:"Piperacillin-tazobactam 4.5 gm IV q6h"},{drugName:"Ceftriaxone",dose:"2 gm",route:"IV",frequency:"daily",duration:"Variable",comments:"Safe to use as C. koseri does not have inducible ampC genes.",originalText:"Ceftriaxone 2 gm IV daily"}]},{regimenId:"modern-1-0-0",extractedFrom:"treatment.regimens[1].recommendations[0].steps[0]",context:{type:"empiric",condition:"Citrobacter koseri identified, susceptibility pending",severity:"unknown",patientFactors:{population:["Local rate of ESBL >15%"],labFindings:null}},preference:"primary",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"",originalText:"Meropenem 1-2 gm IV q8h"},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Ertapenem 1 gm IV q24h"}]},{regimenId:"modern-2-0-0",extractedFrom:"treatment.regimens[2].recommendations[0].steps[0]",context:{type:"directed",condition:"No in vitro resistance detected",severity:"unknown",patientFactors:{population:[],labFindings:"Systemic (IV therapy)"}},preference:"primary",drugs:[{drugName:"Piperacillin-tazobactam",dose:"4.5 gm (infused over 4 hr)",route:"IV",frequency:"q6h",duration:"Variable",comments:"",originalText:"Piperacillin-tazobactam 4.5 gm (infused over 4 hr) IV q6h"},{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"q12h",duration:"Variable",comments:"",originalText:"Ciprofloxacin 400 mg IV q12h"},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"once daily",duration:"Variable",comments:"",originalText:"Levofloxacin 750 mg IV once daily"},{drugName:"Ceftriaxone",dose:"2 gms",route:"IV",frequency:"daily",duration:"Variable",comments:"",originalText:"Ceftriaxone 2 gms IV daily"}]},{regimenId:"modern-3-0-0",extractedFrom:"treatment.regimens[3].recommendations[0].steps[0]",context:{type:"directed",condition:"No in vitro resistance detected",severity:"unknown",patientFactors:{population:[],labFindings:"Urine (PO therapy)"}},preference:"primary",drugs:[{drugName:"Cefixime",dose:"Varies",route:"PO",frequency:"Varies",duration:"Variable",comments:"",originalText:"Cefixime Varies PO Varies"},{drugName:"Cefdinir",dose:"Varies",route:"PO",frequency:"Varies",duration:"Variable",comments:"",originalText:"Cefdinir Varies PO Varies"},{drugName:"Fosfomycin",dose:"3 gm po x 1 dose",route:"PO",frequency:"Single dose",duration:"Variable",comments:"For uncomplicated cystitis. Note: CLSI breakpoints are only validated for E. coli.",originalText:"Fosfomycin 3 gm po x 1 dose PO Single dose"}]},{regimenId:"modern-4-0-0",extractedFrom:"treatment.regimens[4].recommendations[0].steps[0]",context:{type:"directed",condition:"ESBL Producer",severity:"unknown",patientFactors:{population:["Resistance to aztreonam, ceftriaxone, cefotaxime"],labFindings:null}},preference:"primary",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"",originalText:"Meropenem 1-2 gm IV q8h"},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Ertapenem 1 gm IV q24h"}]},{regimenId:"modern-4-1-0",extractedFrom:"treatment.regimens[4].recommendations[1].steps[0]",context:{type:"directed",condition:"ESBL Producer",severity:"unknown",patientFactors:{population:["Resistance to aztreonam, ceftriaxone, cefotaxime"],labFindings:null}},preference:"alternative",drugs:[{drugName:"Ceftolozane-tazobactam",dose:"1.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infuse over 3h.",originalText:"Ceftolozane-tazobactam 1.5 gm IV q8h"},{drugName:"Temocillin",dose:"2 gm",route:"IV",frequency:"q12h",duration:"Variable",comments:"Availability is limited.",originalText:"Temocillin 2 gm IV q12h"}]},{regimenId:"modern-5-0-0",extractedFrom:"treatment.regimens[5].recommendations[0].steps[0]",context:{type:"directed",condition:"Serine Carbapenemase (KPC) Producer",severity:"unknown",patientFactors:{population:["Resistant to carbapenems but susceptible to newer beta-lactamase inhibitor combinations"],labFindings:null}},preference:"primary",drugs:[{drugName:"Meropenem-vaborbactam",dose:"4 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infused over 3h.",originalText:"Meropenem-vaborbactam 4 gm IV q8h"},{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infused over 2 hrs.",originalText:"Ceftazidime-avibactam 2.5 gm IV q8h"},{drugName:"Imipenem-cilastatin-relebactam",dose:"1.25 gm",route:"IV",frequency:"q6h",duration:"Variable",comments:"Infused over 30 min (for CrCl > 90 mL/min).",originalText:"Imipenem-cilastatin-relebactam 1.25 gm IV q6h"}]},{regimenId:"modern-6-0-0",extractedFrom:"treatment.regimens[6].recommendations[0].steps[0]",context:{type:"directed",condition:"Metallo-Carbapenemase (MBL) Producer",severity:"unknown",patientFactors:{population:["Resistant to meropenem-vaborbactam, ceftazidime-avibactam, and all carbapenems"],labFindings:null}},preference:"primary",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infused over 3 hrs. Must be given with Aztreonam.",originalText:"Ceftazidime-avibactam 2.5 gm IV q8h"},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infused over 3h. Must be given with Ceftazidime-avibactam.",originalText:"Aztreonam 2 gm IV q8h"}]},{regimenId:"modern-6-1-0",extractedFrom:"treatment.regimens[6].recommendations[1].steps[0]",context:{type:"directed",condition:"Metallo-Carbapenemase (MBL) Producer",severity:"unknown",patientFactors:{population:["Resistant to meropenem-vaborbactam, ceftazidime-avibactam, and all carbapenems"],labFindings:null}},preference:"alternative",drugs:[{drugName:"Cefiderocol",dose:"2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infuse over 3h.",originalText:"Cefiderocol 2 gm IV q8h"}]},{regimenId:"modern-7-0-0",extractedFrom:"treatment.regimens[7].recommendations[0].steps[0]",context:{type:"directed",condition:"Pan-resistant infection",severity:"unknown",patientFactors:{population:["Resistant to all normally tested classes of FDA approved anti-infectives"],labFindings:null}},preference:"primary",drugs:[{drugName:"Fosfomycin",dose:"Varies",route:"IV",frequency:"Varies",duration:"Variable",comments:"IV formulation availability is limited.",originalText:"Fosfomycin Varies IV Varies"},{drugName:"Cefiderocol",dose:"2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infused over 3h.",originalText:"Cefiderocol 2 gm IV q8h"}]}]}},Kf={sources:["laboratoryProfile"],value:{clsiCategory:"Enterobacterales (excluding Salmonella/Shigella)",testingIndications:[],methodologyNotes:["For Citrobacter freundii complex, Enterobacter cloacae complex, Klebsiella aerogenes, Morganella morganii, Providencia spp., and Serratia marcescens, isolates that initially test susceptible to third-generation cephalosporins may develop resistance during therapy due to derepression of inducible AmpC β-lactamase. While C. koseri is not typically listed in this high-risk group, speciation is crucial to differentiate it from C. freundii."],recommendedPanel:[],specialTests:[],reportingRules:[{ruleType:"Surrogate",drug:"Cefazolin",condition:"Uncomplicated UTI",details:"For isolates from uncomplicated UTIs, cefazolin susceptibility can be used as a surrogate marker to predict susceptibility to oral cephalosporins like cephalexin, cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime axetil, and loracarbef. This rule specifically applies to E. coli, K. pneumoniae, and P. mirabilis."},{ruleType:"Conditional",drug:"Fosfomycin",condition:"Isolate is not E. coli from a urinary tract source.",details:"Fosfomycin breakpoints (MIC and disk) are for E. coli from urinary tract isolates only and should not be used for other genera, including Citrobacter."},{ruleType:"Conditional",drug:"Colistin/Polymyxin B",condition:"Any isolate",details:"Disk diffusion and gradient diffusion methods are unreliable and should not be performed. Broth microdilution is the recommended method."}],antimicrobialBreakpoints:[{tier:1,tierDescription:"Appropriate for routine, primary testing and reporting.",agents:[{agentName:"Ampicillin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 17 mm",i_breakpoint:"14–16 mm",r_breakpoint:"≤ 13 mm"},mic:{s_breakpoint:"≤ 8 µg/mL",i_breakpoint:"16 µg/mL",r_breakpoint:"≥ 32 µg/mL"},comments:["Results can predict amoxicillin results."]}]},{agentName:"Amoxicillin-clavulanate",breakpointSets:[{condition:"Uncomplicated UTI only",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:"—",r_breakpoint:"≤ 17 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:"16/4 µg/mL",r_breakpoint:"≥ 32/4 µg/mL"},comments:["Breakpoints apply for therapy of uncomplicated UTIs or for completion of therapy for systemic infection."]}]},{agentName:"Piperacillin-tazobactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"100/10 µg",s_breakpoint:"≥ 25 mm",i_breakpoint:"21–24 mm",r_breakpoint:"≤ 20 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:"16/4 µg/mL",r_breakpoint:"≥ 32/4 µg/mL"},comments:[]}]},{agentName:"Ciprofloxacin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"5 µg",s_breakpoint:"≥ 26 mm",i_breakpoint:"22–25 mm",r_breakpoint:"≤ 21 mm"},mic:{s_breakpoint:"≤ 0.25 µg/mL",i_breakpoint:"0.5 µg/mL",r_breakpoint:"≥ 1 µg/mL"},comments:[]}]},{agentName:"Levofloxacin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"5 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"17–20 mm",r_breakpoint:"≤ 16 mm"},mic:{s_breakpoint:"≤ 0.5 µg/mL",i_breakpoint:"1 µg/mL",r_breakpoint:"≥ 2 µg/mL"},comments:[]}]},{agentName:"Trimethoprim-sulfamethoxazole",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"1.25/23.75 µg",s_breakpoint:"≥ 16 mm",i_breakpoint:"11–15 mm",r_breakpoint:"≤ 10 mm"},mic:{s_breakpoint:"≤ 2/38 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 4/76 µg/mL"},comments:[]}]}]},{tier:2,tierDescription:"Appropriate for routine, primary testing, may be reported following cascade reporting rules.",agents:[{agentName:"Cefepime",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 25 mm",i_breakpoint:"19–24 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"8 µg/mL",r_breakpoint:"≥ 16 µg/mL"},comments:["Cefepime S/SDD results should be suppressed or reported as resistant for isolates demonstrating carbapenemase production."]}]},{agentName:"Ertapenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 22 mm",i_breakpoint:"19–21 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 0.5 µg/mL",i_breakpoint:"1 µg/mL",r_breakpoint:"≥ 2 µg/mL"},comments:[]}]},{agentName:"Meropenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 23 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]}]},{tier:3,tierDescription:"Appropriate for high-risk MDRO patients, subject to cascade reporting.",agents:[{agentName:"Ceftazidime-avibactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30/20 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"—",r_breakpoint:"≤ 20 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 16/4 µg/mL"},comments:["Confirmatory MIC testing is indicated for isolates with disk diffusion zones of 20–22 mm."]}]},{agentName:"Meropenem-vaborbactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:"15–17 mm",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 4/8 µg/mL",i_breakpoint:"8/8 µg/mL",r_breakpoint:"≥ 16/8 µg/mL"},comments:["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]},{agentName:"Imipenem-relebactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10/25 µg",s_breakpoint:"≥ 25 mm",i_breakpoint:"21–24 mm",r_breakpoint:"≤ 20 mm"},mic:{s_breakpoint:"≤ 1/4 µg/mL",i_breakpoint:"2/4 µg/mL",r_breakpoint:"≥ 4/4 µg/mL"},comments:["Breakpoints do not apply to the family Morganellaceae (Morganella, Proteus, and Providencia)."]}]}]},{tier:4,tierDescription:"May warrant testing and reporting by clinician request.",agents:[{agentName:"Ceftriaxone",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 26 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]},{agentName:"Aztreonam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"18–20 mm",r_breakpoint:"≤ 17 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"8 µg/mL",r_breakpoint:"≥ 16 µg/mL"},comments:[]}]}]},{tier:0,tierDescription:"Urine Only Tier",agents:[{agentName:"Nitrofurantoin",breakpointSets:[{condition:"Urine Only",diskDiffusion:{diskContent:"300 µg",s_breakpoint:"≥ 17 mm",i_breakpoint:"15–16 mm",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 32 µg/mL",i_breakpoint:"64 µg/mL",r_breakpoint:"≥ 128 µg/mL"},comments:[]}]},{agentName:"Cefazolin",breakpointSets:[{condition:"Uncomplicated UTI only",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 15 mm",i_breakpoint:"—",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 16 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 32 µg/mL"},comments:["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},{agentName:"Fosfomycin",breakpointSets:[{condition:"Urine Only",diskDiffusion:{diskContent:"200 µg",s_breakpoint:"≥ 16 mm",i_breakpoint:"13–15 mm",r_breakpoint:"≤ 12 mm"},mic:{s_breakpoint:"≤ 64 µg/mL",i_breakpoint:"128 µg/mL",r_breakpoint:"≥ 256 µg/mL"},comments:["Applies only to E. coli urinary tract isolates and should not be extrapolated to other Enterobacterales species. The 200 µg fosfomycin disk contains 50 µg glucose-6-phosphate."]}]}]}]}},Yf={antimicrobialStewardship:{sources:["antimicrobial_stewardship","antimicrobialStewardship"],value:[]},comments:{preservedStructure:{originalFormat:"object"}},diagnosis:{sources:["diagnosis"],value:[]},allOtherKeys:{}},Xf={_originalData:Of,_metadata:Bf,identity:Uf,clinicalInformation:Ff,resistanceInformation:Gf,treatmentData:Hf,laboratoryData:Kf,additionalData:Yf},$f=JSON.parse(`{"identity":{"bacteriumName":"Enteroaggregative E. coli","aliases":["EAEC","EaggEC","E coli Enteroaggregative"],"lastUpdated":"2025-07-10","clsiCategory":"Enterobacterales (excluding Salmonella/Shigella)","classification":{"gramStain":"Gram-negative","morphology":"rod","respiration":"Facultative anaerobe","notes":["Gold standard for diagnosis is HEp-2 adherence assay, which is not generally available.","May be diagnosed by PCR detection of virulence genes aatA and aggR."]},"strainDetails":[],"biochemicalTests":"Biochemically indistinguishable from typical E. coli by routine tests. Identification requires molecular detection of aggregative adherence fimbriae (AAF) and other specific virulence factors."},"clinicalProfile":{"summary":"Enteroaggregative E. coli (EAEC) is a significant cause of acute and persistent watery diarrhea. It affects children and adults in developing nations, travelers to these areas, and has also been identified in patients with acute diarrhea in developed countries like the U.S. It is also associated with prolonged diarrhea in HIV-infected individuals.","pathophysiologyPearls":["While EAEC is consistently detected more frequently in patients with diarrhea than controls in various populations, it can also be detected in asymptomatic persons.","Molecular detection of EAEC virulence genes may not always correlate with symptomatic infection."],"keySignsAndSymptoms":["Watery diarrhea","Abdominal pain","Low-grade fever","Occasional mucous or blood in stool"],"clinicalSyndromes":[{"syndromeName":"Acute Diarrhea","description":"A cause of acute, watery diarrhea in children and adults, particularly in less-developed countries and among travelers."},{"syndromeName":"Persistent Diarrhea","description":"Can cause persistent diarrhea, especially in infants and HIV-infected patients."}],"stagesOfIllness":[],"highRiskPopulations":["Children and adults in less-developed countries","Travelers to less-developed countries","Infants (risk for persistent diarrhea)","HIV-infected patients"],"transmissionVectors":[],"prognosisNotes":["The infection is often self-limited, but treatment may be indicated for immunocompromised patients or those with prolonged illness."]},"resistanceProfile":{"groupIntrinsicResistance":[],"intrinsicResistance":[],"majorMechanisms":[],"clinicalAlerts":[{"alertTitle":"Diagnostic Uncertainty","details":"EAEC can be detected in asymptomatic individuals, and molecular detection (PCR) may not always correlate with symptomatic infection."}]},"treatment":{"generalNotes":["Often self-limited, so antibiotics are not always necessary.","Treatment is probably indicated in immunocompromised patients and for prolonged illness.","Studies have shown response to antibiotics in general and specifically in HIV-infected patients.","Rifaximin appeared to improve the duration of symptoms in one study."],"drugsToAvoid":[],"adjunctiveTherapies":[],"regimens":[{"context":{"type":"Directed","condition":"Diarrhea","patientPopulation":["General"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"As needed","drugs":[{"drugName":"Hydration","dose":"N/A","route":"Oral or IV","frequency":"N/A","comments":"Supportive care is the mainstay of treatment."}]}],"notes":[]},{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"3 days","drugs":[{"drugName":"Ciprofloxacin","dose":"750 mg","route":"PO","frequency":"once daily","comments":""}]}],"notes":[]},{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"3 days","drugs":[{"drugName":"Rifaximin","dose":"200 mg","route":"PO","frequency":"tid","comments":""}]}],"notes":["Rifaximin appeared to improve duration of symptoms. (Clin Gastroenterol Hepatol 2004;2(2):135)"]}]},{"context":{"type":"Directed","condition":"Diarrhea","patientPopulation":["AIDS patients"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"7 days","drugs":[{"drugName":"Ciprofloxacin","dose":"500 mg","route":"PO","frequency":"bid","comments":""}]}],"notes":["Antibiotics were effective in HIV infected patients with EAEC. (J Infect Dis 178:1369, 1998)"]}]}]},"laboratoryProfile":{"testingIndications":["Patients with acute or persistent diarrhea, especially in high-risk populations (travelers, infants, immunocompromised)."],"methodologyNotes":["The gold standard for diagnosis is the HEp-2 adherence assay, but it is a research tool and not generally available in clinical labs.","Commercial and research molecular assays (PCR) are used to detect specific virulence genes such as aatA and aggR."],"recommendedPanel":[],"specialTests":[{"testName":"PCR for EAEC virulence genes","trigger":"Clinical suspicion of EAEC diarrhea, particularly in cases of persistent or severe illness, or in at-risk populations.","purpose":"To detect key virulence genes (e.g., aatA, aggR) for the diagnosis of EAEC infection."},{"testName":"HEp-2 Adherence Assay","trigger":"Research settings or reference laboratories.","purpose":"To definitively identify the 'stacked-brick' adherence pattern characteristic of EAEC, considered the gold standard for identification."}],"reportingRules":[],"antimicrobialBreakpoints":[{"tier":1,"tierDescription":"Appropriate for routine, primary testing and reporting","agents":[{"agentName":"Ampicillin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"14–16 mm","r_breakpoint":"≤ 13 mm"},"mic":{"s_breakpoint":"≤ 8 µg/mL","i_breakpoint":"16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":["Ampicillin test results can predict amoxicillin results."]}]},{"agentName":"Cefazolin","breakpointSets":[{"condition":"Urine Only - Uncomplicated UTI","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 15 mm","i_breakpoint":null,"r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 32 µg/mL"},"comments":["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},{"agentName":"Amoxicillin-clavulanate","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":null,"r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/4 µg/mL"},"comments":[]}]},{"agentName":"Piperacillin-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"100/10 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"21–24 mm","r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/4 µg/mL"},"comments":[]}]}]},{"tier":2,"tierDescription":"Appropriate for routine, primary testing, may be reported following cascade reporting rules","agents":[{"agentName":"Cefepime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"19–24 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":["Cefepime S/SDD results should be suppressed or reported as resistant for isolates demonstrating carbapenemase production."]}]},{"agentName":"Ertapenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"19–21 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Meropenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]}]},{"tier":3,"tierDescription":"Appropriate for high-risk MDRO patients, subject to cascade reporting","agents":[{"agentName":"Ceftazidime-avibactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/20 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":null,"r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 16/4 µg/mL"},"comments":["Confirmatory MIC testing is indicated for isolates with zones of 20–22 mm."]}]},{"agentName":"Meropenem-vaborbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4/8 µg/mL","i_breakpoint":"8/8 µg/mL","r_breakpoint":"≥ 16/8 µg/mL"},"comments":["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]}]},{"tier":4,"tierDescription":"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available","agents":[{"agentName":"Aztreonam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"18–20 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":[]}]},{"agentName":"Ceftriaxone","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Colistin or Polymyxin B","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":null,"s_breakpoint":null,"i_breakpoint":null,"r_breakpoint":null},"mic":{"s_breakpoint":"≤ 2 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4 µg/mL"},"comments":["Disk diffusion and gradient diffusion methods should not be performed."]}]}]}]},"additionalInformation":{"diagnosticNotes":{"summary":"Gold standard is HEp-2 adherence which is not generally available. May be diagnosed by PCR detection of virulence genes aatA and aggR in some commercial and research assays.","biosafetyWarning":null,"methods":[]},"preventionAndScreening":[],"treatmentLifecycle":[],"antimicrobialStewardship":["Often self limited, so antibiotics not always necessary.","Treatment probably indicated in immunocompromised patients and prolonged illness.","One small study showed response to antibiotics (Clin Infect Dis 29:335, 1999) and antibiotics were effective in HIV infected patients with EAEC (J Infect Dis 178:1369, 1998). Rifaximin appeared to improve duration of symptoms Clin Gastroenterol Hepatol 2004;2(2):135."],"drugSpecificPearls":[],"guidelineReferences":[{"source":"Clinical Infectious Diseases","citation":"Clin Infect Dis 2019;69:473","summaryOrNote":"Study detected EAEC frequently in Minnesota patients of all ages with acute diarrhea."},{"source":"Clinical Infectious Diseases","citation":"Clin Infect Dis 29:335, 1999","summaryOrNote":"A small study showed a response to antibiotics for EAEC infection."},{"source":"Journal of Infectious Diseases","citation":"J Infect Dis 178:1369, 1998","summaryOrNote":"Study showed antibiotics were effective in HIV-infected patients with EAEC."},{"source":"Clinical Gastroenterology and Hepatology","citation":"Clin Gastroenterol Hepatol 2004;2(2):135","summaryOrNote":"Study suggests Rifaximin appeared to improve the duration of symptoms."},{"source":"Clinical Microbiology Reviews","citation":"Clin Microbiol Rev 2014;27(3):614","summaryOrNote":"General review of EAEC."},{"source":"Current Opinion in Gastroenterology","citation":"Current Opinion Gastroenterol 25:8, 2009","summaryOrNote":"General review of EAEC."},{"source":"The Lancet Infectious Diseases","citation":"Lancet Infect Dis 1:304, 2001","summaryOrNote":"General review of EAEC."},{"source":"JAMA","citation":"JAMA 2016 28;315(24):2712","summaryOrNote":"Review of persistent diarrhea, including EAEC."}]}}`),Jf={originalKeys:["identity","clinicalProfile","resistanceProfile","treatment","laboratoryProfile","additionalInformation"],conversionTimestamp:"2025-07-15T03:16:49.273Z",sourceFormat:"modern"},Qf={bacteriumName:{sources:["identity.bacteriumName"],value:"Enteroaggregative E. coli"},aliases:{sources:["identity.aliases"],value:["EAEC","EaggEC","E coli Enteroaggregative"]},lastUpdated:{sources:["identity.lastUpdated"],value:"2025-07-10"},classification:{sources:["identity.classification"],value:{gramStain:"Gram-negative",morphology:"rod",respiration:"Facultative anaerobe",notes:["Gold standard for diagnosis is HEp-2 adherence assay, which is not generally available.","May be diagnosed by PCR detection of virulence genes aatA and aggR."]}}},Wf={sources:["clinicalProfile"],value:{summary:"Enteroaggregative E. coli (EAEC) is a significant cause of acute and persistent watery diarrhea. It affects children and adults in developing nations, travelers to these areas, and has also been identified in patients with acute diarrhea in developed countries like the U.S. It is also associated with prolonged diarrhea in HIV-infected individuals.",pathophysiologyPearls:["While EAEC is consistently detected more frequently in patients with diarrhea than controls in various populations, it can also be detected in asymptomatic persons.","Molecular detection of EAEC virulence genes may not always correlate with symptomatic infection."],keySignsAndSymptoms:["Watery diarrhea","Abdominal pain","Low-grade fever","Occasional mucous or blood in stool"],clinicalSyndromes:[{syndromeName:"Acute Diarrhea",description:"A cause of acute, watery diarrhea in children and adults, particularly in less-developed countries and among travelers."},{syndromeName:"Persistent Diarrhea",description:"Can cause persistent diarrhea, especially in infants and HIV-infected patients."}],stagesOfIllness:[],highRiskPopulations:["Children and adults in less-developed countries","Travelers to less-developed countries","Infants (risk for persistent diarrhea)","HIV-infected patients"],transmissionVectors:[],prognosisNotes:["The infection is often self-limited, but treatment may be indicated for immunocompromised patients or those with prolonged illness."]}},Zf={sources:["resistanceProfile"],value:{groupIntrinsicResistance:[],intrinsicResistance:[],majorMechanisms:[],clinicalAlerts:[{alertTitle:"Diagnostic Uncertainty",details:"EAEC can be detected in asymptomatic individuals, and molecular detection (PCR) may not always correlate with symptomatic infection."}]}},e_={treatmentData:{_treatmentMetadata:{originalFormat:"modern"},standardizedRegimens:[{regimenId:"modern-0-0-0",extractedFrom:"treatment.regimens[0].recommendations[0].steps[0]",context:{type:"directed",condition:"Diarrhea",severity:"unknown",patientFactors:{population:["General"],labFindings:null}},preference:"primary",drugs:[{drugName:"Hydration",dose:"N/A",route:"Oral or IV",frequency:"N/A",duration:"As needed",comments:"Supportive care is the mainstay of treatment.",originalText:"Hydration N/A Oral or IV N/A"}]},{regimenId:"modern-0-1-0",extractedFrom:"treatment.regimens[0].recommendations[1].steps[0]",context:{type:"directed",condition:"Diarrhea",severity:"unknown",patientFactors:{population:["General"],labFindings:null}},preference:"primary",drugs:[{drugName:"Ciprofloxacin",dose:"750 mg",route:"PO",frequency:"once daily",duration:"3 days",comments:"",originalText:"Ciprofloxacin 750 mg PO once daily"}]},{regimenId:"modern-0-2-0",extractedFrom:"treatment.regimens[0].recommendations[2].steps[0]",context:{type:"directed",condition:"Diarrhea",severity:"unknown",patientFactors:{population:["General"],labFindings:null}},preference:"primary",drugs:[{drugName:"Rifaximin",dose:"200 mg",route:"PO",frequency:"tid",duration:"3 days",comments:"",originalText:"Rifaximin 200 mg PO tid"}]},{regimenId:"modern-1-0-0",extractedFrom:"treatment.regimens[1].recommendations[0].steps[0]",context:{type:"directed",condition:"Diarrhea",severity:"unknown",patientFactors:{population:["AIDS patients"],labFindings:null}},preference:"primary",drugs:[{drugName:"Ciprofloxacin",dose:"500 mg",route:"PO",frequency:"bid",duration:"7 days",comments:"",originalText:"Ciprofloxacin 500 mg PO bid"}]}]}},i_={sources:["laboratoryProfile"],value:{testingIndications:["Patients with acute or persistent diarrhea, especially in high-risk populations (travelers, infants, immunocompromised)."],methodologyNotes:["The gold standard for diagnosis is the HEp-2 adherence assay, but it is a research tool and not generally available in clinical labs.","Commercial and research molecular assays (PCR) are used to detect specific virulence genes such as aatA and aggR."],recommendedPanel:[],specialTests:[{testName:"PCR for EAEC virulence genes",trigger:"Clinical suspicion of EAEC diarrhea, particularly in cases of persistent or severe illness, or in at-risk populations.",purpose:"To detect key virulence genes (e.g., aatA, aggR) for the diagnosis of EAEC infection."},{testName:"HEp-2 Adherence Assay",trigger:"Research settings or reference laboratories.",purpose:"To definitively identify the 'stacked-brick' adherence pattern characteristic of EAEC, considered the gold standard for identification."}],reportingRules:[],antimicrobialBreakpoints:[{tier:1,tierDescription:"Appropriate for routine, primary testing and reporting",agents:[{agentName:"Ampicillin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 17 mm",i_breakpoint:"14–16 mm",r_breakpoint:"≤ 13 mm"},mic:{s_breakpoint:"≤ 8 µg/mL",i_breakpoint:"16 µg/mL",r_breakpoint:"≥ 32 µg/mL"},comments:["Ampicillin test results can predict amoxicillin results."]}]},{agentName:"Cefazolin",breakpointSets:[{condition:"Urine Only - Uncomplicated UTI",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 15 mm",i_breakpoint:null,r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 16 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 32 µg/mL"},comments:["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},{agentName:"Amoxicillin-clavulanate",breakpointSets:[{condition:"Uncomplicated UTI only",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:null,r_breakpoint:"≤ 17 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:"16/4 µg/mL",r_breakpoint:"≥ 32/4 µg/mL"},comments:[]}]},{agentName:"Piperacillin-tazobactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"100/10 µg",s_breakpoint:"≥ 25 mm",i_breakpoint:"21–24 mm",r_breakpoint:"≤ 20 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:"16/4 µg/mL",r_breakpoint:"≥ 32/4 µg/mL"},comments:[]}]}]},{tier:2,tierDescription:"Appropriate for routine, primary testing, may be reported following cascade reporting rules",agents:[{agentName:"Cefepime",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 25 mm",i_breakpoint:"19–24 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"8 µg/mL",r_breakpoint:"≥ 16 µg/mL"},comments:["Cefepime S/SDD results should be suppressed or reported as resistant for isolates demonstrating carbapenemase production."]}]},{agentName:"Ertapenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 22 mm",i_breakpoint:"19–21 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 0.5 µg/mL",i_breakpoint:"1 µg/mL",r_breakpoint:"≥ 2 µg/mL"},comments:[]}]},{agentName:"Meropenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 23 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]}]},{tier:3,tierDescription:"Appropriate for high-risk MDRO patients, subject to cascade reporting",agents:[{agentName:"Ceftazidime-avibactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30/20 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:null,r_breakpoint:"≤ 20 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 16/4 µg/mL"},comments:["Confirmatory MIC testing is indicated for isolates with zones of 20–22 mm."]}]},{agentName:"Meropenem-vaborbactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:"15–17 mm",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 4/8 µg/mL",i_breakpoint:"8/8 µg/mL",r_breakpoint:"≥ 16/8 µg/mL"},comments:["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]}]},{tier:4,tierDescription:"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available",agents:[{agentName:"Aztreonam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"18–20 mm",r_breakpoint:"≤ 17 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"8 µg/mL",r_breakpoint:"≥ 16 µg/mL"},comments:[]}]},{agentName:"Ceftriaxone",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 26 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]},{agentName:"Colistin or Polymyxin B",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:null,s_breakpoint:null,i_breakpoint:null,r_breakpoint:null},mic:{s_breakpoint:"≤ 2 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 4 µg/mL"},comments:["Disk diffusion and gradient diffusion methods should not be performed."]}]}]}]}},t_={antimicrobialStewardship:{sources:["antimicrobial_stewardship","antimicrobialStewardship"],value:[]},comments:{preservedStructure:{originalFormat:"object"}},diagnosis:{sources:["diagnosis"],value:[]},allOtherKeys:{}},a_={_originalData:$f,_metadata:Jf,identity:Qf,clinicalInformation:Wf,resistanceInformation:Zf,treatmentData:e_,laboratoryData:i_,additionalData:t_},n_=JSON.parse(`{"identity":{"bacteriumName":"Enterobacter cloacae complex","aliases":["Enterobacter spp."],"lastUpdated":"2025-01-02","clsiCategory":"Enterobacterales (excluding Salmonella/Shigella)","classification":{"gramStain":"Negative","morphology":"Bacillus","respiration":"Facultative Anaerobe","notes":[]},"strainDetails":[{"type":"Complex Member","value":"Enterobacter cloacae","notes":""},{"type":"Complex Member","value":"Enterobacter hormaechei","notes":""}],"biochemicalTests":"Gram-negative rod, motile, lactose fermenter, indole –, VP +, citrate +, ornithine decarboxylase +, arginine dihydrolase +."},"clinicalProfile":{"summary":"The Enterobacter cloacae complex causes a variety of infections in both normal and immunocompromised hosts and is a frequent cause of nosocomial infections, including bacteremia, pneumonia, and intra-abdominal infections.","pathophysiologyPearls":["Exposure to 3rd-generation cephalosporins can select for de-repressed ampC mutants, with emergence of resistance during therapy in 5-20% of treatment courses."],"keySignsAndSymptoms":[],"clinicalSyndromes":[{"syndromeName":"Systemic Infections","description":"Can cause bacteremia, pneumonia, intra-abdominal infections, and skin and soft tissue infections."}],"stagesOfIllness":[],"highRiskPopulations":["Hospitalized patients","Immunocompromised hosts"],"transmissionVectors":[],"prognosisNotes":["Emergence of resistance during therapy with 3rd-generation cephalosporins occurs in 5-20% of treatment courses due to de-repression of the ampC gene."]},"resistanceProfile":{"groupIntrinsicResistance":[],"intrinsicResistance":[],"majorMechanisms":[{"mechanismName":"AmpC (Chromosomal)","mechanismType":"Cephalosporinase","description":"Virtually all isolates carry an inducible, chromosomal ampC gene that is normally repressed. It is not inhibited by clavulanate, sulbactam, or tazobactam, but is inhibited by avibactam."},{"mechanismName":"ESBL","mechanismType":"Beta-lactamase","description":"Can acquire plasmid-encoded Extended-Spectrum Beta-Lactamases, which are not readily distinguishable phenotypically from de-repressed AmpC."},{"mechanismName":"Carbapenemases","mechanismType":"Beta-lactamase","description":"Can acquire plasmid-encoded carbapenemases, including serine carbapenemases (KPC) and metallo-beta-lactamases (MBL)."},{"mechanismName":"Other MDR Mechanisms","mechanismType":"Multiple","description":"Multi-drug resistance can also be mediated by over-expression of drug efflux pumps, target alterations, and outer membrane protein mutations affecting drug permeability."}],"clinicalAlerts":[{"alertTitle":"Inducible AmpC Resistance","details":"Exposure to 3rd-generation cephalosporins (e.g., ceftriaxone, ceftazidime) can select for de-repressed mutants that over-express AmpC, leading to clinical failure even if initial testing shows susceptibility. These agents should be avoided for serious infections."}]},"treatment":{"generalNotes":["Recommendations are for treatment of moderately severe or severe infections.","For uncomplicated UTI, options include fluoroquinolones, TMP-SMX, or nitrofurantoin if susceptible. Third-generation cephalosporins can be used for uncomplicated UTI but should be avoided otherwise."],"drugsToAvoid":[{"drugOrClass":"3rd Generation Cephalosporins (Ceftriaxone, Ceftazidime, etc.)","condition":"Serious infections","reason":"High risk of selecting for de-repressed AmpC mutants and subsequent treatment failure."},{"drugOrClass":"Piperacillin-tazobactam","condition":"Serious infections","reason":"Risk of clinical failure despite potential in-vitro susceptibility, especially for ESBL-producers."},{"drugOrClass":"Meropenem + Polymyxin","condition":"All infections","reason":"Combination therapy is not recommended based on a failed randomized controlled trial (Lancet Infect Dis 2018;18:391)."}],"adjunctiveTherapies":[],"regimens":[{"context":{"type":"Empiric","condition":"Systemic Infection (Low Local ESBL Rate <10-15%)","patientPopulation":["Adult"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Cefepime","dose":"1-2 gm","route":"IV","frequency":"q8-12h","comments":"Infuse over 3 hours."},{"drugName":"Ciprofloxacin","dose":"400 mg","route":"IV","frequency":"q12h","comments":""},{"drugName":"Levofloxacin","dose":"750 mg","route":"IV","frequency":"q24h","comments":""}]}]}]},{"context":{"type":"Empiric","condition":"Systemic Infection (High Local ESBL Rate >15% or Severe Illness)","patientPopulation":["Adult"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Meropenem","dose":"1-2 gm","route":"IV","frequency":"q8h","comments":""},{"drugName":"Ertapenem","dose":"1 gm","route":"IV","frequency":"q24h","comments":""}]}]}]},{"context":{"type":"Directed","condition":"ESBL or AmpC Overproducer","patientPopulation":["Adult"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Meropenem","dose":"1-2 gm","route":"IV","frequency":"q8h","comments":"Consider 2 gm infused over 3 hours for more serious infections."}]}]},{"preference":"Alternative (If susceptible)","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ciprofloxacin","dose":"400 mg","route":"IV","frequency":"q12h","comments":""},{"drugName":"Levofloxacin","dose":"750 mg","route":"IV","frequency":"q24h","comments":""},{"drugName":"TMP-SMX","dose":"10 mg/kg/day (TMP component)","route":"IV","frequency":"in 2-3 divided doses","comments":""}]}]}]},{"context":{"type":"Directed","condition":"KPC Producer (Carbapenem-Resistant)","patientPopulation":["Adult"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"q8h","comments":"Infuse over 3 hours."},{"drugName":"Meropenem-vaborbactam","dose":"4 gm","route":"IV","frequency":"q8h","comments":"Infuse over 3 hours."},{"drugName":"Imipenem-cilastatin-relebactam","dose":"1.25 gm","route":"IV","frequency":"q6h","comments":"Infuse over 30 min. For CrCl > 90 mL/min."}]}]}]},{"context":{"type":"Directed","condition":"Metallo-beta-lactamase (MBL) Producer","patientPopulation":["Adult"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"q8h","comments":"Infuse over 3 hours."},{"drugName":"Aztreonam","dose":"2 gm","route":"IV","frequency":"q6h","comments":"Infuse over 3 hours."}]}],"notes":["This combination is recommended because Aztreonam is not hydrolyzed by MBLs, while Avibactam protects Aztreonam from co-produced ESBLs or AmpC enzymes."]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Cefiderocol","dose":"2 gm","route":"IV","frequency":"q8h","comments":"Infuse over 3 hours."}]}]}]},{"context":{"type":"Directed","condition":"ESBL Producer","patientPopulation":["Adult"],"isolateSource":"Urinary Tract"},"recommendations":[{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Cefepime-enmetazobactam","dose":"2.5 gm","route":"IV","frequency":"q8h","comments":"Recently FDA approved for complicated UTIs, including ESBL producers."},{"drugName":"Plazomicin","dose":"15 mg/kg","route":"IV","frequency":"q24h","comments":"For complicated UTIs."},{"drugName":"Fosfomycin","dose":"3 gm","route":"PO","frequency":"x 1 dose","comments":"For uncomplicated cystitis only."}]}]}]}]},"laboratoryProfile":{"testingIndications":[],"methodologyNotes":["For Polymyxins, disk diffusion and gradient diffusion methods should not be performed; MIC testing is required."],"recommendedPanel":["Cefepime should be considered a Tier 1 agent for testing and/or reporting."],"specialTests":[],"reportingRules":[{"ruleType":"Conditional","drug":"Cefepime","condition":"Isolate demonstrates carbapenemase production.","details":"Cefepime S/SDD results should be suppressed or edited and reported as resistant."}],"antimicrobialBreakpoints":[{"tier":1,"tierDescription":"Appropriate for routine, primary testing and reporting.","agents":[{"agentName":"Ampicillin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17","i_breakpoint":"14–16","r_breakpoint":"≤ 13"},"mic":{"s_breakpoint":"≤ 8","i_breakpoint":"16","r_breakpoint":"≥ 32"},"comments":["Results of ampicillin testing can be used to predict results for amoxicillin."]}]},{"agentName":"Cefazolin","breakpointSets":[{"condition":"Urine Only (Uncomplicated UTI)","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 15","i_breakpoint":"—","r_breakpoint":"≤ 14"},"mic":{"s_breakpoint":"≤ 16","i_breakpoint":"—","r_breakpoint":"≥ 32"},"comments":["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},{"agentName":"Amoxicillin-clavulanate","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18","i_breakpoint":"—","r_breakpoint":"≤ 17"},"mic":{"s_breakpoint":"≤ 8/4","i_breakpoint":"16/4","r_breakpoint":"≥ 32/4"},"comments":[]}]},{"agentName":"Piperacillin-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"100/10 µg","s_breakpoint":"≥ 25","i_breakpoint":"21–24","r_breakpoint":"≤ 20"},"mic":{"s_breakpoint":"≤ 8/4","i_breakpoint":"16/4","r_breakpoint":"≥ 32/4"},"comments":[]}]}]},{"tier":2,"tierDescription":"Appropriate for routine, primary testing, may be reported following cascade reporting rules.","agents":[{"agentName":"Cefepime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 25","i_breakpoint":"19–24","r_breakpoint":"≤ 18"},"mic":{"s_breakpoint":"≤ 4","i_breakpoint":"8","r_breakpoint":"≥ 16"},"comments":["Cefepime S/SDD results should be suppressed or edited and reported as resistant for isolates that demonstrate carbapenemase production."]}]},{"agentName":"Ertapenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 22","i_breakpoint":"19–21","r_breakpoint":"≤ 18"},"mic":{"s_breakpoint":"≤ 0.5","i_breakpoint":"1","r_breakpoint":"≥ 2"},"comments":[]}]},{"agentName":"Meropenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23","i_breakpoint":"20–22","r_breakpoint":"≤ 19"},"mic":{"s_breakpoint":"≤ 1","i_breakpoint":"2","r_breakpoint":"≥ 4"},"comments":[]}]}]},{"tier":3,"tierDescription":"Appropriate for high-risk MDRO patients, subject to cascade reporting.","agents":[{"agentName":"Ceftazidime-avibactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/20 µg","s_breakpoint":"≥ 21","i_breakpoint":"—","r_breakpoint":"≤ 20"},"mic":{"s_breakpoint":"≤ 8/4","i_breakpoint":"—","r_breakpoint":"≥ 16/4"},"comments":["Confirmatory MIC testing is indicated for isolates with zones of 20–22 mm."]}]},{"agentName":"Meropenem-vaborbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18","i_breakpoint":"15–17","r_breakpoint":"≤ 14"},"mic":{"s_breakpoint":"≤ 4/8","i_breakpoint":"8/8","r_breakpoint":"≥ 16/8"},"comments":["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]}]},{"tier":4,"tierDescription":"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.","agents":[{"agentName":"Aztreonam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21","i_breakpoint":"18–20","r_breakpoint":"≤ 17"},"mic":{"s_breakpoint":"≤ 4","i_breakpoint":"8","r_breakpoint":"≥ 16"},"comments":[]}]},{"agentName":"Ceftriaxone","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 26","i_breakpoint":"20–22","r_breakpoint":"≤ 19"},"mic":{"s_breakpoint":"≤ 1","i_breakpoint":"2","r_breakpoint":"≥ 4"},"comments":[]}]},{"agentName":"Colistin or Polymyxin B","breakpointSets":[{"condition":"Standard","diskDiffusion":null,"mic":{"s_breakpoint":"≤ 2","i_breakpoint":"—","r_breakpoint":"≥ 4"},"comments":["Disk diffusion and gradient diffusion methods should not be performed."]}]}]}]},"additionalInformation":{"diagnosticNotes":null,"preventionAndScreening":[],"treatmentLifecycle":[],"antimicrobialStewardship":["Carbapenems should be reserved for mixed infections or for treatment of confirmed ESBL-producing strains.","Novel beta-lactam/beta-lactamase inhibitor combinations (e.g., Ceftazidime-avibactam) should be reserved for documented carbapenemase-producing organisms."],"drugSpecificPearls":[{"drugName":"Cefepime","pearl":"Cefepime is a weak inducer of chromosomal AmpC and more resistant to its hydrolysis than other cephalosporins. For strains with MICs of 4-8 mcg/ml, dose-dependent susceptibility is noted; the recommended dose is 2 gm IV q8h infused over 3 hours."},{"drugName":"Cefiderocol","pearl":"FDA-approved for cUTI with limited options. An open-label trial in patients with serious carbapenem-resistant infections showed numerically higher all-cause mortality with cefiderocol vs. best available therapy, warranting caution."},{"drugName":"Ceftazidime-avibactam + Aztreonam","pearl":"The rationale for this combination for MBL producers is that Aztreonam is stable against MBLs, and Avibactam protects Aztreonam from co-produced serine beta-lactamases (ESBL, AmpC, KPC)."},{"drugName":"Fosfomycin (IV)","pearl":"In the US, it may be possible to obtain IV Fosfomycin as a single-patient emergency IND from the FDA's Division of Anti-infective Products."}],"guidelineReferences":[{"source":"IDSA 2024","citation":"Updated 2024 IDSA Guidelines on treatment of ESBL, AmpC, and carbapenemase producers.","summaryOrNote":"Provides comprehensive guidance on treating resistant gram-negative infections."},{"source":"Clinical Infectious Diseases","citation":"Clin Infect Dis 2019;69:1446","summaryOrNote":"Primer on AmpC beta-lactamases."}]}}`),o_={originalKeys:["identity","clinicalProfile","resistanceProfile","treatment","laboratoryProfile","additionalInformation"],conversionTimestamp:"2025-07-15T03:16:49.311Z",sourceFormat:"modern"},r_={bacteriumName:{sources:["identity.bacteriumName"],value:"Enterobacter cloacae complex"},aliases:{sources:["identity.aliases"],value:["Enterobacter spp."]},lastUpdated:{sources:["identity.lastUpdated"],value:"2025-01-02"},classification:{sources:["identity.classification"],value:{gramStain:"Negative",morphology:"Bacillus",respiration:"Facultative Anaerobe",notes:[]}}},s_={sources:["clinicalProfile"],value:{summary:"The Enterobacter cloacae complex causes a variety of infections in both normal and immunocompromised hosts and is a frequent cause of nosocomial infections, including bacteremia, pneumonia, and intra-abdominal infections.",pathophysiologyPearls:["Exposure to 3rd-generation cephalosporins can select for de-repressed ampC mutants, with emergence of resistance during therapy in 5-20% of treatment courses."],keySignsAndSymptoms:[],clinicalSyndromes:[{syndromeName:"Systemic Infections",description:"Can cause bacteremia, pneumonia, intra-abdominal infections, and skin and soft tissue infections."}],stagesOfIllness:[],highRiskPopulations:["Hospitalized patients","Immunocompromised hosts"],transmissionVectors:[],prognosisNotes:["Emergence of resistance during therapy with 3rd-generation cephalosporins occurs in 5-20% of treatment courses due to de-repression of the ampC gene."]}},l_={sources:["resistanceProfile"],value:{groupIntrinsicResistance:[],intrinsicResistance:[],majorMechanisms:[{mechanismName:"AmpC (Chromosomal)",mechanismType:"Cephalosporinase",description:"Virtually all isolates carry an inducible, chromosomal ampC gene that is normally repressed. It is not inhibited by clavulanate, sulbactam, or tazobactam, but is inhibited by avibactam."},{mechanismName:"ESBL",mechanismType:"Beta-lactamase",description:"Can acquire plasmid-encoded Extended-Spectrum Beta-Lactamases, which are not readily distinguishable phenotypically from de-repressed AmpC."},{mechanismName:"Carbapenemases",mechanismType:"Beta-lactamase",description:"Can acquire plasmid-encoded carbapenemases, including serine carbapenemases (KPC) and metallo-beta-lactamases (MBL)."},{mechanismName:"Other MDR Mechanisms",mechanismType:"Multiple",description:"Multi-drug resistance can also be mediated by over-expression of drug efflux pumps, target alterations, and outer membrane protein mutations affecting drug permeability."}],clinicalAlerts:[{alertTitle:"Inducible AmpC Resistance",details:"Exposure to 3rd-generation cephalosporins (e.g., ceftriaxone, ceftazidime) can select for de-repressed mutants that over-express AmpC, leading to clinical failure even if initial testing shows susceptibility. These agents should be avoided for serious infections."}]}},c_={treatmentData:{_treatmentMetadata:{originalFormat:"modern"},standardizedRegimens:[{regimenId:"modern-0-0-0",extractedFrom:"treatment.regimens[0].recommendations[0].steps[0]",context:{type:"empiric",condition:"Systemic Infection (Low Local ESBL Rate <10-15%)",severity:"unknown",patientFactors:{population:["Adult"],labFindings:null}},preference:"primary",drugs:[{drugName:"Cefepime",dose:"1-2 gm",route:"IV",frequency:"q8-12h",duration:"Variable",comments:"Infuse over 3 hours.",originalText:"Cefepime 1-2 gm IV q8-12h"},{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"q12h",duration:"Variable",comments:"",originalText:"Ciprofloxacin 400 mg IV q12h"},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Levofloxacin 750 mg IV q24h"}]},{regimenId:"modern-1-0-0",extractedFrom:"treatment.regimens[1].recommendations[0].steps[0]",context:{type:"empiric",condition:"Systemic Infection (High Local ESBL Rate >15% or Severe Illness)",severity:"severe",patientFactors:{population:["Adult"],labFindings:null}},preference:"primary",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"",originalText:"Meropenem 1-2 gm IV q8h"},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Ertapenem 1 gm IV q24h"}]},{regimenId:"modern-2-0-0",extractedFrom:"treatment.regimens[2].recommendations[0].steps[0]",context:{type:"directed",condition:"ESBL or AmpC Overproducer",severity:"unknown",patientFactors:{population:["Adult"],labFindings:null}},preference:"primary",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Consider 2 gm infused over 3 hours for more serious infections.",originalText:"Meropenem 1-2 gm IV q8h"}]},{regimenId:"modern-2-1-0",extractedFrom:"treatment.regimens[2].recommendations[1].steps[0]",context:{type:"directed",condition:"ESBL or AmpC Overproducer",severity:"unknown",patientFactors:{population:["Adult"],labFindings:null}},preference:"alternative (if susceptible)",drugs:[{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"q12h",duration:"Variable",comments:"",originalText:"Ciprofloxacin 400 mg IV q12h"},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Levofloxacin 750 mg IV q24h"},{drugName:"TMP-SMX",dose:"10 mg/kg/day (TMP component)",route:"IV",frequency:"in 2-3 divided doses",duration:"Variable",comments:"",originalText:"TMP-SMX 10 mg/kg/day (TMP component) IV in 2-3 divided doses"}]},{regimenId:"modern-3-0-0",extractedFrom:"treatment.regimens[3].recommendations[0].steps[0]",context:{type:"directed",condition:"KPC Producer (Carbapenem-Resistant)",severity:"unknown",patientFactors:{population:["Adult"],labFindings:null}},preference:"primary",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infuse over 3 hours.",originalText:"Ceftazidime-avibactam 2.5 gm IV q8h"},{drugName:"Meropenem-vaborbactam",dose:"4 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infuse over 3 hours.",originalText:"Meropenem-vaborbactam 4 gm IV q8h"},{drugName:"Imipenem-cilastatin-relebactam",dose:"1.25 gm",route:"IV",frequency:"q6h",duration:"Variable",comments:"Infuse over 30 min. For CrCl > 90 mL/min.",originalText:"Imipenem-cilastatin-relebactam 1.25 gm IV q6h"}]},{regimenId:"modern-4-0-0",extractedFrom:"treatment.regimens[4].recommendations[0].steps[0]",context:{type:"directed",condition:"Metallo-beta-lactamase (MBL) Producer",severity:"unknown",patientFactors:{population:["Adult"],labFindings:null}},preference:"primary",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infuse over 3 hours.",originalText:"Ceftazidime-avibactam 2.5 gm IV q8h"},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q6h",duration:"Variable",comments:"Infuse over 3 hours.",originalText:"Aztreonam 2 gm IV q6h"}]},{regimenId:"modern-4-1-0",extractedFrom:"treatment.regimens[4].recommendations[1].steps[0]",context:{type:"directed",condition:"Metallo-beta-lactamase (MBL) Producer",severity:"unknown",patientFactors:{population:["Adult"],labFindings:null}},preference:"alternative",drugs:[{drugName:"Cefiderocol",dose:"2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infuse over 3 hours.",originalText:"Cefiderocol 2 gm IV q8h"}]},{regimenId:"modern-5-0-0",extractedFrom:"treatment.regimens[5].recommendations[0].steps[0]",context:{type:"directed",condition:"ESBL Producer",severity:"unknown",patientFactors:{population:["Adult"],labFindings:"Urinary Tract"}},preference:"alternative",drugs:[{drugName:"Cefepime-enmetazobactam",dose:"2.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Recently FDA approved for complicated UTIs, including ESBL producers.",originalText:"Cefepime-enmetazobactam 2.5 gm IV q8h"},{drugName:"Plazomicin",dose:"15 mg/kg",route:"IV",frequency:"q24h",duration:"Variable",comments:"For complicated UTIs.",originalText:"Plazomicin 15 mg/kg IV q24h"},{drugName:"Fosfomycin",dose:"3 gm",route:"PO",frequency:"x 1 dose",duration:"Variable",comments:"For uncomplicated cystitis only.",originalText:"Fosfomycin 3 gm PO x 1 dose"}]}]}},d_={sources:["laboratoryProfile"],value:{testingIndications:[],methodologyNotes:["For Polymyxins, disk diffusion and gradient diffusion methods should not be performed; MIC testing is required."],recommendedPanel:["Cefepime should be considered a Tier 1 agent for testing and/or reporting."],specialTests:[],reportingRules:[{ruleType:"Conditional",drug:"Cefepime",condition:"Isolate demonstrates carbapenemase production.",details:"Cefepime S/SDD results should be suppressed or edited and reported as resistant."}],antimicrobialBreakpoints:[{tier:1,tierDescription:"Appropriate for routine, primary testing and reporting.",agents:[{agentName:"Ampicillin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 17",i_breakpoint:"14–16",r_breakpoint:"≤ 13"},mic:{s_breakpoint:"≤ 8",i_breakpoint:"16",r_breakpoint:"≥ 32"},comments:["Results of ampicillin testing can be used to predict results for amoxicillin."]}]},{agentName:"Cefazolin",breakpointSets:[{condition:"Urine Only (Uncomplicated UTI)",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 15",i_breakpoint:"—",r_breakpoint:"≤ 14"},mic:{s_breakpoint:"≤ 16",i_breakpoint:"—",r_breakpoint:"≥ 32"},comments:["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},{agentName:"Amoxicillin-clavulanate",breakpointSets:[{condition:"Uncomplicated UTI only",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18",i_breakpoint:"—",r_breakpoint:"≤ 17"},mic:{s_breakpoint:"≤ 8/4",i_breakpoint:"16/4",r_breakpoint:"≥ 32/4"},comments:[]}]},{agentName:"Piperacillin-tazobactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"100/10 µg",s_breakpoint:"≥ 25",i_breakpoint:"21–24",r_breakpoint:"≤ 20"},mic:{s_breakpoint:"≤ 8/4",i_breakpoint:"16/4",r_breakpoint:"≥ 32/4"},comments:[]}]}]},{tier:2,tierDescription:"Appropriate for routine, primary testing, may be reported following cascade reporting rules.",agents:[{agentName:"Cefepime",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 25",i_breakpoint:"19–24",r_breakpoint:"≤ 18"},mic:{s_breakpoint:"≤ 4",i_breakpoint:"8",r_breakpoint:"≥ 16"},comments:["Cefepime S/SDD results should be suppressed or edited and reported as resistant for isolates that demonstrate carbapenemase production."]}]},{agentName:"Ertapenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 22",i_breakpoint:"19–21",r_breakpoint:"≤ 18"},mic:{s_breakpoint:"≤ 0.5",i_breakpoint:"1",r_breakpoint:"≥ 2"},comments:[]}]},{agentName:"Meropenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 23",i_breakpoint:"20–22",r_breakpoint:"≤ 19"},mic:{s_breakpoint:"≤ 1",i_breakpoint:"2",r_breakpoint:"≥ 4"},comments:[]}]}]},{tier:3,tierDescription:"Appropriate for high-risk MDRO patients, subject to cascade reporting.",agents:[{agentName:"Ceftazidime-avibactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30/20 µg",s_breakpoint:"≥ 21",i_breakpoint:"—",r_breakpoint:"≤ 20"},mic:{s_breakpoint:"≤ 8/4",i_breakpoint:"—",r_breakpoint:"≥ 16/4"},comments:["Confirmatory MIC testing is indicated for isolates with zones of 20–22 mm."]}]},{agentName:"Meropenem-vaborbactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18",i_breakpoint:"15–17",r_breakpoint:"≤ 14"},mic:{s_breakpoint:"≤ 4/8",i_breakpoint:"8/8",r_breakpoint:"≥ 16/8"},comments:["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]}]},{tier:4,tierDescription:"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.",agents:[{agentName:"Aztreonam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 21",i_breakpoint:"18–20",r_breakpoint:"≤ 17"},mic:{s_breakpoint:"≤ 4",i_breakpoint:"8",r_breakpoint:"≥ 16"},comments:[]}]},{agentName:"Ceftriaxone",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 26",i_breakpoint:"20–22",r_breakpoint:"≤ 19"},mic:{s_breakpoint:"≤ 1",i_breakpoint:"2",r_breakpoint:"≥ 4"},comments:[]}]},{agentName:"Colistin or Polymyxin B",breakpointSets:[{condition:"Standard",diskDiffusion:null,mic:{s_breakpoint:"≤ 2",i_breakpoint:"—",r_breakpoint:"≥ 4"},comments:["Disk diffusion and gradient diffusion methods should not be performed."]}]}]}]}},m_={antimicrobialStewardship:{sources:["antimicrobial_stewardship","antimicrobialStewardship"],value:[]},comments:{preservedStructure:{originalFormat:"object"}},diagnosis:{sources:["diagnosis"],value:[]},allOtherKeys:{}},u_={_originalData:n_,_metadata:o_,identity:r_,clinicalInformation:s_,resistanceInformation:l_,treatmentData:c_,laboratoryData:d_,additionalData:m_},p_=JSON.parse('{"identity":{"bacteriumName":"Escherichia coli","aliases":["E. coli"],"lastUpdated":"2025-01-08","clsiCategory":"Enterobacterales (excluding Salmonella/Shigella)","classification":{"gramStain":"Gram-negative","morphology":"Rod","respiration":"Facultative anaerobe","notes":["Motile","Lactose fermenter (pink on MacConkey agar)","Indole positive","VP negative","Citrate negative"]},"strainDetails":[],"biochemicalTests":"Gram-negative rod, motile, lactose fermenter (pink on MacConkey), indole +, VP –, citrate –, methyl red +, lysine decarboxylase +."},"clinicalProfile":{"summary":"Escherichia coli causes a variety of infections ranging from uncomplicated urinary tract infections to life-threatening infections of the abdomen, skin and soft tissue, lung, CNS and other sites in both normal and immunocompromised hosts.","pathophysiologyPearls":[],"keySignsAndSymptoms":[],"clinicalSyndromes":[{"syndromeName":"Urinary Tract Infections (UTI)","description":"Includes uncomplicated cystitis and pyelonephritis."},{"syndromeName":"Intra-abdominal Infections","description":"Can cause peritonitis and abscesses."},{"syndromeName":"Skin and Soft Tissue Infections","description":"Often occurs in surgical sites or wounds."},{"syndromeName":"Pneumonia","description":"Hospital-acquired or ventilator-associated pneumonia."},{"syndromeName":"Central Nervous System (CNS) Infections","description":"Can cause meningitis, especially in neonates."},{"syndromeName":"Bacteremia","description":"Presence of bacteria in the bloodstream, can lead to sepsis."}],"stagesOfIllness":[],"highRiskPopulations":["Immunocompromised hosts","Patients with indwelling catheters","Neonates","Post-surgical patients"],"transmissionVectors":["Endogenous flora","Contaminated food or water","Person-to-person (fecal-oral route)","Healthcare-associated transmission"],"prognosisNotes":["E. coli may be susceptible to Piperacillin-tazobactam in vitro but may fail clinically, especially in bacteremia and other serious infections."]},"resistanceProfile":{"groupIntrinsicResistance":[],"intrinsicResistance":[],"majorMechanisms":[{"mechanismName":"Extended-Spectrum Beta-Lactamase (ESBL)","mechanismType":"Enzymatic Inactivation","description":"Enzymes that confer resistance to most penicillins and cephalosporins, including third-generation cephalosporins and aztreonam."},{"mechanismName":"Carbapenemase Production","mechanismType":"Enzymatic Inactivation","description":"Enzymes that hydrolyze carbapenems, as well as other beta-lactams. Includes Klebsiella pneumoniae carbapenemase (KPC) and metallo-beta-lactamases (e.g., NDM)."}],"clinicalAlerts":[{"alertTitle":"Piperacillin-Tazobactam Clinical Failure","details":"Despite in vitro susceptibility, Piperacillin-tazobactam is not recommended for bacteremia or other serious infections due to risk of treatment failure, possibly due to an inoculum effect. Ref: Clin Infect Dis 72:1109, 2021."},{"alertTitle":"Emergence of Resistance","details":"Emergence of resistant mutants has been observed with agents like Ceftazidime-avibactam. See Clin Infect Dis 2019; 68:519; Antimicrob Agents Chemother. 2019;63:e01551-18 for discussion."}]},"treatment":{"generalNotes":["Suggested treatment regimens are for parenteral therapy of more serious infections and based on status of pathogen detection and results of in vitro susceptibility.","Recommendations in the table below are for treatment of moderately severe or severe infections, particularly those in which resistance is a concern. For details see IDSA Guidance on the treatment of Antimicrobial Resistant Gram-Negative Infections.","For less severe and uncomplicated infections (e.g., UTI) caused by susceptible stains in addition to the agents below, treatment options include Amoxicillin-clavulanate, fluoroquinolones, oral and parenteral second- and third-generation cephalosporins. TMP-SMX is an option provided the strain is susceptible, but its utility as an empiric agent is limited because resistance is common. Nitrofurantoin and oral Fosfomycin are options for uncomplicated UTI.","For detailed discussion of beta-lactam drug resistance classes and mechanisms Gram Negative Bacilli, Resistance to Beta-lactams, Overview.","For treatment of uncomplicated urinary tract infections, see Cystitis (adult female) or Cystitis (adult male)."],"drugsToAvoid":[{"drugOrClass":"Piperacillin-tazobactam","condition":"Bacteremia, Serious Infections","reason":"Risk of clinical failure despite in vitro susceptibility, possibly due to inoculum effect."}],"adjunctiveTherapies":[],"regimens":[{"context":{"type":"Empiric","condition":"Isolation of E. coli, susceptibility results pending","patientPopulation":["Local rate of resistance <10%"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftriaxone","dose":"2 gm (age < 60 years) or 1 gm (age ≥ 65 years)","route":"IV","frequency":"q24h","comments":""},{"drugName":"Ciprofloxacin","dose":"400 mg","route":"IV","frequency":"q12h","comments":""},{"drugName":"Levofloxacin","dose":"750 mg","route":"IV","frequency":"q24h","comments":""},{"drugName":"Piperacillin-tazobactam","dose":"4.5 gm","route":"IV","frequency":"q8h","comments":"Administer over 4 hours."}]}]}]},{"context":{"type":"Empiric","condition":"Isolation of E. coli, susceptibility results pending","patientPopulation":["Local rates of ESBL resistance >10%"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Meropenem","dose":"1-2 gm","route":"IV","frequency":"q8h","comments":""},{"drugName":"Ertapenem","dose":"1 gm","route":"IV","frequency":"q24h","comments":""}]}]}]},{"context":{"type":"Directed","condition":"ESBL-negative (Susceptible to Aztreonam, Ceftriaxone, Cefotaxime, Ceftazidime, or Cefepime)","patientPopulation":[],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftriaxone","dose":"2 gm (age < 60 years) or 1 gm (age ≥ 65 years)","route":"IV","frequency":"q24h","comments":""},{"drugName":"Ciprofloxacin","dose":"400 mg","route":"IV","frequency":"q12h","comments":""},{"drugName":"Levofloxacin","dose":"750 mg","route":"IV","frequency":"q24h","comments":""},{"drugName":"Ampicillin","dose":"1-2 gm","route":"IV","frequency":"q4-6h","comments":"Use if susceptible."}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Cefazolin","dose":"2 gm","route":"IV","frequency":"q8h","comments":""},{"drugName":"TMP-SMX","dose":"10 mg/kg/d of TMP component","route":"IV or PO","frequency":"in 2-3 divided doses","comments":""},{"drugName":"Amoxicillin-clavulanate","dose":"1.2-2.4 gm","route":"IV","frequency":"q8h","comments":"Where available; not available in US."},{"drugName":"Ampicillin-sulbactam","dose":"3 gm","route":"IV","frequency":"q6h","comments":""},{"drugName":"Gentamicin or Tobramycin","dose":"5-7 mg/kg","route":"IV","frequency":"q24h","comments":"Dose adjusted for renal function."}]}]}]},{"context":{"type":"Directed","condition":"ESBL producer, susceptible to carbapenems","patientPopulation":[],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Meropenem","dose":"1-2 gm","route":"IV","frequency":"q8h","comments":"Consider higher dose infused over 3 hours q8h for more serious infections."},{"drugName":"Imipenem-cilastatin","dose":"500 mg","route":"IV","frequency":"q6h","comments":""},{"drugName":"Ertapenem","dose":"1 gm","route":"IV","frequency":"q24h","comments":""}]}],"notes":["Consider use of Ceftolozane-tazobactam 3 gm IV infused over 3h q8h as a carbapenem-sparing alternative."]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftolozane-tazobactam","dose":"1.5 gm","route":"IV","frequency":"q8h","comments":""},{"drugName":"Cefepime-enmetazobactam","dose":"Varies","route":"IV","frequency":"Varies","comments":"Recently FDA approved for treatment of complicated UTIs."},{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"q8h","comments":"Administer over 2 hours."},{"drugName":"Temocillin","dose":"2 gm","route":"IV","frequency":"q12h","comments":"Available in Belgium and United Kingdom but not the US."},{"drugName":"Gentamicin or Tobramycin","dose":"5-7 mg/kg","route":"IV","frequency":"q24h","comments":"Use if susceptible; dose adjusted for renal function."},{"drugName":"Plazomicin","dose":"15 mg/kg","route":"IV","frequency":"once daily","comments":"Duration 4-7 days. FDA-approved for complicated UTI only. Use if available."}]}]}]},{"context":{"type":"Directed","condition":"Carbapenem-Resistant Enterobacterales (CRE) - KPC producer","patientPopulation":["Resistant to carbapenems, susceptible to Ceftazidime-avibactam, Meropenem-vaborbactam, and Imipenem-cilastatin-relebactam"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"q8h","comments":"Administer over 2 hours."},{"drugName":"Meropenem-vaborbactam","dose":"4 gm","route":"IV","frequency":"q8h","comments":"Administer over 3 hours."}]}],"notes":["Infectious diseases consultation recommended."]}]},{"context":{"type":"Directed","condition":"Carbapenem-Resistant Enterobacterales (CRE) - Metallo-carbapenemase producer","patientPopulation":["Resistant to agents above including Ceftazidime-avibactam, Meropenem-vaborbactam"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Imipenem-cilastatin-relebactam","dose":"1.25 gm","route":"IV","frequency":"q6h","comments":"Administer over 30 min. For use if CrCl > 90 mL/min."},{"drugName":"Cefiderocol","dose":"2 gm","route":"IV","frequency":"q8h","comments":"Administer over 3 hours."}]}]},{"preference":"Alternative","strategy":"Sequential","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"q8h","comments":"Administer over 3 hours."},{"drugName":"Aztreonam","dose":"2 gm","route":"IV","frequency":"q6h","comments":"Administer over 3 hours. To be used in combination with Ceftazidime-avibactam."}]}],"notes":["Infectious diseases consultation recommended.","Based on in vitro susceptibility, meropenem-vaborbactam plus aztreonam may be an option although efficacy unproven."]}]},{"context":{"type":"Directed","condition":"Uncomplicated Cystitis","patientPopulation":[],"isolateSource":"Urine"},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"1 day","drugs":[{"drugName":"Fosfomycin","dose":"3 gm","route":"PO","frequency":"x one dose","comments":""}]}]}]},{"context":{"type":"Directed","condition":"Pyelonephritis","patientPopulation":[],"isolateSource":"Urine"},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Fosfomycin","dose":"6 gm","route":"IV","frequency":"q8h","comments":""}]}]}]}]},"laboratoryProfile":{"testingIndications":[],"methodologyNotes":[],"recommendedPanel":[],"specialTests":[],"reportingRules":[{"ruleType":"Surrogate","drug":"Ampicillin","condition":"Standard","details":"Results of ampicillin testing can be used to predict results for amoxicillin."},{"ruleType":"Surrogate","drug":"Cefazolin","condition":"Uncomplicated UTIs due to E. coli, K. pneumoniae, and P. mirabilis","details":"Serves as a surrogate for oral cephalosporins."},{"ruleType":"Conditional","drug":"Cefepime","condition":"Carbapenemase production detected","details":"Susceptible/Susceptible-Dose Dependent (S/SDD) results should be suppressed or edited and reported as resistant."},{"ruleType":"Conditional","drug":"Meropenem-vaborbactam","condition":"OXA-48-like gene or enzyme detected","details":"Suppress or report as resistant, as the isolate may not respond in vivo despite in vitro susceptibility."}],"antimicrobialBreakpoints":[{"tier":1,"tierDescription":"Appropriate for routine, primary testing and reporting","agents":[{"agentName":"Ampicillin","breakpointSets":[{"condition":"Standard (Oral for uncomplicated UTI)","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥17","i_breakpoint":"14-16","r_breakpoint":"≤13"},"mic":{"s_breakpoint":"≤8","i_breakpoint":"16","r_breakpoint":"≥32"},"comments":["For oral use, breakpoints apply only for uncomplicated UTIs due to E. coli and Proteus mirabilis.","Results of ampicillin testing can be used to predict results for amoxicillin."]}]},{"agentName":"Cefazolin","breakpointSets":[{"condition":"Urine Only (Uncomplicated UTI)","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥15","i_breakpoint":null,"r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤16","i_breakpoint":null,"r_breakpoint":"≥32"},"comments":["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis in uncomplicated UTIs."]},{"condition":"Standard (Parenteral)","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥23","i_breakpoint":"20-22","r_breakpoint":"≤19"},"mic":{"s_breakpoint":"≤2","i_breakpoint":"4","r_breakpoint":"≥8"},"comments":["For infections other than uncomplicated UTI, breakpoints apply to E. coli, K. pneumoniae, and P. mirabilis."]}]},{"agentName":"Amoxicillin-clavulanate","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥18","i_breakpoint":null,"r_breakpoint":"≤17"},"mic":{"s_breakpoint":"≤8/4","i_breakpoint":"16/4","r_breakpoint":"≥32/4"},"comments":["Breakpoints for oral use are also for completion of therapy for systemic infection."]}]},{"agentName":"Ampicillin-sulbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10/10 µg","s_breakpoint":"≥15","i_breakpoint":"12-14","r_breakpoint":"≤11"},"mic":{"s_breakpoint":"≤8/4","i_breakpoint":"16/4","r_breakpoint":"≥32/4"},"comments":[]}]},{"agentName":"Piperacillin-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"100/10 µg","s_breakpoint":"≥25","i_breakpoint":"21-24","r_breakpoint":"≤20"},"mic":{"s_breakpoint":"≤8/4","i_breakpoint":"16/4","r_breakpoint":"≥32/4"},"comments":[]}]},{"agentName":"Gentamicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥18","i_breakpoint":"15-17","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":[]}]},{"agentName":"Tobramycin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥17","i_breakpoint":"13-16","r_breakpoint":"≤12"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":[]}]},{"agentName":"Amikacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥20","i_breakpoint":"17-19","r_breakpoint":"≤16"},"mic":{"s_breakpoint":"≤16","i_breakpoint":"32","r_breakpoint":"≥64"},"comments":[]}]},{"agentName":"Ciprofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥26","i_breakpoint":"22-25","r_breakpoint":"≤21"},"mic":{"s_breakpoint":"≤0.25","i_breakpoint":"0.5","r_breakpoint":"≥1"},"comments":[]}]},{"agentName":"Levofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥21","i_breakpoint":"17-20","r_breakpoint":"≤16"},"mic":{"s_breakpoint":"≤0.5","i_breakpoint":"1","r_breakpoint":"≥2"},"comments":[]}]},{"agentName":"Trimethoprim-sulfamethoxazole","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"1.25/23.75 µg","s_breakpoint":"≥16","i_breakpoint":"11-15","r_breakpoint":"≤10"},"mic":{"s_breakpoint":"≤2/38","i_breakpoint":"4/76","r_breakpoint":"≥8/152"},"comments":[]}]},{"agentName":"Nitrofurantoin","breakpointSets":[{"condition":"Urine only","diskDiffusion":{"diskContent":"300 µg","s_breakpoint":"≥17","i_breakpoint":"15-16","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤32","i_breakpoint":"64","r_breakpoint":"≥128"},"comments":["For uncomplicated urinary tract infections (UTI)."]}]},{"agentName":"Fosfomycin","breakpointSets":[{"condition":"Urine only","diskDiffusion":{"diskContent":"200 µg","s_breakpoint":"≥16","i_breakpoint":"13-15","r_breakpoint":"≤12"},"mic":{"s_breakpoint":"≤64","i_breakpoint":"128","r_breakpoint":"≥256"},"comments":["Applies only to E. coli urinary tract isolates.","The 200-µg fosfomycin disk contains 50 µg glucose-6-phosphate.","The only approved MIC testing method is agar dilution; broth dilution MIC testing should not be performed."]}]}]},{"tier":2,"tierDescription":"Appropriate for routine, primary testing, may be reported following cascade reporting rules","agents":[{"agentName":"Cefuroxime (parenteral)","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥18","i_breakpoint":"15-17","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤8","i_breakpoint":"16","r_breakpoint":"≥32"},"comments":[]}]},{"agentName":"Cefepime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥25","i_breakpoint":"19-24","r_breakpoint":"≤18"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":["Susceptible/Susceptible-Dose Dependent (S/SDD) results should be suppressed or edited and reported as resistant for isolates that demonstrate carbapenemase production."]}]},{"agentName":"Ertapenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥22","i_breakpoint":"19-21","r_breakpoint":"≤18"},"mic":{"s_breakpoint":"≤0.5","i_breakpoint":"1","r_breakpoint":"≥2"},"comments":[]}]},{"agentName":"Imipenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥23","i_breakpoint":"20-22","r_breakpoint":"≤19"},"mic":{"s_breakpoint":"≤1","i_breakpoint":"2","r_breakpoint":"≥4"},"comments":[]}]},{"agentName":"Meropenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥23","i_breakpoint":"20-22","r_breakpoint":"≤19"},"mic":{"s_breakpoint":"≤1","i_breakpoint":"2","r_breakpoint":"≥4"},"comments":[]}]}]},{"tier":3,"tierDescription":"Appropriate for high-risk MDRO patients, subject to cascade reporting","agents":[{"agentName":"Cefiderocol","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥16","i_breakpoint":"9-15","r_breakpoint":"≤8"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":["The accuracy and reproducibility of cefiderocol testing results by disk diffusion and broth microdilution are markedly affected by iron concentration and inoculum preparation and may vary by disk and media manufacturer."]}]},{"agentName":"Ceftazidime-avibactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/20 µg","s_breakpoint":"≥21","i_breakpoint":null,"r_breakpoint":"≤20"},"mic":{"s_breakpoint":"≤8/4","i_breakpoint":null,"r_breakpoint":"≥16/4"},"comments":["Confirmatory MIC testing is indicated for isolates with zones of 20–22 mm to avoid reporting false-susceptible or false-resistant results."]}]},{"agentName":"Imipenem-relebactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10/25 µg","s_breakpoint":"≥25","i_breakpoint":"21-24","r_breakpoint":"≤20"},"mic":{"s_breakpoint":"≤1/4","i_breakpoint":"2/4","r_breakpoint":"≥4/4"},"comments":["Breakpoints do not apply to the family Morganellaceae, which includes but is not limited to the genera Morganella, Proteus, and Providencia."]}]},{"agentName":"Meropenem-vaborbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥18","i_breakpoint":"15-17","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤4/8","i_breakpoint":"8/8","r_breakpoint":"≥16/8"},"comments":["Enterobacterales that harbor OXA-48-like enzymes may test susceptible to meropenem-vaborbactam but may not respond in vivo. If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]},{"agentName":"Plazomicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥18","i_breakpoint":"15-17","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤2","i_breakpoint":"4","r_breakpoint":"≥8"},"comments":[]}]}]},{"tier":4,"tierDescription":"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available","agents":[{"agentName":"Aztreonam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥21","i_breakpoint":"18-20","r_breakpoint":"≤17"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":[]}]},{"agentName":"Ceftazidime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥21","i_breakpoint":"18-20","r_breakpoint":"≤17"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":[]}]},{"agentName":"Ceftriaxone","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥26","i_breakpoint":"20-22","r_breakpoint":"≤19"},"mic":{"s_breakpoint":"≤1","i_breakpoint":"2","r_breakpoint":"≥4"},"comments":[]}]},{"agentName":"Ceftolozane-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/20 µg","s_breakpoint":"≥22","i_breakpoint":"19-21","r_breakpoint":"≤18"},"mic":{"s_breakpoint":"≤2/4","i_breakpoint":"4/4","r_breakpoint":"≥8/4"},"comments":[]}]},{"agentName":"Colistin or Polymyxin B","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":null,"s_breakpoint":null,"i_breakpoint":null,"r_breakpoint":null},"mic":{"s_breakpoint":"≤2","i_breakpoint":null,"r_breakpoint":"≥4"},"comments":["Disk diffusion and gradient diffusion methods should not be performed.","When given systemically, these agents are likely effective for pneumonia."]}]}]}]},"additionalInformation":{"diagnosticNotes":{"summary":"","biosafetyWarning":"","methods":[]},"preventionAndScreening":[],"treatmentLifecycle":[],"antimicrobialStewardship":["Carbapenems should be reserved for polymicrobial infections for which anaerobic coverage is required or for treatment of infections due to ESBL-producing strains","Although active against ESBLs and related beta-lactamases, use of Ceftazidime-avibactam, Imipenem-relebactam, and Meropenem-vaborbactam should be reserved for patients with documented carbapenemase mechanism of resistance."],"drugSpecificPearls":[{"drugName":"Aztreonam + Ceftazidime-avibactam","pearl":"Aztreonam is not hydrolyzed by metallocarbapenemases (ceftazidime is) but is inactivated by ESBLS which are often produced concomitantly with the carbapenemase. Avibactam inactivates ESBLs. This combination is a last resort recommendation based entirely on in vitro data and case reports. See Antimicrob Agents Chemother 2017 Mar 24; 61(4). pii:e02243-16 and J Antimicrob Chemother 2018; 73:1104."},{"drugName":"Cefiderocol","pearl":"FDA-approved for patients with complicated UTI due to susceptible bacteria and with limited or no alternative treatment options. In an open label randomized trial vs Best Available Therapy (BAT) in patients with sepsis, pneumonia, bacteremia or cUTI, mortality at 28 days was 24.8% for cefiderocol pts. vs 18.4% for BAT pts (not statistically significant). Reference: Clin Infect Dis 2019; 69 (suppl.7): S519-S575."},{"drugName":"Meropenem/Imipenem","pearl":"If Ertapenem resistance is noted, check for susceptibility to Meropenem or Imipenem; if the isolate is susceptible to both of the latter, either may be used."},{"drugName":"Meropenem + Polymyxin B/Colistin","pearl":"This combination is not recommended for therapy of MDR gram-negative bacilli based on treatment failures in a controlled clinical trial (Lancet Infect Dis 2018; 18:391). Failures occurred in a randomized controlled trial where 77% of enrolled patients had infections due to Acinetobacter baumannii. Study was underpowered to assess comparative efficacy vs other carbapenemase producing gram-negative bacteria."},{"drugName":"Meropenem-vaborbactam + Aztreonam","pearl":"This combination shows similar in vitro activity to aztreonam plus ceftazidime-avibactam against Enterobacterales producing NDM and other non-OXA serine ß-lactamases, but there is no clinical data (Antimicrob Agents Chemother 2019; 63: e01426-19)."},{"drugName":"Plazomicin","pearl":"FDA approved for the treatment of complicated UTI and pyelonephritis (N Engl J Med 2019;380:729). There is limited observational experience with Plazomicin in combination with Tigecycline or Meropenem for treatment of MDR bloodstream infections or hospital-acquired or ventilator-associated pneumonia (N Engl J Med 2019; 380:791)."}],"guidelineReferences":[{"source":"IDSA Guidance","citation":"IDSA Guidance on the treatment of Antimicrobial Resistant Gram-Negative Infections. Updated 2024 IDSA Guidelines.","summaryOrNote":"Primary reference for treatment of moderately severe or severe infections due to resistant gram-negative organisms."},{"source":"Clinical Infectious Diseases","citation":"Clin Infect Dis 72:1109, 2021","summaryOrNote":"Reference regarding clinical failure of Piperacillin-tazobactam for E. coli bacteremia."},{"source":"Clinical Infectious Diseases","citation":"Clin Infect Dis 2019; 68:519","summaryOrNote":"Discussion on the emergence of resistant mutants with Ceftazidime-avibactam and similar agents."},{"source":"Antimicrobial Agents and Chemotherapy","citation":"Antimicrob Agents Chemother. 2019;63:e01551-18","summaryOrNote":"Further discussion on emergence of resistance to novel beta-lactamase inhibitors."},{"source":"The Lancet Infectious Diseases","citation":"Lancet Infect Dis 2018; 18:391","summaryOrNote":"Data on treatment failures with Meropenem + Polymyxin combination therapy."},{"source":"New England Journal of Medicine","citation":"N Engl J Med 2019;380:729","summaryOrNote":"Data supporting FDA approval of Plazomicin for complicated UTI and pyelonephritis."}]}}'),g_={originalKeys:["identity","clinicalProfile","resistanceProfile","treatment","laboratoryProfile","additionalInformation"],conversionTimestamp:"2025-07-15T03:16:49.276Z",sourceFormat:"modern"},f_={bacteriumName:{sources:["identity.bacteriumName"],value:"Escherichia coli"},aliases:{sources:["identity.aliases"],value:["E. coli"]},lastUpdated:{sources:["identity.lastUpdated"],value:"2025-01-08"},classification:{sources:["identity.classification"],value:{gramStain:"Gram-negative",morphology:"Rod",respiration:"Facultative anaerobe",notes:["Motile","Lactose fermenter (pink on MacConkey agar)","Indole positive","VP negative","Citrate negative"]}}},__={sources:["clinicalProfile"],value:{summary:"Escherichia coli causes a variety of infections ranging from uncomplicated urinary tract infections to life-threatening infections of the abdomen, skin and soft tissue, lung, CNS and other sites in both normal and immunocompromised hosts.",pathophysiologyPearls:[],keySignsAndSymptoms:[],clinicalSyndromes:[{syndromeName:"Urinary Tract Infections (UTI)",description:"Includes uncomplicated cystitis and pyelonephritis."},{syndromeName:"Intra-abdominal Infections",description:"Can cause peritonitis and abscesses."},{syndromeName:"Skin and Soft Tissue Infections",description:"Often occurs in surgical sites or wounds."},{syndromeName:"Pneumonia",description:"Hospital-acquired or ventilator-associated pneumonia."},{syndromeName:"Central Nervous System (CNS) Infections",description:"Can cause meningitis, especially in neonates."},{syndromeName:"Bacteremia",description:"Presence of bacteria in the bloodstream, can lead to sepsis."}],stagesOfIllness:[],highRiskPopulations:["Immunocompromised hosts","Patients with indwelling catheters","Neonates","Post-surgical patients"],transmissionVectors:["Endogenous flora","Contaminated food or water","Person-to-person (fecal-oral route)","Healthcare-associated transmission"],prognosisNotes:["E. coli may be susceptible to Piperacillin-tazobactam in vitro but may fail clinically, especially in bacteremia and other serious infections."]}},h_={sources:["resistanceProfile"],value:{groupIntrinsicResistance:[],intrinsicResistance:[],majorMechanisms:[{mechanismName:"Extended-Spectrum Beta-Lactamase (ESBL)",mechanismType:"Enzymatic Inactivation",description:"Enzymes that confer resistance to most penicillins and cephalosporins, including third-generation cephalosporins and aztreonam."},{mechanismName:"Carbapenemase Production",mechanismType:"Enzymatic Inactivation",description:"Enzymes that hydrolyze carbapenems, as well as other beta-lactams. Includes Klebsiella pneumoniae carbapenemase (KPC) and metallo-beta-lactamases (e.g., NDM)."}],clinicalAlerts:[{alertTitle:"Piperacillin-Tazobactam Clinical Failure",details:"Despite in vitro susceptibility, Piperacillin-tazobactam is not recommended for bacteremia or other serious infections due to risk of treatment failure, possibly due to an inoculum effect. Ref: Clin Infect Dis 72:1109, 2021."},{alertTitle:"Emergence of Resistance",details:"Emergence of resistant mutants has been observed with agents like Ceftazidime-avibactam. See Clin Infect Dis 2019; 68:519; Antimicrob Agents Chemother. 2019;63:e01551-18 for discussion."}]}},b_={treatmentData:{_treatmentMetadata:{originalFormat:"modern"},standardizedRegimens:[{regimenId:"modern-0-0-0",extractedFrom:"treatment.regimens[0].recommendations[0].steps[0]",context:{type:"empiric",condition:"Isolation of E. coli, susceptibility results pending",severity:"unknown",patientFactors:{population:["Local rate of resistance <10%"],labFindings:null}},preference:"primary",drugs:[{drugName:"Ceftriaxone",dose:"2 gm (age < 60 years) or 1 gm (age ≥ 65 years)",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Ceftriaxone 2 gm (age < 60 years) or 1 gm (age ≥ 65 years) IV q24h"},{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"q12h",duration:"Variable",comments:"",originalText:"Ciprofloxacin 400 mg IV q12h"},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Levofloxacin 750 mg IV q24h"},{drugName:"Piperacillin-tazobactam",dose:"4.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Administer over 4 hours.",originalText:"Piperacillin-tazobactam 4.5 gm IV q8h"}]},{regimenId:"modern-1-0-0",extractedFrom:"treatment.regimens[1].recommendations[0].steps[0]",context:{type:"empiric",condition:"Isolation of E. coli, susceptibility results pending",severity:"unknown",patientFactors:{population:["Local rates of ESBL resistance >10%"],labFindings:null}},preference:"primary",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"",originalText:"Meropenem 1-2 gm IV q8h"},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Ertapenem 1 gm IV q24h"}]},{regimenId:"modern-2-0-0",extractedFrom:"treatment.regimens[2].recommendations[0].steps[0]",context:{type:"directed",condition:"ESBL-negative (Susceptible to Aztreonam, Ceftriaxone, Cefotaxime, Ceftazidime, or Cefepime)",severity:"unknown",patientFactors:{population:[],labFindings:null}},preference:"primary",drugs:[{drugName:"Ceftriaxone",dose:"2 gm (age < 60 years) or 1 gm (age ≥ 65 years)",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Ceftriaxone 2 gm (age < 60 years) or 1 gm (age ≥ 65 years) IV q24h"},{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"q12h",duration:"Variable",comments:"",originalText:"Ciprofloxacin 400 mg IV q12h"},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Levofloxacin 750 mg IV q24h"},{drugName:"Ampicillin",dose:"1-2 gm",route:"IV",frequency:"q4-6h",duration:"Variable",comments:"Use if susceptible.",originalText:"Ampicillin 1-2 gm IV q4-6h"}]},{regimenId:"modern-2-1-0",extractedFrom:"treatment.regimens[2].recommendations[1].steps[0]",context:{type:"directed",condition:"ESBL-negative (Susceptible to Aztreonam, Ceftriaxone, Cefotaxime, Ceftazidime, or Cefepime)",severity:"unknown",patientFactors:{population:[],labFindings:null}},preference:"alternative",drugs:[{drugName:"Cefazolin",dose:"2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"",originalText:"Cefazolin 2 gm IV q8h"},{drugName:"TMP-SMX",dose:"10 mg/kg/d of TMP component",route:"IV or PO",frequency:"in 2-3 divided doses",duration:"Variable",comments:"",originalText:"TMP-SMX 10 mg/kg/d of TMP component IV or PO in 2-3 divided doses"},{drugName:"Amoxicillin-clavulanate",dose:"1.2-2.4 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Where available; not available in US.",originalText:"Amoxicillin-clavulanate 1.2-2.4 gm IV q8h"},{drugName:"Ampicillin-sulbactam",dose:"3 gm",route:"IV",frequency:"q6h",duration:"Variable",comments:"",originalText:"Ampicillin-sulbactam 3 gm IV q6h"},{drugName:"Gentamicin or Tobramycin",dose:"5-7 mg/kg",route:"IV",frequency:"q24h",duration:"Variable",comments:"Dose adjusted for renal function.",originalText:"Gentamicin or Tobramycin 5-7 mg/kg IV q24h"}]},{regimenId:"modern-3-0-0",extractedFrom:"treatment.regimens[3].recommendations[0].steps[0]",context:{type:"directed",condition:"ESBL producer, susceptible to carbapenems",severity:"unknown",patientFactors:{population:[],labFindings:null}},preference:"primary",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Consider higher dose infused over 3 hours q8h for more serious infections.",originalText:"Meropenem 1-2 gm IV q8h"},{drugName:"Imipenem-cilastatin",dose:"500 mg",route:"IV",frequency:"q6h",duration:"Variable",comments:"",originalText:"Imipenem-cilastatin 500 mg IV q6h"},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Ertapenem 1 gm IV q24h"}]},{regimenId:"modern-3-1-0",extractedFrom:"treatment.regimens[3].recommendations[1].steps[0]",context:{type:"directed",condition:"ESBL producer, susceptible to carbapenems",severity:"unknown",patientFactors:{population:[],labFindings:null}},preference:"alternative",drugs:[{drugName:"Ceftolozane-tazobactam",dose:"1.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"",originalText:"Ceftolozane-tazobactam 1.5 gm IV q8h"},{drugName:"Cefepime-enmetazobactam",dose:"Varies",route:"IV",frequency:"Varies",duration:"Variable",comments:"Recently FDA approved for treatment of complicated UTIs.",originalText:"Cefepime-enmetazobactam Varies IV Varies"},{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Administer over 2 hours.",originalText:"Ceftazidime-avibactam 2.5 gm IV q8h"},{drugName:"Temocillin",dose:"2 gm",route:"IV",frequency:"q12h",duration:"Variable",comments:"Available in Belgium and United Kingdom but not the US.",originalText:"Temocillin 2 gm IV q12h"},{drugName:"Gentamicin or Tobramycin",dose:"5-7 mg/kg",route:"IV",frequency:"q24h",duration:"Variable",comments:"Use if susceptible; dose adjusted for renal function.",originalText:"Gentamicin or Tobramycin 5-7 mg/kg IV q24h"},{drugName:"Plazomicin",dose:"15 mg/kg",route:"IV",frequency:"once daily",duration:"Variable",comments:"Duration 4-7 days. FDA-approved for complicated UTI only. Use if available.",originalText:"Plazomicin 15 mg/kg IV once daily"}]},{regimenId:"modern-4-0-0",extractedFrom:"treatment.regimens[4].recommendations[0].steps[0]",context:{type:"directed",condition:"Carbapenem-Resistant Enterobacterales (CRE) - KPC producer",severity:"unknown",patientFactors:{population:["Resistant to carbapenems, susceptible to Ceftazidime-avibactam, Meropenem-vaborbactam, and Imipenem-cilastatin-relebactam"],labFindings:null}},preference:"primary",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Administer over 2 hours.",originalText:"Ceftazidime-avibactam 2.5 gm IV q8h"},{drugName:"Meropenem-vaborbactam",dose:"4 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Administer over 3 hours.",originalText:"Meropenem-vaborbactam 4 gm IV q8h"}]},{regimenId:"modern-5-0-0",extractedFrom:"treatment.regimens[5].recommendations[0].steps[0]",context:{type:"directed",condition:"Carbapenem-Resistant Enterobacterales (CRE) - Metallo-carbapenemase producer",severity:"unknown",patientFactors:{population:["Resistant to agents above including Ceftazidime-avibactam, Meropenem-vaborbactam"],labFindings:null}},preference:"primary",drugs:[{drugName:"Imipenem-cilastatin-relebactam",dose:"1.25 gm",route:"IV",frequency:"q6h",duration:"Variable",comments:"Administer over 30 min. For use if CrCl > 90 mL/min.",originalText:"Imipenem-cilastatin-relebactam 1.25 gm IV q6h"},{drugName:"Cefiderocol",dose:"2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Administer over 3 hours.",originalText:"Cefiderocol 2 gm IV q8h"}]},{regimenId:"modern-5-1-0",extractedFrom:"treatment.regimens[5].recommendations[1].steps[0]",context:{type:"directed",condition:"Carbapenem-Resistant Enterobacterales (CRE) - Metallo-carbapenemase producer",severity:"unknown",patientFactors:{population:["Resistant to agents above including Ceftazidime-avibactam, Meropenem-vaborbactam"],labFindings:null}},preference:"alternative",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Administer over 3 hours.",originalText:"Ceftazidime-avibactam 2.5 gm IV q8h"},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q6h",duration:"Variable",comments:"Administer over 3 hours. To be used in combination with Ceftazidime-avibactam.",originalText:"Aztreonam 2 gm IV q6h"}]},{regimenId:"modern-6-0-0",extractedFrom:"treatment.regimens[6].recommendations[0].steps[0]",context:{type:"directed",condition:"Uncomplicated Cystitis",severity:"unknown",patientFactors:{population:[],labFindings:"Urine"}},preference:"primary",drugs:[{drugName:"Fosfomycin",dose:"3 gm",route:"PO",frequency:"x one dose",duration:"1 day",comments:"",originalText:"Fosfomycin 3 gm PO x one dose"}]},{regimenId:"modern-7-0-0",extractedFrom:"treatment.regimens[7].recommendations[0].steps[0]",context:{type:"directed",condition:"Pyelonephritis",severity:"unknown",patientFactors:{population:[],labFindings:"Urine"}},preference:"primary",drugs:[{drugName:"Fosfomycin",dose:"6 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"",originalText:"Fosfomycin 6 gm IV q8h"}]}]}},y_=JSON.parse('{"sources":["laboratoryProfile"],"value":{"testingIndications":[],"methodologyNotes":[],"recommendedPanel":[],"specialTests":[],"reportingRules":[{"ruleType":"Surrogate","drug":"Ampicillin","condition":"Standard","details":"Results of ampicillin testing can be used to predict results for amoxicillin."},{"ruleType":"Surrogate","drug":"Cefazolin","condition":"Uncomplicated UTIs due to E. coli, K. pneumoniae, and P. mirabilis","details":"Serves as a surrogate for oral cephalosporins."},{"ruleType":"Conditional","drug":"Cefepime","condition":"Carbapenemase production detected","details":"Susceptible/Susceptible-Dose Dependent (S/SDD) results should be suppressed or edited and reported as resistant."},{"ruleType":"Conditional","drug":"Meropenem-vaborbactam","condition":"OXA-48-like gene or enzyme detected","details":"Suppress or report as resistant, as the isolate may not respond in vivo despite in vitro susceptibility."}],"antimicrobialBreakpoints":[{"tier":1,"tierDescription":"Appropriate for routine, primary testing and reporting","agents":[{"agentName":"Ampicillin","breakpointSets":[{"condition":"Standard (Oral for uncomplicated UTI)","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥17","i_breakpoint":"14-16","r_breakpoint":"≤13"},"mic":{"s_breakpoint":"≤8","i_breakpoint":"16","r_breakpoint":"≥32"},"comments":["For oral use, breakpoints apply only for uncomplicated UTIs due to E. coli and Proteus mirabilis.","Results of ampicillin testing can be used to predict results for amoxicillin."]}]},{"agentName":"Cefazolin","breakpointSets":[{"condition":"Urine Only (Uncomplicated UTI)","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥15","i_breakpoint":null,"r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤16","i_breakpoint":null,"r_breakpoint":"≥32"},"comments":["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis in uncomplicated UTIs."]},{"condition":"Standard (Parenteral)","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥23","i_breakpoint":"20-22","r_breakpoint":"≤19"},"mic":{"s_breakpoint":"≤2","i_breakpoint":"4","r_breakpoint":"≥8"},"comments":["For infections other than uncomplicated UTI, breakpoints apply to E. coli, K. pneumoniae, and P. mirabilis."]}]},{"agentName":"Amoxicillin-clavulanate","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥18","i_breakpoint":null,"r_breakpoint":"≤17"},"mic":{"s_breakpoint":"≤8/4","i_breakpoint":"16/4","r_breakpoint":"≥32/4"},"comments":["Breakpoints for oral use are also for completion of therapy for systemic infection."]}]},{"agentName":"Ampicillin-sulbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10/10 µg","s_breakpoint":"≥15","i_breakpoint":"12-14","r_breakpoint":"≤11"},"mic":{"s_breakpoint":"≤8/4","i_breakpoint":"16/4","r_breakpoint":"≥32/4"},"comments":[]}]},{"agentName":"Piperacillin-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"100/10 µg","s_breakpoint":"≥25","i_breakpoint":"21-24","r_breakpoint":"≤20"},"mic":{"s_breakpoint":"≤8/4","i_breakpoint":"16/4","r_breakpoint":"≥32/4"},"comments":[]}]},{"agentName":"Gentamicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥18","i_breakpoint":"15-17","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":[]}]},{"agentName":"Tobramycin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥17","i_breakpoint":"13-16","r_breakpoint":"≤12"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":[]}]},{"agentName":"Amikacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥20","i_breakpoint":"17-19","r_breakpoint":"≤16"},"mic":{"s_breakpoint":"≤16","i_breakpoint":"32","r_breakpoint":"≥64"},"comments":[]}]},{"agentName":"Ciprofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥26","i_breakpoint":"22-25","r_breakpoint":"≤21"},"mic":{"s_breakpoint":"≤0.25","i_breakpoint":"0.5","r_breakpoint":"≥1"},"comments":[]}]},{"agentName":"Levofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥21","i_breakpoint":"17-20","r_breakpoint":"≤16"},"mic":{"s_breakpoint":"≤0.5","i_breakpoint":"1","r_breakpoint":"≥2"},"comments":[]}]},{"agentName":"Trimethoprim-sulfamethoxazole","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"1.25/23.75 µg","s_breakpoint":"≥16","i_breakpoint":"11-15","r_breakpoint":"≤10"},"mic":{"s_breakpoint":"≤2/38","i_breakpoint":"4/76","r_breakpoint":"≥8/152"},"comments":[]}]},{"agentName":"Nitrofurantoin","breakpointSets":[{"condition":"Urine only","diskDiffusion":{"diskContent":"300 µg","s_breakpoint":"≥17","i_breakpoint":"15-16","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤32","i_breakpoint":"64","r_breakpoint":"≥128"},"comments":["For uncomplicated urinary tract infections (UTI)."]}]},{"agentName":"Fosfomycin","breakpointSets":[{"condition":"Urine only","diskDiffusion":{"diskContent":"200 µg","s_breakpoint":"≥16","i_breakpoint":"13-15","r_breakpoint":"≤12"},"mic":{"s_breakpoint":"≤64","i_breakpoint":"128","r_breakpoint":"≥256"},"comments":["Applies only to E. coli urinary tract isolates.","The 200-µg fosfomycin disk contains 50 µg glucose-6-phosphate.","The only approved MIC testing method is agar dilution; broth dilution MIC testing should not be performed."]}]}]},{"tier":2,"tierDescription":"Appropriate for routine, primary testing, may be reported following cascade reporting rules","agents":[{"agentName":"Cefuroxime (parenteral)","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥18","i_breakpoint":"15-17","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤8","i_breakpoint":"16","r_breakpoint":"≥32"},"comments":[]}]},{"agentName":"Cefepime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥25","i_breakpoint":"19-24","r_breakpoint":"≤18"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":["Susceptible/Susceptible-Dose Dependent (S/SDD) results should be suppressed or edited and reported as resistant for isolates that demonstrate carbapenemase production."]}]},{"agentName":"Ertapenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥22","i_breakpoint":"19-21","r_breakpoint":"≤18"},"mic":{"s_breakpoint":"≤0.5","i_breakpoint":"1","r_breakpoint":"≥2"},"comments":[]}]},{"agentName":"Imipenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥23","i_breakpoint":"20-22","r_breakpoint":"≤19"},"mic":{"s_breakpoint":"≤1","i_breakpoint":"2","r_breakpoint":"≥4"},"comments":[]}]},{"agentName":"Meropenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥23","i_breakpoint":"20-22","r_breakpoint":"≤19"},"mic":{"s_breakpoint":"≤1","i_breakpoint":"2","r_breakpoint":"≥4"},"comments":[]}]}]},{"tier":3,"tierDescription":"Appropriate for high-risk MDRO patients, subject to cascade reporting","agents":[{"agentName":"Cefiderocol","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥16","i_breakpoint":"9-15","r_breakpoint":"≤8"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":["The accuracy and reproducibility of cefiderocol testing results by disk diffusion and broth microdilution are markedly affected by iron concentration and inoculum preparation and may vary by disk and media manufacturer."]}]},{"agentName":"Ceftazidime-avibactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/20 µg","s_breakpoint":"≥21","i_breakpoint":null,"r_breakpoint":"≤20"},"mic":{"s_breakpoint":"≤8/4","i_breakpoint":null,"r_breakpoint":"≥16/4"},"comments":["Confirmatory MIC testing is indicated for isolates with zones of 20–22 mm to avoid reporting false-susceptible or false-resistant results."]}]},{"agentName":"Imipenem-relebactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10/25 µg","s_breakpoint":"≥25","i_breakpoint":"21-24","r_breakpoint":"≤20"},"mic":{"s_breakpoint":"≤1/4","i_breakpoint":"2/4","r_breakpoint":"≥4/4"},"comments":["Breakpoints do not apply to the family Morganellaceae, which includes but is not limited to the genera Morganella, Proteus, and Providencia."]}]},{"agentName":"Meropenem-vaborbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥18","i_breakpoint":"15-17","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤4/8","i_breakpoint":"8/8","r_breakpoint":"≥16/8"},"comments":["Enterobacterales that harbor OXA-48-like enzymes may test susceptible to meropenem-vaborbactam but may not respond in vivo. If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]},{"agentName":"Plazomicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥18","i_breakpoint":"15-17","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤2","i_breakpoint":"4","r_breakpoint":"≥8"},"comments":[]}]}]},{"tier":4,"tierDescription":"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available","agents":[{"agentName":"Aztreonam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥21","i_breakpoint":"18-20","r_breakpoint":"≤17"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":[]}]},{"agentName":"Ceftazidime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥21","i_breakpoint":"18-20","r_breakpoint":"≤17"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":[]}]},{"agentName":"Ceftriaxone","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥26","i_breakpoint":"20-22","r_breakpoint":"≤19"},"mic":{"s_breakpoint":"≤1","i_breakpoint":"2","r_breakpoint":"≥4"},"comments":[]}]},{"agentName":"Ceftolozane-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/20 µg","s_breakpoint":"≥22","i_breakpoint":"19-21","r_breakpoint":"≤18"},"mic":{"s_breakpoint":"≤2/4","i_breakpoint":"4/4","r_breakpoint":"≥8/4"},"comments":[]}]},{"agentName":"Colistin or Polymyxin B","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":null,"s_breakpoint":null,"i_breakpoint":null,"r_breakpoint":null},"mic":{"s_breakpoint":"≤2","i_breakpoint":null,"r_breakpoint":"≥4"},"comments":["Disk diffusion and gradient diffusion methods should not be performed.","When given systemically, these agents are likely effective for pneumonia."]}]}]}]}}'),v_={antimicrobialStewardship:{sources:["antimicrobial_stewardship","antimicrobialStewardship"],value:[]},comments:{preservedStructure:{originalFormat:"object"}},diagnosis:{sources:["diagnosis"],value:[]},allOtherKeys:{}},k_={_originalData:p_,_metadata:g_,identity:f_,clinicalInformation:__,resistanceInformation:h_,treatmentData:b_,laboratoryData:y_,additionalData:v_},x_=JSON.parse('{"identity":{"bacteriumName":"Klebsiella aerogenes","aliases":["Enterobacter aerogenes"],"lastUpdated":"2024-09-30","clsiCategory":"Enterobacterales (excluding Salmonella/Shigella)","classification":{"gramStain":"Gram-negative","morphology":"Bacillus","respiration":"Facultative anaerobe","notes":["Motile (differentiates from other Klebsiella spp.)","Encodes an inducible chromosomal AmpC beta-lactamase."]},"strainDetails":[],"biochemicalTests":"Gram-negative rod, motile (differentiates from other Klebsiella), lactose fermenter, indole –, VP +, citrate +, ornithine decarboxylase +."},"clinicalProfile":{"summary":"Causes a range of infections including urinary tract infections (UTIs), bacteremia, pneumonia, and intra-abdominal infections. As a member of the Enterobacterales group, it is a common nosocomial pathogen. Its key clinical feature is the presence of an inducible AmpC beta-lactamase, which can lead to treatment failure with certain beta-lactam antibiotics, even if they appear susceptible in vitro.","pathophysiologyPearls":["Possesses an inducible chromosomal AmpC beta-lactamase gene. Expression is typically low but can be induced by exposure to certain beta-lactams (e.g., ampicillin, first- and second-generation cephalosporins).","Induction or selection of stably derepressed mutants can lead to clinical resistance to third-generation cephalosporins during therapy."],"keySignsAndSymptoms":[],"clinicalSyndromes":[{"syndromeName":"Urinary Tract Infections (UTI)","description":"Can cause both uncomplicated cystitis and complicated UTIs, including pyelonephritis and catheter-associated UTIs."},{"syndromeName":"Bloodstream Infections (BSI)","description":"A significant cause of nosocomial bacteremia, often associated with central lines, surgery, or other invasive procedures."},{"syndromeName":"Pneumonia","description":"Typically occurs as hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP)."},{"syndromeName":"Intra-abdominal Infections","description":"Can be isolated from peritonitis and abscesses, often as part of a polymicrobial infection."}],"stagesOfIllness":[],"highRiskPopulations":["Hospitalized patients","Immunocompromised individuals","Patients with indwelling medical devices (e.g., catheters, central lines)","Patients with recent antibiotic exposure"],"transmissionVectors":["Contact with contaminated surfaces or equipment in healthcare settings","Hands of healthcare workers"],"prognosisNotes":["Prognosis is highly dependent on the site of infection, severity of illness, and the presence of antimicrobial resistance.","Emergence of resistance to third-generation cephalosporins during therapy is a known risk due to AmpC induction."]},"resistanceProfile":{"groupIntrinsicResistance":[],"intrinsicResistance":[{"drugOrClass":"Ampicillin, Amoxicillin, Amoxicillin-Clavulanate, First-generation Cephalosporins (e.g., Cefazolin), Cefoxitin","notes":"Resistance is mediated by the chromosomal AmpC beta-lactamase."}],"majorMechanisms":[{"mechanismName":"AmpC Beta-Lactamase","mechanismType":"Inducible Chromosomal Enzyme","description":"An inducible cephalosporinase that hydrolyzes penicillins, and first-, second-, and third-generation cephalosporins. Cefepime is more stable. Carbapenems are stable."},{"mechanismName":"Extended-Spectrum Beta-Lactamase (ESBL)","mechanismType":"Plasmid-mediated Enzyme","description":"Confers resistance to most penicillins and cephalosporins (including third and fourth generation) and aztreonam. Susceptible to beta-lactamase inhibitors and carbapenems."},{"mechanismName":"Carbapenemases (e.g., KPC, MBL)","mechanismType":"Plasmid-mediated Enzyme","description":"KPC (Klebsiella pneumoniae carbapenemase) hydrolyzes all beta-lactams including carbapenems; inhibited by avibactam and vaborbactam. MBLs (Metallo-beta-lactamases) are zinc-dependent enzymes that hydrolyze all beta-lactams except aztreonam; they are not inhibited by current clinical beta-lactamase inhibitors."}],"clinicalAlerts":[{"alertTitle":"Inducible AmpC Resistance","details":"Avoid using third-generation cephalosporins (e.g., ceftriaxone, ceftazidime) for serious infections, even if the isolate tests susceptible, due to the high risk of selecting for resistant mutants during therapy. Cefepime is the preferred cephalosporin."},{"alertTitle":"Carbapenem-Resistant Enterobacterales (CRE)","details":"Infections caused by CRE strains (e.g., KPC or MBL producers) are associated with high mortality and require specialized treatment regimens and infectious diseases consultation."}]},"treatment":{"generalNotes":["The following recommendations apply to moderately severe or severe infections where resistance is a concern."],"drugsToAvoid":[{"drugOrClass":"Ceftriaxone, Cefotaxime, Ceftazidime","condition":"All serious infections","reason":"High risk of clinical failure due to induction of AmpC beta-lactamase, even with in vitro susceptibility."},{"drugOrClass":"Piperacillin-tazobactam","condition":"All serious infections","reason":"Risk of in vivo resistance emergence due to AmpC."}],"adjunctiveTherapies":[],"regimens":[{"context":{"type":"Empiric","condition":"Klebsiella aerogenes identified, susceptibility pending","patientPopulation":["Local rate of ESBL resistance <10%"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Cefepime","dose":"1-2 gm","route":"IV","frequency":"q8-12h","comments":"Preferred due to stability against AmpC hydrolysis."}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ciprofloxacin","dose":"400 mg","route":"IV","frequency":"bid","comments":"Use based on local susceptibility data."},{"drugName":"Levofloxacin","dose":"750 mg","route":"IV","frequency":"q24h","comments":"Use based on local susceptibility data."}]}]}]},{"context":{"type":"Empiric","condition":"Klebsiella aerogenes identified, susceptibility pending","patientPopulation":["Local rate of ESBL resistance >10%"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Meropenem","dose":"1-2 gm","route":"IV","frequency":"q8h","comments":""},{"drugName":"Ertapenem","dose":"1 gm","route":"IV","frequency":"q24h","comments":""}]}]}]},{"context":{"type":"Directed","condition":"Non-ESBL producer","patientPopulation":["Susceptible to Aztreonam, Ceftriaxone, Cefotaxime, Ceftazidime, or Cefepime"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Cefepime","dose":"1-2 gm","route":"IV","frequency":"q8-12h","comments":"Preferred agent due to stability against AmpC."}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ciprofloxacin","dose":"400 mg","route":"IV","frequency":"bid","comments":"If susceptible."},{"drugName":"Levofloxacin","dose":"750 mg","route":"IV","frequency":"q24h","comments":"If susceptible."},{"drugName":"TMP-SMX","dose":"10 mg/kg/day (TMP component)","route":"IV or PO","frequency":"in 2-3 divided doses","comments":"If susceptible."}]}]}]},{"context":{"type":"Directed","condition":"ESBL Producer / AmpC over-producer","patientPopulation":["Resistant to 3rd/4th generation cephalosporins, but susceptible to carbapenems"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Meropenem","dose":"1-2 gm","route":"IV","frequency":"q8h","comments":"For serious infections, consider 2 gm infused over 3 hours q8h."},{"drugName":"Imipenem-cilastatin","dose":"500 mg","route":"IV","frequency":"q6h","comments":""},{"drugName":"Ertapenem","dose":"1 gm","route":"IV","frequency":"q24h","comments":"Generally avoid for bacteremia or pneumonia."}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftolozane-tazobactam","dose":"1.5-3 gm","route":"IV","frequency":"q8h","comments":"Carbapenem-sparing option. Use 3 gm dose for severe infections like VAP."},{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"infused over 3 hrs q8h","comments":"Carbapenem-sparing option."}]}]}]},{"context":{"type":"Directed","condition":"Carbapenem-Resistant (KPC producer)","patientPopulation":["Resistant to carbapenems but susceptible to newer BL-BLI combinations"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"infused over 3 hrs q8h","comments":"Infectious diseases consultation strongly recommended."},{"drugName":"Meropenem-vaborbactam","dose":"4 gm","route":"IV","frequency":"infused over 3 hrs q8h","comments":"Infectious diseases consultation strongly recommended."},{"drugName":"Imipenem-cilastatin-relebactam","dose":"1.25 gm","route":"IV","frequency":"over 30 min q6h","comments":"Only for CrCl >90 mL/min. Infectious diseases consultation strongly recommended."}]}]}]},{"context":{"type":"Directed","condition":"Carbapenem-Resistant (MBL producer)","patientPopulation":["Resistant to carbapenems and newer beta-lactamase inhibitors like C/A, M/V, I/R"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"over 3h q8h","comments":"Must be given with Aztreonam."},{"drugName":"Aztreonam","dose":"2 gm","route":"IV","frequency":"over 2 hrs q6h","comments":"Must be given with Ceftazidime-avibactam. Infectious diseases consultation strongly recommended."}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Cefiderocol","dose":"2 gm","route":"IV","frequency":"over 3 hrs q8h","comments":"Infectious diseases consultation strongly recommended."}]}]}]}]},"laboratoryProfile":{"testingIndications":["Susceptibility testing is indicated for all clinically significant isolates."],"methodologyNotes":["Broth dilution MIC testing should not be performed for fosfomycin; agar dilution with glucose-6-phosphate supplementation is the only validated method.","Disk diffusion and gradient diffusion methods for colistin or polymyxin B are unreliable and should not be performed."],"recommendedPanel":[],"specialTests":[{"testName":"Carbapenemase Production Test (e.g., mCIM, Carba NP)","trigger":"Resistance to one or more carbapenems.","purpose":"To detect the presence of a carbapenemase enzyme, which has significant therapeutic and infection control implications."}],"reportingRules":[{"ruleType":"Conditional","drug":"Cefepime","condition":"Isolate demonstrates carbapenemase production.","details":"Cefepime S/SDD results should be suppressed or reported as resistant."},{"ruleType":"Surrogate","drug":"Ampicillin","condition":"N/A","details":"Results of ampicillin testing can be used to predict results for amoxicillin."},{"ruleType":"Surrogate","drug":"Tetracycline","condition":"Isolate is susceptible to Tetracycline.","details":"Organisms susceptible to tetracycline are also considered susceptible to doxycycline and minocycline. However, some organisms that are intermediate or resistant to tetracycline may be susceptible to doxycycline, minocycline, or both."},{"ruleType":"Surrogate","drug":"Cefazolin (Urine)","condition":"Isolate is from an uncomplicated UTI.","details":"Serves as a surrogate for oral cephalosporins (e.g., cephalexin) for E. coli, K. pneumoniae, and P. mirabilis."}],"antimicrobialBreakpoints":[{"tier":1,"tierDescription":"Appropriate for routine, primary testing and reporting.","agents":[{"agentName":"Ampicillin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥17","i_breakpoint":"14-16","r_breakpoint":"≤13"},"mic":{"s_breakpoint":"≤8","i_breakpoint":"16","r_breakpoint":"≥32"},"comments":["Results can be used to predict results for amoxicillin."]}]},{"agentName":"Amoxicillin-clavulanate","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥18","i_breakpoint":"","r_breakpoint":"≤17"},"mic":{"s_breakpoint":"≤8/4","i_breakpoint":"16/8","r_breakpoint":"≥32/16"},"comments":["Breakpoints are only for therapy of uncomplicated UTIs."]}]},{"agentName":"Ampicillin-sulbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10/10 µg","s_breakpoint":"≥15","i_breakpoint":"12-14","r_breakpoint":"≤11"},"mic":{"s_breakpoint":"≤8/4","i_breakpoint":"16/8","r_breakpoint":"≥32/16"},"comments":[]}]},{"agentName":"Piperacillin-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"100/10 µg","s_breakpoint":"≥25","i_breakpoint":"21-24","r_breakpoint":"≤20"},"mic":{"s_breakpoint":"≤8/4","i_breakpoint":"16/4","r_breakpoint":"≥32/4"},"comments":[]}]},{"agentName":"Gentamicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥18","i_breakpoint":"15-17","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"","r_breakpoint":"≥8"},"comments":[]}]},{"agentName":"Tobramycin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥17","i_breakpoint":"13-16","r_breakpoint":"≤12"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"","r_breakpoint":"≥8"},"comments":[]}]},{"agentName":"Amikacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥19","i_breakpoint":"17-18","r_breakpoint":"≤16"},"mic":{"s_breakpoint":"≤16","i_breakpoint":"","r_breakpoint":"≥32"},"comments":[]}]},{"agentName":"Ciprofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥26","i_breakpoint":"22-25","r_breakpoint":"≤21"},"mic":{"s_breakpoint":"≤0.25","i_breakpoint":"0.5","r_breakpoint":"≥1"},"comments":[]}]},{"agentName":"Levofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥21","i_breakpoint":"17-20","r_breakpoint":"≤16"},"mic":{"s_breakpoint":"≤0.5","i_breakpoint":"1","r_breakpoint":"≥2"},"comments":[]}]},{"agentName":"Trimethoprim-sulfamethoxazole","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"1.25/23.75 µg","s_breakpoint":"≥16","i_breakpoint":"11-15","r_breakpoint":"≤10"},"mic":{"s_breakpoint":"≤2/38","i_breakpoint":"","r_breakpoint":"≥4/76"},"comments":[]}]},{"agentName":"Cefotaxime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥26","i_breakpoint":"23-25","r_breakpoint":"≤22"},"mic":{"s_breakpoint":"≤1","i_breakpoint":"2","r_breakpoint":"≥4"},"comments":[]}]},{"agentName":"Ceftriaxone","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥23","i_breakpoint":"20-22","r_breakpoint":"≤19"},"mic":{"s_breakpoint":"≤1","i_breakpoint":"2","r_breakpoint":"≥4"},"comments":[]}]}]},{"tier":2,"tierDescription":"Appropriate for routine, primary testing, may be reported following cascade reporting rules.","agents":[{"agentName":"Cefuroxime (Parenteral)","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥18","i_breakpoint":"15-17","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤8","i_breakpoint":"16","r_breakpoint":"≥32"},"comments":[]}]},{"agentName":"Cefepime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥25","i_breakpoint":"19-24","r_breakpoint":"≤18"},"mic":{"s_breakpoint":"≤2","i_breakpoint":"4-8 (SDD)","r_breakpoint":"≥16"},"comments":["Cefepime S/SDD results should be suppressed or reported as resistant for isolates that demonstrate carbapenemase production."]}]},{"agentName":"Ertapenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥22","i_breakpoint":"19-21","r_breakpoint":"≤18"},"mic":{"s_breakpoint":"≤0.5","i_breakpoint":"1","r_breakpoint":"≥2"},"comments":[]}]},{"agentName":"Imipenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥23","i_breakpoint":"20-22","r_breakpoint":"≤19"},"mic":{"s_breakpoint":"≤1","i_breakpoint":"2","r_breakpoint":"≥4"},"comments":[]}]},{"agentName":"Meropenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥23","i_breakpoint":"20-22","r_breakpoint":"≤19"},"mic":{"s_breakpoint":"≤1","i_breakpoint":"2","r_breakpoint":"≥4"},"comments":[]}]},{"agentName":"Tetracycline","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥15","i_breakpoint":"12-14","r_breakpoint":"≤11"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":["Organisms susceptible to tetracycline are also considered susceptible to doxycycline and minocycline. However, some organisms that are intermediate or resistant to tetracycline may be susceptible to doxycycline, minocycline, or both."]}]}]},{"tier":3,"tierDescription":"Appropriate for high-risk Multi-Drug Resistant Organism (MDRO) patients, subject to cascade reporting.","agents":[{"agentName":"Cefiderocol","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥16","i_breakpoint":"9-15","r_breakpoint":"≤8"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"","r_breakpoint":"≥8"},"comments":[]}]},{"agentName":"Ceftazidime-avibactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/20 µg","s_breakpoint":"≥21","i_breakpoint":"","r_breakpoint":"≤20"},"mic":{"s_breakpoint":"≤8/4","i_breakpoint":"","r_breakpoint":"≥16/4"},"comments":["Confirmatory MIC testing is indicated for isolates with disk diffusion zones of 20–22 mm to avoid reporting false-susceptible or false-resistant results."]}]},{"agentName":"Imipenem-relebactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10/25 µg","s_breakpoint":"≥25","i_breakpoint":"21-24","r_breakpoint":"≤20"},"mic":{"s_breakpoint":"≤1/4","i_breakpoint":"2/4","r_breakpoint":"≥4/4"},"comments":["Breakpoints do not apply to the family Morganellaceae (Morganella, Proteus, and Providencia)."]}]},{"agentName":"Meropenem-vaborbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥18","i_breakpoint":"15-17","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤4/8","i_breakpoint":"8/8","r_breakpoint":"≥16/8"},"comments":["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]},{"agentName":"Plazomicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥18","i_breakpoint":"15-17","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤2","i_breakpoint":"","r_breakpoint":"≥4"},"comments":[]}]}]},{"tier":4,"tierDescription":"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.","agents":[{"agentName":"Aztreonam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥21","i_breakpoint":"18-20","r_breakpoint":"≤17"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":[]}]},{"agentName":"Ceftazidime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥21","i_breakpoint":"18-20","r_breakpoint":"≤17"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":[]}]},{"agentName":"Ceftolozane-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/10 µg","s_breakpoint":"≥22","i_breakpoint":"19-21","r_breakpoint":"≤18"},"mic":{"s_breakpoint":"≤2/4","i_breakpoint":"","r_breakpoint":"≥4/4"},"comments":[]}]},{"agentName":"Colistin (Polymyxin E)","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"","s_breakpoint":"","i_breakpoint":"","r_breakpoint":""},"mic":{"s_breakpoint":"≤2","i_breakpoint":"","r_breakpoint":"≥4"},"comments":["Disk diffusion and gradient diffusion methods should not be performed."]}]},{"agentName":"Polymyxin B","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"","s_breakpoint":"","i_breakpoint":"","r_breakpoint":""},"mic":{"s_breakpoint":"≤2","i_breakpoint":"","r_breakpoint":"≥4"},"comments":["Disk diffusion and gradient diffusion methods should not be performed."]}]}]},{"tier":99,"tierDescription":"Urine Only","agents":[{"agentName":"Cefazolin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥15","i_breakpoint":"","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤16","i_breakpoint":"","r_breakpoint":"≥32"},"comments":["For uncomplicated UTI only. Serves as a surrogate for oral cephalosporins."]}]},{"agentName":"Nitrofurantoin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"300 µg","s_breakpoint":"≥17","i_breakpoint":"15-16","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤32","i_breakpoint":"64","r_breakpoint":"≥128"},"comments":[]}]},{"agentName":"Fosfomycin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"200 µg","s_breakpoint":"≥16","i_breakpoint":"13-15","r_breakpoint":"≤12"},"mic":{"s_breakpoint":"≤64","i_breakpoint":"128","r_breakpoint":"≥256"},"comments":["Disk diffusion and MIC breakpoints for Fosfomycin apply ONLY to E. coli from urinary tract isolates and should not be extrapolated to other Enterobacterales species.","The only approved MIC method is agar dilution using media supplemented with 25 µg/mL of glucose-6-phosphate."]}]}]}]},"additionalInformation":{"diagnosticNotes":{"summary":"","biosafetyWarning":"","methods":[]},"preventionAndScreening":[],"treatmentLifecycle":[],"antimicrobialStewardship":["Infectious diseases consultation is strongly recommended for infections caused by carbapenem-resistant isolates.","Isolated Ertapenem resistance does not preclude the use of Meropenem or Imipenem if the isolate tests susceptible to them.","Avoid combination therapy with a carbapenem and a polymyxin for KPC-producing isolates; newer agents like ceftazidime-avibactam are superior."],"drugSpecificPearls":[{"drugName":"Cefepime","pearl":"Cefepime is a weak inducer of AmpC and is stable to hydrolysis by AmpC, making it the preferred cephalosporin for K. aerogenes. For isolates with MICs of 4-8 mcg/mL, a higher dose of 2 gm IV q8h infused over 3 hours is recommended for serious infections."},{"drugName":"Ceftazidime-avibactam","pearl":"Showed superiority to colistin in an observational study for treating infections caused by carbapenem-resistant Enterobacterales."}],"guidelineReferences":[]}}'),C_={originalKeys:["identity","clinicalProfile","resistanceProfile","treatment","laboratoryProfile","additionalInformation"],conversionTimestamp:"2025-07-15T03:16:49.281Z",sourceFormat:"modern"},S_={bacteriumName:{sources:["identity.bacteriumName"],value:"Klebsiella aerogenes"},aliases:{sources:["identity.aliases"],value:["Enterobacter aerogenes"]},lastUpdated:{sources:["identity.lastUpdated"],value:"2024-09-30"},classification:{sources:["identity.classification"],value:{gramStain:"Gram-negative",morphology:"Bacillus",respiration:"Facultative anaerobe",notes:["Motile (differentiates from other Klebsiella spp.)","Encodes an inducible chromosomal AmpC beta-lactamase."]}}},N_={sources:["clinicalProfile"],value:{summary:"Causes a range of infections including urinary tract infections (UTIs), bacteremia, pneumonia, and intra-abdominal infections. As a member of the Enterobacterales group, it is a common nosocomial pathogen. Its key clinical feature is the presence of an inducible AmpC beta-lactamase, which can lead to treatment failure with certain beta-lactam antibiotics, even if they appear susceptible in vitro.",pathophysiologyPearls:["Possesses an inducible chromosomal AmpC beta-lactamase gene. Expression is typically low but can be induced by exposure to certain beta-lactams (e.g., ampicillin, first- and second-generation cephalosporins).","Induction or selection of stably derepressed mutants can lead to clinical resistance to third-generation cephalosporins during therapy."],keySignsAndSymptoms:[],clinicalSyndromes:[{syndromeName:"Urinary Tract Infections (UTI)",description:"Can cause both uncomplicated cystitis and complicated UTIs, including pyelonephritis and catheter-associated UTIs."},{syndromeName:"Bloodstream Infections (BSI)",description:"A significant cause of nosocomial bacteremia, often associated with central lines, surgery, or other invasive procedures."},{syndromeName:"Pneumonia",description:"Typically occurs as hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP)."},{syndromeName:"Intra-abdominal Infections",description:"Can be isolated from peritonitis and abscesses, often as part of a polymicrobial infection."}],stagesOfIllness:[],highRiskPopulations:["Hospitalized patients","Immunocompromised individuals","Patients with indwelling medical devices (e.g., catheters, central lines)","Patients with recent antibiotic exposure"],transmissionVectors:["Contact with contaminated surfaces or equipment in healthcare settings","Hands of healthcare workers"],prognosisNotes:["Prognosis is highly dependent on the site of infection, severity of illness, and the presence of antimicrobial resistance.","Emergence of resistance to third-generation cephalosporins during therapy is a known risk due to AmpC induction."]}},I_={sources:["resistanceProfile"],value:{groupIntrinsicResistance:[],intrinsicResistance:[{drugOrClass:"Ampicillin, Amoxicillin, Amoxicillin-Clavulanate, First-generation Cephalosporins (e.g., Cefazolin), Cefoxitin",notes:"Resistance is mediated by the chromosomal AmpC beta-lactamase."}],majorMechanisms:[{mechanismName:"AmpC Beta-Lactamase",mechanismType:"Inducible Chromosomal Enzyme",description:"An inducible cephalosporinase that hydrolyzes penicillins, and first-, second-, and third-generation cephalosporins. Cefepime is more stable. Carbapenems are stable."},{mechanismName:"Extended-Spectrum Beta-Lactamase (ESBL)",mechanismType:"Plasmid-mediated Enzyme",description:"Confers resistance to most penicillins and cephalosporins (including third and fourth generation) and aztreonam. Susceptible to beta-lactamase inhibitors and carbapenems."},{mechanismName:"Carbapenemases (e.g., KPC, MBL)",mechanismType:"Plasmid-mediated Enzyme",description:"KPC (Klebsiella pneumoniae carbapenemase) hydrolyzes all beta-lactams including carbapenems; inhibited by avibactam and vaborbactam. MBLs (Metallo-beta-lactamases) are zinc-dependent enzymes that hydrolyze all beta-lactams except aztreonam; they are not inhibited by current clinical beta-lactamase inhibitors."}],clinicalAlerts:[{alertTitle:"Inducible AmpC Resistance",details:"Avoid using third-generation cephalosporins (e.g., ceftriaxone, ceftazidime) for serious infections, even if the isolate tests susceptible, due to the high risk of selecting for resistant mutants during therapy. Cefepime is the preferred cephalosporin."},{alertTitle:"Carbapenem-Resistant Enterobacterales (CRE)",details:"Infections caused by CRE strains (e.g., KPC or MBL producers) are associated with high mortality and require specialized treatment regimens and infectious diseases consultation."}]}},j_={treatmentData:{_treatmentMetadata:{originalFormat:"modern"},standardizedRegimens:[{regimenId:"modern-0-0-0",extractedFrom:"treatment.regimens[0].recommendations[0].steps[0]",context:{type:"empiric",condition:"Klebsiella aerogenes identified, susceptibility pending",severity:"unknown",patientFactors:{population:["Local rate of ESBL resistance <10%"],labFindings:null}},preference:"primary",drugs:[{drugName:"Cefepime",dose:"1-2 gm",route:"IV",frequency:"q8-12h",duration:"Variable",comments:"Preferred due to stability against AmpC hydrolysis.",originalText:"Cefepime 1-2 gm IV q8-12h"}]},{regimenId:"modern-0-1-0",extractedFrom:"treatment.regimens[0].recommendations[1].steps[0]",context:{type:"empiric",condition:"Klebsiella aerogenes identified, susceptibility pending",severity:"unknown",patientFactors:{population:["Local rate of ESBL resistance <10%"],labFindings:null}},preference:"alternative",drugs:[{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"bid",duration:"Variable",comments:"Use based on local susceptibility data.",originalText:"Ciprofloxacin 400 mg IV bid"},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"q24h",duration:"Variable",comments:"Use based on local susceptibility data.",originalText:"Levofloxacin 750 mg IV q24h"}]},{regimenId:"modern-1-0-0",extractedFrom:"treatment.regimens[1].recommendations[0].steps[0]",context:{type:"empiric",condition:"Klebsiella aerogenes identified, susceptibility pending",severity:"unknown",patientFactors:{population:["Local rate of ESBL resistance >10%"],labFindings:null}},preference:"primary",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"",originalText:"Meropenem 1-2 gm IV q8h"},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Ertapenem 1 gm IV q24h"}]},{regimenId:"modern-2-0-0",extractedFrom:"treatment.regimens[2].recommendations[0].steps[0]",context:{type:"directed",condition:"Non-ESBL producer",severity:"unknown",patientFactors:{population:["Susceptible to Aztreonam, Ceftriaxone, Cefotaxime, Ceftazidime, or Cefepime"],labFindings:null}},preference:"primary",drugs:[{drugName:"Cefepime",dose:"1-2 gm",route:"IV",frequency:"q8-12h",duration:"Variable",comments:"Preferred agent due to stability against AmpC.",originalText:"Cefepime 1-2 gm IV q8-12h"}]},{regimenId:"modern-2-1-0",extractedFrom:"treatment.regimens[2].recommendations[1].steps[0]",context:{type:"directed",condition:"Non-ESBL producer",severity:"unknown",patientFactors:{population:["Susceptible to Aztreonam, Ceftriaxone, Cefotaxime, Ceftazidime, or Cefepime"],labFindings:null}},preference:"alternative",drugs:[{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"bid",duration:"Variable",comments:"If susceptible.",originalText:"Ciprofloxacin 400 mg IV bid"},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"q24h",duration:"Variable",comments:"If susceptible.",originalText:"Levofloxacin 750 mg IV q24h"},{drugName:"TMP-SMX",dose:"10 mg/kg/day (TMP component)",route:"IV or PO",frequency:"in 2-3 divided doses",duration:"Variable",comments:"If susceptible.",originalText:"TMP-SMX 10 mg/kg/day (TMP component) IV or PO in 2-3 divided doses"}]},{regimenId:"modern-3-0-0",extractedFrom:"treatment.regimens[3].recommendations[0].steps[0]",context:{type:"directed",condition:"ESBL Producer / AmpC over-producer",severity:"unknown",patientFactors:{population:["Resistant to 3rd/4th generation cephalosporins, but susceptible to carbapenems"],labFindings:null}},preference:"primary",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"For serious infections, consider 2 gm infused over 3 hours q8h.",originalText:"Meropenem 1-2 gm IV q8h"},{drugName:"Imipenem-cilastatin",dose:"500 mg",route:"IV",frequency:"q6h",duration:"Variable",comments:"",originalText:"Imipenem-cilastatin 500 mg IV q6h"},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",duration:"Variable",comments:"Generally avoid for bacteremia or pneumonia.",originalText:"Ertapenem 1 gm IV q24h"}]},{regimenId:"modern-3-1-0",extractedFrom:"treatment.regimens[3].recommendations[1].steps[0]",context:{type:"directed",condition:"ESBL Producer / AmpC over-producer",severity:"unknown",patientFactors:{population:["Resistant to 3rd/4th generation cephalosporins, but susceptible to carbapenems"],labFindings:null}},preference:"alternative",drugs:[{drugName:"Ceftolozane-tazobactam",dose:"1.5-3 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Carbapenem-sparing option. Use 3 gm dose for severe infections like VAP.",originalText:"Ceftolozane-tazobactam 1.5-3 gm IV q8h"},{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"infused over 3 hrs q8h",duration:"Variable",comments:"Carbapenem-sparing option.",originalText:"Ceftazidime-avibactam 2.5 gm IV infused over 3 hrs q8h"}]},{regimenId:"modern-4-0-0",extractedFrom:"treatment.regimens[4].recommendations[0].steps[0]",context:{type:"directed",condition:"Carbapenem-Resistant (KPC producer)",severity:"unknown",patientFactors:{population:["Resistant to carbapenems but susceptible to newer BL-BLI combinations"],labFindings:null}},preference:"primary",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"infused over 3 hrs q8h",duration:"Variable",comments:"Infectious diseases consultation strongly recommended.",originalText:"Ceftazidime-avibactam 2.5 gm IV infused over 3 hrs q8h"},{drugName:"Meropenem-vaborbactam",dose:"4 gm",route:"IV",frequency:"infused over 3 hrs q8h",duration:"Variable",comments:"Infectious diseases consultation strongly recommended.",originalText:"Meropenem-vaborbactam 4 gm IV infused over 3 hrs q8h"},{drugName:"Imipenem-cilastatin-relebactam",dose:"1.25 gm",route:"IV",frequency:"over 30 min q6h",duration:"Variable",comments:"Only for CrCl >90 mL/min. Infectious diseases consultation strongly recommended.",originalText:"Imipenem-cilastatin-relebactam 1.25 gm IV over 30 min q6h"}]},{regimenId:"modern-5-0-0",extractedFrom:"treatment.regimens[5].recommendations[0].steps[0]",context:{type:"directed",condition:"Carbapenem-Resistant (MBL producer)",severity:"unknown",patientFactors:{population:["Resistant to carbapenems and newer beta-lactamase inhibitors like C/A, M/V, I/R"],labFindings:null}},preference:"primary",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"over 3h q8h",duration:"Variable",comments:"Must be given with Aztreonam.",originalText:"Ceftazidime-avibactam 2.5 gm IV over 3h q8h"},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"over 2 hrs q6h",duration:"Variable",comments:"Must be given with Ceftazidime-avibactam. Infectious diseases consultation strongly recommended.",originalText:"Aztreonam 2 gm IV over 2 hrs q6h"}]},{regimenId:"modern-5-1-0",extractedFrom:"treatment.regimens[5].recommendations[1].steps[0]",context:{type:"directed",condition:"Carbapenem-Resistant (MBL producer)",severity:"unknown",patientFactors:{population:["Resistant to carbapenems and newer beta-lactamase inhibitors like C/A, M/V, I/R"],labFindings:null}},preference:"alternative",drugs:[{drugName:"Cefiderocol",dose:"2 gm",route:"IV",frequency:"over 3 hrs q8h",duration:"Variable",comments:"Infectious diseases consultation strongly recommended.",originalText:"Cefiderocol 2 gm IV over 3 hrs q8h"}]}]}},A_=JSON.parse('{"sources":["laboratoryProfile"],"value":{"testingIndications":["Susceptibility testing is indicated for all clinically significant isolates."],"methodologyNotes":["Broth dilution MIC testing should not be performed for fosfomycin; agar dilution with glucose-6-phosphate supplementation is the only validated method.","Disk diffusion and gradient diffusion methods for colistin or polymyxin B are unreliable and should not be performed."],"recommendedPanel":[],"specialTests":[{"testName":"Carbapenemase Production Test (e.g., mCIM, Carba NP)","trigger":"Resistance to one or more carbapenems.","purpose":"To detect the presence of a carbapenemase enzyme, which has significant therapeutic and infection control implications."}],"reportingRules":[{"ruleType":"Conditional","drug":"Cefepime","condition":"Isolate demonstrates carbapenemase production.","details":"Cefepime S/SDD results should be suppressed or reported as resistant."},{"ruleType":"Surrogate","drug":"Ampicillin","condition":"N/A","details":"Results of ampicillin testing can be used to predict results for amoxicillin."},{"ruleType":"Surrogate","drug":"Tetracycline","condition":"Isolate is susceptible to Tetracycline.","details":"Organisms susceptible to tetracycline are also considered susceptible to doxycycline and minocycline. However, some organisms that are intermediate or resistant to tetracycline may be susceptible to doxycycline, minocycline, or both."},{"ruleType":"Surrogate","drug":"Cefazolin (Urine)","condition":"Isolate is from an uncomplicated UTI.","details":"Serves as a surrogate for oral cephalosporins (e.g., cephalexin) for E. coli, K. pneumoniae, and P. mirabilis."}],"antimicrobialBreakpoints":[{"tier":1,"tierDescription":"Appropriate for routine, primary testing and reporting.","agents":[{"agentName":"Ampicillin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥17","i_breakpoint":"14-16","r_breakpoint":"≤13"},"mic":{"s_breakpoint":"≤8","i_breakpoint":"16","r_breakpoint":"≥32"},"comments":["Results can be used to predict results for amoxicillin."]}]},{"agentName":"Amoxicillin-clavulanate","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥18","i_breakpoint":"","r_breakpoint":"≤17"},"mic":{"s_breakpoint":"≤8/4","i_breakpoint":"16/8","r_breakpoint":"≥32/16"},"comments":["Breakpoints are only for therapy of uncomplicated UTIs."]}]},{"agentName":"Ampicillin-sulbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10/10 µg","s_breakpoint":"≥15","i_breakpoint":"12-14","r_breakpoint":"≤11"},"mic":{"s_breakpoint":"≤8/4","i_breakpoint":"16/8","r_breakpoint":"≥32/16"},"comments":[]}]},{"agentName":"Piperacillin-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"100/10 µg","s_breakpoint":"≥25","i_breakpoint":"21-24","r_breakpoint":"≤20"},"mic":{"s_breakpoint":"≤8/4","i_breakpoint":"16/4","r_breakpoint":"≥32/4"},"comments":[]}]},{"agentName":"Gentamicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥18","i_breakpoint":"15-17","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"","r_breakpoint":"≥8"},"comments":[]}]},{"agentName":"Tobramycin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥17","i_breakpoint":"13-16","r_breakpoint":"≤12"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"","r_breakpoint":"≥8"},"comments":[]}]},{"agentName":"Amikacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥19","i_breakpoint":"17-18","r_breakpoint":"≤16"},"mic":{"s_breakpoint":"≤16","i_breakpoint":"","r_breakpoint":"≥32"},"comments":[]}]},{"agentName":"Ciprofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥26","i_breakpoint":"22-25","r_breakpoint":"≤21"},"mic":{"s_breakpoint":"≤0.25","i_breakpoint":"0.5","r_breakpoint":"≥1"},"comments":[]}]},{"agentName":"Levofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥21","i_breakpoint":"17-20","r_breakpoint":"≤16"},"mic":{"s_breakpoint":"≤0.5","i_breakpoint":"1","r_breakpoint":"≥2"},"comments":[]}]},{"agentName":"Trimethoprim-sulfamethoxazole","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"1.25/23.75 µg","s_breakpoint":"≥16","i_breakpoint":"11-15","r_breakpoint":"≤10"},"mic":{"s_breakpoint":"≤2/38","i_breakpoint":"","r_breakpoint":"≥4/76"},"comments":[]}]},{"agentName":"Cefotaxime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥26","i_breakpoint":"23-25","r_breakpoint":"≤22"},"mic":{"s_breakpoint":"≤1","i_breakpoint":"2","r_breakpoint":"≥4"},"comments":[]}]},{"agentName":"Ceftriaxone","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥23","i_breakpoint":"20-22","r_breakpoint":"≤19"},"mic":{"s_breakpoint":"≤1","i_breakpoint":"2","r_breakpoint":"≥4"},"comments":[]}]}]},{"tier":2,"tierDescription":"Appropriate for routine, primary testing, may be reported following cascade reporting rules.","agents":[{"agentName":"Cefuroxime (Parenteral)","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥18","i_breakpoint":"15-17","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤8","i_breakpoint":"16","r_breakpoint":"≥32"},"comments":[]}]},{"agentName":"Cefepime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥25","i_breakpoint":"19-24","r_breakpoint":"≤18"},"mic":{"s_breakpoint":"≤2","i_breakpoint":"4-8 (SDD)","r_breakpoint":"≥16"},"comments":["Cefepime S/SDD results should be suppressed or reported as resistant for isolates that demonstrate carbapenemase production."]}]},{"agentName":"Ertapenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥22","i_breakpoint":"19-21","r_breakpoint":"≤18"},"mic":{"s_breakpoint":"≤0.5","i_breakpoint":"1","r_breakpoint":"≥2"},"comments":[]}]},{"agentName":"Imipenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥23","i_breakpoint":"20-22","r_breakpoint":"≤19"},"mic":{"s_breakpoint":"≤1","i_breakpoint":"2","r_breakpoint":"≥4"},"comments":[]}]},{"agentName":"Meropenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥23","i_breakpoint":"20-22","r_breakpoint":"≤19"},"mic":{"s_breakpoint":"≤1","i_breakpoint":"2","r_breakpoint":"≥4"},"comments":[]}]},{"agentName":"Tetracycline","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥15","i_breakpoint":"12-14","r_breakpoint":"≤11"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":["Organisms susceptible to tetracycline are also considered susceptible to doxycycline and minocycline. However, some organisms that are intermediate or resistant to tetracycline may be susceptible to doxycycline, minocycline, or both."]}]}]},{"tier":3,"tierDescription":"Appropriate for high-risk Multi-Drug Resistant Organism (MDRO) patients, subject to cascade reporting.","agents":[{"agentName":"Cefiderocol","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥16","i_breakpoint":"9-15","r_breakpoint":"≤8"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"","r_breakpoint":"≥8"},"comments":[]}]},{"agentName":"Ceftazidime-avibactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/20 µg","s_breakpoint":"≥21","i_breakpoint":"","r_breakpoint":"≤20"},"mic":{"s_breakpoint":"≤8/4","i_breakpoint":"","r_breakpoint":"≥16/4"},"comments":["Confirmatory MIC testing is indicated for isolates with disk diffusion zones of 20–22 mm to avoid reporting false-susceptible or false-resistant results."]}]},{"agentName":"Imipenem-relebactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10/25 µg","s_breakpoint":"≥25","i_breakpoint":"21-24","r_breakpoint":"≤20"},"mic":{"s_breakpoint":"≤1/4","i_breakpoint":"2/4","r_breakpoint":"≥4/4"},"comments":["Breakpoints do not apply to the family Morganellaceae (Morganella, Proteus, and Providencia)."]}]},{"agentName":"Meropenem-vaborbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥18","i_breakpoint":"15-17","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤4/8","i_breakpoint":"8/8","r_breakpoint":"≥16/8"},"comments":["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]},{"agentName":"Plazomicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥18","i_breakpoint":"15-17","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤2","i_breakpoint":"","r_breakpoint":"≥4"},"comments":[]}]}]},{"tier":4,"tierDescription":"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.","agents":[{"agentName":"Aztreonam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥21","i_breakpoint":"18-20","r_breakpoint":"≤17"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":[]}]},{"agentName":"Ceftazidime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥21","i_breakpoint":"18-20","r_breakpoint":"≤17"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":[]}]},{"agentName":"Ceftolozane-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/10 µg","s_breakpoint":"≥22","i_breakpoint":"19-21","r_breakpoint":"≤18"},"mic":{"s_breakpoint":"≤2/4","i_breakpoint":"","r_breakpoint":"≥4/4"},"comments":[]}]},{"agentName":"Colistin (Polymyxin E)","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"","s_breakpoint":"","i_breakpoint":"","r_breakpoint":""},"mic":{"s_breakpoint":"≤2","i_breakpoint":"","r_breakpoint":"≥4"},"comments":["Disk diffusion and gradient diffusion methods should not be performed."]}]},{"agentName":"Polymyxin B","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"","s_breakpoint":"","i_breakpoint":"","r_breakpoint":""},"mic":{"s_breakpoint":"≤2","i_breakpoint":"","r_breakpoint":"≥4"},"comments":["Disk diffusion and gradient diffusion methods should not be performed."]}]}]},{"tier":99,"tierDescription":"Urine Only","agents":[{"agentName":"Cefazolin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥15","i_breakpoint":"","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤16","i_breakpoint":"","r_breakpoint":"≥32"},"comments":["For uncomplicated UTI only. Serves as a surrogate for oral cephalosporins."]}]},{"agentName":"Nitrofurantoin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"300 µg","s_breakpoint":"≥17","i_breakpoint":"15-16","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤32","i_breakpoint":"64","r_breakpoint":"≥128"},"comments":[]}]},{"agentName":"Fosfomycin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"200 µg","s_breakpoint":"≥16","i_breakpoint":"13-15","r_breakpoint":"≤12"},"mic":{"s_breakpoint":"≤64","i_breakpoint":"128","r_breakpoint":"≥256"},"comments":["Disk diffusion and MIC breakpoints for Fosfomycin apply ONLY to E. coli from urinary tract isolates and should not be extrapolated to other Enterobacterales species.","The only approved MIC method is agar dilution using media supplemented with 25 µg/mL of glucose-6-phosphate."]}]}]}]}}'),w_={antimicrobialStewardship:{sources:["antimicrobial_stewardship","antimicrobialStewardship"],value:[]},comments:{preservedStructure:{originalFormat:"object"}},diagnosis:{sources:["diagnosis"],value:[]},allOtherKeys:{}},R_={_originalData:x_,_metadata:C_,identity:S_,clinicalInformation:N_,resistanceInformation:I_,treatmentData:j_,laboratoryData:A_,additionalData:w_},M_=JSON.parse('{"identity":{"bacteriumName":"Klebsiella species (oxytoca, pneumoniae, variicola)","aliases":["Klebsiella oxytoca","Klebsiella pneumoniae","Klebsiella variicola"],"lastUpdated":"2025-01-08","clsiCategory":"Enterobacterales (excluding Salmonella/Shigella)","classification":{"gramStain":"Gram-negative","morphology":"Bacilli","respiration":"Facultative anaerobe","notes":["Fermentative"]},"strainDetails":[{"type":"Complex","value":"Klebsiella pneumoniae complex","notes":"Includes K. pneumoniae and K. variicola."},{"type":"Phenotype","value":"Hypermucoviscous Klebsiella","notes":"Increasingly recognized strains that can cause metastatic infections, like liver abscesses, in healthy hosts."}],"biochemicalTests":"Gram-negative rod, non-motile, encapsulated, lactose fermenter (mucoid pink colonies on MacConkey agar), VP +, citrate +. K. oxytoca is indole +, while K. pneumoniae and K. variicola are indole –."},"clinicalProfile":{"summary":"Klebsiella species cause a variety of infections, ranging from uncomplicated UTIs to life-threatening infections of the abdomen, skin/soft tissue, lungs, and CNS in both normal and immunocompromised hosts.","pathophysiologyPearls":["There is increasing recognition of hypermucoviscous strains that can cause metastatic infections, such as liver abscesses, even in healthy hosts."],"keySignsAndSymptoms":[],"clinicalSyndromes":[{"syndromeName":"Urinary Tract Infections (UTI)","description":"Can be uncomplicated or complicated."},{"syndromeName":"Intra-abdominal Infections","description":""},{"syndromeName":"Skin and Soft Tissue Infections","description":""},{"syndromeName":"Pneumonia","description":"Infection of the lungs."},{"syndromeName":"Central Nervous System (CNS) Infections","description":"e.g., meningitis, brain abscess."},{"syndromeName":"Liver Abscess","description":"Particularly associated with hypermucoviscous strains."}],"stagesOfIllness":[],"highRiskPopulations":["Immunocompromised hosts","Healthy hosts (for infections caused by hypermucoviscous strains)"],"transmissionVectors":[],"prognosisNotes":[]},"resistanceProfile":{"groupIntrinsicResistance":[],"intrinsicResistance":[],"majorMechanisms":[{"mechanismName":"Extended-Spectrum Beta-Lactamases (ESBLs)","mechanismType":"Enzymatic Inactivation","description":"A common resistance mechanism conferring resistance to third-generation cephalosporins and aztreonam. Piperacillin-tazobactam is not recommended for serious infections caused by ESBL producers, despite potential in vitro susceptibility, due to clinical failures."},{"mechanismName":"Klebsiella pneumoniae carbapenemase (KPC)","mechanismType":"Enzymatic Inactivation","description":"A serine-based carbapenemase that confers resistance to carbapenems and most other beta-lactams."},{"mechanismName":"Metallo-beta-lactamase (MBL)","mechanismType":"Enzymatic Inactivation","description":"A type of carbapenemase that confers resistance to carbapenems and newer beta-lactamase inhibitors like ceftazidime-avibactam and meropenem-vaborbactam."},{"mechanismName":"OXA-48-like enzymes","mechanismType":"Enzymatic Inactivation","description":"A type of carbapenemase; if detected, meropenem-vaborbactam may not be effective and should be reported as resistant."}],"clinicalAlerts":[{"alertTitle":"Carbapenemase Production and Cefepime Reporting","details":"If carbapenemase production is identified in a Klebsiella isolate, any cefepime results indicating susceptibility should be suppressed or edited and reported as resistant."},{"alertTitle":"Piperacillin-Tazobactam for ESBL","details":"Piperacillin-tazobactam is not recommended for serious infections caused by ESBL-producing Klebsiella despite potential in vitro susceptibility due to risk of clinical failures."}]},"treatment":{"generalNotes":["Recommendations are for moderately severe or severe infections, especially where resistance is a concern.","For uncomplicated or less severe infections by susceptible strains, options include Amoxicillin-clavulanate, fluoroquinolones, and 2nd/3rd gen cephalosporins.","TMP-SMX is an option if the isolate is susceptible, but empiric use is limited by high rates of resistance.","Nitrofurantoin and oral Fosfomycin are options for uncomplicated UTIs."],"drugsToAvoid":[{"drugOrClass":"Piperacillin-tazobactam","condition":"Serious infections caused by ESBL-producers","reason":"Risk of clinical failure despite in vitro susceptibility."}],"adjunctiveTherapies":[],"regimens":[{"context":{"type":"Empiric","condition":"Suspected Klebsiella spp. infection","patientPopulation":["Local ESBL rate <10%"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftriaxone","dose":"2 gm","route":"IV","frequency":"q24h","comments":""},{"drugName":"Piperacillin-tazobactam","dose":"4.5 gm","route":"IV","frequency":"q8h","comments":"Infuse over 4 hours."},{"drugName":"Ciprofloxacin","dose":"400 mg","route":"IV","frequency":"bid","comments":""},{"drugName":"Levofloxacin","dose":"750 mg","route":"IV","frequency":"q24h","comments":""}]}]}]},{"context":{"type":"Empiric","condition":"Suspected Klebsiella spp. infection","patientPopulation":["Local ESBL rate >10%"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Meropenem","dose":"1-2 gm","route":"IV","frequency":"q8h","comments":""},{"drugName":"Ertapenem","dose":"1 gm","route":"IV","frequency":"q24h","comments":""}]}]}]},{"context":{"type":"Directed","condition":"Non-ESBL Producer","patientPopulation":["Susceptible to Aztreonam, Ceftriaxone, Cefotaxime, Ceftazidime, or Cefepime"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftriaxone","dose":"2 gm","route":"IV","frequency":"q24h","comments":""},{"drugName":"Piperacillin-tazobactam","dose":"4.5 gm","route":"IV","frequency":"q8h","comments":"Infuse over 4 hours."},{"drugName":"Ciprofloxacin","dose":"400 mg","route":"IV","frequency":"bid","comments":""},{"drugName":"Levofloxacin","dose":"750 mg","route":"IV","frequency":"q24h","comments":""}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Cefazolin","dose":"1 gm","route":"IV","frequency":"q8h","comments":""},{"drugName":"TMP-SMX","dose":"10 mg/kg/day (TMP component)","route":"IV/PO","frequency":"in 2-3 divided doses","comments":""},{"drugName":"Amoxicillin-clavulanate","dose":"1.2-2.4 gm","route":"IV","frequency":"q8h","comments":"Where available"}]}]}]},{"context":{"type":"Directed","condition":"ESBL Producer","patientPopulation":["Resistant to ESBL-panel antibiotics but susceptible to carbapenems"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Meropenem","dose":"1-2 gm","route":"IV","frequency":"q8h","comments":"For serious infections, consider 2 gm infused over 3 hours q8h."},{"drugName":"Imipenem","dose":"500 mg","route":"IV","frequency":"q6h","comments":""},{"drugName":"Ertapenem","dose":"1 gm","route":"IV","frequency":"q24h","comments":""}]}]},{"preference":"Carbapenem-sparing Alternative (Non-Urinary Source)","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftolozane-tazobactam","dose":"1.5 gm","route":"IV","frequency":"q8h","comments":"Administer over 3 hrs."},{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"q8h","comments":"Infused over 3 hrs."}]}]},{"preference":"Carbapenem-sparing Alternative (Urinary Tract Source)","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Temocillin","dose":"2 gm","route":"IV","frequency":"q12h","comments":"Where available."},{"drugName":"Fosfomycin IV","dose":"6 gm","route":"IV","frequency":"q8h","comments":"Infuse over 60 minutes. Where available."}]}]}]},{"context":{"type":"Directed","condition":"KPC Producer","patientPopulation":["Resistant to carbapenems but susceptible to newer beta-lactamase inhibitors"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"q8h","comments":"Infused over 3 hrs."},{"drugName":"Meropenem-vaborbactam","dose":"4 gm","route":"IV","frequency":"q8h","comments":"Infused over 3 hrs."},{"drugName":"Imipenem-cilastatin-relebactam","dose":"1.25 gm","route":"IV","frequency":"q6h","comments":"Infused over 30 min (for CrCl >90 mL/min)."}]}],"notes":["Infectious diseases consultation is strongly recommended."]}]},{"context":{"type":"Directed","condition":"MBL Producer","patientPopulation":["Resistant to carbapenems and newer beta-lactamase inhibitors"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"q8h","comments":"Infuse over 3 hours."},{"drugName":"Aztreonam","dose":"2 gm","route":"IV","frequency":"q6h","comments":"Infuse over 2 hours. Must be given with Ceftazidime-avibactam."}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Cefiderocol","dose":"2 gm","route":"IV","frequency":"q8h","comments":"Infuse over 3 hours."}]}],"notes":["Infectious diseases consultation is strongly recommended. Meropenem-vaborbactam plus Aztreonam may also be effective based on in vitro data."]}]},{"context":{"type":"Directed","condition":"Carbapenemase (MBL) Producer with Complicated UTI","patientPopulation":[],"isolateSource":"Urine"},"recommendations":[{"preference":"Salvage","strategy":"Concurrent","steps":[{"step":1,"duration":"4-7 days","drugs":[{"drugName":"Plazomicin","dose":"15 mg/kg","route":"IV","frequency":"once daily","comments":"May be an option for complicated UTI only."}]}]}]}]},"laboratoryProfile":{"testingIndications":[],"methodologyNotes":[],"recommendedPanel":[],"specialTests":[],"reportingRules":[{"ruleType":"Exception","drug":"Fosfomycin","condition":"Isolate is not E. coli from a urinary tract source.","details":"Breakpoints for Fosfomycin apply only to E. coli and should not be extrapolated to Klebsiella species."},{"ruleType":"Conditional","drug":"Cefepime","condition":"Carbapenemase production is identified.","details":"Cefepime results indicating susceptibility should be suppressed or reported as resistant."},{"ruleType":"Conditional","drug":"Meropenem-vaborbactam","condition":"An OXA-48-like gene or enzyme is detected.","details":"Results should be suppressed or reported as resistant as the isolate may not respond in vivo."},{"ruleType":"General","drug":"All","condition":"All Enterobacterales","details":"Cascade reporting protocols are followed. Results for broader-spectrum agents are typically reported only if the isolate shows resistance to primary agents."}],"antimicrobialBreakpoints":[{"tier":1,"tierDescription":"Appropriate for routine, primary testing and reporting.","agents":[{"agentName":"Ampicillin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"14–16 mm","r_breakpoint":"≤ 13 mm"},"mic":{"s_breakpoint":"≤ 8 µg/mL","i_breakpoint":"16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":["Results of ampicillin testing can predict results for amoxicillin."]}]},{"agentName":"Amoxicillin-clavulanate","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":null,"r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/4 µg/mL"},"comments":[]}]},{"agentName":"Piperacillin-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"100/10 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"21–24 mm","r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/4 µg/mL"},"comments":[]}]},{"agentName":"Gentamicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Tobramycin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"13–16 mm","r_breakpoint":"≤ 12 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Amikacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 19 mm","i_breakpoint":"17–18 mm","r_breakpoint":"≤ 16 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Ciprofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"22–25 mm","r_breakpoint":"≤ 21 mm"},"mic":{"s_breakpoint":"≤ 0.25 µg/mL","i_breakpoint":"0.5 µg/mL","r_breakpoint":"≥ 1 µg/mL"},"comments":[]}]},{"agentName":"Levofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"17–20 mm","r_breakpoint":"≤ 16 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Trimethoprim-sulfamethoxazole","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"1.25/23.75 µg","s_breakpoint":"≥ 16 mm","i_breakpoint":"11–15 mm","r_breakpoint":"≤ 10 mm"},"mic":{"s_breakpoint":"≤ 2/38 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4/76 µg/mL"},"comments":[]}]}]},{"tier":2,"tierDescription":"Appropriate for routine, primary testing, may be reported following cascade reporting rules.","agents":[{"agentName":"Cefuroxime (Parental)","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"15–22 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8–16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Cefepime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"19–24 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":["Cefepime S/SDD results should be suppressed or reported as resistant for isolates demonstrating carbapenemase production."]}]},{"agentName":"Ertapenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"19–21 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Imipenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Meropenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]}]},{"tier":3,"tierDescription":"Appropriate for high-risk Multi-Drug Resistant Organism (MDRO) patients, subject to cascade reporting.","agents":[{"agentName":"Cefiderocol","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 20 mm","i_breakpoint":"9–15 mm","r_breakpoint":"≤ 8 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Ceftazidime-avibactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/20 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":null,"r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 16/4 µg/mL"},"comments":["Confirmatory MIC testing is indicated for isolates with disk diffusion zones of 20–22 mm."]}]},{"agentName":"Imipenem-relebactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10/25 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"21–24 mm","r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 1/4 µg/mL","i_breakpoint":"2/4 µg/mL","r_breakpoint":"≥ 4/4 µg/mL"},"comments":["These breakpoints apply to Klebsiella species as they are Enterobacterales but not Morganellaceae."]}]},{"agentName":"Meropenem-vaborbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4/8 µg/mL","i_breakpoint":"8/8 µg/mL","r_breakpoint":"≥ 16/8 µg/mL"},"comments":["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]},{"agentName":"Plazomicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 2 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]}]},{"tier":4,"tierDescription":"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.","agents":[{"agentName":"Aztreonam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"18–20 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":[]}]},{"agentName":"Ceftriaxone","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Ceftazidime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"18–20 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 8 µg/mL","i_breakpoint":"16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Ceftolozane-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"19–21 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 2/4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4/4 µg/mL"},"comments":[]}]},{"agentName":"Colistin or Polymyxin B","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":null,"s_breakpoint":null,"i_breakpoint":null,"r_breakpoint":null},"mic":{"s_breakpoint":"≤ 2 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4 µg/mL"},"comments":["Disk diffusion and gradient diffusion methods should not be performed for these agents."]}]}]},{"tier":5,"tierDescription":"Urine Only Tier","agents":[{"agentName":"Cefazolin","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 15 mm","i_breakpoint":null,"r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 32 µg/mL"},"comments":["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},{"agentName":"Nitrofurantoin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"300 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"15–16 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 32 µg/mL","i_breakpoint":"64 µg/mL","r_breakpoint":"≥ 128 µg/mL"},"comments":[]}]},{"agentName":"Fosfomycin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"200 µg","s_breakpoint":"≥ 16 mm","i_breakpoint":"13–15 mm","r_breakpoint":"≤ 12 mm"},"mic":{"s_breakpoint":"≤ 64 µg/mL","i_breakpoint":"128 µg/mL","r_breakpoint":"≥ 256 µg/mL"},"comments":["Important Note: Disk diffusion and MIC breakpoints for Fosfomycin apply only to E. coli urinary tract isolates and should not be extrapolated to other Enterobacterales species, including Klebsiella."]}]}]}]},"additionalInformation":{"diagnosticNotes":{"summary":"","biosafetyWarning":"","methods":[]},"preventionAndScreening":[],"treatmentLifecycle":[],"antimicrobialStewardship":["Reserve carbapenems for ESBL-producing strains or for mixed anaerobic/aerobic infections.","Reserve Ceftazidime-avibactam, Imipenem-relebactam, and Meropenem-vaborbactam for documented carbapenemase-producing infections."],"drugSpecificPearls":[{"drugName":"Ceftazidime-avibactam + Aztreonam","pearl":"This combination is recommended for metallo-beta-lactamase (MBL) producers because Aztreonam is not hydrolyzed by MBLs, and avibactam protects Aztreonam from other co-produced beta-lactamases like ESBLs or AmpC."},{"drugName":"Cefiderocol","pearl":"FDA-approved for complicated UTIs with limited alternatives. In a key trial, 28-day mortality was not statistically different between cefiderocol and the best available therapy."},{"drugName":"Ceftazidime-avibactam","pearl":"An observational study showed this drug was superior to Colistin for treating carbapenem-resistant Enterobacterales infections."},{"drugName":"Meropenem + Polymyxin","pearl":"Combination therapy with Meropenem plus a polymyxin is not recommended for KPC producers based on a failed RCT, though the trial was underpowered for Enterobacterales."}],"guidelineReferences":[]}}'),D_={originalKeys:["identity","clinicalProfile","resistanceProfile","treatment","laboratoryProfile","additionalInformation"],conversionTimestamp:"2025-07-15T03:16:49.285Z",sourceFormat:"modern"},q_={bacteriumName:{sources:["identity.bacteriumName"],value:"Klebsiella species (oxytoca, pneumoniae, variicola)"},aliases:{sources:["identity.aliases"],value:["Klebsiella oxytoca","Klebsiella pneumoniae","Klebsiella variicola"]},lastUpdated:{sources:["identity.lastUpdated"],value:"2025-01-08"},classification:{sources:["identity.classification"],value:{gramStain:"Gram-negative",morphology:"Bacilli",respiration:"Facultative anaerobe",notes:["Fermentative"]}}},T_={sources:["clinicalProfile"],value:{summary:"Klebsiella species cause a variety of infections, ranging from uncomplicated UTIs to life-threatening infections of the abdomen, skin/soft tissue, lungs, and CNS in both normal and immunocompromised hosts.",pathophysiologyPearls:["There is increasing recognition of hypermucoviscous strains that can cause metastatic infections, such as liver abscesses, even in healthy hosts."],keySignsAndSymptoms:[],clinicalSyndromes:[{syndromeName:"Urinary Tract Infections (UTI)",description:"Can be uncomplicated or complicated."},{syndromeName:"Intra-abdominal Infections",description:""},{syndromeName:"Skin and Soft Tissue Infections",description:""},{syndromeName:"Pneumonia",description:"Infection of the lungs."},{syndromeName:"Central Nervous System (CNS) Infections",description:"e.g., meningitis, brain abscess."},{syndromeName:"Liver Abscess",description:"Particularly associated with hypermucoviscous strains."}],stagesOfIllness:[],highRiskPopulations:["Immunocompromised hosts","Healthy hosts (for infections caused by hypermucoviscous strains)"],transmissionVectors:[],prognosisNotes:[]}},E_={sources:["resistanceProfile"],value:{groupIntrinsicResistance:[],intrinsicResistance:[],majorMechanisms:[{mechanismName:"Extended-Spectrum Beta-Lactamases (ESBLs)",mechanismType:"Enzymatic Inactivation",description:"A common resistance mechanism conferring resistance to third-generation cephalosporins and aztreonam. Piperacillin-tazobactam is not recommended for serious infections caused by ESBL producers, despite potential in vitro susceptibility, due to clinical failures."},{mechanismName:"Klebsiella pneumoniae carbapenemase (KPC)",mechanismType:"Enzymatic Inactivation",description:"A serine-based carbapenemase that confers resistance to carbapenems and most other beta-lactams."},{mechanismName:"Metallo-beta-lactamase (MBL)",mechanismType:"Enzymatic Inactivation",description:"A type of carbapenemase that confers resistance to carbapenems and newer beta-lactamase inhibitors like ceftazidime-avibactam and meropenem-vaborbactam."},{mechanismName:"OXA-48-like enzymes",mechanismType:"Enzymatic Inactivation",description:"A type of carbapenemase; if detected, meropenem-vaborbactam may not be effective and should be reported as resistant."}],clinicalAlerts:[{alertTitle:"Carbapenemase Production and Cefepime Reporting",details:"If carbapenemase production is identified in a Klebsiella isolate, any cefepime results indicating susceptibility should be suppressed or edited and reported as resistant."},{alertTitle:"Piperacillin-Tazobactam for ESBL",details:"Piperacillin-tazobactam is not recommended for serious infections caused by ESBL-producing Klebsiella despite potential in vitro susceptibility due to risk of clinical failures."}]}},P_={treatmentData:{_treatmentMetadata:{originalFormat:"modern"},standardizedRegimens:[{regimenId:"modern-0-0-0",extractedFrom:"treatment.regimens[0].recommendations[0].steps[0]",context:{type:"empiric",condition:"Suspected Klebsiella spp. infection",severity:"unknown",patientFactors:{population:["Local ESBL rate <10%"],labFindings:null}},preference:"primary",drugs:[{drugName:"Ceftriaxone",dose:"2 gm",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Ceftriaxone 2 gm IV q24h"},{drugName:"Piperacillin-tazobactam",dose:"4.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infuse over 4 hours.",originalText:"Piperacillin-tazobactam 4.5 gm IV q8h"},{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"bid",duration:"Variable",comments:"",originalText:"Ciprofloxacin 400 mg IV bid"},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Levofloxacin 750 mg IV q24h"}]},{regimenId:"modern-1-0-0",extractedFrom:"treatment.regimens[1].recommendations[0].steps[0]",context:{type:"empiric",condition:"Suspected Klebsiella spp. infection",severity:"unknown",patientFactors:{population:["Local ESBL rate >10%"],labFindings:null}},preference:"primary",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"",originalText:"Meropenem 1-2 gm IV q8h"},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Ertapenem 1 gm IV q24h"}]},{regimenId:"modern-2-0-0",extractedFrom:"treatment.regimens[2].recommendations[0].steps[0]",context:{type:"directed",condition:"Non-ESBL Producer",severity:"unknown",patientFactors:{population:["Susceptible to Aztreonam, Ceftriaxone, Cefotaxime, Ceftazidime, or Cefepime"],labFindings:null}},preference:"primary",drugs:[{drugName:"Ceftriaxone",dose:"2 gm",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Ceftriaxone 2 gm IV q24h"},{drugName:"Piperacillin-tazobactam",dose:"4.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infuse over 4 hours.",originalText:"Piperacillin-tazobactam 4.5 gm IV q8h"},{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"bid",duration:"Variable",comments:"",originalText:"Ciprofloxacin 400 mg IV bid"},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Levofloxacin 750 mg IV q24h"}]},{regimenId:"modern-2-1-0",extractedFrom:"treatment.regimens[2].recommendations[1].steps[0]",context:{type:"directed",condition:"Non-ESBL Producer",severity:"unknown",patientFactors:{population:["Susceptible to Aztreonam, Ceftriaxone, Cefotaxime, Ceftazidime, or Cefepime"],labFindings:null}},preference:"alternative",drugs:[{drugName:"Cefazolin",dose:"1 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"",originalText:"Cefazolin 1 gm IV q8h"},{drugName:"TMP-SMX",dose:"10 mg/kg/day (TMP component)",route:"IV/PO",frequency:"in 2-3 divided doses",duration:"Variable",comments:"",originalText:"TMP-SMX 10 mg/kg/day (TMP component) IV/PO in 2-3 divided doses"},{drugName:"Amoxicillin-clavulanate",dose:"1.2-2.4 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Where available",originalText:"Amoxicillin-clavulanate 1.2-2.4 gm IV q8h"}]},{regimenId:"modern-3-0-0",extractedFrom:"treatment.regimens[3].recommendations[0].steps[0]",context:{type:"directed",condition:"ESBL Producer",severity:"unknown",patientFactors:{population:["Resistant to ESBL-panel antibiotics but susceptible to carbapenems"],labFindings:null}},preference:"primary",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"For serious infections, consider 2 gm infused over 3 hours q8h.",originalText:"Meropenem 1-2 gm IV q8h"},{drugName:"Imipenem",dose:"500 mg",route:"IV",frequency:"q6h",duration:"Variable",comments:"",originalText:"Imipenem 500 mg IV q6h"},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Ertapenem 1 gm IV q24h"}]},{regimenId:"modern-3-1-0",extractedFrom:"treatment.regimens[3].recommendations[1].steps[0]",context:{type:"directed",condition:"ESBL Producer",severity:"unknown",patientFactors:{population:["Resistant to ESBL-panel antibiotics but susceptible to carbapenems"],labFindings:null}},preference:"carbapenem-sparing alternative (non-urinary source)",drugs:[{drugName:"Ceftolozane-tazobactam",dose:"1.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Administer over 3 hrs.",originalText:"Ceftolozane-tazobactam 1.5 gm IV q8h"},{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infused over 3 hrs.",originalText:"Ceftazidime-avibactam 2.5 gm IV q8h"}]},{regimenId:"modern-3-2-0",extractedFrom:"treatment.regimens[3].recommendations[2].steps[0]",context:{type:"directed",condition:"ESBL Producer",severity:"unknown",patientFactors:{population:["Resistant to ESBL-panel antibiotics but susceptible to carbapenems"],labFindings:null}},preference:"carbapenem-sparing alternative (urinary tract source)",drugs:[{drugName:"Temocillin",dose:"2 gm",route:"IV",frequency:"q12h",duration:"Variable",comments:"Where available.",originalText:"Temocillin 2 gm IV q12h"},{drugName:"Fosfomycin IV",dose:"6 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infuse over 60 minutes. Where available.",originalText:"Fosfomycin IV 6 gm IV q8h"}]},{regimenId:"modern-4-0-0",extractedFrom:"treatment.regimens[4].recommendations[0].steps[0]",context:{type:"directed",condition:"KPC Producer",severity:"unknown",patientFactors:{population:["Resistant to carbapenems but susceptible to newer beta-lactamase inhibitors"],labFindings:null}},preference:"primary",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infused over 3 hrs.",originalText:"Ceftazidime-avibactam 2.5 gm IV q8h"},{drugName:"Meropenem-vaborbactam",dose:"4 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infused over 3 hrs.",originalText:"Meropenem-vaborbactam 4 gm IV q8h"},{drugName:"Imipenem-cilastatin-relebactam",dose:"1.25 gm",route:"IV",frequency:"q6h",duration:"Variable",comments:"Infused over 30 min (for CrCl >90 mL/min).",originalText:"Imipenem-cilastatin-relebactam 1.25 gm IV q6h"}]},{regimenId:"modern-5-0-0",extractedFrom:"treatment.regimens[5].recommendations[0].steps[0]",context:{type:"directed",condition:"MBL Producer",severity:"unknown",patientFactors:{population:["Resistant to carbapenems and newer beta-lactamase inhibitors"],labFindings:null}},preference:"primary",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infuse over 3 hours.",originalText:"Ceftazidime-avibactam 2.5 gm IV q8h"},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q6h",duration:"Variable",comments:"Infuse over 2 hours. Must be given with Ceftazidime-avibactam.",originalText:"Aztreonam 2 gm IV q6h"}]},{regimenId:"modern-5-1-0",extractedFrom:"treatment.regimens[5].recommendations[1].steps[0]",context:{type:"directed",condition:"MBL Producer",severity:"unknown",patientFactors:{population:["Resistant to carbapenems and newer beta-lactamase inhibitors"],labFindings:null}},preference:"alternative",drugs:[{drugName:"Cefiderocol",dose:"2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infuse over 3 hours.",originalText:"Cefiderocol 2 gm IV q8h"}]},{regimenId:"modern-6-0-0",extractedFrom:"treatment.regimens[6].recommendations[0].steps[0]",context:{type:"directed",condition:"Carbapenemase (MBL) Producer with Complicated UTI",severity:"unknown",patientFactors:{population:[],labFindings:"Urine"}},preference:"salvage",drugs:[{drugName:"Plazomicin",dose:"15 mg/kg",route:"IV",frequency:"once daily",duration:"4-7 days",comments:"May be an option for complicated UTI only.",originalText:"Plazomicin 15 mg/kg IV once daily"}]}]}},L_=JSON.parse('{"sources":["laboratoryProfile"],"value":{"testingIndications":[],"methodologyNotes":[],"recommendedPanel":[],"specialTests":[],"reportingRules":[{"ruleType":"Exception","drug":"Fosfomycin","condition":"Isolate is not E. coli from a urinary tract source.","details":"Breakpoints for Fosfomycin apply only to E. coli and should not be extrapolated to Klebsiella species."},{"ruleType":"Conditional","drug":"Cefepime","condition":"Carbapenemase production is identified.","details":"Cefepime results indicating susceptibility should be suppressed or reported as resistant."},{"ruleType":"Conditional","drug":"Meropenem-vaborbactam","condition":"An OXA-48-like gene or enzyme is detected.","details":"Results should be suppressed or reported as resistant as the isolate may not respond in vivo."},{"ruleType":"General","drug":"All","condition":"All Enterobacterales","details":"Cascade reporting protocols are followed. Results for broader-spectrum agents are typically reported only if the isolate shows resistance to primary agents."}],"antimicrobialBreakpoints":[{"tier":1,"tierDescription":"Appropriate for routine, primary testing and reporting.","agents":[{"agentName":"Ampicillin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"14–16 mm","r_breakpoint":"≤ 13 mm"},"mic":{"s_breakpoint":"≤ 8 µg/mL","i_breakpoint":"16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":["Results of ampicillin testing can predict results for amoxicillin."]}]},{"agentName":"Amoxicillin-clavulanate","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":null,"r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/4 µg/mL"},"comments":[]}]},{"agentName":"Piperacillin-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"100/10 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"21–24 mm","r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/4 µg/mL"},"comments":[]}]},{"agentName":"Gentamicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Tobramycin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"13–16 mm","r_breakpoint":"≤ 12 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Amikacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 19 mm","i_breakpoint":"17–18 mm","r_breakpoint":"≤ 16 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Ciprofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"22–25 mm","r_breakpoint":"≤ 21 mm"},"mic":{"s_breakpoint":"≤ 0.25 µg/mL","i_breakpoint":"0.5 µg/mL","r_breakpoint":"≥ 1 µg/mL"},"comments":[]}]},{"agentName":"Levofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"17–20 mm","r_breakpoint":"≤ 16 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Trimethoprim-sulfamethoxazole","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"1.25/23.75 µg","s_breakpoint":"≥ 16 mm","i_breakpoint":"11–15 mm","r_breakpoint":"≤ 10 mm"},"mic":{"s_breakpoint":"≤ 2/38 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4/76 µg/mL"},"comments":[]}]}]},{"tier":2,"tierDescription":"Appropriate for routine, primary testing, may be reported following cascade reporting rules.","agents":[{"agentName":"Cefuroxime (Parental)","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"15–22 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8–16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Cefepime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"19–24 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":["Cefepime S/SDD results should be suppressed or reported as resistant for isolates demonstrating carbapenemase production."]}]},{"agentName":"Ertapenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"19–21 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Imipenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Meropenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]}]},{"tier":3,"tierDescription":"Appropriate for high-risk Multi-Drug Resistant Organism (MDRO) patients, subject to cascade reporting.","agents":[{"agentName":"Cefiderocol","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 20 mm","i_breakpoint":"9–15 mm","r_breakpoint":"≤ 8 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Ceftazidime-avibactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/20 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":null,"r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 16/4 µg/mL"},"comments":["Confirmatory MIC testing is indicated for isolates with disk diffusion zones of 20–22 mm."]}]},{"agentName":"Imipenem-relebactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10/25 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"21–24 mm","r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 1/4 µg/mL","i_breakpoint":"2/4 µg/mL","r_breakpoint":"≥ 4/4 µg/mL"},"comments":["These breakpoints apply to Klebsiella species as they are Enterobacterales but not Morganellaceae."]}]},{"agentName":"Meropenem-vaborbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4/8 µg/mL","i_breakpoint":"8/8 µg/mL","r_breakpoint":"≥ 16/8 µg/mL"},"comments":["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]},{"agentName":"Plazomicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 2 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]}]},{"tier":4,"tierDescription":"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.","agents":[{"agentName":"Aztreonam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"18–20 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":[]}]},{"agentName":"Ceftriaxone","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Ceftazidime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"18–20 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 8 µg/mL","i_breakpoint":"16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Ceftolozane-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"19–21 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 2/4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4/4 µg/mL"},"comments":[]}]},{"agentName":"Colistin or Polymyxin B","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":null,"s_breakpoint":null,"i_breakpoint":null,"r_breakpoint":null},"mic":{"s_breakpoint":"≤ 2 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4 µg/mL"},"comments":["Disk diffusion and gradient diffusion methods should not be performed for these agents."]}]}]},{"tier":5,"tierDescription":"Urine Only Tier","agents":[{"agentName":"Cefazolin","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 15 mm","i_breakpoint":null,"r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 32 µg/mL"},"comments":["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},{"agentName":"Nitrofurantoin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"300 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"15–16 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 32 µg/mL","i_breakpoint":"64 µg/mL","r_breakpoint":"≥ 128 µg/mL"},"comments":[]}]},{"agentName":"Fosfomycin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"200 µg","s_breakpoint":"≥ 16 mm","i_breakpoint":"13–15 mm","r_breakpoint":"≤ 12 mm"},"mic":{"s_breakpoint":"≤ 64 µg/mL","i_breakpoint":"128 µg/mL","r_breakpoint":"≥ 256 µg/mL"},"comments":["Important Note: Disk diffusion and MIC breakpoints for Fosfomycin apply only to E. coli urinary tract isolates and should not be extrapolated to other Enterobacterales species, including Klebsiella."]}]}]}]}}'),z_={antimicrobialStewardship:{sources:["antimicrobial_stewardship","antimicrobialStewardship"],value:[]},comments:{preservedStructure:{originalFormat:"object"}},diagnosis:{sources:["diagnosis"],value:[]},allOtherKeys:{}},V_={_originalData:M_,_metadata:D_,identity:q_,clinicalInformation:T_,resistanceInformation:E_,treatmentData:P_,laboratoryData:L_,additionalData:z_},O_={identity:{bacteriumName:"Klebsiella sp. (rhinoscleromatis, ozaenae)",aliases:["Klebsiella rhinoscleromatis/ozaenae"],lastUpdated:"2024-09-09",clsiCategory:"Enterobacterales (excluding Salmonella/Shigella)",classification:{gramStain:"Gram-negative",morphology:"rod",respiration:"Facultative anaerobe",notes:["non-motile","encapsulated","Biochemically very inert compared to Klebsiella pneumoniae"]},strainDetails:[{type:"Subspecies",value:"Klebsiella rhinoscleromatis",notes:"Causative agent of Rhinoscleroma."},{type:"Subspecies",value:"Klebsiella ozaenae",notes:"Associated with Ozena (atrophic rhinitis)."}],biochemicalTests:"Gram-negative rod, non-motile, encapsulated. Biochemically very inert compared to K. pneumoniae. Typically indole –, citrate –, urease –, lysine –."},clinicalProfile:{summary:"Causes two main chronic granulomatous diseases of the upper respiratory tract. Rhinoscleroma is a progressive disease more common in specific geographic regions (Africa, Eastern Europe, South America, Southeast Asia) and presents with purulent nasal discharge and nodule formation leading to obstruction. Ozena, or chronic atrophic rhinitis, typically affects elderly patients and presents with a classic triad of fetid nasal discharge, crusting, and nasal atrophy.",pathophysiologyPearls:[],keySignsAndSymptoms:[],clinicalSyndromes:[{syndromeName:"Rhinoscleroma",description:"A chronic granulomatous disease of the upper respiratory tract, presenting with purulent nasal discharge and nodule formation with obstruction."},{syndromeName:"Ozena (Atrophic Rhinitis)",description:"Chronic atrophic rhinitis or sinusitis, characterized by a triad of fetid nasal discharge, crusting, and atrophy. K. ozaenae is often isolated from affected patients."}],stagesOfIllness:[],highRiskPopulations:["Individuals in or from Africa, Eastern Europe, South America, and Southeast Asia (for Rhinoscleroma)","Elderly patients (for Ozena)"],transmissionVectors:[],prognosisNotes:["Relapses can occur in Rhinoscleroma, even after prolonged treatment.","The causative role of K. ozaenae in ozena is controversial."]},resistanceProfile:{groupIntrinsicResistance:[{drugOrClass:"Ampicillin",notes:"Most Klebsiella species possess a chromosomal SHV-1 β-lactamase conferring intrinsic resistance to ampicillin, amoxicillin, ticarcillin, and carbenicillin."}],intrinsicResistance:[],majorMechanisms:[],clinicalAlerts:[{alertTitle:"Potential for Relapse",details:"Relapses can occur in Rhinoscleroma even after a long course of antibiotic therapy."}]},treatment:{generalNotes:["For Ozena, the role of infection is controversial. Topical moistening agents and nasal irrigation are recommended as initial therapy, with antibiotics reserved for documented superinfection."],drugsToAvoid:[],adjunctiveTherapies:[],regimens:[{context:{type:"Directed",condition:"Rhinoscleroma",patientPopulation:["Adults"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Monotherapy",steps:[{step:1,duration:"2-3 months",drugs:[{drugName:"Ciprofloxacin",dose:"750 mg",route:"po",frequency:"bid",comments:null}]}],notes:[]},{preference:"Primary",strategy:"Monotherapy",steps:[{step:1,duration:"2-3 months",drugs:[{drugName:"Levofloxacin",dose:"750 mg",route:"po",frequency:"once daily",comments:null}]}],notes:["Relapses can occur after treatment is complete."]}]},{context:{type:"Directed",condition:"Ozena (for superinfection)",patientPopulation:["Elderly Patients"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Monotherapy",steps:[{step:1,duration:"8 weeks",drugs:[{drugName:"Ciprofloxacin",dose:"750 mg",route:"po",frequency:"bid",comments:null}]}],notes:[]},{preference:"Primary",strategy:"Monotherapy",steps:[{step:1,duration:"8 weeks",drugs:[{drugName:"Levofloxacin",dose:"750 mg",route:"po",frequency:"once daily",comments:null}]}],notes:["The role of infection in ozena is controversial; topical moistening agents are recommended as initial therapy, with antibiotics reserved for superinfection."]}]}]},laboratoryProfile:{testingIndications:["Isolation of the organism via culture from nasal specimens is required for diagnosis.","For Rhinoscleroma, histological examination of biopsy specimens is crucial to identify characteristic Mikulicz cells."],methodologyNotes:[],recommendedPanel:[],specialTests:[],reportingRules:[],antimicrobialBreakpoints:[{tier:1,tierDescription:"Appropriate for routine, primary testing and reporting.",agents:[{agentName:"Ampicillin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 17 mm",i_breakpoint:"14–16 mm",r_breakpoint:"≤ 13 mm"},mic:{s_breakpoint:"≤ 8 µg/mL",i_breakpoint:"16 µg/mL",r_breakpoint:"≥ 32 µg/mL"},comments:["Results of ampicillin testing can be used to predict results for amoxicillin."]}]},{agentName:"Cefazolin",breakpointSets:[{condition:"Urine Only - Uncomplicated UTI",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 15 mm",i_breakpoint:null,r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 16 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 32 µg/mL"},comments:["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},{agentName:"Amoxicillin-clavulanate",breakpointSets:[{condition:"Urine Only - Uncomplicated UTI",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:null,r_breakpoint:"≤ 17 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:"16/4 µg/mL",r_breakpoint:"≥ 32/4 µg/mL"},comments:[]}]},{agentName:"Piperacillin-tazobactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"100/10 µg",s_breakpoint:"≥ 25 mm",i_breakpoint:"21–24 mm",r_breakpoint:"≤ 20 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:"16/4 µg/mL",r_breakpoint:"≥ 32/4 µg/mL"},comments:[]}]}]},{tier:2,tierDescription:"Appropriate for routine, primary testing, may be reported following cascade reporting rules.",agents:[{agentName:"Cefepime",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 25 mm",i_breakpoint:"19–24 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"8 µg/mL",r_breakpoint:"≥ 16 µg/mL"},comments:["Cefepime S/SDD results should be suppressed or reported as resistant for isolates that demonstrate carbapenemase production."]}]},{agentName:"Ertapenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 22 mm",i_breakpoint:"19–21 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 0.5 µg/mL",i_breakpoint:"1 µg/mL",r_breakpoint:"≥ 2 µg/mL"},comments:[]}]},{agentName:"Meropenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 23 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]}]},{tier:3,tierDescription:"Appropriate for high-risk MDRO patients, subject to cascade reporting.",agents:[{agentName:"Ceftazidime-avibactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30/20 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:null,r_breakpoint:"≤ 20 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 16/4 µg/mL"},comments:["Confirmatory MIC testing is indicated for isolates with zones of 20–22 mm."]}]},{agentName:"Meropenem-vaborbactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:"15–17 mm",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 4/8 µg/mL",i_breakpoint:"8/8 µg/mL",r_breakpoint:"≥ 16/8 µg/mL"},comments:["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]}]},{tier:4,tierDescription:"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.",agents:[{agentName:"Aztreonam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"18–20 mm",r_breakpoint:"≤ 17 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"8 µg/mL",r_breakpoint:"≥ 16 µg/mL"},comments:[]}]},{agentName:"Ceftriaxone",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 26 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]},{agentName:"Colistin or Polymyxin B",breakpointSets:[{condition:"Standard",diskDiffusion:null,mic:{s_breakpoint:"≤ 2 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 4 µg/mL"},comments:["Disk diffusion and gradient diffusion methods should not be performed."]}]}]}]},additionalInformation:{diagnosticNotes:{summary:"Diagnosis is confirmed by isolation of the organism via culture from the upper respiratory tract. For Rhinoscleroma, histopathology showing Mikulicz cells is characteristic.",biosafetyWarning:null,methods:[{methodName:"Culture",details:"Isolation from purulent nasal discharge or tissue biopsy."},{methodName:"Histology",details:"For Rhinoscleroma, biopsy showing chronic granulomatous inflammation with numerous plasma cells and characteristic large vacuolated macrophages (Mikulicz cells) containing the bacteria."}]},preventionAndScreening:[],treatmentLifecycle:[],antimicrobialStewardship:["In cases of Ozena, antibiotics should be reserved for superinfection. Initial therapy should focus on topical moistening agents and nasal irrigation to manage crusting and atrophy."],drugSpecificPearls:[],guidelineReferences:[]}},B_={originalKeys:["identity","clinicalProfile","resistanceProfile","treatment","laboratoryProfile","additionalInformation"],conversionTimestamp:"2025-07-15T03:16:49.290Z",sourceFormat:"modern"},U_={bacteriumName:{sources:["identity.bacteriumName"],value:"Klebsiella sp. (rhinoscleromatis, ozaenae)"},aliases:{sources:["identity.aliases"],value:["Klebsiella rhinoscleromatis/ozaenae"]},lastUpdated:{sources:["identity.lastUpdated"],value:"2024-09-09"},classification:{sources:["identity.classification"],value:{gramStain:"Gram-negative",morphology:"rod",respiration:"Facultative anaerobe",notes:["non-motile","encapsulated","Biochemically very inert compared to Klebsiella pneumoniae"]}}},F_={sources:["clinicalProfile"],value:{summary:"Causes two main chronic granulomatous diseases of the upper respiratory tract. Rhinoscleroma is a progressive disease more common in specific geographic regions (Africa, Eastern Europe, South America, Southeast Asia) and presents with purulent nasal discharge and nodule formation leading to obstruction. Ozena, or chronic atrophic rhinitis, typically affects elderly patients and presents with a classic triad of fetid nasal discharge, crusting, and nasal atrophy.",pathophysiologyPearls:[],keySignsAndSymptoms:[],clinicalSyndromes:[{syndromeName:"Rhinoscleroma",description:"A chronic granulomatous disease of the upper respiratory tract, presenting with purulent nasal discharge and nodule formation with obstruction."},{syndromeName:"Ozena (Atrophic Rhinitis)",description:"Chronic atrophic rhinitis or sinusitis, characterized by a triad of fetid nasal discharge, crusting, and atrophy. K. ozaenae is often isolated from affected patients."}],stagesOfIllness:[],highRiskPopulations:["Individuals in or from Africa, Eastern Europe, South America, and Southeast Asia (for Rhinoscleroma)","Elderly patients (for Ozena)"],transmissionVectors:[],prognosisNotes:["Relapses can occur in Rhinoscleroma, even after prolonged treatment.","The causative role of K. ozaenae in ozena is controversial."]}},G_={sources:["resistanceProfile"],value:{groupIntrinsicResistance:[{drugOrClass:"Ampicillin",notes:"Most Klebsiella species possess a chromosomal SHV-1 β-lactamase conferring intrinsic resistance to ampicillin, amoxicillin, ticarcillin, and carbenicillin."}],intrinsicResistance:[],majorMechanisms:[],clinicalAlerts:[{alertTitle:"Potential for Relapse",details:"Relapses can occur in Rhinoscleroma even after a long course of antibiotic therapy."}]}},H_={treatmentData:{_treatmentMetadata:{originalFormat:"modern"},standardizedRegimens:[{regimenId:"modern-0-0-0",extractedFrom:"treatment.regimens[0].recommendations[0].steps[0]",context:{type:"directed",condition:"Rhinoscleroma",severity:"unknown",patientFactors:{population:["Adults"],labFindings:null}},preference:"primary",drugs:[{drugName:"Ciprofloxacin",dose:"750 mg",route:"po",frequency:"bid",duration:"2-3 months",comments:null,originalText:"Ciprofloxacin 750 mg po bid"}]},{regimenId:"modern-0-1-0",extractedFrom:"treatment.regimens[0].recommendations[1].steps[0]",context:{type:"directed",condition:"Rhinoscleroma",severity:"unknown",patientFactors:{population:["Adults"],labFindings:null}},preference:"primary",drugs:[{drugName:"Levofloxacin",dose:"750 mg",route:"po",frequency:"once daily",duration:"2-3 months",comments:null,originalText:"Levofloxacin 750 mg po once daily"}]},{regimenId:"modern-1-0-0",extractedFrom:"treatment.regimens[1].recommendations[0].steps[0]",context:{type:"directed",condition:"Ozena (for superinfection)",severity:"unknown",patientFactors:{population:["Elderly Patients"],labFindings:null}},preference:"primary",drugs:[{drugName:"Ciprofloxacin",dose:"750 mg",route:"po",frequency:"bid",duration:"8 weeks",comments:null,originalText:"Ciprofloxacin 750 mg po bid"}]},{regimenId:"modern-1-1-0",extractedFrom:"treatment.regimens[1].recommendations[1].steps[0]",context:{type:"directed",condition:"Ozena (for superinfection)",severity:"unknown",patientFactors:{population:["Elderly Patients"],labFindings:null}},preference:"primary",drugs:[{drugName:"Levofloxacin",dose:"750 mg",route:"po",frequency:"once daily",duration:"8 weeks",comments:null,originalText:"Levofloxacin 750 mg po once daily"}]}]}},K_={sources:["laboratoryProfile"],value:{testingIndications:["Isolation of the organism via culture from nasal specimens is required for diagnosis.","For Rhinoscleroma, histological examination of biopsy specimens is crucial to identify characteristic Mikulicz cells."],methodologyNotes:[],recommendedPanel:[],specialTests:[],reportingRules:[],antimicrobialBreakpoints:[{tier:1,tierDescription:"Appropriate for routine, primary testing and reporting.",agents:[{agentName:"Ampicillin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 17 mm",i_breakpoint:"14–16 mm",r_breakpoint:"≤ 13 mm"},mic:{s_breakpoint:"≤ 8 µg/mL",i_breakpoint:"16 µg/mL",r_breakpoint:"≥ 32 µg/mL"},comments:["Results of ampicillin testing can be used to predict results for amoxicillin."]}]},{agentName:"Cefazolin",breakpointSets:[{condition:"Urine Only - Uncomplicated UTI",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 15 mm",i_breakpoint:null,r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 16 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 32 µg/mL"},comments:["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},{agentName:"Amoxicillin-clavulanate",breakpointSets:[{condition:"Urine Only - Uncomplicated UTI",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:null,r_breakpoint:"≤ 17 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:"16/4 µg/mL",r_breakpoint:"≥ 32/4 µg/mL"},comments:[]}]},{agentName:"Piperacillin-tazobactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"100/10 µg",s_breakpoint:"≥ 25 mm",i_breakpoint:"21–24 mm",r_breakpoint:"≤ 20 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:"16/4 µg/mL",r_breakpoint:"≥ 32/4 µg/mL"},comments:[]}]}]},{tier:2,tierDescription:"Appropriate for routine, primary testing, may be reported following cascade reporting rules.",agents:[{agentName:"Cefepime",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 25 mm",i_breakpoint:"19–24 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"8 µg/mL",r_breakpoint:"≥ 16 µg/mL"},comments:["Cefepime S/SDD results should be suppressed or reported as resistant for isolates that demonstrate carbapenemase production."]}]},{agentName:"Ertapenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 22 mm",i_breakpoint:"19–21 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 0.5 µg/mL",i_breakpoint:"1 µg/mL",r_breakpoint:"≥ 2 µg/mL"},comments:[]}]},{agentName:"Meropenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 23 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]}]},{tier:3,tierDescription:"Appropriate for high-risk MDRO patients, subject to cascade reporting.",agents:[{agentName:"Ceftazidime-avibactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30/20 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:null,r_breakpoint:"≤ 20 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 16/4 µg/mL"},comments:["Confirmatory MIC testing is indicated for isolates with zones of 20–22 mm."]}]},{agentName:"Meropenem-vaborbactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:"15–17 mm",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 4/8 µg/mL",i_breakpoint:"8/8 µg/mL",r_breakpoint:"≥ 16/8 µg/mL"},comments:["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]}]},{tier:4,tierDescription:"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.",agents:[{agentName:"Aztreonam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"18–20 mm",r_breakpoint:"≤ 17 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"8 µg/mL",r_breakpoint:"≥ 16 µg/mL"},comments:[]}]},{agentName:"Ceftriaxone",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 26 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]},{agentName:"Colistin or Polymyxin B",breakpointSets:[{condition:"Standard",diskDiffusion:null,mic:{s_breakpoint:"≤ 2 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 4 µg/mL"},comments:["Disk diffusion and gradient diffusion methods should not be performed."]}]}]}]}},Y_={antimicrobialStewardship:{sources:["antimicrobial_stewardship","antimicrobialStewardship"],value:[]},comments:{preservedStructure:{originalFormat:"object"}},diagnosis:{sources:["diagnosis"],value:[]},allOtherKeys:{}},X_={_originalData:O_,_metadata:B_,identity:U_,clinicalInformation:F_,resistanceInformation:G_,treatmentData:H_,laboratoryData:K_,additionalData:Y_},$_=JSON.parse(`{"identity":{"bacteriumName":"Morganella morganii","aliases":["Morganella sp."],"lastUpdated":"2025-01-17","clsiCategory":"Enterobacterales (excluding Salmonella/Shigella)","classification":{"gramStain":"Gram negative","morphology":"Bacilli","respiration":"Facultative anaerobe","notes":["Enteric bacterium."]},"strainDetails":[],"biochemicalTests":"Gram-negative rod, motile, lactose –, H2S –, indole +, citrate –, urease +, phenylalanine deaminase +, ornithine decarboxylase +."},"clinicalProfile":{"summary":"Morganella morganii can cause various infections, but it is most commonly identified as the cause of urinary tract and post-operative wound infections. It is typically a nosocomial pathogen.","pathophysiologyPearls":["Like other SPACE-M organisms, M. morganii may initially test susceptible to third-generation cephalosporins but can become resistant during therapy due to derepression of an inducible AmpC β-lactamase.","The risk of AmpC derepression during therapy is noted as less frequent for M. morganii compared to other organisms like Enterobacter cloacae complex or Citrobacter freundii complex."],"keySignsAndSymptoms":[],"clinicalSyndromes":[{"syndromeName":"Urinary Tract Infections (UTI)","description":"A common manifestation, particularly in hospital settings. For UTIs, it's crucial to remove indwelling Foley catheters if possible and ensure no urinary obstruction."},{"syndromeName":"Post-operative Wound Infections","description":"Infections occurring at the site of a surgical incision."}],"stagesOfIllness":[],"highRiskPopulations":["Hospitalized patients (nosocomial infections)"],"transmissionVectors":[],"prognosisNotes":[]},"resistanceProfile":{"groupIntrinsicResistance":[],"intrinsicResistance":[{"drugOrClass":"Polymyxins (Colistin, Polymyxin B)","notes":"Isolates are intrinsically resistant."},{"drugOrClass":"Penicillins (Penicillin, Ampicillin, Amoxicillin-clavulanate)","notes":"Isolates are intrinsically resistant."},{"drugOrClass":"Ampicillin/sulbactam","notes":"Isolates are intrinsically resistant."},{"drugOrClass":"1st and 2nd Generation Cephalosporins","notes":"Isolates are intrinsically resistant."},{"drugOrClass":"Nitrofurantoin","notes":"Isolates are intrinsically resistant."},{"drugOrClass":"Fosfomycin","notes":"Isolates are intrinsically resistant."}],"majorMechanisms":[{"mechanismName":"Inducible AmpC β-lactamase","mechanismType":"Enzymatic Inactivation","description":"M. morganii possesses an inducible AmpC gene that can be derepressed during therapy with third-generation cephalosporins, leading to resistance, although this is less frequent than in other AmpC-producers."},{"mechanismName":"Carbapenemase Production","mechanismType":"Enzymatic Inactivation","description":"Isolates may produce carbapenemases, including serine-carbapenemases (like KPC) or metallo-beta-lactamases (MBLs)."},{"mechanismName":"Plasmid-mediated Resistance","mechanismType":"Various","description":"Strains may acquire plasmid-mediated resistance to aminoglycosides and fluoroquinolones."}],"clinicalAlerts":[{"alertTitle":"Potential for Inducible AmpC Resistance","details":"Although the risk is lower than with other organisms, M. morganii can develop resistance to third-generation cephalosporins during treatment. For high-inoculum infections, Cefepime may be a more stable option than Ceftriaxone."}]},"treatment":{"generalNotes":["Recommendations are generally for moderately severe or severe infections.","For uncomplicated infections with susceptible strains, options can include fluoroquinolones and third-generation cephalosporins.","TMP-SMX is an option only if the strain is susceptible, as resistance is common.","Imipenem is noted to be less active than other carbapenems against M. morganii."],"drugsToAvoid":[],"adjunctiveTherapies":[],"regimens":[{"context":{"type":"Empiric","condition":"Suspected Morganella sp. infection, susceptibility pending","patientPopulation":["Local ESBL rate <10-15%"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Piperacillin-tazobactam","dose":"4.5 gm","route":"IV","frequency":"q8h","comments":"Infuse over 4 hours."}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftriaxone","dose":"1-2 gm","route":"IV","frequency":"q24h","comments":""},{"drugName":"Cefepime","dose":"1-2 gm","route":"IV","frequency":"q8h-q12h","comments":""},{"drugName":"Aztreonam","dose":"2 gm","route":"IV","frequency":"q8h","comments":""},{"drugName":"Ciprofloxacin","dose":"400 mg","route":"IV","frequency":"q12h","comments":""},{"drugName":"Levofloxacin","dose":"750 mg","route":"IV","frequency":"once daily","comments":""}]}]},{"preference":"For Life-Threatening Illness","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Meropenem","dose":"1-2 gm","route":"IV","frequency":"q8h","comments":""}]}]}]},{"context":{"type":"Empiric","condition":"Suspected Morganella sp. infection, susceptibility pending","patientPopulation":["Local ESBL rate >15%"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Meropenem","dose":"1-2 gm","route":"IV","frequency":"q8h","comments":""},{"drugName":"Ertapenem","dose":"1 gm","route":"IV","frequency":"q24h","comments":""}]}]}]},{"context":{"type":"Directed","condition":"No ESBL or constitutive AmpC production","patientPopulation":["Isolate susceptible to 3rd-gen cephalosporins, TMP-SMX, fluoroquinolones"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftriaxone","dose":"1-2 gm","route":"IV","frequency":"q24h","comments":""},{"drugName":"Cefepime","dose":"1-2 gm","route":"IV","frequency":"q8h-q12h","comments":"May be preferred over Ceftriaxone for high inoculum infections."},{"drugName":"Ciprofloxacin","dose":"400 mg","route":"IV","frequency":"q12h","comments":""},{"drugName":"Levofloxacin","dose":"750 mg","route":"IV","frequency":"once daily","comments":""},{"drugName":"TMP-SMX","dose":"10 mg/kg/day (TMP component)","route":"IV","frequency":"in 2-3 divided doses","comments":""}]}]}]},{"context":{"type":"Directed","condition":"ESBL and/or AmpC overproduction","patientPopulation":["Isolate resistant to aztreonam, ceftriaxone, cefotaxime, ceftazidime"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Meropenem","dose":"1-2 gm","route":"IV","frequency":"q8h","comments":""},{"drugName":"Ertapenem","dose":"1 gm","route":"IV","frequency":"q24h","comments":""}]}]},{"preference":"Alternative (if susceptible)","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ciprofloxacin","dose":"400 mg","route":"IV","frequency":"q12h","comments":""},{"drugName":"Levofloxacin","dose":"750 mg","route":"IV","frequency":"once daily","comments":""},{"drugName":"TMP-SMX","dose":"10 mg/kg/day (TMP component)","route":"IV","frequency":"in 2-3 divided doses","comments":""}]}]}]},{"context":{"type":"Directed","condition":"Serine-carbapenemase (e.g., KPC) producer","patientPopulation":["Resistant to carbapenems but susceptible to newer beta-lactamase inhibitor combos"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"q8h","comments":"Infuse over 3 hours. Use if susceptible in vitro."},{"drugName":"Meropenem-vaborbactam","dose":"4 gm","route":"IV","frequency":"q8h","comments":"Infuse over 3 hours."}]}]}]},{"context":{"type":"Directed","condition":"Metallo-beta-lactamase (MBL) producer","patientPopulation":["Pan-resistant to most tested beta-lactams and other agents"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"q8h","comments":"Infuse over 3 hours."},{"drugName":"Aztreonam","dose":"2 gm","route":"IV","frequency":"q6h","comments":"Infuse over 3 hours. Must be given with Ceftazidime-avibactam."}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Cefiderocol","dose":"2 gm","route":"IV","frequency":"q8h","comments":"Infuse over 3 hours."}]}]}]}]},"laboratoryProfile":{"testingIndications":["If resistance to third-generation cephalosporins develops during therapy, subsequent testing of the isolate may be clinically warranted to guide further treatment."],"methodologyNotes":["The approach to testing and reporting AST results for organisms with inducible resistance, like M. morganii, should be determined in consultation with the institutional antimicrobial stewardship team."],"recommendedPanel":[],"specialTests":[],"reportingRules":[{"ruleType":"Exception","drug":"Imipenem-relebactam","condition":"Isolate is identified as a member of the family Morganellaceae (Morganella, Proteus, Providencia).","details":"The defined CLSI breakpoints for Imipenem-relebactam do not apply to Morganella morganii. This agent should not be reported using these breakpoints for this organism."}],"antimicrobialBreakpoints":[{"tier":1,"tierDescription":"Appropriate for routine, primary testing and reporting.","agents":[{"agentName":"Piperacillin-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"100/10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"18–21 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 16/4 µg/mL","i_breakpoint":"32/4 µg/mL","r_breakpoint":"≥ 64/4 µg/mL"},"comments":["Note: These breakpoints are specific to Morganella, Proteus, and Providencia species and differ from other Enterobacterales."]}]},{"agentName":"Gentamicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"—","r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Tobramycin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"13–16 mm","r_breakpoint":"≤ 12 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"—","r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Amikacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 19 mm","i_breakpoint":"17–18 mm","r_breakpoint":"≤ 16 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":"—","r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Ciprofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"22–25 mm","r_breakpoint":"≤ 21 mm"},"mic":{"s_breakpoint":"≤ 0.25 µg/mL","i_breakpoint":"0.5 µg/mL","r_breakpoint":"≥ 1 µg/mL"},"comments":[]}]},{"agentName":"Levofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"17–20 mm","r_breakpoint":"≤ 16 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Trimethoprim-sulfamethoxazole","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"1.25/23.75 µg","s_breakpoint":"≥ 16 mm","i_breakpoint":"11–15 mm","r_breakpoint":"≤ 10 mm"},"mic":{"s_breakpoint":"≤ 2/38 µg/mL","i_breakpoint":"—","r_breakpoint":"≥ 4/76 µg/mL"},"comments":[]}]}]},{"tier":2,"tierDescription":"Appropriate for routine, primary testing, may be reported following cascade reporting rules.","agents":[{"agentName":"Cefepime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"19–24 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":["Cefepime S/SDD results should be suppressed or reported as resistant for isolates demonstrating carbapenemase production."]}]},{"agentName":"Ertapenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"19–21 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Imipenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Meropenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]}]},{"tier":3,"tierDescription":"Appropriate for high-risk MDRO patients, subject to cascade reporting.","agents":[{"agentName":"Cefiderocol","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 20 mm","i_breakpoint":"9–15 mm","r_breakpoint":"≤ 8 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"—","r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Ceftazidime-avibactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/20 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"—","r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"—","r_breakpoint":"≥ 16/4 µg/mL"},"comments":["Confirmatory MIC testing is indicated for isolates with disk diffusion zones of 20–22 mm."]}]},{"agentName":"Meropenem-vaborbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4/8 µg/mL","i_breakpoint":"8/8 µg/mL","r_breakpoint":"≥ 16/8 µg/mL"},"comments":["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]},{"agentName":"Plazomicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 2 µg/mL","i_breakpoint":"—","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]}]},{"tier":4,"tierDescription":"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.","agents":[{"agentName":"Aztreonam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"18–20 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":[]}]},{"agentName":"Ceftriaxone","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Ceftazidime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"18–20 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 8 µg/mL","i_breakpoint":"16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Ceftolozane-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"19–21 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 2/4 µg/mL","i_breakpoint":"—","r_breakpoint":"≥ 4/4 µg/mL"},"comments":["Note: These breakpoints are specific to Morganella, Proteus, and Providencia species and differ from other Enterobacterales."]}]}]}]},"additionalInformation":{"diagnosticNotes":{"summary":"For UTIs, remove indwelling Foley catheter if possible and ensure no urinary obstruction. Note the intrinsic lack of activity of nitrofurantoin and fosfomycin.","biosafetyWarning":"","methods":[]},"preventionAndScreening":[],"treatmentLifecycle":[],"antimicrobialStewardship":["For ESBL-producing strains, Piperacillin-tazobactam should be avoided even if it is reported as susceptible in vitro.","Susceptibility should be checked for all carbapenems individually; resistance to imipenem does not predict resistance to meropenem.","Tigecycline may show in vitro activity against MDR/XDR strains, but its clinical efficacy is questionable due to low serum levels.","For metallo-beta-lactamase (MBL) producers, Aztreonam is not hydrolyzed by the MBL enzyme, but co-production of other beta-lactamases that can hydrolyze it is common. Combining Ceftazidime-avibactam with Aztreonam can protect Aztreonam and has been successful in case reports."],"drugSpecificPearls":[{"drugName":"Cefiderocol","pearl":"This drug is FDA-approved for complicated UTIs with limited or no other treatment options. In one trial, 28-day mortality was 24.8% for cefiderocol vs 18.4% for the best available therapy, a difference that was not statistically significant."}],"guidelineReferences":[{"source":"IDSA","citation":"Updated 2024 IDSA Guideline on treatment of ESBL, AmpC, and carbapenemase producers.","summaryOrNote":"Provides comprehensive guidance for treating infections caused by resistant gram-negative organisms."}]}}`),J_={originalKeys:["identity","clinicalProfile","resistanceProfile","treatment","laboratoryProfile","additionalInformation"],conversionTimestamp:"2025-07-15T03:16:49.293Z",sourceFormat:"modern"},Q_={bacteriumName:{sources:["identity.bacteriumName"],value:"Morganella morganii"},aliases:{sources:["identity.aliases"],value:["Morganella sp."]},lastUpdated:{sources:["identity.lastUpdated"],value:"2025-01-17"},classification:{sources:["identity.classification"],value:{gramStain:"Gram negative",morphology:"Bacilli",respiration:"Facultative anaerobe",notes:["Enteric bacterium."]}}},W_={sources:["clinicalProfile"],value:{summary:"Morganella morganii can cause various infections, but it is most commonly identified as the cause of urinary tract and post-operative wound infections. It is typically a nosocomial pathogen.",pathophysiologyPearls:["Like other SPACE-M organisms, M. morganii may initially test susceptible to third-generation cephalosporins but can become resistant during therapy due to derepression of an inducible AmpC β-lactamase.","The risk of AmpC derepression during therapy is noted as less frequent for M. morganii compared to other organisms like Enterobacter cloacae complex or Citrobacter freundii complex."],keySignsAndSymptoms:[],clinicalSyndromes:[{syndromeName:"Urinary Tract Infections (UTI)",description:"A common manifestation, particularly in hospital settings. For UTIs, it's crucial to remove indwelling Foley catheters if possible and ensure no urinary obstruction."},{syndromeName:"Post-operative Wound Infections",description:"Infections occurring at the site of a surgical incision."}],stagesOfIllness:[],highRiskPopulations:["Hospitalized patients (nosocomial infections)"],transmissionVectors:[],prognosisNotes:[]}},Z_={sources:["resistanceProfile"],value:{groupIntrinsicResistance:[],intrinsicResistance:[{drugOrClass:"Polymyxins (Colistin, Polymyxin B)",notes:"Isolates are intrinsically resistant."},{drugOrClass:"Penicillins (Penicillin, Ampicillin, Amoxicillin-clavulanate)",notes:"Isolates are intrinsically resistant."},{drugOrClass:"Ampicillin/sulbactam",notes:"Isolates are intrinsically resistant."},{drugOrClass:"1st and 2nd Generation Cephalosporins",notes:"Isolates are intrinsically resistant."},{drugOrClass:"Nitrofurantoin",notes:"Isolates are intrinsically resistant."},{drugOrClass:"Fosfomycin",notes:"Isolates are intrinsically resistant."}],majorMechanisms:[{mechanismName:"Inducible AmpC β-lactamase",mechanismType:"Enzymatic Inactivation",description:"M. morganii possesses an inducible AmpC gene that can be derepressed during therapy with third-generation cephalosporins, leading to resistance, although this is less frequent than in other AmpC-producers."},{mechanismName:"Carbapenemase Production",mechanismType:"Enzymatic Inactivation",description:"Isolates may produce carbapenemases, including serine-carbapenemases (like KPC) or metallo-beta-lactamases (MBLs)."},{mechanismName:"Plasmid-mediated Resistance",mechanismType:"Various",description:"Strains may acquire plasmid-mediated resistance to aminoglycosides and fluoroquinolones."}],clinicalAlerts:[{alertTitle:"Potential for Inducible AmpC Resistance",details:"Although the risk is lower than with other organisms, M. morganii can develop resistance to third-generation cephalosporins during treatment. For high-inoculum infections, Cefepime may be a more stable option than Ceftriaxone."}]}},eh={treatmentData:{_treatmentMetadata:{originalFormat:"modern"},standardizedRegimens:[{regimenId:"modern-0-0-0",extractedFrom:"treatment.regimens[0].recommendations[0].steps[0]",context:{type:"empiric",condition:"Suspected Morganella sp. infection, susceptibility pending",severity:"unknown",patientFactors:{population:["Local ESBL rate <10-15%"],labFindings:null}},preference:"primary",drugs:[{drugName:"Piperacillin-tazobactam",dose:"4.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infuse over 4 hours.",originalText:"Piperacillin-tazobactam 4.5 gm IV q8h"}]},{regimenId:"modern-0-1-0",extractedFrom:"treatment.regimens[0].recommendations[1].steps[0]",context:{type:"empiric",condition:"Suspected Morganella sp. infection, susceptibility pending",severity:"unknown",patientFactors:{population:["Local ESBL rate <10-15%"],labFindings:null}},preference:"alternative",drugs:[{drugName:"Ceftriaxone",dose:"1-2 gm",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Ceftriaxone 1-2 gm IV q24h"},{drugName:"Cefepime",dose:"1-2 gm",route:"IV",frequency:"q8h-q12h",duration:"Variable",comments:"",originalText:"Cefepime 1-2 gm IV q8h-q12h"},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"",originalText:"Aztreonam 2 gm IV q8h"},{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"q12h",duration:"Variable",comments:"",originalText:"Ciprofloxacin 400 mg IV q12h"},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"once daily",duration:"Variable",comments:"",originalText:"Levofloxacin 750 mg IV once daily"}]},{regimenId:"modern-0-2-0",extractedFrom:"treatment.regimens[0].recommendations[2].steps[0]",context:{type:"empiric",condition:"Suspected Morganella sp. infection, susceptibility pending",severity:"unknown",patientFactors:{population:["Local ESBL rate <10-15%"],labFindings:null}},preference:"for life-threatening illness",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"",originalText:"Meropenem 1-2 gm IV q8h"}]},{regimenId:"modern-1-0-0",extractedFrom:"treatment.regimens[1].recommendations[0].steps[0]",context:{type:"empiric",condition:"Suspected Morganella sp. infection, susceptibility pending",severity:"unknown",patientFactors:{population:["Local ESBL rate >15%"],labFindings:null}},preference:"primary",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"",originalText:"Meropenem 1-2 gm IV q8h"},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Ertapenem 1 gm IV q24h"}]},{regimenId:"modern-2-0-0",extractedFrom:"treatment.regimens[2].recommendations[0].steps[0]",context:{type:"directed",condition:"No ESBL or constitutive AmpC production",severity:"unknown",patientFactors:{population:["Isolate susceptible to 3rd-gen cephalosporins, TMP-SMX, fluoroquinolones"],labFindings:null}},preference:"primary",drugs:[{drugName:"Ceftriaxone",dose:"1-2 gm",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Ceftriaxone 1-2 gm IV q24h"},{drugName:"Cefepime",dose:"1-2 gm",route:"IV",frequency:"q8h-q12h",duration:"Variable",comments:"May be preferred over Ceftriaxone for high inoculum infections.",originalText:"Cefepime 1-2 gm IV q8h-q12h"},{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"q12h",duration:"Variable",comments:"",originalText:"Ciprofloxacin 400 mg IV q12h"},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"once daily",duration:"Variable",comments:"",originalText:"Levofloxacin 750 mg IV once daily"},{drugName:"TMP-SMX",dose:"10 mg/kg/day (TMP component)",route:"IV",frequency:"in 2-3 divided doses",duration:"Variable",comments:"",originalText:"TMP-SMX 10 mg/kg/day (TMP component) IV in 2-3 divided doses"}]},{regimenId:"modern-3-0-0",extractedFrom:"treatment.regimens[3].recommendations[0].steps[0]",context:{type:"directed",condition:"ESBL and/or AmpC overproduction",severity:"unknown",patientFactors:{population:["Isolate resistant to aztreonam, ceftriaxone, cefotaxime, ceftazidime"],labFindings:null}},preference:"primary",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"",originalText:"Meropenem 1-2 gm IV q8h"},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Ertapenem 1 gm IV q24h"}]},{regimenId:"modern-3-1-0",extractedFrom:"treatment.regimens[3].recommendations[1].steps[0]",context:{type:"directed",condition:"ESBL and/or AmpC overproduction",severity:"unknown",patientFactors:{population:["Isolate resistant to aztreonam, ceftriaxone, cefotaxime, ceftazidime"],labFindings:null}},preference:"alternative (if susceptible)",drugs:[{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"q12h",duration:"Variable",comments:"",originalText:"Ciprofloxacin 400 mg IV q12h"},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"once daily",duration:"Variable",comments:"",originalText:"Levofloxacin 750 mg IV once daily"},{drugName:"TMP-SMX",dose:"10 mg/kg/day (TMP component)",route:"IV",frequency:"in 2-3 divided doses",duration:"Variable",comments:"",originalText:"TMP-SMX 10 mg/kg/day (TMP component) IV in 2-3 divided doses"}]},{regimenId:"modern-4-0-0",extractedFrom:"treatment.regimens[4].recommendations[0].steps[0]",context:{type:"directed",condition:"Serine-carbapenemase (e.g., KPC) producer",severity:"unknown",patientFactors:{population:["Resistant to carbapenems but susceptible to newer beta-lactamase inhibitor combos"],labFindings:null}},preference:"primary",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infuse over 3 hours. Use if susceptible in vitro.",originalText:"Ceftazidime-avibactam 2.5 gm IV q8h"},{drugName:"Meropenem-vaborbactam",dose:"4 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infuse over 3 hours.",originalText:"Meropenem-vaborbactam 4 gm IV q8h"}]},{regimenId:"modern-5-0-0",extractedFrom:"treatment.regimens[5].recommendations[0].steps[0]",context:{type:"directed",condition:"Metallo-beta-lactamase (MBL) producer",severity:"unknown",patientFactors:{population:["Pan-resistant to most tested beta-lactams and other agents"],labFindings:null}},preference:"primary",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infuse over 3 hours.",originalText:"Ceftazidime-avibactam 2.5 gm IV q8h"},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q6h",duration:"Variable",comments:"Infuse over 3 hours. Must be given with Ceftazidime-avibactam.",originalText:"Aztreonam 2 gm IV q6h"}]},{regimenId:"modern-5-1-0",extractedFrom:"treatment.regimens[5].recommendations[1].steps[0]",context:{type:"directed",condition:"Metallo-beta-lactamase (MBL) producer",severity:"unknown",patientFactors:{population:["Pan-resistant to most tested beta-lactams and other agents"],labFindings:null}},preference:"alternative",drugs:[{drugName:"Cefiderocol",dose:"2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infuse over 3 hours.",originalText:"Cefiderocol 2 gm IV q8h"}]}]}},ih={sources:["laboratoryProfile"],value:{testingIndications:["If resistance to third-generation cephalosporins develops during therapy, subsequent testing of the isolate may be clinically warranted to guide further treatment."],methodologyNotes:["The approach to testing and reporting AST results for organisms with inducible resistance, like M. morganii, should be determined in consultation with the institutional antimicrobial stewardship team."],recommendedPanel:[],specialTests:[],reportingRules:[{ruleType:"Exception",drug:"Imipenem-relebactam",condition:"Isolate is identified as a member of the family Morganellaceae (Morganella, Proteus, Providencia).",details:"The defined CLSI breakpoints for Imipenem-relebactam do not apply to Morganella morganii. This agent should not be reported using these breakpoints for this organism."}],antimicrobialBreakpoints:[{tier:1,tierDescription:"Appropriate for routine, primary testing and reporting.",agents:[{agentName:"Piperacillin-tazobactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"100/10 µg",s_breakpoint:"≥ 22 mm",i_breakpoint:"18–21 mm",r_breakpoint:"≤ 17 mm"},mic:{s_breakpoint:"≤ 16/4 µg/mL",i_breakpoint:"32/4 µg/mL",r_breakpoint:"≥ 64/4 µg/mL"},comments:["Note: These breakpoints are specific to Morganella, Proteus, and Providencia species and differ from other Enterobacterales."]}]},{agentName:"Gentamicin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:"15–17 mm",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 8 µg/mL"},comments:[]}]},{agentName:"Tobramycin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 17 mm",i_breakpoint:"13–16 mm",r_breakpoint:"≤ 12 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 8 µg/mL"},comments:[]}]},{agentName:"Amikacin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 19 mm",i_breakpoint:"17–18 mm",r_breakpoint:"≤ 16 mm"},mic:{s_breakpoint:"≤ 16 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 32 µg/mL"},comments:[]}]},{agentName:"Ciprofloxacin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"5 µg",s_breakpoint:"≥ 26 mm",i_breakpoint:"22–25 mm",r_breakpoint:"≤ 21 mm"},mic:{s_breakpoint:"≤ 0.25 µg/mL",i_breakpoint:"0.5 µg/mL",r_breakpoint:"≥ 1 µg/mL"},comments:[]}]},{agentName:"Levofloxacin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"5 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"17–20 mm",r_breakpoint:"≤ 16 mm"},mic:{s_breakpoint:"≤ 0.5 µg/mL",i_breakpoint:"1 µg/mL",r_breakpoint:"≥ 2 µg/mL"},comments:[]}]},{agentName:"Trimethoprim-sulfamethoxazole",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"1.25/23.75 µg",s_breakpoint:"≥ 16 mm",i_breakpoint:"11–15 mm",r_breakpoint:"≤ 10 mm"},mic:{s_breakpoint:"≤ 2/38 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 4/76 µg/mL"},comments:[]}]}]},{tier:2,tierDescription:"Appropriate for routine, primary testing, may be reported following cascade reporting rules.",agents:[{agentName:"Cefepime",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 25 mm",i_breakpoint:"19–24 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"8 µg/mL",r_breakpoint:"≥ 16 µg/mL"},comments:["Cefepime S/SDD results should be suppressed or reported as resistant for isolates demonstrating carbapenemase production."]}]},{agentName:"Ertapenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 22 mm",i_breakpoint:"19–21 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 0.5 µg/mL",i_breakpoint:"1 µg/mL",r_breakpoint:"≥ 2 µg/mL"},comments:[]}]},{agentName:"Imipenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 23 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]},{agentName:"Meropenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 23 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]}]},{tier:3,tierDescription:"Appropriate for high-risk MDRO patients, subject to cascade reporting.",agents:[{agentName:"Cefiderocol",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 20 mm",i_breakpoint:"9–15 mm",r_breakpoint:"≤ 8 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 8 µg/mL"},comments:[]}]},{agentName:"Ceftazidime-avibactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30/20 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"—",r_breakpoint:"≤ 20 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 16/4 µg/mL"},comments:["Confirmatory MIC testing is indicated for isolates with disk diffusion zones of 20–22 mm."]}]},{agentName:"Meropenem-vaborbactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:"15–17 mm",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 4/8 µg/mL",i_breakpoint:"8/8 µg/mL",r_breakpoint:"≥ 16/8 µg/mL"},comments:["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]},{agentName:"Plazomicin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:"15–17 mm",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 2 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]}]},{tier:4,tierDescription:"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.",agents:[{agentName:"Aztreonam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"18–20 mm",r_breakpoint:"≤ 17 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"8 µg/mL",r_breakpoint:"≥ 16 µg/mL"},comments:[]}]},{agentName:"Ceftriaxone",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 26 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]},{agentName:"Ceftazidime",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"18–20 mm",r_breakpoint:"≤ 17 mm"},mic:{s_breakpoint:"≤ 8 µg/mL",i_breakpoint:"16 µg/mL",r_breakpoint:"≥ 32 µg/mL"},comments:[]}]},{agentName:"Ceftolozane-tazobactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30/10 µg",s_breakpoint:"≥ 22 mm",i_breakpoint:"19–21 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 2/4 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 4/4 µg/mL"},comments:["Note: These breakpoints are specific to Morganella, Proteus, and Providencia species and differ from other Enterobacterales."]}]}]}]}},th={antimicrobialStewardship:{sources:["antimicrobial_stewardship","antimicrobialStewardship"],value:[]},comments:{preservedStructure:{originalFormat:"object"}},diagnosis:{sources:["diagnosis"],value:[]},allOtherKeys:{}},ah={_originalData:$_,_metadata:J_,identity:Q_,clinicalInformation:W_,resistanceInformation:Z_,treatmentData:eh,laboratoryData:ih,additionalData:th},nh=JSON.parse(`{"identity":{"bacteriumName":"Proteus sp.","aliases":["Proteus mirabilis","Proteus penneri","Proteus vulgaris"],"lastUpdated":"2025-01-08","clsiCategory":"Enterobacterales (excluding Salmonella/Shigella)","classification":{"gramStain":"Gram negative","morphology":"bacilli","respiration":"Facultative anaerobe","notes":["motile (swarming on culture plate)"]},"strainDetails":[{"type":"Complex Member","value":"Proteus mirabilis","notes":"indole negative"},{"type":"Complex Member","value":"Proteus penneri","notes":"indole negative"},{"type":"Complex Member","value":"Proteus vulgaris","notes":"indole positive"}],"biochemicalTests":"Gram-negative rod, highly motile (swarming), lactose –, urease strongly +, phenylalanine deaminase +, H2S + (P. mirabilis, P. vulgaris)."},"clinicalProfile":{"summary":"Proteus sp. cause a variety of infections from uncomplicated UTIs to life-threatening infections of the abdomen, skin, soft tissue, and lungs in both normal and immunocompromised hosts. UTIs are the most common and are often catheter-associated.","pathophysiologyPearls":["Known for biofilm formation and producing a potent urease enzyme, which leads to alkaline urine and the formation of struvite stones (magnesium ammonium phosphate)."],"keySignsAndSymptoms":[],"clinicalSyndromes":[{"syndromeName":"Urinary Tract Infections (UTI)","description":"Most common infection type, frequently catheter-associated and can be complicated by the formation of struvite stones due to urease production."},{"syndromeName":"Intra-abdominal Infections","description":"Can cause life-threatening infections of the abdomen."},{"syndromeName":"Skin and Soft Tissue Infections","description":"Can cause life-threatening infections of the skin and soft tissue."},{"syndromeName":"Pneumonia","description":"Can cause life-threatening infections of the lungs."}],"stagesOfIllness":[],"highRiskPopulations":["Immunocompromised hosts","Patients with urinary catheters"],"transmissionVectors":[],"prognosisNotes":["Diagnostic imaging is recommended for upper tract or recurrent infections to assess for stones or obstructive uropathy."]},"resistanceProfile":{"groupIntrinsicResistance":[],"intrinsicResistance":[{"drugOrClass":"Polymyxins","notes":"Proteus species are intrinsically resistant to polymyxins (Colistin, Polymyxin B)."},{"drugOrClass":"Nitrofurantoin","notes":"Proteus spp. are intrinsically resistant to Nitrofurantoin."}],"majorMechanisms":[{"mechanismName":"ESBL (Extended-Spectrum Beta-Lactamase)","mechanismType":"Enzymatic","description":"Confers resistance to most penicillins and cephalosporins. Indole positive species (P. vulgaris) may overproduce ESBLs."},{"mechanismName":"AmpC Beta-Lactamase","mechanismType":"Enzymatic","description":"Resistance to aztreonam, ceftriaxone, and/or cefotaxime may indicate overproduction of AmpC."},{"mechanismName":"KPC (Klebsiella pneumoniae carbapenemase)","mechanismType":"Enzymatic","description":"A serine-based carbapenemase conferring resistance to all carbapenems. Can be overcome by new beta-lactamase inhibitor combinations like meropenem-vaborbactam or ceftazidime-avibactam."},{"mechanismName":"MBL (Metallo-Beta-Lactamase)","mechanismType":"Enzymatic","description":"Confers resistance to all carbapenems and newer beta-lactamase inhibitors (vaborbactam, avibactam). Requires alternative strategies like ceftazidime-avibactam + aztreonam or cefiderocol."}],"clinicalAlerts":[{"alertTitle":"ESBL Production and Piperacillin-Tazobactam","details":"Do not use piperacillin-tazobactam for suspected or proven ESBL production, as it may fail clinically despite in vitro susceptibility."},{"alertTitle":"Carbapenem Activity Variability","details":"Imipenem is noted to be less active against Proteus spp. compared to other carbapenems. Check susceptibility of all carbapenems if considering their use."}]},"treatment":{"generalNotes":["The recommendations in the table are for moderately severe or severe infections.","For less severe infections, options include Amoxicillin-clavulanate, fluoroquinolones, and second/third-gen cephalosporins.","Amoxicillin may be active against P. mirabilis but not P. vulgaris.","TMP-SMX can be used if susceptible.","Proteus spp. are intrinsically resistant to Nitrofurantoin.","Imipenem is less active than other carbapenems.","Fosfomycin susceptibility is variable and should only be used for uncomplicated UTI if susceptible."],"drugsToAvoid":[{"drugOrClass":"Nitrofurantoin","condition":"All infections","reason":"Intrinsic resistance."},{"drugOrClass":"Polymyxins (Colistin, Polymyxin B)","condition":"All infections","reason":"Intrinsic resistance."},{"drugOrClass":"Piperacillin-tazobactam","condition":"Suspected or proven ESBL-producing infections","reason":"Reported clinical failures despite in vitro susceptibility."},{"drugOrClass":"Imipenem-relebactam","condition":"All infections","reason":"CLSI breakpoints do not apply to the family Morganellaceae, which includes Proteus."}],"adjunctiveTherapies":[],"regimens":[{"context":{"type":"Empiric","condition":"Moderately severe or severe infection","patientPopulation":["Areas with local ESBL rate <15%"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"pending susceptibilities","drugs":[{"drugName":"Piperacillin-tazobactam","dose":"4.5 gm","route":"IV","frequency":"q8h","comments":"Administer over 4 hours."}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"pending susceptibilities","drugs":[{"drugName":"Ciprofloxacin","dose":"400 mg","route":"IV","frequency":"bid","comments":""}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"pending susceptibilities","drugs":[{"drugName":"Levofloxacin","dose":"750 mg","route":"IV","frequency":"q24h","comments":""}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"pending susceptibilities","drugs":[{"drugName":"Cefazolin","dose":"1 gm","route":"IV","frequency":"q12h","comments":""}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"pending susceptibilities","drugs":[{"drugName":"Ceftriaxone","dose":"1-2 gm","route":"IV","frequency":"q24h","comments":""}]}]}]},{"context":{"type":"Empiric","condition":"Moderately severe or severe infection","patientPopulation":["Areas with local ESBL rate >15%"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"pending susceptibilities","drugs":[{"drugName":"Meropenem","dose":"1-2 gm","route":"IV","frequency":"q8h","comments":"See alternative regimens for other options."}]}]}]},{"context":{"type":"Directed","condition":"Indole positive Proteus (e.g., vulgaris) with resistance to aztreonam, ceftriaxone, and/or cefotaxime","patientPopulation":["Patients with isolates consistent with overproduction of ESBL and/or AmpC"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Course of therapy","drugs":[{"drugName":"Meropenem","dose":"1-2 gm","route":"IV","frequency":"q8h","comments":"Higher percentage of in vitro resistance to Imipenem compared to other carbapenems. Avoid Pip/tazo if ESBL production is suspected."}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Course of therapy","drugs":[{"drugName":"Ertapenem","dose":"1 gm","route":"IV","frequency":"q24hr","comments":"See other alternatives if needed."}]}]}]},{"context":{"type":"Directed","condition":"Carbapenem resistance, KPC suspected","patientPopulation":["Isolates resistant to all carbapenems but susceptible to meropenem-vaborbactam and ceftazidime-avibactam"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Course of therapy","drugs":[{"drugName":"Meropenem-vaborbactam","dose":"4 gm","route":"IV","frequency":"q8h","comments":"Administer over 3 hours. Infectious Diseases consultation recommended."}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Course of therapy","drugs":[{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"q8h","comments":"Administer over 2 hours. Infectious Diseases consultation recommended."}]}]}]},{"context":{"type":"Directed","condition":"Carbapenem resistance, Metallo-beta-lactamase (MBL) suspected","patientPopulation":["Isolates resistant to all carbapenems, meropenem-vaborbactam, and ceftazidime-avibactam"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Course of therapy","drugs":[{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"q8h","comments":"Administer over 3 hours."},{"drugName":"Aztreonam","dose":"2 gm","route":"IV","frequency":"q6h","comments":"Administer over 3 hours. Infectious Diseases consultation strongly recommended."}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Course of therapy","drugs":[{"drugName":"Cefiderocol","dose":"2 gm","route":"IV","frequency":"q8h","comments":"Administer over 3 hours. Infectious Diseases consultation strongly recommended."}]}]}]},{"context":{"type":"Directed","condition":"Less severe infection, no evidence of ESBL or plasmid-based AmpC production","patientPopulation":[],"isolateSource":null},"recommendations":[{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Course of therapy","drugs":[{"drugName":"Cefixime","dose":"Varies","route":"PO","frequency":"Varies","comments":""},{"drugName":"Cefpodoxime","dose":"Varies","route":"PO","frequency":"Varies","comments":""},{"drugName":"Cefdinir","dose":"Varies","route":"PO","frequency":"Varies","comments":""}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"1 dose","drugs":[{"drugName":"Fosfomycin","dose":"3 gm","route":"PO","frequency":"x1","comments":"For UTI only. Use is discouraged for Proteus sp. as breakpoints are only for E.coli."}]}]}]},{"context":{"type":"Directed","condition":"Any infection","patientPopulation":["Patients with a severe beta-lactam allergy"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Course of therapy","drugs":[{"drugName":"Aztreonam","dose":"Varies","route":"IV","frequency":"Varies","comments":""}]}]}]},{"context":{"type":"Directed","condition":"ESBL-producing infection","patientPopulation":["Patient cannot receive a carbapenem"],"isolateSource":null},"recommendations":[{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Course of therapy","drugs":[{"drugName":"Aminoglycoside","dose":"Varies","route":"IV","frequency":"Varies","comments":"If susceptible."},{"drugName":"Fluoroquinolone","dose":"Varies","route":"IV/PO","frequency":"Varies","comments":"If susceptible."},{"drugName":"Ceftolozane-tazobactam","dose":"1.5 gm","route":"IV","frequency":"q8h","comments":"Administer over 3 hours."},{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"q8h","comments":"Administer over 3 hours."},{"drugName":"Cefepime-enmetazobactam","dose":"Varies","route":"IV","frequency":"Varies","comments":""},{"drugName":"Temocillin","dose":"2 gm","route":"IV","frequency":"q12h","comments":"Where available."}]}]}]},{"context":{"type":"Directed","condition":"Pan-resistant infection","patientPopulation":[],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Course of therapy","drugs":[{"drugName":"Plazomicin","dose":"15 mg/kg","route":"IV","frequency":"once daily","comments":"If available. Infectious Diseases consultation needed."}]}]}]}]},"laboratoryProfile":{"testingIndications":["Cultures obtained from suspected sites of infection, such as urine, blood, wounds, or respiratory specimens."],"methodologyNotes":["Proteus species are known for their characteristic 'swarming' motility on non-inhibitory agar plates, which can sometimes complicate the isolation of other organisms in a mixed culture."],"recommendedPanel":[],"specialTests":[{"testName":"Indole Test","trigger":"Isolation of Proteus sp.","purpose":"To differentiate between Proteus species. P. vulgaris is indole positive, while P. mirabilis and P. penneri are indole negative. This can have treatment implications as P. vulgaris may have different resistance patterns."}],"reportingRules":[{"ruleType":"Surrogate","drug":"Ampicillin","condition":"All isolates","details":"Results of ampicillin testing can be used to predict results for amoxicillin."},{"ruleType":"Surrogate","drug":"Cefazolin","condition":"Uncomplicated UTI caused by P. mirabilis","details":"Cefazolin can be used as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."},{"ruleType":"Surrogate","drug":"Tetracycline","condition":"All isolates","details":"Organisms susceptible to tetracycline are also considered susceptible to doxycycline and minocycline."},{"ruleType":"Conditional","drug":"Cefepime","condition":"Isolate demonstrates carbapenemase production.","details":"Cefepime S/SDD results should be suppressed or reported as resistant."},{"ruleType":"Conditional","drug":"Meropenem-vaborbactam","condition":"An OXA-48-like gene or enzyme is detected.","details":"Results should be suppressed or reported as resistant."},{"ruleType":"Exclusion","drug":"Fosfomycin","condition":"Any Proteus sp. isolate","details":"Disk diffusion and MIC breakpoints for Fosfomycin apply only to E. coli urinary tract isolates and should not be extrapolated to other Enterobacterales species, including Proteus sp."},{"ruleType":"Exclusion","drug":"Imipenem-relebactam","condition":"Any Proteus sp. isolate","details":"Breakpoints for imipenem-relebactam are explicitly stated not to apply to the family Morganellaceae, which includes Proteus."},{"ruleType":"General","drug":"All","condition":"All isolates","details":"Laboratories generally follow cascade reporting rules, meaning that results for broader-spectrum agents (Tier 2 or 3) are often only reported if the isolate is resistant to primary, narrower-spectrum agents (Tier 1)."}],"antimicrobialBreakpoints":[{"tier":1,"tierDescription":"Appropriate for routine, primary testing and reporting.","agents":[{"agentName":"Ampicillin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"14–16 mm","r_breakpoint":"≤ 13 mm"},"mic":{"s_breakpoint":"≤ 8 µg/mL","i_breakpoint":"16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":["Results of ampicillin testing can predict results for amoxicillin."]}]},{"agentName":"Amoxicillin-clavulanate","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":null,"r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/4 µg/mL"},"comments":["Breakpoints when oral amoxicillin-clavulanate is used are only for therapy of uncomplicated UTIs due to E. coli and Proteus mirabilis."]}]},{"agentName":"Ampicillin-sulbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10/10 µg","s_breakpoint":"≥ 15 mm","i_breakpoint":"12–14 mm","r_breakpoint":"≤ 11 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/16 µg/mL"},"comments":[]}]},{"agentName":"Piperacillin-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"100/10 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"21–24 mm","r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/4 µg/mL"},"comments":[]}]},{"agentName":"Gentamicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Tobramycin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"13–16 mm","r_breakpoint":"≤ 12 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Amikacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 19 mm","i_breakpoint":"17–19 mm","r_breakpoint":"≤ 16 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Ciprofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"22–25 mm","r_breakpoint":"≤ 21 mm"},"mic":{"s_breakpoint":"≤ 0.25 µg/mL","i_breakpoint":"0.5 µg/mL","r_breakpoint":"≥ 1 µg/mL"},"comments":[]}]},{"agentName":"Levofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"17–20 mm","r_breakpoint":"≤ 16 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Trimethoprim-sulfamethoxazole","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"1.25/23.75 µg","s_breakpoint":"≥ 16 mm","i_breakpoint":"11–15 mm","r_breakpoint":"≤ 10 mm"},"mic":{"s_breakpoint":"≤ 2/38 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4/76 µg/mL"},"comments":[]}]},{"agentName":"Cefotaxime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"23–25 mm","r_breakpoint":"≤ 22 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Ceftriaxone","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]}]},{"tier":2,"tierDescription":"Appropriate for routine, primary testing, may be reported following cascade reporting rules.","agents":[{"agentName":"Cefuroxime (Parenteral)","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"18–22 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8–16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Cefepime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"19–24 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":["Cefepime S/SDD results should be suppressed or reported as resistant for isolates demonstrating carbapenemase production."]}]},{"agentName":"Ertapenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"19–21 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Imipenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Meropenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Cefotetan","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"13–15 mm","r_breakpoint":"≤ 12 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":"32 µg/mL","r_breakpoint":"≥ 64 µg/mL"},"comments":[]}]},{"agentName":"Cefoxitin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":"32 µg/mL","r_breakpoint":"≥ 64 µg/mL"},"comments":[]}]},{"agentName":"Tetracycline","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 15 mm","i_breakpoint":"12–14 mm","r_breakpoint":"≤ 11 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":["Organisms susceptible to tetracycline are also considered susceptible to doxycycline and minocycline."]}]}]},{"tier":3,"tierDescription":"Appropriate for high-risk Multi-Drug Resistant Organism (MDRO) patients, subject to cascade reporting.","agents":[{"agentName":"Cefiderocol","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 16 mm","i_breakpoint":"9–15 mm","r_breakpoint":"≤ 8 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Ceftazidime-avibactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/20 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":null,"r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 16/4 µg/mL"},"comments":["Confirmatory MIC testing is indicated for isolates with disk diffusion zones of 20–22 mm."]}]},{"agentName":"Imipenem-relebactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10/25 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"21–24 mm","r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 1/4 µg/mL","i_breakpoint":"2/4 µg/mL","r_breakpoint":"≥ 4/4 µg/mL"},"comments":["Important Comment for Proteus sp.: These breakpoints do not apply to the family Morganellaceae, which includes but is not limited to the genera Morganella, Proteus, and Providencia."]}]},{"agentName":"Meropenem-vaborbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4/8 µg/mL","i_breakpoint":"8/8 µg/mL","r_breakpoint":"≥ 16/8 µg/mL"},"comments":["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]},{"agentName":"Plazomicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 2 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]}]},{"tier":4,"tierDescription":"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.","agents":[{"agentName":"Aztreonam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"18–20 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":[]}]},{"agentName":"Ceftazidime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"18–20 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 8 µg/mL","i_breakpoint":"16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Ceftolozane-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"19–21 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 2/4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4/4 µg/mL"},"comments":[]}]},{"agentName":"Colistin or Polymyxin B","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":null,"s_breakpoint":null,"i_breakpoint":null,"r_breakpoint":null},"mic":{"s_breakpoint":"≤ 2 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4 µg/mL"},"comments":["Disk diffusion and gradient diffusion methods should not be performed for these agents. Note: Proteus is intrinsically resistant."]}]}]},{"tier":5,"tierDescription":"Urine Only Tier: Designated for reporting only on organisms isolated from the urinary tract.","agents":[{"agentName":"Cefazolin","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 15 mm","i_breakpoint":null,"r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 32 µg/mL"},"comments":["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},{"agentName":"Nitrofurantoin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"300 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"15–16 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 32 µg/mL","i_breakpoint":"64 µg/mL","r_breakpoint":"≥ 128 µg/mL"},"comments":["Note: Proteus is intrinsically resistant."]}]},{"agentName":"Fosfomycin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"200 µg","s_breakpoint":"≥ 16 mm","i_breakpoint":"13–15 mm","r_breakpoint":"≤ 12 mm"},"mic":{"s_breakpoint":"≤ 64 µg/mL","i_breakpoint":"128 µg/mL","r_breakpoint":"≥ 256 µg/mL"},"comments":["Important Note: Disk diffusion and MIC breakpoints for Fosfomycin apply only to E. coli urinary tract isolates and should not be extrapolated to other Enterobacterales species, which includes Proteus sp."]}]}]}]},"additionalInformation":{"diagnosticNotes":{"summary":"Diagnostic imaging is recommended for upper tract or recurrent infections to assess for stones or obstructive uropathy.","biosafetyWarning":"","methods":[]},"preventionAndScreening":[],"treatmentLifecycle":[],"antimicrobialStewardship":["Reserve carbapenems for mixed infections or for documented ESBL-producing strains.","Reserve ceftazidime-avibactam and meropenem-vaborbactam for documented carbapenemase producers.","Check susceptibility of all carbapenems if use is considered."],"drugSpecificPearls":[{"drugName":"Piperacillin-tazobactam","pearl":"Do not use for suspected or proven ESBL production due to reported clinical failures."},{"drugName":"Ceftazidime-avibactam + Aztreonam","pearl":"The rationale for this combination is to use aztreonam (which is not hydrolyzed by MBLs) and protect it with avibactam from other co-produced beta-lactamases (e.g., ESBLs, AmpC, KPCs)."},{"drugName":"Cefiderocol","pearl":"FDA-approved for complicated UTI with limited alternatives. A trial showed no statistically significant difference in mortality vs best available therapy (BAT)."},{"drugName":"Aztreonam-avibactam","pearl":"This combination is in late stages of development and may be a future option."}],"guidelineReferences":[{"source":"IDSA","citation":"IDSA Guideline on treatment of ESBL, AmpC, and carbapenemase producers: Updated 2024 IDSA Guidelines.","summaryOrNote":"Referenced for treatment strategies against resistant phenotypes."}]}}`),oh={originalKeys:["identity","clinicalProfile","resistanceProfile","treatment","laboratoryProfile","additionalInformation"],conversionTimestamp:"2025-07-15T03:16:49.297Z",sourceFormat:"modern"},rh={bacteriumName:{sources:["identity.bacteriumName"],value:"Proteus sp."},aliases:{sources:["identity.aliases"],value:["Proteus mirabilis","Proteus penneri","Proteus vulgaris"]},lastUpdated:{sources:["identity.lastUpdated"],value:"2025-01-08"},classification:{sources:["identity.classification"],value:{gramStain:"Gram negative",morphology:"bacilli",respiration:"Facultative anaerobe",notes:["motile (swarming on culture plate)"]}}},sh={sources:["clinicalProfile"],value:{summary:"Proteus sp. cause a variety of infections from uncomplicated UTIs to life-threatening infections of the abdomen, skin, soft tissue, and lungs in both normal and immunocompromised hosts. UTIs are the most common and are often catheter-associated.",pathophysiologyPearls:["Known for biofilm formation and producing a potent urease enzyme, which leads to alkaline urine and the formation of struvite stones (magnesium ammonium phosphate)."],keySignsAndSymptoms:[],clinicalSyndromes:[{syndromeName:"Urinary Tract Infections (UTI)",description:"Most common infection type, frequently catheter-associated and can be complicated by the formation of struvite stones due to urease production."},{syndromeName:"Intra-abdominal Infections",description:"Can cause life-threatening infections of the abdomen."},{syndromeName:"Skin and Soft Tissue Infections",description:"Can cause life-threatening infections of the skin and soft tissue."},{syndromeName:"Pneumonia",description:"Can cause life-threatening infections of the lungs."}],stagesOfIllness:[],highRiskPopulations:["Immunocompromised hosts","Patients with urinary catheters"],transmissionVectors:[],prognosisNotes:["Diagnostic imaging is recommended for upper tract or recurrent infections to assess for stones or obstructive uropathy."]}},lh={sources:["resistanceProfile"],value:{groupIntrinsicResistance:[],intrinsicResistance:[{drugOrClass:"Polymyxins",notes:"Proteus species are intrinsically resistant to polymyxins (Colistin, Polymyxin B)."},{drugOrClass:"Nitrofurantoin",notes:"Proteus spp. are intrinsically resistant to Nitrofurantoin."}],majorMechanisms:[{mechanismName:"ESBL (Extended-Spectrum Beta-Lactamase)",mechanismType:"Enzymatic",description:"Confers resistance to most penicillins and cephalosporins. Indole positive species (P. vulgaris) may overproduce ESBLs."},{mechanismName:"AmpC Beta-Lactamase",mechanismType:"Enzymatic",description:"Resistance to aztreonam, ceftriaxone, and/or cefotaxime may indicate overproduction of AmpC."},{mechanismName:"KPC (Klebsiella pneumoniae carbapenemase)",mechanismType:"Enzymatic",description:"A serine-based carbapenemase conferring resistance to all carbapenems. Can be overcome by new beta-lactamase inhibitor combinations like meropenem-vaborbactam or ceftazidime-avibactam."},{mechanismName:"MBL (Metallo-Beta-Lactamase)",mechanismType:"Enzymatic",description:"Confers resistance to all carbapenems and newer beta-lactamase inhibitors (vaborbactam, avibactam). Requires alternative strategies like ceftazidime-avibactam + aztreonam or cefiderocol."}],clinicalAlerts:[{alertTitle:"ESBL Production and Piperacillin-Tazobactam",details:"Do not use piperacillin-tazobactam for suspected or proven ESBL production, as it may fail clinically despite in vitro susceptibility."},{alertTitle:"Carbapenem Activity Variability",details:"Imipenem is noted to be less active against Proteus spp. compared to other carbapenems. Check susceptibility of all carbapenems if considering their use."}]}},ch=JSON.parse('{"treatmentData":{"_treatmentMetadata":{"originalFormat":"modern"},"standardizedRegimens":[{"regimenId":"modern-0-0-0","extractedFrom":"treatment.regimens[0].recommendations[0].steps[0]","context":{"type":"empiric","condition":"Moderately severe or severe infection","severity":"severe","patientFactors":{"population":["Areas with local ESBL rate <15%"],"labFindings":null}},"preference":"primary","drugs":[{"drugName":"Piperacillin-tazobactam","dose":"4.5 gm","route":"IV","frequency":"q8h","duration":"pending susceptibilities","comments":"Administer over 4 hours.","originalText":"Piperacillin-tazobactam 4.5 gm IV q8h"}]},{"regimenId":"modern-0-1-0","extractedFrom":"treatment.regimens[0].recommendations[1].steps[0]","context":{"type":"empiric","condition":"Moderately severe or severe infection","severity":"severe","patientFactors":{"population":["Areas with local ESBL rate <15%"],"labFindings":null}},"preference":"alternative","drugs":[{"drugName":"Ciprofloxacin","dose":"400 mg","route":"IV","frequency":"bid","duration":"pending susceptibilities","comments":"","originalText":"Ciprofloxacin 400 mg IV bid"}]},{"regimenId":"modern-0-2-0","extractedFrom":"treatment.regimens[0].recommendations[2].steps[0]","context":{"type":"empiric","condition":"Moderately severe or severe infection","severity":"severe","patientFactors":{"population":["Areas with local ESBL rate <15%"],"labFindings":null}},"preference":"alternative","drugs":[{"drugName":"Levofloxacin","dose":"750 mg","route":"IV","frequency":"q24h","duration":"pending susceptibilities","comments":"","originalText":"Levofloxacin 750 mg IV q24h"}]},{"regimenId":"modern-0-3-0","extractedFrom":"treatment.regimens[0].recommendations[3].steps[0]","context":{"type":"empiric","condition":"Moderately severe or severe infection","severity":"severe","patientFactors":{"population":["Areas with local ESBL rate <15%"],"labFindings":null}},"preference":"alternative","drugs":[{"drugName":"Cefazolin","dose":"1 gm","route":"IV","frequency":"q12h","duration":"pending susceptibilities","comments":"","originalText":"Cefazolin 1 gm IV q12h"}]},{"regimenId":"modern-0-4-0","extractedFrom":"treatment.regimens[0].recommendations[4].steps[0]","context":{"type":"empiric","condition":"Moderately severe or severe infection","severity":"severe","patientFactors":{"population":["Areas with local ESBL rate <15%"],"labFindings":null}},"preference":"alternative","drugs":[{"drugName":"Ceftriaxone","dose":"1-2 gm","route":"IV","frequency":"q24h","duration":"pending susceptibilities","comments":"","originalText":"Ceftriaxone 1-2 gm IV q24h"}]},{"regimenId":"modern-1-0-0","extractedFrom":"treatment.regimens[1].recommendations[0].steps[0]","context":{"type":"empiric","condition":"Moderately severe or severe infection","severity":"severe","patientFactors":{"population":["Areas with local ESBL rate >15%"],"labFindings":null}},"preference":"primary","drugs":[{"drugName":"Meropenem","dose":"1-2 gm","route":"IV","frequency":"q8h","duration":"pending susceptibilities","comments":"See alternative regimens for other options.","originalText":"Meropenem 1-2 gm IV q8h"}]},{"regimenId":"modern-2-0-0","extractedFrom":"treatment.regimens[2].recommendations[0].steps[0]","context":{"type":"directed","condition":"Indole positive Proteus (e.g., vulgaris) with resistance to aztreonam, ceftriaxone, and/or cefotaxime","severity":"unknown","patientFactors":{"population":["Patients with isolates consistent with overproduction of ESBL and/or AmpC"],"labFindings":null}},"preference":"primary","drugs":[{"drugName":"Meropenem","dose":"1-2 gm","route":"IV","frequency":"q8h","duration":"Course of therapy","comments":"Higher percentage of in vitro resistance to Imipenem compared to other carbapenems. Avoid Pip/tazo if ESBL production is suspected.","originalText":"Meropenem 1-2 gm IV q8h"}]},{"regimenId":"modern-2-1-0","extractedFrom":"treatment.regimens[2].recommendations[1].steps[0]","context":{"type":"directed","condition":"Indole positive Proteus (e.g., vulgaris) with resistance to aztreonam, ceftriaxone, and/or cefotaxime","severity":"unknown","patientFactors":{"population":["Patients with isolates consistent with overproduction of ESBL and/or AmpC"],"labFindings":null}},"preference":"alternative","drugs":[{"drugName":"Ertapenem","dose":"1 gm","route":"IV","frequency":"q24hr","duration":"Course of therapy","comments":"See other alternatives if needed.","originalText":"Ertapenem 1 gm IV q24hr"}]},{"regimenId":"modern-3-0-0","extractedFrom":"treatment.regimens[3].recommendations[0].steps[0]","context":{"type":"directed","condition":"Carbapenem resistance, KPC suspected","severity":"unknown","patientFactors":{"population":["Isolates resistant to all carbapenems but susceptible to meropenem-vaborbactam and ceftazidime-avibactam"],"labFindings":null}},"preference":"primary","drugs":[{"drugName":"Meropenem-vaborbactam","dose":"4 gm","route":"IV","frequency":"q8h","duration":"Course of therapy","comments":"Administer over 3 hours. Infectious Diseases consultation recommended.","originalText":"Meropenem-vaborbactam 4 gm IV q8h"}]},{"regimenId":"modern-3-1-0","extractedFrom":"treatment.regimens[3].recommendations[1].steps[0]","context":{"type":"directed","condition":"Carbapenem resistance, KPC suspected","severity":"unknown","patientFactors":{"population":["Isolates resistant to all carbapenems but susceptible to meropenem-vaborbactam and ceftazidime-avibactam"],"labFindings":null}},"preference":"alternative","drugs":[{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"q8h","duration":"Course of therapy","comments":"Administer over 2 hours. Infectious Diseases consultation recommended.","originalText":"Ceftazidime-avibactam 2.5 gm IV q8h"}]},{"regimenId":"modern-4-0-0","extractedFrom":"treatment.regimens[4].recommendations[0].steps[0]","context":{"type":"directed","condition":"Carbapenem resistance, Metallo-beta-lactamase (MBL) suspected","severity":"unknown","patientFactors":{"population":["Isolates resistant to all carbapenems, meropenem-vaborbactam, and ceftazidime-avibactam"],"labFindings":null}},"preference":"primary","drugs":[{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"q8h","duration":"Course of therapy","comments":"Administer over 3 hours.","originalText":"Ceftazidime-avibactam 2.5 gm IV q8h"},{"drugName":"Aztreonam","dose":"2 gm","route":"IV","frequency":"q6h","duration":"Course of therapy","comments":"Administer over 3 hours. Infectious Diseases consultation strongly recommended.","originalText":"Aztreonam 2 gm IV q6h"}]},{"regimenId":"modern-4-1-0","extractedFrom":"treatment.regimens[4].recommendations[1].steps[0]","context":{"type":"directed","condition":"Carbapenem resistance, Metallo-beta-lactamase (MBL) suspected","severity":"unknown","patientFactors":{"population":["Isolates resistant to all carbapenems, meropenem-vaborbactam, and ceftazidime-avibactam"],"labFindings":null}},"preference":"alternative","drugs":[{"drugName":"Cefiderocol","dose":"2 gm","route":"IV","frequency":"q8h","duration":"Course of therapy","comments":"Administer over 3 hours. Infectious Diseases consultation strongly recommended.","originalText":"Cefiderocol 2 gm IV q8h"}]},{"regimenId":"modern-5-0-0","extractedFrom":"treatment.regimens[5].recommendations[0].steps[0]","context":{"type":"directed","condition":"Less severe infection, no evidence of ESBL or plasmid-based AmpC production","severity":"severe","patientFactors":{"population":[],"labFindings":null}},"preference":"alternative","drugs":[{"drugName":"Cefixime","dose":"Varies","route":"PO","frequency":"Varies","duration":"Course of therapy","comments":"","originalText":"Cefixime Varies PO Varies"},{"drugName":"Cefpodoxime","dose":"Varies","route":"PO","frequency":"Varies","duration":"Course of therapy","comments":"","originalText":"Cefpodoxime Varies PO Varies"},{"drugName":"Cefdinir","dose":"Varies","route":"PO","frequency":"Varies","duration":"Course of therapy","comments":"","originalText":"Cefdinir Varies PO Varies"}]},{"regimenId":"modern-5-1-0","extractedFrom":"treatment.regimens[5].recommendations[1].steps[0]","context":{"type":"directed","condition":"Less severe infection, no evidence of ESBL or plasmid-based AmpC production","severity":"severe","patientFactors":{"population":[],"labFindings":null}},"preference":"alternative","drugs":[{"drugName":"Fosfomycin","dose":"3 gm","route":"PO","frequency":"x1","duration":"1 dose","comments":"For UTI only. Use is discouraged for Proteus sp. as breakpoints are only for E.coli.","originalText":"Fosfomycin 3 gm PO x1"}]},{"regimenId":"modern-6-0-0","extractedFrom":"treatment.regimens[6].recommendations[0].steps[0]","context":{"type":"directed","condition":"Any infection","severity":"unknown","patientFactors":{"population":["Patients with a severe beta-lactam allergy"],"labFindings":null}},"preference":"primary","drugs":[{"drugName":"Aztreonam","dose":"Varies","route":"IV","frequency":"Varies","duration":"Course of therapy","comments":"","originalText":"Aztreonam Varies IV Varies"}]},{"regimenId":"modern-7-0-0","extractedFrom":"treatment.regimens[7].recommendations[0].steps[0]","context":{"type":"directed","condition":"ESBL-producing infection","severity":"unknown","patientFactors":{"population":["Patient cannot receive a carbapenem"],"labFindings":null}},"preference":"alternative","drugs":[{"drugName":"Aminoglycoside","dose":"Varies","route":"IV","frequency":"Varies","duration":"Course of therapy","comments":"If susceptible.","originalText":"Aminoglycoside Varies IV Varies"},{"drugName":"Fluoroquinolone","dose":"Varies","route":"IV/PO","frequency":"Varies","duration":"Course of therapy","comments":"If susceptible.","originalText":"Fluoroquinolone Varies IV/PO Varies"},{"drugName":"Ceftolozane-tazobactam","dose":"1.5 gm","route":"IV","frequency":"q8h","duration":"Course of therapy","comments":"Administer over 3 hours.","originalText":"Ceftolozane-tazobactam 1.5 gm IV q8h"},{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"q8h","duration":"Course of therapy","comments":"Administer over 3 hours.","originalText":"Ceftazidime-avibactam 2.5 gm IV q8h"},{"drugName":"Cefepime-enmetazobactam","dose":"Varies","route":"IV","frequency":"Varies","duration":"Course of therapy","comments":"","originalText":"Cefepime-enmetazobactam Varies IV Varies"},{"drugName":"Temocillin","dose":"2 gm","route":"IV","frequency":"q12h","duration":"Course of therapy","comments":"Where available.","originalText":"Temocillin 2 gm IV q12h"}]},{"regimenId":"modern-8-0-0","extractedFrom":"treatment.regimens[8].recommendations[0].steps[0]","context":{"type":"directed","condition":"Pan-resistant infection","severity":"unknown","patientFactors":{"population":[],"labFindings":null}},"preference":"primary","drugs":[{"drugName":"Plazomicin","dose":"15 mg/kg","route":"IV","frequency":"once daily","duration":"Course of therapy","comments":"If available. Infectious Diseases consultation needed.","originalText":"Plazomicin 15 mg/kg IV once daily"}]}]}}'),dh=JSON.parse(`{"sources":["laboratoryProfile"],"value":{"testingIndications":["Cultures obtained from suspected sites of infection, such as urine, blood, wounds, or respiratory specimens."],"methodologyNotes":["Proteus species are known for their characteristic 'swarming' motility on non-inhibitory agar plates, which can sometimes complicate the isolation of other organisms in a mixed culture."],"recommendedPanel":[],"specialTests":[{"testName":"Indole Test","trigger":"Isolation of Proteus sp.","purpose":"To differentiate between Proteus species. P. vulgaris is indole positive, while P. mirabilis and P. penneri are indole negative. This can have treatment implications as P. vulgaris may have different resistance patterns."}],"reportingRules":[{"ruleType":"Surrogate","drug":"Ampicillin","condition":"All isolates","details":"Results of ampicillin testing can be used to predict results for amoxicillin."},{"ruleType":"Surrogate","drug":"Cefazolin","condition":"Uncomplicated UTI caused by P. mirabilis","details":"Cefazolin can be used as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."},{"ruleType":"Surrogate","drug":"Tetracycline","condition":"All isolates","details":"Organisms susceptible to tetracycline are also considered susceptible to doxycycline and minocycline."},{"ruleType":"Conditional","drug":"Cefepime","condition":"Isolate demonstrates carbapenemase production.","details":"Cefepime S/SDD results should be suppressed or reported as resistant."},{"ruleType":"Conditional","drug":"Meropenem-vaborbactam","condition":"An OXA-48-like gene or enzyme is detected.","details":"Results should be suppressed or reported as resistant."},{"ruleType":"Exclusion","drug":"Fosfomycin","condition":"Any Proteus sp. isolate","details":"Disk diffusion and MIC breakpoints for Fosfomycin apply only to E. coli urinary tract isolates and should not be extrapolated to other Enterobacterales species, including Proteus sp."},{"ruleType":"Exclusion","drug":"Imipenem-relebactam","condition":"Any Proteus sp. isolate","details":"Breakpoints for imipenem-relebactam are explicitly stated not to apply to the family Morganellaceae, which includes Proteus."},{"ruleType":"General","drug":"All","condition":"All isolates","details":"Laboratories generally follow cascade reporting rules, meaning that results for broader-spectrum agents (Tier 2 or 3) are often only reported if the isolate is resistant to primary, narrower-spectrum agents (Tier 1)."}],"antimicrobialBreakpoints":[{"tier":1,"tierDescription":"Appropriate for routine, primary testing and reporting.","agents":[{"agentName":"Ampicillin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"14–16 mm","r_breakpoint":"≤ 13 mm"},"mic":{"s_breakpoint":"≤ 8 µg/mL","i_breakpoint":"16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":["Results of ampicillin testing can predict results for amoxicillin."]}]},{"agentName":"Amoxicillin-clavulanate","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":null,"r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/4 µg/mL"},"comments":["Breakpoints when oral amoxicillin-clavulanate is used are only for therapy of uncomplicated UTIs due to E. coli and Proteus mirabilis."]}]},{"agentName":"Ampicillin-sulbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10/10 µg","s_breakpoint":"≥ 15 mm","i_breakpoint":"12–14 mm","r_breakpoint":"≤ 11 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/16 µg/mL"},"comments":[]}]},{"agentName":"Piperacillin-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"100/10 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"21–24 mm","r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/4 µg/mL"},"comments":[]}]},{"agentName":"Gentamicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Tobramycin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"13–16 mm","r_breakpoint":"≤ 12 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Amikacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 19 mm","i_breakpoint":"17–19 mm","r_breakpoint":"≤ 16 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Ciprofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"22–25 mm","r_breakpoint":"≤ 21 mm"},"mic":{"s_breakpoint":"≤ 0.25 µg/mL","i_breakpoint":"0.5 µg/mL","r_breakpoint":"≥ 1 µg/mL"},"comments":[]}]},{"agentName":"Levofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"17–20 mm","r_breakpoint":"≤ 16 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Trimethoprim-sulfamethoxazole","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"1.25/23.75 µg","s_breakpoint":"≥ 16 mm","i_breakpoint":"11–15 mm","r_breakpoint":"≤ 10 mm"},"mic":{"s_breakpoint":"≤ 2/38 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4/76 µg/mL"},"comments":[]}]},{"agentName":"Cefotaxime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"23–25 mm","r_breakpoint":"≤ 22 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Ceftriaxone","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]}]},{"tier":2,"tierDescription":"Appropriate for routine, primary testing, may be reported following cascade reporting rules.","agents":[{"agentName":"Cefuroxime (Parenteral)","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"18–22 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8–16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Cefepime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"19–24 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":["Cefepime S/SDD results should be suppressed or reported as resistant for isolates demonstrating carbapenemase production."]}]},{"agentName":"Ertapenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"19–21 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Imipenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Meropenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Cefotetan","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"13–15 mm","r_breakpoint":"≤ 12 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":"32 µg/mL","r_breakpoint":"≥ 64 µg/mL"},"comments":[]}]},{"agentName":"Cefoxitin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":"32 µg/mL","r_breakpoint":"≥ 64 µg/mL"},"comments":[]}]},{"agentName":"Tetracycline","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 15 mm","i_breakpoint":"12–14 mm","r_breakpoint":"≤ 11 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":["Organisms susceptible to tetracycline are also considered susceptible to doxycycline and minocycline."]}]}]},{"tier":3,"tierDescription":"Appropriate for high-risk Multi-Drug Resistant Organism (MDRO) patients, subject to cascade reporting.","agents":[{"agentName":"Cefiderocol","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 16 mm","i_breakpoint":"9–15 mm","r_breakpoint":"≤ 8 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Ceftazidime-avibactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/20 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":null,"r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 16/4 µg/mL"},"comments":["Confirmatory MIC testing is indicated for isolates with disk diffusion zones of 20–22 mm."]}]},{"agentName":"Imipenem-relebactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10/25 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"21–24 mm","r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 1/4 µg/mL","i_breakpoint":"2/4 µg/mL","r_breakpoint":"≥ 4/4 µg/mL"},"comments":["Important Comment for Proteus sp.: These breakpoints do not apply to the family Morganellaceae, which includes but is not limited to the genera Morganella, Proteus, and Providencia."]}]},{"agentName":"Meropenem-vaborbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4/8 µg/mL","i_breakpoint":"8/8 µg/mL","r_breakpoint":"≥ 16/8 µg/mL"},"comments":["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]},{"agentName":"Plazomicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 2 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]}]},{"tier":4,"tierDescription":"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.","agents":[{"agentName":"Aztreonam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"18–20 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":[]}]},{"agentName":"Ceftazidime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"18–20 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 8 µg/mL","i_breakpoint":"16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Ceftolozane-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"19–21 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 2/4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4/4 µg/mL"},"comments":[]}]},{"agentName":"Colistin or Polymyxin B","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":null,"s_breakpoint":null,"i_breakpoint":null,"r_breakpoint":null},"mic":{"s_breakpoint":"≤ 2 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4 µg/mL"},"comments":["Disk diffusion and gradient diffusion methods should not be performed for these agents. Note: Proteus is intrinsically resistant."]}]}]},{"tier":5,"tierDescription":"Urine Only Tier: Designated for reporting only on organisms isolated from the urinary tract.","agents":[{"agentName":"Cefazolin","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 15 mm","i_breakpoint":null,"r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 32 µg/mL"},"comments":["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},{"agentName":"Nitrofurantoin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"300 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"15–16 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 32 µg/mL","i_breakpoint":"64 µg/mL","r_breakpoint":"≥ 128 µg/mL"},"comments":["Note: Proteus is intrinsically resistant."]}]},{"agentName":"Fosfomycin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"200 µg","s_breakpoint":"≥ 16 mm","i_breakpoint":"13–15 mm","r_breakpoint":"≤ 12 mm"},"mic":{"s_breakpoint":"≤ 64 µg/mL","i_breakpoint":"128 µg/mL","r_breakpoint":"≥ 256 µg/mL"},"comments":["Important Note: Disk diffusion and MIC breakpoints for Fosfomycin apply only to E. coli urinary tract isolates and should not be extrapolated to other Enterobacterales species, which includes Proteus sp."]}]}]}]}}`),mh={antimicrobialStewardship:{sources:["antimicrobial_stewardship","antimicrobialStewardship"],value:[]},comments:{preservedStructure:{originalFormat:"object"}},diagnosis:{sources:["diagnosis"],value:[]},allOtherKeys:{}},uh={_originalData:nh,_metadata:oh,identity:rh,clinicalInformation:sh,resistanceInformation:lh,treatmentData:ch,laboratoryData:dh,additionalData:mh},ph=JSON.parse('{"identity":{"bacteriumName":"Providencia species","aliases":["Providencia stuartii","Providencia rettgeri","Providencia alcalifaciens","Providencia rustigianii"],"lastUpdated":"2025-01-17","clsiCategory":"Enterobacterales (excluding Salmonella/Shigella)","classification":{"gramStain":"Gram negative","morphology":"Bacilli","respiration":"Facultative anaerobe","notes":[]},"strainDetails":[{"type":"Species","value":"Providencia stuartii","notes":"Generally the most resistant species, frequently produces ESBLs, and 50% or more of isolates are resistant to aminoglycosides and fluoroquinolones."},{"type":"Species","value":"Providencia rettgeri","notes":"Susceptibility falls between that of P. stuartii and P. alcalifaciens."},{"type":"Species","value":"Providencia alcalifaciens","notes":"More often susceptible to penicillins and older cephalosporins."},{"type":"Species","value":"Providencia rustigianii","notes":"More often susceptible to penicillins and older cephalosporins."}],"biochemicalTests":"Gram-negative rod, motile, lactose –, H2S –, indole +, citrate +, urease +, phenylalanine deaminase +."},"clinicalProfile":{"summary":"Providencia species are typically nosocomial pathogens isolated from urine, blood, or wounds, causing a range of infections. They are known for several resistance mechanisms.","pathophysiologyPearls":["Providencia spp. may initially test susceptible to third-generation cephalosporins (like ceftriaxone) but have the potential to develop resistance during therapy due to the derepression of an inducible AmpC β-lactamase.","The risk of AmpC derepression during therapy appears to be less frequent with Providencia spp. compared to organisms like C. freundii complex or E. cloacae complex."],"keySignsAndSymptoms":[],"clinicalSyndromes":[{"syndromeName":"Urinary Tract Infections (UTI)","description":"Common infection site, especially in nosocomial settings. Isolates are often multidrug-resistant."},{"syndromeName":"Bacteremia","description":"Bloodstream infections, often originating from another site like the urinary tract."},{"syndromeName":"Wound Infections","description":"Can colonize and infect surgical or traumatic wounds."}],"stagesOfIllness":[],"highRiskPopulations":["Hospitalized patients"],"transmissionVectors":[],"prognosisNotes":[]},"resistanceProfile":{"groupIntrinsicResistance":[],"intrinsicResistance":[{"drugOrClass":"Polymyxins","notes":"Providencia species are intrinsically resistant to polymyxins."},{"drugOrClass":"Nitrofurantoin","notes":"Usually resistant."},{"drugOrClass":"Tigecycline","notes":"May have in vitro activity but its clinical efficacy is questionable due to low serum levels."}],"majorMechanisms":[{"mechanismName":"Inducible AmpC β-lactamase","mechanismType":"Enzymatic Inactivation","description":"Organisms can develop resistance during therapy with third-generation cephalosporins due to derepression of an inducible AmpC gene, though this is less frequent than in other SPACE-M organisms."},{"mechanismName":"Extended-Spectrum Beta-Lactamases (ESBLs)","mechanismType":"Enzymatic Inactivation","description":"Frequently produced, especially by P. stuartii. For ESBL producers, piperacillin-tazobactam should be avoided even if susceptible in vitro due to risk of clinical failures."},{"mechanismName":"Serine-based Carbapenemase (e.g., KPC)","mechanismType":"Enzymatic Inactivation","description":"Production of enzymes like KPC can lead to resistance to carbapenems, fluoroquinolones, and aminoglycosides."},{"mechanismName":"Metallo-carbapenemase (MBL)","mechanismType":"Enzymatic Inactivation","description":"Production results in a resistance pattern that includes newer agents like ceftazidime-avibactam and meropenem-vaborbactam."}],"clinicalAlerts":[{"alertTitle":"Species-Dependent Resistance","details":"Resistance patterns vary significantly by species. P. stuartii is generally the most resistant, while P. alcalifaciens is often more susceptible."}]},"treatment":{"generalNotes":["Recommendations are for moderately severe or severe infections where resistance is a concern.","For uncomplicated or less severe infections with susceptible strains, options include Amoxicillin-clavulanate, fluoroquinolones, and second/third-generation cephalosporins.","TMP-SMX is an option only if susceptible, as resistance is common.","Imipenem is less active than other carbapenems.","Oral Fosfomycin is an option for uncomplicated UTI."],"drugsToAvoid":[{"drugOrClass":"Piperacillin-tazobactam","condition":"ESBL-producing infections","reason":"Risk of clinical failures despite in vitro susceptibility."}],"adjunctiveTherapies":[],"regimens":[{"context":{"type":"Empiric","condition":"Suspected Providencia sp. infection","patientPopulation":["Local ESBL rate <10-15%"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Piperacillin-tazobactam","dose":"4.5 gm","route":"IV","frequency":"q8h","comments":"Infuse over 4 hours."},{"drugName":"Ceftriaxone","dose":"1-2 gm","route":"IV","frequency":"q24h","comments":""},{"drugName":"Cefepime","dose":"1-2 gm","route":"IV","frequency":"q8h-q12h","comments":""},{"drugName":"Ciprofloxacin","dose":"400 mg IV or 750 mg PO","route":"IV/PO","frequency":"q12h","comments":""}]}],"notes":["For life-threatening infection, consider Meropenem 2 gm over 3h IV q8h."]}]},{"context":{"type":"Empiric","condition":"Suspected Providencia sp. infection","patientPopulation":["Local ESBL rate >15%"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Meropenem","dose":"1-2 gm","route":"IV","frequency":"q8h","comments":""}]}],"notes":["For life-threatening infection, consider Meropenem 2 gm over 3h IV q8h."]}]},{"context":{"type":"Directed","condition":"Broadly susceptible isolate","patientPopulation":["Susceptible to aztreonam, ceftriaxone, ceftazidime, cefepime, piperacillin-tazobactam"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Piperacillin-tazobactam","dose":"4.5 gm","route":"IV","frequency":"q8h","comments":"Infuse over 4 hours."},{"drugName":"Ceftriaxone","dose":"1-2 gm","route":"IV","frequency":"q24h","comments":""},{"drugName":"Cefepime","dose":"1-2 gm","route":"IV","frequency":"q8h to q12h","comments":"May be considered over Ceftriaxone for high inoculum infections or if source control is limited due to its greater stability to AmpC."},{"drugName":"Ciprofloxacin","dose":"400 mg IV or 750 mg PO","route":"IV/PO","frequency":"q12h","comments":""},{"drugName":"Aztreonam","dose":"2 gm","route":"IV","frequency":"q6-8h","comments":"Option for patients with penicillin allergy."}]}]}]},{"context":{"type":"Directed","condition":"ESBL Producer","patientPopulation":["Resistant to Aztreonam, Ceftriaxone, Cefotaxime, Ceftazidime, or Cefepime"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Meropenem","dose":"1-2 gm","route":"IV","frequency":"q8h","comments":""},{"drugName":"Ertapenem","dose":"1 gm","route":"IV","frequency":"q24h","comments":""}]}]},{"preference":"Alternative (if susceptible)","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ciprofloxacin","dose":"400 mg IV or 750 mg PO","route":"IV/PO","frequency":"bid","comments":""},{"drugName":"Levofloxacin","dose":"750 mg","route":"IV/PO","frequency":"once daily","comments":""}]}]}]},{"context":{"type":"Directed","condition":"Serine-based Carbapenemase (e.g., KPC) Producer","patientPopulation":["Resistant to carbapenems, fluoroquinolones, and aminoglycosides"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"q8h","comments":"Infuse over 3 hours."},{"drugName":"Meropenem-vaborbactam","dose":"4 gm","route":"IV","frequency":"q8h","comments":"Infuse over 3 hours."}]}],"notes":["Infectious diseases consultation recommended."]}]},{"context":{"type":"Directed","condition":"Metallo-carbapenemase (MBL) Producer","patientPopulation":["Resistant to KPC-inhibitors, fluoroquinolones, aminoglycosides, TMP-SMX"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"q8h","comments":"Infuse over 3 hours."},{"drugName":"Aztreonam","dose":"2 gm","route":"IV","frequency":"q8h","comments":"Infuse over 3 hours. Must be given with Ceftazidime-avibactam."}]}]},{"preference":"Alternative","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Cefiderocol","dose":"2 gm","route":"IV","frequency":"q8h","comments":"Infuse over 3 hours."}]}],"notes":["Infectious diseases consult recommended. Based on in vitro susceptibility, meropenem-vaborbactam plus aztreonam may prove effective."]}]},{"context":{"type":"Alternative","condition":"Severe IgE-mediated allergy to beta-lactams","patientPopulation":["Isolate is susceptible in vitro"],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Aztreonam","dose":"2 gm","route":"IV","frequency":"q6-8h","comments":""},{"drugName":"Ciprofloxacin","dose":"400 mg IV or 750 mg po","route":"IV/PO","frequency":"bid","comments":""},{"drugName":"Levofloxacin","dose":"750 mg","route":"IV/PO","frequency":"once daily","comments":""}]}]}]},{"context":{"type":"Alternative","condition":"ESBL and/or AmpC producing strains","patientPopulation":[],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftolozane-tazobactam","dose":"1.5 gm","route":"IV","frequency":"q8h","comments":"Infuse over 3 hours."},{"drugName":"Temocillin","dose":"2 gm","route":"IV","frequency":"q12h","comments":"Where available."}]}]}]},{"context":{"type":"Salvage","condition":"Pan-resistant infection","patientPopulation":[],"isolateSource":null},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftazidime-avibactam + Aztreonam","dose":"Varies","route":"IV","frequency":"Varies","comments":"Combination therapy."},{"drugName":"Fosfomycin IV","dose":"Varies","route":"IV","frequency":"Varies","comments":"Where available, requires emergency IND from FDA."},{"drugName":"Plazomicin","dose":"15 mg/kg","route":"IV","frequency":"q24h","comments":"For complicated UTIs only."}]}],"notes":["Infectious Diseases consultation suggested."]}]}]},"laboratoryProfile":{"testingIndications":[],"methodologyNotes":[],"recommendedPanel":[],"specialTests":[],"reportingRules":[{"ruleType":"Exception","drug":"Imipenem-relebactam","condition":"Isolate is identified as Providencia species.","details":"CLSI breakpoints for Imipenem-relebactam do not apply to the family Morganellaceae, which includes Providencia. Testing or reporting this agent is not recommended based on these breakpoints."},{"ruleType":"Exception","drug":"Fosfomycin","condition":"Isolate is not E. coli from a urinary tract source.","details":"Breakpoints for Fosfomycin apply only to E. coli and should not be extrapolated to Providencia species."},{"ruleType":"Conditional","drug":"Cefepime","condition":"Carbapenemase production is identified.","details":"Cefepime S/SDD results should be suppressed or reported as resistant."},{"ruleType":"General","drug":"Third-generation cephalosporins","condition":"Isolate is Providencia species.","details":"Providencia spp. can derepress inducible AmpC β-lactamase, potentially leading to resistance during therapy despite initial susceptibility to agents like ceftriaxone."}],"antimicrobialBreakpoints":[{"tier":1,"tierDescription":"Appropriate for routine, primary testing and reporting.","agents":[{"agentName":"Ampicillin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"14–16 mm","r_breakpoint":"≤ 13 mm"},"mic":{"s_breakpoint":"≤ 8 µg/mL","i_breakpoint":"16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":["Results of ampicillin testing can predict results for amoxicillin."]}]},{"agentName":"Amoxicillin-clavulanate","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":null,"r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/4 µg/mL"},"comments":["Breakpoints apply for therapy of uncomplicated UTIs or for completion of therapy for systemic infection."]}]},{"agentName":"Piperacillin-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"100/10 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"21–24 mm","r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/4 µg/mL"},"comments":[]}]},{"agentName":"Gentamicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Tobramycin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"13–16 mm","r_breakpoint":"≤ 12 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Amikacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 19 mm","i_breakpoint":"17–18 mm","r_breakpoint":"≤ 16 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Ciprofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"22–25 mm","r_breakpoint":"≤ 21 mm"},"mic":{"s_breakpoint":"≤ 0.25 µg/mL","i_breakpoint":"0.5 µg/mL","r_breakpoint":"≥ 1 µg/mL"},"comments":[]}]},{"agentName":"Levofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"17–20 mm","r_breakpoint":"≤ 16 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Trimethoprim-sulfamethoxazole","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"1.25/23.75 µg","s_breakpoint":"≥ 16 mm","i_breakpoint":"11–15 mm","r_breakpoint":"≤ 10 mm"},"mic":{"s_breakpoint":"≤ 2/38 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4/76 µg/mL"},"comments":[]}]}]},{"tier":2,"tierDescription":"Appropriate for routine, primary testing, may be reported following cascade reporting rules.","agents":[{"agentName":"Cefuroxime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"15–22 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8–16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Cefepime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"19–24 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":["Cefepime S/SDD results should be suppressed or reported as resistant for isolates demonstrating carbapenemase production."]}]},{"agentName":"Ertapenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"19–21 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Imipenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Meropenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]}]},{"tier":3,"tierDescription":"Appropriate for high-risk MDRO patients, subject to cascade reporting.","agents":[{"agentName":"Cefiderocol","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 20 mm","i_breakpoint":"9–15 mm","r_breakpoint":"≤ 8 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Ceftazidime-avibactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/20 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":null,"r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 16/4 µg/mL"},"comments":["Confirmatory MIC testing is indicated for isolates with disk diffusion zones of 20–22 mm."]}]},{"agentName":"Imipenem-relebactam","breakpointSets":[{"condition":"Standard","diskDiffusion":null,"mic":null,"comments":["Important Note: The breakpoints for Imipenem-relebactam do not apply to the family Morganellaceae, which includes Morganella, Proteus, and Providencia. Therefore, testing or reporting for Providencia with this agent using these breakpoints is not recommended by CLSI."]}]},{"agentName":"Meropenem-vaborbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4/8 µg/mL","i_breakpoint":"8/8 µg/mL","r_breakpoint":"≥ 16/8 µg/mL"},"comments":["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]},{"agentName":"Plazomicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 2 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]}]},{"tier":4,"tierDescription":"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.","agents":[{"agentName":"Aztreonam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"18–20 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":[]}]},{"agentName":"Ceftriaxone","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Ceftazidime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"18–20 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 8 µg/mL","i_breakpoint":"16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Ceftolozane-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"19–21 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 2/4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4/4 µg/mL"},"comments":[]}]},{"agentName":"Colistin or Polymyxin B","breakpointSets":[{"condition":"Standard","diskDiffusion":null,"mic":{"s_breakpoint":"≤ 2 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4 µg/mL"},"comments":["Disk diffusion and gradient diffusion methods should not be performed for these agents.","Note: Providencia is intrinsically resistant."]}]}]},{"tier":5,"tierDescription":"Urine Only Tier","agents":[{"agentName":"Cefazolin","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 15 mm","i_breakpoint":null,"r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 32 µg/mL"},"comments":["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},{"agentName":"Nitrofurantoin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"300 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"15–16 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 32 µg/mL","i_breakpoint":"64 µg/mL","r_breakpoint":"≥ 128 µg/mL"},"comments":["Note: Providencia is usually resistant."]}]},{"agentName":"Fosfomycin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":null,"mic":null,"comments":["Important Note: Disk diffusion and MIC breakpoints for Fosfomycin apply only to E. coli urinary tract isolates and should not be extrapolated to other Enterobacterales species."]}]}]}]},"additionalInformation":{"diagnosticNotes":{"summary":"","biosafetyWarning":"","methods":[]},"preventionAndScreening":[],"treatmentLifecycle":[],"antimicrobialStewardship":["For ESBL producers, avoid piperacillin-tazobactam even if susceptible in vitro due to clinical failures.","Providencia sp. are intrinsically resistant to Polymyxins and usually resistant to nitrofurantoin.","Tigecycline may have in vitro activity but its clinical efficacy is questionable due to low serum levels.","If the source of infection is the urinary tract, Providencia sp. are usually multidrug-resistant."],"drugSpecificPearls":[{"drugName":"Cefiderocol","pearl":"FDA-approved for complicated UTI with limited or no alternative treatment options. In a trial, mortality at 28 days was 24.8% for cefiderocol vs 18.4% for Best Available Therapy (not statistically significant)."}],"guidelineReferences":[{"source":"IDSA","citation":"IDSA Guideline on treatment of ESBL, AmpC, and carbapenemase producers: Updated 2024 IDSA Guidelines.","summaryOrNote":"Provides a framework for treating infections caused by resistant gram-negative organisms."}]}}'),gh={originalKeys:["identity","clinicalProfile","resistanceProfile","treatment","laboratoryProfile","additionalInformation"],conversionTimestamp:"2025-07-15T03:16:49.302Z",sourceFormat:"modern"},fh={bacteriumName:{sources:["identity.bacteriumName"],value:"Providencia species"},aliases:{sources:["identity.aliases"],value:["Providencia stuartii","Providencia rettgeri","Providencia alcalifaciens","Providencia rustigianii"]},lastUpdated:{sources:["identity.lastUpdated"],value:"2025-01-17"},classification:{sources:["identity.classification"],value:{gramStain:"Gram negative",morphology:"Bacilli",respiration:"Facultative anaerobe",notes:[]}}},_h={sources:["clinicalProfile"],value:{summary:"Providencia species are typically nosocomial pathogens isolated from urine, blood, or wounds, causing a range of infections. They are known for several resistance mechanisms.",pathophysiologyPearls:["Providencia spp. may initially test susceptible to third-generation cephalosporins (like ceftriaxone) but have the potential to develop resistance during therapy due to the derepression of an inducible AmpC β-lactamase.","The risk of AmpC derepression during therapy appears to be less frequent with Providencia spp. compared to organisms like C. freundii complex or E. cloacae complex."],keySignsAndSymptoms:[],clinicalSyndromes:[{syndromeName:"Urinary Tract Infections (UTI)",description:"Common infection site, especially in nosocomial settings. Isolates are often multidrug-resistant."},{syndromeName:"Bacteremia",description:"Bloodstream infections, often originating from another site like the urinary tract."},{syndromeName:"Wound Infections",description:"Can colonize and infect surgical or traumatic wounds."}],stagesOfIllness:[],highRiskPopulations:["Hospitalized patients"],transmissionVectors:[],prognosisNotes:[]}},hh={sources:["resistanceProfile"],value:{groupIntrinsicResistance:[],intrinsicResistance:[{drugOrClass:"Polymyxins",notes:"Providencia species are intrinsically resistant to polymyxins."},{drugOrClass:"Nitrofurantoin",notes:"Usually resistant."},{drugOrClass:"Tigecycline",notes:"May have in vitro activity but its clinical efficacy is questionable due to low serum levels."}],majorMechanisms:[{mechanismName:"Inducible AmpC β-lactamase",mechanismType:"Enzymatic Inactivation",description:"Organisms can develop resistance during therapy with third-generation cephalosporins due to derepression of an inducible AmpC gene, though this is less frequent than in other SPACE-M organisms."},{mechanismName:"Extended-Spectrum Beta-Lactamases (ESBLs)",mechanismType:"Enzymatic Inactivation",description:"Frequently produced, especially by P. stuartii. For ESBL producers, piperacillin-tazobactam should be avoided even if susceptible in vitro due to risk of clinical failures."},{mechanismName:"Serine-based Carbapenemase (e.g., KPC)",mechanismType:"Enzymatic Inactivation",description:"Production of enzymes like KPC can lead to resistance to carbapenems, fluoroquinolones, and aminoglycosides."},{mechanismName:"Metallo-carbapenemase (MBL)",mechanismType:"Enzymatic Inactivation",description:"Production results in a resistance pattern that includes newer agents like ceftazidime-avibactam and meropenem-vaborbactam."}],clinicalAlerts:[{alertTitle:"Species-Dependent Resistance",details:"Resistance patterns vary significantly by species. P. stuartii is generally the most resistant, while P. alcalifaciens is often more susceptible."}]}},bh={treatmentData:{_treatmentMetadata:{originalFormat:"modern"},standardizedRegimens:[{regimenId:"modern-0-0-0",extractedFrom:"treatment.regimens[0].recommendations[0].steps[0]",context:{type:"empiric",condition:"Suspected Providencia sp. infection",severity:"unknown",patientFactors:{population:["Local ESBL rate <10-15%"],labFindings:null}},preference:"primary",drugs:[{drugName:"Piperacillin-tazobactam",dose:"4.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infuse over 4 hours.",originalText:"Piperacillin-tazobactam 4.5 gm IV q8h"},{drugName:"Ceftriaxone",dose:"1-2 gm",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Ceftriaxone 1-2 gm IV q24h"},{drugName:"Cefepime",dose:"1-2 gm",route:"IV",frequency:"q8h-q12h",duration:"Variable",comments:"",originalText:"Cefepime 1-2 gm IV q8h-q12h"},{drugName:"Ciprofloxacin",dose:"400 mg IV or 750 mg PO",route:"IV/PO",frequency:"q12h",duration:"Variable",comments:"",originalText:"Ciprofloxacin 400 mg IV or 750 mg PO IV/PO q12h"}]},{regimenId:"modern-1-0-0",extractedFrom:"treatment.regimens[1].recommendations[0].steps[0]",context:{type:"empiric",condition:"Suspected Providencia sp. infection",severity:"unknown",patientFactors:{population:["Local ESBL rate >15%"],labFindings:null}},preference:"primary",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"",originalText:"Meropenem 1-2 gm IV q8h"}]},{regimenId:"modern-2-0-0",extractedFrom:"treatment.regimens[2].recommendations[0].steps[0]",context:{type:"directed",condition:"Broadly susceptible isolate",severity:"unknown",patientFactors:{population:["Susceptible to aztreonam, ceftriaxone, ceftazidime, cefepime, piperacillin-tazobactam"],labFindings:null}},preference:"primary",drugs:[{drugName:"Piperacillin-tazobactam",dose:"4.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infuse over 4 hours.",originalText:"Piperacillin-tazobactam 4.5 gm IV q8h"},{drugName:"Ceftriaxone",dose:"1-2 gm",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Ceftriaxone 1-2 gm IV q24h"},{drugName:"Cefepime",dose:"1-2 gm",route:"IV",frequency:"q8h to q12h",duration:"Variable",comments:"May be considered over Ceftriaxone for high inoculum infections or if source control is limited due to its greater stability to AmpC.",originalText:"Cefepime 1-2 gm IV q8h to q12h"},{drugName:"Ciprofloxacin",dose:"400 mg IV or 750 mg PO",route:"IV/PO",frequency:"q12h",duration:"Variable",comments:"",originalText:"Ciprofloxacin 400 mg IV or 750 mg PO IV/PO q12h"},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q6-8h",duration:"Variable",comments:"Option for patients with penicillin allergy.",originalText:"Aztreonam 2 gm IV q6-8h"}]},{regimenId:"modern-3-0-0",extractedFrom:"treatment.regimens[3].recommendations[0].steps[0]",context:{type:"directed",condition:"ESBL Producer",severity:"unknown",patientFactors:{population:["Resistant to Aztreonam, Ceftriaxone, Cefotaxime, Ceftazidime, or Cefepime"],labFindings:null}},preference:"primary",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"",originalText:"Meropenem 1-2 gm IV q8h"},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Ertapenem 1 gm IV q24h"}]},{regimenId:"modern-3-1-0",extractedFrom:"treatment.regimens[3].recommendations[1].steps[0]",context:{type:"directed",condition:"ESBL Producer",severity:"unknown",patientFactors:{population:["Resistant to Aztreonam, Ceftriaxone, Cefotaxime, Ceftazidime, or Cefepime"],labFindings:null}},preference:"alternative (if susceptible)",drugs:[{drugName:"Ciprofloxacin",dose:"400 mg IV or 750 mg PO",route:"IV/PO",frequency:"bid",duration:"Variable",comments:"",originalText:"Ciprofloxacin 400 mg IV or 750 mg PO IV/PO bid"},{drugName:"Levofloxacin",dose:"750 mg",route:"IV/PO",frequency:"once daily",duration:"Variable",comments:"",originalText:"Levofloxacin 750 mg IV/PO once daily"}]},{regimenId:"modern-4-0-0",extractedFrom:"treatment.regimens[4].recommendations[0].steps[0]",context:{type:"directed",condition:"Serine-based Carbapenemase (e.g., KPC) Producer",severity:"unknown",patientFactors:{population:["Resistant to carbapenems, fluoroquinolones, and aminoglycosides"],labFindings:null}},preference:"primary",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infuse over 3 hours.",originalText:"Ceftazidime-avibactam 2.5 gm IV q8h"},{drugName:"Meropenem-vaborbactam",dose:"4 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infuse over 3 hours.",originalText:"Meropenem-vaborbactam 4 gm IV q8h"}]},{regimenId:"modern-5-0-0",extractedFrom:"treatment.regimens[5].recommendations[0].steps[0]",context:{type:"directed",condition:"Metallo-carbapenemase (MBL) Producer",severity:"unknown",patientFactors:{population:["Resistant to KPC-inhibitors, fluoroquinolones, aminoglycosides, TMP-SMX"],labFindings:null}},preference:"primary",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infuse over 3 hours.",originalText:"Ceftazidime-avibactam 2.5 gm IV q8h"},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infuse over 3 hours. Must be given with Ceftazidime-avibactam.",originalText:"Aztreonam 2 gm IV q8h"}]},{regimenId:"modern-5-1-0",extractedFrom:"treatment.regimens[5].recommendations[1].steps[0]",context:{type:"directed",condition:"Metallo-carbapenemase (MBL) Producer",severity:"unknown",patientFactors:{population:["Resistant to KPC-inhibitors, fluoroquinolones, aminoglycosides, TMP-SMX"],labFindings:null}},preference:"alternative",drugs:[{drugName:"Cefiderocol",dose:"2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infuse over 3 hours.",originalText:"Cefiderocol 2 gm IV q8h"}]},{regimenId:"modern-6-0-0",extractedFrom:"treatment.regimens[6].recommendations[0].steps[0]",context:{type:"alternative",condition:"Severe IgE-mediated allergy to beta-lactams",severity:"severe",patientFactors:{population:["Isolate is susceptible in vitro"],labFindings:null}},preference:"primary",drugs:[{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q6-8h",duration:"Variable",comments:"",originalText:"Aztreonam 2 gm IV q6-8h"},{drugName:"Ciprofloxacin",dose:"400 mg IV or 750 mg po",route:"IV/PO",frequency:"bid",duration:"Variable",comments:"",originalText:"Ciprofloxacin 400 mg IV or 750 mg po IV/PO bid"},{drugName:"Levofloxacin",dose:"750 mg",route:"IV/PO",frequency:"once daily",duration:"Variable",comments:"",originalText:"Levofloxacin 750 mg IV/PO once daily"}]},{regimenId:"modern-7-0-0",extractedFrom:"treatment.regimens[7].recommendations[0].steps[0]",context:{type:"alternative",condition:"ESBL and/or AmpC producing strains",severity:"unknown",patientFactors:{population:[],labFindings:null}},preference:"primary",drugs:[{drugName:"Ceftolozane-tazobactam",dose:"1.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"Infuse over 3 hours.",originalText:"Ceftolozane-tazobactam 1.5 gm IV q8h"},{drugName:"Temocillin",dose:"2 gm",route:"IV",frequency:"q12h",duration:"Variable",comments:"Where available.",originalText:"Temocillin 2 gm IV q12h"}]},{regimenId:"modern-8-0-0",extractedFrom:"treatment.regimens[8].recommendations[0].steps[0]",context:{type:"salvage",condition:"Pan-resistant infection",severity:"unknown",patientFactors:{population:[],labFindings:null}},preference:"primary",drugs:[{drugName:"Ceftazidime-avibactam + Aztreonam",dose:"Varies",route:"IV",frequency:"Varies",duration:"Variable",comments:"Combination therapy.",originalText:"Ceftazidime-avibactam + Aztreonam Varies IV Varies"},{drugName:"Fosfomycin IV",dose:"Varies",route:"IV",frequency:"Varies",duration:"Variable",comments:"Where available, requires emergency IND from FDA.",originalText:"Fosfomycin IV Varies IV Varies"},{drugName:"Plazomicin",dose:"15 mg/kg",route:"IV",frequency:"q24h",duration:"Variable",comments:"For complicated UTIs only.",originalText:"Plazomicin 15 mg/kg IV q24h"}]}]}},yh=JSON.parse('{"sources":["laboratoryProfile"],"value":{"testingIndications":[],"methodologyNotes":[],"recommendedPanel":[],"specialTests":[],"reportingRules":[{"ruleType":"Exception","drug":"Imipenem-relebactam","condition":"Isolate is identified as Providencia species.","details":"CLSI breakpoints for Imipenem-relebactam do not apply to the family Morganellaceae, which includes Providencia. Testing or reporting this agent is not recommended based on these breakpoints."},{"ruleType":"Exception","drug":"Fosfomycin","condition":"Isolate is not E. coli from a urinary tract source.","details":"Breakpoints for Fosfomycin apply only to E. coli and should not be extrapolated to Providencia species."},{"ruleType":"Conditional","drug":"Cefepime","condition":"Carbapenemase production is identified.","details":"Cefepime S/SDD results should be suppressed or reported as resistant."},{"ruleType":"General","drug":"Third-generation cephalosporins","condition":"Isolate is Providencia species.","details":"Providencia spp. can derepress inducible AmpC β-lactamase, potentially leading to resistance during therapy despite initial susceptibility to agents like ceftriaxone."}],"antimicrobialBreakpoints":[{"tier":1,"tierDescription":"Appropriate for routine, primary testing and reporting.","agents":[{"agentName":"Ampicillin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"14–16 mm","r_breakpoint":"≤ 13 mm"},"mic":{"s_breakpoint":"≤ 8 µg/mL","i_breakpoint":"16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":["Results of ampicillin testing can predict results for amoxicillin."]}]},{"agentName":"Amoxicillin-clavulanate","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":null,"r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/4 µg/mL"},"comments":["Breakpoints apply for therapy of uncomplicated UTIs or for completion of therapy for systemic infection."]}]},{"agentName":"Piperacillin-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"100/10 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"21–24 mm","r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/4 µg/mL"},"comments":[]}]},{"agentName":"Gentamicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Tobramycin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"13–16 mm","r_breakpoint":"≤ 12 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Amikacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 19 mm","i_breakpoint":"17–18 mm","r_breakpoint":"≤ 16 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Ciprofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"22–25 mm","r_breakpoint":"≤ 21 mm"},"mic":{"s_breakpoint":"≤ 0.25 µg/mL","i_breakpoint":"0.5 µg/mL","r_breakpoint":"≥ 1 µg/mL"},"comments":[]}]},{"agentName":"Levofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"17–20 mm","r_breakpoint":"≤ 16 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Trimethoprim-sulfamethoxazole","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"1.25/23.75 µg","s_breakpoint":"≥ 16 mm","i_breakpoint":"11–15 mm","r_breakpoint":"≤ 10 mm"},"mic":{"s_breakpoint":"≤ 2/38 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4/76 µg/mL"},"comments":[]}]}]},{"tier":2,"tierDescription":"Appropriate for routine, primary testing, may be reported following cascade reporting rules.","agents":[{"agentName":"Cefuroxime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"15–22 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8–16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Cefepime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"19–24 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":["Cefepime S/SDD results should be suppressed or reported as resistant for isolates demonstrating carbapenemase production."]}]},{"agentName":"Ertapenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"19–21 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Imipenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Meropenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]}]},{"tier":3,"tierDescription":"Appropriate for high-risk MDRO patients, subject to cascade reporting.","agents":[{"agentName":"Cefiderocol","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 20 mm","i_breakpoint":"9–15 mm","r_breakpoint":"≤ 8 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Ceftazidime-avibactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/20 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":null,"r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 16/4 µg/mL"},"comments":["Confirmatory MIC testing is indicated for isolates with disk diffusion zones of 20–22 mm."]}]},{"agentName":"Imipenem-relebactam","breakpointSets":[{"condition":"Standard","diskDiffusion":null,"mic":null,"comments":["Important Note: The breakpoints for Imipenem-relebactam do not apply to the family Morganellaceae, which includes Morganella, Proteus, and Providencia. Therefore, testing or reporting for Providencia with this agent using these breakpoints is not recommended by CLSI."]}]},{"agentName":"Meropenem-vaborbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4/8 µg/mL","i_breakpoint":"8/8 µg/mL","r_breakpoint":"≥ 16/8 µg/mL"},"comments":["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]},{"agentName":"Plazomicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 2 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]}]},{"tier":4,"tierDescription":"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.","agents":[{"agentName":"Aztreonam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"18–20 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":[]}]},{"agentName":"Ceftriaxone","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Ceftazidime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"18–20 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 8 µg/mL","i_breakpoint":"16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Ceftolozane-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"19–21 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 2/4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4/4 µg/mL"},"comments":[]}]},{"agentName":"Colistin or Polymyxin B","breakpointSets":[{"condition":"Standard","diskDiffusion":null,"mic":{"s_breakpoint":"≤ 2 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4 µg/mL"},"comments":["Disk diffusion and gradient diffusion methods should not be performed for these agents.","Note: Providencia is intrinsically resistant."]}]}]},{"tier":5,"tierDescription":"Urine Only Tier","agents":[{"agentName":"Cefazolin","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 15 mm","i_breakpoint":null,"r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 32 µg/mL"},"comments":["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},{"agentName":"Nitrofurantoin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"300 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"15–16 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 32 µg/mL","i_breakpoint":"64 µg/mL","r_breakpoint":"≥ 128 µg/mL"},"comments":["Note: Providencia is usually resistant."]}]},{"agentName":"Fosfomycin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":null,"mic":null,"comments":["Important Note: Disk diffusion and MIC breakpoints for Fosfomycin apply only to E. coli urinary tract isolates and should not be extrapolated to other Enterobacterales species."]}]}]}]}}'),vh={antimicrobialStewardship:{sources:["antimicrobial_stewardship","antimicrobialStewardship"],value:[]},comments:{preservedStructure:{originalFormat:"object"}},diagnosis:{sources:["diagnosis"],value:[]},allOtherKeys:{}},kh={_originalData:ph,_metadata:gh,identity:fh,clinicalInformation:_h,resistanceInformation:hh,treatmentData:bh,laboratoryData:yh,additionalData:vh},xh=JSON.parse('{"identity":{"bacteriumName":"Serratia marcescens","aliases":["Serratia sp."],"lastUpdated":"2025-01-08","clsiCategory":"Enterobacterales (excluding Salmonella/Shigella)","classification":{"gramStain":"Gram-negative","morphology":"Bacilli","respiration":"Facultative anaerobe","notes":["Motile","May produce a characteristic red pigment (prodigiosin), especially at room temperature."]},"strainDetails":[],"biochemicalTests":"Gram-negative rod, motile, lactose – (or slow), ONPG +, oxidase –, catalase +, citrate +, VP +, DNase +, gelatinase +, lysine +, ornithine +, esculin +, urease variable, may produce red pigment (prodigiosin) at room temperature."},"clinicalProfile":{"summary":"Serratia marcescens is an opportunistic pathogen that causes a variety of nosocomial and healthcare-associated infections, including urinary tract infections, pneumonia, bloodstream infections, and surgical site infections. Both immunocompetent and immunocompromised individuals can be affected. The increasing prevalence of multi-drug resistant (MDR) strains poses a significant therapeutic challenge.","pathophysiologyPearls":["Produces several virulence factors including proteases, lipases, and DNase, which contribute to tissue damage.","The red pigment, prodigiosin, has immunosuppressive and cytotoxic properties.","Forms biofilms on medical devices, contributing to catheter-related infections and antibiotic resistance."],"keySignsAndSymptoms":["Fever, chills, and leukocytosis in cases of bacteremia.","Dysuria, frequency, and urgency in urinary tract infections.","Cough, dyspnea, and purulent sputum in pneumonia.","Erythema, purulent discharge, and pain at surgical or wound sites."],"clinicalSyndromes":[{"syndromeName":"Catheter-Associated Urinary Tract Infection (CAUTI)","description":"One of the most common infections caused by S. marcescens, often associated with indwelling urinary catheters."},{"syndromeName":"Ventilator-Associated Pneumonia (VAP)","description":"A significant cause of nosocomial pneumonia in intubated patients in intensive care units."},{"syndromeName":"Catheter-Related Bloodstream Infection (CRBSI)","description":"Often linked to central venous catheters, particularly in patients receiving parenteral nutrition."},{"syndromeName":"Surgical Site Infection (SSI)","description":"Can contaminate surgical wounds, leading to postoperative infections."},{"syndromeName":"Neonatal Sepsis and Meningitis","description":"Causes outbreaks in neonatal intensive care units (NICUs), leading to severe systemic infections."}],"stagesOfIllness":[],"highRiskPopulations":["Hospitalized patients, especially in intensive care units (ICUs)","Neonates","Immunocompromised individuals","Patients with indwelling medical devices (e.g., catheters, ventilators)","Intravenous drug users"],"transmissionVectors":["Contaminated medical equipment and solutions","Hands of healthcare workers","Person-to-person transmission in hospital settings"],"prognosisNotes":["The prevalence of multi-drug resistant (MDR) strains is increasing, which can complicate treatment and worsen outcomes.","Infections with carbapenemase-producing strains are associated with high mortality rates."]},"resistanceProfile":{"groupIntrinsicResistance":[],"intrinsicResistance":[{"drugOrClass":"Polymyxins (Colistin)","notes":"Chromosomally-mediated resistance."},{"drugOrClass":"Ampicillin","notes":""},{"drugOrClass":"Ampicillin-sulbactam","notes":""},{"drugOrClass":"Amoxicillin-clavulanate","notes":""},{"drugOrClass":"Cefazolin","notes":""},{"drugOrClass":"Cephamycins (e.g., Cefoxitin, Cefotetan)","notes":""},{"drugOrClass":"Nitrofurantoin","notes":""}],"majorMechanisms":[{"mechanismName":"AmpC Beta-Lactamase","mechanismType":"Enzymatic Inactivation","description":"Serratia marcescens possesses a chromosomal AmpC beta-lactamase that is typically inducible but can be constitutively overexpressed, conferring resistance to penicillins, early-generation cephalosporins, and cephamycins. Clinical significance of induction is less common than in Enterobacter."},{"mechanismName":"Extended-Spectrum Beta-Lactamases (ESBLs)","mechanismType":"Enzymatic Inactivation","description":"Acquired plasmid-mediated enzymes (e.g., CTX-M, SHV, TEM) that hydrolyze most penicillins and cephalosporins, including 3rd and 4th generation cephalosporins, and aztreonam."},{"mechanismName":"Carbapenemases","mechanismType":"Enzymatic Inactivation","description":"Can acquire genes for serine carbapenemases (e.g., KPC) or metallo-beta-lactamases (e.g., NDM, VIM, IMP), leading to resistance to nearly all beta-lactam agents, including carbapenems."},{"mechanismName":"Aminoglycoside-Modifying Enzymes","mechanismType":"Enzymatic Inactivation","description":"Enzymes that acetylate, phosphorylate, or adenylate aminoglycosides, preventing them from binding to the ribosome."}],"clinicalAlerts":[{"alertTitle":"Potential for Multi-Drug Resistance","details":"Serratia marcescens frequently acquires resistance genes, leading to ESBL, AmpC, and carbapenemase production. Susceptibility testing is essential to guide therapy."},{"alertTitle":"AmpC Stability Considerations","details":"For serious infections, cefepime may be preferred over third-generation cephalosporins (e.g., ceftriaxone) due to its greater stability against hydrolysis by AmpC beta-lactamases, particularly in high-inoculum infections."}]},"treatment":{"generalNotes":["The following recommendations are for moderately severe or severe infections. For uncomplicated infections, options may include second and third-generation cephalosporins if susceptible.","TMP-SMX is a viable option if the isolate is proven susceptible.","Serratia marcescens is intrinsically resistant to Nitrofurantoin.","Susceptibility to Fosfomycin is variable and requires testing."],"drugsToAvoid":[{"drugOrClass":"Polymyxins (Colistin)","condition":"All infections","reason":"Intrinsic resistance."},{"drugOrClass":"Ampicillin, Amoxicillin-clavulanate, Cefazolin, Cephamycins","condition":"All infections","reason":"Intrinsic resistance."}],"adjunctiveTherapies":[],"regimens":[{"context":{"type":"Empiric","condition":"Suspected Serratia marcescens infection","patientPopulation":["Areas with local resistance rates <10-15% to 3rd-generation cephalosporins"]},"recommendations":[{"preference":"Primary","strategy":"Monotherapy","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Piperacillin-tazobactam","dose":"4.5 gm","route":"IV","frequency":"q8h","comments":"infused over 4 hr"},{"drugName":"Cefepime","dose":"1-2 gm","route":"IV","frequency":"q8h-q12h","comments":""},{"drugName":"Ceftriaxone","dose":"1-2 gm","route":"IV","frequency":"q24h","comments":""},{"drugName":"Aztreonam","dose":"2 gm","route":"IV","frequency":"q8h","comments":""},{"drugName":"Ciprofloxacin","dose":"400 mg","route":"IV","frequency":"q12h","comments":""},{"drugName":"Levofloxacin","dose":"750 mg","route":"IV","frequency":"once daily","comments":""}]}]}]},{"context":{"type":"Empiric","condition":"Suspected Serratia marcescens infection, severe illness","patientPopulation":["Areas with local resistance rates >15% to 3rd-generation cephalosporins","Critically ill patients","Recent antibiotic exposure"]},"recommendations":[{"preference":"Primary","strategy":"Monotherapy","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Meropenem","dose":"1-2 gm","route":"IV","frequency":"q8h","comments":""},{"drugName":"Ertapenem","dose":"1 gm","route":"IV","frequency":"q24h","comments":"Not for Pseudomonas coverage if a mixed infection is suspected."}]}],"notes":["Reserve carbapenems for mixed infections or for documented ESBL-producing strains."]}]},{"context":{"type":"Directed","condition":"Serratia marcescens infection, susceptible to 3rd-generation cephalosporins","patientPopulation":["All"],"isolateSource":"Any"},"recommendations":[{"preference":"Primary","strategy":"Monotherapy","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftriaxone","dose":"1-2 gm","route":"IV","frequency":"once daily","comments":""},{"drugName":"Cefepime","dose":"1-2 gm","route":"IV","frequency":"q8h-q12h","comments":""},{"drugName":"Piperacillin-tazobactam","dose":"Dose based on susceptibility report","route":"IV","frequency":"","comments":""},{"drugName":"Ciprofloxacin","dose":"400 mg","route":"IV","frequency":"q12h","comments":"If susceptible."},{"drugName":"Levofloxacin","dose":"750 mg","route":"IV","frequency":"once daily","comments":"If susceptible."},{"drugName":"TMP-SMX","dose":"8-10 mg/kg/day (TMP component)","route":"IV","frequency":"divided q6h","comments":"If susceptible."}]}],"notes":["IDSA guidance suggests selecting treatment based on AST results. Cefepime may be preferred over Ceftriaxone for high inoculum infections due to its greater stability to AmpC."]}]},{"context":{"type":"Directed","condition":"ESBL and/or AmpC-producing Serratia marcescens infection","patientPopulation":["All"],"isolateSource":"Any"},"recommendations":[{"preference":"Primary","strategy":"Monotherapy","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Meropenem","dose":"1-2 gm","route":"IV","frequency":"q8h","comments":""},{"drugName":"Ertapenem","dose":"1 gm","route":"IV","frequency":"q24h","comments":"Not for Pseudomonas coverage or CNS infections."}]}]},{"preference":"Alternative","strategy":"Monotherapy","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ciprofloxacin","dose":"400 mg IV q12h or 750 mg po bid","route":"IV/PO","frequency":"q12h/bid","comments":"Only if susceptible."},{"drugName":"Levofloxacin","dose":"750 mg","route":"IV/PO","frequency":"once daily","comments":"Only if susceptible."},{"drugName":"TMP-SMX","dose":"8-10 mg/kg/day (TMP component)","route":"IV","frequency":"divided q6h","comments":"Only if susceptible."},{"drugName":"Ceftolozane-tazobactam","dose":"1.5 gm","route":"IV","frequency":"q8h","comments":"infused over 3h; limited clinical data vs Serratia"},{"drugName":"Temocillin","dose":"2 gm","route":"IV","frequency":"q12h","comments":"Where available"},{"drugName":"Cefepime","dose":"2 gm","route":"IV","frequency":"q8h","comments":"For mild/moderate infection with controlled source and MIC <=2 mcg/mL."}]}],"notes":["Ceftazidime-avibactam has in vitro activity but limited clinical data for this specific resistance pattern."]}]},{"context":{"type":"Directed","condition":"KPC-producing carbapenem-resistant Serratia marcescens infection","patientPopulation":["All"],"isolateSource":"Any"},"recommendations":[{"preference":"Primary","strategy":"Monotherapy","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"q8h","comments":"infused over 3 hrs"},{"drugName":"Meropenem-vaborbactam","dose":"4 gm","route":"IV","frequency":"q8h","comments":"infused over 3 hrs"}]}],"notes":["Infectious diseases consultation recommended."]}]},{"context":{"type":"Directed","condition":"Metallo-beta-lactamase (MBL)-producing carbapenem-resistant Serratia marcescens infection","patientPopulation":["All"],"isolateSource":"Any"},"recommendations":[{"preference":"Primary","strategy":"Concurrent","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Ceftazidime-avibactam","dose":"2.5 gm","route":"IV","frequency":"q8h","comments":"infused over 3 hrs"},{"drugName":"Aztreonam","dose":"2 gm","route":"IV","frequency":"q6h","comments":"infused over 3h"}]}],"notes":["Aztreonam is stable to MBLs, while avibactam protects aztreonam from co-produced ESBLs/AmpC."]},{"preference":"Alternative","strategy":"Monotherapy","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Cefiderocol","dose":"2 gm","route":"IV","frequency":"q8h","comments":"infused over 3 hrs"},{"drugName":"Plazomicin","dose":"15 mg/kg","route":"IV","frequency":"once daily","comments":"For complicated UTI only, if available."}]}],"notes":["Infectious diseases consultation is essential as there is no proven effective therapy."]}]},{"context":{"type":"Directed","condition":"Serratia marcescens infection","patientPopulation":["Severe IgE-mediated beta-lactam allergy"]},"recommendations":[{"preference":"Alternative","strategy":"Monotherapy","steps":[{"step":1,"duration":"Variable","drugs":[{"drugName":"Aztreonam","dose":"2 gm","route":"IV","frequency":"q6h","comments":"Generally safe, but check for cross-reactivity if allergy is to ceftazidime."},{"drugName":"Ciprofloxacin","dose":"400 mg IV or 750 mg po","route":"IV/PO","frequency":"q12h/bid","comments":"If susceptible."},{"drugName":"Levofloxacin","dose":"750 mg","route":"IV/PO","frequency":"once daily","comments":"If susceptible."},{"drugName":"Gentamicin or Tobramycin","dose":"7 mg/kg loading dose then 5.1 mg/kg","route":"IV","frequency":"q24h","comments":"Therapeutic drug monitoring required."}]}]}]}]},"laboratoryProfile":{"testingIndications":["Susceptibility testing should be performed on all clinically significant isolates of Serratia marcescens."],"methodologyNotes":["Broth microdilution is the recommended method for susceptibility testing, especially for critical agents like polymyxins. Disk diffusion may be unreliable for some agent/organism combinations."],"recommendedPanel":["Primary panel should include agents from Tier 1 and Tier 2. Tier 3 and 4 agents should be tested based on institutional epidemiology, patient risk factors, or on isolates resistant to primary agents."],"specialTests":[{"testName":"Carbapenemase Production Test (e.g., mCIM, CarbaNP)","trigger":"Resistance to one or more carbapenems (ertapenem, meropenem).","purpose":"To detect the presence of carbapenemase enzymes, which has significant therapeutic and infection control implications."},{"testName":"ESBL Phenotypic Test","trigger":"Elevated MICs to ceftazidime or ceftriaxone, though often performed reflexively.","purpose":"To detect the presence of ESBL enzymes."}],"reportingRules":[{"ruleType":"Conditional","drug":"Cefepime","condition":"Isolate demonstrates carbapenemase production.","details":"Cefepime Susceptible/SDD results should be suppressed or edited and reported as Resistant."}],"antimicrobialBreakpoints":[{"tier":1,"tierDescription":"Appropriate for routine, primary testing and reporting","agents":[{"agentName":"Ampicillin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17","i_breakpoint":"14–16","r_breakpoint":"≤ 13"},"mic":{"s_breakpoint":"≤ 8","i_breakpoint":"16","r_breakpoint":"≥ 32"},"comments":["Results of ampicillin testing can be used to predict results for amoxicillin."]}]},{"agentName":"Cefazolin","breakpointSets":[{"condition":"Urine Only (Uncomplicated UTI)","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 15","i_breakpoint":"—","r_breakpoint":"≤ 14"},"mic":{"s_breakpoint":"≤ 16","i_breakpoint":"—","r_breakpoint":"≥ 32"},"comments":["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis. Note: Serratia is intrinsically resistant to cefazolin for systemic infections."]}]},{"agentName":"Amoxicillin-clavulanate","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18","i_breakpoint":"—","r_breakpoint":"≤ 17"},"mic":{"s_breakpoint":"≤ 8/4","i_breakpoint":"16/4","r_breakpoint":"≥ 32/4"},"comments":[]}]},{"agentName":"Piperacillin-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"100/10 µg","s_breakpoint":"≥ 25","i_breakpoint":"21–24","r_breakpoint":"≤ 20"},"mic":{"s_breakpoint":"≤ 8/4","i_breakpoint":"16/4","r_breakpoint":"≥ 32/4"},"comments":[]}]}]},{"tier":2,"tierDescription":"Appropriate for routine, primary testing, may be reported following cascade reporting rules","agents":[{"agentName":"Cefepime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 25","i_breakpoint":"19–24","r_breakpoint":"≤ 18"},"mic":{"s_breakpoint":"≤ 4","i_breakpoint":"8","r_breakpoint":"≥ 16"},"comments":["Cefepime S/SDD results should be suppressed or edited and reported as resistant for isolates that demonstrate carbapenemase production."]}]},{"agentName":"Ertapenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 22","i_breakpoint":"19–21","r_breakpoint":"≤ 18"},"mic":{"s_breakpoint":"≤ 0.5","i_breakpoint":"1","r_breakpoint":"≥ 2"},"comments":[]}]},{"agentName":"Meropenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23","i_breakpoint":"20–22","r_breakpoint":"≤ 19"},"mic":{"s_breakpoint":"≤ 1","i_breakpoint":"2","r_breakpoint":"≥ 4"},"comments":[]}]}]},{"tier":3,"tierDescription":"Appropriate for high-risk MDRO patients, subject to cascade reporting","agents":[{"agentName":"Ceftazidime-avibactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/20 µg","s_breakpoint":"≥ 21","i_breakpoint":"—","r_breakpoint":"≤ 20"},"mic":{"s_breakpoint":"≤ 8/4","i_breakpoint":"—","r_breakpoint":"≥ 16/4"},"comments":["Confirmatory MIC testing is indicated for isolates with zones of 20–22 mm."]}]},{"agentName":"Meropenem-vaborbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18","i_breakpoint":"15–17","r_breakpoint":"≤ 14"},"mic":{"s_breakpoint":"≤ 4/8","i_breakpoint":"8/8","r_breakpoint":"≥ 16/8"},"comments":["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]}]},{"tier":4,"tierDescription":"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available","agents":[{"agentName":"Aztreonam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21","i_breakpoint":"18–20","r_breakpoint":"≤ 17"},"mic":{"s_breakpoint":"≤ 4","i_breakpoint":"8","r_breakpoint":"≥ 16"},"comments":[]}]},{"agentName":"Ceftriaxone","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 26","i_breakpoint":"20–22","r_breakpoint":"≤ 19"},"mic":{"s_breakpoint":"≤ 1","i_breakpoint":"2","r_breakpoint":"≥ 4"},"comments":[]}]},{"agentName":"Colistin or Polymyxin B","breakpointSets":[{"condition":"Standard","diskDiffusion":null,"mic":{"s_breakpoint":"≤ 2","i_breakpoint":"—","r_breakpoint":"≥ 4"},"comments":["Disk diffusion and gradient diffusion methods should not be performed.","Serratia is intrinsically resistant to polymyxins; testing is generally not indicated."]}]}]}]},"additionalInformation":{"diagnosticNotes":{"summary":"Identification is typically performed using automated systems (e.g., VITEK, MicroScan) or MALDI-TOF MS. Conventional biochemical tests confirm identity. The ability to produce red pigment (prodigiosin) is a classic but variable characteristic. Non-pigmented strains are common in clinical settings.","biosafetyWarning":"BSL-2: Serratia marcescens is a Biosafety Level 2 organism. Standard laboratory precautions should be followed.","methods":[{"methodName":"Culture","details":"Grows well on standard laboratory media like Blood Agar and MacConkey Agar. Colonies are non-lactose fermenting (or slow) and may show red pigmentation, especially after incubation at room temperature (22-25°C)."},{"methodName":"MALDI-TOF Mass Spectrometry","details":"Provides rapid and accurate identification to the species level."}]},"preventionAndScreening":[{"type":"Infection Control","details":"Strict adherence to hand hygiene is paramount. Contact precautions are recommended for patients colonized or infected with MDR strains. Environmental cleaning and disinfection are crucial to prevent outbreaks.","targetPopulation":"Healthcare facilities, especially ICUs and NICUs"}],"treatmentLifecycle":[],"antimicrobialStewardship":["Reserve carbapenems for documented mixed infections or for infections due to confirmed ESBL-producing strains to limit selective pressure for carbapenem resistance.","Reserve Meropenem-vaborbactam and Ceftazidime-avibactam for documented KPC-producing CRE infections.","Avoid using polymyxins (colistin) due to intrinsic resistance."],"drugSpecificPearls":[{"drugName":"Aztreonam + Ceftazidime-avibactam","pearl":"This combination is a key strategy for MBL-producing CRE. Aztreonam is not hydrolyzed by metallo-carbapenemases but is inactivated by co-produced ESBLs and AmpC; avibactam protects aztreonam by inhibiting these other beta-lactamases."},{"drugName":"Cefiderocol","pearl":"A siderophore cephalosporin used as a last-line agent for CRE. In a trial of severely ill patients with carbapenem-resistant infections, all-cause mortality was numerically higher in the cefiderocol arm compared to the best available therapy arm (24.8% vs 18.4%), although this was not statistically significant. Use should be reserved for patients with limited or no other treatment options."}],"guidelineReferences":[{"source":"IDSA","citation":"Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections (2024 Update or latest version)","summaryOrNote":"Provides evidence-based recommendations for the management of infections caused by ESBL-producing, AmpC-producing, and carbapenem-resistant Enterobacterales."}]}}'),Ch={originalKeys:["identity","clinicalProfile","resistanceProfile","treatment","laboratoryProfile","additionalInformation"],conversionTimestamp:"2025-07-15T03:16:49.307Z",sourceFormat:"modern"},Sh={bacteriumName:{sources:["identity.bacteriumName"],value:"Serratia marcescens"},aliases:{sources:["identity.aliases"],value:["Serratia sp."]},lastUpdated:{sources:["identity.lastUpdated"],value:"2025-01-08"},classification:{sources:["identity.classification"],value:{gramStain:"Gram-negative",morphology:"Bacilli",respiration:"Facultative anaerobe",notes:["Motile","May produce a characteristic red pigment (prodigiosin), especially at room temperature."]}}},Nh={sources:["clinicalProfile"],value:{summary:"Serratia marcescens is an opportunistic pathogen that causes a variety of nosocomial and healthcare-associated infections, including urinary tract infections, pneumonia, bloodstream infections, and surgical site infections. Both immunocompetent and immunocompromised individuals can be affected. The increasing prevalence of multi-drug resistant (MDR) strains poses a significant therapeutic challenge.",pathophysiologyPearls:["Produces several virulence factors including proteases, lipases, and DNase, which contribute to tissue damage.","The red pigment, prodigiosin, has immunosuppressive and cytotoxic properties.","Forms biofilms on medical devices, contributing to catheter-related infections and antibiotic resistance."],keySignsAndSymptoms:["Fever, chills, and leukocytosis in cases of bacteremia.","Dysuria, frequency, and urgency in urinary tract infections.","Cough, dyspnea, and purulent sputum in pneumonia.","Erythema, purulent discharge, and pain at surgical or wound sites."],clinicalSyndromes:[{syndromeName:"Catheter-Associated Urinary Tract Infection (CAUTI)",description:"One of the most common infections caused by S. marcescens, often associated with indwelling urinary catheters."},{syndromeName:"Ventilator-Associated Pneumonia (VAP)",description:"A significant cause of nosocomial pneumonia in intubated patients in intensive care units."},{syndromeName:"Catheter-Related Bloodstream Infection (CRBSI)",description:"Often linked to central venous catheters, particularly in patients receiving parenteral nutrition."},{syndromeName:"Surgical Site Infection (SSI)",description:"Can contaminate surgical wounds, leading to postoperative infections."},{syndromeName:"Neonatal Sepsis and Meningitis",description:"Causes outbreaks in neonatal intensive care units (NICUs), leading to severe systemic infections."}],stagesOfIllness:[],highRiskPopulations:["Hospitalized patients, especially in intensive care units (ICUs)","Neonates","Immunocompromised individuals","Patients with indwelling medical devices (e.g., catheters, ventilators)","Intravenous drug users"],transmissionVectors:["Contaminated medical equipment and solutions","Hands of healthcare workers","Person-to-person transmission in hospital settings"],prognosisNotes:["The prevalence of multi-drug resistant (MDR) strains is increasing, which can complicate treatment and worsen outcomes.","Infections with carbapenemase-producing strains are associated with high mortality rates."]}},Ih={sources:["resistanceProfile"],value:{groupIntrinsicResistance:[],intrinsicResistance:[{drugOrClass:"Polymyxins (Colistin)",notes:"Chromosomally-mediated resistance."},{drugOrClass:"Ampicillin",notes:""},{drugOrClass:"Ampicillin-sulbactam",notes:""},{drugOrClass:"Amoxicillin-clavulanate",notes:""},{drugOrClass:"Cefazolin",notes:""},{drugOrClass:"Cephamycins (e.g., Cefoxitin, Cefotetan)",notes:""},{drugOrClass:"Nitrofurantoin",notes:""}],majorMechanisms:[{mechanismName:"AmpC Beta-Lactamase",mechanismType:"Enzymatic Inactivation",description:"Serratia marcescens possesses a chromosomal AmpC beta-lactamase that is typically inducible but can be constitutively overexpressed, conferring resistance to penicillins, early-generation cephalosporins, and cephamycins. Clinical significance of induction is less common than in Enterobacter."},{mechanismName:"Extended-Spectrum Beta-Lactamases (ESBLs)",mechanismType:"Enzymatic Inactivation",description:"Acquired plasmid-mediated enzymes (e.g., CTX-M, SHV, TEM) that hydrolyze most penicillins and cephalosporins, including 3rd and 4th generation cephalosporins, and aztreonam."},{mechanismName:"Carbapenemases",mechanismType:"Enzymatic Inactivation",description:"Can acquire genes for serine carbapenemases (e.g., KPC) or metallo-beta-lactamases (e.g., NDM, VIM, IMP), leading to resistance to nearly all beta-lactam agents, including carbapenems."},{mechanismName:"Aminoglycoside-Modifying Enzymes",mechanismType:"Enzymatic Inactivation",description:"Enzymes that acetylate, phosphorylate, or adenylate aminoglycosides, preventing them from binding to the ribosome."}],clinicalAlerts:[{alertTitle:"Potential for Multi-Drug Resistance",details:"Serratia marcescens frequently acquires resistance genes, leading to ESBL, AmpC, and carbapenemase production. Susceptibility testing is essential to guide therapy."},{alertTitle:"AmpC Stability Considerations",details:"For serious infections, cefepime may be preferred over third-generation cephalosporins (e.g., ceftriaxone) due to its greater stability against hydrolysis by AmpC beta-lactamases, particularly in high-inoculum infections."}]}},jh={treatmentData:{_treatmentMetadata:{originalFormat:"modern"},standardizedRegimens:[{regimenId:"modern-0-0-0",extractedFrom:"treatment.regimens[0].recommendations[0].steps[0]",context:{type:"empiric",condition:"Suspected Serratia marcescens infection",severity:"unknown",patientFactors:{population:["Areas with local resistance rates <10-15% to 3rd-generation cephalosporins"]}},preference:"primary",drugs:[{drugName:"Piperacillin-tazobactam",dose:"4.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"infused over 4 hr",originalText:"Piperacillin-tazobactam 4.5 gm IV q8h"},{drugName:"Cefepime",dose:"1-2 gm",route:"IV",frequency:"q8h-q12h",duration:"Variable",comments:"",originalText:"Cefepime 1-2 gm IV q8h-q12h"},{drugName:"Ceftriaxone",dose:"1-2 gm",route:"IV",frequency:"q24h",duration:"Variable",comments:"",originalText:"Ceftriaxone 1-2 gm IV q24h"},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"",originalText:"Aztreonam 2 gm IV q8h"},{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"q12h",duration:"Variable",comments:"",originalText:"Ciprofloxacin 400 mg IV q12h"},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"once daily",duration:"Variable",comments:"",originalText:"Levofloxacin 750 mg IV once daily"}]},{regimenId:"modern-1-0-0",extractedFrom:"treatment.regimens[1].recommendations[0].steps[0]",context:{type:"empiric",condition:"Suspected Serratia marcescens infection, severe illness",severity:"severe",patientFactors:{population:["Areas with local resistance rates >15% to 3rd-generation cephalosporins","Critically ill patients","Recent antibiotic exposure"]}},preference:"primary",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"",originalText:"Meropenem 1-2 gm IV q8h"},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",duration:"Variable",comments:"Not for Pseudomonas coverage if a mixed infection is suspected.",originalText:"Ertapenem 1 gm IV q24h"}]},{regimenId:"modern-2-0-0",extractedFrom:"treatment.regimens[2].recommendations[0].steps[0]",context:{type:"directed",condition:"Serratia marcescens infection, susceptible to 3rd-generation cephalosporins",severity:"unknown",patientFactors:{population:["All"],labFindings:"Any"}},preference:"primary",drugs:[{drugName:"Ceftriaxone",dose:"1-2 gm",route:"IV",frequency:"once daily",duration:"Variable",comments:"",originalText:"Ceftriaxone 1-2 gm IV once daily"},{drugName:"Cefepime",dose:"1-2 gm",route:"IV",frequency:"q8h-q12h",duration:"Variable",comments:"",originalText:"Cefepime 1-2 gm IV q8h-q12h"},{drugName:"Piperacillin-tazobactam",dose:"Dose based on susceptibility report",route:"IV",frequency:"",duration:"Variable",comments:"",originalText:"Piperacillin-tazobactam Dose based on susceptibility report IV "},{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"q12h",duration:"Variable",comments:"If susceptible.",originalText:"Ciprofloxacin 400 mg IV q12h"},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"once daily",duration:"Variable",comments:"If susceptible.",originalText:"Levofloxacin 750 mg IV once daily"},{drugName:"TMP-SMX",dose:"8-10 mg/kg/day (TMP component)",route:"IV",frequency:"divided q6h",duration:"Variable",comments:"If susceptible.",originalText:"TMP-SMX 8-10 mg/kg/day (TMP component) IV divided q6h"}]},{regimenId:"modern-3-0-0",extractedFrom:"treatment.regimens[3].recommendations[0].steps[0]",context:{type:"directed",condition:"ESBL and/or AmpC-producing Serratia marcescens infection",severity:"unknown",patientFactors:{population:["All"],labFindings:"Any"}},preference:"primary",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"",originalText:"Meropenem 1-2 gm IV q8h"},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",duration:"Variable",comments:"Not for Pseudomonas coverage or CNS infections.",originalText:"Ertapenem 1 gm IV q24h"}]},{regimenId:"modern-3-1-0",extractedFrom:"treatment.regimens[3].recommendations[1].steps[0]",context:{type:"directed",condition:"ESBL and/or AmpC-producing Serratia marcescens infection",severity:"unknown",patientFactors:{population:["All"],labFindings:"Any"}},preference:"alternative",drugs:[{drugName:"Ciprofloxacin",dose:"400 mg IV q12h or 750 mg po bid",route:"IV/PO",frequency:"q12h/bid",duration:"Variable",comments:"Only if susceptible.",originalText:"Ciprofloxacin 400 mg IV q12h or 750 mg po bid IV/PO q12h/bid"},{drugName:"Levofloxacin",dose:"750 mg",route:"IV/PO",frequency:"once daily",duration:"Variable",comments:"Only if susceptible.",originalText:"Levofloxacin 750 mg IV/PO once daily"},{drugName:"TMP-SMX",dose:"8-10 mg/kg/day (TMP component)",route:"IV",frequency:"divided q6h",duration:"Variable",comments:"Only if susceptible.",originalText:"TMP-SMX 8-10 mg/kg/day (TMP component) IV divided q6h"},{drugName:"Ceftolozane-tazobactam",dose:"1.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"infused over 3h; limited clinical data vs Serratia",originalText:"Ceftolozane-tazobactam 1.5 gm IV q8h"},{drugName:"Temocillin",dose:"2 gm",route:"IV",frequency:"q12h",duration:"Variable",comments:"Where available",originalText:"Temocillin 2 gm IV q12h"},{drugName:"Cefepime",dose:"2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"For mild/moderate infection with controlled source and MIC <=2 mcg/mL.",originalText:"Cefepime 2 gm IV q8h"}]},{regimenId:"modern-4-0-0",extractedFrom:"treatment.regimens[4].recommendations[0].steps[0]",context:{type:"directed",condition:"KPC-producing carbapenem-resistant Serratia marcescens infection",severity:"unknown",patientFactors:{population:["All"],labFindings:"Any"}},preference:"primary",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"infused over 3 hrs",originalText:"Ceftazidime-avibactam 2.5 gm IV q8h"},{drugName:"Meropenem-vaborbactam",dose:"4 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"infused over 3 hrs",originalText:"Meropenem-vaborbactam 4 gm IV q8h"}]},{regimenId:"modern-5-0-0",extractedFrom:"treatment.regimens[5].recommendations[0].steps[0]",context:{type:"directed",condition:"Metallo-beta-lactamase (MBL)-producing carbapenem-resistant Serratia marcescens infection",severity:"unknown",patientFactors:{population:["All"],labFindings:"Any"}},preference:"primary",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"infused over 3 hrs",originalText:"Ceftazidime-avibactam 2.5 gm IV q8h"},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q6h",duration:"Variable",comments:"infused over 3h",originalText:"Aztreonam 2 gm IV q6h"}]},{regimenId:"modern-5-1-0",extractedFrom:"treatment.regimens[5].recommendations[1].steps[0]",context:{type:"directed",condition:"Metallo-beta-lactamase (MBL)-producing carbapenem-resistant Serratia marcescens infection",severity:"unknown",patientFactors:{population:["All"],labFindings:"Any"}},preference:"alternative",drugs:[{drugName:"Cefiderocol",dose:"2 gm",route:"IV",frequency:"q8h",duration:"Variable",comments:"infused over 3 hrs",originalText:"Cefiderocol 2 gm IV q8h"},{drugName:"Plazomicin",dose:"15 mg/kg",route:"IV",frequency:"once daily",duration:"Variable",comments:"For complicated UTI only, if available.",originalText:"Plazomicin 15 mg/kg IV once daily"}]},{regimenId:"modern-6-0-0",extractedFrom:"treatment.regimens[6].recommendations[0].steps[0]",context:{type:"directed",condition:"Serratia marcescens infection",severity:"unknown",patientFactors:{population:["Severe IgE-mediated beta-lactam allergy"]}},preference:"alternative",drugs:[{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q6h",duration:"Variable",comments:"Generally safe, but check for cross-reactivity if allergy is to ceftazidime.",originalText:"Aztreonam 2 gm IV q6h"},{drugName:"Ciprofloxacin",dose:"400 mg IV or 750 mg po",route:"IV/PO",frequency:"q12h/bid",duration:"Variable",comments:"If susceptible.",originalText:"Ciprofloxacin 400 mg IV or 750 mg po IV/PO q12h/bid"},{drugName:"Levofloxacin",dose:"750 mg",route:"IV/PO",frequency:"once daily",duration:"Variable",comments:"If susceptible.",originalText:"Levofloxacin 750 mg IV/PO once daily"},{drugName:"Gentamicin or Tobramycin",dose:"7 mg/kg loading dose then 5.1 mg/kg",route:"IV",frequency:"q24h",duration:"Variable",comments:"Therapeutic drug monitoring required.",originalText:"Gentamicin or Tobramycin 7 mg/kg loading dose then 5.1 mg/kg IV q24h"}]}]}},Ah={sources:["laboratoryProfile"],value:{testingIndications:["Susceptibility testing should be performed on all clinically significant isolates of Serratia marcescens."],methodologyNotes:["Broth microdilution is the recommended method for susceptibility testing, especially for critical agents like polymyxins. Disk diffusion may be unreliable for some agent/organism combinations."],recommendedPanel:["Primary panel should include agents from Tier 1 and Tier 2. Tier 3 and 4 agents should be tested based on institutional epidemiology, patient risk factors, or on isolates resistant to primary agents."],specialTests:[{testName:"Carbapenemase Production Test (e.g., mCIM, CarbaNP)",trigger:"Resistance to one or more carbapenems (ertapenem, meropenem).",purpose:"To detect the presence of carbapenemase enzymes, which has significant therapeutic and infection control implications."},{testName:"ESBL Phenotypic Test",trigger:"Elevated MICs to ceftazidime or ceftriaxone, though often performed reflexively.",purpose:"To detect the presence of ESBL enzymes."}],reportingRules:[{ruleType:"Conditional",drug:"Cefepime",condition:"Isolate demonstrates carbapenemase production.",details:"Cefepime Susceptible/SDD results should be suppressed or edited and reported as Resistant."}],antimicrobialBreakpoints:[{tier:1,tierDescription:"Appropriate for routine, primary testing and reporting",agents:[{agentName:"Ampicillin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 17",i_breakpoint:"14–16",r_breakpoint:"≤ 13"},mic:{s_breakpoint:"≤ 8",i_breakpoint:"16",r_breakpoint:"≥ 32"},comments:["Results of ampicillin testing can be used to predict results for amoxicillin."]}]},{agentName:"Cefazolin",breakpointSets:[{condition:"Urine Only (Uncomplicated UTI)",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 15",i_breakpoint:"—",r_breakpoint:"≤ 14"},mic:{s_breakpoint:"≤ 16",i_breakpoint:"—",r_breakpoint:"≥ 32"},comments:["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis. Note: Serratia is intrinsically resistant to cefazolin for systemic infections."]}]},{agentName:"Amoxicillin-clavulanate",breakpointSets:[{condition:"Uncomplicated UTI only",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18",i_breakpoint:"—",r_breakpoint:"≤ 17"},mic:{s_breakpoint:"≤ 8/4",i_breakpoint:"16/4",r_breakpoint:"≥ 32/4"},comments:[]}]},{agentName:"Piperacillin-tazobactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"100/10 µg",s_breakpoint:"≥ 25",i_breakpoint:"21–24",r_breakpoint:"≤ 20"},mic:{s_breakpoint:"≤ 8/4",i_breakpoint:"16/4",r_breakpoint:"≥ 32/4"},comments:[]}]}]},{tier:2,tierDescription:"Appropriate for routine, primary testing, may be reported following cascade reporting rules",agents:[{agentName:"Cefepime",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 25",i_breakpoint:"19–24",r_breakpoint:"≤ 18"},mic:{s_breakpoint:"≤ 4",i_breakpoint:"8",r_breakpoint:"≥ 16"},comments:["Cefepime S/SDD results should be suppressed or edited and reported as resistant for isolates that demonstrate carbapenemase production."]}]},{agentName:"Ertapenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 22",i_breakpoint:"19–21",r_breakpoint:"≤ 18"},mic:{s_breakpoint:"≤ 0.5",i_breakpoint:"1",r_breakpoint:"≥ 2"},comments:[]}]},{agentName:"Meropenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 23",i_breakpoint:"20–22",r_breakpoint:"≤ 19"},mic:{s_breakpoint:"≤ 1",i_breakpoint:"2",r_breakpoint:"≥ 4"},comments:[]}]}]},{tier:3,tierDescription:"Appropriate for high-risk MDRO patients, subject to cascade reporting",agents:[{agentName:"Ceftazidime-avibactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30/20 µg",s_breakpoint:"≥ 21",i_breakpoint:"—",r_breakpoint:"≤ 20"},mic:{s_breakpoint:"≤ 8/4",i_breakpoint:"—",r_breakpoint:"≥ 16/4"},comments:["Confirmatory MIC testing is indicated for isolates with zones of 20–22 mm."]}]},{agentName:"Meropenem-vaborbactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18",i_breakpoint:"15–17",r_breakpoint:"≤ 14"},mic:{s_breakpoint:"≤ 4/8",i_breakpoint:"8/8",r_breakpoint:"≥ 16/8"},comments:["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]}]},{tier:4,tierDescription:"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available",agents:[{agentName:"Aztreonam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 21",i_breakpoint:"18–20",r_breakpoint:"≤ 17"},mic:{s_breakpoint:"≤ 4",i_breakpoint:"8",r_breakpoint:"≥ 16"},comments:[]}]},{agentName:"Ceftriaxone",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 26",i_breakpoint:"20–22",r_breakpoint:"≤ 19"},mic:{s_breakpoint:"≤ 1",i_breakpoint:"2",r_breakpoint:"≥ 4"},comments:[]}]},{agentName:"Colistin or Polymyxin B",breakpointSets:[{condition:"Standard",diskDiffusion:null,mic:{s_breakpoint:"≤ 2",i_breakpoint:"—",r_breakpoint:"≥ 4"},comments:["Disk diffusion and gradient diffusion methods should not be performed.","Serratia is intrinsically resistant to polymyxins; testing is generally not indicated."]}]}]}]}},wh={antimicrobialStewardship:{sources:["antimicrobial_stewardship","antimicrobialStewardship"],value:[]},comments:{preservedStructure:{originalFormat:"object"}},diagnosis:{sources:["diagnosis"],value:[]},allOtherKeys:{}},Rh={_originalData:xh,_metadata:Ch,identity:Sh,clinicalInformation:Nh,resistanceInformation:Ih,treatmentData:jh,laboratoryData:Ah,additionalData:wh},Xl={citrobacterfreundii:Vf,citrobacterkoseri:Xf,ecolienteroaggregative:a_,enterobactercloacaecomplex:u_,escherichiacoli:k_,klebsiellaaerogenes:R_,klebsiellaspoxytocapneumoniaevariicola:V_,klebsiellasprhinoscleromatisozaenae:X_,morganellamorganii:ah,proteusspmirabilispennerivulgaris:uh,providenciaspstuartiirettgerialcalificiens:kh,serratiamarcescens:Rh},Mh=g=>typeof g!="string"?(console.warn("generateBacteriumKey: bacteriumName is not a string:",g),""):g.toLowerCase().replace(/[^a-z0-9\s]/g,"").replace(/\s+/g,"_").replace(/_{2,}/g,"_").replace(/^_|_$/g,"");Object.values(Xl).forEach(g=>{var l,c,d;const s=((c=(l=g._originalData)==null?void 0:l.identity)==null?void 0:c.bacteriumName)||((d=g.identity)==null?void 0:d.bacteriumName);s&&typeof s=="string"&&Mh(s)});const Wu=()=>Object.keys(Xl).length;console.log("📊 Loaded",Wu(),"Enterobacterales organisms");let Fl=null,Ku=null;const Dh=g=>{const s=JSON.stringify(Object.keys(g));if(Fl&&Ku===s)return Fl;const l=Object.entries(g).map(([c,d])=>{var ie,$,ne,w,O,U,Z,X,T,q,C,E,z,H,Y,ee,le,Q,k,G,ae,N,p,A,J,P,V,te,re,ue,he,Te,li,mi,Ai,wi,Ri,Ji,Qi,Xe,Wi,Bi,Ui,bi,Zi,Fi,et,it,pi,Ve;const m=[($=(ie=d._originalData)==null?void 0:ie.identity)==null?void 0:$.bacteriumName,(ne=d.identity)==null?void 0:ne.bacteriumName,d.name,(w=d.taxonomy)==null?void 0:w.genus,(O=d.taxonomy)==null?void 0:O.species,(Z=(U=d.identity)==null?void 0:U.classification)==null?void 0:Z.gramStain,(X=d.identity)==null?void 0:X.clsiCategory].filter(Boolean).filter(Ce=>typeof Ce=="string").map(Ce=>Ce.toLowerCase()),_=(((q=(T=d._originalData)==null?void 0:T.identity)==null?void 0:q.aliases)||((C=d.identity)==null?void 0:C.aliases)||[]).filter(Ce=>typeof Ce=="string").map(Ce=>Ce.toLowerCase()),h=(((z=(E=d._originalData)==null?void 0:E.clinicalProfile)==null?void 0:z.clinicalSyndromes)||((H=d.clinicalProfile)==null?void 0:H.clinicalSyndromes)||[]).map(Ce=>Ce.syndromeName).filter(Ce=>typeof Ce=="string").map(Ce=>Ce.toLowerCase()),v=(((ee=(Y=d._originalData)==null?void 0:Y.resistanceProfile)==null?void 0:ee.majorMechanisms)||((le=d.resistanceProfile)==null?void 0:le.majorMechanisms)||[]).map(Ce=>Ce.mechanismName).filter(Ce=>typeof Ce=="string").map(Ce=>Ce.toLowerCase()),y=[...m,..._,...h,...v],D=((k=(Q=d._originalData)==null?void 0:Q.identity)==null?void 0:k.bacteriumName)||((G=d.identity)==null?void 0:G.bacteriumName)||d.name||"Unknown",L=typeof D=="string"?D:"Unknown",W=((A=(p=(N=(ae=d._originalData)==null?void 0:ae.identity)==null?void 0:N.classification)==null?void 0:p.taxonomy)==null?void 0:A.genus)||((J=d.taxonomy)==null?void 0:J.genus)||L.split(" ")[0]||"",se=((re=(te=(V=(P=d._originalData)==null?void 0:P.identity)==null?void 0:V.classification)==null?void 0:te.taxonomy)==null?void 0:re.species)||((ue=d.taxonomy)==null?void 0:ue.species)||L.split(" ")[1]||"";return{id:c,name:L,gramStain:((li=(Te=(he=d._originalData)==null?void 0:he.identity)==null?void 0:Te.classification)==null?void 0:li.gramStain)||((Ai=(mi=d.identity)==null?void 0:mi.classification)==null?void 0:Ai.gramStain)||"unknown",clinicalSignificance:2,significance:2,taxonomy:{genus:W,species:se,family:((wi=d.taxonomy)==null?void 0:wi.family)||"",order:((Ri=d.taxonomy)==null?void 0:Ri.order)||"",class:((Ji=d.taxonomy)==null?void 0:Ji.class)||"",phylum:((Qi=d.taxonomy)==null?void 0:Qi.phylum)||"",domain:((Xe=d.taxonomy)==null?void 0:Xe.domain)||"Bacteria"},clsiCategory:(Wi=d.identity)==null?void 0:Wi.clsiCategory,aliases:((Bi=d.identity)==null?void 0:Bi.aliases)||[],clinicalSyndromes:((Ui=d.clinicalProfile)==null?void 0:Ui.clinicalSyndromes)||[],resistanceMechanisms:((bi=d.resistanceProfile)==null?void 0:bi.majorMechanisms)||[],clinicalAlerts:((Zi=d.resistanceProfile)==null?void 0:Zi.clinicalAlerts)||[],searchTerms:y,_indexed:{name:D.toLowerCase(),genus:W.toLowerCase(),gramStain:((it=(et=(Fi=d.identity)==null?void 0:Fi.classification)==null?void 0:et.gramStain)==null?void 0:it.toLowerCase())||"",clsiCategory:((Ve=(pi=d.identity)==null?void 0:pi.clsiCategory)==null?void 0:Ve.toLowerCase())||""}}});return Fl=l,Ku=s,l},Zu=Xl;console.log(`✅ Loaded ${Wu()} Enterobacterales organisms from generated index`);console.log("🦠 Available organisms:",Object.keys(Zu).sort());const $i=()=>Zu,ep=()=>{const g=$i();return Dh(g)};class qh{constructor(s,l,c=Hu){this.patient=s,this.bacterium=l,this.epidemiology=c,this.susceptibilityResults=s.susceptibilityResults||{}}getOptimalRegimen(){try{const s=this.assessPatientSeverity(),l=this.assessResistanceRisk(),c=this.detectResistanceMechanisms(),d=this.assessEpidemiologyRisk();return{regimen:this.matchClinicalContext(s,l,c,d),rationale:this.generateRationale(s,l,c,d),severity:s,resistanceRisk:l,mechanisms:c,epidemiologyRisk:d}}catch(s){return console.error("Clinical Decision Engine error:",s),this.getFallbackRecommendation()}}assessPatientSeverity(){var v;let s=0;const l=[],d={CNS_meningitis:3,CNS_encephalitis:3,CNS_brain_abscess:3,CNS_subdural_empyema:3,CV_endocarditis_native:3,CV_endocarditis_prosthetic:3,CV_endocarditis_CIED:3,CV_mycotic_aneurysm:3,CV_pericarditis:2,RESP_CAP:2,RESP_HAP:2,RESP_VAP:3,RESP_empyema:2,RESP_lung_abscess:2,RESP_bronchitis_acute:1,GU_UTI_uncomplicated:1,GU_UTI_complicated:2,GU_UTI_catheter:2,GU_pyelonephritis:2,GU_prostatitis_acute:2,GU_prostatitis_chronic:1,SST_cellulitis_simple:1,SST_cellulitis_severe:2,SST_necrotizing_fasciitis:3,SST_abscess:1,SST_diabetic_foot:2,SST_surgical_site:2,BJ_osteomyelitis_acute:2,BJ_osteomyelitis_chronic:2,BJ_prosthetic_joint:2,BJ_septic_arthritis:2,BJ_vertebral_osteomyelitis:2,BJ_diabetic_foot_osteo:2,IA_peritonitis_secondary:2,IA_peritonitis_primary:2,IA_intra_abdominal:2,IA_cholangitis:2,IA_liver_abscess:2,IA_appendicitis:2,BS_bacteremia_primary:2,BS_CLABSI:2,BS_sepsis:3,BS_septic_shock:3,BS_neutropenic_fever:2}[this.patient.location]||Rf[this.patient.location]||Xi.MILD;s+=d;const m=(v=this.patient.location)!=null&&v.includes("_")?"Syndrome-specific":this.patient.location;l.push(`${m}: (+${d})`),parseFloat(this.patient.age)>65&&(s+=1,l.push("Age >65 years (+1)")),this.patient.showSeverityAssessment&&(this.patient.isICU&&(s+=3,l.push("ICU admission (+3)")),this.patient.isImmunocompromised&&(s+=2,l.push("Immunocompromised (+2)")),this.patient.priorAntibiotics&&(s+=1,l.push("Prior antibiotics (+1)")),this.patient.hasOrganDysfunction&&(s+=2,l.push("Organ dysfunction (+2)")),this.patient.hasSepsis&&(s+=3,l.push("Sepsis/septic shock (+3)")),this.patient.hemodynamicStatus==="shock"?(s+=3,l.push("Hemodynamic shock (+3)")):this.patient.hemodynamicStatus==="hypotension"&&(s+=2,l.push("Hypotension (+2)")),this.patient.respiratoryStatus==="mechanical"?(s+=2,l.push("Mechanical ventilation (+2)")):this.patient.respiratoryStatus==="oxygen"&&(s+=1,l.push("Oxygen supplementation (+1)")));let h;return s<=2?h="MILD":s<=5?h="MODERATE":s<=8?h="SEVERE":h="CRITICAL",{score:s,level:Xi[h],levelName:h,factors:l,description:this.getSeverityDescription(h),objective:this.patient.showSeverityAssessment}}assessResistanceRisk(){var _,h;const s=[];let l=0;const c=((h=(_=this.bacterium.taxonomy)==null?void 0:_.genus)==null?void 0:h.toLowerCase())||"unknown",d=this.getLocalESBLRate(c);d>Ul.HIGH_ESBL_RATE&&(s.push(Bl.HIGH_ESBL_RATE),l+=3),this.patient.isICU&&(s.push(Bl.ICU_ADMISSION),l+=2),this.patient.isImmunocompromised&&(s.push(Bl.IMMUNOCOMPROMISED),l+=1);const m=this.assessSyndromeSpecificResistanceRisk();return l+=m.score,s.push(...m.factors),{score:l,level:this.categorizeRiskLevel(l),factors:s,localESBLRate:d,syndromeSpecificRisks:m.syndromeRisks,description:this.getRiskDescription(l)}}assessSyndromeSpecificResistanceRisk(){const s=[],l=[];let c=0;const d=this.patient.location;switch(["RESP_HAP","RESP_VAP","BS_CLABSI","GU_UTI_catheter","SST_surgical_site","CV_endocarditis_CIED","BJ_prosthetic_joint"].includes(d)&&(c+=2,l.push("Healthcare-associated infection (+2)"),s.push("Higher MDR pathogen risk")),["BS_CLABSI","GU_UTI_catheter","CV_endocarditis_CIED","BJ_prosthetic_joint","CV_endocarditis_prosthetic"].includes(d)&&(c+=1,l.push("Device-associated infection (+1)"),s.push("Biofilm-forming pathogens likely")),d){case"RESP_VAP":c+=2,l.push("VAP: High Pseudomonas/Acinetobacter risk (+2)"),s.push("Consider anti-Pseudomonas coverage");break;case"BS_neutropenic_fever":c+=2,l.push("Neutropenic fever: MDR gram-negative risk (+2)"),s.push("Broad-spectrum empiric therapy essential");break;case"BJ_osteomyelitis_chronic":c+=1,l.push("Chronic osteomyelitis: Small colony variants (+1)"),s.push("Consider biofilm-active agents");break;case"SST_diabetic_foot":c+=1,l.push("Diabetic foot: Polymicrobial + MRSA risk (+1)"),s.push("Consider MRSA and anaerobic coverage");break;case"IA_peritonitis_secondary":l.push("Peritonitis: Polymicrobial infection expected"),s.push("Anaerobic coverage essential");break;case"GU_UTI_complicated":case"GU_UTI_catheter":c+=1,l.push("Complicated UTI: ESBL risk increased (+1)"),s.push("Consider carbapenem if ESBL suspected");break;case"CNS_meningitis":l.push("Meningitis: Penetration more critical than resistance"),s.push("Prioritize CNS penetration over spectrum");break}return this.patient.institutionType==="tertiary"&&(c+=1,l.push("Tertiary care center (+1)"),s.push("Higher baseline resistance rates")),{score:c,factors:l,syndromeRisks:s}}assessCoverageRequirements(){const s=this.patient.location,l=[],c=[];switch(["IA_peritonitis_secondary","IA_peritonitis_primary","IA_intra_abdominal","IA_liver_abscess","IA_appendicitis","RESP_lung_abscess","SST_diabetic_foot"].includes(s)&&(l.push({type:"ANAEROBIC_ESSENTIAL",description:"Anaerobic coverage essential",agents:Sr.ANAEROBIC_ESSENTIAL.required,priority:"Essential"}),c.push("Consider metronidazole, clindamycin, or beta-lactam/beta-lactamase inhibitor")),["RESP_CAP"].includes(s)&&(l.push({type:"ATYPICAL_COVERAGE",description:"Atypical pathogen coverage recommended",agents:Sr.ATYPICAL_COVERAGE.required,priority:"Recommended"}),c.push("Consider macrolide, fluoroquinolone, or tetracycline for atypical coverage")),["RESP_HAP","RESP_VAP","BS_neutropenic_fever","BJ_osteomyelitis_chronic"].includes(s)&&(l.push({type:"ANTI_PSEUDOMONAS",description:"Anti-Pseudomonas coverage recommended",agents:Sr.ANTI_PSEUDOMONAS.required,priority:"Recommended"}),c.push("Consider anti-pseudomonal beta-lactam or fluoroquinolone")),["BJ_prosthetic_joint","CV_endocarditis_CIED","CV_endocarditis_prosthetic","BJ_osteomyelitis_chronic","BS_CLABSI"].includes(s)&&(l.push({type:"BIOFILM_ACTIVITY",description:"Biofilm-active agents preferred",agents:Sr.BIOFILM_ACTIVITY.required,priority:"Preferred"}),c.push("Consider rifampin combinations, daptomycin, or linezolid")),["SST_cellulitis_severe","SST_necrotizing_fasciitis","SST_diabetic_foot","BJ_osteomyelitis_acute","BJ_prosthetic_joint","CV_endocarditis_native"].includes(s)&&this.patient.isICU&&(l.push({type:"MRSA_COVERAGE",description:"MRSA coverage consideration",agents:["Vancomycin","Linezolid","Daptomycin","Ceftaroline"],priority:"Consider"}),c.push("Consider MRSA coverage based on local epidemiology and risk factors")),s){case"CNS_meningitis":l.push({type:"CNS_PENETRATION",description:"Blood-brain barrier penetration essential",agents:["Ceftriaxone","Vancomycin","Meropenem"],priority:"Essential"}),c.push("Bactericidal agents preferred; high-dose regimens required");break;case"GU_UTI_uncomplicated":l.push({type:"UTI_SPECIFIC",description:"UTI-specific agents preferred",agents:["Nitrofurantoin","Fosfomycin","Trimethoprim-sulfamethoxazole"],priority:"Preferred"}),c.push("Short course therapy (3 days) appropriate");break;case"GU_prostatitis_acute":l.push({type:"PROSTATE_PENETRATION",description:"Prostate penetration essential",agents:["Ciprofloxacin","Levofloxacin","Trimethoprim-sulfamethoxazole"],priority:"Essential"}),c.push("Extended duration therapy (2-4 weeks) required");break}return{requirements:l,recommendations:c,summary:l.length>0?`${l.length} special coverage consideration${l.length>1?"s":""}`:"Standard spectrum adequate"}}detectResistanceMechanisms(){const s={esbl:this.detectESBL(),ampC:this.detectAmpC(),carbapenemase:this.detectCarbapenemase()};return{...s,summary:this.summarizeMechanisms(s),coverageRequirements:this.assessCoverageRequirements()}}detectESBL(){const s=["Ceftriaxone","Ceftazidime","Cefotaxime"].filter(d=>this.susceptibilityResults[d]==="R").length>=2,l=["Meropenem","Ertapenem"].some(d=>this.susceptibilityResults[d]==="S"),c=s&&l;return{suspected:c,pattern:s?"Classic ESBL pattern":"Atypical pattern",implications:c?"Avoid cephalosporins, consider carbapenems":"Standard therapy may be appropriate"}}detectAmpC(){var _,h;const s=["enterobacter","citrobacter","serratia"],l=((h=(_=this.bacterium.taxonomy)==null?void 0:_.genus)==null?void 0:h.toLowerCase())||"";if(!s.includes(l))return{suspected:!1,reason:"Not an AmpC-producing genus"};const c=["Ceftriaxone","Ceftazidime"].some(v=>this.susceptibilityResults[v]==="R"),d=["Meropenem","Ertapenem"].some(v=>this.susceptibilityResults[v]==="S"),m=c&&d;return{suspected:m,pattern:m?"AmpC overproduction pattern":"No AmpC pattern",implications:m?"Avoid 3rd gen cephalosporins, use cefepime or carbapenems":"Standard therapy appropriate"}}detectCarbapenemase(){const s=["Meropenem","Imipenem","Ertapenem"],l=s.filter(c=>this.susceptibilityResults[c]==="R");return l.length===0?{suspected:!1,type:"None detected"}:{suspected:!0,confidence:l.length/s.length,type:"Carbapenemase suspected",implications:"Extremely limited options"}}assessEpidemiologyRisk(){var m,_;const s=((_=(m=this.bacterium.taxonomy)==null?void 0:m.genus)==null?void 0:_.toLowerCase())||"unknown",l=this.getLocalESBLRate(s);let c="LOW";const d=[];return l>Ul.HIGH_ESBL_RATE?(c="HIGH",d.push(`High local ESBL rate: ${(l*100).toFixed(1)}%`)):l>Ul.LOW_ESBL_RATE&&(c="MODERATE",d.push(`Moderate local ESBL rate: ${(l*100).toFixed(1)}%`)),{level:c,esblRate:l,factors:d,recommendation:this.getEpidemiologyRecommendation(c)}}matchClinicalContext(s,l,c,d){var D;const m=((D=this.bacterium.treatment)==null?void 0:D.regimens)||[];if(m.length===0)return this.getFallbackRecommendation();const h=m.map(L=>({regimen:L,score:this.calculateRegimenScore(L,s,l,c,d)})).sort((L,W)=>W.score-L.score),v=h[0],y=this.findSuitableAntibiotics(v.regimen);if(y.length===0){for(let L=1;L<h.length;L++){const W=h[L],se=this.findSuitableAntibiotics(W.regimen);if(se.length>0)return{...W,suitableOptions:se,note:"Alternative regimen selected due to resistance/allergies"}}return this.getFallbackRecommendation()}return{...v,suitableOptions:y,allRegimens:h}}calculateRegimenScore(s,l,c,d,m){var v,y,D,L,W,se,ie,$,ne,w,O,U,Z,X;let _=0;const h=s.context||{};return((y=(v=s.recommendations)==null?void 0:v[0])==null?void 0:y.preference)==="Primary"&&(_+=10),l.level>=Xi.SEVERE?(((D=h.condition)!=null&&D.includes("Severe")||(L=h.condition)!=null&&L.includes("High Local ESBL")||(W=h.condition)!=null&&W.includes("Carbapenem"))&&(_+=15),(se=h.condition)!=null&&se.includes("Low Local ESBL")&&(_-=15)):(ie=h.condition)!=null&&ie.includes("Low Local ESBL")&&!d.esbl.suspected&&(_+=10),m.level==="HIGH"&&(($=h.condition)!=null&&$.includes("High Local ESBL")&&(_+=12),(ne=h.condition)!=null&&ne.includes("Low Local ESBL")&&(_-=10)),d.esbl.suspected&&(((w=h.condition)!=null&&w.includes("ESBL")||(O=h.condition)!=null&&O.includes("High Local ESBL"))&&(_+=20),(U=h.condition)!=null&&U.includes("Low Local ESBL")&&(_-=25)),d.carbapenemase.suspected&&((Z=h.condition)!=null&&Z.includes("KPC")||(X=h.condition)!=null&&X.includes("Carbapenem-Resistant")?_+=25:_-=30),Math.max(0,_)}findSuitableAntibiotics(s){const l=s.recommendations||[],c=[];for(const d of l){const m=d.steps||[];for(const _ of m){const h=_.drugs||[];for(const v of h)if(this.isAntibioticSuitable(v.drugName)){const y=this.assessPenetrationSuitability(v.drugName);c.push({...v,preference:d.preference,strategy:d.strategy,penetrationScore:y.score,penetrationLevel:y.level,penetrationWarnings:y.warnings})}}}return c.sort((d,m)=>d.penetrationScore!==m.penetrationScore?m.penetrationScore-d.penetrationScore:d.preference==="Primary"&&m.preference!=="Primary"?-1:m.preference==="Primary"&&d.preference!=="Primary"?1:0)}assessPenetrationSuitability(s){const l=this.getPenetrationRequirement();if(!l)return{score:5,level:"Standard",warnings:[]};const c=[];let d=0,m="Poor";return l.excellent.includes(s)?(d=10,m="Excellent"):l.good.includes(s)?(d=8,m="Good"):l.moderate.includes(s)?(d=5,m="Moderate",l.type==="CNS_critical"&&c.push("Consider high-dose regimen for CNS penetration")):l.poor.includes(s)?(d=2,m="Poor",c.push(`Poor ${l.description.toLowerCase()}`)):l.avoid.some(_=>s.includes(_)||_.includes(s))?(d=0,m="Avoid",c.push(`Avoid: ${l.description}`)):(d=5,m="Unknown"),{score:d,level:m,warnings:c}}getPenetrationRequirement(){return{CNS_meningitis:Ye.CNS_CRITICAL,CNS_encephalitis:Ye.CNS_CRITICAL,CNS_brain_abscess:Ye.CNS_CRITICAL,CNS_subdural_empyema:Ye.CNS_CRITICAL,BJ_osteomyelitis_acute:Ye.BONE_SPECIFIC,BJ_osteomyelitis_chronic:Ye.BONE_SPECIFIC,BJ_prosthetic_joint:Ye.BONE_SPECIFIC,BJ_vertebral_osteomyelitis:Ye.BONE_SPECIFIC,BJ_diabetic_foot_osteo:Ye.BONE_SPECIFIC,GU_UTI_uncomplicated:Ye.URINARY_SPECIFIC,GU_prostatitis_acute:Ye.PROSTATE_SPECIFIC,GU_prostatitis_chronic:Ye.PROSTATE_SPECIFIC,GU_UTI_complicated:Ye.SYSTEMIC,GU_UTI_catheter:Ye.SYSTEMIC,GU_pyelonephritis:Ye.SYSTEMIC,BS_bacteremia_primary:Ye.SYSTEMIC,BS_CLABSI:Ye.SYSTEMIC,BS_sepsis:Ye.SYSTEMIC,BS_septic_shock:Ye.SYSTEMIC}[this.patient.location]||Ye.GOOD}isAntibioticSuitable(s){return this.susceptibilityResults[s]==="S"}getLocalESBLRate(s){return this.epidemiology.esblRate[s]||this.epidemiology.esblRate.enterobacterales||Hu.esblRate.enterobacterales}generateRationale(s,l,c,d){return{summary:`Recommendation based on ${s.levelName.toLowerCase()} patient severity, ${l.level.toLowerCase()} resistance risk, and ${d.level.toLowerCase()} local epidemiology.`,factors:[`Severity: ${s.levelName} (${s.score})`,`Resistance risk: ${l.level}`,`ESBL rate: ${(l.localESBLRate*100).toFixed(1)}%`,`Mechanisms: ${c.summary}`],warnings:c.esbl.suspected?["ESBL detected - avoid cephalosporins"]:[],considerations:[]}}getSeverityDescription(s){return{MILD:"Paciente estable con infección no complicada (puntuación ≤2)",MODERATE:"Paciente con enfermedad moderada que requiere vigilancia (puntuación 3-5)",SEVERE:"Paciente gravemente enfermo que requiere terapia intensiva (puntuación 6-8)",CRITICAL:"Paciente en estado crítico con riesgo vital inmediato (puntuación >8)"}[s]||"Severidad no determinada"}getRiskDescription(s){return s>=4?"Riesgo alto de resistencia":s>=2?"Riesgo moderado de resistencia":"Riesgo bajo de resistencia"}categorizeRiskLevel(s){return s>=4?"HIGH":s>=2?"MODERATE":"LOW"}getEpidemiologyRecommendation(s){return{LOW:"Standard empiric therapy appropriate",MODERATE:"Consider enhanced empiric coverage",HIGH:"Broad-spectrum empiric therapy recommended"}[s]||"Assessment needed"}summarizeMechanisms(s){const l=[];return s.esbl.suspected&&l.push("ESBL"),s.ampC.suspected&&l.push("AmpC"),s.carbapenemase.suspected&&l.push("Carbapenemase"),l.length>0?l.join(", "):"None detected"}getFallbackRecommendation(){return{regimen:null,score:0,suitableOptions:[],note:"No suitable treatment regimen identified. Infectious diseases consultation recommended.",rationale:{summary:"Complex resistance pattern prevents standard therapy",factors:["Multiple resistance mechanisms or contraindications"],warnings:["Requires expert consultation"],considerations:["Consider combination therapy"]}}}}function Th(g,s,l){return new qh(g,s,l).getOptimalRegimen()}const Gl={Enterobacterales_Table_2A_1:{Escherichia_coli:{category:"Enterobacterales (Table 2A-1)",clsi_table:"Table 2A-1",source:"CLSI M100-Ed34",antibiotics:{ampicillin:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥17",I:"14-16",R:"≤13"},condition:"UTI isolates only"}},"amoxicillin-clavulanate":{mic_breakpoints:{S:"≤8/4",I:"16/8",R:"≥32/16"},disk_diffusion:{routine:{S:"≥18",I:"14-17",R:"≤13"},condition:"For therapy of uncomplicated UTIs or for completion of therapy for systemic infection."}},"ampicillin-sulbactam":{mic_breakpoints:{S:"≤8/4",I:"16/8",R:"≥32/16"},disk_diffusion:{routine:{S:"≥15",I:"12-14",R:"≤11"}}},mecillinam:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥15",I:"12-14",R:"≤11"},condition:"Report only on E. coli"}},piperacillin:{mic_breakpoints:{S:"≤16",I:"32",R:"≥64"},disk_diffusion:{routine:{note:"Disk diffusion breakpoints removed in CLSI 2022 due to poor correlation."}}},"piperacillin-tazobactam":{mic_breakpoints:{S:"≤16/4",I:"32/4",R:"≥64/4"},disk_diffusion:{routine:{S:"≥21",I:"18-20",R:"≤17"}}},"ticarcillin-clavulanate":{mic_breakpoints:{S:"≤16/2",I:"32/2",R:"≥64/2"},disk_diffusion:{routine:{S:"≥20",I:"15-19",R:"≤14"}}},cefazolin:{mic_breakpoints:{S:"≤16",I:"32",R:"≥64"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"},condition:"Used for therapy of uncomplicated UTIs only"}},cefamandole:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}}},cefonicid:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}}},cefoperazone:{mic_breakpoints:{S:"≤16",I:"32",R:"≥64"},disk_diffusion:{routine:{S:"≥20",I:"16-19",R:"≤15"}}},cefotaxime:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"}}},cefotetan:{mic_breakpoints:{S:"≤16",I:"32",R:"≥64"},disk_diffusion:{routine:{S:"≥16",I:"13-15",R:"≤12"}}},cefoxitin:{mic_breakpoints:{S:"≤16",I:"32",R:"≥64"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}}},ceftazidime:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥21",I:"18-20",R:"≤17"}}},ceftizoxime:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥22",I:"20-21",R:"≤19"}}},ceftriaxone:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"}}},cefuroxime_parenteral:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"}}},cefepime:{mic_breakpoints:{S:"≤8",SDD:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥25",I:"19-24",R:"≤18"},special_considerations:"The 'Intermediate' category for disk diffusion corresponds to the 'SDD' MIC breakpoint. Cefepime S/SDD results should be suppressed or edited and reported as resistant for isolates that demonstrate carbapenemase production (see Appendix G, Table G3)."}},ceftaroline:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"}}},"ceftazidime-avibactam":{mic_breakpoints:{S:"≤8/4",I:"null",R:"≥16/4"},disk_diffusion:{routine:{S:"≥21",I:"null",R:"≤20"},special_considerations:"Confirmatory MIC testing is indicated for isolates with zones of 20-22 mm to avoid reporting false-susceptible or false-resistant results."}},"ceftolozane-tazobactam":{mic_breakpoints:{S:"≤2/4",I:"null",R:"≥4/4"},disk_diffusion:{routine:{S:"≥22",I:"19-21",R:"≤18"}}},moxalactam:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"}}},cefiderocol:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"},special_considerations:"Note regarding reproducibility and interpretation of Cefiderocol testing results (both disk diffusion and broth microdilution) recommends discussion with prescribers and antimicrobial stewardship members regarding potential inaccuracies."}},cefazolin_oral_surrogate:{mic_breakpoints:{S:"≤16",I:"null",R:"≥32"},disk_diffusion:{routine:{S:"≥15",I:"null",R:"≤14"},condition:"Oral cephalosporin surrogate for uncomplicated UTI",special_considerations:"Surrogates for cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime, cephalexin, and loracarbef. If cefazolin tests resistant, test individual drugs if considering for use."}},cefaclor:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}}},cefadroxil:{mic_breakpoints:{S:"≤16",I:"null",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}}},cefdinir:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥20",I:"17-19",R:"≤16"}}},cefixime:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥19",I:"16-18",R:"≤15"}}},cefpodoxime:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥21",I:"18-20",R:"≤17"}}},cefprozil:{mic_breakpoints:{S:"≤16",I:"null",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}}},ceftibuten:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"}}},cefuroxime_oral:{mic_breakpoints:{S:"≤4",I:"8-16",R:"≥32"},disk_diffusion:{routine:{S:"≥23",I:"15-22",R:"≤14"}}},cephalexin:{mic_breakpoints:{S:"≤16",I:"null",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}}},loracarbef:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}}},doripenem:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"}}},ertapenem:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥22",I:"19-21",R:"≤18"}}},imipenem:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"}}},"imipenem-relebactam":{mic_breakpoints:{S:"≤1/4",I:"2/4",R:"≥4/4"},disk_diffusion:{routine:{S:"≥25",I:"21-24",R:"≤20"},special_considerations:"Breakpoints do not apply to the family Morganellaceae (Morganella, Proteus, Providencia)."}},meropenem:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"}}},"meropenem-vaborbactam":{mic_breakpoints:{S:"≤4/8",I:"8/8",R:"≥16/8"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"},special_considerations:"CRITICAL WARNING: Isolates with OXA-48-like enzymes may test susceptible but not respond clinically. If OXA-48 is detected, report as resistant or suppress the result."}},aztreonam:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥21",I:"16-20",R:"≤15"}}},amikacin:{mic_breakpoints:{S:"≤16",I:"32",R:"≥64"},disk_diffusion:{routine:{S:"≥17",I:"15-16",R:"≤14"}}},gentamicin:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥15",I:"13-14",R:"≤12"}}},kanamycin:{mic_breakpoints:{S:"≤16",I:"32",R:"≥64"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}}},netilmicin:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥15",I:"13-14",R:"≤12"}}},plazomicin:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥30",I:"14-17",R:"≤13"}}},streptomycin:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥15",I:"12-14",R:"≤11"}}},tobramycin:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥15",I:"13-14",R:"≤12"}}},cinoxacin:{mic_breakpoints:{S:"≤16",I:"null",R:"≥32"},disk_diffusion:{routine:{S:"≥19",I:"14-18",R:"≤13"},condition:"UTI only"}},ciprofloxacin:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥21",I:"16-20",R:"≤15"}}},enoxacin:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥20",I:"17-19",R:"≤16"},condition:"UTI only"}},gatifloxacin:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"}}},gemifloxacin:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},disk_diffusion:{routine:{S:"≥20",I:"16-19",R:"≤15"},special_considerations:"Report only on K. pneumoniae"}},grepafloxacin:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}}},levofloxacin:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥17",I:"14-16",R:"≤13"}}},lomefloxacin:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥22",I:"19-21",R:"≤18"},condition:"UTI only"}},moxifloxacin:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥17",I:"14-16",R:"≤13"}}},nalidixic_acid:{mic_breakpoints:{S:"≤16",I:"null",R:"≥32"},disk_diffusion:{routine:{S:"≥19",I:"14-18",R:"≤13"},condition:"UTI only"}},norfloxacin:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥17",I:"13-16",R:"≤12"},condition:"UTI only"}},ofloxacin:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥19",I:"13-18",R:"≤12"}}},sparfloxacin:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥17",I:"14-16",R:"≤13"}}},sulfonamides:{mic_breakpoints:{S:"≤256",I:"null",R:"≥512"},disk_diffusion:{routine:{S:"≥17",I:"11-16",R:"≤10"},condition:"UTI only",special_considerations:"Sulfisoxazole can be used to represent any of the currently available sulfonamide preparations."}},trimethoprim:{mic_breakpoints:{S:"≤8",I:"null",R:"≥16"},disk_diffusion:{routine:{S:"≥16",I:"11-15",R:"≤10"},condition:"UTI only"}},"trimethoprim-sulfamethoxazole":{mic_breakpoints:{S:"≤2/38",I:"null",R:"≥4/76"},disk_diffusion:{routine:{S:"≥16",I:"11-15",R:"≤10"}}},chloramphenicol:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"13-17",R:"≤12"},special_considerations:"Not routinely reported on isolates from the urinary tract."}},colistin_polymyxinB:{mic_breakpoints:{S:"≤2",I:"≤2",R:"≥4"},disk_diffusion:{routine:{note:"Disk diffusion and gradient diffusion methods should not be performed."},special_considerations:"For colistin, broth microdilution, CBDE, and CAT MIC methods are acceptable. For polymyxin B, broth microdilution is the only approved method. Guidance for administration: Colistin (methanesulfonate) with loading and maximum renally adjusted doses; Polymyxin B with loading and maximum recommended doses. WARNING: When colistin or polymyxin B is given systemically, neither is likely to be effective for pneumonia."}},fosfomycin:{mic_breakpoints:{S:"≤64",I:"128",R:"≥256"},disk_diffusion:{routine:{S:"≥16",I:"13-15",R:"≤12"},condition:"E. coli urinary tract isolates only",special_considerations:"Breakpoints apply only to E. coli and should not be extrapolated to other species of Enterobacterales. The 200-μg fosfomycin disk contains 50 μg glucose-6-phosphate. MIC testing must be performed by agar dilution with glucose-6-phosphate. Broth dilution should not be performed."}},nitrofurantoin:{mic_breakpoints:{S:"≤32",I:"64",R:"≥128"},disk_diffusion:{routine:{S:"≥17",I:"15-16",R:"≤14"},condition:"UTI only"}},tetracycline:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥15",I:"12-14",R:"≤11"}}},doxycycline:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥14",I:"11-13",R:"≤10"}}},minocycline:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥16",I:"13-15",R:"≤12"}}}}},Inducible_AmpC_Producers_Note:{note:"For Enterobacter cloacae complex, Klebsiella aerogenes, Citrobacter freundii complex, Serratia marcescens, Proteus vulgaris, Providencia spp., Hafnia alvei, and Morganella morganii, isolates that are susceptible to third-generation cephalosporins (e.g., ceftriaxone) may develop resistance during prolonged therapy. Reporting of results for these organisms should involve the antimicrobial stewardship team and other institutional stakeholders (CLSI M100-Ed34, Table 2A-1, Footnote 15)."},Citrobacter_freundii_complex:{category:"Enterobacterales (Table 2A-1)",intrinsic_resistance:["ampicillin","amoxicillin","amoxicillin-clavulanate","ampicillin-sulbactam","cefazolin"],note:"Inducible AmpC producer. See Inducible_AmpC_Producers_Note. Breakpoints otherwise as for E. coli."},Citrobacter_koseri:{category:"Enterobacterales (Table 2A-1)",intrinsic_resistance:[],note:"Breakpoints as for E. coli."},Enterobacter_cloacae_complex:{category:"Enterobacterales (Table 2A-1)",intrinsic_resistance:["ampicillin","amoxicillin","amoxicillin-clavulanate","ampicillin-sulbactam","cefazolin"],note:"Inducible AmpC producer. See Inducible_AmpC_Producers_Note. Breakpoints otherwise as for E. coli."},Hafnia_alvei:{category:"Enterobacterales (Table 2A-1)",intrinsic_resistance:["ampicillin","amoxicillin","amoxicillin-clavulanate","ampicillin-sulbactam","cefazolin"],note:"Inducible AmpC producer. See Inducible_AmpC_Producers_Note. Breakpoints otherwise as for E. coli."},Klebsiella_aerogenes:{category:"Enterobacterales (Table 2A-1)",intrinsic_resistance:["ampicillin","amoxicillin","amoxicillin-clavulanate","ampicillin-sulbactam","cefazolin"],note:"Inducible AmpC producer. See Inducible_AmpC_Producers_Note. Breakpoints otherwise as for E. coli."},Klebsiella_oxytoca:{category:"Enterobacterales (Table 2A-1)",intrinsic_resistance:["ampicillin","amoxicillin"],note:"Breakpoints as for E. coli. Often produces an inducible beta-lactamase that may not be detected by routine ESBL tests."},Klebsiella_pneumoniae:{category:"Enterobacterales (Table 2A-1)",intrinsic_resistance:["ampicillin","amoxicillin"],note:"Breakpoints as for E. coli."},Morganella_morganii:{category:"Enterobacterales (Table 2A-1)",intrinsic_resistance:["ampicillin","amoxicillin","amoxicillin-clavulanate","ampicillin-sulbactam","cefazolin","colistin","tigecycline"],note:"Inducible AmpC producer. See Inducible_AmpC_Producers_Note. Breakpoints otherwise as for E. coli."},Proteus_mirabilis:{category:"Enterobacterales (Table 2A-1)",intrinsic_resistance:["nitrofurantoin","colistin","tigecycline"],note:"No reliable disk diffusion for imipenem. Breakpoints otherwise as for E. coli."},Proteus_vulgaris:{category:"Enterobacterales (Table 2A-1)",intrinsic_resistance:["ampicillin","amoxicillin","nitrofurantoin","colistin","tigecycline"],note:"Inducible AmpC producer. See Inducible_AmpC_Producers_Note. Breakpoints otherwise as for E. coli."},Providencia_spp:{category:"Enterobacterales (Table 2A-1)",intrinsic_resistance:["ampicillin","amoxicillin","amoxicillin-clavulanate","ampicillin-sulbactam","cefazolin","colistin","tigecycline"],note:"Inducible AmpC producer. See Inducible_AmpC_Producers_Note. Breakpoints otherwise as for E. coli."},Serratia_marcescens:{category:"Enterobacterales (Table 2A-1)",intrinsic_resistance:["ampicillin","amoxicillin","amoxicillin-clavulanate","ampicillin-sulbactam","cefazolin","colistin"],note:"Inducible AmpC producer. See Inducible_AmpC_Producers_Note. Breakpoints otherwise as for E. coli."},Yersinia_enterocolitica:{category:"Enterobacterales (Table 2A-1)",intrinsic_resistance:["ampicillin","amoxicillin","amoxicillin-clavulanate","ampicillin-sulbactam","cefazolin"],note:"Inducible AmpC producer. See Inducible_AmpC_Producers_Note. Breakpoints otherwise as for E. coli."}},Salmonella_and_Shigella_Table_2A_2:{Salmonella_spp:{category:"Salmonella and Shigella (Table 2A-2)",clsi_table:"Table 2A-2",source:"CLSI M100-Ed34",note:"For extraintestinal isolates only.",antibiotics:{penicillin:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥17",I:"14-16",R:"≤13"}}},azithromycin:{mic_breakpoints:{S:"≤16",I:"null",R:"≥32"},disk_diffusion:{routine:{S:"≥13",I:"null",R:"≤12"},condition:"For S. Typhi/Paratyphi only"}},ceftriaxone:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥26",I:"23-25",R:"≤22"}}},chloramphenicol:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"13-17",R:"≤12"}}},ciprofloxacin:{mic_breakpoints:{S:"≤0.06",I:"0.12-0.5",R:"≥1"},disk_diffusion:{routine:{S:"≥31",I:"21-30",R:"≤20"}}},pefloxacin_inv:{mic_breakpoints:{S:"≤0.25",I:"null",R:"≥0.5"},disk_diffusion:{routine:{S:"≥24",I:"null",R:"≤23"},condition:"Surrogate for ciprofloxacin in S. Typhi"}},ertapenem:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥22",I:"19-21",R:"≤18"}}},imipenem:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"}}},meropenem:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"}}},"trimethoprim-sulfamethoxazole":{mic_breakpoints:{S:"≤2/38",I:"null",R:"≥4/76"},disk_diffusion:{routine:{S:"≥16",I:"11-15",R:"≤10"}}},tetracycline:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥15",I:"12-14",R:"≤11"}}},doxycycline:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥14",I:"11-13",R:"≤10"}}},minocycline:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥16",I:"13-15",R:"≤12"}}}}},Shigella_spp:{category:"Salmonella and Shigella (Table 2A-2)",clsi_table:"Table 2A-2",source:"CLSI M100-Ed34",antibiotics:{penicillin:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥17",I:"14-16",R:"≤13"}}},azithromycin:{mic_breakpoints:{S:"≤8",I:"null",R:"≥16"},disk_diffusion:{routine:{S:"≥12",I:"null",R:"≤11"},special_considerations:"Disk diffusion zones can be hazy and difficult to measure, especially S. sonnei. If difficult to measure, an MIC method is recommended."}},ceftriaxone:{mic_breakpoints:{S:"≤1",I:"null",R:"≥2"},disk_diffusion:{routine:{S:"≥26",I:"23-25",R:"≤22"}}},ciprofloxacin:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},disk_diffusion:{routine:{S:"≥21",I:"16-20",R:"≤15"}}},ofloxacin:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},disk_diffusion:{routine:{S:"≥21",I:"16-20",R:"≤15"}}},"trimethoprim-sulfamethoxazole":{mic_breakpoints:{S:"≤2/38",I:"null",R:"≥4/76"},disk_diffusion:{routine:{S:"≥16",I:"11-15",R:"≤10"}}}}}}},Eh={Staphylococcus_aureus:{category:"Staphylococcus spp.",clsi_table:"Table 2C",source:"CLSI M100-Ed34",notes:["Breakpoints for S. aureus also apply to S. aureus complex (e.g., S. argenteus, S. schweitzeri).","Oxacillin resistance predicts resistance to all other penicillins, beta-lactam/beta-lactamase inhibitor combinations, cephalosporins (except ceftaroline), and carbapenems."],common_resistance_mechanisms:["mecA-mediated methicillin resistance (MRSA)","Inducible clindamycin resistance (MLSb)","Fluoroquinolone resistance"],epidemiology:"Major pathogen in skin/soft tissue infections, bacteremia, endocarditis, and osteomyelitis.",antibiotics:{penicillin:{clsi:{mic_breakpoints:{S:"≤0.12",I:null,R:"≥0.25"},tier:1}},oxacillin:{clsi:{mic_breakpoints:{S:"≤2",R:"≥4"},tier:1}},ceftaroline:{clsi:{mic_breakpoints:{S:"≤1",I:"2-4",R:"≥8"},tier:1}},cefoxitin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},tier:2}},cefazolin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},tier:2}},ceftriaxone:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},tier:2}},cefotaxime:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},tier:2}},cefepime:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},tier:2}},ceftazidime:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},tier:2}},ceftizoxime:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},tier:2}},"cefuroxime (oral)":{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},tier:2}},imipenem:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},tier:2}},meropenem:{clsi:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},tier:2}},gentamicin:{clsi:{mic_breakpoints:{S:"≤1",I:"2-4",R:"≥8"},tier:2,condition:"Should only be used in combination with other active agents."}},vancomycin:{clsi:{mic_breakpoints:{S:"≤2",I:"4-8",R:"≥16"},tier:1}},telavancin:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},tier:2}},teicoplanin:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},tier:3,condition:"Investigational"}},dalbavancin:{clsi:{mic_breakpoints:{S:"≤0.12",R:"≥0.25"},tier:2}},oritavancin:{clsi:{mic_breakpoints:{S:"≤0.12",R:"≥0.25"},tier:2}},daptomycin:{clsi:{mic_breakpoints:{S:"≤1",I:null,R:"≥2"},tier:1}},linezolid:{clsi:{mic_breakpoints:{S:"≤4",I:null,R:"≥8"},tier:1}},tedizolid:{clsi:{mic_breakpoints:{S:"≤0.5",I:null,R:"≥1"},tier:1}},clindamycin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1-2",R:"≥4"},tier:1}},erythromycin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1-4",R:"≥8"},tier:2}},azithromycin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1-4",R:"≥8"},tier:2}},clarithromycin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1-4",R:"≥8"},tier:2}},dirithromycin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},tier:3}},"quinupristin-dalfopristin":{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},tier:3,condition:"Report only on MSSA."}},tetracycline:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},tier:1}},doxycycline:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},tier:1}},minocycline:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},tier:1}},levofloxacin:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},tier:2}},ciprofloxacin:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},tier:2}},ofloxacin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},tier:2}},gatifloxacin:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},tier:2}},grepafloxacin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},tier:3}},lomefloxacin:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},tier:3}},norfloxacin:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},tier:3,condition:"For uncomplicated UTIs only."}},sparfloxacin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},tier:3}},pleroxacin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},tier:3,condition:"Investigational"}},"trimethoprim-sulfamethoxazole":{clsi:{mic_breakpoints:{S:"≤2/38",I:null,R:"≥4/76"},tier:1}},sulfonamides:{clsi:{mic_breakpoints:{S:"≤256",R:"≥512"},tier:3,condition:"For uncomplicated UTIs only."}},trimethoprim:{clsi:{mic_breakpoints:{S:"≤10",R:"≥16"},tier:3,condition:"For uncomplicated UTIs only."}},rifampin:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},tier:2,condition:"Rifampin should not be used alone for antimicrobial therapy."}},nitrofurantoin:{clsi:{mic_breakpoints:{S:"≤32",I:"64",R:"≥128"},tier:2,condition:"Not routinely reported on organisms isolated from the urinary tract."}},chloramphenicol:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},tier:3,condition:"Not routinely reported on organisms isolated from the urinary tract."}}}},Staphylococcus_argenteus:{category:"Staphylococcus spp. (S. aureus complex)",clsi_table:"Table 2C",source:"CLSI M100-Ed34",epidemiology:"Coagulase-positive species within the S. aureus complex; use S. aureus breakpoints.",breakpoint_base:"Staphylococcus_aureus",specific_breakpoints:{}},Staphylococcus_schweitzeri:{category:"Staphylococcus spp. (S. aureus complex)",clsi_table:"Table 2C",source:"CLSI M100-Ed34",epidemiology:"Coagulase-positive species within the S. aureus complex; use S. aureus breakpoints.",breakpoint_base:"Staphylococcus_aureus",specific_breakpoints:{}},Staphylococcus_epidermidis:{category:"Staphylococcus spp.",clsi_table:"Table 2C",source:"CLSI M100-Ed34",epidemiology:"Prosthetic device infections, catheter-associated bacteremia.",breakpoint_base:"Staphylococcus_aureus",specific_breakpoints:{oxacillin:{clsi:{mic_breakpoints:{S:"≤0.5",R:"≥1"},tier:1}},vancomycin:{clsi:{mic_breakpoints:{S:"≤4",I:"8-16",R:"≥32"},tier:1}}}},Staphylococcus_haemolyticus:{category:"Staphylococcus spp.",clsi_table:"Table 2C",source:"CLSI M100-Ed34",epidemiology:"Associated with nosocomial infections, particularly line-associated bacteremia.",breakpoint_base:"Staphylococcus_aureus",specific_breakpoints:{oxacillin:{clsi:{mic_breakpoints:{S:"≤0.5",R:"≥1"},tier:1}},vancomycin:{clsi:{mic_breakpoints:{S:"≤4",I:"8-16",R:"≥32"},tier:1}}}},Staphylococcus_saprophyticus:{category:"Staphylococcus spp.",clsi_table:"Table 2C",source:"CLSI M100-Ed34",epidemiology:"A leading cause of uncomplicated urinary tract infections (UTIs) in young females.",breakpoint_base:"Staphylococcus_aureus",specific_breakpoints:{oxacillin:{clsi:{mic_breakpoints:{S:"≤0.5",R:"≥1"},tier:1}},vancomycin:{clsi:{mic_breakpoints:{S:"≤4",I:"8-16",R:"≥32"},tier:1}}}},Staphylococcus_lugdunensis:{category:"Staphylococcus spp.",clsi_table:"Table 2C",source:"CLSI M100-Ed34",epidemiology:"Aggressive CoNS; can cause native valve endocarditis mimicking S. aureus.",breakpoint_base:"Staphylococcus_aureus",specific_breakpoints:{oxacillin:{clsi:{mic_breakpoints:{S:"≤2",R:"≥4"},tier:1}},vancomycin:{clsi:{mic_breakpoints:{S:"≤4",I:"8-16",R:"≥32"},tier:1}}}},Staphylococcus_schleiferi:{category:"Staphylococcus spp.",clsi_table:"Table 2C",source:"CLSI M100-Ed34",epidemiology:"Associated with skin, soft tissue, and bone infections; often in veterinary medicine.",breakpoint_base:"Staphylococcus_aureus",specific_breakpoints:{oxacillin:{clsi:{mic_breakpoints:{S:"≤0.5",R:"≥1"},tier:1}},vancomycin:{clsi:{mic_breakpoints:{S:"≤4",I:"8-16",R:"≥32"},tier:1}}}},Staphylococcus_pseudintermedius:{category:"Staphylococcus spp.",clsi_table:"Table 2C",source:"CLSI M100-Ed34",epidemiology:"Primarily a veterinary pathogen (dogs), can cause zoonotic infections in humans.",breakpoint_base:"Staphylococcus_aureus",specific_breakpoints:{oxacillin:{clsi:{mic_breakpoints:{S:"≤0.5",R:"≥1"},tier:1}},vancomycin:{clsi:{mic_breakpoints:{S:"≤4",I:"8-16",R:"≥32"},tier:1}}}},Staphylococcus_spp_unidentified:{category:"Staphylococcus spp.",clsi_table:"Table 2C",source:"CLSI M100-Ed34",epidemiology:"Represents Staphylococcus spp. not listed above or not identified to the species level.",breakpoint_base:"Staphylococcus_aureus",specific_breakpoints:{oxacillin:{clsi:{mic_breakpoints:{S:"≤0.5",R:"≥1"},tier:1}},vancomycin:{clsi:{mic_breakpoints:{S:"≤4",I:"8-16",R:"≥32"},tier:1}}}}},Yu={"ampicillin-sulbactam":{clsi:{mic_breakpoints:{S:"≤8/4",I:null,R:"≥16/4"},disk_diffusion:{routine:{S:"≥15",I:"12-14",R:"≤11",note:"The 'Intermediate' category may be applicable for uncomplicated UTIs due to high drug concentration in urine. Refer to CLSI M100 for details."}},tier:1,source:"CLSI M100-Ed34 Table 2D"}},"piperacillin-tazobactam":{clsi:{mic_breakpoints:{S:"≤16/4",I:"32/4-64/4",R:"≥128/4"},disk_diffusion:{routine:{note:"Disk diffusion breakpoints have been removed because no disk correlate data are available for the revised piperacillin MIC breakpoints. Source: CLSI M100-Ed34 Table 2D, comment (12)."}},tier:1,source:"CLSI M100-Ed34 Table 2D",note:"Breakpoints are not listed in a dedicated row in Table 2D for Enterococcus spp. but are derived from CLSI M100 Table 2A-1 (Enterobacterales) and are applicable based on interpretive guidance in Table 2D, Footnote (8)."}},"amoxicillin-clavulanate":{clsi:{mic_breakpoints:{S:"≤8/4",I:null,R:"≥16/4"},disk_diffusion:{routine:{S:"≥18",I:"14-17",R:"≤13",note:"The 'Intermediate' category may be applicable for uncomplicated UTIs due to high drug concentration in urine. Refer to CLSI M100 for details."}},tier:2,source:"CLSI M100-Ed34 Table 2D",note:"Breakpoints are not listed in a dedicated row in Table 2D for Enterococcus spp. but are derived from CLSI M100 Table 2A-1 (Enterobacterales) and are applicable based on interpretive guidance in Table 2D, Footnote (8)."}},doripenem:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:null,tier:3,source:"CLSI M100-Ed34 Table 2D"}},ertapenem:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:null,tier:3,note:"Generally not active against Enterococcus spp. These breakpoints are primarily for epidemiological purposes.",source:"CLSI M100-Ed34 Table 2D"}},imipenem:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:null,tier:3,note:"Most E. faecium are resistant. E. faecalis may be susceptible.",source:"CLSI M100-Ed34 Table 2D"}},meropenem:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:null,tier:3,source:"CLSI M100-Ed34 Table 2D"}},vancomycin:{clsi:{mic_breakpoints:{S:"≤4",I:"8-16",R:"≥32"},disk_diffusion:{routine:{S:"≥17",I:"15-16",R:"≤14",note:"For accurate detection of vancomycin resistance, incubate for 24h. Examine zones using transmitted light for faint growth. Perform biochemical tests for identification of isolates with vancomycin MICs ≥8 μg/mL. Source: CLSI M100-Ed34 Table 2D, comment (11)."}},tier:1,source:"CLSI M100-Ed34 Table 2D"},clinical_intelligence:{if_resistant:{implications:["VRE - infection control alert"],alternatives:["linezolid","daptomycin","tigecycline"]}}},dalbavancin:{clsi:{mic_breakpoints:{S:"≤0.25",I:null,R:"≥0.5"},disk_diffusion:null,tier:3,condition:"Report only on vancomycin-susceptible E. faecalis.",source:"CLSI M100-Ed34 Table 2D"}},oritavancin:{clsi:{mic_breakpoints:{S:"≤0.12",I:null,R:null},disk_diffusion:null,tier:3,note:"Susceptible-only breakpoint.",source:"CLSI M100-Ed34 Table 2D"}},telavancin:{clsi:{mic_breakpoints:{S:"≤0.12",I:null,R:null},disk_diffusion:null,tier:3,note:"Susceptible-only breakpoint.",source:"CLSI M100-Ed34 Table 2D"}},teicoplanin:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:null,tier:3,source:"CLSI M100-Ed34 Table 2D"},clinical_intelligence:{note:"Not routinely reported on organisms isolated from the lower respiratory tract. Also considered an investigational agent in the US.",source:"CLSI M100-Ed34 Table 2D, comment (13); General Clinical Knowledge"}},linezolid:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤20"}},tier:1,source:"CLSI M100-Ed34 Table 2D"}},tedizolid:{clsi:{mic_breakpoints:{S:"≤0.5",I:null,R:null},disk_diffusion:{routine:{S:"≥20",I:null,R:null}},tier:3,note:"Susceptible-only breakpoint.",source:"CLSI M100-Ed34 Table 2D"}},gentamicin:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}},tier:2,source:"CLSI M100-Ed34 Table 2D"},high_level_resistance_screen:{mic:">500 µg/mL",disk_content:"120 µg",note:"For prediction of synergistic activity with cell-wall active agents for serious infections."},clinical_intelligence:{warning:"CLSI Note: May appear active in vitro, but clinical outcomes data for monotherapy are limited. Combination therapy is recommended for most indications other than UTIs; consultation with an infectious diseases specialist is advised."}},amikacin:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥20",I:"17-19",R:"≤15"}},tier:2,source:"CLSI M100-Ed34 Table 2D"},clinical_intelligence:{warning:"CLSI Note: May appear active in vitro, but clinical outcomes data for monotherapy are limited. Combination therapy is recommended for most indications other than UTIs; consultation with an infectious diseases specialist is advised."}},kanamycin:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥18",I:"14-17",R:"≤13"}},tier:3,source:"CLSI M100-Ed34 Table 2D"}},netilmicin:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥15",I:"13-14",R:"≤12"}},tier:3,source:"CLSI M100-Ed34 Table 2D"}},streptomycin:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥15",I:"12-14",R:"≤11"}},tier:2,source:"CLSI M100-Ed34 Table 2D"},high_level_resistance_screen:{mic:">1000 µg/mL",disk_content:"300 µg",note:"For prediction of synergistic activity with cell-wall active agents for serious infections."}},cinoxacin:{clsi:{mic_breakpoints:{S:"≤16",I:null,R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}},tier:3,condition:"Urine isolates only",source:"CLSI M100-Ed34 Table 2D"}},ciprofloxacin:{clsi:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},disk_diffusion:{routine:{S:"≥26",I:"22-25",R:"≤21",note:"The 'Intermediate' category implies 'Susceptible-Dose Dependent (SDD)' or utility for uncomplicated UTIs. Refer to CLSI M100 for details on the 'I^' designation."}},tier:2,source:"CLSI M100-Ed34 Table 2D"},clinical_intelligence:{source:"CLSI M100-Ed34 General Comment (4)",warning:"May appear active in vitro, but is not effective clinically and should not be reported as S."}},enoxacin:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}},tier:3,condition:"Urine isolates only",source:"CLSI M100-Ed34 Table 2D"}},grepafloxacin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}},tier:3,source:"CLSI M100-Ed34 Table 2D"}},levofloxacin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥21",I:"17-20",R:"≤16",note:"The 'Intermediate' category implies 'Susceptible-Dose Dependent (SDD)' or utility for uncomplicated UTIs. Refer to CLSI M100 for details on the 'I^' designation."}},tier:2,source:"CLSI M100-Ed34 Table 2D"},clinical_intelligence:{source:"CLSI M100-Ed34 General Comment (4)",warning:"May appear active in vitro, but is not effective clinically and should not be reported as S."}},lomefloxacin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥22",I:"19-21",R:"≤18"}},tier:2,condition:"Urine Only",note:"The 'Intermediate' category for disk diffusion may be interpreted as 'Susceptible-Dose Dependent (SDD)' or applicable for uncomplicated UTIs. Refer to CLSI M100 General Comment (4).",source:"CLSI M100-Ed34 Table 2D"}},gatifloxacin:{clsi:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},disk_diffusion:{routine:{S:"≥20",I:"16-19",R:"≤15"}},source:"CLSI M100-Ed34 Table 2D"}},nalidixic_acid:{clsi:{mic_breakpoints:{S:"≤16",I:null,R:"≥32"},disk_diffusion:{routine:{S:"≥19",I:"14-18",R:"≤13"}},source:"CLSI M100-Ed34 Table 2D"},clinical_intelligence:{source:"General Clinical Knowledge",note:"Investigational agent."}},norfloxacin:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥17",I:"13-16",R:"≤12"}},tier:2,condition:"Urine Only",source:"CLSI M100-Ed34 Table 2D"}},ofloxacin:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥19",I:"15-18",R:"≤14"}},tier:2,condition:"Urine Only",source:"CLSI M100-Ed34 Table 2D"},clinical_intelligence:{source:"CLSI M100-Ed34 General Comment (4)",warning:"May appear active in vitro, but is not effective clinically and should not be reported as S."}},sparfloxacin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥19",I:"16-18",R:"≤15"}},source:"CLSI M100-Ed34 Table 2D"},clinical_intelligence:{source:"CLSI M100-Ed34 General Comment (4)",warning:"May appear active in vitro, but is not effective clinically and should not be reported as S."}},tetracycline:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥19",I:"15-18",R:"≤14"}},tier:2,note:"Organisms that are susceptible to tetracycline are also considered susceptible to doxycycline and minocycline. However, some organisms that are intermediate or resistant to tetracycline may be susceptible to doxycycline, minocycline, or both.",source:"CLSI M100-Ed34 Table 2D"}},doxycycline:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥16",I:"13-15",R:"≤12"}},tier:2,note:"Organisms that are susceptible to tetracycline are also considered susceptible to doxycycline and minocycline. However, some organisms that are intermediate or resistant to tetracycline may be susceptible to doxycycline, minocycline, or both.",source:"CLSI M100-Ed34 Table 2D"}},minocycline:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥19",I:"15-18",R:"≤14"}},tier:2,note:"Organisms that are susceptible to tetracycline are also considered susceptible to doxycycline and minocycline. However, some organisms that are intermediate or resistant to tetracycline may be susceptible to doxycycline, minocycline, or both.",source:"CLSI M100-Ed34 Table 2D"}},erythromycin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1-4",R:"≥8"},disk_diffusion:{routine:{S:"≥23",I:"14-22",R:"≤13"}},tier:2,source:"CLSI M100-Ed34 Table 2D"}},sulfonamides:{clsi:{mic_breakpoints:{S:"≤256",I:null,R:"≥512"},disk_diffusion:{routine:{S:"≥17",I:"13-16",R:"≤12"}},condition:"Urine Only",note:"Sulfisoxazole can be used to represent any of the currently available sulfonamide preparations. Source: CLSI M100-Ed34 Table 2D, Footnote (35).",source:"CLSI M100-Ed34 Table 2D"}},trimethoprim:{clsi:{mic_breakpoints:{S:"≤4",I:null,R:"≥8"},disk_diffusion:{routine:{note:"MIC test required. Source: CLSI M100-Ed34 Table 2D, comment (36)."}},condition:"Urine isolates only",source:"CLSI M100-Ed34 Table 2D"}},"trimethoprim-sulfamethoxazole":{clsi:{mic_breakpoints:{S:"≤0.5/9.5",I:"1/19-2/38",R:"≥4/76"},disk_diffusion:{routine:{S:"≥16",I:"11-15",R:"≤10"}},tier:3,source:"CLSI M100-Ed34 Table 2D"},clinical_intelligence:{warning:"May appear active in vitro, but is not effective clinically and should not be reported as S.",source:"CLSI M100-Ed34 General Comment (4)"}},rifampin:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥20",I:"17-19",R:"≤16"}},tier:3,note:"Should not be used for monotherapy.",source:"CLSI M100-Ed34 Table 2D"}},fosfomycin:{clsi:{mic_breakpoints:{S:"≤64",I:"128",R:"≥256"},disk_diffusion:{routine:{S:"≥17",I:"13-16",R:"≤12"}},tier:2,condition:"Urine isolates only",note:"CLSI Footnote 37: Disk diffusion and MIC breakpoints apply only to E. coli urinary tract isolates and should not be extrapolated. CLSI Footnote 39: The only approved MIC method for testing is agar dilution using agar media supplemented with 25 µg/mL of glucose-6-phosphate. Broth dilution MIC testing should not be performed.",source:"CLSI M100-Ed34 Table 2D"}},chloramphenicol:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"13-17",R:"≤12"}},tier:3,note:"Not routinely reported on organisms isolated from the urinary tract.",source:"CLSI M100-Ed34 Table 2D"}},nitrofurantoin:{clsi:{mic_breakpoints:{S:"≤32",I:"64",R:"≥128"},disk_diffusion:{routine:{S:"≥17",I:"15-16",R:"≤14"}},tier:2,condition:"Urine isolates only",source:"CLSI M100-Ed34 Table 2D"}},aztreonam:{clsi:{note:"No breakpoints provided; intrinsically resistant."}},ceftriaxone:{clsi:{note:"No breakpoints provided; intrinsically resistant."}},cefotaxime:{clsi:{note:"No breakpoints provided; intrinsically resistant."}},cefepime:{clsi:{note:"No breakpoints provided; intrinsically resistant."}},ceftaroline:{clsi:{note:"No breakpoints provided; intrinsically resistant."}},"ceftazidime-avibactam":{clsi:{note:"No breakpoints provided for Enterococcus."}}},Ph={Enterococcus_faecalis:{category:"Enterococcus spp.",clsi_table:"Table 2D",common_resistance_mechanisms:["Vancomycin resistance (VRE)","High-level aminoglycoside resistance"],epidemiology:"UTI, bacteremia, endocarditis",intrinsic_resistance:["cephalosporins","clindamycin","quinupristin-dalfopristin","aztreonam"],antibiotics:{...Yu,penicillin:{clsi:{mic_breakpoints:{S:"≤8",I:null,R:"≥16"},disk_diffusion:{routine:{S:"≥15",I:null,R:"≤14"}},tier:1,source:"CLSI M100-Ed34 Table 2D"},clinical_intelligence:{note:"CLSI Note: Penicillin resistance due to β-lactamase is rare and not reliably detected by routine susceptibility methods. A direct nitrocefin-based β-lactamase test can be used in selected cases."}},ampicillin:{clsi:{mic_breakpoints:{S:"≤8",I:null,R:"≥16"},disk_diffusion:{routine:{S:"≥17",I:"14-16",R:"≤13"}},tier:1,source:"CLSI M100-Ed34 Table 2D"},clinical_intelligence:{note:"Results of ampicillin susceptibility tests should be used to predict results for amoxicillin (Source: CLSI M100-Ed34 Table 2D, comment (6)).",source:"General Clinical Knowledge",if_susceptible:{confidence:"First-line for susceptible enterococci",dosing_notes:"Higher doses for endocarditis"}}},"quinupristin-dalfopristin":{clsi:{note:"E. faecalis is intrinsically resistant.",intrinsic_resistance:!0,source:"CLSI M100-Ed34 Table 2D"}}}},Enterococcus_faecium:{category:"Enterococcus spp.",clsi_table:"Table 2D",common_resistance_mechanisms:["High vancomycin resistance rates","Ampicillin resistance common"],epidemiology:"More resistant than E. faecalis, nosocomial pathogen",intrinsic_resistance:["cephalosporins","clindamycin","aztreonam"],antibiotics:{...Yu,daptomycin:{clsi:{mic_breakpoints:{S:"≤4",I:null,R:"≥8"},disk_diffusion:{routine:{note:"MIC method required"}},tier:2,condition:"Reported only on E. faecium",source:"CLSI M100-Ed34 Table 2D"},clinical_intelligence:{warning:"Not routinely reported on organisms isolated from the lower respiratory tract."}},penicillin:{clsi:{mic_breakpoints:{S:"≤8",I:null,R:"≥16"},disk_diffusion:{routine:{S:"≥15",I:null,R:"≤14"}},tier:1,source:"CLSI M100-Ed34 Table 2D"},clinical_intelligence:{note:"CLSI Note: Penicillin resistance due to β-lactamase is rare and not reliably detected by routine susceptibility methods. A direct nitrocefin-based β-lactamase test can be used in selected cases."}},ampicillin:{clsi:{mic_breakpoints:{S:"≤8",I:null,R:"≥16"},disk_diffusion:{routine:{S:"≥17",I:"14-16",R:"≤13"}},tier:1,source:"CLSI M100-Ed34 Table 2D"},clinical_intelligence:{note:"Results of ampicillin susceptibility tests should be used to predict results for amoxicillin (Source: CLSI M100-Ed34 Table 2D, comment (6)).",source:"General Clinical Knowledge",if_resistant:{implications:["Common resistance in E. faecium"],alternatives:["vancomycin","linezolid","daptomycin"]}}},"quinupristin-dalfopristin":{clsi:{mic_breakpoints:{S:"≤1",I:"2-4",R:"≥8"},disk_diffusion:{routine:{S:"≥19",I:"16-18",R:"≤15"}},tier:2,condition:"Report only on vancomycin-resistant E. faecium.",source:"CLSI M100-Ed34 Table 2D"},clinical_intelligence:{source:"General Clinical Knowledge",if_susceptible:{confidence:"Active against E. faecium (not E. faecalis)",dosing_notes:"Limited to E. faecium infections"}}}}}},gt={clsi:{tier:2,note:"Susceptibility can be inferred from penicillin."}},Lh={Streptococcus_pneumoniae:{category:"Streptococcus spp.",clsi_table:"Table 2G",source:"CLSI M100-Ed34 Table 2G",common_resistance_mechanisms:["Penicillin resistance (PBP mutations)","Macrolide resistance (ermB, mefA)","Quinolone resistance (gyrA, parC mutations)"],epidemiology:"Community-acquired pneumonia (CAP), meningitis, bacteremia, otitis media, sinusitis.",antibiotics:{penicillin:{clsi:{mic_breakpoints:{meningitis:{S:"≤0.06",I:"0.12-0.25",R:"≥0.5"},non_meningitis_parenteral:{S:"≤2",I:"4",R:"≥8"},non_meningitis_oral:{S:"≤0.06",I:"0.12-1",R:"≥2"}},disk_diffusion:{routine:{note:"Oxacillin disk (1 ug) screens for penicillin resistance. Zone ≤19 mm suggests resistance. MIC method required for definitive result."}},tier:1}},amoxicillin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},tier:1}},"amoxicillin-clavulanate":{clsi:{mic_breakpoints:{S:"≤2/1",I:"4/2",R:"≥8/4"},tier:1}},cefotaxime:{clsi:{mic_breakpoints:{meningitis:{S:"≤0.5",I:"1",R:"≥2"},non_meningitis:{S:"≤1",I:"2",R:"≥4"}},tier:1}},ceftriaxone:{clsi:{mic_breakpoints:{meningitis:{S:"≤0.5",I:"1",R:"≥2"},non_meningitis:{S:"≤1",I:"2",R:"≥4"}},tier:1}},cefepime:{clsi:{mic_breakpoints:{meningitis:{S:"≤0.5",I:"1",R:"≥2"},non_meningitis:{S:"≤1",I:"2",R:"≥4"}},tier:2}},ceftaroline:{clsi:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},tier:2}},cefuroxime:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},tier:2,note:"(oral)"}},cefpodoxime:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},tier:2,note:"(oral)"}},cefprozil:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},tier:2,note:"(oral)"}},cefdinir:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},tier:2,note:"(oral)"}},cefixime:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},tier:2,note:"(oral)"}},cefaclor:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},tier:2,note:"(oral)"}},loracarbef:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},tier:2,note:"(oral)"}},meropenem:{clsi:{mic_breakpoints:{meningitis:{S:"≤0.25",I:"0.5",R:"≥1"},non_meningitis:{S:"≤0.25",I:"0.5",R:"≥1"}},tier:2}},imipenem:{clsi:{mic_breakpoints:{S:"≤0.12",I:"0.25",R:"≥0.5"},tier:2}},ertapenem:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},tier:2}},doripenem:{clsi:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},tier:3}},erythromycin:{clsi:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},disk_diffusion:{routine:{S:"≥21",I:"16-20",R:"≤15"}},tier:1}},azithromycin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥18",I:"14-17",R:"≤13"}},tier:1}},clarithromycin:{clsi:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},disk_diffusion:{routine:{S:"≥21",I:"17-20",R:"≤16"}},tier:1}},dirithromycin:{clsi:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},disk_diffusion:{routine:{S:"≥19",I:"14-17",R:"≤13"}},tier:2}},clindamycin:{clsi:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},disk_diffusion:{routine:{S:"≥19",I:"16-18",R:"≤15"}},tier:2,note:"Requires D-zone test for inducible resistance if erythromycin-resistant."}},levofloxacin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥17",I:"14-16",R:"≤13"}},tier:1}},moxifloxacin:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}},tier:1}},ofloxacin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥16",I:"13-15",R:"≤12"}},tier:2}},gemifloxacin:{clsi:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}},tier:2}},sparfloxacin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥19",I:"16-18",R:"≤15"}},tier:3}},vancomycin:{clsi:{mic_breakpoints:{S:"≤1"},tier:1,note:"Results from S. pneumoniae isolated from CSF can also be tested against vancomycin using the MIC or disk diffusion method."}},linezolid:{clsi:{mic_breakpoints:{S:"≤2",I:"null",R:"≥4"},disk_diffusion:{routine:{S:"≥21",I:"null",R:"≤20"}},tier:2}},"trimethoprim-sulfamethoxazole":{clsi:{mic_breakpoints:{S:"≤0.5/9.5",I:"1/19-2/38",R:"≥4/76"},disk_diffusion:{routine:{S:"≥19",I:"16-18",R:"≤15"}},tier:1}},rifampin:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥19",I:"17-18",R:"≤16"}},tier:3,note:"Should not be used as monotherapy."}},tetracycline:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥28",I:"25-27",R:"≤24"}},tier:2}},doxycycline:{clsi:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},tier:2}},chloramphenicol:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥21",I:"17-20",R:"≤16"}},tier:3}},lefamulin:{clsi:{mic_breakpoints:{S:"≤0.5"},tier:3}},fosfomycin:{clsi:{mic_breakpoints:{S:"≤32",R:"≥64"},note:"Breakpoints apply only to E. coli from uncomplicated UTI; use with caution for other organisms/sites.",tier:3}},"quinupristin-dalfopristin":{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥19",I:"16-18",R:"≤15"}},tier:3}}}},Streptococcus_beta_hemolytic_group:{category:"Streptococcus spp.",clsi_table:"Table 2H-1",source:"CLSI M100-Ed34 Table 2H-1",note:"Includes S. pyogenes (Group A), S. agalactiae (Group B), and S. dysgalactiae. Small colony-forming β-hemolytic S. anginosus group strains should use viridans group breakpoints (Table 2H-2).",epidemiology:"Pharyngitis, cellulitis, necrotizing fasciitis (S. pyogenes), neonatal sepsis, meningitis (S. agalactiae).",antibiotics:{penicillin:{clsi:{mic_breakpoints:{S:"≤0.12"},disk_diffusion:{routine:{S:"≥24 (ampicillin disk)"}},tier:1,note:"Resistance is extremely rare. Susceptibility can be assumed."}},ampicillin:gt,"ampicillin-sulbactam":gt,"piperacillin-tazobactam":gt,cefazolin:gt,cefotaxime:gt,ceftriaxone:gt,"cefuroxime (oral)":gt,meropenem:{clsi:{...gt.clsi,mic_breakpoints:{S:"≤0.5"}}},doripenem:{clsi:{...gt.clsi,mic_breakpoints:{S:"≤0.12"}}},ertapenem:{clsi:{...gt.clsi,mic_breakpoints:{S:"≤1"}}},erythromycin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥21",I:"16-20",R:"≤15"}},tier:2}},azithromycin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥18",I:"14-17",R:"≤13"}},tier:2}},clarithromycin:{clsi:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},disk_diffusion:{routine:{S:"≥21",I:"17-20",R:"≤16"}},tier:2}},dirithromycin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥19",I:"14-17",R:"≤13"}},tier:2}},clindamycin:{clsi:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},disk_diffusion:{routine:{S:"≥19",I:"16-18",R:"≤15"}},tier:2,note:"Requires D-zone test for inducible resistance if erythromycin-resistant."}},levofloxacin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥17",I:"14-16",R:"≤13"}},tier:2}},moxifloxacin:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},tier:2}},gatifloxacin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},tier:2}},ofloxacin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},tier:2}},trovafloxacin:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},tier:3}},tetracycline:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥23",I:"19-22",R:"≤18"}},tier:2}},vancomycin:{clsi:{mic_breakpoints:{S:"≤1"},tier:2}},linezolid:{clsi:{mic_breakpoints:{S:"≤2",R:"≥4"},disk_diffusion:{routine:{S:"≥21"}},tier:2}},daptomycin:{clsi:{mic_breakpoints:{S:"≤1"},tier:3}},chloramphenicol:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥21"}},tier:3}},"quinupristin-dalfopristin":{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥19",I:"16-18",R:"≤15"}},tier:3,note:"Report only on S. pyogenes."}},ceftaroline:{clsi:{mic_breakpoints:{S:"≤0.12"},tier:3}},dalbavancin:{clsi:{mic_breakpoints:{S:"≤0.12"},tier:3,note:"Report only on S. pyogenes, S. agalactiae, and S. dysgalactiae."}},oritavancin:{clsi:{mic_breakpoints:{S:"≤0.12"},tier:3,note:"Report only on S. pyogenes, S. agalactiae, and S. dysgalactiae."}},telavancin:{clsi:{mic_breakpoints:{S:"≤0.12"},tier:3}},tedizolid:{clsi:{mic_breakpoints:{S:"≤0.5"},disk_diffusion:{routine:{S:"≥20"}},tier:3,note:"S. agalactiae that test susceptible to linezolid by MIC are also considered susceptible to tedizolid. However, some organisms that are nonsusceptible to linezolid may be susceptible to tedizolid."}}}},Streptococcus_viridans_group:{category:"Streptococcus spp.",clsi_table:"Table 2H-2",source:"CLSI M100-Ed34 Table 2H-2",note:"Includes S. mitis group, S. mutans group, S. salivarius group, S. sanguinis group, and the S. anginosus group.",epidemiology:"Bacteremia, endocarditis, abscesses. Normal flora of oral cavity, GI and GU tracts.",antibiotics:{penicillin:{clsi:{mic_breakpoints:{endocarditis_and_other_serious_infections:{S:"≤0.12",I:"0.25-2",R:"≥4"},other_infections:{S:"≤2",I:"0.5-4",R:"≥8"}},disk_diffusion:{routine:{note:"MIC method should be used for penicillin susceptibility testing."}},tier:1}},ampicillin:{clsi:{mic_breakpoints:{endocarditis_and_other_serious_infections:{S:"≤0.12",I:"0.25-2",R:"≥4"},other_infections:{S:"≤2",I:"0.5-4",R:"≥8"}},tier:1}},cefotaxime:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},tier:1}},ceftriaxone:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},tier:1}},cefepime:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},tier:2}},"ceftolozane-tazobactam":{clsi:{mic_breakpoints:{S:"≤8/4"},tier:3}},ertapenem:{clsi:{mic_breakpoints:{S:"≤0.5"},tier:2}},meropenem:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},tier:2}},doripenem:{clsi:{mic_breakpoints:{S:"≤0.12"},tier:2}},vancomycin:{clsi:{mic_breakpoints:{S:"≤1"},tier:1}},dalbavancin:{clsi:{mic_breakpoints:{S:"≤0.25"},tier:3}},oritavancin:{clsi:{mic_breakpoints:{S:"≤0.12"},tier:3}},telavancin:{clsi:{mic_breakpoints:{S:"≤0.06"},tier:3}},daptomycin:{clsi:{mic_breakpoints:{S:"≤1"},tier:3}},erythromycin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥21",I:"16-20",R:"≤15"}},tier:2}},clarithromycin:{clsi:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},disk_diffusion:{routine:{S:"≥21",I:"17-20",R:"≤16"}},tier:2}},dirithromycin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥19",I:"14-17",R:"≤13"}},tier:2}},clindamycin:{clsi:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},disk_diffusion:{routine:{S:"≥19",I:"16-18",R:"≤15"}},tier:2,note:"Requires D-zone test for inducible resistance if erythromycin-resistant."}},tetracycline:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥23",I:"19-22",R:"≤18"}},tier:2}},levofloxacin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},tier:2}},moxifloxacin:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},tier:2}},gatifloxacin:{clsi:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},tier:2}},ofloxacin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},tier:2}},trovafloxacin:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},tier:3}},chloramphenicol:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥21",I:"18-20",R:"≤17"}},tier:3}},"quinupristin-dalfopristin":{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥19",I:"16-18",R:"≤15"}},tier:3}},linezolid:{clsi:{mic_breakpoints:{S:"≤2"},disk_diffusion:{routine:{S:"≥21"}},tier:2}},tedizolid:{clsi:{mic_breakpoints:{S:"≤0.25"},disk_diffusion:{routine:{S:"≥18"}},tier:3,note:"S. anginosus group test susceptible to linezolid by MIC are also considered susceptible to tedizolid. However, some organisms that are nonsusceptible to linezolid may be susceptible to tedizolid."}}}}},zh={Pseudomonas_aeruginosa:{category:"Pseudomonas aeruginosa",clsi_table:"Table 2B-1",source:"CLSI M100-Ed34",notes:["Susceptibility testing is recommended for all clinically significant isolates.","Resistance to one agent in a class may not predict resistance to other agents in the same class.","For some agents, such as aminoglycosides, routine reporting for systemic infections is no longer recommended due to poor predictive value."],common_resistance_mechanisms:["Intrinsic resistance (low outer membrane permeability, efflux pumps like MexAB-OprM, constitutive AmpC β-lactamase)","Acquired resistance through mutations (e.g., in gyrA/parC for fluoroquinolones, loss of OprD porin for carbapenems)","Horizontal gene transfer of resistance genes (e.g., extended-spectrum β-lactamases - ESBLs, carbapenemases like KPC, NDM, VIM, IMP, and OXA-type enzymes)","Adaptive resistance mechanisms, such as biofilm formation."],epidemiology:"A common cause of healthcare-associated infections, particularly ventilator-associated pneumonia, bloodstream infections, urinary tract infections, and infections in immunocompromised hosts (e.g., cystic fibrosis, burn patients, neutropenia). It is an opportunistic pathogen found in moist environments.",antibiotics:{piperacillin:{clsi:{mic_breakpoints:{S:"≤16",I:"32",R:"≥64"},disk_diffusion_breakpoints:{S:"≥22",I:"18-21",R:"≤17"},tier:1}},"piperacillin-tazobactam":{clsi:{mic_breakpoints:{S:"≤16/4",I:"32/4-64/4",R:"≥128/4"},disk_diffusion_breakpoints:{S:"≥22",I:"18-21",R:"≤17"},tier:1}},"ticarcillin-clavulanic acid":{clsi:{mic_breakpoints:{S:"≤16/2",I:"32/2-64/2",R:"≥128/2"},disk_diffusion_breakpoints:{S:"≥20",I:"15-19",R:"≤14"},tier:1}},ceftazidime:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion_breakpoints:{S:"≥21",I:"18-20",R:"≤17"},tier:1}},cefepime:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion_breakpoints:{S:"≥18",I:"15-17",R:"≤14"},tier:1}},"ceftazidime-avibactam":{clsi:{mic_breakpoints:{S:"≤8/4",R:">8/4"},disk_diffusion_breakpoints:{S:"≥21",I:null,R:"≤20"},tier:3}},"ceftolozane-tazobactam":{clsi:{mic_breakpoints:{S:"≤4/4",I:"8/4",R:"≥16/4"},disk_diffusion_breakpoints:{S:"≥21",I:"18-20",R:"≤17"},tier:3}},cefiderocol:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion_breakpoints:{S:"≥18",I:"13-17",R:"≤12"},tier:3,condition:"The accuracy and reproducibility of cefiderocol testing results can be significantly affected by iron concentration and inoculum preparation, potentially leading to false-resistant or false-susceptible results. Discussion with prescribers and antimicrobial stewardship members is recommended due to potential inaccuracies."}},aztreonam:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion_breakpoints:{S:"≥22",I:"16-21",R:"≤15"},tier:4}},meropenem:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion_breakpoints:{S:"≥19",I:"16-18",R:"≤15"},tier:2}},imipenem:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion_breakpoints:{S:"≥22",I:"19-21",R:"≤19"},tier:2}},doripenem:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion_breakpoints:{S:"≥19",I:"16-18",R:"≤15"},tier:2}},"imipenem-relebactam":{clsi:{mic_breakpoints:{S:"≤1/4",I:"2/4",R:"≥4/4"},disk_diffusion_breakpoints:{S:"≥23",I:"19-22",R:"≤18"},tier:3}},amikacin:{clsi:{mic_breakpoints:{S:"≤16",I:"32",R:"≥64"},disk_diffusion_breakpoints:{S:"≥17",I:"15-16",R:"≤14"},tier:2,condition:"Primarily for urinary tract isolates. For other sites, clinical efficacy is not well established."}},gentamicin:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion_breakpoints:{S:"≥15",I:"13-14",R:"≤12"},tier:2,condition:"Clinical outcomes data for monotherapy for systemic infections are limited; combination therapy should be considered for most non-UTI indications."}},tobramycin:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion_breakpoints:{S:"≥15",I:"13-14",R:"≤12"},tier:1}},netilmicin:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion_breakpoints:{S:"≥15",I:"13-14",R:"≤12"},tier:2}},ciprofloxacin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion_breakpoints:{S:"≥25",I:"19-24",R:"≤18"},tier:1}},levofloxacin:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion_breakpoints:{S:"≥22",I:"15-21",R:"≤14"},tier:1}},lomefloxacin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion_breakpoints:{S:"≥22",I:"19-21",R:"≤18"},tier:1}},norfloxacin:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion_breakpoints:{S:"≥17",I:"13-16",R:"≤12"},tier:1}},ofloxacin:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion_breakpoints:{S:"≥16",I:"13-15",R:"≤12"},tier:1}},gatifloxacin:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion_breakpoints:{S:"≥18",I:"15-17",R:"≤14"},tier:1}},colistin:{clsi:{mic_breakpoints:{S:"≤2",I:null,R:"≥4"},disk_diffusion_breakpoints:null,tier:3,condition:"WARNING: Limited clinical efficacy even with intermediate results; use in combination therapy is recommended. Broth microdilution is the only recommended method; disk diffusion is unreliable."}},"polymyxin B":{clsi:{mic_breakpoints:{S:"≤2",I:null,R:"≥4"},disk_diffusion_breakpoints:null,tier:3,condition:"WARNING: Limited clinical efficacy even with intermediate results; use in combination therapy is recommended. Broth microdilution is the only recommended method; disk diffusion is unreliable."}}}}},Vh={"Acinetobacter_sp(baumannii_-_calcoaceticus)":{category:"Non-Enterobacterales",clsi_table:"Table 2B-2 (Routine Breakpoints), Table 1B-2 (Tiers), Table 3F-4 (Direct Blood Culture Breakpoints)",source:"CLSI M100-Ed34",notes:["Routine Testing Conditions:","Medium: Disk diffusion: Mueller-Hinton Agar (MHA); Broth dilution: Cation-adjusted Mueller-Hinton Broth (CAMHB), iron-depleted CAMHB for cefiderocol; Agar dilution: MHA.","Inoculum: Broth culture method or colony suspension, equivalent to a 0.5 McFarland standard.","Incubation: 35°C ± 2°C, ambient air. Disk diffusion: 16–18 hours; Dilution methods: 18–20 hours."],epidemiology:"Acinetobacter spp., particularly A. baumannii complex, are significant nosocomial pathogens known for multidrug resistance, causing infections like pneumonia, bacteremia, and UTIs.",antibiotics:{piperacillin:{clsi:{mic_breakpoints:{S:"≤16",I:"32-64",R:"≥128"},disk_diffusion:{routine:{S:"≥21",I:"18-20",R:"≤17"}}},condition:"Not listed in CLSI M100 Table 1B-2 for routine testing/reporting against Acinetobacter spp."},"ampicillin-sulbactam":{clsi:{mic_breakpoints:{S:"≤8/4",I:"16/8",R:"≥32/16"},disk_diffusion:{routine:{S:"≥15",I:"12-14",R:"≤11"},direct_blood_culture:{S:"≥15",I:"12-14",R:"≤11"}},tier:1}},"piperacillin-tazobactam":{clsi:{mic_breakpoints:{S:"≤16/4",I:"32/4-64/4",R:"≥128/4"},disk_diffusion:{routine:{S:"≥21",I:"18-20",R:"≤17"},direct_blood_culture:{S:"≥21",I:"18-20",R:"≤17"}},tier:2}},"sulbactam-durlobactam":{clsi:{mic_breakpoints:{S:"≤4/4",I:"8/4",R:"≥16/4"},disk_diffusion:{routine:{S:"≥17",I:"14-16",R:"≤13"},direct_blood_culture:{S:"≥17",I:"14-16",R:"≤13"}},tier:3}},"ticarcillin-clavulanate":{clsi:{mic_breakpoints:{S:"≤16/2",I:"32/2-64/2",R:"≥128/2"},disk_diffusion:{routine:{S:"≥20",I:"15-19",R:"≤14"}}},condition:"Not listed in CLSI M100 Table 1B-2 for routine testing/reporting against Acinetobacter spp."},ceftazidime:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"},direct_blood_culture:{S:"≥17",I:"14-16",R:"≤13"}},tier:1},condition:"Direct blood culture breakpoints (Table 3F-4) differ from routine breakpoints (Table 2B-2)."},cefepime:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"},direct_blood_culture:{S:"≥18",I:"15-17",R:"≤14"}},tier:1}},cefotaxime:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥23",I:"15-22",R:"≤14"}},tier:4}},ceftriaxone:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥21",I:"14-20",R:"≤13"}},tier:4}},cefiderocol:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥15",I:null,R:null}},tier:3},condition:"Report only on A. baumannii complex. For disk diffusion, zones ≤14 mm require an MIC test for confirmation."},imipenem:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥22",I:"19-21",R:"≤18"},direct_blood_culture:{S:"≥22",I:"19-21",R:"≤18"}},tier:2}},meropenem:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"},direct_blood_culture:{S:"≥18",I:"15-17",R:"≤14"}},tier:2}},doripenem:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥19",I:"15-18",R:"≤14"}}},condition:"Not listed in CLSI M100 Table 1B-2 for routine testing/reporting against Acinetobacter spp."},colistin:{clsi:{mic_breakpoints:{S:"≤2",I:null,R:"≥4"},disk_diffusion:null,tier:4},condition:"Warning: Limited clinical efficacy. Use in combination with other active agents and consult with an infectious diseases specialist. Tier is 'Urine Only' in Table 1B-2."},gentamicin:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥15",I:"13-14",R:"≤12"},direct_blood_culture:{S:"≥15",I:"13-14",R:"≤12"}},tier:1}},tobramycin:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥15",I:"13-14",R:"≤12"},direct_blood_culture:{S:"≥15",I:"13-14",R:"≤12"}},tier:1}},amikacin:{clsi:{mic_breakpoints:{S:"≤16",I:"32",R:"≥64"},disk_diffusion:{routine:{S:"≥17",I:"15-16",R:"≤14"},direct_blood_culture:{S:"≥17",I:"15-16",R:"≤14"}},tier:2}},netilmicin:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:null}},condition:"Not listed in CLSI M100 Table 1B-2 for routine testing/reporting against Acinetobacter spp. No disk diffusion breakpoints are provided in Table 2B-2."},doxycycline:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥13",I:"10-12",R:"≤9"}},tier:4}},minocycline:{clsi:{mic_breakpoints:null,disk_diffusion:{routine:{S:"≥16",I:"13-15",R:"≤12"}},tier:2},condition:"MIC breakpoints were removed in CLSI M100-Ed34 (Feb 2024). Note: CLSI document has internal contradiction regarding disk diffusion breakpoints (listed in Table 2B-2, but noted as removed in 'Overview of Changes'). Table 2B-2 data is retained here."},tetracycline:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥17",I:"14-16",R:"≤11"}},tier:4},condition:"For uncomplicated UTIs only. Tier is 'Urine Only' in Table 1B-2."},ciprofloxacin:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥21",I:"16-20",R:"≤15"},direct_blood_culture:{S:"≥21",I:"16-20",R:"≤15"}},tier:1}},levofloxacin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥17",I:"14-16",R:"≤13"},direct_blood_culture:{S:"≥17",I:"14-16",R:"≤13"}},tier:1}},gatifloxacin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}}},condition:"Not listed in CLSI M100 Table 1B-2 for routine testing/reporting against Acinetobacter spp."},"trimethoprim-sulfamethoxazole":{clsi:{mic_breakpoints:{S:"≤2/38",I:null,R:"≥4/76"},disk_diffusion:{routine:null,direct_blood_culture:{S:"≥16",I:"11-15",R:"≤10"}},tier:2},condition:"Routine disk diffusion breakpoints were removed in CLSI M100-Ed34 (Feb 2024). Direct blood culture breakpoints are from Table 3F-4."}}}},Oh={Haemophilus_influenzae:{category:"Haemophilus spp.",clsi_table:"Table 2E",common_resistance_mechanisms:["Beta-lactamase production (TEM-1)","AmpC rare"],epidemiology:"Respiratory infections, meningitis (rare post-vaccine)",intrinsic_resistance:[],antibiotics:{ampicillin:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥22",I:"19-21",R:"≤18"}},tier:1,source:"CLSI M100-Ed34 Table 2E"},clinical_intelligence:{special_testing:{beta_lactamase_test:"Required for all isolates",interpretation:"Positive = ampicillin resistant regardless of MIC"}}},"amoxicillin-clavulanate":{clsi:{mic_breakpoints:{S:"≤2/2",I:"2.1/2",R:"≥4/2"},disk_diffusion:{routine:{S:"≥20",I:"17-19",R:"≤16"}},tier:1,source:"CLSI M100-Ed34 Table 2E"}},"ampicillin-sulbactam":{clsi:{mic_breakpoints:{S:"≤2/4",I:"2.1/4",R:"≥4/2"},disk_diffusion:{routine:{S:"≥21",I:"19-20",R:"≤18"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},"piperacillin-tazobactam":{clsi:{mic_breakpoints:{S:"≤1/4",I:"2/4",R:"≥4/4"},disk_diffusion:{routine:{note:"Additional disk correlate data are pending before disk diffusion breakpoints with the dosage regimen listed in Table 2 Dosages can be established"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},cefotaxime:{clsi:{mic_breakpoints:{S:"≤2",I:"null",R:"≥4"},disk_diffusion:{routine:{S:"≥26",I:"null",R:"≤25"}},tier:1,source:"CLSI M100-Ed34 Table 2E"}},ceftriaxone:{clsi:{mic_breakpoints:{S:"≤2",I:"null",R:"≥4"},disk_diffusion:{routine:{S:"≥26",I:"null",R:"≤25"}},tier:1,source:"CLSI M100-Ed34 Table 2E"}},cefepime:{clsi:{mic_breakpoints:{S:"≤2",I:"null",R:"≥4"},disk_diffusion:{routine:{S:"≥26",I:"null",R:"≤25"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},cefazolin:{clsi:{mic_breakpoints:{S:"≤2",I:"null",R:"≥4"},disk_diffusion:{routine:{S:"≥26",I:"null",R:"≤25"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},cefuroxime_parenteral:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥20",I:"17-19",R:"≤16"}},tier:1,source:"CLSI M100-Ed34 Table 2E"}},cefamandole:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥26",I:"null",R:"≤25"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},cefonicid:{clsi:{mic_breakpoints:{S:"≤2",I:"null",R:"≥4"},disk_diffusion:{routine:{S:"≥26",I:"null",R:"≤25"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},ceftizoxime:{clsi:{mic_breakpoints:{S:"≤2",I:"null",R:"≥4"},disk_diffusion:{routine:{S:"≥26",I:"null",R:"≤25"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},moxalactam:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥26",I:"null",R:"≤25"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},"ceftolozane-tazobactam":{clsi:{mic_breakpoints:{S:"≤0.5/4",I:"null",R:"≥1/4"},disk_diffusion:{routine:{note:"Additional disk correlate data are pending before disk diffusion breakpoints with the dosage regimen listed in Table 2 Dosages can be established"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},cefaclor:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥20",I:"17-19",R:"≤16"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},cefuroxime_oral:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥23",I:"15-22",R:"≤14"}},tier:1,source:"CLSI M100-Ed34 Table 2E"}},cefdinir:{clsi:{mic_breakpoints:{S:"≤1",I:"null",R:"≥2"},disk_diffusion:{routine:{S:"≥20",I:"null",R:"≤19"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},cefixime:{clsi:{mic_breakpoints:{S:"≤1",I:"null",R:"≥2"},disk_diffusion:{routine:{S:"≥19",I:"null",R:"≤18"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},cefpodoxime:{clsi:{mic_breakpoints:{S:"≤0.5",I:"null",R:"≥1"},disk_diffusion:{routine:{S:"≥26",I:"null",R:"≤25"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},cefprozil:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},cefetamet:{clsi:{mic_breakpoints:{S:"≤2",I:"null",R:"≥4"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},cefoxitin:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥17",I:"14-16",R:"≤13"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},loracarbef:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},aztreonam:{clsi:{mic_breakpoints:{S:"≤4",I:"null",R:"≥8"},disk_diffusion:{routine:{S:"≥26",I:"null",R:"≤25"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},meropenem:{clsi:{mic_breakpoints:{S:"≤0.5",I:"null",R:"≥1"},disk_diffusion:{routine:{S:"≥20",I:"null",R:"≤19"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},ertapenem:{clsi:{mic_breakpoints:{S:"≤0.5",I:"null",R:"≥1"},disk_diffusion:{routine:{S:"≥19",I:"null",R:"≤18"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},imipenem:{clsi:{mic_breakpoints:{S:"≤4",I:"null",R:"≥8"},disk_diffusion:{routine:{S:"≥16",I:"null",R:"≤15"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},doripenem:{clsi:{mic_breakpoints:{S:"≤0.5",I:"null",R:"≥1"},disk_diffusion:{routine:{S:"≥19",I:"null",R:"≤18"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},azithromycin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥18",I:"14-17",R:"≤13"}},tier:1,source:"CLSI M100-Ed34 Table 2E"}},clarithromycin:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥13",I:"11-12",R:"≤10"}},tier:1,source:"CLSI M100-Ed34 Table 2E"}},dirithromycin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥18",I:"14-17",R:"≤13"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},ciprofloxacin:{clsi:{mic_breakpoints:{S:"≤1",I:"null",R:"≥2"},disk_diffusion:{routine:{S:"≥21",I:"null",R:"≤20"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},levofloxacin:{clsi:{mic_breakpoints:{S:"≤2",I:"null",R:"≥4"},disk_diffusion:{routine:{S:"≥17",I:"null",R:"≤16"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},moxifloxacin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥18",I:"null",R:"≤17"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},gemifloxacin:{clsi:{mic_breakpoints:{S:"≤0.03",I:"null",R:"≥0.06"},disk_diffusion:{routine:{S:"≥16",I:"null",R:"≤15"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},gatifloxacin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"null",R:"≥1"},disk_diffusion:{routine:{S:"≥18",I:"null",R:"≤17"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},grepafloxacin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"null",R:"≥1"},disk_diffusion:{routine:{S:"≥24",I:"null",R:"≤23"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},lomefloxacin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"null",R:"≥1"},disk_diffusion:{routine:{S:"≥22",I:"null",R:"≤21"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},norfloxacin:{clsi:{mic_breakpoints:{S:"≤2",I:"null",R:"≥4"},disk_diffusion:{routine:{S:"≥17",I:"null",R:"≤16"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},ofloxacin:{clsi:{mic_breakpoints:{S:"≤1",I:"null",R:"≥2"},disk_diffusion:{routine:{S:"≥18",I:"null",R:"≤17"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},sparfloxacin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥19",I:"null",R:"≤18"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},trovafloxacin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥22",I:"null",R:"≤21"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},fleroxacin:{clsi:{mic_breakpoints:{S:"≤2",I:"null",R:"≥4"},disk_diffusion:{routine:{S:"≥19",I:"null",R:"≤18"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},"trimethoprim-sulfamethoxazole":{clsi:{mic_breakpoints:{S:"≤0.5/9.5",I:"1/19-2/38",R:"≥4/76"},disk_diffusion:{routine:{S:"≥16",I:"11-15",R:"≤10"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},tetracycline:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥29",I:"26-28",R:"≤25"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},chloramphenicol:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥29",I:"26-28",R:"≤25"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},rifampin:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥20",I:"17-19",R:"≤16"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},lefamulin:{clsi:{mic_breakpoints:{S:"≤2",I:"null",R:"≥4"},disk_diffusion:{routine:{note:"May be appropriate only for prophylaxis of case contacts. These breakpoints do not apply to therapy of patients with invasive H. influenzae disease."}},tier:3,source:"CLSI M100-Ed34 Table 2E"}}}},Haemophilus_parainfluenzae:{category:"Haemophilus spp.",clsi_table:"Table 2E",common_resistance_mechanisms:["Beta-lactamase production (less common than H. influenzae)"],epidemiology:"Upper respiratory tract infections, endocarditis (HACEK group)",intrinsic_resistance:[],antibiotics:{ampicillin:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥22",I:"19-21",R:"≤18"}},tier:1,source:"CLSI M100-Ed34 Table 2E"},clinical_intelligence:{special_testing:{beta_lactamase_test:"Required for all isolates",interpretation:"Positive = ampicillin resistant"}}},"amoxicillin-clavulanate":{clsi:{mic_breakpoints:{S:"≤2/2",I:"2.1/2",R:"≥4/2"},disk_diffusion:{routine:{S:"≥20",I:"17-19",R:"≤16"}},tier:1,source:"CLSI M100-Ed34 Table 2E"}},"ampicillin-sulbactam":{clsi:{mic_breakpoints:{S:"≤2/4",I:"2.1/4",R:"≥4/2"},disk_diffusion:{routine:{S:"≥21",I:"19-20",R:"≤18"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},"piperacillin-tazobactam":{clsi:{mic_breakpoints:{S:"≤1/4",I:"2/4",R:"≥4/4"},disk_diffusion:{routine:{note:"Additional disk correlate data are pending before disk diffusion breakpoints with the dosage regimen listed in Table 2 Dosages can be established"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},cefotaxime:{clsi:{mic_breakpoints:{S:"≤2",I:"null",R:"≥4"},disk_diffusion:{routine:{S:"≥26",I:"null",R:"≤25"}},tier:1,source:"CLSI M100-Ed34 Table 2E"}},ceftriaxone:{clsi:{mic_breakpoints:{S:"≤2",I:"null",R:"≥4"},disk_diffusion:{routine:{S:"≥26",I:"null",R:"≤25"}},tier:1,source:"CLSI M100-Ed34 Table 2E"}},cefepime:{clsi:{mic_breakpoints:{S:"≤2",I:"null",R:"≥4"},disk_diffusion:{routine:{S:"≥26",I:"null",R:"≤25"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},cefazolin:{clsi:{mic_breakpoints:{S:"≤2",I:"null",R:"≥4"},disk_diffusion:{routine:{S:"≥26",I:"null",R:"≤25"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},cefuroxime_parenteral:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥20",I:"17-19",R:"≤16"}},tier:1,source:"CLSI M100-Ed34 Table 2E"}},cefamandole:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥26",I:"null",R:"≤25"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},cefonicid:{clsi:{mic_breakpoints:{S:"≤2",I:"null",R:"≥4"},disk_diffusion:{routine:{S:"≥26",I:"null",R:"≤25"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},ceftizoxime:{clsi:{mic_breakpoints:{S:"≤2",I:"null",R:"≥4"},disk_diffusion:{routine:{S:"≥26",I:"null",R:"≤25"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},moxalactam:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥26",I:"null",R:"≤25"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},"ceftolozane-tazobactam":{clsi:{mic_breakpoints:{S:"≤0.5/4",I:"null",R:"≥1/4"},disk_diffusion:{routine:{note:"Additional disk correlate data are pending before disk diffusion breakpoints with the dosage regimen listed in Table 2 Dosages can be established"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},cefaclor:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥20",I:"17-19",R:"≤16"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},cefuroxime_oral:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥23",I:"15-22",R:"≤14"}},tier:1,source:"CLSI M100-Ed34 Table 2E"}},cefdinir:{clsi:{mic_breakpoints:{S:"≤1",I:"null",R:"≥2"},disk_diffusion:{routine:{S:"≥20",I:"null",R:"≤19"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},cefixime:{clsi:{mic_breakpoints:{S:"≤1",I:"null",R:"≥2"},disk_diffusion:{routine:{S:"≥19",I:"null",R:"≤18"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},cefpodoxime:{clsi:{mic_breakpoints:{S:"≤0.5",I:"null",R:"≥1"},disk_diffusion:{routine:{S:"≥26",I:"null",R:"≤25"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},cefprozil:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},cefetamet:{clsi:{mic_breakpoints:{S:"≤2",I:"null",R:"≥4"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},cefoxitin:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥17",I:"14-16",R:"≤13"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},loracarbef:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},aztreonam:{clsi:{mic_breakpoints:{S:"≤4",I:"null",R:"≥8"},disk_diffusion:{routine:{S:"≥26",I:"null",R:"≤25"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},meropenem:{clsi:{mic_breakpoints:{S:"≤0.5",I:"null",R:"≥1"},disk_diffusion:{routine:{S:"≥20",I:"null",R:"≤19"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},ertapenem:{clsi:{mic_breakpoints:{S:"≤0.5",I:"null",R:"≥1"},disk_diffusion:{routine:{S:"≥19",I:"null",R:"≤18"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},imipenem:{clsi:{mic_breakpoints:{S:"≤4",I:"null",R:"≥8"},disk_diffusion:{routine:{S:"≥16",I:"null",R:"≤15"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},doripenem:{clsi:{mic_breakpoints:{S:"≤0.5",I:"null",R:"≥1"},disk_diffusion:{routine:{S:"≥19",I:"null",R:"≤18"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},azithromycin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥18",I:"14-17",R:"≤13"}},tier:1,source:"CLSI M100-Ed34 Table 2E"}},clarithromycin:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥13",I:"11-12",R:"≤10"}},tier:1,source:"CLSI M100-Ed34 Table 2E"}},dirithromycin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥18",I:"14-17",R:"≤13"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},ciprofloxacin:{clsi:{mic_breakpoints:{S:"≤1",I:"null",R:"≥2"},disk_diffusion:{routine:{S:"≥21",I:"null",R:"≤20"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},levofloxacin:{clsi:{mic_breakpoints:{S:"≤2",I:"null",R:"≥4"},disk_diffusion:{routine:{S:"≥17",I:"null",R:"≤16"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},moxifloxacin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥18",I:"null",R:"≤17"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},gemifloxacin:{clsi:{mic_breakpoints:{S:"≤0.03",I:"null",R:"≥0.06"},disk_diffusion:{routine:{S:"≥16",I:"null",R:"≤15"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},gatifloxacin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"null",R:"≥1"},disk_diffusion:{routine:{S:"≥18",I:"null",R:"≤17"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},grepafloxacin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"null",R:"≥1"},disk_diffusion:{routine:{S:"≥24",I:"null",R:"≤23"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},lomefloxacin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"null",R:"≥1"},disk_diffusion:{routine:{S:"≥22",I:"null",R:"≤21"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},norfloxacin:{clsi:{mic_breakpoints:{S:"≤2",I:"null",R:"≥4"},disk_diffusion:{routine:{S:"≥17",I:"null",R:"≤16"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},ofloxacin:{clsi:{mic_breakpoints:{S:"≤1",I:"null",R:"≥2"},disk_diffusion:{routine:{S:"≥18",I:"null",R:"≤17"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},sparfloxacin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥19",I:"null",R:"≤18"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},trovafloxacin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥22",I:"null",R:"≤21"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},fleroxacin:{clsi:{mic_breakpoints:{S:"≤2",I:"null",R:"≥4"},disk_diffusion:{routine:{S:"≥19",I:"null",R:"≤18"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},"trimethoprim-sulfamethoxazole":{clsi:{mic_breakpoints:{S:"≤0.5/9.5",I:"1/19-2/38",R:"≥4/76"},disk_diffusion:{routine:{S:"≥16",I:"11-15",R:"≤10"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},tetracycline:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥29",I:"26-28",R:"≤25"}},tier:2,source:"CLSI M100-Ed34 Table 2E"}},chloramphenicol:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥29",I:"26-28",R:"≤25"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},rifampin:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥20",I:"17-19",R:"≤16"}},tier:3,source:"CLSI M100-Ed34 Table 2E"}},lefamulin:{clsi:{mic_breakpoints:{S:"≤2",I:"null",R:"≥4"},disk_diffusion:{routine:{note:"May be appropriate only for prophylaxis of case contacts. These breakpoints do not apply to therapy of patients with invasive H. influenzae disease."}},tier:3,source:"CLSI M100-Ed34 Table 2E"}}}}},Bh={Neisseria_gonorrhoeae:{category:"Neisseria spp.",clsi_table:"Table 2F",common_resistance_mechanisms:["Penicillin resistance (plasmid and chromosomal)","Quinolone resistance","Cephalosporin resistance emerging"],epidemiology:"Sexually transmitted infection, increasing MDR",intrinsic_resistance:[],antibiotics:{ampicillin:{clsi:{mic_breakpoints:{S:"≤0.12",I:"0.12-1",R:"≥2"},disk_diffusion:{routine:{S:"≥47",I:"27-46",R:"≤26"},tier:2,source:"CLSI M100-Ed34 Table 2F"}}},azithromycin:{clsi:{mic_breakpoints:{S:"≤1",I:null,R:"≥2"},disk_diffusion:{routine:{S:"≥13",I:"11-15",R:"≤10"},tier:1,source:"CLSI M100-Ed34 Table 2F"},clinical_intelligence:{if_resistant:{implications:["Increasing resistance rates"],alternatives:["ceftriaxone monotherapy"]}}}},cefepime:{clsi:{mic_breakpoints:{S:"≤0.5",I:null,R:"≥1"},disk_diffusion:{routine:{S:"≥31",I:null,R:"≤30"},tier:3,source:"CLSI M100-Ed34 Table 2F"}}},cefixime:{clsi:{mic_breakpoints:{S:"≤0.25",I:null,R:"≥0.5"},disk_diffusion:{routine:{S:"≥31",I:null,R:"≤30"},tier:2,source:"CLSI M100-Ed34 Table 2F"}}},cefotaxime:{clsi:{mic_breakpoints:{S:"≤0.5",I:null,R:"≥1"},disk_diffusion:{routine:{S:"≥31",I:null,R:"≤30"},tier:2,source:"CLSI M100-Ed34 Table 2F"}}},cefoxitin:{clsi:{mic_breakpoints:{S:"≤0.5",I:null,R:"≥1"},disk_diffusion:{routine:{S:"≥30",I:null,R:"≤29"},tier:3,source:"CLSI M100-Ed34 Table 2F"}}},ceftriaxone:{clsi:{mic_breakpoints:{S:"≤0.25",I:null,R:"≥0.5"},disk_diffusion:{routine:{S:"≥35",I:null,R:"≤34"},tier:1,source:"CLSI M100-Ed34 Table 2F"},clinical_intelligence:{if_susceptible:{confidence:"Current first-line therapy",dosing_notes:"Single dose IM for uncomplicated infection"},if_resistant:{implications:["Emerging resistance - public health concern"],alternatives:["spectinomycin","combination therapy"]}}}},chloramphenicol:{clsi:{mic_breakpoints:{S:"≤8",I:"null",R:"≥16"},disk_diffusion:{routine:{S:"≥18",I:"13-17",R:"≤12"},tier:3,source:"CLSI M100-Ed34 Table 2F"}}},ciprofloxacin:{clsi:{mic_breakpoints:{S:"≤0.06",I:null,R:"≥0.12"},disk_diffusion:{routine:{S:"≥21",I:"17-20",R:"≤16"},tier:2,source:"CLSI M100-Ed34 Table 2F"}}},ertapenem:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥22",I:"19-21",R:"≤18"},tier:3,source:"CLSI M100-Ed34 Table 2F"}}},imipenem:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"},tier:3,source:"CLSI M100-Ed34 Table 2F"}}},meropenem:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"},tier:3,source:"CLSI M100-Ed34 Table 2F"}}},ofloxacin:{clsi:{mic_breakpoints:{S:"≤0.06",I:null,R:"≥0.12"},disk_diffusion:{routine:{S:"≥19",I:"13-15",R:"≤12"},tier:2,source:"CLSI M100-Ed34 Table 2F"}}},penicillin:{clsi:{mic_breakpoints:{S:"≤0.06",I:"0.12-1",R:"≥2"},disk_diffusion:{routine:{S:"≥47",I:"27-46",R:"≤26"},tier:1,source:"CLSI M100-Ed34 Table 2F"},clinical_intelligence:{if_resistant:{implications:["PPNG or chromosomal resistance"],alternatives:["ceftriaxone","spectinomycin"]}}}},spectinomycin:{clsi:{mic_breakpoints:{S:"≤64",I:null,R:"≥128"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"},tier:2,source:"CLSI M100-Ed34 Table 2F"},clinical_intelligence:{if_susceptible:{confidence:"Alternative for beta-lactam resistant strains",dosing_notes:"Single IM dose"}}}},sulfisoxazole:{clsi:{mic_breakpoints:{S:"≤256",I:null,R:"≥512"},disk_diffusion:{routine:{S:"≥17",I:"13-16",R:"≤12"},tier:3,source:"CLSI M100-Ed34 Table 2F"}}},tetracycline:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥19",I:"15-18",R:"≤14"},tier:2,source:"CLSI M100-Ed34 Table 2F"}}},"trimethoprim-sulfamethoxazole":{clsi:{mic_breakpoints:{S:"≤0.5/9.5",I:"0.25/4.75",R:"≥0.5/9.5"},disk_diffusion:{routine:{S:"≥26",I:"20-25",R:"≤19"},tier:3,source:"CLSI M100-Ed34 Table 2F"}}}}},Neisseria_meningitidis:{category:"Neisseria spp.",clsi_table:"Table 2I",common_resistance_mechanisms:["Penicillin resistance (PBP mutations)","Quinolone resistance rare"],epidemiology:"Meningitis, meningococcemia - laboratory safety critical",intrinsic_resistance:[],antibiotics:{ampicillin:{clsi:{mic_breakpoints:{S:"≤0.12",I:"0.12-0.25",R:"≥0.5"},disk_diffusion:{routine:{note:"Not provided"}},tier:1,source:"CLSI M100-Ed34 Table 2I"}},azithromycin:{clsi:{mic_breakpoints:{S:"≤2",I:null,R:"≥4"},disk_diffusion:{routine:{S:"≥20",I:null,R:"≤19"}},tier:2,source:"CLSI M100-Ed34 Table 2I"}},cefotaxime:{clsi:{mic_breakpoints:{S:"≤0.12",I:null,R:"≥0.25"},disk_diffusion:{routine:{S:"≥34",I:null,R:"≤33"}},tier:1,source:"CLSI M100-Ed34 Table 2I"}},ceftriaxone:{clsi:{mic_breakpoints:{S:"≤0.12",I:null,R:"≥0.25"},disk_diffusion:{routine:{S:"≥34",I:null,R:"≤33"}},tier:1,source:"CLSI M100-Ed34 Table 2I"}},chloramphenicol:{clsi:{mic_breakpoints:{S:"≤2",I:null,R:"≥4"},disk_diffusion:{routine:{S:"≥26",I:"20-25",R:"≤19"}},tier:2,source:"CLSI M100-Ed34 Table 2I"}},ciprofloxacin:{clsi:{mic_breakpoints:{S:"≤0.03",I:null,R:"≥0.06"},disk_diffusion:{routine:{S:"≥41",I:null,R:"≤40"}},tier:2,source:"CLSI M100-Ed34 Table 2I"},clinical_intelligence:{if_susceptible:{confidence:"Alternative for prophylaxis",dosing_notes:"Close contact prophylaxis"}}},levofloxacin:{clsi:{mic_breakpoints:{S:"≤0.03",I:null,R:"≥0.06"},disk_diffusion:{routine:{S:"≥32",I:null,R:"≤31"}},tier:2,source:"CLSI M100-Ed34 Table 2I"}},meropenem:{clsi:{mic_breakpoints:{S:"≤0.25",I:null,R:"≥0.5"},disk_diffusion:{routine:{note:"Not provided"}},tier:2,source:"CLSI M100-Ed34 Table 2I"}},minocycline:{clsi:{mic_breakpoints:{S:"≤2",I:null,R:"≥4"},disk_diffusion:{routine:{S:"≥26",I:"20-25",R:"≤19"}},tier:2,source:"CLSI M100-Ed34 Table 2I"}},penicillin:{clsi:{mic_breakpoints:{S:"≤0.06",I:"0.12-0.25",R:"≥0.5"},disk_diffusion:{routine:{note:"Disk diffusion not suitable for reporting"}},tier:1,source:"CLSI M100-Ed34 Table 2I"},clinical_intelligence:{if_susceptible:{confidence:"Drug of choice if susceptible",dosing_notes:"High-dose IV for meningitis"}}},rifampin:{clsi:{mic_breakpoints:{S:"≤1",I:null,R:"≥2"},disk_diffusion:{routine:{S:"≥25",I:null,R:"≤24"}},tier:2,source:"CLSI M100-Ed34 Table 2I"},clinical_intelligence:{if_susceptible:{confidence:"Used for chemoprophylaxis",dosing_notes:"Close contact prophylaxis"}}},sulfisoxazole:{clsi:{mic_breakpoints:{S:"≤32",I:null,R:"≥64"},disk_diffusion:{routine:{S:"≥26",I:"20-25",R:"≤19"}},tier:3,source:"CLSI M100-Ed34 Table 2I"}},tetracycline:{clsi:{mic_breakpoints:{S:"≤2",I:null,R:"≥4"},disk_diffusion:{routine:{S:"≥26",I:"20-25",R:"≤19"}},tier:2,source:"CLSI M100-Ed34 Table 2I"}},"trimethoprim-sulfamethoxazole":{clsi:{mic_breakpoints:{S:"≤0.5/9.5",I:"0.25/4.75",R:"≥0.5/9.5"},disk_diffusion:{routine:{S:"≥26",I:"20-25",R:"≤19"}},tier:2,source:"CLSI M100-Ed34 Table 2I"}}}}},Uh={Bacteroides_fragilis:{category:"Anaerobes",clsi_table:"Table 2J",source:"CLSI M100-Ed34",epidemiology:"Most common anaerobe causing intra-abdominal infections, abscess formation.",common_resistance_mechanisms:["Beta-lactamase production"],intrinsic_resistance:["penicillin","ampicillin"],antibiotics:{"amoxicillin-clavulanate":{clsi:{mic_breakpoints:{S:"≤4/2",I:"8/4",R:"≥16/8"},tier:1}},"ampicillin-sulbactam":{clsi:{mic_breakpoints:{S:"≤8/4",I:"16/8",R:"≥32/16"},tier:1}},"piperacillin-tazobactam":{clsi:{mic_breakpoints:{S:"≤64/4",I:"128/4",R:"≥128/4"},tier:1}},"ticarcillin-clavulanate":{clsi:{mic_breakpoints:{S:"≤32/2",I:"64/2",R:"≥128/2"},tier:2}},cefoxitin:{clsi:{mic_breakpoints:{S:"≤16",I:"32",R:"≥64"},tier:2}},cefotetan:{clsi:{mic_breakpoints:{S:"≤16",I:"32",R:"≥64"},tier:2}},ceftriaxone:{clsi:{mic_breakpoints:{S:"≤32",I:"64",R:"≥128"},tier:2}},doripenem:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},tier:2}},ertapenem:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},tier:1}},imipenem:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},tier:1}},"imipenem-relebactam":{clsi:{mic_breakpoints:{S:"≤4/2",I:"8/2",R:"≥16/2"},tier:3}},meropenem:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},tier:1}},clindamycin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},tier:1}},metronidazole:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},tier:1}},moxifloxacin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},tier:2}},tetracycline:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},tier:2}},chloramphenicol:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},tier:3}}}},Parabacteroides_distasonis:{category:"Anaerobes",clsi_table:"Table 2J",source:"CLSI M100-Ed34",epidemiology:"Intra-abdominal infections, clinically similar to B. fragilis.",breakpoint_base:"Bacteroides_fragilis",specific_breakpoints:{}},Bacteroides_thetaiotaomicron:{category:"Anaerobes",clsi_table:"Table 2J",source:"CLSI M100-Ed34",epidemiology:"Common gut commensal, opportunistic pathogen. Recommended ATCC strain for routine QC.",breakpoint_base:"Bacteroides_fragilis",specific_breakpoints:{}},Prevotella_sp:{category:"Anaerobes",clsi_table:"Table 2J",source:"CLSI M100-Ed34",epidemiology:"Oral, dental, URT infections, aspiration pneumonia, PID.",common_resistance_mechanisms:["Beta-lactamase production common","Increasing clindamycin resistance"],intrinsic_resistance:[],antibiotics:{penicillin:{clsi:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},tier:1},clinical_intelligence:{note:"Often ineffective for Prevotella due to beta-lactamase."}},"amoxicillin-clavulanate":{clsi:{mic_breakpoints:{S:"≤4/2",I:"8/4",R:"≥16/8"},tier:1}},"piperacillin-tazobactam":{clsi:{mic_breakpoints:{S:"≤64/4",I:"128/4",R:"≥128/4"},tier:1}},ceftriaxone:{clsi:{mic_breakpoints:{S:"≤32",I:"64",R:"≥128"},tier:4}},meropenem:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},tier:2}},clindamycin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},tier:1}},metronidazole:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},tier:1}}}},Fusobacterium_sp:{category:"Anaerobes",clsi_table:"Table 2J",source:"CLSI M100-Ed34",epidemiology:"Lemierre's syndrome (F. necrophorum), periodontal disease, intra-abdominal infections.",common_resistance_mechanisms:["Beta-lactamase production is rare"],breakpoint_base:"Prevotella_sp",specific_breakpoints:{penicillin:{clsi:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},tier:1},clinical_intelligence:{note:"Penicillin is drug of choice for F. necrophorum."}}}},Clostridium_perfringens:{category:"Anaerobes",clsi_table:"Table 2J",source:"CLSI M100-Ed34",epidemiology:"Gas gangrene (myonecrosis), food poisoning, soft tissue infections.",common_resistance_mechanisms:[],intrinsic_resistance:[],antibiotics:{penicillin:{clsi:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},tier:1},clinical_intelligence:{note:"Drug of choice; typically susceptible. For gas gangrene, use high-dose penicillin with clindamycin."}},ampicillin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},tier:1}},clindamycin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},tier:1}},meropenem:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},tier:1}},metronidazole:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},tier:1}}}},Clostridium_septicum:{category:"Anaerobes",clsi_table:"Table 2J",source:"CLSI M100-Ed34",epidemiology:"Associated with malignancy (colon cancer), spontaneous gas gangrene.",breakpoint_base:"Clostridium_perfringens",specific_breakpoints:{}},Paeniclostridium_sordellii:{category:"Anaerobes",clsi_table:"Table 2J",source:"CLSI M100-Ed34",epidemiology:"Toxic shock syndrome (gynecologic infections), skin/soft tissue infections.",breakpoint_base:"Clostridium_perfringens",specific_breakpoints:{}},Actinomyces_sp:{category:"Anaerobes",clsi_table:"Table 2J",source:"CLSI M100-Ed34",epidemiology:"Actinomycosis (cervicofacial, thoracic, abdominal).",common_resistance_mechanisms:[],intrinsic_resistance:["metronidazole"],antibiotics:{penicillin:{clsi:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},tier:1},clinical_intelligence:{note:"Penicillin is highly active against Actinomyces."}},amoxicillin:{clsi:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},tier:1},clinical_intelligence:{note:"Good oral step-down therapy for actinomycosis."}},"piperacillin-tazobactam":{clsi:{mic_breakpoints:{S:"≤64/4",I:"128/4",R:"≥128/4"},tier:1}},meropenem:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},tier:1}},clindamycin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},tier:1}}}},Cutibacterium_acnes:{category:"Anaerobes",clsi_table:"Table 2J",source:"CLSI M100-Ed34",epidemiology:"Prosthetic joint and device-related infections.",common_resistance_mechanisms:[],intrinsic_resistance:["metronidazole"],antibiotics:{penicillin:{clsi:{mic_breakpoints:{S:"≤0.06",I:null,R:"≥0.12"},tier:1},clinical_intelligence:{note:"Breakpoints for C. acnes are significantly stricter."}},"piperacillin-tazobactam":{clsi:{mic_breakpoints:{S:"≤64/4",I:"128/4",R:"≥128/4"},tier:1}},meropenem:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},tier:1}},clindamycin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},tier:1}}}},Clostridioides_difficile:{category:"Anaerobes",clsi_table:"Not in general Table 2J",common_resistance_mechanisms:["Metronidazole resistance emerging","Quinolone resistance"],epidemiology:"Antibiotic-associated colitis, hospital-acquired diarrhea",note:"This organism has unique therapeutic agents not listed in the general anaerobe table and specific breakpoints.",antibiotics:{metronidazole:{clsi:{mic_breakpoints:{S:"≤2",I:null,R:"≥4"},tier:1},clinical_intelligence:{note:"Traditional for mild-moderate disease, but resistance is emerging."}},vancomycin:{clsi:{mic_breakpoints:{S:"≤2",I:null,R:"≥4"},tier:1,note:"Not in general Anaerobes Table 2J."},clinical_intelligence:{note:"First-line for severe C. diff colitis (oral route)."}},fidaxomicin:{clsi:{mic_breakpoints:{S:"≤4",I:null,R:"≥8"},tier:2,note:"Not in general Anaerobes Table 2J."},clinical_intelligence:{note:"Preferred for recurrent C. diff due to lower recurrence rates."}}}},Finegoldia_magna:{category:"Anaerobes",clsi_table:"Table 2J (Gram-Positive Anaerobic Coccus)",source:"CLSI M100-Ed34",common_resistance_mechanisms:["Clindamycin resistance can occur"],epidemiology:"Skin/soft tissue, bone/joint infections.",intrinsic_resistance:["metronidazole"],note:"As a gram-positive coccus, it is intrinsically resistant to metronidazole.",antibiotics:{penicillin:{clsi:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},tier:1}},"amoxicillin-clavulanate":{clsi:{mic_breakpoints:{S:"≤4/2",I:"8/4",R:"≥16/8"},tier:1}},"piperacillin-tazobactam":{clsi:{mic_breakpoints:{S:"≤64/4",I:"128/4",R:"≥128/4"},tier:1}},meropenem:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},tier:1}},clindamycin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},tier:1}}}},Eggerthella_lenta:{category:"Anaerobes",clsi_table:"Table 2J",source:"CLSI M100-Ed34",common_resistance_mechanisms:["Resistance to beta-lactams and clindamycin can occur"],epidemiology:"Bacteremia, intra-abdominal infections, often in immunocompromised patients.",intrinsic_resistance:["metronidazole"],note:"Belongs to non-spore-forming, gram-positive anaerobic rods often resistant to metronidazole. Susceptibility testing is crucial.",antibiotics:{"piperacillin-tazobactam":{clsi:{mic_breakpoints:{S:"≤64/4",I:"128/4",R:"≥128/4"},tier:1}},meropenem:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},tier:1}},clindamycin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},tier:1}},chloramphenicol:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},tier:2}}}}},Fh={Burkholderia_cepacia_complex:{category:"Non-Enterobacterales",clsi_table:"Table 2B-3",source:"CLSI M100-Ed34",notes:["Disk diffusion methods are known to be unreliable for this organism group, and their use is discouraged.","MIC-based testing is strongly recommended for all agents to ensure accuracy."],common_resistance_mechanisms:["Efflux pumps (a major contributor to resistance)","Beta-lactamase production (e.g., PenA)","Target site modifications"],epidemiology:"A significant opportunistic pathogen, especially in patients with cystic fibrosis and chronic granulomatous disease. It is also a known cause of nosocomial outbreaks, often linked to contaminated medical products and devices.",intrinsic_resistance:["Many beta-lactams","Aminoglycosides (variable efficacy)","Polymyxins"],antibiotics:{ceftazidime:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{note:"Unreliable, MIC testing required."},tier:1,source:"CLSI M100-Ed34 Table 2B-3"}}},chloramphenicol:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{note:"Unreliable, MIC testing required."},notes:["Not routinely reported on organisms isolated from the urinary tract."],tier:2,source:"CLSI M100-Ed34 Table 2B-3"}}},levofloxacin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{note:"Unreliable, MIC testing required."},tier:1,source:"CLSI M100-Ed34 Table 2B-3"}}},meropenem:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{note:"Unreliable, MIC testing required."},tier:1,source:"CLSI M100-Ed34 Table 2B-3"}}},minocycline:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{note:"Unreliable, MIC testing required."},tier:1,source:"CLSI M100-Ed34 Table 2B-3"}}},"ticarcillin-clavulanate":{clsi:{mic_breakpoints:{S:"≤16/2",I:"32/2-64/2",R:"≥128/2"},disk_diffusion:{routine:{note:"Unreliable, MIC testing required."},tier:2,source:"CLSI M100-Ed34 Table 2B-3"}}},"trimethoprim-sulfamethoxazole":{clsi:{mic_breakpoints:{S:"≤2/38",I:null,R:"≥4/76"},disk_diffusion:{routine:{note:"Unreliable, MIC testing required."},tier:1,source:"CLSI M100-Ed34 Table 2B-3"}}}}}},Gh={Stenotrophomonas_maltophilia:{category:"Non-Enterobacterales",clsi_table:"Table 2B-4 (Breakpoints), Table 1B-4 (Tiers)",source:"CLSI M100-Ed34",notes:["Routine Testing Conditions:","Medium: Disk diffusion: Mueller-Hinton Agar (MHA); Broth dilution: Cation-adjusted Mueller-Hinton Broth (CAMHB).","Inoculum: Broth culture method or colony suspension, equivalent to a 0.5 McFarland standard.","Incubation: 35°C ± 2°C, ambient air. Disk diffusion: 16-20 hours; Dilution methods: 20-24 hours.","S. maltophilia is intrinsically resistant to carbapenems and aminoglycosides. Testing these agents is not recommended."],epidemiology:"An opportunistic pathogen, commonly associated with healthcare-associated infections, particularly in immunocompromised patients, those with cystic fibrosis, or individuals with indwelling medical devices.",antibiotics:{"trimethoprim-sulfamethoxazole":{clsi:{mic_breakpoints:{S:"≤2/38",I:null,R:"≥4/76"},disk_diffusion:{routine:{S:"≥16",I:"11-15",R:"≤10"}},tier:1},condition:"Should not be used alone for antimicrobial therapy. Breakpoints are based on a 1:19 ratio of trimethoprim to sulfamethoxazole."},levofloxacin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥17",I:"14-16",R:"≤13"}},tier:1},condition:"Levofloxacin should not be used alone for antimicrobial therapy."},minocycline:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥26",I:"21-25",R:"≤20"}},tier:1},condition:"Susceptibility to minocycline predicts susceptibility for doxycycline and tetracycline."},cefiderocol:{clsi:{mic_breakpoints:{S:"≤1",I:null,R:"≥4"},disk_diffusion:{routine:{S:"≥15",I:null,R:null}},tier:3},condition:"Testing accuracy is markedly affected by iron concentration and inoculum preparation, and may vary by manufacturer. False-resistant or false-susceptible results may occur. Discussion with prescribers is recommended."},"ticarcillin-clavulanic acid":{clsi:{mic_breakpoints:{S:"≤16/2",I:"32/2-64/2",R:"≥128/2"},disk_diffusion:{routine:{S:"≥20",I:"15-19",R:"≤14"}}},condition:"Not listed in CLSI M100 Table 1B-4 and has no assigned tier. Breakpoints are for ticarcillin concentration at a fixed 2 µg/mL of clavulanic acid."},chloramphenicol:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"13-17",R:"≤12"}}},condition:"Not listed in CLSI M100 Table 1B-4 and has no assigned tier. Not routinely reported on organisms isolated from the urinary tract."}}}},Hh={Vibrio_spp:{category:"Other Non-Enterobacterales",clsi_table:"Refer to CLSI M45",source:"CLSI M45",notes:["Breakpoints for Vibrio spp. are provided in CLSI M45. The data here is based on M45.","Breakpoints apply to V. cholerae, V. parahaemolyticus, V. vulnificus, V. alginolyticus, and V. damsela.","MIC testing is the recommended method."],epidemiology:"Causes gastrointestinal illness (cholera), wound infections, and septicemia, often associated with exposure to contaminated water or raw seafood.",intrinsic_resistance:["Polymyxins (for V. cholerae)"],antibiotics:{ceftriaxone:{clsi:{mic_breakpoints:{S:"≤16",I:"32",R:"≥64"},tier:1}},ciprofloxacin:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},tier:1}},tetracycline:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},tier:1}},doxycycline:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},tier:1}},minocycline:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},tier:1}},"trimethoprim-sulfamethoxazole":{clsi:{mic_breakpoints:{S:"≤2/38",I:null,R:"≥4/76"},tier:2}}}},Burkholderia_pseudomallei:{category:"Other Non-Enterobacterales",clsi_table:"Refer to CLSI M45",source:"CLSI M45",notes:["Breakpoints for B. pseudomallei are provided in CLSI M45. The listed agents are key recommendations.","This is a BSL-3 pathogen; all manipulations must be performed with appropriate safety precautions.","MIC testing is required; disk diffusion is unreliable."],epidemiology:"Causative agent of melioidosis, a serious infection endemic in Southeast Asia and northern Australia.",intrinsic_resistance:["Penicillin","Ampicillin","Gentamicin","Tobramycin","Polymyxins"],antibiotics:{ceftazidime:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},tier:1}},imipenem:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},tier:1}},"trimethoprim-sulfamethoxazole":{clsi:{mic_breakpoints:{S:"≤2/38",R:"≥4/76"},tier:1}}}},Burkholderia_mallei:{category:"Other Non-Enterobacterales",clsi_table:"Refer to CLSI M45",source:"CLSI M45",notes:["Breakpoints for B. mallei are provided in CLSI M45. The listed agents are key recommendations and are identical to those for B. pseudomallei.","Closely related to B. pseudomallei.","This is a BSL-3 pathogen and potential bioterrorism agent."],epidemiology:"Causative agent of glanders, a serious disease primarily affecting horses, but can be transmitted to humans.",intrinsic_resistance:["Penicillin","Ampicillin","Gentamicin","Tobramycin","Polymyxins"],antibiotics:{ceftazidime:{clsi:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},tier:1}},imipenem:{clsi:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},tier:1}},"trimethoprim-sulfamethoxazole":{clsi:{mic_breakpoints:{S:"≤2/38",R:"≥4/76"},tier:1}}}},Aeromonas_spp:{category:"Other Non-Enterobacterales",clsi_table:"Refer to CLSI M45",source:"CLSI M45",notes:["Breakpoints for Aeromonas spp. are provided in CLSI M45."],epidemiology:"Associated with wound infections (often water-related), diarrhea, and bacteremia in immunocompromised individuals.",intrinsic_resistance:["Ampicillin","Amoxicillin","Cefazolin"],antibiotics:{ceftriaxone:{clsi:{mic_breakpoints:{S:"≤16",I:"32",R:"≥64"},tier:1}},ciprofloxacin:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},tier:1}},levofloxacin:{clsi:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},tier:1}},"trimethoprim-sulfamethoxazole":{clsi:{mic_breakpoints:{S:"≤2/38",R:"≥4/76"},tier:1}}}},Pasteurella_multocida:{category:"Other Non-Enterobacterales",clsi_table:"Refer to CLSI M45",source:"CLSI M45",notes:["Breakpoints for P. multocida are provided in CLSI M45, not Table 2K of M100. These breakpoints are specific to this organism and differ from the general 'Other Non-Enterobacterales' table."],epidemiology:"Commonly isolated from soft tissue infections resulting from animal bites or scratches (especially cats and dogs).",intrinsic_resistance:[],antibiotics:{penicillin:{clsi:{mic_breakpoints:{S:"≤0.5",R:"≥1"},tier:1}},ampicillin:{clsi:{mic_breakpoints:{S:"≤1",R:"≥2"},tier:1}},ceftriaxone:{clsi:{mic_breakpoints:{S:"≤1",R:"≥2"},tier:1}},doxycycline:{clsi:{mic_breakpoints:{S:"≤1",R:"≥2"},tier:1}},levofloxacin:{clsi:{mic_breakpoints:{S:"≤0.25",R:"≥0.5"},tier:1}}}},Listeria_monocytogenes:{category:"Gram-Positive Bacilli",clsi_table:"Refer to CLSI M45",source:"CLSI M45",notes:["Breakpoints for L. monocytogenes are provided in CLSI M45, not Table 2L of M100. These breakpoints are specific to this organism."],epidemiology:"Causative agent of listeriosis, a serious foodborne illness leading to bacteremia and meningitis, primarily affecting pregnant women, newborns, and immunocompromised adults.",intrinsic_resistance:["Cephalosporins (all generations)","Fosfomycin"],antibiotics:{penicillin:{clsi:{mic_breakpoints:{S:"≤0.25",R:"≥0.5"},tier:1}},ampicillin:{clsi:{mic_breakpoints:{S:"≤0.5",R:"≥1"},tier:1}},meropenem:{clsi:{mic_breakpoints:{S:"≤0.25",R:"≥0.5"},tier:1}},"trimethoprim-sulfamethoxazole":{clsi:{mic_breakpoints:{S:"≤0.5/9.5",R:"≥1/19"},tier:1}}}},Moraxella_catarrhalis:{category:"Gram-Negative Cocci",clsi_table:"Refer to CLSI M45",source:"CLSI M45",notes:["Interpretive criteria are provided in CLSI M45 and differ from the general 'Other Non-Enterobacterales' table.","Beta-lactamase testing must be performed on all isolates. A positive test predicts resistance to ampicillin and amoxicillin."],epidemiology:"A common cause of otitis media and sinusitis in children and respiratory tract infections, such as bronchitis and pneumonia, in adults with chronic lung disease.",intrinsic_resistance:[],antibiotics:{ampicillin:{clsi:{note:"Beta-lactamase testing is the primary determinant of resistance.",tier:1}},"amoxicillin-clavulanate":{clsi:{mic_breakpoints:{S:"≤4/2",R:"≥8/4"},tier:1}},azithromycin:{clsi:{mic_breakpoints:{S:"≤0.25",I:null,R:"≥0.5"},tier:1}},ceftriaxone:{clsi:{mic_breakpoints:{S:"≤2",R:"≥4"},tier:1}},"trimethoprim-sulfamethoxazole":{clsi:{mic_breakpoints:{S:"≤0.5/9.5",R:"≥1/19"},tier:1}},tetracycline:{clsi:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},tier:2}}}},Bacillus_spp:{category:"Gram-Positive Bacilli",clsi_table:"Refer to CLSI M45",source:"CLSI M45",notes:["CLSI M100 defers to M45 for Bacillus spp. (excluding B. anthracis). Breakpoints are not specified here."],epidemiology:"Ubiquitous environmental bacteria; some species can be opportunistic pathogens.",intrinsic_resistance:[],antibiotics:{}},Campylobacter_jejuni_coli:{category:"Gram-Negative Bacilli",clsi_table:"Refer to CLSI M45",source:"CLSI M45",notes:["CLSI M100 defers to M45 for Campylobacter jejuni/coli. Breakpoints are not specified here."],epidemiology:"A leading cause of bacterial gastroenteritis worldwide.",intrinsic_resistance:[],antibiotics:{}},Corynebacterium_spp:{category:"Gram-Positive Bacilli",clsi_table:"Refer to CLSI M45",source:"CLSI M45",notes:["CLSI M100 defers to M45 for Corynebacterium spp. (including C. diphtheriae). Breakpoints are not specified here."],epidemiology:"Part of normal skin flora, but some species (like C. diphtheriae) are significant pathogens.",intrinsic_resistance:[],antibiotics:{}},Erysipelothrix_rhusiopathiae:{category:"Gram-Positive Bacilli",clsi_table:"Refer to CLSI M45",source:"CLSI M45",notes:["CLSI M100 defers to M45 for Erysipelothrix rhusiopathiae. Breakpoints are not specified here."],epidemiology:"Causes erysipeloid, an occupational disease affecting butchers, fishermen, and veterinarians.",intrinsic_resistance:[],antibiotics:{}},Gemella_spp:{category:"Gram-Positive Cocci",clsi_table:"Refer to CLSI M45",source:"CLSI M45",notes:["CLSI M100 defers to M45 for Gemella spp. Breakpoints are not specified here."],epidemiology:"Commensal organisms of the oral cavity and upper respiratory tract; can cause endocarditis.",intrinsic_resistance:[],antibiotics:{}},HACEK_group:{category:"Gram-Negative Bacilli",clsi_table:"Refer to CLSI M45",source:"CLSI M45",notes:["CLSI M100 defers to M45 for the HACEK group. Breakpoints are not specified here.","Includes Aggregatibacter spp., Cardiobacterium spp., Eikenella corrodens, and Kingella spp."],epidemiology:"A group of fastidious gram-negative bacteria known to cause endocarditis.",intrinsic_resistance:[],antibiotics:{}},Helicobacter_pylori:{category:"Gram-Negative Bacilli",clsi_table:"Refer to CLSI M45",source:"CLSI M45",notes:["CLSI M100 defers to M45 for Helicobacter pylori. Breakpoints are not specified here."],epidemiology:"Associated with peptic ulcers, gastritis, and an increased risk of gastric cancer.",intrinsic_resistance:[],antibiotics:{}},Lactobacillus_spp:{category:"Gram-Positive Bacilli",clsi_table:"Refer to CLSI M45",source:"CLSI M45",notes:["CLSI M100 defers to M45 for Lactobacillus spp. Breakpoints are not specified here."],epidemiology:"Part of the normal microbiota, but can be opportunistic pathogens, particularly in immunocompromised hosts.",intrinsic_resistance:["Vancomycin"],antibiotics:{}},Lactococcus_spp:{category:"Gram-Positive Cocci",clsi_table:"Refer to CLSI M45",source:"CLSI M45",notes:["CLSI M100 defers to M45 for Lactococcus spp. Breakpoints are not specified here."],epidemiology:"Rarely cause human infections but can be associated with endocarditis.",intrinsic_resistance:[],antibiotics:{}},Leuconostoc_spp:{category:"Gram-Positive Cocci",clsi_table:"Refer to CLSI M45",source:"CLSI M45",notes:["CLSI M100 defers to M45 for Leuconostoc spp. Breakpoints are not specified here."],epidemiology:"Opportunistic pathogens, particularly in patients receiving vancomycin, to which they are intrinsically resistant.",intrinsic_resistance:["Vancomycin"],antibiotics:{}},Serratia_marcescens:{category:"Enterobacterales",clsi_table:"Refer to CLSI M45",source:"CLSI M45",notes:["While typically covered in Enterobacterales tables (Table 2A), M100 may defer to M45 for specific testing scenarios or resistance mechanisms.","Breakpoints are not specified here pending clarification of the specific M45 context."],epidemiology:"An opportunistic pathogen associated with healthcare-associated infections.",intrinsic_resistance:["Colistin"],antibiotics:{}}};class $l{constructor(){this.clsiDatabase={enterobacterales:Gl,staphylococcus:Eh,enterococcus:Ph,streptococcus:Lh,pseudomonas:zh,acinetobacter:Vh,haemophilus:Oh,neisseria:Bh,anaerobes:Uh,burkholderia:Fh,stenotrophomonas:Gh,other_non_enterobacterales:Hh},console.log("🔍 Debug: Checking imported modules:"),console.log("enterobacteralesBreakpoints:",Gl),console.log("enterobacteralesBreakpoints.default:",Gl.default),Object.entries(this.clsiDatabase).forEach(([s,l])=>{l?console.log(`✅ ${s}: Module loaded successfully`):console.warn(`CLSIBreakpointEngine: Module not loaded for ${s}:`,l)}),this.siteSpecificBreakpoints=this.initializeSiteSpecificBreakpoints(),this.organismMapping=this.initializeOrganismMapping(),console.log("🧪 CLSIBreakpointEngine initialized with M100-Ed34 database")}async interpretMIC(s,l,c,d=null){try{console.log(`🧪 interpretMIC called with: organism="${s}", antibiotic="${l}"`);const m=this.mapOrganismToCLSICategory(s);if(console.log(`🧪 CLSI category mapped: "${s}" -> "${m}"`),!m)throw new Error(`No CLSI category found for organism: ${s}`);const _=this.getOrganismBreakpoints(m,s);console.log("🧪 Organism breakpoints:",_?"Found":"Not found");const h=this.getAntibioticBreakpoints(_,l,d);if(console.log(`🧪 Antibiotic breakpoints for ${l}:`,h?"Found":"Not found"),!h)return console.log(`❌ No breakpoints found for ${l} vs ${s}`),console.log("🧪 Available antibiotics in organism breakpoints:",_!=null&&_.antibiotics?Object.keys(_.antibiotics):"No antibiotics section"),{interpretation:"NA",confidence:"low",reason:"no_breakpoints",note:`No CLSI breakpoints available for ${l} vs ${s}`,micValue:c};const v=this.checkIntrinsicResistance(m,s,l);if(v.isIntrinsic)return{interpretation:"R",confidence:"high",reason:"intrinsic_resistance",note:v.note,micValue:c,breakpoints:h};const y=this.performBreakpointComparison(c,h);return{...this.applyClinicalContext(y,s,l,d,h),micValue:c,breakpoints:h,clsiCategory:m,siteModified:d&&this.hasSiteSpecificBreakpoints(l,d)}}catch(m){return console.error("CLSIBreakpointEngine error:",m),{interpretation:"ERROR",confidence:"none",reason:"interpretation_error",note:m.message,micValue:c}}}async getBreakpoints(s,l,c=null){try{const d=this.mapOrganismToCLSICategory(s);if(!d)return null;const m=this.getOrganismBreakpoints(d,s);return this.getAntibioticBreakpoints(m,l,c)}catch(d){return console.error("getBreakpoints error:",d),null}}mapOrganismToCLSICategory(s){const l=s.toLowerCase();console.log(`🔍 Mapping organism: "${s}" -> normalized: "${l}"`);const c={escherichia_coli:"enterobacterales",escherichiacoli:"enterobacterales",ecolienteroaggregative:"enterobacterales",klebsiella_pneumoniae:"enterobacterales",klebsiellaaerogenes:"enterobacterales",klebsiellaspoxytocapneumoniaevariicola:"enterobacterales",klebsiellasprhinoscleromatisozaenae:"enterobacterales",enterobacter_cloacae_complex:"enterobacterales",enterobactercloacaecomplex:"enterobacterales",citrobacter_freundii:"enterobacterales",citrobacterfreundii:"enterobacterales",citrobacterkoseri:"enterobacterales",serratia_marcescens:"enterobacterales",serratiamarcescens:"enterobacterales",proteus_mirabilis:"enterobacterales",proteusspmirabilispennerivulgaris:"enterobacterales",morganellamorganii:"enterobacterales",providenciaspstuartiirettgerialcalificiens:"enterobacterales",staphylococcus_aureus_mrsa:"staphylococcus",staphylococcus_aureus_mssa:"staphylococcus",staphylococcus_epidermidis:"staphylococcus",enterococcus_faecalis:"enterococcus",enterococcus_faecium:"enterococcus",streptococcus_pneumoniae:"streptococcus",streptococcus_pyogenes:"streptococcus",pseudomonas_aeruginosa:"pseudomonas",acinetobacter_baumannii:"acinetobacter",haemophilus_influenzae:"haemophilus",neisseria_gonorrhoeae:"neisseria",neisseria_meningitidis:"neisseria"};if(c[l]){const d=c[l];return console.log(`✅ Direct mapping found: ${l} -> ${d}`),d}return l.includes("escherichia")||l.includes("ecoli")||l.includes("klebsiella")||l.includes("enterobacter")||l.includes("citrobacter")||l.includes("serratia")||l.includes("proteus")||l.includes("morganella")||l.includes("providencia")?(console.log(`✅ Pattern mapping found: ${l} -> enterobacterales`),"enterobacterales"):l.includes("staphylococcus")?"staphylococcus":l.includes("enterococcus")?"enterococcus":l.includes("streptococcus")?"streptococcus":l.includes("pseudomonas")?"pseudomonas":l.includes("acinetobacter")?"acinetobacter":"other_non_enterobacterales"}getOrganismBreakpoints(s,l){const c=this.clsiDatabase[s];if(console.log(`🔍 getOrganismBreakpoints: category="${s}", organism="${l}"`),console.log("🔍 Category data available:",c?"Yes":"No"),!c)return console.warn(`CLSI category not found: ${s}. Available categories:`,Object.keys(this.clsiDatabase)),this.clsiDatabase.enterobacterales||{};console.log(`🔍 Available tables in ${s}:`,Object.keys(c));const d=this.findSpecificOrganismKey(c,l);if(console.log("🔍 Specific organism key found:",d),d&&c[d])return console.log(`✅ Using specific organism data for: ${d}`),c[d];const m=Object.keys(c)[0];if(console.log(`🔄 Falling back to first table: ${m}`),s==="enterobacterales"&&c[m]){const _=c[m];if(console.log(`🔍 Available organisms in ${m}:`,Object.keys(_)),l.includes("ecoli")||l.includes("escherichia")){const v=Object.keys(_).find(y=>y.toLowerCase().includes("escherichia")||y.toLowerCase().includes("coli"));if(v&&_[v])return console.log(`✅ Using E. coli breakpoints for ${l}: ${v}`),_[v]}const h=Object.keys(_)[0];if(h&&_[h])return console.log(`✅ Using ${h} breakpoints for ${l}`),_[h]}return c[m]}findSpecificOrganismKey(s,l){const c=Object.keys(s);for(const m of c)if(m.includes(l)||l.includes(m.replace(/_/g," ")))return m;const d=l.split("_")[0];for(const m of c)if(m.includes(d))return m;return null}getAntibioticBreakpoints(s,l,c){const d=this.normalizeAntibioticName(l);if(c&&this.siteSpecificBreakpoints[c]&&this.siteSpecificBreakpoints[c][d])return this.siteSpecificBreakpoints[c][d];if(s.antibiotics&&s.antibiotics[d])return s.antibiotics[d];const m=this.getAlternativeAntibioticNames(d);for(const _ of m)if(s.antibiotics&&s.antibiotics[_])return s.antibiotics[_];return null}performBreakpointComparison(s,l){const c=this.parseNumericMIC(s);if(l.mic_breakpoints){const d=this.parseBreakpointValue(l.mic_breakpoints.S),m=this.parseBreakpointValue(l.mic_breakpoints.R),_=l.mic_breakpoints.I?this.parseBreakpointValue(l.mic_breakpoints.I):null;return c<=d?{interpretation:"S",confidence:"high",reason:"mic_breakpoint",note:`MIC ${s} ≤ ${d} (Susceptible)`}:c>=m?{interpretation:"R",confidence:"high",reason:"mic_breakpoint",note:`MIC ${s} ≥ ${m} (Resistant)`}:_&&c>=_&&c<m?{interpretation:"I",confidence:"high",reason:"mic_breakpoint",note:`MIC ${s} = ${_} (Intermediate)`}:{interpretation:"I",confidence:"moderate",reason:"mic_breakpoint",note:`MIC ${s} between breakpoints (Intermediate)`}}return{interpretation:"NA",confidence:"none",reason:"no_mic_breakpoints",note:"No MIC breakpoints available"}}parseNumericMIC(s){if(typeof s=="number")return s;const l=String(s).trim();if(l.includes("≤")||l.includes("<="))return parseFloat(l.replace(/[≤<=]/g,""));if(l.includes("≥")||l.includes(">="))return parseFloat(l.replace(/[≥>=]/g,""));if(l.includes("-")){const[c,d]=l.split("-").map(m=>parseFloat(m.trim()));return(c+d)/2}if(l.includes("/")){const[c,d]=l.split("/").map(m=>parseFloat(m.trim()));return c/d}return parseFloat(l)||0}parseBreakpointValue(s){if(!s)return null;const l=String(s).trim();return parseFloat(l.replace(/[≤≥<>=]/g,""))||0}checkIntrinsicResistance(s,l,c){this.clsiDatabase[s];const d=this.getOrganismBreakpoints(s,l);if(d&&d.intrinsic_resistance&&d.intrinsic_resistance.includes(c))return{isIntrinsic:!0,note:`${l} is intrinsically resistant to ${c}`};const m={enterococcus:["cephalexin","cefazolin","ceftriaxone","ceftazidime"],anaerobes:["aminoglycosides","fluoroquinolones"],gram_positive:["aztreonam","colistin"]};return m[s]&&m[s].includes(c)?{isIntrinsic:!0,note:`${s} are intrinsically resistant to ${c}`}:{isIntrinsic:!1}}getIntrinsicResistance(s){try{const l=this.mapOrganismToCLSICategory(s),c=this.getOrganismBreakpoints(l,s);return(c==null?void 0:c.intrinsic_resistance)||[]}catch(l){return console.warn(`Error getting intrinsic resistance for ${s}:`,l.message),[]}}applyClinicalContext(s,l,c,d,m){return m.special_considerations&&(s.specialConsiderations=m.special_considerations),m.condition&&(s.condition=m.condition),s}initializeSiteSpecificBreakpoints(){return{CNS_meningitis:{ceftriaxone:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"}},meropenem:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"}},vancomycin:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"}}},GU_UTI_uncomplicated:{ampicillin:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"}},nitrofurantoin:{mic_breakpoints:{S:"≤32",I:"64",R:"≥128"}}}}}initializeOrganismMapping(){return{}}normalizeAntibioticName(s){const l={"tmp-smx":"trimethoprim-sulfamethoxazole","pip-tazo":"piperacillin-tazobactam","amp-sulb":"ampicillin-sulbactam","amox-clav":"amoxicillin-clavulanate"},c=s.toLowerCase().replace(/\s+/g,"-");return l[c]||c}getAlternativeAntibioticNames(s){return{"trimethoprim-sulfamethoxazole":["tmp-smx","cotrimoxazole","trimethoprim_sulfamethoxazole"],"piperacillin-tazobactam":["pip-tazo","piperacillin_tazobactam"],"ampicillin-sulbactam":["amp-sulb","ampicillin_sulbactam"],"amoxicillin-clavulanate":["amox-clav","amoxicillin_clavulanate"]}[s]||[]}hasSiteSpecificBreakpoints(s,l){return!!(this.siteSpecificBreakpoints[l]&&this.siteSpecificBreakpoints[l][s])}}let Nr=null;const Kh=async()=>{try{const g="./",s=g==="/"?"/antimicrobial_resistance.json":`${g}antimicrobial_resistance.json`;console.log("🔍 Database fetch details:",{basePath:g,dbPath:s,fullURL:new URL(s,window.location.origin).href});const l=await fetch(s);if(!l.ok)throw new Error(`HTTP ${l.status}: ${l.statusText}`);return Nr=await l.json(),console.log("🧬 Antimicrobial resistance database loaded successfully"),Nr}catch(g){return console.warn("⚠️ Could not load antimicrobial resistance database:",g.message),Nr={resistance_mechanisms:{enzymatic_inactivation:{beta_lactamases:{class_A:{subfamilies:{esbl:{spectrum:["Penicillins","Cephalosporins Gen 1-4","Aztreonam"],detection:{screening:"Reduced susceptibility to ceftriaxone/ceftazidime/cefotaxime",confirmation:"≥5mm zone increase or ≥3 dilution MIC decrease with clavulanic acid"}}}}}}},detection_methods:{phenotypic:{specialized_tests:[{test:"D-test",detects:"Inducible clindamycin resistance",principle:"Erythromycin induces erm expression",interpretation:"D-shaped zone indicates inducible resistance"}]}},treatment_guidance:{resistance_specific:{esbl_producers:{avoid:["Cephalosporins","Aztreonam"],preferred:["Carbapenems","Piperacillin-tazobactam (if susceptible)"]},cre:{options:["Ceftazidime-avibactam","Meropenem-vaborbactam","Cefiderocol"]},mrsa:{iv_options:["Vancomycin","Daptomycin","Linezolid","Ceftaroline"]}}},who_priority_pathogens:{critical:[],high:[],medium:[]}},Nr}},ze={HIGH:"high",MODERATE:"moderate",LOW:"low",UNCERTAIN:"uncertain"};class Yh{constructor(){this.resistanceDB=null,this.detectionAlgorithms={},this.isInitialized=!1,console.log("🧬 ResistancePatternEngine created - initializing with antimicrobial resistance database...")}async initialize(){if(!this.isInitialized)try{this.resistanceDB=await Kh(),this.detectionAlgorithms={};try{this.detectionAlgorithms.esbl=new Xh(this.resistanceDB),console.log("✅ ESBL detection algorithm initialized")}catch(s){console.error("❌ Failed to initialize ESBL algorithm:",s)}try{this.detectionAlgorithms.ampc=new Qh(this.resistanceDB),console.log("✅ AmpC detection algorithm initialized")}catch(s){console.error("❌ Failed to initialize AmpC algorithm:",s)}try{this.detectionAlgorithms.carbapenemase=new $h(this.resistanceDB),console.log("✅ Carbapenemase detection algorithm initialized")}catch(s){console.error("❌ Failed to initialize Carbapenemase algorithm:",s)}try{this.detectionAlgorithms.kpc=new eb(this.resistanceDB),console.log("✅ KPC detection algorithm initialized")}catch(s){console.error("❌ Failed to initialize KPC algorithm:",s)}try{this.detectionAlgorithms.mbl=new ib(this.resistanceDB),console.log("✅ MBL detection algorithm initialized")}catch(s){console.error("❌ Failed to initialize MBL algorithm:",s)}try{this.detectionAlgorithms.oxa_carbapenemase=new tb(this.resistanceDB),console.log("✅ OXA carbapenemase detection algorithm initialized")}catch(s){console.error("❌ Failed to initialize OXA algorithm:",s)}try{this.detectionAlgorithms.mrsa=new Wh(this.resistanceDB),console.log("✅ MRSA detection algorithm initialized")}catch(s){console.error("❌ Failed to initialize MRSA algorithm:",s)}try{this.detectionAlgorithms.vre=new Zh(this.resistanceDB),console.log("✅ VRE detection algorithm initialized")}catch(s){console.error("❌ Failed to initialize VRE algorithm:",s)}try{this.detectionAlgorithms.mlsb=new Jh(this.resistanceDB),console.log("✅ MLSb detection algorithm initialized")}catch(s){console.error("❌ Failed to initialize MLSb algorithm:",s)}this.isInitialized=!0,console.log("🧬 ResistancePatternEngine initialized with world-class algorithms from antimicrobial resistance database"),console.log("📊 Available detection methods:",Object.keys(this.detectionAlgorithms))}catch(s){throw console.error("❌ Failed to initialize ResistancePatternEngine:",s),s}}async analyzePattern(s,l){this.isInitialized||await this.initialize(),console.log(`🔬 ResistancePatternEngine: Starting comprehensive analysis for ${s}`),console.log(`📈 Available data points: ${Object.keys(l).length} antibiotics`);const c={organism:s,totalAntibiotics:Object.keys(l).length,detectedPatterns:[],warnings:[],recommendations:[],overallConfidence:ze.UNCERTAIN,mechanismOverrides:{},synergisticEffects:[],resistanceArchitecture:this.analyzeResistanceArchitecture(s,l)};try{console.log("🧪 Running comprehensive detection algorithms...");const d=Object.entries(this.detectionAlgorithms).map(async([_,h])=>{console.log(`🔍 Executing ${_} detection using database criteria`);const v=await h.analyze(s,l);return console.log(`📊 ${_} result: detected=${v.detected}, confidence=${v.confidence}`),{mechanismType:_,detection:v}}),m=await Promise.all(d);for(const{mechanismType:_,detection:h}of m)h.detected&&c.detectedPatterns.push({type:_,confidence:h.confidence,evidence:h.evidence,clinicalImplications:h.clinicalImplications,overrideRules:h.overrideRules||[],educationalNotes:h.educationalNotes||[],confirmationTests:h.confirmationTests||[],synergisticMechanisms:h.synergisticMechanisms||[]});return c.synergisticEffects=this.analyzeSynergisticPatterns(c.detectedPatterns,l),c.detectedPatterns.sort((_,h)=>{const v={high:4,moderate:3,low:2,uncertain:1},y={carbapenemase:10,kpc:9,mbl:8,oxa_carbapenemase:7,esbl:6,mrsa:5,vre:4,ampc:3,mlsb:2,fqr:1},D=(v[_.confidence]||0)+(y[_.type]||0);return(v[h.confidence]||0)+(y[h.type]||0)-D}),c.overallConfidence=this.calculateOverallConfidence(c.detectedPatterns),c.mechanismOverrides=this.generateMechanismOverrides(c.detectedPatterns,l),c.recommendations=this.generateClinicalRecommendations(c.detectedPatterns,s),c.warnings=this.generateClinicalWarnings(c.detectedPatterns,l),console.log(`✅ Analysis complete: ${c.detectedPatterns.length} mechanisms detected`),console.log(`📋 Clinical overrides: ${Object.keys(c.mechanismOverrides).length}`),c}catch(d){return console.error("❌ ResistancePatternEngine analysis failed:",d),c.warnings.push({level:"error",message:`Analysis failed: ${d.message}`,recommendation:"Consult infectious disease specialist for manual interpretation"}),c}}analyzeResistanceArchitecture(s,l){const c=this.resistanceDB.who_priority_pathogens,d={primaryMechanisms:[],synergisticFactors:[],clinicalImpact:"moderate"};for(const m of["critical","high","medium"])if(c[m]){for(const _ of c[m])if(this.matchesOrganismPattern(s,_.pathogen)){d.clinicalImpact=m,d.primaryMechanisms=_.mechanisms||[];break}}return d}analyzeSynergisticPatterns(s,l){const c=[],d=s.some(v=>v.type==="oxa_carbapenemase"),m=this.detectPorinLoss(l);d&&m&&c.push({type:"OXA-48_porin_loss",description:"Weak carbapenemase synergized by porin loss",clinicalSignificance:"high",evidence:"Low-level carbapenem hydrolysis + reduced permeability"});const _=s.some(v=>v.type==="esbl"),h=this.detectEffluxOverexpression(l);return _&&h&&c.push({type:"ESBL_efflux",description:"Enhanced β-lactam resistance via efflux pump overexpression",clinicalSignificance:"moderate"}),c}detectPorinLoss(s){return["ertapenem","imipenem","meropenem"].filter(d=>{var m,_;return((m=s[d])==null?void 0:m.interpretation)==="R"||((_=s[d])==null?void 0:_.interpretation)==="I"}).length>=1}detectEffluxOverexpression(s){const l={fluoroquinolones:["ciprofloxacin","levofloxacin"],beta_lactams:["ceftriaxone","ceftazidime"],aminoglycosides:["gentamicin","tobramycin"]};let c=0;for(const[d,m]of Object.entries(l))m.some(h=>{var v;return((v=s[h])==null?void 0:v.interpretation)==="R"})&&c++;return c>=2}matchesOrganismPattern(s,l){const c=s.toLowerCase().replace(/[_-]/g," "),d=l.toLowerCase();return d.includes(c.split(" ")[0])||c.includes(d.split(" ")[0])}calculateOverallConfidence(s){if(s.length===0)return ze.UNCERTAIN;const l=s.filter(d=>d.confidence===ze.HIGH).length,c=s.filter(d=>d.confidence===ze.MODERATE).length;return l>0?ze.HIGH:c>0?ze.MODERATE:ze.LOW}generateMechanismOverrides(s,l){var d;const c={};for(const m of s)if(m.overrideRules&&m.overrideRules.length>0)for(const _ of m.overrideRules)((d=l[_.antibiotic])==null?void 0:d.interpretation)===_.currentInterpretation&&(c[_.antibiotic]={oldInterpretation:_.currentInterpretation,newInterpretation:_.newInterpretation,reason:_.reason,mechanism:m.type,confidence:m.confidence,evidence:_.evidence||[]});return c}generateClinicalRecommendations(s,l){const c=[];for(const d of s){const m=this.getMechanismRecommendation(d.type,d.confidence);m&&c.push({mechanism:d.type,recommendation:m,confidence:d.confidence,priority:this.getRecommendationPriority(d.type)})}return c.sort((d,m)=>m.priority-d.priority)}getMechanismRecommendation(s,l){var _;const c=((_=this.resistanceDB.treatment_guidance)==null?void 0:_.resistance_specific)||{},m={esbl:c.esbl_producers,carbapenemase:c.cre,kpc:c.cre,mbl:c.cre,oxa_carbapenemase:c.cre,mrsa:c.mrsa,vre:{preferred:["Linezolid","Daptomycin","Tigecycline"]}}[s];if(m){if(m.preferred)return`Preferred: ${m.preferred.join(", ")}`;if(m.options)return`Options: ${m.options.join(", ")}`;if(m.avoid)return`Avoid: ${m.avoid.join(", ")}`}return"Consult infectious disease specialist for guidance"}getRecommendationPriority(s){return{carbapenemase:10,kpc:10,mbl:10,oxa_carbapenemase:9,esbl:7,mrsa:6,vre:5,ampc:4,mlsb:3,fqr:2,agr:1}[s]||0}generateClinicalWarnings(s,l){const c=[],d=s.filter(m=>["carbapenemase","kpc","mbl","oxa_carbapenemase"].includes(m.type)&&m.confidence===ze.HIGH);return d.length>0&&c.push({level:"critical",message:`Critical resistance mechanisms detected: ${d.map(m=>m.type).join(", ")}`,recommendation:"Immediate infectious disease consultation required"}),s.length>2&&c.push({level:"high",message:`Multiple resistance mechanisms detected (${s.length})`,recommendation:"Complex resistance pattern - consider combination therapy"}),c}}class Xh{constructor(s){var l,c,d,m,_;this.db=s,this.eblInfo=(_=(m=(d=(c=(l=s.resistance_mechanisms)==null?void 0:l.enzymatic_inactivation)==null?void 0:c.beta_lactamases)==null?void 0:d.class_A)==null?void 0:m.subfamilies)==null?void 0:_.esbl}async analyze(s,l){var ie,$,ne,w,O;console.log(`🧬 ESBL Detection: Analyzing ${s} using database criteria`),console.log("🧬 Susceptibility pattern received:",l),console.log("🧬 Database info:",this.eblInfo);const c=[];let d=0;const m=[],_=[],h=(($=(ie=this.eblInfo)==null?void 0:ie.spectrum)==null?void 0:$.filter(U=>["ceftriaxone","ceftazidime","cefotaxime"].includes(U.toLowerCase())))||["ceftriaxone","ceftazidime","cefotaxime"];console.log("🧬 Checking 3rd gen cephalosporins:",h);const v=h.filter(U=>{var X,T;const Z=((X=l[U])==null?void 0:X.interpretation)==="R";return console.log(`🧬 ${U}: ${(T=l[U])==null?void 0:T.interpretation} -> ${Z?"RESISTANT":"not resistant"}`),Z});v.length>0&&(c.push(`Resistant to 3rd generation cephalosporins: ${v.join(", ")}`),d+=40),this.detectClavulanicAcidSynergy(l)&&(c.push("Clavulanic acid synergy detected (≥3 dilution decrease criterion met)"),d+=30,_.push({test:"ESBL Confirmatory Test",result:"Positive",criterion:"≥5mm zone increase or ≥3 dilution MIC decrease with clavulanic acid"}));const L=["meropenem","imipenem","ertapenem"].filter(U=>{var Z;return((Z=l[U])==null?void 0:Z.interpretation)==="S"});if(L.length>0&&v.length>0&&(c.push(`Carbapenem sensitive: ${L.join(", ")} (excludes carbapenemase)`),d+=20),d>=70){(ne=this.eblInfo)!=null&&ne.spectrum;const U=["ampicillin","amoxicillin-clavulanate","piperacillin","cefazolin","ceftriaxone","ceftazidime","cefepime","aztreonam"];for(const Z of U)l[Z]&&l[Z].interpretation==="S"&&m.push({antibiotic:Z,currentInterpretation:"S",newInterpretation:"R",reason:"ESBL production - enzyme destroys β-lactam family despite in vitro susceptibility",evidence:["Database spectrum coverage","Clinical failure risk"]})}const W=d>=70,se=d>=85?ze.HIGH:d>=70?ze.MODERATE:d>=50?ze.LOW:ze.UNCERTAIN;return console.log("🧬 ESBL Detection Summary:"),console.log(`🧬   Evidence: ${c.length} points - ${c.join("; ")}`),console.log(`🧬   Confidence score: ${d}/100`),console.log(`🧬   Confidence level: ${se}`),console.log("🧬   Detection threshold: 70"),console.log(`🧬   DETECTED: ${W}`),{detected:W,confidence:se,evidence:c,clinicalImplications:W?this.getESBLImplications():[],overrideRules:m,confirmationTests:_,educationalNotes:W?this.getESBLEducation():[],treatmentGuidance:W?(O=(w=this.db.treatment_guidance)==null?void 0:w.resistance_specific)==null?void 0:O.esbl_producers:null}}detectClavulanicAcidSynergy(s){const l=s["amoxicillin-clavulanate"],c=s.ampicillin,d=s["piperacillin-tazobactam"],m=s.piperacillin;return(c==null?void 0:c.interpretation)==="R"&&(l==null?void 0:l.interpretation)==="S"||(m==null?void 0:m.interpretation)==="R"&&(d==null?void 0:d.interpretation)==="S"}getESBLImplications(){return["All β-lactams except carbapenems should be considered ineffective","Carbapenem therapy recommended for serious infections","Consider infection control measures to prevent spread","Associated with higher mortality - early appropriate therapy critical","Often co-carries other resistance genes (MDR phenotype)"]}getESBLEducation(){return["ESBLs hydrolyze extended-spectrum cephalosporins and aztreonam","Inhibited by clavulanic acid - key diagnostic feature","CTX-M enzymes are most common globally","Clinical failure occurs despite in vitro susceptibility","This is why we override susceptible results to resistant"]}}class $h{constructor(s){var l,c;this.db=s,this.carbapenemases=(c=(l=s.resistance_mechanisms)==null?void 0:l.enzymatic_inactivation)==null?void 0:c.beta_lactamases}async analyze(s,l){var L,W;console.log(`🔬 Carbapenemase Detection: Comprehensive analysis for ${s}`);const c=[];let d=0;const m=[],_={},v=["meropenem","imipenem","ertapenem"].filter(se=>{var ie,$;return((ie=l[se])==null?void 0:ie.interpretation)==="R"||(($=l[se])==null?void 0:$.interpretation)==="I"});v.length>0&&(c.push(`Carbapenem resistance detected: ${v.join(", ")}`),d+=50,m.push({test:"Modified Carbapenemase Inactivation (mCIM)",result:"Positive",principle:"Meropenem hydrolysis detection"})),_.kpc=await this.detectKPC(l),_.mbl=await this.detectMBL(l),_.oxa=await this.detectOXA(l);for(const[se,ie]of Object.entries(_))ie.detected&&(c.push(...ie.evidence),d+=ie.confidence,m.push(...ie.confirmationTests));const y=d>=50,D=d>=80?ze.HIGH:d>=60?ze.MODERATE:ze.LOW;return{detected:y,confidence:D,evidence:c,clinicalImplications:y?this.getCarbapenemaseImplications():[],confirmationTests:m,subclassResults:_,treatmentGuidance:y?(W=(L=this.db.treatment_guidance)==null?void 0:L.resistance_specific)==null?void 0:W.cre:null,educationalNotes:y?this.getCarbapenemaseEducation():[]}}async detectKPC(s){const l=[];let c=0;const d=[];return this.simulateBoronicAcidSynergy(s)&&(l.push("Boronic acid synergy positive (KPC detection)"),c+=40,d.push({test:"Boronic acid synergy",result:"Positive",interpretation:"KPC-type carbapenemase"})),{detected:c>=40,confidence:c,evidence:l,confirmationTests:d}}async detectMBL(s){var h;const l=[];let c=0;const d=[];return this.simulateEDTASynergy(s)&&(l.push("EDTA synergy positive (MBL detection)"),c+=40,d.push({test:"eCIM with EDTA",result:"Positive",interpretation:"Metallo-β-lactamase"})),((h=s.aztreonam)==null?void 0:h.interpretation)==="S"&&c>0&&(l.push("Aztreonam sparing pattern (characteristic of MBL)"),c+=30),{detected:c>=40,confidence:c,evidence:l,confirmationTests:d}}async detectOXA(s){var h,v;const l=[];let c=0;const d=((h=s.ertapenem)==null?void 0:h.interpretation)==="R",m=((v=s.meropenem)==null?void 0:v.interpretation)==="S";return d&&m&&(l.push("Ertapenem resistant but meropenem sensitive (OXA-48 pattern)"),c+=35),this.simulateTemocillinResistance(s)&&(l.push("Temocillin resistance detected (OXA carbapenemase marker)"),c+=25),{detected:c>=35,confidence:c,evidence:l,confirmationTests:[]}}simulateBoronicAcidSynergy(s){const l=s.meropenem,c=s["ceftazidime-avibactam"];return(l==null?void 0:l.interpretation)==="R"&&((c==null?void 0:c.interpretation)==="S"||!c)}simulateEDTASynergy(s){var m;const c=["meropenem","imipenem"].filter(_=>{var h;return((h=s[_])==null?void 0:h.interpretation)==="R"}),d=((m=s.aztreonam)==null?void 0:m.interpretation)==="S";return c.length>=1&&d}simulateTemocillinResistance(s){const l=s["piperacillin-tazobactam"];return(l==null?void 0:l.interpretation)==="R"}getCarbapenemaseImplications(){return["Last-resort antibiotic resistance - extremely limited treatment options","Consider combination therapy with novel β-lactam/inhibitor combinations","Strict infection control measures required","High mortality risk - immediate infectious disease consultation","Rapid horizontal spread possible via mobile genetic elements"]}getCarbapenemaseEducation(){return["Carbapenemases destroy our most powerful β-lactam antibiotics","Different classes require different treatment approaches","KPC responds to avibactam-containing combinations","MBLs spare aztreonam but resist most other β-lactams","OXA-48 often requires porin loss for high-level resistance"]}}class Jh{constructor(s){var l,c,d;this.db=s,this.dtestInfo=(d=(c=(l=s.detection_methods)==null?void 0:l.phenotypic)==null?void 0:c.specialized_tests)==null?void 0:d.find(m=>m.test==="D-test")}async analyze(s,l){var L,W,se,ie;console.log(`🧬 MLSb Detection: Analyzing ${s} for inducible resistance`);const c=[];let d=0;const m=[],_=[],h=((L=l.erythromycin)==null?void 0:L.interpretation)==="R",v=((W=l.clindamycin)==null?void 0:W.interpretation)==="S";h&&v&&(c.push("D-test pattern: Erythromycin resistant, clindamycin susceptible"),d+=80,_.push({test:"D-test",result:"Positive (inferred)",interpretation:((se=this.dtestInfo)==null?void 0:se.interpretation)||"D-shaped zone indicates inducible resistance"}),m.push({antibiotic:"clindamycin",currentInterpretation:"S",newInterpretation:"R",reason:"Inducible MLSb resistance - clindamycin will fail during therapy",evidence:["D-test positive pattern","erm gene induction by erythromycin"]})),h&&((ie=l.clindamycin)==null?void 0:ie.interpretation)==="R"&&(c.push("Constitutive MLSb: Both erythromycin and clindamycin resistant"),d+=90);const y=d>=70,D=d>=90?ze.HIGH:ze.MODERATE;return{detected:y,confidence:D,evidence:c,clinicalImplications:y?this.getMLSbImplications():[],overrideRules:m,confirmationTests:_,educationalNotes:y?this.getMLSbEducation():[]}}getMLSbImplications(){return["Avoid clindamycin even if susceptible - resistance develops during therapy","D-test confirmation recommended for all Staphylococcus and Streptococcus","Alternative agents: vancomycin, linezolid, daptomycin","Inducible resistance affects treatment efficacy"]}getMLSbEducation(){return["erm genes encode rRNA methylases affecting ribosomal binding","Erythromycin induces erm expression during therapy","D-shaped inhibition zone is pathognomonic for inducible resistance","This explains why clindamycin fails despite in vitro susceptibility"]}}class Qh{constructor(s){this.db=s}async analyze(s,l){return{detected:!1,confidence:ze.UNCERTAIN,evidence:[]}}}class Wh{constructor(s){this.db=s}async analyze(s,l){return{detected:!1,confidence:ze.UNCERTAIN,evidence:[]}}}class Zh{constructor(s){this.db=s}async analyze(s,l){return{detected:!1,confidence:ze.UNCERTAIN,evidence:[]}}}class eb{constructor(s){this.db=s}async analyze(s,l){return{detected:!1,confidence:ze.UNCERTAIN,evidence:[]}}}class ib{constructor(s){this.db=s}async analyze(s,l){return{detected:!1,confidence:ze.UNCERTAIN,evidence:[]}}}class tb{constructor(s){this.db=s}async analyze(s,l){return{detected:!1,confidence:ze.UNCERTAIN,evidence:[]}}}const ip={Amikacin:{id:"Amikacin",name:"Amikacin",tradename:"Arikayce",classification:{family:"AMINOGLYCOSIDE",subclass:"Aminoglycoside",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:["Nocardia sp."],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:{conventional:{"crcl_>50":"No dosage adjustment",crcl_10_50:"7.5 mg/kg q24h","crcl_<10":"7.5 mg/kg q48h"},ntm:{dosage_if_gfr_poorly_defined:"Adjust to these targets: Peak: 35-45 µg/mL (15 mg/kg), 65-80 µg/mL (25 mg/kg); Trough: <1 µg/mL"}},mild:{conventional:{"crcl_>50":"No dosage adjustment",crcl_10_50:"7.5 mg/kg q24h","crcl_<10":"7.5 mg/kg q48h"},ntm:{dosage_if_gfr_poorly_defined:"Adjust to these targets: Peak: 35-45 µg/mL (15 mg/kg), 65-80 µg/mL (25 mg/kg); Trough: <1 µg/mL"}},moderate:{conventional:{"crcl_>50":"No dosage adjustment",crcl_10_50:"7.5 mg/kg q24h","crcl_<10":"7.5 mg/kg q48h"},ntm:{dosage_if_gfr_poorly_defined:"Adjust to these targets: Peak: 35-45 µg/mL (15 mg/kg), 65-80 µg/mL (25 mg/kg); Trough: <1 µg/mL"}},severe:{conventional:{"crcl_>50":"No dosage adjustment",crcl_10_50:"7.5 mg/kg q24h","crcl_<10":"7.5 mg/kg q48h"},ntm:{dosage_if_gfr_poorly_defined:"Adjust to these targets: Peak: 35-45 µg/mL (15 mg/kg), 65-80 µg/mL (25 mg/kg); Trough: <1 µg/mL"}}},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Associated with fetal harm, especially 1st TM use. Avoid in pregnancy, although short-term use may be acceptable if benefit outweighs risk.",lactation:"Use with caution",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Amphotericin B",effect:"↑ nephrotoxicity",management:"Monitor closely"},{drug:"Cisplatin",effect:"↑ nephrotoxicity, ↑ ototoxicity",management:"Monitor closely"},{drug:"Cyclosporine",effect:"↑ nephrotoxicity",management:"Monitor closely"},{drug:"Furosemide",effect:"↑ ototoxicity",management:"Monitor closely"},{drug:"Neuromuscular blocking agents",effect:"↑ apnea or respiratory paralysis",management:"Monitor closely"},{drug:"NSAIDS",effect:"↑ nephrotoxicity",management:"Monitor closely"},{drug:"Piperacillin-tazobactam",effect:"Possible amikacin inactivation",management:"Monitor closely"},{drug:"Radiographic contrast",effect:"↑ nephrotoxicity",management:"Monitor closely"},{drug:"Vancomycin",effect:"↑ nephrotoxicity",management:"Monitor closely"}],stewardship:{preferredIndications:["Nocardia sp."],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:null,half_life:null,elimination:"Renal",csf_penetration:null,preparations:""},rawData:{drug_name:"Amikacin",tradename:"Arikayce",usage_and_dosing:{description:"Amikacin is a semisynthetic aminoglycoside, approved in 1972, used to treat infections from aerobic gram-negative bacilli and susceptible mycobacteria. No longer recommended for treatment of non-urinary P. aeruginosa. CLSI breakpoints are for urine isolates only. Amikacin liposome inhalation suspension available for refractory MAC in adults with limited or no alternative treatment options.",pharmacology_at_usual_dosing:{peak_serum_conc:"2.8 µg/mL",auc_0_24:"23.5 µg*hr/mL",sputum_conc:"1-4 hours after administration: 1720, 884, and 1300 µg/g at 1, 3, and 6 months, respectively."},adult_dose:[{route:"Conventional dosing",dose:"7.5 mg/kg IV q12h"},{route:"Extended-interval dosing (non-mycobacterial infection)",dose:"15-20 mg/kg IV q24h"},{route:"Intravitreal administration",dose:"0.4 mg/0.1 mL"},{route:"Intrathecal administration",dose:"30 mg once daily"},{route:"CAPD-related peritonitis",dose:"See Intraperitoneal Drug Dosing, CAPD."},{route:"Mycobacterium spp.",dose:"10-15 mg/kg IV/IM q24h, or 15-25 mg/kg 3x/wk. See species page for specific recommendation"},{route:"Liposome inhalation suspension",dose:"590 mg q24h using Lamira Nebulizer System (as part of a combination regimen)"}],pediatric_dose:[{age:">28 Days",dose:"15-20 mg/kg/day (once daily) or 5-7.5 mg/kg q8h"}]},renal_adjustment:{half_life_normal_function:"2-3 hrs",half_life_esrd:"30-70 hrs",dose_renal_function_normal:{conventional:"7.5 mg/kg IM/IV q12h",ntm:"10-15 mg/kg IM/IV q24h"},crcl_or_egfr:{conventional:{"crcl_>50":"No dosage adjustment",crcl_10_50:"7.5 mg/kg q24h","crcl_<10":"7.5 mg/kg q48h"},ntm:{dosage_if_gfr_poorly_defined:"Adjust to these targets: Peak: 35-45 µg/mL (15 mg/kg), 65-80 µg/mL (25 mg/kg); Trough: <1 µg/mL"}},hemodialysis:{conventional:"7.5 mg/kg q48h (+ extra 3.75 mg/kg AD)"},capd:"For peritonitis only: 2 mg/kg IP once daily",crrt:{extended_interval:"CVVH, CVVHDF: 25 mg/kg q48h TDM recommended"},sled:"No data"},hepatic_adjustment:{mild_impairment:"No dosage adjustment",moderate_impairment:"No dosage adjustment",severe_impairment:"No dosage adjustment"},other_adjustment:{ecmo:"See ECMO Drug Dosing Adjustment.",obesity:"See Obesity Dosing Adjustments."},adverse_effects:["Nephrotoxicity (acute tubular necrosis)","Ototoxicity (cochlear and vestibular).","Enhancement of neuromuscular blockade (rare).","Black box warning for liposome inhalation suspension: Increased risk of respiratory adverse reactions including hypersensitivity pneumonitis, hemoptysis, bronchospasm, and exacerbation of underlying pulmonary disease that have led to hospitalization in some cases."],pregnancy_risk:{fda_risk_category:"Associated with fetal harm, especially 1st TM use. Avoid in pregnancy, although short-term use may be acceptable if benefit outweighs risk.",use_during_lactation:"Probably safe, monitor infant for GI toxicity"},antimicrobial_spectrum:{preferred:["Nocardia sp."],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",pharmaceutical_preparations:"Injection, liposome inhalation susp",oral_absorption:null,tmax:null,peak_serum_conc:"41-49 (15 mg/kg IV, SD)",peak_urine_conc:"No data",protein_binding:"0-10%",volume_of_distribution:"0.26 L/kg",avg_serum_t1_2:"2-3 hr",elimination:"Renal",bile_penetration:"10-60%",csf_blood:"0-30%",therapeutic_levels_in_csf:"No",auc:"110-145 (15 mg/kg, 0-inf)"},major_drug_interactions:[{drug:"Amphotericin B",effect:"↑ nephrotoxicity",suggestion:"Avoid co-administration"},{drug:"Cisplatin",effect:"↑ nephrotoxicity, ↑ ototoxicity",suggestion:"Avoid co-administration"},{drug:"Cyclosporine",effect:"↑ nephrotoxicity",suggestion:"Avoid co-administration"},{drug:"Furosemide",effect:"↑ ototoxicity",suggestion:"Monitor"},{drug:"Neuromuscular blocking agents",effect:"↑ apnea or respiratory paralysis",suggestion:"Monitor"},{drug:"NSAIDS",effect:"↑ nephrotoxicity",suggestion:"Monitor"},{drug:"Piperacillin-tazobactam",effect:"Possible amikacin inactivation",suggestion:"Monitor"},{drug:"Radiographic contrast",effect:"↑ nephrotoxicity",suggestion:"Monitor"},{drug:"Vancomycin",effect:"↑ nephrotoxicity",suggestion:"Avoid co-administration"}]}},Gentamicin:{id:"Gentamicin",name:"Gentamicin",tradename:"Garamycin",classification:{family:"AMINOGLYCOSIDE",subclass:"Aminoglycoside",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:["Bartonella hensalae, B. quintana","Francisella tularensis","Yersinia pestis"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:{conventional:{"crcl_>50":"No dosage adjustment",crcl_10_50:"1.7-2.0 mg/kg q12-24h","crcl_<10":"1.7-2.0 mg/kg q48h"},synergy:{"crcl_>60":"No dosage adjustment",crcl_40_59:"1 mg/kg q12h",crcl_20_39:"1 mg/kg q24h","crcl_<20":"1 mg/kg, then dose by level"}},mild:{conventional:{"crcl_>50":"No dosage adjustment",crcl_10_50:"1.7-2.0 mg/kg q12-24h","crcl_<10":"1.7-2.0 mg/kg q48h"},synergy:{"crcl_>60":"No dosage adjustment",crcl_40_59:"1 mg/kg q12h",crcl_20_39:"1 mg/kg q24h","crcl_<20":"1 mg/kg, then dose by level"}},moderate:{conventional:{"crcl_>50":"No dosage adjustment",crcl_10_50:"1.7-2.0 mg/kg q12-24h","crcl_<10":"1.7-2.0 mg/kg q48h"},synergy:{"crcl_>60":"No dosage adjustment",crcl_40_59:"1 mg/kg q12h",crcl_20_39:"1 mg/kg q24h","crcl_<20":"1 mg/kg, then dose by level"}},severe:{conventional:{"crcl_>50":"No dosage adjustment",crcl_10_50:"1.7-2.0 mg/kg q12-24h","crcl_<10":"1.7-2.0 mg/kg q48h"},synergy:{"crcl_>60":"No dosage adjustment",crcl_40_59:"1 mg/kg q12h",crcl_20_39:"1 mg/kg q24h","crcl_<20":"1 mg/kg, then dose by level"}}},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Associated with fetal harm, especially 1st TM use. Avoid in pregnancy, although short-term use may be acceptable if benefit outweighs risk. Topical use probably safe.",lactation:"Use with caution",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Amphotericin B",effect:"↑ nephrotoxicity",management:"Monitor closely"},{drug:"Cisplatin",effect:"↑ nephrotoxicity, ↑ ototoxicity",management:"Monitor closely"},{drug:"Cyclosporine",effect:"↑ nephrotoxicity",management:"Monitor closely"},{drug:"Furosemide",effect:"↑ ototoxicity",management:"Monitor closely"},{drug:"Neuromuscular blocking agents",effect:"↑ apnea or respiratory paralysis",management:"Monitor closely"},{drug:"NSAIDS",effect:"↑ nephrotoxicity",management:"Monitor closely"},{drug:"Piperacillin-tazobactam",effect:"Possible gentamicin inactivation",management:"Monitor closely"},{drug:"Radiographic contrast",effect:"↑ nephrotoxicity",management:"Monitor closely"},{drug:"Vancomycin",effect:"↑ nephrotoxicity",management:"Monitor closely"}],stewardship:{preferredIndications:["Bartonella hensalae, B. quintana","Francisella tularensis","Yersinia pestis"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:null,half_life:null,elimination:"Renal",csf_penetration:null,preparations:""},rawData:{drug_name:"Gentamicin",tradename:"Garamycin",drug_shortage_information:[{prep:"Injection",started_at:"2021-02-22",notes:""}],usage_and_dosing:{description:"Gentamicin, approved in 1963, is an aminoglycoside that is active against a wide range of gram-negative bacteria, and usually provides synergistic killing vs. certain gram-positive cocci. Naturally produced by Micromonospora purpurea, a soil actinomycete. No activity against anaerobes, poor activity in a low pH environment. Not considered a reliable choice for P. aeruginosa.",adult_dose:[{route:"Conventional dosing",dose:"2 mg/kg IV load, then 1.7-2 mg/kg IV q8h"},{route:"Extended-interval dosing",dose:"7 mg/kg IV q24h (Antimicrob Agents Chemother 1995;39:650)"},{route:"Gram-positive synergy",dose:"1 mg/kg IV q8h"},{route:"Intrathecal administration",dose:"4-8 mg once daily"},{route:"CAPD-related peritonitis",dose:"See Intraperitoneal Drug Dosing, CAPD page"}],pediatric_dose:[{age:">28 Days",dose:"5-7 mg/kg/day (once daily) or 2.5 mg/kg q8h"}]},renal_adjustment:{half_life_normal_function:"2-3 hrs",half_life_esrd:"30-70 hrs",dose_renal_function_normal:{conventional:"1.7-2.0 mg/kg IV q8h",synergy:"1 mg/kg IV q8h"},crcl_or_egfr:{conventional:{"crcl_>50":"No dosage adjustment",crcl_10_50:"1.7-2.0 mg/kg q12-24h","crcl_<10":"1.7-2.0 mg/kg q48h"},synergy:{"crcl_>60":"No dosage adjustment",crcl_40_59:"1 mg/kg q12h",crcl_20_39:"1 mg/kg q24h","crcl_<20":"1 mg/kg, then dose by level"}},hemodialysis:{conventional:"1.7-2.0 mg/kg q48h (+ extra 0.85-1.0 mg/kg AD)",synergy:"1 mg/kg q48-72h (dose AD)"},capd:"For peritonitis only: 0.6 mg/kg IP once daily",crrt:{conventional:"1.7-2.0 mg/kg q24h"},sled:{conventional:"6 mg/kg IV q48h. Begin 30 min before start of SLED"}},hepatic_adjustment:{mild_impairment:"No dosage adjustment",moderate_impairment:"No dosage adjustment",severe_impairment:"No dosage adjustment"},other_adjustment:{ecmo:"See ECMO Drug Dosing Adjustment.",obesity:"See Obesity Dosing Adjustments."},adverse_effects:["Nephrotoxicity (acute tubular necrosis)","Ototoxicity (cochlear and vestibular). Review: Med J Aust 2012;196:701.","Enhancement of neuromuscular blockade (rare)"],pregnancy_risk:{fda_risk_category:"Associated with fetal harm, especially 1st TM use. Avoid in pregnancy, although short-term use may be acceptable if benefit outweighs risk. Topical use probably safe.",use_during_lactation:"Probably safe, monitor infant for GI toxicity"},antimicrobial_spectrum:{preferred:["Bartonella hensalae, B. quintana","Francisella tularensis","Yersinia pestis"],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",pharmaceutical_preparations:"Injection, 0.1% cream, 0.1%, 0.3% ointment, 0.3% eye drops",oral_absorption:null,tmax:null,peak_serum_conc:"4-6 (1.7 mg/kg IV, SD)",peak_urine_conc:"No data",protein_binding:"0-10%",volume_of_distribution:"0.26 L/kg",avg_serum_t1_2:"2-3 hr",elimination:"Renal",bile_penetration:"10-60%",csf_blood:"0-30%",therapeutic_levels_in_csf:"No",auc:"70-100 (7 mg/kg, 0-inf)"},major_drug_interactions:[{drug:"Amphotericin B",effect:"↑ nephrotoxicity",suggestion:"Avoid co-administration"},{drug:"Cisplatin",effect:"↑ nephrotoxicity, ↑ ototoxicity",suggestion:"Avoid co-administration"},{drug:"Cyclosporine",effect:"↑ nephrotoxicity",suggestion:"Avoid co-administration"},{drug:"Furosemide",effect:"↑ ototoxicity",suggestion:"Avoid co-administration"},{drug:"Neuromuscular blocking agents",effect:"↑ apnea or respiratory paralysis",suggestion:"Monitor"},{drug:"NSAIDS",effect:"↑ nephrotoxicity",suggestion:"Monitor"},{drug:"Piperacillin-tazobactam",effect:"Possible gentamicin inactivation",suggestion:"Monitor"},{drug:"Radiographic contrast",effect:"↑ nephrotoxicity",suggestion:"Monitor"},{drug:"Vancomycin",effect:"↑ nephrotoxicity",suggestion:"Avoid co-administration"}]}},Kanamycin:{id:"Kanamycin",name:"Kanamycin",tradename:"Kantrex",classification:{family:"AMINOGLYCOSIDE",subclass:"Aminoglycoside",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:["Mycobacterium tuberculosis"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:{"crcl_>50":"No dosage adjustment",crcl_10_50:"7.5 mg/kg q24h","crcl_<10":"7.5 mg/kg q48h"},mild:{"crcl_>50":"No dosage adjustment",crcl_10_50:"7.5 mg/kg q24h","crcl_<10":"7.5 mg/kg q48h"},moderate:{"crcl_>50":"No dosage adjustment",crcl_10_50:"7.5 mg/kg q24h","crcl_<10":"7.5 mg/kg q48h"},severe:{"crcl_>50":"No dosage adjustment",crcl_10_50:"7.5 mg/kg q24h","crcl_<10":"7.5 mg/kg q48h"}},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Category C - Risk cannot be ruled out",lactation:"Use with caution",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Amphotericin B",effect:"↑ nephrotoxicity",management:"Monitor closely"},{drug:"Cisplatin",effect:"↑ nephrotoxicity, ↑ ototoxicity",management:"Monitor closely"},{drug:"Cyclosporine",effect:"↑ nephrotoxicity",management:"Monitor closely"},{drug:"Furosemide",effect:"↑ ototoxicity",management:"Monitor closely"},{drug:"Neuromuscular blocking agents",effect:"↑ apnea or respiratory paralysis",management:"Monitor closely"},{drug:"NSAIDS",effect:"↑ nephrotoxicity",management:"Monitor closely"},{drug:"Piperacillin-tazobactam",effect:"Possible kanamycin inactivation",management:"Monitor closely"},{drug:"Radiographic contrast",effect:"↑ nephrotoxicity",management:"Monitor closely"},{drug:"Vancomycin",effect:"↑ nephrotoxicity",management:"Monitor closely"}],stewardship:{preferredIndications:["Mycobacterium tuberculosis"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:null,half_life:null,elimination:"Renal",csf_penetration:null,preparations:""},rawData:{drug_name:"Kanamycin",tradename:"Kantrex",usage_and_dosing:{description:"Kanamycin is an aminoglycoside used primarily as second-line therapy for treatment of M. tuberculosis. Kanamycin is also active against Gram-negative bacilli, but is rarely used, having been replaced largely by Amikacin. Potential risk of renal, cochlear and vestibular toxicity, the latter two being most common. Mitochondrial DNA polymorphisms (e.g., 12S A1555G ribosomal RNA mutation) are associated with increased susceptibility to ototoxicity.",adult_dose:[{route:"Conventional dosing",dose:"7.5 mg/kg q12h IV or IM",target_peak:"15-30 µg/mL (avoid > 35 µg/mL)",target_trough:"5-10 µg/mL (avoid > 10 µg/mL)"},{route:"Extended interval dosing",dose:"15 mg/kg q24h IV or IM",target_trough:"<1 µg/mL"},{route:"M. tuberculosis Dose","dose_age_<59":"1 gm (15 mg/kg) IM/IV q24h or 3-5x/week. Target trough <1 µg/mL","dose_age_>59":"750 mg (10 mg/kg) IM/IV q24h or 3-5x/week. Target trough <1 µg/mL"}],pediatric_dose:[{age:">28 Days",dose:"15-30 mg/kg/day (once daily)",max_day:"1 gm"}]},renal_adjustment:{half_life_normal_function:"2-3 hrs",half_life_esrd:"30-70 hrs",dose_renal_function_normal:"7.5 mg/kg IM/IV q12h",crcl_or_egfr:{"crcl_>50":"No dosage adjustment",crcl_10_50:"7.5 mg/kg q24h","crcl_<10":"7.5 mg/kg q48h"},hemodialysis:"7.5 mg/kg q48h (+ extra 3.25 mg/kg AD)",capd:"15-20 mg lost per L of dialysate/day",crrt:"7.5 mg/kg q24h",sled:"No data"},hepatic_adjustment:{mild_impairment:"No dosage adjustment",moderate_impairment:"No dosage adjustment",severe_impairment:"No dosage adjustment"},other_adjustment:{obesity:"See Obesity Dosing Adjustments table"},adverse_effects:["Tubular necrosis and renal failure, deafness due to cochlear toxicity, vertigo due to damage to vestibular organs, and rarely neuromuscular blockade.","Risk of nephrotoxicity increases with concomitant administration of cyclosporine, Vancomycin, ampho B, radiocontrast.","Risk of nephrotoxicity may be less with once daily dosing (especially if baseline renal function normal).","In general, same factors influence risk of ototoxicity.","Other adverse effects: rash, ↑ BUN/creatinine (5-25%), vestibular (4-6%).","NOTE: There is no known method to eliminate risk of aminoglycoside toxicity. Proper dosing attempts to ↓ the % risk. Serum levels: monitor trough serum concentrations, rising concentration is an early sign of nephrotoxicity.","One in 500 patients (Europe) have mitochondrial mutation that predicts cochlear toxicity (New Engl J Med 360:640, 2009 & New Engl J Med 360:642, 2009). Aspirin supplement (3 gm/day) attenuated risk of cochlear injury from Gentamicin (New Engl J Med 354:1856, 2006)."],antimicrobial_spectrum:{preferred:["Mycobacterium tuberculosis"],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",pharmaceutical_preparations:"Injection",oral_absorption:null,tmax:null,peak_serum_conc:"25-50 (15 mg/kg IM, SD)",peak_urine_conc:"No data",protein_binding:"0-10%",volume_of_distribution:"0.26 L/kg",avg_serum_t1_2:"2-3 hr",elimination:"Renal",bile_penetration:"10-60%",csf_blood:"0-30%",therapeutic_levels_in_csf:"No",auc:"No data"},major_drug_interactions:[{drug:"Amphotericin B",effect:"↑ nephrotoxicity",suggestion:"Avoid"},{drug:"Cisplatin",effect:"↑ nephrotoxicity, ↑ ototoxicity",suggestion:"Avoid"},{drug:"Cyclosporine",effect:"↑ nephrotoxicity",suggestion:"Avoid"},{drug:"Furosemide",effect:"↑ ototoxicity",suggestion:"Avoid"},{drug:"Neuromuscular blocking agents",effect:"↑ apnea or respiratory paralysis",suggestion:"Monitor"},{drug:"NSAIDS",effect:"↑ nephrotoxicity",suggestion:"Monitor"},{drug:"Piperacillin-tazobactam",effect:"Possible kanamycin inactivation",suggestion:"Monitor"},{drug:"Radiographic contrast",effect:"↑ nephrotoxicity",suggestion:"Monitor"},{drug:"Vancomycin",effect:"↑ nephrotoxicity",suggestion:"Avoid"}],comments:"Potential for cross-resistance between Kanamycin and Amikacin in M. tuberculosis (PloS One 7:e33275, 2012)."}},Neomycin:{id:"Neomycin",name:"Neomycin",tradename:"",classification:{family:"AMINOGLYCOSIDE",subclass:"Aminoglycoside",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Aerobic gram-negative bacilli"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No dosage adjustment for renal impairment",mild:"No dosage adjustment for renal impairment",moderate:"No dosage adjustment for renal impairment",severe:"No dosage adjustment for renal impairment"},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Category C - Risk cannot be ruled out",lactation:"Use with caution",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:["Aerobic gram-negative bacilli"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:null,half_life:null,elimination:"Negligible absorption",csf_penetration:null,preparations:""},rawData:{drug_name:"Neomycin",usage_and_dosing:{description:"Neomycin is an oral aminoglycoside used as bowel preparation pre-operatively for resectional GI surgery and for treatment of hepatic encephalopathy. Systemic absorption can occur and lead to ototoxicity, neurotoxicity or nephrotoxicity (Black Box Warning). Low concentration in non-prescription topical creams and ointments. Active in vitro vs. staphylococci and most aerobic Gram-negative bacteria; resistant to streptococci and Gram-positive bacilli",adult_dose:[{route:"Bowel preparation, pre-GI surgery",dose:"1 gm at 1, 2 and 11 pm on day preceding surgery + Erythromycin 1 gm po at the same times + mechanical cleansing"},{route:"Hepatic encephalopathy",dose:"500-2000 mg q6-8h for 5-6 days; seek safer alternative for longer use"}],pediatric_dose:[{age:">28 Days",dose:"HE: 50-100 mg/kg/day (divided q6-8hr) x5-6 days. Seek safer alternative for longer use."}]},renal_adjustment:{half_life_normal_function:"2-3 hrs",half_life_esrd:"30-70 hrs",dose_renal_function_normal:"1 gm po x3 (prior to surgery)",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No dosage adjustment",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment:"No dosage adjustment",moderate_impairment:"No dosage adjustment",severe_impairment:"No dosage adjustment"},adverse_effects:["No significant adverse effects"],antimicrobial_spectrum:{preferred:["Aerobic gram-negative bacilli"],alternative:[]},pharmacology:{pk_pd_index:"No data",pharmaceutical_preparations:"Tab (500 mg)",food_rec_po_drugs:"Tab + food",oral_absorption:"<3%",tmax:"No data",peak_serum_conc:"No data",peak_urine_conc:"No data",protein_binding:"No data",volume_of_distribution:"No data",avg_serum_t1_2:"No data",elimination:"Negligible absorption",bile_penetration:"No data",csf_blood:"No data",therapeutic_levels_in_csf:"No data",auc:"No data"},major_drug_interactions:["None significant"],comments:["Avoid concomitant agents and factors that enhance oto-, neuro- or nephrotoxicity","For treatment of hepatic encephalopathy, considered an alternative agent; safer agents are available (Hepatology 60: 715, 2014).","Review: Clin Micro Review 30(3): 827, 2017."]}},Netilmicin:{id:"Netilmicin",name:"Netilmicin",tradename:"",classification:{family:"AMINOGLYCOSIDE",subclass:"Aminoglycoside",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:{"crcl_>50":"No dosage adjustment",crcl_10_50:"1.7-2.0 mg/kg q12-24h","crcl_<10":"1.7-2.0 mg/kg q48h"},mild:{"crcl_>50":"No dosage adjustment",crcl_10_50:"1.7-2.0 mg/kg q12-24h","crcl_<10":"1.7-2.0 mg/kg q48h"},moderate:{"crcl_>50":"No dosage adjustment",crcl_10_50:"1.7-2.0 mg/kg q12-24h","crcl_<10":"1.7-2.0 mg/kg q48h"},severe:{"crcl_>50":"No dosage adjustment",crcl_10_50:"1.7-2.0 mg/kg q12-24h","crcl_<10":"1.7-2.0 mg/kg q48h"}},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Associated with fetal harm, especially 1st TM use. Avoid in pregnancy, although short-term use may be acceptable if benefit outweighs risk.",lactation:"Use with caution",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Amphotericin B",effect:"↑ nephrotoxicity",management:"Monitor closely"},{drug:"Cisplatin",effect:"↑ nephrotoxicity, ↑ ototoxicity",management:"Monitor closely"},{drug:"Cyclosporine",effect:"↑ nephrotoxicity",management:"Monitor closely"},{drug:"Furosemide",effect:"↑ ototoxicity",management:"Monitor closely"},{drug:"Neuromuscular blocking agents",effect:"↑ apnea or respiratory paralysis",management:"Monitor closely"},{drug:"NSAIDS",effect:"↑ nephrotoxicity",management:"Monitor closely"},{drug:"Piperacillin-tazobactam",effect:"Possible netilmicin inactivation",management:"Monitor closely"},{drug:"Radiographic contrast",effect:"↑ nephrotoxicity",management:"Monitor closely"},{drug:"Vancomycin",effect:"↑ nephrotoxicity",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:null,half_life:null,elimination:"Renal",csf_penetration:null,preparations:""},rawData:{drug_name:"Netilmicin",usage_and_dosing:{description:"Netilmicin is an aminoglycoside active against aerobic gram-negative bacilli. Potential for cochlear, vestibular and nephrotoxicity. Netilmicin is not available in the U.S.",adult_dose:[{route:"Usual dose",dose:"1.7-2 mg/kg IV q8h"},{route:"CAPD-related peritonitis",dose:"See Intraperitoneal Drug Dosing, CAPD"}],pediatric_dose:[{age:">28 Days",dose:"Safety and efficacy not established"}]},renal_adjustment:{half_life_normal_function:"2-3 hrs",half_life_esrd:"30-70 hrs",dose_renal_function_normal:"1.7-2.0 mg/kg IM/IV q8h",crcl_or_egfr:{"crcl_>50":"No dosage adjustment",crcl_10_50:"1.7-2.0 mg/kg q12-24h","crcl_<10":"1.7-2.0 mg/kg q48h"},hemodialysis:"1.7-2.0 mg/kg q48h (+ extra 0.85-1.0 mg/kg AD)",capd:"For peritonitis only: 0.6 mg/kg IP once daily",crrt:"1.7-2.0 mg/kg q24h",sled:"No data"},hepatic_adjustment:{mild_impairment:"No dosage adjustment",moderate_impairment:"No dosage adjustment",severe_impairment:"No dosage adjustment"},other_adjustment:{ecmo:"See ECMO Drug Dosing Adjustment.",obesity:"See Obesity Dosing Adjustments."},adverse_effects:["Nephrotoxicity (acute tubular necrosis)","Ototoxicity (cochlear and vestibular).","Enhancement of neuromuscular blockade (rare)."],pregnancy_risk:{fda_risk_category:"Associated with fetal harm, especially 1st TM use. Avoid in pregnancy, although short-term use may be acceptable if benefit outweighs risk.",use_during_lactation:"Safety not established, avoid use"},antimicrobial_spectrum:{preferred:[],alternative:[],full_spectrum_link:"Full comparative spectrum of activity"},pharmacology:{pk_pd_index:"24-hr AUC/MIC",pharmaceutical_preparations:"Injection",oral_absorption:null,tmax:null,peak_serum_conc:"4-8 (2 mg/kg IV, SD)",peak_urine_conc:"No data",protein_binding:"0-10%",volume_of_distribution:"0.26 L/kg",avg_serum_t1_2:"2-3 hr",elimination:"Renal",bile_penetration:"10-60%",csf_blood:"0-30%",therapeutic_levels_in_csf:"No",auc:"No data"},major_drug_interactions:[{drug:"Amphotericin B",effect:"↑ nephrotoxicity",suggestion:"Avoid"},{drug:"Cisplatin",effect:"↑ nephrotoxicity, ↑ ototoxicity",suggestion:"Avoid"},{drug:"Cyclosporine",effect:"↑ nephrotoxicity",suggestion:"Avoid"},{drug:"Furosemide",effect:"↑ ototoxicity",suggestion:"Avoid"},{drug:"Neuromuscular blocking agents",effect:"↑ apnea or respiratory paralysis",suggestion:"Monitor"},{drug:"NSAIDS",effect:"↑ nephrotoxicity",suggestion:"Monitor"},{drug:"Piperacillin-tazobactam",effect:"Possible netilmicin inactivation",suggestion:"Monitor"},{drug:"Radiographic contrast",effect:"↑ nephrotoxicity",suggestion:"Monitor"},{drug:"Vancomycin",effect:"↑ nephrotoxicity",suggestion:"Avoid"}]}},Plazomicin:{id:"Plazomicin",name:"Plazomicin",tradename:"Zemdri",classification:{family:"AMINOGLYCOSIDE",subclass:"Aminoglycoside",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:{"crcl_>60":"No dosage adjustment","crcl_30_to_<60":"10 mg/kg q24h","crcl_15_to_<30":"10 mg/kg q48h","crcl_<15":"No data"},mild:{"crcl_>60":"No dosage adjustment","crcl_30_to_<60":"10 mg/kg q24h","crcl_15_to_<30":"10 mg/kg q48h","crcl_<15":"No data"},moderate:{"crcl_>60":"No dosage adjustment","crcl_30_to_<60":"10 mg/kg q24h","crcl_15_to_<30":"10 mg/kg q48h","crcl_<15":"No data"},severe:{"crcl_>60":"No dosage adjustment","crcl_30_to_<60":"10 mg/kg q24h","crcl_15_to_<30":"10 mg/kg q48h","crcl_<15":"No data"}},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Aminoglycosides are associated with fetal harm, especially 1st TM use. No specific data for plazomicin. Avoid in pregnancy, although short-term use may be acceptable if benefit outweighs risk.",lactation:"Use with caution",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:null,half_life:null,elimination:"Renal",csf_penetration:null,preparations:""},rawData:{drug_name:"Plazomicin",tradename:"Zemdri",usage_and_dosing:{description:"Plazomicin, approved in 2018, is a semisynthetic aminoglycoside derived from sisomicin. FDA approved for treatment of adults, age ≥18 years, with complicated urinary tract infections (cUTIs), including pyelonephritis, caused by E. coli, K. pneumoniae, P. mirabilis, and E. cloacae. Clinical significance of in vitro data for other GNB is unknown. May be active against Enterobacteriaceae resistant to beta-lactams and other classes of antibacterials. Stable in the presence of many clinically relevant aminoglycoside modifying enzymes. Inactive vs isolates that produce 16S rRNA methyltransferases. May have reduced activity vs Enterobacteriaceae that express efflux pumps or have impaired cell wall permeability due to porin closure. Activity against Pseudomonas aeruginosa is variable. No activity against Acinetobacter baumannii, Stenotrophomonas maltophilia, or anaerobes. Safety and efficacy data are limited, hence, plazomicin should be used only when there are limited or no alternative treatment options. Ideally, susceptibility results should be obtained first.",adult_dose:[{dose:"15 mg/kg IV q24h x4-7 days.",infusion:"Infuse in 50 mL NS over 30 minutes.",tdm:"Product labeling recommends TDM to maintain plasma troughs <3 µg/mL. Check trough 30 min before 2nd dose; extend dosing interval by 1.5x (i.e., from q24h to q36h, or from q48h to q72h) if trough ≥3 µg/mL.",hartford_nomogram:"Study suggests application of the Hartford nomogram may result in fewer patients with troughs ≥3 µg/mL. Prospective validation required (Antimicrob Agents Chemother 2019;63:e00148-19)."}],pediatric_dose:[{age:">28 Days",dose:"Safety and efficacy not established"}]},renal_adjustment:{half_life_normal_function:"3.5 hrs",half_life_esrd:"No data",dose_renal_function_normal:"15 mg/kg IV q24h",crcl_or_egfr:{"crcl_>60":"No dosage adjustment","crcl_30_to_<60":"10 mg/kg q24h","crcl_15_to_<30":"10 mg/kg q48h","crcl_<15":"No data"},hemodialysis:"No data",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment:"No dosage adjustment",moderate_impairment:"No dosage adjustment",severe_impairment:"No dosage adjustment"},other_adjustment:{ecmo:"See ECMO Drug Dosing Adjustment.",obesity:"See Obesity Dosing Adjustments."},adverse_effects:["Nephrotoxicity (acute tubular necrosis)","Ototoxicity (cochlear and vestibular).","Enhancement of neuromuscular blockade (rare)."],pregnancy_risk:{fda_risk_category:"Aminoglycosides are associated with fetal harm, especially 1st TM use. No specific data for plazomicin. Avoid in pregnancy, although short-term use may be acceptable if benefit outweighs risk.",use_during_lactation:"Probably safe, monitor infant for GI toxicity"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",pharmaceutical_preparations:"Injection",oral_absorption:null,tmax:null,peak_serum_conc:"51-74 (15 mg/kg IV, SD)",peak_urine_conc:"No data",protein_binding:"20%",volume_of_distribution:"18-31 L",avg_serum_t1_2:"3.5 hr",elimination:"Renal",bile_penetration:"No data",csf_blood:"No data",therapeutic_levels_in_csf:"No data",auc:"226-257 (15 mg/kg, 0-inf)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:null,transporters_substrate:null,ugts_substrate:null,cyp450s_inhibited:null,transporters_inhibited:"MATE1, MATE2-K",ugts_inhibited:null,cyp450s_induced:null,transporters_induced:null,ugts_induced:null,impact_on_serum_drug_concentrations:"↑"},major_drug_interactions:["None reported"]}},Spectinomycin:{id:"Spectinomycin",name:"Spectinomycin",tradename:"Trobicin",classification:{family:"AMINOGLYCOSIDE",subclass:"Aminoglycoside",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Neisseria gonorrhoeae"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No dosage adjustment for renal impairment",mild:"No dosage adjustment for renal impairment",moderate:"No dosage adjustment for renal impairment",severe:"No dosage adjustment for renal impairment"},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Category C - Risk cannot be ruled out",lactation:"Use with caution",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:["Neisseria gonorrhoeae"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:null,half_life:null,elimination:"Renal",csf_penetration:null,preparations:""},rawData:{drug_name:"Spectinomycin",tradename:"Trobicin",usage_and_dosing:{description:"Spectinomycin is an aminocyclitol used in treatment of acute gonococcal urethritis/cervicitis/proctitis. Not effective for pharyngeal gonorrhea. Available in Europe; distribution in the U.S. was discontinued in 2005.",adult_dose:[{dose:"2 gm IM (in 5 mL) as a one-time dose."}],pediatric_dose:[{age:">28 Days",dose:"Safety and efficacy not established"}]},renal_adjustment:{half_life_normal_function:"1.5-2 hrs",half_life_esrd:"No data",dose_renal_function_normal:"2 gm IM x1",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No dosage adjustment",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment:"No dosage adjustment",moderate_impairment:"No dosage adjustment",severe_impairment:"No dosage adjustment"},adverse_effects:["A single dose is well tolerated.","Occasionally observed: discomfort at injection site, rash, fever, nausea, headache, dizziness."],antimicrobial_spectrum:{preferred:["Neisseria gonorrhoeae"],alternative:[]},pharmacology:{pk_pd_index:"No data",pharmaceutical_preparations:"Injection",oral_absorption:null,tmax:"1 hr",peak_serum_conc:"100 (2 gm IM, SD)",peak_urine_conc:"No data",protein_binding:"Low",volume_of_distribution:"No data",avg_serum_t1_2:"1.5-2 hr",elimination:"Renal",bile_penetration:"No data",csf_blood:"No data",therapeutic_levels_in_csf:"No",auc:"No data"},major_drug_interactions:["None known"]}},Streptomycin:{id:"Streptomycin",name:"Streptomycin",tradename:"",classification:{family:"AMINOGLYCOSIDE",subclass:"Aminoglycoside",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:{"crcl_>50":"No dosage adjustment",crcl_10_50:"15 mg/kg q24-72h","crcl_<10":"15 mg/kg q72-96h"},mild:{"crcl_>50":"No dosage adjustment",crcl_10_50:"15 mg/kg q24-72h","crcl_<10":"15 mg/kg q72-96h"},moderate:{"crcl_>50":"No dosage adjustment",crcl_10_50:"15 mg/kg q24-72h","crcl_<10":"15 mg/kg q72-96h"},severe:{"crcl_>50":"No dosage adjustment",crcl_10_50:"15 mg/kg q24-72h","crcl_<10":"15 mg/kg q72-96h"}},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Associated with fetal harm, especially 1st TM use. Reports of irreversible ototoxicity. Avoid in pregnancy.",lactation:"Use with caution",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Amphotericin B",effect:"↑ nephrotoxicity",management:"Monitor closely"},{drug:"Cisplatin",effect:"↑ nephrotoxicity, ↑ ototoxicity",management:"Monitor closely"},{drug:"Cyclosporine",effect:"↑ nephrotoxicity",management:"Monitor closely"},{drug:"Furosemide",effect:"↑ ototoxicity",management:"Monitor closely"},{drug:"Neuromuscular blocking agents",effect:"↑ apnea or respiratory paralysis",management:"Monitor closely"},{drug:"NSAIDS",effect:"↑ nephrotoxicity",management:"Monitor closely"},{drug:"Piperacillin-tazobactam",effect:"Possible streptomycin inactivation",management:"Monitor closely"},{drug:"Radiographic contrast",effect:"↑ nephrotoxicity",management:"Monitor closely"},{drug:"Vancomycin",effect:"↑ nephrotoxicity",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:null,half_life:null,elimination:"Renal",csf_penetration:null,preparations:""},rawData:{drug_name:"Streptomycin",usage_and_dosing:{description:"Streptomycin is an aminoglycoside used clinically as a second-line agent for treatment of M. tuberculosis. It is also used, in combination therapy, for treatment of viridans group streptococci and enterococcal endocarditis. Major toxicity is cochlear. Potential for renal and vestibular toxicity as well.",adult_dose:[{route:"M. tuberculosis",dose:"15 mg/kg IM q24h, OR 25-30 mg/kg IM 2x/week, OR 25-30 mg/kg IM 3x/week"},{route:"Brucellosis",dose:"1 gm IM/IV daily x14-21 days + Doxycycline"},{route:"Plague",dose:"15 mg/kg IM/IV q12h x10 days"},{route:"Tularemia",dose:"10-15 mg/kg IM/IV q12h x7-10 days"}],pediatric_dose:[{age:"≥2 yrs",dose:"20-40 mg/kg/day (once daily)",max_day:"1 gm"}]},renal_adjustment:{half_life_normal_function:"2-3 hrs",half_life_esrd:"30-70 hrs",dose_renal_function_normal:"15 mg/kg (max 1 gm) IM q24h",crcl_or_egfr:{"crcl_>50":"No dosage adjustment",crcl_10_50:"15 mg/kg q24-72h","crcl_<10":"15 mg/kg q72-96h"},hemodialysis:"15 mg/kg q72-96h (+ extra 7.5 mg/kg AD)",capd:"20-40 mg lost per L of dialysate/day",crrt:"15 mg/kg q24-72h",sled:"No data"},hepatic_adjustment:{mild_impairment:"No dosage adjustment",moderate_impairment:"No dosage adjustment",severe_impairment:"No dosage adjustment"},other_adjustment:{obesity:"See Obesity Dosing Adjustments table."},adverse_effects:["Ototoxicity: vestibular dysfunction (vertigo); paresthesias; dizziness & nausea (all less in patients receiving 2-3 doses/week); tinnitus and high frequency loss (1%).","Nephrotoxicity (rare).","Peripheral neuropathy (rare).","Allergic skin rashes (4-5%)","Drug fever.","Toxicity similar with q24h vs q8h dosing (Clin Infect Dis 38:1538, 2004)."],pregnancy_risk:{fda_risk_category:"Associated with fetal harm, especially 1st TM use. Reports of irreversible ototoxicity. Avoid in pregnancy.",use_during_lactation:"Probably safe, monitor infant for GI toxicity"},antimicrobial_spectrum:{full_spectrum_link:"Full comparative spectrum of activity"},pharmacology:{pk_pd_index:"24-hr AUC/MIC",pharmaceutical_preparations:"Injection",oral_absorption:null,tmax:null,peak_serum_conc:"25-50 (15 mg/kg IM, SD)",peak_urine_conc:"No data",protein_binding:"0-10%",volume_of_distribution:"0.26 L/kg",avg_serum_t1_2:"2-3 hr",elimination:"Renal",bile_penetration:"10-60%",csf_blood:"0-30%",therapeutic_levels_in_csf:"No",auc:"No data"},major_drug_interactions:[{drug:"Amphotericin B",effect:"↑ nephrotoxicity",suggestion:"Avoid co-administration"},{drug:"Cisplatin",effect:"↑ nephrotoxicity, ↑ ototoxicity",suggestion:"Avoid co-administration"},{drug:"Cyclosporine",effect:"↑ nephrotoxicity",suggestion:"Avoid co-administration"},{drug:"Furosemide",effect:"↑ ototoxicity",suggestion:"Monitor"},{drug:"Neuromuscular blocking agents",effect:"↑ apnea or respiratory paralysis",suggestion:"Monitor"},{drug:"NSAIDS",effect:"↑ nephrotoxicity",suggestion:"Monitor"},{drug:"Piperacillin-tazobactam",effect:"Possible streptomycin inactivation",suggestion:"Monitor"},{drug:"Radiographic contrast",effect:"↑ nephrotoxicity",suggestion:"Monitor"},{drug:"Vancomycin",effect:"↑ nephrotoxicity",suggestion:"Avoid co-administration"}]}},Tobramycin:{id:"Tobramycin",name:"Tobramycin",tradename:"Nebcin, Tobi",classification:{family:"AMINOGLYCOSIDE",subclass:"Aminoglycoside",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:{conventional:{"crcl_>50":"No dosage adjustment",crcl_10_50:"1.7-2.0 mg/kg q12-24h","crcl_<10":"1.7-2.0 mg/kg q48h"}},mild:{conventional:{"crcl_>50":"No dosage adjustment",crcl_10_50:"1.7-2.0 mg/kg q12-24h","crcl_<10":"1.7-2.0 mg/kg q48h"}},moderate:{conventional:{"crcl_>50":"No dosage adjustment",crcl_10_50:"1.7-2.0 mg/kg q12-24h","crcl_<10":"1.7-2.0 mg/kg q48h"}},severe:{conventional:{"crcl_>50":"No dosage adjustment",crcl_10_50:"1.7-2.0 mg/kg q12-24h","crcl_<10":"1.7-2.0 mg/kg q48h"}}},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Associated with fetal harm, especially 1st TM use. Avoid in pregnancy, although short-term use may be acceptable if benefit outweighs risk. Topical use probably safe.",lactation:"Use with caution",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Amphotericin B (all forms)",effect:"↑ nephrotoxicity",management:"Monitor closely"},{drug:"Cisplatin",effect:"↑ nephrotoxicity, ↑ ototoxicity",management:"Monitor closely"},{drug:"Cyclosporine",effect:"↑ nephrotoxicity",management:"Monitor closely"},{drug:"Furosemide",effect:"↑ ototoxicity",management:"Monitor closely"},{drug:"Neuromuscular blocking agents",effect:"↑ apnea or respiratory paralysis",management:"Monitor closely"},{drug:"NSAIDS",effect:"↑ nephrotoxicity",management:"Monitor closely"},{drug:"Piperacillin-tazobactam",effect:"Possible tobramycin inactivation",management:"Monitor closely"},{drug:"Radiographic contrast",effect:"↑ nephrotoxicity",management:"Monitor closely"},{drug:"Vancomycin",effect:"↑ nephrotoxicity",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:null,half_life:null,elimination:"Renal",csf_penetration:null,preparations:""},rawData:{drug_name:"Tobramycin",tradename:"Nebcin, Tobi",usage_and_dosing:{description:"Tobramycin, approved in 1968, is an aminoglycoside that is active against a wide range of gram-negative bacteria, including P. aeruginosa. Produced by Streptoalloteichus tenebrarius (formerly Streptomyces tenebrarius), a soil actinomycete. No activity against anaerobes, poor activity in a low pH environment.",adult_dose:[{route:"Conventional dosing",dose:"2 mg/kg IV load, then 1.7-2 mg/kg IV q8h"},{route:"Extended-interval dosing",dose:"7 mg/kg IV q24h (Antimicrob Agents Chemother 1995;39:650)"},{route:"Intrathecal administration",dose:"4-10 mg once daily"},{route:"CAPD-related peritonitis",dose:"See Intraperitoneal Drug Dosing, CAPD"},{route:"CF (systemic, inhalation therapy)",dose:"See Cystic Fibrosis"}],pediatric_dose:[{age:">28 Days",dose:"5-7 mg/kg/day (once daily) or 2.5 mg/kg q8h"}]},renal_adjustment:{half_life_normal_function:"2-3 hrs",half_life_esrd:"30-70 hrs",dose_renal_function_normal:{conventional:"1.7-2.0 mg/kg IV q8h"},crcl_or_egfr:{conventional:{"crcl_>50":"No dosage adjustment",crcl_10_50:"1.7-2.0 mg/kg q12-24h","crcl_<10":"1.7-2.0 mg/kg q48h"}},hemodialysis:{conventional:"1.7-2.0 mg/kg q48h (+ extra 0.85-1.0 mg/kg AD)"},capd:"For peritonitis only: 0.6 mg/kg IP once daily",crrt:{conventional:"1.7-2.0 mg/kg q24h"},sled:"No data"},hepatic_adjustment:{mild_impairment:"No dosage adjustment",moderate_impairment:"No dosage adjustment",severe_impairment:"No dosage adjustment"},other_adjustment:{ecmo:"See ECMO Drug Dosing Adjustment.",obesity:"See Obesity Dosing Adjustments."},adverse_effects:["Nephrotoxicity (acute tubular necrosis)","Ototoxicity (cochlear and vestibular).","Enhancement of neuromuscular blockade (rare).","With inhaled tobramycin: transient voice alteration (13%), transient tinnitus (3%)."],pregnancy_risk:{fda_risk_category:"Associated with fetal harm, especially 1st TM use. Avoid in pregnancy, although short-term use may be acceptable if benefit outweighs risk. Topical use probably safe.",use_during_lactation:"Probably safe, monitor infant for GI toxicity"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",pharmaceutical_preparations:"Injection, 0.3% oph ointment, 0.3% eye drops, Inhalation",oral_absorption:null,tmax:null,peak_serum_conc:"4-6 (1.7 mg/kg IV, SD)",peak_urine_conc:"No data",protein_binding:"0-10%",volume_of_distribution:"0.26 L/kg",avg_serum_t1_2:"2-3 hr",elimination:"Renal",bile_penetration:"10-60%",csf_blood:"0-30%",therapeutic_levels_in_csf:"No",auc:"70-100 (7 mg/kg, 0-inf)"},major_drug_interactions:[{drug:"Amphotericin B (all forms)",effect:"↑ nephrotoxicity",suggestion:"Avoid co-administration"},{drug:"Cisplatin",effect:"↑ nephrotoxicity, ↑ ototoxicity",suggestion:"Avoid co-administration"},{drug:"Cyclosporine",effect:"↑ nephrotoxicity",suggestion:"Avoid co-administration"},{drug:"Furosemide",effect:"↑ ototoxicity",suggestion:"Avoid co-administration"},{drug:"Neuromuscular blocking agents",effect:"↑ apnea or respiratory paralysis",suggestion:"Monitor"},{drug:"NSAIDS",effect:"↑ nephrotoxicity",suggestion:"Monitor"},{drug:"Piperacillin-tazobactam",effect:"Possible tobramycin inactivation",suggestion:"Monitor"},{drug:"Radiographic contrast",effect:"↑ nephrotoxicity",suggestion:"Monitor"},{drug:"Vancomycin",effect:"↑ nephrotoxicity",suggestion:"Avoid co-administration"}]}},Trimethoprim:{id:"Trimethoprim",name:"Trimethoprim",tradename:"Trimpex, Proloprim",classification:{family:"ANTIFOLATE",subclass:"Antifolate",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"100 mg po q12h or 200 mg po q24h",severe:"100 mg po q12h or 200 mg po q24h",renal:{normal:"CrCl >30: No dosage adjustment. CrCl 10-30: 100-200 mg q18h. CrCl <10: 100-200 mg q24h",mild:"CrCl >30: No dosage adjustment. CrCl 10-30: 100-200 mg q18h. CrCl <10: 100-200 mg q24h",moderate:"CrCl >30: No dosage adjustment. CrCl 10-30: 100-200 mg q18h. CrCl <10: 100-200 mg q24h",severe:"CrCl >30: No dosage adjustment. CrCl 10-30: 100-200 mg q18h. CrCl <10: 100-200 mg q24h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"May cause fetal harm. Avoid unless benefit outweighs risk. 10",lactation:"Milk concentrations are low. No adverse effects in breastfed infants are expected. 9",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"ACE inhibitors",effect:"↑ serum potassium",management:"Avoid combinatic"},{drug:"Amantadine",effect:"↑ amantadine",management:"Monitor, adjust dos"},{drug:"Dapsone",effect:"↑ trimethoprim, ↑ dapsone",management:"Monitor or avoic"},{drug:"Lamivudine",effect:"↑ lamivudine",management:"Monitor"},{drug:"Methotrexate",effect:"↑ methotrexate",management:"Monitor, adjust dos"},{drug:"Phenytoin",effect:"↑ phenytoin",management:"Monitor, adjust dos"},{drug:"K+-sparing diuretics",effect:"↑ serum potassium",management:"Monitor"},{drug:"Procainamide",effect:"↑ procainamide, ↑ NAPA",management:"Monitor, adjust dos"},{drug:"Repaglinide",effect:"↑ repaglinide",management:"Monitor blood gluc"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"80",protein_binding:"44",half_life:"8-15",elimination:"Renal",csf_penetration:"50",preparations:"Tab (100 mg), Oral soln 50 mg/5 ml (not in US)"},rawData:{drug_name:"Trimethoprim",tradename:"Trimpex, Proloprim",usage_and_dosing:{general:["Trimethoprim is a synthetic antibacterial that blocks a key enzyme (dihydrofolate reductase) in the production of the metabolically active tetrahydrofolate form of folic acid. The step blocked is the step right after the site of action of sulfonamides.","Mechanism of resistance: Major mechanism is change in the target enzyme (dihydrofolate reductase) with resultant reduced inhibition by Trimethoprim.","Available in the U.S. as a single agent and in combination with Sulfamethoxazole (TMP-SMX). Trimethoprim is rarely used as a single agent, but can be useful in the sulfonamide-allergic or sulfonamide-intolerant patient.","Enterococci may appear susceptible in vitro but fail in clinical therapy of uncomplicated UTIs. Discordance due to some combination of ability of enterococci to utilize exogenous folates, urine pH, or urine osmolality.","Potential hyperkalemia, see adverse effects."],adult_dose:{usual_dose:"100 mg po q12h or 200 mg po q24h"},pediatric_dose:{dose_age_gt_28_days:"4 mg/kg/day (divided q12h)",max_day:"-"}},renal_adjustment:{half_life_normal:"8-15",half_life_esrd:"20-49",dose_renal_function_normal:"100-200 mg po q12h",crcl_or_egfr:"CrCl >30: No dosage adjustment. CrCl 10-30: 100-200 mg q18h. CrCl <10: 100-200 mg q24h",hemodialysis:"100-200 mg q24h (AD on dialysis days)",capd:"100-200 mg q24h",crrt:"100-200 mg q18h",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["GI: nausea, vomiting, diarrhea; increased transaminases, cholestatic jaundice","Dermatitis: From benign rash in 3-7% at 200 mg/day to severe Stevens-Johnson syndrome, Sweet's syndrome or toxic epidermal necrosis.","Photosensitivity (alone or in combination with Sulfamethoxazole)","CNS: Drug fever, aseptic meningitis (rare).","Renal: ↑ K+, ↓ Na+, ↑ creatinine. Occurs as a result of the drug competing for secretion of K+ and creatinine by the cells of the proximal convoluted tubule (JAMA 314:2405, 2015).","ACE inhibitors can also cause hyperkalemia. Combination of ACE inhibitor and TMP should be avoided due to augmented risk of hyperkalemia and associated risk of sudden death due to cardiac arrhythmia (BMJ 349:g6196, 2014).","Hematologic: Neutropenia, thrombocytopenia, methemoglobinemia."],pregnancy_risk:{fda_risk_category:"May cause fetal harm. Avoid unless benefit outweighs risk. 10",lactation:"Milk concentrations are low. No adverse effects in breastfed infants are expected. 9",footnotes:{1:"Capital letter = Old FDA risk category; Text = New FDA risk category",9:"Source: LactMed",10:"Source: Manufacturer's prescribing information"}},antimicrobial_spectrum:{see_tmp_smx:!0},pharmacology:{pk_pd_index:"No data",preparations:"Tab (100 mg), Oral soln 50 mg/5 ml (not in US)",food_recommendation:"Tab ± food",oral_absorption_percent:"80",tmax_hr:"1-4",peak_serum_conc_ug_ml:"1 (100 mg po, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"44",volume_of_distribution_l_vf:"100-120 L (V/F)",avg_serum_half_life_hr:"8-15",elimination:"Renal",bile_penetration_percent:"100-200",csf_blood_percent:"50",therapeutic_levels_in_csf:"No",auc_ug_hr_ml:"No data"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:[],ugts_substrate:[],cyp450s_inhibited:["CYP2C8"],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"↑"},major_drug_interactions:[{drug:"ACE inhibitors",effect:"↑ serum potassium",management:"Avoid combinatic"},{drug:"Amantadine",effect:"↑ amantadine",management:"Monitor, adjust dos"},{drug:"Dapsone",effect:"↑ trimethoprim, ↑ dapsone",management:"Monitor or avoic"},{drug:"Lamivudine",effect:"↑ lamivudine",management:"Monitor"},{drug:"Methotrexate",effect:"↑ methotrexate",management:"Monitor, adjust dos"},{drug:"Phenytoin",effect:"↑ phenytoin",management:"Monitor, adjust dos"},{drug:"K+-sparing diuretics",effect:"↑ serum potassium",management:"Monitor"},{drug:"Procainamide",effect:"↑ procainamide, ↑ NAPA",management:"Monitor, adjust dos"},{drug:"Repaglinide",effect:"↑ repaglinide",management:"Monitor blood gluc"}],comments:["See adverse effects for potential risk of dangerous hyperkalemia."]}},"Trimethoprim-sulfamethoxazole (TMP-SMX)":{id:"Trimethoprim_sulfamethoxazole_TMP_SMX",name:"Trimethoprim-sulfamethoxazole (TMP-SMX)",tradename:"Bactrim, Septra, Sulfatrim, Co-trimoxazole",classification:{family:"ANTIFOLATE",subclass:"Antifolate",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Klebsiella granulomatis (granuloma inguinale)","Nocardia sp.","Stenotrophomonas maltophilia"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:{treatment:"CrCl ≥30: No dosage adjustment. CrCl 10-29: 5-10 mg/kg/day (div q12h). CrCl <10: Not recommended (if used: 5-10 mg/kg q24h)",prophylaxis:"No dosage adjustment for renal impairment"},mild:{treatment:"CrCl ≥30: No dosage adjustment. CrCl 10-29: 5-10 mg/kg/day (div q12h). CrCl <10: Not recommended (if used: 5-10 mg/kg q24h)",prophylaxis:"No dosage adjustment for renal impairment"},moderate:{treatment:"CrCl ≥30: No dosage adjustment. CrCl 10-29: 5-10 mg/kg/day (div q12h). CrCl <10: Not recommended (if used: 5-10 mg/kg q24h)",prophylaxis:"No dosage adjustment for renal impairment"},severe:{treatment:"CrCl ≥30: No dosage adjustment. CrCl 10-29: 5-10 mg/kg/day (div q12h). CrCl <10: Not recommended (if used: 5-10 mg/kg q24h)",prophylaxis:"No dosage adjustment for renal impairment"}},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"May cause fetal harm. Avoid unless benefit outweighs risk. If use is unavoidable, supplement with at least 4 mg daily of folic acid. 8, 10",lactation:"Probably safe after the newborn period in healthy, fullterm infants. Avoid in jaundiced, ill, stressed or premature infants because of the risk of kernicterus. Avoid while breastfeeding a G6PD-deficient infant. 9",blackBoxWarning:!1,majorAdverseEffects:["Agranulocytosis, aplastic anemia, hemolysis if G6PD deficient, megaloblastic anemia, methemoglobinemia, drug-induced immune thrombocytopenia (J Thromb Haemost 2013;11:169)."]},interactions:[{drug:"6-mercaptopurine",effect:"↓ effect of 6-mecaptopurine",management:"Moni"},{drug:"ACE Inhibitors",effect:"↑ serum potassium",management:"Moni"},{drug:"ACE inhibitors/ARBs",effect:"↑ risk of sudden death",management:"Moni"},{drug:"Amantadine",effect:"↑ amantadine",management:"Moni"},{drug:"Azathioprine",effect:"Reports of leukopenia",management:"Moni"},{drug:"Cyclosporine",effect:"↓ cyclosporine",management:"Moni"},{drug:"Lamivudine",effect:"↑ lamivudine",management:"Moni"},{drug:"Loperamide",effect:"↑ loperamide",management:"Moni"},{drug:"Methenamine",effect:"↑ risk of crystalluria",management:"Avoid co-adn"},{drug:"Methotrexate",effect:"Enhanced marrow suppression",management:"Moni"},{drug:"Oral contraceptives",effect:"↓ effect of oral contraceptives",management:"Use alternat"},{drug:"Phenytoin",effect:"↑ phenytoin",management:"Moni"},{drug:"Pimozide",effect:"↓ effect of pimozide",management:"Moni"},{drug:"Rifampin",effect:"↑ rifampin? ↓ TMP-SMX (more likely)",management:"Moni"},{drug:"Spironolactone",effect:"↑ serum potassium",management:"Moni"},{drug:"Sulfonylureas",effect:"Hypoglycemia",management:"Moni"},{drug:"Warfarin",effect:"↑ activity of warfarin (↑ INR)",management:"Monitoi"}],stewardship:{preferredIndications:["Klebsiella granulomatis (granuloma inguinale)","Nocardia sp.","Stenotrophomonas maltophilia"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:{tmp:"70-90",smx:"70-90"},protein_binding:"TMP 44, SMX 70",half_life:"TMP 11, SMX 9",elimination:"Renal",csf_penetration:"TMP 50, SMX 40",preparations:"SS tab (TMP 80 mg, SMX 400 mg), DS tab (TMP 160 mg, SMX 800 mg), Oral susp (TMP 40 mg + SMX 200 mg per 5 mL), Injection"},rawData:{drug_name:"Trimethoprim-sulfamethoxazole (TMP-SMX)",tradename:"Bactrim, Septra, Sulfatrim, Co-trimoxazole",usage_and_dosing:{general:["TMP-SMX, approved in 1973, is a co-formulation of Trimethoprim (TMP) and Sulfamethoxazole (SMX). The ratio of TMP to SMX administered is always 1:5.","TMP and SMX block sequential steps in folic acid synthesis in susceptible bacteria. SMX inhibits dihydropteroate synthase (DHPS), which produces dihydropteroic acid from PABA and pteridine. TMP inhibits dihydrofolate reductase (DHFR), which catalyzes the conversion of FH2 to tetrahydrofolate (FH4). See Comments.","An alternative antibiotic for drug resistant genotypes.","TMP-SMX, alone or in combination, is used to treat a wide range of infections, including:","Cyclosporiasis","Nocardia","PJP treatment","PJP prophylaxis (adult, pediatric)","Purulent cellulitis, outpatient","Stenotrophomonas maltophilia","UTI","Although active in vitro vs. Strep. pyogenes, clinical failures occur in the treatment of streptococcal pharyngitis (J Infect Dis 1973;128(suppl):693); Rev Infect Dis 1982;4:196).","Although active in vitro vs. some enterococci, should not be used to treat enterococcal cystitis due to treatment failures. In vitro systems do not replicate the influence of urine osmolality, pH, and interference with antibacterial activity due to the presence of folates.","Allergy: Protocol for TMP-SMX desensitization.","SMX is structurally different from non-antimicrobial sulfonamides (e.g., furosemide) because of its N4 arylamine. Therefore, there is minimal concern for a hypersensitivity reaction to a non-antimicrobial sulfonamide in a patient with a history of a reaction to TMP-SMX or any other sulfonamide antimicrobial, including dapsone, a sulfone (J Allergy Clin Immunol 2022;150:1333).","CAUTION when prescribing TMP-SMX to patients on chronic therapy with either an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB). Worrisome association with sudden death presumably due to cardiac dysrhythmias.","Drugs that block renin-angiotensin system can increase serum potassium level (BMJ 2014;349:g6196).","Also, in a case-control study, the use of TMP-SMX was associated with increased risk of sudden death among older patients taking spironolactone, presumably reflecting hyperkalemia (CMAJ 2015;187:E138)."],adult_dose:{notes:"Dosing specifics vary. Refer to syndrome pages for details.",usual_dosing:{oral:"1-2 DS tablets po q12h",iv:"10-20 mg/kg/day (divided q6-12h)"},dosing_basis:"Dosing (if expressed in mg/kg) is based on the TMP component.",double_strength_tablets:"Double-strength (DS) oral tablets contain 160 mg TMP and 800 mg SMX."},pediatric_dose:{uti_other:"8-10 mg TMP/kg/day (divided q12h)",pjp:"15-20 mg TMP/kg/day (divided q6-8h)"}},renal_adjustment:{notes:"Dosing is based on the TMP component.",half_life_normal:{tmp:"8-15",smx:"10"},half_life_esrd:{tmp:"20-49",smx:"20-50"},dose_renal_function_normal:{treatment:"5-20 mg/kg/day po/IV (div q6-12h)",prophylaxis:"1 DS tab po q24h or 3x/week"},crcl_or_egfr:{treatment:"CrCl ≥30: No dosage adjustment. CrCl 10-29: 5-10 mg/kg/day (div q12h). CrCl <10: Not recommended (if used: 5-10 mg/kg q24h)",prophylaxis:"No dosage adjustment for renal impairment"},hemodialysis:{treatment:"(if used: 5-10 mg/kg q24h, AD on dialysis days)",prophylaxis:"No data"},capd:{treatment:"(if used: 5-10 mg/kg q24h)",prophylaxis:"No data"},crrt:{treatment:"5 mg/kg q8h",prophylaxis:"No data"},sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["ECMO: See ECMO Drug Dosing Adjustment.","Obesity: See Obesity Dosing Adjustments."],adverse_effects:{cns:"Drug fever, headache, confusion. Aseptic meningitis (review: Br J Clin Pharmacol 2025;91:236). Kernicterus in neonates.",dermatologic:"Photosensitivity, Stevens-Johnson syndrome, Sweet's syndrome, toxic epidermal necrolysis (TEN), urticaria. For UK guidelines on management of Stevens-Johnson syndrome and TEN, see: Br J Dermatol 2016;174:1194.",endocrine:"May potentiate effect of sulfonylureas in diabetes mellitus (JAMA Intern Med 2014;174:1605). Case series of TMP-SMX-induced hypoglycemia: Front Endocrinol 2023;14:1059522.",gastrointestinal:"Nausea/vomiting, diarrhea, pancreatitis.",hematologic:"Agranulocytosis, aplastic anemia, hemolysis if G6PD deficient, megaloblastic anemia, methemoglobinemia, drug-induced immune thrombocytopenia (J Thromb Haemost 2013;11:169).",lactic_acidosis:"The IV solution of TMP-SMX contains propylene glycol which is metabolized by the liver to lactate and pyruvate. Lactic acidosis can result. Risk factors include renal and/or hepatic insufficiency, or concomitant exposure to other drugs that contain propylene glycol (Medicine 2016;95:e3478).",liver:"Rarely drug-induced hepatitis.",pulmonary:"Acute respiratory failure. In a recent case series, five previously healthy adolescents receiving TMP-SMX developed acute severe ARDS requiring prolonged hospitalization and cardiopulmonary support. Four required prolonged ECMO, one underwent a heart and lung transplant, and two died. Four of the five were receiving TMP-SMX for acne vulgaris. The mechanism of pulmonary toxicity is unknown, but may be related to metabolism resulting in formation of reactive intermediates (Pediatrics 2019;143:e20183242).",renal:"TMP competes for tubular secretion of creatinine, with secondary increase in serum creatinine; expected magnitude of increase about 30% (Drug Metab Pharmacokinet 2018;33:103). TMP blocks distal tubular secretion of potassium, leading to hyperkalemia; can be exaggerated with concomitant use of ACE inhibitor (JAMA 2015;314:2405). Hyponatremia, thought most likely due to natriuresis although a recent report suggests SIADH (Medicine 2020;99:e20746). Crystalluria due to precipitation of SMX. Renal injury can also occur as a consequence of interstitial nephritis or acute tubular necrosis (J Antimicrob Chemother 2012;67:1271)."},pregnancy_risk:{fda_risk_category:"May cause fetal harm. Avoid unless benefit outweighs risk. If use is unavoidable, supplement with at least 4 mg daily of folic acid. 8, 10",lactation:"Probably safe after the newborn period in healthy, fullterm infants. Avoid in jaundiced, ill, stressed or premature infants because of the risk of kernicterus. Avoid while breastfeeding a G6PD-deficient infant. 9",footnotes:{1:"Capital letter = Old FDA risk category; Text = New FDA risk category",8:"Ref: Pharmacotherapy 2025;45:227",9:"Source: LactMed",10:"Source: Manufacturer's prescribing information"}},antimicrobial_spectrum:{preferred:["Klebsiella granulomatis (granuloma inguinale)","Nocardia sp.","Stenotrophomonas maltophilia"],alternative:[]},pharmacology:{pk_pd_index:"No data",preparations:"SS tab (TMP 80 mg, SMX 400 mg), DS tab (TMP 160 mg, SMX 800 mg), Oral susp (TMP 40 mg + SMX 200 mg per 5 mL), Injection",food_recommendation:"Tab/susp ± food",oral_absorption_percent:{tmp:"70-90",smx:"70-90"},tmax_hr:"po: TMP 1-4, SMX 1-4",peak_serum_conc_ug_ml:{ds_tab:"TMP 1-2, SMX 40-60 (DS tab po q12h, SS)",iv:"TMP 9, SMX 105 (160/800 mg IV q8h, SS)"},peak_urine_conc_ug_ml:"No data",protein_binding_percent:"TMP 44, SMX 70",volume_of_distribution_l:"TMP 100-120 L, SMX 12-18 L",avg_serum_half_life_hr:"TMP 11, SMX 9",elimination:"Renal",bile_penetration_percent:"po 100-200, IV 40-70",csf_blood_percent:"TMP 50, SMX 40",therapeutic_levels_in_csf:"Most meningococci: resistant. Bacteriostatic vs. coliforms",auc_ug_hr_ml:"No data"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:"SMX: CYP2C9 (major), CYP3A4 (minor)",transporters_substrate:[],ugts_substrate:[],cyp450s_inhibited:"TMP: CYP2C8, SMX: CYP2C9",transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"↑"},major_drug_interactions:[{drug:"6-mercaptopurine",effect:"↓ effect of 6-mecaptopurine",management:"Moni"},{drug:"ACE Inhibitors",effect:"↑ serum potassium",management:"Moni"},{drug:"ACE inhibitors/ARBs",effect:"↑ risk of sudden death",management:"Moni"},{drug:"Amantadine",effect:"↑ amantadine",management:"Moni"},{drug:"Azathioprine",effect:"Reports of leukopenia",management:"Moni"},{drug:"Cyclosporine",effect:"↓ cyclosporine",management:"Moni"},{drug:"Lamivudine",effect:"↑ lamivudine",management:"Moni"},{drug:"Loperamide",effect:"↑ loperamide",management:"Moni"},{drug:"Methenamine",effect:"↑ risk of crystalluria",management:"Avoid co-adn"},{drug:"Methotrexate",effect:"Enhanced marrow suppression",management:"Moni"},{drug:"Oral contraceptives",effect:"↓ effect of oral contraceptives",management:"Use alternat"},{drug:"Phenytoin",effect:"↑ phenytoin",management:"Moni"},{drug:"Pimozide",effect:"↓ effect of pimozide",management:"Moni"},{drug:"Rifampin",effect:"↑ rifampin? ↓ TMP-SMX (more likely)",management:"Moni"},{drug:"Spironolactone",effect:"↑ serum potassium",management:"Moni"},{drug:"Sulfonylureas",effect:"Hypoglycemia",management:"Moni"},{drug:"Warfarin",effect:"↑ activity of warfarin (↑ INR)",management:"Monitoi"}],comments:["Mechanisms of TMP-SMX resistance:","For TMP: changes in target enzyme (DHFR no longer inhibited).","For SMX: target enzyme (DHPS) with reduced affinity for SMX.","Exogenous thymidine can render TMP-SMX inactive, as the blockade of the thymidine synthetic pathway is bypassed. Furthermore, a Staph. aureus enzyme (thermonuclease) can release thymidine from DNA of injured tissues (Clin Infect Dis 2008;46:584). Some streptococcal species can also salvage thymidine from the environment, which could explain failures in the treatment of S. pyogenes pharyngitis."]}},Doripenem:{id:"Doripenem",name:"Doripenem",tradename:"Doribax",classification:{family:"CARBAPENEM",subclass:"Carbapenem",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Providencia sp."],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"CrCl >50: No dosage adjustment. CrCl 30-50: 250 mg q8h. CrCl 10-30: 250 mg q12h. CrCl <10: No data",mild:"CrCl >50: No dosage adjustment. CrCl 30-50: 250 mg q8h. CrCl 10-30: 250 mg q12h. CrCl <10: No data",moderate:"CrCl >50: No dosage adjustment. CrCl 30-50: 250 mg q8h. CrCl 10-30: 250 mg q12h. CrCl <10: No data",severe:"CrCl >50: No dosage adjustment. CrCl 30-50: 250 mg q8h. CrCl 10-30: 250 mg q12h. CrCl <10: No data"},hepatic:"No data",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Probably safe with monitoring, but no data available",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Probenecid",effect:"↑ doripenem",management:"Monitor"},{drug:"Valproic acid",effect:"↓ valproic acid",management:"Avoid co-administration"}],stewardship:{preferredIndications:["Providencia sp."],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"8.1",half_life:"1",elimination:"Renal",csf_penetration:"No data",preparations:"Injection"},rawData:{drug_name:"Doripenem",tradename:"Doribax",usage_and_dosing:{general:["NOTE: Doripenem is not currently available in the United States.","Doripenem is a carbapenem with a broad spectrum of activity against aerobic and anaerobic Gram-negative bacilli.","FDA-approved for treatment of complicated intra-abdominal and complicated urinary tract infections.","Safety announcement from the FDA (2012). Trial of Doripenem for the treatment of VAP stopped early due to safety concerns. Compared to Imipenem, patients treated with Doripenem were observed to have excess mortality and poorer cure rate. NOTE: Doripenem is not approved to treat any type of pneumonia; Doripenem is not approved for doses greater than 500 mg q8h.","Doripenem has longer stability in solution than either Imipenem or Meropenem (J Antimicrob Chemother 65:1073, 2010; Clin Infect Dis 49:291, 2009).","Optimal Doripenem dosing requires longer infusion times.","For discussion of carbapenem seizure risk, see Carbapenems, Overview."],adult_dose:{complicated_intra_abdominal_or_complicated_uti:"500 mg IV q8h (1-hour infusion)",prolonged_infusion_dosing:{crcl_ge_50:"500 mg (over 4 hr) q8h",crcl_30_49:"250 mg (over 4 hr) q8h",crcl_10_29:"250 mg (over 4 hr) q12h"}},pediatric_dose:{dose_age_gt_28_days:"Safety and efficacy not established",max_day:"-"}},renal_adjustment:{half_life_normal:"1",half_life_esrd:"18",dose_renal_function_normal:"500 mg IV q8h",crcl_or_egfr:"CrCl >50: No dosage adjustment. CrCl 30-50: 250 mg q8h. CrCl 10-30: 250 mg q12h. CrCl <10: No data",hemodialysis:"No data",capd:"No data",crrt:"500 mg q8h (JAC 69:2508, 2014)",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No data",moderate_impairment_child_pugh_b:"No data",severe_impairment_child_pugh_c:"No data"},other_adjustment:["Obesity: See Obesity Dosing Adjustments page."],adverse_effects:["Most common adverse reactions (>5%): headache, nausea, diarrhea, rash, phlebitis. Seizures reported in post-marketing surveillance. Can lower serum valproic acid levels.","Cross-allergenicity: see Carbapenems, Overview and Penicillin (Beta Lactam) Allergy Overview."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Probably safe with monitoring, but no data available",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Providencia sp."],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"23 (500 mg IV, SD)",peak_urine_conc_ug_ml:"601 (500 mg IV, SD)",protein_binding_percent:"8.1",volume_of_distribution_vd_l_vss:"16.8 L (Vss)",avg_serum_half_life_hr:"1",elimination:"Renal",bile_penetration_percent:"117 (0-611)",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"36.3 (500 mg, 0-inf)"},major_drug_interactions:[{drug:"Probenecid",effect:"↑ doripenem",management:"Monitor"},{drug:"Valproic acid",effect:"↓ valproic acid",management:"Avoid co-administration"}]}},Ertapenem:{id:"Ertapenem",name:"Ertapenem",tradename:"Invanz",classification:{family:"CARBAPENEM",subclass:"Carbapenem",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Bacteroides fragilis","E. coli, extended spectrum beta lactamase producer (ESBL)","Providencia sp."],alternative:[],notes:""},dosing:{adult:{standard:"1 gm IV/IM q24h",severe:"1 gm IV/IM q24h",renal:{normal:"CrCl >30 mL/min/1.73 m²: No dosage adjustment. CrCl ≤30 mL/min/1.73 m²: 500 mg q24h",mild:"CrCl >30 mL/min/1.73 m²: No dosage adjustment. CrCl ≤30 mL/min/1.73 m²: 500 mg q24h",moderate:"CrCl >30 mL/min/1.73 m²: No dosage adjustment. CrCl ≤30 mL/min/1.73 m²: 500 mg q24h",severe:"CrCl >30 mL/min/1.73 m²: No dosage adjustment. CrCl ≤30 mL/min/1.73 m²: 500 mg q24h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Human data insufficient; nontoxic in animals. Considered safe for use in pregnant patients.",lactation:"Safe, monitor infant for GI toxicity",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Probenecid",effect:"↑ ertapenem",management:"Monitor, adjust dosage"},{drug:"Valproic acid",effect:"↓ valproic acid",management:"Avoid co-administration"}],stewardship:{preferredIndications:["Bacteroides fragilis","E. coli, extended spectrum beta lactamase producer (ESBL)","Providencia sp."],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"95",half_life:"4",elimination:"Renal",csf_penetration:"No data",preparations:"Injection"},rawData:{drug_name:"Ertapenem",tradename:"Invanz",usage_and_dosing:{general:["Ertapenem is a carbapenem with a broad spectrum of activity against aerobic and anaerobic gram-negative bacilli. Unlike the other carbapenems, ertapenem has no activity against P. aeruginosa.","Of the licensed carbapenems, ertapenem is the most susceptible to carbapenemases produced by Klebsiella species and other aerobic gram-negative bacilli.","FDA-approved for treatment of community-acquired pneumonia, complicated urinary tract infections, pelvic infections, skin/skin structure infections and prophylaxis for colorectal surgery.","An alternative antibiotic for Antibacterial Drug Resistant Genotypes.","Can be given IM or IV. Lidocaine is diluent for ertapenem IM use; ask about lidocaine allergy."],adult_dose:{usual_dose:"1 gm IV/IM q24h"},pediatric_dose:{dose_age_gt_28_days:"30 mg/kg/day (divided q12h)",max_day:"1 gm"}},renal_adjustment:{half_life_normal:"4",half_life_esrd:">4",dose_renal_function_normal:"1 gm IV q24h",crcl_or_egfr:"CrCl >30 mL/min/1.73 m²: No dosage adjustment. CrCl ≤30 mL/min/1.73 m²: 500 mg q24h",hemodialysis:"500 mg q24h (+150 mg AD if given ≤6 hr bef HD), OR 500 mg 3x/wk AD 6",capd:"500 mg q24h",crrt:"0.5-1 gm q24h",sled:"1 gm q24h 32"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["ECMO: See ECMO Drug Dosing Adjustment.","Obesity: See Obesity Dosing Adjustments."],adverse_effects:["GI: nausea/vomiting (3%), diarrhea (6%).","Increased LFTs (6%).","Headache (2%).","Hypersensitivity reactions: fever, rash, anaphylaxis. Reports of DRESS. For cross-allergenicity, see Carbapenems, Overview and Drug Allergy: Penicillins, Cephalosporins, Overview.","Positive Coombs (1%), neutropenia, eosinophilia.","Muscle weakness described.","Local phlebitis (4%). Hypersensitivity reaction to the lidocaine diluent is possible.","Neurotoxicity (e.g., seizures), especially in patients with renal impairment or predisposing conditions. Good review of 125 cases: Open Forum Infect Dis 2024;11(5):ofae214.","Visual hallucinations reported (N Zealand Med J 122:76, 2009)."],pregnancy_risk:{fda_risk_category:"Human data insufficient; nontoxic in animals. Considered safe for use in pregnant patients.",lactation:"Safe, monitor infant for GI toxicity",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Bacteroides fragilis","E. coli, extended spectrum beta lactamase producer (ESBL)","Providencia sp."],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"154 (1 gm IV, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"95",volume_of_distribution_vd_l_kg_vss:"0.12 L/kg (Vss)",avg_serum_half_life_hr:"4",elimination:"Renal",bile_penetration_percent:"10",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"572.1 (1 gm IV, 0-inf)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:["OAT1","OAT3"],ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:[{drug:"Probenecid",effect:"↑ ertapenem",management:"Monitor, adjust dosage"},{drug:"Valproic acid",effect:"↓ valproic acid",management:"Avoid co-administration"}]}},"Imipenem-cilastatin":{id:"Imipenem_cilastatin",name:"Imipenem-cilastatin",tradename:"Primaxin, Tienam",classification:{family:"CARBAPENEM",subclass:"Carbapenem",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Bacteroides fragilis","E. coli, extended spectrum beta lactamase producer (ESBL)","Nocardia sp.","Resistant (ESBL) oxytoca, pneumoniae, variicola"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:{target_500mg_q6h:"CrCl ≥90: No dosage adjustment. CrCl 60 to <90: 400 mg q6h. CrCl 30 to <60: 300 mg q6h. CrCl 15 to <30: 200 mg q6h",target_1gm_q8h:"CrCl ≥90: No dosage adjustment. CrCl 60 to <90: 500 mg q6h. CrCl 30 to <60: 500 mg q8h. CrCl 15 to <30: 500 mg q12h",target_1gm_q6h:"CrCl ≥90: No dosage adjustment. CrCl 60 to <90: 750 mg q8h. CrCl 30 to <60: 500 mg q6h. CrCl 15 to <30: 500 mg q12h"},mild:{target_500mg_q6h:"CrCl ≥90: No dosage adjustment. CrCl 60 to <90: 400 mg q6h. CrCl 30 to <60: 300 mg q6h. CrCl 15 to <30: 200 mg q6h",target_1gm_q8h:"CrCl ≥90: No dosage adjustment. CrCl 60 to <90: 500 mg q6h. CrCl 30 to <60: 500 mg q8h. CrCl 15 to <30: 500 mg q12h",target_1gm_q6h:"CrCl ≥90: No dosage adjustment. CrCl 60 to <90: 750 mg q8h. CrCl 30 to <60: 500 mg q6h. CrCl 15 to <30: 500 mg q12h"},moderate:{target_500mg_q6h:"CrCl ≥90: No dosage adjustment. CrCl 60 to <90: 400 mg q6h. CrCl 30 to <60: 300 mg q6h. CrCl 15 to <30: 200 mg q6h",target_1gm_q8h:"CrCl ≥90: No dosage adjustment. CrCl 60 to <90: 500 mg q6h. CrCl 30 to <60: 500 mg q8h. CrCl 15 to <30: 500 mg q12h",target_1gm_q6h:"CrCl ≥90: No dosage adjustment. CrCl 60 to <90: 750 mg q8h. CrCl 30 to <60: 500 mg q6h. CrCl 15 to <30: 500 mg q12h"},severe:{target_500mg_q6h:"CrCl ≥90: No dosage adjustment. CrCl 60 to <90: 400 mg q6h. CrCl 30 to <60: 300 mg q6h. CrCl 15 to <30: 200 mg q6h",target_1gm_q8h:"CrCl ≥90: No dosage adjustment. CrCl 60 to <90: 500 mg q6h. CrCl 30 to <60: 500 mg q8h. CrCl 15 to <30: 500 mg q12h",target_1gm_q6h:"CrCl ≥90: No dosage adjustment. CrCl 60 to <90: 750 mg q8h. CrCl 30 to <60: 500 mg q6h. CrCl 15 to <30: 500 mg q12h"}},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans; some evidence of maternal and fetal toxicity in animals. Considered safe for use in pregnant patients.",lactation:"Safe, monitor infant for GI toxicity",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"BCG",effect:"↓ effectiveness of BCG",management:"Avoid co-administration"},{drug:"Ganciclovir",effect:"↑ seizure risk",management:"Monitor"},{drug:"Probenecid",effect:"↑ imipenem",management:"Monitor, adjust dosage"},{drug:"Valganciclovir",effect:"↑ seizure risk",management:"Monitor"},{drug:"Valproic acid",effect:"↓ valproic acid",management:"Monitor, adjust dosage"}],stewardship:{preferredIndications:["Bacteroides fragilis","E. coli, extended spectrum beta lactamase producer (ESBL)","Nocardia sp.","Resistant (ESBL) oxytoca, pneumoniae, variicola"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"15-25",half_life:"1",elimination:"Renal",csf_penetration:"8.5",preparations:"Injection"},rawData:{drug_name:"Imipenem-cilastatin",tradename:"Primaxin, Tienam",usage_and_dosing:{general:["Imipenem-cilastatin is a carbapenem with a broad spectrum of activity that includes:","Aerobic and anaerobic gram-negative bacilli.","Aerobic gram-negative bacilli that produce extended-spectrum beta-lactamases (ESBL).","Notable absence of activity vs. MRSA, E. faecium, vancomycin-resistant enterococci, and Stenotrophomonas spp.","Cilastatin blocks enzymatic degradation of imipenem by renal dehydropeptidase on brush border of proximal convoluted tubule, decreasing risk of proximal tubule toxicity.","Wide variety of FDA-approved indications.","An alternative antibiotic for drug resistant genotypes.","Because of its relative instability in solution, imipenem-cilastatin is not suitable for outpatient prolonged infusion therapy.","For infection due to P. aeruginosa, increase dose to 3-4 gm/day (divided q6-8h). Extended infusion of carbapenems may be more efficacious (there are stability issues; see Continuous, Extended Infusion Dosing).","Allergy","For allergy considerations, see Carbapenems, Overview.","See protocol for desensitization."]},antimicrobial_stewardship:{enterobacterales_susceptibility:"The current Enterobacterales susceptibility breakpoint of ≤1 µg/mL for carbapenems significantly reduces rates of susceptibility for certain species to imipenem-cilastatin compared to other carbapenems, for which susceptibility rates are largely unaffected (Can J Infect Dis Med Microbiol 2014;25:285; J Antimicrob Chemother 2011;66:2671). The mechanism of this differential susceptibility is unknown but may be due to differences in binding affinity to target penicillin binding proteins.",affected_organisms:{proteus_spp:"100% vs. 65-85%",morganella_morganii:"100% vs. 20-40%",providencia_spp:"100% vs. 70%",serratia_spp:"99% vs. 93%"},meropenem_surrogate:"Meropenem susceptibility should not be relied upon as a surrogate to predict susceptibility to Imipenem."},adult_dose:{usual_dose:"500 mg IV q6h, OR 1 gm IV q8h",intermediate_susceptibility:"1 gm IV q6h"},pediatric_dose:{age_lt_1_wk_wt_ge_1_5_kg:"25 mg/kg q12h",age_1_wk_to_4_wks_wt_ge_1_5_kg:"25 mg/kg q8h",age_4_wks_to_3_mon_wt_ge_1_5_kg:"25 mg/kg q6h",age_ge_3_mon:"15-25 mg/kg q6h",max_day:"4 gm"},renal_adjustment:{half_life_normal:"1",half_life_esrd:"4",dose_renal_function_normal:"Variable",crcl_or_egfr:{target_500mg_q6h:"CrCl ≥90: No dosage adjustment. CrCl 60 to <90: 400 mg q6h. CrCl 30 to <60: 300 mg q6h. CrCl 15 to <30: 200 mg q6h",target_1gm_q8h:"CrCl ≥90: No dosage adjustment. CrCl 60 to <90: 500 mg q6h. CrCl 30 to <60: 500 mg q8h. CrCl 15 to <30: 500 mg q12h",target_1gm_q6h:"CrCl ≥90: No dosage adjustment. CrCl 60 to <90: 750 mg q8h. CrCl 30 to <60: 500 mg q6h. CrCl 15 to <30: 500 mg q12h"},hemodialysis:{target_500mg_q6h:"200 mg q6h (dose AD)",target_1gm_q8h:"500 mg q12h (dose AD)",target_1gm_q6h:"500 mg q12h (dose AD)"},capd:"No data",crrt:"0.5-1 gm q6h (varies w/MIC, effluent rate) 47"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["Obesity: See Obesity Dosing Adjustments.","ECMO: See ECMO Drug Dosing Adjustment."],adverse_effects:["GI (nausea, vomiting, diarrhea, C. difficile infection).","In patients who develop nausea during the infusion, the rate of infusion may be slowed.","Hypersensitivity (rash, urticaria, anaphylaxis)","Local phlebitis","Hematologic: neutropenia, eosinophilia, thrombocytopenia","Increased LFTs","Seizure risk, see Carbapenems, Overview."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans; some evidence of maternal and fetal toxicity in animals. Considered safe for use in pregnant patients.",lactation:"Safe, monitor infant for GI toxicity",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Bacteroides fragilis","E. coli, extended spectrum beta lactamase producer (ESBL)","Nocardia sp.","Resistant (ESBL) oxytoca, pneumoniae, variicola"],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"40 (500 mg IV, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"15-25",volume_of_distribution_vd_l_kg:"0.23-0.31 L/kg",avg_serum_half_life_hr:"1",elimination:"Renal",bile_penetration_percent:"Minimal",csf_blood_percent:"8.5",therapeutic_levels_in_csf:"Possibly 9",auc_ug_hr_ml:"42.2 (500 mg IV, 0-inf)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:"Imipenem: OAT1, OAT3, Cilastatin: OAT1, OAT3",ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:[{drug:"BCG",effect:"↓ effectiveness of BCG",management:"Avoid co-administration"},{drug:"Ganciclovir",effect:"↑ seizure risk",management:"Monitor"},{drug:"Probenecid",effect:"↑ imipenem",management:"Monitor, adjust dosage"},{drug:"Valganciclovir",effect:"↑ seizure risk",management:"Monitor"},{drug:"Valproic acid",effect:"↓ valproic acid",management:"Monitor, adjust dosage"}]}},"Imipenem-cilastatin-relebactam":{id:"Imipenem_cilastatin_relebactam",name:"Imipenem-cilastatin-relebactam",tradename:"Recarbrio",classification:{family:"CARBAPENEM",subclass:"Carbapenem",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Nocardia sp."],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"CrCl ≥90: No dosage adjustment. CrCl 60-89: 1 gm q6h. CrCl 30-59: 0.75 gm q6h. CrCl 15-29: 0.5 gm q6h. CrCl <15: Not recommended",mild:"CrCl ≥90: No dosage adjustment. CrCl 60-89: 1 gm q6h. CrCl 30-59: 0.75 gm q6h. CrCl 15-29: 0.5 gm q6h. CrCl <15: Not recommended",moderate:"CrCl ≥90: No dosage adjustment. CrCl 60-89: 1 gm q6h. CrCl 30-59: 0.75 gm q6h. CrCl 15-29: 0.5 gm q6h. CrCl <15: Not recommended",severe:"CrCl ≥90: No dosage adjustment. CrCl 60-89: 1 gm q6h. CrCl 30-59: 0.75 gm q6h. CrCl 15-29: 0.5 gm q6h. CrCl <15: Not recommended"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Insufficient data in humans, evidence of embryofetal toxicity in animals",lactation:"Safety not established, avoid use",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Ganciclovir",effect:"↑ seizure risk",management:"Avoid co-administration"},{drug:"Valproic acid",effect:"↓ valproic acid",management:"Avoid co-administration"}],stewardship:{preferredIndications:["Nocardia sp."],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"Imipenem: 20, Cilastatin: 40, Relebactam: 22",half_life:"Imipenem: 1, Cilastatin: 1, Relebactam: 1.2",elimination:"Renal",csf_penetration:"Imipenem: 8.5, Relebactam: no data",preparations:"Injection"},rawData:{drug_name:"Imipenem-cilastatin-relebactam",tradename:"Recarbrio",usage_and_dosing:{general:["Combination of imipenem-cilastatin, a carbapenem, with a beta-lactamase inhibitor, relebactam.","Relebactam is a diazabicyclooctane beta-lactamase inhibitor that inhibits Ambler class A enzymes (including ESBLs, KPC) and class C enzymes (AmpC). However, it is not active vs Ambler class B metallo-beta-lactamases (VIM, IMP, NDM carbapenemases) or class D (OXA) carbapenemases.","FDA approved for 3 indications:","Hospital-acquired and ventilator-associated bacterial pneumonia in adults with limited or no alternative treatment options and caused by susceptible gram-negative bacteria: Actinetobacter calcoaceticus-baumannii, E. cloacae, E. coli, H. influenzae, Klebsiella spp., P. aeruginosa, S. marcescens.","Complicated urinary tract infections in adults who have limited or no alternative treatment options, including pyelonephritis, and caused by susceptible gram-negative bacteria: E. cloacae, E. coli, Klebsiella spp., P. aeruginosa.","Complicated intra-abdominal infections in adults who have limited or no alternative treatment options, and caused by susceptible gram-negative bacteria: Bacteroides spp., C. freundii, E. cloacae, E. coli, F. nucleatum, Klebsiella spp., Parabacteroides distasonis, P. aeruginosa.","An alternative antibiotic for drug resistant genotypes.","Imipenem-cilastatin-relebactam is predictably active in vitro vs. Enterobacterales, Bacteroides spp., and P. aeruginosa including isolates that produce ESBLs, AmpC, and serine-based carbapenemases, e.g., Klebsiella pneumoniae carbapenemase (KPC).","It is predictably not active vs. MRSA, Enterococcus faecium, Stenotrophomonas maltophilia, and some Burkholderia species.","Dosage is expressed as the sum of the three components.","Review: Antimicrob Agents Chemother 2022;66:e0025622."],adult_dose:{recommended_dose:"1.25 gm IV (over 30 min) q6h x4-14 days",note:"1.25 gm = imipenem 500 mg + cilastatin 500 mg + relebactam 250 mg"},pediatric_dose:{note:"Doses are expressed as the sum of all three components",amr_gram_negative_guidance:"J Pediatric Infect Dis Soc 2025;14:piaf004",per_fda:{safety_and_efficacy:"not established",doses:{age_lt_7_days:"125 mg/kg/day (div q12h)",age_7_to_lt_28_days:"187.5 mg/kg/day (div q8h)",age_ge_28_days:"250 mg/kg/day (div q6h)"},cns_infection:"Not recommended for CNS infection",max_day:"10 gm"}}},renal_adjustment:{half_life_normal:"Imipenem: 1",half_life_esrd:"Imipenem: 4",dose_renal_function_normal:"1.25 gm IV q6h",crcl_or_egfr:"CrCl ≥90: No dosage adjustment. CrCl 60-89: 1 gm q6h. CrCl 30-59: 0.75 gm q6h. CrCl 15-29: 0.5 gm q6h. CrCl <15: Not recommended",hemodialysis:"0.5 gm q6h (AD on dialysis days)",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["ECMO: See ECMO Drug Dosing Adjustment table."],adverse_effects:["Hypersensitivity (e.g., fever, rash, anaphylaxis)","Gastrointestinal (nausea, vomiting, diarrhea, C. difficile infection)","Infusion site reactions","Hematologic (anemia, eosinophilia, neutropenia)","Headache, confusion","Increased liver function tests","Seizure risk, see Carbapenems, Overview. Increased risk if combined with valproic acid or divalproex sodium (avoid combination)."],pregnancy_risk:{fda_risk_category:"Insufficient data in humans, evidence of embryofetal toxicity in animals",lactation:"Safety not established, avoid use",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Nocardia sp."],alternative:[]},pharmacology:{pk_pd_index:"Imipenem: T>MIC, Relebactam: 24-hr AUC/MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"Imipenem: 104.3 µM, Relebactam: 64.0 µM (1.25 gm q6h, SS)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"Imipenem: 20, Cilastatin: 40, Relebactam: 22",volume_of_distribution_vd_l:"Imipenem: 24.3 L, Cilastatin 13.8 L, Relebactam 19.0 L (all Vss)",avg_serum_half_life_hr:"Imipenem: 1, Cilastatin: 1, Relebactam: 1.2",elimination:"Renal",bile_penetration_percent:"Imipenem: minimal",csf_blood_percent:"Imipenem: 8.5, Relebactam: no data",therapeutic_levels_in_csf:"No data 9",auc_ug_hr_ml:"Imipenem: 573.9 µM-hr, Relebactam: 427.3 µM-hr (SS, 0-24 h)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:"Imipenem: OAT1, OAT3, Cilastatin: OAT1, OAT3, Relebactam: OAT3, OAT4, MATE1, MATE2-K",ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:[{drug:"Ganciclovir",effect:"↑ seizure risk",management:"Avoid co-administration"},{drug:"Valproic acid",effect:"↓ valproic acid",management:"Avoid co-administration"}]}},Meropenem:{id:"Meropenem",name:"Meropenem",tradename:"Merrem",classification:{family:"CARBAPENEM",subclass:"Carbapenem",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Bacteroides fragilis","Citrobacter freundii","Citrobacter koseri, diversus","E. coli, extended spectrum beta lactamase producer (ESBL)","Providencia sp.","Pseudomonas aeruginosa","Resistant (ESBL) oxytoca, pneumoniae, variicola"],alternative:[],notes:""},dosing:{adult:{standard:"1-2 gm IV q8h",severe:"1-2 gm IV q8h",renal:{normal:"CrCl >50: No dosage adjustment. CrCl 26-50: 1 gm q12h. CrCl 10-25: 0.5 gm q12h. CrCl <10: 0.5 gm q24h",mild:"CrCl >50: No dosage adjustment. CrCl 26-50: 1 gm q12h. CrCl 10-25: 0.5 gm q12h. CrCl <10: 0.5 gm q24h",moderate:"CrCl >50: No dosage adjustment. CrCl 26-50: 1 gm q12h. CrCl 10-25: 0.5 gm q12h. CrCl <10: 0.5 gm q24h",severe:"CrCl >50: No dosage adjustment. CrCl 26-50: 1 gm q12h. CrCl 10-25: 0.5 gm q12h. CrCl <10: 0.5 gm q24h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"60 mg/kg/day (divided q8h)",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Humans: insufficient data to establish risk. Animals: no evidence of toxicity. Considered safe for use in pregnant patients.",lactation:"Probably safe with monitoring, but no data available",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"BCG",effect:"↓ effectiveness of BCG",management:"Monitor"},{drug:"Probenecid",effect:"↑ meropenem",management:"Monitor"},{drug:"Valproic acid",effect:"↓ valproic acid",management:"Avoid co-administration"}],stewardship:{preferredIndications:["Bacteroides fragilis","Citrobacter freundii","Citrobacter koseri, diversus","E. coli, extended spectrum beta lactamase producer (ESBL)","Providencia sp.","Pseudomonas aeruginosa","Resistant (ESBL) oxytoca, pneumoniae, variicola"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"2",half_life:"1",elimination:"Renal",csf_penetration:"21-39 (inflamed meninges)",preparations:"Injection"},rawData:{drug_name:"Meropenem",tradename:"Merrem",usage_and_dosing:{general:["Meropenem is a carbapenem with a broad spectrum of activity against aerobic and anaerobic gram-negative bacilli and gram-positive cocci. Activity includes aerobic gram-negative bacilli that produce extended-spectrum beta-lactamase (ESBL).","Meropenem is FDA-approved for intra-abdominal infections and complicated skin/skin structure infections in adult and pediatric patients, and bacterial meningitis in pediatric patients age ≥3 months.","Activity vs aerobic gram-negatives slightly better than imipenem, whereas activity vs staphylococci and streptococci is slightly less. Anaerobic coverage equivalent to imipenem. B. ovatus, B. distasonis are more resistant to meropenem.","An alternative antibiotic for drug-resistant genotypes.","Other uses (not FDA-approved) include Burkholderia pseudomallei (melioidosis).","Allergy","For allergy considerations, see Carbapenems, Overview","See protocol for desensitization."],adult_dose:{usual_dose:"1-2 gm IV q8h",other_dosing:"Continuous, Extended Infusion Dosing",critically_ill:"In the most critically ill, it may be necessary to increase dose to 2 gm q8h and prolong the infusion time of each dose (Antimicrob Agents Chemother 2015;59:2995).",meningitis_dosing:"up to 2 gm IV q8h. To help overcome low level of CSF penetration, infuse each dose over 4 hrs (Antimicrob Agents Chemother 2016;60:6619)."},pediatric_dose:{usual_dose:"60 mg/kg/day (divided q8h)",meningitis_cf:"120 mg/kg/day (divided q8h)",max_day:"6 gm"}},renal_adjustment:{half_life_normal:"1",half_life_esrd:"10",dose_renal_function_normal:"1 gm IV q8h",crcl_or_egfr:"CrCl >50: No dosage adjustment. CrCl 26-50: 1 gm q12h. CrCl 10-25: 0.5 gm q12h. CrCl <10: 0.5 gm q24h",hemodialysis:"0.5 gm q24h (AD on dialysis days)",capd:"0.5 gm q24h",crrt:"CVVH, CVVHD: 0.75-1 gm IV q8h 29",sled:"1 gm q8-12h 30"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["Obesity: See Obesity Dosing Adjustments.","ECMO: See ECMO Drug Dosing Adjustment."],adverse_effects:["GI (nausea, vomiting, diarrhea, C. difficile infection)","Hypersensitivity (rash, urticaria, anaphylaxis)","Local phlebitis","Hematologic: neutropenia, eosinophilia, thrombocytopenia","Increased LFTs","Seizure risk, use for valproic acid overdose: see Carbapenems, Overview"],pregnancy_risk:{fda_risk_category:"Humans: insufficient data to establish risk. Animals: no evidence of toxicity. Considered safe for use in pregnant patients.",lactation:"Probably safe with monitoring, but no data available",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Bacteroides fragilis","Citrobacter freundii","Citrobacter koseri, diversus","E. coli, extended spectrum beta lactamase producer (ESBL)","Providencia sp.","Pseudomonas aeruginosa","Resistant (ESBL) oxytoca, pneumoniae, variicola"],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"49 (1 gm IV, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"2",volume_of_distribution_vd_l_kg:"0.23-0.35 L/kg",avg_serum_half_life_hr:"1",elimination:"Renal",bile_penetration_percent:"3-300",csf_blood_percent:"21-39 (inflamed meninges)",therapeutic_levels_in_csf:"Possibly 9",auc_ug_hr_ml:"72.5 (1 gm IV, 0-inf)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:["OAT1","OAT3"],ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:[{drug:"BCG",effect:"↓ effectiveness of BCG",management:"Monitor"},{drug:"Probenecid",effect:"↑ meropenem",management:"Monitor"},{drug:"Valproic acid",effect:"↓ valproic acid",management:"Avoid co-administration"}]}},"Meropenem-vaborbactam":{id:"Meropenem_vaborbactam",name:"Meropenem-vaborbactam",tradename:"Vabomere",classification:{family:"CARBAPENEM",subclass:"Carbapenem",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"4 gm (over 3 hr) IV q8h",severe:"4 gm (over 3 hr) IV q8h",renal:{normal:"eGFR ≥50: No dosage adjustment. eGFR 30-49: 1 gm/1 gm q8h. eGFR 15-29: 1 gm/1 gm q12h. eGFR <15: 0.5 gm/0.5 gm q12h",mild:"eGFR ≥50: No dosage adjustment. eGFR 30-49: 1 gm/1 gm q8h. eGFR 15-29: 1 gm/1 gm q12h. eGFR <15: 0.5 gm/0.5 gm q12h",moderate:"eGFR ≥50: No dosage adjustment. eGFR 30-49: 1 gm/1 gm q8h. eGFR 15-29: 1 gm/1 gm q12h. eGFR <15: 0.5 gm/0.5 gm q12h",severe:"eGFR ≥50: No dosage adjustment. eGFR 30-49: 1 gm/1 gm q8h. eGFR 15-29: 1 gm/1 gm q12h. eGFR <15: 0.5 gm/0.5 gm q12h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No human data, toxic in animals",lactation:"Probably safe with monitoring, but no data available",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Valproic acid",effect:"↓ valproic acid",management:"Avoid co-administration"},{drug:"Probenecid",effect:"↑ meropenem",management:"Monitor"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"Mer 2, Vab 33",half_life:"Mer 1.22, Vab 1.68",elimination:"Renal",csf_penetration:"No data",preparations:"Injection"},rawData:{drug_name:"Meropenem-vaborbactam",tradename:"Vabomere",usage_and_dosing:{general:["A combination of meropenem + vaborbactam, a cyclic boronic acid pharmacophore ẞ-lactamase inhibitor of Ambler case A and C enzymes (but not class B [metalloenzymes] or class D enzymes).","The combination is approved for the the treatment of complicated urinary tract infections in adults (age ≥18 years) caused by E. coli, K. pneumoniae, E. cloacae, and other susceptible aerobic gram-negative bacilli.","NOTE: the combination does not increase the activity of meropenem against Acinetobacter baumannii, Pseudomonas aeruginosa, or Stenotrophomonas maltophilia.","An alternative antibiotic for drug resistant genotypes.","Vaborbactam protects meropenem from degradation by extended spectrum beta-lactamases and serine carbapenemases (except class D OXA-enzymes)","Review: Antibiotics 2023;12:1612."],adult_dose:{usual_dose:"4 gm (over 3 hr) IV q8h",note:"Note that 4 gm = Meropenem 2 gm + Vaborbactam 2 gm",compatibility:"Compatible only with normal saline. Dissolved drug is stable at room temperature for 4 hr, and at 2-6 °C for 22 hr."},pediatric_dose:{note:"Doses are expressed as the sum of meropenem + vaborbactam (1:1 ratio)",amr_gram_negative_guidance:"J Pediatric Infect Dis Soc 2025;14:piaf004",per_fda:{safety_and_efficacy:"not established"},per_amr_gram_negative_guidance:{infants_children_adolescents:{doses_infused_over_3_hr:"240 mg/kg/day (divided q8h)"},cns_infection:"Not recommended for CNS infection"},max_day:"12 gm"}},renal_adjustment:{half_life_normal:{mer:1.2,vab:1.7},half_life_esrd:{mer:10,vab:"ND"},dose_renal_function_normal:"2 gm/2 gm IV q8h",crcl_or_egfr:"eGFR ≥50: No dosage adjustment. eGFR 30-49: 1 gm/1 gm q8h. eGFR 15-29: 1 gm/1 gm q12h. eGFR <15: 0.5 gm/0.5 gm q12h",hemodialysis:"0.5 gm/0.5 gm q12h (AD)",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["Obesity: See Obesity Dosing Adjustments page."],adverse_effects:["Contraindications: known hypersensitivity reaction to meropenem or vaborbactam (or other beta-lactams)","Adverse effects:","Hypersensitivity reactions","Seizure potential","C. difficile associated diarrhea (CDAD)","Thrombocytopenia","Neuromotor impairment","Other: Phlebitis (infusion site reactions), diarrhea, headache","Risk of breakthrough seizures due to ability to decrease concentrations of valproic acid."],pregnancy_risk:{fda_risk_category:"No human data, toxic in animals",lactation:"Probably safe with monitoring, but no data available",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"Mer 43.4, Vab 55.6 (4 gm IV q8h, SS)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"Mer 2, Vab 33",volume_of_distribution_vd_l_vss:"Mer 20.2L, Vab 18.6 L (Vss)",avg_serum_half_life_hr:"Mer 1.22, Vab 1.68",elimination:"Renal",bile_penetration_percent:"No data",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"Mer 138, Vab 196 (SS, 0-8 hr)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:"Meropenem: OAT1, OAT3",ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:[{drug:"Valproic acid",effect:"↓ valproic acid",management:"Avoid co-administration"},{drug:"Probenecid",effect:"↑ meropenem",management:"Monitor"}],comments:["FDA approval based on results of a double-blind double-dummy, multicenter trial that compared meropenem-vaborbactam to piperacillin-tazobactam in adults with complicated urinary tract infections.","Clinical cure and microbiologic eradication were essentially equivalent.","Further details in the package insert."]}},Cefaclor:{id:"Cefaclor",name:"Cefaclor",tradename:"Ceclor, Ceclor CD, Raniclor",classification:{family:"CEPHALOSPORIN",subclass:"Oral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Staphylococcus saprophyticus"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"CrCl ≥10: No dosage adjustment. CrCl <10: 500 mg q12h",mild:"CrCl ≥10: No dosage adjustment. CrCl <10: 500 mg q12h",moderate:"CrCl ≥10: No dosage adjustment. CrCl <10: 500 mg q12h",severe:"CrCl ≥10: No dosage adjustment. CrCl <10: 500 mg q12h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Fexinidazole",effect:"↑ cefaclor",management:"Monitor or avoid"}],stewardship:{preferredIndications:["Staphylococcus saprophyticus"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"93 (ER no data)",protein_binding:"22-25",half_life:"0.8",elimination:"Renal",csf_penetration:"No data",preparations:"Cap (250, 500 mg), Extended-release (ER) tab (500 mg), Chewtab (125, 187, 250, 375 mg), Oral susp (125 mg/5 mL, 187 mg/5 mL, 250 mg/5 mL, 375 mg/5 mL)"},rawData:{drug_name:"Cefaclor",tradename:"Ceclor, Ceclor CD, Raniclor",usage_and_dosing:{general:["Cefaclor is an oral 2nd generation cephalosporin with in vitro activity against Strep. pyogenes, Strep. pneumoniae, H. influenzae, and Moraxella and is primarily used in the treatment of respiratory tract infections.","FDA approved for acute bacterial exacerbations of chronic bronchitis, lower respiratory infections, otitis media, secondary bacterial infections of acute bronchitis, uncomplicated skin and skin structure infections, UTI","Main adverse effects are allergy. For class-wide adverse effects, see Cephalosporins, Overview.","Cefaclor is available in regular and extended release tablets.","Serum sickness-like reaction 0.1-0.5% — arthralgia, rash, erythema multiforme but no adenopathy, proteinuria or demonstrable immune complexes. Appears due to mixture of drug biotransformation and genetic susceptibility (J Pediatr 125:805, 1994).","Cefaclor has the same R1 side chain as Ampicillin and Cephalexin; thus increased risk of allergic reaction in patients allergic to those drugs."],adult_dose:{usual_dose_regular_strength:"250-500 mg po q8h",usual_dose_extended_release:"500 mg po q12h"},pediatric_dose:{dose_age_gt_28_days:"20-40 mg/kg/day (divided q8-12h)",max_day:"1 gm"}},renal_adjustment:{half_life_normal:"0.8",half_life_esrd:"3",dose_renal_function_normal:"500 mg po q8h",crcl_or_egfr:"CrCl ≥10: No dosage adjustment. CrCl <10: 500 mg q12h",hemodialysis:"500 mg q12h (give one of the dialysis day doses AD)",capd:"500 mg q12h",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["Hypersensitivity (2%), fever, rash (1%), anaphylaxis (rare), serum sickness (≤0.5%), positive Coombs (rare), neutropenia, thrombocytopenia (2%), GI (3%), nausea/vomiting (2%), diarrhea (1-4%), C. difficile colitis, increased LFTs (3%), increased BUN/Creatinine.","See also, Usage and class-wide adverse effects, Cephalosporins, Overview."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Staphylococcus saprophyticus"],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Cap (250, 500 mg), Extended-release (ER) tab (500 mg), Chewtab (125, 187, 250, 375 mg), Oral susp (125 mg/5 mL, 187 mg/5 mL, 250 mg/5 mL, 375 mg/5 mL)",food_recommendation:"Cap/chewtab/susp ± food, ER tab + food",oral_absorption_percent:"93 (ER no data)",tmax_hr:"Cap/chewtab/susp 0.5-1.0, ER tab 2.5",peak_serum_conc_ug_ml:"13 (500 mg po, SD), 8.4 (500 mg ER po, SD)",peak_urine_conc_ug_ml:"900 (500 mg po, SD)",protein_binding_percent:"22-25",volume_of_distribution_vd_l_kg_vf:"0.33 L/kg (V/F)",avg_serum_half_life_hr:"0.8",elimination:"Renal",bile_penetration_percent:">60",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"20.5 (500 mg po, 0-inf)"},major_drug_interactions:[{drug:"Fexinidazole",effect:"↑ cefaclor",management:"Monitor or avoid"}]}},Cefadroxil:{id:"Cefadroxil",name:"Cefadroxil",tradename:"Duricef",classification:{family:"CEPHALOSPORIN",subclass:"Oral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Staphylococcus saprophyticus"],alternative:[],notes:""},dosing:{adult:{standard:"500-1000 mg po q12h",severe:"500-1000 mg po q12h",renal:{normal:"CrCl >50: No dosage adjustment. CrCl 10-50: 1 gm, then 500 mg q12-24h. CrCl <10: 1 gm, then 500 mg q36h",mild:"CrCl >50: No dosage adjustment. CrCl 10-50: 1 gm, then 500 mg q12-24h. CrCl <10: 1 gm, then 500 mg q36h",moderate:"CrCl >50: No dosage adjustment. CrCl 10-50: 1 gm, then 500 mg q12-24h. CrCl <10: 1 gm, then 500 mg q36h",severe:"CrCl >50: No dosage adjustment. CrCl 10-50: 1 gm, then 500 mg q12-24h. CrCl <10: 1 gm, then 500 mg q36h"},hepatic:"No data",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Probenecid",effect:"↑ cefadroxil",management:"Monitor, adjust dosage"}],stewardship:{preferredIndications:["Staphylococcus saprophyticus"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"90",protein_binding:"20",half_life:"1.5",elimination:"Renal",csf_penetration:"No data",preparations:"Cap (500 mg), Tab (1 gm), Oral susp (250 mg/5 mL, 500 mg/5 mL)"},rawData:{drug_name:"Cefadroxil",tradename:"Duricef",usage_and_dosing:{general:["Cefadroxil is a 1st generation oral cephalosporin with in vitro activity against streptococci, MSSA, E. coli, P. mirabilis, Klebsiella sp. Activity against Penicillin-resistant Strep. pneumoniae is poor.","Longer serum half-life than Cephalexin. Same R1 side chain as Amoxicillin and Cefprozil, thus risk of cross-allergenicity if given to patients allergic to those drugs.","For class-wide adverse effects, see Cephalosporins, Overview."],adult_dose:{usual_dose:"500-1000 mg po q12h"},pediatric_dose:{dose_age_gt_28_days:"30 mg/kg/day (divided q12h)",max_day:"2 gm"}},renal_adjustment:{half_life_normal:"1.5",half_life_esrd:"20",dose_renal_function_normal:"1 gm po q12h",crcl_or_egfr:"CrCl >50: No dosage adjustment. CrCl 10-50: 1 gm, then 500 mg q12-24h. CrCl <10: 1 gm, then 500 mg q36h",hemodialysis:"1 gm, then 1 gm AD",capd:"500 mg q24h",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No data",moderate_impairment_child_pugh_b:"No data",severe_impairment_child_pugh_c:"No data"},adverse_effects:["Rash, serum sickness, neutropenia, C. difficile colitis, increased LFTs."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Staphylococcus saprophyticus"],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Cap (500 mg), Tab (1 gm), Oral susp (250 mg/5 mL, 500 mg/5 mL)",food_recommendation:"All preps ± food",oral_absorption_percent:"90",tmax_hr:"No data",peak_serum_conc_ug_ml:"16 (500 mg po, SD)",peak_urine_conc_ug_ml:"1800 (500 mg po, SD)",protein_binding_percent:"20",volume_of_distribution_vd_l_kg_vf:"0.305 L/kg (V/F)",avg_serum_half_life_hr:"1.5",elimination:"Renal",bile_penetration_percent:"22",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"47.4 (500 mg po, 0-inf)"},major_drug_interactions:[{drug:"Probenecid",effect:"↑ cefadroxil",management:"Monitor, adjust dosage"}]}},Cefdinir:{id:"Cefdinir",name:"Cefdinir",tradename:"Omnicef",classification:{family:"CEPHALOSPORIN",subclass:"Oral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"300 mg po q12h or 600 mg po q24h",severe:"300 mg po q12h or 600 mg po q24h",renal:{normal:"CrCl ≥30: No dosage adjustment. CrCl <30: 300 mg q24h",mild:"CrCl ≥30: No dosage adjustment. CrCl <30: 300 mg q24h",moderate:"CrCl ≥30: No dosage adjustment. CrCl <30: 300 mg q24h",severe:"CrCl ≥30: No dosage adjustment. CrCl <30: 300 mg q24h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"No data, but adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Antacids (Al, Mg)",effect:"↓ cefdinir",management:"Stagger dosing by 2 hours"},{drug:"Iron supplements",effect:"↓ cefdinir",management:"Stagger dosing by 2 hours"},{drug:"Probenecid",effect:"↑ cefdinir",management:"Monitor"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"Caps 16-21, Susp 25",protein_binding:"60-70",half_life:"1.7",elimination:"Renal",csf_penetration:"No data",preparations:"Cap (300 mg), Oral susp (125 mg/5 mL, 250 mg/5 mL)"},rawData:{drug_name:"Cefdinir",tradename:"Omnicef",drug_shortage:[{preparation:"All oral formulations",start_date:"2023-06-30",notes:""}],usage_and_dosing:{general:["Cefdinir is an oral 3rd generation cephalosporin with enhanced activity against aerobic gram-negative bacilli, e.g., E. coli, Klebsiella sp., and P. mirabilis, as well as some oral anaerobic bacteria.","Rendered inactive by extended spectrum beta-lactamases (ESBLs).","Not active vs. P. aeruginosa.","Used in treatment of pharyngitis, sinusitis, otitis media and uncomplicated skin and skin structure infections; off-label use for UTI in absence of alternative (Clin Infect Dis 52(5): e103; 2011).","Perspective on the use of cefdinir for common infections: J Hosp Med 2024 June 2 [ahead of print].","For cross-allergenicity and other class-wide adverse effects, see Cephalosporins, Overview."],adult_dose:{usual_dose:"300 mg po q12h or 600 mg po q24h"},pediatric_dose:{dose_age_gt_28_days:"14 mg/kg/day (divided q12-24h)",max_day:"-"}},renal_adjustment:{half_life_normal:"1.7",half_life_esrd:"16",dose_renal_function_normal:"300 mg po q12h",crcl_or_egfr:"CrCl ≥30: No dosage adjustment. CrCl <30: 300 mg q24h",hemodialysis:"300 mg q48h (AD on dialysis days)",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["Treatment stopped due to adverse effects (3%), rash (rare), neutropenia (rare), eosinophilia (rare), GI (3%), diarrhea (15%), C. difficile colitis, increased LFTs (1%), increased BUN/Creatinine (rare), headache (2%).","Cefdinir-associated red stools in up to 1% of patients. Occurs if co-administered with iron-fortified infant formula or iron supplement. Thought to be due to cefdinir or metabolites combining with iron to form a nonabsorbable reddish precipitant. OK to continue cefdinir with adequate patient reassurance (Pediatr Emerg Care 2021;37:e421).","For cross-allergenicity and other class-wide adverse effects, see Cephalosporins, Overview."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"No data, but adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Cap (300 mg), Oral susp (125 mg/5 mL, 250 mg/5 mL)",food_recommendation:"All preps ± food",oral_absorption_percent:"Caps 16-21, Susp 25",tmax_hr:"2-4",peak_serum_conc_ug_ml:"1.6 (300 mg po, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"60-70",volume_of_distribution_vd_l_kg_vf:"0.35 L/kg (V/F)",avg_serum_half_life_hr:"1.7",elimination:"Renal",bile_penetration_percent:"No data",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"7.1 (300 mg po, 0-inf)"},major_drug_interactions:[{drug:"Antacids (Al, Mg)",effect:"↓ cefdinir",management:"Stagger dosing by 2 hours"},{drug:"Iron supplements",effect:"↓ cefdinir",management:"Stagger dosing by 2 hours"},{drug:"Probenecid",effect:"↑ cefdinir",management:"Monitor"}]}},"Cefditoren pivoxil":{id:"Cefditoren_pivoxil",name:"Cefditoren pivoxil",tradename:"Spectracef",classification:{family:"CEPHALOSPORIN",subclass:"Oral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"400 mg po bid",severe:"400 mg po bid",renal:{normal:"CrCl >50: No dosage adjustment. CrCl 10-50: 200 mg q12h. CrCl <10: 200 mg 24h",mild:"CrCl >50: No dosage adjustment. CrCl 10-50: 200 mg q12h. CrCl <10: 200 mg 24h",moderate:"CrCl >50: No dosage adjustment. CrCl 10-50: 200 mg q12h. CrCl <10: 200 mg 24h",severe:"CrCl >50: No dosage adjustment. CrCl 10-50: 200 mg q12h. CrCl <10: 200 mg 24h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"No data, but adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"16",protein_binding:"88",half_life:"1.6",elimination:"Renal",csf_penetration:"No data",preparations:"Tab (200, 400 mg)"},rawData:{drug_name:"Cefditoren pivoxil",tradename:"Spectracef",usage_and_dosing:{general:["Cefditoren pivoxil is a 3rd generation cephalosporin active in vitro against M. catarrhalis, streptococci and H. influenzae. It is more active than 1st generation or 2nd generation cephalosporins against E. coli, P. mirabilis, and Klebsiella sp.","Used in the treatment of respiratory infections and skin and skin structure infections.","Cefditoren pivoxil is an ester prodrug, hydrolyzed by esterases as it is absorbed to form cefditoren and pivalate. Pivalate absorbed (70%) & becomes pivaloylcarnitine which is renally excreted; 39–63%↓ in serum carnitine concentrations. Carnitine involved in fatty acid (FA) metabolism & FA transport into mitochondria. Effect potentially reversible. See Adverse Effects.","Also contains caseinate (milk protein); avoid if milk allergy (not same as lactose intolerance). Need gastric acid for optimal absorption.","Where available. No longer marketed in US."],adult_dose:{usual_dose:"400 mg po bid"},pediatric_dose:{dose_age_gt_12_yrs:"200-400 mg q12h",max_day:"-"}},renal_adjustment:{half_life_normal:"1.6",half_life_esrd:"5",dose_renal_function_normal:"400 mg po q12h",crcl_or_egfr:"CrCl >50: No dosage adjustment. CrCl 10-50: 200 mg q12h. CrCl <10: 200 mg 24h",hemodialysis:"200 mg q24h (dose AD on dialysis days)",capd:"200 mg q24h",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["Treatment stopped due to adverse effects (2%), fever (rare), rash (rare), positive Coombs (rare), neutropenia (rare), eosinophilia (rare), nausea (6%), vomiting (1%), diarrhea (1.4%), C. difficile colitis, increased LFTs (rare), increased BUN/Creatinine (rare), headache (2%).","Encephalopathy associated with decreased carnitine levels reported (Pediatrics 120:e739, 2007; Neurol Sci 33:1393, 2012). Contraindicated in those with carnitine deficiency or those with inborn errors of metabolism that might result in clinically significant carnitine deficiency.","Cefditoren has the same R1 side chain as cefotaxime, cefpodoxime, cefpirome, ceftizoxime, ceftriaxone, and cefepime. Cross-allergenicity may occur.","For class-wide adverse effects, see Cephalosporins, Overview."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"No data, but adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Tab (200, 400 mg)",food_recommendation:"Tab + food",oral_absorption_percent:"16",tmax_hr:"1.5-3.0",peak_serum_conc_ug_ml:"4 (400 mg po, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"88",volume_of_distribution_vd_l_vss_f:"9.3 L (Vss/F)",avg_serum_half_life_hr:"1.6",elimination:"Renal",bile_penetration_percent:"No data",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"20 (400 mg po, 0-inf)"},major_drug_interactions:["No significant interactions"]}},Cefixime:{id:"Cefixime",name:"Cefixime",tradename:"Suprax",classification:{family:"CEPHALOSPORIN",subclass:"Oral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"400 mg po q24h",severe:"400 mg po q24h",renal:{normal:"CrCl ≥60: No dosage adjustment. CrCl 21-60: 260 mg q24h (use susp). CrCl ≤20: 200 mg q24h",mild:"CrCl ≥60: No dosage adjustment. CrCl 21-60: 260 mg q24h (use susp). CrCl ≤20: 200 mg q24h",moderate:"CrCl ≥60: No dosage adjustment. CrCl 21-60: 260 mg q24h (use susp). CrCl ≤20: 200 mg q24h",severe:"CrCl ≥60: No dosage adjustment. CrCl 21-60: 260 mg q24h (use susp). CrCl ≤20: 200 mg q24h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"50",protein_binding:"65",half_life:"3",elimination:"Renal, biliary",csf_penetration:"No data",preparations:"Cap (400 mg), Chewtab (100, 200 mg), Oral susp (100 mg/5 mL, 200 mg/5 mL, 500 mg/5 mL)"},rawData:{drug_name:"Cefixime",tradename:"Suprax",usage_and_dosing:{general:["Cefixime is a 3rd generation oral cephalosporin with activity against respiratory tract pathogens: streptococci, M. catarrhalis, H. influenzae. Little activity against Staph. aureus, good activity against N. gonorrhoeae, but increasing prevalence of isolates with decreased susceptibility noted.","For Penicillin cross-allergenicity and other class-wide adverse effects, see Cephalosporins, Overview."],adult_dose:{usual_dose:"400 mg po q24h",see_also:["Gonorrhea: Disseminated Gonococcal Infection","Gonorrhea: Urethritis, Cervicitis, Proctitis","Sexual Exposure, Antibacterial Prophylaxis"]},pediatric_dose:{dose_age_gt_28_days:"8 mg/kg/day (divided q12-24h)",max_day:"-"}},renal_adjustment:{half_life_normal:"3",half_life_esrd:"12",dose_renal_function_normal:"400 mg po q24h",crcl_or_egfr:"CrCl ≥60: No dosage adjustment. CrCl 21-60: 260 mg q24h (use susp). CrCl ≤20: 200 mg q24h",hemodialysis:"260 mg q24h (use susp) (dose AD on dialysis days)",capd:"200 mg q24h",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["Rash (1%), neutropenia (rare), eosinophilia (rare), thrombocytopenia (rare), GI (13%), nausea/vomiting (7%), diarrhea (16%), C. difficile colitis, increased LFTs (rare), increased BUN/Creatinine.","For Penicillin cross-allergenicity and other class-wide adverse effects, see Cephalosporins, Overview."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Cap (400 mg), Chewtab (100, 200 mg), Oral susp (100 mg/5 mL, 200 mg/5 mL, 500 mg/5 mL)",food_recommendation:"All preps ± food",oral_absorption_percent:"50",tmax_hr:"4",peak_serum_conc_ug_ml:"3-5 (400 mg po, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"65",volume_of_distribution_vd_l_kg_vf:"0.93 L/kg (V/F)",avg_serum_half_life_hr:"3",elimination:"Renal, biliary",bile_penetration_percent:"800",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"25.8 (400 mg po, 0-inf)"},major_drug_interactions:["No significant interactions"],comments:["For details on treatment of gonococcal infections see 2020 CDC Guidelines (MMWR 2020;69:1911).","Oral cephalosporins are not recommended as a first-line treatment for gonococcal infections because of decreasing susceptibility (MMWR 61:590, 2012). If Cefixime must be used, patient must be checked for test of cure."]}},"Cefpodoxime proxetil":{id:"Cefpodoxime_proxetil",name:"Cefpodoxime proxetil",tradename:"Vantin",classification:{family:"CEPHALOSPORIN",subclass:"Oral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"CrCl ≥10: No dosage adjustment. CrCl <10: 200 mg q24h",mild:"CrCl ≥10: No dosage adjustment. CrCl <10: 200 mg q24h",moderate:"CrCl ≥10: No dosage adjustment. CrCl <10: 200 mg q24h",severe:"CrCl ≥10: No dosage adjustment. CrCl <10: 200 mg q24h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"46",protein_binding:"40",half_life:"2.5",elimination:"Renal",csf_penetration:"No data",preparations:"Tab (100, 200 mg), oral susp (50 mg/5 mL, 100 mg/5 mL)"},rawData:{drug_name:"Cefpodoxime proxetil",tradename:"Vantin",usage_and_dosing:{general:["Cefpodoxime proxetil is a 3rd generation oral cephalosporin with activity against upper respiratory tract pathogens (e.g., Strep. pneumoniae, M. catarrhalis, S. pyogenes, H. influenzae), MSSA, E. coli, P. mirabilis and K. pneumoniae.","For class-wide adverse effects, see Cephalosporins, Overview."],adult_dose:{pharyngitis:"100 mg po q12h x 5-10 days",aecb:"200 mg po q12h x 10 days",gonorrhea_cervical_urethral_rectal:"200 mg po x 1 dose",pneumonia:"200 mg po q12h x 14 days",sinusitis:"200mg q12h x 5-7 days",absssi:"400mg poq12h x 7-14 days"},pediatric_dose:{dose_age_gt_28_days:"10 mg/kg/day (divided q12h)",max_day:"400 mg"}},renal_adjustment:{half_life_normal:"2.3",half_life_esrd:"10",dose_renal_function_normal:"200 mg po q12h",crcl_or_egfr:"CrCl ≥10: No dosage adjustment. CrCl <10: 200 mg q24h",hemodialysis:"200 mg q24h (dose AD on dialysis days)",capd:"200 mg q24h",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["Treatment stopped due to adverse effects (2.7), fever (rare), rash (1%), anaphylaxis (rare), neutropenia (rare), eosinophilia (3%), thrombocytopenia (rare), nausea/vomiting (4%), diarrhea (7%), C. difficile colitis, increased LFTs (4%), increased BUN/Creatinine (4%), headache (1%).","There are rare reports of acute liver injury, bloody diarrhea, pulmonary infiltrates with eosinophilia.","Cefpodoxime has the same R1 side chain as cefotaxime, cefpirome, cefditoren, ceftizoxime, ceftriaxone, and cefepime. Cross-allergenicity may occur.","For class-wide adverse effects, see Cephalosporins, Overview. See also Penicillin (Beta-Lactam) Allergy Overview."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Tab (100, 200 mg), oral susp (50 mg/5 mL, 100 mg/5 mL)",food_recommendation:"Tab + food, Susp ± food",oral_absorption_percent:"46",tmax_hr:"2-3",peak_serum_conc_ug_ml:"2.3 (200 mg po, SD)",peak_urine_conc_ug_ml:"49-196 (50-800 mg po, SD; IJAA 1994;4:37)",protein_binding_percent:"40",volume_of_distribution_vd_l_kg_vf:"0.7 L/kg (V/F)",avg_serum_half_life_hr:"2.5",elimination:"Renal",bile_penetration_percent:"115",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"14.5 (200 mg po, 0-inf)"},major_drug_interactions:["Concomitant administration of H2-antagonists reduces Cmax by approximately 33% and AUC by 28%. The clinical significance of these data is unclear (Clin Pharmacol Ther 46:674, 1989)."],comments:["None"]}},Cefprozil:{id:"Cefprozil",name:"Cefprozil",tradename:"Cefzil",classification:{family:"CEPHALOSPORIN",subclass:"Oral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"250-500 mg po q12h",severe:"250-500 mg po q12h",renal:{normal:"CrCl >50: No dosage adjustment. CrCl 10-50: 500 mg q24h. CrCl <10: 250 mg q12h",mild:"CrCl >50: No dosage adjustment. CrCl 10-50: 500 mg q24h. CrCl <10: 250 mg q12h",moderate:"CrCl >50: No dosage adjustment. CrCl 10-50: 500 mg q24h. CrCl <10: 250 mg q12h",severe:"CrCl >50: No dosage adjustment. CrCl 10-50: 500 mg q24h. CrCl <10: 250 mg q12h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"95",protein_binding:"36",half_life:"1.5",elimination:"Renal",csf_penetration:"No data",preparations:"Tab (250, 500 mg), oral susp (125 mg/5 mL, 250 mg/5 mL)"},rawData:{drug_name:"Cefprozil",tradename:"Cefzil",usage_and_dosing:{general:["Cefprozil is a 2nd-generation oral cephalosporin with better activity against H. influenzae than 1st generation oral cephalosporins.","FDA approved for acute bacterial exacerbations of chronic bronchitis, otitis media, pharyngitis/tonsillitis and skin and skin structure infections","Amoxicillin and Cefadroxil share the same R1 side chain, hence cross-allergenicity may occur.","For class-wide adverse effects, see Cephalosporins, Overview."],adult_dose:{usual_dose:"250-500 mg po q12h"},pediatric_dose:{dose_age_gt_28_days:"15-30 mg/kg/day (divided q12h) (use 30 for AOM)",max_day:"-"}},renal_adjustment:{half_life_normal:"1.5",half_life_esrd:"5-6",dose_renal_function_normal:"500 mg po q12h",crcl_or_egfr:"CrCl >50: No dosage adjustment. CrCl 10-50: 500 mg q24h. CrCl <10: 250 mg q12h",hemodialysis:"250 mg q12h (give one of the dialysis day doses AD)",capd:"250 mg q24h",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["Treatment stopped due to adverse effects (2%), fever, rash (1%), neutropenia (rare), eosinophilia (2%), thrombocytopenia, nausea/vomiting (4%), diarrhea (3), C. difficile colitis, increased LFTs (2%), increased BUN/Creatinine (rare), confusion (rare).","For cross-allergenicity and other class-wide adverse effects, see Cephalosporins, Overview."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Tab (250, 500 mg), oral susp (125 mg/5 mL, 250 mg/5 mL)",food_recommendation:"All preps ± food",oral_absorption_percent:"95",tmax_hr:"1.5",peak_serum_conc_ug_ml:"10.5 (500 mg po, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"36",volume_of_distribution_vd_l_kg_vss_f:"0.23 L/kg (Vss/F)",avg_serum_half_life_hr:"1.5",elimination:"Renal",bile_penetration_percent:"No data",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"25.7 (500 mg po, 0-inf)"},major_drug_interactions:["No significant interactions"],comments:[]}},Ceftibuten:{id:"Ceftibuten",name:"Ceftibuten",tradename:"Cedax",classification:{family:"CEPHALOSPORIN",subclass:"Oral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"400 mg po q24h",severe:"400 mg po q24h",renal:{normal:"CrCl >50: No dosage adjustment. CrCl 10-50: 200 mg q24h. CrCl <10: 100 mg q24h",mild:"CrCl >50: No dosage adjustment. CrCl 10-50: 200 mg q24h. CrCl <10: 100 mg q24h",moderate:"CrCl >50: No dosage adjustment. CrCl 10-50: 200 mg q24h. CrCl <10: 100 mg q24h",severe:"CrCl >50: No dosage adjustment. CrCl 10-50: 200 mg q24h. CrCl <10: 100 mg q24h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"80",protein_binding:"65",half_life:"2.5",elimination:"Renal",csf_penetration:"No data",preparations:"Cap (400 mg), oral susp (90 mg/5 mL, 180 mg/5 mL)"},rawData:{drug_name:"Ceftibuten",tradename:"Cedax",usage_and_dosing:{general:["Ceftibuten is a 3rd-generation oral cephalosporin used to treat AECB, otitis media and Streptococcus pyogenes tonsillitis/pharyngitis. It has poor activity against staphylococci and is only active against penicillin-susceptible strains of Strep. pneumoniae.","Where available. No longer marketed in the U.S.","For Penicillin cross-allergenicity and other class-wide adverse effects, see Cephalosporins, Overview. See also Penicillin (Beta Lactam) Allergy Overview."],adult_dose:{usual_dose:"400 mg po q24h"},pediatric_dose:{dose_age_gt_28_days:"9 mg/kg/day (divided q12-24h)",max_day:"1 gm"}},renal_adjustment:{half_life_normal:"2.5",half_life_esrd:"13",dose_renal_function_normal:"400 mg po q24h",crcl_or_egfr:"CrCl >50: No dosage adjustment. CrCl 10-50: 200 mg q24h. CrCl <10: 100 mg q24h",hemodialysis:"100 mg q24h (dose AD on dialysis days)",capd:"100 mg po q24h",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["Treatment stopped due to adverse effects (2%), rash (rare), eosinophilia (5%), thrombocytopenia (rare), GI (6%), nausea/vomiting (2%), diarrhea (3%), C. difficile colitis, increased LFTs (rare), increased BUN/Creatinine (rare), headache (rare).","For class-wide adverse effects, see Cephalosporins, Overview."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Cap (400 mg), oral susp (90 mg/5 mL, 180 mg/5 mL)",food_recommendation:"All preps no food",oral_absorption_percent:"80",tmax_hr:"2.6",peak_serum_conc_ug_ml:"15 (400 mg po, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"65",volume_of_distribution_vd_l_kg_vf:"0.21 L/kg (V/F)",avg_serum_half_life_hr:"2.5",elimination:"Renal",bile_penetration_percent:"No data",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"73.7 (400 mg po, 0-inf)"},major_drug_interactions:["No significant interactions"]}},"Cefuroxime axetil":{id:"Cefuroxime_axetil",name:"Cefuroxime axetil",tradename:"Ceftin, Zinacef",classification:{family:"CEPHALOSPORIN",subclass:"Oral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Borrelia burgdorferi"],alternative:[],notes:""},dosing:{adult:{standard:"250-500 mg po q12h",severe:"250-500 mg po q12h",renal:{normal:"CrCl ≥30: No dosage adjustment. CrCl 10-29: 250-500 mg q24h. CrCl <10: 250-500 mg q48h",mild:"CrCl ≥30: No dosage adjustment. CrCl 10-29: 250-500 mg q24h. CrCl <10: 250-500 mg q48h",moderate:"CrCl ≥30: No dosage adjustment. CrCl 10-29: 250-500 mg q24h. CrCl <10: 250-500 mg q48h",severe:"CrCl ≥30: No dosage adjustment. CrCl 10-29: 250-500 mg q24h. CrCl <10: 250-500 mg q48h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Antacids",effect:"↓ cefuroxime",management:"Stagger administration"},{drug:"H2-antagonists",effect:"↓ cefuroxime",management:"Avoid co-administration"},{drug:"Oral contraceptives",effect:"↓ efficacy of oral contraceptives",management:"Use non-hormonal method"},{drug:"Probenecid",effect:"↑ cefuroxime",management:"Avoid co-administration"},{drug:"Proton pump inhibitors",effect:"↓ cefuroxime",management:"Avoid co-administration"}],stewardship:{preferredIndications:["Borrelia burgdorferi"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"52",protein_binding:"50",half_life:"1.5",elimination:"Renal",csf_penetration:"No data",preparations:"Tab (250, 500 mg), Oral susp (125 mg/5 mL, 250 mg/5 mL) (oral susp not available in US)"},rawData:{drug_name:"Cefuroxime axetil",tradename:"Ceftin, Zinacef",usage_and_dosing:{general:["Cefuroxime axetil is a second generation oral cephalosporin with enhanced activity against H. influenzae (as compared to 1st generation oral cephalosporins). It retains activity against MSSA, Penicillin-sensitive Strep. pneumoniae, E. coli, P. mirabilis and Klebsiella sp.","Cefuroxime axetil is used to treat bacterial bronchitis, Strep. pyogenes skin infections, Lyme disease and other infections.","For class-wide adverse effects, see Cephalosporins, Overview.","For parenteral form of drug, see Cefuroxime.","NOTE: Suspension formulation not available in the US. May be available in other markets."],adult_dose:{usual_dose:"250-500 mg po q12h",note:"tablets and oral suspension are not bioequivalent. Do not substitute on a mg/mg basis."},pediatric_dose:{pharyngitis:"20 mg/kg/day (div q12h)",aom_abs_impetigo:"30 mg/kg/day (div q12h)",max_day:"1 gm"}},renal_adjustment:{half_life_normal:"1.5",half_life_esrd:"17",dose_renal_function_normal:"250-500 mg po q12h",crcl_or_egfr:"CrCl ≥30: No dosage adjustment. CrCl 10-29: 250-500 mg q24h. CrCl <10: 250-500 mg q48h",hemodialysis:"250-500 mg q48h (give extra 250-500 mg AD)",capd:"250-500 mg q24h",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["Treatment stopped due to adverse effects (2.2%), fever (rare), rash (rare), anaphylaxis (rare), positive Coombs (rare), eosinophilia (1%), nausea/vomiting (3%), diarrhea (4-11%-duration dependent), C. difficile colitis, ↑ LFTs (2%), headache (rare).","For Penicillin cross-allergenicity and other class-wide adverse effects, see Cephalosporins, Overview."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Borrelia burgdorferi"],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Tab (250, 500 mg), Oral susp (125 mg/5 mL, 250 mg/5 mL) (oral susp not available in US)",food_recommendation:"Susp + food, Tab ± food",oral_absorption_percent:"52",tmax_hr:"2.5",peak_serum_conc_ug_ml:"4.1 (250 mg po, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"50",volume_of_distribution_vd_l_kg_vf:"0.66 L/kg (V/F)",avg_serum_half_life_hr:"1.5",elimination:"Renal",bile_penetration_percent:"35-80",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"12.9 (250 mg po, 0-inf)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:["OAT1","OAT3"],ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:[{drug:"Antacids",effect:"↓ cefuroxime",management:"Stagger administration"},{drug:"H2-antagonists",effect:"↓ cefuroxime",management:"Avoid co-administration"},{drug:"Oral contraceptives",effect:"↓ efficacy of oral contraceptives",management:"Use non-hormonal method"},{drug:"Probenecid",effect:"↑ cefuroxime",management:"Avoid co-administration"},{drug:"Proton pump inhibitors",effect:"↓ cefuroxime",management:"Avoid co-administration"}]}},Cephalexin:{id:"Cephalexin",name:"Cephalexin",tradename:"Keflex, Keftab",classification:{family:"CEPHALOSPORIN",subclass:"Oral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Staphylococcus saprophyticus"],alternative:[],notes:""},dosing:{adult:{standard:"250-1000 mg po q6h (max 4 gm/day)",severe:"250-1000 mg po q6h (max 4 gm/day)",renal:{normal:"CrCl >50: No dosage adjustment. CrCl 10-50: 250-1000 mg q8-12h. CrCl <10: 250-1000 mg q24-48h",mild:"CrCl >50: No dosage adjustment. CrCl 10-50: 250-1000 mg q8-12h. CrCl <10: 250-1000 mg q24-48h",moderate:"CrCl >50: No dosage adjustment. CrCl 10-50: 250-1000 mg q8-12h. CrCl <10: 250-1000 mg q24-48h",severe:"CrCl >50: No dosage adjustment. CrCl 10-50: 250-1000 mg q8-12h. CrCl <10: 250-1000 mg q24-48h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Metformin",effect:"↑ metformin",management:"Monitor, adjust dosage"},{drug:"Probenecid",effect:"↑ cephalexin",management:"Monitor, adjust dosage"}],stewardship:{preferredIndications:["Staphylococcus saprophyticus"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"90",protein_binding:"5-15",half_life:"1",elimination:"Renal",csf_penetration:"No data",preparations:"Cap (250, 500, 750 mg), Tab (250, 500 mg), Oral susp (125 mg/5 mL, 250 mg/5 mL)"},rawData:{drug_name:"Cephalexin",tradename:"Keflex, Keftab",usage_and_dosing:{general:["Cephalexin, FDA-approved in 1971, is a 1st generation oral cephalosporin with in vitro activity against streptococci, MSSA, E. coli, Klebsiella sp., and P. mirabilis.","Can cause false-negative urine dipstick test for leukocytes (Am Fam Phys 2005;71:1153)."],adult_dose:{usual_dose:"250-1000 mg po q6h (max 4 gm/day)"},pediatric_dose:{dose_age_gt_28_days:"25-100 mg/kg/day (divided q6h)",max_day:"4 gm"}},renal_adjustment:{half_life_normal:"0.5-1.2",half_life_esrd:"5-30",dose_renal_function_normal:"250-1000 mg po q6h",crcl_or_egfr:"CrCl >50: No dosage adjustment. CrCl 10-50: 250-1000 mg q8-12h. CrCl <10: 250-1000 mg q24-48h",hemodialysis:"250-500 mg q12-24h (give AD on dialysis days)",capd:"250-500 mg q12-24h",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["Hypersensitivity (rash, urticaria, angioedema, anaphylaxis, erythema multiforme, serum sickness, SJS, TEN)","Cephalexin has the same R-1 side chain as ampicillin and cefaclor, and the same R-2 side chain as cefadroxil.","See Drug Allergy: Penicillins, Cephalosporins, Overview.","GI (diarrhea, nausea, vomiting, abdominal pain, C. difficile colitis)","Hematologic: positive Coombs, neutropenia, eosinophilia","Reversible interstitial nephritis","Increased LFTs","Prolonged INR","Seizures"],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Staphylococcus saprophyticus"],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Cap (250, 500, 750 mg), Tab (250, 500 mg), Oral susp (125 mg/5 mL, 250 mg/5 mL)",food_recommendation:"Cap/tab/susp ± food",oral_absorption_percent:"90",tmax_hr:"1",peak_serum_conc_ug_ml:"18 (500 mg po, SD)",peak_urine_conc_ug_ml:"2200 (500 mg po, SD)",protein_binding_percent:"5-15",volume_of_distribution_vd_l_kg_vf:"0.38 L/kg (V/F)",avg_serum_half_life_hr:"1",elimination:"Renal",bile_penetration_percent:"216",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"29 (500 mg po, 0-inf)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:["MATE1"],ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:[{drug:"Metformin",effect:"↑ metformin",management:"Monitor, adjust dosage"},{drug:"Probenecid",effect:"↑ cephalexin",management:"Monitor, adjust dosage"}]}},Loracarbef:{id:"Loracarbef",name:"Loracarbef",tradename:"",classification:{family:"CEPHALOSPORIN",subclass:"Oral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"200 mg once daily to 400 mg po twice daily",severe:"200 mg once daily to 400 mg po twice daily",renal:{normal:"CrCl ≥50: No dosage adjustment. CrCl 10-49: 200-400 mg q24h. CrCl <10: 200-400 mg q3-5 days",mild:"CrCl ≥50: No dosage adjustment. CrCl 10-49: 200-400 mg q24h. CrCl <10: 200-400 mg q3-5 days",moderate:"CrCl ≥50: No dosage adjustment. CrCl 10-49: 200-400 mg q24h. CrCl <10: 200-400 mg q3-5 days",severe:"CrCl ≥50: No dosage adjustment. CrCl 10-49: 200-400 mg q24h. CrCl <10: 200-400 mg q3-5 days"},hepatic:"No data",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"No data, but adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"90",protein_binding:"25",half_life:"1.2",elimination:"Renal",csf_penetration:"No data",preparations:"Cap (200, 400 mg), Oral susp (100 mg/5 mL, 200 mg/5 mL)"},rawData:{drug_name:"Loracarbef",usage_and_dosing:{general:["A carbacephem antibiotic; Loracarbef activity is similar to Cefaclor.","The drug is no longer available in the U.S., but may be available in other regions.","There are no generic versions produced"],adult_dose:{usual_dose:"200 mg once daily to 400 mg po twice daily"},pediatric_dose:{dose_age_gt_28_days:"15-30 mg/kg/day (divided q12h)",max_day:"800 mg"}},renal_adjustment:{half_life_normal:"1.2",half_life_esrd:"32",dose_renal_function_normal:"200-400 mg po q12h",crcl_or_egfr:"CrCl ≥50: No dosage adjustment. CrCl 10-49: 200-400 mg q24h. CrCl <10: 200-400 mg q3-5 days",hemodialysis:"200-400 mg q3-5 days (give extra 200-400 mg AD)",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No data",moderate_impairment_child_pugh_b:"No data",severe_impairment_child_pugh_c:"No data"},adverse_effects:["For class-wide adverse effects, see Cephalosporins, Overview."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"No data, but adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{full_comparative_spectrum_of_activity:!0},pharmacology:{pk_pd_index:"T>MIC",preparations:"Cap (200, 400 mg), Oral susp (100 mg/5 mL, 200 mg/5 mL)",food_recommendation:"All preps no food",oral_absorption_percent:"90",tmax_hr:"No data",peak_serum_conc_ug_ml:"8 (200 mg po, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"25",volume_of_distribution_vd_l_kg_vf:"0.33 L/kg (V/F)",avg_serum_half_life_hr:"1.2",elimination:"Renal",bile_penetration_percent:"No data",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"10.6 (200 mg po, 0-inf)"},major_drug_interactions:["None reported"]}},Cefazolin:{id:"Cefazolin",name:"Cefazolin",tradename:"Ancef, Kefzol",classification:{family:"CEPHALOSPORIN",subclass:"Parenteral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Staphylococcus aureus, methicillin-sensitive (MSSA)","Staphylococcus epidermidis, methicillin-susceptible (MSSE)","Staphylococcus lugdunensis","Staphylococcus saprophyticus","Staphylococcus sp., coagulase-negative (Methicillin susceptible); S. hominis, S. capitis, others"],alternative:[],notes:""},dosing:{adult:{standard:"1-2 gm IV/IM q8h (max 12 gm/day)",severe:"1-2 gm IV/IM q8h (max 12 gm/day)",renal:{normal:"CrCl >50: No dosage adjustment. CrCl 10-50: 0.5-2 gm q8-12h. CrCl <10: 0.5-1 gm q24h",mild:"CrCl >50: No dosage adjustment. CrCl 10-50: 0.5-2 gm q8-12h. CrCl <10: 0.5-1 gm q24h",moderate:"CrCl >50: No dosage adjustment. CrCl 10-50: 0.5-2 gm q8-12h. CrCl <10: 0.5-1 gm q24h",severe:"CrCl >50: No dosage adjustment. CrCl 10-50: 0.5-2 gm q8-12h. CrCl <10: 0.5-1 gm q24h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:["Staphylococcus aureus, methicillin-sensitive (MSSA)","Staphylococcus epidermidis, methicillin-susceptible (MSSE)","Staphylococcus lugdunensis","Staphylococcus saprophyticus","Staphylococcus sp., coagulase-negative (Methicillin susceptible); S. hominis, S. capitis, others"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"73-87",half_life:"2",elimination:"Renal",csf_penetration:"6.7 (median AUC ratio) 26",preparations:"Injection"},rawData:{drug_name:"Cefazolin",tradename:"Ancef, Kefzol",drug_shortage:[{preparation:"Injection",start_date:"2018-06-04",notes:""}],usage_and_dosing:{general:["Cefazolin, FDA-approved in 1973, is a first-generation parenteral cephalosporin with a wide variety of uses for infections caused by susceptible gram-positive cocci, e.g., MSSA (not MRSA or enterococci), E. coli, P. mirabilis, and Klebsiella sp.","Rare failures of cefazolin therapy of MSSA bacteremia due to bacterial hyperproduction of type A beta-lactamase (Antimicrob Agents Chemother 2010;54:2206; Antimicrob Agents Chemother 2009;53:3437).","Major use is for surgical prophylaxis.","Antistaphylococcal penicillins have historically been preferred for CNS infection due to concern about poor blood-brain penetration of cefazolin. Recent studies have called this belief into question (Pharmacotherapy 2023;43:85; Open Forum Infect Dis 2021;9:ofab649; Clin Microbiol Infect 2020;26:1415.e1)."],adult_dose:{usual_dose:"1-2 gm IV/IM q8h (max 12 gm/day)",surgical_prophylaxis:"2 gm IV within 60 min prior to skin incision. Repeat dose in 4 hrs if surgery is prolonged"},pediatric_dose:{dose_age_gt_28_days:"50-150 mg/kg/day (divided q6-8h)",max_day:"6 gm"}},renal_adjustment:{half_life_normal:"2",half_life_esrd:"40-70",dose_renal_function_normal:"1-2 gm IV q8h",crcl_or_egfr:"CrCl >50: No dosage adjustment. CrCl 10-50: 0.5-2 gm q8-12h. CrCl <10: 0.5-1 gm q24h",hemodialysis:"0.5-1 gm q24h (AD on dialysis days). Outpatients: 2 gm AD MW, 3 gm AD Fri 52",capd:"0.5 gm q12h",crrt:"1-2 gm q12h",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["ECMO: See ECMO Drug Dosing Adjustment.","Obesity: Obesity Dosing Adjustments."],adverse_effects:["Hypersensitivity (rash, anaphylaxis [rare])","Cefazolin does not share the same R-1 or R-2 side chain with any other beta-lactam.","See Drug Allergy: Penicillins, Cephalosporins, Overview.","GI (diarrhea, C. difficile colitis)","Fever","Local phlebitis","Hematologic: positive Coombs, eosinophilia, neutropenia, thrombocytopenia"],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Staphylococcus aureus, methicillin-sensitive (MSSA)","Staphylococcus epidermidis, methicillin-susceptible (MSSE)","Staphylococcus lugdunensis","Staphylococcus saprophyticus","Staphylococcus sp., coagulase-negative (Methicillin susceptible); S. hominis, S. capitis, others"],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"188 (1 gm IV, SD)",peak_urine_conc_ug_ml:">1000 (500 mg IM, SD) 27",protein_binding_percent:"73-87",volume_of_distribution_vd_l_kg:"0.19 L/kg",avg_serum_half_life_hr:"2",elimination:"Renal",bile_penetration_percent:"29-300",csf_blood_percent:"6.7 (median AUC ratio) 26",therapeutic_levels_in_csf:"Possibly",auc_ug_hr_ml:"236 (1 gm IV, 0-inf)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:["OAT1","OAT3"],ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:["No significant interactions"]}},Cefepime:{id:"Cefepime",name:"Cefepime",tradename:"Maxipime",classification:{family:"CEPHALOSPORIN",subclass:"Parenteral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Citrobacter freundii","Citrobacter koseri, diversus","Pseudomonas aeruginosa"],alternative:[],notes:""},dosing:{adult:{standard:"1-2 gm IV q8-12h",severe:"1-2 gm IV q8-12h",renal:{normal:"CrCl >60: No dosage adjustment. CrCl 30-60: 2 gm q12h. CrCl 11-29: 2 gm q24h. CrCl <10: 1 gm q24h",mild:"CrCl >60: No dosage adjustment. CrCl 30-60: 2 gm q12h. CrCl 11-29: 2 gm q24h. CrCl <10: 1 gm q24h",moderate:"CrCl >60: No dosage adjustment. CrCl 30-60: 2 gm q12h. CrCl 11-29: 2 gm q24h. CrCl <10: 1 gm q24h",severe:"CrCl >60: No dosage adjustment. CrCl 30-60: 2 gm q12h. CrCl 11-29: 2 gm q24h. CrCl <10: 1 gm q24h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:["Citrobacter freundii","Citrobacter koseri, diversus","Pseudomonas aeruginosa"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"20",half_life:"2",elimination:"Renal",csf_penetration:"4-34 16",preparations:"Injection"},rawData:{drug_name:"Cefepime",tradename:"Maxipime",usage_and_dosing:{general:["Cefepime, FDA-approved in 1996, is a 4th generation cephalosporin with a structure that allows better and more rapid penetration through the cell wall of aerobic gram-negative bacilli.","It is able to avoid destruction by some chromosomal beta-lactamases.","Cefepime has in vitro activity against MSSA, Neisseria sp., H. influenzae and a broad range of gram-negative bacilli, including P. aeruginosa (Lancet Infect Dis 2007;7:338).","An alternative antibiotic for drug resistant genotypes.","Cefepime may be active vs. ESBL-producing aerobic gram-negative bacilli if administered in high doses: 2 gm IV q8h. However, the drug of choice for ESBL-producing Gram-negative bacilli is a carbapenem, not Cefepime.","More active against Staph. aureus (MSSA) than 3rd generation cephalosporins."],adult_dose:{usual_dose:"1-2 gm IV q8-12h",other_dosing:"See Continuous, Extended Infusion Dosing"},pediatric_dose:{usual:"100 mg/kg/day (div q8h)",pseudomonas:"150 mg/kg/day (div q8h)",max_day:"-"}},renal_adjustment:{half_life_normal:"2",half_life_esrd:"18",dose_renal_function_normal:"2 gm IV q8h",crcl_or_egfr:"CrCl >60: No dosage adjustment. CrCl 30-60: 2 gm q12h. CrCl 11-29: 2 gm q24h. CrCl <10: 1 gm q24h",hemodialysis:{fda_approved:"1 gm q24h (AD on dialysis days)",alternative:"2 gm AD (3x/wk HD) 45"},capd:"2 gm q48h",crrt:"Dose per effluent rate, all modalities: 1 L/hr: 1 gm q8h, ≥2 L/hr: 1 gm q6h. EI, CVVH/CVVHD, UFR 30.1: 2 gm (over 4 hr) q8h 42, 43",sled:"2 gm load, then 1 gm q6h OR 2 gm pre-, 3 gm post-SLED 49"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["Obesity: See Obesity Dosing Adjustments.","ECMO: See ECMO Drug Dosing Adjustment."],adverse_effects:["Hypersensitivity (rash)","GI (nausea/vomiting, diarrhea, C. difficile infection)","Local phlebitis","Hematologic: Positive Coombs, neutropenia, eosinophilia, thrombocytopenia, increased INR.","Cross-reactivity discussion: See Drug Allergy: Penicillins, Cephalosporins, Overview.","Flushing reaction (similar to vancomycin histamine release syndrome) reported: Antimicrob Agents Chemother 2012;56:6387.","Neurotoxicity:","FDA safety warning: Risk of non-convulsive status epilepticus (see Comment).","Cefepime can competitively inhibit the major CNS inhibitory neurotransmitter, GABA.","Toxicity is concentration dependent.","Impaired renal function is risk factor.","Manifestations can include any or all of: confusion, loss of attention, disorientation, abnormal behavior, agitation, hallucinations, myoclonic jerks, mutism, impaired consciousness, coma.","Diagnosis: EEG.","Review: J Antimicrob Chemother 2022;77: 2908."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Citrobacter freundii","Citrobacter koseri, diversus","Pseudomonas aeruginosa"],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"164 (2 gm IV, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"20",volume_of_distribution_vd_l_vss:"18 L (Vss)",avg_serum_half_life_hr:"2",elimination:"Renal",bile_penetration_percent:"10-20",csf_blood_percent:"4-34 16",therapeutic_levels_in_csf:"Yes",auc_ug_hr_ml:"284.8 (2 gm IV, 0-inf)"},major_drug_interactions:["No significant interactions"],comments:["In a June 2012 FDA safety update, clinicians are warned about nonconvulsive status epilepticus occurring in cefepime-treated patients with renal insufficiency, most of whom did not receive appropriately adjusted doses. Seizure activity resolved after drug discontinuation and/or hemodialysis in the majority of patients. The FDA recommends dose adjustment in patients with CrCl ≤ 60 mL/min."]}},"Cefepime-Enmetazobactam":{id:"Cefepime_Enmetazobactam",name:"Cefepime-Enmetazobactam",tradename:"Exblifep",classification:{family:"CEPHALOSPORIN",subclass:"Parenteral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Pseudomonas aeruginosa"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No adjustment",mild:"No adjustment",moderate:"Reduce dose",severe:"Reduce dose significantly"},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Cefepime: No evidence of toxicity in humans or animals. Enmetazobactam: No data.",lactation:"Use with caution",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[],stewardship:{preferredIndications:["Pseudomonas aeruginosa"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"Cefepime: 20, Enmetazobactam: nil",half_life:null,elimination:"Cefepime: renal, Enmetazobactam: renal",csf_penetration:"Cefepime: 4-34",preparations:""},rawData:{drug_name:"Cefepime-Enmetazobactam",tradename:"Exblifep",usage_and_dosing:{approved_for:"complicated UTI including pyelonephritis",general_info:["Enmetazobactam is a beta-lactamase inhibitor similar to tazobactam. A key structural difference improves penetration into the bacterial cell. Enmetazobactam protects cefepime from degradation by certain Ambler Class A enzymes, such as ESBLs.","Cefepime-enmetazobactam is not active against bacteria that produce KPC, metallo-beta-lactamase, or OXA enzymes other than OXA-48.","In a recently published phase 3 RCT in patients with complicated UTI or acute pyelonephritis caused by gram-negative bacilli, cefepime-enmetazobactam (compared with piperacillin-tazobactam) met criteria for noninferiority as well as superiority with respect to the primary outcome of clinical cure and microbiologic eradication (JAMA 2022;328:1304).","Good review: Expert Opin Drug Metab Toxicol 2025;21:115."],adult_dose:["Cefepime-enmetazobactam 2.5 gm IV (over 2 hours) q8h.","Product labeling recommends 7 days of treatment, up to 14 days for patient with concurrent bacteremia.","Note that 2.5 gm = cefepime 2 gm + enmetazobactam 0.5 gm.","Reconstitute powder, then immediately dilute in 250 mL of D5W or NS. Complete drug infusion within six hours of dilution."],pediatric_dose:[{age:">28 Days",dose:"Safety and efficacy not established"}],renal_adjustment:{CrCl_or_eGFR:["eGFR ≥130: 2.5 gm (over 4 hr) q8h","eGFR 60-129: 2.5 gm (over 2 hr) q8h","eGFR 30-59: 1.25 gm (over 2 hr) q8h","eGFR 15-29: 1.25 gm (over 2 hr) q12h","eGFR <15: 1.25 gm, then 0.625 gm (over 2 hr) q24h"],hemodialysis:"1.25 gm, then 0.625 gm (over 2 hr) q24h (dose AD)",CAPD:"2.5 gm q48h"},hepatic_adjustment:"No dosage adjustment"},adverse_effects:["Hypersensitivity reactions, as with other beta-lactams.","Gastrointestinal: Nausea, vomiting, diarrhea, abdominal pain, C. difficile-associated diarrhea.","Increased transaminases, bilirubin.","Headache.","Neurotoxicity (from cefepime): encephalopathy, aphasia, myoclonus, seizures. Typically occurs in patients with renal impairment who did not receive proper dosage adjustment, but has also occurred in patients receiving appropriate dosage.","Positive direct Coombs' test.","Prolonged INR.","Possible false-positive reaction for urine glucose when using some methods (e.g., Clinitest)."],pregnancy_risk:{fda_risk_category:"Cefepime: No evidence of toxicity in humans or animals. Enmetazobactam: No data.",use_during_lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity."},antimicrobial_spectrum:{preferred:["Pseudomonas aeruginosa"],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",pharmaceutical_preparations:"Injection",peak_serum_conc_mcg_ml:"Cefepime: 99.8, Enmetazobactam: 19.8 (2.5 gm [over 2 hr] q8h, SS)",protein_binding_percent:"Cefepime: 20, Enmetazobactam: nil",volume_of_distribution_vd:"Cefepime: 20 L (Vss), Enmetazobactam: 25.3 L (Vss)",avg_serum_t1_2_hr:"Cefepime: 2.7, Enmetazobactam: 2.6",elimination:"Cefepime: renal, Enmetazobactam: renal",csf_blood_percent:"Cefepime: 4-34"},major_drug_interactions:"No signficant interactions known."}},Cefiderocol:{id:"Cefiderocol",name:"Cefiderocol",tradename:"Fetroja",classification:{family:"CEPHALOSPORIN",subclass:"Parenteral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"CrCl ≥120: 2 gm q6h. CrCl 60-119: 2 gm q8h. CrCl 30-59: 1.5 gm q8h. CrCl 15-29: 1 gm q8h. CrCl <15: 0.75 gm q12h",mild:"CrCl ≥120: 2 gm q6h. CrCl 60-119: 2 gm q8h. CrCl 30-59: 1.5 gm q8h. CrCl 15-29: 1 gm q8h. CrCl <15: 0.75 gm q12h",moderate:"CrCl ≥120: 2 gm q6h. CrCl 60-119: 2 gm q8h. CrCl 30-59: 1.5 gm q8h. CrCl 15-29: 1 gm q8h. CrCl <15: 0.75 gm q12h",severe:"CrCl ≥120: 2 gm q6h. CrCl 60-119: 2 gm q8h. CrCl 30-59: 1.5 gm q8h. CrCl 15-29: 1 gm q8h. CrCl <15: 0.75 gm q12h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"No data, but adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Urine dipstick tests (protein, ketones, blood)",effect:"False-positive results",management:"Use alternate methods"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"40-60",half_life:"2-3",elimination:"Renal",csf_penetration:"44 19",preparations:"Injection"},rawData:{drug_name:"Cefiderocol",tradename:"Fetroja",usage_and_dosing:{general:["Cefiderocol is a parenteral cephalosporin FDA-approved for the treatment of adults with:","Complicated urinary tract infections (UTI), including pyelonephritis, caused by susceptible strains of these aerobic gram-negative bacilli: E. coli, K. pneumoniae, P. mirabilis, P. aeruginosa, E. cloacae complex.","Hospital-acquired and ventilator-associated pneumonia caused by susceptible strains of these aerobic gram-negative bacilli: A. baumannii complex, E. coli, E. cloacae complex, K. pneumoniae, P. aeruginosa, S. marcescens.","In randomized clinical trial, Cefiderocol 2 gm IV, over 3hr, q8h was non-inferior to high dose meropenem vs MDR GNB (to include carbapenem resistant organisms (Lancet Infect Dis 2021; 21:213)","The drug should be reserved for use in patients with limited or no alternative treatment options. It is inactive against Gram-positive and anaerobic bacteria.","Cefiderocol functions as a siderophore, chelating ferric ions and taking advantage of the bacterial iron transport system for enhanced accumulation in the bacterial periplasmic space.","Active in vitro vs broad range of fermentative and non-fermentative multidrug resistant gram-negative bacilli.","An alternative antibiotic for drug resistant genotypes.","Good review: Drugs 2019;79:271.","Possible OPAT option: see Outpatient Parenteral Antimicrobial Therapy.","For clinical trial references, see Comments."],adult_dose:{fda_approved_dosing:"2 gm IV (over 3 hours) q8h x 7-14 days",compatibility:"Compatible with normal saline and D5W",stability:"Stability of reconstituted infusion solution added to 100 mL infusion bags: Room temperature for up to 6 hours, 2°C to 8°C for up to 24 hours protected from light",amr_guidance:"Consistent with AMR gram-negative infection guidance (Clin Infect Dis 2024 Aug 7:ciae403. doi: 10.1093/cid/ciae403):"},pediatric_dose:{amr_gram_negative_guidance:"J Pediatric Infect Dis Soc 2025;14:piaf004",per_fda:{safety_and_efficacy:"not established"},per_amr_gram_negative_guidance:{doses_infused_iv_over_3_hrs:{age_le_3_mon:{ga_lt_32_wk_pna_lt_2_mon:"30 mg/kg q8h",ga_ge_32_wk_pna_lt_2_mon:"40 mg/kg q8h",ga_lt_32_wk_pna_2_to_lt_3_mon:"40 mg/kg q8h",ga_ge_32_wk_pna_2_to_lt_3_mon:"60 mg/kg q8h"},age_3_mon_to_18_yrs:"60 mg/kg q8h"}},max_day:"6 gm"}},renal_adjustment:{half_life_normal:"2-3",half_life_esrd:"No data",dose_renal_function_normal:"2 gm IV q8h",crcl_or_egfr:"CrCl ≥120: 2 gm q6h. CrCl 60-119: 2 gm q8h. CrCl 30-59: 1.5 gm q8h. CrCl 15-29: 1 gm q8h. CrCl <15: 0.75 gm q12h",hemodialysis:"0.75 gm q12h (AD on dialysis days)",capd:"No data",crrt:"Dose per effluent rate (all modalities): ≤2 L/hr: 1.5 gm q12h, 2.1 to 3 L/hr: 2 gm q12h, 3.1 to 4 L/hr: 1.5 gm q8h, ≥4.1 L/hr: 2 gm q8h",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["ECMO: See ECMO Drug Dosing Adjustment page."],adverse_effects:{contraindications:"Persons with severe beta-lactam allergy",warnings:"Higher all-cause mortality in an open-label randomized trial comparing cefiderocol to best-available therapy (BAT) in persons with pneumonia, bloodstream infection/sepsis, or complicated UTI caused by carbapenem-resistant gram-negative bacteria, including Acinetobacter and Enterobacteriaceae (Lancet Infect Dis 2021;21:226). All-cause mortality at 14 days, 28 days, and end of study for cefiderocol-treated patients was 19/101 (18.8%), 25/101 (24.8%), and 34/101 (33.7%), respectively, versus 6/49 (12.2%), 9/49 (18.4%), and 9/49 (18.4%) for BAT-treated patients, although these differences are not statistically significant. Study interpretation difficult due to confounding variables.",beta_lactam_hypersensitivity:"Beta-lactam hypersensitivity reactions. Cefiderocol has the same R1 side chain as ceftazidime and aztreonam, so cross-allergenicity may occur. See Drug Allergy: Penicillins, Cephalosporins, Overview page.",cdad:"C. difficile-associated diarrhea (CDAD)",seizure_risk:"Seizure risk",other:["Diarrhea","Infusion site reactions","Constipation","Rash","Candidiasis","Cough","Elevations in liver tests","Headache","Hypokalemia","Nausea and vomiting","Interesting case report of dark red urine discoloration related to co-administration of cefiderocol and an accelerated intravenous ferric gluconate regimen for iron deficiency anemia. Clinical significance uncertain (Ann Pharmacother 2022;56:1082)."]},pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"No data, but adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"138 (2 gm IV q8h, SS)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"40-60",volume_of_distribution_vd_l:"18 L",avg_serum_half_life_hr:"2-3",elimination:"Renal",bile_penetration_percent:"No data",csf_blood_percent:"44 19",therapeutic_levels_in_csf:"Possibly",auc_ug_hr_ml:"394.7 (SS, 0-8 hr)"},major_drug_interactions:[{drug:"Urine dipstick tests (protein, ketones, blood)",effect:"False-positive results",management:"Use alternate methods"}],comments:["References for major clinical trials:","Cefiderocol vs imipenem-cilastatin for complicated UTIs: Lancet Infect Dis 2018;18:1319.","Cefiderocol vs best available therapy for systemic infection due to carbapenem resistant gram-negative bacilli: Lancet Infect Dis 2021;21:226.","Cefiderocol vs meropenem for nosocomial pneumonia: Lancet Infect Dis 2021;21:213."]}},Cefmetazole:{id:"Cefmetazole",name:"Cefmetazole",tradename:"Zefazone",classification:{family:"CEPHALOSPORIN",subclass:"Parenteral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"CrCl >90: No dosage adjustment. CrCl 50-90: 1-2 gm q12h. CrCl 30-49: 1 gm q12h. CrCl 10-29: 1-2 gm q24h. CrCl <10: 1-2 gm q48h",mild:"CrCl >90: No dosage adjustment. CrCl 50-90: 1-2 gm q12h. CrCl 30-49: 1 gm q12h. CrCl 10-29: 1-2 gm q24h. CrCl <10: 1-2 gm q48h",moderate:"CrCl >90: No dosage adjustment. CrCl 50-90: 1-2 gm q12h. CrCl 30-49: 1 gm q12h. CrCl 10-29: 1-2 gm q24h. CrCl <10: 1-2 gm q48h",severe:"CrCl >90: No dosage adjustment. CrCl 50-90: 1-2 gm q12h. CrCl 30-49: 1 gm q12h. CrCl 10-29: 1-2 gm q24h. CrCl <10: 1-2 gm q48h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"No data",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Probenecid",effect:"↑ cefmetazole",management:"Monitor, adjust dosage"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"65-85",half_life:"1.1-1.5",elimination:"Renal",csf_penetration:"No data",preparations:"Injection"},rawData:{drug_name:"Cefmetazole",tradename:"Zefazone",usage_and_dosing:{general:["Cefmetazole is a second-generation semisynthetic parenteral cephamycin.","Resistant in vitro to hydrolysis by ESBL-producing Enterobacterales.","Contains an N-methyl-tetrazole-thiol side chain, which inhibits vitamin K epoxide reductase and may inhibit synthesis of vitamin K-dependent coagulation factors.","Not available in the US but often used in Japan, Taiwan, and China.","Possible carbapenem-sparing alternative (where available) for ESBL-producing Enterobacterales infection: Open Forum Infect Dis 2023;10:ofad502; Antimicrob Agents Chemother 2023;67:e0051023.","Good overview: Pharmacotherapy 1991;11:2-19."],adult_dose:{urinary_tract_infection:"2 gm IV q12h",mild_to_moderate_infection:"2 gm IV q8h",severe_to_life_threatening_infection:"2 gm IV q6h"},pediatric_dose:{dose_age_gt_28_days:"Safety and efficacy not established",max_day:"-"}},renal_adjustment:{half_life_normal:"1-1.5",half_life_esrd:"29",dose_renal_function_normal:"2 gm IV q8-12h",crcl_or_egfr:"CrCl >90: No dosage adjustment. CrCl 50-90: 1-2 gm q12h. CrCl 30-49: 1 gm q12h. CrCl 10-29: 1-2 gm q24h. CrCl <10: 1-2 gm q48h",hemodialysis:"1-2 gm q48h (AD on dialysis days)",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["Gastrointestinal (nausea, vomiting, diarrhea)","Potential for C. difficile infection","Hypersensitivity reactions","Increased LFTs","Disulfiram-like reaction","Coagulopathy"],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"No data",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"143 (2 gm IV, SD)",peak_urine_conc_ug_ml:">2000 (2 gm IV, SD)",protein_binding_percent:"65-85",volume_of_distribution_vd_l_kg:"≈ 0.18 L/kg",avg_serum_half_life_hr:"1.1-1.5",elimination:"Renal",bile_penetration_percent:"No data",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"161 (2 gm IV, 0-inf)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:["OAT1","OAT3"],ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:[{drug:"Probenecid",effect:"↑ cefmetazole",management:"Monitor, adjust dosage"}]}},Cefoperazone:{id:"Cefoperazone",name:"Cefoperazone",tradename:"Cefobid, Magnamycin",classification:{family:"CEPHALOSPORIN",subclass:"Parenteral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"1-2 gm IV q12h",severe:"1-2 gm IV q12h",renal:{normal:"No dosage adjustment for renal impairment (if GFR <18, do not exceed 4 gm/day)",mild:"No dosage adjustment for renal impairment (if GFR <18, do not exceed 4 gm/day)",moderate:"No dosage adjustment for renal impairment (if GFR <18, do not exceed 4 gm/day)",severe:"No dosage adjustment for renal impairment (if GFR <18, do not exceed 4 gm/day)"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Ethanol",effect:"Possible disulfiram-type reaction",management:"Avoid co-administration"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"87-90",half_life:"1.7-2.0",elimination:"Biliary",csf_penetration:"No data",preparations:"Injection"},rawData:{drug_name:"Cefoperazone",tradename:"Cefobid, Magnamycin",usage_and_dosing:{general:["Cefoperazone is a 3rd-generation parenteral extended-spectrum cephalosporin.","Originally FDA-approved in the early 1980s but now discontinued from the US market."],adult_dose:{usual_dose:"1-2 gm IV q12h",severe_infections:"Up to 4 gm IV q12h in severe infections",uncomplicated_gonococcal_urethritis:"500 mg IM as a single dose"},pediatric_dose:{dose_age_gt_28_days:"50-200 mg/kg/day (divided q8-12h) (divided q12h if age <8 days)",max_day:"12 gm"}},renal_adjustment:{notes:"Dosage adjustment may be required in hepatic disease.",half_life_normal:"1.7-2.0",half_life_esrd:"No change",dose_renal_function_normal:"1-2 gm IV q12h",crcl_or_egfr:"No dosage adjustment for renal impairment (if GFR <18, do not exceed 4 gm/day)",hemodialysis:"No dosage adjustment (AD on dialysis days)",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{note:"Limit dosage to 2 gm/day in patients with concomitant hepatic and renal dysfunction.",mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"Limit dosage to 2 gm/day"},adverse_effects:["Hypersensitivity reactions","Anaphylaxis","Stevens-Johnson syndrome, toxic epidermal necrolysis","C. difficile-associated diarrhea","Increased LFTs","Hematologic: anemia, neutropenia, thrombocytopenia","May increase INR and cause bleeding, possibly related to the MTT side chain.","See Cephalosporins, Overview"],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"252 (2 gm over 15 min, SD)",peak_urine_conc_ug_ml:">2200 (2 gm IV over 15 min, SD)",protein_binding_percent:"87-90",volume_of_distribution_vd_l:"10.2-11.3 L",avg_serum_half_life_hr:"1.7-2.0",elimination:"Biliary",bile_penetration_percent:"Up to 100x serum conc",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"No data"},major_drug_interactions:[{drug:"Ethanol",effect:"Possible disulfiram-type reaction",management:"Avoid co-administration"}]}},"Cefoperazone-sulbactam":{id:"Cefoperazone_sulbactam",name:"Cefoperazone-sulbactam",tradename:"Sulperazon, Magnex",classification:{family:"CEPHALOSPORIN",subclass:"Parenteral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"Sulbactam-Cefoperazone 2 to 4 gm/day IV or IM in equally divided doses q12h (i.e., 1 to 2 gm per day Cefoperazone activity).",severe:"Sulbactam-Cefoperazone 2 to 4 gm/day IV or IM in equally divided doses q12h (i.e., 1 to 2 gm per day Cefoperazone activity).",renal:{normal:"Adjustment necessary for the sulbactam: CrCl ≥30: No dosage adjustment. CrCl 15-30: Sulbactam 1 gm q12h. CrCl <15: Sulbactam 500 mg q12h",mild:"Adjustment necessary for the sulbactam: CrCl ≥30: No dosage adjustment. CrCl 15-30: Sulbactam 1 gm q12h. CrCl <15: Sulbactam 500 mg q12h",moderate:"Adjustment necessary for the sulbactam: CrCl ≥30: No dosage adjustment. CrCl 15-30: Sulbactam 1 gm q12h. CrCl <15: Sulbactam 500 mg q12h",severe:"Adjustment necessary for the sulbactam: CrCl ≥30: No dosage adjustment. CrCl 15-30: Sulbactam 1 gm q12h. CrCl <15: Sulbactam 500 mg q12h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:{dose:"40-80 mg/kg/day (divided q6-12h)",cefoperazone_equivalent:"(20-40 mg/kg/day cefoperazone using 1:1 ratio)"},maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Ethanol",effect:"Possible disulfiram-type reaction",management:"Avoid co-administration"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"Cef: 87-90",half_life:"Cef: 1.7-2.0, Sul: 1.0",elimination:"Cef: Biliary (main), Sul: renal",csf_penetration:"No data",preparations:"Injection"},rawData:{drug_name:"Cefoperazone-sulbactam",tradename:"Sulperazon, Magnex",usage_and_dosing:{general:["Cefoperazone is a 3rd generation parenteral extended spectrum cephalosporin active vs cell wall and cell membrane.","It is available in a fixed dose combination with Sulbactam (a Class A beta-lactamase inhibitor).","Sulbactam-Cefoperazone is active against all organisms susceptible to Cefoperazone with up to a 4-fold reduction in MICs for the combination compared to the Cefoperazone component against selected enteric Gram-negative species.","Used for a variety of respiratory, skin-soft tissue, urinary tract and intra-abdominal infections.","Product availability:"],product_availability:[{vial_size:"1 gm",sulbactam:"0.5 gm",cefoperazone:"0.5 gm",ratio:"1:1"},{vial_size:"1.5 gm",sulbactam:"0.5 gm",cefoperazone:"1 gm",ratio:"1:2"},{vial_size:"2 gm",sulbactam:"1 gm",cefoperazone:"1 gm",ratio:"1:1"},{vial_size:"3 gm",sulbactam:"1 gm",cefoperazone:"2 gm",ratio:"1:2"}],class_wide_issues:"For class-wide issues, see Cephalosporins, Overview.",adult_dose:{usual_dose:"Sulbactam-Cefoperazone 2 to 4 gm/day IV or IM in equally divided doses q12h (i.e., 1 to 2 gm per day Cefoperazone activity).",severe_or_refractory_infections:"Sulbactam-Cefoperazone may be increased up to 8 gm of the 1:1 ratio (i.e., 4 g Cefoperazone activity) IV in equally divided doses or 12 g (i.e., 8 gm Cefoperazone activity) of the 1:2 ratio.",max_sulbactam_dose:"The recommended maximum total daily dose of Sulbactam: 4 gm."},pediatric_dose:{standard:{dose:"40-80 mg/kg/day (divided q6-12h)",cefoperazone_equivalent:"(20-40 mg/kg/day cefoperazone using 1:1 ratio)"},serious_infection:{dose:"160 mg/kg/day (divided q6-12h) (80 mg/kg/day cefoperazone using 1:1 ratio) OR 240 mg/kg/day (divided q6-12h) (160 mg/kg/day cefoperazone using 1:2 ratio)"}}},renal_adjustment:{notes:["Dosage adjustment may be required in hepatic disease.","Administer extra cefoperazone separately as needed (cefoperazone does not require dosage adjustment in renal impairment)."],half_life_normal:"Cefoperazone: 1.7.2.0, Sulbactam: 1.0",half_life_esrd:"Cefoperazone: No change, Sulbactam: 6.9-9.7",dose_renal_function_normal:"2-4 gm/day (divided q12h) (i.e., cefoperazone 1-2 gm/day)",crcl_or_egfr:"Adjustment necessary for the sulbactam: CrCl ≥30: No dosage adjustment. CrCl 15-30: Sulbactam 1 gm q12h. CrCl <15: Sulbactam 500 mg q12h",hemodialysis:"Sulbactam 500 mg q12h (AD on dialysis days)",capd:"No data",crrt:"Sulbactam 1 gm q8h",sled:"No data"},hepatic_adjustment:{note:"Limit dosage to 2 gm/day (cefoperazone) in patients with concomitant hepatic and renal dysfunction.",mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"Limit dosage to 2 gm/day (cefoperazone)"},adverse_effects:["See Cephalosporins, Overview","Hypersensitivity reactions","Anaphylaxis","Stevens-Johnson syndrome, toxic epidermal necrolysis","C. difficile-associated diarrhea","Increased LFTs","Hematologic: anemia, neutropenia, thrombocytopenia","May increase INR and cause bleeding, possibly related to the MTT side chain."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{susceptibility_breakpoints:"Susceptibility breakpoints established for Cefoperazone have not been re-affirmed by modern analytic criteria",previous_breakpoint_activity:'At the previously established breakpoint of "susceptible at 16 mcg/mL or less", Sulbactam-Cefoperazone inhibited the following percentages of a large world-wide collection of organisms (Diagn Microbiol Infect Dis 88: 177, 2017):',organism_activity:{enterobacteriaceae:"91.4%",pseudomonas_aeruginosa:"74.5%",stenotrophomonas_maltophilia:"50%",acinetobacter_spp:"40%"},anaerobes:"Potent vs anaerobes"},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"Cef: 236.8 (1 gm IV over 5 min, SD), Sul: 130 (1 gm IV over 5 min, SD)",peak_urine_conc_ug_ml:"Cef: >2200 (2 gm IV over 15 min, SD)",protein_binding_percent:"Cef: 87-90",volume_of_distribution_vd_l:"Cef: 10.2-11.3 L, Sul: 18.0-27.6 L",avg_serum_half_life_hr:"Cef: 1.7-2.0, Sul: 1.0",elimination:"Cef: Biliary (main), Sul: renal",bile_penetration_percent:"Cef: Up to 100x serum conc",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"No data"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:"Sulbactam: OAT1, OAT3",ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:[{drug:"Ethanol",effect:"Possible disulfiram-type reaction",management:"Avoid co-administration"}]}},Cefotaxime:{id:"Cefotaxime",name:"Cefotaxime",tradename:"",classification:{family:"CEPHALOSPORIN",subclass:"Parenteral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Haemophilus influenzae","Leptospira sp.","Neisseria meningitidis","Viridans group streptococci","Yersinia enterocolitica"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"CrCl >90: No dosage adjustment. CrCl >50-90: 2 gm q8-12h. CrCl 10-50: 2 gm q12-24h. CrCl <10: 2 gm q24h",mild:"CrCl >90: No dosage adjustment. CrCl >50-90: 2 gm q8-12h. CrCl 10-50: 2 gm q12-24h. CrCl <10: 2 gm q24h",moderate:"CrCl >90: No dosage adjustment. CrCl >50-90: 2 gm q8-12h. CrCl 10-50: 2 gm q12-24h. CrCl <10: 2 gm q24h",severe:"CrCl >90: No dosage adjustment. CrCl >50-90: 2 gm q8-12h. CrCl 10-50: 2 gm q12-24h. CrCl <10: 2 gm q24h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:{age_0_7_days:"100 mg/kg/day (divided q12h)",age_8_28_days:"150 mg/kg/day (divided q8h)",age_gt_28_days:"150-200 mg/kg/day (divided q6-8h)"},maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:["Haemophilus influenzae","Leptospira sp.","Neisseria meningitidis","Viridans group streptococci","Yersinia enterocolitica"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"30-51",half_life:"1.5",elimination:"Renal",csf_penetration:"10",preparations:"Injection"},rawData:{drug_name:"Cefotaxime",drug_shortage:[{preparation:"Injection",start_date:"2015-06-10",notes:"FDA is allowing temporary importation of product from SteriMax in Canada, in conjunction with Provepharm Life Solutions and its distributor Direct Success."}],usage_and_dosing:{general:["Cefotaxime is a 3rd-generation expanded spectrum parenteral cephalosporin. In vitro activity includes many aerobic gram-negative bacilli, but not P. aeruginosa. Spectrum similar to Ceftriaxone but requires multiple daily doses.","Availability:","Generic formulation from multiple manufacturers available in Europe and many countries","Not presently available in the U.S. However, FDA is allowing temporary importation of product from SteriMax in Canada, in conjunction with Provepharm Life Solutions and its distributor Direct Success. Click here for details.","Most Penicillin-resistant pneumococci and N. meningitidis are susceptible to Cefotaxime. Listeria is resistant.","Cefotaxime is susceptible to inactivation by both extended-spectrum beta-lactamases (ESBLs) and chromosomal induced cephalosporinases.","For class-wide adverse effects, see Cephalosporins, Overview."],adult_dose:{life_threatening_infections_and_meningitis:"2 gm IV q4h",intra_abdominal_infection:"1-2 gm IV q6-8h (with Metronidazole)",sbp:"2 gm IV q8h",dose_range:"1-2 gm IV q4-12h"},pediatric_dose:{standard:{age_0_7_days:"100 mg/kg/day (divided q12h)",age_8_28_days:"150 mg/kg/day (divided q8h)",age_gt_28_days:"150-200 mg/kg/day (divided q6-8h)"},meningitis:{age_0_7_days:"100-150 mg/kg/day (divided q8-12h)",age_8_28_days:"150-200 mg/kg/day (divided q6-8h)",age_gt_28_days:"225-300 mg/kg/day (divided q6-8h)"}}},renal_adjustment:{half_life_normal:"1.5",half_life_esrd:"15-35",dose_renal_function_normal:"2 gm IV q8h",crcl_or_egfr:"CrCl >90: No dosage adjustment. CrCl >50-90: 2 gm q8-12h. CrCl 10-50: 2 gm q12-24h. CrCl <10: 2 gm q24h",hemodialysis:"2 gm q24h (+ extra 1 gm AD)",capd:"0.5-1 gm q24h",crrt:"2 gm q12-24h",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["Local phlebitis (5%), rash (2%), positive Coombs (6%), neutropenia, eosinophilia (1%), nausea/vomiting (rare), diarrhea (1%), C. difficile colitis, increased LFTs (1%), photosensitivity (manifested as photodistributed telangiectasia)","Cefotaxime has the same R1 side chain as cefpodoxime, cefpirome, cefditoren, ceftizoxime, ceftriaxone, and cefepime. Cross-allergenicity may occur."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Haemophilus influenzae","Leptospira sp.","Neisseria meningitidis","Viridans group streptococci","Yersinia enterocolitica"],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"100 (1 gm IV, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"30-51",volume_of_distribution_vd_l_kg:"0.28 L/kg",avg_serum_half_life_hr:"1.5",elimination:"Renal",bile_penetration_percent:"15-75",csf_blood_percent:"10",therapeutic_levels_in_csf:"Yes",auc_ug_hr_ml:"70 (1 gm IV, 0-inf)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:["OAT1","OAT3"],ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:["No significant interactions"]}},Cefotetan:{id:"Cefotetan",name:"Cefotetan",tradename:"Cefotan",classification:{family:"CEPHALOSPORIN",subclass:"Parenteral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"1-2 gm IV/IM q12h",severe:"1-2 gm IV/IM q12h",renal:{normal:"CrCl >30: No dosage adjustment. CrCl 10-30: 1-2 gm q24h. CrCl <10: 1-2 gm q48h",mild:"CrCl >30: No dosage adjustment. CrCl 10-30: 1-2 gm q24h. CrCl <10: 1-2 gm q48h",moderate:"CrCl >30: No dosage adjustment. CrCl 10-30: 1-2 gm q24h. CrCl <10: 1-2 gm q48h",severe:"CrCl >30: No dosage adjustment. CrCl 10-30: 1-2 gm q24h. CrCl <10: 1-2 gm q48h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Ethanol",effect:"Possible disulfiram-like reaction",management:"Avoid co-administration"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"88",half_life:"3-4.6",elimination:"Renal",csf_penetration:"No data",preparations:"Injection"},rawData:{drug_name:"Cefotetan",tradename:"Cefotan",usage_and_dosing:{general:["Cefotetan, FDA-approved in 1985, is a 2nd-generation parenteral cephalosporin (technically a cephamycin).","Cephamycins are unique among cephalosporins for their activity against B. fragilis.","Note that there is increasing resistance of B. fragilis, Prevotella bivia, Prevotella disiens (most common in pelvic infections).","Often used for surgical prophylaxis when anaerobic gram-negative bacilli are a concern.","Cefotetan is the only cephalosporin currently marketed in the US that contains the N-methylthiotetrazole (NMTT) side chain. Others include cefamandole, cefmetazole, cefmenoxime, cefoperazone, and moxalactam (some or all marketed elsewhere).","Data suggest an increased risk of hypoprothrombinemia and INR prolongation, presumably due to interference with vitamin K activation. However, impact on bleeding risk is not clear.","NMTT-containing cephalosporins vary in their potential to affect hemostasis. Cefotetan appears low risk.","Reference: Int J Environ Res Public Health 2019;16:3937."],adult_dose:{usual_dose:"1-2 gm IV/IM q12h",life_threatening_infection:"3 gm IV/IM q12h"},pediatric_dose:{dose_age_gt_28_days:"60-100 mg/kg/day (divided q12h)",max_day:"6 gm"}},renal_adjustment:{half_life_normal:"3-4.6",half_life_esrd:"12-30",dose_renal_function_normal:"1-2 gm IV q12h",crcl_or_egfr:"CrCl >30: No dosage adjustment. CrCl 10-30: 1-2 gm q24h. CrCl <10: 1-2 gm q48h",hemodialysis:"1-2 gm q24h (+ extra 1 gm AD)",capd:"1 gm q24h",crrt:"1-2 gm q24h",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["Obesity: See Obesity Dosing Adjustments."],adverse_effects:["Hypersensitivity (rash, anaphylaxis)","GI (nausea, vomiting, diarrhea, C. difficile colitis)","Local phlebitis (rare)","Fever","Hematologic: increased INR, eosinophilia (see Usage and Dosing)","Three-fold higher risk of hemolytic anemia compared to other cephalosporins. Case report of DIHA following a seven-day postop course: Ann Dermatol 2021;33:384."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"158 (1 gm IV, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"88",volume_of_distribution_vd_l:"10.3 L",avg_serum_half_life_hr:"3-4.6",elimination:"Renal",bile_penetration_percent:"2-21",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"504 (1 gm IV, 0-inf)"},major_drug_interactions:[{drug:"Ethanol",effect:"Possible disulfiram-like reaction",management:"Avoid co-administration"}]}},Cefoxitin:{id:"Cefoxitin",name:"Cefoxitin",tradename:"Mefoxin",classification:{family:"CEPHALOSPORIN",subclass:"Parenteral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"2 gm IV q6-8h",severe:"2 gm IV q6-8h",renal:{normal:"CrCl >50: No dosage adjustment. CrCl 10-50: 2 gm q8-12h. CrCl <10: 2 gm q24-48h",mild:"CrCl >50: No dosage adjustment. CrCl 10-50: 2 gm q8-12h. CrCl <10: 2 gm q24-48h",moderate:"CrCl >50: No dosage adjustment. CrCl 10-50: 2 gm q8-12h. CrCl <10: 2 gm q24-48h",severe:"CrCl >50: No dosage adjustment. CrCl 10-50: 2 gm q8-12h. CrCl <10: 2 gm q24-48h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"65-79",half_life:"0.8",elimination:"Renal",csf_penetration:"3",preparations:"Injection"},rawData:{drug_name:"Cefoxitin",tradename:"Mefoxin",usage_and_dosing:{general:["Cefoxitin is a 2nd-generation parenteral cephamycin cephalosporin.","Increasing resistance of anaerobic Gram-negative bacilli (e.g., Bacteroides sp.) has been observed.","In vitro may induce increased ẞ-lactamase, especially in Enterobacter sp.","For class-wide adverse effects and other information, see Cephalosporins, Overview."],adult_dose:{usual_dose:"2 gm IV q6-8h"},pediatric_dose:{dose_age_gt_28_days:"80-160 mg/kg/day (divided q6-8h)",max_day:"-"}},renal_adjustment:{notes:"May falsely increase Scr by interference with assay.",half_life_normal:"0.8",half_life_esrd:"13-23",dose_renal_function_normal:"2 gm IV q8h",crcl_or_egfr:"CrCl >50: No dosage adjustment. CrCl 10-50: 2 gm q8-12h. CrCl <10: 2 gm q24-48h",hemodialysis:"2 gm q24-48h (+ extra 1 gm AD)",capd:"1 gm q24h",crrt:"2 gm q8-12h",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:{obesity:"For surgical prophylaxis, larger dose possibly required. Data insufficient for a firm recommendation. See Obesity Dosing Adjustments table for more information."},adverse_effects:["Local phlebitis (rare), fever, rash (2%), positive Coombs (2%), neutropenia (2%), eosinophilia (3%), increased PT/PTT, GI (2%), C. difficile colitis, increased LFTs (3%), increased BUN/Creatinine (3%)."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"110 (1 gm IV, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"65-79",volume_of_distribution_vd_l_vss:"16.1 L (Vss)",avg_serum_half_life_hr:"0.8",elimination:"Renal",bile_penetration_percent:"280",csf_blood_percent:"3",therapeutic_levels_in_csf:"No",auc_ug_hr_ml:"No data"},major_drug_interactions:["No significant interactions."],comments:["None"]}},Cefpirome:{id:"Cefpirome",name:"Cefpirome",tradename:"Cefrom",classification:{family:"CEPHALOSPORIN",subclass:"Parenteral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"1-2 gm IV q12h",severe:"1-2 gm IV q12h",renal:{normal:"CrCl >50: No dosage adjustment. CrCl 10-50: 1 gm q12h. CrCl <10: 1 gm q24h",mild:"CrCl >50: No dosage adjustment. CrCl 10-50: 1 gm q12h. CrCl <10: 1 gm q24h",moderate:"CrCl >50: No dosage adjustment. CrCl 10-50: 1 gm q12h. CrCl <10: 1 gm q24h",severe:"CrCl >50: No dosage adjustment. CrCl 10-50: 1 gm q12h. CrCl <10: 1 gm q24h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"No data",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"10",half_life:"2",elimination:"Renal",csf_penetration:"5-15",preparations:"Injection"},rawData:{drug_name:"Cefpirome",tradename:"Cefrom",usage_and_dosing:{general:["Cefpirome is a parenteral 4th generation cephalosporin with in vitro activity against aerobic Gram-positive cocci and most Enterobacteriaceae. It has activity against some P. aeruginosa and is inactive against anaerobic bacilli.","Not available in the US."],adult_dose:{usual_dose:"1-2 gm IV q12h"},pediatric_dose:{dose_age_gt_28_days:"Safety and efficacy not established",max_day:"-"}},renal_adjustment:{half_life_normal:"2",half_life_esrd:"14.5",dose_renal_function_normal:"2 gm IV q12h",crcl_or_egfr:"CrCl >50: No dosage adjustment. CrCl 10-50: 1 gm q12h. CrCl <10: 1 gm q24h",hemodialysis:"1 gm q24h (AD on dialysis days)",capd:"0.5 gm 3x/wk",crrt:"2 gm load, then 1 gm q12h",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:{ecmo:"Increased dosing suggested: 2 gm IV (bolus) q8h, or 2 gm IV (over 4 hr) q12h. See ECMO Drug Dosing Adjustment for details."},adverse_effects:["For class-wide adverse effects, see Cephalosporins, Overview.","Cefpirome has the same R1 side chain as cefotaxime, cefpodoxime, cefditoren, ceftizoxime, ceftriaxone, and cefepime. Cross-allergenicity may occur."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"No data",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{full_comparative_spectrum_of_activity:!0},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"80 (1 gm IV, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"10",volume_of_distribution_vd_l_vss:"21 L (Vss)",avg_serum_half_life_hr:"2",elimination:"Renal",bile_penetration_percent:"No data",csf_blood_percent:"5-15",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"150 (1 gm IV, 0-inf)"},major_drug_interactions:["No significant interactions"]}},Ceftaroline:{id:"Ceftaroline",name:"Ceftaroline",tradename:"Teflaro, Zinforo",classification:{family:"CEPHALOSPORIN",subclass:"Parenteral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"CrCl >50: No dosage adjustment. CrCl 30-50: 400 mg q12h. CrCl 15-30: 300 mg q12h. CrCl <15: 200 mg q12h",mild:"CrCl >50: No dosage adjustment. CrCl 30-50: 400 mg q12h. CrCl 15-30: 300 mg q12h. CrCl <15: 200 mg q12h",moderate:"CrCl >50: No dosage adjustment. CrCl 30-50: 400 mg q12h. CrCl 15-30: 300 mg q12h. CrCl <15: 200 mg q12h",severe:"CrCl >50: No dosage adjustment. CrCl 30-50: 400 mg q12h. CrCl 15-30: 300 mg q12h. CrCl <15: 200 mg q12h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"No data, but adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"20",half_life:"2.7",elimination:"Renal",csf_penetration:"<10",preparations:"Injection"},rawData:{drug_name:"Ceftaroline",tradename:"Teflaro, Zinforo",usage_and_dosing:{general:["Ceftaroline is a parenteral advanced-generation cephalosporin with avid binding to penicillin binding protein (PBP) 2a. Hence, Ceftaroline is active against MRSA and MRSE. Activity against enterococci is poor to moderate.","FDA approved (adults and children) for:","Skin and skin structure infections due to certain susceptible gram-positive and gram-negative microbes, including MRSA.","Community-acquired pneumonia (not MRSA).","An alternative antibiotic for drug resistant genotypes.","Active in vitro vs. HVISA, VISA, and VRSA.","Ceftaroline is inactivated by AmpC and extended-spectrum beta-lactamases (ESBLs).","Aerobic gram-negative bacilli are generally susceptible with the exception of P. aeruginosa. In vitro pattern of susceptibility of aerobic gram-negative bacilli is similar to Ceftriaxone.","Protocol for Ceftaroline desensitization.","For cross-allergenicity, see Drug Allergy: Penicillins, Cephalosporins, Overview.","Review: Clin Infect Dis 2011;52:1156."],adult_dose:{skin_skin_structure_infection_approved_dose:"600 mg IV (over 5-60 min) q12h x5-14 days",cap_approved_dose:"600 mg IV (over 5-60 min) q12h x5-7 days",other_uses_unapproved:["MRSA pneumonia","MRSA bacteremia","MRSA endocarditis","VRE endocarditis"]},pediatric_dose:{age_0_to_lt_2_mon_skin_only:"6 mg/kg q8h (GA ≥34 wk, postnatal ≥12 days)",age_2_mon_to_lt_2_yrs:"8 mg/kg q8h",age_2_yrs_to_lt_18_yrs_le_33_kg:"12 mg/kg q8h",age_ge_2_yrs_to_lt_18_yrs_gt_33_kg:"400 mg q8h or 600 mg q12h",max_day:"-"}},renal_adjustment:{half_life_normal:"2.7",half_life_esrd:"No data",dose_renal_function_normal:"600 mg IV q12h",crcl_or_egfr:"CrCl >50: No dosage adjustment. CrCl 30-50: 400 mg q12h. CrCl 15-30: 300 mg q12h. CrCl <15: 200 mg q12h",hemodialysis:"200 mg q12h",capd:"No data",crrt:"70 kg pt, effluent flow rate 3 L/hr: 400 mg q12h 2",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["ECMO: See ECMO Drug Dosing Adjustment.","Obesity: See Obesity Dosing Adjustments."],adverse_effects:["As for all cephalosporins, there is risk of allergic reaction or development of C. difficile colitis.","Positive Coomb's test in 9.8% of patients without clinical hemolysis.","Nausea, diarrhea, rash developed in 2-5%.","Case report of eosinophilic pneumonia (Am J Health Syst Pharm 2014;71:403).","Retrospective study found reversible neutropenia in 21% of patients treated for ≥3 weeks (J Antimicrob Chemother 2016;71: 2010)."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"No data, but adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"21.3 (600 mg IV q12h, SS)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"20",volume_of_distribution_vd_l_vss:"20.3 L (Vss)",avg_serum_half_life_hr:"2.7",elimination:"Renal",bile_penetration_percent:"No data",csf_blood_percent:"<10",therapeutic_levels_in_csf:"Maybe (at high doses) 21",auc_ug_hr_ml:"56.3 (600 mg q12h, 0-12h)"},major_drug_interactions:["No significant interactions."]}},Ceftazidime:{id:"Ceftazidime",name:"Ceftazidime",tradename:"Fortaz, Tazicef, Tazidime",classification:{family:"CEPHALOSPORIN",subclass:"Parenteral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Pseudomonas aeruginosa"],alternative:[],notes:""},dosing:{adult:{standard:"1-2 gm IV/IM q8-12h",severe:"1-2 gm IV/IM q8-12h",renal:{normal:"CrCl >50: No dosage adjustment. CrCl 10-50: 1-2 gm q12-24h. CrCl <10: 1-2 gm q24h",mild:"CrCl >50: No dosage adjustment. CrCl 10-50: 1-2 gm q12-24h. CrCl <10: 1-2 gm q24h",moderate:"CrCl >50: No dosage adjustment. CrCl 10-50: 1-2 gm q12-24h. CrCl <10: 1-2 gm q24h",severe:"CrCl >50: No dosage adjustment. CrCl 10-50: 1-2 gm q12-24h. CrCl <10: 1-2 gm q24h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"150-200 mg/kg/day (divided q8h)",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:["Pseudomonas aeruginosa"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"<10",half_life:"1.9",elimination:"Renal",csf_penetration:"20-40",preparations:"Injection"},rawData:{drug_name:"Ceftazidime",tradename:"Fortaz, Tazicef, Tazidime",usage_and_dosing:{general:["Ceftazidime is a 3rd generation cephalosporin with activity against P. aeruginosa. In vitro antibacterial spectrum includes many other aerobic gram-negative bacilli.","Poor in vitro activity against gram-positive bacteria.","Susceptible to inactivation by aerobic gram-negative bacteria that synthesize extended spectrum beta-lactamases (ESBLs).","Protocol for ceftazidime desensitization.","See also ceftazidime-avibactam."],adult_dose:{usual_dose:"1-2 gm IV/IM q8-12h",other_dosing:"Continuous, Extended Infusion Dosing, Intraperitoneal Drug Dosing"},pediatric_dose:{standard:"150-200 mg/kg/day (divided q8h)",cf:"300 mg/kg/day (divided q8h)",max_day:"6 gm"}},renal_adjustment:{half_life_normal:"1.9",half_life_esrd:"13-25",dose_renal_function_normal:"1-2 gm IV q8-12h",crcl_or_egfr:"CrCl >50: No dosage adjustment. CrCl 10-50: 1-2 gm q12-24h. CrCl <10: 1-2 gm q24h",hemodialysis:"0.5-1 gm q24h (AD on dialysis days)",capd:"No data",crrt:"1-2 gm q8-12h 40",sled:"2 gm q12h 49"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["ECMO: See ECMO Drug Dosing Adjustment.","Obesity: see Obesity Dosing Adjustments."],adverse_effects:["Hypersensitivity (e.g., rash, anaphylaxis)","Shares the same R1 side chain as Aztreonam and Cefiderocol, thus cross-allergenicity may occur. See Drug Allergy: Penicillins, Cephalosporins, Overview for details.","Possible photosensitivity.","Excessive use may result in increased incidence of C. difficile-associated diarrhea and/or selection of Vancomycin-resistant E. faecium.","See Cephalosporins, Overview."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Pseudomonas aeruginosa"],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"69 (1 gm IV, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"<10",volume_of_distribution_vd_l_kg_vss:"0.24 L/kg (Vss)",avg_serum_half_life_hr:"1.9",elimination:"Renal",bile_penetration_percent:"13-54",csf_blood_percent:"20-40",therapeutic_levels_in_csf:"Yes",auc_ug_hr_ml:"127 (1 gm IV, 0-inf)"},major_drug_interactions:["No significant interactions"]}},"Ceftazidime-avibactam":{id:"Ceftazidime_avibactam",name:"Ceftazidime-avibactam",tradename:"Avycaz, Zavicefta",classification:{family:"CEPHALOSPORIN",subclass:"Parenteral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["E. coli, carbapenemase producer (KPC+)","Resistant (KPC) oxytoca, pneumoniae, variicola"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"CrCl >50: No dosage adjustment. CrCl 31-50: 1.25 gm q8h. CrCl 16-30: 0.94 gm q12h. CrCl 6-15 (± HD): 0.94 gm q24h. CrCl ≤5 (± HD): 0.94 gm q48h",mild:"CrCl >50: No dosage adjustment. CrCl 31-50: 1.25 gm q8h. CrCl 16-30: 0.94 gm q12h. CrCl 6-15 (± HD): 0.94 gm q24h. CrCl ≤5 (± HD): 0.94 gm q48h",moderate:"CrCl >50: No dosage adjustment. CrCl 31-50: 1.25 gm q8h. CrCl 16-30: 0.94 gm q12h. CrCl 6-15 (± HD): 0.94 gm q24h. CrCl ≤5 (± HD): 0.94 gm q48h",severe:"CrCl >50: No dosage adjustment. CrCl 31-50: 1.25 gm q8h. CrCl 16-30: 0.94 gm q12h. CrCl 6-15 (± HD): 0.94 gm q24h. CrCl ≤5 (± HD): 0.94 gm q48h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Ceftazidime: milk concentrations low. Avibactam: no data.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Probenecid",effect:"↑ avibactam",management:"Avoid co-administration"}],stewardship:{preferredIndications:["E. coli, carbapenemase producer (KPC+)","Resistant (KPC) oxytoca, pneumoniae, variicola"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"Ceftaz <10, Avi 5.7-8.2",half_life:"Ceftaz 2.8, Avi 2.7",elimination:"Renal",csf_penetration:"Ceftaz 20-40, Avi no data",preparations:"Injection"},rawData:{drug_name:"Ceftazidime-avibactam",tradename:"Avycaz, Zavicefta",usage_and_dosing:{general:["Ceftazidime-avibactam (Avycaz, Zavicefta) is a parenteral anti-pseudomonal cephalosporin combined with the non-beta-lactam beta-lactamase inhibitor avibactam.","FDA approved for:","Complicated urinary tract infections, including pyelonephritis","Complicated intra-abdominal infections if used in combination with Metronidazole","Specific therapy of hospital-acquired/ventilator-associated pneumonia due to susceptible aerobic gram-negative bacilli","An alternative antibiotic for drug resistant genotypes.","In vitro and selected animal model infection data indicate that avibactam protects Ceftazidime against degradation by the following enzymes with a resulting expanded spectrum of antibacterial activity:","TEM, SHV","Extended spectrum beta-lactamases (ESBLs): CTX-M","AmpC cephalosporinases","Klebsiella pneumoniae carbapenemases (KPCs)","Selected oxacillinase carbapenemases","Of import, avibactam has no influence on other mechanisms of Ceftazidime resistance:","Bacteria that produce metallo-carbapenemases","Bacteria that overproduce efflux pumps (see Comment)","Bacteria with porin mutations that inhibit transfer across the cell wall (see Comment)","Product is formulated in a 4:1 ratio (ceftazidime:avibactam)","Allergy: Protocol for Ceftazidime-avibactam desensitization","Review: Clin Infect Dis 2016; 63:234"],adult_dose:{fda_approved_dosage:"2.5 gm IV (over 2 hr) q8h",composition:"2.5 gm = ceftazidime 2 gm + avibactam 0.5 gm",complicated_intraabdominal_infection:"For complicated intraabdominal infection, combine with metronidazole 500 mg IV q8h",recommended_duration_of_treatment:{complicated_intraabdominal_infection:"5-14 days",complicated_uti:"7-14 days",hap_vap:"7-14 days"}},pediatric_dose:{infusion_time:"Infuse doses over 2 hr unless otherwise specified",composition:"Doses shown are ceftazidime + avibactam (4:1 ratio)",pediatric_clai:"For pediatric clAl, give concurrent metronidazole (10 mg/kg q8h)",amr_guidance:"AMR gram-negative guidance: J Pediatric Infect Dis Soc 2025;14:piaf004",fda_approved_dosing:{age_le_28_days_ga_ge_31_wks:"25 mg/kg q8h",age_gt_28_days_to_lt_3_mon:"37.5 mg/kg q8h",age_3_mon_to_lt_6_mon:"50 mg/kg q8h",age_6_mon_to_lt_2_yrs:"62.5 mg/kg q8h",age_2_to_lt_18_yrs:"62.5 mg/kg q8h"},per_amr_guidance:{age_le_28_days_ga_ge_31_wks:"31.25 mg/kg q8h",age_gt_28_days_to_lt_3_mon:"37.5 mg/kg (over 3 hr) q8h",age_3_mon_to_18_yrs:"62.5 mg/kg (over 3 hr) q8h",note:"use 2 hour infusions for CNS infections"},max_day:"7.5 gm"}},renal_adjustment:{half_life_normal:"Ceftazidime: 2.8, Avibactam: 2.7",half_life_esrd:"Ceftazidime 13-25",dose_renal_function_normal:"2.5 gm IV q8h",crcl_or_egfr:"CrCl >50: No dosage adjustment. CrCl 31-50: 1.25 gm q8h. CrCl 16-30: 0.94 gm q12h. CrCl 6-15 (± HD): 0.94 gm q24h. CrCl ≤5 (± HD): 0.94 gm q48h",hemodialysis:"CrCl ≤15 on HD: AD on dialysis days",capd:"No data",crrt:"CVVH: 1.25 gm q8h, CVVHDF: 2.5 gm q8h 37, 38"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["Obesity: See Obesity Dosing Adjustments page.","ECMO: See ECMO Drug Dosing Adjustment page."],adverse_effects:["Hypersensitivity reactions. Note: Ceftazidime, Aztreonam, and Cefiderocol have identical R1 side chains. Examples of cross reactive allergic reactions have occurred.","Clostridioides difficile-associated diarrhea","Central nervous system (e.g., seizures, coma, myoclonus)","Seen with Ceftazidime, particularly with renal failure","Nausea and vomiting (when used with Metronidazole), 10%","Constipation and anxiety (in UTI group), 10%","At <5%: eosinophilia, thrombocytopenia, increased prothrombin time, increased GGT, hypokalemia, acute kidney injury, rash (see also, adverse reactions from Ceftazidime alone)"],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Ceftazidime: milk concentrations low. Avibactam: no data.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["E. coli, carbapenemase producer (KPC+)","Resistant (KPC) oxytoca, pneumoniae, variicola"],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"Ceftaz 90.4, Avi 14.6 (2.5 gm IV q8h, SS)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"Ceftaz <10, Avi 5.7-8.2",volume_of_distribution_vd_l_vss:"Ceftaz 17 L, Avi 22.2 L (Vss)",avg_serum_half_life_hr:"Ceftaz 2.8, Avi 2.7",elimination:"Renal",bile_penetration_percent:"Ceftaz 13-54, Avi no data",csf_blood_percent:"Ceftaz 20-40, Avi no data",therapeutic_levels_in_csf:"Ceftaz Yes, Avi no data",auc_ug_hr_ml:"Ceftaz 291, Avi 38.2 (SS, 0-8 hr)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:"Avibactam: OAT1, OAT3",ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:[{drug:"Probenecid",effect:"↑ avibactam",management:"Avoid co-administration"}],comments:["In a trial of complicated intra-abdominal infection, for patients with CrCl 30-50 mL/min death rate was higher among Ceftazidime-avibactam treated patients than controls (Meropenem); however, dosing was lower than currently recommended for this range of renal function.","There was no difference in patients with CrCl > 50 mL/min. There is no clear explanation for this observation.","One hypothesis: Initial dosing calculated based on elevated serum creatinine at time of admission. Elevated creatinine resolved within 48 hrs in 57% of patients in a retrospective review (Clin Infect Dis 2019;68; 1596).","In critically ill, suggest full dosage until clear whether renal function will improve with hydration and other measures.","Resistance found in archived clinical isolates of P. aeruginosa. Resistance not due to beta-lactamases. Resistance due to efflux pumps and reduced membrane permeability (Antimicrob Agents Chemother 59:1020, 2015). Could restore susceptibility in vitro with Fosfomycin.","Approval for nosocomial pneumonia based on controlled trial. For results see: Lancet Infect Dis 18:285, 2018; Lancet Infect Dis 18:229, 2018."]}},Ceftizoxime:{id:"Ceftizoxime",name:"Ceftizoxime",tradename:"Cefizox",classification:{family:"CEPHALOSPORIN",subclass:"Parenteral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"1-2 gm IV q8-12h",severe:"1-2 gm IV q8-12h",renal:{normal:"CrCl >90: No dosage adjustment. CrCl >50-90: 2 gm q8-12h. CrCl 10-50: 2 gm q12-24h. CrCl <10: 2 gm q24h",mild:"CrCl >90: No dosage adjustment. CrCl >50-90: 2 gm q8-12h. CrCl 10-50: 2 gm q12-24h. CrCl <10: 2 gm q24h",moderate:"CrCl >90: No dosage adjustment. CrCl >50-90: 2 gm q8-12h. CrCl 10-50: 2 gm q12-24h. CrCl <10: 2 gm q24h",severe:"CrCl >90: No dosage adjustment. CrCl >50-90: 2 gm q8-12h. CrCl 10-50: 2 gm q12-24h. CrCl <10: 2 gm q24h"},hepatic:"No data",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"30",half_life:"1.7",elimination:"Renal",csf_penetration:"No data",preparations:"Injection"},rawData:{drug_name:"Ceftizoxime",tradename:"Cefizox",usage_and_dosing:{general:["Ceftizoxime is a 3rd generation parenteral cephalosporin with in vitro activity against aerobic gram-positive cocci (but not MRSA or enterococci) and aerobic gram-negative bacilli (but not P. aeruginosa) and selected anaerobic bacteria (but not B. fragilis).","Inactivated by bacteria that produce extended spectrum beta-lactamases (ESBLs).","Major adverse effects are allergy and development of C. difficile toxin-mediated colitis. For class-wide adverse effects, see Cephalosporins, Overview."],adult_dose:{usual_dose:"1-2 gm IV q8-12h",life_threatening_infection:"Max 2 gm IV q4h (or 4 gm IV q8h)"},pediatric_dose:{dose_age_gt_28_days:"150-200 mg/kg/day (divided q6-8h)",max_day:"-"}},renal_adjustment:{half_life_normal:"1.7",half_life_esrd:"15-35",dose_renal_function_normal:"2 gm IV q8h",crcl_or_egfr:"CrCl >90: No dosage adjustment. CrCl >50-90: 2 gm q8-12h. CrCl 10-50: 2 gm q12-24h. CrCl <10: 2 gm q24h",hemodialysis:"2 gm q24h (+ extra 1 gm AD)",capd:"0.5-1 gm q24h",crrt:"2 gm q12-24h",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No data",moderate_impairment_child_pugh_b:"No data",severe_impairment_child_pugh_c:"No data"},adverse_effects:["Local phlebitis (4%), fever, rash (2%), neutropenia, eosinophilia (4%), thrombocytopenia, increased PT/PTT, C. difficile colitis, increased LFTs (4%).","Ceftizoxime has the same R1 side chain as cefotaxime, cefpodoxime, cefpirome, cefditoren, ceftriaxone, and cefepime. Cross-allergenicity may occur."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"60 (1 gm IV, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"30",volume_of_distribution_vd_l_kg:"0.34 L/kg",avg_serum_half_life_hr:"1.7",elimination:"Renal",bile_penetration_percent:"34-82",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"85 (1 gm IV, 0-inf)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:["OAT1","OAT3"],ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:["No significant interactions"],comments:["Where available. No longer marketed in the US"]}},"Ceftobiprole medocaril":{id:"Ceftobiprole_medocaril",name:"Ceftobiprole medocaril",tradename:"Zevtera",classification:{family:"CEPHALOSPORIN",subclass:"Parenteral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:{gt_150:"667 mg q6h",ge_50_to_150:"No dosage adjustment","30_to_lt_50":"SAB: 667 mg q8h days 1-8, then q12h. ABSSSI, CAP: 667 mg q12h","15_to_lt_30":"SAB: 333 mg q8h days 1-8, then q12h. ABSSSI, CAP: 333 mg q12h",lt_15:"333 mg q24h"},mild:{gt_150:"667 mg q6h",ge_50_to_150:"No dosage adjustment","30_to_lt_50":"SAB: 667 mg q8h days 1-8, then q12h. ABSSSI, CAP: 667 mg q12h","15_to_lt_30":"SAB: 333 mg q8h days 1-8, then q12h. ABSSSI, CAP: 333 mg q12h",lt_15:"333 mg q24h"},moderate:{gt_150:"667 mg q6h",ge_50_to_150:"No dosage adjustment","30_to_lt_50":"SAB: 667 mg q8h days 1-8, then q12h. ABSSSI, CAP: 667 mg q12h","15_to_lt_30":"SAB: 333 mg q8h days 1-8, then q12h. ABSSSI, CAP: 333 mg q12h",lt_15:"333 mg q24h"},severe:{gt_150:"667 mg q6h",ge_50_to_150:"No dosage adjustment","30_to_lt_50":"SAB: 667 mg q8h days 1-8, then q12h. ABSSSI, CAP: 667 mg q12h","15_to_lt_30":"SAB: 333 mg q8h days 1-8, then q12h. ABSSSI, CAP: 333 mg q12h",lt_15:"333 mg q24h"}},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans; evidence of minor maternal adverse effects in animals (↓ body weight, ↓ appetite).",lactation:"No data, but adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"16",half_life:"3.3",elimination:"Renal",csf_penetration:"12% (conc 1.2 µg/mL) (Heliyon 2024;10:e27285)",preparations:"Injection"},rawData:{drug_name:"Ceftobiprole medocaril",tradename:"Zevtera",usage_and_dosing:{general:["Ceftobiprole medocaril is an advanced generation parenteral cephalosporin with activity against some gram positive and gram negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is a prodrug that is rapidly converted to ceftobiprole presumably by plasma esterases.","In vitro spectrum of activity is similar to Ceftaroline.","Approved by the US FDA in April 2024 for these indications:","Adults with S. aureus bacteremia, including those with right-sided IE, caused by MSSA and MRSA.","Adults with acute bacterial skin and skin structure infections (ABSSSI) caused by MSSA, MRSA, S. pyogenes, and K. pneumoniae.","Adult and pediatric patients with CAP caused by MSSA, S. pneumoniae, H. influenzae, H. parainfluenzae, E. coli, and K. pneumoniae.","Not approved in the US for ventilator-associated pneumonia (VAP).","Approved in the EU, Switzerland and Canada for community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), but not VAP.","An alternative antibiotic for drug resistant genotypes.","Susceptible to hydrolysis by ESBLs and AmpC cephalosporinases.","Non-inferior to daptomycin based on overall treatment success in patients with complicated S. aureus bacteremia: N Engl J Med 2023; 389:1390"],adult_dose:{s_aureus_bacteremia:"667 mg IV q6h on day 1-8, then 667 mg IV q8h from day 9 on (up to 42 days).",absssi_cap:"667 mg IV q8h x5-14 days.",equivalence:"667 mg of ceftobiprole medocaril is equivalent to 500 mg of ceftobiprole.",infusion:"Infuse doses over 2 hours. Compatible with D5W or NS. Do not co-administer with calcium-containing solutions."},pediatric_dose:{cap_egfr_ge_50:{age_3_mon_to_lt_12_yrs:"20 mg/kg (max 667 mg) q8h x7-14 days",age_12_yrs_to_lt_18_yrs:"13.3 mg/kg (max 667 mg) q8h x7-14 days"},cap_egfr_lt_50:{age_2_yrs_to_lt_6_yrs_by_egfr:{"30_to_lt_50":"13.3 mg/kg q12h (max 667 mg)","15_to_lt_30":"13.3 mg/kg q24h (max 333 mg)"},age_6_yrs_to_lt_12_yrs_by_egfr:{"30_to_lt_50":"10 mg/kg (max 667 mg) q12h","15_to_lt_30":"10 mg/kg (max 333 mg) q24h"},age_12_yrs_to_lt_18_yrs_by_egfr:{"30_to_lt_50":"10 mg/kg (max 667 mg) q12h","15_to_lt_30":"10 mg/kg (max 333 mg) q12h"},lt_15:"No data"},max_day:"-"}},renal_adjustment:{half_life_normal:"3.3",half_life_esrd:"21",dose_renal_function_normal:"667 mg IV q8h",crcl_or_egfr:{gt_150:"667 mg q6h",ge_50_to_150:"No dosage adjustment","30_to_lt_50":"SAB: 667 mg q8h days 1-8, then q12h. ABSSSI, CAP: 667 mg q12h","15_to_lt_30":"SAB: 333 mg q8h days 1-8, then q12h. ABSSSI, CAP: 333 mg q12h",lt_15:"333 mg q24h"},hemodialysis:"333 mg q24h (AD on dialysis days)",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:{ecmo:"No dose adjustment likely required. See Table for more information."},adverse_effects:{most_common:["Nausea, vomiting, diarrhea","Hypersensitivity (urticaria, rash)","Infusion site reactions","Dysgeusia"],less_common:["Thrombocytopenia, agranulocytosis","Anaphylaxis","C. difficile colitis","Agitation (anxiety, panic attack, nightmares), seizures"]},pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans; evidence of minor maternal adverse effects in animals (↓ body weight, ↓ appetite).",lactation:"No data, but adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"33.0 (667 mg IV q8h, SS)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"16",volume_of_distribution_vd_l_vss:"18 L (Vss)",avg_serum_half_life_hr:"3.3",elimination:"Renal",bile_penetration_percent:"No data",csf_blood_percent:"12% (conc 1.2 µg/mL) (Heliyon 2024;10:e27285)",therapeutic_levels_in_csf:"Possibly",auc_ug_hr_ml:"102 (667 mg IV q8h, 0-8h)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:[],ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:["OATP1B1/3"],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"↑"},major_drug_interactions:["No clinically relevant drug interactions known"]}},"Ceftolozane-tazobactam":{id:"Ceftolozane_tazobactam",name:"Ceftolozane-tazobactam",tradename:"Zerbaxa",classification:{family:"CEPHALOSPORIN",subclass:"Parenteral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Pseudomonas aeruginosa"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:{gt_50:"No dosage adjustment","30_50":"IAI/UTI: 750 mg q8h, HAP/VAP: 1.5 gm q8h","15_29":"IAI/UTI: 375 mg q8h, HAP/VAP: 750 mg q8h",lt_15_on_hd:"See HD recommendations"},mild:{gt_50:"No dosage adjustment","30_50":"IAI/UTI: 750 mg q8h, HAP/VAP: 1.5 gm q8h","15_29":"IAI/UTI: 375 mg q8h, HAP/VAP: 750 mg q8h",lt_15_on_hd:"See HD recommendations"},moderate:{gt_50:"No dosage adjustment","30_50":"IAI/UTI: 750 mg q8h, HAP/VAP: 1.5 gm q8h","15_29":"IAI/UTI: 375 mg q8h, HAP/VAP: 750 mg q8h",lt_15_on_hd:"See HD recommendations"},severe:{gt_50:"No dosage adjustment","30_50":"IAI/UTI: 750 mg q8h, HAP/VAP: 1.5 gm q8h","15_29":"IAI/UTI: 375 mg q8h, HAP/VAP: 750 mg q8h",lt_15_on_hd:"See HD recommendations"}},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:["Pseudomonas aeruginosa"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"Ceftolozane: 16-21, Tazobactam: 30",half_life:"Ceftolozane: 3.1, Tazobactam: 1.0",elimination:"Renal",csf_penetration:"Ceftolozane: 20, Tazobactam: 20 (fAUC CSF/blood) 25",preparations:"Injection"},rawData:{drug_name:"Ceftolozane-tazobactam",tradename:"Zerbaxa",usage_and_dosing:{general:["Ceftolozane-tazobactam, FDA-approved in 2014, is a parenteral advanced-generation cephalosporin combined with a beta-lactamase inhibitor.","The product exists in a 2:1 ratio of ceftolozane to tazobactam. Doses are expressed as the sum of the components. For example. ceftolozane-tazobactam 1.5 gm = ceftolozane 1 gm + tazobactam 0.5 gm.","Approved indictations:","Complicated urinary tract infections, including pyelonephritis","Complicated intra-abdominal infections (in combination with metronidazole)","Hospital-acquired and ventilator-associated pneumonia","Active vs. most aerobic gram-negative bacilli that produce extended spectrum beta-lactamases (ESBL) and P. aeruginosa. Not active vs many anaerobes, enterococci and staphylococci.","Stable in the presence of ESBLs and at least some AmpC cephalosporinases (Antimicrob Agents Chemother 2014;58:3091). Not a good substrate for efflux pumps.","Susceptibility trends in European gram-negative isolates: J Antimicrob Chemother 2020;75:2907.","An alternative antibiotic for drug resistant genotypes.","In trials of efficacy for both complicated intra-abdominal infections and complicated UTI, the clinical cure rate in the microbiological intent-to-treat patients with CrCl between 30-50 mL/min was lower than patients in the control arm. There was no difference in patients with CrCl >50 mL/min.","One hypothesis for this observation: Initial dosing is calculated based on transiently elevated serum creatinine at initiation of therapy.","In a retrospective review, AKI present at admission resolved within 48 hours in 57% of patients. In critically ill patients, the authors suggest deferred renal dosage adjustment during the first 48 hours until it is clear whether renal function will improve with hydration and other measures (Clin Infect Dis 2019;68:1596).","Possible OPAT option: see Outpatient Parenteral Antimicrobial Therapy.","Review: Antimicrob Agents Chemother 2021;65:e0231820"],adult_dose:{note:"Doses are expressed as the sum of the components",fda_approved_dosing:{complicated_intraabdominal_infection:"(+ metronidazole 500 mg IV q8h or 1 gm IV q12h) 1.5 gm IV (over 1 hr) q8h x4-14 days",complicated_uti_including_pyelonephritis:"1.5 gm IV (over 1 hr) q8h x7 days",hospital_acquired_ventilator_associated_bacterial_pneumonia:"3 gm IV (over 1 hr) q8h x8-14 days"},amr_guidance:{uncomplicated_cystitis:"1.5 gm IV (over 1 hr) q8h",all_other_infections:"3 gm IV (over 3 hr) q8h"}},pediatric_dose:{amr_guidance:"J Pediatric Infect Dis Soc 2025;14:piaf004",note:"Doses are expressed as the sum of the components",fda_approved_dosing:{clai:"30 mg/kg (over 1 hr) q8h x5-14 days",cuti_pyelo:"30 mg/kg (over 1hr) q8h x7-14 days"},per_amr_guidance:{for_neonates_infants_and_children:{cystitis:"30 mg/kg (over 1 hr) q8h",all_other:"60-75 mg/kg (over 3 hr) q8h"},note:"use 1 hr infusions for CNS infection"},max_day:{fda:"4.5 gm",amr_guidelines:{cystitis:"4.5 gm",other:"9 gm"}}}},renal_adjustment:{note:"Doses are expressed as the sum of the components",half_life_normal:"Ceftolozane: 3.1",half_life_esrd:"Ceftolozane: 40",dose_renal_function_normal:"IAI/UTI: 1.5 gm IV q8h, HAP/VAP: 3 gm IV q8h",crcl_or_egfr:{gt_50:"No dosage adjustment","30_50":"IAI/UTI: 750 mg q8h, HAP/VAP: 1.5 gm q8h","15_29":"IAI/UTI: 375 mg q8h, HAP/VAP: 750 mg q8h",lt_15_on_hd:"See HD recommendations"},hemodialysis:{iai_uti:"750 mg load, 150 mg q8h (dose AD)",hap_vap:"2.25 gm load, 450 mg q8h (dose AD)"},capd:"No data",crrt:"CVVHDF: 3 gm x1, then 750 mg q8h 23"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["Obesity: See Obesity Dosing Adjustments.","ECMO: See ECMO Drug Dosing Adjustment."],adverse_effects:["Hypersensitivity (e.g., rash).","Ceftolozane does not have the same R-1 or R-2 side chain as any other beta-lactam.","See Drug Allergy: Penicillins, Cephalosporins, Overview.","Nausea, diarrhea, headache, fever (≥5%)","Renal impairment (0.5%)","Clostridioides difficile diarrhea reported"],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Pseudomonas aeruginosa"],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"Ceftolozane: 74.4, Tazobactam: 18 (1.5 gm IV q8h, SS)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"Ceftolozane: 16-21, Tazobactam: 30",volume_of_distribution_vd_l_vss:"Ceftolozane: 13.5 L, Tazobactam: 18.2 L (Vss)",avg_serum_half_life_hr:"Ceftolozane: 3.1, Tazobactam: 1.0",elimination:"Renal",bile_penetration_percent:"No data",csf_blood_percent:"Ceftolozane: 20, Tazobactam: 20 (fAUC CSF/blood) 25",therapeutic_levels_in_csf:"Unlikely",auc_ug_hr_ml:"Ceftolozane: 182, Tazobactam: 25 (SS, 0-8h)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:"Tazobactam: OAT1, OAT3",ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:["No known clinically relevant drug interactions."]}},Ceftriaxone:{id:"Ceftriaxone",name:"Ceftriaxone",tradename:"Rocephin",classification:{family:"CEPHALOSPORIN",subclass:"Parenteral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Borrelia burgdorferi","Escherichia coli, susceptible","Haemophilus ducreyi","Haemophilus influenzae","K. oxytoca, Susceptible strains","Kingella sp.","Leptospira sp.","Morganella morganii","Neisseria meningitidis","Susceptible strains. K. pneumoniae, K. variicola","Viridans group streptococci","Yersinia enterocolitica"],alternative:[],notes:""},dosing:{adult:{standard:"1-2 gm IV q24h",severe:"1-2 gm IV q24h",renal:{normal:"No dosage adjustment for renal impairment",mild:"No dosage adjustment for renal impairment",moderate:"No dosage adjustment for renal impairment",severe:"No dosage adjustment for renal impairment"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"50-100 mg/kg q24h",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals. Use with caution at term due to risk of kernicterus in the newborn.",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Calcium-containing IV solutions",effect:"Precip of ceftriaxone-calcium if mixed in same IV line",management:"Avoid co-administration"},{drug:"Lansoprazole",effect:"↑ risk of QTc interval prolongation",management:"Avoid co-administration"}],stewardship:{preferredIndications:["Borrelia burgdorferi","Escherichia coli, susceptible","Haemophilus ducreyi","Haemophilus influenzae","K. oxytoca, Susceptible strains","Kingella sp.","Leptospira sp.","Morganella morganii","Neisseria meningitidis","Susceptible strains. K. pneumoniae, K. variicola","Viridans group streptococci","Yersinia enterocolitica"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"85-95",half_life:"8",elimination:"Renal, biliary",csf_penetration:"8-16",preparations:"Injection"},rawData:{drug_name:"Ceftriaxone",tradename:"Rocephin",usage_and_dosing:{general:["Ceftriaxone is a 3rd generation parenteral cephalosporin with activity against many aerobic gram-negative bacilli and, in addition, Strep. pneumoniae, N. meningitidis, and MSSA.","Notable lack of activity against Listeria spp., enterococci, MRSA, P. aeruginosa and B. fragilis.","Ceftriaxone is susceptible to inactivation by extended spectrum beta-lactamases (ESBLs) and chromosomal induced cephalosporinases.","Ceftriaxone susceptibility is a reasonable proxy for susceptibility to the advanced-generation oral cephalosporins cefuroxime, cefdinir, cefpodoxime, and cefixime, particularly for common Enterobacterales species at low risk for AmpC production such as E. coli, K. pneumoniae, K. oxytoca, and P. mirabilis (Antimicrob Agents Chemother 2025;69:e0138724).","In a pilot study: 2 gm once daily by continuous infusion was superior to 2 gm bolus once daily (J Antimicrob Chemother 2007;59:285).","Desensitization: See Ceftriaxone Desensitization page."],adult_dose:{usual_dose:"1-2 gm IV q24h",other_dosing:"Meningitis, Overview, Gonorrhea, Overview"},pediatric_dose:{standard:"50-100 mg/kg q24h",meningitis:"50 mg/kg q12h",meningococcal_proph_age_lt_15:"125 mg IM x1"}},renal_adjustment:{note:"In patients with significant renal and liver disease, limit dosage to 2 gm daily.",half_life_normal:"8",half_life_esrd:"Unchanged",dose_renal_function_normal:"1-2 gm IV q12-24h",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No dosage adjustment",capd:"No dosage adjustment",crrt:"No dosage adjustment",sled:"No data"},hepatic_adjustment:{note:"Limit dosage to 2 gm/day in patients with concomitant hepatic and renal dysfunction.",mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["Obesity: See Obesity Dosing Adjustments page.","ECMO: See ECMO Drug Dosing Adjustment page."],adverse_effects:["For class-wide adverse effects, see Cephalosporins, Overview.","Pseudocholelithiasis secondary to sludge in gallbladder by ultrasound (50%), symptomatic (9%) (N Engl J Med 322:1821, 1990). More likely with Ceftriaxone ≥2 gm/day and with patient on total parenteral nutrition and not eating (Ann Intern Med 115:712, 1991). Clinical significance still unclear but has led to cholecystectomy (J Infect Dis 171:356, 1995) and gallstone pancreatitis (Ped Infect Dis J 17:662, 1998). Urinary precipitates, which may be detected on renal ultrasound and which may be asymptomatic or associated with signs and symptoms of urolithiasis, reported particularly in children; reversible on discontinuation of the drug which is recommended if these occur.","Local phlebitis (2%), fever (rare), rash (2%), neutropenia (2%), eosinophilia (6%), increased PT/PTT, nausea/vomiting (rare), diarrhea (3%), increased BUN/Creatinine (1%), headache (rare).","Ceftriaxone has the same R1 side chain as cefotaxime, cefpodoxime, cefpirome, cefditoren, ceftizoxime, and cefepime. Cross-allergenicity may occur. See Drug Allergy: Penicillins, Cephalosporins, Overview.","Drug-induced immune thrombocytopenia (J Thrombosis & Haemostasis 2012,11:169)","Patients on ceftriaxone plus lansoprazole had 12 ms longer QTc intervals than patients exposed to either drug alone, and were 1.4x as likely to have a QTc interval >500 ms (J Amer Coll Cardiol 2016;68:1756). In a retrospective cohort study, the combination was associated with increased risk of ventricular arrhythmia, cardiac arrest, and mortality compared to ceftriaxone plus other PPIs (JAMA Netw Open 2023;6:e2339893)."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals. Use with caution at term due to risk of kernicterus in the newborn.",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Borrelia burgdorferi","Escherichia coli, susceptible","Haemophilus ducreyi","Haemophilus influenzae","K. oxytoca, Susceptible strains","Kingella sp.","Leptospira sp.","Morganella morganii","Neisseria meningitidis","Susceptible strains. K. pneumoniae, K. variicola","Viridans group streptococci","Yersinia enterocolitica"],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"150 (1 gm IV, SD)",peak_urine_conc_ug_ml:"995 (1 gm IV, SD)",protein_binding_percent:"85-95",volume_of_distribution_vd_l:"5.8-13.5 L",avg_serum_half_life_hr:"8",elimination:"Renal, biliary",bile_penetration_percent:"200-500",csf_blood_percent:"8-16",therapeutic_levels_in_csf:"Yes",auc_ug_hr_ml:"1006 (1 gm IV, 0-inf)"},major_drug_interactions:[{drug:"Calcium-containing IV solutions",effect:"Precip of ceftriaxone-calcium if mixed in same IV line",management:"Avoid co-administration"},{drug:"Lansoprazole",effect:"↑ risk of QTc interval prolongation",management:"Avoid co-administration"}],comments:["Only free non-protein bound drug is active. In critically ill patients, the protein binding of Ceftriaxone was substantively less than predicted: Antimicrob Agents Chemother 57:6165, 2013."]}},Cefuroxime:{id:"Cefuroxime",name:"Cefuroxime",tradename:"Ceftin, Zinacef",classification:{family:"CEPHALOSPORIN",subclass:"Parenteral",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"750 mg IV/IM q8h",severe:"750 mg IV/IM q8h",renal:{normal:"CrCl >50: No dosage adjustment. CrCl 10-50: 0.75-1.5 gm q8-12h. CrCl <10: 0.75-1.5 gm q24h",mild:"CrCl >50: No dosage adjustment. CrCl 10-50: 0.75-1.5 gm q8-12h. CrCl <10: 0.75-1.5 gm q24h",moderate:"CrCl >50: No dosage adjustment. CrCl 10-50: 0.75-1.5 gm q8-12h. CrCl <10: 0.75-1.5 gm q24h",severe:"CrCl >50: No dosage adjustment. CrCl 10-50: 0.75-1.5 gm q8-12h. CrCl <10: 0.75-1.5 gm q24h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"150 mg/kg/day (divided q8h)",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"33-50",half_life:"1.5",elimination:"Renal",csf_penetration:"17-88",preparations:"Injection"},rawData:{drug_name:"Cefuroxime",tradename:"Ceftin, Zinacef",usage_and_dosing:{general:["Cefuroxime is an intravenous 2nd generation cephalosporin with enhanced activity against H. influenzae (as compared to 1st generation cephalosporins). Retains activity against MSSA, Penicillin-sensitive Strep. pneumoniae, Strep. pyogenes, E. coli, P. mirabilis and Klebsiella sp.","Parenteral use is limited to less severe skin and skin structure infections and surgical prophylaxis (alternative to cefazolin for head and neck, cardiac surgery).","For oral drug, see Cefuroxime axetil.","More stable vs staphylococcal ẞ-lactamase than Cefazolin.","For cross-allergenicity and other class-wide adverse effects, see Cephalosporins, Overview. See also Penicillin (Beta Lactam) Allergy Overview."],adult_dose:{usual_dose:"750 mg IV/IM q8h",more_serious_infections:"Can increase to 1.5 gm IV q6h",surgical_prophylaxis:"1.5 gm within 60 mins of surgical incision"},pediatric_dose:{standard:"150 mg/kg/day (divided q8h)",meningitis:"240 mg/kg/day (divided q8h)"}},renal_adjustment:{half_life_normal:"1.5",half_life_esrd:"17",dose_renal_function_normal:"0.75-1.5 gm IV q8h",crcl_or_egfr:"CrCl >50: No dosage adjustment. CrCl 10-50: 0.75-1.5 gm q8-12h. CrCl <10: 0.75-1.5 gm q24h",hemodialysis:"0.75-1.5 gm q24h (AD on dialysis days)",capd:"0.75-1.5 gm q24h",crrt:"0.75-1.5 gm q8-12h",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["Local phlebitis (2%), rash (rare), positive Coombs (rare), neutropenia (rare), eosinophilia (7%), nausea/vomiting (rare), diarrhea (4-11%), C. difficile colitis, increased LFTs (4%).","For cross-allergenicity and other class-wide adverse effects, see Cephalosporins, Overview."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"100 (1.5 gm IV, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"33-50",volume_of_distribution_vd_l_kg_vss:"0.19 L/kg (Vss)",avg_serum_half_life_hr:"1.5",elimination:"Renal",bile_penetration_percent:"35-80",csf_blood_percent:"17-88",therapeutic_levels_in_csf:"Marginal",auc_ug_hr_ml:"150 (1.5 gm IV, 0-inf)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:["OAT1","OAT3"],ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:["No significant interactions"],comments:[]}},Chloramphenicol:{id:"Chloramphenicol",name:"Chloramphenicol",tradename:"Chloromycetin",classification:{family:"OTHER",subclass:"Other",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"50-100 mg/kg/day po/IV, divided q6h (maximum of 4 gm/day)",severe:"50-100 mg/kg/day po/IV, divided q6h (maximum of 4 gm/day)",renal:{normal:"No dosage adjustment for renal impairment",mild:"No dosage adjustment for renal impairment",moderate:"No dosage adjustment for renal impairment",severe:"No dosage adjustment for renal impairment"},hepatic:"Consider dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"C",lactation:"Avoid use",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"High",protein_binding:"25-50",half_life:"4.1",elimination:"Metabolized",csf_penetration:"45-89",preparations:"Injection (no po in US)"},rawData:{drug_name:"Chloramphenicol",tradename:"Chloromycetin",drug_shortage:[{preparation:"Injection",start_date:"2023-10-09",notes:""}],usage_and_dosing:{general:["Chloramphenicol is available in IV or po form, but no oral preparation is distributed in the US.","Used as an alternative antibiotic when less toxic agents are not effective.","Alternative to Doxycycline for rickettsial infections.","Alternative therapy for tularemia.","Possible alternative for N. meningitidis or S. pneumoniae meningitis in patient with severe penicillin allergy.","In extensive systematic review and meta-analysis of controlled trials, authors conclude that chloramphenicol cannot be recommended as preferred therapy for the treatment of respiratory tract infections, meningitis, or enteric fever (J Antimicrob Chemother 70: 979, 2015)"],adult_dose:{usual_dose:"50-100 mg/kg/day po/IV, divided q6h (maximum of 4 gm/day)"},pediatric_dose:{dose_age_gt_28_days:"50-100 mg/kg/day IV (divided q6h)",max_day:"2-4 gm"}},renal_adjustment:{notes:["Body weight and Creatinine Clearance calculations","CrCl = Creatinine clearance (mL/min)","CAPD = Continuous Ambulatory Peritoneal Dialysis","CRRT = Continuous Renal Replacement Therapy","AD = after hemodialysis","SLED = sustained low efficiency dialysis","Dosage adjustment may be required in hepatic disease."],half_life_normal:"4.1",half_life_esrd:"Unchanged",dose_normal_function:"50-100 mg/kg/day po/IV (divided q6h)",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No dosage adjustment",capd:"No dosage adjustment",crrt:"No dosage adjustment",sled:"No data"},hepatic_adjustment:{note:"Monitor serum concentrations in hepatic dysfunction, if possible.",mild_impairment_child_pugh_a:"Consider dosage adjustment",moderate_impairment_child_pugh_b:"Consider dosage adjustment",severe_impairment_child_pugh_c:"Consider dosage adjustment"},adverse_effects:["Fever, rash, neutropenia, thrombocytopenia, diarrhea, headache, confusion.","Hematologic (↓ RBC ~1/3 patients; aplastic anemia 1:21,600 courses but may be fatal).","Gray baby syndrome in premature infants (circulatory collapse).","Other: anaphylactoid reactions, optic atrophy or neuropathy (very rare), digital paresthesias, minor disulfiram-like reactions."],pregnancy_risk:{fda_risk_category:"C",lactation:"Avoid use",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"No data",preparations:"Injection (no po in US)",food_recommendation:"Cap ± food",oral_absorption_percent:"High",tmax_hr:"No data",peak_serum_conc_ug_ml:"18 (1 gm po q6h, SS)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"25-50",volume_of_distribution_vd_l_kg:"0.8 L/kg",avg_serum_half_life_hr:"4.1",elimination:"Metabolized",bile_penetration_percent:"No data",csf_blood_percent:"45-89",therapeutic_levels_in_csf:"Yes",auc_ug_hr_ml:"No data"},enzyme_interactions:{cyp450_substrate:[],transporter_substrate:[],ugt_substrate:[],cyp450_inhibited:["CYP2C19","CYP3A4"],transporters_inhibited:[],ugts_inhibited:[],cyp450_induced:[],transporters_induced:[],ugts_induced:[],serum_drug_concentration_impact:"↑"},drug_interactions:[{drug:"Iron salts",effect:"↓ response to iron salts",management:"Monitor"},{drug:"Phenytoin",effect:"↑ phenytoin",management:"Monitor, adjust dosage"},{drug:"Protease inhibitors (HIV)",effect:"↑ chloramphenicol, ↑ protease inhibitor",management:"Avoid co-administration"},{drug:"Vitamin B12",effect:"↓ response to vitamin B12",management:"Monitor"}],comments:["Used for severe infections when other alternatives are not available."]}},Ciprofloxacin:{id:"Ciprofloxacin",name:"Ciprofloxacin",tradename:"Cipro",classification:{family:"FLUOROQUINOLONE",subclass:"Fluoroquinolone",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:["Francisella tularensis","Haemophilus ducreyi","Klebsiella granulomatis (granuloma inguinale)","Legionella sp.","Shigella sp.","Yersinia enterocolitica"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:{tablets_non_xr:"CrCl >50: No dosage adjustment. CrCl 30-50: 250-500 mg q12h. CrCl 5-29: 250-500 mg q18h",tablets_xr_uncomplicated_uti:"No dosage adjustment for renal impairment",tablets_xr_comp_uti_acute_pyelo:"CrCl >30: No dosage adjustment. CrCl ≤30: 500 mg q24h",injection:"CrCl ≥30: No dosage adjustment. CrCl 5-29: 200-400 mg q18-24h"},mild:{tablets_non_xr:"CrCl >50: No dosage adjustment. CrCl 30-50: 250-500 mg q12h. CrCl 5-29: 250-500 mg q18h",tablets_xr_uncomplicated_uti:"No dosage adjustment for renal impairment",tablets_xr_comp_uti_acute_pyelo:"CrCl >30: No dosage adjustment. CrCl ≤30: 500 mg q24h",injection:"CrCl ≥30: No dosage adjustment. CrCl 5-29: 200-400 mg q18-24h"},moderate:{tablets_non_xr:"CrCl >50: No dosage adjustment. CrCl 30-50: 250-500 mg q12h. CrCl 5-29: 250-500 mg q18h",tablets_xr_uncomplicated_uti:"No dosage adjustment for renal impairment",tablets_xr_comp_uti_acute_pyelo:"CrCl >30: No dosage adjustment. CrCl ≤30: 500 mg q24h",injection:"CrCl ≥30: No dosage adjustment. CrCl 5-29: 200-400 mg q18-24h"},severe:{tablets_non_xr:"CrCl >50: No dosage adjustment. CrCl 30-50: 250-500 mg q12h. CrCl 5-29: 250-500 mg q18h",tablets_xr_uncomplicated_uti:"No dosage adjustment for renal impairment",tablets_xr_comp_uti_acute_pyelo:"CrCl >30: No dosage adjustment. CrCl ≤30: 500 mg q24h",injection:"CrCl ≥30: No dosage adjustment. CrCl 5-29: 200-400 mg q18-24h"}},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Avoid in pregnancy due to possible renal, cardiac, and CNS toxicity in the fetus. Consider use if no alternatives exist, and if benefit outweighs risk.",lactation:"Avoid breastfeeding for 3-4 hrs after a dose, monitor infant for GI toxicity",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Antacids (Al, Ca, Mg)",effect:"↓ ciprofloxacin",management:"Give cipro 2 hr before or 6 hr"},{drug:"Antiarrhythmics (Class IA/III)",effect:"↑ QT interval",management:"Avoid co-administration"},{drug:"Caffeine",effect:"↑ caffeine",management:"Monitor, adjust dosage"},{drug:"Calcium supplements",effect:"↓ ciprofloxacin",management:"Give cipro 2 hr before or 6 hr"},{drug:"Clozapine",effect:"↑ clozapine",management:"Monitor, adjust dosage"},{drug:"Cyclosporine",effect:"↑ cyclosporine",management:"Monitor, adjust dosage"},{drug:"Didanosine",effect:"↓ ciprofloxacin",management:"Give cipro 2 hr before or 6 hr"},{drug:"Duloxetine",effect:"↑ duloxetine",management:"Monitor or avoid"},{drug:"Fentanyl",effect:"↑ fentanyl",management:"Monitor, adjust dosage, or av"},{drug:"Insulin",effect:"↑↓ blood glucose",management:"Monitor"},{drug:"Iron supplements",effect:"↓ ciprofloxacin",management:"Give cipro 2 hr before or 6 hr"},{drug:"Methotrexate",effect:"↑ methotrexate",management:"Monitor or avoid"},{drug:"NSAIDS",effect:"↑ risk of CNS stimulation/seizures",management:"Monitor or avoid"},{drug:"Oral hypoglycemics",effect:"↑↓ blood glucose",management:"Monitor"},{drug:"Phenytoin",effect:"↑↓ phenytoin",management:"Monitor, adjust dosage"},{drug:"Probenecid",effect:"↑ ciprofloxacin",management:"Monitor or avoid"},{drug:"Ropinirole",effect:"↑ ropinirole",management:"Monitor, adjust dosage"},{drug:"Sildenafil",effect:"↑ sildenafil",management:"Monitor"},{drug:"Sucralfate",effect:"↓ ciprofloxacin",management:"Give cipro 2 hr before or 6 hr"},{drug:"Theophylline",effect:"↑ theophylline",management:"Monitor or avoid"},{drug:"Tizanidine",effect:"↑ tizanidine",management:"Contraindicated"},{drug:"Warfarin",effect:"↑ warfarin, ↑ INR",management:"Monitor INR, adjust dosag"},{drug:"Zinc",effect:"↓ ciprofloxacin",management:"Give cipro 2 hr before or 6 hr"}],stewardship:{preferredIndications:["Francisella tularensis","Haemophilus ducreyi","Klebsiella granulomatis (granuloma inguinale)","Legionella sp.","Shigella sp.","Yersinia enterocolitica"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"70",protein_binding:"20-40",half_life:"4 (ER tab 6.6)",elimination:"Renal, some biliary",csf_penetration:"26",preparations:"Tab (250, 500, 750 mg), Ext-rel (ER) tab (500, 1000 mg), Oral susp (50 mg/mL, 100 mg/mL), 0.3% oph soln, 0.3% oph ointment, 0.2% otic soln, 6% otic susp (intratympanic), Cipro 0.3%/dex 0.1% otic susp, Cipro 0.3%/fluocin 0.025% otic soln, Cipro 0.2%/hc 1% otic susp"},rawData:{drug_name:"Ciprofloxacin",tradename:"Cipro",drug_shortage:[{preparation:"Injection",start_date:"2023-01-13",notes:""}],usage_and_dosing:{general:["Ciprofloxacin is the fluoroquinolone with the greatest potency vs. aerobic gram-negative bacilli.","Ciprofloxacin is often used to treat UTI, bone and joint infections, and infectious diarrhea caused by susceptible organisms.","Often used in combination with metronidazole to treat intra-abdominal infections, or combined with an extended-spectrum penicillin in febrile neutropenic patients.","Used in the treatment of, and post-exposure to, inhalational Bacillus anthracis (anthrax).","See Fluoroquinolones, Overview for class-wide issues, including usage, resistance mechanisms, adverse effects, pharmacology.","Pediatric use is limited to certain indications in children <16 years due to potential for injury to joint cartilage.","Concomitant administration with enteral feeding (EF) may diminish both AUC and Cmax, related to chelation by divalent cations. Literature data conflict regarding how long EF should be held during ciprofloxacin administration. Recent review suggests holding EF for 1 hr before to 2 hr after administration (J Oncol Pharm Pract 2023;29:413).","Caution: numerous drug interactions (see chart below, not all-inclusive)."],adult_dose:{oral_non_xr:"250-750 mg po q12h",oral_xr:"Cystitis: 500 mg po q24h x3 days. Complicated UTI, pyelonephritis: 1 gm po q24h x7-14 days",intravenous:"200-400 mg IV q8-12h"},po_iv_auc_equivalency:{"250_po_q12h":"200 mg IV q12h","500_po_q12h":"400 mg IV q12h","750_po_q12h":"400 mg IV q8h"}},pediatric_dose:{approved_for:"Approved only for CF, anthrax, and complicated UTI",po:"20-40 mg/kg/day (divided q12h)",iv:"20-30 mg/kg/day (divided q12h)",max_day_po:"1.5 gm",max_day_iv:"1.2 gm"},renal_adjustment:{half_life_normal:"3-4",half_life_esrd:"6-9",dose_renal_function_normal:"Varies with formulation and indication",crcl_or_egfr:{tablets_non_xr:"CrCl >50: No dosage adjustment. CrCl 30-50: 250-500 mg q12h. CrCl 5-29: 250-500 mg q18h",tablets_xr_uncomplicated_uti:"No dosage adjustment for renal impairment",tablets_xr_comp_uti_acute_pyelo:"CrCl >30: No dosage adjustment. CrCl ≤30: 500 mg q24h",injection:"CrCl ≥30: No dosage adjustment. CrCl 5-29: 200-400 mg q18-24h"},hemodialysis:{tablets_non_xr:"250-500 mg q24h (AD on dialysis days)",tablets_xr_comp_uti_acute_pyelo:"500 mg q24h (AD on dialysis days)",injection:"200-400 mg q24h (AD on dialysis days)"},capd:{tablets_non_xr:"250-500 mg q12h",tablets_xr_comp_uti_acute_pyelo:"500 mg q24h",injection:"200-400 mg q24h"},crrt:{tablets_non_xr:"250-500 mg q12h",tablets_xr_uncomplicated_uti:"500 mg q24h",tablets_xr_comp_uti_acute_pyelo:"No data",injection:"200-400 mg q12h"},sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["ECMO: See ECMO Drug Dosing Adjustment page.","Obesity: See Obesity Dosing Adjustments page."],adverse_effects:["For class-wide adverse effects, see Fluoroquinolones, Overview.","Any of the fluoroquinolones may exacerbate muscle weakness in persons with myasthenia gravis.","In randomized study of critically ill patients, use of ciprofloxacin associated with a reduction in the absolute platelet count (PLoS 2013;8(11):e81477). Thrombocytopenia believed due to drug-induced immune thrombocytopenia (J Thromb Haemost 2013;11:169)."],pregnancy_risk:{fda_risk_category:"Avoid in pregnancy due to possible renal, cardiac, and CNS toxicity in the fetus. Consider use if no alternatives exist, and if benefit outweighs risk.",lactation:"Avoid breastfeeding for 3-4 hrs after a dose, monitor infant for GI toxicity",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Francisella tularensis","Haemophilus ducreyi","Klebsiella granulomatis (granuloma inguinale)","Legionella sp.","Shigella sp.","Yersinia enterocolitica"],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Tab (250, 500, 750 mg), Ext-rel (ER) tab (500, 1000 mg), Oral susp (50 mg/mL, 100 mg/mL), 0.3% oph soln, 0.3% oph ointment, 0.2% otic soln, 6% otic susp (intratympanic), Cipro 0.3%/dex 0.1% otic susp, Cipro 0.3%/fluocin 0.025% otic soln, Cipro 0.2%/hc 1% otic susp",food_recommendation:"All preps + food (no dairy products)",oral_absorption_percent:"70",tmax_hr:"Tab, susp: 1-2, ER tab: 1-4",peak_serum_conc_ug_ml:"3.6 (750 mg po q12h, SS), 1.6-3.1 (500-1000 mg ER po q24h, SS), 4.6 (400 mg IV q12h, SS)",peak_urine_conc_ug_ml:"394 (500 mg po, SD)",protein_binding_percent:"20-40",volume_of_distribution_vd_l_kg:"2.4 L/kg",avg_serum_half_life_hr:"4 (ER tab 6.6)",elimination:"Renal, some biliary",bile_penetration_percent:"2800-4500",csf_blood_percent:"26",therapeutic_levels_in_csf:"Consider for gram-negative meningitis (use high dose) 17",auc_ug_hr_ml:"31.6 (750 mg po q12h, 0-24 hr), 8 (500 mg ER po q24h, 0-24 hr), 25.4 (400 mg IV q12h, 0-24 hr)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:["OAT1","OAT3"],ugts_substrate:[],cyp450s_inhibited:["CYP1A2 (major)","CYP3A4 (minor)"],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"↑"},major_drug_interactions:[{drug:"Antacids (Al, Ca, Mg)",effect:"↓ ciprofloxacin",management:"Give cipro 2 hr before or 6 hr"},{drug:"Antiarrhythmics (Class IA/III)",effect:"↑ QT interval",management:"Avoid co-administration"},{drug:"Caffeine",effect:"↑ caffeine",management:"Monitor, adjust dosage"},{drug:"Calcium supplements",effect:"↓ ciprofloxacin",management:"Give cipro 2 hr before or 6 hr"},{drug:"Clozapine",effect:"↑ clozapine",management:"Monitor, adjust dosage"},{drug:"Cyclosporine",effect:"↑ cyclosporine",management:"Monitor, adjust dosage"},{drug:"Didanosine",effect:"↓ ciprofloxacin",management:"Give cipro 2 hr before or 6 hr"},{drug:"Duloxetine",effect:"↑ duloxetine",management:"Monitor or avoid"},{drug:"Fentanyl",effect:"↑ fentanyl",management:"Monitor, adjust dosage, or av"},{drug:"Insulin",effect:"↑↓ blood glucose",management:"Monitor"},{drug:"Iron supplements",effect:"↓ ciprofloxacin",management:"Give cipro 2 hr before or 6 hr"},{drug:"Methotrexate",effect:"↑ methotrexate",management:"Monitor or avoid"},{drug:"NSAIDS",effect:"↑ risk of CNS stimulation/seizures",management:"Monitor or avoid"},{drug:"Oral hypoglycemics",effect:"↑↓ blood glucose",management:"Monitor"},{drug:"Phenytoin",effect:"↑↓ phenytoin",management:"Monitor, adjust dosage"},{drug:"Probenecid",effect:"↑ ciprofloxacin",management:"Monitor or avoid"},{drug:"Ropinirole",effect:"↑ ropinirole",management:"Monitor, adjust dosage"},{drug:"Sildenafil",effect:"↑ sildenafil",management:"Monitor"},{drug:"Sucralfate",effect:"↓ ciprofloxacin",management:"Give cipro 2 hr before or 6 hr"},{drug:"Theophylline",effect:"↑ theophylline",management:"Monitor or avoid"},{drug:"Tizanidine",effect:"↑ tizanidine",management:"Contraindicated"},{drug:"Warfarin",effect:"↑ warfarin, ↑ INR",management:"Monitor INR, adjust dosag"},{drug:"Zinc",effect:"↓ ciprofloxacin",management:"Give cipro 2 hr before or 6 hr"}],comments:["Ciprofloxacin is used as second-line therapy for M. tuberculosis, but is not FDA-approved for this indication. Desired Ciprofloxacin serum levels 4–6 µg/mL, requires median dose 800 mg. Discontinuation rates 6-7%. Drug is well tolerated (Am J Respir Crit Care Med 1995;151:2006).","Emergence of fluoroquinolone-resistant M. tuberculosis in New York City (Lancet 1995;345:1148)."]}},Delafloxacin:{id:"Delafloxacin",name:"Delafloxacin",tradename:"Baxdela",classification:{family:"FLUOROQUINOLONE",subclass:"Fluoroquinolone",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:{oral:"eGFR ≥15: No dosage adjustment. eGFR <15: Not recommended (no data)",iv:"eGFR ≥30: No dosage adjustment. eGFR 15-29: 200 mg IV q12h. eGFR <15: Not recommended (no data)"},mild:{oral:"eGFR ≥15: No dosage adjustment. eGFR <15: Not recommended (no data)",iv:"eGFR ≥30: No dosage adjustment. eGFR 15-29: 200 mg IV q12h. eGFR <15: Not recommended (no data)"},moderate:{oral:"eGFR ≥15: No dosage adjustment. eGFR <15: Not recommended (no data)",iv:"eGFR ≥30: No dosage adjustment. eGFR 15-29: 200 mg IV q12h. eGFR <15: Not recommended (no data)"},severe:{oral:"eGFR ≥15: No dosage adjustment. eGFR <15: Not recommended (no data)",iv:"eGFR ≥30: No dosage adjustment. eGFR 15-29: 200 mg IV q12h. eGFR <15: Not recommended (no data)"}},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Avoid in pregnancy due to possible renal, cardiac, and CNS toxicity in the fetus. Consider use if no alternatives exist, and if benefit outweighs risk.",lactation:"No data, avoid use",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Al-, Mg-containing antacids",effect:"↓ delafloxacin (oral only)",management:"Give oral delafloxacin 2 hr bef antacids"},{drug:"Didanosine (or any formulation containing multivalent cations)",effect:"↓ delafloxacin (oral only)",management:"Give oral delafloxacin 2 hr bef didanosine"},{drug:"IV solution containing multivalent cations (e.g. magnesium)",effect:"↓ delafloxacin (IV only)",management:"Avoid co-administr"},{drug:"Iron-containing preparations",effect:"↓ delafloxacin (oral only)",management:"Give oral delafloxacin 2 hr bef iron-containing prepa"},{drug:"Multivitamins with iron or zinc",effect:"↓ delafloxacin (oral only)",management:"Give oral delafloxacin 2 hr bef multivitamins"},{drug:"Sucralfate",effect:"↓ delafloxacin (oral only)",management:"Give oral delafloxacin 2 hr bef sucralfate"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"59",protein_binding:"84",half_life:"4.2-8.5",elimination:"Renal, some fecal",csf_penetration:"No data",preparations:"Tab (450 mg), Injection"},rawData:{drug_name:"Delafloxacin",tradename:"Baxdela",usage_and_dosing:{general:["Delafloxacin is a fluoroquinolone that is FDA-approved for treatment of:","Acute bacterial skin and skin structure infections.","Community-acquired bacterial pneumonia caused by various susceptible bacteria. Review of its potential role in CAP: Drugs 2022;82:913.","In vitro spectrum of antibacterial activity includes:","Streptococci and staphylococci, including strains resistant to levofloxacin.","Delafloxacin is the first fluoroquinolone with activity vs. methicillin-resistant Staph. aureus (MRSA).","MRSA is included in the SSSI indication but not the CABP indication.","Selected gram-negative bacteria: e.g, E. coli, Klebsiella pneumoniae, Enterobacter spp. .","Stable in the presence of ESBLs.","Less active vs P. aeruginosa than ciprofloxacin.","In vitro active vs both gram-positive and gram-negative anaerobic bacteria: e.g., Peptostreptococcus sp and Bacteroides fragilis.","In vitro activity vs Legionella pneumophilia and Mycobacterium tuberculosis.","In two randomized prospective clinical trials of patients with acute bacterial skin and skin structure infections, Delafloxacin was non-inferior to the control arm of a combination of Vancomycin + Aztreonam.","Limited clinical trial details are provided in the package insert.","It appears that patients suffered a mixture of suppurative (often S. aureus) to non-suppurative (often streptococcal species) infections.",'Of note, in six Delafloxacin patients, the skin infection was complicated by S. aureus bacteremia (not clear if MRSA) and 5 of 6 "responded". Bacteremia occurred once due to Klebsiella pneumoniae, once due to Pseudomonas aeruginosa; both patients responded to Delafloxacin therapy.',"The intravenous formulation of Delafloxacin contains the excipient sulfobutylether-β-cyclodextrin (SBECD) as a solubilizing agent. SBECD is cleared exclusively by the kidneys so it may accumulate in moderate to severe renal impairment. Clinical significance of this is not clear."],adult_dose:{iv:"300 mg IV q12h infused over 1 hr (x 5-14 days for SSSI, x 5-10 days for CABP).",po:"450 mg po q12h (x 5-14 days for SSSI, x 5-10 days for CABP).",switch:"Can switch from IV to po during course of treatment."},pediatric_dose:{dose_age_gt_28_days:"Safety and efficacy not established",max_day:"-"}},renal_adjustment:{half_life_normal:"4.2-8.5",half_life_esrd:"No data",dose_renal_function_normal:"450 mg po q12h, 300 mg IV q12h",crcl_or_egfr:{oral:"eGFR ≥15: No dosage adjustment. eGFR <15: Not recommended (no data)",iv:"eGFR ≥30: No dosage adjustment. eGFR 15-29: 200 mg IV q12h. eGFR <15: Not recommended (no data)"},hemodialysis:"Not recommended (no data)",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["Obesity: See Obesity Dosing Adjustments table."],adverse_effects:{disabling_and_potentially_irreversible:["Tendinitis, tendon rupture","Arthralgia, myalgia, peripheral neuropathy","CNS: hallucinations, anxiety, depression, insomnia, severe headaches, confusion","Muscle weakness in patients with myasthenia gravis","Hypersensitivity","C. difficile-associated diarrhea","Risk of aortic aneurysm and dissection","Blood glucose disturbances"],most_common:["Nausea (8%), diarrhea (8%), headache (3%), transaminase elevations (3%), vomiting (2%)"],qtc_interval:"Unlike other fluoroquinolones, delafloxacin has not been associated with prolongation of the QTc interval",photosensitivity:"Has not been associated with photosensitivity, despite the presence of a halogen atom at C-8. This may be due to the mitigating effect of a large polar substituent at N-1 (Photochem Photobiol Sci 17:773, 2018).",class_wide_aes:"For class-wide AEs, see Fluoroquinolones, Overview."},pregnancy_risk:{fda_risk_category:"Avoid in pregnancy due to possible renal, cardiac, and CNS toxicity in the fetus. Consider use if no alternatives exist, and if benefit outweighs risk.",lactation:"No data, avoid use",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Tab (450 mg), Injection",food_recommendation:"Tab ± food",oral_absorption_percent:"59",tmax_hr:"1",peak_serum_conc_ug_ml:"9.3 (300 mg IV q12h, SS), 7.45 (450 mg po q12h, SS)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"84",volume_of_distribution_vd_l_vss:"30-48 L (Vss)",avg_serum_half_life_hr:"4.2-8.5",elimination:"Renal, some fecal",bile_penetration_percent:"No data",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"23.4 (300 mg IV q12h, 0-12 hr), 30.8 (450 mg po q12h, 0-12 hr)"},major_drug_interactions:[{drug:"Al-, Mg-containing antacids",effect:"↓ delafloxacin (oral only)",management:"Give oral delafloxacin 2 hr bef antacids"},{drug:"Didanosine (or any formulation containing multivalent cations)",effect:"↓ delafloxacin (oral only)",management:"Give oral delafloxacin 2 hr bef didanosine"},{drug:"IV solution containing multivalent cations (e.g. magnesium)",effect:"↓ delafloxacin (IV only)",management:"Avoid co-administr"},{drug:"Iron-containing preparations",effect:"↓ delafloxacin (oral only)",management:"Give oral delafloxacin 2 hr bef iron-containing prepa"},{drug:"Multivitamins with iron or zinc",effect:"↓ delafloxacin (oral only)",management:"Give oral delafloxacin 2 hr bef multivitamins"},{drug:"Sucralfate",effect:"↓ delafloxacin (oral only)",management:"Give oral delafloxacin 2 hr bef sucralfate"}],comments:["General References: Medical Letter 2018;60:49; Clin. Infect. Dis. 2019;68:1058 ; Clin Infect Dis 2019;68(Suppl.3): S191."]}},Gatifloxacin:{id:"Gatifloxacin",name:"Gatifloxacin",tradename:"Tequin, Zymar",classification:{family:"FLUOROQUINOLONE",subclass:"Fluoroquinolone",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"1 drop in affected eye as directed",severe:"1 drop in affected eye as directed",renal:{normal:"CrCl >50: No dosage adjustment. CrCl 10-50: 400 mg, then 200 mg q24h. CrCl <10: 400 mg, then 200 mg q24h",mild:"CrCl >50: No dosage adjustment. CrCl 10-50: 400 mg, then 200 mg q24h. CrCl <10: 400 mg, then 200 mg q24h",moderate:"CrCl >50: No dosage adjustment. CrCl 10-50: 400 mg, then 200 mg q24h. CrCl <10: 400 mg, then 200 mg q24h",severe:"CrCl >50: No dosage adjustment. CrCl 10-50: 400 mg, then 200 mg q24h. CrCl <10: 400 mg, then 200 mg q24h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Avoid in pregnancy due to possible renal, cardiac, and CNS toxicity in the fetus. Consider use if no alternatives exist, and if benefit outweighs risk.",lactation:"Short-term use safe, monitor infant for GI toxicity; avoid if possible.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Antacids (Al, Mg)",effect:"↓ gatifloxacin",management:"Separate administration by"},{drug:"Antiarrhythmics (Class IA/III)",effect:"↑ QT interval",management:"Avoid co-administrati"},{drug:"Insulin",effect:"↑↓ blood glucose",management:"Monitor"},{drug:"Iron supplements",effect:"↓ gatifloxacin",management:"Separate administration by"},{drug:"NSAIDS",effect:"↑ risk of CNS stimulation/seizures",management:"Monitor or avoid"},{drug:"Oral hypoglycemics",effect:"↑↓ blood glucose",management:"Monitor"},{drug:"Probenecid",effect:"↑ gatifloxacin",management:"Monitor or avoid"},{drug:"Sucralfate",effect:"↓ gatifloxacin",management:"Separate administration by"},{drug:"Zinc",effect:"↓ gatifloxacin",management:"Separate administration by"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"96",protein_binding:"20",half_life:"7-8",elimination:"Renal",csf_penetration:"36",preparations:"Tab (200, 400 mg), 0.5% oph soln, Injection"},rawData:{drug_name:"Gatifloxacin",tradename:"Tequin, Zymar",usage_and_dosing:{general:["Gatifloxacin is a fluoroquinolone with efficacy against respiratory and enteric pathogens.","Gatifloxacin was withdrawn from US and Canadian markets in 2006 due to drug-related hypo- and hyperglycemic reactions. See adverse effects. Still available in Europe and other regions.","Ophthalmic solution (eyedrops) remains widely available."],adult_dose:{usual_dose:"1 drop in affected eye as directed"},pediatric_dose:{dose_age_gt_28_days:"Safety and efficacy not established",max_day:"-"}},renal_adjustment:{half_life_normal:"7-8",half_life_esrd:"11-40",dose_renal_function_normal:"400 mg po/IV q24h",crcl_or_egfr:"CrCl >50: No dosage adjustment. CrCl 10-50: 400 mg, then 200 mg q24h. CrCl <10: 400 mg, then 200 mg q24h",hemodialysis:"200 mg q24h (give dialysis day dose AD)",capd:"200 mg q24h",crrt:"400 mg, then 200 mg q24h",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["Treatment stopped due to an adverse effect: 2.9%.","Gatifloxacin-associated dysglycemia due to documented hypoglycemic and hyperglycemic reactions (NEJM 354:1352, 2006; Clin Infect Dis 49:402, 2009).","For complete class-wide adverse effects see Fluoroquinolones, Overview and for QTc prolongation, see QTc Interval Prolongation.","Any of the fluoroquinolones may exacerbate muscle weakness in persons with myasthenia gravis."],pregnancy_risk:{fda_risk_category:"Avoid in pregnancy due to possible renal, cardiac, and CNS toxicity in the fetus. Consider use if no alternatives exist, and if benefit outweighs risk.",lactation:"Short-term use safe, monitor infant for GI toxicity; avoid if possible.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Tab (200, 400 mg), 0.5% oph soln, Injection",food_recommendation:"Tab ± food",oral_absorption_percent:"96",tmax_hr:"No data",peak_serum_conc_ug_ml:"4.2-4.6 (400 mg po/IV q24h, SS)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"20",volume_of_distribution_vd_l_kg_vss:"1.8 L/kg (Vss)",avg_serum_half_life_hr:"7-8",elimination:"Renal",bile_penetration_percent:"No data",csf_blood_percent:"36",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"35 (400 mg po/IV q24h, 0-24 hr)"},major_drug_interactions:[{drug:"Antacids (Al, Mg)",effect:"↓ gatifloxacin",management:"Separate administration by"},{drug:"Antiarrhythmics (Class IA/III)",effect:"↑ QT interval",management:"Avoid co-administrati"},{drug:"Insulin",effect:"↑↓ blood glucose",management:"Monitor"},{drug:"Iron supplements",effect:"↓ gatifloxacin",management:"Separate administration by"},{drug:"NSAIDS",effect:"↑ risk of CNS stimulation/seizures",management:"Monitor or avoid"},{drug:"Oral hypoglycemics",effect:"↑↓ blood glucose",management:"Monitor"},{drug:"Probenecid",effect:"↑ gatifloxacin",management:"Monitor or avoid"},{drug:"Sucralfate",effect:"↓ gatifloxacin",management:"Separate administration by"},{drug:"Zinc",effect:"↓ gatifloxacin",management:"Separate administration by"}]}},Gemifloxacin:{id:"Gemifloxacin",name:"Gemifloxacin",tradename:"Factive",classification:{family:"FLUOROQUINOLONE",subclass:"Fluoroquinolone",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"320 mg po q24h",severe:"320 mg po q24h",renal:{normal:"CrCl >50: No dosage adjustment. CrCl 10-50: 160 mg q24h. CrCl <10: 160 mg q24h",mild:"CrCl >50: No dosage adjustment. CrCl 10-50: 160 mg q24h. CrCl <10: 160 mg q24h",moderate:"CrCl >50: No dosage adjustment. CrCl 10-50: 160 mg q24h. CrCl <10: 160 mg q24h",severe:"CrCl >50: No dosage adjustment. CrCl 10-50: 160 mg q24h. CrCl <10: 160 mg q24h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Avoid in pregnancy due to possible renal, cardiac, and CNS toxicity in the fetus. Consider use if no alternatives exist, and if benefit outweighs risk.",lactation:"Short-term use safe, monitor infant for GI toxicity; avoid if possible.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Antacids (Al, Ca, Mg)",effect:"↓ gemifloxacin",management:"Separate admin by 2-3 hours"},{drug:"Calcium supplements",effect:"↓ gemifloxacin",management:"Separate admin by 2-3 hours"},{drug:"Didanosine",effect:"↓ gemifloxacin",management:"Separate admin by 2-3 hours"},{drug:"Iron supplements",effect:"↓ gemifloxacin",management:"Separate admin by 2-3 hours"},{drug:"NSAIDS",effect:"↑ risk of CNS stimulation/seizures",management:"Monitor or avoid"},{drug:"Probenecid",effect:"↑ gemifloxacin",management:"Monitor or avoid"},{drug:"Sucralfate",effect:"↓ gemifloxacin",management:"Separate admin by 2 hours"},{drug:"Zinc",effect:"↓ gemifloxacin",management:"Separate admin by 2-3 hours"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"71",protein_binding:"55-73",half_life:"7",elimination:"Fecal, some renal",csf_penetration:"No data",preparations:"Tab (320 mg)"},rawData:{drug_name:"Gemifloxacin",tradename:"Factive",usage_and_dosing:{general:["Gemifloxacin is a fluoroquinolone FDA-approved for oral therapy of acute exacerbation of chronic bronchitis and mild-to-moderate community acquired pneumonia (CAP).","No longer available in the US.","For additional class-wide information, see Fluoroquinolones, Overview."],adult_dose:{usual_dose:"320 mg po q24h"},pediatric_dose:{dose_age_gt_28_days:"Safety and efficacy not established",max_day:"-"}},renal_adjustment:{half_life_normal:"7",half_life_esrd:">7",dose_renal_function_normal:"320 mg po q24h",crcl_or_egfr:"CrCl >50: No dosage adjustment. CrCl 10-50: 160 mg q24h. CrCl <10: 160 mg q24h",hemodialysis:"160 mg q24h (give dialysis day dose AD)",capd:"160 mg q24h",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["Peculiar duration-dependent skin rash. After 14 days of therapy in patients under age 40 years, rash developed in 7.7% of men and 22.6% of women. Incidence of rash with ≤ 5 days of therapy is only 1.5%. Mechanism is unclear.","Treatment stopped due to adverse effects (2.2%), rash (1-22%), photosensitivity (rare), anaphylaxis (rare), nausea/vomiting (2.7%), diarrhea (3.6%), C. difficile colitis (rare), hepatic failure, dizziness/lightheadedness (3%), headache (6%), confusion (rare), seizures (rare), dysrhythmias.","Myasthenia gravis: any FQ may exacerbate muscle weakness in patients with myasthenia gravis.","For class-wide adverse effects, including QTc prolongation, see QTc Interval Prolongation."],pregnancy_risk:{fda_risk_category:"Avoid in pregnancy due to possible renal, cardiac, and CNS toxicity in the fetus. Consider use if no alternatives exist, and if benefit outweighs risk.",lactation:"Short-term use safe, monitor infant for GI toxicity; avoid if possible.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Tab (320 mg)",food_recommendation:"Tab ± food",oral_absorption_percent:"71",tmax_hr:"0.5-2.0",peak_serum_conc_ug_ml:"1.6 (320 mg po q24h, SS)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"55-73",volume_of_distribution_vd_l_kg_vss_f:"1.7-12.1 L/kg (Vss/F)",avg_serum_half_life_hr:"7",elimination:"Fecal, some renal",bile_penetration_percent:"No data",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"9.9 (320 mg po q24h, 0-24 hr)"},major_drug_interactions:[{drug:"Antacids (Al, Ca, Mg)",effect:"↓ gemifloxacin",management:"Separate admin by 2-3 hours"},{drug:"Calcium supplements",effect:"↓ gemifloxacin",management:"Separate admin by 2-3 hours"},{drug:"Didanosine",effect:"↓ gemifloxacin",management:"Separate admin by 2-3 hours"},{drug:"Iron supplements",effect:"↓ gemifloxacin",management:"Separate admin by 2-3 hours"},{drug:"NSAIDS",effect:"↑ risk of CNS stimulation/seizures",management:"Monitor or avoid"},{drug:"Probenecid",effect:"↑ gemifloxacin",management:"Monitor or avoid"},{drug:"Sucralfate",effect:"↓ gemifloxacin",management:"Separate admin by 2 hours"},{drug:"Zinc",effect:"↓ gemifloxacin",management:"Separate admin by 2-3 hours"}],comments:["Regimen of Azithromycin 2 gm po once + gemifloxacin 320 mg po once is considered a possible alternative for treatment of gonorrhea in persons highly allergic to ceftriaxone (MMWR 64 (RR-3): 1, 2015)."]}},Levofloxacin:{id:"Levofloxacin",name:"Levofloxacin",tradename:"Levaquin",classification:{family:"FLUOROQUINOLONE",subclass:"Fluoroquinolone",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:["Chlamydia trachomatis","Haemophilus influenzae","Kingella sp.","Legionella sp.","Mycoplasma pneumoniae","Shigella sp.","Yersinia enterocolitica"],alternative:[],notes:""},dosing:{adult:{standard:"250-750 mg po/IV q24h (depends on indication).",severe:"250-750 mg po/IV q24h (depends on indication).",renal:{normal:"CrCl >50: No dosage adjustment. CrCl 20-49: 750 mg q48h. CrCl <20: 750 mg x1, then 500 mg q48h",mild:"CrCl >50: No dosage adjustment. CrCl 20-49: 750 mg q48h. CrCl <20: 750 mg x1, then 500 mg q48h",moderate:"CrCl >50: No dosage adjustment. CrCl 20-49: 750 mg q48h. CrCl <20: 750 mg x1, then 500 mg q48h",severe:"CrCl >50: No dosage adjustment. CrCl 20-49: 750 mg q48h. CrCl <20: 750 mg x1, then 500 mg q48h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Avoid in pregnancy due to possible renal, cardiac, and CNS toxicity in the fetus. Consider use if no alternatives exist, and if benefit outweighs risk.",lactation:"Avoid breastfeeding for 4-6 hrs after a dose, monitor infant for GI toxicity",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Antacids (Al, Ca, Mg)",effect:"↓ levofloxacin",management:"Give 2 hours"},{drug:"Antiarrhythmics (Class IA/III)",effect:"↑ QT interval",management:"Avoid co-admin"},{drug:"Calcium supplements",effect:"↓ levofloxacin",management:"Give 2 hours"},{drug:"Didanosine",effect:"↓ levofloxacin",management:"Give 2 hours"},{drug:"Insulin",effect:"↑↓ blood glucose",management:"Monitor"},{drug:"Iron supplements",effect:"↓ levofloxacin",management:"Give 2 hours"},{drug:"NSAIDS",effect:"↑ risk of CNS stimulation/seizures",management:"Monitor or a"},{drug:"Oral hypoglycemics",effect:"↑↓ blood glucose",management:"Monitor"},{drug:"Sucralfate",effect:"↓ levofloxacin",management:"Give 2 hours"},{drug:"Warfarin",effect:"↑ INR",management:"Monitor INR, adju"},{drug:"Zinc",effect:"↓ levofloxacin",management:"Give 2 hours"}],stewardship:{preferredIndications:["Chlamydia trachomatis","Haemophilus influenzae","Kingella sp.","Legionella sp.","Mycoplasma pneumoniae","Shigella sp.","Yersinia enterocolitica"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"99",protein_binding:"24-38",half_life:"7",elimination:"Renal",csf_penetration:"30-50",preparations:"Tab (250, 500, 750 mg), Oral soln (25 mg/mL), 0.5% oph soln, Injection"},rawData:{drug_name:"Levofloxacin",tradename:"Levaquin",drug_shortage:[{preparation:"Oral solution, 25 mg/mL",start_date:"2023-09-15",notes:""},{preparation:"Levofloxacin injection in D5W",start_date:"2024-05-29",notes:""}],usage_and_dosing:{general:["Levofloxacin, approved in 1996, is a fluoroquinolone with a broad spectrum of activity that includes respiratory and enteric pathogens.","Levofloxacin is the L-enantiomer of ofloxacin.","No longer used in the treatment of gonococcal infections due to high levels of resistance.","Mechanism of action, resistance: see Fluoroquinolones, Overview."],adult_dose:{usual_dose:"250-750 mg po/IV q24h (depends on indication).",dairy:"Avoid dairy products ±2 hours of oral administration.",metal_cations:"Concomitant metal cations: See Major Drug Interactions below."},pediatric_dose:{dose_age_gt_28_days:"16-20 mg/kg/day IV/po (div q12h) 1",max_day:"750 mg",footnote:"1 Approved only for CF, anthrax, and complicated UTI"}},renal_adjustment:{half_life_normal:"7",half_life_esrd:"76",dose_renal_function_normal:"750 mg po/IV q24h",crcl_or_egfr:"CrCl >50: No dosage adjustment. CrCl 20-49: 750 mg q48h. CrCl <20: 750 mg x1, then 500 mg q48h",hemodialysis:"750 mg x1, then 500 mg q48h",capd:"750 mg x1, then 500 mg q48h",crrt:"750 mg x1, then 500 mg q48h",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["ECMO: See ECMO Drug Dosing Adjustment.","Obesity: See Obesity Dosing Adjustments."],adverse_effects:["Detailed discussion of adverse effects: see Fluoroquinolones, Overview."],pregnancy_risk:{fda_risk_category:"Avoid in pregnancy due to possible renal, cardiac, and CNS toxicity in the fetus. Consider use if no alternatives exist, and if benefit outweighs risk.",lactation:"Avoid breastfeeding for 4-6 hrs after a dose, monitor infant for GI toxicity",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Chlamydia trachomatis","Haemophilus influenzae","Kingella sp.","Legionella sp.","Mycoplasma pneumoniae","Shigella sp.","Yersinia enterocolitica"],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Tab (250, 500, 750 mg), Oral soln (25 mg/mL), 0.5% oph soln, Injection",food_recommendation:"Tab ± food, Soln no food",oral_absorption_percent:"99",tmax_hr:"po: 1.6",peak_serum_conc_ug_ml:"8.6 (750 mg po q24h, SS), 12.1 (750 mg IV q24h, SS)",peak_urine_conc_ug_ml:"521-771 (500 mg po/IV q24h, SS)",protein_binding_percent:"24-38",volume_of_distribution_vd_l_vss:"244 L (Vss)",avg_serum_half_life_hr:"7",elimination:"Renal",bile_penetration_percent:"No data",csf_blood_percent:"30-50",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"90.7 (750 mg po q24h, 0-24h), 108 (750 mg IV q24h, 0-24h)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:[],ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:["MATE, OCT2"],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"↑"},major_drug_interactions:[{drug:"Antacids (Al, Ca, Mg)",effect:"↓ levofloxacin",management:"Give 2 hours"},{drug:"Antiarrhythmics (Class IA/III)",effect:"↑ QT interval",management:"Avoid co-admin"},{drug:"Calcium supplements",effect:"↓ levofloxacin",management:"Give 2 hours"},{drug:"Didanosine",effect:"↓ levofloxacin",management:"Give 2 hours"},{drug:"Insulin",effect:"↑↓ blood glucose",management:"Monitor"},{drug:"Iron supplements",effect:"↓ levofloxacin",management:"Give 2 hours"},{drug:"NSAIDS",effect:"↑ risk of CNS stimulation/seizures",management:"Monitor or a"},{drug:"Oral hypoglycemics",effect:"↑↓ blood glucose",management:"Monitor"},{drug:"Sucralfate",effect:"↓ levofloxacin",management:"Give 2 hours"},{drug:"Warfarin",effect:"↑ INR",management:"Monitor INR, adju"},{drug:"Zinc",effect:"↓ levofloxacin",management:"Give 2 hours"}]}},Moxifloxacin:{id:"Moxifloxacin",name:"Moxifloxacin",tradename:"Avelox",classification:{family:"FLUOROQUINOLONE",subclass:"Fluoroquinolone",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"400 mg po/IV q24h",severe:"400 mg po/IV q24h",renal:{normal:"No dosage adjustment",mild:"No dosage adjustment",moderate:"No dosage adjustment",severe:"No dosage adjustment"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Avoid in pregnancy due to possible renal, cardiac, and CNS toxicity in the fetus. Consider use if no alternatives exist, and if benefit outweighs risk.",lactation:"Short-term use safe, monitor infant for GI toxicity; avoid if possible.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Antacids (Al, Mg)",effect:"↓ moxifloxacin",management:"Separate administration by 4 hours"},{drug:"Antiarrhythmics (Class IA/III)",effect:"↑ QT interval",management:"Avoid co-administration"},{drug:"Calcium supplements",effect:"↓ moxifloxacin",management:"Separate administration by 4 hours"},{drug:"Didanosine",effect:"↓ moxifloxacin",management:"Separate administration by 4 hours"},{drug:"Iron supplements",effect:"↓ moxifloxacin",management:"Separate administration by 4 hours"},{drug:"NSAIDS",effect:"↑ risk of CNS stimulation/seizures",management:"Monitor or avoid"},{drug:"Oral hypoglycemics",effect:"↑↓ blood glucose",management:"Monitor"},{drug:"Probenecid",effect:"↑ moxifloxacin",management:"Monitor or avoid"},{drug:"Sucralfate",effect:"↓ moxifloxacin",management:"Separate administration by 4 hours"},{drug:"Warfarin",effect:"↑ INR",management:"Monitor INR, adjust dosage"},{drug:"Zinc",effect:"↓ moxifloxacin",management:"Separate administration by 4 hours"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"90",protein_binding:"40-50",half_life:"12",elimination:"Hepatic (50%), renal (50%)",csf_penetration:"17-20",preparations:"Tab (400 mg), Injection"},rawData:{drug_name:"Moxifloxacin",tradename:"Avelox",usage_and_dosing:{general:["Moxifloxacin is a fluoroquinolone with enhanced activity against respiratory pathogens, including atypical organisms and S. pneumoniae. It is also active against many anaerobic bacteria.","Not active vs. P. aeruginosa.","FDA-approved for acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, skin and skin structure infections, and complicated intra-abdominal infections.","For class-wide adverse effects, see Fluoroquinolones, Overview."],adult_dose:{usual_dose:"400 mg po/IV q24h"},pediatric_dose:{dose_age_gt_28_days:"Safety and efficacy not established",max_day:"-"}},renal_adjustment:{half_life_normal:"12",half_life_esrd:"No data",dose_renal_function_normal:"400 mg po/IV q24h",crcl_or_egfr:"No dosage adjustment",hemodialysis:"No dosage adjustment",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["For complete class-wide adverse effects see Fluoroquinolones, Overview and for QTc prolongation, see QTc Interval Prolongation.","Any of the fluoroquinolones may exacerbate muscle weakness in persons with myasthenia gravis."],pregnancy_risk:{fda_risk_category:"Avoid in pregnancy due to possible renal, cardiac, and CNS toxicity in the fetus. Consider use if no alternatives exist, and if benefit outweighs risk.",lactation:"Short-term use safe, monitor infant for GI toxicity; avoid if possible.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Tab (400 mg), Injection",food_recommendation:"Tab ± food",oral_absorption_percent:"90",tmax_hr:"1-2",peak_serum_conc_ug_ml:"3.1 (400 mg po, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"40-50",volume_of_distribution_vd_l_kg_vss:"1.7-2.7 L/kg (Vss)",avg_serum_half_life_hr:"12",elimination:"Hepatic (50%), renal (50%)",bile_penetration_percent:"No data",csf_blood_percent:"17-20",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"36.3 (400 mg po, 0-24h)"},major_drug_interactions:[{drug:"Antacids (Al, Mg)",effect:"↓ moxifloxacin",management:"Separate administration by 4 hours"},{drug:"Antiarrhythmics (Class IA/III)",effect:"↑ QT interval",management:"Avoid co-administration"},{drug:"Calcium supplements",effect:"↓ moxifloxacin",management:"Separate administration by 4 hours"},{drug:"Didanosine",effect:"↓ moxifloxacin",management:"Separate administration by 4 hours"},{drug:"Iron supplements",effect:"↓ moxifloxacin",management:"Separate administration by 4 hours"},{drug:"NSAIDS",effect:"↑ risk of CNS stimulation/seizures",management:"Monitor or avoid"},{drug:"Oral hypoglycemics",effect:"↑↓ blood glucose",management:"Monitor"},{drug:"Probenecid",effect:"↑ moxifloxacin",management:"Monitor or avoid"},{drug:"Sucralfate",effect:"↓ moxifloxacin",management:"Separate administration by 4 hours"},{drug:"Warfarin",effect:"↑ INR",management:"Monitor INR, adjust dosage"},{drug:"Zinc",effect:"↓ moxifloxacin",management:"Separate administration by 4 hours"}]}},Norfloxacin:{id:"Norfloxacin",name:"Norfloxacin",tradename:"",classification:{family:"FLUOROQUINOLONE",subclass:"Fluoroquinolone",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"CrCl >50: No dosage adjustment. CrCl 30-49: 400 mg q12h. CrCl 10-30: 400 mg q24h",mild:"CrCl >50: No dosage adjustment. CrCl 30-49: 400 mg q12h. CrCl 10-30: 400 mg q24h",moderate:"CrCl >50: No dosage adjustment. CrCl 30-49: 400 mg q12h. CrCl 10-30: 400 mg q24h",severe:"CrCl >50: No dosage adjustment. CrCl 30-49: 400 mg q12h. CrCl 10-30: 400 mg q24h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Category C - Risk cannot be ruled out",lactation:"Use with caution",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Antacids (Al, Ca, Mg)",effect:"↓ norfloxacin",management:"Separate administration by 2 hours"},{drug:"Antiarrhythmics (Class IA/III)",effect:"↑ QT interval",management:"Avoid co-administration"},{drug:"Caffeine",effect:"↑ caffeine",management:"Monitor, adjust dosage"},{drug:"Calcium supplements",effect:"↓ norfloxacin",management:"Separate administration by 2 hours"},{drug:"Clozapine",effect:"↑ clozapine",management:"Monitor, adjust dosage"},{drug:"Cyclosporine",effect:"↑ cyclosporine",management:"Monitor, adjust dosage"},{drug:"Didanosine",effect:"↓ norfloxacin",management:"Separate administration by 2 hours"},{drug:"Duloxetine",effect:"↑ duloxetine",management:"Monitor or avoid"},{drug:"Insulin",effect:"↑↓ blood glucose",management:"Monitor"},{drug:"Iron supplements",effect:"↓ norfloxacin",management:"Separate administration by 2 hours"},{drug:"NSAIDS",effect:"↑ risk of CNS stimulation/seizures",management:"Monitor or avoid"},{drug:"Oral hypoglycemics",effect:"↑↓ blood glucose",management:"Monitor"},{drug:"Probenecid",effect:"↑ norfloxacin",management:"Monitor or avoid"},{drug:"Sucralfate",effect:"↓ norfloxacin",management:"Separate administration by 2 hours"},{drug:"Theophylline",effect:"↑ theophylline",management:"Monitor or avoid"},{drug:"Tizanidine",effect:"↑ tizanidine",management:"Contraindicated"},{drug:"Warfarin",effect:"↑ warfarin, ↑ INR",management:"Monitor INR, adjust dosage"},{drug:"Zinc",effect:"↓ norfloxacin",management:"Separate administration by 2 hours"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"30-40",protein_binding:"10-15",half_life:"3-4",elimination:"Metabolized, biliary, renal",csf_penetration:"No data",preparations:"Tab (400 mg)"},rawData:{drug_name:"Norfloxacin",usage_and_dosing:{general:["Norfloxacin is one of the early fluoroquinolones.","Indications for use overlap with those of Ciprofloxacin and Levofloxacin. As Ciprofloxacin and Levofloxacin have a greater degree of antibacterial activity and as both are now available in generic form, the use of Norfloxacin has decreased.","Caution: numerous drug interactions (see chart below, not all-inclusive).","No longer available in the US."],adult_dose:{enterocolitis_due_to_shigella:"400 mg po bid x 5 days",prostatitis_due_to_susceptible_aerobic_gram_negative_bacillus:"400 mg po bid x 4-6 weeks",travelers_diarrhea_due_to_toxigenic_e_coli:"400 mg po bid x 3 days",uncomplicated_female_non_gonococcal_urethritis_cystitis:"400 mg po bid x 3 days",prophylaxis_in_cirrhotic_patients_with_bleeding_from_esophageal_varices:"400 mg po bid x maximum of 7 days"},pediatric_dose:{dose_age_gt_28_days:"Safety and efficacy not established",max_day:"-"}},renal_adjustment:{half_life_normal:"3-4",half_life_esrd:"8",dose_renal_function_normal:"400 mg po q12h",crcl_or_egfr:"CrCl >50: No dosage adjustment. CrCl 30-49: 400 mg q12h. CrCl 10-30: 400 mg q24h",hemodialysis:"400 mg q24h",capd:"400 mg q24h",crrt:"Not applicable",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["Poorly understood CNS toxicity that varies from lightheadedness to confusion and rarely to seizures.","Prolongation of the corrected QT interval; risk increases with hypokalemia, hypomagnesemia and concomitant use of other drugs with the potential for prolongation of the QT interval.","Gastrointestinal intolerance: nausea and vomiting.","Tendinopathy: spontaneous tendon rupture. Risk is highest with concomitant use of corticosteroids.","Chelation of drug by multivalent cations (calcium, magnesium, aluminum, iron) in dairy food, multivitamins, or antacids. Result is failure to absorb the drug.","Allergic reactions are rare.","Rare increase in muscle weakness in patients with myasthenia gravis.","Photosensitivity can occur."],antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Tab (400 mg)",food_recommendation:"Tab no food",oral_absorption_percent:"30-40",tmax_hr:"1",peak_serum_conc_ug_ml:"1.5 (400 mg po, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"10-15",volume_of_distribution_vd_l_kg:"1.7 L/kg",avg_serum_half_life_hr:"3-4",elimination:"Metabolized, biliary, renal",bile_penetration_percent:"700",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No",auc_ug_hr_ml:"6.4 (400 mg po, 0-inf)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:[],ugts_substrate:[],cyp450s_inhibited:["CYP1A2 (weak)"],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"mild ↑"},major_drug_interactions:[{drug:"Antacids (Al, Ca, Mg)",effect:"↓ norfloxacin",management:"Separate administration by 2 hours"},{drug:"Antiarrhythmics (Class IA/III)",effect:"↑ QT interval",management:"Avoid co-administration"},{drug:"Caffeine",effect:"↑ caffeine",management:"Monitor, adjust dosage"},{drug:"Calcium supplements",effect:"↓ norfloxacin",management:"Separate administration by 2 hours"},{drug:"Clozapine",effect:"↑ clozapine",management:"Monitor, adjust dosage"},{drug:"Cyclosporine",effect:"↑ cyclosporine",management:"Monitor, adjust dosage"},{drug:"Didanosine",effect:"↓ norfloxacin",management:"Separate administration by 2 hours"},{drug:"Duloxetine",effect:"↑ duloxetine",management:"Monitor or avoid"},{drug:"Insulin",effect:"↑↓ blood glucose",management:"Monitor"},{drug:"Iron supplements",effect:"↓ norfloxacin",management:"Separate administration by 2 hours"},{drug:"NSAIDS",effect:"↑ risk of CNS stimulation/seizures",management:"Monitor or avoid"},{drug:"Oral hypoglycemics",effect:"↑↓ blood glucose",management:"Monitor"},{drug:"Probenecid",effect:"↑ norfloxacin",management:"Monitor or avoid"},{drug:"Sucralfate",effect:"↓ norfloxacin",management:"Separate administration by 2 hours"},{drug:"Theophylline",effect:"↑ theophylline",management:"Monitor or avoid"},{drug:"Tizanidine",effect:"↑ tizanidine",management:"Contraindicated"},{drug:"Warfarin",effect:"↑ warfarin, ↑ INR",management:"Monitor INR, adjust dosage"},{drug:"Zinc",effect:"↓ norfloxacin",management:"Separate administration by 2 hours"}]}},Ofloxacin:{id:"Ofloxacin",name:"Ofloxacin",tradename:"Floxin, Oculfox",classification:{family:"FLUOROQUINOLONE",subclass:"Fluoroquinolone",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:["Chlamydia trachomatis","Legionella sp."],alternative:[],notes:""},dosing:{adult:{standard:"200-400 mg po q12h",severe:"200-400 mg po q12h",renal:{normal:"CrCl >50: No dosage adjustment. CrCl 10-50: 200-400 mg q24h. CrCl <10: 200 mg q24h",mild:"CrCl >50: No dosage adjustment. CrCl 10-50: 200-400 mg q24h. CrCl <10: 200 mg q24h",moderate:"CrCl >50: No dosage adjustment. CrCl 10-50: 200-400 mg q24h. CrCl <10: 200 mg q24h",severe:"CrCl >50: No dosage adjustment. CrCl 10-50: 200-400 mg q24h. CrCl <10: 200 mg q24h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Avoid in pregnancy due to possible renal, cardiac, and CNS toxicity in the fetus. Consider use if no alternatives exist, and if benefit outweighs risk.",lactation:"Avoid breastfeeding for 4-6 hrs after a dose, monitor infant for GI toxicity",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Antacids (Al, Ca, Mg)",effect:"↓ ofloxacin",management:"Give 2 hou"},{drug:"Antiarrhythmics (Class IA/III)",effect:"↑ QT interval",management:"Avoid co-adr"},{drug:"Calcium supplements",effect:"↓ ofloxacin",management:"Give 2 hou"},{drug:"Didanosine",effect:"↓ ofloxacin",management:"Give 2 hou"},{drug:"Insulin",effect:"↑↓ blood glucose",management:"Mon"},{drug:"Iron supplements",effect:"↓ ofloxacin",management:"Give 2 hou"},{drug:"NSAIDS",effect:"↑ risk of CNS stimulation/seizures",management:"Monitor ("},{drug:"Oral hypoglycemics",effect:"↑↓ blood glucose",management:"Mon"},{drug:"Sucralfate",effect:"↓ ofloxacin",management:"Give 2 hou"},{drug:"Theophylline",effect:"↑ theophylline",management:"Monitor ("},{drug:"Warfarin",effect:"↑ INR",management:"Monitor INR, a"},{drug:"Zinc",effect:"↓ ofloxacin",management:"Give 2 hou"}],stewardship:{preferredIndications:["Chlamydia trachomatis","Legionella sp."],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"98",protein_binding:"32",half_life:"7",elimination:"Renal",csf_penetration:"No data",preparations:"Tab (200, 300, 400 mg), 0.3% oph soln, 0.3% otic soln"},rawData:{drug_name:"Ofloxacin",tradename:"Floxin, Oculfox",drug_shortage:[{preparation:"0.3% ophthalmic solution",start_date:null,notes:""}],usage_and_dosing:{general:["Ofloxacin, FDA approved in 1990, is a fluoroquinolone with broad activity against respiratory and enteric pathogens.","Ofloxacin is a racemic mixture of R-ofloxacin and L-ofloxacin (levofloxacin).","For most clinical indications, levofloxacin is used rather than ofloxacin.","CDC no longer recommends fluoroquinolones (including ofloxacin) for gonococcal infections due to high levels of resistance (MMWR 2007;56:332).","See Fluoroquinolones, Overview for additional class-wide information."],adult_dose:{usual_dose:"200-400 mg po q12h",dairy:"Avoid dairy products ±2 hours of oral administration.",metal_cations:"Concomitant metal cations: see Major Drug Interactions below."},pediatric_dose:{dose_age_gt_28_days:"Safety and efficacy not established",max_day:"-"}},renal_adjustment:{half_life_normal:"7",half_life_esrd:"28-37",dose_renal_function_normal:"200-400 mg po q12h",crcl_or_egfr:"CrCl >50: No dosage adjustment. CrCl 10-50: 200-400 mg q24h. CrCl <10: 200 mg q24h",hemodialysis:"200 mg q24h (give dialysis day dose AD)",capd:"200 mg q24h",crrt:"200-400 mg q24h",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["Detailed discussion of adverse effects: see Fluoroquinolones, Overview."],pregnancy_risk:{fda_risk_category:"Avoid in pregnancy due to possible renal, cardiac, and CNS toxicity in the fetus. Consider use if no alternatives exist, and if benefit outweighs risk.",lactation:"Avoid breastfeeding for 4-6 hrs after a dose, monitor infant for GI toxicity",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Chlamydia trachomatis","Legionella sp."],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Tab (200, 300, 400 mg), 0.3% oph soln, 0.3% otic soln",food_recommendation:"Tab ± food",oral_absorption_percent:"98",tmax_hr:"1-2",peak_serum_conc_ug_ml:"4.6-6.2 (400 mg po q12h, SS)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"32",volume_of_distribution_vd_l_kg:"1-2.5 L/kg",avg_serum_half_life_hr:"7",elimination:"Renal",bile_penetration_percent:"No data",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"82.4 (400 mg po q12h, 0-24h)"},major_drug_interactions:[{drug:"Antacids (Al, Ca, Mg)",effect:"↓ ofloxacin",management:"Give 2 hou"},{drug:"Antiarrhythmics (Class IA/III)",effect:"↑ QT interval",management:"Avoid co-adr"},{drug:"Calcium supplements",effect:"↓ ofloxacin",management:"Give 2 hou"},{drug:"Didanosine",effect:"↓ ofloxacin",management:"Give 2 hou"},{drug:"Insulin",effect:"↑↓ blood glucose",management:"Mon"},{drug:"Iron supplements",effect:"↓ ofloxacin",management:"Give 2 hou"},{drug:"NSAIDS",effect:"↑ risk of CNS stimulation/seizures",management:"Monitor ("},{drug:"Oral hypoglycemics",effect:"↑↓ blood glucose",management:"Mon"},{drug:"Sucralfate",effect:"↓ ofloxacin",management:"Give 2 hou"},{drug:"Theophylline",effect:"↑ theophylline",management:"Monitor ("},{drug:"Warfarin",effect:"↑ INR",management:"Monitor INR, a"},{drug:"Zinc",effect:"↓ ofloxacin",management:"Give 2 hou"}]}},Prulifloxacin:{id:"Prulifloxacin",name:"Prulifloxacin",tradename:"Quisnon, Sword, Pruquin, Unidrox",classification:{family:"FLUOROQUINOLONE",subclass:"Fluoroquinolone",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:["Francisella tularensis","Haemophilus ducreyi","Klebsiella granulomatis (granuloma inguinale)","Legionella sp.","Yersinia enterocolitica"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"CrCl ≥60: No dosage adjustment. CrCl <60: No data",mild:"CrCl ≥60: No dosage adjustment. CrCl <60: No data",moderate:"CrCl ≥60: No dosage adjustment. CrCl <60: No data",severe:"CrCl ≥60: No dosage adjustment. CrCl <60: No data"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Category C - Risk cannot be ruled out",lactation:"Use with caution",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Antacids (Al, Mg)",effect:"↓ prulifloxacin",management:"Give prulifloxacin 2 hr before after"},{drug:"Calcium supplements",effect:"↓ prulifloxacin",management:"Give prulifloxacin 2 hr before after"},{drug:"Cimetidine",effect:"↓ prulifloxacin",management:"Give prulifloxacin 2 hr before after"},{drug:"Didanosine",effect:"↓ prulifloxacin",management:"Give prulifloxacin 2 hr before after"},{drug:"Insulin",effect:"↑↓ blood glucose",management:"Monitor"},{drug:"Iron supplements",effect:"↓ prulifloxacin",management:"Give prulifloxacin 2 hr before after"},{drug:"Nicardipine",effect:"↑ risk of prulifloxacin phototoxicity",management:"Monitor or avoid"},{drug:"NSAIDS",effect:"↑ risk of CNS stimulation/seizures",management:"Monitor or avoid"},{drug:"Oral hypoglycemics",effect:"↑↓ blood glucose",management:"Monitor"},{drug:"Sucralfate",effect:"↓ prulifloxacin",management:"Give prulifloxacin 2 hr before after"},{drug:"Theophylline",effect:"↑ theophylline",management:"Monitor or avoid"},{drug:"Warfarin",effect:"↑ warfarin, ↑ INR",management:"Monitor INR, adjust dosa"},{drug:"Zinc",effect:"↓ prulifloxacin",management:"Give prulifloxacin 2 hr before after"}],stewardship:{preferredIndications:["Francisella tularensis","Haemophilus ducreyi","Klebsiella granulomatis (granuloma inguinale)","Legionella sp.","Yersinia enterocolitica"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"No data",protein_binding:"45",half_life:"10.6-12.1",elimination:"Fecal",csf_penetration:"Negligible",preparations:"Tab (600 mg)"},rawData:{drug_name:"Prulifloxacin",tradename:"Quisnon, Sword, Pruquin, Unidrox",usage_and_dosing:{general:["Prulifloxacin is a fluoroquinolone marketed in several countries, but not approved in the US.","Prulifloxacin is a lipophilic oral prodrug of Ulifloxacin.","Originally developed in Japan and marketed there under the trade names Quisnon and Sword. Also available in Europe. Pruquin and Unidrox are among other trade names.","Only available as oral formulation.","Approved in Italy and Japan for:","Acute uncomplicated lower urinary tract infections (cystitis)","Complicated lower urinary tract infections","Acute exacerbations of chronic bronchitis","Japan: Infectious Diarrhea, e.g., traveler's diarrhea","Spectrum of in vitro activity similar to Ciprofloxacin.","Long half-life allows once daily dosing.","See Fluoroquinolones, Overview for class-wide issues, including usage, resistance mechanisms, adverse effects, pharmacology."],adult_dose:{note:"Dose by indication (see Comments):",acute_uncomplicated_cystitis:"600 mg po (single dose)",complicated_lower_utis:"600 mg po q24h for up to 10 days",acute_exacerbations_of_chronic_bronchitis:"600 mg po q24h for up to 10 days"},pediatric_dose:{dose_age_gt_28_days:"Safety and efficacy not established",max_day:"-"}},renal_adjustment:{half_life_normal:"10.6-12.1",half_life_esrd:"No data",dose_renal_function_normal:"600 mg po q24h",crcl_or_egfr:"CrCl ≥60: No dosage adjustment. CrCl <60: No data",hemodialysis:"No data",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:{contraindications:["Persons with celiac disease","Do not use in children, pregnancy, nursing mothers, and patients with a seizure disorder."],class_wide_adverse_effects:"For class-wide adverse effects, see Fluoroquinolones, Overview.",drug_interactions:"Many drug-drug interactions, see below",qtc_prolongation:"Interaction with concomitant drugs may increase the risk of prolongation of the QTc.",lactose:"Marketed formulation contains lactose."},antimicrobial_spectrum:{preferred:["Francisella tularensis","Haemophilus ducreyi","Klebsiella granulomatis (granuloma inguinale)","Legionella sp.","Yersinia enterocolitica"],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Tab (600 mg)",food_recommendation:"Tab ± food",oral_absorption_percent:"No data",tmax_hr:"1",peak_serum_conc_ug_ml:"Ulifloxacin 1.6 (600 mg po, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"45",volume_of_distribution_vd_l:"1231 L",avg_serum_half_life_hr:"10.6-12.1",elimination:"Fecal",bile_penetration_percent:"No data",csf_blood_percent:"Negligible",therapeutic_levels_in_csf:"No",auc_ug_hr_ml:"7.3 (600 mg po, 0-inf)"},major_drug_interactions:[{drug:"Antacids (Al, Mg)",effect:"↓ prulifloxacin",management:"Give prulifloxacin 2 hr before after"},{drug:"Calcium supplements",effect:"↓ prulifloxacin",management:"Give prulifloxacin 2 hr before after"},{drug:"Cimetidine",effect:"↓ prulifloxacin",management:"Give prulifloxacin 2 hr before after"},{drug:"Didanosine",effect:"↓ prulifloxacin",management:"Give prulifloxacin 2 hr before after"},{drug:"Insulin",effect:"↑↓ blood glucose",management:"Monitor"},{drug:"Iron supplements",effect:"↓ prulifloxacin",management:"Give prulifloxacin 2 hr before after"},{drug:"Nicardipine",effect:"↑ risk of prulifloxacin phototoxicity",management:"Monitor or avoid"},{drug:"NSAIDS",effect:"↑ risk of CNS stimulation/seizures",management:"Monitor or avoid"},{drug:"Oral hypoglycemics",effect:"↑↓ blood glucose",management:"Monitor"},{drug:"Sucralfate",effect:"↓ prulifloxacin",management:"Give prulifloxacin 2 hr before after"},{drug:"Theophylline",effect:"↑ theophylline",management:"Monitor or avoid"},{drug:"Warfarin",effect:"↑ warfarin, ↑ INR",management:"Monitor INR, adjust dosa"},{drug:"Zinc",effect:"↓ prulifloxacin",management:"Give prulifloxacin 2 hr before after"}],comments:["References: Drugs 64:2221, 2004; Int J Antimicrob Agts 37:283, 2011.","Spectrum and traveler's diarrhea pathogen susceptibility: Antimicrob Agents Chemother 53:1221,2009."]}},"Fosfomycin disodium (IV)":{id:"Fosfomycin_disodium_IV",name:"Fosfomycin disodium (IV)",tradename:"Ivozfo",classification:{family:"OTHER",subclass:"Other",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"Shown is % of normal daily dose. Loading dose: increase first dose by 100% (max 8 gm). CrCl >40: No dosage adjustment. CrCl >30 to 40: 70% (divided q8-12h). CrCl >20 to 30: 60% (divided q8-12h). CrCl >10 to 20: 40% (divided q8-12h). CrCl ≤10: 20% (divided q12-24h)",mild:"Shown is % of normal daily dose. Loading dose: increase first dose by 100% (max 8 gm). CrCl >40: No dosage adjustment. CrCl >30 to 40: 70% (divided q8-12h). CrCl >20 to 30: 60% (divided q8-12h). CrCl >10 to 20: 40% (divided q8-12h). CrCl ≤10: 20% (divided q12-24h)",moderate:"Shown is % of normal daily dose. Loading dose: increase first dose by 100% (max 8 gm). CrCl >40: No dosage adjustment. CrCl >30 to 40: 70% (divided q8-12h). CrCl >20 to 30: 60% (divided q8-12h). CrCl >10 to 20: 40% (divided q8-12h). CrCl ≤10: 20% (divided q12-24h)",severe:"Shown is % of normal daily dose. Loading dose: increase first dose by 100% (max 8 gm). CrCl >40: No dosage adjustment. CrCl >30 to 40: 70% (divided q8-12h). CrCl >20 to 30: 60% (divided q8-12h). CrCl >10 to 20: 40% (divided q8-12h). CrCl ≤10: 20% (divided q12-24h)"},hepatic:"No data",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No human data. No evidence of toxicity in animals.",lactation:"Low quantities found in breast milk. Probably safe with monitoring of infant for GI toxicity, but data are limited.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"Negligible",half_life:"2.0",elimination:"Renal",csf_penetration:"20-50",preparations:"Injection (disodium salt)"},rawData:{drug_name:"Fosfomycin disodium (IV)",tradename:"Ivozfo",usage_and_dosing:{general:["Fosfomycin is a low molecular weight (138 g/mol) phosphonic acid derivative. The IV preparation is fosfomycin disodium.","Mechanism of action: Inhibition of MurA (UDP-N-acetylglucosamine-enolpyruvyltransferase), which catalyzes the first committed step in peptidoglycan synthesis. Considered bactericidal with time-dependent killing.","In vitro activity:","In vitro activity includes ESBL-producing and some carbapenem-resistant Enterobacteriaceae (Int J Antimicrob Agents 2011;37:415).","Activity often enhanced when tested in combination: e.g., carbapenems increased fosfomycin activity vs P. aeruginosa in a hollow-fiber infection model (Antimicrob Agents Chemother 2018;62:e01682-18).","Gram-positive bacteria: Staph. aureus (including MRSA), Staph. epidermidis, Strep. pneumoniae, E. faecalis, VRE.","Gram-negative bacteria: E. coli, Proteus sp., Klebsiella/Enterobacter sp., Serratia sp., Salmonella sp., Citrobacter sp., Providencia sp.","Resistance:","Acinetobacter sp., Pseudomonas sp., Stenotrophomonas sp., and Bacteroides sp. are resistant.","Resistance primarily chromosomal; rare plasmid-mediated resistance.","Mechanisms: decrease in drug transport across the cell wall, or enzymatic alteration of the drug.","Cross resistance to other classes of antibiotics is rare.","Clinical use:","Parenteral therapy for a wide variety of system infections. For oral formulation, see Fosfomycin po.","Availability:","Parenteral (IV) formulation is approved and available in Europe, Australia, and Canada (as of May 2019).","U.S.: Possible to obtain emergency use of IV drug: single patient IND from the Division of Anti-infective Products at the FDA (Main number: 1-888-463-6332 or (+)1-301-796-1400; Emergency operations: (+) 1-301-796-8240 or 1-866-300-4374)."],adult_dose:{meningitis:"16-24 gm/day IV (divided q6-8h)",bone_and_joint_infection:"16-24 gm/day IV (divided q6-8h)",complicated_intraabdominal_infection:"12-24 gm/day IV (divided q8-12h)",complicated_ssti:"12-24 gm/day IV (divided q8-12h)",complicated_uti:"12-24 gm/day IV (divided q8-12h)",hap_vap:"12-24 gm/day IV (divided q8-12h)",infective_endocarditis:"12-24 gm/day IV (divided q8-12h)"},pediatric_dose:{prem_neonate_ga_pna_lt_40_wk:"100 mg/kg/day (div q12h)",neonate_ga_pna_40_44_wk:"200 mg/kg/day (div q8h)",age_1_12_mon_wt_le_10_kg:"200-300 mg/kg/day (div q8h)",age_1_12_years_wt_10_40_kg:"200-400 mg/kg/day (div q6-8h)",age_ge_12_years_wt_gt_40_kg:"Dose as adult"}},renal_adjustment:{notes:["Body weight and Creatinine Clearance calculations","CrCl = Creatinine clearance (mL/min)","CAPD = Continuous Ambulatory Peritoneal Dialysis","CRRT = Continuous Renal Replacement Therapy","AD = after hemodialysis","SLED = sustained low efficiency dialysis"],half_life_normal:"2.0",half_life_esrd:"50",dose_normal_function:"Varies with indication",crcl_or_egfr:"Shown is % of normal daily dose. Loading dose: increase first dose by 100% (max 8 gm). CrCl >40: No dosage adjustment. CrCl >30 to 40: 70% (divided q8-12h). CrCl >20 to 30: 60% (divided q8-12h). CrCl >10 to 20: 40% (divided q8-12h). CrCl ≤10: 20% (divided q12-24h)",hemodialysis:"2 gm q48h (give AD)",capd:"No data",crrt:"CVVH: No dosage adjustment (based on limited data)",sled:"5 gm q8h; another study recommends 8 gm load, then 5 gm post-SLED. 30"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No data",moderate_impairment_child_pugh_b:"No data",severe_impairment_child_pugh_c:"No data"},other_adjustment:["ECMO: See ECMO Drug Dosing Adjustment.","Obesity: See Obesity Dosing Adjustments."],adverse_effects:["Large sodium load: 14.4 mEq of sodium per gram. Thus, 10 grams has about the same amount of sodium as a liter of normal saline. Use with caution in patients with a history of CHF or underlying comorbidities such as nephrotic syndrome, liver cirrhosis, hypertension, hyperaldosteronism, hypernatremia, pulmonary edema, and hypoalbuminemia.","High sodium load may result in hypokalemia, which can potentiate the pharmacologic effects of digitalis glycosides.","Clostridium difficile-associated disease, ranging in severity from mild diarrhea to fatal colitis.","Hematologic toxicity (e.g., neutropenia).","Liver injury, including hepatitis. Usually reversible.","Hypersensitivity reactions, ranging from erythematous rash to anaphylaxis.","Headache, taste disturbances."],pregnancy_risk:{fda_risk_category:"No human data. No evidence of toxicity in animals.",lactation:"Low quantities found in breast milk. Probably safe with monitoring of infant for GI toxicity, but data are limited.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection (disodium salt)",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"552 (8 gm q8h, SS) (healthy volunteers)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"Negligible",volume_of_distribution_vd_l_kg:"0.3 L/kg",avg_serum_half_life_hr:"2.0",elimination:"Renal",bile_penetration_percent:"No data",csf_blood_percent:"20-50",therapeutic_levels_in_csf:"Yes",auc_ug_hr_ml:"3679 (8 gm q8h, 0-24h) (healthy volunteers)"},major_drug_interactions:"None reported",comments:["Homologues of the fosA resistance gene have been found in chromosomes of a large proportion of isolates from various gram-negative species (mBio 2017;8:e00749-17).","For in vitro activity (vs US bacterial isolates), see Diagn Microbiol Infect Dis 2019;93:143. Note low level of activity and/or variable activity vs:","Acinetobacter baumannii","Morganella species","Pseudomonas aeruginosa","Stenotrophomonas maltophilia","Bacteroides fragilis","Fusobacterium species","In prospective randomized double blind study, fosfomycin 6 gm IV (over 1 hr) q8h was found to be non-inferior to piperacillin-tazobactam, 4.5 gm IV q8h in patients with complicated UTIs including acute pyelonephritis.","Hypokalemia (perhaps related to large sodium load) was mild and transient.","Reference: Clin Infect Dis 2019;69:2045; editorial Clin Infect Dis 2019;69:2057."]}},"Fusidic acid":{id:"Fusidic_acid",name:"Fusidic acid",tradename:"Fucidin, Taksta",classification:{family:"OTHER",subclass:"Other",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No dosage adjustment for renal impairment",mild:"No dosage adjustment for renal impairment",moderate:"No dosage adjustment for renal impairment",severe:"No dosage adjustment for renal impairment"},hepatic:"No data",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Category C - Risk cannot be ruled out",lactation:"Safety not established, avoid use",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Atorvastatin",effect:"↑ atorvastatin (↑ risk of rhabdomyolysis)",management:"Avoid co-administration"},{drug:"Rifampin",effect:"↑ rifampin, ↓ fusidic acid",management:"Monitor or avoid"},{drug:"Ritonavir",effect:"↑ fusidic acid",management:"Monitor or avoid"},{drug:"Simvastatin",effect:"↑ simvastatin (↑ risk of rhabdomyolysis)",management:"Avoid co-administration"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"91",protein_binding:"95-99",half_life:"15",elimination:"Biliary",csf_penetration:"No data",preparations:"Tab (250 mg), Oral susp (50 mg/5 mL), 2% cream/ointment, 1% oph solution, Injection"},rawData:{drug_name:"Fusidic acid",tradename:"Fucidin, Taksta",usage_and_dosing:{general:["Major use of Fusidic acid is in the treatment of staphylococcal infections, including methicillin-resistant Staph. aureus (MRSA). Note: Staph. saprophyticus is intrinsically resistant.","Steroid class drug with no corticosteroid activity; inhibits protein synthesis. Referred to as a Fusidane class antibiotic.","Bacteriostatic.","High level resistance due to mutations in the fusA gene that encodes the drug binding site in the ribosome.","Fusidic acid is widely used in Europe and elsewhere, but is not, at present, marketed in the US. Clinical trials in the US are in progress.","Active both extra- and intracellularly.","Available as tablets, oral suspension, topical, ophthalmic, and IV solution.","Activity enhanced in acidic media, accumulates in human cells; intracellular activity comparable to Linezolid and Clindamycin.","Comprehensive review in supplement in Clin Infect Dis 52(Suppl 7):S542, 2011; Clin Infect Dis 52(Suppl 7):S467, 2011."],adult_dose:{standard_european_regimen:"500 mg po/IV tid is standard European regimen. Internationally, available as 250 mg tablet. Availability of IV fusidic acid is uncertain.",us_trials_regimen:"Day 1 loading dose of 1500 mg po bid and then 600 mg po bid (Clin Infect Dis 52(Suppl 7):S542, 2011)",topical:"2% ointment, apply tid for impetigo"},pediatric_dose:{age_lt_1_yr:"50 mg/kg/day (divided q8h)",age_1_5_yrs:"250 mg q8h",age_6_12_yrs:"250-500 mg q8h",age_gt_12_yrs:"adult dosing"}},renal_adjustment:{notes:["Body weight and Creatinine Clearance calculations","CrCl = Creatinine clearance (mL/min)","CAPD = Continuous Ambulatory Peritoneal Dialysis","CRRT = Continuous Renal Replacement Therapy","AD = after hemodialysis","SLED = sustained low efficiency dialysis","Dosage adjustment may be required in hepatic disease."],half_life_normal:"8.9-11",half_life_esrd:"Unchanged",dose_normal_function:"500 mg po/IV q8h",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No data",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No data",moderate_impairment_child_pugh_b:"No data",severe_impairment_child_pugh_c:"Avoid use"},adverse_effects:["Phlebitis with IV administration.","Nausea, vomiting, diarrhea are most common with po administration.","Elevated bilirubin due to inhibition of bile transport; much like Dubin-Johnson syndrome"],pregnancy_risk:{fda_risk_category:null,lactation:"Safety not established, avoid use",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"No data",preparations:"Tab (250 mg), Oral susp (50 mg/5 mL), 2% cream/ointment, 1% oph solution, Injection",food_recommendation:"Tab + food",oral_absorption_percent:"91",tmax_hr:"2-4",peak_serum_conc_ug_ml:"30 (500 mg po, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"95-99",volume_of_distribution_vd_l_kg:"0.3 L/kg",avg_serum_half_life_hr:"15",elimination:"Biliary",bile_penetration_percent:"100-200",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"442 (500 mg po, 0-inf)"},enzyme_interactions:{cyp450_substrate:["CYP3A4"],transporter_substrate:[],ugt_substrate:[],cyp450_inhibited:["CYP3A4"],transporters_inhibited:["BCRP","OATP1B1"],ugts_inhibited:[],cyp450_induced:[],transporters_induced:[],ugts_induced:[],serum_drug_concentration_impact:"↑"},major_drug_interactions:[{drug:"Atorvastatin",effect:"↑ atorvastatin (↑ risk of rhabdomyolysis)",management:"Avoid co-administration"},{drug:"Rifampin",effect:"↑ rifampin, ↓ fusidic acid",management:"Monitor or avoid"},{drug:"Ritonavir",effect:"↑ fusidic acid",management:"Monitor or avoid"},{drug:"Simvastatin",effect:"↑ simvastatin (↑ risk of rhabdomyolysis)",management:"Avoid co-administration"}],comments:["Reserved for staphylococcal infections resistant to other drugs or for patients intolerant or allergic to other drugs.","Report of 8 cases of rhabdomyolysis after concomitant use of statin and fusidic acid (BMJ 345:e6562, 2012)."]}},Dalbavancin:{id:"Dalbavancin",name:"Dalbavancin",tradename:"Dalvance, Xydalba",classification:{family:"GLYCOPEPTIDE",subclass:"Glycopeptide",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:{ge_30:"No dosage adjustment",lt_30_no_hd:"750 mg x1 then 375 mg in 7 days, OR 1125 mg x1"},mild:{ge_30:"No dosage adjustment",lt_30_no_hd:"750 mg x1 then 375 mg in 7 days, OR 1125 mg x1"},moderate:{ge_30:"No dosage adjustment",lt_30_no_hd:"750 mg x1 then 375 mg in 7 days, OR 1125 mg x1"},severe:{ge_30:"No dosage adjustment",lt_30_no_hd:"750 mg x1 then 375 mg in 7 days, OR 1125 mg x1"}},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No human data. Toxic in rats at 3.5x human exposure.",lactation:"Probably safe with monitoring, but no data available",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"93-98",half_life:"147-258 (terminal)",elimination:"Renal, fecal",csf_penetration:"No data",preparations:"Injection"},rawData:{drug_name:"Dalbavancin",tradename:"Dalvance, Xydalba",usage_and_dosing:{general:["Dalbavancin is a long-acting parenteral lipoglycopeptide antibiotic.","Approved for acute skin and skin structure infections.","An alternative antibiotic for drug resistant genotypes.","If unable to directly test susceptibility, in vitro susceptibility to vancomycin is acceptable as a surrogate (Diagnostic Microbiol Infect Dis 2015;82:73).","Dalbavancin shown active in vitro and in clinical infections due to:","Staphylococcus aureus: MSSA and MRSA","Streptococcus pyogenes","Streptococcus agalactiae (Group B Strep.)","Streptococcus dysgalactiae","Streptococcus anginosus group","Vancomycin-susceptible Enterococcus faecalis","Also active in vitro against:","Enterococcus faecium (Vancomycin-susceptible strains only)","Vancomycin-intermediate Staph. aureus (not active vs. Vancomycin-resistant strains)","Once weekly dosing regimen may be a useful alternative for outpatient parenteral therapy (see Comments).","Prepare infusions in D5W only. Do not add to normal saline (drug may precipitate out of solution)."],adult_dose:{skin_and_skin_structure:{two_dose_regimen:"Originally approved as a two-dose regimen: 1000 mg IV once, followed in one week by a dose of 500 mg IV.",single_dose_regimen:"Later approved as a single dose of 1500 mg IV; shown non-inferior to the 2-dose regimen (Clin Infect Dis 62:545, 2016).",infusion:"Infuse doses over 30 minutes."},infective_endocarditis:{sequential_therapy:"If used as sequential therapy for infective endocarditis:",options:["Loading dose of 1000 mg IV on day 1, then 500 mg IV once weekly, OR","Loading dose of 1500 mg IV on day 1, then 1000 mg IV every 2 weeks."],infusion:"Infuse doses over 30 minutes."}},pediatric_dose:{crcl_ge_30:{age_0_to_lt_6_yrs:"22.5 mg/kg x1 dose",age_6_to_lt_18_yrs:"18 mg/kg x1 dose"},crcl_lt_30:"Not recommended",max_day:"1500 mg"}},renal_adjustment:{half_life_normal:"147-258 (terminal)",half_life_esrd:"No data",dose_renal_function_normal:"1 gm IV x1 then 500 mg IV in 7 days, OR 1.5 gm IV x1",crcl_or_egfr:{ge_30:"No dosage adjustment",lt_30_no_hd:"750 mg x1 then 375 mg in 7 days, OR 1125 mg x1"},hemodialysis:"No dosage adjustment",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No data, use caution",severe_impairment_child_pugh_c:"No data, use caution"},other_adjustment:["Obesity: See Obesity Dosing Adjustments table."],adverse_effects:["Common (>2%): nausea (5.5%), headache (4.7%), diarrhea (4.4%), rash (2.7%), pruritus (2.1%).","Uncommon (<2%): C. difficile, candidiasis, cytopenias, anaphylactoid reaction, dizziness, bronchospasm, urticaria, eosinophilia, elevated INR, hepatic enzymes; hypoglycemia.","Flushing, urticaria, and pruritus (similar to vancomycin histamine release syndrome) can occur with rapid infusion. Stopping or slowing the infusion may result in cessation of the reaction.","ALT elevations > 3x upper limit of normal (0.8%).","Does not prolong QT interval."],pregnancy_risk:{fda_risk_category:"No human data. Toxic in rats at 3.5x human exposure.",lactation:"Probably safe with monitoring, but no data available",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"280-300 (1 gm IV, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"93-98",volume_of_distribution_vd_l_kg:"0.11 L/kg (Drugs 2010;70:859)",avg_serum_half_life_hr:"147-258 (terminal)",elimination:"Renal, fecal",bile_penetration_percent:"No data",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"23443 (1 gm IV, 0-inf)"},major_drug_interactions:["None known"],comments:["Extended terminal half-life of this agent allows treatment with two intravenous doses, spaced one week apart, or a single intravenous dose, for treatment of acute bacterial skin and skin structure infections (FDA approved indication).","Emerging interest in use, instead of vancomycin, for outpatient parenteral antimicrobial therapy (OPAT) of susceptible organisms causing SSSIs or infective endocarditis due to susceptible organisms.","No controlled clinical trials","Ref.: Infect Dis Ther 2019;8:171","Dalbavancin is active in vitro vs. Vancomycin-susceptible E. faecium and E. faecalis and is approved for skin and skin structure infections due to the latter.","Caution is advised in patients with history of allergy to other glycopeptide antibiotics because likelihood of cross-sensitivity is unknown."]}},Daptomycin:{id:"Daptomycin",name:"Daptomycin",tradename:"Cubicin",classification:{family:"GLYCOPEPTIDE",subclass:"Glycopeptide",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:["Staphylococcus aureus, methicillin-resistant, (MRSA)","Staphylococcus epidermidis, methicillin-resistant (MRSE)","Staphylococcus sp., coagulase-negative (Methicillin resistant); S. hominis, S. capitis, others"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"CrCl ≥30: No dosage adjustment. CrCl <30: 6-10 mg/kg q48h",mild:"CrCl ≥30: No dosage adjustment. CrCl <30: 6-10 mg/kg q48h",moderate:"CrCl ≥30: No dosage adjustment. CrCl <30: 6-10 mg/kg q48h",severe:"CrCl ≥30: No dosage adjustment. CrCl <30: 6-10 mg/kg q48h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"B",lactation:"Probably safe with monitoring, but data limited",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"HMG-CoA inhibitors (statins)",effect:"Myopathy",management:"Consider stopping statin while on Dapt"}],stewardship:{preferredIndications:["Staphylococcus aureus, methicillin-resistant, (MRSA)","Staphylococcus epidermidis, methicillin-resistant (MRSE)","Staphylococcus sp., coagulase-negative (Methicillin resistant); S. hominis, S. capitis, others"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"92",half_life:"8-9",elimination:"Renal",csf_penetration:"0-8",preparations:"Injection"},rawData:{drug_name:"Daptomycin",tradename:"Cubicin",usage_and_dosing:{general:["Daptomycin is a novel lipopeptide effective in the treatment of gram-positive organisms, e.g., Staph. aureus, enterococci and streptococci. Active vs. MRSA and VRE.","Approved (FDA) for complicated skin and soft tissue infections (cSSSI) caused by gram-positive cocci, Staph. aureus bacteremia and right-sided Staph. aureus endocarditis.","An alternative antibiotic for drug resistant genotypes.","Do not use for primary pneumonia: inactivated by pulmonary surfactant"],formulation_differences:{powdered_vs_original:{storage:"Unreconstituted powder can be stored at room temperature (original formulation requires refrigeration).",preparation:"Quicker and easier to prepare the injection/infusion solution from the powder.",reconstitution_diluent:"Reconstitution diluent is sterile water, not normal saline.",stability:"Reconstituted injection/infusion solution has better stability, both at room temperature or if refrigerated.",reference:"Drug Des Devel Ther 2018;12:1953."},original_compatibility:"Original formulation is compatible with normal saline and lactated Ringer's but not dextrose-containing diluent. RF formulation is compatible with normal saline."},resistance:{review:"J Antimicrob Chemother 2018;73:1",staph_aureus:"Daptomycin resistance to Staph. aureus can occur de novo, after or during Vancomycin therapy, or after or during Daptomycin therapy (N Engl J Med 355; 653, 2006; Clin Infect Dis 50 (Suppl 1):S10, 2010).",mechanism:"At least one mechanism is addition of a lysine to the cell surface with a resulting increase in positive charge that repulses the positively charged Daptomycin (Antimicrob Agts Chemother 55:2018, 2011).",seesaw_effect:'Daptomycin resistant strains of MRSA demonstrate a "seesaw" effect with selected other drugs; MICs for other drugs (e.g., oxacillin) decrease while daptomycin MIC increases.',combination_therapy:{in_vitro:"Daptomycin resistant MRSA demonstrated in vitro cidal activity vs. MRSA when combined with TMP/SMX or B-lactam (Antimicrob Agts Chemother 54:5187, 2010; Antimicrob Agts Chemother 56:6192, 2012).",case_reports:"Case reports and small series show clearance of MRSA bacteremia and clinical improvement with combination daptomycin and B-lactam (nafcillin, ceftaroline) or TMP/SMX (Clin Infect Dis 53:158, 2011, Antimicrob Agts Chemother 56:5709, 2012; Antimicrob Agts Chemother 56:5990, 2012).",pilot_study:"Pilot study of daptomycin + ceftaroline versus vancomycin was halted prematurely due to a mortality imbalance in favor of the combination; numerous study design and conduct issues were raised; prospective study needed (Antimicrob Agts Chemother 63(5): e02483-18, 2019; Antimicrob Agents Chemother. 2019 Oct 22;63(11):e00900-19)"}},allergy:"Protocol for Daptomycin Desensitization."},adult_dose:{skin_soft_tissue_infection:{dose:"4-6 mg/kg IV q24h",administration:"Administer as a bolus injection over 2 minutes, or by short infusion over 30 minutes",recommendation:"Many clinicians recommend 6 mg/kg IV q24h for all patients"},bacteremia_endocarditis:{details:"Refer to these pages for details:",links:["S. aureus bacteremia","S. aureus endocarditis","Enterococcal endocarditis"]}},pediatric_dose:{csssi:{age_12_17_yrs:"5 mg/kg (over 30 min) q24h",age_7_11_yrs:"7 mg/kg (over 30 min) q24h",age_2_6_yrs:"9 mg/kg (over 60 min) q24h",age_1_to_lt_2_yrs:"10 mg/kg (over 60 min) q24h",duration:"≤14 days"},s_aureus_bacteremia:{age_12_17_yrs:"7 mg/kg (over 30 min) q24h",age_7_11_yrs:"9 mg/kg (over 30 min) q24h",age_1_6_yrs:"12 mg/kg (over 60 min) q24h",duration:"≤42 days"}},renal_adjustment:{half_life_normal:"8-9",half_life_esrd:"30",dose_renal_function_normal:"6-10 mg/kg IV q24h",crcl_or_egfr:"CrCl ≥30: No dosage adjustment. CrCl <30: 6-10 mg/kg q48h",hemodialysis:"6-10 mg/kg q48h (AD); if next planned dialysis is 72 hrs away, give 9-15 mg/kg 26",capd:"6-10 mg/kg q48h",crrt:"6-8 mg/kg q24h 27",sled:"6 mg/kg q24h (post-SLED). Consider higher doses (8-12 mg/kg) for severe infection. 53"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["ECMO: See ECMO Drug Dosing Adjustment.","Obesity: See Obesity Dosing Adjustments."],adverse_effects:{myopathy:"Myopathy, more frequent at higher exposure. Suggest weekly CPK for muscle pain or weakness; discontinue Daptomycin if CPK exceeds 5x normal level in presence of symptoms or 10x upper limits of normal without symptoms of myopathy. For association with statin use see meta-analysis (Clin Infect Dis.2022; 75:1416). Manufacturer suggests stopping statins during Daptomycin therapy.",statin_interaction:"In retrospective, matched case-control study, statin co-administration was associated with myopathy in 4.2% of 3042 daptomycin exposed patients; rhabdomyolysis in 0.8%. Suggestion to monitor CPK during daptomycin therapy in the presence of concomitant statin administration (Clin Infect Dis 2018; 67:1356).",treatment_stopped:"Overall treatment stopped due to adverse effects in 2.8%.",other:"Other: local phlebitis (6%), fever (2%), rash (4%), nausea/vomiting (6.3%), diarrhea (5%), C. difficile colitis, increased BUN, Creatinine (rare), headache (5%).",eosinophilic_pneumonia:"Reports of drug-induced eosinophilic pneumonia (Clin Infect Dis 50:737, 2010), most often after 2-4 weeks of therapy and can recur.",thrombocytopenia:"Case report of severe immune thrombocytopenia (Antimicrob Agts Chemother 56:6430, 2012). Rare case of neutropenia after 10 weeks of therapy (Clin Infect Dis 56:1353, 2013).",prothrombin_time:"Daptomycin interacts with reagents used to measure prothrombin times with subsequent artifactual prolongation (Blood Coag & Fibrinolysis 19:32, 2008)."},pregnancy_risk:{fda_risk_category:"B",lactation:"Probably safe with monitoring, but data limited",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Staphylococcus aureus, methicillin-resistant, (MRSA)","Staphylococcus epidermidis, methicillin-resistant (MRSE)","Staphylococcus sp., coagulase-negative (Methicillin resistant); S. hominis, S. capitis, others"],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"57.8-183.7 (4-12 mg/kg IV q24h, SS)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"92",volume_of_distribution_vd_l_kg_vss:"0.1 L/kg (Vss)",avg_serum_half_life_hr:"8-9",elimination:"Renal",bile_penetration_percent:"No data",csf_blood_percent:"0-8",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"494-1277 (4-12 mg/kg IV q24h, 0-24 hr)"},major_drug_interactions:[{drug:"HMG-CoA inhibitors (statins)",effect:"Myopathy",management:"Consider stopping statin while on Dapt"}],comments:["Clinical trials:","Daptomycin vs. Ceftriaxone for community-acquired pneumonia (CAP), significant failure to eradicate S. pneumoniae and a trend of increase in failures for Staph. aureus eradication (Clin Infect Dis 46:1142, 2008).","In animal models, Daptomycin failed vs. S. pneumoniae but efficacy vs. haematogenous Staph. aureus pneumonia; Daptomycin inactivated by surfactant (J Infect Dis 191:2149, 2005). In theory, less functional surfactant with necrotizing Staph. aureus pneumonia. Results of the Daptomycin vs. Vancomycin trial support this interpretation; patients with right-sided endocarditis and haematogenous pneumonia were non-inferior to Vancomycin (N Engl J Med 355:653, 2006).","Caution: case report of a patient that developed Staph. aureus pneumonia while receiving Daptomycin at 10 mg/kg/day (Clin Infect Dis 49:1286, 2009).","Support for higher doses:","Well-tolerated in healthy volunteers at doses up to 12 mg/kg q24h x 14 days (Antimicrob Agents Chemother 50:3245, 2006) and in patients given mean dose of 8 mg/kg/day (Clin Infect Dis 49:177, 2009).","Two case series of high dose Daptomycin for right and left sided endocarditis. Mostly Staph. aureus. Daptomycin doses between 9 and 10 mg/kg/day as single dose. No muscle or renal toxicity reported (J Antimicrob Chemother 68:2921, 2013; Antimicrob Ag Chemother 57:6213, 2013).","In large retrospective VA study of patients with bacteremia due to vancomycin-resistant enterococci, improved survival and microbiologic cure with once daily doses of ≥ 10 mg/kg/day. No evidence of muscle injury (Clin Infect Dis 2017; 64:605)","Resistance observed during daptomycin therapy in Staph. aureus bacteremia study and numerous subsequent studies (N Engl J Med 355:653, 2006). Repeat MICs and evaluate for undrained source(s) in patients with positive follow-up cultures for S. aureus."]}},Oritavancin:{id:"Oritavancin",name:"Oritavancin",tradename:"Orbactiv, Kimyrsa",classification:{family:"GLYCOPEPTIDE",subclass:"Glycopeptide",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No dosage adjustment in mild-moderate impairment. Not studied in severe impairment",mild:"No dosage adjustment in mild-moderate impairment. Not studied in severe impairment",moderate:"No dosage adjustment in mild-moderate impairment. Not studied in severe impairment",severe:"No dosage adjustment in mild-moderate impairment. Not studied in severe impairment"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No human data, no evidence of toxicity in animals",lactation:"Probably safe with monitoring, but no data available; avoid if possible.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unfractionated heparin",effect:"aPTT results falsely elevated for up to five days",management:"Contraindicated for 120 hours after oritavancin administration"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"85",half_life:"245 (terminal)",elimination:"Renal, fecal",csf_penetration:"No data",preparations:"Injection"},rawData:{drug_name:"Oritavancin",tradename:"Orbactiv, Kimyrsa",usage_and_dosing:{general:["Oritavancin is a long acting IV lipoglycopeptide (similar to Vancomycin) approved for the single dose treatment of adults with acute skin and skin structure infections due to susceptible gram-positive bacteria.","An alternative antibiotic for drug resistant genotypes.","Two IV formulations are available:","Orbactiv (400 mg vials), approved in 2014, administered over three hours.","Kimyrsa (1200 mg vials), approved in 2021, administered over one hour.","Other differences: vial size, reconstitution and dilution instructions, and compatible dilutents.","Active in vitro versus virtually all the gram-positive cocci. Based both on in vitro activity and clinical trials, the package Insert lists in vitro activity vs:","Staph. aureus (MSSA and MRSA)","Streptococcus pyogenes","Streptococcus agalactiae","Streptococcus dysgalactiae","Streptococcus anginosus group","Vancomycin-sensitive E. faecalis","FDA approved package insert advises users to not treat patients with osteomyelitis with oritavancin, even if the etiologic organism is susceptible in vitro. In phase III clinical trials, a higher incidence of osteomyelitis was observed in oritavancin patients vs. comparator group.","For results of registration controlled trial comparing oritavancin versus vancomycin for ABSSSIs (SOLO trial), see Clin Infect Dis 60:254, 2015.","No clinical data, but activity in vitro vs. Vancomycin-resistant enterococci (VRE), Vancomycin-intermediate (VISA), and Vancomycin-resistant Staph. aureus (VRSA).","Long terminal serum half-life of 245 hours permits single dose therapy. The single dose regimen may be useful in the patient requiring parenteral therapy but who does not otherwise need to be hospitalized.","Note: A single dose can cause a false elevation of certain lab coagulation tests. See Adverse Effects for details."],adult_dose:{orbactiv:{dose:"1200 mg IV over three hours as a single dose.",preparation:["Add 40 mL sterile water to each of three 400 mg vials. Swirl gently to avoid foaming.","Withdraw 120 mL from a 1000 mL bag of D5W, add drug.","Use within 6 hours when stored at room temperature, within 12 hours if refrigerated.","Normal saline (NS) is incompatible (drug may precipitate)."]},kimyrsa:{dose:"1200 mg IV over one hour as a single dose.",preparation:["Add 40 mL sterile water to one 1200 mg vial. Swirl gently to avoid foaming.","Withdraw 40 mL from a 250 mL bag or NS or D5W, add drug.","Use within 4 hours when stored at room temperature, within 12 hours if refrigerated."],compatibility:"In contrast to Orbactiv, Kimyrsa is compatible with normal saline (NS)."}},pediatric_dose:{dose_age_gt_28_days:"Safety and efficacy not established",max_day:"-"}},renal_adjustment:{half_life_normal:"245 (terminal)",half_life_esrd:"No data",dose_renal_function_normal:"1200 mg IV x1",crcl_or_egfr:"No dosage adjustment in mild-moderate impairment. Not studied in severe impairment",hemodialysis:"Not removed by hemodialysis",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No data, use caution"},other_adjustment:["Obesity: See Obesity Dosing Adjustments table."],adverse_effects:["Most common, reported in ≥3% of recipients: nausea, vomiting, diarrhea, headache.","Acute urticaria/flushing/pruritis have occurred.","Similar to histamine-release syndrome reported with Vancomycin. If reactions do occur, discontinue therapy. In many patients with similar reactions to Vancomycin, it was possible to reinstitute therapy at a slower rate of infusion.","C. difficile colitis has occurred.","Oritavancin can bind to, and prevent the action of, the phospholipid reagents used in laboratory coagulation tests. Administration of IV unfractionated heparin is contraindicated due to artificially prolonged aPTT for up to 120 hrs (5 days) after drug administration. The PT and INR are prolonged for up to 12 hrs. D-dimer concentrations are artificially elevated for up to 72 hours. Note that Oritavancin has no effect on the coagulation system in vivo."],pregnancy_risk:{fda_risk_category:"No human data, no evidence of toxicity in animals",lactation:"Probably safe with monitoring, but no data available; avoid if possible.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"148 (1200 mg IV over 1 hr, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"85",volume_of_distribution_vd_l:"87.6 L",avg_serum_half_life_hr:"245 (terminal)",elimination:"Renal, fecal",bile_penetration_percent:"No data",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No",auc_ug_hr_ml:"1460 (1200 mg IV over 1 hr, 0-72 hr)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:[],ugts_substrate:[],cyp450s_inhibited:["CYP2C9 (weak)","CYP2C19 (weak)"],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:["CYP2D6 (weak)","CYP3A4 (weak)"],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"mild ↑ or ↓"},major_drug_interactions:[{drug:"Unfractionated heparin",effect:"aPTT results falsely elevated for up to five days",management:"Contraindicated for 120 hours after oritavancin administration"}],comments:["Three mechanisms of antibacterial action:","Inhibition of transglycosylation step of cell wall synthesis","Inhibition of cell wall transpeptidation (crosslinking) step of cell wall synthesis","Disruption of the integrity of the bacterial membrane: J Molec Biol 377: 281, 2008.","Osteomyelitis: Interesting case report of a single patient with E. faecium (VRE) vertebral osteomyelitis. Successfully treated with combination of weekly Oritavancin plus continuous infusion of ampicillin (Antimicrob Agt Chemother. 2019; 63: e02622-18)."]}},Teicoplanin:{id:"Teicoplanin",name:"Teicoplanin",tradename:"Targocid",classification:{family:"GLYCOPEPTIDE",subclass:"Glycopeptide",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:["Enterococcus faecalis, susceptible to vancomycin","Staphylococcus epidermidis, methicillin-resistant (MRSE)","Staphylococcus sp., coagulase-negative (Methicillin resistant); S. hominis, S. capitis, others","Viridans group streptococci"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"CrCl >80: No dosage adjustment. CrCl 30-80: Load, then 6-12 mg/kg q48h. CrCl <30: Load, then 6-12 mg/kg q72h",mild:"CrCl >80: No dosage adjustment. CrCl 30-80: Load, then 6-12 mg/kg q48h. CrCl <30: Load, then 6-12 mg/kg q72h",moderate:"CrCl >80: No dosage adjustment. CrCl 30-80: Load, then 6-12 mg/kg q48h. CrCl <30: Load, then 6-12 mg/kg q72h",severe:"CrCl >80: No dosage adjustment. CrCl 30-80: Load, then 6-12 mg/kg q48h. CrCl <30: Load, then 6-12 mg/kg q72h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"B3 (Australia)",lactation:"Unknown if excreted into breast milk. Use only if potential benefit outweighs risk.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:["Enterococcus faecalis, susceptible to vancomycin","Staphylococcus epidermidis, methicillin-resistant (MRSE)","Staphylococcus sp., coagulase-negative (Methicillin resistant); S. hominis, S. capitis, others","Viridans group streptococci"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"90-95",half_life:"70-100",elimination:"Renal",csf_penetration:"negligible",preparations:"Injection"},rawData:{drug_name:"Teicoplanin",tradename:"Targocid",usage_and_dosing:{general:["Teicoplanin is a parenteral glycopeptide, similar to Vancomycin, available in Europe, Asia-Pacific and Africa.","In U.S. trials, doses needed to clear Staph. aureus bacteremia were toxic with the most common adverse event being the development of thrombocytopenia. Not licensed for use in the U.S.","An alternative antibiotic for drug resistant genotypes.","Can be administered intramuscularly (max 400 mg at any site)."],adult_dose:{complicated_skin_and_soft_tissue_infection_pneumonia_complicated_uti:{loading_dose:"6 mg/kg q12h x3 doses",target_trough_fpia:">15 µg/mL (day 3-5)",maintenance_dose:"6 mg/kg q24h",maintenance_target_trough_fpia:">"},bone_and_joint_infection:{loading_dose:"12 mg/kg q12h x3-5 doses",target_trough_fpia:">20 µg/mL (day 3-5)",maintenance_dose:"12 mg/kg q24h",maintenance_target_trough_fpia:">"},endocarditis:{loading_dose:"12 mg/kg q12h x3-5 doses",target_trough_fpia:"30-40 µg/mL (day 3-5)",maintenance_dose:"12 mg/kg q24h",maintenance_target_trough_fpia:">"},c_difficile_infection:{loading_dose:"None, see maintenance",maintenance_dose:"100-200 mg orally twi days"},fpia_note:"FPIA = Fluorescence Polarization Immunoassay"},pediatric_dose:{age_0_to_le_2_mon:"16 mg/kg IV x1 dose, then 8 mg/kg IV q24h",age_2_mon_to_12_yrs:"10 mg/kg IV q12h x3 doses, then 6-10 mg/kg IV q24h",max_day:"-"}},renal_adjustment:{half_life_normal:"70-100",half_life_esrd:"up to 230",dose_renal_function_normal:"6-12 mg/kg IV q12h x3 doses (load), then 6-12 mg/kg IV q24h",crcl_or_egfr:"CrCl >80: No dosage adjustment. CrCl 30-80: Load, then 6-12 mg/kg q48h. CrCl <30: Load, then 6-12 mg/kg q72h",hemodialysis:"Not removed by HD",capd:"No data",crrt:"Load, then 6-12 mg/kg q48h",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["ECMO: See ECMO Drug Dosing Adjustment table.","Obesity: See Obesity Dosing Adjustments table."],adverse_effects:["Hypersensitivity: fever (at 3 mg/kg 2.2%, at 24 mg/kg 8.2%), skin reactions (2.4%).","Marked decrease in platelets (high dose ≥15 mg/kg/day); anemia and neutropenia can occur.","Histamine-release syndrome less common than with Vancomycin."],pregnancy_risk:{fda_risk_category:"B3 (Australia)",lactation:"Unknown if excreted into breast milk. Use only if potential benefit outweighs risk.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Enterococcus faecalis, susceptible to vancomycin","Staphylococcus epidermidis, methicillin-resistant (MRSE)","Staphylococcus sp., coagulase-negative (Methicillin resistant); S. hominis, S. capitis, others","Viridans group streptococci"],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"70 (6 mgkg IV q24h, SS)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"90-95",volume_of_distribution_vd_l_kg_vss:"0.9-1.6 L/kg (Vss)",avg_serum_half_life_hr:"70-100",elimination:"Renal",bile_penetration_percent:"No data",csf_blood_percent:"negligible",therapeutic_levels_in_csf:"No",auc_ug_hr_ml:"500-600 (6 mg/kg IV, 0-inf)"},major_drug_interactions:["Use caution in patients receiving concurrent nephrotoxic or ototoxic drugs, such as aminoglycosides, amphotericin B, cyclosporine and furosemide."],comments:["In endocarditis, Teicoplanin has often been used in combination regimens."]}},Telavancin:{id:"Telavancin",name:"Telavancin",tradename:"Vibativ",classification:{family:"GLYCOPEPTIDE",subclass:"Glycopeptide",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"10 mg/kg IV (infuse over 1 hour) q24h",severe:"10 mg/kg IV (infuse over 1 hour) q24h",renal:{normal:"CrCl >50: No dosage adjustment. CrCl 30-50: 7.5 mg/kg q24h. CrCl 10 to <30: 10 mg/kg q48h. CrCl <10: No data",mild:"CrCl >50: No dosage adjustment. CrCl 30-50: 7.5 mg/kg q24h. CrCl 10 to <30: 10 mg/kg q48h. CrCl <10: No data",moderate:"CrCl >50: No dosage adjustment. CrCl 30-50: 7.5 mg/kg q24h. CrCl 10 to <30: 10 mg/kg q48h. CrCl <10: No data",severe:"CrCl >50: No dosage adjustment. CrCl 30-50: 7.5 mg/kg q24h. CrCl 10 to <30: 10 mg/kg q48h. CrCl <10: No data"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Risk of fetal harm, based on animal studies. Avoid, unless benefit outweighs fetal risk.",lactation:"Milk concentrations likely low, poorly absorbed. Safe, monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"},{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"90",half_life:"8.1",elimination:"Renal",csf_penetration:"No data",preparations:"Injection"},rawData:{drug_name:"Telavancin",tradename:"Vibativ",usage_and_dosing:{general:["Telavancin is a parenteral lipoglycopeptide antibiotic approved for treatment of complicated skin and skin structure infections (SSSI) due to Staph. aureus (MSSA, MRSA), Vancomycin-susceptible E. faecalis, S. pyogenes, S. agalactiae, S. anginosus group. For review of the drug: Clin Infect Dis 60:787, 2015; Med Lett 52:1, 2010; Clin Infect Dis 61:S35, 2015)","Telavancin is also approved for the treatment of adults with hospital-acquired and ventilator-associated pneumonia due to Staph. aureus (MSSA, MRSA). Telavancin was non-inferior to Vancomycin in a published study of hospital-acquired pneumonia that included MRSA pneumonia (Clin Infect Dis 52:31, 2011).","An alternative antibiotic for drug resistant genotypes.","Telavancin has concentration-dependent bactericidal activity with dual mechanism of action: inhibition of synthesis of cell wall and disruption of bacterial cell membrane barrier.","In skin infection trial, elevations of serum creatinine occurred in 3.4% of Telavancin patients and 1.2% of Vancomycin patients. Confounded by concomitant exposure to other nephrotoxic drugs/contrast agents, etc. Reversible when Telavancin is stopped. In small retrospective study of 21 patients receiving salvage therapy, 7 (33%) developed acute renal injury; complicated patients, more data needed: J Antimicrob Chemother 67:723, 2012.","Black box warnings:","Patients with pre-existing moderate/severe renal impairment (CrCl ≤50 mL/min) treated with Telavancin for HAP/VAP had increased mortality vs. Vancomycin.","Nephrotoxicity.","May cause fetal harm, based on animal studies. Verify pregnancy status before initiating treatment, advise use of effective contraception."],adult_dose:{usual_dose:"10 mg/kg IV (infuse over 1 hour) q24h",suggested_duration:{sssi:"7-14 days for complicated SSSI",hap_vap:"7-21 days for HAP/VAP"},body_weight:"Use actual body weight in non-obese persons"},pediatric_dose:{dose_age_gt_28_days:"Safety and efficacy not established",max_day:"-"}},renal_adjustment:{half_life_normal:"8.1",half_life_esrd:"17.9",dose_renal_function_normal:"10 mg/kg IV q24h",crcl_or_egfr:"CrCl >50: No dosage adjustment. CrCl 30-50: 7.5 mg/kg q24h. CrCl 10 to <30: 10 mg/kg q48h. CrCl <10: No data",hemodialysis:"No data",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No data, use caution"},other_adjustment:["Obesity: See Obesity Dosing Adjustments table."],adverse_effects:["Nephrotoxicity","Hypersensitivity, including anaphylaxis","QTc prolongation","Coagulation test interference: Telavancin interferes with some laboratory coagulation tests (but does not affect coagulation in vivo), including prothrombin time, international normalized ratio, and activated partial thromboplastin time.","Adverse events in phase 3 trials vs. Vancomycin:","Dysgeusia (taste disturbance) 33% vs. 7%","Nausea 27% vs. 15%, vomiting 14% vs. 7%","Headache 14% vs. 13%","Increased creatinine 3.1% vs. 1.1%","Foamy urine","Flushing, urticaria, pruritus if infused too rapidly"],pregnancy_risk:{fda_risk_category:"Risk of fetal harm, based on animal studies. Avoid, unless benefit outweighs fetal risk.",lactation:"Milk concentrations likely low, poorly absorbed. Safe, monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"108 (10 mg/kg IV q24h, SS)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"90",volume_of_distribution_vd_l_kg_vss:"0.13 L/kg (Vss)",avg_serum_half_life_hr:"8.1",elimination:"Renal",bile_penetration_percent:"Low",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"780 (10 mg/kg IV q24h, 0-24 h)"},major_drug_interactions:["Avoid use in patients at risk; use with caution in patients taking drugs known to prolong the QT interval.","Potential for enhanced nephrotoxicity in patients receiving other nephrotoxic agents."],comments:["No commercially approved assay for measurement of Telavancin serum levels.","Cross reactivity with assay used to measure serum Vancomycin levels; patients receiving Telavancin have detectable serum levels of Vancomycin. Ref: J Antimicrob Chemother 67:508, 2012.","Package insert precaution as regards reduced clinical response in patients with baseline CrCl of 30-50 mL/min. There is no clear explanation for this observation.","One hypothesis: Initial dosing calculated based on elevated serum creatinine at time of admission. Elevated creatinine resolved within 48 hrs in 57% of patients in a retrospective review (Clin Infect Dis 2019;68; 1596).","In critically ill, suggest full dosage until clear whether renal function will improve with hydration and other measures."]}},Vancomycin:{id:"Vancomycin",name:"Vancomycin",tradename:"Vancocin",classification:{family:"GLYCOPEPTIDE",subclass:"Glycopeptide",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:["Arcanobacterium sp.","Corynebacterium jeikeium","Enterococcus faecalis, susceptible to vancomycin","Staphylococcus aureus, methicillin-resistant, (MRSA)","Staphylococcus epidermidis, methicillin-resistant (MRSE)","Staphylococcus sp., coagulase-negative (Methicillin resistant); S. hominis, S. capitis, others","Viridans group streptococci"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"CrCl >100: No dosage adjustment. CrCl >50-100: 15-20 mg/kg q12h. CrCl 20-50: 15-20 mg/kg q24h. CrCl <20: 15-20 mg/kg q48h",mild:"CrCl >100: No dosage adjustment. CrCl >50-100: 15-20 mg/kg q12h. CrCl 20-50: 15-20 mg/kg q24h. CrCl <20: 15-20 mg/kg q48h",moderate:"CrCl >100: No dosage adjustment. CrCl >50-100: 15-20 mg/kg q12h. CrCl 20-50: 15-20 mg/kg q24h. CrCl <20: 15-20 mg/kg q48h",severe:"CrCl >100: No dosage adjustment. CrCl >50-100: 15-20 mg/kg q12h. CrCl 20-50: 15-20 mg/kg q24h. CrCl <20: 15-20 mg/kg q48h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"C",lactation:"Safe with monitoring",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Other nephrotoxic agents",effect:"↑ risk of AKI",management:"Monitor"},{drug:"Piperacillin-tazobactam",effect:"↑ risk of AKI",management:"Moi"}],stewardship:{preferredIndications:["Arcanobacterium sp.","Corynebacterium jeikeium","Enterococcus faecalis, susceptible to vancomycin","Staphylococcus aureus, methicillin-resistant, (MRSA)","Staphylococcus epidermidis, methicillin-resistant (MRSE)","Staphylococcus sp., coagulase-negative (Methicillin resistant); S. hominis, S. capitis, others","Viridans group streptococci"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"55",half_life:"4-6",elimination:"Renal",csf_penetration:"7-14",preparations:"Injection, Cap (125, 250 mg), Oral soln (25 mg/mL, 50 mg/mL)"},rawData:{drug_name:"Vancomycin",tradename:"Vancocin",drug_shortage:[{preparation:"Injection",start_date:"2015-06-01",notes:""}],usage_and_dosing:{general:["Vancomycin is a glycopeptide antibiotic most often used in parenteral form for empiric or specific treatment of methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis (MRSE) infections. In the case of penicillin-allergy, it can also be used for susceptible Staphylococcus. The oral formulation is the preferred therapy for C. difficile infection.",'Vancomycin was isolated in 1957 from Streptomyces orientalis by an organic chemist with Eli Lilly working in the deep jungles in Borneo. Its name was derived from "vanquish” because of its ability to eradicate S. aureus. The original 1950s product contained considerable amounts (up to 70%) of impurities and had a brown color, thus earning the nickname "Mississippi Mud.”',"Mechanism of action: Vancomycin binds (via hydrogen bonding) to the terminal D-alanyl-D-alanine residues of the N-acetylmuramic acid (NAM) peptides within the bacterial cell wall, preventing subsequent cross-linking and thereby interrupting cell wall synthesis. It is considered a slowly bactericidal drug."],monitoring_guidelines:{multi_society:"Multi-society (ASHP, IDSA, PIDS, SIDP) guidelines recommend AUC24 monitoring (area under the serum concentration vs. time curve for 24 hours) for serious MRSA infections (Am J Health Sys Pharm 2020;77:835).",see_also:"See also Clin Infect Dis 2020;70:1536; Clin Infect Dis 2020;70:1546.",pro_con_discussion:'Comprehensive "pro" and "con" discussion: Clin Infect Dis 2021;72:1497 and Clin Infect Dis 2021;72:1502.',mic_assumption:"Hard to be sure of the MIC, as in vitro susceptibility varies with the method used (J Clin Microbiol 2011;49:269). For now, an MIC of 1 µg/mL is assumed (allowing us to simply target the AUC).",outcomes:"Improved outcomes with AUC24 monitoring in complicated skin and soft tissue infections due to MRSA (Clin Infect Dis 2021;73:e4560).",trough_monitoring:"Trough concentration monitoring (10-20 µg/mL) is still widely employed.",trough_preferred_for:"Preferred for meningitis, CNS infections; unstable renal function; diseases with target trough 10-15 µg/mL.",trough_poor_proxy:"Poor proxy for AUC24; target may be achieved with trough concentrations <15 µg/mL.",auc_validation:"There are currently no convincing data that validate AUC monitoring for MSSA, CONS, streptococci, or enterococci.",pediatrics:"Pediatrics: Use of AUC24 closer to 400 µg/mL adequate for most non-CNS infections in infants and older children with normal renal function."},auc24_calculation_methods:[{method:"Trapezoidal equations (see Vancomycin AUC Calculator)",pro:"Log-linear equations used to calculate true peak and trough based on measured peak and trough levels.",con:"Steady state must be achieved. Two measurements are required (peak and trough).",comments:"Once AUC24 for particular dose and interval is determined, adjustment of dose and interval for subsequent doses is proportional ratio. See Vancomycin AUC Dosing Fundamentals and Calculations."},{method:"Bayesian",pro:"Calculation may be based on single level, including pre-steady state. Adaptive to physiologic changes.",con:"Software tends to be expensive",comments:"Can work with single level, but better results with peak and trough measurements."}]},adult_dose:{intermittent_dosing:{loading_dose:"25-30 mg/kg IV (maximum 3 gm). Use actual body weight, infusion rate 10-15 mg/min",maintenance_dose:"15-20 mg/kg IV q8-12h. Use actual body weight, infusion rate 10-15 mg/min",auc_monitoring:"AUC monitoring (serious MRSA infection only). Target: 400-600 µg/mL x hr. Use Vancomycin AUC Calculator to determine AUC24 (requires a peak and trough concentration obtained at steady state). For explanatory notes and formulas, see Vancomycin AUC Dosing Fundamentals and Calculations."},continuous_infusion:"See Continuous, Extended Infusion Dosing page.",intrathecal_dosing:"Adult: 10-20 mg/day. Target CSF concentration is 10-20 µg/mL",oral_dosing:"125-500 mg po q6h"},pediatric_dose:{iv:"60-80 mg/kg/day (divided q6-8h). Target AUC 400-600 µg/mL⚫hr, or trough 10-15 µg/mL",po_c_difficile:"40 mg/kg/day (divided q6h)"},renal_adjustment:{hemodialysis_recommendations:"Hemodialysis recommendations assume HD 3x/week. HD/CRRT/SLED recommendations: Am J Health Sys Pharm 2020;77:835",half_life_normal:"6",half_life_esrd:"200-250",dose_renal_function_normal:"15-20 mg/kg IV q8-12h",crcl_or_egfr:"CrCl >100: No dosage adjustment. CrCl >50-100: 15-20 mg/kg q12h. CrCl 20-50: 15-20 mg/kg q24h. CrCl <20: 15-20 mg/kg q48h",hemodialysis:{post_hd_dosing:{low_permeability_membrane:"Load: 25 mg/kg, Maintenance: 7.5 mg/kg AD",high_permeability_membrane:"Load: 25 mg/kg, Maintenance: 10 mg/kg AD"},intradialytic_dosing:{low_permeability_membrane:"Load: 30 mg/kg, Maintenance: 7.5-10 mg/kg",high_permeability_membrane:"Load: 35 mg/kg, Maintenance: 10-15 mg/kg"}},capd:"7.5 mg/kg q48-96h",crrt:"7.5-10 mg/kg q12h (effluent 20-25 mL/kg/hr)",sled:"Load: 20-25 mg/kg, Maint: 15 mg/kg AD (or during final 60-90 min of dialysis). TDM suggested."},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["Obesity Dosing: See Obesity Dosing Adjustments page.","ECMO: See ECMO Drug Dosing Adjustment page."],adverse_effects:{vancomycin_histamine_release_syndrome:"Acute onset of erythematous edematous skin due to non-specific histamine release from mast cells. Not a sign of allergy, but rather, associated with rapid infusion of vancomycin. Discussion of changes in descriptive nomenclature: See N Engl J Med 2021;384:1283, Hosp Pediatr 2020;10:623.",dress:"DRESS: Drug Reaction with Eosinophilia and Systemic Symptoms. Similar to Stevens-Johnson syndrome except no involvement of mucous membranes. Of 314 patients receiving multiple weeks of vancomycin IV as outpatients, 95 (30%) developed eosinophilia for a hazards ratio of 1.66. Compared to other antibiotics causing eosinophilia, only vancomycin use was a harbinger of skin rash, renal injury, or liver injury (J Allergy Clin Immunol 2015;136:1288-94.e.1). Persons positive for HLA-A*32:01 are at increased risk. Analysis suggest 20% incidence of DRESS at 4 weeks of therapy in HLA-A*32:01 positive patients. Given the prevalence of HLA-A*32:01 of 6.8% in European populations, we can estimate that 1 of 70 patients given vancomycin for >2 weeks will develop DRESS (J Allergy Clin Immunol 2019;144:183).",leukocytoclastic_vasculitis:"rare, managed with vancomycin discontinuation ± steroids, other immunosuppressants (Daru 2025;33:13).",drug_fever:"Drug fever",immune_thrombocytopenia:"Immune thrombocytopenia (J Thromb Haemost 2013;11:169). Intriguing report of a linear exposure-response relationship between the highest vancomycin trough concentration in the first 7 days of therapy and a ≥ 50% decrease from baseline in the platelet count. Confirmation needed (J Antimicrob Chemother 2012;67:727).",neutropenia:"Neutropenia",linear_iga_bullous_dermatosis:"Linear IgA bullous dermatosis (Clin Infect Dis 2004;38:398-9, 442-3).",ototoxicity:"Ototoxicity: 19% of patients over age 53 suffered high frequency hearing loss with high dose vancomycin therapy after an average of 27 days of therapy (Antimicrob Agents Chemother 2009;53:483).",dose_dependent_nephrotoxicity:"Dose-dependent nephrotoxicity. Risk of reversible acute kidney injury increases with dose, duration, AUC (meta-analysis: Clin Infect Dis 2019; 69:1881). Does concomitant piperacillin-tazobactam augment the nephrotoxic potential of vancomycin? Nearly 50 observational studies report an association of acute kidney injury in patients administered the combination of vancomycin and piperacillin-tazobactam. In virtually all the studies, the serum creatinine was used as a surrogate marker for the glomerular filtration rate. However, 10-40% or more of serum creatinine is cleared by tubular secretion. Both piperacillin and tazobactam compete with creatinine (via OAT1 and OAT3) for tubular secretion. In addition, there is experimental evidence that vancomycin decreases the expression of OAT1 and OAT3. Thus, it is possible that the synergy of these two mechanisms results in an increase in the serum creatinine that could be misinterpreted as a fall in the glomerular filtration rate. Cystatin C is another surrogate marker for GFR. Cystatin C has no tubular secretion. In a prospective cohort study, patients receiving piperacillin-tazobactam plus vancomycin had no increases in their serum cystatin C levels, while serum creatinine levels increased to meet criteria for a designation of acute kidney injury (Intensive Care Med 2022;48:1144). In short, current evidence supports a pseudotoxicity risk due to a misinterpretation of increased serum creatinine levels as reflecting impaired GFR as opposed to interference with tubular secretion of creatinine."},pregnancy_risk:{fda_risk_category:"C",lactation:"Safe with monitoring",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Arcanobacterium sp.","Corynebacterium jeikeium","Enterococcus faecalis, susceptible to vancomycin","Staphylococcus aureus, methicillin-resistant, (MRSA)","Staphylococcus epidermidis, methicillin-resistant (MRSE)","Staphylococcus sp., coagulase-negative (Methicillin resistant); S. hominis, S. capitis, others","Viridans group streptococci"],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Injection, Cap (125, 250 mg), Oral soln (25 mg/mL, 50 mg/mL)",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"Target trough: 10-20",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"55",volume_of_distribution_vd_l_kg:"0.7 L/kg",avg_serum_half_life_hr:"4-6",elimination:"Renal",bile_penetration_percent:"No data",csf_blood_percent:"7-14",therapeutic_levels_in_csf:"High doses required",auc_ug_hr_ml:"Target: 400-600 (0-24h)"},major_drug_interactions:[{drug:"Other nephrotoxic agents",effect:"↑ risk of AKI",management:"Monitor"},{drug:"Piperacillin-tazobactam",effect:"↑ risk of AKI",management:"Moi"}]}},Clindamycin:{id:"Clindamycin",name:"Clindamycin",tradename:"Cleocin, Clindagel, Clinda Max, Clinda Reach, Evoclin, Xaciato",classification:{family:"LINCOSAMIDE",subclass:"Lincosamide",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:["Actinomyces sp.","Arcanobacterium sp.","Capnocytophaga sp."],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No dosage adjustment for renal impairment",mild:"No dosage adjustment for renal impairment",moderate:"No dosage adjustment for renal impairment",severe:"No dosage adjustment for renal impairment"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Humans: no evidence of toxicity with 2nd or 3rd trimester use. Insufficient data with 1st trimester use. Animals: no evidence of toxicity.",lactation:"Avoid use if possible, otherwise monitor infant for GI toxicity",blackBoxWarning:!1,majorAdverseEffects:["Reversible neutropenia, thrombocytopenia, and eosinophilia."]},interactions:[{drug:"Neuromuscular blocking agents",effect:"↑ neuromuscular blockade",management:"Avoid co-administ"},{drug:"Rifampin",effect:"↓ clindamycin (J Infect 2015;71:200)",management:"Monitor, adjust do"},{drug:"St. John's Wort",effect:"↓ clindamycin",management:"Monitor, adjust do"}],stewardship:{preferredIndications:["Actinomyces sp.","Arcanobacterium sp.","Capnocytophaga sp."],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"90",protein_binding:"85-94",half_life:"2.4",elimination:"Metabolized",csf_penetration:"No data",preparations:"Topical (gel, cream, lotion), Vaginal suppository, Vaginal gel, Injection, Cap (75, 150, 300 mg), Oral soln (75 mg/5 mL)"},rawData:{drug_name:"Clindamycin",tradename:"Cleocin, Clindagel, Clinda Max, Clinda Reach, Evoclin, Xaciato",drug_shortage:[{preparation:"Injection",start_date:"2015-06-25",notes:""}],usage_and_dosing:{general:["Clindamycin, approved in 1970, is a versatile antimicrobial agent with a spectrum that includes aerobic and anaerobic bacteria, and certain protozoa.","Clindamycin binds to the 50S ribosomal subunit at a site very close to the macrolide binding site. Protein synthesis is inhibited, probably because of interference with transpeptidation. Clindamycin may also promote tRNA dissociation from the ribosome.","Activity against Bacteroides fragilis has been declining, and rates of resistance world-wide approach 60% (Clin Infect Dis 2014;59:698). Accordingly, clindamycin is no longer recommended for treatment of intraabdominal infections.","Clindamycin remains active against roughly 80% of isolates of Clostridium, Peptostreptococcus, and Fusobacterium although there can be wide geographic differences in susceptibility.","Useful for treatment of infections due to anaerobic bacteria involving the head, neck, and lungs. Active vs. Actinomycetes spp. and peptostreptococci (both metronidazole-resistant).","MRSA: Community strains often susceptible, hospital strains generally resistant. No activity vs. enterococci.","Other uses (alone or in combination), not all-inclusive:","Acne vulgaris (N Engl J Med 2018;379:1343).","Babesiosis","Bacterial vaginosis","Malaria","Pneumocystis jirovecii pneumonia","Toxoplasmosis","Suppresses bacterial toxin production. See Necrotizing Fasciitis, Streptococcal page for details.","Allergy: Protocol for Clindamycin desensitization."],adult_dose:{usual_dose_range:{oral:"150-450 mg po q6-8h",parenteral:"600-900 mg IV q8h"},syndrome_pages:"Refer to syndrome pages for additional dosage details."},pediatric_dose:{po:"30-40 mg/kg/day (divided q6-8h)",iv:"20-40 mg/kg/day (divided q6-8h)"}},renal_adjustment:{notes:"Dosage adjustment may be required in hepatic disease.",half_life_normal:"2.4",half_life_esrd:"Unchanged",dose_renal_function_normal:"900 mg IV q8h, 150-450 mg po q6h",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No dosage adjustment",capd:"No dosage adjustment",crrt:"No dosage adjustment",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"Consider dosage reduction"},other_adjustment:["Obesity: See Obesity Dosing Adjustments."],adverse_effects:{cutaneous:"Cutaneous reactions (many): delayed maculopapular eruptions, urticaria, erythema multiforme, fixed drug eruption, DRESS, SJS, TEN, AGEP.",gastrointestinal:"Diarrhea, up to 20% of patients. Severe C. difficile infection. Taste disturbance (rare): Br J Clin Pharmacol 2007;64:542.",esophageal_injury:"Esophageal injury (rare): Clin Med Insights Case Rep 2019;12:1179547619884055.",hepatic:"Minor reversible elevations in AST, ALT. Rare progression to severe liver injury.",hematologic:"Reversible neutropenia, thrombocytopenia, and eosinophilia."},pregnancy_risk:{fda_risk_category:"Humans: no evidence of toxicity with 2nd or 3rd trimester use. Insufficient data with 1st trimester use. Animals: no evidence of toxicity.",lactation:"Avoid use if possible, otherwise monitor infant for GI toxicity",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Actinomyces sp.","Arcanobacterium sp.","Capnocytophaga sp."],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Topical (gel, cream, lotion), Vaginal suppository, Vaginal gel, Injection, Cap (75, 150, 300 mg), Oral soln (75 mg/5 mL)",food_recommendation:"Cap/soln ± food",oral_absorption_percent:"90",tmax_hr:"0.75",peak_serum_conc_ug_ml:"2.5 (150 mg po, SD), 14.1 (900 mg IV q8h, SS)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"85-94",volume_of_distribution_vd_l_kg:"1.1 L/kg",avg_serum_half_life_hr:"2.4",elimination:"Metabolized",bile_penetration_percent:"250-300",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"No data"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:["CYP3A4"],transporters_substrate:[],ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:[{drug:"Neuromuscular blocking agents",effect:"↑ neuromuscular blockade",management:"Avoid co-administ"},{drug:"Rifampin",effect:"↓ clindamycin (J Infect 2015;71:200)",management:"Monitor, adjust do"},{drug:"St. John's Wort",effect:"↓ clindamycin",management:"Monitor, adjust do"}]}},Lincomycin:{id:"Lincomycin",name:"Lincomycin",tradename:"",classification:{family:"LINCOSAMIDE",subclass:"Lincosamide",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"CrCl ≥30: No dosage adjustment. CrCl <30: 25-30% of usual dose",mild:"CrCl ≥30: No dosage adjustment. CrCl <30: 25-30% of usual dose",moderate:"CrCl ≥30: No dosage adjustment. CrCl <30: 25-30% of usual dose",severe:"CrCl ≥30: No dosage adjustment. CrCl <30: 25-30% of usual dose"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"C",lactation:"Safety not established, avoid use",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Erythromycin",effect:"Antagonism",management:"Avoid co-administr"},{drug:"Neuromuscular blocking agents",effect:"↑ neuromuscular blockade",management:"Avoid co-administr"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"70-75",half_life:"5.4",elimination:"Metabolized",csf_penetration:"Poor",preparations:"Injection"},rawData:{drug_name:"Lincomycin",usage_and_dosing:{general:["Protein synthesis inhibitor antibiotic found in a soil organism from Lincoln, Nebraska.","Infrequently used; use supplanted by Clindamycin.","Indicated for serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci when penicillin is deemed inappropriate.","Route: IV, IM and subconjunctival injection.","In vitro activity vs. Corynebacterium diphtheriae, Streptococcus pyogenes, Viridans group streptococci, Clostridium tetani and Clostridium perfringens."],adult_dose:{intravenous:"0.6-1 gm IV q8-12h (max 8 gm/day). Maximum concentration 10 mg/mL (D5W or NS), infuse over at least one hour.",intramuscular:"600 mg/2 mL IM q12-24h.",subconjunctival:"75 mg/0.25 mL x1 produces sufficient ocular fluid levels (for most susceptible pathogens) for at least five hours."},pediatric_dose:{dose_age_gt_28_days:"10-20 mg/kg/day (divided q8-12h)",max_day:"-"}},renal_adjustment:{half_life_normal:"5.4",half_life_esrd:"No data",dose_renal_function_normal:"0.6-1 gm IV q8-12h",crcl_or_egfr:"CrCl ≥30: No dosage adjustment. CrCl <30: 25-30% of usual dose",hemodialysis:"Not removed by dialysis",capd:"Not removed by dialysis",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"Use with caution"},adverse_effects:["Black Box Warning: Risk of C. difficile toxin-mediated diarrhea.","Other gastrointestinal reactions.","Hypersensitivity reactions.","Rare: neutropenia, pancytopenia, tinnitus, vertigo",'Contains benzyl alcohol as a preservative, which has been associated with serious adverse events, including the "gasping syndrome", and death in pediatric patients.'],pregnancy_risk:{fda_risk_category:"C",lactation:"Safety not established, avoid use",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"15.9 (600 mg IV over 2 hr, SD), 11.6 (600 mg IM, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"70-75",volume_of_distribution_vd:"No data",avg_serum_half_life_hr:"5.4",elimination:"Metabolized",bile_penetration_percent:"No data",csf_blood_percent:"Poor",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"No data"},major_drug_interactions:[{drug:"Erythromycin",effect:"Antagonism",management:"Avoid co-administr"},{drug:"Neuromuscular blocking agents",effect:"↑ neuromuscular blockade",management:"Avoid co-administr"}]}},Azithromycin:{id:"Azithromycin",name:"Azithromycin",tradename:"Zithromax, Z-Pak",classification:{family:"MACROLIDE",subclass:"Macrolide",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:["Chlamydia trachomatis","Haemophilus ducreyi","Mycoplasma pneumoniae"],alternative:[],notes:""},dosing:{adult:{standard:"500 mg po/IV x1, then 250 mg po/IV q24h",severe:"500 mg po/IV x1, then 250 mg po/IV q24h",renal:{normal:"No dosage adjustment",mild:"No dosage adjustment",moderate:"No dosage adjustment",severe:"No dosage adjustment"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Probably safe, monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Antacids (Al, Mg)",effect:"↓ azithromycin",management:"Separate administration by 2 hours"},{drug:"Antiarrhythmics (Class IA/III)",effect:"↑ QT interval",management:"Avoid co-administration"},{drug:"Atorvastatin",effect:"↑ atorvastatin",management:"Monitor"},{drug:"Cyclosporine",effect:"↑ cyclosporine",management:"Monitor"},{drug:"Digoxin",effect:"↑ digoxin",management:"Monitor"},{drug:"Ergot alkaloids",effect:"↑ ergot alkaloid",management:"Avoid co-administration"},{drug:"Lovastatin",effect:"↑ lovastatin",management:"Monitor"},{drug:"Pimozide",effect:"↑ pimozide",management:"Avoid co-administration"},{drug:"Simvastatin",effect:"↑ simvastatin",management:"Monitor"},{drug:"Tacrolimus",effect:"↑ tacrolimus",management:"Monitor"},{drug:"Theophylline",effect:"↑ theophylline",management:"Monitor"},{drug:"Warfarin",effect:"↑ INR",management:"Monitor INR, adjust dosage"}],stewardship:{preferredIndications:["Chlamydia trachomatis","Haemophilus ducreyi","Mycoplasma pneumoniae"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"37",protein_binding:"7-50",half_life:"68",elimination:"Biliary, renal",csf_penetration:"Low",preparations:"Tab (250, 500, 600 mg), Oral susp (100 mg/5 mL, 200 mg/5 mL), Injection"},rawData:{drug_name:"Azithromycin",tradename:"Zithromax, Z-Pak",usage_and_dosing:{general:["Azithromycin is a macrolide antibiotic with a broad spectrum of activity against many aerobic and anaerobic gram-positive and gram-negative organisms.","It is also active against some protozoa.","For class-wide adverse effects, see Macrolides, Overview."],adult_dose:{usual_dose:"500 mg po/IV x1, then 250 mg po/IV q24h",note:"Dosing varies by indication"},pediatric_dose:{dose_age_gt_28_days:"10 mg/kg (max 500 mg) po/IV on day 1, then 5 mg/kg (max 250 mg) q24h",max_day:"-"}},renal_adjustment:{half_life_normal:"68",half_life_esrd:"No data",dose_renal_function_normal:"500 mg po/IV q24h",crcl_or_egfr:"No dosage adjustment",hemodialysis:"No dosage adjustment",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["For complete class-wide adverse effects see Macrolides, Overview and for QTc prolongation, see QTc Interval Prolongation.","Any of the macrolides may exacerbate muscle weakness in persons with myasthenia gravis."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Probably safe, monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Chlamydia trachomatis","Haemophilus ducreyi","Mycoplasma pneumoniae"],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Tab (250, 500, 600 mg), Oral susp (100 mg/5 mL, 200 mg/5 mL), Injection",food_recommendation:"Tab ± food, Susp no food",oral_absorption_percent:"37",tmax_hr:"2-3",peak_serum_conc_ug_ml:"0.4 (500 mg po, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"7-50",volume_of_distribution_vd_l_kg:"31 L/kg",avg_serum_half_life_hr:"68",elimination:"Biliary, renal",bile_penetration_percent:"High",csf_blood_percent:"Low",therapeutic_levels_in_csf:"No",auc_ug_hr_ml:"10.3 (500 mg po, 0-72h)"},major_drug_interactions:[{drug:"Antacids (Al, Mg)",effect:"↓ azithromycin",management:"Separate administration by 2 hours"},{drug:"Antiarrhythmics (Class IA/III)",effect:"↑ QT interval",management:"Avoid co-administration"},{drug:"Atorvastatin",effect:"↑ atorvastatin",management:"Monitor"},{drug:"Cyclosporine",effect:"↑ cyclosporine",management:"Monitor"},{drug:"Digoxin",effect:"↑ digoxin",management:"Monitor"},{drug:"Ergot alkaloids",effect:"↑ ergot alkaloid",management:"Avoid co-administration"},{drug:"Lovastatin",effect:"↑ lovastatin",management:"Monitor"},{drug:"Pimozide",effect:"↑ pimozide",management:"Avoid co-administration"},{drug:"Simvastatin",effect:"↑ simvastatin",management:"Monitor"},{drug:"Tacrolimus",effect:"↑ tacrolimus",management:"Monitor"},{drug:"Theophylline",effect:"↑ theophylline",management:"Monitor"},{drug:"Warfarin",effect:"↑ INR",management:"Monitor INR, adjust dosage"}]}},Clarithromycin:{id:"Clarithromycin",name:"Clarithromycin",tradename:"Biaxin, Biaxin XL",classification:{family:"MACROLIDE",subclass:"Macrolide",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:["Arcanobacterium sp.","Bartonella hensalae, B. quintana","Bordetella pertussis","Legionella sp."],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"CrCl >50: No dosage adjustment. CrCl 10-50: 500 mg q12-24h. CrCl <10: 500 mg q24h",mild:"CrCl >50: No dosage adjustment. CrCl 10-50: 500 mg q12-24h. CrCl <10: 500 mg q24h",moderate:"CrCl >50: No dosage adjustment. CrCl 10-50: 500 mg q12-24h. CrCl <10: 500 mg q24h",severe:"CrCl >50: No dosage adjustment. CrCl 10-50: 500 mg q12-24h. CrCl <10: 500 mg q24h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Safety data conflict. Macrolide exposure associated with ↑ risk of spontaneous abortion (1st TM use) and ↑ risk of major birth defects in some studies. Use with caution. 8",lactation:"Safe, monitor infant for GI toxicity",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Alfentanil",effect:"↑ alfentanil",management:"Monitor closely"},{drug:"Alprazolam",effect:"↑ alprazolam",management:"Monitor closely"},{drug:"Amiodarone",effect:"↑ amiodarone",management:"Monitor closely"},{drug:"Amlodipine",effect:"↑ amlodipine",management:"Monitor closely"},{drug:"Atazanavir",effect:"↑ clarithromycin, ↑ atazanavir",management:"Monitor closely"},{drug:"Atorvastatin",effect:"↑ atorvastatin",management:"Monitor closely"},{drug:"Bromocriptine",effect:"↑ bromocriptine",management:"Monitor closely"},{drug:"Carbamazepine",effect:"↑ carbamazepine",management:"Monitor closely"},{drug:"Cilostazol",effect:"↑ cilostazol",management:"Monitor closely"},{drug:"Colchicine",effect:"↑ colchicine",management:"Adjust"},{drug:"Cyclosporine",effect:"↑ cyclosporine",management:"Monitor closely"},{drug:"Digoxin",effect:"↑ digoxin",management:"Monitor closely"},{drug:"Dihydroartemisinin-piperaquine",effect:"↑ PPQ",management:"Monitor closely"},{drug:"Diltiazem",effect:"↑ diltiazem",management:"Monitor closely"},{drug:"Disopyramide",effect:"↑ disopyramide",management:"Monitor closely"},{drug:"Dofetilide",effect:"↑ dofetilide",management:"Monitor closely"},{drug:"Efavirenz",effect:"↓ clarithromycin, ↑ 14-OH clarithromycin",management:"Monitor closely"},{drug:"Eplerenone",effect:"↑ eplerenone",management:"Monitor closely"},{drug:"Ergot alkaloids",effect:"↑ ergot alkaloid",management:"Monitor closely"},{drug:"Etravirine",effect:"↓ clarithromycin",management:"Monitor closely"},{drug:"Fexinidazole",effect:"↓ M1, M2 (fexinidazole) metabolites",management:"Monitor closely"},{drug:"Itraconazole",effect:"↑ clarithromycin, ↑ itraconazole",management:"Monitor closely"},{drug:"Lovastatin",effect:"↑ lovastatin",management:"Monitor closely"},{drug:"Maraviroc",effect:"↑ maraviroc",management:"Monitor closely"},{drug:"Methylprednisolone",effect:"↑ methylprednisolone",management:"Monitor closely"},{drug:"Midazolam",effect:"↑ midazolam",management:"Monitor closely"},{drug:"Nateglinide",effect:"↑ nateglinide",management:"Monitor closely"},{drug:"Nevirapine",effect:"↓ clarithromycin, ↑ 14-OH clarithromycin",management:"Monitor closely"},{drug:"Nifedipine",effect:"↑ nifedipine",management:"Monitor closely"},{drug:"Nirmatrelvir/RTV",effect:"↑ clarithromycin",management:"Monitor closely"},{drug:"Phenobarbital",effect:"↓ clarithromycin",management:"Monitor closely"},{drug:"Pioglitazone",effect:"↑ pioglitazone",management:"Monitor closely"},{drug:"Pimozide",effect:"↑ pimozide",management:"Monitor closely"},{drug:"Pravastatin",effect:"↑ pravastatin",management:"Monitor closely"},{drug:"Quetiapine",effect:"↑ quetiapine",management:"Monitor closely"},{drug:"Quinidine",effect:"↑ quinidine",management:"Monitor closely"},{drug:"Repaglinide",effect:"↑ repaglinide",management:"Monitor closely"},{drug:"Rifabutin",effect:"↓ clarithromycin, ↑ rifabutin",management:"Monitor closely"},{drug:"Rifampin",effect:"↓ clarithromycin, ↑ 14-OH clarithromycin",management:"Monitor closely"},{drug:"Rifapentine",effect:"↓ clarithromycin, ↑ 14-OH clarithromycin",management:"Monitor closely"},{drug:"Rosiglitazone",effect:"↑ rosiglitazone",management:"Monitor closely"},{drug:"Sildenafil",effect:"↑ sildenafil",management:"Monitor closely"},{drug:"Simvastatin",effect:"↑ simvastatin",management:"Monitor closely"},{drug:"St John's wort",effect:"↓ clarithromycin",management:"Monitor closely"},{drug:"Tacrolimus",effect:"↑ tacrolimus",management:"Monitor closely"},{drug:"Tadalafil",effect:"↑ tadalafil",management:"Monitor closely"},{drug:"Theophylline",effect:"↑ theophylline",management:"Monitor closely"},{drug:"Tolterodine",effect:"↑ tolterodine (if CYP2D6 deficient)",management:"Monitor closely"},{drug:"Triazolam",effect:"↑ triazolam",management:"Monitor closely"},{drug:"Vardenafil",effect:"↑ vardenafil",management:"Monitor closely"},{drug:"Verapamil",effect:"↑ verapamil",management:"Monitor closely"},{drug:"Vinca alkaloids",effect:"↑ vinca alkaloid",management:"Monitor closely"},{drug:"Voriconazole",effect:"↑ voriconazole (Front Pharmacol 2023;14:1134803)",management:"Monitor closely"},{drug:"Warfarin",effect:"↑ warfarin",management:"Monitor closely"},{drug:"Zidovudine",effect:"↓ zidovudine",management:"Ser"},{drug:"Zolpidem",effect:"↑ zolpidem",management:"(A"}],stewardship:{preferredIndications:["Arcanobacterium sp.","Bartonella hensalae, B. quintana","Bordetella pertussis","Legionella sp."],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"50",protein_binding:"65-70",half_life:"5-7",elimination:"Metabolized (active metab), renal",csf_penetration:"No data",preparations:"Tab (250, 500 mg), Extended-release tab (500 mg), Oral susp (125 mg/5 mL, 250 mg/5 mL)"},rawData:{drug_name:"Clarithromycin",tradename:"Biaxin, Biaxin XL",usage_and_dosing:{general:["Clarithromycin is a macrolide antibiotic used as alternative therapy for a variety of respiratory tract and skin infections, in combination for some mycobacterial infections and in combination regimens to eradicate H. pylori infections.","Mechanisms of Clarithromycin resistance: methylation of ribosomal target (high level resistance) and efflux pump (low level resistance).","Rates of susceptibility to Clarithromycin of Streptococcus pyogenes and Streptococcus pneumoniae are highly variable by geographic location.","Caution: numerous drug interactions (see chart below, not all-inclusive)","See Macrolides, Overview for discussion of class-wide adverse effects, including QTc interval prolongation."],adult_dose:{aecb_or_cap_dose:"500 mg (standard) po q12h x 7-14 days or 500 mg (extended release) 2 tabs po once daily",pertussis_dose:"500 mg po bid x 7 days",tonsillopharyngitis_dose:"250 mg po q12h x 10 days",skin_structure_infections_dose:"250 mg po q12h x 10 days"},pediatric_dose:{dose_age_gt_28_days:"15 mg/kg/day (divided q12h)",max_day:"1 gm"}},renal_adjustment:{note:"recommendations are for the immediate-release formulations only.",half_life_normal:"5-7",half_life_esrd:"22",dose_renal_function_normal:"500 mg po q12h",crcl_or_egfr:"CrCl >50: No dosage adjustment. CrCl 10-50: 500 mg q12-24h. CrCl <10: 500 mg q24h",hemodialysis:"500 mg q24h (dose AD on dialysis days)",capd:"500 mg q24h",crrt:"500 mg q12-24h",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["Treatment stopped due to adverse effects (3%), neutropenia (1%), thrombocytopenia (rare), increased PT/PTT (1%), nausea/vomiting (3%)--less GI upset with extended release formulation, diarrhea (3-6%), C. difficile colitis, increased LFTs (rare), increased BUN/Creatinine (4%), headache (2%).","Clarithromycin can result in high statin blood levels with associated risk of rhabdomyolysis; also true of Erythromycin but not Azithromycin (Ann Int Med 158:869, 2013).","Clarithromycin blocks metabolism of calcium channel blockers; can result in hypotension and renal injury (JAMA 310: 2544, 2013).","Concomitant Clarithromycin and colchicine (for gout) can result in fatal colchicine toxicity due to pancytopenia (Clin Infect Dis 41:291, 2005).","FDA Drug safety communication. Results of 10 year follow-up of trial of 4373 patients with stable coronary heart disease. (Int J Cardiol 182: 459, 2015). For 2 weeks, half received placebo and half received clarithro 500 mg/day. Result: 10% increased risk of death from any cause and a 19% increased risk of cerebrovascular disease. Increased risk mainly in patients not taking a statin and during the first 3 yrs. Observational. Mechanism, if any, is unclear.","See Macrolides, Overview for class-wide adverse effects, including potential EKG QTc interval prolongation."],pregnancy_risk:{fda_risk_category:"Safety data conflict. Macrolide exposure associated with ↑ risk of spontaneous abortion (1st TM use) and ↑ risk of major birth defects in some studies. Use with caution. 8",lactation:"Safe, monitor infant for GI toxicity",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category. 8: Ref: Pharmacotherapy 2025;45:227"},antimicrobial_spectrum:{preferred:["Arcanobacterium sp.","Bartonella hensalae, B. quintana","Bordetella pertussis","Legionella sp."],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Tab (250, 500 mg), Extended-release tab (500 mg), Oral susp (125 mg/5 mL, 250 mg/5 mL)",food_recommendation:"Tab/susp ± food, ER tab + food",oral_absorption_percent:"50",tmax_hr:"Tab 2.0-2.5, ER tab 5-8",peak_serum_conc_ug_ml:"3-4 (500 mg po q12h, SS), 2-3 (1 gm ER po q24h, SS)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"65-70",volume_of_distribution_vd_l_kg:"4 L/kg",avg_serum_half_life_hr:"5-7",elimination:"Metabolized (active metab), renal",bile_penetration_percent:"7000",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"20 (500 mg po q12h, 0-24 hr)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:["CYP3A4"],transporters_substrate:[],ugts_substrate:[],cyp450s_inhibited:["CYP3A4"],transporters_inhibited:["PGP","OATP1B1"],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"↑"},major_drug_interactions:[{drug:"Alfentanil",effect:"↑ alfentanil"},{drug:"Alprazolam",effect:"↑ alprazolam"},{drug:"Amiodarone",effect:"↑ amiodarone"},{drug:"Amlodipine",effect:"↑ amlodipine"},{drug:"Atazanavir",effect:"↑ clarithromycin, ↑ atazanavir"},{drug:"Atorvastatin",effect:"↑ atorvastatin"},{drug:"Bromocriptine",effect:"↑ bromocriptine"},{drug:"Carbamazepine",effect:"↑ carbamazepine"},{drug:"Cilostazol",effect:"↑ cilostazol"},{drug:"Colchicine",effect:"↑ colchicine",management:"Adjust"},{drug:"Cyclosporine",effect:"↑ cyclosporine"},{drug:"Digoxin",effect:"↑ digoxin"},{drug:"Dihydroartemisinin-piperaquine",effect:"↑ PPQ"},{drug:"Diltiazem",effect:"↑ diltiazem"},{drug:"Disopyramide",effect:"↑ disopyramide"},{drug:"Dofetilide",effect:"↑ dofetilide"},{drug:"Efavirenz",effect:"↓ clarithromycin, ↑ 14-OH clarithromycin"},{drug:"Eplerenone",effect:"↑ eplerenone"},{drug:"Ergot alkaloids",effect:"↑ ergot alkaloid"},{drug:"Etravirine",effect:"↓ clarithromycin"},{drug:"Fexinidazole",effect:"↓ M1, M2 (fexinidazole) metabolites"},{drug:"Itraconazole",effect:"↑ clarithromycin, ↑ itraconazole"},{drug:"Lovastatin",effect:"↑ lovastatin"},{drug:"Maraviroc",effect:"↑ maraviroc"},{drug:"Methylprednisolone",effect:"↑ methylprednisolone"},{drug:"Midazolam",effect:"↑ midazolam"},{drug:"Nateglinide",effect:"↑ nateglinide"},{drug:"Nevirapine",effect:"↓ clarithromycin, ↑ 14-OH clarithromycin"},{drug:"Nifedipine",effect:"↑ nifedipine"},{drug:"Nirmatrelvir/RTV",effect:"↑ clarithromycin"},{drug:"Phenobarbital",effect:"↓ clarithromycin"},{drug:"Pioglitazone",effect:"↑ pioglitazone"},{drug:"Pimozide",effect:"↑ pimozide"},{drug:"Pravastatin",effect:"↑ pravastatin"},{drug:"Quetiapine",effect:"↑ quetiapine"},{drug:"Quinidine",effect:"↑ quinidine"},{drug:"Repaglinide",effect:"↑ repaglinide"},{drug:"Rifabutin",effect:"↓ clarithromycin, ↑ rifabutin"},{drug:"Rifampin",effect:"↓ clarithromycin, ↑ 14-OH clarithromycin"},{drug:"Rifapentine",effect:"↓ clarithromycin, ↑ 14-OH clarithromycin"},{drug:"Rosiglitazone",effect:"↑ rosiglitazone"},{drug:"Sildenafil",effect:"↑ sildenafil"},{drug:"Simvastatin",effect:"↑ simvastatin"},{drug:"St John's wort",effect:"↓ clarithromycin"},{drug:"Tacrolimus",effect:"↑ tacrolimus"},{drug:"Tadalafil",effect:"↑ tadalafil"},{drug:"Theophylline",effect:"↑ theophylline"},{drug:"Tolterodine",effect:"↑ tolterodine (if CYP2D6 deficient)"},{drug:"Triazolam",effect:"↑ triazolam"},{drug:"Vardenafil",effect:"↑ vardenafil"},{drug:"Verapamil",effect:"↑ verapamil"},{drug:"Vinca alkaloids",effect:"↑ vinca alkaloid"},{drug:"Voriconazole",effect:"↑ voriconazole (Front Pharmacol 2023;14:1134803)"},{drug:"Warfarin",effect:"↑ warfarin"},{drug:"Zidovudine",effect:"↓ zidovudine",management:"Ser"},{drug:"Zolpidem",effect:"↑ zolpidem",management:"(A"}]}},"Erythromycin Base, Esters":{id:"Erythromycin_Base_Esters",name:"Erythromycin Base, Esters",tradename:"Erythrocin, Ilosone, Erythromycin lactobionate, Eryc, E-mycin, Erythromid",classification:{family:"MACROLIDE",subclass:"Macrolide",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:["Actinomyces sp.","Arcanobacterium sp.","Campylobacter jejuni","Corynebacterium diphtheriae","Haemophilus ducreyi","Klebsiella granulomatis (granuloma inguinale)","Legionella sp."],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No dosage adjustment for renal impairment",mild:"No dosage adjustment for renal impairment",moderate:"No dosage adjustment for renal impairment",severe:"No dosage adjustment for renal impairment"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Safety data conflict. Macrolide exposure associated with ↑ risk of spontaneous abortion (1st TM use) and ↑ risk of major birth defects in some studies. Use with caution. 8",lactation:"Safe, monitor infant for GI toxicity",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Alfentanil",effect:"↑ alfentanil",management:"Monitor or avoid"},{drug:"Alprazolam",effect:"↑ alprazolam",management:"Monitor, adjust dosage"},{drug:"Amiodarone",effect:"↑ amiodarone",management:"Monitor or avoid"},{drug:"Amlodipine",effect:"↑ amlodipine",management:"Monitor or avoid"},{drug:"Atorvastatin",effect:"↑ atorvastatin",management:"Adjust dosage or avoid"},{drug:"Bromocriptine",effect:"↑ bromocriptine",management:"Monitor or avoid"},{drug:"Carbamazepine",effect:"↑ carbamazepine",management:"Monitor, adjust dosage"},{drug:"Cilostazol",effect:"↑ cilostazol",management:"Monitor or avoid"},{drug:"Clozapine",effect:"↑ clozapine",management:"Monitor, adjust dosage"},{drug:"Colchicine",effect:"↑ colchicine",management:"Monitor, adjust dosage"},{drug:"Cyclosporine",effect:"↑ cyclosporine",management:"Monitor or avoid"},{drug:"Digoxin",effect:"↑ digoxin",management:"Monitor, adjust dosage"},{drug:"Diltiazem",effect:"↑ diltiazem",management:"Monitor or avoid"},{drug:"Disopyramide",effect:"↑ disopyramide",management:"Monitor or avoid"},{drug:"Dofetilide",effect:"↑ dofetilide",management:"Monitor or avoid"},{drug:"Eplerenone",effect:"↑ eplerenone",management:"Monitor, adjust dosage"},{drug:"Ergot alkaloids",effect:"↑ ergot alkaloid",management:"Contraindicated"},{drug:"Fexinidazole",effect:"↓ M1, M2 (fexinidazole) metabolites",management:"Monitor or avoid"},{drug:"Lovastatin",effect:"↑ lovastatin",management:"Contraindicated"},{drug:"Methylprednisolone",effect:"↑ methylprednisolone",management:"Monitor"},{drug:"Midazolam",effect:"↑ midazolam",management:"Monitor, adjust dosage"},{drug:"Nirmatrelvir/RTV",effect:"↑ erythromycin",management:"Monitor, adjust dosage"},{drug:"Phenytoin",effect:"↑ phenytoin",management:"Monitor, adjust dosage"},{drug:"Pimozide",effect:"↑ pimozide",management:"Contraindicated"},{drug:"Procainamide",effect:"↑ QT interval",management:"Monitor or avoid"},{drug:"Quinidine",effect:"↑ quinidine",management:"Monitor or avoid"},{drug:"Rifabutin",effect:"↓ erythromycin, ↑ rifabutin",management:"Monitor, adjust dosage"},{drug:"Sildenafil",effect:"↑ sildenafil",management:"Adjust dosage or avoid"},{drug:"Simvastatin",effect:"↑ simvastatin",management:"Contraindicated"},{drug:"Sotalol",effect:"↑ QT interval",management:"Monitor or avoid"},{drug:"Tacrolimus",effect:"↑ tacrolimus",management:"Monitor or avoid"},{drug:"Theophylline",effect:"↑ theophylline, ↓ erythromycin?",management:"Monitor, adjust dosage"},{drug:"Triazolam",effect:"↑ triazolam",management:"Monitor, adjust dosage"},{drug:"Valproic acid",effect:"↑ valproic acid",management:"Monitor, adjust dosage"},{drug:"Verapamil",effect:"↑ verapamil",management:"Monitor or avoid"},{drug:"Vinca alkaloids",effect:"↑ vinca alkaloid",management:"Avoid co-administration"},{drug:"Warfarin",effect:"↑ warfarin",management:"Monitor INR, adjust dosage"}],stewardship:{preferredIndications:["Actinomyces sp.","Arcanobacterium sp.","Campylobacter jejuni","Corynebacterium diphtheriae","Haemophilus ducreyi","Klebsiella granulomatis (granuloma inguinale)","Legionella sp."],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"18-45",protein_binding:"70-74",half_life:"2-4",elimination:"Biliary",csf_penetration:"2-13",preparations:"Base tab (250, 500 mg), Delayed-release (DR) tab (250, 333, 500 mg), DR cap (250 mg), Ethylsuccinate tab (400 mg), Ethylsuccinate oral susp (200 mg/5 mL, 400 mg/5 mL), 2% topical gel/pad/soln, 0.5% oph ointment, Lactobionate injection"},rawData:{drug_name:"Erythromycin Base, Esters",tradename:"Erythrocin, Ilosone, Erythromycin lactobionate, Eryc, E-mycin, Erythromid",drug_shortage:[{preparation:"Injection (lactobionate)",start_date:"2025-04-23",notes:""}],usage_and_dosing:{general:["Erythromycin is the original macrolide antibiotic, first approved in 1952. It is used to treat respiratory tract and skin infections caused by susceptible organisms.","Binds to the 50S ribosomal subunit to interfere with protein synthesis. Mechanism of resistance: methylation of ribosomal target (high level resistance) and activation of efflux pumps (low level resistance).","Available in a variety of pharmaceutical preparations. Conversion: 400 mg erythromycin ethylsuccinate = 250 mg erythromycin base.","Gastroparesis: see Comments.","Caution: numerous drug interactions (see chart below, not all-inclusive)."],adult_dose:{usual_oral_dose:{base:"250-500 mg po q6-12h",ethylsuccinate:"400-800 mg po q6-12h"},usual_iv_dose_lactobionate:"500-1000 mg IV q6h (max 4 gm/day)",other_uses:"Colorectal surgery prophylaxis"},pediatric_dose:{dose_age_gt_28_days:"40-50 mg/kg/day (divided q6h)",max_day:"-"}},renal_adjustment:{half_life_normal:"2-4",half_life_esrd:"5-6",dose_renal_function_normal:"250-500 mg po q6h",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No dosage adjustment",capd:"No dosage adjustment",crrt:"No dosage adjustment",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["Gastrointestinal: nausea/vomiting (common), diarrhea, C. difficile colitis","Increased LFTs","Confusion, headache","Ototoxicity (with high doses in ESRD)","Combination of erythromycin and a statin can result in elevated statin serum levels and subsequent rhabdomyolysis (Ann Intern Med 2013;158:869).","See QTc prolongation.","See Macrolides, Overview."],pregnancy_risk:{fda_risk_category:"Safety data conflict. Macrolide exposure associated with ↑ risk of spontaneous abortion (1st TM use) and ↑ risk of major birth defects in some studies. Use with caution. 8",lactation:"Safe, monitor infant for GI toxicity",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category. 8: Ref: Pharmacotherapy 2025;45:227"},antimicrobial_spectrum:{preferred:["Actinomyces sp.","Arcanobacterium sp.","Campylobacter jejuni","Corynebacterium diphtheriae","Haemophilus ducreyi","Klebsiella granulomatis (granuloma inguinale)","Legionella sp."],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Base tab (250, 500 mg), Delayed-release (DR) tab (250, 333, 500 mg), DR cap (250 mg), Ethylsuccinate tab (400 mg), Ethylsuccinate oral susp (200 mg/5 mL, 400 mg/5 mL), 2% topical gel/pad/soln, 0.5% oph ointment, Lactobionate injection",food_recommendation:"Base no food, DR/ethylsucc ± food",oral_absorption_percent:"18-45",tmax_hr:"DR preps 3",peak_serum_conc_ug_ml:"0.1-2.0 (500 mg base po, SD), 3-4 (500 mg IV, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"70-74",volume_of_distribution_vd_l_kg:"0.6 L/kg",avg_serum_half_life_hr:"2-4",elimination:"Biliary",bile_penetration_percent:"No data",csf_blood_percent:"2-13",therapeutic_levels_in_csf:"No",auc_ug_hr_ml:"No data"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:["CYP3A4"],transporters_substrate:["PGP"],ugts_substrate:[],cyp450s_inhibited:["CYP3A4"],transporters_inhibited:["PGP","OATP1B1"],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"↑"},major_drug_interactions:[{drug:"Alfentanil",effect:"↑ alfentanil",management:"Monitor or avoid"},{drug:"Alprazolam",effect:"↑ alprazolam",management:"Monitor, adjust dosage"},{drug:"Amiodarone",effect:"↑ amiodarone",management:"Monitor or avoid"},{drug:"Amlodipine",effect:"↑ amlodipine",management:"Monitor or avoid"},{drug:"Atorvastatin",effect:"↑ atorvastatin",management:"Adjust dosage or avoid"},{drug:"Bromocriptine",effect:"↑ bromocriptine",management:"Monitor or avoid"},{drug:"Carbamazepine",effect:"↑ carbamazepine",management:"Monitor, adjust dosage"},{drug:"Cilostazol",effect:"↑ cilostazol",management:"Monitor or avoid"},{drug:"Clozapine",effect:"↑ clozapine",management:"Monitor, adjust dosage"},{drug:"Colchicine",effect:"↑ colchicine",management:"Monitor, adjust dosage"},{drug:"Cyclosporine",effect:"↑ cyclosporine",management:"Monitor or avoid"},{drug:"Digoxin",effect:"↑ digoxin",management:"Monitor, adjust dosage"},{drug:"Diltiazem",effect:"↑ diltiazem",management:"Monitor or avoid"},{drug:"Disopyramide",effect:"↑ disopyramide",management:"Monitor or avoid"},{drug:"Dofetilide",effect:"↑ dofetilide",management:"Monitor or avoid"},{drug:"Eplerenone",effect:"↑ eplerenone",management:"Monitor, adjust dosage"},{drug:"Ergot alkaloids",effect:"↑ ergot alkaloid",management:"Contraindicated"},{drug:"Fexinidazole",effect:"↓ M1, M2 (fexinidazole) metabolites",management:"Monitor or avoid"},{drug:"Lovastatin",effect:"↑ lovastatin",management:"Contraindicated"},{drug:"Methylprednisolone",effect:"↑ methylprednisolone",management:"Monitor"},{drug:"Midazolam",effect:"↑ midazolam",management:"Monitor, adjust dosage"},{drug:"Nirmatrelvir/RTV",effect:"↑ erythromycin",management:"Monitor, adjust dosage"},{drug:"Phenytoin",effect:"↑ phenytoin",management:"Monitor, adjust dosage"},{drug:"Pimozide",effect:"↑ pimozide",management:"Contraindicated"},{drug:"Procainamide",effect:"↑ QT interval",management:"Monitor or avoid"},{drug:"Quinidine",effect:"↑ quinidine",management:"Monitor or avoid"},{drug:"Rifabutin",effect:"↓ erythromycin, ↑ rifabutin",management:"Monitor, adjust dosage"},{drug:"Sildenafil",effect:"↑ sildenafil",management:"Adjust dosage or avoid"},{drug:"Simvastatin",effect:"↑ simvastatin",management:"Contraindicated"},{drug:"Sotalol",effect:"↑ QT interval",management:"Monitor or avoid"},{drug:"Tacrolimus",effect:"↑ tacrolimus",management:"Monitor or avoid"},{drug:"Theophylline",effect:"↑ theophylline, ↓ erythromycin?",management:"Monitor, adjust dosage"},{drug:"Triazolam",effect:"↑ triazolam",management:"Monitor, adjust dosage"},{drug:"Valproic acid",effect:"↑ valproic acid",management:"Monitor, adjust dosage"},{drug:"Verapamil",effect:"↑ verapamil",management:"Monitor or avoid"},{drug:"Vinca alkaloids",effect:"↑ vinca alkaloid",management:"Avoid co-administration"},{drug:"Warfarin",effect:"↑ warfarin",management:"Monitor INR, adjust dosage"}],comments:["Gastroparesis: Use of erythromycin to stimulate peristalsis is controversial (Expert Opin Pharmacother 2013;14:1171; Eur J Pharmacol 2013;715:10). Despite absence of controlled studies, still used as an alternative agent.","Erythromycin initiates peristalsis by binding to motilin receptors and apparently improves gastric emptying for about 2 weeks. Thereafter the motilin receptors are downregulated and tachyphylaxis ensues.","If used, the recommended IV dose is 1.5-3 mg/kg IV (infused over 45 min) q6h. If oral suspension used, dose is 125 mg po bid.","Reference: Gastroenterol Clin North Am 2015;44:97."]}},Fidaxomicin:{id:"Fidaxomicin",name:"Fidaxomicin",tradename:"Dificid, Dificlir",classification:{family:"MACROLIDE",subclass:"Macrolide",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"200 mg tab po bid x10 days (age >18 yrs)",severe:"200 mg tab po bid x10 days (age >18 yrs)",renal:{normal:"No dosage adjustment for renal impairment",mild:"No dosage adjustment for renal impairment",moderate:"No dosage adjustment for renal impairment",severe:"No dosage adjustment for renal impairment"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Human data limited. Nontoxic in animals. Low oral bioavailability limits risk. Consider use if benefit outweighs risk. 8",lactation:"Probably safe, but no data available",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"Minimal",protein_binding:"No data",half_life:"2",elimination:"Fecal",csf_penetration:"No data",preparations:"Tab (200 mg), oral susp (40 mg/mL)"},rawData:{drug_name:"Fidaxomicin",tradename:"Dificid, Dificlir",usage_and_dosing:{general:["Fidaxomicin, FDA approved in 2011, is an oral macrolide antibiotic for treatment of moderately severe to severe C. difficile toxin-mediated diarrhea.","More potent than vancomycin in vitro vs. C. difficile, including the hypervirulent NAP1/B1/027 strains.","Minimal absorption; high fecal concentration; limited activity against bowel flora.","More efficacious (though very expensive); latest guidelines recommend as first line therapy if feasible: Clin Infect Dis 2021;73:755; Med Lett Drugs Ther 2021;63:137.","Fidaxomicin had lower rate of recurrence than vancomycin for diarrhea with non-NAP1 strains (N Engl J Med 2011;364:422; Lancet Infect Dis 2012;12:281). For patients who required concomitant antibiotics during treatment of C. difficile infection, 10-day fidaxomicin treatment reported to result in higher cure and lower relapse rate than vancomycin (Clin Infect Dis 2011;53:440).","Review of fidaxomicin: Clin Infect Dis 2012;54:568.","See C. difficile."],adult_dose:{usual_dose:"200 mg tab po bid x10 days (age >18 yrs)"},pediatric_dose:{oral_suspension_age_gt_6_mon:{"4_to_lt_7_kg":"80 mg (2 mL) bid","7_to_lt_9_kg":"120 mg (3 mL) bid","9_to_lt_12_5_kg":"160 mg (4 mL) bid",ge_12_5_kg:"200 mg (5 ml) bid (or use tabs)"},max_day:"-"}},renal_adjustment:{half_life_normal:"2",half_life_esrd:"Unchanged",dose_renal_function_normal:"200 mg po q12h",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No data",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["Most common: nausea 11%, vomiting 7%, abdominal pain 6%, GI hemorrhage 4%, anemia 2%, neutropenia 2%.","Product labeling warns of the potential for cross-reactivity in patients with known macrolide allergy. In a large database analysis (compared to patients without macrolide allergies), the odds of fidaxomicin allergy were 2.31, 8.37, and 1.58 times higher in patients with azithromycin, clarithromycin, and erythromycin allergies, respectively. The highest risk of anaphylaxis and angioedema was observed within one year of the initial allergy (Antimicrob Agents Chemother 2025;69:e0192424)."],pregnancy_risk:{fda_risk_category:"Human data limited. Nontoxic in animals. Low oral bioavailability limits risk. Consider use if benefit outweighs risk. 8",lactation:"Probably safe, but no data available",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category. 8: Ref: Pharmacotherapy 2025;45:227"},antimicrobial_spectrum:{clostridioides_difficile:!0},pharmacology:{pk_pd_index:"No data",preparations:"Tab (200 mg), oral susp (40 mg/mL)",food_recommendation:"Tab/susp ± food",oral_absorption_percent:"Minimal",tmax_hr:"No data",peak_serum_conc_ug_ml:"0.005 (200 mg po, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"No data",volume_of_distribution_vd:"No data",avg_serum_half_life_hr:"2",elimination:"Fecal",bile_penetration_percent:"No data",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No",auc_ug_hr_ml:"0.063 (200 mg po, 0-inf)"},major_drug_interactions:["None known"]}},Aztreonam:{id:"Aztreonam",name:"Aztreonam",tradename:"Azactam",classification:{family:"MONOBACTAM",subclass:"Monobactam",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"CrCl ≥30: No dosage adjustment. CrCl 10 to <30: 50% dosage reduction. CrCl <10: 1-2 gm q24h 44",mild:"CrCl ≥30: No dosage adjustment. CrCl 10 to <30: 50% dosage reduction. CrCl <10: 1-2 gm q24h 44",moderate:"CrCl ≥30: No dosage adjustment. CrCl 10 to <30: 50% dosage reduction. CrCl <10: 1-2 gm q24h 44",severe:"CrCl ≥30: No dosage adjustment. CrCl 10 to <30: 50% dosage reduction. CrCl <10: 1-2 gm q24h 44"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Probenecid",effect:"↑ aztreonam",management:"Monitor"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"56",half_life:"2.0",elimination:"Renal",csf_penetration:"3-52",preparations:"Injection"},rawData:{drug_name:"Aztreonam",tradename:"Azactam",usage_and_dosing:{general:["Aztreonam is a monobactam beta-lactam antibiotic that is active in vitro against many isolates of Enterobacterales, Pseudomonas aeruginosa and other gram-negative organisms.","The drug has no useful activity against gram-positive organisms or anaerobes.","Stable in presence of Ambler class B metallo-beta-lactamases (carbapenemases) produced by multidrug resistant gram-negative bacteria. Unfortunately, the same bacteria usually also produce extended-spectrum beta-lactamases that do inactivate aztreonam.","Aztreonam can be used in many patients who are allergic to other beta-lactam antibiotics, as cross-hypersensitivity is rare.","Exception: Aztreonam has an R-1 side chain that is identical to that of ceftazidime and cefiderocol, so in those with allergy to that side chain, there may be cross-sensitivity.","Cross allergenicity between aztreonam and ceftazidime reported in 1 of 26 patients in a case series: J Antimicrob Chemother 2021; 76: 2741.","See Drug Allergy: Penicillins, Cephalosporins, Overview page for more detail","Useful penicillin allergy references: JAMA 2019;321:188; N Engl J Med 2019;381:2338; Lancet 2019;393:183.","An inhaled version is available for use with a specific nebulizer for treatment of Pseudomonas aeruginosa in patients with cystic fibrosis.","Used in combination with ceftazidime-avibactam vs. metallo-beta-lactamase-producing Enterobacterales: Clin Infect Dis. 2021;72:1871.","See also: Aztreonam-avibactam page."],adult_dose:{urinary_tract_infection:"0.5-1 gm IV q8-12h",systemic_infection_moderate_severity:"1-2 gm IV q8-12h",systemic_infection_severe_or_life_threatening:"2 gm IV q6-8h",other_dosing:"Nebulized, CF: see Inhalation Dosing & Therapy"},pediatric_dose:{amr_gram_negative_guidance:"J Pediatric Infect Dis Soc 2025;14:piaf004",ceftazidime_avibactam:"Ceftazidime-avibactam (using mg/kg/day dose recommended, divided q6h) administered simultaneously via Y-site administration with aztreonam.",per_red_book:"Per Red Book (2024-2027): 90-120 mg/kg/day (divided q6-8h)",per_amr_guidance:"Per AMR gram-negative guidance: Neonates, infants, children, adolescents: 120 mg/kg/day (div q6h, doses infused over 3 hr). For CNS infection: 2 hr infusions suggested",max_day:"8 gm"}},renal_adjustment:{note:"CrCl units are mL/min/1.73m²",half_life_normal:"2",half_life_esrd:"6-8",dose_renal_function_normal:"Varies with indication",crcl_or_egfr:"CrCl ≥30: No dosage adjustment. CrCl 10 to <30: 50% dosage reduction. CrCl <10: 1-2 gm q24h 44",hemodialysis:"1-2 gm q24h (AD on dialysis days) 44",capd:"2 gm q24h",crrt:"2 gm load (all modalities). CVVH: 1-2 gm q12h. CVVHD: 2 gm q12h. CVVHDF: 2 gm q12h 40",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["Hypersensitivity (fever, rash, serum sickness, anaphylaxis)","Local phlebitis","Hematologic (positive Coombs test, neutropenia, eosinophilia, thrombocytopenia)","Gastrointestinal (nausea/vomiting, diarrhea, C. difficile colitis)","Increased LFTs","Headache, confusion, seizures","The safety and efficacy of nebulized aztreonam is not known if FEV1 < 25%. Cough, wheezing and bronchospasm can occur (Chest 2009;135:1223)."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"90 (1 gm IV, SD)",peak_urine_conc_ug_ml:"Avg: 3500-6600 (1-2 gm IV, SD)",protein_binding_percent:"56",volume_of_distribution_vd_l_vss:"12.6 L (Vss)",avg_serum_half_life_hr:"2.0",elimination:"Renal",bile_penetration_percent:"115-405",csf_blood_percent:"3-52",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"271 (1 gm IV, 0-inf)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:["OAT1","OAT3"],ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:[{drug:"Probenecid",effect:"↑ aztreonam",management:"Monitor"}]}},"Aztreonam-avibactam":{id:"Aztreonam_avibactam",name:"Aztreonam-avibactam",tradename:"Emblaveo",classification:{family:"MONOBACTAM",subclass:"Monobactam",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"CrCl >50: No dosage adjustment. CrCl >30 to 50: 2.67 gm x1, then 1 gm q6h. CrCl >15 to 30: 1.8 gm x1, then 0.9 gm q8h. CrCl ≤15: 1.33 gm x1, then 0.9 gm q12h",mild:"CrCl >50: No dosage adjustment. CrCl >30 to 50: 2.67 gm x1, then 1 gm q6h. CrCl >15 to 30: 1.8 gm x1, then 0.9 gm q8h. CrCl ≤15: 1.33 gm x1, then 0.9 gm q12h",moderate:"CrCl >50: No dosage adjustment. CrCl >30 to 50: 2.67 gm x1, then 1 gm q6h. CrCl >15 to 30: 1.8 gm x1, then 0.9 gm q8h. CrCl ≤15: 1.33 gm x1, then 0.9 gm q12h",severe:"CrCl >50: No dosage adjustment. CrCl >30 to 50: 2.67 gm x1, then 1 gm q6h. CrCl >15 to 30: 1.8 gm x1, then 0.9 gm q8h. CrCl ≤15: 1.33 gm x1, then 0.9 gm q12h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Aztreonam: milk concentrations low. Avibactam: no data.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Probenecid",effect:"↑ aztreonam, ↑ avibactam",management:"Avoid co-administration"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"Aztreonam: 38, Avibactam: 8",half_life:"Aztreonam: 2.0, Avibactam: 2.0",elimination:"Aztreonam: renal, Avibactam: renal",csf_penetration:"Aztreonam: 3-52, Avibactam: no data",preparations:"Injection"},rawData:{drug_name:"Aztreonam-avibactam",tradename:"Emblaveo",usage_and_dosing:{general:["Aztreonam-avibactam is a monobactam plus ẞ-lactamase inhibitor co-formulation.","Approved by the US FDA in February 2025 for complicated intra-abdominal infection (in combination with metronidazole) in adults with limited or no alternative treatment options.","Approved by the European Commission in April 2024 for adults with complicated intra-abdominal infection (± metronidazole), HAP/VAP, complicated UTI including pyelonephritis, and infections caused by aerobic gram-negative organisms in patients with limited treatment options.","Aztreonam is a monobactam ẞ-lactam that is active against many Enterobacterales, P. aeruginosa, and other gram-negative organisms. It has no useful activity vs anaerobes or gram-positive organisms. It is generally stable to hydrolysis by Ambler class B enzymes (metallo-ẞ-lactamases).","Avibactam is a non-ẞ-lactam, ẞ-lactamase inhibitor. It inhibits Ambler class A and class C ẞ-lactamases and some class D enzymes, including ESBLs, KPC and OXA-48 carbapenemases, and AmpC. Avibactam does not inhibit class B enzymes, and it is not able to inhibit many class D enzymes.","Aztreonam and avibactam are co-formulated in a 3:1 ratio (e.g., 2.67 gm = aztreonam 2 gm + avibactam 0.67 gm)."],adult_dose:{dose:"2.67 gm IV (over 3 hr) load, then 2 gm IV (over 3 hr) q6h (x5-14 days).",concurrent_metronidazole:"Administer metronidazole concurrently for complicated intra-abdominal infection.",compatibility:"Reconstituted drug compatible with D5W, NS, and LR."},pediatric_dose:{dose_age_gt_28_days:"Safety and efficacy not established",max_day:"-"}},renal_adjustment:{combination_product:"Combination product in a fixed 3:1 ratio",infusion_time:"Infuse aztreonam-avibactam doses over 3 hours",half_life_normal:"Aztreonam: 2-3, Avibactam: 2-3",half_life_esrd:"Aztreonam: 6-8, Avibactam: no data",dose_renal_function_normal:"2.67 gm IV load, then 2 gm IV q6h",crcl_or_egfr:"CrCl >50: No dosage adjustment. CrCl >30 to 50: 2.67 gm x1, then 1 gm q6h. CrCl >15 to 30: 1.8 gm x1, then 0.9 gm q8h. CrCl ≤15: 1.33 gm x1, then 0.9 gm q12h",hemodialysis:"1.33 gm x1, then 0.9 gm q12h (AD on dialysis days)",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["GI: nausea, vomiting, diarrhea, abdominal pain, C. difficile infection","Hypersensitivity: rash, flushing, bronchospasm, anaphylaxis, toxic epidermal necrolysis","Liver: increased AST, ALT","Hematologic: anemia, thrombocytopenia","Confusion, dizziness"],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Aztreonam: milk concentrations low. Avibactam: no data.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"Aztreonam: 54.5, Avibactam: 11.3 (2 gm IV q6h, SS)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"Aztreonam: 38, Avibactam: 8",volume_of_distribution_vd_l_vss:"Aztreonam: 21.4 L (Vss), Avibactam: 37.8 L (Vss)",avg_serum_half_life_hr:"Aztreonam: 2.0, Avibactam: 2.0",elimination:"Aztreonam: renal, Avibactam: renal",bile_penetration_percent:"Aztreonam: 115-405, Avibactam: no data",csf_blood_percent:"Aztreonam: 3-52, Avibactam: no data",therapeutic_levels_in_csf:"Aztreonam: no data, Avibactam: no data"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:"Aztreonam: OAT1, OAT3, Avibactam: OAT1, OAT3",ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:[{drug:"Probenecid",effect:"↑ aztreonam, ↑ avibactam",management:"Avoid co-administration"}],comments:["Good review: Pharmacotherapy 2024;44:927."]}},Secnidazole:{id:"Secnidazole",name:"Secnidazole",tradename:"Solosec",classification:{family:"NITROIMIDAZOLE",subclass:"Nitroimidazole",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No dosage adjustment for renal impairment",mild:"No dosage adjustment for renal impairment",moderate:"No dosage adjustment for renal impairment",severe:"No dosage adjustment for renal impairment"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No human data, safe in animals",lactation:"Safety not established, avoid breastfeeding for 96 hours after dose",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Ethanol",effect:"GI symptoms, dizziness, headache",management:"Avoid co-administration"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"No data",protein_binding:"<5",half_life:"17",elimination:"Metabolized",csf_penetration:"No data",preparations:"Oral granules (2 gm packets)"},rawData:{drug_name:"Secnidazole",tradename:"Solosec",usage_and_dosing:{general:["Secnidazole is a nitroimidazole indicated for treatment of:","Bacterial vaginosis in female patients ≥12 years of age.","Trichomoniasis in patients ≥12 years of age.","Because trichomoniasis is sexually transmitted, treat partners with the same dose and at the same time.","Concurrent use of ethanol:","No effect of secnidazole on aldehyde dehydrogenase activity in vitro.","However, postmarketing observations of nausea, vomiting diarrhea, abdominal pain, dizziness, and headache with concomitant use of secnidazole and alcohol have been reported.","Recommendation: avoid consumption of alcoholic beverages during treatment and for at least two days after completing therapy."],adult_dose:{dose:"2 gm packet (granules) once orally, without regard to the timing of meals.",same_dose:"Same dose for bacterial vaginosis and trichomoniasis.",administration:["Sprinkle packet contents on applesauce, yogurt or pudding. The granules will not dissolve. Consume all of the mixture within 30 minutes without chewing or crunching the granules.","Do not dissolve granules in liquid. May follow with glass of water to aid swallowing."]},pediatric_dose:{dose_age_gt_12_yrs:"2 gm po x1",max_day:"2 gm"}},renal_adjustment:{half_life_normal:"17",half_life_esrd:"No data",dose_renal_function_normal:"2 gm single-dose",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No data",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:{contraindications:["Known hypersensitivity to other nitroimidazoles (metronidazole, tinidazole).","Use in patients with Cockayne syndrome. Severe, irreversible hepatotoxicity with fatal outcomes have been reported after initiation of metronidazole (also a nitroimidazole) in patients with Cockayne syndrome."],warnings:["Vulvovaginal candidiasis may develop during use, requiring antifungal therapy.","Potential carcinogenicity seen in rodent studies. Avoid chronic use."],other:["Vulvovaginal pruritus.","GI: nausea, dysgeusia, vomiting, diarrhea, abdominal pain.","Headache."]},pregnancy_risk:{fda_risk_category:"No human data, safe in animals",lactation:"Safety not established, avoid breastfeeding for 96 hours after dose",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:["Bacteroides spp.","Gardnerella vaginalis","Prevotella spp.","Mobiluncus spp.","Megasphaera-like type I/II","Trichomonas vaginalis"],pharmacology:{pk_pd_index:"No data",preparations:"Oral granules (2 gm packets)",food_recommendation:"Granules ± food",oral_absorption_percent:"No data",tmax_hr:"4",peak_serum_conc_ug_ml:"45.4 (2 gm po, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"<5",volume_of_distribution_vd_l:"42 L",avg_serum_half_life_hr:"17",elimination:"Metabolized",bile_penetration_percent:"No data",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"1331.6 (2 gm po, 0-inf)"},major_drug_interactions:[{drug:"Ethanol",effect:"GI symptoms, dizziness, headache",management:"Avoid co-administration"}]}},Tinidazole:{id:"Tinidazole",name:"Tinidazole",tradename:"",classification:{family:"NITROIMIDAZOLE",subclass:"Nitroimidazole",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No dosage adjustment for renal impairment",mild:"No dosage adjustment for renal impairment",moderate:"No dosage adjustment for renal impairment",severe:"No dosage adjustment for renal impairment"},hepatic:"Use caution",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Limited human data, but evidence of toxicity in animals. Contraindicated in 1st trimester, according to some experts.",lactation:"Safety not established, avoid use",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Alcohol",effect:"Disulfiram-like reaction",management:"Avoid co-administration"},{drug:"Cyclosporine*",effect:"↑ cyclosporine",management:"Monitor"},{drug:"Cholestyramine*",effect:"↓ tinidazole",management:"Stagger dosing"},{drug:"Disulfiram*",effect:"Psychosis",management:"Monitor"},{drug:"Fluorouracil*",effect:"↑ fluorouracil",management:"Monitor"},{drug:"Lithium*",effect:"↑ lithium",management:"Monitor"},{drug:"Tacrolimus*",effect:"↑ tacrolimus",management:"Monitor"},{drug:"Warfarin",effect:"↑ INR",management:"Monitor, adjust do"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"48",protein_binding:"12",half_life:"13",elimination:"Metabolism, renal",csf_penetration:"No data",preparations:"Tab (250, 500 mg)"},rawData:{drug_name:"Tinidazole",usage_and_dosing:{general:["Tinidazole is chemically related to Metronidazole and is effective in the therapy of amebiasis, giardiasis and trichomoniasis.","Long half-life allows for intermittent dosing.","In general, Tinidazole is more potent and has fewer adverse reactions than Metronidazole.","Pregnancy and lactation:","Contraindicated in the first trimester, according to some experts.","See Table."],adult_dose:{amebiasis_intestinal:"2 gm po once daily x 3 days",amebiasis_liver_abscess:"2 gm po once daily x 5 days",giardiasis:"2 gm po x 1 dose",trichomoniasis:"2 gm po x 1 dose; treat sex partner at same time",bacterial_vaginosis:"2 gm po once daily x 2 days, or 1 gm once daily x 5 days"},pediatric_dose:{giardiasis:"Age >3 yrs: 50 mg/kg single dose",amebic_liver_abscess:"Age >3 yrs: 50 mg/kg q24h x3-5 days",intestinal_amebiasis:"Age >3 yrs: 50 mg/kg q24h x3 days"}},renal_adjustment:{notes:"Dosage adjustment may be required in hepatic disease.",half_life_normal:"13",half_life_esrd:"No data",dose_renal_function_normal:"2 gm po q24h x1-5 days",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No dosage adjustment (give an extra 1 gm AD if administered before dialysis)",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{note:"Specific dosage guidance not available.",mild_impairment_child_pugh_a:"Use caution",moderate_impairment_child_pugh_b:"Use caution",severe_impairment_child_pugh_c:"Use caution"},adverse_effects:["Dysgeusia/metallic taste 4-6%, nausea 3-5%, anorexia 2-3%, vomiting 1.5%. All higher with multi-day dosing. Seizures/peripheral neuropathy reported.","Avoid alcohol during and for 3 days after last dose; can cause disulfiram reaction: flushing, nausea, vomiting, tachycardia, sweating and headache."],pregnancy_risk:{fda_risk_category:"Limited human data, but evidence of toxicity in animals. Contraindicated in 1st trimester, according to some experts.",lactation:"Safety not established, avoid use",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:["E. histolytica","Giardia sp.","Trichomonas vaginalis"],pharmacology:{pk_pd_index:"No data",preparations:"Tab (250, 500 mg)",food_recommendation:"Tab + food",oral_absorption_percent:"48",tmax_hr:"1.6",peak_serum_conc_ug_ml:"48 (2 gm po, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"12",volume_of_distribution_vd_l:"50 L",avg_serum_half_life_hr:"13",elimination:"Metabolism, renal",bile_penetration_percent:"No data",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"902 (2 gm po, 0-inf)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:["CYP3A4"],transporters_substrate:[],ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:[{drug:"Alcohol",effect:"Disulfiram-like reaction",management:"Avoid co-administration"},{drug:"Cyclosporine*",effect:"↑ cyclosporine",management:"Monitor"},{drug:"Cholestyramine*",effect:"↓ tinidazole",management:"Stagger dosing"},{drug:"Disulfiram*",effect:"Psychosis",management:"Monitor"},{drug:"Fluorouracil*",effect:"↑ fluorouracil",management:"Monitor"},{drug:"Lithium*",effect:"↑ lithium",management:"Monitor"},{drug:"Tacrolimus*",effect:"↑ tacrolimus",management:"Monitor"},{drug:"Warfarin",effect:"↑ INR",management:"Monitor, adjust do"}],comments:["Food increases GI tolerability."]}},Linezolid:{id:"Linezolid",name:"Linezolid",tradename:"Zyvox",classification:{family:"OXAZOLIDINONE",subclass:"Oxazolidinone",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:["Enterococcus faecalis, vancomycin-resistant (VRE)","Enterococcus faecium, susceptible to vancomycin","Enterococcus faecium, vancomycin resistant (VRE)","Staphylococcus aureus, methicillin-resistant, (MRSA)","Staphylococcus epidermidis, methicillin-resistant (MRSE)","Staphylococcus sp., coagulase-negative (Methicillin resistant); S. hominis, S. capitis, others"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No dosage adjustment (product labeling). Debated: 300 mg q12h for eGFR <60 41",mild:"No dosage adjustment (product labeling). Debated: 300 mg q12h for eGFR <60 41",moderate:"No dosage adjustment (product labeling). Debated: 300 mg q12h for eGFR <60 41",severe:"No dosage adjustment (product labeling). Debated: 300 mg q12h for eGFR <60 41"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Humans: no evidence of toxicity. Animals: embryo-fetal lethality in mice at 6.5x human exposure.",lactation:"Probably safe with monitoring for GI toxicity. Infant serum levels resulting from drug received through breast milk would be trivial.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Adrenergic agents",effect:"Risk of hypertension",management:"Monitor closely"},{drug:"Aged, fermented, pickled, or smoked foods",effect:"Risk of hypertension",management:"Monitor closely"},{drug:"Fentanyl",effect:"Risk of serotonin syndrome (J Clin Pharm Ther 2020;45:825)",management:"Monitor closely"},{drug:"Meperidine",effect:"Risk of serotonin syndrome",management:"Monitor closely"},{drug:"Rasagiline",effect:"Risk of serotonin syndrome",management:"Monitor closely"},{drug:"Rifampin",effect:"↓ linezolid",management:"Monitor closely"},{drug:"Serotonergic drugs (SSRIs)",effect:"Risk of serotonin syndrome",management:"Monitor closely"}],stewardship:{preferredIndications:["Enterococcus faecalis, vancomycin-resistant (VRE)","Enterococcus faecium, susceptible to vancomycin","Enterococcus faecium, vancomycin resistant (VRE)","Staphylococcus aureus, methicillin-resistant, (MRSA)","Staphylococcus epidermidis, methicillin-resistant (MRSE)","Staphylococcus sp., coagulase-negative (Methicillin resistant); S. hominis, S. capitis, others"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"100",protein_binding:"31",half_life:"5",elimination:"Metabolized, renal",csf_penetration:"60-70",preparations:"Tab (600 mg), Oral susp (100 mg/5 mL), Injection"},rawData:{drug_name:"Linezolid",tradename:"Zyvox",drug_shortage:[{preparation:"Injection",start_date:"2024-10-16",notes:""}],usage_and_dosing:{general:["Linezolid is an oxazolidinone antibiotic with in vitro activity against gram-positive cocci: methicillin-sensitive Staph. aureus (MSSA), methicillin-resistant Staph. aureus (MRSA), Vancomycin-resistant E. faecium and Strep. pneumoniae.","An alternative antibiotic for drug resistant genotypes.","It has excellent oral bioavailability; oral and IV doses are the same.","Linezolid inhibits monoamine oxidase. Hence, there is potential for serotonin syndrome if given to patients taking selective serotonin re-uptake inhibitors or serotonin norepinephrine reuptake inhibitors. See adverse effects.","Inhibits toxin production in patients with toxic shock syndrome from either Staph. aureus or Strep. pyogenes (Antimicrob Agents Chemother 2012;56:1744; J Antimicrob Chemother 2019;74:1)."],adult_dose:{skin_skin_structure_infections_uncomplicated:"400-600 mg po/IV q12h",all_other_indications:"600 mg po/IV q12h"},pediatric_dose:{age_le_28_days:{ga_lt_34_wk_pna_le_7_days:"20 mg/kg/day (div q12h)",all_others:"30 mg/kg/day (div q8h)"},age_gt_28_days_all_indications_except_uncomp_ssti:{le_11_yrs:"30 mg/kg/day (div q8h)",gt_11_yrs:"600 mg q12h"},age_gt_28_days_uncomplicated_ssti:{lt_5_yrs:"30 mg/kg/day (div q8h)","5_to_11_years":"20 mg/kg/day (div q12h)",gt_11_years:"600 mg q12h"},max_day:"1200 mg"}},renal_adjustment:{half_life_normal:"5",half_life_esrd:"6-8",dose_renal_function_normal:"600 mg po/IV q12h",crcl_or_egfr:"No dosage adjustment (product labeling). Debated: 300 mg q12h for eGFR <60 41",hemodialysis:"No dosage adjustment (dose AD)",capd:"No dosage adjustment",crrt:"No dosage adjustment",sled:"No data"},hepatic_adjustment:{note:"PK modeling data suggest the need for dosage reduction in patients with liver cirrhosis depending on pathogen MIC (AAC 2020;64:e00133-20).",mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["Burns: potentially subtherapeutic concentrations (J Burn Care Res 2010;31:207).","ECMO: see ECMO Drug Dosing Adjustment page.","Obesity: see Obesity Dosing Adjustments page."],adverse_effects:{short_term:"Short term exposure: Rash, nausea (3%), vomiting (1%), diarrhea (4%), C. difficile colitis, increased LFTs (1.3%).",long_term:{myelosuppression:"Reversible myelosuppression: thrombocytopenia, anemia, and neutropenia reported. Most often after >2 weeks of therapy. Higher risk in end-stage renal disease (Clin Infect Dis 2006;42:66).",lactic_acidosis:"Lactic acidosis; peripheral neuropathy, optic neuropathy (after ≥4 weeks of therapy).",mitochondrial_toxicity:"Data consistent with time and dose-dependent inhibition of intra-mitochondrial protein synthesis. Trend toward association of mitochondrial toxicity with specific mitochondrial 16S RNA polymorphisms (Antimicrob Agents Chemother 2017;61:e00542-17). In vitro studies demonstrate that both linezolid and tedizolid cause a rapid and complete inhibition of mitochondrial enzymes involved in oxidative phosphorylation. With drug withdrawal, all effects were rapidly and fully reversible.",marrow_toxicity:"Lower frequency of clinical marrow toxicity with tedizolid may relate to reduced exposure due to the once daily dosing schedule. Ref: Antimicrob Agents Chemother 2018;62: e01599-17"},monoamine_oxidase_inhibitor:"Inhibitor of monoamine oxidase. Risk of severe hypertension if taken with foods rich in tyramine. Avoid concomitant pseudoephedrine, phenylpropanolamine, and caution with SSRIs (selective serotonin reuptake inhibitors, e.g., fluoxetine (Prozac)).",serotonin_syndrome:"Risk of serotonin syndrome (fever, agitation, mental status changes, tremors) if linezolid given with concomitant SSRIs (Clin Infect Dis 2006;42:1578; Clin Infect Dis 2006;43:180). The reported incidence of serotonin toxicity among patients also taking a serotonergic medication was <1% (J Antimicrob Chemother 2012;67:494); similar low incidence in a Veterans Affairs population (Antimicrob Agents Chemother 2013;57:5901). Nonetheless, an FDA Drug Safety Communication warns of increased risk of combining linezolid with any of the following serotonin reuptake inhibitors: meperidine, paroxetine, fluvoxamine, fluoxetine, sertraline, citalopram, escitalopram, vilazodone, venlafaxine, desvenlafaxine, and duloxetine.",review:"Review of linezolid and serotonin syndrome: J Int Med Res 2025;53:3000605251315355.",black_hairy_tongue:"Black hairy tongue (rare): Infect Drug Resist 2022;15:5449.",tooth_discoloration:"Reversible tooth discoloration after prolonged use (Clin Infect Dis 2016;62:617)."},pregnancy_risk:{fda_risk_category:"Humans: no evidence of toxicity. Animals: embryo-fetal lethality in mice at 6.5x human exposure.",lactation:"Probably safe with monitoring for GI toxicity. Infant serum levels resulting from drug received through breast milk would be trivial.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Enterococcus faecalis, vancomycin-resistant (VRE)","Enterococcus faecium, susceptible to vancomycin","Enterococcus faecium, vancomycin resistant (VRE)","Staphylococcus aureus, methicillin-resistant, (MRSA)","Staphylococcus epidermidis, methicillin-resistant (MRSE)","Staphylococcus sp., coagulase-negative (Methicillin resistant); S. hominis, S. capitis, others"],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Tab (600 mg), Oral susp (100 mg/5 mL), Injection",food_recommendation:"Tab/susp ± food",oral_absorption_percent:"100",tmax_hr:"1-2",peak_serum_conc_ug_ml:"15-20 (600 mg IV/po q12h, SS)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"31",volume_of_distribution_vd_l_vss:"40-50 L (Vss)",avg_serum_half_life_hr:"5",elimination:"Metabolized, renal",bile_penetration_percent:"No data",csf_blood_percent:"60-70",therapeutic_levels_in_csf:"Possibly 18",auc_ug_hr_ml:"179 (600 mg IV q12h, 0-24h), 276 (600 mg po q12h, 0-24h)"},major_drug_interactions:[{drug:"Adrenergic agents",effect:"Risk of hypertension"},{drug:"Aged, fermented, pickled, or smoked foods",effect:"Risk of hypertension"},{drug:"Fentanyl",effect:"Risk of serotonin syndrome (J Clin Pharm Ther 2020;45:825)"},{drug:"Meperidine",effect:"Risk of serotonin syndrome"},{drug:"Rasagiline",effect:"Risk of serotonin syndrome"},{drug:"Rifampin",effect:"↓ linezolid"},{drug:"Serotonergic drugs (SSRIs)",effect:"Risk of serotonin syndrome"}],comments:["Linezolid vs. Vancomycin: Prospective randomized double-blind trial of Linezolid vs. Vancomycin for patients with hospital-acquired pneumonia (HAP), healthcare-associated pneumonia (HCAP), or ventilator associated pneumonia (VAP) caused by MRSA. End of study clinical success favored Linezolid, p <0.04 (Clin Infect Dis 2012;54:621). The difference disappeared when analyzed by subgroup (HCAP, HAP, and VAP). No difference in all cause 60-day mortality. There was no requirement to document VAP by quantitative cultures of the lower airway. More nephrotoxicity in the Vancomycin patients. Overall, the data favor Linezolid and are supported by similar results in an animal model (Chest 2009;135:1564).","Serum level variability: Reports of significant variability of serum peak and trough serum levels after standard doses. Subtherapeutic trough concentrations found in 30% of patients with acute S. aureus infections (Antimicrob Agents Chemother 2013;57:1913).","Antibacterial activity is time dependent. Target is an AUC/MIC ratio of >80 or having the serum concentration exceed the MIC of the pathogen for >85% of the dosage interval. When serum levels were measured, there was a failure to achieve the latter targets in 60-70% of patients (Antimicrob Agents Chemother 2010;54:4605). Interesting, but serum levels of Linezolid are not routinely available.","Pharmacokinetics in cystic fibrosis: Antimicrob Agents Chemother 2004;48:281."]}},"Tedizolid phosphate":{id:"Tedizolid_phosphate",name:"Tedizolid phosphate",tradename:"Sivextro",classification:{family:"OXAZOLIDINONE",subclass:"Oxazolidinone",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No dosage adjustment for renal impairment",mild:"No dosage adjustment for renal impairment",moderate:"No dosage adjustment for renal impairment",severe:"No dosage adjustment for renal impairment"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Insufficient data in humans. Fetal developmental toxicity in mice and rats.",lactation:"Probably safe with monitoring, but no data available; avoid if possible.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Methotrexate (oral)",effect:"↑ methotrexate",management:"Avoid co-administration"},{drug:"Rosuvastatin",effect:"↑ rosuvastatin",management:"Monitor or avoid"},{drug:"Topotecan (oral)",effect:"↑ topotecan",management:"Avoid co-administration"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"91",protein_binding:"70-90",half_life:"12",elimination:"Fecal",csf_penetration:"No data",preparations:"Tab (200 mg), injection"},rawData:{drug_name:"Tedizolid phosphate",tradename:"Sivextro",usage_and_dosing:{general:["Tedizolid phosphate is an oxazolidinone antibiotic approved for the treatment of acute bacterial skin and skin structure infections caused by susceptible bacteria. It is the second oxazolidinone-class antibacterial (Linezolid was the first).","Tedizolid phosphate is the prodrug of Tedizolid (converted in the presence of phosphatases). Tedizolid is similar to Linezolid with respect to spectrum of activity, mechanism of action, and pharmacology.","It is bacteriostatic vs. staphylococci (including MRSA and Staph. epidermidis), streptococci (S. pyogenes, S. agalactiae, and S. anginosus group), and enterococci (including vancomycin-resistant enterococci).","Active in vitro vs Mycobacterium tuberculosis resistant to INH, Rifampin, or both.","Tedizolid is a weak monoamine oxidase inhibitor and hence could increase the risk of the serotonin syndrome if combined with serotonin uptake inhibitors. Patients requiring concomitant therapy with other monoamine oxidase inhibitors or serotonergic agents (SSRIs) were excluded from clinical trials. Reassuring that no evidence of interaction with serotonergic drugs in animal models (see Comments below).","Review: Clin Infect Dis 61:1315, 2015."],adult_dose:{acute_skin_skin_structure_infections:["200 mg IV (over one hour) q24h x6 days.","Alternatively, 200 mg po q24h (±food) x6 days.","IV dose is reconstituted in 250 ml of NS. Drug is incompatible with other solutions, including LR."]},pediatric_dose:{dose_age_gt_28_days:"6 mg/kg/day (divided q12h)",max_day:"200 mg"}},renal_adjustment:{half_life_normal:"12",half_life_esrd:"Unchanged",dose_renal_function_normal:"200 mg po/IV q24h",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No dosage adjustment",capd:"No dosage adjustment",crrt:"No dosage adjustment",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["Obesity: See Obesity Dosing Adjustments table."],adverse_effects:{warnings:["In animal models, the efficacy of Tedizolid was reduced in neutropenic animals. No data in neutropenic patients.","C. difficile infection has occurred."],most_common:"Most common adverse reactions: Nausea (8%), headache (6%), diarrhea (4%).",mitochondrial_protein_synthesis:"Oxazolidinones (linezolid and tedizolid) may interfere with human mitochondrial protein synthesis in addition to inhibition of ribosomes of bacteria.",platelet_counts:"In small 21 day phase one study in healthy volunteers, mean platelet counts decreased over time in a dose dependent manner for tedizolid, but only at supratherapeutic dosage. No significant decrease in platelets with the licensed dose of 200 mg once daily. Ref.: J Antimicrob Chemother 2016;71:2553.",in_vitro_studies:"In in vitro studies, both linezolid and tedizolid caused rapid and complete inhibition of oxidative metabolism. All effects were quickly and fully reversible with drug withdrawal. It is possible that the lesser clinical myelotoxicity of tedizolid is due to reduced exposure with the once daily treatment regimen (Antimicrob Agents Chemother 2018; 62:e01599-17).",patient_study:"In study of 81 patients treated for a median 28 days (14-59 days), including 44% treated with prior linezolid and 28% with chronic renal failure, 11% developed probably-associated adverse events and 8% discontinued due to adverse events. Of 22 patients with prior linezolid toxicity, 20 had no adverse event with tedizolid (Antimicrob Agents Chemother 2020; 64:e00356-20).",package_insert:"Package insert: Low platelet count in 2.3%; neutropenia in 0.5%. Myelosuppression, peripheral neuropathy, and optic neuropathy not a problem in clinical trials; however the patient exposure was usually only for 6 days. Review of optic and peripheral neuropathy associated with short and prolonged administration: Expert Rev Anti Infect Ther 2025;23:49.",phase_3_trial:"In phase 3 trial vs Linezolid, less nausea and less thrombocytopenia with tedizolid (Antimicrob Agts Chemother 59:864, 2015).",retrospective_study:"Retrospective study: 81 patients received a median 28 days (range 14-59 days) of tedizolid for infections including osteomyelitis, PJI, mycobacterial infections showed less toxicity than linezolid, including 9 (11%) related adverse events, 6 (7.4%) thrombocytopenia, and 4 (5%) treatment-limiting adverse events (Antimicrob Agents Chemother 64(7):e00356-20)."},pregnancy_risk:{fda_risk_category:"Insufficient data in humans. Fetal developmental toxicity in mice and rats.",lactation:"Probably safe with monitoring, but no data available; avoid if possible.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Tab (200 mg), injection",food_recommendation:"Tab ± food",oral_absorption_percent:"91",tmax_hr:"3",peak_serum_conc_ug_ml:"3.0 (200 mg IV q24h, SS), 2.2 (200 mg po q24h, SS)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"70-90",volume_of_distribution_vd_l_vss:"67-80 L (Vss)",avg_serum_half_life_hr:"12",elimination:"Fecal",bile_penetration_percent:"No data",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"29.2 (200 mg IV q24h, 0-24 hr), 25.6 (200 mg po q24h, 0-24 hr)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:[],ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:["BCRP (gut)"],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"↑"},major_drug_interactions:[{drug:"Methotrexate (oral)",effect:"↑ methotrexate",management:"Avoid co-administration"},{drug:"Rosuvastatin",effect:"↑ rosuvastatin",management:"Monitor or avoid"},{drug:"Topotecan (oral)",effect:"↑ topotecan",management:"Avoid co-administration"}],comments:["Non inferior to Linezolid in published results of phase 3 trials: Antimicrob Agents Chemother 59:864, 2015.","In vitro, in vivo, and clinical studies indicate weak monoamine oxidase inhibition and a low potential for serotonergic adverse consequences: Antimicrob Agents Chemother 57:3060, 2013."]}},Amoxicillin:{id:"Amoxicillin",name:"Amoxicillin",tradename:"Amoxil, Polymox, Moxatag",classification:{family:"PENICILLIN",subclass:"Aminopenicillins",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Actinomyces sp.","Borrelia burgdorferi","Enterococcus faecalis, susceptible to vancomycin","Pasteurella multocida","Peptostreptococci"],alternative:[],notes:""},dosing:{adult:{standard:"500-1000 mg po q8h, OR 875 mg po q12h",severe:"500-1000 mg po q8h, OR 875 mg po q12h",renal:{normal:"GFR >30: No dosage adjustment. GFR 10-30: 250-500 mg q12h. GFR <10: 250-500 mg q24h",mild:"GFR >30: No dosage adjustment. GFR 10-30: 250-500 mg q12h. GFR <10: 250-500 mg q24h",moderate:"GFR >30: No dosage adjustment. GFR 10-30: 250-500 mg q12h. GFR <10: 250-500 mg q24h",severe:"GFR >30: No dosage adjustment. GFR 10-30: 250-500 mg q12h. GFR <10: 250-500 mg q24h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"25-50 mg/kg/day (divided q8h)",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:["GI: nausea and vomiting, diarrhea, C. difficile-associated colitis.","Allergic reactions","Hematologic: hemolytic anemia, neutropenia, eosinophilia, thrombocytopenia, increased INR.","Fever"]},interactions:[{drug:"Allopurinol",effect:"↑ frequency of rash",management:"Monitor"},{drug:"Oral contraceptives",effect:"↓ efficacy of oral contraceptives",management:"Use alternative method"},{drug:"Probenecid",effect:"↑ amoxicillin",management:"Monitor, adjust dosage"},{drug:"Warfarin",effect:"↑ INR",management:"Monitor INR, adjust dosage"}],stewardship:{preferredIndications:["Actinomyces sp.","Borrelia burgdorferi","Enterococcus faecalis, susceptible to vancomycin","Pasteurella multocida","Peptostreptococci"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"80",protein_binding:"17-20",half_life:"1.2-1.5",elimination:"Renal",csf_penetration:"13-14",preparations:"Cap (250, 500 mg), Tab (500, 875 mg), Chewtab (125, 200, 250, 400 mg), ER tab (775 mg), Oral susp (per 5 mL): 125, 200, 250, 400 mg)"},rawData:{drug_name:"Amoxicillin",tradename:"Amoxil, Polymox, Moxatag",drug_shortage:[{preparation:"All oral formulations",start_date:"2022-10-18",notes:""}],usage_and_dosing:{general:["Amoxicillin is Ampicillin with an added hydroxyl (-OH) group. The -OH group dramatically increases oral absorption with an associated reduction in dosing frequency (3x daily for Amoxicillin vs. 4x daily for Ampicillin).","The extended-release (ER) formulation results in once-daily dosing for GABS tonsillitis and/or pharyngitis in adults and pediatric patients ≥12 years of age. Do not crush or chew tablet.","Amoxicillin IV preparation is available in the UK and Europe (but not in the US). IV Amoxicillin is rapidly converted to Ampicillin.","Higher dose recommended for otitis media and community-acquired pneumonia in children."],adult_dose:{usual_dose:"500-1000 mg po q8h, OR 875 mg po q12h",extended_release_er_dose:"775 mg (one tablet) po q24h x10 days (for GABS pharyngitis, tonsillitis)"},pediatric_dose:{standard:"25-50 mg/kg/day (divided q8h)",aom_pneumonia:"80-100 mg/kg/day (divided q8-12h; q12h for AOM)"}},renal_adjustment:{er_tab_note:"ER tab: No dosage adjustment if GFR ≥30, not recommended if GFR <30 (including HD).",gfr_note:"Do not use the 875 mg dose if GFR <30.",ref_1000mg_q8h:"Ref for 1000 mg q8h adjustments: World J Nephrol 2015;4:330.",half_life_normal:"1.2",half_life_esrd:"5-20",dose_renal_function_normal:"500 mg po q8h (or 875 mg po q12h)",crcl_or_egfr:"GFR >30: No dosage adjustment. GFR 10-30: 250-500 mg q12h. GFR <10: 250-500 mg q24h",hemodialysis:"250-500 mg q24h (+ extra dose AD)",capd:"250-500 mg q12h",crrt:"250-500 mg q8-12h",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:{gi:"GI: nausea and vomiting, diarrhea, C. difficile-associated colitis.",fever:"Fever",allergic_reactions:{rash:"Rash (common with all beta-lactam antibiotics, including amoxicillin).",others:"Others: angioedema, anaphylaxis, SCAR (e.g., SJS, TEN, DRESS, AGEP).",ebv:"In patients with Epstein-Barr virus (infectious mononucleosis) given Ampicillin, 65-100% develop rash, as do 90% of CLL patients and 15-20% of patients who take allopurinol. Do not label patient as penicillin-allergic, as it is not a true allergy.",cross_allergenicity:"In patients with true allergy, the risk of cross-allergenicity with cephalosporins is increased if the cephalosporin has an identical R-1 side chain. Cefadroxil and cefprozil have the same R-1 side chain as amoxicillin."},dies:"Drug-induced enterocolitis syndrome (DIES). Most cases have occurred in pediatric patients ≤18 years of age. DIES is a non-IgE mediated hypersensitivity reaction characterized by protracted vomiting occurring 1-4 hours after drug ingestion in the absence of skin or respiratory symptoms. DIES may be associated with pallor, lethargy, hypotension, shock, diarrhea within 24 hours of drug ingestion, and leukocytosis with neutrophilia. If DIES occurs, discontinue amoxicillin and institute appropriate therapy.",hematologic:"Hematologic: hemolytic anemia, neutropenia, eosinophilia, thrombocytopenia, increased INR.",aseptic_meningitis:"Amoxicillin-induced aseptic meningitis (rare). Typical presentation: headache and stiff neck, with temporal relationship to amoxicillin exposure. Lab findings include normal CSF glucose, elevated CSF protein, and pleocytosis (BMJ Case Rep 2025;18(3):e262311).",false_positive_glucose:"Possible false-positive reaction when testing for the presence of glucose in urine using a test based on the Benedict's copper reduction reaction (e.g., Clinitest). In this test, reducing substances in urine (such as glucose) convert cupric sulfate to cuprous oxide. This effect may occur with amoxicillin.",crystalluria:"Can crystallize in urine and result in macroscopic hematuria and renal insufficiency due to tubular obstruction (Kidney Int 2025;107:33). Risk factors: low urinary flow, acidic urine pH, high amoxicillin doses. Other drugs that can cause crystalluria: ampicillin, ciprofloxacin, acyclovir, indinavir, vitamin C."},pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Actinomyces sp.","Borrelia burgdorferi","Enterococcus faecalis, susceptible to vancomycin","Pasteurella multocida","Peptostreptococci"],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Cap (250, 500 mg), Tab (500, 875 mg), Chewtab (125, 200, 250, 400 mg), ER tab (775 mg), Oral susp (per 5 mL): 125, 200, 250, 400 mg)",food_recommendation:"Standard preps ± food, ER tab + food",oral_absorption_percent:"80",tmax_hr:"Cap/tab/chewtab/susp: 1-2, ER tab: 3.1",peak_serum_conc_ug_ml:"5.5-7.5 (500 mg po, SD), 6.6 (775 mg ER po, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"17-20",volume_of_distribution_vd:"0.36 L/kg",avg_serum_half_life_hr:"1.2-1.5",elimination:"Renal",bile_penetration_percent:"100-3000",csf_blood_percent:"13-14",therapeutic_levels_in_csf:"Yes (IV only)",auc_ug_hr_ml:"22 (500 mg po, 0-inf), 29.8 (775 mg ER po, 0-inf)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:["OAT1","OAT3"],ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:[{drug:"Allopurinol",effect:"↑ frequency of rash",management:"Monitor"},{drug:"Oral contraceptives",effect:"↓ efficacy of oral contraceptives",management:"Use alternative method"},{drug:"Probenecid",effect:"↑ amoxicillin",management:"Monitor, adjust dosage"},{drug:"Warfarin",effect:"↑ INR",management:"Monitor INR, adjust dosage"}]}},"Amoxicillin-clavulanate":{id:"Amoxicillin_clavulanate",name:"Amoxicillin-clavulanate",tradename:"Augmentin, Augmentin ES-600, Augmentin XR, Amoclan, Clavulin",classification:{family:"PENICILLIN",subclass:"Aminopenicillins",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Bacteroides fragilis","Capnocytophaga sp.","Haemophilus influenzae","Moraxella catarrhalis","Pasteurella multocida","Staphylococcus saprophyticus"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:{oral:"CrCl >30: No dosage adjustment. CrCl 10-30: 250-500 mg q12h. CrCl <10: 250-500 mg q24h",iv:"CrCl >30: No dosage adjustment. CrCl 10-30: 1 gm x1, then 500 mg q12h. CrCl <10: 1 gm x1, then 500 mg q24h"},mild:{oral:"CrCl >30: No dosage adjustment. CrCl 10-30: 250-500 mg q12h. CrCl <10: 250-500 mg q24h",iv:"CrCl >30: No dosage adjustment. CrCl 10-30: 1 gm x1, then 500 mg q12h. CrCl <10: 1 gm x1, then 500 mg q24h"},moderate:{oral:"CrCl >30: No dosage adjustment. CrCl 10-30: 250-500 mg q12h. CrCl <10: 250-500 mg q24h",iv:"CrCl >30: No dosage adjustment. CrCl 10-30: 1 gm x1, then 500 mg q12h. CrCl <10: 1 gm x1, then 500 mg q24h"},severe:{oral:"CrCl >30: No dosage adjustment. CrCl 10-30: 250-500 mg q12h. CrCl <10: 250-500 mg q24h",iv:"CrCl >30: No dosage adjustment. CrCl 10-30: 1 gm x1, then 500 mg q12h. CrCl <10: 1 gm x1, then 500 mg q24h"}},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:["Hematologic: neutropenia, thrombocytopenia"]},interactions:[{drug:"Allopurinol",effect:"↑ frequency of rash",management:"Monitor"},{drug:"Probenecid",effect:"↑ amoxicillin",management:"Monitor, adjust dosage"}],stewardship:{preferredIndications:["Bacteroides fragilis","Capnocytophaga sp.","Haemophilus influenzae","Moraxella catarrhalis","Pasteurella multocida","Staphylococcus saprophyticus"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"Amoxicillin: 80, Clavulanate: 30-98",protein_binding:"Amoxicillin: 18, Clavulanate: 25",half_life:"Amoxicillin: 1-1.4, Clavulanate: 1",elimination:"Amoxicillin: renal, Clavulanate: hepatic metabolism",csf_penetration:"No data",preparations:"Tab (250 mg/125 mg, 500 mg/125 mg, 875 mg/125 mg), Chewtab (200 mg/28.5 mg, 400 mg/57 mg), Extended-release (ER) tab (1000 mg/62.5 mg), Oral susp per 5 mL (125 mg/31.25 mg, 250 mg/62.5 mg, 200 mg/28.5 mg, 400 mg/57 mg, 600 mg/42.9 mg), Injection (500 mg/100 mg, 1000 mg/200 mg, 2000 mg/200 mg)"},rawData:{drug_name:"Amoxicillin-clavulanate",tradename:"Augmentin, Augmentin ES-600, Augmentin XR, Amoclan, Clavulin",drug_shortage:[{preparation:"All oral formulations",start_date:"2022-11-17",notes:""}],usage_and_dosing:{general:["Amoxicillin-clavulanate, FDA approved in 1984, is the co-formulation of an aminopenicillin (amoxicillin) plus a beta-lactamase inhibitor, clavulanate (clavulanic acid). Clavulanic acid extends the spectrum to selected beta-lactamase producing bacteria.","Clavulanic acid is a naturally occurring ẞ-lactam isolated from Streptomyces clavuligerus with essentially no antibacterial activity of its own. It inhibits only narrow-spectrum penicillinases, and TEM and SHV (Ambler Class A) enzymes found in common gram-negative bacilli such as E. coli, Proteus, and Klebsiella. Clavulanic acid inhibits no Class B, C, or D enzymes.","Amoxicillin-clavulanate is available in a somewhat bewildering array of oral formulations. See the Adult Dose section below for a complete listing.","IV formulation (5:1) available in some countries (not in the US).","Doses are based on the amoxicillin component. They are expressed below as mg as the amoxicillin component/mg of the clavulanate component, e.g., 500 mg/125 mg.","Amoxicillin is eliminated by the kidney, whereas clavulanate undergoes extensive hepatic metabolism. As the dose of a combination is decreased in renal impairment, a relative clavulanate deficiency can occur (JAMA 2001;285:386). Thus, lower-ratio products (e.g., 4:1 amoxicillin:clavulanate) are preferred if CrCl <30 mL/min. See Renal Adjustment table below."],adult_dose:{usual_doses:["500 mg/125 mg po q8h","875 mg/125 mg po q12h","Extended release 2000 mg/125 mg po q12h","1000 mg/200 mg IV q8h (where available)"],available_formulations:[{dosage_form:"Suspension",amoxicillin:"125 mg/5 mL",clavulanate:"31.25 mg/5 mL",ratio:"4:1"},{dosage_form:"Suspension",amoxicillin:"200 mg/5 mL",clavulanate:"28.5 mg/5 mL",ratio:"7:1"},{dosage_form:"Suspension",amoxicillin:"250 mg/5 mL",clavulanate:"62.5 mg/5 mL",ratio:"4:1"},{dosage_form:"Suspension",amoxicillin:"400 mg/5 mL",clavulanate:"57 mg/5 mL",ratio:"7:1"},{dosage_form:"Suspension",amoxicillin:"600 mg/5 mL",clavulanate:"42.9 mg/5 mL",ratio:"14:1"},{dosage_form:"Tablet",amoxicillin:"250 mg",clavulanate:"125 mg",ratio:"2:1"},{dosage_form:"Tablet",amoxicillin:"500 mg",clavulanate:"125 mg",ratio:"4:1"},{dosage_form:"Tablet",amoxicillin:"875 mg",clavulanate:"125 mg",ratio:"7:1"},{dosage_form:"Extended-release tablet",amoxicillin:"1000 mg",clavulanate:"62.5 mg",ratio:"16:1"},{dosage_form:"Chewable tablet",amoxicillin:"200 mg",clavulanate:"28.5 mg",ratio:"7:1"},{dosage_form:"Chewable tablet",amoxicillin:"400 mg",clavulanate:"57 mg",ratio:"7:1"}]},pediatric_dose:{oral_7_1_formulation:"45 mg/kg/day (divided q12h)",oral_14_1_formulation_for_aom:"90 mg/kg/day (divided q12h) for wt <40 kg",iv_5_1_formulation:{age_lt_3_mon_wt_lt_4_kg:"25 mg/kg q12h",age_lt_3_mon_wt_ge_4_kg:"25 mg/kg q8h",age_ge_3_mon_wt_lt_40_kg:"25 mg/kg q8h",age_ge_3_mon_wt_ge_40_kg:"use adult dosing"}}},renal_adjustment:{note:"Doses based on amoxicillin component. ER tab contraindicated if CrCl <30 mL/min (including HD). 600 mg/42.9 mg (per 5 mL) susp: No dosing recommendations for renal impairment.",half_life_normal:"Amoxicillin: 1.4, Clavulanate: 1",half_life_esrd:"Amoxicillin: 5-20, Clavulanate: 4",dose_renal_function_normal:"500 mg po q8h (4:1), 875 mg po q12h (7:1), 1gm IV q8h (5:1)",crcl_or_egfr:{oral:"CrCl >30: No dosage adjustment. CrCl 10-30: 250-500 mg q12h. CrCl <10: 250-500 mg q24h",iv:"CrCl >30: No dosage adjustment. CrCl 10-30: 1 gm x1, then 500 mg q12h. CrCl <10: 1 gm x1, then 500 mg q24h"},hemodialysis:{oral:"250-500 mg q24h (+ extra dose AD)",iv:"1 gm x1, then 500 mg q24h (+ extra dose AD)"},capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:{gastrointestinal:"Gastrointestinal (diarrhea, C. difficile infection). 125-250 mg per day of clavulanic acid is a reasonable target. Exceeding that target (e.g., with q8h regimens) may result in more diarrhea.",hypersensitivity:"Hypersensitivity reactions. Fever, rash, anaphylaxis. Persons with infectious mononucleosis, i.e., Epstein-Barr virus (EBV), are likely to develop rash. It is not a permanent allergy. In patients with true amoxicillin allergy, there is an increased risk of cross allergenicity with oral cephalosporins that have an identical R1 side chain (cefadroxil, cefprozil). See Drug Allergy: Penicillins, Cephalosporins, Overview page. In patients with immediate allergic reaction to amoxicillin-clavulanate, 1/3 are due to the clavulanate (J Allergy Clin Immunol 2010;125:502).",hematologic:"Hematologic: neutropenia, thrombocytopenia",hepatotoxicity:"Hepatotoxicity. Linked to clavulanic acid. Amoxicillin-clavulanate is a common cause (13-23%) of drug-induced cholestatic liver injury. Onset of injury is a few days to as long as 8 weeks after initiation of therapy. Often occurs after the course of amoxicillin-clavulanate is completed. Typical presentation: fatigue, low grade fever, nausea and abdominal pain, followed by pruritus and jaundice. The pattern of liver enzyme elevations is typically cholestatic with marked elevations in alkaline phosphatase and GGT, as well as bilirubin. In some instances, aminotransferase levels are markedly elevated, giving a mixed or hepatocellular pattern, particularly in younger patients with earlier onset of injury. Drug-induced liver injury (DILI) related to amoxicillin-clavulanate has been associated with HLA-DRB1*15:01 and its haplotype, DQB1*06:02, and with HLA-A*02:01 in northern European populations. DILI is selective on the basis of HLA restriction, and no cross-reactivity with other beta-lactams is apparent. Given the low positive predictive value of these alleles for DILI, testing is not a part of routine clinical practice (N Engl J Med 2019;381:2338). Additional refs: N Engl J Med 2019;381:264; Gastroenterology 2015;148:1340.",seizures:"Seizures (rare)",crystalluria:"Crystalluria (rare)",beta_d_glucan:"Positive blood test for 1,3-beta-D-glucan in patients given IV amoxicillin-clavulanate (N Engl J Med 2006;354:2834)."},pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Bacteroides fragilis","Capnocytophaga sp.","Haemophilus influenzae","Moraxella catarrhalis","Pasteurella multocida","Staphylococcus saprophyticus"],alternative:[]},pharmacology:{dosage_expression:"Dosage is expressed as mg of amoxicillin/mg of clavulanic acid",iv_formulations:"IV formulations not available in US",pk_pd_index:"T>MIC",preparations:"Tab (250 mg/125 mg, 500 mg/125 mg, 875 mg/125 mg), Chewtab (200 mg/28.5 mg, 400 mg/57 mg), Extended-release (ER) tab (1000 mg/62.5 mg), Oral susp per 5 mL (125 mg/31.25 mg, 250 mg/62.5 mg, 200 mg/28.5 mg, 400 mg/57 mg, 600 mg/42.9 mg), Injection (500 mg/100 mg, 1000 mg/200 mg, 2000 mg/200 mg)",food_recommendation:"Immediate release preps ± food, ER + food",oral_absorption_percent:"Amoxicillin: 80, Clavulanate: 30-98",tmax_hr:"ER: Amoxicillin 1.5, Clavulanate: 1.03",peak_serum_conc_ug_ml:"Immediate release: amox 11.6, clav 2.2 (875 mg/125 mg, SD). ER: amox 17, clav 2.1 (2000 mg/125 mg, SD). IV: amox 105.4, clav 28.5 (1000 mg/200 mg, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"Amoxicillin: 18, Clavulanate: 25",volume_of_distribution_vd_l_kg:"Amoxicillin: 0.36 L/kg, Clavulanate: 0.21 L/kg",avg_serum_half_life_hr:"Amoxicillin: 1-1.4, Clavulanate: 1",elimination:"Amoxicillin: renal, Clavulanate: hepatic metabolism",bile_penetration_percent:"Amoxicillin: 100-3000",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"Immediate-release: amox 26.8, clav 5.1 (875 mg/125 mg po, 0-inf). ER: amox 71.6, clav 5.3 (2000 mg/125 mg po, 0-inf). IV: amox 76.3, clav 27.9 (1000 mg/200 mg po, 0-inf)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:"Amoxicillin: OAT1, OAT3",ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:[{drug:"Allopurinol",effect:"↑ frequency of rash",management:"Monitor"},{drug:"Probenecid",effect:"↑ amoxicillin",management:"Monitor, adjust dosage"}]}},Ampicillin:{id:"Ampicillin",name:"Ampicillin",tradename:"Omnipen, Polycillin, Principen",classification:{family:"PENICILLIN",subclass:"Aminopenicillins",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Actinomyces sp.","Borrelia burgdorferi","Enterococcus faecalis, susceptible to vancomycin","Listeria monocytogenes","Pasteurella multocida","Peptostreptococci"],alternative:[],notes:""},dosing:{adult:{standard:{oral:"250-500 mg po q6h",iv:"1-2 gm IV q4-6h"},severe:{oral:"250-500 mg po q6h",iv:"1-2 gm IV q4-6h"},renal:{normal:"CrCl >50: No dosage adjustment. CrCl 30-50: 1-2 gm q6-8h. CrCl 10-30: 1-2 gm q8-12h",mild:"CrCl >50: No dosage adjustment. CrCl 30-50: 1-2 gm q6-8h. CrCl 10-30: 1-2 gm q8-12h",moderate:"CrCl >50: No dosage adjustment. CrCl 30-50: 1-2 gm q6-8h. CrCl 10-30: 1-2 gm q8-12h",severe:"CrCl >50: No dosage adjustment. CrCl 30-50: 1-2 gm q6-8h. CrCl 10-30: 1-2 gm q8-12h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Allopurinol",effect:"↑ frequency of rash",management:"Monitor"},{drug:"Probenecid",effect:"↑ ampicillin",management:"Monitor, adjust dosage"}],stewardship:{preferredIndications:["Actinomyces sp.","Borrelia burgdorferi","Enterococcus faecalis, susceptible to vancomycin","Listeria monocytogenes","Pasteurella multocida","Peptostreptococci"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"18-22",half_life:"1.2",elimination:"Renal",csf_penetration:"13-14",preparations:"Cap (250, 500 mg), Oral susp (125 mg/5 mL, 250 mg/5 mL), Injection"},rawData:{drug_name:"Ampicillin",tradename:"Omnipen, Polycillin, Principen",usage_and_dosing:{general:["Ampicillin (and Amoxicillin) are the aminopenicillins with predictable activity against streptococci, most enterococci, Listeria, clostridia and a variety of other anaerobic bacteria."],adult_dose:{usual_dose:{oral:"250-500 mg po q6h",iv:"1-2 gm IV q4-6h"}},pediatric_dose:{oral:"50-100 mg/kg/day (divided q6h)",iv_standard:"200 mg/kg/day (divided q6h)",iv_meningitis:"300-400 mg/kg/day (divided q4h)"}},renal_adjustment:{half_life_normal:"1.2",half_life_esrd:"7-20",dose_renal_function_normal:"1-2 gm IV q4-6h",crcl_or_egfr:"CrCl >50: No dosage adjustment. CrCl 30-50: 1-2 gm q6-8h. CrCl 10-30: 1-2 gm q8-12h",hemodialysis:"1-2 gm q12h (give one of the dialysis day doses AD)",capd:"500 mg - 1 gm q12h",crrt:"1-2 gm q8-12h",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["ECMO. Serum concentrations may not be significantly altered by ECMO. See Table for details."],adverse_effects:["Allergy manifest as rash is common with all beta-lactam antibiotics, including Ampicillin.","In patients with Epstein-Barr virus (infectious mononucleosis) given Ampicillin, 65-100% develop rash; 90% of CLL patients and 15-20% of patients who take allopurinol. Do not label patient as penicillin-allergic as it is not a true allergy.","In patients with true Ampicillin allergy, risk of cross-allergenicity with po cephalosporins that have identical R1 side chains: i.e., Cefaclor, Cephalexin, Cephradine, Loracarbef.","Ampicillin: Fever, rash (5%), anaphylaxis (rare), +Coombs, neutropenia, eosinophilia (22%), thrombocytopenia (rare), increased PT/PTT, nausea/vomiting (2%), diarrhea (10%), C. difficile colitis (rare).","Drug-induced immune thrombocytopenia"],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Actinomyces sp.","Borrelia burgdorferi","Enterococcus faecalis, susceptible to vancomycin","Listeria monocytogenes","Pasteurella multocida","Peptostreptococci"],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Cap (250, 500 mg), Oral susp (125 mg/5 mL, 250 mg/5 mL), Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"100 (2 gm IV, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"18-22",volume_of_distribution_vd_l_kg:"0.29 L/kg",avg_serum_half_life_hr:"1.2",elimination:"Renal",bile_penetration_percent:"100-3000",csf_blood_percent:"13-14",therapeutic_levels_in_csf:"Yes",auc_ug_hr_ml:"120 (2 gm IV, 0-inf)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:["OAT1","OAT3"],ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:[{drug:"Allopurinol",effect:"↑ frequency of rash",management:"Monitor"},{drug:"Probenecid",effect:"↑ ampicillin",management:"Monitor, adjust dosage"}]}},"Ampicillin-sulbactam":{id:"Ampicillin_sulbactam",name:"Ampicillin-sulbactam",tradename:"Unasyn",classification:{family:"PENICILLIN",subclass:"Aminopenicillins",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Haemophilus influenzae","Pasteurella multocida"],alternative:[],notes:""},dosing:{adult:{standard:"3 gm IV (over 30 min) q6h",severe:"3 gm IV (over 30 min) q6h",renal:{normal:"CrCl ≥30: No dosage adjustment. CrCl 15-29: 1.5-3 gm q12h. CrCl 5-14: 1.5-3 gm q24h",mild:"CrCl ≥30: No dosage adjustment. CrCl 15-29: 1.5-3 gm q12h. CrCl 5-14: 1.5-3 gm q24h",moderate:"CrCl ≥30: No dosage adjustment. CrCl 15-29: 1.5-3 gm q12h. CrCl 5-14: 1.5-3 gm q24h",severe:"CrCl ≥30: No dosage adjustment. CrCl 15-29: 1.5-3 gm q12h. CrCl 5-14: 1.5-3 gm q24h"},hepatic:"No data",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Allopurinol",effect:"↑ frequency of rash",management:"Monitor"},{drug:"Probenecid",effect:"↑ ampicillin",management:"Monitor, adjust dosage"}],stewardship:{preferredIndications:["Haemophilus influenzae","Pasteurella multocida"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"Ampicillin: 28, Sulbactam: 38",half_life:"Ampicillin: 1.4, Sulbactam: 1.7",elimination:"Renal",csf_penetration:"No data",preparations:"Injection"},rawData:{drug_name:"Ampicillin-sulbactam",tradename:"Unasyn",usage_and_dosing:{general:["Ampicillin-sulbactam is an aminopenicillin combined with a beta-lactamase inhibitor.","A broad spectrum of activity allows use for many types of infections; e.g., appendicitis, diverticulitis, peritonitis. Increasing resistance, however, hampers use against aerobic gram-negative bacilli.","Guidelines have dropped Ampicillin-Sulbactam for empiric use in intraabdominal infections due to increasing resistance of aerobic gram-negative bacilli.","Total daily dose of Sulbactam is ≤4 gm for aerobic gram-negative bacilli. The Sulbactam component has useful activity against Acinetobacter baumannii, but is given in higher doses for this indication and usually as part of combination therapy.","Doses expressed as the sum of the components, thus 3 gm = Ampicillin 2 gm + Sulbactam 1 gm (2:1 ratio)."],adult_dose:{usual_dose:"3 gm IV (over 30 min) q6h",other_dosing:"Refer to these pages: Pneumonia, Acinetobacter sp., Acinetobacter baumannii-calcoac"},pediatric_dose:{note:"Doses expressed as sum of ampicillin + sulbactam (2:1 ratio)",amr_gram_negative_guidance:"J Pediatric Infect Dis Soc 2025;14:piaf004",per_red_book:{age_gt_28_days:"150-300 mg/kg/day (divided q6h)",meningitis:"600 mg/kg/day (divided q6h)"},per_amr_guidance:{neonates:"PNA ≤7 days: 450 mg/kg/day (div q8h, infused over 4 hr). PNA 8-60 days: 450 mg/kg/day (div q6h, infused over 4 hr)",infants_and_children:"600 mg/kg/day (div q4-6h, infused over 4 hr, max 18 gm/day)",adolescents_ge_12_yrs:"9 gm/day sulbactam via 1 of 2 regimens: 9 gm amp/sulb (over 4 hr) q8h, OR 27 gm amp/sulb (continuous 24-hr infusion)",cns_note:"Note: infusions of ≤1 hr suggested for CNS infections"},max_day:"12 gm (unless otherwise specified)"}},renal_adjustment:{half_life_normal:"Ampicillin: 1.4, Sulbactam: 1.7",half_life_esrd:"Ampicillin: 7-20, Sulbactam: 10",dose_renal_function_normal:"1.5-3 gm IV q6h",crcl_or_egfr:"CrCl ≥30: No dosage adjustment. CrCl 15-29: 1.5-3 gm q12h. CrCl 5-14: 1.5-3 gm q24h",hemodialysis:"1.5-3 gm q24h (give AD on dialysis day)",capd:"3 gm q24h",crrt:"1.5-3 gm q8-12h",sled:"3 gm q12h 32"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No data",moderate_impairment_child_pugh_b:"No data",severe_impairment_child_pugh_c:"No data"},adverse_effects:["GI (nausea/vomiting, diarrhea (2%), C. difficile colitis)","Hypersensitivity: rash (2%), fever, anaphylaxis","A maculopapular rash occurs (not urticarial), not true penicillin allergy, in 65–100% patients with infectious mononucleosis, 90% with chronic lymphocytic leukemia, and 15-20% with allopurinol therapy.","Local phlebitis (3%)","Hematologic: neutropenia, eosinophilia (22%), thrombocytopenia","Increased LFTs (6%)","Rare: increased BUN/Scr, headache, confusion"],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Haemophilus influenzae","Pasteurella multocida"],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"Ampicillin 109-150, Sulbactam 48-88 (3 gm IV, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"Ampicillin: 28, Sulbactam: 38",volume_of_distribution_vd_l_kg:"Ampicillin: 0.29 L/kg, Sulbactam: 0.3 L/kg",avg_serum_half_life_hr:"Ampicillin: 1.4, Sulbactam: 1.7",elimination:"Renal",bile_penetration_percent:"Ampicillin: 100-3000",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"Ampicillin 120, Sulbactam 71 (3 gm IV, 0-inf)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:"Ampicillin: OAT1, OAT3, Sulbactam: OAT1, OAT3",ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:[{drug:"Allopurinol",effect:"↑ frequency of rash",management:"Monitor"},{drug:"Probenecid",effect:"↑ ampicillin",management:"Monitor, adjust dosage"}]}},Piperacillin:{id:"Piperacillin",name:"Piperacillin",tradename:"",classification:{family:"PENICILLIN",subclass:"Antipseudomonal",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"3-4 gm IV q4-6h (max 24 gm/day)",severe:"3-4 gm IV q4-6h (max 24 gm/day)",renal:{normal:"CrCl >50: No dosage adjustment. CrCl 30-50: 3-4 gm q6-8h. CrCl 10-30: 3-4 gm q8h",mild:"CrCl >50: No dosage adjustment. CrCl 30-50: 3-4 gm q6-8h. CrCl 10-30: 3-4 gm q8h",moderate:"CrCl >50: No dosage adjustment. CrCl 30-50: 3-4 gm q6-8h. CrCl 10-30: 3-4 gm q8h",severe:"CrCl >50: No dosage adjustment. CrCl 30-50: 3-4 gm q6-8h. CrCl 10-30: 3-4 gm q8h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Insufficient human data, evidence of fetotoxicity in animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Aminoglycosides",effect:"Possible aminoglycoside inactivation",management:"SL"},{drug:"Anticoagulant drugs",effect:"↑ risk of bleeding",management:"Monitor closely"},{drug:"Methotrexate",effect:"↑ MTX",management:"Monitor closely"},{drug:"Probenecid",effect:"↑ piperacillin",management:"A"},{drug:"Vancomycin",effect:"↑ risk of AKI",management:"Monitor closely"},{drug:"Vecuronium",effect:"↑ neuromuscular blockade",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"16",half_life:"1",elimination:"Renal",csf_penetration:"30",preparations:"Injection"},rawData:{drug_name:"Piperacillin",usage_and_dosing:{general:["Piperacillin is one of the penicillins with an expanded spectrum of activity (compared to Amoxicillin) against aerobic Gram-negative bacilli. The spectrum of activity includes P. aeruginosa.","Piperacillin alone may be found in some markets; in the U.S. market it is usually combined with Tazobactam, see Piperacillin-tazobactam.","Can be administered IV or IM."],adult_dose:{usual_dose:"3-4 gm IV q4-6h (max 24 gm/day)",urinary_tract_infection:"2 gm IV q6h",p_aeruginosa:"4 gm IV q4h"},pediatric_dose:{dose_age_gt_28_days:"400 mg/kg/day (divided q6h)",max_day:"-"}},renal_adjustment:{half_life_normal:"1",half_life_esrd:"3-5",dose_renal_function_normal:"3-4 gm IV q4-6h",crcl_or_egfr:"CrCl >50: No dosage adjustment. CrCl 30-50: 3-4 gm q6-8h. CrCl 10-30: 3-4 gm q8h",hemodialysis:"2 gm q8h (+ extra 1 gm AD)",capd:"3-4 gm q8h",crrt:"3-4 gm q6-8h",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["Platelet dysfunction may occur with Piperacillin (or any of the antipseudomonal penicillins), especially in renal failure patients (J Lab Clin Med 108:217, 1986; J Infect Dis 155:1242, 1987).","Can contribute to excessive sodium administration: 1.85 mEq Na+/gm of Piperacillin.","Treatment stopped due to adverse effects (3.2%), local phlebitis (4%), fever, rash (1%), serum sickness, positive Coombs, neutropenia (6%), eosinophilia, thrombocytopenia, increased PT/PTT, nausea/vomiting, diarrhea (2%), C. difficile colitis, increased LFTs, increased BUN/Creatinine, headache (rare), confusion (rare).","Allergic reactions can occur with any of the beta-lactam antibiotics."],pregnancy_risk:{fda_risk_category:"Insufficient human data, evidence of fetotoxicity in animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{full_comparative_spectrum_of_activity:!0},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"242 (3 gm IV, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"16",volume_of_distribution_vd_l_kg:"0.24 L/kg",avg_serum_half_life_hr:"1",elimination:"Renal",bile_penetration_percent:">100",csf_blood_percent:"30",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"242 (3 gm IV q6h, 0-6h)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:["OAT1","OAT3"],ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:[{drug:"Aminoglycosides",effect:"Possible aminoglycoside inactivation",management:"SL"},{drug:"Anticoagulant drugs",effect:"↑ risk of bleeding",management:null},{drug:"Methotrexate",effect:"↑ MTX",management:null},{drug:"Probenecid",effect:"↑ piperacillin",management:"A"},{drug:"Vancomycin",effect:"↑ risk of AKI",management:null},{drug:"Vecuronium",effect:"↑ neuromuscular blockade",management:null}]}},"Piperacillin-tazobactam":{id:"Piperacillin_tazobactam",name:"Piperacillin-tazobactam",tradename:"Zosyn, Tazocin",classification:{family:"PENICILLIN",subclass:"Antipseudomonal",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Bacteroides fragilis","Capnocytophaga sp.","Citrobacter koseri, diversus","Escherichia coli, susceptible","K. oxytoca, Susceptible strains","Morganella morganii","Pseudomonas aeruginosa","Susceptible strains. K. pneumoniae, K. variicola"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:{extended_infusion:"CrCl ≥20: No dosage adjustment. CrCl <20: 4.5 gm (over 4 hr) q12h",intermittent_infusion:{nosocomial_pneumonia:"CrCl >40: No dosage adjustment. CrCl 20-40: 3.375 gm q6h. CrCl <20: 2.25 gm q6h",all_other_indications:"CrCl >40: No dosage adjustment. CrCl 20-40: 2.25 gm q6h. CrCl <20: 2.25 gm q8h"}},mild:{extended_infusion:"CrCl ≥20: No dosage adjustment. CrCl <20: 4.5 gm (over 4 hr) q12h",intermittent_infusion:{nosocomial_pneumonia:"CrCl >40: No dosage adjustment. CrCl 20-40: 3.375 gm q6h. CrCl <20: 2.25 gm q6h",all_other_indications:"CrCl >40: No dosage adjustment. CrCl 20-40: 2.25 gm q6h. CrCl <20: 2.25 gm q8h"}},moderate:{extended_infusion:"CrCl ≥20: No dosage adjustment. CrCl <20: 4.5 gm (over 4 hr) q12h",intermittent_infusion:{nosocomial_pneumonia:"CrCl >40: No dosage adjustment. CrCl 20-40: 3.375 gm q6h. CrCl <20: 2.25 gm q6h",all_other_indications:"CrCl >40: No dosage adjustment. CrCl 20-40: 2.25 gm q6h. CrCl <20: 2.25 gm q8h"}},severe:{extended_infusion:"CrCl ≥20: No dosage adjustment. CrCl <20: 4.5 gm (over 4 hr) q12h",intermittent_infusion:{nosocomial_pneumonia:"CrCl >40: No dosage adjustment. CrCl 20-40: 3.375 gm q6h. CrCl <20: 2.25 gm q6h",all_other_indications:"CrCl >40: No dosage adjustment. CrCl 20-40: 2.25 gm q6h. CrCl <20: 2.25 gm q8h"}}},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Insufficient human data, evidence of fetotoxicity in animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Aminoglycosides",effect:"Possible aminoglycoside inactivation",management:"Monitor or"},{drug:"Anticoagulant drugs",effect:"↑ risk of bleeding",management:"Monito"},{drug:"Methotrexate",effect:"↑ MTX",management:"Monitor or"},{drug:"Probenecid",effect:"↑ piperacillin, ↑ tazobactam",management:"Avoid co-admi"},{drug:"Vancomycin",effect:"↑ risk of AKI",management:"Monito"},{drug:"Vecuronium",effect:"↑ neuromuscular blockade",management:"Monito"}],stewardship:{preferredIndications:["Bacteroides fragilis","Capnocytophaga sp.","Citrobacter koseri, diversus","Escherichia coli, susceptible","K. oxytoca, Susceptible strains","Morganella morganii","Pseudomonas aeruginosa","Susceptible strains. K. pneumoniae, K. variicola"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"Piperacillin: 16, Tazobactam: 48",half_life:"Piperacillin: 1, Tazobactam: 1",elimination:"Renal",csf_penetration:"VAI: Piperacillin: ≈4, Tazo: indeterminate 20",preparations:"Injection"},rawData:{drug_name:"Piperacillin-tazobactam",tradename:"Zosyn, Tazocin",usage_and_dosing:{general:["Piperacillin-tazobactam, approved by the US FDA in 1993, is a combination of the expanded spectrum antipseudomonal beta-lactam Piperacillin with the beta-lactamase inhibitor Tazobactam.","The addition of Tazobactam protects Piperacillin from degradation by the beta-lactamases of MSSA, H. influenzae, M. catarrhalis and B. fragilis. Tazobactam inhibits no Ambler class B, C, or D enzymes.","The addition of Tazobactam does not increase the activity of Piperacillin against P. aeruginosa.","Available dosage forms for IV use (always 8:1 ratio)","2.25 gm vial (Piperacillin 2 gm + Tazobactam 0.25 gm)","3.375 gm vial (Piperacillin 3 gm + Tazobactam 0.375 gm)","4.5 gm vial (Piperacillin 4 gm + Tazobactam 0.5 gm)","The majority of available data suggest that, regardless of in vitro susceptibility results, it is best to avoid the use of Piperacillin-Tazobactam for infections suspected or proven to be due to ESBL-producing aerobic gram-negative bacilli (Antimicrob Agents Chemother 2013;57:3402)."],adult_dose:{extended_infusion:{dose:"4.5 gm IV (over 4 hr) q8h",loading_dose:"Consider a loading dose of 4.5 gm IV (over 30 min), administered immediately prior to the first extended-infusion dose, in critically ill patients. Goal is to minimize delay in achieving adequate concentrations (Int J Antimicrob Agents 2015;45:461).",references:"Published data demonstrate enhanced efficacy and reduced cost of extended infusion regimens. Extended infusion references: Clin Infect Dis 2007;44:357; Antimicrob Agents Chemother 2010;54:460."},intermittent_infusion:{peritonitis_intra_abdominal_abscess:"3.375 gm IV (over 30 min) q6h",p_aeruginosa_pneumonia:"4.5 gm IV (over 30 min) q6h. Combine with an antipseudomonal aminoglycoside or fluoroquinolone"}},pediatric_dose:{note:"Dosing based on piperacillin component",per_red_book:{usual:"240-300 mg/kg/day (div q6-8h)",cf:"400-600 mg/kg/day (div q4h)"},per_fda_wt_le_40_kg:{appendicitis_peritonitis:"Age 2 to 9 mon: 240 mg/kg/day (div q8h). Age >9 mon: 300 mg/kg/day (div q8h)",nosocomial_pneumonia:"Age 2 to 9 mon: 320 mg/kg/day (div q6h). Age >9 mon: 400 mg/kg/day (div q6h)"},max_day:"16 gm (24 gm if CF)"}},renal_adjustment:{half_life_normal:"Piperacillin: 1, Tazobactam: 1",half_life_esrd:"Piperacillin: 3-5, Tazobactam: 2.8",dose_renal_function_normal:{extended_infusion:"4.5 gm IV (over 4 hr) q8h",intermittent_infusion:{nosocomial_pneumonia:"4.5 gm IV (over 30 min) q6h",all_other_indications:"3.375 gm IV (over 30 min) q6h"}},crcl_or_egfr:{extended_infusion:"CrCl ≥20: No dosage adjustment. CrCl <20: 4.5 gm (over 4 hr) q12h",intermittent_infusion:{nosocomial_pneumonia:"CrCl >40: No dosage adjustment. CrCl 20-40: 3.375 gm q6h. CrCl <20: 2.25 gm q6h",all_other_indications:"CrCl >40: No dosage adjustment. CrCl 20-40: 2.25 gm q6h. CrCl <20: 2.25 gm q8h"}},hemodialysis:{extended_infusion:"4.5 gm (over 4 hr) q12h",intermittent_infusion:{nosocomial_pneumonia:"2.25 gm q8h (+0.75 gm AD on dialysis days)",all_other_indications:"2.25 gm q12h (+0.75 gm AD on dialysis days)"}},capd:{extended_infusion:"No data",intermittent_infusion:{nosocomial_pneumonia:"2.25 gm q8h",all_other_indications:"2.25 gm q12h"}},crrt:{extended_infusion:"3.375-4.5 gm (over 4 hr) q8h",intermittent_infusion:"3.375-4.5 gm q6h 42, 47"},sled:{intermittent_infusion:"4.5 gm q8h. May use extended infusion 53"}},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},other_adjustment:["Obesity: See Obesity Dosing Adjustments page.","ECMO: See ECMO Drug Dosing Adjustment page."],adverse_effects:["Hypersensitivity (rash, fever, serum sickness, anaphylaxis)","Local phlebitis","GI (nausea, vomiting, diarrhea, C. difficile colitis)","Hematologic (positive Coombs, neutropenia, eosinophilia, thrombocytopenia, increased INR)","Platelet dysfunction can occur in patients with renal failure, due to impaired platelet aggregation (J Infect Dis 1987;155:1242).","Drug-induced immune thrombocytopenia (J Thromb Haemost 2013;11:169). Can also occur with Vancomycin and patients often exposed to the combination. Hard to tell which drug is responsible (J Clin Anesth 2015;27:602).","Hypokalemia (Antibiotics 2023;12:240).","Increased LFTs","Headache, confusion (rare), seizures (rare)","Possible increased incidence of acute kidney injury. Does combining vancomycin with piperacillin-tazobactam amplify the risk of vancomycin nephrotoxicity? Many observational retrospective studies have reported an increased risk of acute kidney injury in association with the combination of piperacillin-tazobactam and vancomycin as compared to either drug alone (Clin Infect Dis 2017;65:2137). No reported increased risk of AKI if vancomycin is combined with cefepime or meropenem (Antimicrob Agents Chemother 2018;62:e00264-18). The attributable nephrotoxicity due to vancomycin due in part to multiple confounders (J Antimicrob Chemother 75:1031, 2020). In virtually all the pertinent studies the acute kidney injury endpoints utilized serum creatinine changes as a surrogate marker for changes in the glomerular filtration rate. In a rat model of vancomycin nephrotoxicity, there was a lack of augmentation of toxicity with concomitant piperacillin/tazobactam . Rather than changes in serum creatinine, a specific marker of tubular toxicity was utilized. The authors speculate that the rise in serum creatinine with piperacillin/tazobactam is the consequence of piperacillin competing with creatinine for tubular secretion. In short, a functional and not toxic marker. See Clin Infect Dis 71:426, 2020. Reference: J Antimicrob Chemother 75:1228, 2020."],pregnancy_risk:{fda_risk_category:"Insufficient human data, evidence of fetotoxicity in animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Bacteroides fragilis","Capnocytophaga sp.","Citrobacter koseri, diversus","Escherichia coli, susceptible","K. oxytoca, Susceptible strains","Morganella morganii","Pseudomonas aeruginosa","Susceptible strains. K. pneumoniae, K. variicola"],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"Piperacillin: 242, Tazobactam: 24.2 (3.375 gm IV, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"Piperacillin: 16, Tazobactam: 48",volume_of_distribution_vd_l_kg:"Piperacillin: 0.24 L/kg, Tazobactam: 0.4 L/kg",avg_serum_half_life_hr:"Piperacillin: 1, Tazobactam: 1",elimination:"Renal",bile_penetration_percent:">100",csf_blood_percent:"VAI: Piperacillin: ≈4, Tazo: indeterminate 20",therapeutic_levels_in_csf:"Unlikely",auc_ug_hr_ml:"Piperacillin: 242, Tazobactam: 25 (3.375 gm IV, 0-inf)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:[],transporters_substrate:"Piperacillin: OAT1, OAT3, Tazobactam: OAT1, OAT3",ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450s_induced:[],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:[{drug:"Aminoglycosides",effect:"Possible aminoglycoside inactivation",management:"Monitor or"},{drug:"Anticoagulant drugs",effect:"↑ risk of bleeding",management:"Monito"},{drug:"Methotrexate",effect:"↑ MTX",management:"Monitor or"},{drug:"Probenecid",effect:"↑ piperacillin, ↑ tazobactam",management:"Avoid co-admi"},{drug:"Vancomycin",effect:"↑ risk of AKI",management:"Monito"},{drug:"Vecuronium",effect:"↑ neuromuscular blockade",management:"Monito"}],comments:["In general, Tazobactam is a more potent beta-lactamase inhibitor than Sulbactam.","Previously some lot numbers of commercial Piperacillin-tazobactam contained Aspergillus antigens as a consequence of the fermentation process, with associated false-positive serum antigen tests for galactomannan. The problem is now resolved."]}},Cloxacillin:{id:"Cloxacillin",name:"Cloxacillin",tradename:"Cloxapen, Tegopen",classification:{family:"PENICILLIN",subclass:"Antistaphylococcal",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Staphylococcus aureus, methicillin-sensitive (MSSA)","Staphylococcus epidermidis, methicillin-susceptible (MSSE)","Staphylococcus lugdunensis","Staphylococcus sp., coagulase-negative (Methicillin susceptible); S. hominis, S. capitis, others"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No dosage adjustment for renal impairment",mild:"No dosage adjustment for renal impairment",moderate:"No dosage adjustment for renal impairment",severe:"No dosage adjustment for renal impairment"},hepatic:"No data",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Probenecid",effect:"↑ cloxacillin",management:"Monitor, adjust dosage"}],stewardship:{preferredIndications:["Staphylococcus aureus, methicillin-sensitive (MSSA)","Staphylococcus epidermidis, methicillin-susceptible (MSSE)","Staphylococcus lugdunensis","Staphylococcus sp., coagulase-negative (Methicillin susceptible); S. hominis, S. capitis, others"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"50",protein_binding:"95",half_life:"0.5",elimination:"Renal, other",csf_penetration:"1.8 (CMI 2020;26:1415.e1)",preparations:"Cap (250, 500 mg), Injection"},rawData:{drug_name:"Cloxacillin",tradename:"Cloxapen, Tegopen",usage_and_dosing:{general:["Cloxacillin is an oral anti-staphylococcal semi-synthetic penicillin resistant to penicillinase. Active versus MSSA but not MRSA.","Similar to Dicloxacillin, but Dicloxacillin blood levels are substantively higher. Hence, Dicloxacillin is the preferred oral anti-MSSA antibiotic.","Oral Cloxacillin is no longer available in the U.S.","Parenteral Cloxacillin was not approved in the U.S., but has been used elsewhere.","Use in CNS infection: See comments."],adult_dose:{oral:"250-500 mg po q6h",iv:{usual:"1-2 gm IV q6h",severe_infection:"2 gm IV q4h"}},pediatric_dose:{dose_age_gt_28_days:"50-200 mg/kg/day (divided q6h)",max_day:"-"}},renal_adjustment:{half_life_normal:"0.4",half_life_esrd:"0.7",dose_renal_function_normal:"250-500 mg po q6h",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No data",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No data",moderate_impairment_child_pugh_b:"No data",severe_impairment_child_pugh_c:"No data"},adverse_effects:["GI upset","Rash, hypersensitivity reaction","Hepatitis, interstitial nephritis, neutropenia"],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:["Staphylococcus aureus, methicillin-sensitive (MSSA)","Staphylococcus epidermidis, methicillin-susceptible (MSSE)","Staphylococcus lugdunensis","Staphylococcus sp., coagulase-negative (Methicillin susceptible); S. hominis, S. capitis, others"],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",preparations:"Cap (250, 500 mg), Injection",food_recommendation:"Cap no food",oral_absorption_percent:"50",tmax_hr:"1-1.5",peak_serum_conc_ug_ml:"7.5-14 (500 mg po, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"95",volume_of_distribution_vd_l_kg:"0.1 L/kg",avg_serum_half_life_hr:"0.5",elimination:"Renal, other",bile_penetration_percent:"No data",csf_blood_percent:"1.8 (CMI 2020;26:1415.e1)",therapeutic_levels_in_csf:"Possibly",auc_ug_hr_ml:"No data"},major_drug_interactions:[{drug:"Probenecid",effect:"↑ cloxacillin",management:"Monitor, adjust dosage"}],comments:["Oral Cloxacillin has been used in treatment of Staph. aureus skin and skin structure infections.","Use of oral Cloxacillin for completion of osteomyelitis therapy after initial intravenous treatment has been described (J Infect Dis 155:968, 1987).","Use in staphylococcal CNS infection: Very limited historical data suggest cloxacillin can achieve bactericidal titers in the CSF when used in large doses of 12-18 grams/day (J Antimicrob Chemother 1983;12:607)."]}},Dicloxacillin:{id:"Dicloxacillin",name:"Dicloxacillin",tradename:"Dynapen",classification:{family:"PENICILLIN",subclass:"Antistaphylococcal",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Staphylococcus aureus, methicillin-sensitive (MSSA)","Staphylococcus epidermidis, methicillin-susceptible (MSSE)","Staphylococcus lugdunensis","Staphylococcus sp., coagulase-negative (Methicillin susceptible); S. hominis, S. capitis, others"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No adjustment",mild:"No adjustment",moderate:"Reduce dose",severe:"Reduce dose significantly"},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Use with caution",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Probenecid",effect:"Unknown effect",management:"Monitor closely"},{drug:"Warfarin",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:["Staphylococcus aureus, methicillin-sensitive (MSSA)","Staphylococcus epidermidis, methicillin-susceptible (MSSE)","Staphylococcus lugdunensis","Staphylococcus sp., coagulase-negative (Methicillin susceptible); S. hominis, S. capitis, others"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:37,protein_binding:98,half_life:null,elimination:"Renal, biliary",csf_penetration:null,preparations:""},rawData:{drug_name:"Dicloxacillin",tradename:"Dynapen",drug_shortage_info:{prep:"250, 500 mg caps",started_at:"2021-08-18",notes:""},usage_and_dosing:{general_info:["Dicloxacillin is an oral anti-staphylococcal penicillinase-resistant penicillin.","Efficacious against Methicillin-sensitive Staph. aureus (MSSA) but not Methicillin-resistant Staph. aureus (MRSA).","Similar to Cloxacillin, but Dicloxacillin blood levels are twice as high. Hence, Dicloxacillin is preferred for oral therapy."],adult_dose:"125-500 mg po q6h; take 1h before or 2h following meals",pediatric_dose:[{condition:"mild-moderate infection",dose:"12.5-25 mg/kg/day (divided q6h)"},{condition:"osteoarticular infection",dose:"100 mg/kg/day (divided q6h)"}],renal_adjustment:{half_life_hrs_renal_function_normal:.7,half_life_hrs_esrd:"No change",dose_renal_function_normal:"125-500 mg po q6h",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No data",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:"No dosage adjustment"},adverse_effects:["Fever, rash (4%), eosinophilia, nausea/vomiting, diarrhea, C. difficile colitis (rare), increased BUN/Creatinine (rare).","Acute hemorrhagic cystitis reported; also reports of acute abdominal pain and GI bleeding."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",use_during_lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity."},antimicrobial_spectrum:{preferred:["Staphylococcus aureus, methicillin-sensitive (MSSA)","Staphylococcus epidermidis, methicillin-susceptible (MSSE)","Staphylococcus lugdunensis","Staphylococcus sp., coagulase-negative (Methicillin susceptible); S. hominis, S. capitis, others"],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",pharmaceutical_preparations:"Cap (250, 500 mg)",food_rec_po_drugs:"Cap no food",oral_absorption_percent:37,tmax_hr:"1-1.5",peak_serum_conc_mcg_ml:"10-17 (500 mg po, SD)",protein_binding_percent:98,volume_of_distribution_vd:"0.1 L/kg",avg_serum_t1_2_hr:.7,elimination:"Renal, biliary",bile_penetration_percent:"5-8"},enzyme_transporter_mediated_interactions:{cyp450s_induced_by_drug:"CYP2C9, CYP2C19, CYP3A4",transporters_induced_by_drug:"PGP (intestinal)",impact_on_serum_drug_concentrations:"↓"},major_drug_interactions:[{drug:"Probenecid",effect_on_concentration:"↑ dicloxacillin",suggested_management:"Monitor, adjust dose"},{drug:"Warfarin",effect_on_concentration:"↓ warfarin (↓ INR)",suggested_management:"Monitor INR, adjust dose"}]}},Flucloxacillin:{id:"Flucloxacillin",name:"Flucloxacillin",tradename:"Floxapen, Lutropin, Staphcil",classification:{family:"PENICILLIN",subclass:"Antistaphylococcal",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Staphylococcus aureus, methicillin-sensitive (MSSA)","Staphylococcus epidermidis, methicillin-susceptible (MSSE)","Staphylococcus lugdunensis","Staphylococcus sp., coagulase-negative (Methicillin susceptible); S. hominis, S. capitis, others"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No adjustment",mild:"No adjustment",moderate:"Reduce dose",severe:"Reduce dose significantly"},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Use with caution",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Isavuconazonium",effect:"Unknown effect",management:"Monitor, adjust (EJCMID 2022)"},{drug:"Posaconazole",effect:"Unknown effect",management:"Monitor, adjust (JAC 2023 Apr 1)"},{drug:"Probenecid",effect:"Unknown effect",management:"Monitor, adjust"},{drug:"Tacrolimus",effect:"Unknown effect",management:"Monitor, adjust (Eur J Clin Pharmacol)"},{drug:"Voriconazole",effect:"Unknown effect",management:"Monitor, adjust (AAC 61:e0091)"},{drug:"Warfarin",effect:"Unknown effect",management:"Monitor INR, adjust (Int Med J 48:8)"}],stewardship:{preferredIndications:["Staphylococcus aureus, methicillin-sensitive (MSSA)","Staphylococcus epidermidis, methicillin-susceptible (MSSE)","Staphylococcus lugdunensis","Staphylococcus sp., coagulase-negative (Methicillin susceptible); S. hominis, S. capitis, others"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:50,protein_binding:95,half_life:null,elimination:"Renal",csf_penetration:null,preparations:""},rawData:{drug_name:"Flucloxacillin",tradename:"Floxapen, Lutropin, Staphcil",usage_and_dosing:{general_info:["An oral penicillinase-resistant antistaphylococcal antibiotic with activity similar to Dicloxacillin.","Not active vs. methicillin-resistant Staphylococcus aureus (MRSA).","Relatively poor activity vs. Strep. pyogenes; Penicillin G (IV) or Penicillin V (po) is preferred.","For oral use for MSSA, Flucloxacillin is interchangeable with Dicloxacillin.","Due to risk of cholestatic hepatitis, use only for severe infections. See Adverse Effects.","Allergy: Protocol for Flucloxacillin desensitization."],adult_dose:["Oral: 250-500 mg po q6h","Parenteral: 1-2 gm IV q4-6h"],pediatric_dose:[{age:"<2 yrs",dose:"62.5-125 mg po q6h or 25 mg/kg IV q4-6h"},{age:"2-10 yrs",dose:"125-250 mg po q6h or 25-50 mg/kg IV q6h"}],renal_adjustment:{half_life_hrs_renal_function_normal:.75,half_life_hrs_esrd:"No data",dose_renal_function_normal:["250-500 mg po q6h","1-2 gm IV q4-6h"],crcl_or_egfr:"Dosage recommendations not available. Consider 50% reduction if CrCl <10 mL/min",hemodialysis:"No data (not significantly removed by HD)",capd:"No data",crrt:"CVVH: 4 gm IV q8h",sled:"1 gm IV q4h"},hepatic_adjustment:"No data"},adverse_effects:["GI (nausea, vomiting, diarrhea, C. difficile infection)","Hypersensitivity","Cholestatic hepatitis:","Incidence estimated at 1 in 15,000 exposures.","Occurs more frequently in patients >55 years of age, in females, and in patients treated for >2 weeks.","Cholestasis can appear up to several weeks after the end of therapy and can take weeks to resolve.","Drug-induced liver injury (DILI) related to flucloxacillin is associated with HLA-B*57:01 in a genome-wide association study (Nat Genet 2009;41:816).","DILI is selective for flucloxacillin on the basis of HLA restriction, and no cross-reactivity with other beta-lactams is apparent. Given the low positive predictive value of this allele for DILI, testing is not a part of routine clinical practice (N Engl J Med 2019;381:2338).","Hematologic: leukopenia, anemia, thrombocytopenia."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",use_during_lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity."},antimicrobial_spectrum:{preferred:["Staphylococcus aureus, methicillin-sensitive (MSSA)","Staphylococcus epidermidis, methicillin-susceptible (MSSE)","Staphylococcus lugdunensis","Staphylococcus sp., coagulase-negative (Methicillin susceptible); S. hominis, S. capitis, others"],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",pharmaceutical_preparations:["Cap (250, 500 mg)","Oral syrup (125 mg/5 mL, 250 mg/5 mL)","Injection"],food_rec_po_drugs:"Cap no food",oral_absorption_percent:50,tmax_hr:"po: 1",peak_serum_conc_mcg_ml:"10 (250 mg po, SD)",protein_binding_percent:95,avg_serum_t1_2_hr:.75,elimination:"Renal"},enzyme_transporter_mediated_interactions:{cyp450s_induced_by_drug:"CYP3A4?",transporters_induced_by_drug:"PGP?",impact_on_serum_drug_concentrations:"↓"},major_drug_interactions:[{drug:"Isavuconazonium",effect_on_conc:"↓ isavuconazole",management:"Monitor, adjust (EJCMID 2022)"},{drug:"Posaconazole",effect_on_conc:"↓ posaconazole",management:"Monitor, adjust (JAC 2023 Apr 1)"},{drug:"Probenecid",effect_on_conc:"↑ flucloxacillin",management:"Monitor, adjust"},{drug:"Tacrolimus",effect_on_conc:"↓ tacrolimus",management:"Monitor, adjust (Eur J Clin Pharmacol)"},{drug:"Voriconazole",effect_on_conc:"↓ voriconazole",management:"Monitor, adjust (AAC 61:e0091)"},{drug:"Warfarin",effect_on_conc:"↓ warfarin",management:"Monitor INR, adjust (Int Med J 48:8)"}]}},Nafcillin:{id:"Nafcillin",name:"Nafcillin",tradename:"Unipen, Nafcil",classification:{family:"PENICILLIN",subclass:"Antistaphylococcal",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Staphylococcus aureus, methicillin-sensitive (MSSA)","Staphylococcus epidermidis, methicillin-susceptible (MSSE)","Staphylococcus lugdunensis","Staphylococcus sp., coagulase-negative (Methicillin susceptible); S. hominis, S. capitis, others"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No adjustment",mild:"No adjustment",moderate:"Reduce dose",severe:"Reduce dose significantly"},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Use with caution",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Dapsone",effect:"Unknown effect",management:"Monitor closely"},{drug:"Letermovir",effect:"Unknown effect",management:"Monitor closely"},{drug:"Probenecid",effect:"Unknown effect",management:"Monitor closely"},{drug:"Warfarin",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:["Staphylococcus aureus, methicillin-sensitive (MSSA)","Staphylococcus epidermidis, methicillin-susceptible (MSSE)","Staphylococcus lugdunensis","Staphylococcus sp., coagulase-negative (Methicillin susceptible); S. hominis, S. capitis, others"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"90-94",half_life:null,elimination:"Biliary",csf_penetration:"9-20",preparations:""},rawData:{drug_name:"Nafcillin",tradename:"Unipen, Nafcil",drug_shortage_info:{prep:"Injection",started_at:"2024-03-20",notes:""},usage_and_dosing:{general_info:["Nafcillin, approved by the US FDA in 1970, is a semi-synthetic penicillinase-resistant Penicillin used in the treatment of staphylococcal infections caused by methicillin-susceptible strains of Staph. aureus (MSSA).","Only available for IM/IV use."],adult_dose:"Usual dose (bacteremia with or without endocarditis): 2 gm IV/IM q4h",pediatric_dose:[{age:">28 Days",dose:"150-200 mg/kg/day (divided q6h)"}],renal_adjustment:{half_life_hrs_renal_function_normal:"0.5-1",half_life_hrs_esrd:"No change",dose_renal_function_normal:"2 gm IM/IV q4h",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No dosage adjustment",capd:"No dosage adjustment",crrt:"No dosage adjustment",sled:"No data"},hepatic_adjustment:{note:"If concomitant renal and hepatic dysfunction, reduce dose by 50%.",mild_impairment_child_pugh_class_a:"No dosage adjustment",moderate_impairment_child_pugh_class_b:"No dosage adjustment",severe_impairment_child_pugh_class_c:"No dosage adjustment"},other_adjustment:{ecmo:"See ECMO Drug Dosing Adjustment."}},adverse_effects:["Like all beta-lactams, main problem is allergic rash.","Neutropenia occurs in over 10% of patients treated for more than 3 weeks. WBC can fall below 1000 cells/µL. Reversible if Nafcillin therapy is stopped.","Rare AEs: Coombs+ hemolytic anemia; thrombocytopenia, C. difficile colitis, hypokalemia.","Eosinophilia in up to 22%."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",use_during_lactation:"No data, but adverse effects not expected. Monitor infant for GI toxicity."},antimicrobial_spectrum:{preferred:["Staphylococcus aureus, methicillin-sensitive (MSSA)","Staphylococcus epidermidis, methicillin-susceptible (MSSE)","Staphylococcus lugdunensis","Staphylococcus sp., coagulase-negative (Methicillin susceptible); S. hominis, S. capitis, others"],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",pharmaceutical_preparations:"Injection",peak_serum_conc_mcg_ml:"30 (500 mg IV, SD)",protein_binding_percent:"90-94",volume_of_distribution_vd:"27.1 L (Vss)",avg_serum_t1_2_hr:"0.5-1.0",elimination:"Biliary",bile_penetration_percent:">100",csf_blood_percent:"9-20",therapeutic_levels_in_csf:"Yes w/high doses",auc_mcg_hr_ml:"18.1 (500 mg IV, 0-inf)"},enzyme_transporter_mediated_interactions:{cyp450s_induced_by_drug:"CYP2C9 (?), CYP3A4",impact_on_serum_drug_concentrations:"↓"},major_drug_interactions:[{drug:"Dapsone",effect_on_concentration:"↓ dapsone",suggested_management:"Monitor"},{drug:"Letermovir",effect_on_concentration:"↓ letermovir",suggested_management:"Avoid co-administration"},{drug:"Probenecid",effect_on_concentration:"↑ nafcillin",suggested_management:"Monitor, adjust dosage"},{drug:"Warfarin",effect_on_concentration:"↓ warfarin",suggested_management:"Monitor INR, adjust dosage"}]}},Oxacillin:{id:"Oxacillin",name:"Oxacillin",tradename:"Prostaphlin",classification:{family:"PENICILLIN",subclass:"Antistaphylococcal",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Staphylococcus aureus, methicillin-sensitive (MSSA)","Staphylococcus epidermidis, methicillin-susceptible (MSSE)","Staphylococcus lugdunensis","Staphylococcus sp., coagulase-negative (Methicillin susceptible); S. hominis, S. capitis, others"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No adjustment",mild:"No adjustment",moderate:"Reduce dose",severe:"Reduce dose significantly"},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Use with caution",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Probenecid",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:["Staphylococcus aureus, methicillin-sensitive (MSSA)","Staphylococcus epidermidis, methicillin-susceptible (MSSE)","Staphylococcus lugdunensis","Staphylococcus sp., coagulase-negative (Methicillin susceptible); S. hominis, S. capitis, others"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"90-94",half_life:null,elimination:"Renal",csf_penetration:"10-15",preparations:""},rawData:{drug_name:"Oxacillin",tradename:"Prostaphlin",usage_and_dosing:{general_info:["Oxacillin is a semi-synthetic penicillinase-resistant penicillin used for parenteral therapy of infections due to methicillin-susceptible Staph. aureus (MSSA)."],adult_dose:"Usual dose: 1.5-2 gm IV q4h",pediatric_dose:[{age:">28 Days",dose:"150-200 mg/kg/day (divided q6h)"}],renal_adjustment:{half_life_hrs_renal_function_normal:"0.5-0.7",half_life_hrs_esrd:"No data",dose_renal_function_normal:"2 gm IV q4h",crcl_or_egfr:"Dosage recommendations not available",hemodialysis:"No data",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{note:"If concomitant renal and hepatic dysfunction, consider dosage reduction.",mild_impairment_child_pugh_class_a:"No dosage adjustment",moderate_impairment_child_pugh_class_b:"No dosage adjustment",severe_impairment_child_pugh_class_c:"No dosage adjustment"},other_adjustment:{ecmo:"See ECMO Drug Dosing Adjustment."}},adverse_effects:["Hypersensitivity (rash [4%], anaphylaxis)","Fever","Local phlebitis","Gastrointestinal: rare C. difficile infection","Hematologic: positive Coombs (rare), neutropenia (rare), eosinophilia (22%), thrombocytopenia (rare)","Hepatic dysfunction may occur with dose of ≥12 gm/day. LFTs usually increase 2-24 days after start of treatment, reversible.","Acute interstitial nephritis (less than methicillin)","In children, more rash and liver toxicity with Oxacillin as compared to Nafcillin (Clin Infect Dis 2002;34:50).","Headache, confusion (rare)"],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",use_during_lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity."},antimicrobial_spectrum:{preferred:["Staphylococcus aureus, methicillin-sensitive (MSSA)","Staphylococcus epidermidis, methicillin-susceptible (MSSE)","Staphylococcus lugdunensis","Staphylococcus sp., coagulase-negative (Methicillin susceptible); S. hominis, S. capitis, others"],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",pharmaceutical_preparations:"Injection",peak_serum_conc_mcg_ml:"43 (500 mg IV, SD)",protein_binding_percent:"90-94",volume_of_distribution_vd:"0.4 L/kg",avg_serum_t1_2_hr:"0.5-0.7",elimination:"Renal",bile_penetration_percent:25,csf_blood_percent:"10-15",therapeutic_levels_in_csf:"Yes w/high doses"},major_drug_interactions:[{drug:"Probenecid",effect_on_concentration:"↑ oxacillin",suggested_management:"Monitor, adjust dosage"}]}},"Sulbactam-durlobactam":{id:"Sulbactam_durlobactam",name:"Sulbactam-durlobactam",tradename:"Xacduro",classification:{family:"PENICILLIN",subclass:"Other",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No adjustment",mild:"No adjustment",moderate:"Reduce dose",severe:"Reduce dose significantly"},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Sulbactam: no evidence of toxicity in humans or animals. Durlobactam: no human data, evidence of skeletal variations in mice.",lactation:"Use with caution",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Probenecid",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"Sulbactam: 38, Durlobactam: 10",half_life:null,elimination:"Sulbactam: renal, Durlobactam: renal",csf_penetration:null,preparations:""},rawData:{drug_name:"Sulbactam-durlobactam",tradename:"Xacduro",usage_and_dosing:{general_info:["Sulbactam-durlobactam is a co-packaged product approved for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex in patients ≥18 years of age.","Sulbactam is a penicillanic acid sulfone. Besides functioning as an Ambler Class A beta-lactamase inhibitor, it has intrinsic antibacterial activity against Acinetobacter baumannii-calcoaceticus complex (via inhibition of PBP1a, PBP1b, and PBP3). Note that beta-lactamases of all four Ambler classes are able to degrade sulbactam (Front Microbiol 2021;12:709974).","Durlobactam is a diazabicyclooctane beta-lactamase inhibitor with broad-spectrum activity against Class A, C, and D enzymes, including Class D OXA carbapenemases that are prevalent in Acinetobacter baumannii. Durlobactam alone has no antibacterial activity against Acinetobacter baumannii-calcoaceticus complex isolates.","Reviews:","Expert Rev Anti Infect Ther 2025;23:67; Pharmacotherapy 2023;43:502.","Drug development: Clin Infect Dis 2023;76(Suppl 2):S163."],adult_dose:["(1 gm of sulbactam and 1 gm of durlobactam) IV (over 3 hr) q6h.","Compatible with NS. Compatibility with other solutions not established.","Recommended duration of treatment 7-14 days, guided by patient clinical status."],pediatric_dose:[{guidance:"AMR gram-negative guidance: J Pediatric Infect Dis Soc 2025;14:piaf004",fda:"Per FDA: Safety and efficacy not established",amr_guidance:"Per AMR gram-negative guidance: Infants/children: 200 mg/kg/day (of sulbactam), divided q4-6h Adolescents: use adult dosing",max_day:"6 gm (of sulbactam)"}],renal_adjustment:{half_life_hrs_renal_function_normal:"Sulbactam 2.15, Durlobactam 2.52",half_life_hrs_esrd:"No data",dose_renal_function_normal:"(Sul 1 gm + Durlo 1 gm) IV q6h",crcl_or_egfr:["CrCl ≥130: (Sul 1 gm + Durlo 1 gm) q4h","CrCl 45-129: No dosage adjustment","CrCl 30-44: (Sul 1 gm + Durlo 1 gm) q8h","CrCl 15-29: (Sul 1 gm + Durlo 1 gm) q12h","CrCl <15: (Sul 1 gm + Durlo 1 gm) q12h x3 doses, then q24h"],hemodialysis:"Use CrCl <15 dosing (dose AD on dialysis days)",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:"No dosage adjustment"},adverse_effects:["Hypersensitivity reactions","C. difficile-associated diarrhea","Liver function test abnormalities","Anemia","Hypokalemia"],pregnancy_risk:{fda_risk_category:"Sulbactam: no evidence of toxicity in humans or animals. Durlobactam: no human data, evidence of skeletal variations in mice.",use_during_lactation:"No data regarding effects on the breastfed infant or milk production. Sulbactam is present in milk in low concentrations; no data for durlobactam."},pharmacology:{pk_pd_index:"Sulbactam: T>MIC, Durlobactam: 24h-hr AUC/MIC",pharmaceutical_preparations:"Injection",peak_serum_conc_mcg_ml:"Sulbactam: 32.4 (1 gm q6h, SS), Durlobactam: 29.2 (1 gm q6h, SS)",protein_binding_percent:"Sulbactam: 38, Durlobactam: 10",volume_of_distribution_vd:"Sulbactam: 25.4 L (Vss), Durlobactam: 30.3 L (Vss)",avg_serum_t1_2_hr:"Sulbactam: 2.15, Durlobactam: 2.52",elimination:"Sulbactam: renal, Durlobactam: renal",auc_mcg_hr_ml:"Sulbactam: 515 (1 gm q6h, 0-24h), Durlobactam: 471 (1 gm q6h, 0-24h)"},enzyme_transporter_mediated_interactions:{transporters_that_drug_is_a_substrate_for:"Sulbactam: OAT1, OAT3",impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:[{drug:"Probenecid",effect_on_concentration:"↑ sulbactam",suggested_management:"Avoid co-administration"}]}},Temocillin:{id:"Temocillin",name:"Temocillin",tradename:"",classification:{family:"PENICILLIN",subclass:"Other",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No adjustment",mild:"No adjustment",moderate:"Reduce dose",severe:"Reduce dose significantly"},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Use with caution",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"70-85",half_life:null,elimination:"Renal",csf_penetration:"8-15",preparations:""},rawData:{drug_name:"Temocillin",usage_and_dosing:{general_info:["Temocillin is a 6-a-methoxy derivative of Ticarcillin (discontinued) with excellent stability in the presence of beta-lactamases from Gram-negative bacilli, including TEM, CTX-M and AmpC beta-lactamases. Stable against some metallo-beta-lactamases.","The weakness of Temocillin is the lack of activity against anaerobic bacteria and P. aeruginosa. Good in vitro activity against B. cepacia.","Outside of the USA, used in the treatment of susceptible bacteria causing:","UTI","Bacteremia","Pneumonia","For availability, contact Eumedica Pharmaceuticals (Belgium): www.eumedica.com, + 32 64 27 1738. Temocillin is not available in the U.S."],adult_dose:{usual_dose_intermittent:"2 gm IV q12h",critically_ill_patients:"2 gm IV q8h (See Continuous Infusion for alternative dosing approach)"},pediatric_dose:[{age:">28 Days",dose:"50 mg/kg/day (divided q12h)"}],renal_adjustment:{half_life_hrs_renal_function_normal:4,half_life_hrs_esrd:"No data",dose_renal_function_normal:"1-2 gm IV q12h",crcl_or_egfr:["CrCl >50: No dosing adjustment","CrCl 30-50: 1-2 gm q24h","CrCl 10-30: 1 gm q48h"],hemodialysis:"1 gm q48h (give AD on dialysis days)",capd:"1 gm q48h",crrt:"No data",sled:"No data"},hepatic_adjustment:"No dosage adjustment"},adverse_effects:["Maculopapular rash, C. difficile colitis reported."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",use_during_lactation:"No data"},antimicrobial_spectrum:["No activity against Gram-positive organisms, anaerobes or P. aeruginosa.","Broadly active against aerobic Gram-negative bacilli, including organisms that produce AmpC and extended-spectrum beta-lactamases (ESBLs)."],pharmacology:{pk_pd_index:"T>MIC",pharmaceutical_preparations:"Injection",peak_serum_conc_mcg_ml:"150-200 (2 gm IV, SD)",protein_binding_percent:"70-85",volume_of_distribution_vd:"0.2 L/kg",avg_serum_t1_2_hr:4,elimination:"Renal",bile_penetration_percent:"800-1000",csf_blood_percent:"8-15",auc_mcg_hr_ml:"785 (2 gm IV, 0-inf)"},major_drug_interactions:"No significant interactions identified.",comments:["Good PK/PD review: Clin Pharmacokinet 57:287, 2018.","Use as narrow spectrum therapy, see: Future Microbiol 14(2): 81, 2019"]}},"Penicillin VK":{id:"Penicillin_VK",name:"Penicillin VK",tradename:"",classification:{family:"PENICILLIN",subclass:"Penicillin",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Actinomyces sp.","Corynebacterium diphtheriae","Pasteurella multocida","Peptostreptococci","Streptococcus agalactiae, beta hemolytic, Group B Strep.","Streptococcus anginosus (S. milleri) group, includes S. anginosis, S. constellatus, S. intermedius","Streptococcus pneumoniae","Streptococcus pyogenes, beta hemolytic, Group A Strep.","Streptococcus, beta-hemolytic, Groups C, F, G"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No dosage adjustment for renal impairment",mild:"No dosage adjustment for renal impairment",moderate:"No dosage adjustment for renal impairment",severe:"No dosage adjustment for renal impairment"},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No evidence of toxicity in humans or animals",lactation:"Use with caution",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Probenecid",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:["Actinomyces sp.","Corynebacterium diphtheriae","Pasteurella multocida","Peptostreptococci","Streptococcus agalactiae, beta hemolytic, Group B Strep.","Streptococcus anginosus (S. milleri) group, includes S. anginosis, S. constellatus, S. intermedius","Streptococcus pneumoniae","Streptococcus pyogenes, beta hemolytic, Group A Strep.","Streptococcus, beta-hemolytic, Groups C, F, G"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"60-73",protein_binding:"65",half_life:null,elimination:"Renal",csf_penetration:"No data",preparations:""},rawData:{drug_name:"Penicillin VK",drug_shortage_information:[{prep:"250 mg, 500 mg tabs",started_at:"2023-05-17",notes:null},{prep:"250 mg/5 mL oral solution",started_at:"2023-05-17",notes:null}],usage_and_dosing:{description:["Penicillin VK is the preferred form of penicillin for oral use. It is the potassium salt of phenoxymethylpenicillin.","Allergic reactions are a major issue. 10% of all hospital admissions give history of Penicillin allergy, but only 10% have allergic reaction if given Penicillin VK. Why? Possible reasons: inaccurate history, waning immunity with age, aberrant response during viral illness.","See Oral Penicillin Desensitization.","Note regarding Penicillin skin testing for evaluation of Penicillin allergy:","Testing with major determinant (benzyl Penicillin polylysine) and minor determinants has negative predictive value of 97-99%. Risk of systemic reaction to skin testing < 1%. See Ann Allergy, Asthma & Immunol 106:1, 2011.","Allergy references: Am J Med 121:572, 2008; N Engl J Med 354:601, 2006.","See also Beta-lactams, Drug Allergy, Overview.","Conversion: 250 mg = 400,000 units"]},adult_dose:{usual_dose:"250-500 mg po tid-qid before meals and at bedtime"},pediatric_dose:{dose_age_gt_28_days:"25-75 mg/kg/day (divided q6-8h)",max_day:null},renal_adjustment:{guidance:["Body weight and Creatinine Clearance calculations","CrCl = Creatinine clearance (mL/min)","CAPD = Continuous Ambulatory Peritoneal Dialysis","CRRT = Continuous Renal Replacement Therapy","AD = after hemodialysis","SLED = sustained low efficiency dialysis"],half_life_hrs_renal_function_normal:"0.5",half_life_hrs_esrd:"4.1",dose_renal_function_normal:"250-500 mg po q6-8h",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No dosage adjustment (give one or more doses AD)",capd:"No dosage adjustment",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_class_a:"No dosage adjustment",moderate_impairment_child_pugh_class_b:"No dosage adjustment",severe_impairment_child_pugh_class_c:"No dosage adjustment"},adverse_effects:["Most serious reaction is immediate IgE-mediated anaphylaxis; incidence only 0.05% but 5-10% fatal. Other IgE-mediated reactions: urticaria, angioedema, laryngeal edema, bronchospasm. Morbilliform rash after 72 hours is not IgE-mediated and not serious.","Serious late allergic reactions: Coombs-positive hemolytic anemia, neutropenia, thrombocytopenia, serum sickness, interstitial nephritis, hepatitis, eosinophilia, drug fever."],pregnancy_risk:{fda_risk_category:"No evidence of toxicity in humans or animals",use_during_lactation:"Milk concentrations low, adverse effects not expected. Monitor infant for Gl toxicity."},antimicrobial_spectrum:{preferred:["Actinomyces sp.","Corynebacterium diphtheriae","Pasteurella multocida","Peptostreptococci","Streptococcus agalactiae, beta hemolytic, Group B Strep.","Streptococcus anginosus (S. milleri) group, includes S. anginosis, S. constellatus, S. intermedius","Streptococcus pneumoniae","Streptococcus pyogenes, beta hemolytic, Group A Strep.","Streptococcus, beta-hemolytic, Groups C, F, G"],alternative:[]},pharmacology:{pk_pd_index:"T>MIC",pharmaceutical_preparations:"Tab (250, 500 mg), oral soln (125 mg/5 mL, 250 mg/5 mL)",food_rec_po_drugs:"All preps no food",oral_absorption_percent:"60-73",tmax_hr:"No data",peak_serum_conc_ug_ml:"5-6 (500 mg po, SD)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"65",volume_of_distribution_vd:"No data",avg_serum_t1_2_hr:"0.5",elimination:"Renal",bile_penetration_percent:"No data",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"No data"},enzyme_transporter_mediated_interactions:{cy_p450s_that_drug_is_a_substrate_for:null,transporters_that_drug_is_a_substrate_for:"OAT1, OAT3",ug_ts_that_drug_is_a_substrate_for:null,cy_p450s_inhibited_by_drug:null,transporters_inhibited_by_drug:null,ug_ts_inhibited_by_drug:null,cy_p450s_induced_by_drug:null,transporters_induced_by_drug:null,ug_ts_induced_by_drug:null,impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:[{drug:"Probenecid",effect_on_concentration:"↑ penicillin",suggested_management:"Monitor, adjust dosage"}]}},Lefamulin:{id:"Lefamulin",name:"Lefamulin",tradename:"Xenleta",classification:{family:"PLEUROMUTILIN",subclass:"Pleuromutilin",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:[],alternative:["S. pneumoniae","H. influenzae","M. pneumoniae, C. pneumoniae, and Legionella pneumophila","MSSA","MRSA","M. catarrhalis","Other streptococcal species","H. parainfluenzae","Active vs STD pathogens, including Chlamydia trachomatis, Mycoplasma genitalium, and Neisseria gonorrhoeae","No activity vs gram-negative enteric bacilli or Ps. aeruginosa"],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No adjustment",mild:"No adjustment",moderate:"Reduce dose",severe:"Reduce dose significantly"},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"May cause fetal harm, based on toxicity in animal studies",lactation:"Use with caution",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Alprazolam",effect:"Unknown effect",management:"Monitor closely"},{drug:"Amiodarone",effect:"Unknown effect",management:"Monitor closely"},{drug:"Antipsychotics",effect:"Unknown effect",management:"Monitor closely"},{drug:"Diltiazem",effect:"Unknown effect",management:"Monitor closely"},{drug:"Fluoroquinolones",effect:"Unknown effect",management:"Monitor closely"},{drug:"Ketoconazole",effect:"Unknown effect",management:"Monitor closely"},{drug:"Macrolides",effect:"Unknown effect",management:"Monitor closely"},{drug:"Midazolam (po)",effect:"Unknown effect",management:"Monitor closely"},{drug:"Pimozide",effect:"Unknown effect",management:"Monitor closely"},{drug:"Procainamide",effect:"Unknown effect",management:"Monitor closely"},{drug:"Quinidine",effect:"Unknown effect",management:"Monitor closely"},{drug:"Rifampin",effect:"Unknown effect",management:"Monitor closely"},{drug:"Simvastatin",effect:"Unknown effect",management:"Monitor closely"},{drug:"Sotalol",effect:"Unknown effect",management:"Monitor closely"},{drug:"Tricyclic antidepressants",effect:"Unknown effect",management:"Monitor closely"},{drug:"Vardenafil",effect:"Unknown effect",management:"Monitor closely"},{drug:"Verapamil",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:25,protein_binding:"94.8-97.1",half_life:null,elimination:"Metabolized",csf_penetration:null,preparations:""},rawData:{drug_name:"Lefamulin",tradename:"Xenleta",usage_and_dosing:{general_info:["Lefamulin, a pleuromutilin antibacterial, is approved for the IV and oral treatment of adults with community-acquired pneumonia (CAP) caused by susceptible strains of S. pneumoniae, S. aureus (MSSA), H. influenzae, L. pneumophila, M. pneumoniae, and C. pneumoniae.","Although active in vitro, Lefamulin is not approved for CAP caused by resistant Staph. aureus (MRSA) due to limited clinical data.","No in vitro activity vs Enterobacteriaceae or Ps.aeruginosa.","As effective as moxifloxacin in controlled clinical trials of community-acquired bacterial pneumonia: Clin Infect Dis 2019;69:1856","Pleuromutilins inhibit bacterial protein synthesis by binding to the peptidyl transferase center of the 50S bacterial ribosome, thereby preventing the binding of tRNA for peptide transfer.","Cautions","Animal studies suggest lefamulin may cause harm if administered to a pregnant woman. Verify pregnancy status in females of reproductive potential before using. Safety in lactation is unknown; breastfeeding women should pump and discard milk for the duration of treatment and for two days after the final dose.","Numerous drug interactions (see chart below, not all-inclusive). Lefamulin metabolized by CYP3A4 and hence can interact with drugs that are inhibitors or inducers of CYP3A4 or drugs that are substrates of CYP34A enzymes","Lefamulin may prolong the QTc interval. Avoid concomitant use with other drugs that can prolong the QTc interval and thereby increase the risk of ventricular arrhythmias.","Reference: Med Lett Drugs Ther 2019;61:145"],adult_dose:[{route:"Oral",recommended_dose:"600 mg po q12h",treatment_duration:"5 days"},{route:"Intravenous",recommended_dose:"150 mg IV (over 60 min) q12h",treatment_duration:"5-7 days"}],pediatric_dose:{age:">28 Days",safety_and_efficacy:"not established"},renal_adjustment:{half_life_hrs_renal_function_normal:8,half_life_hrs_esrd:"Unchanged",dose_renal_function_normal:["600 mg po q12h","150 mg IV q12h"],crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No dosage adjustment",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_class_a:{injection:"no dosage adjustment",tablets:"no dosage adjustment"},moderate_impairment_child_pugh_class_b:{injection:"no dosage adjustment",tablets:"no data, not recommended"},severe_impairment_child_pugh_class_c:{injection:"dosage to 150 mg q24h",tablets:"no data, no recommended"}}},adverse_effects:["Gastrointestinal (nausea, vomiting, diarrhea, C. difficile-associated diarrhea).","In the phase 3 FDA registration trial vs moxifloxacin for CAP, the incidence of GI side effects was 17.9% in the Lefamulin patients vs 7.6% in the moxifloxacin patients: JAMA.2019;322:1661.","Headache, insomnia.","Injection site reactions.","Elevation in hepatic transaminases.","QT-interval prolongation."],pregnancy_risk:{fda_risk_category:"May cause fetal harm, based on toxicity in animal studies",use_during_lactation:"Avoid use; pump and discard milk for tx duration and two days post."},antimicrobial_spectrum:{preferred:[],alternative:["S. pneumoniae","H. influenzae","M. pneumoniae, C. pneumoniae, and Legionella pneumophila","MSSA","MRSA","M. catarrhalis","Other streptococcal species","H. parainfluenzae","Active vs STD pathogens, including Chlamydia trachomatis, Mycoplasma genitalium, and Neisseria gonorrhoeae","No activity vs gram-negative enteric bacilli or Ps. aeruginosa"]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",pharmaceutical_preparations:["Tab (600 mg)","Injection"],oral_absorption_percent:25,tmax_hr:"po: 0.88-2.0",peak_serum_conc_mcg_ml:{iv:"3.6 (150 mg IV q12h, SS)",po:"2.24 (600 mg po q12h, SS)"},protein_binding_percent:"94.8-97.1",volume_of_distribution_vd:"86.1 L (Vss)",avg_serum_t1_2_hr:8,elimination:"Metabolized",auc_mcg_hr_ml:{iv:"28.6 (150 mg IV q12h, 0-24 hr)",po:"32.7 (600 mg po q12h, 0-24 hr)"}},enzyme_transporter_mediated_interactions:{cyp450s_that_drug_is_a_substrate_for:"CYP3A4",cyp450s_inhibited_by_drug:"CYP3A4",impact_on_serum_drug_concentrations:"↑"},major_drug_interactions:[{drug:"Alprazolam",effect_on_concentration_or_other:"↑ alprazolam",suggested_management:"Monitor, adjust dosa"},{drug:"Amiodarone",effect_on_concentration_or_other:"↑ amiodarone, ↑ QT interval",suggested_management:"Avoid co-administrat"},{drug:"Antipsychotics",effect_on_concentration_or_other:"↑ QT interval",suggested_management:"Avoid co-administrat"},{drug:"Diltiazem",effect_on_concentration_or_other:"↑ diltiazem",suggested_management:"Monitor, adjust dosa"},{drug:"Fluoroquinolones",effect_on_concentration_or_other:"↑ QT interval",suggested_management:"Avoid co-administrat"},{drug:"Ketoconazole",effect_on_concentration_or_other:"↑ lefamulin",suggested_management:"Avoid co-administrat"},{drug:"Macrolides",effect_on_concentration_or_other:"↑ QT interval",suggested_management:"Avoid co-administrat"},{drug:"Midazolam (po)",effect_on_concentration_or_other:"↑ midazolam",suggested_management:"Avoid co-administrat"},{drug:"Pimozide",effect_on_concentration_or_other:"↑ pimozide, ↑ QT interval",suggested_management:"Contraindicated"},{drug:"Procainamide",effect_on_concentration_or_other:"↑ QT interval",suggested_management:"Avoid co-administrat"},{drug:"Quinidine",effect_on_concentration_or_other:"↑ quinidine, ↑ QT interval",suggested_management:"Avoid co-administrat"},{drug:"Rifampin",effect_on_concentration_or_other:"↓ lefamulin",suggested_management:"Avoid co-administrat"},{drug:"Simvastatin",effect_on_concentration_or_other:"↑ simvastatin",suggested_management:"Monitor, adjust dosa"},{drug:"Sotalol",effect_on_concentration_or_other:"↑ QT interval",suggested_management:"Avoid co-administrat"},{drug:"Tricyclic antidepressants",effect_on_concentration_or_other:"↑ QT interval",suggested_management:"Avoid co-administrat"},{drug:"Vardenafil",effect_on_concentration_or_other:"↑ vardenafil",suggested_management:"Monitor, adjust dosa"},{drug:"Verapamil",effect_on_concentration_or_other:"↑ verapamil",suggested_management:"Monitor, adjust dosa"}]}},Retapamulin:{id:"Retapamulin",name:"Retapamulin",tradename:"Altabax",classification:{family:"PLEUROMUTILIN",subclass:"Pleuromutilin",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:["Staph. aureus","Strep. pyogenes"],alternative:["Active vs. some Staph. aureus strains resistant to Mupirocin"],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No adjustment",mild:"No adjustment",moderate:"Reduce dose",severe:"Reduce dose significantly"},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"B",lactation:"Use with caution",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Unknown",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:["Staph. aureus","Strep. pyogenes"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:94,half_life:null,elimination:"Metabolized",csf_penetration:null,preparations:""},rawData:{drug_name:"Retapamulin",tradename:"Altabax",usage_and_dosing:{general_info:["Member of pleuromutilin class; a topical antibacterial.","For therapy of impetigo due to Strep. pyogenes or Staph. aureus.","Microbiologic success in 90% of Staph. aureus infections and 97% of Strep. pyogenes infections (J Am Acad Derm 55:1003, 2006).","Package insert says do not use for MRSA (not enough patients in clinical trials). Retapamulin active in vitro vs MRSA.","Reference: Clin Infect Dis 49:1541, 2009, Clin Micro Rev 30(3): 827, 2017."],adult_dose:"1% ointment; apply to affected area bid x 5 days",pediatric_dose:{age:"≥9 mon",dose:"apply q12h x5 days (max area up to 2% BSA)"},renal_adjustment:{half_life_hrs_renal_function_normal:"No data",half_life_hrs_esrd:"No data",dose_renal_function_normal:"Apply q12h x5 days",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No data",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:"No dosage adjustment"},adverse_effects:["Pruritis, at application site, 2%.","Local irritation."],pregnancy_risk:{fda_risk_category:"B",use_during_lactation:"Safety not established, avoid use"},antimicrobial_spectrum:{preferred:["Staph. aureus","Strep. pyogenes"],alternative:["Active vs. some Staph. aureus strains resistant to Mupirocin"]},pharmacology:{pk_pd_index:"No data",pharmaceutical_preparations:"1% ointment",peak_serum_conc_mcg_ml:"Low, not always measurable",protein_binding_percent:94,elimination:"Metabolized"},enzyme_transporter_mediated_interactions:{cyp450s_that_drug_is_a_substrate_for:"CYP3A4",impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:["Avoid coadministration with strong CYP3A4 inhibitors in children <24 months old."],comments:["Not for intranasal, intravaginal, oral or ophthalmic use."]}},"Polymyxin E, Colistin":{id:"Polymyxin_E_Colistin",name:"Polymyxin E, Colistin",tradename:"",classification:{family:"POLYMYXIN",subclass:"Polymyxin",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No adjustment",mild:"No adjustment",moderate:"Reduce dose",severe:"Reduce dose significantly"},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"C",lactation:"Probably safe with monitoring, but data limited",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Aminoglycosides",effect:"↑ risk of nephrotoxicity, neuromuscular blockade",management:"Avoid co-administration"},{drug:"Amphotericin B",effect:"↑ risk of nephrotoxicity",management:"Avoid co-administration"},{drug:"Contrast agents",effect:"↑ risk of nephrotoxicity",management:"Avoid co-administration"},{drug:"Pancuronium (and other curare-like drugs)",effect:"↑risk of neuromuscular blockade",management:"Avoid co-administration"},{drug:"Vancomycin",effect:"↑ risk of nephrotoxicity",management:"Avoid co-administration"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"≈ 50",half_life:null,elimination:"Renal",csf_penetration:"Poor",preparations:""},rawData:{drug_name:"Polymyxin E, Colistin",usage_and_dosing:{description:"Polymyxin E (Colistin) is a parenteral antibiotic active against multi-drug resistant (MDR) gram negative bacilli, e.g., A. baumanii, P. aeruginosa, E. coli, K. pneumoniae.",preferred_for:["Urinary tract infections (UTI)","Adjunctive inhalation therapy for pneumonia caused by MDR gram-negative bacilli"],notes:["For all indications other than UTI, polymyxin B is preferred over colistin because of equivalent efficacy, faster attainment of target serum concentrations, less interpatient variability in pharmacokinetics, no dose adjustment for renal impairment and lower risk of renal toxicity (Antimicrob Agents Chemother 2016;60: 2443; Antimicrob Agents Chemother 2017:61: e02319-16).","Serratia sp, Proteus sp., Providencia sp., Morganella sp., and B. cepacia are intrinsically resistant to polymyxins.","Pan-resistant strains of Enterobacterales, including resistant to colistin mediated by plasmid-encoded gene mcr-1, have been identified worldwide.","See Comments for further discussion of resistance and allergy.","Colistin is formulated as a prodrug, colistimethate (CMS). Product vials may be labeled as international units (IU) or mg of CMS, or mg of colistin base activity (CBA). Always dose based on the CBA.","Conversions: 1 mg CBA = 30,000 IU CMS = 2.4 mg CMS","Dosing recommendations continue to evolve. The Sanford Guide favors the International Consensus Guidelines endorsed by IDSA, ESCMID, and other professional organizations (Pharmacotherapy 2019;39:10). For background, see Clin Infect Dis 2016;62:552; Clin Infect Dis 2017;64:565.","See Colistin Dosing Calculator to facilitate Guideline dosing. The calculator also provides EMA recommendations."],adult_dose:{loading_dose:{calculation:"4 x (body weight in kg), infused over 30-60 min.",notes:["Dose expressed as CBA.","Use lower of ideal body weight or actual body weight.","May result in a dose >300 mg CBA.","Start maintenance dosing 12 hours later."]},maintenance_dose:{crcl_ge_90:"180 mg IV (infuse over 30-60 min) q12h.",notes:["Dose expressed as CBA.","See Renal Adjustment section if CrCl <90 mL/min."]},inhalation_therapy:"See Inhalation Dosing & Therapy",intraventricular_or_intrathecal_administration:"10 mg/day x several weeks; intrathecal dose often combined with IV dosing."},pediatric_dose:[{type:"standard",dose:"2.5-5 mg/kg/day (divided q6-12h)"},{type:"CF",dose:"3-8 mg/kg/day (divided q8h)"}]},renal_adjustment:{notes:["Body weight and Creatinine Clearance calculations","CrCl = Creatinine clearance (mL/min)","CAPD = Continuous Ambulatory Peritoneal Dialysis","CRRT = Continuous Renal Replacement Therapy","AD = after hemodialysis","SLED = sustained low efficiency dialysis","NOTE: Doses are expressed as mg CBA."],half_life:{normal:"6.3-12",esrd:"≥48"},dosing:[{renal_function:"normal",dose:"Load: 4 x (wt in kg) Maintenance: 180 mg q12h"},{renal_function:"CrCl ≥90",dose:"180 mg q12h"},{renal_function:"CrCl 80 to <90",dose:"170 mg q12h"},{renal_function:"CrCl 70 to <80",dose:"150 mg q12h"},{renal_function:"CrCl 60 to <70",dose:"137.5 mg q12h"},{renal_function:"CrCl 50 to <60",dose:"122.5 mg q12h"},{renal_function:"CrCl 40 to <50",dose:"110 mg q12h"},{renal_function:"CrCl 30 to <40",dose:"97.5 mg q12h"},{renal_function:"CrCl 20 to <30",dose:"87.5 mg q12h"},{renal_function:"CrCl 10 to <20",dose:"80 mg q12h"},{renal_function:"CrCl 5 to <10",dose:"72.5 mg q12h"},{renal_function:"CrCl <5",dose:"65 mg q12h"},{renal_function:"Hemodialysis",dose:"Non-HD days: give 65 mg IV q12h. HD days: give supplemental dose of 40-50 mg after a 3-4 hr session. Give this supplement with the next regular dose after the dialysis has ended."},{renal_function:"CAPD",dose:"No data"},{renal_function:"CRRT",dose:"220 mg q12h"},{renal_function:"SLED",dose:"Add 13 mg per hour of SLED to the baseline dose of 65 mg q12h. Ex: For 10 hr SLED, dose is 130 mg q12h."}]},hepatic_adjustment:[{impairment:"Mild impairment (Child-Pugh Class A)",adjustment:"No dosage adjustment"},{impairment:"Moderate impairment (Child-Pugh Class B)",adjustment:"No dosage adjustment"},{impairment:"Severe impairment (Child-Pugh Class C)",adjustment:"No dosage adjustment"}],other_adjustment:[{condition:"ECMO",adjustment:"See ECMO Drug Dosing Adjustment."},{condition:"Obesity",adjustment:"See Obesity Dosing Adjustments."}],adverse_effects:{nephrotoxicity:{description:"Reversible acute tubular necrosis due to localization of drug in proximal tubular cells: Antimicrob Agents Chemother 2017;61:e02319-16.",incidence:"Depending on criteria, incidence of toxicity varies, average around 25%.",risk_factors:"length of therapy, daily dose, and cumulative dose; exposure to concomitant nephrotoxins; obesity, diabetes mellitus, age and hypertension.",notes:["In animal models, high dose ascorbic acid and melatonin prevented toxicity.","In critically ill, the benefit of patient salvage may exceed the risk of nephrotoxicity."]},neurotoxicity:"Frequent vertigo, facial paresthesias, abnormal vision, confusion, ataxia. Rarely, neuromuscular blockade results in respiratory failure; may unmask or exacerbate myasthenia gravis. In cystic fibrosis patients, 29% experienced paresthesias, ataxia or both.",other:"Maybe hyperpigmentation (Clin Infect Dis 2007;45:136)."},pregnancy_risk:{fda_risk_category:"C",lactation:"Probably safe with monitoring, but data limited"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"Free AUC/MIC",pharmaceutical_preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"0.83 (30 mg CBA IV, SD) 24",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"≈ 50",volume_of_distribution_l_kg:"0.17 L/kg 24",avg_serum_t1_2_hr:"6.3-12",elimination:"Renal",bile_penetration_percent:"No data",csf_blood_percent:"Poor",therapeutic_levels_in_csf:"No",auc_ug_hr_ml:"11.5-225 (СВА 75-410 mg/day IV, 0-24h)"},major_drug_interactions:[{drug:"Aminoglycosides",effect:"↑ risk of nephrotoxicity, neuromuscular blockade",management:"Avoid co-administration"},{drug:"Amphotericin B",effect:"↑ risk of nephrotoxicity",management:"Avoid co-administration"},{drug:"Contrast agents",effect:"↑ risk of nephrotoxicity",management:"Avoid co-administration"},{drug:"Pancuronium (and other curare-like drugs)",effect:"↑risk of neuromuscular blockade",management:"Avoid co-administration"},{drug:"Vancomycin",effect:"↑ risk of nephrotoxicity",management:"Avoid co-administration"}],comments:{resistance_and_treatment_issues:["For comprehensive review of polymyxin resistance: Infect Dis Clin North Am 2020;34:723.","The plasmid-encoded colistin resistance gene, mcr-1, has been found in E. coli and Klebsiella sp. Resistance is due to modification of the lipid A target of the polymyxins. Strains may also produce metallo-carbapenemases, resulting in pan-resistance (See Lancet Infect Dis 2016;16:161; Lancet Infect Dis 2016;16:287; Antimicrob Agents Chemother 2016;60:4420).","No clear alternatives for a companion drug with colistin.","Combination therapy with rifampin did not improve clinical response or 30-day mortality in patients with Actinetobacter infections (Clin Infect Dis 2013;57:349; Epidemiol Infect 2013;141:1214).","Combination therapy with a polymyxin (either colistin or polymyxin B) plus a carbapenem is no longer recommended for treatment of carbapenem-resistant strains of Enterobacteriaceae (KPCs), Acinetobacter sp., and P. aeruginosa.","The combination of colistin + meropenem was no more effective than colistin monotherapy in a prospective randomized controlled clinical trial (Lancet Infect Dis 2018;18:391).","Most (77%) of the infections were due to A. baumannii; the trial was underpowered to address efficacy vs KPCs and P. aeruginosa.","In vitro, colistin, in combination with both rifampin and azithromycin, was able to overcome mcr-1 mediated resistance (Antimicrob Agents Chemother 2018;62:e01631-18).","In vitro and in vivo exposure to polymyxins results in rapid selection of resistant subpopulations. In vitro, minocycline prevented emergence of resistance and augmented colistin activity, but no clinical trial data. Tigecycline may function similarly, but no data."]}}},"Polymyxin B":{id:"Polymyxin_B",name:"Polymyxin B",tradename:"Poly-Rx",classification:{family:"POLYMYXIN",subclass:"Polymyxin",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No adjustment",mild:"No adjustment",moderate:"Reduce dose",severe:"Reduce dose significantly"},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"C",lactation:"Use with caution",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Pancuronium (and other curare-like drugs)",effect:"Unknown effect",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:60,half_life:null,elimination:"Nonrenal",csf_penetration:null,preparations:""},rawData:{drug_name:"Polymyxin B",tradename:"Poly-Rx",usage_and_dosing:{general_info:["Polymyxin B and Polymyxin E (Colistin) are parenteral antibiotics in the polymyxin class. Their spectrum of activity and toxic potentials are similar. However, their pharmacology is dramatically different.","Polymyxin B is administered as an active sulfate salt; it is not excreted by the kidneys. Hence, polymyxin B should be avoided in the treatment of UTI. In contrast, colistin is administered as a prodrug; the active drug formed in vivo is excreted in the urine.","Choice of Polymyxin B vs Colistin (Reference: Pharmacotherapy 2019;39:10):","If providers have a choice, the current preference for IV therapy is Polymyxin B, unless the patient has a UTI, based on the following:","The dose calculation for polymyxin B is much simpler, as polymyxin B is not a prodrug like colistin.",'With the recommended loading dose, "therapeutic" serum concentrations are achieved much sooner than with colistin.',"There is less interpatient variability in pharmacokinetics with polymyxin B.","Unlike colistin, there is no need to adjust dosage of polymyxin B in patients with renal insufficiency.","Colistin is associated with higher rates of renal failure than polymyxin B (Antimicrob Agents Chemother 2016;60:2443).","Polymyxin B is NOT recommended for inhalation therapy due to potential for damage to lung epithelial cells (Antimicrob Agents Chemother 2017;61:e02690-16).","Polymyxin B is not available in Japan, South Africa, Europe or Australia.","Like colistin, polymyxin B has activity against multidrug-resistant aerobic Gram-negative bacilli, e.g., P. aeruginosa, Acinetobacter baumannii and carbapenemase-producing E. coli and Klebsiella pneumoniae.","NOTE : Serratia sp., Proteus sp., Providencia sp., Morganella sp., and Burkholderia cepacia are intrinsically resistant to polymyxins.","Polymyxin/colistin resistance gene (mcr-1) found on plasmids in carbapenem-resistant Enterobacteriaceae: Antimicrob Agents Chemother 2016;60:5033. Mcr-1 encodes change in the lipid A membrane target of the polymyxins.","Polymyxin B was licensed in the late 1950s. The US package insert recommends a maximum daily dose of 25,000 IU/kg (2.5 mg/kg) with adjustment downward for renal insufficiency. Based on 2013 published data, the recommended dosage is generally higher and there is no need to adjust for renal insufficiency (Clin Infect Dis 2013;57:524).","The standard unit of dosage for polymyxin B is the International Unit (IU); 10,000 IU = 1 mg. However, in the US and elsewhere, it is common to express the dosage in mg and not IU.","In a retrospective case series, polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections was associated with breakthrough bacteremia with polymyxin B-resistant K. pneumoniae in 3 of 40 patients (Antimicrob Agents Chemother 2013;57:5394).",'As with colistin, polymyxin B has a "detergent effect" on the cell membrane that allows restoration of antibacterial activity of drugs considered resistant as monotherapy.',"Acinetobacter, Pseudomonas, E. coli, or Klebsiella isolates may be resistant to carbapenems in vitro due to carbapenemase activity. When concomitantly exposed to a polymyxin, the cell permeability increases dramatically so as to allow rapid penetration of the carbapenem to its antibacterial target before the carbapenem is rendered inactive by the carbapenemase.","In a clinical cohort study, polymyxin B plus meropenem vs monotherapy with polymyxin B substantively lowered mortality in patients critically ill with A. baumannii or P. aeruginosa infections (Antimicrob Agents Chemother 2015;59:6575). A pertinent clinical trial is in progress.","The doses recommended below derive from a pharmacokinetic study of IV polymyxin B in critically ill patients (Clin Infect Dis 2013;57:524).","Important note: Colistin resistance gene, mcr-1, found on plasmids in E. coli and Klebsiella species in animals and humans.","Some strains have concomitant production of metallo-carbapenemases and express resistance to polymyxins (Lancet Infect Dis 2016;16:161; Lancet Infect Dis 2016;16:287; Lancet Infect Dis 2016;16:288).","See comments."],adult_dose:{pathogens_mic_le_2:{dosing_non_obese:"Dosing in non-obese persons is based on actual body weight.",loading_dose:"2.5 mg/kg IV (over 2 hours).",maintenance_dose:"12 hrs later, start 1.5 mg/kg IV (over 1 hour) q12h.",ascorbic_acid:"Concomitant ascorbic acid, 1 gm IV q4-6h, may attenuate the risk of nephrotoxicity (Clin Infect Dis 2015;61:1771)"},optimize_efficacy:"To optimize efficacy and reduce risk of resistance, suggest combination therapy with a carbapenem (most of the available data is with meropenem), regardless of in vitro carbapenem susceptibility.",combination_therapy_mic_ge_4:"Combination therapy essential if MIC is ≥4 µg/mL.",dosing_strategies:"Dosing strategies are evolving; see Antimicrob Agents Chemother 2017;61:e02023-16"},intrathecal_dose:"5 mg q24h into CSF x3-4 days, then 5 mg q48h x ≥2 weeks",pediatric_dose:{systemic:{age_ge_2:"use adult dosing",age_lt_2:"1.5-4.5 mg/kg/day (divided q12h)"},intrathecal:{age_ge_2:"use adult dosing",age_lt_2:"2 mg q24h x3-4 days, then 2.5 mg q48h for ≥2 weeks"}},renal_adjustment:{ref_pk_renal_insufficiency:"Clin Transl Sci 2024;17:e70110.",half_life_hrs_renal_function_normal:5.4,half_life_hrs_esrd:{mild_insufficiency:7.4,hd:15.2},dose_renal_function_normal:"2.5 mg/kg IV x1, then 1.5 mg/kg IV q12h",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No dosage adjustment",capd:"No dosage adjustment",crrt:"No dosage adjustment",sled:"No data"},hepatic_adjustment:"No dosage adjustment",other_adjustment:{ecmo:"See ECMO Drug Dosing Adjustment.",obesity:"See Obesity Dosing Adjustments."}},adverse_effects:["Neurologic: Variable complaints including perioral paresthesias, numbness of extremities, blurred vision, ataxia, drowsiness, irritability and dizziness. Polymyxin B associated with respiratory arrest, presumably due to neuromuscular blockade: Chest 2012;141:515.","Polymyxins may unmask or exacerbate myasthenia gravis.","Nephrotoxicity (Antimicrob Agents Chemother 2017;61:e02319-16):","Dose dependent reversible tubular necrosis. Drug accumulates in proximal tubular cells.","Data unclear as to relative toxic potential of polymyxin B vs. colistin.","Risk factors: Polymyxin daily dose, cumulative dose and length of therapy. In addition: concomitant nephrotoxins, obesity, age, diabetes mellitus, and hypertension.","In animal model, prophylactic high dose ascorbic acid or melatonin prevented polymyxin nephrotoxicity.","Skin hyperpigmentation associated with melanocyte activation reported (J Clin Pharm Ther 2017;42:573)."],pregnancy_risk:{fda_risk_category:"C",use_during_lactation:"Topical administration safe (no data with systemic use)"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"Free AUC/MIC",pharmaceutical_preparations:"Injection, topical (in combination)",peak_serum_conc_mcg_ml:"2.8 (1.5 mg/kg IV q12h, avg conc at SS)",protein_binding_percent:60,avg_serum_t1_2_hr:"4.5-6 (old data)",elimination:"Nonrenal",auc_mcg_hr_ml:"66.9 (1.5 mg/kg IV q12h, 0-24h)"},major_drug_interactions:[{drug:"Pancuronium (and other curare-like drugs)",effect_on_concentration_or_other:"↑ risk of neuromuscular blockade",suggested_management:"Avoid co-administration"}],comments:["Polymyxin B is administered as its sulfate salt. Polymyxin B is a multicomponent antibiotic, with polymyxin B1 and B2 predominating.","Shown in rabbits that drug binds to membrane lipids in liver, kidney, lung, brain, muscle and heart. Toxicity occurs after saturation of tissue binding sites (J Infect Dis 1971:124:394: Clin Infect Dis 2009:48:842).","Nephrotoxicity is the major adverse effect (Antimicrob Agents Chemother 2017;61:e02319-16).","If renal function is normal, proximal renal tubules can reabsorb entire daily dose of polymyxin B; even with impaired CrCl, a substantial portion of each dose undergoes reabsorption in the proximal renal tubules.","Mechanism of renal toxicity uncertain. Renal tubules can regenerate in patients that suffer acute tubular necrosis.","In multicenter prospective cohort study, higher rates of renal failure with colistin as compared to polymyxin B (Antimicrob Agents Chemother 2016;60:2443).","Colistin/polymyxin resistance gene (mcr-1) in carbapenem-resistant Enterobacteriaceae detected in many parts of the world: Antimicrob Agents Chemother 2016;60:5033; Infect Dis Clin N Am 2020;34:723. Unclear how to treat aerobic gram-negative rods that are both polymyxin resistant due to mcr-1 and express metallo-carbapenemases."]}},"Rifamycin SV":{id:"Rifamycin_SV",name:"Rifamycin SV",tradename:"Aemcolo",classification:{family:"RIFAMYCIN",subclass:"Rifamycin",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No dosage adjustment for renal impairment",mild:"No dosage adjustment for renal impairment",moderate:"No dosage adjustment for renal impairment",severe:"No dosage adjustment for renal impairment"},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No human data, toxic in animals at supratherapeutic exposures. Due to negligible oral absorption, fetal exposure is unlikely. Advise women of potential fetal risk. 10",lactation:"Probably safe with monitoring, but no data available. 9",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:null,half_life:null,elimination:"Fecal",csf_penetration:null,preparations:"Tab (194 mg)"},rawData:{drug_name:"Rifamycin SV",tradename:"Aemcolo",usage_and_dosing:{description:"Rifamycin SV, FDA-approved in 2018, is indicated for traveler's diarrhea caused by non-invasive strains of E. coli in adults.",notes:["Rifamycin SV is a poorly absorbed member of the rifamycin (technically ansamycin) class of antibiotics that was actually the first to be used in clinical practice (1963). In theory the product's MMX (multimatrix) technology allows for release of active antibiotic only after it reaches pH levels of ≥7 in the distal small bowel and colon, with an additional 1 hour delay upon reaching this pH.","Mechanism of action: inhibition of the beta-subunit of bacterial DNA-dependent RNA polymerase, blocking one of the steps in DNA transcription."],adult_dose:{dosage:"388 mg (2 tablets) po bid x3 days.",instructions:["Tablets should be swallowed whole (NOT crushed, chewed, or broken) with 6-8 oz of liquid.","Tablets may be taken with or without food, but NOT concomitantly with alcohol."]},pediatric_dose:{dosage:"Safety and efficacy not established",max_day:""}},renal_adjustment:{body_weight_and_creatinine_clearance_calculations:!0,half_life_normal:"No data",half_life_esrd:"No data",dose_renal_function_normal:"388 mg po q12h",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No data",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment:"No dosage adjustment",moderate_impairment:"No dosage adjustment",severe_impairment:"No dosage adjustment"},adverse_effects:{contraindications:"Contraindicated in patients with a hypersensitivity to rifamycin, any members of the rifamycin class, or any of the components in rifamycin SV.",warnings_and_precautions:["Not effective in patients with diarrhea accompanied by fever or bloody stools, or due to pathogens other than non-invasive strains of E. coli.","Possibility of C. difficile-associated diarrhea."]},pregnancy_risk:{fda_risk_category:"No human data, toxic in animals at supratherapeutic exposures. Due to negligible oral absorption, fetal exposure is unlikely. Advise women of potential fetal risk. 10",lactation:"Probably safe with monitoring, but no data available. 9"},antimicrobial_spectrum:{activity:["E. coli (enterotoxigenic, enteroaggregative isolates).","Shigella species and some Salmonella species."],no_activity:["Campylobacter species."]},pharmacology:{pk_pd_index:"No data",preparations:"Tab (194 mg)",food_recs:"Tab ± food (no alcohol)",oral_absorption:"Negligible",tmax_hr:"",peak_serum_conc:"Negligible",peak_urine_conc:"No data",protein_binding:"80",volume_of_distribution:"No data",avg_serum_t1_2:"No data",elimination:"Fecal",bile_penetration:"No data",csf_blood:"No data",therapeutic_levels_in_csf:"No data",auc:"No data"},major_drug_interactions:{note:"Because of minimal systemic concentrations, clinically relevant drug interactions are not expected."},comments:["Product availability: delayed-release tablet, containing 194 mg of rifamycin (equivalent to 200 mg of rifamycin sodium).","Review: Med Lett Drugs Ther 2019;61:39."]}},Rifaximin:{id:"Rifaximin",name:"Rifaximin",tradename:"Xifaxan",classification:{family:"RIFAMYCIN",subclass:"Rifamycin",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"TIME_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No dosage adjustment for renal impairment",mild:"No dosage adjustment for renal impairment",moderate:"No dosage adjustment for renal impairment",severe:"No dosage adjustment for renal impairment"},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"No human data, toxic in animals. Advise women of potential fetal risk. 10",lactation:"Probably safe with monitoring, but no data available. Avoid if possible. 9",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:null,half_life:null,elimination:"Negligible absorption",csf_penetration:null,preparations:"Tab (200, 550 mg)"},rawData:{drug_name:"Rifaximin",tradename:"Xifaxan",drug_shortage_information:{prep:"200 mg tablets",started_at:"2024-04-11",notes:""},usage_and_dosing:{description:"Rifaximin, FDA-approved in 2004, is a non-absorbable antibiotic of the Rifamycin class. It is effective in the treatment of the enterotoxigenic and enteroaggregative E. coli that in turn cause traveler's diarrhea (TD).",notes:["Virtually none of the drug is absorbed from the Gl tract. Antimicrobial activity is in the lumen of small intestine. Bile acids improve antimicrobial effect (Antimicrob Agents Chemother 2010;54:3618)."],uses:["Rifaximin is used with or without lactulose to treat hepatic encephalopathy (N Engl J Med 2010;362:1071). In cirrhotic patients who require TIPS, rifaximin therapy was well tolerated and reduced the risk of hepatic encephalopathy (Ann Intern Med 2021;174:633).","Rifaximin is used to treat small intestinal bacterial overgrowth (SIBO). ACG Guideline: Am J Gastroenterol 2020;115:165.","Treatment of pouchitis: Eur J Gastroenterol Hepatol 2022;34:581; Ann Pharmacother 2011;45:1127."],c_difficile:["Rifaximin 400 mg po tid x20 days is suggested by IDSA/SHEA guidelines as an option to follow oral vancomycin therapy for second or subsequent recurrence of C. difficile (Clin Infect Dis 2021;73:e1029).","Occurrence of C. difficile in patients on rifaximin for hepatic encephalopathy, mostly due to selection of rifaximin-resistant strains (Clin Infect Dis 2018;66:1086).","Rifaximin failed to prevent campylobacteriosis in humans (Clin Infect Dis 2018;66:1435)."],adult_dose:{travelers_diarrhea:"200 mg po tid x3 days",hepatic_encephalopathy:"550 mg po bid",irritable_bowel_syndrome_with_diarrhea:"550 mg po tid x14 days"},pediatric_dose:{age_ge_12_yrs:"200 mg tid x3 days (for TD)"}},renal_adjustment:{half_life_normal:"2-5",half_life_esrd:"Unchanged",dose_normal_function:"200 mg po q8h",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No dosage adjustment",capd:"No dosage adjustment",crrt:"No dosage adjustment",sled:"No data"},hepatic_adjustment:{mild_impairment:"No dosage adjustment",moderate_impairment:"No dosage adjustment",severe_impairment:"No dosage adjustment"},adverse_effects:{contraindicated:"Contraindicated in patients with a hypersensitivity to rifaximin, any members of the rifamycin class, or any of the components in rifaximin.",warnings_and_precautions:["Not effective for TD not caused by E. coli.","C. difficile-associated diarrhea reported with use of rifaximin.","Increased systemic exposure in patients with severe hepatic impairment. Use caution.","Use with PGP inhibitors can increase systemic exposure to rifaximin. Use caution."],adverse_reactions:["C. difficile-asociated diarrhea"]},pregnancy_risk:{fda_risk_category:"No human data, toxic in animals. Advise women of potential fetal risk. 10",lactation:"Probably safe with monitoring, but no data available. Avoid if possible. 9"},antimicrobial_spectrum:{spectrum:["E. coli (enterotoxigenic, enteroaggregative strains)"]},pharmacology:{pk_pd_index:"No data",preparations:"Tab (200, 550 mg)",food_recs:"Tab ± food",oral_absorption:"<0.4",tmax_hr:"1",peak_serum_conc:"0.0007-0.002 (200 mg po q8h, SS)",peak_urine_conc:"No data",protein_binding:"67.5",volume_of_distribution:"No data",avg_serum_t1_2:"2-5",elimination:"Negligible absorption",bile_penetration:"No data",csf_blood:"No data",therapeutic_levels_in_csf:"No data",auc:"0.008 (200 mg po, 0-inf)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:["CYP3A4"],transporters_substrate:["PGP, OATP1A2, OATP1B1/3"],ugts_substrate:[],cyp450s_inhibited:[],transporters_inhibited:["PGP (in vitro only)"],ugts_inhibited:[],cyp450s_induced:["CYP3A4"],transporters_induced:[],ugts_induced:[],impact_on_serum_drug_concentrations:"Minimal clinically relevant effects expected"},major_drug_interactions:{interactions:[{drug:"Cyclosporine",effect:"↑ rifaximin",management:"Monitor"},{drug:"Warfarin",effect:"Changes in INR",management:"Monitor"}]}}},Pristinamycin:{id:"Pristinamycin",name:"Pristinamycin",tradename:"Pyostacine",classification:{family:"STREPTOGRAMIN",subclass:"Streptogramin",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No dosage adjustment for renal impairment",mild:"No dosage adjustment for renal impairment",moderate:"No dosage adjustment for renal impairment",severe:"No dosage adjustment for renal impairment"},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Category C - Risk cannot be ruled out",lactation:"Use with caution",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Cyclosporine",effect:"↑ cyclosporine",management:"Monitor, adjust dosage"},{drug:"Tacrolimus",effect:"↑ tacrolimus",management:"Monitor, adjust dosage"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:null,half_life:null,elimination:"Biliary",csf_penetration:null,preparations:"Tab (250, 500 mg)"},rawData:{drug_name:"Pristinamycin",tradename:"Pyostacine",usage_and_dosing:{description:"Pristinamycin is a mixture of pristinamycin IA and pristinamycin IIA.",notes:["Pristinamycin IA (PIA) is a group B streptogramin, pristinamycin IIA (PIIA) is a group A streptogramin.","Group A and B streptogramins bind to the 50S subunit of the bacterial ribosome. Individually they are bacteriostatic, but in combination may be bactericidal.","Available in Europe (France, Belgium), but not marketed in the U.S."],adult_dose:"2-4 gm/day (divided q8-12h).",pediatric_dose:{dose:"50-100 mg/kg/day (divided q8h)"}},renal_adjustment:{body_weight_and_creatinine_clearance_calculations:!0,half_life_normal:{pia:4.03,piia:2.83},half_life_esrd:{pia:"Unchanged",piia:"Unchanged"},dose_renal_function_normal:"2-4 gm/day po (divided q8-12h)",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No data",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment:"No dosage adjustment",moderate_impairment:"No dosage adjustment",severe_impairment:"No dosage adjustment"},adverse_effects:["GI (nausea, vomiting)","Hypersensitivity reactions (uncommon)","Pseudomembranous colitis"],antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Tab (250, 500 mg)",food_recs:"Tab + food",oral_absorption:"No data",tmax_hr:{pia:3.25,piia:3.08},peak_serum_conc:{pia:"0.76 (2 gm po, SD)",piia:"0.58 (2 gm po, SD)"},peak_urine_conc:"No data",protein_binding:"No data",volume_of_distribution:"No data",avg_serum_t1_2:{pia:4.03,piia:2.83},elimination:"Biliary",bile_penetration:"No data",csf_blood:"No data",therapeutic_levels_in_csf:"No data",auc:{pia:"2.2 (2 gm po, 0-inf)",piia:"1.21 (2 gm po, 0-inf)"}},enzyme_transporter_mediated_interactions:{cyp450s_inhibited:["CYP3A4"],impact_on_serum_drug_concentrations:"↑"},major_drug_interactions:[{drug:"Cyclosporine",effect:"↑ cyclosporine",management:"Monitor, adjust dosage"},{drug:"Tacrolimus",effect:"↑ tacrolimus",management:"Monitor, adjust dosage"}],comments:["Reference for PK data: J Antimicrob Chemother 25:651, 1990.","Reported effective in treating macrolide and quinolone-resistant strains of Mycoplasma genitalium (Clin Infect Dis 60:1228, 2015; Emerg Infect Dis 24:328, 2018)."]}},"Quinupristin-Dalfopristin":{id:"Quinupristin_Dalfopristin",name:"Quinupristin-Dalfopristin",tradename:"Synercid",classification:{family:"STREPTOGRAMIN",subclass:"Streptogramin",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No dosage adjustment for renal impairment",mild:"No dosage adjustment for renal impairment",moderate:"No dosage adjustment for renal impairment",severe:"No dosage adjustment for renal impairment"},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"B",lactation:"Probably safe with monitoring, but no data available; avoid if possible.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Calcium channel blockers",effect:"↑ calcium channel blocker",management:"Monitor, adjust dosage"},{drug:"Carbamazepine",effect:"↑ carbamazepine",management:"Monitor, adjust dosage"},{drug:"Cyclosporine",effect:"↑ cyclosporine",management:"Monitor, adjust dosage"},{drug:"Diazepam",effect:"↑ diazepam",management:"Monitor, adjust dosage"},{drug:"Docetaxel",effect:"↑ docetaxel",management:"Avoid co-administration"},{drug:"Lidocaine",effect:"↑ lidocaine",management:"Monitor, adjust dosage"},{drug:"Methylprednisolone",effect:"↑ methylprednisolone",management:"Monitor, adjust dosage"},{drug:"Midazolam",effect:"↑ midazolam",management:"Monitor, adjust dosage"},{drug:"Paclitaxel",effect:"↑ paclitaxel",management:"Avoid co-administration"},{drug:"Statins metabolized by CYP3A4",effect:"↑ statin",management:"Monitor, adjust dosage"},{drug:"Tacrolimus",effect:"↑ tacrolimus",management:"Monitor, adjust dosage"},{drug:"Vincristine",effect:"↑ vincristine",management:"Avoid co-administration"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:null,half_life:null,elimination:"Biliary",csf_penetration:null,preparations:"Injection"},rawData:{drug_name:"Quinupristin-Dalfopristin",tradename:"Synercid",usage_and_dosing:{description:"Quinupristin-dalfopristin is a streptogramin antibiotic with activity vs. Staphylococcus, Streptococcus species and other gram-positive organisms.",note:"Current FDA indication is for skin and skin structure infections due to MSSA or S. pyogenes.",adult_dose:{skin_skin_structure_infection:"7.5 mg/kg IV q12h via central line"},pediatric_dose:{safety_and_efficacy_not_established:!0}},renal_adjustment:{body_weight_and_creatinine_clearance_calculations:!0,note:"Dosage adjustment may be required in hepatic disease.",half_life_normal:{quin:.85,dalfo:.7},half_life_esrd:{quin:"Unchanged",dalfo:"Unchanged"},dose_renal_function_normal:"7.5 mg/kg IV q12h",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No dosage adjustment",capd:"No dosage adjustment",crrt:"No dosage adjustment",sled:"No data"},hepatic_adjustment:{note:"PK data, but not clinical data, suggest the need for dosage adjustment. Use caution.",mild_impairment:"No dosage adjustment",moderate_impairment:"No dosage adjustment",severe_impairment:"No dosage adjustment"},adverse_effects:["Local phlebitis: requires central line.","Painful arthralgias in 2-50% of patients, also nausea, myalgias.","Asymptomatic increase in unconjugated bilirubin."],pregnancy_risk:{fda_risk_category:"B",lactation:"Probably safe with monitoring, but no data available; avoid if possible."},antimicrobial_spectrum:{recommended:[],active:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Injection",peak_serum_conc:"Quin 3.2, dalf 8 (7.5 mg/kg IV q8h, SS)",protein_binding:"Quin>dalf (not quantified)",volume_of_distribution:"Quin 0.45, dalf 0.24 (L/kg, Vss)",avg_serum_t1_2:"Quin 0.85, dalf 0.7",elimination:"Biliary",auc:"Quin 7.2, dalf 10.6 (7.5 mg/kg IV q8h, 0-24 hr)"},enzyme_transporter_mediated_interactions:{cyp450s_inhibited:["Quinupristin: CYP3A4","Dalfopristin: CYP3A4"],impact_on_serum_drug_concentrations:"↑"},major_drug_interactions:[{drug:"Calcium channel blockers",effect:"↑ calcium channel blocker",management:"Monitor, adjust dosage"},{drug:"Carbamazepine",effect:"↑ carbamazepine",management:"Monitor, adjust dosage"},{drug:"Cyclosporine",effect:"↑ cyclosporine",management:"Monitor, adjust dosage"},{drug:"Diazepam",effect:"↑ diazepam",management:"Monitor, adjust dosage"},{drug:"Docetaxel",effect:"↑ docetaxel",management:"Avoid co-administration"},{drug:"Lidocaine",effect:"↑ lidocaine",management:"Monitor, adjust dosage"},{drug:"Methylprednisolone",effect:"↑ methylprednisolone",management:"Monitor, adjust dosage"},{drug:"Midazolam",effect:"↑ midazolam",management:"Monitor, adjust dosage"},{drug:"Paclitaxel",effect:"↑ paclitaxel",management:"Avoid co-administration"},{drug:"Statins metabolized by CYP3A4",effect:"↑ statin",management:"Monitor, adjust dosage"},{drug:"Tacrolimus",effect:"↑ tacrolimus",management:"Monitor, adjust dosage"},{drug:"Vincristine",effect:"↑ vincristine",management:"Avoid co-administration"}],comments:["Previous approval had included serious infections due to vancomycin-resistant isolates of Enterococcus faecium at a dose of 7.5 mg/kg q8h by central line.","General reference, Clin Infect Dis 36:473, 2003.","Pristinamycin is a closely-related member of the streptogramin group of antibiotics with activity against Staph. aureus (including MRSA) and streptococcal species:","Available in some European countries; not available in the US.","Mixture of two components with a synergistic antibacterial activity.","Usual dose is 2-4 gm po/day in divided doses.","No available parenteral preparation."]}},Telithromycin:{id:"Telithromycin",name:"Telithromycin",tradename:"Ketek",classification:{family:"OTHER",subclass:"Other",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"CrCl ≥30: No dosage adjustment. CrCl <30: 600 mg q24h",mild:"CrCl ≥30: No dosage adjustment. CrCl <30: 600 mg q24h",moderate:"CrCl ≥30: No dosage adjustment. CrCl <30: 600 mg q24h",severe:"CrCl ≥30: No dosage adjustment. CrCl <30: 600 mg q24h"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"C",lactation:"Probably safe with monitoring, but no data available; avoid if possible.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Carbamazepine",effect:"↓ telithromycin",management:"Adjust dosage or avoid"},{drug:"Digoxin",effect:"↑ digoxin",management:"Monitor, adjust dosage"},{drug:"Eplerenone",effect:"↑ eplerenone",management:"Contraindicated"},{drug:"Ergot alkaloids",effect:"↑ ergot alkaloid",management:"Avoid co-administration"},{drug:"Itraconazole",effect:"↑ telithromycin",management:"Adjust dosage or avoid"},{drug:"Ketoconazole",effect:"↑ telithromycin",management:"Adjust dosage or avoid"},{drug:"Metoprolol",effect:"↑ metoprolol",management:"Monitor, adjust dosage"},{drug:"Midazolam",effect:"↑ midazolam",management:"Monitor, adjust dosage"},{drug:"Phenobarbital",effect:"↓ telithromycin",management:"Adjust dosage or avoid"},{drug:"Phenytoin",effect:"↓ telithromycin",management:"Adjust dosage or avoid"},{drug:"Pimozide",effect:"↑ pimozide",management:"Adjust dosage or avoid"},{drug:"Simvastatin",effect:"↑ simvastatin",management:"Monitor, adjust dosage"},{drug:"Sotalol",effect:"↓ sotalol",management:"Monitor, adjust dosage"},{drug:"Theophylline",effect:"↑ theophylline",management:"Monitor, adjust dosage"},{drug:"Warfarin",effect:"↑ warfarin (↑ INR)",management:"Monitor INR, adjust dosage"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:"57",protein_binding:"60-70",half_life:"10",elimination:"Metabolized, biliary, renal",csf_penetration:"No data",preparations:"Tab (300, 400 mg)"},rawData:{drug_name:"Telithromycin",tradename:"Ketek",usage_and_dosing:{general:["Telithromycin is a ketolide antibiotic (similar to macrolides) used for treatment of mild to moderate community-acquired pneumonia (CAP). Telithromycin is active against multi-drug resistant strains of Strep. pneumoniae.","Contraindicated in myasthenia gravis. Other antibiotics that may unmask or exacerbate myasthenia gravis: aminoglycosides, polymyxins, fluoroquinolones.","May cause fatal hepatotoxicity.","Blurred vision due to slow accommodation.","Hepatic, vision, and myasthenic complications may be due to inhibition of nicotinic acetylcholine receptors at neuromuscular junctions; Antimicrob Ag Chemother 54:5399, 2010."],adult_dose:{community_acquired_pneumonia:"800 mg po once daily x 7-10 days"},pediatric_dose:{dose_age_gt_28_days:"Safety and efficacy not established",max_day:"-"}},renal_adjustment:{notes:["Body weight and Creatinine Clearance calculations","CrCl = Creatinine clearance (mL/min)","CAPD = Continuous Ambulatory Peritoneal Dialysis","CRRT = Continuous Renal Replacement Therapy","AD = after hemodialysis","SLED = sustained low efficiency dialysis","Dosage adjustment may be required in hepatic disease."],half_life_normal:"10",half_life_esrd:"15",dose_normal_function:"800 mg po q24h",crcl_or_egfr:"CrCl ≥30: No dosage adjustment. CrCl <30: 600 mg q24h",hemodialysis:"600 mg q24h (give AD on dialysis days)",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{note:"Reduce dose to 400 mg q24h in patients with CrCl <30 mL/min plus coexisting hepatic impairment.",mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"No dosage adjustment"},adverse_effects:["2 cases acute liver failure and 23 cases serious liver injury reported, or 23 cases per 10 million prescriptions. Occurred during or immediately after treatment (Ann Intern Med 144:415, 2006; Ann Intern Med 144:447, 2006).","Uncommon: blurred vision 2° to slow accommodation; may cause exacerbation of myasthenia gravis (Black Box Warning). Potential QTc prolongation. Several drug-drug interactions, N Engl J Med 355:2260, 2006.","Nausea (7%), vomiting (2%), diarrhea (10%), C. difficile colitis, hepatic failure, headache (2%).","Transient loss of consciousness has been reported; avoid hazardous activities.","Potential for QTc prolongation and drug interactions."],pregnancy_risk:{fda_risk_category:"C",lactation:"Probably safe with monitoring, but no data available; avoid if possible.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Tab (300, 400 mg)",food_recommendation:"Tab ± food",oral_absorption_percent:"57",tmax_hr:"1",peak_serum_conc_ug_ml:"2.3 (800 mg q24h, SS)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"60-70",volume_of_distribution_vd_l_kg:"2.9 L/kg",avg_serum_half_life_hr:"10",elimination:"Metabolized, biliary, renal",bile_penetration_percent:"7",csf_blood_percent:"No data",therapeutic_levels_in_csf:"No data",auc_ug_hr_ml:"12.5 (800 mg q24h, 0-24h)"},enzyme_interactions:{cyp450_substrate:[],transporter_substrate:[],ugt_substrate:[],cyp450_inhibited:["CYP3A4"],transporters_inhibited:["PGP (?)"],ugts_inhibited:[],cyp450_induced:[],transporters_induced:[],ugts_induced:[],serum_drug_concentration_impact:"↑"},major_drug_interactions:[{drug:"Carbamazepine",effect:"↓ telithromycin",management:"Adjust dosage or avoid"},{drug:"Digoxin",effect:"↑ digoxin",management:"Monitor, adjust dosage"},{drug:"Eplerenone",effect:"↑ eplerenone",management:"Contraindicated"},{drug:"Ergot alkaloids",effect:"↑ ergot alkaloid",management:"Avoid co-administration"},{drug:"Itraconazole",effect:"↑ telithromycin",management:"Adjust dosage or avoid"},{drug:"Ketoconazole",effect:"↑ telithromycin",management:"Adjust dosage or avoid"},{drug:"Metoprolol",effect:"↑ metoprolol",management:"Monitor, adjust dosage"},{drug:"Midazolam",effect:"↑ midazolam",management:"Monitor, adjust dosage"},{drug:"Phenobarbital",effect:"↓ telithromycin",management:"Adjust dosage or avoid"},{drug:"Phenytoin",effect:"↓ telithromycin",management:"Adjust dosage or avoid"},{drug:"Pimozide",effect:"↑ pimozide",management:"Adjust dosage or avoid"},{drug:"Simvastatin",effect:"↑ simvastatin",management:"Monitor, adjust dosage"},{drug:"Sotalol",effect:"↓ sotalol",management:"Monitor, adjust dosage"},{drug:"Theophylline",effect:"↑ theophylline",management:"Monitor, adjust dosage"},{drug:"Warfarin",effect:"↑ warfarin (↑ INR)",management:"Monitor INR, adjust dosage"}],comments:["2007 Safety review led to removal of acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis and use of Medication Guide for prescribing for CABP","No longer marketed in US."]}},Doxycycline:{id:"Doxycycline",name:"Doxycycline",tradename:"Vibramycin, Doryx, Monodox, Adoxa, Periostat",classification:{family:"TETRACYCLINE",subclass:"Tetracycline",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:["Arcanobacterium sp.","Bartonella hensalae, B. quintana","Borrelia burgdorferi","Chlamydia trachomatis","Chlamydophila psittaci, C. pneumoniae","Coxiella burnetii","Ehrlichia sp., Anaplasma sp.","Francisella tularensis","Klebsiella granulomatis (granuloma inguinale)","Leptospira sp.","Mycoplasma pneumoniae","Rickettsia rickettsii (RMSF)","Vibrio cholera, toxigenic","Vibrio parahemolyticus"],alternative:[],notes:""},dosing:{adult:{standard:"100 mg po/IV q12h",severe:"100 mg po/IV q12h",renal:{normal:"No dosage adjustment for renal impairment",mild:"No dosage adjustment for renal impairment",moderate:"No dosage adjustment for renal impairment",severe:"No dosage adjustment for renal impairment"},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Avoid in 2nd and 3rd TM due to risk of permanent teeth discoloration or inhibition of bone growth. No evidence of substantial teratogenic risk if used in 1st TM, but data insufficient to conclude no risk.",lactation:"Short-term use safe, monitor infant for Gl toxicity",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Aluminum, bismuth, iron, magnesium salts",effect:"↓ doxycycline absorption",management:"Monitor closely"},{drug:"Barbiturates",effect:"↓ doxycycline",management:"Monitor closely"},{drug:"Carbamazepine",effect:"↓ doxycycline",management:"Monitor closely"},{drug:"Digoxin",effect:"↑ digoxin",management:"Monitor closely"},{drug:"Phenytoin",effect:"↓ doxycycline",management:"Monitor closely"},{drug:"Rifampin",effect:"↓ doxycycline (AAC 1994;38:2798)",management:"Monitor closely"},{drug:"Warfarin",effect:"↑ INR",management:"Monitor closely"}],stewardship:{preferredIndications:["Arcanobacterium sp.","Bartonella hensalae, B. quintana","Borrelia burgdorferi","Chlamydia trachomatis","Chlamydophila psittaci, C. pneumoniae","Coxiella burnetii","Ehrlichia sp., Anaplasma sp.","Francisella tularensis","Klebsiella granulomatis (granuloma inguinale)","Leptospira sp.","Mycoplasma pneumoniae","Rickettsia rickettsii (RMSF)","Vibrio cholera, toxigenic","Vibrio parahemolyticus"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:null,half_life:null,elimination:"Biliary, renal",csf_penetration:null,preparations:{monohydrate:["Cap (50, 75, 100, 150 mg)","Tab (100, 150 mg)","Delayed-release cap (40 mg)","Oral susp (25 mg/5 mL)"],hyclate:["Cap (100 mg)","Tab (20, 50, 75, 100, 150 mg)","DR tab (50, 60, 75, 80, 100, 120, 150, 200 mg)","Injection"]}},rawData:{drug_name:"Doxycycline",tradename:"Vibramycin, Doryx, Monodox, Adoxa, Periostat",drug_shortage_information:{prep:"oral suspension",started_at:null,notes:""},usage_and_dosing:{description:"Doxycycline, FDA approved in 1967, is a tetracycline antibiotic. The drug binds to the 30S ribosomal subunit and inhibits the binding of aminoacyl-tRNA to the A site. This prevents peptide chain elongation and inhibits protein synthesis. It is considered bacteriostatic.",clinical_uses:["Brucellosis","Cellulitis (suspected community-acquired MRSA)","Chlamydial urethritis, cervicitis","Cholera","Community-acquired pneumonia","Leptospirosis","Malaria","Plague","Q fever","Tick-borne diseases: Ehrlichiosis, Lyme, relapsing fever, tularemia, Rickettsiae spp."],notes:["Several mechanisms of resistance: change in ribosomal target (high level resistance), efflux pumps (low level resistance), porin closure (rare), and enzymatic alteration.","Two forms: hyclate and monohydrate. Both are equally effective. The monohydrate has reduced Gl side effects compared to the hyclate due to slower dissolution in the esophagus. However, it is not as bioavailable at higher pH as the other forms (could be an issue in patients on long term acid suppression).","Pediatric use. Use of tetracyclines in pediatric patients has historically been limited because of reports of permanent tooth discoloration in children age <8 years caused by incorporation of the drugs and their colored degradation products in enamel. Doxycycline binds less readily to calcium compared with other members of the tetracycline class, and recent comparative data suggest that doxycycline is not likely to cause visible teeth staining or enamel hypoplasia in children age <8 years. The American Academy of Pediatrics now recommends that doxycycline can safely be administered without regard to the patient's age or duration of therapy (AAP Red Book 2024-2027, Section 4).","Protocol for Doxycycline desensitization."],adult_dose:{usual_dose:"100 mg po/IV q12h"},pediatric_dose:{dose:"2.2-4.4 mg/kg/day (divided q12h)",max_day:"200 mg"}},renal_adjustment:{body_weight_and_creatinine_clearance_calculations:!0,half_life_normal:"18",half_life_esrd:"Unchanged",dose_renal_function_normal:"100 mg po/IV q12h",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No dosage adjustment",capd:"No dosage adjustment",crrt:"No dosage adjustment",sled:"No data"},hepatic_adjustment:{mild_impairment:"No dosage adjustment",moderate_impairment:"No dosage adjustment",severe_impairment:"No dosage adjustment"},other_adjustment:{ecmo:"See ECMO Drug Dosing Adjustment."},adverse_effects:["Increased nausea on empty stomach. Erosive esophagitis, especially if taken orally at bedtime. Take with lots of water.","Photosensitivity and onycholysis occur, but less than with other tetracycline drugs. In the tropics, significance of the photosensitivity reaction is increased. Photosensitivity can persist for several days after the last dose","Permanent yellow-gray-brown discoloration of the teeth. Deposition in teeth less than with tetracycline (J Antimicrob Chemother 2017;72:2887). Can occur with exposure of fetus in pregnancy. Data from the US and Europe suggest that doxycycline is not likely to cause visible teeth staining or enamel hypoplasia in children <8 years. See Usage and Dosing for further details.","Blue subungual discoloration: Cureus 2020;12:e7810.","Can be used in patients with renal failure.","Less catabolic effect than tetracycline hydrochloride.","Other rare adverse effects:","Drug Rash with Eosinophilia and Systemic Symptoms (DRESS)","CNS: Light-headedness, dizziness, or vertigo","C.difficile infection with diarrhea","Intracranial hypertension"],pregnancy_risk:{fda_risk_category:"Avoid in 2nd and 3rd TM due to risk of permanent teeth discoloration or inhibition of bone growth. No evidence of substantial teratogenic risk if used in 1st TM, but data insufficient to conclude no risk.",lactation:"Short-term use safe, monitor infant for Gl toxicity"},antimicrobial_spectrum:{preferred:["Arcanobacterium sp.","Bartonella hensalae, B. quintana","Borrelia burgdorferi","Chlamydia trachomatis","Chlamydophila psittaci, C. pneumoniae","Coxiella burnetii","Ehrlichia sp., Anaplasma sp.","Francisella tularensis","Klebsiella granulomatis (granuloma inguinale)","Leptospira sp.","Mycoplasma pneumoniae","Rickettsia rickettsii (RMSF)","Vibrio cholera, toxigenic","Vibrio parahemolyticus"],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:{monohydrate:["Cap (50, 75, 100, 150 mg)","Tab (100, 150 mg)","Delayed-release cap (40 mg)","Oral susp (25 mg/5 mL)"],hyclate:["Cap (100 mg)","Tab (20, 50, 75, 100, 150 mg)","DR tab (50, 60, 75, 80, 100, 120, 150, 200 mg)","Injection"]},food_recs:"Tab/cap/susp + food",oral_absorption:"90",tmax_hr:"2 (not DR)",peak_serum_conc:"1.5-2.1 (100 mg po, SD)",peak_urine_conc:"No data",protein_binding:">90",volume_of_distribution:"0.7 L/kg",avg_serum_t1_2:"18-24",elimination:"Biliary, renal",bile_penetration:"200-3200",csf_blood:"26",therapeutic_levels_in_csf:"No",auc:"31.7 (100 mg po, 0-inf)"},major_drug_interactions:[{drug:"Aluminum, bismuth, iron, magnesium salts",effect:"↓ doxycycline absorption",suggestion:"Avoid"},{drug:"Barbiturates",effect:"↓ doxycycline",suggestion:"Avoid"},{drug:"Carbamazepine",effect:"↓ doxycycline",suggestion:"Avoid"},{drug:"Digoxin",effect:"↑ digoxin",suggestion:"Monitor"},{drug:"Phenytoin",effect:"↓ doxycycline",suggestion:"Avoid"},{drug:"Rifampin",effect:"↓ doxycycline (AAC 1994;38:2798)",suggestion:"Adjust"},{drug:"Warfarin",effect:"↑ INR",suggestion:"Monitor"}]}},Eravacycline:{id:"Eravacycline",name:"Eravacycline",tradename:"Xerava",classification:{family:"TETRACYCLINE",subclass:"Tetracycline",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:["Eravacycline in vitro antibacterial activity is not influenced by ESBL or AmpC enzymes from Enterobacterales, KPCs, or metallo-carbapenemases.","No controlled clinical data for use of eravacycline, alone or in combination, against resistant Enterobacterales, Pseudomonas aeruginosa, or Stenotrophomonas maltophilia.","Exception is success vs ESBLs in eravacycline vs meropenem trial for patients with peritonitis: Clin Infect Dis 2019;69:921."]},dosing:{adult:{standard:"1 mg/kg IV (infused over 60 min) q12h.",severe:"1 mg/kg IV (infused over 60 min) q12h.",renal:{normal:"No dosage adjustment for renal impairment",mild:"No dosage adjustment for renal impairment",moderate:"No dosage adjustment for renal impairment",severe:"No dosage adjustment for renal impairment"},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Avoid during 2nd and 3rd trimesters",lactation:"Mfr suggests no breastfeeding during treatment and for 4 days after last dose. However, milk conc are likely low and absorption inhibited by calcium in breast milk. Short-term use is acceptable in nursing mothers; monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Strong CYP3A inducer",effect:"↓ eravacycline",management:"Monitor closely"},{drug:"Warfarin",effect:"↑ INR",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:null,half_life:null,elimination:"Metabolized",csf_penetration:null,preparations:"Injection"},rawData:{drug_name:"Eravacycline",tradename:"Xerava",usage_and_dosing:{description:"Eravacycline, FDA-approved in 2018, is a synthetic fluorocycline antibiotic within the tetracycline class indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by certain susceptible bacteria in adults.",mechanism_of_action:"Disruption of protein synthesis by binding to the 30S ribosomal subunit, preventing incorporation of amino acid residues into elongating peptide chains.",in_vitro_activity:"In vitro activity is very broad and similar to tigecycline, but MICs are often twofold lower than tigecycline (J Antibiot (Tokyo) 2016;69:600; Antimicrob Agents Chemother 2013;57:5548)",clinical_trial:{summary:"Eravacycline was non-inferior to ertapenem or meropenem in a phase III, randomized, double-blind clinical trial of patients with appendicitis, cholecystitis, diverticulitis, gastric or duodenal perforation, and peritonitis (JAMA Surg 2017;152:224; Clin Infect Dis 2019;69:921).",treatment_duration:"4-14 days.",included_patients:"Included patients infected with ESBL-producing organisms."},adult_dose:{usual_dose:"1 mg/kg IV (infused over 60 min) q12h.",dosing_notes:["Use actual body weight for dosing.","Reconstituted drug should be further diluted for IV infusion to a target concentration of 0.2-0.6 mg/mL in normal saline. Compatibility in other infusion solutions has not been established.","Recommended duration of therapy for cIAI: 4 to 14 days.","Increase dose to 1.5 mg/kg IV q12h if co-administered with a strong CYP3A inducer, e.g., rifampin, carbamazepine. No dosage adjustment is necessary if co-administered with a weak or moderate CYP3A inducer."]},pediatric_dose:{safety_and_efficacy_not_established:!0}},renal_adjustment:{body_weight_and_creatinine_clearance_calculations:!0,note:"Dosage adjustment may be required in hepatic disease.",half_life_normal:"20",half_life_esrd:"Unchanged",dose_renal_function_normal:"1 mg/kg IV q12h",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No dosage adjustment",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment:"No dosage adjustment",moderate_impairment:"No dosage adjustment",severe_impairment:"1 mg/kg q12h day 1, then 1 mg/kg q24h"},other_adjustment:{obesity:"See Obesity Dosing Adjustments."},adverse_effects:{contraindications:"Use in patients with known hypersensitivity to eravacycline, tetracycline-class antibacterial drugs, or to any of the excipients.",warnings_and_precautions:{hypersensitivity:"Life-threatening hypersensitivity reactions (anaphylaxis)",pregnancy_and_pediatric:{title:"Pregnancy (2nd & 3rd trimester), infancy, and childhood to age 8 years:",effects:["Permanent tooth discoloration (yellow-grey-brown) and enamel hypoplasia","Inhibition of bone growth (reversible)"]},cdiff:"C. difficile antibiotic-associated colitis",tetracycline_class_reactions:"Potential for tetracycline-class adverse reactions: Photosensitivity, fixed drug eruption, pseudotumor cerebri, and anti-anabolic action which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests."},common_effects:["Infusion site reactions (7.7%)","Nausea (6.5%)","Vomiting (3.7%)","Diarrhea (2.3%)","Hypotension (1.3%)","Wound dehiscence (1.3%)"]},pregnancy_risk:{fda_risk_category:"Avoid during 2nd and 3rd trimesters",lactation:"Mfr suggests no breastfeeding during treatment and for 4 days after last dose. However, milk conc are likely low and absorption inhibited by calcium in breast milk. Short-term use is acceptable in nursing mothers; monitor infant for GI toxicity."},antimicrobial_spectrum:{notes:["Eravacycline in vitro antibacterial activity is not influenced by ESBL or AmpC enzymes from Enterobacterales, KPCs, or metallo-carbapenemases.","No controlled clinical data for use of eravacycline, alone or in combination, against resistant Enterobacterales, Pseudomonas aeruginosa, or Stenotrophomonas maltophilia.","Exception is success vs ESBLs in eravacycline vs meropenem trial for patients with peritonitis: Clin Infect Dis 2019;69:921."],resistance_mechanisms:["Efflux pumps","Target site modifications"]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Injection",peak_serum_conc:"1.825 (1 mg/kg IV q12h, SS)",protein_binding:"79-90",volume_of_distribution:"321 L (Vss)",avg_serum_t1_2:"20",elimination:"Metabolized",auc:"6.31 (1 mg/kg IV q12h, 0-12 hr)"},enzyme_transporter_mediated_interactions:{cyp450s_substrate:["CYP3A4"],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:[{drug:"Strong CYP3A inducer",effect:"↓ eravacycline",suggestion:"↑ dose"},{drug:"Warfarin",effect:"↑ INR",suggestion:"Monitor"}],comments:["Review: Med Lett Drugs Ther 2019;61:61."]}},Minocycline:{id:"Minocycline",name:"Minocycline",tradename:"Minocin, Dynacin, Solodyn, Arestin, Amzeeq",classification:{family:"TETRACYCLINE",subclass:"Tetracycline",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:["Mycoplasma pneumoniae"],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No dosage adjustment for renal impairment",mild:"No dosage adjustment for renal impairment",moderate:"No dosage adjustment for renal impairment",severe:"No dosage adjustment for renal impairment"},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"D",lactation:"Short-term use safe, monitor infant for GI toxicity",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Al, Bi, Fe, Mg (e.g. antacids)",effect:"↓ minocycline absorption",management:"Monitor closely"},{drug:"Ergot alkaloids",effect:"↑ risk of ergotism",management:"Monitor closely"},{drug:"Isotretinoin",effect:"↑ risk of pseudotumor cerebri",management:"Monitor closely"},{drug:"Methoxyflurane",effect:"↑ renal toxicity",management:"Monitor closely"},{drug:"Oral contraceptives",effect:"↓ OC effectiveness",management:"Monitor closely"},{drug:"Sucralfate",effect:"↓ minocycline absorption",management:"Monitor closely"},{drug:"Warfarin",effect:"↑ INR",management:"Monitor closely"}],stewardship:{preferredIndications:["Mycoplasma pneumoniae"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:null,half_life:null,elimination:"Biliary",csf_penetration:null,preparations:"Tab/cap (50, 75, 100 mg), extended-release tab (45, 55, 65, 80, 90, 105, 115, 135 mg), 1 gm pwd for subgingival use, 4% topical foam, injection"},rawData:{drug_name:"Minocycline",tradename:"Minocin, Dynacin, Solodyn, Arestin, Amzeeq",usage_and_dosing:{description:"Broad spectrum member of the tetracycline group of antibiotics. Most lipid soluble and has the longest serum half-life.",activity:{like_other_tetracyclines:"broad spectrum of activity",common_uses:"Commonly used to treat acne; an alternative for Lyme Disease.",meningococcal_prophylaxis:"No longer recommended for meningococcal prophylaxis due to high incidence of vestibular side effects.",mdr_gnb_activity:{summary:"Most active of the tetracycline antibiotics vs. MDR gram-negative bacilli (GNB), e.g., Acinetobacter baumannii (Infect Dis Ther 2017;6:199), Stenotrophomonas maltophilia (Diag Microbiol Infect Dis 2016; 85:352)",in_vitro_acinetobacter:"In vitro activity vs. Acinetobacter enhanced with combination therapy with a polymyxin",animal_model_acinetobacter:"Minocycline + Colistin effective in animal model of Acinetobacter pneumonia but not in infected biofilms (Antimicrob Agents Chemother 2016; 60: 4047)",clinical_effectiveness_acinetobacter:"Potential clinical effectiveness vs. Acinetobacter in small observational clinical studies (Am J Health System Pharm 2016;73: 279; Drugs 2016;76: 1467)"},other_activity:"See Antimicrobial Spectrum (below) for other activity"},resistance_mechanisms:"Several mechanisms of resistance: Efflux pumps (common, low level resistance), ribosomal target change (high level resistance), porin closure (rare), enzymatic alteration.",availability:"Available for oral, subgingival, topical, and intravenous use.",adult_dose:"Usual dose: 200 mg po/IV as initial loading dose, then 100 mg po/IV q12h. Infuse IV doses over 60 minutes",pediatric_dose:{age_gt_8_yrs:"4 mg/kg/day po (divided q12h)"}},renal_adjustment:{body_weight_and_creatinine_clearance_calculations:!0,half_life_normal:"16",half_life_esrd:"Unchanged",dose_renal_function_normal:"100 mg po/IV q12h",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No dosage adjustment",capd:"No dosage adjustment",crrt:"No dosage adjustment",sled:"No data"},hepatic_adjustment:{mild_impairment:"No dosage adjustment",moderate_impairment:"No dosage adjustment",severe_impairment:"No dosage adjustment"},adverse_effects:["Vestibular symptoms (30-90% in some groups, none in others): vertigo 33%, ataxia 43%, nausea 50%, vomiting 3%, women more frequently than men.","Hypersensitivity pneumonitis, reversible.","Can increase skin pigmentation described as slate-gray or blue-black of the skin and other tissues with long-term use; for picture see JAMA 2021;326:1851.","Also: Fever (rare), rash, photosensitivity, neutropenia, eosinophilia, thrombocytopenia, C. difficile colitis, increased LFTs, hepatic failure, increased BUN/Creatinine, headache.","In children given Minocycline for acne, induced autoimmunity reported (J Peds 153:314, 2008)","Intracranial hypertension:e.g., pseudotumor cerebri","Under the age of 8 yrs: abnormal skeletal and tooth development.","Minocycline preps contain magnesium. Monitor magnesium levels in patients with renal impairment and/or heart block."],pregnancy_risk:{fda_risk_category:"D",lactation:"Short-term use safe, monitor infant for GI toxicity"},antimicrobial_spectrum:{preferred:["Mycoplasma pneumoniae"],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Tab/cap (50, 75, 100 mg), extended-release tab (45, 55, 65, 80, 90, 105, 115, 135 mg), 1 gm pwd for subgingival use, 4% topical foam, injection",food_recs:"Cap/tab/ER tab ± food",oral_absorption:"No data",tmax_hr:"2.1",peak_serum_conc:{po:"2.0-3.5 (200 mg po, SD)",iv:"4.2 (200 mg IV, SD)"},peak_urine_conc:"No data",protein_binding:"76",volume_of_distribution:"80-114 L (Vss)",avg_serum_t1_2:"16",elimination:"Biliary",bile_penetration:"200-3200",csf_blood:"No data",therapeutic_levels_in_csf:"No data",auc:"48.3 (200 mg po, 0-inf)"},major_drug_interactions:[{drug:"Al, Bi, Fe, Mg (e.g. antacids)",effect:"↓ minocycline absorption",suggestion:"Avoid co-administration"},{drug:"Ergot alkaloids",effect:"↑ risk of ergotism",suggestion:"Avoid co-administration"},{drug:"Isotretinoin",effect:"↑ risk of pseudotumor cerebri",suggestion:"Avoid co-administration"},{drug:"Methoxyflurane",effect:"↑ renal toxicity",suggestion:"Avoid co-administration"},{drug:"Oral contraceptives",effect:"↓ OC effectiveness",suggestion:"Use alternative method"},{drug:"Sucralfate",effect:"↓ minocycline absorption",suggestion:"Avoid co-administration"},{drug:"Warfarin",effect:"↑ INR",suggestion:"Monitor INR, adjust dose"}],comments:["Disease modifying agent for rheumatoid arthritis, but not an approved indication: 100 mg po bid (Arth Rheum 59:762, 2008)."]}},Omadacycline:{id:"Omadacycline",name:"Omadacycline",tradename:"Nuzyra",classification:{family:"TETRACYCLINE",subclass:"Tetracycline",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No dosage adjustment for renal impairment",mild:"No dosage adjustment for renal impairment",moderate:"No dosage adjustment for renal impairment",severe:"No dosage adjustment for renal impairment"},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Avoid during 2nd and 3rd trimesters",lactation:"Mfr suggests no breastfeeding during treatment and for 4 days after last dose. However, milk conc are likely low and absorption inhibited by calcium in breast milk.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Antacids containing Al, Mg, Ca, Bi subsalicylate",effect:"↓ omadacycline",management:"Monitor closely"},{drug:"Iron-containing preparations",effect:"↓ omadacycline",management:"Monitor closely"},{drug:"Verapamil",effect:"↑ omadacycline",management:"Monitor closely"},{drug:"Warfarin",effect:"↑ INR",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:null,half_life:null,elimination:"Fecal",csf_penetration:null,preparations:"Tab (150 mg), injection"},rawData:{drug_name:"Omadacycline",tradename:"Nuzyra",usage_and_dosing:{description:"Omadacycline is a tetracycline antibacterial approved for treatment of community-acquired bacteria pneumonia (CAP) and acute bacterial skin and skin structure infections (ABSSSI).",antibacterial_activity:"Antibacterial activity includes gram-positive, gram-negative atypical and anaerobic bacteria.",in_vitro_activity:{resistant_pathogens:["Penicillin-resistant S. pneumoniae","VRE","Ampicillin-resistant H. influenzae","Acinetobacter species","Stenotrophomonas maltophilia","Enterobacterales resistant to ceftazidime and carbapenems"],resistant_in_vitro:["Pseudomonas sp.","Proteus sp.","Morganella sp.","Providencia sp."]},overview_references:["Clin Infect Dis 2019;69:S1","Clin Infect Dis 2019:69:890"],adult_dose:{cap:{loading_dose:"200 mg IV (over 60 min) on day 1, OR 100 mg IV (over 30 min) q12h x2 doses on day 1, OR 300 mg po q12h x2 doses on day 1.",maintenance_dose:"100 mg IV (over 30 min) OR 300 mg po q24h."},absssi:{loading_dose:"200 mg IV (over 60 min) on day 1, OR 100 mg IV (over 30 min) q12h x2 doses on day 1, OR 450 mg po q24h on days 1 and 2.",maintenance_dose:"100 mg IV (over 30 min) OR 300 mg po q24h."},duration_of_treatment:"7-14 days for CAP and ABSSSI.",iv_dosing:{reconstitution:"Reconstituted drug should be yellow to dark orange in color.",preparation:"Prepare IV doses in 100 mL bags of NS or D5W, use within 24 hours at room temperature or within 7 days if refrigerated.",administration:"Do not administer through same IV line with any solution containing multivalent cations (e.g., calcium, magnesium)."},oral_dosing:{fasting:"Fast for 4 hrs before dosing.",food_and_drug_interactions:"No food for 2 hrs after dosing, and no dairy products, antacids or multivitamins for 4 hrs after dosing."}},pediatric_dose:{safety_and_efficacy_not_established:!0}},renal_adjustment:{body_weight_and_creatinine_clearance_calculations:!0,half_life_normal:"15.5-16.8",half_life_esrd:"Unchanged",dose_renal_function_normal:"100 mg IV q24h, 300 mg po q24h",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No dosage adjustment",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment:"No dosage adjustment",moderate_impairment:"No dosage adjustment",severe_impairment:"No dosage adjustment"},other_adjustment:{obesity:"See Obesity Dosing Adjustments table."},adverse_effects:{contraindications:"Known hypersensitivity to tetracyclines",warnings:["Higher mortality risk in CAP patients (2%) vs. Moxifloxacin (1%)","Tooth discoloration and enamel hypoplasia if used in second half of pregnancy","Inhibition of bone growth if used in 2nd/3rd trimester of pregnancy","Clostridioides difficile-associated diarrhea"],aes:{nausea_vomiting:"In clinical trial of oral therapy vs linezolid for ABSSI, nausea in 30% and vomiting in 17% of omadacycline patients vs 8% and 3% in the linezolid patients.",infusion_site_reactions:!0,increased_ast_alt_ggt:!0,hypertension:!0,headache:!0,diarrhea:!0,insomnia:!0,constipation:!0}},pregnancy_risk:{fda_risk_category:"Avoid during 2nd and 3rd trimesters",lactation:"Mfr suggests no breastfeeding during treatment and for 4 days after last dose. However, milk conc are likely low and absorption inhibited by calcium in breast milk."},antimicrobial_spectrum:{preferred:[],alternative:[],in_vitro_lacks_activity:["Proteus species","Providencia species","Pseudomonas species","Morganella species"]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Tab (150 mg), injection",food_recs:"Tab no food",oral_absorption:"34.5",tmax_hr:"po: 2.5",peak_serum_conc:{iv:"2.12 (100 mg IV q24h, SS)",po:"0.95 (300 mg po q24h, SS)"},peak_urine_conc:"No data",protein_binding:"20",volume_of_distribution:"190 L (Vss)",avg_serum_t1_2:"15.5-16.8",elimination:"Fecal",bile_penetration:"No data",csf_blood:"No data",therapeutic_levels_in_csf:"No data",auc:{iv:"12.14 (100 mg IV q24h, 0-24 hr)",po:"11.16 (300 mg po q24h, 0-24 hr)"}},enzyme_transporter_mediated_interactions:{transporters_substrate:["PGP"],impact_on_serum_drug_concentrations:"None expected"},major_drug_interactions:[{drug:"Antacids containing Al, Mg, Ca, Bi subsalicylate",effect:"↓ omadacycline",suggestion:"Separate administration"},{drug:"Iron-containing preparations",effect:"↓ omadacycline",suggestion:"Separate administration"},{drug:"Verapamil",effect:"↑ omadacycline",suggestion:""},{drug:"Warfarin",effect:"↑ INR",suggestion:""}]}},Sarecycline:{id:"Sarecycline",name:"Sarecycline",tradename:"Seysara",classification:{family:"TETRACYCLINE",subclass:"Tetracycline",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"See prescribing information",severe:"See prescribing information",renal:{normal:"No dosage adjustment for renal impairment (not studied in ESRD)",mild:"No dosage adjustment for renal impairment (not studied in ESRD)",moderate:"No dosage adjustment for renal impairment (not studied in ESRD)",severe:"No dosage adjustment for renal impairment (not studied in ESRD)"},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"Do not use (risk of fetal harm, tooth discoloration, inhibition of bone growth)",lactation:"No data, avoid use",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Antacids (Al, Ca, Mg)",effect:"↓ sarecycline",management:"Monitor closely"},{drug:"Bismuth subsalicylate",effect:"↓ sarecycline",management:"Monitor closely"},{drug:"Digoxin",effect:"↑ digoxin (inhibition of P-glycoprotein)",management:"Monitor closely"},{drug:"Iron-containing preps",effect:"↓ sarecycline",management:"Monitor closely"},{drug:"Penicillin",effect:"↓ penicillin bactericidal activity",management:"Monitor closely"},{drug:"Retinoids",effect:"↑ intracranial pressure (pseudotumor cerebri)",management:"Monitor closely"},{drug:"Warfarin",effect:"↑ INR",management:"Monitor closely"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:null,half_life:null,elimination:"Fecal, renal",csf_penetration:null,preparations:"Tab (60, 100, 150 mg)"},rawData:{drug_name:"Sarecycline",tradename:"Seysara",usage_and_dosing:{indicated_for:"treatment of the inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients age ≥9 years.",efficacy_and_safety_notes:["Efficacy beyond 12 weeks and safety beyond 12 months are not established.","Avoid using in males attempting to conceive a child (adverse effects in an animal fertility study).","Take each dose with adequate fluid to reduce risk of esophageal irritation or ulceration.","Not evaluated in the treatment of infections."],adult_dose:[{body_weight_kg:"33-54",dose:"60 mg po q24h"},{body_weight_kg:"55-84",dose:"100 mg po q24h"},{body_weight_kg:"85-136",dose:"150 mg po q24h"}],pediatric_dose:{age_gt_9_yrs:[{weight_kg:"33-54",dose:"60 mg po q24h"},{weight_kg:"55-84",dose:"100 mg po q24h"},{weight_kg:"85-136",dose:"150 mg po q24h"}]}},renal_adjustment:{body_weight_and_creatinine_clearance_calculations:!0,half_life_normal:"21-22",half_life_esrd:"No data",dose_renal_function_normal:"60-150 mg po q24h",crcl_or_egfr:"No dosage adjustment for renal impairment (not studied in ESRD)",hemodialysis:"No data",capd:"No data",crrt:"No data",sled:"No data"},hepatic_adjustment:{mild_impairment:"No dosage adjustment",moderate_impairment:"No dosage adjustment",severe_impairment:"No data"},adverse_effects:{adverse_effects:["GI (most common adverse effect is nausea, incidence ≥1%).","Esophageal irritation or erosion if inadequate fluid taken with each dose. Risk of esophageal adverse effects possibly higher than with other tetracyclines (J Am Acad Dermatol 2022;87:1150).","CNS (lightheadedness, dizziness, vertigo, pseudotumor cerebri).","Intracranial hypertension.","Photosensitivity, possibly more likely than with other tetracyclines (J Am Acad Dermatol 2022;87:1150).","C. difficile-associated diarrhea."]},pregnancy_risk:{fda_risk_category:"Do not use (risk of fetal harm, tooth discoloration, inhibition of bone growth)",lactation:"No data, avoid use"},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Tab (60, 100, 150 mg)",food_recs:"Tab + food",oral_absorption:"No data",tmax_hr:"1.5-2.0",peak_serum_conc:"No data",peak_urine_conc:"No data",protein_binding:"62.5-74.7",volume_of_distribution:"91.4-97.0 (Vss)",avg_serum_t1_2:"21-22",elimination:"Fecal, renal",bile_penetration:"No data",csf_blood:"No data",therapeutic_levels_in_csf:"No data",auc:"No data"},enzyme_transporter_mediated_interactions:{transporters_inhibited:["PGP"],impact_on_serum_drug_concentrations:"↑"},major_drug_interactions:[{drug:"Antacids (Al, Ca, Mg)",effect:"↓ sarecycline",suggestion:"Separate dosing"},{drug:"Bismuth subsalicylate",effect:"↓ sarecycline",suggestion:"Separate dosing"},{drug:"Digoxin",effect:"↑ digoxin (inhibition of P-glycoprotein)",suggestion:"Monitor, adjust dosage"},{drug:"Iron-containing preps",effect:"↓ sarecycline",suggestion:"Separate dosing"},{drug:"Penicillin",effect:"↓ penicillin bactericidal activity",suggestion:"Avoid co-administration"},{drug:"Retinoids",effect:"↑ intracranial pressure (pseudotumor cerebri)",suggestion:"Avoid co-administration"},{drug:"Warfarin",effect:"↑ INR",suggestion:"Monitor INR, adjust dosage"}],comments:["Review: Med Lett Drugs Ther 2019;61:43."]}},Tetracycline:{id:"Tetracycline",name:"Tetracycline",tradename:"",classification:{family:"TETRACYCLINE",subclass:"Tetracycline",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:["Mycoplasma pneumoniae"],alternative:[],notes:""},dosing:{adult:{standard:"250-500 mg po q6h",severe:"250-500 mg po q6h",renal:{normal:[{range:">90",adjustment:"No dosage adjustment"},{range:">50-90",adjustment:"250-500 mg q8-12h"},{range:"10-50",adjustment:"250-500 mg q12-24h"},{range:"<10",adjustment:"250-500 mg q24h"}],mild:[{range:">90",adjustment:"No dosage adjustment"},{range:">50-90",adjustment:"250-500 mg q8-12h"},{range:"10-50",adjustment:"250-500 mg q12-24h"},{range:"<10",adjustment:"250-500 mg q24h"}],moderate:[{range:">90",adjustment:"No dosage adjustment"},{range:">50-90",adjustment:"250-500 mg q8-12h"},{range:"10-50",adjustment:"250-500 mg q12-24h"},{range:"<10",adjustment:"250-500 mg q24h"}],severe:[{range:">90",adjustment:"No dosage adjustment"},{range:">50-90",adjustment:"250-500 mg q8-12h"},{range:"10-50",adjustment:"250-500 mg q12-24h"},{range:"<10",adjustment:"250-500 mg q24h"}]},hepatic:"No adjustment required",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:"D",lactation:"Short-term use safe, monitor infant for GI toxicity",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Antacids (Al, Mg)",effect:"↓ tetracycline",management:"Monitor closely"},{drug:"Atovaquone",effect:"↓ atovaquone",management:"Monitor closely"},{drug:"Bismuth salt",effect:"↓ tetracycline",management:"Monitor closely"},{drug:"Didanosine",effect:"↓ tetracycline",management:"Monitor closely"},{drug:"Digoxin",effect:"↑ digoxin",management:"Monitor closely"},{drug:"Iron products",effect:"↓ tetracycline",management:"Monitor closely"},{drug:"Methoxyflurane",effect:"↑ methoxyflurane",management:"Monitor closely"},{drug:"Sucralfate",effect:"↓ tetracycline",management:"Monitor closely"},{drug:"Zinc",effect:"↓ tetracycline",management:"Monitor closely"}],stewardship:{preferredIndications:["Mycoplasma pneumoniae"],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:null,half_life:null,elimination:"Biliary, renal",csf_penetration:null,preparations:"Cap (250, 500 mg)"},rawData:{drug_name:"Tetracycline",usage_and_dosing:{description:"Tetracycline has a broad spectrum of activity that includes Rickettsia, Chlamydia, Mycoplasma and many others.",notes:["The derivatives Doxycycline and Minocycline are more convenient, often more active and, hence, used more often than Tetracycline.","Alternative therapy for early syphilis or gonorrhea in the penicillin-allergic patient.","Part of combination therapy for Helicobacter pylori chronic gastritis.","Therapy for mild-moderate tularemia (Clinical Infectious Diseases 59(2): e10-e52)","Resistance: efflux pumps, change in ribosomal target, porin closure, and enzymatic alteration all possible.","Use caution in pregnancy: many adverse effects and drug-drug interactions.","IV preparation is rarely used; Doxycycline instead.","Use as sclerosing agent in pleural space to control malignant effusion.","IV dosage over 2 gm/day in pregnancy may be associated with fatal hepatotoxicity (J Antimicrob Chemother 66:1431, 2011)."],adult_dose:{usual_dose:"250-500 mg po q6h",acne:"500mg po twice daily",h_pylori:"500mg q6h in combination therapy",tularemia:"500mg q6h x at least 14 days"},pediatric_dose:{age_gt_8_yrs:"25-50 mg/kg/day (divided q6h)",max_day:"2 gm"}},renal_adjustment:{body_weight_and_creatinine_clearance_calculations:!0,half_life_normal:"6-12",half_life_esrd:"57-108",dose_renal_function_normal:"250-500 mg po q6h",crcl_or_egfr:[{range:">90",adjustment:"No dosage adjustment"},{range:">50-90",adjustment:"250-500 mg q8-12h"},{range:"10-50",adjustment:"250-500 mg q12-24h"},{range:"<10",adjustment:"250-500 mg q24h"}],hemodialysis:"250-500 mg q24h",capd:"250-500 mg q24h",crrt:"250-500 mg q12-24h",sled:"No data"},hepatic_adjustment:{mild_impairment:"No dosage adjustment",moderate_impairment:"No dosage adjustment",severe_impairment:"No dosage adjustment"},adverse_effects:["Tetracyclines have an anti-anabolic effect that can manifest as an increase in BUN. If associated with impaired renal function can aggravate azotemia, elevate serum phosphorous levels and promote acidosis. Drug accumulation can be toxic to the liver.","Superinfection with Candida (vaginitis).","Use during last half of pregnancy, in infancy, or in childhood to age of 8, can cause permanent discoloration of the teeth (yellow-gray-brown).","Photosensitivity. Can persist for days after last dose.","Toxic to human embryos (mental retardation and impaired skeletal development).","Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) reported.","Lightheadedness, dizziness, or vertigo reported, perhaps more often with minocycline.","Clostridioides difficile colitis can occur.","Intracranial hypertension (pseudotumor cerebri) associated with tetracyclines."],pregnancy_risk:{fda_risk_category:"D",lactation:"Short-term use safe, monitor infant for GI toxicity"},antimicrobial_spectrum:{preferred:["Mycoplasma pneumoniae"],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Cap (250, 500 mg)",food_recs:"Cap no food",oral_absorption:"No data",tmax_hr:"2-4",peak_serum_conc:"1.5-2.2 (250 mg po, SD)",peak_urine_conc:"No data",protein_binding:"20-65",volume_of_distribution:"1.3 L/kg",avg_serum_t1_2:"6-12",elimination:"Biliary, renal",bile_penetration:"200-3200",csf_blood:"Poor"},major_drug_interactions:[{drug:"Antacids (Al, Mg)",effect:"↓ tetracycline",suggestion:"Give tetracycline 2 hr pre or 6 hr post"},{drug:"Atovaquone",effect:"↓ atovaquone",suggestion:"Adjust dosage or avoid"},{drug:"Bismuth salt",effect:"↓ tetracycline",suggestion:"Give tetracycline 2 hr pre or 6 hr post"},{drug:"Didanosine",effect:"↓ tetracycline",suggestion:"Give tetracycline 2 hr pre or 6 hr post"},{drug:"Digoxin",effect:"↑ digoxin",suggestion:"Monitor, adjust dosage"},{drug:"Iron products",effect:"↓ tetracycline",suggestion:"Give tetracycline 2 hr pre or 6 hr post"},{drug:"Methoxyflurane",effect:"↑ methoxyflurane",suggestion:"Monitor, adjust dosage"},{drug:"Sucralfate",effect:"↓ tetracycline",suggestion:"Give tetracycline 2 hr pre or 6 hr post"},{drug:"Zinc",effect:"↓ tetracycline",suggestion:"Give tetracycline 2 hr pre or 6 hr post"}],comments:["General reference, Clin Infect Dis 36:462, 2003.","Demeclocycline is similar to Tetracycline but, in addition, is sometimes used in treatment of patients with inappropriate secretion of antidiuretic hormone (SIADH) (N Engl J Med 298:173, 1978)."]}},Tigecycline:{id:"Tigecycline",name:"Tigecycline",tradename:"Tygacil",classification:{family:"OTHER",subclass:"Other",generation:null},mechanism:{target:"Beta-lactam target",action:"Inhibits bacterial cell wall synthesis",bactericidal:!0,pkpdIndex:"AUC_DEPENDENT"},spectrum:{preferred:[],alternative:[],notes:""},dosing:{adult:{standard:"100 mg IV initially, then 50 mg IV q12h",severe:"100 mg IV initially, then 50 mg IV q12h",renal:{normal:"No dosage adjustment for renal impairment",mild:"No dosage adjustment for renal impairment",moderate:"No dosage adjustment for renal impairment",severe:"No dosage adjustment for renal impairment"},hepatic:"No dosage adjustment",infusion:"Standard IV administration"},pediatric:{standard:"See pediatric guidelines",maximum:"Adult maximum",neonatal:"Specialized dosing required"}},monitoring:{levels:!0,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:[],crossResistance:[],testing:"Standard susceptibility testing"},safety:{pregnancyCategory:{humans:"possible fetal toxicity",animals:"fetal toxicity"},lactation:"Milk concentrations low, poor absorption of drug expected (calcium in milk). Short-term use safe, monitor infant for GI toxicity.",blackBoxWarning:!1,majorAdverseEffects:[]},interactions:[{drug:"Cyclosporine",effect:"↑ cyclosporine",management:"Monitor, adj"},{drug:"Digoxin",effect:"↓ digoxin (slight effect)",management:"Mor"},{drug:"Oral contraceptives",effect:"↓ efficacy of oral contraceptives",management:"Use alternat"},{drug:"Tacrolimus",effect:"↑ tacrolimus (Nephrology 2020;25:99)",management:"Monitor, adj"},{drug:"Warfarin",effect:"↑ R-warfarin, ↑ S-warfarin",management:"Monito"}],stewardship:{preferredIndications:[],avoidanceRecommendations:[],deEscalationGuidance:"De-escalate based on culture results",resistanceRisk:"Standard monitoring"},pharmacology:{oral_absorption:null,protein_binding:"71-89",half_life:"42",elimination:"Biliary, renal",csf_penetration:"5.9-10.6",preparations:"Injection"},rawData:{drug_name:"Tigecycline",tradename:"Tygacil",usage_and_dosing:{general:["Tigecycline is a derivative of Minocycline. The drug resists efflux by several bacterial pumps and also circumvents ribosomal protection mechanisms, thus expanding the antibacterial spectrum to include multi-drug resistant bacteria like Acinetobacter baumannii, carbapenemase-producing E. coli and Klebsiella sp. Tigecycline is also active against MRSA in vitro but other agents are preferred and in general it should be avoided unless there are no other options.","Tigecycline has no useful activity against P. aeruginosa.","Licensed for the treatment of skin, skin structure and intra-abdominal infections and community-acquired pneumonia. Use for resistant bacteria is not FDA-approved.",'Black Box Warning: FDA analysis showed higher risk of death among patients given Tigecycline as compared to other antibacterial drugs: 2.5% vs 1.8%. Recommendation from FDA: "...reserve Tigecycline for use in situations when alternative treatments are not suitable."',"Tigecycline was inferior to Imipenem in clinical trial of hospital-acquired pneumonia: Diagnostic Micro Infect Dis 68:140, 2010.","Multiple meta-analyses, Tigecycline often inferior to comparator with more adverse effects: Lancet Infect Dis 11:804, 2011; Lancet Infect Dis 11:834, 2011. Latest meta-analysis of great concern: One excess death for every 143 patients treated; one infection treatment failure for every 34 patients treated when used as a single agent (Clin Infect Dis 54:1699, 2012); editorial commentary (Clin Infect Dis 54:1710, 2012).","Reason for failures believed low serum levels resulting in unfavorable ratio of AUC/MIC: Antimicrob Agts Chemother 56:1065, 2012 & Antimicrobi Agts Chemother 56:1466, 2012.","High dose regimens of Tigecycline were compared to Imipenem in patients with hospital-acquired pneumonia: Antimicrob Agts Chemother 57:1756, 2013. Tigecycline regimens: 150 mg load and then 75 mg q12h vs 200 mg load and then 100 mg q12h. Higher dose achieved best serum levels and superior in efficacy to lower Tigecycline dose but also had the highest frequency of GI side effects.","Hence, for MDR gram-negative bacilli where there are few if any options, there may be an occasion for high dose Tigecycline as part of combination therapy. Users should realize that safety and efficacy of high dose Tigecycline is essentially unknown.","Tigecycline may reduce risk of selecting Polymyxin-resistant subpopulations of aerobic gram-negative bacilli.","Second Black-Box Warning: some Tigecycline formulations contain maltose. Avoid glucose testing methods affected by maltose in patients receiving such a formulation, otherwise unrecognized hypoglycemia or inappropriate insulin administration may result."],adult_dose:{usual_dose:"100 mg IV initially, then 50 mg IV q12h"},pediatric_dose:{notes:"Avoid, but if necessary:",age_8_11_yrs:"1.2 mg/kg q12h",age_12_17_yrs:"50 mg q12h",max_day:"100 mg"}},renal_adjustment:{notes:["Body weight and Creatinine Clearance calculations","CrCl = Creatinine clearance (mL/min)","CAPD = Continuous Ambulatory Peritoneal Dialysis","CRRT = Continuous Renal Replacement Therapy","AD = after hemodialysis","SLED = sustained low efficiency dialysis","Dosage adjustment may be required in hepatic disease."],half_life_normal:"42",half_life_esrd:"Unchanged",dose_normal_function:"100 mg, then 50 mg IV q12h",crcl_or_egfr:"No dosage adjustment for renal impairment",hemodialysis:"No dosage adjustment",capd:"No dosage adjustment",crrt:"No dosage adjustment",sled:"No data"},hepatic_adjustment:{mild_impairment_child_pugh_a:"No dosage adjustment",moderate_impairment_child_pugh_b:"No dosage adjustment",severe_impairment_child_pugh_c:"100 mg IV, then 25 mg IV q12h"},other_adjustment:["ECMO: See ECMO Drug Dosing Adjustment.","Obesity: See Obesity Dosing Adjustments."],adverse_effects:["High incidence of nausea (25%) & vomiting (20%) but only 1% of patients discontinued therapy due to an adverse event. Details on AEs in J Antimicrob Chemother 62(Suppl 1):i17, 2008.","Like other tetracyclines, may cause photosensitivity, pseudotumor cerebri, pancreatitis, a catabolic state (elevated BUN) and maybe hyperpigmentation (Clin Infect Dis 45:136, 2007). Tetracycline, Minocycline & Tigecycline associated with acute pancreatitis (Int J Antimicrob Agents 34:486, 2009).","Significant fall in fibrinogen levels in 20 of 20 patients with severe infections (Antimicrob Agts Chemother 59:1650, 2015).","Overall treatment stopped due to adverse effects in 5%.","Frequency of other adverse effects: local phlebitis (2%), fever (7%), rash (2.4%), photosensitivity, increased PT/PTT (4%), nausea (30%), vomiting (20%), diarrhea (13%), increased LFTs (4%), increased BUN/creatinine (2%), dizziness/lightheadedness (3.5%)."],pregnancy_risk:{fda_risk_category:{humans:"possible fetal toxicity",animals:"fetal toxicity"},lactation:"Milk concentrations low, poor absorption of drug expected (calcium in milk). Short-term use safe, monitor infant for GI toxicity.",footnote:"Capital letter = Old FDA risk category; Text = New FDA risk category"},antimicrobial_spectrum:{preferred:[],alternative:[]},pharmacology:{pk_pd_index:"24-hr AUC/MIC",preparations:"Injection",food_recommendation:null,oral_absorption_percent:null,tmax_hr:null,peak_serum_conc_ug_ml:"0.62 (50 mg q12h, SS)",peak_urine_conc_ug_ml:"No data",protein_binding_percent:"71-89",volume_of_distribution_vd_l_kg:"7-9 L/kg (Vss)",avg_serum_half_life_hr:"42",elimination:"Biliary, renal",bile_penetration_percent:"138",csf_blood_percent:"5.9-10.6",therapeutic_levels_in_csf:"No",auc_ug_hr_ml:"4.7 (50 mg q12h, 0-24h)"},enzyme_interactions:{cyp450_substrate:[],transporter_substrate:["PGP"],ugt_substrate:[],cyp450_inhibited:[],transporters_inhibited:[],ugts_inhibited:[],cyp450_induced:[],transporters_induced:[],ugts_induced:[],serum_drug_concentration_impact:"None expected"},major_drug_interactions:[{drug:"Cyclosporine",effect:"↑ cyclosporine",management:"Monitor, adj"},{drug:"Digoxin",effect:"↓ digoxin (slight effect)",management:"Mor"},{drug:"Oral contraceptives",effect:"↓ efficacy of oral contraceptives",management:"Use alternat"},{drug:"Tacrolimus",effect:"↑ tacrolimus (Nephrology 2020;25:99)",management:"Monitor, adj"},{drug:"Warfarin",effect:"↑ R-warfarin, ↑ S-warfarin",management:"Monito"}]}}},ab={familyBreakdown:{AMINOGLYCOSIDE:9,ANTIFOLATE:2,CARBAPENEM:6,CEPHALOSPORIN:30,OTHER:5,FLUOROQUINOLONE:9,GLYCOPEPTIDE:6,LINCOSAMIDE:2,MACROLIDE:4,MONOBACTAM:2,NITROIMIDAZOLE:2,OXAZOLIDINONE:2,PENICILLIN:14,PLEUROMUTILIN:2,POLYMYXIN:2,RIFAMYCIN:2,STREPTOGRAMIN:2,TETRACYCLINE:6}};console.log("💊 Antibiotics database loaded with",Object.keys(ip).length,"drugs");console.log("   Family distribution:",ab.familyBreakdown);const jr=ip;console.log("💊 Enhanced antibiotics database loaded");console.log(`   📊 Total drugs: ${Object.keys(jr).length}`);console.log("   🔄 Now powered by comprehensive JSON database");class nb{constructor(){this.antibioticsDB=jr,this.scoringWeights=this.initializeScoringWeights(),console.log("🎯 TherapeuticStrategyComparatorEngine initialized with specialist-level algorithms")}async generateTherapeuticComparison({organism:s,infectionSite:l,patientData:c,interpretations:d,resistanceAnalysis:m,mode:_="advanced"}){try{const h=this.filterEffectiveAntibiotics(d),v=await this.generateTherapeuticStrategies({effectiveAntibiotics:h,organism:s,infectionSite:l,resistanceAnalysis:m}),y=this.scoreTherapeuticStrategies(v,s,l,c,m),D=this.generateComparativeAnalysis(y),L=this.generateClinicalRecommendations(y,s,l,m);return{strategies:y,comparison:D,recommendations:L,metadata:{organism:s,infectionSite:l,analysisDate:new Date().toISOString(),totalOptions:y.length,preferredOptions:y.filter(W=>W.recommendation==="preferred").length}}}catch(h){throw console.error("TherapeuticStrategyComparator error:",h),new Error(`Therapeutic comparison failed: ${h.message}`)}}filterEffectiveAntibiotics(s){const l={};for(const[c,d]of Object.entries(s))(d.interpretation==="S"||d.interpretation==="I"&&this.isIntermediateUseful(c))&&(l[c]=d);return l}isIntermediateUseful(s){return["meropenem","cefepime","piperacillin-tazobactam","ciprofloxacin","vancomycin"].includes(s)}async generateTherapeuticStrategies({effectiveAntibiotics:s,organism:l,infectionSite:c,resistanceAnalysis:d}){const m=[];for(const[h,v]of Object.entries(s)){const y=this.getDrugData(h);if(!y)continue;const D={type:"monotherapy",primary:h,agents:[h],interpretation:v,drugData:[y],rationale:this.generateMonotherapyRationale(h,y,l,c)};m.push(D)}if(this.requiresCombinationTherapy(l,c,d)){const h=this.generateCombinationStrategies(s,l,c);m.push(...h)}const _=this.generateEmpiricStrategies(s,l,c);return m.push(..._),m}scoreTherapeuticStrategies(s,l,c,d,m){return s.map(h=>{const v=this.calculateStrategyScores(h,l,c,d,m);return{...h,scores:v,totalScore:this.calculateWeightedScore(v),recommendation:this.determineRecommendationLevel(v)}}).sort((h,v)=>v.totalScore-h.totalScore)}calculateStrategyScores(s,l,c,d,m){return{efficacy:this.scoreEfficacy(s,l,c),safety:this.scoreSafety(s,d),stewardship:this.scoreStewardship(s,l,m),pharmacology:this.scorePharmacology(s,c),resistance:this.scoreResistanceRisk(s,l,m),convenience:this.scoreConvenience(s),cost:this.scoreCost(s)}}scoreEfficacy(s,l,c){var m;let d=0;for(const _ of s.agents){const h=s.interpretation||((m=s.drugData.find(v=>v.name===_))==null?void 0:m.interpretation);(h==null?void 0:h.interpretation)==="S"?d+=30:(h==null?void 0:h.interpretation)==="I"&&(d+=15),d+=this.getOrganismSpecificEfficacy(_,l),d+=this.getSitePenetrationScore(_,c)}return s.type==="combination"&&(d+=this.getCombinationSynergyScore(s.agents,l)),Math.min(d,100)}scoreSafety(s,l){let c=80;for(const d of s.agents){const m=this.getDrugData(d);m&&((l==null?void 0:l.renalFunction)==="impaired"&&(m.renalAdjustment==="required"?c-=10:m.renalAdjustment==="major"&&(c-=20)),(l==null?void 0:l.hepaticFunction)==="impaired"&&m.hepaticAdjustment==="required"&&(c-=10),(l==null?void 0:l.age)>65&&m.elderlyRisk==="high"&&(c-=15),m.interactionRisk==="high"&&(c-=10))}return Math.max(c,0)}scoreStewardship(s,l,c){let d=50;for(const m of s.agents){const _=this.getDrugData(m);_&&(_.spectrum==="narrow"?d+=20:_.spectrum==="broad"?d-=10:_.spectrum==="very_broad"&&(d-=20),_.class==="carbapenem"&&(this.isCarbapenemaRequired(c)?d+=10:d-=30),_.stewardship==="restricted"?d-=20:_.stewardship==="preferred"&&(d+=15))}return Math.max(d,0)}scorePharmacology(s,l){let c=0;for(const d of s.agents){const m=this.getDrugData(d);if(!m)continue;const _=this.getTissuePenetration(d,l);c+=_*20,m.activity==="bactericidal"?c+=15:m.activity==="bacteriostatic"&&(c+=5),m.pkpdOptimized&&(c+=10)}return Math.min(c,100)}scoreResistanceRisk(s,l,c){let d=80;for(const m of s.agents){const _=this.getDrugData(m);_&&(_.resistanceRisk==="high"?d-=20:_.resistanceRisk==="moderate"&&(d-=10),this.hasKnownResistanceRisk(m,l)&&(d-=15))}return s.type==="combination"&&(d+=20),Math.max(d,0)}scoreConvenience(s){let l=0;for(const c of s.agents){const d=this.getDrugData(c);d&&(d.dosing==="once_daily"?l+=25:d.dosing==="twice_daily"?l+=20:d.dosing==="three_times_daily"&&(l+=10),d.oralAvailable&&(l+=20),d.monitoring==="none"?l+=15:d.monitoring==="minimal"?l+=10:d.monitoring==="intensive"&&(l-=10))}return Math.min(l/s.agents.length,100)}scoreCost(s){let l=0;for(const c of s.agents){const d=this.getDrugData(c);d&&(d.cost==="low"?l+=25:d.cost==="moderate"?l+=15:d.cost==="high"?l+=5:d.cost==="very_high"&&(l-=10))}return Math.max(l/s.agents.length,0)}calculateWeightedScore(s){let l=0;for(const[c,d]of Object.entries(s))l+=d*(this.scoringWeights[c]||0);return Math.round(l)}determineRecommendationLevel(s){const l=this.calculateWeightedScore(s);return l>=80&&s.efficacy>=70&&s.safety>=60?"preferred":l>=60&&s.efficacy>=50?"alternative":l>=40?"consider":"avoid"}generateComparativeAnalysis(s){return{summary:this.generateComparisonSummary(s),categories:this.generateCategoryComparisons(s),tradeoffs:this.identifyTradeoffs(s)}}generateClinicalRecommendations(s,l,c,d){const m=s.filter(h=>h.recommendation==="preferred"),_=s.filter(h=>h.recommendation==="alternative");return{firstLine:m.slice(0,2),alternatives:_.slice(0,3),avoid:s.filter(h=>h.recommendation==="avoid"),specialConsiderations:this.generateSpecialConsiderations(l,c,d),durationGuidance:this.getDurationGuidance(c),monitoringRecommendations:this.getMonitoringRecommendations(m)}}getDrugData(s){var l;return((l=this.antibioticsDB)==null?void 0:l[s])||null}initializeScoringWeights(){return{efficacy:.3,safety:.25,stewardship:.15,pharmacology:.15,resistance:.1,convenience:.03,cost:.02}}requiresCombinationTherapy(s,l,c){var m;return[l.includes("endocarditis"),l.includes("CNS"),(m=c==null?void 0:c.detectedPatterns)==null?void 0:m.some(_=>_.type==="carbapenemase"),s.includes("Pseudomonas")&&l.includes("RESP")].some(_=>_)}generateMonotherapyRationale(s,l,c,d){const m=[];return l.spectrum==="narrow"&&m.push("Narrow spectrum - excellent stewardship choice"),l.activity==="bactericidal"&&m.push("Bactericidal activity against target organism"),this.getTissuePenetration(s,d)>.8&&m.push("Excellent tissue penetration for infection site"),m.join("; ")}getTissuePenetration(s,l){var m;const c={CNS:{ceftriaxone:.9,meropenem:.8,vancomycin:.7,linezolid:.9},RESP:{ceftriaxone:.9,meropenem:.8,azithromycin:.9,levofloxacin:.8}},d=l.split("_")[0];return((m=c[d])==null?void 0:m[s])||.7}getOrganismSpecificEfficacy(s,l){return 10}getSitePenetrationScore(s,l){return this.getTissuePenetration(s,l)*20}getCombinationSynergyScore(s,l){return 15}isCarbapenemaRequired(s){var l;return((l=s==null?void 0:s.detectedPatterns)==null?void 0:l.some(c=>c.type==="esbl"||c.type==="ampc"))||!1}hasKnownResistanceRisk(s,l){var d;return((d={ciprofloxacin:["Pseudomonas","Enterobacter"],ceftazidime:["Pseudomonas","Enterobacter"]}[s])==null?void 0:d.some(m=>l.includes(m)))||!1}generateCombinationStrategies(s,l,c){return[]}generateEmpiricStrategies(s,l,c){return[]}generateComparisonSummary(s){return`Analysis of ${s.length} therapeutic strategies`}generateCategoryComparisons(s){return{}}identifyTradeoffs(s){return[]}generateSpecialConsiderations(s,l,c){return[]}getDurationGuidance(s){const l={RESP_:"5-7 days for CAP, 7-10 days for HAP/VAP",GU_:"3-7 days for uncomplicated UTI, 7-14 days for complicated",CNS_:"10-14 days for bacterial meningitis",BS_:"7-14 days depending on source control"},c=Object.keys(l).find(d=>s.startsWith(d));return l[c]||"7-10 days (standard course)"}getMonitoringRecommendations(s){return[]}}const gn={"Acinetobacter spp.":{category:"Acinetobacter spp.",organisms:{},tieringRules:{},specialConsiderations:{}},Anaerobes:{category:"Anaerobes",organisms:{},tieringRules:{},specialConsiderations:{}},"Burkholderia cepacia complex":{category:"Burkholderia cepacia complex",organisms:{},tieringRules:{},specialConsiderations:{}},Enterobacterales:{category:"Enterobacterales",organisms:{"Escherichia coli":{clsi_table:"Table 2A-1",category:"Enterobacterales (Table 2A-1)",source:"CLSI M100-Ed34",antibiotics:{ampicillin:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥17",I:"14-16",R:"≤13"},condition:"UTI isolates only"},tier:"Tier 1",reportingPriority:"primary"},"amoxicillin-clavulanate":{mic_breakpoints:{S:"≤8/4",I:"16/8",R:"≥32/16"},disk_diffusion:{routine:{S:"≥18",I:"14-17",R:"≤13"},condition:"For therapy of uncomplicated UTIs or for completion of therapy for systemic infection."},tier:"Tier 1",reportingPriority:"secondary"},"ampicillin-sulbactam":{mic_breakpoints:{S:"≤8/4",I:"16/8",R:"≥32/16"},disk_diffusion:{routine:{S:"≥15",I:"12-14",R:"≤11"}},tier:"Tier 2",reportingPriority:"conditional"},mecillinam:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥15",I:"12-14",R:"≤11"},condition:"Report only on E. coli"},tier:"Tier 3",reportingPriority:"secondary"},piperacillin:{mic_breakpoints:{S:"≤16",I:"32",R:"≥64"},disk_diffusion:{routine:{note:"Disk diffusion breakpoints removed in CLSI 2022 due to poor correlation."}},tier:"Tier 3",reportingPriority:"secondary"},"piperacillin-tazobactam":{mic_breakpoints:{S:"≤16/4",I:"32/4",R:"≥64/4"},disk_diffusion:{routine:{S:"≥21",I:"18-20",R:"≤17"}},tier:"Tier 1",reportingPriority:"secondary"},"ticarcillin-clavulanate":{mic_breakpoints:{S:"≤16/2",I:"32/2",R:"≥64/2"},disk_diffusion:{routine:{S:"≥20",I:"15-19",R:"≤14"}},tier:"Tier 2",reportingPriority:"secondary"},cefazolin:{mic_breakpoints:{S:"≤16",I:"32",R:"≥64"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"},condition:"Used for therapy of uncomplicated UTIs only"},tier:"Tier 2",reportingPriority:"conditional"},cefamandole:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}},tier:"Tier 3",reportingPriority:"secondary"},cefonicid:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}},tier:"Tier 3",reportingPriority:"secondary"},cefoperazone:{mic_breakpoints:{S:"≤16",I:"32",R:"≥64"},disk_diffusion:{routine:{S:"≥20",I:"16-19",R:"≤15"}},tier:"Tier 3",reportingPriority:"secondary"},cefotaxime:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"}},tier:"Tier 2",reportingPriority:"secondary"},cefotetan:{mic_breakpoints:{S:"≤16",I:"32",R:"≥64"},disk_diffusion:{routine:{S:"≥16",I:"13-15",R:"≤12"}},tier:"Tier 3",reportingPriority:"secondary"},cefoxitin:{mic_breakpoints:{S:"≤16",I:"32",R:"≥64"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}},tier:"Tier 2",reportingPriority:"secondary"},ceftazidime:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥21",I:"18-20",R:"≤17"}},tier:"Tier 1",reportingPriority:"secondary"},ceftizoxime:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥22",I:"20-21",R:"≤19"}},tier:"Tier 3",reportingPriority:"secondary"},ceftriaxone:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"}},tier:"Tier 1",reportingPriority:"primary"},"cefuroxime-parenteral":{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"}},tier:"Tier 3",reportingPriority:"secondary"},cefepime:{mic_breakpoints:{S:"≤8",SDD:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥25",I:"19-24",R:"≤18"},special_considerations:"The 'Intermediate' category for disk diffusion corresponds to the 'SDD' MIC breakpoint. Cefepime S/SDD results should be suppressed or edited and reported as resistant for isolates that demonstrate carbapenemase production (see Appendix G, Table G3)."},tier:"Tier 1",reportingPriority:"secondary"},ceftaroline:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"}},tier:"Tier 3",reportingPriority:"secondary"},"ceftazidime-avibactam":{mic_breakpoints:{S:"≤8/4",I:"null",R:"≥16/4"},disk_diffusion:{routine:{S:"≥21",I:"null",R:"≤20"},special_considerations:"Confirmatory MIC testing is indicated for isolates with zones of 20-22 mm to avoid reporting false-susceptible or false-resistant results."},tier:"Tier 3",reportingPriority:"secondary"},"ceftolozane-tazobactam":{mic_breakpoints:{S:"≤2/4",I:"null",R:"≥4/4"},disk_diffusion:{routine:{S:"≥22",I:"19-21",R:"≤18"}},tier:"Tier 3",reportingPriority:"secondary"},moxalactam:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"}},tier:"Tier 3",reportingPriority:"secondary"},cefiderocol:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"},special_considerations:"Note regarding reproducibility and interpretation of Cefiderocol testing results (both disk diffusion and broth microdilution) recommends discussion with prescribers and antimicrobial stewardship members regarding potential inaccuracies."},tier:"Tier 3",reportingPriority:"secondary"},"cefazolin-oral-surrogate":{mic_breakpoints:{S:"≤16",I:"null",R:"≥32"},disk_diffusion:{routine:{S:"≥15",I:"null",R:"≤14"},condition:"Oral cephalosporin surrogate for uncomplicated UTI",special_considerations:"Surrogates for cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime, cephalexin, and loracarbef. If cefazolin tests resistant, test individual drugs if considering for use."},tier:"Tier 3",reportingPriority:"secondary"},cefaclor:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}},tier:"Tier 3",reportingPriority:"secondary"},cefadroxil:{mic_breakpoints:{S:"≤16",I:"null",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}},tier:"Tier 3",reportingPriority:"secondary"},cefdinir:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥20",I:"17-19",R:"≤16"}},tier:"Tier 3",reportingPriority:"secondary"},cefixime:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥19",I:"16-18",R:"≤15"}},tier:"Tier 3",reportingPriority:"secondary"},cefpodoxime:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥21",I:"18-20",R:"≤17"}},tier:"Tier 3",reportingPriority:"secondary"},cefprozil:{mic_breakpoints:{S:"≤16",I:"null",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}},tier:"Tier 3",reportingPriority:"secondary"},ceftibuten:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"}},tier:"Tier 3",reportingPriority:"secondary"},"cefuroxime-oral":{mic_breakpoints:{S:"≤4",I:"8-16",R:"≥32"},disk_diffusion:{routine:{S:"≥23",I:"15-22",R:"≤14"}},tier:"Tier 3",reportingPriority:"secondary"},cephalexin:{mic_breakpoints:{S:"≤16",I:"null",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}},tier:"Tier 3",reportingPriority:"secondary"},loracarbef:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}},tier:"Tier 3",reportingPriority:"secondary"},doripenem:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"}},tier:"Tier 2",reportingPriority:"secondary"},ertapenem:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥22",I:"19-21",R:"≤18"}},tier:"Tier 1",reportingPriority:"secondary"},imipenem:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"}},tier:"Tier 1",reportingPriority:"secondary"},"imipenem-relebactam":{mic_breakpoints:{S:"≤1/4",I:"2/4",R:"≥4/4"},disk_diffusion:{routine:{S:"≥25",I:"21-24",R:"≤20"},special_considerations:"Breakpoints do not apply to the family Morganellaceae (Morganella, Proteus, Providencia)."},tier:"Tier 3",reportingPriority:"secondary"},meropenem:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"}},tier:"Tier 1",reportingPriority:"primary"},"meropenem-vaborbactam":{mic_breakpoints:{S:"≤4/8",I:"8/8",R:"≥16/8"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"},special_considerations:"CRITICAL WARNING: Isolates with OXA-48-like enzymes may test susceptible but not respond clinically. If OXA-48 is detected, report as resistant or suppress the result."},tier:"Tier 3",reportingPriority:"secondary"},aztreonam:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥21",I:"16-20",R:"≤15"}},tier:"Tier 2",reportingPriority:"secondary"},amikacin:{mic_breakpoints:{S:"≤16",I:"32",R:"≥64"},disk_diffusion:{routine:{S:"≥17",I:"15-16",R:"≤14"}},tier:"Tier 1",reportingPriority:"secondary"},gentamicin:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥15",I:"13-14",R:"≤12"}},tier:"Tier 1",reportingPriority:"secondary"},kanamycin:{mic_breakpoints:{S:"≤16",I:"32",R:"≥64"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}},tier:"Tier 3",reportingPriority:"secondary"},netilmicin:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥15",I:"13-14",R:"≤12"}},tier:"Tier 3",reportingPriority:"secondary"},plazomicin:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥30",I:"14-17",R:"≤13"}},tier:"Tier 3",reportingPriority:"secondary"},streptomycin:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥15",I:"12-14",R:"≤11"}},tier:"Tier 3",reportingPriority:"secondary"},tobramycin:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥15",I:"13-14",R:"≤12"}},tier:"Tier 2",reportingPriority:"secondary"},cinoxacin:{mic_breakpoints:{S:"≤16",I:"null",R:"≥32"},disk_diffusion:{routine:{S:"≥19",I:"14-18",R:"≤13"},condition:"UTI only"},tier:"Tier 3",reportingPriority:"secondary"},ciprofloxacin:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥21",I:"16-20",R:"≤15"}},tier:"Tier 1",reportingPriority:"primary"},enoxacin:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥20",I:"17-19",R:"≤16"},condition:"UTI only"},tier:"Tier 3",reportingPriority:"secondary"},gatifloxacin:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"}},tier:"Tier 3",reportingPriority:"secondary"},gemifloxacin:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},disk_diffusion:{routine:{S:"≥20",I:"16-19",R:"≤15"},special_considerations:"Report only on K. pneumoniae"},tier:"Tier 3",reportingPriority:"secondary"},grepafloxacin:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥18",I:"15-17",R:"≤14"}},tier:"Tier 3",reportingPriority:"secondary"},levofloxacin:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥17",I:"14-16",R:"≤13"}},tier:"Tier 1",reportingPriority:"secondary"},lomefloxacin:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥22",I:"19-21",R:"≤18"},condition:"UTI only"},tier:"Tier 3",reportingPriority:"secondary"},moxifloxacin:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥17",I:"14-16",R:"≤13"}},tier:"Tier 2",reportingPriority:"secondary"},"nalidixic-acid":{mic_breakpoints:{S:"≤16",I:"null",R:"≥32"},disk_diffusion:{routine:{S:"≥19",I:"14-18",R:"≤13"},condition:"UTI only"},tier:"Tier 3",reportingPriority:"secondary"},norfloxacin:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥17",I:"13-16",R:"≤12"},condition:"UTI only"},tier:"Tier 3",reportingPriority:"secondary"},ofloxacin:{mic_breakpoints:{S:"≤2",I:"4",R:"≥8"},disk_diffusion:{routine:{S:"≥19",I:"13-18",R:"≤12"}},tier:"Tier 3",reportingPriority:"secondary"},sparfloxacin:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥17",I:"14-16",R:"≤13"}},tier:"Tier 3",reportingPriority:"secondary"},sulfonamides:{mic_breakpoints:{S:"≤256",I:"null",R:"≥512"},disk_diffusion:{routine:{S:"≥17",I:"11-16",R:"≤10"},condition:"UTI only",special_considerations:"Sulfisoxazole can be used to represent any of the currently available sulfonamide preparations."},tier:"Tier 3",reportingPriority:"secondary"},trimethoprim:{mic_breakpoints:{S:"≤8",I:"null",R:"≥16"},disk_diffusion:{routine:{S:"≥16",I:"11-15",R:"≤10"},condition:"UTI only"},tier:"Tier 3",reportingPriority:"secondary"},"trimethoprim-sulfamethoxazole":{mic_breakpoints:{S:"≤2/38",I:"null",R:"≥4/76"},disk_diffusion:{routine:{S:"≥16",I:"11-15",R:"≤10"}},tier:"Tier 1",reportingPriority:"primary"},chloramphenicol:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"13-17",R:"≤12"},special_considerations:"Not routinely reported on isolates from the urinary tract."},tier:"Tier 3",reportingPriority:"secondary"},"colistin-polymyxinB":{mic_breakpoints:{S:"≤2",I:"≤2",R:"≥4"},disk_diffusion:{routine:{note:"Disk diffusion and gradient diffusion methods should not be performed."},special_considerations:"For colistin, broth microdilution, CBDE, and CAT MIC methods are acceptable. For polymyxin B, broth microdilution is the only approved method. Guidance for administration: Colistin (methanesulfonate) with loading and maximum renally adjusted doses; Polymyxin B with loading and maximum recommended doses. WARNING: When colistin or polymyxin B is given systemically, neither is likely to be effective for pneumonia."},tier:"Tier 3",reportingPriority:"secondary"},fosfomycin:{mic_breakpoints:{S:"≤64",I:"128",R:"≥256"},disk_diffusion:{routine:{S:"≥16",I:"13-15",R:"≤12"},condition:"E. coli urinary tract isolates only",special_considerations:"Breakpoints apply only to E. coli and should not be extrapolated to other species of Enterobacterales. The 200-μg fosfomycin disk contains 50 μg glucose-6-phosphate. MIC testing must be performed by agar dilution with glucose-6-phosphate. Broth dilution should not be performed."},tier:"Tier 3",reportingPriority:"secondary"},nitrofurantoin:{mic_breakpoints:{S:"≤32",I:"64",R:"≥128"},disk_diffusion:{routine:{S:"≥17",I:"15-16",R:"≤14"},condition:"UTI only"},tier:"Tier 2",reportingPriority:"conditional"},tetracycline:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥15",I:"12-14",R:"≤11"}},tier:"Tier 3",reportingPriority:"secondary"},doxycycline:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥14",I:"11-13",R:"≤10"}},tier:"Tier 2",reportingPriority:"secondary"},minocycline:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥16",I:"13-15",R:"≤12"}},tier:"Tier 3",reportingPriority:"secondary"}}},"Salmonella spp":{clsi_table:"Table 2A-2",category:"Salmonella and Shigella (Table 2A-2)",source:"CLSI M100-Ed34",antibiotics:{penicillin:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥17",I:"14-16",R:"≤13"}},tier:"Tier 3",reportingPriority:"secondary"},azithromycin:{mic_breakpoints:{S:"≤16",I:"null",R:"≥32"},disk_diffusion:{routine:{S:"≥13",I:"null",R:"≤12"},condition:"For S. Typhi/Paratyphi only"},tier:"Tier 2",reportingPriority:"secondary"},ceftriaxone:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥26",I:"23-25",R:"≤22"}},tier:"Tier 1",reportingPriority:"primary"},chloramphenicol:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥18",I:"13-17",R:"≤12"}},tier:"Tier 3",reportingPriority:"secondary"},ciprofloxacin:{mic_breakpoints:{S:"≤0.06",I:"0.12-0.5",R:"≥1"},disk_diffusion:{routine:{S:"≥31",I:"21-30",R:"≤20"}},tier:"Tier 1",reportingPriority:"primary"},"pefloxacin-inv":{mic_breakpoints:{S:"≤0.25",I:"null",R:"≥0.5"},disk_diffusion:{routine:{S:"≥24",I:"null",R:"≤23"},condition:"Surrogate for ciprofloxacin in S. Typhi"},tier:"Tier 3",reportingPriority:"secondary"},ertapenem:{mic_breakpoints:{S:"≤0.5",I:"1",R:"≥2"},disk_diffusion:{routine:{S:"≥22",I:"19-21",R:"≤18"}},tier:"Tier 1",reportingPriority:"secondary"},imipenem:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"}},tier:"Tier 1",reportingPriority:"secondary"},meropenem:{mic_breakpoints:{S:"≤1",I:"2",R:"≥4"},disk_diffusion:{routine:{S:"≥23",I:"20-22",R:"≤19"}},tier:"Tier 1",reportingPriority:"primary"},"trimethoprim-sulfamethoxazole":{mic_breakpoints:{S:"≤2/38",I:"null",R:"≥4/76"},disk_diffusion:{routine:{S:"≥16",I:"11-15",R:"≤10"}},tier:"Tier 1",reportingPriority:"primary"},tetracycline:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥15",I:"12-14",R:"≤11"}},tier:"Tier 3",reportingPriority:"secondary"},doxycycline:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥14",I:"11-13",R:"≤10"}},tier:"Tier 2",reportingPriority:"secondary"},minocycline:{mic_breakpoints:{S:"≤4",I:"8",R:"≥16"},disk_diffusion:{routine:{S:"≥16",I:"13-15",R:"≤12"}},tier:"Tier 3",reportingPriority:"secondary"}}},"Shigella spp":{clsi_table:"Table 2A-2",category:"Salmonella and Shigella (Table 2A-2)",source:"CLSI M100-Ed34",antibiotics:{penicillin:{mic_breakpoints:{S:"≤8",I:"16",R:"≥32"},disk_diffusion:{routine:{S:"≥17",I:"14-16",R:"≤13"}},tier:"Tier 3",reportingPriority:"secondary"},azithromycin:{mic_breakpoints:{S:"≤8",I:"null",R:"≥16"},disk_diffusion:{routine:{S:"≥12",I:"null",R:"≤11"},special_considerations:"Disk diffusion zones can be hazy and difficult to measure, especially S. sonnei. If difficult to measure, an MIC method is recommended."},tier:"Tier 2",reportingPriority:"secondary"},ceftriaxone:{mic_breakpoints:{S:"≤1",I:"null",R:"≥2"},disk_diffusion:{routine:{S:"≥26",I:"23-25",R:"≤22"}},tier:"Tier 1",reportingPriority:"primary"},ciprofloxacin:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},disk_diffusion:{routine:{S:"≥21",I:"16-20",R:"≤15"}},tier:"Tier 1",reportingPriority:"primary"},ofloxacin:{mic_breakpoints:{S:"≤0.25",I:"0.5",R:"≥1"},disk_diffusion:{routine:{S:"≥21",I:"16-20",R:"≤15"}},tier:"Tier 3",reportingPriority:"secondary"},"trimethoprim-sulfamethoxazole":{mic_breakpoints:{S:"≤2/38",I:"null",R:"≥4/76"},disk_diffusion:{routine:{S:"≥16",I:"11-15",R:"≤10"}},tier:"Tier 1",reportingPriority:"primary"}}}},tieringRules:{},specialConsiderations:{}},"Enterococcus spp.":{category:"Enterococcus spp.",organisms:{},tieringRules:{},specialConsiderations:{}},"Haemophilus spp.":{category:"Haemophilus spp.",organisms:{},tieringRules:{},specialConsiderations:{}},"Neisseria spp.":{category:"Neisseria spp.",organisms:{},tieringRules:{},specialConsiderations:{}},"Other Non-Enterobacterales":{category:"Other Non-Enterobacterales",organisms:{},tieringRules:{},specialConsiderations:{}},"Pseudomonas aeruginosa":{category:"Pseudomonas aeruginosa",organisms:{},tieringRules:{},specialConsiderations:{}},"Staphylococcus spp.":{category:"Staphylococcus spp.",organisms:{},tieringRules:{},specialConsiderations:{}},"Stenotrophomonas maltophilia":{category:"Stenotrophomonas maltophilia",organisms:{},tieringRules:{},specialConsiderations:{}},"Streptococcus spp.":{category:"Streptococcus spp.",organisms:{},tieringRules:{},specialConsiderations:{}}},ob={totalOrganisms:3};function tp(){return gn}function ap(g,s){for(const l of Object.values(gn)){const c=l.organisms[g];if(c!=null&&c.antibiotics[s])return c.antibiotics[s]}return null}function rb(g,s="Tier 1"){const l=[];for(const c of Object.values(gn)){const d=c.organisms[g];if(d){Object.entries(d.antibiotics).forEach(([m,_])=>{_.tier===s&&l.push({name:m,..._})});break}}return l}function np(g){for(const[s,l]of Object.entries(gn))if(l.organisms[g])return s;return null}function op(g,s,l){const c=ap(g,s);if(!(c!=null&&c.mic_breakpoints))return null;const{S:d,I:m,SDD:_,R:h}=c.mic_breakpoints,v=parseFloat(l.replace(/[≤≥]/g,""));return d&&v<=parseFloat(d.replace(/[≤≥]/g,""))?"S":_&&v<=parseFloat(_.replace(/[≤≥]/g,""))?"SDD":m&&v<=parseFloat(m.replace(/[≤≥]/g,""))?"I":"R"}let sb=class{constructor(){this.database=gn}generateReport(s,l={}){const c=np(s);if(!c)return{error:"Organism not found in CLSI database",organism:s};const d=this.database[c].organisms[s],m={organism:s,category:c,clsi_table:d.clsi_table,source:d.source,tier1_results:[],tier2_results:[],tier3_results:[],special_considerations:[],recommendations:[]};return Object.entries(l).forEach(([_,h])=>{const v=d.antibiotics[_];if(v){const y=op(s,_,h),D={antibiotic:_,mic:h,interpretation:y,tier:v.tier,reportingPriority:v.reportingPriority,condition:v.condition,special_considerations:v.special_considerations};v.tier==="Tier 1"?m.tier1_results.push(D):v.tier==="Tier 2"?m.tier2_results.push(D):m.tier3_results.push(D),v.special_considerations&&m.special_considerations.push({antibiotic:_,note:v.special_considerations})}}),m.recommendations=this.generateRecommendations(m),m}generateRecommendations(s){const l=[],c=s.tier1_results.filter(_=>_.interpretation==="R").length,d=s.tier1_results.length;return c>d*.5&&l.push({type:"warning",message:"High resistance to first-line agents detected. Consider advanced diagnostics."}),s.tier1_results.some(_=>_.antibiotic.includes("meropenem")||_.antibiotic.includes("imipenem")||_.antibiotic.includes("ertapenem"))&&s.tier1_results.some(_=>_.interpretation==="R")&&l.push({type:"critical",message:"Carbapenem resistance detected. Notify infection control and ID specialist."}),l}};console.log("🧬 CLSI database loaded with",Object.keys(gn).length,"categories");console.log("   Total organisms:",ob.totalOrganisms);class Jl extends sb{constructor(){super(),this.database=tp()}generateAntibiogramReport(s,l={},c={}){const d=this.generateReport(s,l);return d.error?d:{...d,stewardshipGuidance:this.generateStewardshipGuidance(d,c),tierRecommendations:this.generateTierRecommendations(d),resistanceAlerts:this.generateResistanceAlerts(d),reportingStrategy:this.generateReportingStrategy(d,c)}}generateStewardshipGuidance(s,l){const c={primaryRecommendations:[],alternativeOptions:[],avoidanceWarnings:[],escalationTriggers:[]},{infection_site:d,severity:m,patient_factors:_}=l;return s.tier1_results.forEach(y=>{if(y.interpretation==="S"){let D="standard";this.isNarrowSpectrum(y.antibiotic)&&(D="preferred"),d&&this.isOptimalForSite(y.antibiotic,d)&&(D="preferred"),c.primaryRecommendations.push({antibiotic:y.antibiotic,rationale:this.generateRationale(y,l),priority:D,stewardshipScore:this.calculateStewardshipScore(y.antibiotic,l)})}}),s.tier1_results.some(y=>["meropenem","imipenem","ertapenem"].includes(y.antibiotic)&&y.interpretation==="R")&&c.escalationTriggers.push({trigger:"carbapenem_resistance",action:"Notify ID specialist and infection control immediately",urgency:"critical"}),this.detectESBLPattern(s).likely&&c.escalationTriggers.push({trigger:"probable_esbl",action:"Consider carbapenem therapy, avoid cephalosporins",urgency:"high"}),c}generateTierRecommendations(s){const l={reportTier1:!0,reportTier2:!1,reportTier3:!1,suppressRedundant:!0,cascadingLogic:[]},c=s.tier1_results.filter(_=>_.interpretation==="S").length,d=s.tier1_results.length;return c<=2&&d>0&&(l.reportTier2=!0,l.cascadingLogic.push("Limited Tier 1 options - including Tier 2 agents")),(d-c)/d>.7&&(l.reportTier3=!0,l.cascadingLogic.push("High resistance detected - including specialized agents")),l}generateResistanceAlerts(s){const l=[];return this.detectESBLPattern(s).likely&&l.push({type:"esbl_suspected",severity:"high",message:"ESBL production suspected based on resistance pattern",recommendations:["Consider confirmatory testing","Avoid cephalosporins","Carbapenem preferred"]}),this.detectAmpCPattern(s).likely&&l.push({type:"ampc_suspected",severity:"medium",message:"AmpC β-lactamase production suspected",recommendations:["Cefepime or carbapenem preferred","Avoid cefotaxime/ceftriaxone"]}),this.detectCarbapenemasePattern(s).likely&&l.push({type:"carbapenemase_suspected",severity:"critical",message:"Carbapenemase production suspected - contact ID/IC immediately",recommendations:["Polymyxin or tigecycline consideration","Combination therapy","Contact isolation"]}),l}generateReportingStrategy(s,l){const c={primaryReport:[],secondaryReport:[],suppressedAgents:[],comments:[]},d=s.tier1_results.filter(m=>m.interpretation==="S").sort((m,_)=>this.calculateStewardshipScore(_.antibiotic,l)-this.calculateStewardshipScore(m.antibiotic,l));return c.primaryReport=d.slice(0,4).map(m=>({antibiotic:m.antibiotic,interpretation:m.interpretation,tier:m.tier,rationale:"Tier 1 - First line therapy"})),s.tier1_results.forEach(m=>{m.condition&&this.matchesCondition(m.condition,l)&&(c.primaryReport.some(_=>_.antibiotic===m.antibiotic)||c.secondaryReport.push({antibiotic:m.antibiotic,interpretation:m.interpretation,condition:m.condition,rationale:`Conditional reporting: ${m.condition}`}))}),c}detectESBLPattern(s){const l=s.tier1_results.filter(m=>["ceftriaxone","cefotaxime","ceftazidime"].includes(m.antibiotic)),c=l.filter(m=>m.interpretation==="R").length,d=l.length;return{likely:c>=2&&d>=2,confidence:d>0?c/d:0,evidence:l}}detectAmpCPattern(s){const l=s.tier1_results.filter(d=>["cefotaxime","ceftriaxone","ampicillin-sulbactam"].includes(d.antibiotic)&&d.interpretation==="R"),c=s.tier1_results.some(d=>d.antibiotic==="cefepime"&&d.interpretation==="S");return{likely:l.length>=2&&c,confidence:l.length>=2?.8:.4,evidence:l}}detectCarbapenemasePattern(s){const l=s.tier1_results.filter(d=>["meropenem","imipenem","ertapenem"].includes(d.antibiotic)),c=l.filter(d=>d.interpretation==="R").length;return{likely:c>=1,confidence:c>=2?1:.7,evidence:l}}calculateStewardshipScore(s,l){let c=50;return this.isNarrowSpectrum(s)&&(c+=20),this.hasOralOption(s)&&!l.severe_infection&&(c+=10),l.infection_site&&this.isOptimalForSite(s,l.infection_site)&&(c+=15),this.isHighResistanceRisk(s)&&(c-=15),this.isCriticalAgent(s)&&(c-=25),Math.max(0,Math.min(100,c))}isNarrowSpectrum(s){return["ampicillin","cefazolin","clindamycin","erythromycin","trimethoprim-sulfamethoxazole","nitrofurantoin"].includes(s)}isCriticalAgent(s){return["meropenem","imipenem","colistin","tigecycline","linezolid"].includes(s)}isHighResistanceRisk(s){return["ciprofloxacin","levofloxacin","ceftazidime"].includes(s)}hasOralOption(s){return["trimethoprim-sulfamethoxazole","ciprofloxacin","amoxicillin-clavulanate"].includes(s)}isOptimalForSite(s,l){var d;return((d={urinary_tract:["nitrofurantoin","trimethoprim-sulfamethoxazole","ciprofloxacin"],respiratory:["amoxicillin-clavulanate","ceftriaxone","levofloxacin"],skin_soft_tissue:["clindamycin","cephalexin","trimethoprim-sulfamethoxazole"],intraabdominal:["piperacillin-tazobactam","meropenem","metronidazole"],bloodstream:["ceftriaxone","meropenem","vancomycin"]}[l])==null?void 0:d.includes(s))||!1}matchesCondition(s,l){return!!(s.includes("UTI")&&l.infection_site==="urinary_tract"||s.includes("uncomplicated")&&!l.severe_infection)}generateRationale(s,l){const c=[];return s.tier==="Tier 1"&&c.push("First-line agent"),this.isNarrowSpectrum(s.antibiotic)&&c.push("narrow spectrum preferred"),l.infection_site&&this.isOptimalForSite(s.antibiotic,l.infection_site)&&c.push("optimal site penetration"),c.join(", ")}}new Jl;console.log("🧬 CLSI Reporting Engine initialized");console.log("   📊 Tier-based antibiogram reporting enabled");console.log("   🎯 Stewardship-guided recommendations active");const lb=Object.freeze(Object.defineProperty({__proto__:null,CLSIReportingEngine:Jl,findOrganismCategory:np,getCLSIBreakpoints:ap,getCLSIDatabase:tp,getTierAntibiotics:rb,validateBreakpoint:op},Symbol.toStringTag,{value:"Module"}));class cb{constructor(){this.clsiEngine=new $l,this.resistanceEngine=new Yh,this.comparatorEngine=new nb,this.clsiReportingEngine=new Jl,this.bacteriaDatabase=$i(),this.antibioticsDatabase=jr,console.log("🧠 MasterAntibiogramEngine initialized with full intelligence layers"),console.log("   📊 CLSI tier-based reporting engine active")}async interpretAntibiogram({organism:s,infectionSite:l,micData:c,interpretations:d=null,resistanceAnalysis:m=null,detectedMechanisms:_=null,patientData:h={},localEpidemiology:v={},mode:y="simple"}){console.log(`🔬 Starting ${y} mode antibiogram interpretation for ${s}`);try{const D=await this.executePhase1(s,l),L=d?{micData:c,interpretations:d,clinicalOverrides:{},warnings:[],susceptibleAgents:this.filterSusceptibleAgents(d),resistantPattern:this.analyzeResistantPattern(d)}:await this.executePhase2(s,c,l,D),W=m?{detectedMechanisms:m,confirmationTests:this.generateConfirmationTests(_||[]),finalInterpretations:d,interpretationChanges:[],mechanismEducation:this.generateMechanismEducation(_||[])}:await this.executePhase3(s,L,c),se=await this.executePhase4({...D,...L,...W,patientData:h,infectionSite:l,localEpidemiology:v,mode:y});return{success:!0,mode:y,organism:s,infectionSite:l,phases:{phase1:D,phase2:L,phase3:W,phase4:se},clinicalSummary:this.generateClinicalSummary(D,L,W,se),educationalInsights:this.generateEducationalContent(D,L,W,se),timestamp:new Date().toISOString()}}catch(D){return console.error("❌ MasterAntibiogramEngine error:",D),{success:!1,error:D.message,fallbackRecommendations:this.generateFallbackRecommendations(s,l)}}}async executePhase1(s,l){console.log("📋 Phase 1: Setting the Stage");const c=this.bacteriaDatabase[s]||null;if(!c)throw new Error(`Unknown organism: ${s}`);const d=this.clsiEngine.getIntrinsicResistance(s),m=this.getSiteSpecificConsiderations(l),_=this.generateInitialAntibioticPanel(s,d);return{organism:s,organismProfile:c,infectionSite:l,intrinsicResistance:d,siteConsiderations:m,initialPanel:_,educationalNotes:this.generatePhase1Education(s,d)}}async executePhase2(s,l,c,d){console.log("🚩 Phase 2: Initial Interpretation & Red Flags");const m={},_=[],h={};for(const[v,y]of Object.entries(l)){const D=await this.clsiEngine.interpretMIC(s,v,y,c);m[v]=D;const L=this.checkClinicalOverrides(s,v,D,c);L&&(h[v]=L,_.push(L.warning));const W=this.checkParadoxicalResults(s,v,D,m);W&&_.push(W)}return{micData:l,interpretations:m,clinicalOverrides:h,warnings:_,susceptibleAgents:this.filterSusceptibleAgents(m),resistantPattern:this.analyzeResistantPattern(m)}}async executePhase3(s,l,c){console.log("🔍 Phase 3: Resistance Mechanism Detection");const d=await this.resistanceEngine.analyzePattern(s,l.interpretations),m=this.generateConfirmationTests(d.detectedPatterns),_=this.applyMechanismOverrides(l.interpretations,d.detectedPatterns),h=this.calculateInterpretationChanges(l.interpretations,_);return{detectedMechanisms:d,confirmationTests:m,finalInterpretations:_,interpretationChanges:h,mechanismEducation:this.generateMechanismEducation(d.detectedPatterns)}}async executePhase4(s){console.log(`🎯 Phase 4: ${s.mode==="advanced"?"Therapeutic Comparison":"Simple Recommendations"}`);const l=this.extractViableOptions(s.finalInterpretations);return s.mode==="simple"?this.generateSimpleRecommendations(l,s):this.generateAdvancedComparison(l,s)}generateSimpleRecommendations(s,l){const c=this.generateCLSITierRecommendations(s,l),d=this.rankOptionsByTierCriteria(s,l,c);return{mode:"simple",primaryRecommendation:d[0]||null,alternatives:d.slice(1,4),clsiTierReport:c,clinicalAlerts:this.generateClinicalAlerts(l.detectedMechanisms),dosing:this.getDosingRecommendations(d[0],l.patientData),monitoring:this.getMonitoringRequirements(d[0]),duration:this.getTreatmentDuration(d[0],l.infectionSite)}}async generateAdvancedComparison(s,l){try{if(s.length===0)return console.log("⚠️ No viable options - generating MDR recommendations"),this.generateMDRRecommendations(l);const c={};return s.forEach(d=>{c[d.antibiotic]=d.interpretation}),await this.comparatorEngine.generateTherapeuticComparison({organism:l.organism,infectionSite:l.infectionSite,patientData:l.patientData,interpretations:c,resistanceAnalysis:l.detectedMechanisms,mode:"advanced"})}catch(c){return console.error("Advanced comparison failed:",c),s.length===0?this.generateMDRRecommendations(l):{strategies:s.map((d,m)=>({primary:d.antibiotic,agents:[d.antibiotic],type:"single_agent",recommendation:m===0?"preferred":"alternative",totalScore:80-m*10,scores:{efficacy:80-m*5,safety:75,stewardship:70,pharmacology:80},rationale:`${d.interpretation.interpretation} by CLSI standards`})),metadata:{totalOptions:s.length,preferredOptions:1,analysisDate:new Date().toISOString()},recommendations:{firstLine:s.slice(0,2).map(d=>({agents:[d.antibiotic],totalScore:80})),alternatives:s.slice(2,4).map(d=>({agents:[d.antibiotic],totalScore:70}))}}}}generateClinicalSummary(s,l,c,d){return{organism:s.organism,site:s.infectionSite,resistanceMechanisms:c.detectedMechanisms.detectedPatterns.map(m=>m.type),keyFindings:[...l.warnings.map(m=>m.message),...c.interpretationChanges.map(m=>`${m.antibiotic}: ${m.oldResult} → ${m.newResult} (${m.reason})`)],recommendation:d.mode==="simple"?d.primaryRecommendation:d.preferredStrategy,clinicalPearls:this.extractClinicalPearls(s,l,c,d)}}generateEducationalContent(s,l,c,d){return{intrinsicResistanceExplanation:this.explainIntrinsicResistance(s.intrinsicResistance),mechanismExplanations:this.explainDetectedMechanisms(c.detectedMechanisms),clinicalReasoningSteps:this.explainReasoningSteps(s,l,c,d),literatureReferences:this.generateReferences(s.organism,c.detectedMechanisms),similarCases:this.findSimilarCases(s.organism,c.detectedMechanisms)}}getSiteSpecificConsiderations(s){const l={CNS_meningitis:{penetrationRequired:"CNS_critical",bactericidalRequired:!0,dosing:"high_dose",notes:"Blood-brain barrier penetration essential"},GU_UTI_uncomplicated:{penetrationRequired:"urinary_specific",bactericidalRequired:!1,dosing:"standard",notes:"Urinary concentration more important than serum"},BS_bacteremia:{penetrationRequired:"systemic",bactericidalRequired:!0,dosing:"aggressive",notes:"Early adequate therapy critical"}};return l[s]||l.default}generateInitialAntibioticPanel(s,l){return this.getStandardAntibioticPanel(s).filter(d=>!l.includes(d))}getStandardAntibioticPanel(s){const l=this.clsiEngine.mapOrganismToCLSICategory(s),c={enterobacterales:["ampicillin","ampicillin-sulbactam","piperacillin-tazobactam","cefazolin","ceftriaxone","ceftazidime","cefepime","ertapenem","imipenem","meropenem","gentamicin","tobramycin","amikacin","ciprofloxacin","levofloxacin","trimethoprim-sulfamethoxazole","nitrofurantoin"],staphylococcus:["penicillin","oxacillin","ampicillin","cefazolin","ceftriaxone","gentamicin","clindamycin","erythromycin","ciprofloxacin","levofloxacin","trimethoprim-sulfamethoxazole","tetracycline","vancomycin","linezolid","daptomycin"],enterococcus:["penicillin","ampicillin","vancomycin","gentamicin","streptomycin","ciprofloxacin","levofloxacin","tetracycline","chloramphenicol","linezolid","daptomycin"],streptococcus:["penicillin","ampicillin","ceftriaxone","cefotaxime","vancomycin","erythromycin","clindamycin","levofloxacin","moxifloxacin","trimethoprim-sulfamethoxazole"],pseudomonas:["piperacillin","piperacillin-tazobactam","ceftazidime","cefepime","aztreonam","imipenem","meropenem","doripenem","gentamicin","tobramycin","amikacin","ciprofloxacin","levofloxacin","colistin"],acinetobacter:["ampicillin-sulbactam","piperacillin-tazobactam","ceftazidime","cefepime","imipenem","meropenem","doripenem","gentamicin","tobramycin","amikacin","ciprofloxacin","levofloxacin","trimethoprim-sulfamethoxazole","tigecycline","colistin"],haemophilus:["ampicillin","amoxicillin-clavulanate","ceftriaxone","cefotaxime","cefuroxime","azithromycin","clarithromycin","ciprofloxacin","levofloxacin","trimethoprim-sulfamethoxazole","tetracycline","chloramphenicol"],other_non_enterobacterales:["ampicillin","amoxicillin-clavulanate","ceftriaxone","ceftazidime","imipenem","meropenem","gentamicin","tobramycin","ciprofloxacin","levofloxacin","trimethoprim-sulfamethoxazole","tetracycline","doxycycline"]};return c[l]||c.enterobacterales}checkClinicalOverrides(s,l,c,d){const m={Daptomycin:{RESP_pneumonia:"Clinically ineffective due to pulmonary surfactant inactivation"},"Piperacillin-Tazobactam":{BS_bacteremia:"Risk of treatment failure in E. coli bacteremia despite susceptibility"}};return m[l]&&m[l][d]&&c.interpretation==="S"?{originalInterpretation:c,overriddenInterpretation:"Clinically Ineffective",reason:m[l][d],warning:{level:"high",message:`${l}: ${m[l][d]}`}}:null}extractViableOptions(s){console.log("🔍 Extracting viable options from finalInterpretations:",s);const l=Object.entries(s).filter(([c,d])=>d.interpretation==="S"||d.interpretation==="I").map(([c,d])=>({antibiotic:c,interpretation:d,micValue:d.micValue,confidence:d.confidence}));return console.log("🎯 Viable options found:",l),console.log("🎯 Number of viable options:",l.length),l}generateMDRRecommendations(s){const l=[{primary:"Infectious Disease Consultation",agents:["ID Consult Required"],type:"consultation",recommendation:"preferred",totalScore:95,scores:{efficacy:90,safety:95,stewardship:100,pharmacology:95},rationale:"No standard therapies effective - specialist guidance required",keyBenefits:["Expert resistance interpretation","Alternative agent selection","Combination therapy guidance"]},{primary:"Consider Combination Therapy",agents:["Multiple Agents"],type:"combination",recommendation:"alternative",totalScore:75,scores:{efficacy:85,safety:60,stewardship:70,pharmacology:85},rationale:"Synergistic combinations may overcome resistance",keyBenefits:["Potential synergy","Resistance suppression","Broader coverage"]},{primary:"Repeat Susceptibility Testing",agents:["Extended Panel"],type:"diagnostic",recommendation:"consider",totalScore:70,scores:{efficacy:80,safety:90,stewardship:80,pharmacology:30},rationale:"Extended testing may identify viable options",keyBenefits:["Additional agents tested","Molecular resistance profiling","Treatment options expansion"]}];return{strategies:l,metadata:{analysisType:"mdr_scenario",totalOptions:0,mdrDetected:!0,analysisDate:new Date().toISOString(),clinicalAlert:"MULTIDRUG RESISTANT ORGANISM - SPECIALIST CONSULTATION RECOMMENDED"},recommendations:{firstLine:[l[0]],alternatives:l.slice(1),durationGuidance:"Duration depends on specialist recommendations and clinical response",clinicalNotes:["No standard therapies show in vitro activity","Consider extended susceptibility panel","Infectious disease consultation strongly recommended","Source control may be critical for treatment success"]}}}generateFallbackRecommendations(s,l){return{message:"Unable to complete advanced interpretation. Providing basic guidance.",recommendations:["Consult infectious disease specialist","Consider broad-spectrum empiric therapy","Obtain additional susceptibility testing"]}}filterSusceptibleAgents(s){return Object.entries(s).filter(([l,c])=>c.interpretation==="S").map(([l,c])=>l)}analyzeResistantPattern(s){const l=Object.entries(s).filter(([c,d])=>d.interpretation==="R").map(([c,d])=>c);return{resistantAntibiotics:l,resistancePercentage:l.length/Object.keys(s).length*100,isMultidrugResistant:l.length>=3}}generateConfirmationTests(s){const l=[];for(const c of s)switch(c.type){case"esbl":l.push({test:"ESBL Phenotypic Confirmation",method:"Clavulanate enhancement test",indication:"Confirm ESBL production"});break;case"ampc":l.push({test:"AmpC Detection",method:"Boronic acid inhibition test",indication:"Differentiate AmpC from ESBL"});break;case"carbapenemase":l.push({test:"Carbapenemase Detection",method:"Modified Hodge Test or PCR",indication:"Confirm carbapenemase production"});break;case"mrsa":l.push({test:"mecA Gene Detection",method:"PCR or latex agglutination",indication:"Confirm methicillin resistance"});break}return l}generateMechanismEducation(s){const l=[];for(const c of s)l.push({mechanism:c.type,explanation:this.getMechanismExplanation(c.type),clinicalImpact:this.getMechanismClinicalImpact(c.type)});return l}getMechanismExplanation(s){return{esbl:"Extended-spectrum beta-lactamases are enzymes that destroy most penicillins and cephalosporins",ampc:"AmpC beta-lactamases are inducible enzymes that can be turned on during antibiotic therapy",carbapenemase:"Carbapenemases destroy our most powerful antibiotics including carbapenems",mrsa:"MRSA has altered penicillin-binding proteins that make all beta-lactams ineffective"}[s]||"Unknown resistance mechanism"}getMechanismClinicalImpact(s){return{esbl:"Use carbapenems for serious infections, avoid cephalosporins",ampc:"Prefer cefepime over 3rd generation cephalosporins",carbapenemase:"Last-resort therapy required, consider combination treatment",mrsa:"Use anti-MRSA agents like vancomycin, linezolid, or daptomycin"}[s]||"Consult infectious disease specialist"}generateCLSITierRecommendations(s,l){var c;try{const d={};s.forEach(h=>{d[h.antibiotic]=h.interpretation.mic||"≤1"});const m={infection_site:this.mapInfectionSite(l.infectionSite),severe_infection:((c=l.patientData)==null?void 0:c.severity)==="severe",patient_factors:l.patientData};return this.clsiReportingEngine.generateAntibiogramReport(l.organism,d,m)}catch(d){return console.warn("CLSI tier reporting not available, using fallback:",d.message),{error:"CLSI database not available",fallback:!0,tier1_results:s.slice(0,3),recommendations:["Standard empiric therapy guidelines apply"]}}}rankOptionsByTierCriteria(s,l,c){return s.map(d=>({...d,score:this.calculateTierBasedScore(d,l,c)})).sort((d,m)=>m.score-d.score)}calculateTierBasedScore(s,l,c){var _;let d=50;if(s.interpretation.interpretation==="S"&&(d+=30),s.interpretation.interpretation==="I"&&(d+=10),c&&!c.error){const h=c.tier1_results||[],v=c.tier2_results||[];h.some(y=>y.antibiotic===s.antibiotic)?d+=25:v.some(y=>y.antibiotic===s.antibiotic)&&(d+=15),(_=c.stewardshipGuidance)!=null&&_.primaryRecommendations&&c.stewardshipGuidance.primaryRecommendations.some(D=>D.antibiotic===s.antibiotic&&D.priority==="preferred")&&(d+=20)}else d+=this.calculateFallbackScore(s,l);const m=this.getAntibioticPenetration(s.antibiotic,l.infectionSite);return m==="excellent"&&(d+=15),m==="good"&&(d+=10),d}calculateFallbackScore(s,l){let c=0;return this.getPreferredAntibiotics(l.organism).includes(s.antibiotic)&&(c+=20),this.isNarrowSpectrum(s.antibiotic)&&(c+=15),this.isFirstLine(s.antibiotic)&&(c+=10),c}mapInfectionSite(s){return{"Urinary Tract":"urinary_tract","Respiratory Tract":"respiratory","Skin and Soft Tissue":"skin_soft_tissue","Intra-abdominal":"intraabdominal",Bloodstream:"bloodstream",CNS:"cns"}[s]||"other"}isNarrowSpectrum(s){return["ampicillin","cefazolin","clindamycin","erythromycin","trimethoprim-sulfamethoxazole","nitrofurantoin"].includes(s)}isFirstLine(s){return["amoxicillin-clavulanate","ceftriaxone","ciprofloxacin","trimethoprim-sulfamethoxazole","cephalexin"].includes(s)}rankOptionsBySimpleCriteria(s,l){return s.map(c=>({...c,score:this.calculateSimpleScore(c,l)})).sort((c,d)=>d.score-c.score)}calculateSimpleScore(s,l){let c=50;s.interpretation.interpretation==="S"&&(c+=30),s.interpretation.interpretation==="I"&&(c+=10),this.getPreferredAntibiotics(l.organism).includes(s.antibiotic)&&(c+=20);const m=this.getAntibioticPenetration(s.antibiotic,l.infectionSite);return m==="excellent"&&(c+=15),m==="good"&&(c+=10),c}getPreferredAntibiotics(s){return s!=null&&s.toLowerCase().includes("escherichia")?["ciprofloxacin","trimethoprim-sulfamethoxazole","nitrofurantoin"]:[]}getAntibioticPenetration(s,l){var d;return((d={ciprofloxacin:{GU_UTI_uncomplicated:"excellent"},nitrofurantoin:{GU_UTI_uncomplicated:"excellent"},"trimethoprim-sulfamethoxazole":{GU_UTI_uncomplicated:"good"}}[s])==null?void 0:d[l])||"moderate"}generatePhase1Education(s,l){return{organismProfile:`Understanding ${s} characteristics and expected resistance patterns`,intrinsicResistanceExplanation:l.length>0?`This organism is naturally resistant to: ${l.join(", ")}`:"No significant intrinsic resistance patterns for this organism",keyLearningPoints:["Organism identification guides antibiotic panel selection","Intrinsic resistance prevents clinical errors","Site-specific factors affect treatment choices"]}}getDosingRecommendations(s,l){return s?{antibiotic:s.antibiotic,standardDose:"Standard dosing per guidelines",renalAdjustment:l.creatinine>2?"Consider dose reduction":"No adjustment needed",hepaticAdjustment:l.hasHepaticDisease?"Monitor closely":"No adjustment needed"}:null}getMonitoringRequirements(s){return s?{vancomycin:["Trough levels","Renal function"],gentamicin:["Peak/trough levels","Renal function","Hearing"],daptomycin:["CPK levels"],linezolid:["CBC","Visual changes"]}[s.antibiotic]||["Standard monitoring"]:[]}getTreatmentDuration(s,l){return s?{GU_UTI_uncomplicated:"3-5 days",GU_UTI_complicated:"7-14 days",RESP_CAP:"7-10 days",BS_bacteremia:"14 days"}[l]||"7-14 days":"Consult guidelines"}generateClinicalAlerts(s){const l=[];if(s!=null&&s.detectedPatterns)for(const c of s.detectedPatterns)l.push({level:c.confidence==="high"?"high":"medium",message:`${c.type.toUpperCase()} detected - ${this.getMechanismClinicalImpact(c.type)}`});return l}extractClinicalPearls(s,l,c,d){var _;const m=[];if((_=c.detectedMechanisms)!=null&&_.detectedPatterns)for(const h of c.detectedMechanisms.detectedPatterns)m.push(`${h.type.toUpperCase()} mechanism detected: ${this.getMechanismClinicalImpact(h.type)}`);return c.interpretationChanges&&c.interpretationChanges.length>0&&m.push(`Expert interpretation modified ${c.interpretationChanges.length} results based on resistance patterns`),s.siteConsiderations&&(s.siteConsiderations.bactericidalRequired&&m.push("Bactericidal therapy preferred for this infection site"),s.siteConsiderations.penetrationRequired==="CNS_critical"&&m.push("Blood-brain barrier penetration is critical - verify CNS activity")),l.warnings&&l.warnings.length>0&&m.push("Clinical alerts identified: Consider alternative agents despite in vitro activity"),d&&(d.mode==="combination"&&d.combinationTherapy&&m.push("Combination therapy recommended for enhanced coverage or synergy"),d.stewardshipGuidance&&m.push(`Stewardship consideration: ${d.stewardshipGuidance}`)),m.length===0&&m.push("Standard CLSI interpretation guidelines applied"),m}checkParadoxicalResults(s,l,c,d){return c.interpretation==="S"&&l.includes("ampicillin")&&Object.entries(d).some(([_,h])=>_.includes("cefazolin")&&h.interpretation==="R")?{level:"medium",message:`Paradoxical result: ${l} susceptible but related beta-lactams resistant`}:null}applyMechanismOverrides(s,l){const c={...s};for(const d of l||[])d.type==="esbl"&&Object.keys(c).forEach(m=>{(m.includes("ceftriaxone")||m.includes("ceftazidime"))&&c[m].interpretation==="S"&&(c[m]={...c[m],interpretation:"R",overrideReason:"ESBL production makes cephalosporins clinically ineffective"})});return c}calculateInterpretationChanges(s,l){const c=[];return Object.keys(s).forEach(d=>{const m=s[d],_=l[d];m.interpretation!==_.interpretation&&c.push({antibiotic:d,oldResult:m.interpretation,newResult:_.interpretation,reason:_.overrideReason||"Mechanism-based override"})}),c}explainIntrinsicResistance(s){return!s||s.length===0?"No significant intrinsic resistance patterns identified":`This organism naturally resists: ${s.join(", ")}. These agents should not be tested or reported.`}explainDetectedMechanisms(s){return s!=null&&s.detectedPatterns?s.detectedPatterns.map(l=>({mechanism:l.type,explanation:this.getMechanismExplanation(l.type),clinicalImpact:this.getMechanismClinicalImpact(l.type)})):"No specific resistance mechanisms detected"}explainReasoningSteps(s,l,c){var m,_;const d=[];return d.push({step:1,title:"Organism Identification",description:`Identified ${s.organism} with known characteristics`}),d.push({step:2,title:"CLSI Interpretation",description:`Applied CLSI breakpoints for ${Object.keys(l.interpretations).length} antibiotics`}),((_=(m=c.detectedMechanisms)==null?void 0:m.detectedPatterns)==null?void 0:_.length)>0&&d.push({step:3,title:"Resistance Mechanism Detection",description:`Detected ${c.detectedMechanisms.detectedPatterns.length} resistance mechanism(s)`}),d.push({step:4,title:"Clinical Recommendations",description:"Generated evidence-based treatment recommendations"}),d}generateReferences(s,l){var d;const c=["CLSI M100-Ed34: Performance Standards for Antimicrobial Susceptibility Testing","IDSA Guidelines for Antimicrobial Therapy"];return((d=l==null?void 0:l.detectedPatterns)==null?void 0:d.length)>0&&c.push("Bush K, Bradford PA. Epidemiology of β-lactamase-producing pathogens. Clin Microbiol Rev. 2020"),c}findSimilarCases(){return[{case:"Similar organism with standard susceptibility pattern",outcome:"Standard therapy successful"},{case:"Similar resistance pattern in clinical practice",outcome:"Alternative agent required for cure"}]}}const db={CNS_brain_abscess_brain_abscess_bacterial:{id:"CNS_brain_abscess_brain_abscess_bacterial",filePath:"./syndromes_json/CNS/brain_abscess/brain_abscess_bacterial.json",category:"CNS",subcategory:"brain_abscess",filename:"brain_abscess_bacterial",title:"Brain Abscess, Bacterial",loaded:!1,data:null},CNS_brain_abscess_brain_abscess_nocardia:{id:"CNS_brain_abscess_brain_abscess_nocardia",filePath:"./syndromes_json/CNS/brain_abscess/brain_abscess_nocardia.json",category:"CNS",subcategory:"brain_abscess",filename:"brain_abscess_nocardia",title:"Brain Abscess, Nocardia",loaded:!1,data:null},CNS_brain_abscess_brain_abscess_post_traumatic_or_post_surgical:{id:"CNS_brain_abscess_brain_abscess_post_traumatic_or_post_surgical",filePath:"./syndromes_json/CNS/brain_abscess/brain_abscess_post-traumatic_or_post-surgical.json",category:"CNS",subcategory:"brain_abscess",filename:"brain_abscess_post-traumatic_or_post-surgical",title:"Brain Abscess, Post-traumatic or Post-surgical",loaded:!1,data:null},CNS_brain_abscess_toxoplasmosis_hiv_aids:{id:"CNS_brain_abscess_toxoplasmosis_hiv_aids",filePath:"./syndromes_json/CNS/brain_abscess/toxoplasmosis_hiv_aids.json",category:"CNS",subcategory:"brain_abscess",filename:"toxoplasmosis_hiv_aids",title:"Toxoplasmosis, HIV/AIDS",loaded:!1,data:null},CNS_encephalitis_encephalopathy:{id:"CNS_encephalitis_encephalopathy",filePath:"./syndromes_json/CNS/encephalitis_encephalopathy.json",category:"CNS",subcategory:null,filename:"encephalitis_encephalopathy",title:"Encephalitis, Encephalopathy",loaded:!1,data:null},CNS_lyme_lyme_disease_facial_nerve_paralysis:{id:"CNS_lyme_lyme_disease_facial_nerve_paralysis",filePath:"./syndromes_json/CNS/lyme/lyme_disease_facial_nerve_paralysis.json",category:"CNS",subcategory:"lyme",filename:"lyme_disease_facial_nerve_paralysis",title:"Lyme Disease, Facial Nerve Paralysis",loaded:!1,data:null},CNS_lyme_lyme_disease_meningitis_encephalitis:{id:"CNS_lyme_lyme_disease_meningitis_encephalitis",filePath:"./syndromes_json/CNS/lyme/lyme_disease_meningitis_encephalitis.json",category:"CNS",subcategory:"lyme",filename:"lyme_disease_meningitis_encephalitis",title:"Lyme Disease, Meningitis, Encephalitis",loaded:!1,data:null},CNS_lyme_lyme_disease_post_lyme_syndrome_ptlds:{id:"CNS_lyme_lyme_disease_post_lyme_syndrome_ptlds",filePath:"./syndromes_json/CNS/lyme/lyme_disease_post-lyme_syndrome_ptlds.json",category:"CNS",subcategory:"lyme",filename:"lyme_disease_post-lyme_syndrome_ptlds",title:"Lyme Disease, Post-Lyme Syndrome (PTLDS)",loaded:!1,data:null},CNS_meningitis_empiric_therapy_meningitis_age_1_mo_to_50_years:{id:"CNS_meningitis_empiric_therapy_meningitis_age_1_mo_to_50_years",filePath:"./syndromes_json/CNS/meningitis/empiric_therapy/meningitis_age_1_mo_to_50_years.json",category:"CNS",subcategory:"meningitis",filename:"meningitis_age_1_mo_to_50_years",title:"Meningitis, Age 1 month to 50 years",loaded:!1,data:null},CNS_meningitis_empiric_therapy_meningitis_age_gt_50_years:{id:"CNS_meningitis_empiric_therapy_meningitis_age_gt_50_years",filePath:"./syndromes_json/CNS/meningitis/empiric_therapy/meningitis_age_gt_50_years.json",category:"CNS",subcategory:"meningitis",filename:"meningitis_age_gt_50_years",title:"Meningitis, Age > 50 years",loaded:!1,data:null},CNS_meningitis_empiric_therapy_meningitis_bacterial_positive_gram_stain:{id:"CNS_meningitis_empiric_therapy_meningitis_bacterial_positive_gram_stain",filePath:"./syndromes_json/CNS/meningitis/empiric_therapy/meningitis_bacterial_positive_gram_stain.json",category:"CNS",subcategory:"meningitis",filename:"meningitis_bacterial_positive_gram_stain",title:"Meningitis, Bacterial, Positive Gram Stain",loaded:!1,data:null},CNS_meningitis_empiric_therapy_meningitis_bacterial_preterm_to_age_1_month:{id:"CNS_meningitis_empiric_therapy_meningitis_bacterial_preterm_to_age_1_month",filePath:"./syndromes_json/CNS/meningitis/empiric_therapy/meningitis_bacterial_preterm_to_age_1_month.json",category:"CNS",subcategory:"meningitis",filename:"meningitis_bacterial_preterm_to_age_1_month",title:"Meningitis, Bacterial, Preterm to Age < 1 month",loaded:!1,data:null},CNS_meningitis_empiric_therapy_meningitis_catheter_shunt_related:{id:"CNS_meningitis_empiric_therapy_meningitis_catheter_shunt_related",filePath:"./syndromes_json/CNS/meningitis/empiric_therapy/meningitis_catheter_shunt_related.json",category:"CNS",subcategory:"meningitis",filename:"meningitis_catheter_shunt_related",title:"Meningitis, Catheter, Shunt Related",loaded:!1,data:null},CNS_meningitis_empiric_therapy_meningitis_chemoprophylaxis:{id:"CNS_meningitis_empiric_therapy_meningitis_chemoprophylaxis",filePath:"./syndromes_json/CNS/meningitis/empiric_therapy/meningitis_chemoprophylaxis.json",category:"CNS",subcategory:"meningitis",filename:"meningitis_chemoprophylaxis",title:"Meningitis, Chemoprophylaxis",loaded:!1,data:null},CNS_meningitis_empiric_therapy_meningitis_post_trauma_or_post_neurosurgery:{id:"CNS_meningitis_empiric_therapy_meningitis_post_trauma_or_post_neurosurgery",filePath:"./syndromes_json/CNS/meningitis/empiric_therapy/meningitis_post-trauma_or_post-neurosurgery.json",category:"CNS",subcategory:"meningitis",filename:"meningitis_post-trauma_or_post-neurosurgery",title:"Meningitis, Post-Trauma or Post-Neurosurgery",loaded:!1,data:null},CNS_meningitis_empiric_therapy_meningitis_post_basilar_skull_fracture:{id:"CNS_meningitis_empiric_therapy_meningitis_post_basilar_skull_fracture",filePath:"./syndromes_json/CNS/meningitis/empiric_therapy/meningitis_post_basilar_skull_fracture.json",category:"CNS",subcategory:"meningitis",filename:"meningitis_post_basilar_skull_fracture",title:"Meningitis, Post basilar skull fracture",loaded:!1,data:null},CNS_meningitis_meningitis_overview:{id:"CNS_meningitis_meningitis_overview",filePath:"./syndromes_json/CNS/meningitis/meningitis_overview.json",category:"CNS",subcategory:"meningitis",filename:"meningitis_overview",title:"Meningitis, Overview",loaded:!1,data:null},CNS_meningitis_specific_therapy_lyme_disease_meningitis_encephalitis:{id:"CNS_meningitis_specific_therapy_lyme_disease_meningitis_encephalitis",filePath:"./syndromes_json/CNS/meningitis/specific_therapy/lyme_disease_meningitis_encephalitis.json",category:"CNS",subcategory:"meningitis",filename:"lyme_disease_meningitis_encephalitis",title:"Lyme Disease, Meningitis, Encephalitis",loaded:!1,data:null},CNS_meningitis_specific_therapy_meningitis_gram_negative_bacilli:{id:"CNS_meningitis_specific_therapy_meningitis_gram_negative_bacilli",filePath:"./syndromes_json/CNS/meningitis/specific_therapy/meningitis_gram-negative_bacilli.json",category:"CNS",subcategory:"meningitis",filename:"meningitis_gram-negative_bacilli",title:"Meningitis, Gram-negative Bacilli",loaded:!1,data:null},CNS_meningitis_specific_therapy_meningitis_haemophilus_influenzae:{id:"CNS_meningitis_specific_therapy_meningitis_haemophilus_influenzae",filePath:"./syndromes_json/CNS/meningitis/specific_therapy/meningitis_haemophilus_influenzae.json",category:"CNS",subcategory:"meningitis",filename:"meningitis_haemophilus_influenzae",title:"Meningitis, Haemophilus influenzae",loaded:!1,data:null},CNS_meningitis_specific_therapy_meningitis_listeria_monocytogenes:{id:"CNS_meningitis_specific_therapy_meningitis_listeria_monocytogenes",filePath:"./syndromes_json/CNS/meningitis/specific_therapy/meningitis_listeria_monocytogenes.json",category:"CNS",subcategory:"meningitis",filename:"meningitis_listeria_monocytogenes",title:"Meningitis, Listeria monocytogenes",loaded:!1,data:null},CNS_meningitis_specific_therapy_meningitis_neisseria_meningitidis:{id:"CNS_meningitis_specific_therapy_meningitis_neisseria_meningitidis",filePath:"./syndromes_json/CNS/meningitis/specific_therapy/meningitis_neisseria_meningitidis.json",category:"CNS",subcategory:"meningitis",filename:"meningitis_neisseria_meningitidis",title:"Meningitis, Neisseria meningitidis",loaded:!1,data:null},CNS_meningitis_specific_therapy_meningitis_streptococcus_pneumoniae:{id:"CNS_meningitis_specific_therapy_meningitis_streptococcus_pneumoniae",filePath:"./syndromes_json/CNS/meningitis/specific_therapy/meningitis_streptococcus_pneumoniae.json",category:"CNS",subcategory:"meningitis",filename:"meningitis_streptococcus_pneumoniae",title:"Meningitis, Streptococcus pneumoniae",loaded:!1,data:null},Lyme_disease_erythema_migrans_lyme_disease_early:{id:"Lyme_disease_erythema_migrans_lyme_disease_early",filePath:"./syndromes_json/Lyme_disease/erythema_migrans_lyme_disease_early.json",category:"Lyme_disease",subcategory:null,filename:"erythema_migrans_lyme_disease_early",title:"Erythema migrans, Lyme Disease, Early",loaded:!1,data:null},Lyme_disease_lyme_disease_arthritis:{id:"Lyme_disease_lyme_disease_arthritis",filePath:"./syndromes_json/Lyme_disease/lyme_disease_arthritis.json",category:"Lyme_disease",subcategory:null,filename:"lyme_disease_arthritis",title:"Lyme Disease, Arthritis",loaded:!1,data:null},Lyme_disease_lyme_disease_carditis:{id:"Lyme_disease_lyme_disease_carditis",filePath:"./syndromes_json/Lyme_disease/lyme_disease_carditis.json",category:"Lyme_disease",subcategory:null,filename:"lyme_disease_carditis",title:"Lyme Disease, Carditis",loaded:!1,data:null},Lyme_disease_lyme_disease_diagnosis:{id:"Lyme_disease_lyme_disease_diagnosis",filePath:"./syndromes_json/Lyme_disease/lyme_disease_diagnosis.json",category:"Lyme_disease",subcategory:null,filename:"lyme_disease_diagnosis",title:"Lyme Disease, Diagnosis",loaded:!1,data:null},Lyme_disease_lyme_disease_facial_nerve_paralysis:{id:"Lyme_disease_lyme_disease_facial_nerve_paralysis",filePath:"./syndromes_json/Lyme_disease/lyme_disease_facial_nerve_paralysis.json",category:"Lyme_disease",subcategory:null,filename:"lyme_disease_facial_nerve_paralysis",title:"Lyme Disease, Facial Nerve Paralysis",loaded:!1,data:null},Lyme_disease_lyme_disease_meningitis_encephalitis:{id:"Lyme_disease_lyme_disease_meningitis_encephalitis",filePath:"./syndromes_json/Lyme_disease/lyme_disease_meningitis_encephalitis.json",category:"Lyme_disease",subcategory:null,filename:"lyme_disease_meningitis_encephalitis",title:"Lyme Disease, Meningitis, Encephalitis",loaded:!1,data:null},Lyme_disease_lyme_disease_overview:{id:"Lyme_disease_lyme_disease_overview",filePath:"./syndromes_json/Lyme_disease/lyme_disease_overview.json",category:"Lyme_disease",subcategory:null,filename:"lyme_disease_overview",title:"Lyme Disease, Overview",loaded:!1,data:null},Lyme_disease_lyme_disease_post_exposure_prophylaxis:{id:"Lyme_disease_lyme_disease_post_exposure_prophylaxis",filePath:"./syndromes_json/Lyme_disease/lyme_disease_post-exposure_prophylaxis.json",category:"Lyme_disease",subcategory:null,filename:"lyme_disease_post-exposure_prophylaxis",title:"Lyme Disease, Post-Exposure Prophylaxis",loaded:!1,data:null},Lyme_disease_lyme_disease_post_lyme_syndrome_ptlds:{id:"Lyme_disease_lyme_disease_post_lyme_syndrome_ptlds",filePath:"./syndromes_json/Lyme_disease/lyme_disease_post-lyme_syndrome_ptlds.json",category:"Lyme_disease",subcategory:null,filename:"lyme_disease_post-lyme_syndrome_ptlds",title:"Lyme Disease, Post-Lyme Syndrome (PTLDS)",loaded:!1,data:null},Lyme_disease_tick_borne_illness_overview:{id:"Lyme_disease_tick_borne_illness_overview",filePath:"./syndromes_json/Lyme_disease/tick-borne_illness_overview.json",category:"Lyme_disease",subcategory:null,filename:"tick-borne_illness_overview",title:"Tick-borne Illness, Overview",loaded:!1,data:null},Toxin_mediated_botulism:{id:"Toxin_mediated_botulism",filePath:"./syndromes_json/Toxin_mediated/botulism.json",category:"Toxin_mediated",subcategory:null,filename:"botulism",title:"Botulism",loaded:!1,data:null},Toxin_mediated_corynebacterium_diphtheriae:{id:"Toxin_mediated_corynebacterium_diphtheriae",filePath:"./syndromes_json/Toxin_mediated/corynebacterium_diphtheriae.json",category:"Toxin_mediated",subcategory:null,filename:"corynebacterium_diphtheriae",title:"Corynebacterium diphtheriae",loaded:!1,data:null},Toxin_mediated_tetanus_treatment:{id:"Toxin_mediated_tetanus_treatment",filePath:"./syndromes_json/Toxin_mediated/tetanus_treatment.json",category:"Toxin_mediated",subcategory:null,filename:"tetanus_treatment",title:"Tetanus, Treatment",loaded:!1,data:null},Toxin_mediated_toxic_shock_syndrome_staphylococcal:{id:"Toxin_mediated_toxic_shock_syndrome_staphylococcal",filePath:"./syndromes_json/Toxin_mediated/toxic_shock_syndrome_staphylococcal.json",category:"Toxin_mediated",subcategory:null,filename:"toxic_shock_syndrome_staphylococcal",title:"Toxic Shock Syndrome (TSS), Staphylococcal",loaded:!1,data:null},Toxin_mediated_toxic_shock_syndrome_streptococcal:{id:"Toxin_mediated_toxic_shock_syndrome_streptococcal",filePath:"./syndromes_json/Toxin_mediated/toxic_shock_syndrome_streptococcal.json",category:"Toxin_mediated",subcategory:null,filename:"toxic_shock_syndrome_streptococcal",title:"Toxic Shock Syndrome (TSS), Streptococcal",loaded:!1,data:null},cardiovascular_acute_rheumatic_fever_empiric_therapy:{id:"cardiovascular_acute_rheumatic_fever_empiric_therapy",filePath:"./syndromes_json/cardiovascular/acute_rheumatic_fever_empiric_therapy.json",category:"cardiovascular",subcategory:null,filename:"acute_rheumatic_fever_empiric_therapy",title:"Acute Rheumatic Fever, Empiric Therapy",loaded:!1,data:null},cardiovascular_cardiac_implantable_electronic_device_infections:{id:"cardiovascular_cardiac_implantable_electronic_device_infections",filePath:"./syndromes_json/cardiovascular/cardiac_implantable_electronic_device_infections.json",category:"cardiovascular",subcategory:null,filename:"cardiac_implantable_electronic_device_infections",title:"Cardiac Implantable Electronic Device Infections",loaded:!1,data:null},cardiovascular_endocarditis_endocarditis_candida:{id:"cardiovascular_endocarditis_endocarditis_candida",filePath:"./syndromes_json/cardiovascular/endocarditis/endocarditis_candida.json",category:"cardiovascular",subcategory:"endocarditis",filename:"endocarditis_candida",title:"Endocarditis, Candida",loaded:!1,data:null},cardiovascular_endocarditis_endocarditis_cardiac_implantable_electronic_device_cied:{id:"cardiovascular_endocarditis_endocarditis_cardiac_implantable_electronic_device_cied",filePath:"./syndromes_json/cardiovascular/endocarditis/endocarditis_cardiac_implantable_electronic_device_cied.json",category:"cardiovascular",subcategory:"endocarditis",filename:"endocarditis_cardiac_implantable_electronic_device_cied",title:"Endocarditis, Cardiac Implantable Electronic Device (CIED)",loaded:!1,data:null},cardiovascular_endocarditis_endocarditis_culture_negative:{id:"cardiovascular_endocarditis_endocarditis_culture_negative",filePath:"./syndromes_json/cardiovascular/endocarditis/endocarditis_culture_negative.json",category:"cardiovascular",subcategory:"endocarditis",filename:"endocarditis_culture_negative",title:"Endocarditis, Culture Negative",loaded:!1,data:null},cardiovascular_endocarditis_endocarditis_native_valve_empiric_therapy:{id:"cardiovascular_endocarditis_endocarditis_native_valve_empiric_therapy",filePath:"./syndromes_json/cardiovascular/endocarditis/endocarditis_native_valve_empiric_therapy.json",category:"cardiovascular",subcategory:"endocarditis",filename:"endocarditis_native_valve_empiric_therapy",title:"Endocarditis, Native Valve, Empiric Therapy",loaded:!1,data:null},cardiovascular_endocarditis_endocarditis_overview:{id:"cardiovascular_endocarditis_endocarditis_overview",filePath:"./syndromes_json/cardiovascular/endocarditis/endocarditis_overview.json",category:"cardiovascular",subcategory:"endocarditis",filename:"endocarditis_overview",title:"Endocarditis, Overview",loaded:!1,data:null},cardiovascular_endocarditis_endocarditis_prosthetic_valve_empiric_therapy:{id:"cardiovascular_endocarditis_endocarditis_prosthetic_valve_empiric_therapy",filePath:"./syndromes_json/cardiovascular/endocarditis/endocarditis_prosthetic_valve_empiric_therapy.json",category:"cardiovascular",subcategory:"endocarditis",filename:"endocarditis_prosthetic_valve_empiric_therapy",title:"Endocarditis, Prosthetic Valve, Empiric Therapy",loaded:!1,data:null},cardiovascular_endocarditis_endocarditis_transcatheter_valve_replacement:{id:"cardiovascular_endocarditis_endocarditis_transcatheter_valve_replacement",filePath:"./syndromes_json/cardiovascular/endocarditis/endocarditis_transcatheter_valve_replacement.json",category:"cardiovascular",subcategory:"endocarditis",filename:"endocarditis_transcatheter_valve_replacement",title:"Endocarditis, Transcatheter Valve Replacement",loaded:!1,data:null},cardiovascular_endocarditis_specific_therapy_endocarditis_bartonella_sp:{id:"cardiovascular_endocarditis_specific_therapy_endocarditis_bartonella_sp",filePath:"./syndromes_json/cardiovascular/endocarditis/specific_therapy/endocarditis_bartonella_sp.json",category:"cardiovascular",subcategory:"endocarditis",filename:"endocarditis_bartonella_sp",title:"Endocarditis, Bartonella sp.",loaded:!1,data:null},cardiovascular_endocarditis_specific_therapy_endocarditis_chlamydial:{id:"cardiovascular_endocarditis_specific_therapy_endocarditis_chlamydial",filePath:"./syndromes_json/cardiovascular/endocarditis/specific_therapy/endocarditis_chlamydial.json",category:"cardiovascular",subcategory:"endocarditis",filename:"endocarditis_chlamydial",title:"Endocarditis, Chlamydial",loaded:!1,data:null},cardiovascular_endocarditis_specific_therapy_endocarditis_coagulase_negative_staphylococci:{id:"cardiovascular_endocarditis_specific_therapy_endocarditis_coagulase_negative_staphylococci",filePath:"./syndromes_json/cardiovascular/endocarditis/specific_therapy/endocarditis_coagulase-negative_staphylococci.json",category:"cardiovascular",subcategory:"endocarditis",filename:"endocarditis_coagulase-negative_staphylococci",title:"Endocarditis, Coagulase-Negative Staphylococci",loaded:!1,data:null},cardiovascular_endocarditis_specific_therapy_endocarditis_enterococcus_sp:{id:"cardiovascular_endocarditis_specific_therapy_endocarditis_enterococcus_sp",filePath:"./syndromes_json/cardiovascular/endocarditis/specific_therapy/endocarditis_enterococcus_sp.json",category:"cardiovascular",subcategory:"endocarditis",filename:"endocarditis_enterococcus_sp",title:"Endocarditis, Enterococcus sp.",loaded:!1,data:null},cardiovascular_endocarditis_specific_therapy_endocarditis_gonococcal:{id:"cardiovascular_endocarditis_specific_therapy_endocarditis_gonococcal",filePath:"./syndromes_json/cardiovascular/endocarditis/specific_therapy/endocarditis_gonococcal.json",category:"cardiovascular",subcategory:"endocarditis",filename:"endocarditis_gonococcal",title:"Endocarditis, Gonococcal",loaded:!1,data:null},cardiovascular_endocarditis_specific_therapy_endocarditis_gram_negative_bacilli:{id:"cardiovascular_endocarditis_specific_therapy_endocarditis_gram_negative_bacilli",filePath:"./syndromes_json/cardiovascular/endocarditis/specific_therapy/endocarditis_gram-negative_bacilli.json",category:"cardiovascular",subcategory:"endocarditis",filename:"endocarditis_gram-negative_bacilli",title:"Endocarditis, Gram-negative bacilli",loaded:!1,data:null},cardiovascular_endocarditis_specific_therapy_endocarditis_hacek_habcek:{id:"cardiovascular_endocarditis_specific_therapy_endocarditis_hacek_habcek",filePath:"./syndromes_json/cardiovascular/endocarditis/specific_therapy/endocarditis_hacek_habcek.json",category:"cardiovascular",subcategory:"endocarditis",filename:"endocarditis_hacek_habcek",title:"Endocarditis, HACEK, HABCEK",loaded:!1,data:null},cardiovascular_endocarditis_specific_therapy_endocarditis_legionella:{id:"cardiovascular_endocarditis_specific_therapy_endocarditis_legionella",filePath:"./syndromes_json/cardiovascular/endocarditis/specific_therapy/endocarditis_legionella.json",category:"cardiovascular",subcategory:"endocarditis",filename:"endocarditis_legionella",title:"Endocarditis, Legionella",loaded:!1,data:null},cardiovascular_endocarditis_specific_therapy_endocarditis_nutritionally_variant_gram_positive_species:{id:"cardiovascular_endocarditis_specific_therapy_endocarditis_nutritionally_variant_gram_positive_species",filePath:"./syndromes_json/cardiovascular/endocarditis/specific_therapy/endocarditis_nutritionally_variant_gram-positive_species.json",category:"cardiovascular",subcategory:"endocarditis",filename:"endocarditis_nutritionally_variant_gram-positive_species",title:"Endocarditis, Nutritionally Variant Gram-positive Species",loaded:!1,data:null},cardiovascular_endocarditis_specific_therapy_endocarditis_q_fever:{id:"cardiovascular_endocarditis_specific_therapy_endocarditis_q_fever",filePath:"./syndromes_json/cardiovascular/endocarditis/specific_therapy/endocarditis_q_fever.json",category:"cardiovascular",subcategory:"endocarditis",filename:"endocarditis_q_fever",title:"Endocarditis, Q Fever",loaded:!1,data:null},cardiovascular_endocarditis_specific_therapy_endocarditis_staph_aureus:{id:"cardiovascular_endocarditis_specific_therapy_endocarditis_staph_aureus",filePath:"./syndromes_json/cardiovascular/endocarditis/specific_therapy/endocarditis_staph_aureus.json",category:"cardiovascular",subcategory:"endocarditis",filename:"endocarditis_staph_aureus",title:"Endocarditis, Staph. aureus",loaded:!1,data:null},cardiovascular_endocarditis_specific_therapy_endocarditis_tropheryma_whipplei:{id:"cardiovascular_endocarditis_specific_therapy_endocarditis_tropheryma_whipplei",filePath:"./syndromes_json/cardiovascular/endocarditis/specific_therapy/endocarditis_tropheryma_whipplei.json",category:"cardiovascular",subcategory:"endocarditis",filename:"endocarditis_tropheryma_whipplei",title:"Endocarditis, Tropheryma whipplei",loaded:!1,data:null},cardiovascular_endocarditis_specific_therapy_endocarditis_viridans_group_streptococci:{id:"cardiovascular_endocarditis_specific_therapy_endocarditis_viridans_group_streptococci",filePath:"./syndromes_json/cardiovascular/endocarditis/specific_therapy/endocarditis_viridans_group_streptococci.json",category:"cardiovascular",subcategory:"endocarditis",filename:"endocarditis_viridans_group_streptococci",title:"Endocarditis, Viridans Group Streptococci",loaded:!1,data:null},cardiovascular_endocarditis_prevention_dental_procedures:{id:"cardiovascular_endocarditis_prevention_dental_procedures",filePath:"./syndromes_json/cardiovascular/endocarditis_prevention_dental_procedures.json",category:"cardiovascular",subcategory:null,filename:"endocarditis_prevention_dental_procedures",title:"Endocarditis Prevention, Dental Procedures",loaded:!1,data:null},cardiovascular_lyme_disease_carditis:{id:"cardiovascular_lyme_disease_carditis",filePath:"./syndromes_json/cardiovascular/lyme_disease_carditis.json",category:"cardiovascular",subcategory:null,filename:"lyme_disease_carditis",title:"Lyme Disease, Carditis",loaded:!1,data:null},cardiovascular_mycotic_aneurysm:{id:"cardiovascular_mycotic_aneurysm",filePath:"./syndromes_json/cardiovascular/mycotic_aneurysm.json",category:"cardiovascular",subcategory:null,filename:"mycotic_aneurysm",title:"Mycotic Aneurysm",loaded:!1,data:null},cardiovascular_pericarditis_histoplasmosis_pericarditis:{id:"cardiovascular_pericarditis_histoplasmosis_pericarditis",filePath:"./syndromes_json/cardiovascular/pericarditis/histoplasmosis_pericarditis.json",category:"cardiovascular",subcategory:"pericarditis",filename:"histoplasmosis_pericarditis",title:"Histoplasmosis, Pericarditis",loaded:!1,data:null},cardiovascular_pericarditis_pericarditis_bacterial:{id:"cardiovascular_pericarditis_pericarditis_bacterial",filePath:"./syndromes_json/cardiovascular/pericarditis/pericarditis_bacterial.json",category:"cardiovascular",subcategory:"pericarditis",filename:"pericarditis_bacterial",title:"Pericarditis, Bacterial",loaded:!1,data:null},cardiovascular_pericarditis_tuberculosis_extrapulmonary:{id:"cardiovascular_pericarditis_tuberculosis_extrapulmonary",filePath:"./syndromes_json/cardiovascular/pericarditis/tuberculosis_extrapulmonary.json",category:"cardiovascular",subcategory:"pericarditis",filename:"tuberculosis_extrapulmonary",title:"Tuberculosis, Extrapulmonary",loaded:!1,data:null},cardiovascular_vascular_cavernous_sinus_suppurative_septic_thrombophlebitis:{id:"cardiovascular_vascular_cavernous_sinus_suppurative_septic_thrombophlebitis",filePath:"./syndromes_json/cardiovascular/vascular/cavernous_sinus_suppurative_septic_thrombophlebitis.json",category:"cardiovascular",subcategory:"vascular",filename:"cavernous_sinus_suppurative_septic_thrombophlebitis",title:"Cavernous Sinus Suppurative (Septic) Thrombophlebitis",loaded:!1,data:null},cardiovascular_vascular_iv_line_infection_catheter_related_bloodstream_infections:{id:"cardiovascular_vascular_iv_line_infection_catheter_related_bloodstream_infections",filePath:"./syndromes_json/cardiovascular/vascular/iv_line_infection_catheter-related_bloodstream_infections.json",category:"cardiovascular",subcategory:"vascular",filename:"iv_line_infection_catheter-related_bloodstream_infections",title:"IV Line Infection, Catheter-Related Bloodstream Infections",loaded:!1,data:null},cardiovascular_vascular_iv_line_infection_tunneled_catheters:{id:"cardiovascular_vascular_iv_line_infection_tunneled_catheters",filePath:"./syndromes_json/cardiovascular/vascular/iv_line_infection_tunneled_catheters.json",category:"cardiovascular",subcategory:"vascular",filename:"iv_line_infection_tunneled_catheters",title:"IV Line Infection, Tunneled Catheters",loaded:!1,data:null},cardiovascular_vascular_pelvic_vein_thrombophlebitis_suppurative_septic:{id:"cardiovascular_vascular_pelvic_vein_thrombophlebitis_suppurative_septic",filePath:"./syndromes_json/cardiovascular/vascular/pelvic_vein_thrombophlebitis_suppurative_septic.json",category:"cardiovascular",subcategory:"vascular",filename:"pelvic_vein_thrombophlebitis_suppurative_septic",title:"Pelvic Vein Thrombophlebitis, Suppurative (Septic)",loaded:!1,data:null},cardiovascular_vascular_portal_vein_suppurative_septic_thrombophlebitis:{id:"cardiovascular_vascular_portal_vein_suppurative_septic_thrombophlebitis",filePath:"./syndromes_json/cardiovascular/vascular/portal_vein_suppurative_septic_thrombophlebitis.json",category:"cardiovascular",subcategory:"vascular",filename:"portal_vein_suppurative_septic_thrombophlebitis",title:"Portal Vein Suppurative (Septic) Thrombophlebitis",loaded:!1,data:null},cardiovascular_vascular_suppurative_septic_thrombophlebitis_overview:{id:"cardiovascular_vascular_suppurative_septic_thrombophlebitis_overview",filePath:"./syndromes_json/cardiovascular/vascular/suppurative_septic_thrombophlebitis_overview.json",category:"cardiovascular",subcategory:"vascular",filename:"suppurative_septic_thrombophlebitis_overview",title:"Suppurative (Septic) Thrombophlebitis, Overview",loaded:!1,data:null},cardiovascular_vascular_ventricular_assist_device_infection:{id:"cardiovascular_vascular_ventricular_assist_device_infection",filePath:"./syndromes_json/cardiovascular/vascular/ventricular_assist_device_infection.json",category:"cardiovascular",subcategory:"vascular",filename:"ventricular_assist_device_infection",title:"Ventricular Assist Device Infection",loaded:!1,data:null},duration_of_therapy_antibacterial:{id:"duration_of_therapy_antibacterial",filePath:"./syndromes_json/duration_of_therapy_antibacterial.json",category:"duration_of_therapy_antibacterial.json",subcategory:null,filename:"duration_of_therapy_antibacterial",title:"Suggested Duration of Therapy",loaded:!1,data:null},genitourinary_STDS_chancroid:{id:"genitourinary_STDS_chancroid",filePath:"./syndromes_json/genitourinary/STDS/chancroid.json",category:"genitourinary",subcategory:"STDS",filename:"chancroid",title:"Chancroid",loaded:!1,data:null},genitourinary_STDS_gonorrhea_overview:{id:"genitourinary_STDS_gonorrhea_overview",filePath:"./syndromes_json/genitourinary/STDS/gonorrhea_overview.json",category:"genitourinary",subcategory:"STDS",filename:"gonorrhea_overview",title:"Gonorrhea, Overview",loaded:!1,data:null},genitourinary_STDS_gonorrhea_urethritis_cervicitis_proctitis:{id:"genitourinary_STDS_gonorrhea_urethritis_cervicitis_proctitis",filePath:"./syndromes_json/genitourinary/STDS/gonorrhea_urethritis_cervicitis_proctitis.json",category:"genitourinary",subcategory:"STDS",filename:"gonorrhea_urethritis_cervicitis_proctitis",title:"Gonorrhea: Urethritis, Cervicitis, Proctitis",loaded:!1,data:null},genitourinary_STDS_granuloma_inguinale_donovanosis:{id:"genitourinary_STDS_granuloma_inguinale_donovanosis",filePath:"./syndromes_json/genitourinary/STDS/granuloma_inguinale_donovanosis.json",category:"genitourinary",subcategory:"STDS",filename:"granuloma_inguinale_donovanosis",title:"Granuloma Inguinale (Donovanosis)",loaded:!1,data:null},genitourinary_STDS_herpes_simplex_genital:{id:"genitourinary_STDS_herpes_simplex_genital",filePath:"./syndromes_json/genitourinary/STDS/herpes_simplex_genital.json",category:"genitourinary",subcategory:"STDS",filename:"herpes_simplex_genital",title:"Genital Herpes Simplex Infection",loaded:!1,data:null},genitourinary_STDS_lymphogranuloma_venereum:{id:"genitourinary_STDS_lymphogranuloma_venereum",filePath:"./syndromes_json/genitourinary/STDS/lymphogranuloma_venereum.json",category:"genitourinary",subcategory:"STDS",filename:"lymphogranuloma_venereum",title:"Lymphogranuloma Venereum",loaded:!1,data:null},genitourinary_STDS_pelvic_inflammatory_disease:{id:"genitourinary_STDS_pelvic_inflammatory_disease",filePath:"./syndromes_json/genitourinary/STDS/pelvic_inflammatory_disease.json",category:"genitourinary",subcategory:"STDS",filename:"pelvic_inflammatory_disease",title:"Pelvic Inflammatory Disease",loaded:!1,data:null},genitourinary_STDS_urethritis_cervicitis_chlamydial:{id:"genitourinary_STDS_urethritis_cervicitis_chlamydial",filePath:"./syndromes_json/genitourinary/STDS/urethritis_cervicitis_chlamydial.json",category:"genitourinary",subcategory:"STDS",filename:"urethritis_cervicitis_chlamydial",title:"Urethritis, Cervicitis_ Chlamydial",loaded:!1,data:null},genitourinary_amnionitis_chorioamnionitis_septic_abortion:{id:"genitourinary_amnionitis_chorioamnionitis_septic_abortion",filePath:"./syndromes_json/genitourinary/amnionitis_chorioamnionitis_septic_abortion.json",category:"genitourinary",subcategory:null,filename:"amnionitis_chorioamnionitis_septic_abortion",title:"Amnionitis, Chorioamnionitis, Septic Abortion",loaded:!1,data:null},genitourinary_bacteriuria_asymptomatic:{id:"genitourinary_bacteriuria_asymptomatic",filePath:"./syndromes_json/genitourinary/bacteriuria_asymptomatic.json",category:"genitourinary",subcategory:null,filename:"bacteriuria_asymptomatic",title:"Bacteriuria, Asymptomatic",loaded:!1,data:null},genitourinary_balanitis:{id:"genitourinary_balanitis",filePath:"./syndromes_json/genitourinary/balanitis.json",category:"genitourinary",subcategory:null,filename:"balanitis",title:"Balanitis",loaded:!1,data:null},genitourinary_bartholins_gland_abscess:{id:"genitourinary_bartholins_gland_abscess",filePath:"./syndromes_json/genitourinary/bartholins_gland_abscess.json",category:"genitourinary",subcategory:null,filename:"bartholins_gland_abscess",title:"Bartholin's Gland Abscess",loaded:!1,data:null},genitourinary_cervicitis_mucopurulent:{id:"genitourinary_cervicitis_mucopurulent",filePath:"./syndromes_json/genitourinary/cervicitis_mucopurulent.json",category:"genitourinary",subcategory:null,filename:"cervicitis_mucopurulent",title:"Cervicitis, Mucopurulent",loaded:!1,data:null},genitourinary_cystitis_UTI_Acute_Child_Age_2_months:{id:"genitourinary_cystitis_UTI_Acute_Child_Age_2_months",filePath:"./syndromes_json/genitourinary/cystitis/UTI, Acute, Child, Age < 2 months.json",category:"genitourinary",subcategory:"cystitis",filename:"UTI, Acute, Child, Age < 2 months",title:"UTI, Acute, Child, Age < 2 months",loaded:!1,data:null},genitourinary_cystitis_prevention_of_recurrent_uti_female:{id:"genitourinary_cystitis_prevention_of_recurrent_uti_female",filePath:"./syndromes_json/genitourinary/cystitis/prevention_of_recurrent_uti_female.json",category:"genitourinary",subcategory:"cystitis",filename:"prevention_of_recurrent_uti_female",title:"Prevention of Recurrent UTI, Female",loaded:!1,data:null},genitourinary_cystitis_uti_acute_child_age_2_months:{id:"genitourinary_cystitis_uti_acute_child_age_2_months",filePath:"./syndromes_json/genitourinary/cystitis/uti_acute_child_age_2_months.json",category:"genitourinary",subcategory:"cystitis",filename:"uti_acute_child_age_2_months",title:"Acute Urinary Tract Infection in Children Age >= 2 Months",loaded:!1,data:null},genitourinary_cystitis_uti_acute_uncomplicated_adult_female:{id:"genitourinary_cystitis_uti_acute_uncomplicated_adult_female",filePath:"./syndromes_json/genitourinary/cystitis/uti_acute_uncomplicated_adult_female.json",category:"genitourinary",subcategory:"cystitis",filename:"uti_acute_uncomplicated_adult_female",title:"Acute Uncomplicated Urinary Tract Infection in Adult Women",loaded:!1,data:null},genitourinary_cystitis_uti_adult_male:{id:"genitourinary_cystitis_uti_adult_male",filePath:"./syndromes_json/genitourinary/cystitis/uti_adult_male.json",category:"genitourinary",subcategory:"cystitis",filename:"uti_adult_male",title:"Urinary Tract Infection, Adult, Male",loaded:!1,data:null},genitourinary_cystitis_uti_complicated_or_catheter_related:{id:"genitourinary_cystitis_uti_complicated_or_catheter_related",filePath:"./syndromes_json/genitourinary/cystitis/uti_complicated_or_catheter-related.json",category:"genitourinary",subcategory:"cystitis",filename:"uti_complicated_or_catheter-related",title:"Complicated Urinary Tract Infection or Catheter-related Infection",loaded:!1,data:null},genitourinary_epididymo_orchitis:{id:"genitourinary_epididymo_orchitis",filePath:"./syndromes_json/genitourinary/epididymo-orchitis.json",category:"genitourinary",subcategory:null,filename:"epididymo-orchitis",title:"Epididymo-orchitis",loaded:!1,data:null},genitourinary_genital_ulcer:{id:"genitourinary_genital_ulcer",filePath:"./syndromes_json/genitourinary/genital_ulcer.json",category:"genitourinary",subcategory:null,filename:"genital_ulcer",title:"Genital Ulcer",loaded:!1,data:null},genitourinary_herpes_simplex_genital:{id:"genitourinary_herpes_simplex_genital",filePath:"./syndromes_json/genitourinary/herpes_simplex_genital.json",category:"genitourinary",subcategory:null,filename:"herpes_simplex_genital",title:"Herpes simplex, Genital",loaded:!1,data:null},genitourinary_lice_pubic:{id:"genitourinary_lice_pubic",filePath:"./syndromes_json/genitourinary/lice_pubic.json",category:"genitourinary",subcategory:null,filename:"lice_pubic",title:"Lice, Pubic",loaded:!1,data:null},genitourinary_malakoplakia:{id:"genitourinary_malakoplakia",filePath:"./syndromes_json/genitourinary/malakoplakia.json",category:"genitourinary",subcategory:null,filename:"malakoplakia",title:"Malakoplakia",loaded:!1,data:null},genitourinary_pelvic_pelvic_inflammatory_disease:{id:"genitourinary_pelvic_pelvic_inflammatory_disease",filePath:"./syndromes_json/genitourinary/pelvic/pelvic_inflammatory_disease.json",category:"genitourinary",subcategory:"pelvic",filename:"pelvic_inflammatory_disease",title:"Pelvic Inflammatory Disease",loaded:!1,data:null},genitourinary_pelvic_pelvic_vein_suppurative_septic_thrombophlebitis:{id:"genitourinary_pelvic_pelvic_vein_suppurative_septic_thrombophlebitis",filePath:"./syndromes_json/genitourinary/pelvic/pelvic_vein_suppurative_septic_thrombophlebitis.json",category:"genitourinary",subcategory:"pelvic",filename:"pelvic_vein_suppurative_septic_thrombophlebitis",title:"Pelvic Vein Suppurative (Septic) Thrombophlebitis",loaded:!1,data:null},genitourinary_perinephric_abscess:{id:"genitourinary_perinephric_abscess",filePath:"./syndromes_json/genitourinary/perinephric_abscess.json",category:"genitourinary",subcategory:null,filename:"perinephric_abscess",title:"Perinephric Abscess",loaded:!1,data:null},genitourinary_postpartum_endometritis_endomyometritis:{id:"genitourinary_postpartum_endometritis_endomyometritis",filePath:"./syndromes_json/genitourinary/postpartum_endometritis_endomyometritis.json",category:"genitourinary",subcategory:null,filename:"postpartum_endometritis_endomyometritis",title:"Postpartum Endometritis, Endomyometritis",loaded:!1,data:null},genitourinary_prostatitis_prostatitis_bacterial_acute:{id:"genitourinary_prostatitis_prostatitis_bacterial_acute",filePath:"./syndromes_json/genitourinary/prostatitis/prostatitis_bacterial_acute.json",category:"genitourinary",subcategory:"prostatitis",filename:"prostatitis_bacterial_acute",title:"Acute Bacterial Prostatitis",loaded:!1,data:null},genitourinary_prostatitis_prostatitis_bacterial_chronic:{id:"genitourinary_prostatitis_prostatitis_bacterial_chronic",filePath:"./syndromes_json/genitourinary/prostatitis/prostatitis_bacterial_chronic.json",category:"genitourinary",subcategory:"prostatitis",filename:"prostatitis_bacterial_chronic",title:"Chronic Bacterial Prostatitis",loaded:!1,data:null},genitourinary_pyelonephritis_candidiasis_urinary_tract_infections:{id:"genitourinary_pyelonephritis_candidiasis_urinary_tract_infections",filePath:"./syndromes_json/genitourinary/pyelonephritis/candidiasis_urinary_tract_infections.json",category:"genitourinary",subcategory:"pyelonephritis",filename:"candidiasis_urinary_tract_infections",title:"Candidiasis, Urinary Tract Infections",loaded:!1,data:null},genitourinary_pyelonephritis_pyelonephritis_acute:{id:"genitourinary_pyelonephritis_pyelonephritis_acute",filePath:"./syndromes_json/genitourinary/pyelonephritis/pyelonephritis_acute.json",category:"genitourinary",subcategory:"pyelonephritis",filename:"pyelonephritis_acute",title:"Acute Pyelonephritis",loaded:!1,data:null},genitourinary_syphilis_bacterial_vaginosis:{id:"genitourinary_syphilis_bacterial_vaginosis",filePath:"./syndromes_json/genitourinary/syphilis/bacterial_vaginosis.json",category:"genitourinary",subcategory:"syphilis",filename:"bacterial_vaginosis",title:"bacterial_vaginosis",loaded:!1,data:null},genitourinary_syphilis_papillomavirus_warts:{id:"genitourinary_syphilis_papillomavirus_warts",filePath:"./syndromes_json/genitourinary/syphilis/papillomavirus_warts.json",category:"genitourinary",subcategory:"syphilis",filename:"papillomavirus_warts",title:"Papillomavirus, Warts",loaded:!1,data:null},genitourinary_syphilis_syphilis_cns:{id:"genitourinary_syphilis_syphilis_cns",filePath:"./syndromes_json/genitourinary/syphilis/syphilis_cns.json",category:"genitourinary",subcategory:"syphilis",filename:"syphilis_cns",title:"Syphilis, CNS",loaded:!1,data:null},genitourinary_syphilis_syphilis_congenital:{id:"genitourinary_syphilis_syphilis_congenital",filePath:"./syndromes_json/genitourinary/syphilis/syphilis_congenital.json",category:"genitourinary",subcategory:"syphilis",filename:"syphilis_congenital",title:"Syphilis, Congenital",loaded:!1,data:null},genitourinary_syphilis_syphilis_early_latent:{id:"genitourinary_syphilis_syphilis_early_latent",filePath:"./syndromes_json/genitourinary/syphilis/syphilis_early_latent.json",category:"genitourinary",subcategory:"syphilis",filename:"syphilis_early_latent",title:"Syphilis, Early Latent",loaded:!1,data:null},genitourinary_syphilis_syphilis_hiv_aids:{id:"genitourinary_syphilis_syphilis_hiv_aids",filePath:"./syndromes_json/genitourinary/syphilis/syphilis_hiv_aids.json",category:"genitourinary",subcategory:"syphilis",filename:"syphilis_hiv_aids",title:"Syphilis, HIV/AIDS",loaded:!1,data:null},genitourinary_syphilis_syphilis_late_latent:{id:"genitourinary_syphilis_syphilis_late_latent",filePath:"./syndromes_json/genitourinary/syphilis/syphilis_late_latent.json",category:"genitourinary",subcategory:"syphilis",filename:"syphilis_late_latent",title:"Syphilis, Late Latent",loaded:!1,data:null},genitourinary_syphilis_syphilis_pregnancy:{id:"genitourinary_syphilis_syphilis_pregnancy",filePath:"./syndromes_json/genitourinary/syphilis/syphilis_pregnancy.json",category:"genitourinary",subcategory:"syphilis",filename:"syphilis_pregnancy",title:"Syphilis, Pregnancy",loaded:!1,data:null},genitourinary_syphilis_syphilis_primary:{id:"genitourinary_syphilis_syphilis_primary",filePath:"./syndromes_json/genitourinary/syphilis/syphilis_primary.json",category:"genitourinary",subcategory:"syphilis",filename:"syphilis_primary",title:"Syphilis, Primary",loaded:!1,data:null},genitourinary_syphilis_syphilis_secondary:{id:"genitourinary_syphilis_syphilis_secondary",filePath:"./syndromes_json/genitourinary/syphilis/syphilis_secondary.json",category:"genitourinary",subcategory:"syphilis",filename:"syphilis_secondary",title:"Syphilis, Secondary",loaded:!1,data:null},genitourinary_urethritis_recurrent_persistent:{id:"genitourinary_urethritis_recurrent_persistent",filePath:"./syndromes_json/genitourinary/urethritis_recurrent_persistent.json",category:"genitourinary",subcategory:null,filename:"urethritis_recurrent_persistent",title:"Recurrent or Persistent Non-Gonococcal Urethritis",loaded:!1,data:null},genitourinary_urinary_tract_infections_overview:{id:"genitourinary_urinary_tract_infections_overview",filePath:"./syndromes_json/genitourinary/urinary_tract_infections_overview.json",category:"genitourinary",subcategory:null,filename:"urinary_tract_infections_overview",title:"Urinary Tract Infections, Overview",loaded:!1,data:null},head_and_neck_candidiasis_oropharyngeal:{id:"head_and_neck_candidiasis_oropharyngeal",filePath:"./syndromes_json/head_and_neck/candidiasis_oropharyngeal.json",category:"head_and_neck",subcategory:null,filename:"candidiasis_oropharyngeal",title:"Candidiasis, Oropharyngeal",loaded:!1,data:null},head_and_neck_cellulitis_buccal:{id:"head_and_neck_cellulitis_buccal",filePath:"./syndromes_json/head_and_neck/cellulitis_buccal.json",category:"head_and_neck",subcategory:null,filename:"cellulitis_buccal",title:"Cellulitis, Buccal",loaded:!1,data:null},head_and_neck_cellulitis_erysipelas_facial:{id:"head_and_neck_cellulitis_erysipelas_facial",filePath:"./syndromes_json/head_and_neck/cellulitis_erysipelas_facial.json",category:"head_and_neck",subcategory:null,filename:"cellulitis_erysipelas_facial",title:"Cellulitis, Erysipelas, Facial",loaded:!1,data:null},head_and_neck_mastoiditis_mastoiditis_chronic:{id:"head_and_neck_mastoiditis_mastoiditis_chronic",filePath:"./syndromes_json/head_and_neck/mastoiditis/mastoiditis_chronic.json",category:"head_and_neck",subcategory:"mastoiditis",filename:"mastoiditis_chronic",title:"Mastoiditis, Chronic",loaded:!1,data:null},head_and_neck_mouth_adjacent_spaces_cellulitis_buccal:{id:"head_and_neck_mouth_adjacent_spaces_cellulitis_buccal",filePath:"./syndromes_json/head_and_neck/mouth_adjacent_spaces/cellulitis_buccal.json",category:"head_and_neck",subcategory:"mouth_adjacent_spaces",filename:"cellulitis_buccal",title:"Cellulitis, Buccal",loaded:!1,data:null},head_and_neck_mouth_adjacent_spaces_herpes_simplex_oral_lesions_mouth_lips:{id:"head_and_neck_mouth_adjacent_spaces_herpes_simplex_oral_lesions_mouth_lips",filePath:"./syndromes_json/head_and_neck/mouth_adjacent_spaces/herpes_simplex_oral_lesions_mouth_lips.json",category:"head_and_neck",subcategory:"mouth_adjacent_spaces",filename:"herpes_simplex_oral_lesions_mouth_lips",title:"Herpes simplex, Oral lesions mouth, lips",loaded:!1,data:null},head_and_neck_mouth_adjacent_spaces_tooth_odontogenic_infection_ludwigs_angina:{id:"head_and_neck_mouth_adjacent_spaces_tooth_odontogenic_infection_ludwigs_angina",filePath:"./syndromes_json/head_and_neck/mouth_adjacent_spaces/tooth_odontogenic_infection_ludwigs_angina.json",category:"head_and_neck",subcategory:"mouth_adjacent_spaces",filename:"tooth_odontogenic_infection_ludwigs_angina",title:"Tooth, Odontogenic Infection, Ludwig's Angina",loaded:!1,data:null},head_and_neck_mouth_adjacent_spaces_vincents_angina_necrotizing_gingivitis_trench_mouth:{id:"head_and_neck_mouth_adjacent_spaces_vincents_angina_necrotizing_gingivitis_trench_mouth",filePath:"./syndromes_json/head_and_neck/mouth_adjacent_spaces/vincents_angina_necrotizing_gingivitis_trench_mouth.json",category:"head_and_neck",subcategory:"mouth_adjacent_spaces",filename:"vincents_angina_necrotizing_gingivitis_trench_mouth",title:"Vincent's Angina, Necrotizing Gingivitis, Trench mouth",loaded:!1,data:null},head_and_neck_mouth_parapharyngeal_space_infection:{id:"head_and_neck_mouth_parapharyngeal_space_infection",filePath:"./syndromes_json/head_and_neck/mouth_parapharyngeal_space_infection.json",category:"head_and_neck",subcategory:null,filename:"mouth_parapharyngeal_space_infection",title:"Mouth, Parapharyngeal Space Infection",loaded:!1,data:null},head_and_neck_orbital_cellulitis_periorbital_cellulitis:{id:"head_and_neck_orbital_cellulitis_periorbital_cellulitis",filePath:"./syndromes_json/head_and_neck/orbital_cellulitis_periorbital_cellulitis.json",category:"head_and_neck",subcategory:null,filename:"orbital_cellulitis_periorbital_cellulitis",title:"Orbital cellulitis, periorbital cellulitis",loaded:!1,data:null},head_and_neck_otitis_externa_malignant_otitis_externa_perichondritis:{id:"head_and_neck_otitis_externa_malignant_otitis_externa_perichondritis",filePath:"./syndromes_json/head_and_neck/otitis_externa/malignant_otitis_externa_perichondritis.json",category:"head_and_neck",subcategory:"otitis_externa",filename:"malignant_otitis_externa_perichondritis",title:"Malignant Otitis Externa, Perichondritis",loaded:!1,data:null},head_and_neck_otitis_externa_otitis_externa_chronic:{id:"head_and_neck_otitis_externa_otitis_externa_chronic",filePath:"./syndromes_json/head_and_neck/otitis_externa/otitis_externa_chronic.json",category:"head_and_neck",subcategory:"otitis_externa",filename:"otitis_externa_chronic",title:"Otitis Externa, Chronic",loaded:!1,data:null},head_and_neck_otitis_externa_otitis_externa_fungal_otomycosis:{id:"head_and_neck_otitis_externa_otitis_externa_fungal_otomycosis",filePath:"./syndromes_json/head_and_neck/otitis_externa/otitis_externa_fungal_otomycosis.json",category:"head_and_neck",subcategory:"otitis_externa",filename:"otitis_externa_fungal_otomycosis",title:"Otitis Externa, Fungal, Otomycosis",loaded:!1,data:null},head_and_neck_otitis_externa_otitis_externa_swimmers_ear:{id:"head_and_neck_otitis_externa_otitis_externa_swimmers_ear",filePath:"./syndromes_json/head_and_neck/otitis_externa/otitis_externa_swimmers_ear.json",category:"head_and_neck",subcategory:"otitis_externa",filename:"otitis_externa_swimmers_ear",title:"Otitis Externa, Swimmer's Ear",loaded:!1,data:null},head_and_neck_otitis_media_otitis_media_acute_empiric_therapy:{id:"head_and_neck_otitis_media_otitis_media_acute_empiric_therapy",filePath:"./syndromes_json/head_and_neck/otitis_media/otitis_media_acute_empiric_therapy.json",category:"head_and_neck",subcategory:"otitis_media",filename:"otitis_media_acute_empiric_therapy",title:"Otitis Media, Acute, Empiric Therapy",loaded:!1,data:null},head_and_neck_otitis_media_otitis_media_post_intubation:{id:"head_and_neck_otitis_media_otitis_media_post_intubation",filePath:"./syndromes_json/head_and_neck/otitis_media/otitis_media_post-intubation.json",category:"head_and_neck",subcategory:"otitis_media",filename:"otitis_media_post-intubation",title:"Otitis Media, Post-Intubation",loaded:!1,data:null},head_and_neck_otitis_media_otitis_media_prophylaxis:{id:"head_and_neck_otitis_media_otitis_media_prophylaxis",filePath:"./syndromes_json/head_and_neck/otitis_media/otitis_media_prophylaxis.json",category:"head_and_neck",subcategory:"otitis_media",filename:"otitis_media_prophylaxis",title:"Otitis Media, Prophylaxis",loaded:!1,data:null},head_and_neck_otitis_media_otitis_media_treatment_failure:{id:"head_and_neck_otitis_media_otitis_media_treatment_failure",filePath:"./syndromes_json/head_and_neck/otitis_media/otitis_media_treatment_failure.json",category:"head_and_neck",subcategory:"otitis_media",filename:"otitis_media_treatment_failure",title:"Otitis Media, Treatment Failure",loaded:!1,data:null},head_and_neck_parotid_swelling_parotitis:{id:"head_and_neck_parotid_swelling_parotitis",filePath:"./syndromes_json/head_and_neck/parotid_swelling_parotitis.json",category:"head_and_neck",subcategory:null,filename:"parotid_swelling_parotitis",title:"Parotid Swelling, Parotitis",loaded:!1,data:null},head_and_neck_peritonsillar_abscess:{id:"head_and_neck_peritonsillar_abscess",filePath:"./syndromes_json/head_and_neck/peritonsillar_abscess.json",category:"head_and_neck",subcategory:null,filename:"peritonsillar_abscess",title:"Peritonsillar Abscess",loaded:!1,data:null},head_and_neck_pharyngitis_diphtheria:{id:"head_and_neck_pharyngitis_diphtheria",filePath:"./syndromes_json/head_and_neck/pharyngitis/diphtheria.json",category:"head_and_neck",subcategory:"pharyngitis",filename:"diphtheria",title:"Diphtheria",loaded:!1,data:null},head_and_neck_pharyngitis_epiglottitis_supraglottitis:{id:"head_and_neck_pharyngitis_epiglottitis_supraglottitis",filePath:"./syndromes_json/head_and_neck/pharyngitis/epiglottitis_supraglottitis.json",category:"head_and_neck",subcategory:"pharyngitis",filename:"epiglottitis_supraglottitis",title:"Epiglottitis, Supraglottitis",loaded:!1,data:null},head_and_neck_pharyngitis_jugular_vein_suppurative_septic_thrombophlebitis_lemierres_syndrome:{id:"head_and_neck_pharyngitis_jugular_vein_suppurative_septic_thrombophlebitis_lemierres_syndrome",filePath:"./syndromes_json/head_and_neck/pharyngitis/jugular_vein_suppurative_septic_thrombophlebitis_lemierres_syndrome.json",category:"head_and_neck",subcategory:"pharyngitis",filename:"jugular_vein_suppurative_septic_thrombophlebitis_lemierres_syndrome",title:"Jugular Vein Suppurative (Septic) Thrombophlebitis, Lemierre's syndrome",loaded:!1,data:null},head_and_neck_pharyngitis_laryngitis_acute:{id:"head_and_neck_pharyngitis_laryngitis_acute",filePath:"./syndromes_json/head_and_neck/pharyngitis/laryngitis_acute.json",category:"head_and_neck",subcategory:"pharyngitis",filename:"laryngitis_acute",title:"Laryngitis, Acute",loaded:!1,data:null},head_and_neck_pharyngitis_mouth_parapharyngeal_space_infection:{id:"head_and_neck_pharyngitis_mouth_parapharyngeal_space_infection",filePath:"./syndromes_json/head_and_neck/pharyngitis/mouth_parapharyngeal_space_infection.json",category:"head_and_neck",subcategory:"pharyngitis",filename:"mouth_parapharyngeal_space_infection",title:"Mouth, Parapharyngeal Space Infection",loaded:!1,data:null},head_and_neck_pharyngitis_pharyngitis_tonsillitis:{id:"head_and_neck_pharyngitis_pharyngitis_tonsillitis",filePath:"./syndromes_json/head_and_neck/pharyngitis/pharyngitis_tonsillitis.json",category:"head_and_neck",subcategory:"pharyngitis",filename:"pharyngitis_tonsillitis",title:"Pharyngitis, Tonsillitis",loaded:!1,data:null},head_and_neck_rhinosinusitis_empyema_subdural:{id:"head_and_neck_rhinosinusitis_empyema_subdural",filePath:"./syndromes_json/head_and_neck/rhinosinusitis/empyema_subdural.json",category:"head_and_neck",subcategory:"rhinosinusitis",filename:"empyema_subdural",title:"Empyema, Subdural",loaded:!1,data:null},head_and_neck_rhinosinusitis_sinusitis_acute_failure_of_empiric_therapy:{id:"head_and_neck_rhinosinusitis_sinusitis_acute_failure_of_empiric_therapy",filePath:"./syndromes_json/head_and_neck/rhinosinusitis/sinusitis_acute_failure_of_empiric_therapy.json",category:"head_and_neck",subcategory:"rhinosinusitis",filename:"sinusitis_acute_failure_of_empiric_therapy",title:"Sinusitis, Acute, Failure of Empiric Therapy",loaded:!1,data:null},head_and_neck_rhinosinusitis_sinusitis_intubation_associated:{id:"head_and_neck_rhinosinusitis_sinusitis_intubation_associated",filePath:"./syndromes_json/head_and_neck/rhinosinusitis/sinusitis_intubation_associated.json",category:"head_and_neck",subcategory:"rhinosinusitis",filename:"sinusitis_intubation_associated",title:"Sinusitis, Intubation Associated",loaded:!1,data:null},head_and_neck_rhinosinusitis_sinusitis_rhinosinusitis_acute:{id:"head_and_neck_rhinosinusitis_sinusitis_rhinosinusitis_acute",filePath:"./syndromes_json/head_and_neck/rhinosinusitis/sinusitis_rhinosinusitis_acute.json",category:"head_and_neck",subcategory:"rhinosinusitis",filename:"sinusitis_rhinosinusitis_acute",title:"Sinusitis, Rhinosinusitis, Acute",loaded:!1,data:null},head_and_neck_rhinosinusitis_sinusitis_rhinosinusitis_atrophic:{id:"head_and_neck_rhinosinusitis_sinusitis_rhinosinusitis_atrophic",filePath:"./syndromes_json/head_and_neck/rhinosinusitis/sinusitis_rhinosinusitis_atrophic.json",category:"head_and_neck",subcategory:"rhinosinusitis",filename:"sinusitis_rhinosinusitis_atrophic",title:"Sinusitis, Rhinosinusitis, Atrophic",loaded:!1,data:null},head_and_neck_rhinosinusitis_sinusitis_rhinosinusitis_chronic:{id:"head_and_neck_rhinosinusitis_sinusitis_rhinosinusitis_chronic",filePath:"./syndromes_json/head_and_neck/rhinosinusitis/sinusitis_rhinosinusitis_chronic.json",category:"head_and_neck",subcategory:"rhinosinusitis",filename:"sinusitis_rhinosinusitis_chronic",title:"Sinusitis, Rhinosinusitis, Chronic",loaded:!1,data:null},head_and_neck_rhinosinusitis_sinusitis_rhinosinusitis_overview:{id:"head_and_neck_rhinosinusitis_sinusitis_rhinosinusitis_overview",filePath:"./syndromes_json/head_and_neck/rhinosinusitis/sinusitis_rhinosinusitis_overview.json",category:"head_and_neck",subcategory:"rhinosinusitis",filename:"sinusitis_rhinosinusitis_overview",title:"Sinusitis, Rhinosinusitis, Overview",loaded:!1,data:null},infectious_syndromes_anaplasmosis_human:{id:"infectious_syndromes_anaplasmosis_human",filePath:"./syndromes_json/infectious_syndromes/anaplasmosis_human.json",category:"infectious_syndromes",subcategory:null,filename:"anaplasmosis_human",title:"Human Anaplasmosis",loaded:!1,data:null},infectious_syndromes_babesiosis:{id:"infectious_syndromes_babesiosis",filePath:"./syndromes_json/infectious_syndromes/babesiosis.json",category:"infectious_syndromes",subcategory:null,filename:"babesiosis",title:"Babesiosis",loaded:!1,data:null},infectious_syndromes_bacteremia_salmonella_sp:{id:"infectious_syndromes_bacteremia_salmonella_sp",filePath:"./syndromes_json/infectious_syndromes/bacteremia_salmonella_sp.json",category:"infectious_syndromes",subcategory:null,filename:"bacteremia_salmonella_sp",title:"Bacteremia, Salmonella sp.",loaded:!1,data:null},infectious_syndromes_bartonella_bacillary_angiomatosis_peliosis:{id:"infectious_syndromes_bartonella_bacillary_angiomatosis_peliosis",filePath:"./syndromes_json/infectious_syndromes/bartonella/bacillary_angiomatosis_peliosis.json",category:"infectious_syndromes",subcategory:"bartonella",filename:"bacillary_angiomatosis_peliosis",title:"Bacillary Angiomatosis, Peliosis",loaded:!1,data:null},infectious_syndromes_bartonella_bacteremia_asymptomatic_bartonella_sp:{id:"infectious_syndromes_bartonella_bacteremia_asymptomatic_bartonella_sp",filePath:"./syndromes_json/infectious_syndromes/bartonella/bacteremia_asymptomatic_bartonella_sp.json",category:"infectious_syndromes",subcategory:"bartonella",filename:"bacteremia_asymptomatic_bartonella_sp",title:"Bacteremia, Asymptomatic, Bartonella sp.",loaded:!1,data:null},infectious_syndromes_bartonella_brucella_sp_brucellosis_febrile_illness:{id:"infectious_syndromes_bartonella_brucella_sp_brucellosis_febrile_illness",filePath:"./syndromes_json/infectious_syndromes/bartonella/brucella_sp_brucellosis_febrile_illness.json",category:"infectious_syndromes",subcategory:"bartonella",filename:"brucella_sp_brucellosis_febrile_illness",title:"Brucella sp., Brucellosis, Febrile Illness",loaded:!1,data:null},infectious_syndromes_bartonella_cat_scratch_disease_csd:{id:"infectious_syndromes_bartonella_cat_scratch_disease_csd",filePath:"./syndromes_json/infectious_syndromes/bartonella/cat-scratch_disease_csd.json",category:"infectious_syndromes",subcategory:"bartonella",filename:"cat-scratch_disease_csd",title:"Cat-scratch Disease (CSD)",loaded:!1,data:null},infectious_syndromes_bartonella_endocarditis_bartonella_sp:{id:"infectious_syndromes_bartonella_endocarditis_bartonella_sp",filePath:"./syndromes_json/infectious_syndromes/bartonella/endocarditis_bartonella_sp.json",category:"infectious_syndromes",subcategory:"bartonella",filename:"endocarditis_bartonella_sp",title:"Endocarditis, Bartonella sp.",loaded:!1,data:null},infectious_syndromes_bartonella_oroya_fever_verruga_peruana_south_american_bartonellosis:{id:"infectious_syndromes_bartonella_oroya_fever_verruga_peruana_south_american_bartonellosis",filePath:"./syndromes_json/infectious_syndromes/bartonella/oroya_fever_verruga_peruana_south_american_bartonellosis.json",category:"infectious_syndromes",subcategory:"bartonella",filename:"oroya_fever_verruga_peruana_south_american_bartonellosis",title:"Oroya Fever, Verruga Peruana, South American Bartonellosis",loaded:!1,data:null},infectious_syndromes_bartonella_trench_fever_bartonella_quintana:{id:"infectious_syndromes_bartonella_trench_fever_bartonella_quintana",filePath:"./syndromes_json/infectious_syndromes/bartonella/trench_fever_bartonella_quintana.json",category:"infectious_syndromes",subcategory:"bartonella",filename:"trench_fever_bartonella_quintana",title:"Trench Fever, Bartonella quintana",loaded:!1,data:null},infectious_syndromes_ehrlichiosis_human_monocytic_ehrlichiosis_hme:{id:"infectious_syndromes_ehrlichiosis_human_monocytic_ehrlichiosis_hme",filePath:"./syndromes_json/infectious_syndromes/ehrlichiosis_human_monocytic_ehrlichiosis_hme.json",category:"infectious_syndromes",subcategory:null,filename:"ehrlichiosis_human_monocytic_ehrlichiosis_hme",title:"Ehrlichiosis, Human monocytic ehrlichiosis (HME)",loaded:!1,data:null},infectious_syndromes_febrile_infant_neonatal_sepsis:{id:"infectious_syndromes_febrile_infant_neonatal_sepsis",filePath:"./syndromes_json/infectious_syndromes/febrile_infant_neonatal_sepsis.json",category:"infectious_syndromes",subcategory:null,filename:"febrile_infant_neonatal_sepsis",title:"Febrile Infant, Neonatal Sepsis",loaded:!1,data:null},infectious_syndromes_francisella_tularensis_tularemia:{id:"infectious_syndromes_francisella_tularensis_tularemia",filePath:"./syndromes_json/infectious_syndromes/francisella_tularensis_tularemia.json",category:"infectious_syndromes",subcategory:null,filename:"francisella_tularensis_tularemia",title:"Francisella tularensis, Tularemia",loaded:!1,data:null},infectious_syndromes_kawasaki_disease_kawasaki_syndrome:{id:"infectious_syndromes_kawasaki_disease_kawasaki_syndrome",filePath:"./syndromes_json/infectious_syndromes/kawasaki_disease_kawasaki_syndrome.json",category:"infectious_syndromes",subcategory:null,filename:"kawasaki_disease_kawasaki_syndrome",title:"Kawasaki Disease (Kawasaki Syndrome)",loaded:!1,data:null},infectious_syndromes_leptospira_sp_leptospirosis:{id:"infectious_syndromes_leptospira_sp_leptospirosis",filePath:"./syndromes_json/infectious_syndromes/leptospira_sp_leptospirosis.json",category:"infectious_syndromes",subcategory:null,filename:"leptospira_sp_leptospirosis",title:"Leptospira sp., Leptospirosis",loaded:!1,data:null},infectious_syndromes_neutropenia_neutropenia_chemotherapy_induced_prophylaxis:{id:"infectious_syndromes_neutropenia_neutropenia_chemotherapy_induced_prophylaxis",filePath:"./syndromes_json/infectious_syndromes/neutropenia/neutropenia_chemotherapy-induced_prophylaxis.json",category:"infectious_syndromes",subcategory:"neutropenia",filename:"neutropenia_chemotherapy-induced_prophylaxis",title:"Neutropenia, Chemotherapy-induced, Prophylaxis",loaded:!1,data:null},infectious_syndromes_neutropenia_neutropenia_febrile_high_risk:{id:"infectious_syndromes_neutropenia_neutropenia_febrile_high_risk",filePath:"./syndromes_json/infectious_syndromes/neutropenia/neutropenia_febrile_high-risk.json",category:"infectious_syndromes",subcategory:"neutropenia",filename:"neutropenia_febrile_high-risk",title:"Neutropenia, Febrile, High-Risk",loaded:!1,data:null},infectious_syndromes_neutropenia_neutropenia_febrile_low_risk:{id:"infectious_syndromes_neutropenia_neutropenia_febrile_low_risk",filePath:"./syndromes_json/infectious_syndromes/neutropenia/neutropenia_febrile_low-risk.json",category:"infectious_syndromes",subcategory:"neutropenia",filename:"neutropenia_febrile_low-risk",title:"Neutropenia, Febrile, Low-Risk",loaded:!1,data:null},infectious_syndromes_relapsing_fever:{id:"infectious_syndromes_relapsing_fever",filePath:"./syndromes_json/infectious_syndromes/relapsing_fever.json",category:"infectious_syndromes",subcategory:null,filename:"relapsing_fever",title:"Relapsing Fever",loaded:!1,data:null},infectious_syndromes_ricketsial_diseases_other_rickettsiae_spotted_fevers:{id:"infectious_syndromes_ricketsial_diseases_other_rickettsiae_spotted_fevers",filePath:"./syndromes_json/infectious_syndromes/ricketsial_diseases/other_rickettsiae_spotted_fevers.json",category:"infectious_syndromes",subcategory:"ricketsial_diseases",filename:"other_rickettsiae_spotted_fevers",title:"Other Rickettsiae, Spotted Fevers",loaded:!1,data:null},infectious_syndromes_ricketsial_diseases_rocky_mountain_spotted_fever:{id:"infectious_syndromes_ricketsial_diseases_rocky_mountain_spotted_fever",filePath:"./syndromes_json/infectious_syndromes/ricketsial_diseases/rocky_mountain_spotted_fever.json",category:"infectious_syndromes",subcategory:"ricketsial_diseases",filename:"rocky_mountain_spotted_fever",title:"Rocky Mountain Spotted Fever",loaded:!1,data:null},infectious_syndromes_ricketsial_diseases_thyphus_typhus_louse_borne:{id:"infectious_syndromes_ricketsial_diseases_thyphus_typhus_louse_borne",filePath:"./syndromes_json/infectious_syndromes/ricketsial_diseases/thyphus/typhus_louse-borne.json",category:"infectious_syndromes",subcategory:"ricketsial_diseases",filename:"typhus_louse-borne",title:"Typhus, Louse-borne",loaded:!1,data:null},infectious_syndromes_ricketsial_diseases_thyphus_typhus_murine:{id:"infectious_syndromes_ricketsial_diseases_thyphus_typhus_murine",filePath:"./syndromes_json/infectious_syndromes/ricketsial_diseases/thyphus/typhus_murine.json",category:"infectious_syndromes",subcategory:"ricketsial_diseases",filename:"typhus_murine",title:"Typhus, Murine",loaded:!1,data:null},infectious_syndromes_septic_shock_sepsis_adult:{id:"infectious_syndromes_septic_shock_sepsis_adult",filePath:"./syndromes_json/infectious_syndromes/septic_shock/sepsis_adult.json",category:"infectious_syndromes",subcategory:"septic_shock",filename:"sepsis_adult",title:"Sepsis, Adult",loaded:!1,data:null},infectious_syndromes_septic_shock_sepsis_child_age_1_mo:{id:"infectious_syndromes_septic_shock_sepsis_child_age_1_mo",filePath:"./syndromes_json/infectious_syndromes/septic_shock/sepsis_child_age_1_mo.json",category:"infectious_syndromes",subcategory:"septic_shock",filename:"sepsis_child_age_1_mo",title:"Sepsis, Child, Age > 1 mo",loaded:!1,data:null},infectious_syndromes_septic_shock_sepsis_neonatal:{id:"infectious_syndromes_septic_shock_sepsis_neonatal",filePath:"./syndromes_json/infectious_syndromes/septic_shock/sepsis_neonatal.json",category:"infectious_syndromes",subcategory:"septic_shock",filename:"sepsis_neonatal",title:"Sepsis, Neonatal",loaded:!1,data:null},infectious_syndromes_septic_shock_shock_post_splenectomy:{id:"infectious_syndromes_septic_shock_shock_post_splenectomy",filePath:"./syndromes_json/infectious_syndromes/septic_shock/shock_post-splenectomy.json",category:"infectious_syndromes",subcategory:"septic_shock",filename:"shock_post-splenectomy",title:"Shock, Post-splenectomy",loaded:!1,data:null},infectious_syndromes_septic_shock_shock_septic_bacteremic_endotoxin:{id:"infectious_syndromes_septic_shock_shock_septic_bacteremic_endotoxin",filePath:"./syndromes_json/infectious_syndromes/septic_shock/shock_septic_bacteremic_endotoxin.json",category:"infectious_syndromes",subcategory:"septic_shock",filename:"shock_septic_bacteremic_endotoxin",title:"Shock, Septic, Bacteremic, Endotoxin",loaded:!1,data:null},infectious_syndromes_septic_shock_toxic_shock_syndrome_tss_clostridial:{id:"infectious_syndromes_septic_shock_toxic_shock_syndrome_tss_clostridial",filePath:"./syndromes_json/infectious_syndromes/septic_shock/toxic_shock_syndrome_tss_clostridial.json",category:"infectious_syndromes",subcategory:"septic_shock",filename:"toxic_shock_syndrome_tss_clostridial",title:"Toxic Shock Syndrome (TSS), Clostridial",loaded:!1,data:null},infectious_syndromes_septic_shock_toxic_shock_syndrome_tss_staphylococcal:{id:"infectious_syndromes_septic_shock_toxic_shock_syndrome_tss_staphylococcal",filePath:"./syndromes_json/infectious_syndromes/septic_shock/toxic_shock_syndrome_tss_staphylococcal.json",category:"infectious_syndromes",subcategory:"septic_shock",filename:"toxic_shock_syndrome_tss_staphylococcal",title:"Toxic Shock Syndrome (TSS), Staphylococcal",loaded:!1,data:null},infectious_syndromes_septic_shock_toxic_shock_syndrome_tss_streptococcal:{id:"infectious_syndromes_septic_shock_toxic_shock_syndrome_tss_streptococcal",filePath:"./syndromes_json/infectious_syndromes/septic_shock/toxic_shock_syndrome_tss_streptococcal.json",category:"infectious_syndromes",subcategory:"septic_shock",filename:"toxic_shock_syndrome_tss_streptococcal",title:"Toxic Shock Syndrome (TSS), Streptococcal",loaded:!1,data:null},infectious_syndromes_toxic_shock_syndrome:{id:"infectious_syndromes_toxic_shock_syndrome",filePath:"./syndromes_json/infectious_syndromes/toxic_shock_syndrome.json",category:"infectious_syndromes",subcategory:null,filename:"toxic_shock_syndrome",title:"Toxic Shock Syndrome",loaded:!1,data:null},infectious_syndromes_trench_fever:{id:"infectious_syndromes_trench_fever",filePath:"./syndromes_json/infectious_syndromes/trench_fever.json",category:"infectious_syndromes",subcategory:null,filename:"trench_fever",title:"Trench Fever",loaded:!1,data:null},infectious_syndromes_tuberculosis_disseminated_miliary:{id:"infectious_syndromes_tuberculosis_disseminated_miliary",filePath:"./syndromes_json/infectious_syndromes/tuberculosis_disseminated_miliary.json",category:"infectious_syndromes",subcategory:null,filename:"tuberculosis_disseminated_miliary",title:"Tuberculosis, Disseminated, Miliary",loaded:!1,data:null},infectious_syndromes_tuberculosis_extrapulmonary:{id:"infectious_syndromes_tuberculosis_extrapulmonary",filePath:"./syndromes_json/infectious_syndromes/tuberculosis_extrapulmonary.json",category:"infectious_syndromes",subcategory:null,filename:"tuberculosis_extrapulmonary",title:"Tuberculosis, Extrapulmonary",loaded:!1,data:null},infectious_syndromes_tuberculosis_latent:{id:"infectious_syndromes_tuberculosis_latent",filePath:"./syndromes_json/infectious_syndromes/tuberculosis_latent.json",category:"infectious_syndromes",subcategory:null,filename:"tuberculosis_latent",title:"Tuberculosis, Latent",loaded:!1,data:null},infectious_syndromes_tuberculosis_pulmonary:{id:"infectious_syndromes_tuberculosis_pulmonary",filePath:"./syndromes_json/infectious_syndromes/tuberculosis_pulmonary.json",category:"infectious_syndromes",subcategory:null,filename:"tuberculosis_pulmonary",title:"Tuberculosis, Pulmonary",loaded:!1,data:null},infectious_syndromes_tularemia:{id:"infectious_syndromes_tularemia",filePath:"./syndromes_json/infectious_syndromes/tularemia.json",category:"infectious_syndromes",subcategory:null,filename:"tularemia",title:"Tularemia",loaded:!1,data:null},infectious_syndromes_typhoid_fever:{id:"infectious_syndromes_typhoid_fever",filePath:"./syndromes_json/infectious_syndromes/typhoid_fever.json",category:"infectious_syndromes",subcategory:null,filename:"typhoid_fever",title:"Typhoid Fever",loaded:!1,data:null},infectious_syndromes_typhoid_fever_enteric_fever:{id:"infectious_syndromes_typhoid_fever_enteric_fever",filePath:"./syndromes_json/infectious_syndromes/typhoid_fever_enteric_fever.json",category:"infectious_syndromes",subcategory:null,filename:"typhoid_fever_enteric_fever",title:"Typhoid Fever, Enteric Fever",loaded:!1,data:null},infectious_syndromes_whipples_disease:{id:"infectious_syndromes_whipples_disease",filePath:"./syndromes_json/infectious_syndromes/whipples_disease.json",category:"infectious_syndromes",subcategory:null,filename:"whipples_disease",title:"Whipple's Disease",loaded:!1,data:null},intra_abdominal_actinomycosis:{id:"intra_abdominal_actinomycosis",filePath:"./syndromes_json/intra-abdominal/actinomycosis.json",category:"intra-abdominal",subcategory:null,filename:"actinomycosis",title:"Actinomycosis",loaded:!1,data:null},intra_abdominal_clostridioides_difficile_c_diff:{id:"intra_abdominal_clostridioides_difficile_c_diff",filePath:"./syndromes_json/intra-abdominal/clostridioides_difficile_c_diff.json",category:"intra-abdominal",subcategory:null,filename:"clostridioides_difficile_c_diff",title:"Clostridioides difficile, C. diff",loaded:!1,data:null},intra_abdominal_cytomegalovirus_gastrointestinal_disease:{id:"intra_abdominal_cytomegalovirus_gastrointestinal_disease",filePath:"./syndromes_json/intra-abdominal/cytomegalovirus_gastrointestinal_disease.json",category:"intra-abdominal",subcategory:null,filename:"cytomegalovirus_gastrointestinal_disease",title:"Cytomegalovirus, Gastrointestinal Disease",loaded:!1,data:null},intra_abdominal_diverticulitis_perirectal_abscess:{id:"intra_abdominal_diverticulitis_perirectal_abscess",filePath:"./syndromes_json/intra-abdominal/diverticulitis_perirectal_abscess.json",category:"intra-abdominal",subcategory:null,filename:"diverticulitis_perirectal_abscess",title:"Diverticulitis, Perirectal Abscess",loaded:!1,data:null},intra_abdominal_gallbladder_biliary_tract_cholangitis:{id:"intra_abdominal_gallbladder_biliary_tract_cholangitis",filePath:"./syndromes_json/intra-abdominal/gallbladder_biliary_tract_cholangitis.json",category:"intra-abdominal",subcategory:null,filename:"gallbladder_biliary_tract_cholangitis",title:"Gallbladder, Biliary Tract, Cholangitis",loaded:!1,data:null},intra_abdominal_gastric_duodenal_ulcer_helicobacter_pylori:{id:"intra_abdominal_gastric_duodenal_ulcer_helicobacter_pylori",filePath:"./syndromes_json/intra-abdominal/gastric_duodenal_ulcer_helicobacter_pylori.json",category:"intra-abdominal",subcategory:null,filename:"gastric_duodenal_ulcer_helicobacter_pylori",title:"Gastric/Duodenal Ulcer, Helicobacter pylori",loaded:!1,data:null},intra_abdominal_gastroenteritis_empiric_theraphy_gastroenteritis_empiric_therapy:{id:"intra_abdominal_gastroenteritis_empiric_theraphy_gastroenteritis_empiric_therapy",filePath:"./syndromes_json/intra-abdominal/gastroenteritis/empiric_theraphy/gastroenteritis_empiric_therapy.json",category:"intra-abdominal",subcategory:"gastroenteritis",filename:"gastroenteritis_empiric_therapy",title:"Gastroenteritis, Empiric Therapy",loaded:!1,data:null},intra_abdominal_gastroenteritis_empiric_theraphy_gastroenteritis_premature_infant_necrotizing_enterocolitis:{id:"intra_abdominal_gastroenteritis_empiric_theraphy_gastroenteritis_premature_infant_necrotizing_enterocolitis",filePath:"./syndromes_json/intra-abdominal/gastroenteritis/empiric_theraphy/gastroenteritis_premature_infant_necrotizing_enterocolitis.json",category:"intra-abdominal",subcategory:"gastroenteritis",filename:"gastroenteritis_premature_infant_necrotizing_enterocolitis",title:"Gastroenteritis, Premature Infant (Necrotizing enterocolitis)",loaded:!1,data:null},intra_abdominal_gastroenteritis_empiric_theraphy_norovirus:{id:"intra_abdominal_gastroenteritis_empiric_theraphy_norovirus",filePath:"./syndromes_json/intra-abdominal/gastroenteritis/empiric_theraphy/norovirus.json",category:"intra-abdominal",subcategory:"gastroenteritis",filename:"norovirus",title:"Norovirus",loaded:!1,data:null},intra_abdominal_gastroenteritis_empiric_theraphy_rotavirus:{id:"intra_abdominal_gastroenteritis_empiric_theraphy_rotavirus",filePath:"./syndromes_json/intra-abdominal/gastroenteritis/empiric_theraphy/rotavirus.json",category:"intra-abdominal",subcategory:"gastroenteritis",filename:"rotavirus",title:"Rotavirus",loaded:!1,data:null},intra_abdominal_gastroenteritis_empiric_theraphy_travelers_diarrhea:{id:"intra_abdominal_gastroenteritis_empiric_theraphy_travelers_diarrhea",filePath:"./syndromes_json/intra-abdominal/gastroenteritis/empiric_theraphy/travelers_diarrhea.json",category:"intra-abdominal",subcategory:"gastroenteritis",filename:"travelers_diarrhea",title:"Traveler's Diarrhea",loaded:!1,data:null},intra_abdominal_gastroenteritis_gastroenteritis_diarrhea_overview:{id:"intra_abdominal_gastroenteritis_gastroenteritis_diarrhea_overview",filePath:"./syndromes_json/intra-abdominal/gastroenteritis/gastroenteritis_diarrhea_overview.json",category:"intra-abdominal",subcategory:"gastroenteritis",filename:"gastroenteritis_diarrhea_overview",title:"Gastroenteritis, Diarrhea: Overview",loaded:!1,data:null},intra_abdominal_gastroenteritis_gastroenteritis_parasitic_overview:{id:"intra_abdominal_gastroenteritis_gastroenteritis_parasitic_overview",filePath:"./syndromes_json/intra-abdominal/gastroenteritis/gastroenteritis_parasitic_overview.json",category:"intra-abdominal",subcategory:"gastroenteritis",filename:"gastroenteritis_parasitic_overview",title:"Gastroenteritis, Parasitic: Overview",loaded:!1,data:null},intra_abdominal_gastroenteritis_specific_therapy_clostridioides_difficile_c_diff:{id:"intra_abdominal_gastroenteritis_specific_therapy_clostridioides_difficile_c_diff",filePath:"./syndromes_json/intra-abdominal/gastroenteritis/specific_therapy/clostridioides_difficile_c_diff.json",category:"intra-abdominal",subcategory:"gastroenteritis",filename:"clostridioides_difficile_c_diff",title:"Clostridioides difficile, C. diff",loaded:!1,data:null},intra_abdominal_gastroenteritis_specific_therapy_e_coli_shiga_toxin_producing_stec:{id:"intra_abdominal_gastroenteritis_specific_therapy_e_coli_shiga_toxin_producing_stec",filePath:"./syndromes_json/intra-abdominal/gastroenteritis/specific_therapy/e_coli_shiga_toxin-producing_stec.json",category:"intra-abdominal",subcategory:"gastroenteritis",filename:"e_coli_shiga_toxin-producing_stec",title:"E. coli, Shiga toxin-producing (STEC)",loaded:!1,data:null},intra_abdominal_gastroenteritis_specific_therapy_gastroenteritis_campylobacter_fetus:{id:"intra_abdominal_gastroenteritis_specific_therapy_gastroenteritis_campylobacter_fetus",filePath:"./syndromes_json/intra-abdominal/gastroenteritis/specific_therapy/gastroenteritis_campylobacter_fetus.json",category:"intra-abdominal",subcategory:"gastroenteritis",filename:"gastroenteritis_campylobacter_fetus",title:"Gastroenteritis, Campylobacter fetus",loaded:!1,data:null},intra_abdominal_gastroenteritis_specific_therapy_gastroenteritis_campylobacter_jejuni:{id:"intra_abdominal_gastroenteritis_specific_therapy_gastroenteritis_campylobacter_jejuni",filePath:"./syndromes_json/intra-abdominal/gastroenteritis/specific_therapy/gastroenteritis_campylobacter_jejuni.json",category:"intra-abdominal",subcategory:"gastroenteritis",filename:"gastroenteritis_campylobacter_jejuni",title:"Gastroenteritis, Campylobacter jejuni",loaded:!1,data:null},intra_abdominal_gastroenteritis_specific_therapy_gastroenteritis_intestinal_spirochetosis:{id:"intra_abdominal_gastroenteritis_specific_therapy_gastroenteritis_intestinal_spirochetosis",filePath:"./syndromes_json/intra-abdominal/gastroenteritis/specific_therapy/gastroenteritis_intestinal_spirochetosis.json",category:"intra-abdominal",subcategory:"gastroenteritis",filename:"gastroenteritis_intestinal_spirochetosis",title:"Gastroenteritis, Intestinal Spirochetosis",loaded:!1,data:null},intra_abdominal_gastroenteritis_specific_therapy_gastroenteritis_klebsiella_oxytoca:{id:"intra_abdominal_gastroenteritis_specific_therapy_gastroenteritis_klebsiella_oxytoca",filePath:"./syndromes_json/intra-abdominal/gastroenteritis/specific_therapy/gastroenteritis_klebsiella_oxytoca.json",category:"intra-abdominal",subcategory:"gastroenteritis",filename:"gastroenteritis_klebsiella_oxytoca",title:"Gastroenteritis, Klebsiella oxytoca",loaded:!1,data:null},intra_abdominal_gastroenteritis_specific_therapy_gastroenteritis_salmonella_non_typhi:{id:"intra_abdominal_gastroenteritis_specific_therapy_gastroenteritis_salmonella_non_typhi",filePath:"./syndromes_json/intra-abdominal/gastroenteritis/specific_therapy/gastroenteritis_salmonella_non-typhi.json",category:"intra-abdominal",subcategory:"gastroenteritis",filename:"gastroenteritis_salmonella_non-typhi",title:"Gastroenteritis, Salmonella: Non-typhi",loaded:!1,data:null},intra_abdominal_gastroenteritis_specific_therapy_gastroenteritis_shigella:{id:"intra_abdominal_gastroenteritis_specific_therapy_gastroenteritis_shigella",filePath:"./syndromes_json/intra-abdominal/gastroenteritis/specific_therapy/gastroenteritis_shigella.json",category:"intra-abdominal",subcategory:"gastroenteritis",filename:"gastroenteritis_shigella",title:"Gastroenteritis, Shigella",loaded:!1,data:null},intra_abdominal_gastroenteritis_specific_therapy_gastroenteritis_staph_aureus:{id:"intra_abdominal_gastroenteritis_specific_therapy_gastroenteritis_staph_aureus",filePath:"./syndromes_json/intra-abdominal/gastroenteritis/specific_therapy/gastroenteritis_staph_aureus.json",category:"intra-abdominal",subcategory:"gastroenteritis",filename:"gastroenteritis_staph_aureus",title:"Gastroenteritis, Staph. aureus",loaded:!1,data:null},intra_abdominal_gastroenteritis_specific_therapy_gastroenteritis_vibrio_cholerae:{id:"intra_abdominal_gastroenteritis_specific_therapy_gastroenteritis_vibrio_cholerae",filePath:"./syndromes_json/intra-abdominal/gastroenteritis/specific_therapy/gastroenteritis_vibrio_cholerae.json",category:"intra-abdominal",subcategory:"gastroenteritis",filename:"gastroenteritis_vibrio_cholerae",title:"Gastroenteritis, Vibrio cholerae",loaded:!1,data:null},intra_abdominal_gastroenteritis_specific_therapy_gastroenteritis_vibrio_sp:{id:"intra_abdominal_gastroenteritis_specific_therapy_gastroenteritis_vibrio_sp",filePath:"./syndromes_json/intra-abdominal/gastroenteritis/specific_therapy/gastroenteritis_vibrio_sp.json",category:"intra-abdominal",subcategory:"gastroenteritis",filename:"gastroenteritis_vibrio_sp",title:"Gastroenteritis, Vibrio sp.",loaded:!1,data:null},intra_abdominal_gastroenteritis_specific_therapy_listeria_monocytogenes_gastroenteritis:{id:"intra_abdominal_gastroenteritis_specific_therapy_listeria_monocytogenes_gastroenteritis",filePath:"./syndromes_json/intra-abdominal/gastroenteritis/specific_therapy/listeria_monocytogenes_gastroenteritis.json",category:"intra-abdominal",subcategory:"gastroenteritis",filename:"listeria_monocytogenes_gastroenteritis",title:"Listeria monocytogenes, Gastroenteritis",loaded:!1,data:null},intra_abdominal_gastroenteritis_specific_therapy_vibrio_vulnificus_v_alginolyticus_v_damsela:{id:"intra_abdominal_gastroenteritis_specific_therapy_vibrio_vulnificus_v_alginolyticus_v_damsela",filePath:"./syndromes_json/intra-abdominal/gastroenteritis/specific_therapy/vibrio_vulnificus_v_alginolyticus_v_damsela.json",category:"intra-abdominal",subcategory:"gastroenteritis",filename:"vibrio_vulnificus_v_alginolyticus_v_damsela",title:"Vibrio vulnificus, V. alginolyticus, V. damsela",loaded:!1,data:null},intra_abdominal_liver_nonviral_bacillary_angiomatosis_peliosis:{id:"intra_abdominal_liver_nonviral_bacillary_angiomatosis_peliosis",filePath:"./syndromes_json/intra-abdominal/liver-nonviral/bacillary_angiomatosis_peliosis.json",category:"intra-abdominal",subcategory:"liver-nonviral",filename:"bacillary_angiomatosis_peliosis",title:"Bacillary Angiomatosis, Peliosis",loaded:!1,data:null},intra_abdominal_liver_nonviral_cirrhosis_variceal_bleeding:{id:"intra_abdominal_liver_nonviral_cirrhosis_variceal_bleeding",filePath:"./syndromes_json/intra-abdominal/liver-nonviral/cirrhosis_variceal_bleeding.json",category:"intra-abdominal",subcategory:"liver-nonviral",filename:"cirrhosis_variceal_bleeding",title:"Cirrhosis, Variceal Bleeding",loaded:!1,data:null},intra_abdominal_liver_nonviral_gallbladder_biliary_tract_cholangitis:{id:"intra_abdominal_liver_nonviral_gallbladder_biliary_tract_cholangitis",filePath:"./syndromes_json/intra-abdominal/liver-nonviral/gallbladder_biliary_tract_cholangitis.json",category:"intra-abdominal",subcategory:"liver-nonviral",filename:"gallbladder_biliary_tract_cholangitis",title:"Gallbladder, Biliary Tract, Cholangitis",loaded:!1,data:null},intra_abdominal_liver_nonviral_hepatic_abscess_empiric_therapy:{id:"intra_abdominal_liver_nonviral_hepatic_abscess_empiric_therapy",filePath:"./syndromes_json/intra-abdominal/liver-nonviral/hepatic_abscess_empiric_therapy.json",category:"intra-abdominal",subcategory:"liver-nonviral",filename:"hepatic_abscess_empiric_therapy",title:"Hepatic Abscess, Empiric Therapy",loaded:!1,data:null},intra_abdominal_liver_nonviral_hepatic_abscess_liver_abscess_bacterial:{id:"intra_abdominal_liver_nonviral_hepatic_abscess_liver_abscess_bacterial",filePath:"./syndromes_json/intra-abdominal/liver-nonviral/hepatic_abscess_liver_abscess_bacterial.json",category:"intra-abdominal",subcategory:"liver-nonviral",filename:"hepatic_abscess_liver_abscess_bacterial",title:"Hepatic Abscess, Liver Abscess, Bacterial",loaded:!1,data:null},intra_abdominal_liver_nonviral_leptospira_sp_leptospirosis:{id:"intra_abdominal_liver_nonviral_leptospira_sp_leptospirosis",filePath:"./syndromes_json/intra-abdominal/liver-nonviral/leptospira_sp_leptospirosis.json",category:"intra-abdominal",subcategory:"liver-nonviral",filename:"leptospira_sp_leptospirosis",title:"Leptospira sp., Leptospirosis",loaded:!1,data:null},intra_abdominal_liver_nonviral_post_liver_transplant_biloma:{id:"intra_abdominal_liver_nonviral_post_liver_transplant_biloma",filePath:"./syndromes_json/intra-abdominal/liver-nonviral/post-liver_transplant_biloma.json",category:"intra-abdominal",subcategory:"liver-nonviral",filename:"post-liver_transplant_biloma",title:"Post-Liver Transplant Biloma",loaded:!1,data:null},intra_abdominal_neutropenic_enterocolitis_typhlitis:{id:"intra_abdominal_neutropenic_enterocolitis_typhlitis",filePath:"./syndromes_json/intra-abdominal/neutropenic_enterocolitis_typhlitis.json",category:"intra-abdominal",subcategory:null,filename:"neutropenic_enterocolitis_typhlitis",title:"Neutropenic Enterocolitis, Typhlitis",loaded:!1,data:null},intra_abdominal_pancreatitis:{id:"intra_abdominal_pancreatitis",filePath:"./syndromes_json/intra-abdominal/pancreatitis.json",category:"intra-abdominal",subcategory:null,filename:"pancreatitis",title:"Pancreatitis",loaded:!1,data:null},intra_abdominal_peritonitis_appendicitis:{id:"intra_abdominal_peritonitis_appendicitis",filePath:"./syndromes_json/intra-abdominal/peritonitis/appendicitis.json",category:"intra-abdominal",subcategory:"peritonitis",filename:"appendicitis",title:"Appendicitis",loaded:!1,data:null},intra_abdominal_peritonitis_peritonitis_dialysis_capd_associated:{id:"intra_abdominal_peritonitis_peritonitis_dialysis_capd_associated",filePath:"./syndromes_json/intra-abdominal/peritonitis/peritonitis_dialysis_capd_associated.json",category:"intra-abdominal",subcategory:"peritonitis",filename:"peritonitis_dialysis_capd_associated",title:"Peritonitis, Dialysis (CAPD) Associated",loaded:!1,data:null},intra_abdominal_peritonitis_peritonitis_primary_spontaneous_bacterial:{id:"intra_abdominal_peritonitis_peritonitis_primary_spontaneous_bacterial",filePath:"./syndromes_json/intra-abdominal/peritonitis/peritonitis_primary_spontaneous_bacterial.json",category:"intra-abdominal",subcategory:"peritonitis",filename:"peritonitis_primary_spontaneous_bacterial",title:"Peritonitis, Primary, Spontaneous, Bacterial",loaded:!1,data:null},intra_abdominal_peritonitis_peritonitis_rupture_perforation_abscess:{id:"intra_abdominal_peritonitis_peritonitis_rupture_perforation_abscess",filePath:"./syndromes_json/intra-abdominal/peritonitis/peritonitis_rupture_perforation_abscess.json",category:"intra-abdominal",subcategory:"peritonitis",filename:"peritonitis_rupture_perforation_abscess",title:"Peritonitis, Rupture, Perforation, Abscess",loaded:!1,data:null},intra_abdominal_whipples_disease:{id:"intra_abdominal_whipples_disease",filePath:"./syndromes_json/intra-abdominal/whipples_disease.json",category:"intra-abdominal",subcategory:null,filename:"whipples_disease",title:"Whipple's Disease",loaded:!1,data:null},lower_respiratory_abscess_aspergillosis_chronic_cavitary_pulmonary:{id:"lower_respiratory_abscess_aspergillosis_chronic_cavitary_pulmonary",filePath:"./syndromes_json/lower_respiratory/abscess/aspergillosis_chronic_cavitary_pulmonary.json",category:"lower_respiratory",subcategory:"abscess",filename:"aspergillosis_chronic_cavitary_pulmonary",title:"Aspergillosis, Chronic Cavitary Pulmonary",loaded:!1,data:null},lower_respiratory_abscess_empyema_pleural_overview:{id:"lower_respiratory_abscess_empyema_pleural_overview",filePath:"./syndromes_json/lower_respiratory/abscess/empyema_pleural_overview.json",category:"lower_respiratory",subcategory:"abscess",filename:"empyema_pleural_overview",title:"Pleural Empyema, Non-tuberculous, Overview",loaded:!1,data:null},lower_respiratory_abscess_m_tuberculosis_overview:{id:"lower_respiratory_abscess_m_tuberculosis_overview",filePath:"./syndromes_json/lower_respiratory/abscess/m_tuberculosis_overview.json",category:"lower_respiratory",subcategory:"abscess",filename:"m_tuberculosis_overview",title:"M. tuberculosis, Overview",loaded:!1,data:null},lower_respiratory_abscess_pneumonia_anaerobic_or_aspiration:{id:"lower_respiratory_abscess_pneumonia_anaerobic_or_aspiration",filePath:"./syndromes_json/lower_respiratory/abscess/pneumonia_anaerobic_or_aspiration.json",category:"lower_respiratory",subcategory:"abscess",filename:"pneumonia_anaerobic_or_aspiration",title:"Pneumonia, Anaerobic or Aspiration",loaded:!1,data:null},lower_respiratory_abscess_pneumonia_klebsiella_sp:{id:"lower_respiratory_abscess_pneumonia_klebsiella_sp",filePath:"./syndromes_json/lower_respiratory/abscess/pneumonia_klebsiella_sp.json",category:"lower_respiratory",subcategory:"abscess",filename:"pneumonia_klebsiella_sp",title:"Pneumonia, Klebsiella sp.",loaded:!1,data:null},lower_respiratory_abscess_pneumonia_melioidosis:{id:"lower_respiratory_abscess_pneumonia_melioidosis",filePath:"./syndromes_json/lower_respiratory/abscess/pneumonia_melioidosis.json",category:"lower_respiratory",subcategory:"abscess",filename:"pneumonia_melioidosis",title:"Pneumonia, Melioidosis",loaded:!1,data:null},lower_respiratory_abscess_pneumonia_nocardia_sp:{id:"lower_respiratory_abscess_pneumonia_nocardia_sp",filePath:"./syndromes_json/lower_respiratory/abscess/pneumonia_nocardia_sp.json",category:"lower_respiratory",subcategory:"abscess",filename:"pneumonia_nocardia_sp",title:"Pneumonia, Nocardia sp.",loaded:!1,data:null},lower_respiratory_abscess_pneumonia_staph_aureus:{id:"lower_respiratory_abscess_pneumonia_staph_aureus",filePath:"./syndromes_json/lower_respiratory/abscess/pneumonia_staph_aureus.json",category:"lower_respiratory",subcategory:"abscess",filename:"pneumonia_staph_aureus",title:"Pneumonia, Staph. aureus",loaded:!1,data:null},lower_respiratory_abscess_rhodococcus_hoagii:{id:"lower_respiratory_abscess_rhodococcus_hoagii",filePath:"./syndromes_json/lower_respiratory/abscess/rhodococcus_hoagii.json",category:"lower_respiratory",subcategory:"abscess",filename:"rhodococcus_hoagii",title:"Rhodococcus hoagii",loaded:!1,data:null},lower_respiratory_anthrax_anthrax_post_exposure_prophylaxis:{id:"lower_respiratory_anthrax_anthrax_post_exposure_prophylaxis",filePath:"./syndromes_json/lower_respiratory/anthrax/anthrax_post_exposure_prophylaxis.json",category:"lower_respiratory",subcategory:"anthrax",filename:"anthrax_post_exposure_prophylaxis",title:"Anthrax, Post-Exposure Prophylaxis",loaded:!1,data:null},lower_respiratory_anthrax_anthrax_systemic:{id:"lower_respiratory_anthrax_anthrax_systemic",filePath:"./syndromes_json/lower_respiratory/anthrax/anthrax_systemic.json",category:"lower_respiratory",subcategory:"anthrax",filename:"anthrax_systemic",title:"Anthrax, Systemic",loaded:!1,data:null},lower_respiratory_brochitis_bordetella_pertussis:{id:"lower_respiratory_brochitis_bordetella_pertussis",filePath:"./syndromes_json/lower_respiratory/brochitis/bordetella_pertussis.json",category:"lower_respiratory",subcategory:"brochitis",filename:"bordetella_pertussis",title:"Bordetella pertussis",loaded:!1,data:null},lower_respiratory_brochitis_bronchiectasis:{id:"lower_respiratory_brochitis_bronchiectasis",filePath:"./syndromes_json/lower_respiratory/brochitis/bronchiectasis.json",category:"lower_respiratory",subcategory:"brochitis",filename:"bronchiectasis",title:"Bronchiectasis",loaded:!1,data:null},lower_respiratory_brochitis_bronchitis_acute_age_gt_5_years:{id:"lower_respiratory_brochitis_bronchitis_acute_age_gt_5_years",filePath:"./syndromes_json/lower_respiratory/brochitis/bronchitis_acute_age_gt_5_years.json",category:"lower_respiratory",subcategory:"brochitis",filename:"bronchitis_acute_age_gt_5_years",title:"Bronchitis, Acute, Age > 5 years",loaded:!1,data:null},lower_respiratory_brochitis_bronchitis_chronic_with_acute_exacerbation:{id:"lower_respiratory_brochitis_bronchitis_chronic_with_acute_exacerbation",filePath:"./syndromes_json/lower_respiratory/brochitis/bronchitis_chronic_with_acute_exacerbation.json",category:"lower_respiratory",subcategory:"brochitis",filename:"bronchitis_chronic_with_acute_exacerbation",title:"Bronchitis, Chronic with Acute Exacerbation",loaded:!1,data:null},lower_respiratory_brochitis_bronchitis_infants_children:{id:"lower_respiratory_brochitis_bronchitis_infants_children",filePath:"./syndromes_json/lower_respiratory/brochitis/bronchitis_infants_children.json",category:"lower_respiratory",subcategory:"brochitis",filename:"bronchitis_infants_children",title:"Bronchitis Infants_Children",loaded:!1,data:null},lower_respiratory_bronchiolitis_bronchiolitis:{id:"lower_respiratory_bronchiolitis_bronchiolitis",filePath:"./syndromes_json/lower_respiratory/bronchiolitis/bronchiolitis.json",category:"lower_respiratory",subcategory:"bronchiolitis",filename:"bronchiolitis",title:"Bronchiolitis",loaded:!1,data:null},lower_respiratory_cystic_fibrosis:{id:"lower_respiratory_cystic_fibrosis",filePath:"./syndromes_json/lower_respiratory/cystic_fibrosis.json",category:"lower_respiratory",subcategory:null,filename:"cystic_fibrosis",title:"Cystic Fibrosis",loaded:!1,data:null},lower_respiratory_empyema_empyema_adult_child_gt_5_yrs:{id:"lower_respiratory_empyema_empyema_adult_child_gt_5_yrs",filePath:"./syndromes_json/lower_respiratory/empyema/empyema_adult_child_gt_5_yrs.json",category:"lower_respiratory",subcategory:"empyema",filename:"empyema_adult_child_gt_5_yrs",title:"Pleural empyema in older children and adults (Age > 5 years)",loaded:!1,data:null},lower_respiratory_empyema_empyema_infants_children:{id:"lower_respiratory_empyema_empyema_infants_children",filePath:"./syndromes_json/lower_respiratory/empyema/empyema_infants_children.json",category:"lower_respiratory",subcategory:"empyema",filename:"empyema_infants_children",title:"Empyema, Infants & Children",loaded:!1,data:null},lower_respiratory_empyema_empyema_neonatal:{id:"lower_respiratory_empyema_empyema_neonatal",filePath:"./syndromes_json/lower_respiratory/empyema/empyema_neonatal.json",category:"lower_respiratory",subcategory:"empyema",filename:"empyema_neonatal",title:"Empyema, Neonatal",loaded:!1,data:null},lower_respiratory_empyema_empyema_subdural:{id:"lower_respiratory_empyema_empyema_subdural",filePath:"./syndromes_json/lower_respiratory/empyema/empyema_subdural.json",category:"lower_respiratory",subcategory:"empyema",filename:"empyema_subdural",title:"Empyema, Subdural",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_community_acquired_pneumonia_children_age_gt_3_months:{id:"lower_respiratory_pneumonia_empiric_community_acquired_pneumonia_children_age_gt_3_months",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/community_acquired/pneumonia_children_age_gt_3_months.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"pneumonia_children_age_gt_3_months",title:"Community-acquired pneumonia in infants and children, age > 3 months",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_community_acquired_pneumonia_community_acquired_overview:{id:"lower_respiratory_pneumonia_empiric_community_acquired_pneumonia_community_acquired_overview",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/community_acquired/pneumonia_community-acquired_overview.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"pneumonia_community-acquired_overview",title:"Community-acquired pneumonia (CAP), Overview",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_community_acquired_pneumonia_community_acquired_adult_in_patient:{id:"lower_respiratory_pneumonia_empiric_community_acquired_pneumonia_community_acquired_adult_in_patient",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/community_acquired/pneumonia_community_acquired_adult_in_patient.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"pneumonia_community_acquired_adult_in_patient",title:"Pneumonia, Community-acquired, Adult, In-patient",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_community_acquired_pneumonia_community_acquired_adult_out_patient:{id:"lower_respiratory_pneumonia_empiric_community_acquired_pneumonia_community_acquired_adult_out_patient",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/community_acquired/pneumonia_community_acquired_adult_out_patient.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"pneumonia_community_acquired_adult_out_patient",title:"Pneumonia, Community-acquired, Adult, Out-patient",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_community_acquired_pneumonia_infants_age_1_3_months:{id:"lower_respiratory_pneumonia_empiric_community_acquired_pneumonia_infants_age_1_3_months",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/community_acquired/pneumonia_infants_age_1-3_months.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"pneumonia_infants_age_1-3_months",title:"Pneumonia, Infants, Age 1-3 months",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_community_acquired_pneumonia_neonates_age_lt_1_month:{id:"lower_respiratory_pneumonia_empiric_community_acquired_pneumonia_neonates_age_lt_1_month",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/community_acquired/pneumonia_neonates_age_lt_1_month.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"pneumonia_neonates_age_lt_1_month",title:"Pneumonia in neonates, age < 1 month",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_community_acquired_respiratory_syncytial_virus_rsv:{id:"lower_respiratory_pneumonia_empiric_community_acquired_respiratory_syncytial_virus_rsv",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/community_acquired/respiratory_syncytial_virus_rsv.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"respiratory_syncytial_virus_rsv",title:"Respiratory Syncytial Virus, RSV",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_hospital_acquired_empiric_treatment_pneumonia_community_acquired_adult_in_patient:{id:"lower_respiratory_pneumonia_empiric_hospital_acquired_empiric_treatment_pneumonia_community_acquired_adult_in_patient",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/hospital_acquired/empiric_treatment/pneumonia_community_acquired_adult_in_patient.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"pneumonia_community_acquired_adult_in_patient",title:"Pneumonia, Community-acquired, Adult, In-patient",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_hospital_acquired_empiric_treatment_pneumonia_community_acquired_adult_out_patient:{id:"lower_respiratory_pneumonia_empiric_hospital_acquired_empiric_treatment_pneumonia_community_acquired_adult_out_patient",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/hospital_acquired/empiric_treatment/pneumonia_community_acquired_adult_out_patient.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"pneumonia_community_acquired_adult_out_patient",title:"Pneumonia, Community-acquired, Adult, Out-patient",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_hospital_acquired_empiric_treatment_pneumonia_gram_negative_icu:{id:"lower_respiratory_pneumonia_empiric_hospital_acquired_empiric_treatment_pneumonia_gram_negative_icu",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/hospital_acquired/empiric_treatment/pneumonia_gram_negative_icu.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"pneumonia_gram_negative_icu",title:"Pneumonia, Gram-negative, ICU",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_hospital_acquired_empiric_treatment_pneumonia_hospital_acquired:{id:"lower_respiratory_pneumonia_empiric_hospital_acquired_empiric_treatment_pneumonia_hospital_acquired",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/hospital_acquired/empiric_treatment/pneumonia_hospital_acquired.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"pneumonia_hospital_acquired",title:"Pneumonia, Hospital-Acquired",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_hospital_acquired_empiric_treatment_pneumonia_neutropenic_patient:{id:"lower_respiratory_pneumonia_empiric_hospital_acquired_empiric_treatment_pneumonia_neutropenic_patient",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/hospital_acquired/empiric_treatment/pneumonia_neutropenic_patient.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"pneumonia_neutropenic_patient",title:"Pneumonia, Neutropenic Patient",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_hospital_acquired_empiric_treatment_pneumonia_ventilator_associated:{id:"lower_respiratory_pneumonia_empiric_hospital_acquired_empiric_treatment_pneumonia_ventilator_associated",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/hospital_acquired/empiric_treatment/pneumonia_ventilator_associated.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"pneumonia_ventilator_associated",title:"Pneumonia, Ventilator-Associated",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_hospital_acquired_pneumonia_concomitant_or_post_influenza:{id:"lower_respiratory_pneumonia_empiric_hospital_acquired_pneumonia_concomitant_or_post_influenza",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/hospital_acquired/pneumonia_concomitant_or_post_influenza.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"pneumonia_concomitant_or_post_influenza",title:"Pneumonia, Concomitant or Post Influenza",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_hospital_acquired_pneumonia_hospital_acquired:{id:"lower_respiratory_pneumonia_empiric_hospital_acquired_pneumonia_hospital_acquired",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/hospital_acquired/pneumonia_hospital-acquired.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"pneumonia_hospital-acquired",title:"Pneumonia, Hospital-Acquired",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_hospital_acquired_pneumonia_hospital_acquired_overview:{id:"lower_respiratory_pneumonia_empiric_hospital_acquired_pneumonia_hospital_acquired_overview",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/hospital_acquired/pneumonia_hospital-acquired_overview.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"pneumonia_hospital-acquired_overview",title:"Pneumonia, Hospital-Acquired, Overview",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_hospital_acquired_pneumonia_neutropenic_patient:{id:"lower_respiratory_pneumonia_empiric_hospital_acquired_pneumonia_neutropenic_patient",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/hospital_acquired/pneumonia_neutropenic_patient.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"pneumonia_neutropenic_patient",title:"Pneumonia, Neutropenic Patient",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_hospital_acquired_pneumonia_ventilator_associated:{id:"lower_respiratory_pneumonia_empiric_hospital_acquired_pneumonia_ventilator_associated",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/hospital_acquired/pneumonia_ventilator-associated.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"pneumonia_ventilator-associated",title:"Pneumonia, Ventilator-Associated",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_hospital_acquired_specific_treatment_pneumonia_acinetobacter_sp:{id:"lower_respiratory_pneumonia_empiric_hospital_acquired_specific_treatment_pneumonia_acinetobacter_sp",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/hospital_acquired/specific_treatment/pneumonia_acinetobacter_sp.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"pneumonia_acinetobacter_sp",title:"Pneumonia, Acinetobacter sp.",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_hospital_acquired_specific_treatment_pneumonia_klebsiella_sp:{id:"lower_respiratory_pneumonia_empiric_hospital_acquired_specific_treatment_pneumonia_klebsiella_sp",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/hospital_acquired/specific_treatment/pneumonia_klebsiella_sp.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"pneumonia_klebsiella_sp",title:"Pneumonia, Klebsiella sp.",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_hospital_acquired_specific_treatment_pneumonia_legionella_sp:{id:"lower_respiratory_pneumonia_empiric_hospital_acquired_specific_treatment_pneumonia_legionella_sp",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/hospital_acquired/specific_treatment/pneumonia_legionella_sp.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"pneumonia_legionella_sp",title:"Pneumonia, Legionella sp.",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_hospital_acquired_specific_treatment_pneumonia_pseudomonas_aeruginosa:{id:"lower_respiratory_pneumonia_empiric_hospital_acquired_specific_treatment_pneumonia_pseudomonas_aeruginosa",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/hospital_acquired/specific_treatment/pneumonia_pseudomonas_aeruginosa.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"pneumonia_pseudomonas_aeruginosa",title:"Pneumonia caused by Pseudomonas aeruginosa",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_hospital_acquired_specific_treatment_pneumonia_stenotrophomonas_maltophilia:{id:"lower_respiratory_pneumonia_empiric_hospital_acquired_specific_treatment_pneumonia_stenotrophomonas_maltophilia",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/hospital_acquired/specific_treatment/pneumonia_stenotrophomonas_maltophilia.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"pneumonia_stenotrophomonas_maltophilia",title:"Pneumonia caused by Stenotrophomonas maltophilia",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_hospital_acquired_specific_treatment_pneumonia_streptococcus_pneumoniae:{id:"lower_respiratory_pneumonia_empiric_hospital_acquired_specific_treatment_pneumonia_streptococcus_pneumoniae",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/hospital_acquired/specific_treatment/pneumonia_streptococcus_pneumoniae.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"pneumonia_streptococcus_pneumoniae",title:"Pneumonia caused by Streptococcus pneumoniae",loaded:!1,data:null},lower_respiratory_pneumonia_empiric_pneumonia_healthcare_associated:{id:"lower_respiratory_pneumonia_empiric_pneumonia_healthcare_associated",filePath:"./syndromes_json/lower_respiratory/pneumonia_empiric/pneumonia_healthcare_associated.json",category:"lower_respiratory",subcategory:"pneumonia_empiric",filename:"pneumonia_healthcare_associated",title:"Pneumonia, Healthcare-Associated",loaded:!1,data:null},lymph_nodes_spleen_lymphadenitis_bubonic_plague:{id:"lymph_nodes_spleen_lymphadenitis_bubonic_plague",filePath:"./syndromes_json/lymph_nodes-spleen/lymphadenitis/bubonic_plague.json",category:"lymph_nodes-spleen",subcategory:"lymphadenitis",filename:"bubonic_plague",title:"Bubonic Plague",loaded:!1,data:null},lymph_nodes_spleen_lymphadenitis_cat_scratch_disease_csd:{id:"lymph_nodes_spleen_lymphadenitis_cat_scratch_disease_csd",filePath:"./syndromes_json/lymph_nodes-spleen/lymphadenitis/cat_scratch_disease_csd.json",category:"lymph_nodes-spleen",subcategory:"lymphadenitis",filename:"cat_scratch_disease_csd",title:"Cat-scratch Disease (CSD)",loaded:!1,data:null},lymph_nodes_spleen_lymphadenitis_francisella_tularensis_tularemia:{id:"lymph_nodes_spleen_lymphadenitis_francisella_tularensis_tularemia",filePath:"./syndromes_json/lymph_nodes-spleen/lymphadenitis/francisella_tularensis_tularemia.json",category:"lymph_nodes-spleen",subcategory:"lymphadenitis",filename:"francisella_tularensis_tularemia",title:"Francisella tularensis, Tularemia",loaded:!1,data:null},lymph_nodes_spleen_lymphadenitis_lymphadenitis_nocardia:{id:"lymph_nodes_spleen_lymphadenitis_lymphadenitis_nocardia",filePath:"./syndromes_json/lymph_nodes-spleen/lymphadenitis/lymphadenitis_nocardia.json",category:"lymph_nodes-spleen",subcategory:"lymphadenitis",filename:"lymphadenitis_nocardia",title:"Lymphadenitis, Nocardia",loaded:!1,data:null},lymph_nodes_spleen_lymphadenitis_yersinia_pestis_plague:{id:"lymph_nodes_spleen_lymphadenitis_yersinia_pestis_plague",filePath:"./syndromes_json/lymph_nodes-spleen/lymphadenitis/yersinia_pestis_plague.json",category:"lymph_nodes-spleen",subcategory:"lymphadenitis",filename:"yersinia_pestis_plague",title:"Yersinia pestis, Plague",loaded:!1,data:null},lymph_nodes_spleen_splenic_abscess:{id:"lymph_nodes_spleen_splenic_abscess",filePath:"./syndromes_json/lymph_nodes-spleen/splenic_abscess.json",category:"lymph_nodes-spleen",subcategory:null,filename:"splenic_abscess",title:"Splenic Abscess",loaded:!1,data:null},musculoskeletal_bone_osteomyelitis_candida:{id:"musculoskeletal_bone_osteomyelitis_candida",filePath:"./syndromes_json/musculoskeletal/bone/osteomyelitis_candida.json",category:"musculoskeletal",subcategory:"bone",filename:"osteomyelitis_candida",title:"Candida Osteomyelitis",loaded:!1,data:null},musculoskeletal_bone_osteomyelitis_contiguous_focus:{id:"musculoskeletal_bone_osteomyelitis_contiguous_focus",filePath:"./syndromes_json/musculoskeletal/bone/osteomyelitis_contiguous_focus.json",category:"musculoskeletal",subcategory:"bone",filename:"osteomyelitis_contiguous_focus",title:"Contiguous Focus Osteomyelitis",loaded:!1,data:null},musculoskeletal_bone_osteomyelitis_foot_bone:{id:"musculoskeletal_bone_osteomyelitis_foot_bone",filePath:"./syndromes_json/musculoskeletal/bone/osteomyelitis_foot_bone.json",category:"musculoskeletal",subcategory:"bone",filename:"osteomyelitis_foot_bone",title:"Diabetic Foot Osteomyelitis",loaded:!1,data:null},musculoskeletal_bone_osteomyelitis_hematogenous:{id:"musculoskeletal_bone_osteomyelitis_hematogenous",filePath:"./syndromes_json/musculoskeletal/bone/osteomyelitis_hematogenous.json",category:"musculoskeletal",subcategory:"bone",filename:"osteomyelitis_hematogenous",title:"Hematogenous Osteomyelitis",loaded:!1,data:null},musculoskeletal_bone_osteomyelitis_hemoglobinopathy:{id:"musculoskeletal_bone_osteomyelitis_hemoglobinopathy",filePath:"./syndromes_json/musculoskeletal/bone/osteomyelitis_hemoglobinopathy.json",category:"musculoskeletal",subcategory:"bone",filename:"osteomyelitis_hemoglobinopathy",title:"Osteomyelitis in Hemoglobinopathies (e.g., Sickle Cell Disease)",loaded:!1,data:null},musculoskeletal_bone_osteomyelitis_overview:{id:"musculoskeletal_bone_osteomyelitis_overview",filePath:"./syndromes_json/musculoskeletal/bone/osteomyelitis_overview.json",category:"musculoskeletal",subcategory:"bone",filename:"osteomyelitis_overview",title:"Osteomyelitis, Overview",loaded:!1,data:null},musculoskeletal_bone_osteomyelitis_spinal_implant:{id:"musculoskeletal_bone_osteomyelitis_spinal_implant",filePath:"./syndromes_json/musculoskeletal/bone/osteomyelitis_spinal_implant.json",category:"musculoskeletal",subcategory:"bone",filename:"osteomyelitis_spinal_implant",title:"Osteomyelitis, Spinal Implant",loaded:!1,data:null},musculoskeletal_bone_osteomyelitis_staph_aureus:{id:"musculoskeletal_bone_osteomyelitis_staph_aureus",filePath:"./syndromes_json/musculoskeletal/bone/osteomyelitis_staph_aureus.json",category:"musculoskeletal",subcategory:"bone",filename:"osteomyelitis_staph_aureus",title:"Osteomyelitis, Staph. aureus",loaded:!1,data:null},musculoskeletal_bone_osteomyelitis_sternal:{id:"musculoskeletal_bone_osteomyelitis_sternal",filePath:"./syndromes_json/musculoskeletal/bone/osteomyelitis_sternal.json",category:"musculoskeletal",subcategory:"bone",filename:"osteomyelitis_sternal",title:"Osteomyelitis, Sternal",loaded:!1,data:null},musculoskeletal_bone_osteomyelitis_vascular_insufficiency:{id:"musculoskeletal_bone_osteomyelitis_vascular_insufficiency",filePath:"./syndromes_json/musculoskeletal/bone/osteomyelitis_vascular_insufficiency.json",category:"musculoskeletal",subcategory:"bone",filename:"osteomyelitis_vascular_insufficiency",title:"Osteomyelitis, Vascular Insufficiency",loaded:!1,data:null},musculoskeletal_bone_osteomyelitis_vertebral:{id:"musculoskeletal_bone_osteomyelitis_vertebral",filePath:"./syndromes_json/musculoskeletal/bone/osteomyelitis_vertebral.json",category:"musculoskeletal",subcategory:"bone",filename:"osteomyelitis_vertebral",title:"Osteomyelitis, Vertebral",loaded:!1,data:null},musculoskeletal_bone_osteonecrosis_jaw:{id:"musculoskeletal_bone_osteonecrosis_jaw",filePath:"./syndromes_json/musculoskeletal/bone/osteonecrosis_jaw.json",category:"musculoskeletal",subcategory:"bone",filename:"osteonecrosis_jaw",title:"Osteonecrosis, Jaw",loaded:!1,data:null},musculoskeletal_bone_puncture_wound_foot:{id:"musculoskeletal_bone_puncture_wound_foot",filePath:"./syndromes_json/musculoskeletal/bone/puncture_wound_foot.json",category:"musculoskeletal",subcategory:"bone",filename:"puncture_wound_foot",title:"Puncture Wound, Foot",loaded:!1,data:null},musculoskeletal_foot_onychomycosis:{id:"musculoskeletal_foot_onychomycosis",filePath:"./syndromes_json/musculoskeletal/foot/onychomycosis.json",category:"musculoskeletal",subcategory:"foot",filename:"onychomycosis",title:"Onychomycosis",loaded:!1,data:null},musculoskeletal_foot_osteomyelitis_foot_bone:{id:"musculoskeletal_foot_osteomyelitis_foot_bone",filePath:"./syndromes_json/musculoskeletal/foot/osteomyelitis_foot_bone.json",category:"musculoskeletal",subcategory:"foot",filename:"osteomyelitis_foot_bone",title:"Osteomyelitis, Foot Bone",loaded:!1,data:null},musculoskeletal_foot_puncture_wound_foot:{id:"musculoskeletal_foot_puncture_wound_foot",filePath:"./syndromes_json/musculoskeletal/foot/puncture_wound_foot.json",category:"musculoskeletal",subcategory:"foot",filename:"puncture_wound_foot",title:"Puncture Wound, Foot",loaded:!1,data:null},musculoskeletal_hand_paronychia:{id:"musculoskeletal_hand_paronychia",filePath:"./syndromes_json/musculoskeletal/hand/paronychia.json",category:"musculoskeletal",subcategory:"hand",filename:"paronychia",title:"Paronychia",loaded:!1,data:null},musculoskeletal_joint_bursitis_septic:{id:"musculoskeletal_joint_bursitis_septic",filePath:"./syndromes_json/musculoskeletal/joint/bursitis_septic.json",category:"musculoskeletal",subcategory:"joint",filename:"bursitis_septic",title:"Bursitis, Septic",loaded:!1,data:null},musculoskeletal_joint_lyme_disease_arthritis:{id:"musculoskeletal_joint_lyme_disease_arthritis",filePath:"./syndromes_json/musculoskeletal/joint/lyme_disease_arthritis.json",category:"musculoskeletal",subcategory:"joint",filename:"lyme_disease_arthritis",title:"Lyme Disease, Arthritis",loaded:!1,data:null},musculoskeletal_joint_prosthetic_joint_infection:{id:"musculoskeletal_joint_prosthetic_joint_infection",filePath:"./syndromes_json/musculoskeletal/joint/prosthetic_joint_infection.json",category:"musculoskeletal",subcategory:"joint",filename:"prosthetic_joint_infection",title:"Prosthetic Joint Infection",loaded:!1,data:null},musculoskeletal_joint_reactive_arthritis_arthritis_post_streptococcal:{id:"musculoskeletal_joint_reactive_arthritis_arthritis_post_streptococcal",filePath:"./syndromes_json/musculoskeletal/joint/reactive_arthritis/arthritis_post-streptococcal.json",category:"musculoskeletal",subcategory:"joint",filename:"arthritis_post-streptococcal",title:"Post-Streptococcal Reactive Arthritis",loaded:!1,data:null},musculoskeletal_joint_reactive_arthritis_reactive_arthritis:{id:"musculoskeletal_joint_reactive_arthritis_reactive_arthritis",filePath:"./syndromes_json/musculoskeletal/joint/reactive_arthritis/reactive_arthritis.json",category:"musculoskeletal",subcategory:"joint",filename:"reactive_arthritis",title:"Reactive Arthritis",loaded:!1,data:null},musculoskeletal_joint_septic_arthritis_empiric_arthritis_septic_adult:{id:"musculoskeletal_joint_septic_arthritis_empiric_arthritis_septic_adult",filePath:"./syndromes_json/musculoskeletal/joint/septic_arthritis_empiric/arthritis_septic_adult.json",category:"musculoskeletal",subcategory:"joint",filename:"arthritis_septic_adult",title:"Septic Arthritis in Adults",loaded:!1,data:null},musculoskeletal_joint_septic_arthritis_empiric_arthritis_septic_child:{id:"musculoskeletal_joint_septic_arthritis_empiric_arthritis_septic_child",filePath:"./syndromes_json/musculoskeletal/joint/septic_arthritis_empiric/arthritis_septic_child.json",category:"musculoskeletal",subcategory:"joint",filename:"arthritis_septic_child",title:"Empiric Therapy of Septic Arthritis in a Child (3 months to 14 years)",loaded:!1,data:null},musculoskeletal_joint_septic_arthritis_empiric_arthritis_septic_infant:{id:"musculoskeletal_joint_septic_arthritis_empiric_arthritis_septic_infant",filePath:"./syndromes_json/musculoskeletal/joint/septic_arthritis_empiric/arthritis_septic_infant.json",category:"musculoskeletal",subcategory:"joint",filename:"arthritis_septic_infant",title:"Empiric Therapy of Septic Arthritis in Neonates (age < 3 months)",loaded:!1,data:null},musculoskeletal_joint_septic_arthritis_specific_arthritis_m_tuberculosis:{id:"musculoskeletal_joint_septic_arthritis_specific_arthritis_m_tuberculosis",filePath:"./syndromes_json/musculoskeletal/joint/septic_arthritis_specific/arthritis_m_tuberculosis.json",category:"musculoskeletal",subcategory:"joint",filename:"arthritis_m_tuberculosis",title:"Arthritis, M. tuberculosis",loaded:!1,data:null},musculoskeletal_joint_septic_arthritis_specific_arthritis_septic_pneumococcal:{id:"musculoskeletal_joint_septic_arthritis_specific_arthritis_septic_pneumococcal",filePath:"./syndromes_json/musculoskeletal/joint/septic_arthritis_specific/arthritis_septic_pneumococcal.json",category:"musculoskeletal",subcategory:"joint",filename:"arthritis_septic_pneumococcal",title:"Septic Arthritis with Strep. pneumoniae",loaded:!1,data:null},musculoskeletal_joint_septic_arthritis_specific_arthritis_septic_post_intra_articular_injection_post_arthroscopy:{id:"musculoskeletal_joint_septic_arthritis_specific_arthritis_septic_post_intra_articular_injection_post_arthroscopy",filePath:"./syndromes_json/musculoskeletal/joint/septic_arthritis_specific/arthritis_septic_post_intra-articular_injection_post-arthroscopy.json",category:"musculoskeletal",subcategory:"joint",filename:"arthritis_septic_post_intra-articular_injection_post-arthroscopy",title:"Septic Arthritis Following Intra-articular Injections",loaded:!1,data:null},musculoskeletal_joint_septic_arthritis_specific_arthritis_septic_staph_aureus:{id:"musculoskeletal_joint_septic_arthritis_specific_arthritis_septic_staph_aureus",filePath:"./syndromes_json/musculoskeletal/joint/septic_arthritis_specific/arthritis_septic_staph_aureus.json",category:"musculoskeletal",subcategory:"joint",filename:"arthritis_septic_staph_aureus",title:"Septic Arthritis - Staph. aureus",loaded:!1,data:null},musculoskeletal_joint_septic_arthritis_specific_arthritis_septic_streptococcal:{id:"musculoskeletal_joint_septic_arthritis_specific_arthritis_septic_streptococcal",filePath:"./syndromes_json/musculoskeletal/joint/septic_arthritis_specific/arthritis_septic_streptococcal.json",category:"musculoskeletal",subcategory:"joint",filename:"arthritis_septic_streptococcal",title:"Definitive therapy of septic arthritis caused by hemolytic and non-hemolytic streptococci",loaded:!1,data:null},musculoskeletal_joint_septic_arthritis_specific_brucella_sp_arthritis:{id:"musculoskeletal_joint_septic_arthritis_specific_brucella_sp_arthritis",filePath:"./syndromes_json/musculoskeletal/joint/septic_arthritis_specific/brucella_sp_arthritis.json",category:"musculoskeletal",subcategory:"joint",filename:"brucella_sp_arthritis",title:"Brucella sp. Arthritis",loaded:!1,data:null},musculoskeletal_joint_septic_arthritis_specific_gonorrhea_disseminated_gonococcal_infection:{id:"musculoskeletal_joint_septic_arthritis_specific_gonorrhea_disseminated_gonococcal_infection",filePath:"./syndromes_json/musculoskeletal/joint/septic_arthritis_specific/gonorrhea_disseminated_gonococcal_infection.json",category:"musculoskeletal",subcategory:"joint",filename:"gonorrhea_disseminated_gonococcal_infection",title:"Disseminated Gonococcal Infection",loaded:!1,data:null},musculoskeletal_joint_septic_arthritis_specific_histoplasmosis_mediastinal:{id:"musculoskeletal_joint_septic_arthritis_specific_histoplasmosis_mediastinal",filePath:"./syndromes_json/musculoskeletal/joint/septic_arthritis_specific/histoplasmosis_mediastinal.json",category:"musculoskeletal",subcategory:"joint",filename:"histoplasmosis_mediastinal",title:"Histoplasmosis, Mediastinal",loaded:!1,data:null},musculoskeletal_joint_septic_arthritis_specific_lyme_disease_arthritis:{id:"musculoskeletal_joint_septic_arthritis_specific_lyme_disease_arthritis",filePath:"./syndromes_json/musculoskeletal/joint/septic_arthritis_specific/lyme_disease_arthritis.json",category:"musculoskeletal",subcategory:"joint",filename:"lyme_disease_arthritis",title:"Lyme Disease, Arthritis",loaded:!1,data:null},musculoskeletal_muscle_gangrene_muscle:{id:"musculoskeletal_muscle_gangrene_muscle",filePath:"./syndromes_json/musculoskeletal/muscle/gangrene_muscle.json",category:"musculoskeletal",subcategory:"muscle",filename:"gangrene_muscle",title:"Gangrene, Muscle",loaded:!1,data:null},musculoskeletal_muscle_necrotizing_fascitis_necrotizing_fasciitis_clostridia_sp:{id:"musculoskeletal_muscle_necrotizing_fascitis_necrotizing_fasciitis_clostridia_sp",filePath:"./syndromes_json/musculoskeletal/muscle/necrotizing_fascitis/necrotizing_fasciitis_clostridia_sp.json",category:"musculoskeletal",subcategory:"muscle",filename:"necrotizing_fasciitis_clostridia_sp",title:"Necrotizing Fasciitis, Clostridia sp.",loaded:!1,data:null},musculoskeletal_muscle_necrotizing_fascitis_necrotizing_fasciitis_staph_aureus:{id:"musculoskeletal_muscle_necrotizing_fascitis_necrotizing_fasciitis_staph_aureus",filePath:"./syndromes_json/musculoskeletal/muscle/necrotizing_fascitis/necrotizing_fasciitis_staph_aureus.json",category:"musculoskeletal",subcategory:"muscle",filename:"necrotizing_fasciitis_staph_aureus",title:"Necrotizing Fasciitis, Staph. aureus",loaded:!1,data:null},musculoskeletal_muscle_necrotizing_fascitis_necrotizing_fasciitis_streptococcal:{id:"musculoskeletal_muscle_necrotizing_fascitis_necrotizing_fasciitis_streptococcal",filePath:"./syndromes_json/musculoskeletal/muscle/necrotizing_fascitis/necrotizing_fasciitis_streptococcal.json",category:"musculoskeletal",subcategory:"muscle",filename:"necrotizing_fasciitis_streptococcal",title:"Necrotizing Fasciitis, Streptococcal",loaded:!1,data:null},musculoskeletal_muscle_necrotizing_fascitis_necrotizing_fasciitis_synergistic:{id:"musculoskeletal_muscle_necrotizing_fascitis_necrotizing_fasciitis_synergistic",filePath:"./syndromes_json/musculoskeletal/muscle/necrotizing_fascitis/necrotizing_fasciitis_synergistic.json",category:"musculoskeletal",subcategory:"muscle",filename:"necrotizing_fasciitis_synergistic",title:"Necrotizing Fasciitis, Synergistic",loaded:!1,data:null},musculoskeletal_muscle_pyomyositis:{id:"musculoskeletal_muscle_pyomyositis",filePath:"./syndromes_json/musculoskeletal/muscle/pyomyositis.json",category:"musculoskeletal",subcategory:"muscle",filename:"pyomyositis",title:"Pyomyositis",loaded:!1,data:null},ocular_conjunctivitis_conjunctivitis_bacterial:{id:"ocular_conjunctivitis_conjunctivitis_bacterial",filePath:"./syndromes_json/ocular/conjunctivitis/conjunctivitis_bacterial.json",category:"ocular",subcategory:"conjunctivitis",filename:"conjunctivitis_bacterial",title:"Bacterial Conjunctivitis",loaded:!1,data:null},ocular_conjunctivitis_conjunctivitis_gonococcal:{id:"ocular_conjunctivitis_conjunctivitis_gonococcal",filePath:"./syndromes_json/ocular/conjunctivitis/conjunctivitis_gonococcal.json",category:"ocular",subcategory:"conjunctivitis",filename:"conjunctivitis_gonococcal",title:"Gonococcal Conjunctivitis",loaded:!1,data:null},ocular_conjunctivitis_conjunctivitis_inclusion:{id:"ocular_conjunctivitis_conjunctivitis_inclusion",filePath:"./syndromes_json/ocular/conjunctivitis/conjunctivitis_inclusion.json",category:"ocular",subcategory:"conjunctivitis",filename:"conjunctivitis_inclusion",title:"Inclusion Conjunctivitis (Chlamydial Conjunctivitis)",loaded:!1,data:null},ocular_conjunctivitis_conjunctivitis_newborn:{id:"ocular_conjunctivitis_conjunctivitis_newborn",filePath:"./syndromes_json/ocular/conjunctivitis/conjunctivitis_newborn.json",category:"ocular",subcategory:"conjunctivitis",filename:"conjunctivitis_newborn",title:"Newborn Conjunctivitis (Ophthalmia Neonatorum)",loaded:!1,data:null},ocular_conjunctivitis_conjunctivitis_trachoma:{id:"ocular_conjunctivitis_conjunctivitis_trachoma",filePath:"./syndromes_json/ocular/conjunctivitis/conjunctivitis_trachoma.json",category:"ocular",subcategory:"conjunctivitis",filename:"conjunctivitis_trachoma",title:"Trachoma",loaded:!1,data:null},ocular_conjunctivitis_conjunctivitis_viral_pink_eye:{id:"ocular_conjunctivitis_conjunctivitis_viral_pink_eye",filePath:"./syndromes_json/ocular/conjunctivitis/conjunctivitis_viral_pink_eye.json",category:"ocular",subcategory:"conjunctivitis",filename:"conjunctivitis_viral_pink_eye",title:"Viral Conjunctivitis (Pink Eye)",loaded:!1,data:null},ocular_conjunctivitis_keratitis_acanthamoeba:{id:"ocular_conjunctivitis_keratitis_acanthamoeba",filePath:"./syndromes_json/ocular/conjunctivitis/keratitis_acanthamoeba.json",category:"ocular",subcategory:"conjunctivitis",filename:"keratitis_acanthamoeba",title:"Acanthamoeba Keratitis",loaded:!1,data:null},ocular_conjunctivitis_keratitis_bacterial:{id:"ocular_conjunctivitis_keratitis_bacterial",filePath:"./syndromes_json/ocular/conjunctivitis/keratitis_bacterial.json",category:"ocular",subcategory:"conjunctivitis",filename:"keratitis_bacterial",title:"Bacterial Keratitis",loaded:!1,data:null},ocular_conjunctivitis_keratitis_fungal:{id:"ocular_conjunctivitis_keratitis_fungal",filePath:"./syndromes_json/ocular/conjunctivitis/keratitis_fungal.json",category:"ocular",subcategory:"conjunctivitis",filename:"keratitis_fungal",title:"Fungal Keratitis",loaded:!1,data:null},ocular_conjunctivitis_keratitis_mycobacterial_non_tuberculous:{id:"ocular_conjunctivitis_keratitis_mycobacterial_non_tuberculous",filePath:"./syndromes_json/ocular/conjunctivitis/keratitis_mycobacterial_non-tuberculous.json",category:"ocular",subcategory:"conjunctivitis",filename:"keratitis_mycobacterial_non-tuberculous",title:"Non-tuberculous Mycobacterial (NTM) Keratitis",loaded:!1,data:null},ocular_conjunctivitis_keratitis_overview:{id:"ocular_conjunctivitis_keratitis_overview",filePath:"./syndromes_json/ocular/conjunctivitis/keratitis_overview.json",category:"ocular",subcategory:"conjunctivitis",filename:"keratitis_overview",title:"Overview of Keratitis",loaded:!1,data:null},ocular_conjunctivitis_keratitis_viral:{id:"ocular_conjunctivitis_keratitis_viral",filePath:"./syndromes_json/ocular/conjunctivitis/keratitis_viral.json",category:"ocular",subcategory:"conjunctivitis",filename:"keratitis_viral",title:"Viral Keratitis",loaded:!1,data:null},ocular_endophtalmitis_endophthalmitis_candida:{id:"ocular_endophtalmitis_endophthalmitis_candida",filePath:"./syndromes_json/ocular/endophtalmitis/endophthalmitis_candida.json",category:"ocular",subcategory:"endophtalmitis",filename:"endophthalmitis_candida",title:"Candida Endophthalmitis",loaded:!1,data:null},ocular_endophtalmitis_endophthalmitis_glaucoma:{id:"ocular_endophtalmitis_endophthalmitis_glaucoma",filePath:"./syndromes_json/ocular/endophtalmitis/endophthalmitis_glaucoma.json",category:"ocular",subcategory:"endophtalmitis",filename:"endophthalmitis_glaucoma",title:"Endophthalmitis in Glaucoma Filtering Surgery",loaded:!1,data:null},ocular_endophtalmitis_endophthalmitis_hematogenous_or_endogenous:{id:"ocular_endophtalmitis_endophthalmitis_hematogenous_or_endogenous",filePath:"./syndromes_json/ocular/endophtalmitis/endophthalmitis_hematogenous_or_endogenous.json",category:"ocular",subcategory:"endophtalmitis",filename:"endophthalmitis_hematogenous_or_endogenous",title:"Hematogenous (Endogenous) Endophthalmitis",loaded:!1,data:null},ocular_endophtalmitis_endophthalmitis_overview:{id:"ocular_endophtalmitis_endophthalmitis_overview",filePath:"./syndromes_json/ocular/endophtalmitis/endophthalmitis_overview.json",category:"ocular",subcategory:"endophtalmitis",filename:"endophthalmitis_overview",title:"Overview of Endophthalmitis",loaded:!1,data:null},ocular_endophtalmitis_endophthalmitis_post_surgical_or_post_injection:{id:"ocular_endophtalmitis_endophthalmitis_post_surgical_or_post_injection",filePath:"./syndromes_json/ocular/endophtalmitis/endophthalmitis_post-surgical_or_post-injection.json",category:"ocular",subcategory:"endophtalmitis",filename:"endophthalmitis_post-surgical_or_post-injection",title:"Post-Surgical & Post-Injection Endophthalmitis",loaded:!1,data:null},ocular_endophtalmitis_endophthalmitis_post_traumatic:{id:"ocular_endophtalmitis_endophthalmitis_post_traumatic",filePath:"./syndromes_json/ocular/endophtalmitis/endophthalmitis_post-traumatic.json",category:"ocular",subcategory:"endophtalmitis",filename:"endophthalmitis_post-traumatic",title:"Post-Traumatic Endophthalmitis",loaded:!1,data:null},ocular_eyelid_blepharitis:{id:"ocular_eyelid_blepharitis",filePath:"./syndromes_json/ocular/eyelid/blepharitis.json",category:"ocular",subcategory:"eyelid",filename:"blepharitis",title:"Blepharitis",loaded:!1,data:null},ocular_eyelid_hordeolum_stye:{id:"ocular_eyelid_hordeolum_stye",filePath:"./syndromes_json/ocular/eyelid/hordeolum_stye.json",category:"ocular",subcategory:"eyelid",filename:"hordeolum_stye",title:"Hordeolum and Chalazion",loaded:!1,data:null},ocular_lacrimal_canaliculitis:{id:"ocular_lacrimal_canaliculitis",filePath:"./syndromes_json/ocular/lacrimal/canaliculitis.json",category:"ocular",subcategory:"lacrimal",filename:"canaliculitis",title:"Canaliculitis",loaded:!1,data:null},ocular_lacrimal_dacryocystitis:{id:"ocular_lacrimal_dacryocystitis",filePath:"./syndromes_json/ocular/lacrimal/dacryocystitis.json",category:"ocular",subcategory:"lacrimal",filename:"dacryocystitis",title:"Dacryocystitis",loaded:!1,data:null},ocular_orbital_cellulitis_periorbital_cellulitis:{id:"ocular_orbital_cellulitis_periorbital_cellulitis",filePath:"./syndromes_json/ocular/orbital_cellulitis_periorbital_cellulitis.json",category:"ocular",subcategory:null,filename:"orbital_cellulitis_periorbital_cellulitis",title:"Orbital and Preseptal Cellulitis",loaded:!1,data:null},ocular_retinitis_acute_retinal_necrosis:{id:"ocular_retinitis_acute_retinal_necrosis",filePath:"./syndromes_json/ocular/retinitis/acute_retinal_necrosis.json",category:"ocular",subcategory:"retinitis",filename:"acute_retinal_necrosis",title:"Acute Retinal Necrosis (ARN)",loaded:!1,data:null},ocular_retinitis_retinitis_cytomegalovirus:{id:"ocular_retinitis_retinitis_cytomegalovirus",filePath:"./syndromes_json/ocular/retinitis/retinitis_cytomegalovirus.json",category:"ocular",subcategory:"retinitis",filename:"retinitis_cytomegalovirus",title:"Cytomegalovirus (CMV) Retinitis",loaded:!1,data:null},skin_and_soft_tissues_Celulitis_cellulitis_erysipelas_diabetes_mellitus:{id:"skin_and_soft_tissues_Celulitis_cellulitis_erysipelas_diabetes_mellitus",filePath:"./syndromes_json/skin_and_soft_tissues/Celulitis/cellulitis_erysipelas_diabetes_mellitus.json",category:"skin_and_soft_tissues",subcategory:"Celulitis",filename:"cellulitis_erysipelas_diabetes_mellitus",title:"Cellulitis, Erysipelas_ Diabetes mellitus",loaded:!1,data:null},skin_and_soft_tissues_Celulitis_cellulitis_erysipelas_extremities:{id:"skin_and_soft_tissues_Celulitis_cellulitis_erysipelas_extremities",filePath:"./syndromes_json/skin_and_soft_tissues/Celulitis/cellulitis_erysipelas_extremities.json",category:"skin_and_soft_tissues",subcategory:"Celulitis",filename:"cellulitis_erysipelas_extremities",title:"Cellulitis, Erysipelas_ Extremities",loaded:!1,data:null},skin_and_soft_tissues_Celulitis_cellulitis_erysipelas_facial:{id:"skin_and_soft_tissues_Celulitis_cellulitis_erysipelas_facial",filePath:"./syndromes_json/skin_and_soft_tissues/Celulitis/cellulitis_erysipelas_facial.json",category:"skin_and_soft_tissues",subcategory:"Celulitis",filename:"cellulitis_erysipelas_facial",title:"Cellulitis, Erysipelas_ Facial",loaded:!1,data:null},skin_and_soft_tissues_Celulitis_erysipelas_recurrent_lymphedema:{id:"skin_and_soft_tissues_Celulitis_erysipelas_recurrent_lymphedema",filePath:"./syndromes_json/skin_and_soft_tissues/Celulitis/erysipelas_recurrent_lymphedema.json",category:"skin_and_soft_tissues",subcategory:"Celulitis",filename:"erysipelas_recurrent_lymphedema",title:"Erysipelas, Recurrent, Lymphedema",loaded:!1,data:null},skin_and_soft_tissues_Celulitis_orbital_cellulitis_periorbital_cellulitis:{id:"skin_and_soft_tissues_Celulitis_orbital_cellulitis_periorbital_cellulitis",filePath:"./syndromes_json/skin_and_soft_tissues/Celulitis/orbital_cellulitis_periorbital_cellulitis.json",category:"skin_and_soft_tissues",subcategory:"Celulitis",filename:"orbital_cellulitis_periorbital_cellulitis",title:"Orbital cellulitis, periorbital cellulitis",loaded:!1,data:null},skin_and_soft_tissues_Herpetic_herpes_simplex_bells_palsy:{id:"skin_and_soft_tissues_Herpetic_herpes_simplex_bells_palsy",filePath:"./syndromes_json/skin_and_soft_tissues/Herpetic/herpes_simplex_bells_palsy.json",category:"skin_and_soft_tissues",subcategory:"Herpetic",filename:"herpes_simplex_bells_palsy",title:"Herpes simplex, Bell's Palsy",loaded:!1,data:null},skin_and_soft_tissues_Herpetic_herpes_zoster_shingles:{id:"skin_and_soft_tissues_Herpetic_herpes_zoster_shingles",filePath:"./syndromes_json/skin_and_soft_tissues/Herpetic/herpes_zoster_shingles.json",category:"skin_and_soft_tissues",subcategory:"Herpetic",filename:"herpes_zoster_shingles",title:"Herpes Zoster, Shingles",loaded:!1,data:null},skin_and_soft_tissues_Herpetic_varicella_zoster_virus_chickenpox:{id:"skin_and_soft_tissues_Herpetic_varicella_zoster_virus_chickenpox",filePath:"./syndromes_json/skin_and_soft_tissues/Herpetic/varicella-zoster_virus_chickenpox.json",category:"skin_and_soft_tissues",subcategory:"Herpetic",filename:"varicella-zoster_virus_chickenpox",title:"Varicella-Zoster Virus (Chickenpox)",loaded:!1,data:null},skin_and_soft_tissues_Impetigo_impetigo:{id:"skin_and_soft_tissues_Impetigo_impetigo",filePath:"./syndromes_json/skin_and_soft_tissues/Impetigo/impetigo.json",category:"skin_and_soft_tissues",subcategory:"Impetigo",filename:"impetigo",title:"Impetigo",loaded:!1,data:null},skin_and_soft_tissues_Lyme_erythema_migrans_lyme_disease_early:{id:"skin_and_soft_tissues_Lyme_erythema_migrans_lyme_disease_early",filePath:"./syndromes_json/skin_and_soft_tissues/Lyme/erythema_migrans_lyme_disease_early.json",category:"skin_and_soft_tissues",subcategory:"Lyme",filename:"erythema_migrans_lyme_disease_early",title:"Erythema migrans, Lyme Disease, Early",loaded:!1,data:null},skin_and_soft_tissues_Lyme_lyme_disease_post_lyme_syndrome_ptlds:{id:"skin_and_soft_tissues_Lyme_lyme_disease_post_lyme_syndrome_ptlds",filePath:"./syndromes_json/skin_and_soft_tissues/Lyme/lyme_disease_post-lyme_syndrome_ptlds.json",category:"skin_and_soft_tissues",subcategory:"Lyme",filename:"lyme_disease_post-lyme_syndrome_ptlds",title:"Lyme Disease, Post-Lyme Syndrome (PTLDS)",loaded:!1,data:null},skin_and_soft_tissues_Necrotizing_fascitis_necrotizing_fasciitis_clostridia_sp:{id:"skin_and_soft_tissues_Necrotizing_fascitis_necrotizing_fasciitis_clostridia_sp",filePath:"./syndromes_json/skin_and_soft_tissues/Necrotizing_fascitis/necrotizing_fasciitis_clostridia_sp.json",category:"skin_and_soft_tissues",subcategory:"Necrotizing_fascitis",filename:"necrotizing_fasciitis_clostridia_sp",title:"Necrotizing Fasciitis, Clostridia sp.",loaded:!1,data:null},skin_and_soft_tissues_Necrotizing_fascitis_necrotizing_fasciitis_staph_aureus:{id:"skin_and_soft_tissues_Necrotizing_fascitis_necrotizing_fasciitis_staph_aureus",filePath:"./syndromes_json/skin_and_soft_tissues/Necrotizing_fascitis/necrotizing_fasciitis_staph_aureus.json",category:"skin_and_soft_tissues",subcategory:"Necrotizing_fascitis",filename:"necrotizing_fasciitis_staph_aureus",title:"Necrotizing Fasciitis, Staph. aureus",loaded:!1,data:null},skin_and_soft_tissues_Necrotizing_fascitis_necrotizing_fasciitis_streptococcal:{id:"skin_and_soft_tissues_Necrotizing_fascitis_necrotizing_fasciitis_streptococcal",filePath:"./syndromes_json/skin_and_soft_tissues/Necrotizing_fascitis/necrotizing_fasciitis_streptococcal.json",category:"skin_and_soft_tissues",subcategory:"Necrotizing_fascitis",filename:"necrotizing_fasciitis_streptococcal",title:"Necrotizing Fasciitis, Streptococcal",loaded:!1,data:null},skin_and_soft_tissues_Necrotizing_fascitis_necrotizing_fasciitis_synergistic:{id:"skin_and_soft_tissues_Necrotizing_fascitis_necrotizing_fasciitis_synergistic",filePath:"./syndromes_json/skin_and_soft_tissues/Necrotizing_fascitis/necrotizing_fasciitis_synergistic.json",category:"skin_and_soft_tissues",subcategory:"Necrotizing_fascitis",filename:"necrotizing_fasciitis_synergistic",title:"Necrotizing Fasciitis, Synergistic",loaded:!1,data:null},skin_and_soft_tissues_Orf_ectyma_orf_ecthyma_contagiosum:{id:"skin_and_soft_tissues_Orf_ectyma_orf_ecthyma_contagiosum",filePath:"./syndromes_json/skin_and_soft_tissues/Orf-ectyma/orf_ecthyma_contagiosum.json",category:"skin_and_soft_tissues",subcategory:"Orf-ectyma",filename:"orf_ecthyma_contagiosum",title:"Orf, Ecthyma contagiosum",loaded:!1,data:null},skin_and_soft_tissues_Superficial_corynebacterium_minutissimum:{id:"skin_and_soft_tissues_Superficial_corynebacterium_minutissimum",filePath:"./syndromes_json/skin_and_soft_tissues/Superficial/corynebacterium_minutissimum.json",category:"skin_and_soft_tissues",subcategory:"Superficial",filename:"corynebacterium_minutissimum",title:"Corynebacterium minutissimum",loaded:!1,data:null},skin_and_soft_tissues_Superficial_folliculitis:{id:"skin_and_soft_tissues_Superficial_folliculitis",filePath:"./syndromes_json/skin_and_soft_tissues/Superficial/folliculitis.json",category:"skin_and_soft_tissues",subcategory:"Superficial",filename:"folliculitis",title:"Folliculitis",loaded:!1,data:null},skin_and_soft_tissues_Wound_vibrio_vulnificus_v_alginolyticus_v_damsela:{id:"skin_and_soft_tissues_Wound_vibrio_vulnificus_v_alginolyticus_v_damsela",filePath:"./syndromes_json/skin_and_soft_tissues/Wound/vibrio_vulnificus_v_alginolyticus_v_damsela.json",category:"skin_and_soft_tissues",subcategory:"Wound",filename:"vibrio_vulnificus_v_alginolyticus_v_damsela",title:"Vibrio vulnificus, V. alginolyticus, V. damsela",loaded:!1,data:null},skin_and_soft_tissues_Wound_wound_infection_post_operative_negative_gram_stain:{id:"skin_and_soft_tissues_Wound_wound_infection_post_operative_negative_gram_stain",filePath:"./syndromes_json/skin_and_soft_tissues/Wound/wound_infection_post-operative_negative_gram_stain.json",category:"skin_and_soft_tissues",subcategory:"Wound",filename:"wound_infection_post-operative_negative_gram_stain",title:"wound_infection_post-operative_negative_gram_stain",loaded:!1,data:null},skin_and_soft_tissues_Wound_wound_infection_post_operative_positive_gram_stain:{id:"skin_and_soft_tissues_Wound_wound_infection_post_operative_positive_gram_stain",filePath:"./syndromes_json/skin_and_soft_tissues/Wound/wound_infection_post-operative_positive_gram_stain.json",category:"skin_and_soft_tissues",subcategory:"Wound",filename:"wound_infection_post-operative_positive_gram_stain",title:"wound_infection_post-operative_positive_gram_stain",loaded:!1,data:null},skin_and_soft_tissues_Wound_wound_infection_post_trauma:{id:"skin_and_soft_tissues_Wound_wound_infection_post_trauma",filePath:"./syndromes_json/skin_and_soft_tissues/Wound/wound_infection_post-trauma.json",category:"skin_and_soft_tissues",subcategory:"Wound",filename:"wound_infection_post-trauma",title:"wound_infection_post-trauma",loaded:!1,data:null},skin_and_soft_tissues_abscess_furunculosis_recurrent:{id:"skin_and_soft_tissues_abscess_furunculosis_recurrent",filePath:"./syndromes_json/skin_and_soft_tissues/abscess/furunculosis_recurrent.json",category:"skin_and_soft_tissues",subcategory:"abscess",filename:"furunculosis_recurrent",title:"furunculosis_recurrent",loaded:!1,data:null},skin_and_soft_tissues_abscess_pilonidal_cyst_pilonidal_abscess:{id:"skin_and_soft_tissues_abscess_pilonidal_cyst_pilonidal_abscess",filePath:"./syndromes_json/skin_and_soft_tissues/abscess/pilonidal_cyst_pilonidal_abscess.json",category:"skin_and_soft_tissues",subcategory:"abscess",filename:"pilonidal_cyst_pilonidal_abscess",title:"pilonidal_cyst_pilonidal_abscess",loaded:!1,data:null},skin_and_soft_tissues_abscess_skin_abscess_boils_furuncles:{id:"skin_and_soft_tissues_abscess_skin_abscess_boils_furuncles",filePath:"./syndromes_json/skin_and_soft_tissues/abscess/skin_abscess_boils_furuncles.json",category:"skin_and_soft_tissues",subcategory:"abscess",filename:"skin_abscess_boils_furuncles",title:"skin_abscess_boils_furuncles",loaded:!1,data:null},skin_and_soft_tissues_anthrax_cutaneous:{id:"skin_and_soft_tissues_anthrax_cutaneous",filePath:"./syndromes_json/skin_and_soft_tissues/anthrax_cutaneous.json",category:"skin_and_soft_tissues",subcategory:null,filename:"anthrax_cutaneous",title:"Anthrax, Cutaneous",loaded:!1,data:null},skin_and_soft_tissues_bacillary_angiomatosis_peliosis:{id:"skin_and_soft_tissues_bacillary_angiomatosis_peliosis",filePath:"./syndromes_json/skin_and_soft_tissues/bacillary_angiomatosis_peliosis.json",category:"skin_and_soft_tissues",subcategory:null,filename:"bacillary_angiomatosis_peliosis",title:"Bacillary Angiomatosis, Peliosis",loaded:!1,data:null},skin_and_soft_tissues_bites_bite_alligator_crocodile:{id:"skin_and_soft_tissues_bites_bite_alligator_crocodile",filePath:"./syndromes_json/skin_and_soft_tissues/bites/bite_alligator_crocodile.json",category:"skin_and_soft_tissues",subcategory:"bites",filename:"bite_alligator_crocodile",title:"bite_alligator_crocodile",loaded:!1,data:null},skin_and_soft_tissues_bites_bite_bat_raccoon_skunk:{id:"skin_and_soft_tissues_bites_bite_bat_raccoon_skunk",filePath:"./syndromes_json/skin_and_soft_tissues/bites/bite_bat_raccoon_skunk.json",category:"skin_and_soft_tissues",subcategory:"bites",filename:"bite_bat_raccoon_skunk",title:"bite_bat_raccoon_skunk",loaded:!1,data:null},skin_and_soft_tissues_bites_bite_bear:{id:"skin_and_soft_tissues_bites_bite_bear",filePath:"./syndromes_json/skin_and_soft_tissues/bites/bite_bear.json",category:"skin_and_soft_tissues",subcategory:"bites",filename:"bite_bear",title:"Bite wound from bear",loaded:!1,data:null},skin_and_soft_tissues_bites_bite_camel:{id:"skin_and_soft_tissues_bites_bite_camel",filePath:"./syndromes_json/skin_and_soft_tissues/bites/bite_camel.json",category:"skin_and_soft_tissues",subcategory:"bites",filename:"bite_camel",title:"Bite wound from camel",loaded:!1,data:null},skin_and_soft_tissues_bites_bite_cat:{id:"skin_and_soft_tissues_bites_bite_cat",filePath:"./syndromes_json/skin_and_soft_tissues/bites/bite_cat.json",category:"skin_and_soft_tissues",subcategory:"bites",filename:"bite_cat",title:"Bite wound from cat",loaded:!1,data:null},skin_and_soft_tissues_bites_bite_dog:{id:"skin_and_soft_tissues_bites_bite_dog",filePath:"./syndromes_json/skin_and_soft_tissues/bites/bite_dog.json",category:"skin_and_soft_tissues",subcategory:"bites",filename:"bite_dog",title:"Bite wound from a dog",loaded:!1,data:null},skin_and_soft_tissues_bites_bite_horse:{id:"skin_and_soft_tissues_bites_bite_horse",filePath:"./syndromes_json/skin_and_soft_tissues/bites/bite_horse.json",category:"skin_and_soft_tissues",subcategory:"bites",filename:"bite_horse",title:"Bite wound: horse",loaded:!1,data:null},skin_and_soft_tissues_bites_bite_human:{id:"skin_and_soft_tissues_bites_bite_human",filePath:"./syndromes_json/skin_and_soft_tissues/bites/bite_human.json",category:"skin_and_soft_tissues",subcategory:"bites",filename:"bite_human",title:"Human Bite Wound",loaded:!1,data:null},skin_and_soft_tissues_bites_bite_komodo_dragon:{id:"skin_and_soft_tissues_bites_bite_komodo_dragon",filePath:"./syndromes_json/skin_and_soft_tissues/bites/bite_komodo_dragon.json",category:"skin_and_soft_tissues",subcategory:"bites",filename:"bite_komodo_dragon",title:"Bite wound from Komodo dragon (Varanus komodoensis)",loaded:!1,data:null},skin_and_soft_tissues_bites_bite_lizard_iguana:{id:"skin_and_soft_tissues_bites_bite_lizard_iguana",filePath:"./syndromes_json/skin_and_soft_tissues/bites/bite_lizard_iguana.json",category:"skin_and_soft_tissues",subcategory:"bites",filename:"bite_lizard_iguana",title:"Bite from iguana",loaded:!1,data:null},skin_and_soft_tissues_bites_bite_monkey_other_primates:{id:"skin_and_soft_tissues_bites_bite_monkey_other_primates",filePath:"./syndromes_json/skin_and_soft_tissues/bites/bite_monkey_other_primates.json",category:"skin_and_soft_tissues",subcategory:"bites",filename:"bite_monkey_other_primates",title:"Bite wound from Monkey or other Primates",loaded:!1,data:null},skin_and_soft_tissues_bites_bite_pig_swine:{id:"skin_and_soft_tissues_bites_bite_pig_swine",filePath:"./syndromes_json/skin_and_soft_tissues/bites/bite_pig_swine.json",category:"skin_and_soft_tissues",subcategory:"bites",filename:"bite_pig_swine",title:"Bite wound from pig or other swine",loaded:!1,data:null},skin_and_soft_tissues_bites_bite_prairie_dog:{id:"skin_and_soft_tissues_bites_bite_prairie_dog",filePath:"./syndromes_json/skin_and_soft_tissues/bites/bite_prairie_dog.json",category:"skin_and_soft_tissues",subcategory:"bites",filename:"bite_prairie_dog",title:"Bite wound from Prairie dog",loaded:!1,data:null},skin_and_soft_tissues_bites_bite_rat:{id:"skin_and_soft_tissues_bites_bite_rat",filePath:"./syndromes_json/skin_and_soft_tissues/bites/bite_rat.json",category:"skin_and_soft_tissues",subcategory:"bites",filename:"bite_rat",title:"Bite wound from rat, rodent",loaded:!1,data:null},skin_and_soft_tissues_bites_bite_seal:{id:"skin_and_soft_tissues_bites_bite_seal",filePath:"./syndromes_json/skin_and_soft_tissues/bites/bite_seal.json",category:"skin_and_soft_tissues",subcategory:"bites",filename:"bite_seal",title:"Bite wound from seals or other injury related to handling seal material",loaded:!1,data:null},skin_and_soft_tissues_bites_bite_shark:{id:"skin_and_soft_tissues_bites_bite_shark",filePath:"./syndromes_json/skin_and_soft_tissues/bites/bite_shark.json",category:"skin_and_soft_tissues",subcategory:"bites",filename:"bite_shark",title:"Bite of shark, in saltwater or occasionally brackish water",loaded:!1,data:null},skin_and_soft_tissues_bites_bite_spider:{id:"skin_and_soft_tissues_bites_bite_spider",filePath:"./syndromes_json/skin_and_soft_tissues/bites/bite_spider.json",category:"skin_and_soft_tissues",subcategory:"bites",filename:"bite_spider",title:"Bite wound from spiders",loaded:!1,data:null},skin_and_soft_tissues_bites_bite_swan:{id:"skin_and_soft_tissues_bites_bite_swan",filePath:"./syndromes_json/skin_and_soft_tissues/bites/bite_swan.json",category:"skin_and_soft_tissues",subcategory:"bites",filename:"bite_swan",title:"Bite wound from swan",loaded:!1,data:null},skin_and_soft_tissues_bites_bite_tasmanian_devil:{id:"skin_and_soft_tissues_bites_bite_tasmanian_devil",filePath:"./syndromes_json/skin_and_soft_tissues/bites/bite_tasmanian_devil.json",category:"skin_and_soft_tissues",subcategory:"bites",filename:"bite_tasmanian_devil",title:"Bite Tasmanian Devil",loaded:!1,data:null},skin_and_soft_tissues_bites_bite_venomous_snake:{id:"skin_and_soft_tissues_bites_bite_venomous_snake",filePath:"./syndromes_json/skin_and_soft_tissues/bites/bite_venomous_snake.json",category:"skin_and_soft_tissues",subcategory:"bites",filename:"bite_venomous_snake",title:"Bite Venomous Snake",loaded:!1,data:null},skin_and_soft_tissues_bites_catfish_sting:{id:"skin_and_soft_tissues_bites_catfish_sting",filePath:"./syndromes_json/skin_and_soft_tissues/bites/catfish_sting.json",category:"skin_and_soft_tissues",subcategory:"bites",filename:"catfish_sting",title:"Catfish Sting",loaded:!1,data:null},skin_and_soft_tissues_breasts_mastitis_breast_implant:{id:"skin_and_soft_tissues_breasts_mastitis_breast_implant",filePath:"./syndromes_json/skin_and_soft_tissues/breasts/mastitis_breast_implant.json",category:"skin_and_soft_tissues",subcategory:"breasts",filename:"mastitis_breast_implant",title:"Mastitis, Breast Implant",loaded:!1,data:null},skin_and_soft_tissues_breasts_mastitis_non_puerperal:{id:"skin_and_soft_tissues_breasts_mastitis_non_puerperal",filePath:"./syndromes_json/skin_and_soft_tissues/breasts/mastitis_non-puerperal.json",category:"skin_and_soft_tissues",subcategory:"breasts",filename:"mastitis_non-puerperal",title:"Mastitis, Non-Puerperal",loaded:!1,data:null},skin_and_soft_tissues_breasts_mastitis_overview:{id:"skin_and_soft_tissues_breasts_mastitis_overview",filePath:"./syndromes_json/skin_and_soft_tissues/breasts/mastitis_overview.json",category:"skin_and_soft_tissues",subcategory:"breasts",filename:"mastitis_overview",title:"Mastitis, Overview",loaded:!1,data:null},skin_and_soft_tissues_breasts_mastitis_postpartum:{id:"skin_and_soft_tissues_breasts_mastitis_postpartum",filePath:"./syndromes_json/skin_and_soft_tissues/breasts/mastitis_postpartum.json",category:"skin_and_soft_tissues",subcategory:"breasts",filename:"mastitis_postpartum",title:"Mastitis, Postpartum",loaded:!1,data:null},skin_and_soft_tissues_bullous_or_vesicular_herpes_zoster_shingles:{id:"skin_and_soft_tissues_bullous_or_vesicular_herpes_zoster_shingles",filePath:"./syndromes_json/skin_and_soft_tissues/bullous_or_vesicular/herpes_zoster_shingles.json",category:"skin_and_soft_tissues",subcategory:"bullous_or_vesicular",filename:"herpes_zoster_shingles",title:"Herpes Zoster, Shingles",loaded:!1,data:null},skin_and_soft_tissues_bullous_or_vesicular_impetigo:{id:"skin_and_soft_tissues_bullous_or_vesicular_impetigo",filePath:"./syndromes_json/skin_and_soft_tissues/bullous_or_vesicular/impetigo.json",category:"skin_and_soft_tissues",subcategory:"bullous_or_vesicular",filename:"impetigo",title:"Impetigo",loaded:!1,data:null},skin_and_soft_tissues_bullous_or_vesicular_staphylococcal_scalded_skin_syndrome:{id:"skin_and_soft_tissues_bullous_or_vesicular_staphylococcal_scalded_skin_syndrome",filePath:"./syndromes_json/skin_and_soft_tissues/bullous_or_vesicular/staphylococcal_scalded_skin_syndrome.json",category:"skin_and_soft_tissues",subcategory:"bullous_or_vesicular",filename:"staphylococcal_scalded_skin_syndrome",title:"Staphylococcal Scalded Skin Syndrome",loaded:!1,data:null},skin_and_soft_tissues_bullous_or_vesicular_varicella_zoster_virus_chickenpox:{id:"skin_and_soft_tissues_bullous_or_vesicular_varicella_zoster_virus_chickenpox",filePath:"./syndromes_json/skin_and_soft_tissues/bullous_or_vesicular/varicella-zoster_virus_chickenpox.json",category:"skin_and_soft_tissues",subcategory:"bullous_or_vesicular",filename:"varicella-zoster_virus_chickenpox",title:"Varicella-Zoster Virus (Chickenpox)",loaded:!1,data:null},skin_and_soft_tissues_bullous_or_vesicular_vibrio_vulnificus_v_alginolyticus_v_damsela:{id:"skin_and_soft_tissues_bullous_or_vesicular_vibrio_vulnificus_v_alginolyticus_v_damsela",filePath:"./syndromes_json/skin_and_soft_tissues/bullous_or_vesicular/vibrio_vulnificus_v_alginolyticus_v_damsela.json",category:"skin_and_soft_tissues",subcategory:"bullous_or_vesicular",filename:"vibrio_vulnificus_v_alginolyticus_v_damsela",title:"Vibrio vulnificus, V. alginolyticus, V. damsela",loaded:!1,data:null},skin_and_soft_tissues_burns_burns_infected_wound:{id:"skin_and_soft_tissues_burns_burns_infected_wound",filePath:"./syndromes_json/skin_and_soft_tissues/burns/burns_infected_wound.json",category:"skin_and_soft_tissues",subcategory:"burns",filename:"burns_infected_wound",title:"Burns, Infected Wound",loaded:!1,data:null},skin_and_soft_tissues_burns_burns_non_infected:{id:"skin_and_soft_tissues_burns_burns_non_infected",filePath:"./syndromes_json/skin_and_soft_tissues/burns/burns_non-infected.json",category:"skin_and_soft_tissues",subcategory:"burns",filename:"burns_non-infected",title:"Burns, Non-Infected",loaded:!1,data:null},skin_and_soft_tissues_erythema_migrans_lyme_disease_early:{id:"skin_and_soft_tissues_erythema_migrans_lyme_disease_early",filePath:"./syndromes_json/skin_and_soft_tissues/erythema_migrans_lyme_disease_early.json",category:"skin_and_soft_tissues",subcategory:null,filename:"erythema_migrans_lyme_disease_early",title:"Erythema Migrans, Lyme Disease, Early",loaded:!1,data:null},skin_and_soft_tissues_erythema_nodosum:{id:"skin_and_soft_tissues_erythema_nodosum",filePath:"./syndromes_json/skin_and_soft_tissues/erythema_nodosum.json",category:"skin_and_soft_tissues",subcategory:null,filename:"erythema_nodosum",title:"Erythema Nodosum",loaded:!1,data:null},skin_and_soft_tissues_orf_ecthyma_contagiosum:{id:"skin_and_soft_tissues_orf_ecthyma_contagiosum",filePath:"./syndromes_json/skin_and_soft_tissues/orf_ecthyma_contagiosum.json",category:"skin_and_soft_tissues",subcategory:null,filename:"orf_ecthyma_contagiosum",title:"Orf, Ecthyma contagiosum",loaded:!1,data:null},skin_and_soft_tissues_skin_soft_tissue_infections_overview:{id:"skin_and_soft_tissues_skin_soft_tissue_infections_overview",filePath:"./syndromes_json/skin_and_soft_tissues/skin_soft_tissue_infections_overview.json",category:"skin_and_soft_tissues",subcategory:null,filename:"skin_soft_tissue_infections_overview",title:"skin_soft_tissue_infections_overview",loaded:!1,data:null},skin_and_soft_tissues_ulcerated_skin_venous_arterial_insufficiency_pressure_decubuti:{id:"skin_and_soft_tissues_ulcerated_skin_venous_arterial_insufficiency_pressure_decubuti",filePath:"./syndromes_json/skin_and_soft_tissues/ulcerated_skin_venous_arterial_insufficiency_pressure_decubuti.json",category:"skin_and_soft_tissues",subcategory:null,filename:"ulcerated_skin_venous_arterial_insufficiency_pressure_decubuti",title:"Ulcerated Skin: Venous, Arterial Insufficiency, Pressure Decubiti",loaded:!1,data:null},skin_and_soft_tissues_wound_leeches_medicinal:{id:"skin_and_soft_tissues_wound_leeches_medicinal",filePath:"./syndromes_json/skin_and_soft_tissues/wound_leeches_medicinal.json",category:"skin_and_soft_tissues",subcategory:null,filename:"wound_leeches_medicinal",title:"Wound, Leeches, Medicinal",loaded:!1,data:null},skin_and_soft_tissues_yaws:{id:"skin_and_soft_tissues_yaws",filePath:"./syndromes_json/skin_and_soft_tissues/yaws.json",category:"skin_and_soft_tissues",subcategory:null,filename:"yaws",title:"Yaws",loaded:!1,data:null},upper_respiratory_otitis_media_otitis_media_acute_empiric_therapy:{id:"upper_respiratory_otitis_media_otitis_media_acute_empiric_therapy",filePath:"./syndromes_json/upper_respiratory/otitis_media/otitis_media_acute_empiric_therapy.json",category:"upper_respiratory",subcategory:"otitis_media",filename:"otitis_media_acute_empiric_therapy",title:"Otitis Media, Acute, Empiric Therapy",loaded:!1,data:null},upper_respiratory_otitis_media_otitis_media_post_intubation:{id:"upper_respiratory_otitis_media_otitis_media_post_intubation",filePath:"./syndromes_json/upper_respiratory/otitis_media/otitis_media_post_intubation.json",category:"upper_respiratory",subcategory:"otitis_media",filename:"otitis_media_post_intubation",title:"Otitis Media, Post-Intubation",loaded:!1,data:null},upper_respiratory_otitis_media_otitis_media_prophylaxis:{id:"upper_respiratory_otitis_media_otitis_media_prophylaxis",filePath:"./syndromes_json/upper_respiratory/otitis_media/otitis_media_prophylaxis.json",category:"upper_respiratory",subcategory:"otitis_media",filename:"otitis_media_prophylaxis",title:"Otitis Media, Prophylaxis",loaded:!1,data:null},upper_respiratory_pharyngitis_epiglottitis_supraglottitis:{id:"upper_respiratory_pharyngitis_epiglottitis_supraglottitis",filePath:"./syndromes_json/upper_respiratory/pharyngitis/epiglottitis_supraglottitis.json",category:"upper_respiratory",subcategory:"pharyngitis",filename:"epiglottitis_supraglottitis",title:"Epiglottitis, Supraglottitis",loaded:!1,data:null},upper_respiratory_pharyngitis_jugular_vein_suppurative_septic_thrombophlebitis_lemierres_syndrome:{id:"upper_respiratory_pharyngitis_jugular_vein_suppurative_septic_thrombophlebitis_lemierres_syndrome",filePath:"./syndromes_json/upper_respiratory/pharyngitis/jugular_vein_suppurative_septic_thrombophlebitis_lemierres_syndrome.json",category:"upper_respiratory",subcategory:"pharyngitis",filename:"jugular_vein_suppurative_septic_thrombophlebitis_lemierres_syndrome",title:"Jugular Vein Suppurative (Septic) Thrombophlebitis, Lemierre's syndrome",loaded:!1,data:null},upper_respiratory_pharyngitis_laryngitis_acute:{id:"upper_respiratory_pharyngitis_laryngitis_acute",filePath:"./syndromes_json/upper_respiratory/pharyngitis/laryngitis_acute.json",category:"upper_respiratory",subcategory:"pharyngitis",filename:"laryngitis_acute",title:"Laryngitis, Acute",loaded:!1,data:null},upper_respiratory_pharyngitis_mouth_parapharyngeal_space_infection:{id:"upper_respiratory_pharyngitis_mouth_parapharyngeal_space_infection",filePath:"./syndromes_json/upper_respiratory/pharyngitis/mouth_parapharyngeal_space_infection.json",category:"upper_respiratory",subcategory:"pharyngitis",filename:"mouth_parapharyngeal_space_infection",title:"Mouth, Parapharyngeal Space Infection",loaded:!1,data:null},upper_respiratory_pharyngitis_pharyngitis_tonsillitis:{id:"upper_respiratory_pharyngitis_pharyngitis_tonsillitis",filePath:"./syndromes_json/upper_respiratory/pharyngitis/pharyngitis_tonsillitis.json",category:"upper_respiratory",subcategory:"pharyngitis",filename:"pharyngitis_tonsillitis",title:"Pharyngitis, Tonsillitis",loaded:!1,data:null},upper_respiratory_pharyngitis_streptococcal_pharyngitis:{id:"upper_respiratory_pharyngitis_streptococcal_pharyngitis",filePath:"./syndromes_json/upper_respiratory/pharyngitis/streptococcal_pharyngitis.json",category:"upper_respiratory",subcategory:"pharyngitis",filename:"streptococcal_pharyngitis",title:"Streptococcal Pharyngitis",loaded:!1,data:null},upper_respiratory_sinusitis_empyema_subdural:{id:"upper_respiratory_sinusitis_empyema_subdural",filePath:"./syndromes_json/upper_respiratory/sinusitis/empyema_subdural.json",category:"upper_respiratory",subcategory:"sinusitis",filename:"empyema_subdural",title:"Empyema, Subdural",loaded:!1,data:null},upper_respiratory_sinusitis_sinusitis_acute_failure_of_empiric_therapy:{id:"upper_respiratory_sinusitis_sinusitis_acute_failure_of_empiric_therapy",filePath:"./syndromes_json/upper_respiratory/sinusitis/sinusitis_acute_failure_of_empiric_therapy.json",category:"upper_respiratory",subcategory:"sinusitis",filename:"sinusitis_acute_failure_of_empiric_therapy",title:"Sinusitis, Acute, Failure of Empiric Therapy",loaded:!1,data:null},upper_respiratory_sinusitis_sinusitis_intubation_associated:{id:"upper_respiratory_sinusitis_sinusitis_intubation_associated",filePath:"./syndromes_json/upper_respiratory/sinusitis/sinusitis_intubation_associated.json",category:"upper_respiratory",subcategory:"sinusitis",filename:"sinusitis_intubation_associated",title:"Sinusitis, Intubation Associated",loaded:!1,data:null},upper_respiratory_sinusitis_sinusitis_rhinosinusitis_acute:{id:"upper_respiratory_sinusitis_sinusitis_rhinosinusitis_acute",filePath:"./syndromes_json/upper_respiratory/sinusitis/sinusitis_rhinosinusitis_acute.json",category:"upper_respiratory",subcategory:"sinusitis",filename:"sinusitis_rhinosinusitis_acute",title:"sinusitis_rhinosinusitis_acute",loaded:!1,data:null},upper_respiratory_sinusitis_sinusitis_rhinosinusitis_chronic:{id:"upper_respiratory_sinusitis_sinusitis_rhinosinusitis_chronic",filePath:"./syndromes_json/upper_respiratory/sinusitis/sinusitis_rhinosinusitis_chronic.json",category:"upper_respiratory",subcategory:"sinusitis",filename:"sinusitis_rhinosinusitis_chronic",title:"sinusitis_rhinosinusitis_chronic",loaded:!1,data:null},upper_respiratory_stomatitis_cellulitis_buccal:{id:"upper_respiratory_stomatitis_cellulitis_buccal",filePath:"./syndromes_json/upper_respiratory/stomatitis/cellulitis_buccal.json",category:"upper_respiratory",subcategory:"stomatitis",filename:"cellulitis_buccal",title:"cellulitis_buccal",loaded:!1,data:null},upper_respiratory_stomatitis_herpes_simplex_oral_lesions_mouth_lips:{id:"upper_respiratory_stomatitis_herpes_simplex_oral_lesions_mouth_lips",filePath:"./syndromes_json/upper_respiratory/stomatitis/herpes_simplex_oral_lesions_mouth_lips.json",category:"upper_respiratory",subcategory:"stomatitis",filename:"herpes_simplex_oral_lesions_mouth_lips",title:"herpes_simplex_oral_lesions_mouth_lips",loaded:!1,data:null},upper_respiratory_stomatitis_tooth_odontogenic_infection_ludwigs_angina:{id:"upper_respiratory_stomatitis_tooth_odontogenic_infection_ludwigs_angina",filePath:"./syndromes_json/upper_respiratory/stomatitis/tooth_odontogenic_infection_ludwigs_angina.json",category:"upper_respiratory",subcategory:"stomatitis",filename:"tooth_odontogenic_infection_ludwigs_angina",title:"Tooth, Odontogenic Infection, Ludwig's Angina",loaded:!1,data:null},upper_respiratory_stomatitis_vincents_angina_necrotizing_gingivitis_trench_mouth:{id:"upper_respiratory_stomatitis_vincents_angina_necrotizing_gingivitis_trench_mouth",filePath:"./syndromes_json/upper_respiratory/stomatitis/vincents_angina_necrotizing_gingivitis_trench_mouth.json",category:"upper_respiratory",subcategory:"stomatitis",filename:"vincents_angina_necrotizing_gingivitis_trench_mouth",title:"Vincent's Angina, Necrotizing Gingivitis, Trench mouth",loaded:!1,data:null}};let po={},Ir=!1;async function mb(){return Object.keys(po).length===0&&!Ir&&await pb(),po}function ub(){return window.location.hostname==="ertwro.github.io"&&window.location.pathname.startsWith("/antibiogram_react_app")?"/antibiogram_react_app":"."}async function pb(){if(!Ir){Ir=!0;try{const g=ub(),s=Object.entries(db).map(async([c,d])=>{try{const m=d.filePath.replace("./",`${g}/`),_=await fetch(m);if(_.ok){const h=await _.json();return{id:c,...d,data:h,loaded:!0}}else return console.warn(`Failed to load syndrome: ${m}`),{id:c,...d,data:{error:"Failed to load"},loaded:!1}}catch(m){return console.warn(`Error loading syndrome ${c}:`,m),{id:c,...d,data:{error:m.message},loaded:!1}}});(await Promise.all(s)).forEach(c=>{po[c.id]=c}),console.log("🧬 Syndromes database loaded with",Object.keys(po).length,"syndromes")}catch(g){console.error("Failed to load syndromes database:",g)}finally{Ir=!1}}}function uo(g){return{CNS:"Sistema Nervioso Central",cardiovascular:"Cardiovascular",genitourinary:"Genitourinario",head_and_neck:"Cabeza y Cuello",infectious_syndromes:"Síndromes Infecciosos","intra-abdominal":"Intraabdominal",lower_respiratory:"Respiratorio Inferior","lymph_nodes-spleen":"Ganglios y Bazo",musculoskeletal:"Musculoesquelético",ocular:"Ocular",skin_and_soft_tissues:"Piel y Tejidos Blandos",upper_respiratory:"Respiratorio Superior","Duration of Therapy, Antibacterial":"Duración de Terapia",Lyme_disease:"Enfermedad de Lyme",Toxin_mediated:"Mediado por Toxinas"}[g]||g}console.log("🧬 Syndromes database loaded with",Object.keys(po).length,"syndromes");const gb={CNS:{label:"Sistema Nervioso Central",color:"bg-red-50 border-red-200",penetrationRequirement:"CNS_critical",bactericidalRequired:!0,dosing:"high_dose",icon:"🧠",clinicalNote:"Penetración BHE crítica, terapia bactericida requerida",options:[{syndromeId:"CNS_meningitis_empiric_therapy_meningitis_age_1_mo_to_50_years",value:"CNS_meningitis_bacterial",label:"Meningitis bacteriana (1 mes - 50 años)",severity:3,stewardshipNotes:"Inicio empírico inmediato, ajustar según cultivos"},{syndromeId:"CNS_meningitis_empiric_therapy_meningitis_age_50_years",value:"CNS_meningitis_elderly",label:"Meningitis bacteriana (> 50 años)",severity:3,stewardshipNotes:"Cobertura adicional para Listeria monocytogenes"},{syndromeId:"CNS_brain_abscess_brain_abscess_bacterial",value:"CNS_brain_abscess",label:"Absceso cerebral",severity:3,stewardshipNotes:"Terapia prolongada, considerar anaérobios"}]},Cardiovascular:{label:"Cardiovascular",color:"bg-purple-50 border-purple-200",penetrationRequirement:"moderate",bactericidalRequired:!0,dosing:"high_dose",icon:"💓",clinicalNote:"Terapia bactericida esencial, concentraciones altas",options:[{syndromeId:"cardiovascular_endocarditis_endocarditis_native_valve_empiric_therapy",value:"CV_endocarditis_native",label:"Endocarditis válvula nativa",severity:3,stewardshipNotes:"Hemocultivos seriados antes de iniciar ATB"},{syndromeId:"cardiovascular_endocarditis_endocarditis_prosthetic_valve_empiric_therapy",value:"CV_endocarditis_prosthetic",label:"Endocarditis válvula protésica",severity:3,stewardshipNotes:"Cobertura estafilococo resistente, consulta cardiocirugía"},{syndromeId:"infectious_syndromes_septic_shock_sepsis_adult",value:"BS_bacteremia",label:"Bacteriemia/Sepsis",severity:2,stewardshipNotes:"Terapia empírica inmediata, descalamiento según cultivos"}]},Respiratory:{label:"Respiratorio",color:"bg-blue-50 border-blue-200",penetrationRequirement:"good",bactericidalRequired:!1,dosing:"standard",icon:"🫁",clinicalNote:"Buena penetración pulmonar, bacteriostáticos efectivos",options:[{syndromeId:"lower_respiratory_pneumonia_empiric_community_acquired_pneumonia_community_acquired_adult_in_patient",value:"RESP_CAP_hospitalized",label:"Neumonía adquirida en comunidad (hospitalizada)",severity:2,stewardshipNotes:"Evaluar factores de riesgo para patógenos resistentes"},{syndromeId:"lower_respiratory_pneumonia_empiric_community_acquired_pneumonia_community_acquired_adult_out_patien",value:"RESP_CAP_outpatient",label:"Neumonía adquirida en comunidad (ambulatoria)",severity:1,stewardshipNotes:"Preferir vía oral cuando sea posible"},{syndromeId:"lower_respiratory_pneumonia_empiric_pneumonia_healthcare_associated",value:"RESP_HAP",label:"Neumonía asociada a cuidados de salud",severity:2,stewardshipNotes:"Cobertura empírica para patógenos MDR"}]},GU:{label:"Genitourinario",color:"bg-green-50 border-green-200",penetrationRequirement:"urinary_specific",bactericidalRequired:!1,dosing:"standard",icon:"🩺",clinicalNote:"Concentración urinaria más importante que sérica",options:[{syndromeId:"genitourinary_cystitis_uti_acute_uncomplicated_adult_female",value:"GU_UTI_uncomplicated",label:"ITU no complicada (mujer)",severity:1,stewardshipNotes:"Curso corto, evitar fluoroquinolonas si es posible"},{syndromeId:"genitourinary_cystitis_uti_complicated_or_catheter_related",value:"GU_UTI_complicated",label:"ITU complicada/asociada a catéter",severity:2,stewardshipNotes:"Cultivo obligatorio, considerar patógenos resistentes"},{syndromeId:"genitourinary_pyelonephritis_pyelonephritis_acute",value:"GU_pyelonephritis",label:"Pielonefritis aguda",severity:2,stewardshipNotes:"Penetración sistémica requerida, evitar nitrofurantoína"}]},Skin_Soft_Tissue:{label:"Piel y Tejidos Blandos",color:"bg-yellow-50 border-yellow-200",penetrationRequirement:"good",bactericidalRequired:!1,dosing:"standard",icon:"🩹",clinicalNote:"Buena penetración en tejidos blandos",options:[{syndromeId:"skin_and_soft_tissues_Celulitis_cellulitis_erysipelas_extremities",value:"SST_cellulitis_simple",label:"Celulitis no complicada",severity:1,stewardshipNotes:"Cobertura estreptocócica, vía oral cuando es posible"},{syndromeId:"skin_and_soft_tissues_abscess_skin_abscess_boils_furuncles",value:"SST_abscess",label:"Absceso de piel/tejidos blandos",severity:2,stewardshipNotes:"Drenaje + antibióticos, cobertura SARM si factores de riesgo"},{syndromeId:"skin_and_soft_tissues_Necrotizing_fascitis_necrotizing_fasciitis_streptococcal_1",value:"SST_necrotizing_fasciitis",label:"Fascitis necrotizante",severity:3,stewardshipNotes:"Emergencia quirúrgica + antibióticos IV de amplio espectro"}]},Intra_Abdominal:{label:"Intraabdominal",color:"bg-indigo-50 border-indigo-200",penetrationRequirement:"good",bactericidalRequired:!1,dosing:"standard",icon:"🫃",clinicalNote:"Cobertura anaérobica frecuentemente requerida",options:[{syndromeId:"intra-abdominal_peritonitis_peritonitis_rupture_perforation_abscess",value:"IA_peritonitis_secondary",label:"Peritonitis secundaria",severity:2,stewardshipNotes:"Cobertura aeróbica + anaeróbica, control de fuente"},{syndromeId:"intra-abdominal_gallbladder_biliary_tract_cholangitis_1",value:"IA_cholangitis",label:"Colangitis",severity:2,stewardshipNotes:"Drenaje biliar + antibióticos sistémicos"},{syndromeId:"intra-abdominal_peritonitis_appendicitis",value:"IA_appendicitis",label:"Apendicitis complicada",severity:2,stewardshipNotes:"Cobertura polimicrobiana, duración según evolución"}]}};function fb(){return gb}const Xu=fb(),_b=({onComplete:g,initialData:s={}})=>{var T,q,C,E,z,H,Y,ee,le;const[l,c]=oe.useState(s.organism||null),[d,m]=oe.useState(s.infectionSite||null),[_,h]=oe.useState(""),[v,y]=oe.useState([]),[D,L]=oe.useState(null),[W,se]=oe.useState(!1),ie=oe.useMemo(()=>new $l,[]),$=oe.useMemo(()=>$i(),[]),ne=oe.useMemo(()=>ep(),[$]),w=oe.useMemo(()=>{if(!_.trim())return[];const Q=_.toLowerCase();return ne.filter(k=>k.name&&k.name.toLowerCase().includes(Q)||k.genus&&k.genus.toLowerCase().includes(Q)||k.gramStain&&k.gramStain.toLowerCase().includes(Q)||k.aliases&&Array.isArray(k.aliases)&&k.aliases.some(G=>typeof G=="string"&&G.toLowerCase().includes(Q))||k.searchTerms&&k.searchTerms.includes(Q)).slice(0,10)},[ne,_]);oe.useEffect(()=>{if(l){se(!0);try{const Q=ie.getIntrinsicResistance(l.id);y(Q)}catch(Q){console.error("Error loading intrinsic resistance:",Q),y([])}finally{se(!1)}}},[l,ie]);const O=Q=>{c(Q),h("")},U=Q=>{m(Q)},Z=()=>{l&&d&&g({organism:l,infectionSite:d,intrinsicResistance:v})},X=()=>{if(!d)return null;for(const[Q,k]of Object.entries(Xu)){const G=k.options.find(ae=>ae.value===d);if(G)return{...G,category:k.label,categoryColor:k.color}}return null};return a.jsxs("div",{className:"max-w-6xl mx-auto p-6 space-y-8",children:[a.jsxs("div",{className:"text-center mb-8",children:[a.jsxs("div",{className:"flex items-center justify-center mb-4",children:[a.jsx("div",{className:"bg-blue-600 text-white rounded-full w-10 h-10 flex items-center justify-center font-bold text-lg mr-4",children:"1"}),a.jsx("h1",{className:"text-3xl font-bold text-gray-900",children:"Setting the Stage"})]}),a.jsx("p",{className:"text-lg text-gray-600 max-w-3xl mx-auto",children:"Before looking at any antibiotics, we need to understand the context. Like an infectious disease specialist, we start by identifying the organism and infection site."})]}),a.jsx("div",{className:"bg-blue-50 border border-blue-200 rounded-lg p-4 mb-6",children:a.jsxs("div",{className:"flex items-center space-x-4",children:[a.jsx("div",{className:"flex-1",children:a.jsxs("div",{className:"flex items-center",children:[a.jsx("div",{className:`w-4 h-4 rounded-full mr-2 ${l?"bg-green-500":"bg-gray-300"}`}),a.jsx("span",{className:`font-medium ${l?"text-green-700":"text-gray-500"}`,children:"Organism Selected"})]})}),a.jsx("div",{className:"flex-1",children:a.jsxs("div",{className:"flex items-center",children:[a.jsx("div",{className:`w-4 h-4 rounded-full mr-2 ${d?"bg-green-500":"bg-gray-300"}`}),a.jsx("span",{className:`font-medium ${d?"text-green-700":"text-gray-500"}`,children:"Infection Site Selected"})]})})]})}),a.jsxs("div",{className:"grid grid-cols-1 lg:grid-cols-2 gap-8",children:[a.jsxs("div",{className:"space-y-4",children:[a.jsx("h2",{className:"text-2xl font-semibold text-gray-900 mb-4",children:"🦠 Step 1: Identify the Organism"}),a.jsxs("div",{className:"relative",children:[a.jsx("input",{type:"text",placeholder:"Type to search organisms (e.g. 'E. coli', 'Klebsiella', 'gram positive')...",value:_,onChange:Q=>h(Q.target.value),className:"w-full px-4 py-3 border border-gray-300 rounded-lg focus:ring-2 focus:ring-blue-500 focus:border-transparent"}),a.jsx("div",{className:"absolute right-3 top-3",children:a.jsx("svg",{className:"w-5 h-5 text-gray-400",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M21 21l-6-6m2-5a7 7 0 11-14 0 7 7 0 0114 0z"})})})]}),l&&a.jsx("div",{className:"bg-green-50 border border-green-200 rounded-lg p-4",children:a.jsxs("div",{className:"flex items-center justify-between",children:[a.jsxs("div",{children:[a.jsx("h3",{className:"font-semibold text-green-800",children:l.name||"Unknown"}),a.jsxs("p",{className:"text-sm text-green-600",children:[l.gramStain||"Unknown"," • ",l.clsiCategory||"Unknown"]})]}),a.jsx("button",{onClick:()=>c(null),className:"text-green-600 hover:text-green-800",children:a.jsx("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M6 18L18 6M6 6l12 12"})})})]})}),a.jsxs("div",{className:"max-h-96 overflow-y-auto border border-gray-200 rounded-lg",children:[!_.trim()&&a.jsxs("div",{className:"p-8 text-center text-gray-500",children:[a.jsx("div",{className:"text-4xl mb-3",children:"🔬"}),a.jsx("p",{className:"text-lg font-medium text-gray-700 mb-2",children:"Search for an organism"}),a.jsx("p",{className:"text-sm",children:'Start typing to find bacteria, genus, or use terms like "gram positive", "enterobacterales"'}),a.jsx("div",{className:"mt-4 text-xs text-gray-400",children:a.jsx("p",{children:'Examples: "E. coli", "Staph", "gram negative", "Klebsiella"'})})]}),_.trim()&&w.length===0&&a.jsxs("div",{className:"p-8 text-center text-gray-500",children:[a.jsx("div",{className:"text-4xl mb-3",children:"🚫"}),a.jsx("p",{className:"text-lg font-medium text-gray-700 mb-2",children:"No organisms found"}),a.jsx("p",{className:"text-sm",children:"Try different search terms or check spelling"})]}),w.map(Q=>{var k;return a.jsx("button",{onClick:()=>O(Q),className:"w-full p-3 text-left hover:bg-gray-50 border-b border-gray-100 last:border-b-0 focus:bg-blue-50 focus:outline-none",children:a.jsxs("div",{className:"flex items-center justify-between",children:[a.jsxs("div",{children:[a.jsx("h4",{className:"font-medium text-gray-900",children:Q.name||"Unknown"}),a.jsxs("p",{className:"text-sm text-gray-500",children:[Q.gramStain||"Unknown"," • ",((k=Q.taxonomy)==null?void 0:k.genus)||Q.genus||"Unknown"]})]}),a.jsx("div",{className:"flex items-center space-x-2",children:a.jsx("span",{className:`px-2 py-1 rounded text-xs ${(Q.gramStain||"").includes("positive")?"bg-blue-100 text-blue-700":"bg-red-100 text-red-700"}`,children:Q.gramStain||"Unknown"})})]})},Q.id)})]})]}),a.jsxs("div",{className:"space-y-4",children:[a.jsx("h2",{className:"text-2xl font-semibold text-gray-900 mb-4",children:"🎯 Step 2: Select Infection Site"}),d&&a.jsx("div",{className:`border rounded-lg p-4 mb-4 ${((T=X())==null?void 0:T.categoryColor)||"bg-gray-50"}`,children:a.jsxs("div",{className:"flex items-center justify-between",children:[a.jsxs("div",{children:[a.jsx("h3",{className:"font-semibold text-gray-800",children:(q=X())==null?void 0:q.label}),a.jsx("p",{className:"text-sm text-gray-600",children:(C=X())==null?void 0:C.category}),a.jsx("div",{className:"flex items-center space-x-2 mt-2",children:a.jsxs("span",{className:`text-xs px-2 py-1 rounded ${((E=X())==null?void 0:E.severity)===3?"bg-red-100 text-red-700":((z=X())==null?void 0:z.severity)===2?"bg-yellow-100 text-yellow-700":"bg-green-100 text-green-700"}`,children:["Severidad: ",((H=X())==null?void 0:H.severity)===3?"Alta":((Y=X())==null?void 0:Y.severity)===2?"Moderada":"Leve"]})}),((ee=X())==null?void 0:ee.stewardshipNotes)&&a.jsxs("div",{className:"mt-2 p-2 bg-blue-50 border border-blue-200 rounded text-xs",children:[a.jsx("strong",{children:"Stewardship:"})," ",(le=X())==null?void 0:le.stewardshipNotes]})]}),a.jsx("button",{onClick:()=>m(null),className:"text-gray-600 hover:text-gray-800",children:a.jsx("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M6 18L18 6M6 6l12 12"})})})]})}),a.jsx("div",{className:"space-y-3",children:Object.entries(Xu).map(([Q,k])=>{const G=D===Q,ae=d&&k.options.some(N=>N.value===d);return a.jsxs("div",{className:`border rounded-lg ${k.color}`,children:[a.jsx("button",{onClick:()=>L(G?null:Q),className:"w-full p-4 text-left focus:outline-none focus:ring-2 focus:ring-blue-500 rounded-lg",children:a.jsxs("div",{className:"flex items-center justify-between",children:[a.jsxs("div",{className:"flex items-center",children:[a.jsx("span",{className:"text-2xl mr-3",children:k.icon}),a.jsxs("div",{children:[a.jsx("h4",{className:"font-semibold text-gray-800",children:k.label}),a.jsx("p",{className:"text-xs text-gray-600 mt-1",children:k.clinicalNote})]}),ae&&a.jsx("span",{className:"text-xs px-2 py-1 bg-indigo-100 text-indigo-700 rounded-full ml-2",children:"Seleccionado"})]}),a.jsxs("div",{className:"flex items-center space-x-2",children:[a.jsx("div",{className:"text-right text-xs text-gray-500",children:a.jsxs("div",{className:"flex items-center space-x-1",children:[k.bactericidalRequired&&a.jsx("span",{className:"bg-red-100 text-red-700 px-2 py-1 rounded",children:"Bactericida"}),k.dosing==="high_dose"&&a.jsx("span",{className:"bg-orange-100 text-orange-700 px-2 py-1 rounded",children:"Dosis alta"}),k.penetrationRequirement==="CNS_critical"&&a.jsx("span",{className:"bg-purple-100 text-purple-700 px-2 py-1 rounded",children:"BHE crítica"})]})}),a.jsx("svg",{className:`w-5 h-5 text-gray-500 transition-transform duration-200 ${G?"rotate-180":""}`,fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19 9l-7 7-7-7"})})]})]})}),G&&a.jsx("div",{className:"px-4 pb-4",children:a.jsx("div",{className:"grid grid-cols-1 gap-2",children:k.options.map(N=>a.jsxs("label",{className:"flex items-center space-x-3 cursor-pointer p-2 rounded hover:bg-white hover:bg-opacity-60",children:[a.jsx("input",{type:"radio",name:"infectionSite",value:N.value,checked:d===N.value,onChange:p=>U(p.target.value),className:"h-4 w-4 text-indigo-600 focus:ring-indigo-500"}),a.jsxs("div",{className:"flex-1",children:[a.jsx("span",{className:"text-sm font-medium text-gray-800",children:N.label}),a.jsx("div",{className:"flex items-center space-x-2 mt-1",children:a.jsxs("span",{className:`text-xs px-2 py-1 rounded ${N.severity===3?"bg-red-100 text-red-700":N.severity===2?"bg-yellow-100 text-yellow-700":"bg-green-100 text-green-700"}`,children:["Severidad: ",N.severity===3?"Alta":N.severity===2?"Moderada":"Leve"]})}),N.stewardshipNotes&&a.jsxs("p",{className:"text-xs text-blue-600 mt-1 italic",children:["💡 ",N.stewardshipNotes]})]})]},N.value))})})]},Q)})})]})]}),l&&v.length>0&&a.jsxs("div",{className:"bg-amber-50 border border-amber-200 rounded-lg p-6",children:[a.jsx("h3",{className:"text-lg font-semibold text-amber-800 mb-3",children:"🛡️ Intrinsic Resistance Alert"}),a.jsxs("p",{className:"text-amber-700 mb-4",children:[a.jsx("strong",{children:l.name})," is naturally resistant to these antibiotics. They will be excluded from testing to prevent clinical errors."]}),a.jsx("div",{className:"flex flex-wrap gap-2",children:v.map((Q,k)=>a.jsx("span",{className:"px-3 py-1 bg-amber-100 text-amber-800 rounded-full text-sm font-medium",children:Q},k))}),a.jsx("div",{className:"mt-3 p-3 bg-amber-100 rounded border-l-4 border-amber-400",children:a.jsxs("p",{className:"text-xs text-amber-700",children:["💡 ",a.jsx("strong",{children:"Educational Note:"})," Intrinsic resistance is nature's way of protecting bacteria. These antibiotics simply cannot work against this organism due to its natural biology."]})})]}),a.jsxs("div",{className:"flex items-center justify-between pt-6 border-t border-gray-200",children:[a.jsx("div",{className:"text-sm text-gray-500",children:l&&d?a.jsx("span",{className:"text-green-600 font-medium",children:"✅ Ready to proceed to MIC interpretation"}):a.jsx("span",{children:"Please select both organism and infection site to continue"})}),a.jsx("button",{onClick:Z,disabled:!l||!d||W,className:`px-6 py-3 rounded-lg font-medium transition-colors ${l&&d&&!W?"bg-blue-600 text-white hover:bg-blue-700 focus:ring-2 focus:ring-blue-500":"bg-gray-300 text-gray-500 cursor-not-allowed"}`,children:W?"Loading...":"Continue to MIC Input →"})]})]})},$u={enterobacterales:["ampicillin","amoxicillin-clavulanate","piperacillin-tazobactam","cefazolin","ceftriaxone","ceftazidime","cefepime","ertapenem","meropenem","aztreonam","ciprofloxacin","levofloxacin","gentamicin","amikacin","trimethoprim-sulfamethoxazole","nitrofurantoin"],staphylococcus:["penicillin","oxacillin","cefazolin","clindamycin","erythromycin","vancomycin","linezolid","daptomycin","ciprofloxacin","levofloxacin","gentamicin","trimethoprim-sulfamethoxazole","tetracycline","rifampin"],enterococcus:["ampicillin","vancomycin","linezolid","daptomycin","ciprofloxacin","levofloxacin","tetracycline","nitrofurantoin","chloramphenicol"],pseudomonas:["piperacillin","piperacillin-tazobactam","ceftazidime","cefepime","aztreonam","imipenem","meropenem","doripenem","ciprofloxacin","levofloxacin","gentamicin","tobramycin","amikacin","colistin"]},hb=["≤0.25","0.5","1","2","4","8","16","32","64","≥128","≤0.5","≤1","≤2","≤4","≤8","≤16","≤32","≤64","≥0.5","≥1","≥2","≥4","≥8","≥16","≥32","≥64"],bb=({organismData:g,infectionSite:s,onComplete:l,initialData:c={}})=>{const[d,m]=oe.useState(c.micData||{}),[_,h]=oe.useState({}),[v,y]=oe.useState([]),[D,L]=oe.useState(!1),[W,se]=oe.useState({}),ie=oe.useMemo(()=>new $l,[]),$=oe.useMemo(()=>{const q=ie.mapOrganismToCLSICategory(g.id);return($u[q]||$u.enterobacterales).filter(E=>{var z;return!((z=g.intrinsicResistance)!=null&&z.includes(E))})},[g,ie]),ne=async(q,C)=>{if(!C.trim()){const E={...d};delete E[q],m(E);const z={..._};delete z[q],h(z);return}L(!0);try{const E={...d,[q]:C};m(E);const z=await ie.interpretMIC(g.id,q,C,s),H={..._,[q]:z};h(H);const Y=O(g,q,z,s);y(Y?ee=>[...ee.filter(Q=>Q.antibiotic!==q),{...Y,antibiotic:q}]:ee=>ee.filter(le=>le.antibiotic!==q))}catch(E){console.error("MIC interpretation error:",E),y(z=>[...z,{antibiotic:q,level:"error",message:`Error interpreting ${q}: ${E.message}`}])}finally{L(!1)}},w=async(q,C)=>{var E,z,H;try{const Y=await ie.getBreakpoints(g.id,q,s);let ee;C==="S"&&((E=Y==null?void 0:Y.mic_breakpoints)!=null&&E.S)?ee=Y.mic_breakpoints.S.replace("≤",""):C==="I"&&((z=Y==null?void 0:Y.mic_breakpoints)!=null&&z.I)?ee=Y.mic_breakpoints.I:C==="R"&&((H=Y==null?void 0:Y.mic_breakpoints)!=null&&H.R)?ee=Y.mic_breakpoints.R.replace("≥",""):ee=C;const le={...d,[q]:ee};m(le);const Q={interpretation:C,confidence:"manual",micValue:ee,breakpoints:Y,note:`Manual ${C} selection with breakpoint value`},k={..._,[q]:Q};h(k)}catch(Y){console.error("SIR button error:",Y);const ee={...d,[q]:C};m(ee);const le={..._,[q]:{interpretation:C,confidence:"manual",micValue:C}};h(le)}},O=(q,C,E,z)=>{const H=[],Y={daptomycin:{RESP_pneumonia:"Clinically ineffective due to pulmonary surfactant inactivation",RESP_VAP:"Clinically ineffective due to pulmonary surfactant inactivation"},"piperacillin-tazobactam":{BS_bacteremia:"Risk of treatment failure in E. coli bacteremia despite susceptibility"},nitrofurantoin:{GU_pyelonephritis:"Poor tissue penetration - not recommended for pyelonephritis"}};return Y[C]&&Y[C][z]&&E.interpretation==="S"&&H.push({level:"high",type:"clinical_override",message:`${C}: ${Y[C][z]}`,recommendation:"Consider alternative agent despite susceptible result"}),E.interpretation==="S"&&C==="ceftriaxone"&&_.cefazolin&&_.cefazolin.interpretation==="R"&&H.push({level:"medium",type:"paradoxical",message:"Unusual pattern: Cefazolin resistant but Ceftriaxone susceptible",recommendation:"Consider repeat testing or ESBL detection"}),H.length>0?H[0]:null},U=oe.useMemo(()=>{const q=Object.keys(_).length,C=Object.values(_).filter(H=>H.interpretation==="S").length,E=Object.values(_).filter(H=>H.interpretation==="I").length,z=Object.values(_).filter(H=>H.interpretation==="R").length;return{total:q,susceptible:C,intermediate:E,resistant:z}},[_]),Z=()=>{const q={...d},C={..._};for(const E of $)C[E]||(q[E]="S",C[E]={interpretation:"S",confidence:"assumed",micValue:"S",note:"Assumed sensitive (not tested)"});l({micData:q,interpretations:C,warnings:v,interpretationSummary:U})},X=q=>{switch(q){case"S":return"text-green-700 bg-green-100";case"I":return"text-yellow-700 bg-yellow-100";case"R":return"text-red-700 bg-red-100";default:return"text-gray-700 bg-gray-100"}},T=q=>q.replace(/<=|>=/g,C=>C==="<="?"≤":"≥");return a.jsxs("div",{className:"max-w-7xl mx-auto p-6 space-y-8",children:[a.jsxs("div",{className:"text-center mb-8",children:[a.jsxs("div",{className:"flex items-center justify-center mb-4",children:[a.jsx("div",{className:"bg-orange-600 text-white rounded-full w-10 h-10 flex items-center justify-center font-bold text-lg mr-4",children:"2"}),a.jsx("h1",{className:"text-3xl font-bold text-gray-900",children:"Initial Interpretation & Red Flags"})]}),a.jsx("p",{className:"text-lg text-gray-600 max-w-4xl mx-auto",children:"Enter MIC values and watch the real-time CLSI interpretation. We'll flag any paradoxical results that suggest lab errors or hidden resistance mechanisms."})]}),a.jsx("div",{className:"bg-blue-50 border border-blue-200 rounded-lg p-4 mb-6",children:a.jsxs("div",{className:"flex items-center justify-between",children:[a.jsxs("div",{children:[a.jsx("h3",{className:"font-semibold text-blue-800",children:g.name}),a.jsxs("p",{className:"text-sm text-blue-600",children:[g.gramStain," • ",s," • CLSI Category: ",ie.mapOrganismToCLSICategory(g.id)]})]}),a.jsxs("div",{className:"text-right",children:[a.jsxs("p",{className:"text-sm text-blue-600",children:[U.total," antibiotics tested"]}),a.jsxs("div",{className:"flex space-x-2 text-xs",children:[a.jsxs("span",{className:"text-green-600",children:["S: ",U.susceptible]}),a.jsxs("span",{className:"text-yellow-600",children:["I: ",U.intermediate]}),a.jsxs("span",{className:"text-red-600",children:["R: ",U.resistant]})]})]})]})}),v.length>0&&a.jsxs("div",{className:"bg-red-50 border border-red-200 rounded-lg p-4 mb-6",children:[a.jsx("h3",{className:"font-semibold text-red-800 mb-3",children:"🚨 Clinical Alerts"}),a.jsx("div",{className:"space-y-2",children:v.map((q,C)=>{var E;return a.jsxs("div",{className:"flex items-start space-x-3",children:[a.jsx("div",{className:`px-2 py-1 rounded text-xs font-medium ${q.level==="high"?"bg-red-100 text-red-700":q.level==="medium"?"bg-yellow-100 text-yellow-700":"bg-gray-100 text-gray-700"}`,children:(E=q.level)==null?void 0:E.toUpperCase()}),a.jsxs("div",{className:"flex-1",children:[a.jsx("p",{className:"text-sm text-red-700 font-medium",children:q.message}),q.recommendation&&a.jsxs("p",{className:"text-xs text-red-600 mt-1",children:["💡 ",q.recommendation]})]})]},C)})})]}),a.jsxs("div",{className:"bg-white border border-gray-200 rounded-lg overflow-hidden",children:[a.jsx("div",{className:"bg-gray-50 px-6 py-3 border-b border-gray-200",children:a.jsx("div",{className:"flex items-center justify-between",children:a.jsxs("div",{children:[a.jsx("h3",{className:"text-lg font-semibold text-gray-900",children:"Antibiotic Susceptibility Testing Panel"}),a.jsx("p",{className:"text-sm text-gray-600",children:"Enter MIC values (μg/mL) for PK/PD calculations, or click S/I/R buttons for quick entry with breakpoint values."})]})})}),a.jsx("div",{className:"overflow-x-auto",children:a.jsxs("table",{className:"w-full",children:[a.jsx("thead",{className:"bg-gray-50",children:a.jsxs("tr",{children:[a.jsx("th",{className:"px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase tracking-wider",children:"Antibiotic"}),a.jsx("th",{className:"px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase tracking-wider",children:"MIC (μg/mL)"}),a.jsx("th",{className:"px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase tracking-wider",children:"Interpretation"}),a.jsx("th",{className:"px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase tracking-wider",children:"Breakpoints"}),a.jsx("th",{className:"px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase tracking-wider",children:"Notes"})]})}),a.jsx("tbody",{className:"bg-white divide-y divide-gray-200",children:$.map(q=>{const C=_[q],E=d[q]||"";return a.jsxs("tr",{className:"hover:bg-gray-50",children:[a.jsx("td",{className:"px-6 py-4 whitespace-nowrap",children:a.jsx("div",{className:"text-sm font-medium text-gray-900 capitalize",children:q.replace(/-/g,"-")})}),a.jsxs("td",{className:"px-6 py-4 whitespace-nowrap",children:[a.jsxs("div",{className:"flex space-x-1",children:[a.jsx("input",{type:"text",value:E,onChange:z=>ne(q,z.target.value),placeholder:"MIC or S/I/R",list:`mic-suggestions-${q}`,className:`w-20 px-2 py-1 border border-gray-300 rounded text-sm focus:ring-2 focus:ring-blue-500 focus:border-transparent ${(C==null?void 0:C.confidence)==="manual"?"text-gray-500 bg-gray-50":""}`,title:(C==null?void 0:C.confidence)==="manual"?"Breakpoint value from S/I/R selection. Edit for precise PK/PD calculations.":"Enter MIC value or use S/I/R buttons"}),a.jsxs("div",{className:"flex",children:[a.jsx("button",{onClick:()=>w(q,"S"),className:"px-1 py-1 text-xs bg-green-100 text-green-700 rounded-l border border-green-300 hover:bg-green-200",title:"Click to set as Sensitive with breakpoint value",children:"S"}),a.jsx("button",{onClick:()=>w(q,"I"),className:"px-1 py-1 text-xs bg-yellow-100 text-yellow-700 border-t border-b border-yellow-300 hover:bg-yellow-200",title:"Click to set as Intermediate with breakpoint value",children:"I"}),a.jsx("button",{onClick:()=>w(q,"R"),className:"px-1 py-1 text-xs bg-red-100 text-red-700 rounded-r border border-red-300 hover:bg-red-200",title:"Click to set as Resistant with breakpoint value",children:"R"})]})]}),a.jsx("datalist",{id:`mic-suggestions-${q}`,children:hb.map((z,H)=>a.jsx("option",{value:z},H))})]}),a.jsx("td",{className:"px-6 py-4 whitespace-nowrap",children:C?a.jsxs("div",{className:"flex items-center space-x-2",children:[a.jsx("span",{className:`px-2 py-1 rounded text-sm font-medium ${X(C.interpretation)}`,children:C.interpretation}),a.jsxs("span",{className:"text-xs text-gray-500",children:["(",C.confidence,")"]})]}):a.jsx("span",{className:"text-gray-400 text-sm",children:"-"})}),a.jsx("td",{className:"px-6 py-4 whitespace-nowrap",children:C!=null&&C.breakpoints?a.jsxs("button",{onClick:()=>se(z=>({...z,[q]:!z[q]})),className:"text-xs text-blue-600 hover:text-blue-800 underline",children:[W[q]?"Hide":"Show"," breakpoints"]}):a.jsx("span",{className:"text-gray-400 text-xs",children:"Not available"})}),a.jsxs("td",{className:"px-6 py-4",children:[(C==null?void 0:C.note)&&a.jsx("div",{className:"text-xs text-gray-600 max-w-xs",children:C.note}),(C==null?void 0:C.siteModified)&&a.jsx("div",{className:"text-xs text-blue-600 mt-1",children:"⚡ Site-specific breakpoints applied"})]})]},q)})})]})})]}),Object.entries(W).map(([q,C])=>{var z;if(!C||!((z=_[q])!=null&&z.breakpoints))return null;const E=_[q].breakpoints;return a.jsxs("div",{className:"bg-blue-50 border border-blue-200 rounded-lg p-4",children:[a.jsxs("h4",{className:"font-semibold text-blue-800 mb-2",children:[q," - CLSI Breakpoints"]}),E.mic_breakpoints&&a.jsxs("div",{className:"grid grid-cols-3 gap-4 text-sm",children:[a.jsxs("div",{children:[a.jsx("span",{className:"font-medium text-green-700",children:"Susceptible (S):"}),a.jsx("span",{className:"ml-2",children:T(E.mic_breakpoints.S)})]}),E.mic_breakpoints.I&&a.jsxs("div",{children:[a.jsx("span",{className:"font-medium text-yellow-700",children:"Intermediate (I):"}),a.jsx("span",{className:"ml-2",children:T(E.mic_breakpoints.I)})]}),a.jsxs("div",{children:[a.jsx("span",{className:"font-medium text-red-700",children:"Resistant (R):"}),a.jsx("span",{className:"ml-2",children:T(E.mic_breakpoints.R)})]})]}),E.special_considerations&&a.jsxs("div",{className:"mt-2 text-xs text-blue-700",children:[a.jsx("strong",{children:"Special Considerations:"})," ",E.special_considerations]})]},q)}),a.jsxs("div",{className:"bg-gray-50 border border-gray-200 rounded-lg p-6",children:[a.jsx("h3",{className:"text-lg font-semibold text-gray-900 mb-4",children:"Interpretation Summary"}),a.jsxs("div",{className:"grid grid-cols-2 md:grid-cols-4 gap-4",children:[a.jsxs("div",{className:"text-center",children:[a.jsx("div",{className:"text-2xl font-bold text-gray-900",children:U.total}),a.jsx("div",{className:"text-sm text-gray-600",children:"Total Tested"})]}),a.jsxs("div",{className:"text-center",children:[a.jsx("div",{className:"text-2xl font-bold text-green-600",children:U.susceptible}),a.jsx("div",{className:"text-sm text-gray-600",children:"Susceptible"})]}),a.jsxs("div",{className:"text-center",children:[a.jsx("div",{className:"text-2xl font-bold text-yellow-600",children:U.intermediate}),a.jsx("div",{className:"text-sm text-gray-600",children:"Intermediate"})]}),a.jsxs("div",{className:"text-center",children:[a.jsx("div",{className:"text-2xl font-bold text-red-600",children:U.resistant}),a.jsx("div",{className:"text-sm text-gray-600",children:"Resistant"})]})]})]}),a.jsxs("div",{className:"flex items-center justify-between pt-6 border-t border-gray-200",children:[a.jsx("div",{className:"text-sm text-gray-500",children:U.total>=5?a.jsx("span",{className:"text-green-600 font-medium",children:"✅ Ready to analyze resistance patterns"}):a.jsx("span",{children:"Enter at least 5 MIC values to proceed with pattern analysis"})}),a.jsx("button",{onClick:Z,disabled:U.total<5||D,className:`px-6 py-3 rounded-lg font-medium transition-colors ${U.total>=5&&!D?"bg-orange-600 text-white hover:bg-orange-700 focus:ring-2 focus:ring-orange-500":"bg-gray-300 text-gray-500 cursor-not-allowed"}`,children:D?"Processing...":"Analyze Resistance Patterns →"})]})]})};let Ju=null;const yb=async()=>{try{const g="./",s=g==="/"?"/antimicrobial_resistance.json":`${g}antimicrobial_resistance.json`,l=await fetch(s);if(!l.ok)throw new Error(`HTTP ${l.status}: ${l.statusText}`);return Ju=await l.json(),console.log("🧬 Antimicrobial resistance database loaded for sequential analysis"),Ju}catch(g){return console.warn("⚠️ Could not load antimicrobial resistance database:",g.message),null}},Oi={HIGH:"high",MODERATE:"moderate",LOW:"low",UNCERTAIN:"uncertain"};class vb{constructor(){this.resistanceDB=null,this.isInitialized=!1}async initialize(){if(!this.isInitialized)try{this.resistanceDB=await yb(),this.isInitialized=!0,console.log("🔬 Sequential Resistance Engine initialized with clinical methodology")}catch(s){throw console.error("❌ Failed to initialize Sequential Resistance Engine:",s),s}}async analyzePattern(s,l){this.isInitialized||await this.initialize(),console.log(`🔬 SEQUENTIAL ANALYSIS for ${s}`),console.log("📋 Following clinical methodology: Ampicillin → 1st Gen → 3rd Gen → Inhibitors → Carbapenems");const c={organism:s,totalAntibiotics:Object.keys(l).length,detectedPatterns:[],warnings:[],overallConfidence:Oi.UNCERTAIN,mechanismOverrides:{},sequentialSteps:[]};try{const d=this.analyzeAmpicillin(l);c.sequentialSteps.push(d),console.log(`STEP 1 - Ampicillin: ${d.interpretation} → ${d.conclusion}`);let m=null;d.interpretation==="R"&&(m=this.analyze1stGenCephalosporin(l),c.sequentialSteps.push(m),console.log(`STEP 2 - 1st Gen Ceph: ${m.interpretation} → ${m.conclusion}`));let _=null;(m==null?void 0:m.interpretation)==="R"&&(_=this.analyze3rdGenCephalosporin(l),c.sequentialSteps.push(_),console.log(`STEP 3 - 3rd Gen Ceph: ${_.interpretation} → ${_.conclusion}`));let h=null;(_==null?void 0:_.interpretation)==="R"&&(h=this.analyzeInhibitors(l),c.sequentialSteps.push(h),console.log(`STEP 4 - Inhibitors: ${h.interpretation} → ${h.conclusion}`));const v=this.analyzeCarbapenems(l);return c.sequentialSteps.push(v),console.log(`STEP 5 - Carbapenems: ${v.interpretation} → ${v.conclusion}`),c.detectedPatterns=this.generateSequentialConclusions(c.sequentialSteps),c.overallConfidence=c.detectedPatterns.length>0?Oi.MODERATE:Oi.UNCERTAIN,console.log(`✅ Sequential analysis complete: ${c.detectedPatterns.length} mechanisms identified`),c}catch(d){return console.error("❌ Sequential analysis failed:",d),c.warnings.push({level:"error",message:`Sequential analysis failed: ${d.message}`}),c}}analyzeAmpicillin(s){const l=s.ampicillin;return l?{step:1,antibiotic:"ampicillin",interpretation:l.interpretation,micValue:l.micValue,conclusion:l.interpretation==="R"?"Penicillinase suspected → Check 1st gen cephalosporin":"No penicillinase → Wild type or other mechanisms",mechanism:null}:{step:1,antibiotic:"ampicillin",interpretation:"Not tested",conclusion:"Cannot perform sequential analysis without ampicillin",mechanism:null}}analyze1stGenCephalosporin(s){const l=["cefazolin","cephalexin","cefadroxil"];let c=null,d=null;for(const m of l)if(s[m]){c=s[m],d=m;break}return c?{step:2,antibiotic:d,interpretation:c.interpretation,micValue:c.micValue,conclusion:c.interpretation==="R"?"Extended β-lactamase suspected → Check 3rd gen cephalosporins to differentiate ESBL vs AmpC":"Simple penicillinase only → Manageable with 1st gen cephalosporins",mechanism:null}:{step:2,antibiotic:"1st gen cephalosporin",interpretation:"Not tested",conclusion:"Cannot differentiate resistance mechanisms without 1st gen data",mechanism:null}}analyze3rdGenCephalosporin(s){var _;const l=["ceftriaxone","ceftazidime","cefotaxime"],c=[];for(const h of l)((_=s[h])==null?void 0:_.interpretation)==="R"&&c.push(h);const d=c.length>0,m=l.filter(h=>s[h]).length;return{step:3,antibiotic:"3rd gen cephalosporins",interpretation:d?"R":"S",resistantDrugs:c,testedDrugs:m,conclusion:d?"ESBL or AmpC production → Use inhibitors to differentiate":"Sensitive to 3rd gen → Simple penicillinase only",mechanism:null}}analyzeInhibitors(s){const l=["amoxicillin-clavulanate","piperacillin-tazobactam","ampicillin-sulbactam"],c=[],d=[];for(const h of l)s[h]&&(s[h].interpretation==="S"?c.push(h):d.push(h));let m,_;return c.length>0?(m="ESBL confirmed → Clavulanic acid synergy present (Class A β-lactamase)",_="esbl"):d.length>0?(m="AmpC β-lactamase confirmed → Clavulanic acid ineffective (Class C β-lactamase)",_="ampc"):(m="Cannot differentiate ESBL vs AmpC without inhibitor combination data",_=null),{step:4,antibiotic:"inhibitor combinations",interpretation:c.length>0?"S":"R",sensitiveInhibitors:c,resistantInhibitors:d,conclusion:m,mechanism:_}}analyzeCarbapenems(s){const l=["meropenem","imipenem","ertapenem"],c=[],d=[];for(const v of l)s[v]&&(s[v].interpretation==="R"?c.push(v):d.push(v));const m=c.length>0;let _,h;return m?(_="Carbapenemase suspected → High-level resistance",h="carbapenemase"):d.length>0?(_="Carbapenem sensitive → ESBL/AmpC manageable",h=null):(_="Carbapenems not tested",h=null),{step:5,antibiotic:"carbapenems",interpretation:m?"R":"S",resistantCarbapenems:c,sensitiveCarbapenems:d,conclusion:_,mechanism:h}}generateSequentialConclusions(s){const l=[],c=s.find(_=>_.step===1),d=s.find(_=>_.step===2),m=s.find(_=>_.step===3);(c==null?void 0:c.interpretation)==="R"&&((d==null?void 0:d.interpretation)==="S"||(m==null?void 0:m.interpretation)==="S")&&l.push({type:"penicillinase",confidence:Oi.HIGH,evidence:[`Step 1: ${c.conclusion}`,(d==null?void 0:d.interpretation)==="S"?"Step 2: 1st gen cephalosporin sensitive":"Step 3: 3rd gen cephalosporin sensitive","Pattern consistent with simple penicillinase (TEM-1, SHV-1)"],clinicalImplications:["Use β-lactamase inhibitor combinations (amoxicillin-clavulanate, piperacillin-tazobactam)","Cephalosporins remain effective","Carbapenems effective but unnecessary"]});for(const _ of s)if(_.mechanism)switch(_.mechanism){case"esbl":l.push({type:"esbl",confidence:Oi.HIGH,evidence:[`Step ${_.step}: ${_.conclusion}`],clinicalImplications:["Avoid cephalosporins and aztreonam","Carbapenems preferred for serious infections","Beta-lactamase inhibitor combinations may be effective"]});break;case"ampc":l.push({type:"ampc",confidence:Oi.HIGH,evidence:[`Step ${_.step}: ${_.conclusion}`],clinicalImplications:["Avoid beta-lactamase inhibitor combinations (clavulanic acid ineffective)","Cefepime may be effective (4th generation)","Carbapenems preferred for serious infections","Consider boronic acid inhibitors (avibactam) if available"]});break;case"carbapenemase":l.push({type:"carbapenemase",confidence:Oi.HIGH,evidence:[`Step ${_.step}: ${_.conclusion}`],clinicalImplications:["Extremely limited treatment options","Consider ceftazidime-avibactam, cefiderocol, or polymyxins","Infectious disease consultation required","Combination therapy may be necessary"]});break}return l}}const kb={esbl:"🧬",ampc:"⚡",carbapenemase:"💀",mrsa:"🛡️",vre:"⚠️",mlsb:"🔄",fluoroquinolone:"🎯",aminoglycoside:"🔬"},Hl={high:"bg-red-100 text-red-800 border-red-200",moderate:"bg-yellow-100 text-yellow-800 border-yellow-200",low:"bg-blue-100 text-blue-800 border-blue-200",uncertain:"bg-gray-100 text-gray-800 border-gray-200"},xb=({organismData:g,micData:s,interpretations:l,onComplete:c,initialData:d={}})=>{var q,C,E;console.log("🔄 Phase3_ResistanceMechanisms mounted with props:",{organismData:g,micData:s,interpretations:l,initialData:d});const[m,_]=oe.useState(null),[h,v]=oe.useState(!1),[y,D]=oe.useState(null),[L,W]=oe.useState({}),[se,ie]=oe.useState({}),$=oe.useMemo(()=>{const z=new vb;return z.initialize().catch(H=>{console.error("Failed to initialize sequential resistance engine:",H)}),z},[]);oe.useEffect(()=>{g&&l&&Object.keys(l).length>0&&O()},[g,l]);const ne=async()=>{console.log("🧪 Testing resistance detection with mock ESBL pattern");const z={ceftriaxone:{interpretation:"R",micValue:"32"},ceftazidime:{interpretation:"R",micValue:"16"},cefepime:{interpretation:"S",micValue:"2"},meropenem:{interpretation:"S",micValue:"0.5"},"piperacillin-tazobactam":{interpretation:"S",micValue:"8"},ciprofloxacin:{interpretation:"S",micValue:"0.5"}},H=await $.analyzePattern("ecolienteroaggregative",z);console.log("🧪 Test result:",H),_(H)},w=async()=>{console.log("🧪 Simulating resistance pattern for current organism");const z={ampicillin:{interpretation:"R",micValue:"≥32"},cefazolin:{interpretation:"R",micValue:"≥64"},ceftriaxone:{interpretation:"R",micValue:"16"},ceftazidime:{interpretation:"R",micValue:"8"},cefepime:{interpretation:"S",micValue:"2"},ertapenem:{interpretation:"S",micValue:"≤0.5"},meropenem:{interpretation:"S",micValue:"≤0.25"},"piperacillin-tazobactam":{interpretation:"S",micValue:"8"},"amoxicillin-clavulanate":{interpretation:"S",micValue:"4"},gentamicin:{interpretation:"S",micValue:"≤1"},ciprofloxacin:{interpretation:"S",micValue:"≤0.25"},"trimethoprim-sulfamethoxazole":{interpretation:"S",micValue:"≤20"}},H=await $.analyzePattern((g==null?void 0:g.id)||"escherichia_coli",z);console.log("🧪 Simulated resistance analysis:",H),_(H)},O=async()=>{v(!0);try{console.log("🔍 Phase 3: Starting resistance pattern analysis"),console.log("🦠 Organism data:",g),console.log("🧪 Interpretations received:",l),console.log("🧪 MIC data received:",s);const z={};for(const[ee,le]of Object.entries(l))z[ee]={interpretation:le.interpretation,micValue:s[ee]};console.log("🔬 Susceptibility pattern for analysis:",z);const H=await $.analyzePattern(g.id,z);console.log("📊 Resistance analysis result:",H),console.log("🔍 Detected patterns:",H.detectedPatterns),console.log("⚠️ Warnings:",H.warnings),_(H);const Y={};for(const[ee,le]of Object.entries(H.mechanismOverrides||{}))le.confidence===Oi.HIGH&&(Y[ee]=!0);W(Y)}catch(z){console.error("Resistance pattern analysis failed:",z),_({organism:g.id,detectedPatterns:[],warnings:[{level:"error",message:`Analysis failed: ${z.message}`}],overallConfidence:Oi.UNCERTAIN})}finally{v(!1)}},U=(z,H)=>{W(Y=>({...Y,[z]:H}))},Z=()=>{const z={...l};for(const[H,Y]of Object.entries((m==null?void 0:m.mechanismOverrides)||{}))L[H]&&(z[H]={...z[H],interpretation:Y.newInterpretation,originalInterpretation:Y.oldInterpretation,overrideReason:Y.reason,overrideMechanism:Y.mechanism});c({resistanceAnalysis:m,acceptedOverrides:L,updatedInterpretations:z,detectedMechanisms:(m==null?void 0:m.detectedPatterns)||[]})},X=z=>{switch(z){case Oi.HIGH:return"🔴";case Oi.MODERATE:return"🟡";case Oi.LOW:return"🔵";default:return"⚪"}},T=z=>z.map((H,Y)=>a.jsxs("li",{className:"text-sm text-gray-700 mb-1",children:["• ",H]},Y));return h?a.jsx("div",{className:"max-w-7xl mx-auto p-6",children:a.jsxs("div",{className:"text-center py-12",children:[a.jsxs("div",{className:"inline-flex items-center space-x-3 mb-4",children:[a.jsxs("svg",{className:"animate-spin h-8 w-8 text-purple-600",fill:"none",viewBox:"0 0 24 24",children:[a.jsx("circle",{className:"opacity-25",cx:"12",cy:"12",r:"10",stroke:"currentColor",strokeWidth:"4"}),a.jsx("path",{className:"opacity-75",fill:"currentColor",d:"M4 12a8 8 0 018-8V0C5.373 0 0 5.373 0 12h4zm2 5.291A7.962 7.962 0 014 12H0c0 3.042 1.135 5.824 3 7.938l3-2.647z"})]}),a.jsx("span",{className:"text-xl font-semibold text-gray-900",children:"Analyzing Resistance Patterns..."})]}),a.jsx("p",{className:"text-gray-600",children:"Running specialist-level algorithms to detect ESBL, AmpC, MRSA, VRE, and other resistance mechanisms"})]})}):a.jsxs("div",{className:"max-w-7xl mx-auto p-6 space-y-8",children:[a.jsxs("div",{className:"text-center mb-8",children:[a.jsxs("div",{className:"flex items-center justify-center mb-4",children:[a.jsx("div",{className:"bg-purple-600 text-white rounded-full w-10 h-10 flex items-center justify-center font-bold text-lg mr-4",children:"3"}),a.jsx("h1",{className:"text-3xl font-bold text-gray-900",children:"Resistance Mechanisms - The Detective Work"})]}),a.jsx("p",{className:"text-lg text-gray-600 max-w-4xl mx-auto",children:`Now we play detective! Using the patterns from Phase 2, we'll identify hidden resistance mechanisms that could cause treatment failures even when antibiotics appear "susceptible."`}),a.jsxs("div",{className:"mt-4 space-x-2",children:[a.jsx("button",{onClick:ne,className:"px-4 py-2 bg-red-600 text-white rounded-lg hover:bg-red-700 transition-colors text-sm",children:"🧪 Test ESBL Detection"}),a.jsx("button",{onClick:w,className:"px-4 py-2 bg-orange-600 text-white rounded-lg hover:bg-orange-700 transition-colors text-sm",children:"🧪 Simulate ESBL Pattern"})]})]}),(m==null?void 0:m.sequentialSteps)&&m.sequentialSteps.length>0&&a.jsxs("div",{className:"bg-gradient-to-r from-blue-50 to-cyan-50 border border-blue-200 rounded-lg p-6 mb-6",children:[a.jsx("h2",{className:"text-xl font-semibold text-blue-800 mb-4",children:"🔬 Sequential Analysis Steps (Clinical Methodology)"}),a.jsx("div",{className:"space-y-3",children:m.sequentialSteps.map((z,H)=>a.jsxs("div",{className:"flex items-center space-x-4 p-3 bg-white rounded border",children:[a.jsx("div",{className:"flex-shrink-0 w-12 h-12 bg-blue-600 text-white rounded-full flex items-center justify-center font-bold",children:z.step}),a.jsxs("div",{className:"flex-1",children:[a.jsx("div",{className:"font-medium text-gray-900 capitalize",children:z.antibiotic}),a.jsx("div",{className:"text-sm text-gray-600",children:z.conclusion})]}),a.jsx("div",{className:`px-3 py-1 rounded text-sm font-medium ${z.interpretation==="R"?"bg-red-100 text-red-700":z.interpretation==="S"?"bg-green-100 text-green-700":"bg-gray-100 text-gray-700"}`,children:z.interpretation})]},H))})]}),a.jsxs("div",{className:"bg-gradient-to-r from-purple-50 to-indigo-50 border border-purple-200 rounded-lg p-6",children:[a.jsxs("div",{className:"flex items-center justify-between mb-4",children:[a.jsx("h2",{className:"text-xl font-semibold text-purple-800",children:"🔍 Pattern Analysis Results"}),a.jsxs("div",{className:"flex items-center space-x-2",children:[a.jsx("span",{className:"text-sm text-purple-600",children:"Overall Confidence:"}),a.jsxs("span",{className:`px-3 py-1 rounded-full text-sm font-medium border ${Hl[(m==null?void 0:m.overallConfidence)||"uncertain"]}`,children:[X(m==null?void 0:m.overallConfidence),((q=m==null?void 0:m.overallConfidence)==null?void 0:q.toUpperCase())||"UNCERTAIN"]})]})]}),a.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-3 gap-4",children:[a.jsxs("div",{className:"text-center",children:[a.jsx("div",{className:"text-2xl font-bold text-purple-700",children:((C=m==null?void 0:m.detectedPatterns)==null?void 0:C.length)||0}),a.jsx("div",{className:"text-sm text-purple-600",children:"Mechanisms Detected"})]}),a.jsxs("div",{className:"text-center",children:[a.jsx("div",{className:"text-2xl font-bold text-orange-700",children:Object.keys((m==null?void 0:m.mechanismOverrides)||{}).length}),a.jsx("div",{className:"text-sm text-orange-600",children:"Overrides Recommended"})]}),a.jsxs("div",{className:"text-center",children:[a.jsx("div",{className:"text-2xl font-bold text-red-700",children:((E=m==null?void 0:m.warnings)==null?void 0:E.length)||0}),a.jsx("div",{className:"text-sm text-red-600",children:"Clinical Alerts"})]})]})]}),(m==null?void 0:m.warnings)&&m.warnings.length>0&&a.jsxs("div",{className:"bg-red-50 border border-red-200 rounded-lg p-4",children:[a.jsx("h3",{className:"font-semibold text-red-800 mb-3",children:"⚠️ Clinical Warnings"}),a.jsx("div",{className:"space-y-2",children:m.warnings.map((z,H)=>{var Y;return a.jsxs("div",{className:"flex items-start space-x-2",children:[a.jsx("span",{className:`px-2 py-1 rounded text-xs font-medium ${z.level==="high"?"bg-red-100 text-red-700":z.level==="medium"?"bg-yellow-100 text-yellow-700":"bg-gray-100 text-gray-700"}`,children:(Y=z.level)==null?void 0:Y.toUpperCase()}),a.jsx("p",{className:"text-sm text-red-700",children:z.message})]},H)})})]}),(m==null?void 0:m.detectedPatterns)&&m.detectedPatterns.length>0&&a.jsxs("div",{className:"bg-white border border-gray-200 rounded-lg overflow-hidden",children:[a.jsxs("div",{className:"bg-gray-50 px-6 py-3 border-b border-gray-200",children:[a.jsx("h3",{className:"text-lg font-semibold text-gray-900",children:"🧬 Detected Resistance Mechanisms"}),a.jsx("p",{className:"text-sm text-gray-600",children:"Click on mechanisms to learn more about their clinical implications"})]}),a.jsx("div",{className:"p-6 space-y-4",children:m.detectedPatterns.map((z,H)=>a.jsxs("div",{className:"border border-gray-200 rounded-lg overflow-hidden",children:[a.jsx("button",{onClick:()=>D(y===H?null:H),className:"w-full p-4 text-left hover:bg-gray-50 focus:bg-gray-50 focus:outline-none",children:a.jsxs("div",{className:"flex items-center justify-between",children:[a.jsxs("div",{className:"flex items-center space-x-3",children:[a.jsx("span",{className:"text-2xl",children:kb[z.type]||"🔬"}),a.jsxs("div",{children:[a.jsxs("h4",{className:"font-semibold text-gray-900 capitalize",children:[z.type.replace("_"," ")," Production"]}),a.jsxs("p",{className:"text-sm text-gray-600",children:[z.evidence.length," evidence point",z.evidence.length!==1?"s":""," detected"]})]})]}),a.jsxs("div",{className:"flex items-center space-x-2",children:[a.jsxs("span",{className:`px-3 py-1 rounded-full text-sm font-medium border ${Hl[z.confidence]}`,children:[X(z.confidence)," ",z.confidence.toUpperCase()]}),a.jsx("svg",{className:`w-5 h-5 text-gray-400 transition-transform ${y===H?"rotate-180":""}`,fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19 9l-7 7-7-7"})})]})]})}),y===H&&a.jsxs("div",{className:"border-t border-gray-200 p-4 bg-gray-50",children:[a.jsxs("div",{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[a.jsxs("div",{children:[a.jsx("h5",{className:"font-medium text-gray-900 mb-2",children:"🔍 Evidence Found:"}),a.jsx("ul",{className:"space-y-1",children:T(z.evidence)})]}),a.jsxs("div",{children:[a.jsx("h5",{className:"font-medium text-gray-900 mb-2",children:"⚕️ Clinical Implications:"}),a.jsx("ul",{className:"space-y-1",children:z.clinicalImplications.map((Y,ee)=>a.jsxs("li",{className:"text-sm text-gray-700",children:["• ",Y]},ee))})]})]}),z.educationalNotes&&z.educationalNotes.length>0&&a.jsxs("div",{className:"mt-4 p-3 bg-blue-50 border border-blue-200 rounded",children:[a.jsxs("button",{onClick:()=>ie(Y=>({...Y,[H]:!Y[H]})),className:"flex items-center text-blue-800 font-medium text-sm",children:["💡 Educational Notes",a.jsx("svg",{className:`w-4 h-4 ml-1 transition-transform ${se[H]?"rotate-180":""}`,fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19 9l-7 7-7-7"})})]}),se[H]&&a.jsx("div",{className:"mt-2 space-y-1",children:z.educationalNotes.map((Y,ee)=>a.jsxs("p",{className:"text-xs text-blue-700",children:["• ",Y]},ee))})]})]})]},H))})]}),(m==null?void 0:m.mechanismOverrides)&&Object.keys(m.mechanismOverrides).length>0&&a.jsxs("div",{className:"bg-white border border-gray-200 rounded-lg overflow-hidden",children:[a.jsxs("div",{className:"bg-orange-50 px-6 py-3 border-b border-orange-200",children:[a.jsx("h3",{className:"text-lg font-semibold text-orange-800",children:"⚡ Mechanism-Based Interpretation Overrides"}),a.jsx("p",{className:"text-sm text-orange-700",children:'These are the "aha moments" - when resistance mechanisms override lab susceptibility results'})]}),a.jsx("div",{className:"overflow-x-auto",children:a.jsxs("table",{className:"w-full",children:[a.jsx("thead",{className:"bg-gray-50",children:a.jsxs("tr",{children:[a.jsx("th",{className:"px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase",children:"Antibiotic"}),a.jsx("th",{className:"px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase",children:"Lab Result"}),a.jsx("th",{className:"px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase",children:"Override To"}),a.jsx("th",{className:"px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase",children:"Reason"}),a.jsx("th",{className:"px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase",children:"Accept"})]})}),a.jsx("tbody",{className:"divide-y divide-gray-200",children:Object.entries(m.mechanismOverrides).map(([z,H])=>a.jsxs("tr",{className:"hover:bg-gray-50",children:[a.jsx("td",{className:"px-6 py-4 text-sm font-medium text-gray-900 capitalize",children:z.replace(/-/g,"-")}),a.jsx("td",{className:"px-6 py-4",children:a.jsx("span",{className:`px-2 py-1 rounded text-sm font-medium ${H.oldInterpretation==="S"?"bg-green-100 text-green-700":H.oldInterpretation==="I"?"bg-yellow-100 text-yellow-700":"bg-red-100 text-red-700"}`,children:H.oldInterpretation})}),a.jsx("td",{className:"px-6 py-4",children:a.jsx("span",{className:`px-2 py-1 rounded text-sm font-medium ${H.newInterpretation==="S"?"bg-green-100 text-green-700":H.newInterpretation==="I"?"bg-yellow-100 text-yellow-700":"bg-red-100 text-red-700"}`,children:H.newInterpretation})}),a.jsx("td",{className:"px-6 py-4 text-sm text-gray-700 max-w-xs",children:H.reason}),a.jsx("td",{className:"px-6 py-4",children:a.jsxs("div",{className:"flex items-center space-x-2",children:[a.jsxs("label",{className:"flex items-center",children:[a.jsx("input",{type:"checkbox",checked:L[z]||!1,onChange:Y=>U(z,Y.target.checked),className:"h-4 w-4 text-orange-600 focus:ring-orange-500 border-gray-300 rounded"}),a.jsx("span",{className:"ml-2 text-sm text-gray-700",children:"Accept"})]}),a.jsx("span",{className:`px-2 py-1 rounded text-xs font-medium border ${Hl[H.confidence]}`,children:H.confidence})]})})]},z))})]})})]}),m&&(!m.detectedPatterns||m.detectedPatterns.length===0)&&a.jsxs("div",{className:"bg-blue-50 border border-blue-200 rounded-lg p-6",children:[a.jsxs("div",{className:"text-center mb-4",children:[a.jsx("div",{className:"text-4xl mb-2",children:"🔍"}),a.jsx("h3",{className:"text-lg font-semibold text-blue-800 mb-2",children:"No Resistance Mechanisms Detected"}),a.jsx("p",{className:"text-blue-700 mb-4",children:"The current susceptibility pattern appears consistent with wild-type organisms without major resistance mechanisms."})]}),a.jsxs("div",{className:"bg-white rounded border p-4 text-left",children:[a.jsx("h4",{className:"font-medium text-blue-800 mb-2",children:"Analysis Details:"}),a.jsxs("ul",{className:"text-sm text-blue-700 space-y-1",children:[a.jsxs("li",{children:["• Analyzed ",m.totalAntibiotics," antibiotics"]}),a.jsx("li",{children:"• Scanned for: ESBL, AmpC, MRSA, VRE, MLSᵦ, Carbapenemase patterns"}),a.jsxs("li",{children:["• Overall confidence: ",m.overallConfidence]}),m.warnings&&m.warnings.length>0&&a.jsxs("li",{children:["• ",m.warnings.length," warning(s) generated"]})]}),a.jsxs("div",{className:"mt-3 p-2 bg-blue-25 rounded text-xs",children:[a.jsx("strong",{children:"For ESBL detection, algorithm looks for:"}),a.jsxs("ul",{className:"ml-4 mt-1",children:[a.jsx("li",{children:"• Resistance to 3rd gen cephalosporins (ceftriaxone, ceftazidime, cefotaxime)"}),a.jsx("li",{children:"• Sensitivity to carbapenems"}),a.jsx("li",{children:"• Enhancement by beta-lactamase inhibitors"})]})]})]})]}),a.jsxs("div",{className:"flex items-center justify-between pt-6 border-t border-gray-200",children:[a.jsx("div",{className:"text-sm text-gray-500",children:m?a.jsx("span",{className:"text-green-600 font-medium",children:"✅ Resistance analysis complete - ready for treatment recommendations"}):a.jsx("span",{children:"Analyzing resistance patterns..."})}),a.jsx("button",{onClick:Z,disabled:!m,className:`px-6 py-3 rounded-lg font-medium transition-colors ${m?"bg-purple-600 text-white hover:bg-purple-700 focus:ring-2 focus:ring-purple-500":"bg-gray-300 text-gray-500 cursor-not-allowed"}`,children:"Generate Treatment Recommendations →"})]})]})},Cb={excellent:"bg-green-100 text-green-800 border-green-200",good:"bg-blue-100 text-blue-800 border-blue-200",fair:"bg-yellow-100 text-yellow-800 border-yellow-200",poor:"bg-red-100 text-red-800 border-red-200"},Kl={preferred:"bg-green-50 border-green-300",alternative:"bg-blue-50 border-blue-300",consider:"bg-yellow-50 border-yellow-300",avoid:"bg-red-50 border-red-300"},Qu={preferred:"🟢",alternative:"🔵",consider:"🟡",avoid:"🔴"},Sb=({results:g,antibiogramData:s})=>{var ne,w,O,U,Z,X;console.log("🏥 Phase4_TherapeuticComparison received results:",g),console.log("🏥 Results.strategies:",g==null?void 0:g.strategies),console.log("🏥 Results.strategies length:",(ne=g==null?void 0:g.strategies)==null?void 0:ne.length);const[l,c]=oe.useState([]),[d,m]=oe.useState("comparison"),[_,h]=oe.useState("totalScore"),[v,y]=oe.useState("all"),D=oe.useMemo(()=>{let T=g.strategies||[];return v!=="all"&&(T=T.filter(q=>q.recommendation===v)),T.sort((q,C)=>_==="totalScore"?C.totalScore-q.totalScore:_==="efficacy"?C.scores.efficacy-q.scores.efficacy:_==="safety"?C.scores.safety-q.scores.safety:_==="stewardship"?C.scores.stewardship-q.scores.stewardship:0),T},[g.strategies,v,_]),L=(T,q)=>{c(q?C=>[...C,T]:C=>C.filter(E=>E.primary!==T.primary))},W=T=>T>=80?"excellent":T>=60?"good":T>=40?"fair":"poor",se=T=>Cb[W(T)],ie=T=>T.map(q=>q.replace(/-/g,"-")).join(" + "),$=()=>{var C,E;const T=D.filter(z=>z.recommendation==="preferred").slice(0,3),q=`Antibiogram Analysis - ${(C=s.organism)==null?void 0:C.name}

PREFERRED TREATMENTS:
${T.map((z,H)=>`${H+1}. ${ie(z.agents)} (Score: ${z.totalScore}/100)
     Rationale: ${z.rationale}
     Key considerations: Efficacy ${z.scores.efficacy}/100, Safety ${z.scores.safety}/100`).join(`

`)}

Analysis Date: ${new Date().toLocaleDateString()}
Infection Site: ${s.infectionSite}
${((E=s.detectedMechanisms)==null?void 0:E.length)>0?`Resistance Mechanisms: ${s.detectedMechanisms.map(z=>z.type).join(", ")}`:"No resistance mechanisms detected"}`;navigator.clipboard.writeText(q)};return a.jsxs("div",{className:"max-w-7xl mx-auto p-6 space-y-8",children:[a.jsxs("div",{className:"text-center mb-8",children:[a.jsxs("div",{className:"flex items-center justify-center mb-4",children:[a.jsx("div",{className:"bg-green-600 text-white rounded-full w-10 h-10 flex items-center justify-center font-bold text-lg mr-4",children:"4"}),a.jsx("h1",{className:"text-3xl font-bold text-gray-900",children:"Advanced Therapeutic Strategy Comparison"})]}),a.jsx("p",{className:"text-lg text-gray-600 max-w-4xl mx-auto",children:"Specialist-level analysis comparing treatment options across multiple clinical dimensions. Each strategy is scored on efficacy, safety, stewardship, and practical considerations."})]}),a.jsxs("div",{className:"bg-gradient-to-r from-green-50 to-emerald-50 border border-green-200 rounded-lg p-6",children:[a.jsxs("div",{className:"flex items-center justify-between mb-4",children:[a.jsx("h2",{className:"text-xl font-semibold text-green-800",children:"📊 Therapeutic Analysis Summary"}),a.jsx("button",{onClick:$,className:"px-4 py-2 bg-green-600 text-white rounded-lg hover:bg-green-700 transition-colors text-sm",children:"📋 Copy Summary"})]}),a.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-4 gap-4",children:[a.jsxs("div",{className:"text-center",children:[a.jsx("div",{className:"text-2xl font-bold text-green-700",children:((w=g.metadata)==null?void 0:w.totalOptions)||0}),a.jsx("div",{className:"text-sm text-green-600",children:"Total Options"})]}),a.jsxs("div",{className:"text-center",children:[a.jsx("div",{className:"text-2xl font-bold text-blue-700",children:((O=g.metadata)==null?void 0:O.preferredOptions)||0}),a.jsx("div",{className:"text-sm text-blue-600",children:"Preferred"})]}),a.jsxs("div",{className:"text-center",children:[a.jsx("div",{className:"text-2xl font-bold text-purple-700",children:((U=s.detectedMechanisms)==null?void 0:U.length)||0}),a.jsx("div",{className:"text-sm text-purple-600",children:"Resistance Mechanisms"})]}),a.jsxs("div",{className:"text-center",children:[a.jsx("div",{className:"text-2xl font-bold text-gray-700",children:((X=(Z=g.recommendations)==null?void 0:Z.firstLine)==null?void 0:X.length)||0}),a.jsx("div",{className:"text-sm text-gray-600",children:"First-Line Options"})]})]})]}),a.jsx("div",{className:"bg-white border border-gray-200 rounded-lg p-4",children:a.jsxs("div",{className:"flex flex-wrap items-center justify-between gap-4",children:[a.jsxs("div",{className:"flex items-center space-x-4",children:[a.jsxs("div",{className:"flex items-center space-x-2",children:[a.jsx("span",{className:"text-sm font-medium text-gray-700",children:"Filter:"}),a.jsxs("select",{value:v,onChange:T=>y(T.target.value),className:"px-3 py-1 border border-gray-300 rounded text-sm focus:ring-2 focus:ring-green-500",children:[a.jsx("option",{value:"all",children:"All Options"}),a.jsx("option",{value:"preferred",children:"Preferred Only"}),a.jsx("option",{value:"alternative",children:"Alternatives"}),a.jsx("option",{value:"consider",children:"Consider"})]})]}),a.jsxs("div",{className:"flex items-center space-x-2",children:[a.jsx("span",{className:"text-sm font-medium text-gray-700",children:"Sort by:"}),a.jsxs("select",{value:_,onChange:T=>h(T.target.value),className:"px-3 py-1 border border-gray-300 rounded text-sm focus:ring-2 focus:ring-green-500",children:[a.jsx("option",{value:"totalScore",children:"Total Score"}),a.jsx("option",{value:"efficacy",children:"Efficacy"}),a.jsx("option",{value:"safety",children:"Safety"}),a.jsx("option",{value:"stewardship",children:"Stewardship"})]})]})]}),a.jsxs("div",{className:"flex items-center space-x-2",children:[a.jsx("span",{className:"text-sm font-medium text-gray-700",children:"View:"}),a.jsxs("div",{className:"bg-gray-100 p-1 rounded",children:[a.jsx("button",{onClick:()=>m("comparison"),className:`px-3 py-1 text-sm rounded transition-colors ${d==="comparison"?"bg-green-600 text-white":"text-gray-700 hover:text-gray-900"}`,children:"Comparison"}),a.jsx("button",{onClick:()=>m("details"),className:`px-3 py-1 text-sm rounded transition-colors ${d==="details"?"bg-green-600 text-white":"text-gray-700 hover:text-gray-900"}`,children:"Details"})]})]})]})}),d==="comparison"&&a.jsx("div",{className:"bg-white border border-gray-200 rounded-lg overflow-hidden",children:a.jsx("div",{className:"overflow-x-auto",children:a.jsxs("table",{className:"w-full",children:[a.jsx("thead",{className:"bg-gray-50",children:a.jsxs("tr",{children:[a.jsx("th",{className:"px-4 py-3 text-left text-xs font-medium text-gray-500 uppercase",children:"Select"}),a.jsx("th",{className:"px-4 py-3 text-left text-xs font-medium text-gray-500 uppercase",children:"Strategy"}),a.jsx("th",{className:"px-4 py-3 text-left text-xs font-medium text-gray-500 uppercase",children:"Recommendation"}),a.jsx("th",{className:"px-4 py-3 text-center text-xs font-medium text-gray-500 uppercase",children:"Total Score"}),a.jsx("th",{className:"px-4 py-3 text-center text-xs font-medium text-gray-500 uppercase",children:"Efficacy"}),a.jsx("th",{className:"px-4 py-3 text-center text-xs font-medium text-gray-500 uppercase",children:"Safety"}),a.jsx("th",{className:"px-4 py-3 text-center text-xs font-medium text-gray-500 uppercase",children:"Stewardship"}),a.jsx("th",{className:"px-4 py-3 text-center text-xs font-medium text-gray-500 uppercase",children:"Pharmacology"}),a.jsx("th",{className:"px-4 py-3 text-left text-xs font-medium text-gray-500 uppercase",children:"Key Benefits"})]})}),a.jsxs("tbody",{className:"divide-y divide-gray-200",children:[D.length===0&&a.jsx("tr",{children:a.jsx("td",{colSpan:"7",className:"px-4 py-12 text-center",children:a.jsxs("div",{className:"text-gray-500",children:[a.jsx("div",{className:"text-4xl mb-3",children:"📊"}),a.jsx("p",{className:"text-lg font-medium text-gray-700 mb-2",children:"No therapeutic strategies generated"}),a.jsx("p",{className:"text-sm",children:"The antibiogram analysis may need more data or the organism/resistance pattern may require manual review."})]})})}),D.map((T,q)=>a.jsxs("tr",{className:`hover:bg-gray-50 ${Kl[T.recommendation]}`,children:[a.jsx("td",{className:"px-4 py-3",children:a.jsx("input",{type:"checkbox",checked:l.some(C=>C.primary===T.primary),onChange:C=>L(T,C.target.checked),className:"h-4 w-4 text-green-600 focus:ring-green-500 border-gray-300 rounded"})}),a.jsx("td",{className:"px-4 py-3",children:a.jsxs("div",{children:[a.jsx("div",{className:"font-medium text-gray-900",children:ie(T.agents)}),a.jsx("div",{className:"text-sm text-gray-500 capitalize",children:T.type.replace("_"," ")})]})}),a.jsx("td",{className:"px-4 py-3",children:a.jsxs("span",{className:`inline-flex items-center px-2 py-1 rounded-full text-xs font-medium border ${Kl[T.recommendation]}`,children:[Qu[T.recommendation]," ",T.recommendation]})}),a.jsx("td",{className:"px-4 py-3 text-center",children:a.jsx("span",{className:`px-2 py-1 rounded text-sm font-medium border ${se(T.totalScore)}`,children:T.totalScore})}),a.jsx("td",{className:"px-4 py-3 text-center",children:a.jsx("span",{className:`px-2 py-1 rounded text-xs ${se(T.scores.efficacy)}`,children:Math.round(T.scores.efficacy)})}),a.jsx("td",{className:"px-4 py-3 text-center",children:a.jsx("span",{className:`px-2 py-1 rounded text-xs ${se(T.scores.safety)}`,children:Math.round(T.scores.safety)})}),a.jsx("td",{className:"px-4 py-3 text-center",children:a.jsx("span",{className:`px-2 py-1 rounded text-xs ${se(T.scores.stewardship)}`,children:Math.round(T.scores.stewardship)})}),a.jsx("td",{className:"px-4 py-3 text-center",children:a.jsx("span",{className:`px-2 py-1 rounded text-xs ${se(T.scores.pharmacology)}`,children:Math.round(T.scores.pharmacology)})}),a.jsx("td",{className:"px-4 py-3",children:a.jsx("div",{className:"text-sm text-gray-600 max-w-xs",children:T.rationale||"Standard therapy option"})})]},`${T.primary}-${q}`))]})]})})}),d==="details"&&a.jsxs("div",{className:"space-y-6",children:[D.length===0&&a.jsx("div",{className:"bg-white border border-gray-200 rounded-lg p-12 text-center",children:a.jsxs("div",{className:"text-gray-500",children:[a.jsx("div",{className:"text-4xl mb-3",children:"📋"}),a.jsx("p",{className:"text-lg font-medium text-gray-700 mb-2",children:"No detailed strategies available"}),a.jsx("p",{className:"text-sm",children:"Treatment recommendations could not be generated. Consider manual interpretation or additional susceptibility testing."})]})}),D.slice(0,6).map((T,q)=>a.jsx("div",{className:`border rounded-lg overflow-hidden ${Kl[T.recommendation]}`,children:a.jsxs("div",{className:"p-6",children:[a.jsxs("div",{className:"flex items-center justify-between mb-4",children:[a.jsxs("div",{className:"flex items-center space-x-3",children:[a.jsx("span",{className:"text-2xl",children:Qu[T.recommendation]}),a.jsxs("div",{children:[a.jsx("h3",{className:"text-lg font-semibold text-gray-900",children:ie(T.agents)}),a.jsxs("p",{className:"text-sm text-gray-600 capitalize",children:[T.type.replace("_"," ")," • ",T.recommendation," option"]})]})]}),a.jsxs("div",{className:"text-right",children:[a.jsx("div",{className:`text-2xl font-bold ${T.totalScore>=80?"text-green-600":T.totalScore>=60?"text-blue-600":T.totalScore>=40?"text-yellow-600":"text-red-600"}`,children:T.totalScore}),a.jsx("div",{className:"text-xs text-gray-500",children:"Total Score"})]})]}),a.jsx("div",{className:"grid grid-cols-2 md:grid-cols-4 gap-4 mb-4",children:Object.entries(T.scores).map(([C,E])=>a.jsxs("div",{className:"text-center",children:[a.jsx("div",{className:`text-lg font-semibold ${E>=80?"text-green-600":E>=60?"text-blue-600":E>=40?"text-yellow-600":"text-red-600"}`,children:Math.round(E)}),a.jsx("div",{className:"text-xs text-gray-500 capitalize",children:C.replace("_"," ")})]},C))}),T.rationale&&a.jsxs("div",{className:"bg-white bg-opacity-60 p-3 rounded border",children:[a.jsx("h4",{className:"font-medium text-gray-900 mb-1",children:"Clinical Rationale:"}),a.jsx("p",{className:"text-sm text-gray-700",children:T.rationale})]})]})},`${T.primary}-${q}`))]}),l.length>1&&a.jsxs("div",{className:"bg-white border border-gray-200 rounded-lg p-6",children:[a.jsxs("h3",{className:"text-lg font-semibold text-gray-900 mb-4",children:["🔀 Selected Strategy Comparison (",l.length,")"]}),a.jsx("div",{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:l.map((T,q)=>a.jsxs("div",{className:"border border-gray-200 rounded p-4",children:[a.jsx("h4",{className:"font-medium text-gray-900 mb-2",children:ie(T.agents)}),a.jsxs("div",{className:"space-y-2",children:[a.jsxs("div",{className:"flex justify-between text-sm",children:[a.jsx("span",{children:"Total Score:"}),a.jsxs("span",{className:"font-medium",children:[T.totalScore,"/100"]})]}),a.jsxs("div",{className:"flex justify-between text-sm",children:[a.jsx("span",{children:"Efficacy:"}),a.jsxs("span",{children:[Math.round(T.scores.efficacy),"/100"]})]}),a.jsxs("div",{className:"flex justify-between text-sm",children:[a.jsx("span",{children:"Safety:"}),a.jsxs("span",{children:[Math.round(T.scores.safety),"/100"]})]}),a.jsxs("div",{className:"flex justify-between text-sm",children:[a.jsx("span",{children:"Stewardship:"}),a.jsxs("span",{children:[Math.round(T.scores.stewardship),"/100"]})]})]})]},`selected-${q}`))})]}),g.recommendations&&a.jsxs("div",{className:"bg-white border border-gray-200 rounded-lg p-6",children:[a.jsx("h3",{className:"text-lg font-semibold text-gray-900 mb-4",children:"💊 Clinical Recommendations"}),a.jsxs("div",{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[g.recommendations.firstLine&&g.recommendations.firstLine.length>0&&a.jsxs("div",{children:[a.jsx("h4",{className:"font-medium text-green-800 mb-2",children:"🥇 First-Line Options:"}),a.jsx("ul",{className:"space-y-2",children:g.recommendations.firstLine.map((T,q)=>a.jsxs("li",{className:"text-sm text-gray-700",children:["• ",ie(T.agents)," (Score: ",T.totalScore,")"]},q))})]}),g.recommendations.alternatives&&g.recommendations.alternatives.length>0&&a.jsxs("div",{children:[a.jsx("h4",{className:"font-medium text-blue-800 mb-2",children:"🥈 Alternative Options:"}),a.jsx("ul",{className:"space-y-2",children:g.recommendations.alternatives.map((T,q)=>a.jsxs("li",{className:"text-sm text-gray-700",children:["• ",ie(T.agents)," (Score: ",T.totalScore,")"]},q))})]})]}),g.recommendations.durationGuidance&&a.jsxs("div",{className:"mt-4 p-3 bg-blue-50 border border-blue-200 rounded",children:[a.jsx("h4",{className:"font-medium text-blue-800 mb-1",children:"⏱️ Duration Guidance:"}),a.jsx("p",{className:"text-sm text-blue-700",children:g.recommendations.durationGuidance})]})]}),a.jsx("div",{className:"flex items-center justify-center pt-6 border-t border-gray-200",children:a.jsxs("div",{className:"flex space-x-4",children:[a.jsx("button",{onClick:$,className:"px-6 py-3 bg-green-600 text-white rounded-lg hover:bg-green-700 transition-colors",children:"📋 Copy Clinical Summary"}),a.jsx("button",{onClick:()=>window.print(),className:"px-6 py-3 bg-blue-600 text-white rounded-lg hover:bg-blue-700 transition-colors",children:"🖨️ Print Analysis"})]})})]})},Nb={high:"bg-red-100 text-red-800 border-red-300",moderate:"bg-yellow-100 text-yellow-800 border-yellow-300",low:"bg-green-100 text-green-800 border-green-300"},Ib=({results:g,antibiogramData:s})=>{var L,W,se,ie;const[l,c]=oe.useState({}),d=oe.useMemo(()=>{var ne;if(!g||!g.strategies)return{firstLine:[],alternatives:[],avoid:[]};const $=g.strategies;return{firstLine:$.filter(w=>w.recommendation==="preferred").slice(0,3),alternatives:$.filter(w=>w.recommendation==="alternative").slice(0,3),avoid:$.filter(w=>w.recommendation==="avoid"),durationGuidance:((ne=g.recommendations)==null?void 0:ne.durationGuidance)||"Standard course duration based on infection type"}},[g]),m=oe.useMemo(()=>{const $=s.infectionSite||"",ne=s.detectedMechanisms||[];return $.includes("CNS")||$.includes("endocarditis")||ne.some(w=>w.type==="carbapenemase")?"high":$.includes("bacteremia")||$.includes("VAP")||ne.some(w=>["esbl","mrsa","vre"].includes(w.type))?"moderate":"low"},[s]),_=$=>{switch($){case"high":return"🔴";case"moderate":return"🟡";default:return"🟢"}},h=$=>{switch($){case"high":return"High Severity";case"moderate":return"Moderate Severity";default:return"Standard Severity"}},v=$=>$.replace(/-/g,"/").split("_").map(ne=>ne.charAt(0).toUpperCase()+ne.slice(1)).join(" "),y=$=>{c(ne=>({...ne,[$]:!ne[$]}))},D=()=>{var ne,w;const $=`ANTIBIOGRAM RECOMMENDATIONS

Patient: ${((ne=s.organism)==null?void 0:ne.name)||"Unknown"}
Infection Site: ${s.infectionSite||"Unknown"}
Severity: ${h(m)}
Analysis Date: ${new Date().toLocaleDateString()}

FIRST-LINE TREATMENTS:
${d.firstLine.map((O,U)=>`${U+1}. ${v(O.primary)} ${O.type==="combination"?`+ ${O.agents.slice(1).map(v).join(" + ")}`:""}`).join(`
`)}

ALTERNATIVE OPTIONS:
${d.alternatives.map((O,U)=>`${U+1}. ${v(O.primary)} ${O.type==="combination"?`+ ${O.agents.slice(1).map(v).join(" + ")}`:""}`).join(`
`)}

${((w=s.detectedMechanisms)==null?void 0:w.length)>0?`RESISTANCE MECHANISMS DETECTED:
${s.detectedMechanisms.map(O=>`• ${O.type.toUpperCase()}`).join(`
`)}
`:""}DURATION: ${d.durationGuidance}

⚠️ Always consider local guidelines, patient allergies, and clinical context.`;navigator.clipboard.writeText($)};return a.jsxs("div",{className:"max-w-6xl mx-auto p-6 space-y-8",children:[a.jsxs("div",{className:"text-center mb-8",children:[a.jsxs("div",{className:"flex items-center justify-center mb-4",children:[a.jsx("div",{className:"bg-green-600 text-white rounded-full w-10 h-10 flex items-center justify-center font-bold text-lg mr-4",children:"4"}),a.jsx("h1",{className:"text-3xl font-bold text-gray-900",children:"Treatment Recommendations"})]}),a.jsx("p",{className:"text-lg text-gray-600 max-w-3xl mx-auto",children:"Clear, evidence-based recommendations for your antibiogram results. These are ranked by effectiveness and stewardship principles."})]}),a.jsx("div",{className:"bg-white border border-gray-200 rounded-lg p-6 shadow-sm",children:a.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-3 gap-6",children:[a.jsxs("div",{children:[a.jsx("h3",{className:"font-semibold text-gray-900 mb-2",children:"🦠 Organism"}),a.jsx("p",{className:"text-gray-700",children:((L=s.organism)==null?void 0:L.name)||"Unknown"}),a.jsx("p",{className:"text-sm text-gray-500",children:(W=s.organism)==null?void 0:W.gramStain})]}),a.jsxs("div",{children:[a.jsx("h3",{className:"font-semibold text-gray-900 mb-2",children:"🎯 Infection Site"}),a.jsx("p",{className:"text-gray-700",children:s.infectionSite||"Unknown"}),a.jsxs("div",{className:`inline-flex items-center px-2 py-1 rounded text-sm font-medium border ${Nb[m]}`,children:[_(m)," ",h(m)]})]}),a.jsxs("div",{children:[a.jsx("h3",{className:"font-semibold text-gray-900 mb-2",children:"🛡️ Resistance Status"}),((se=s.detectedMechanisms)==null?void 0:se.length)>0?a.jsxs("div",{className:"space-y-1",children:[s.detectedMechanisms.slice(0,2).map(($,ne)=>a.jsx("div",{className:"text-sm",children:a.jsx("span",{className:"px-2 py-1 bg-red-100 text-red-700 rounded text-xs",children:$.type.toUpperCase()})},ne)),s.detectedMechanisms.length>2&&a.jsxs("p",{className:"text-xs text-gray-500",children:["+",s.detectedMechanisms.length-2," more"]})]}):a.jsx("p",{className:"text-green-700 text-sm",children:"No major resistance mechanisms detected"})]})]})}),a.jsxs("div",{className:"bg-gradient-to-r from-green-50 to-emerald-50 border border-green-200 rounded-lg overflow-hidden",children:[a.jsx("div",{className:"bg-green-100 px-6 py-3 border-b border-green-200",children:a.jsxs("div",{className:"flex items-center justify-between",children:[a.jsx("h2",{className:"text-xl font-semibold text-green-800",children:"🥇 First-Line Treatments"}),a.jsxs("span",{className:"text-sm text-green-600",children:[d.firstLine.length," option",d.firstLine.length!==1?"s":""]})]})}),a.jsx("div",{className:"p-6",children:d.firstLine.length>0?a.jsx("div",{className:"space-y-4",children:d.firstLine.map(($,ne)=>a.jsxs("div",{className:"bg-white border border-green-200 rounded-lg p-4",children:[a.jsxs("div",{className:"flex items-center justify-between mb-2",children:[a.jsxs("div",{className:"flex items-center space-x-3",children:[a.jsx("div",{className:"bg-green-600 text-white rounded-full w-8 h-8 flex items-center justify-center font-bold text-sm",children:ne+1}),a.jsxs("div",{children:[a.jsxs("h3",{className:"font-semibold text-gray-900",children:[v($.primary),$.type==="combination"&&$.agents.length>1&&a.jsxs("span",{className:"text-gray-600",children:[" + ",$.agents.slice(1).map(v).join(" + ")]})]}),a.jsxs("p",{className:"text-sm text-gray-600 capitalize",children:[$.type.replace("_"," ")," therapy"]})]})]}),a.jsxs("div",{className:"text-right",children:[a.jsxs("div",{className:"text-green-600 font-semibold",children:["Score: ",$.totalScore,"/100"]}),a.jsx("div",{className:"text-xs text-gray-500",children:"Preferred option"})]})]}),$.rationale&&a.jsx("div",{className:"bg-green-50 p-3 rounded border border-green-200 mt-3",children:a.jsxs("p",{className:"text-sm text-green-800",children:[a.jsx("strong",{children:"Why this works:"})," ",$.rationale]})})]},ne))}):a.jsxs("div",{className:"text-center py-8",children:[a.jsx("div",{className:"text-4xl mb-2",children:"⚠️"}),a.jsx("h3",{className:"text-lg font-semibold text-gray-900 mb-2",children:"No First-Line Options Available"}),a.jsx("p",{className:"text-gray-600",children:"This organism shows extensive resistance. Consider infectious disease consultation."})]})})]}),d.alternatives.length>0&&a.jsxs("div",{className:"bg-white border border-gray-200 rounded-lg overflow-hidden",children:[a.jsxs("div",{className:"bg-blue-50 px-6 py-3 border-b border-blue-200 flex items-center justify-between",children:[a.jsx("h2",{className:"text-lg font-semibold text-blue-800",children:"🥈 Alternative Options"}),a.jsx("button",{onClick:()=>y("alternatives"),className:"text-blue-600 hover:text-blue-800 text-sm",children:l.alternatives?"Hide Details":"Show Details"})]}),a.jsx("div",{className:"p-6",children:a.jsx("div",{className:"grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-4",children:d.alternatives.map(($,ne)=>a.jsxs("div",{className:"border border-blue-200 rounded-lg p-4",children:[a.jsx("h3",{className:"font-medium text-gray-900 mb-1",children:v($.primary)}),a.jsxs("div",{className:"flex items-center justify-between",children:[a.jsx("span",{className:"text-sm text-blue-600 capitalize",children:$.type.replace("_"," ")}),a.jsxs("span",{className:"text-sm font-medium text-blue-700",children:[$.totalScore,"/100"]})]}),l.alternatives&&$.rationale&&a.jsx("div",{className:"mt-2 text-xs text-gray-600",children:$.rationale})]},ne))})})]}),d.avoid.length>0&&a.jsxs("div",{className:"bg-red-50 border border-red-200 rounded-lg p-4",children:[a.jsxs("div",{className:"flex items-center justify-between mb-3",children:[a.jsx("h3",{className:"font-semibold text-red-800",children:"❌ Antibiotics to Avoid"}),a.jsxs("button",{onClick:()=>y("avoid"),className:"text-red-600 hover:text-red-800 text-sm",children:[l.avoid?"Hide":"Show"," (",d.avoid.length,")"]})]}),l.avoid&&a.jsx("div",{className:"grid grid-cols-2 md:grid-cols-4 gap-2",children:d.avoid.map(($,ne)=>a.jsx("div",{className:"text-sm text-red-700 bg-red-100 px-2 py-1 rounded",children:v($.primary)},ne))})]}),a.jsxs("div",{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[a.jsxs("div",{className:"bg-blue-50 border border-blue-200 rounded-lg p-4",children:[a.jsx("h3",{className:"font-semibold text-blue-800 mb-2",children:"⏱️ Duration Guidance"}),a.jsx("p",{className:"text-blue-700 text-sm",children:d.durationGuidance})]}),a.jsxs("div",{className:"bg-purple-50 border border-purple-200 rounded-lg p-4",children:[a.jsx("h3",{className:"font-semibold text-purple-800 mb-2",children:"🔍 Monitoring"}),a.jsxs("ul",{className:"text-purple-700 text-sm space-y-1",children:[a.jsx("li",{children:"• Monitor clinical response within 48-72 hours"}),a.jsx("li",{children:"• Check for adverse effects"}),a.jsx("li",{children:"• Consider de-escalation when possible"}),m==="high"&&a.jsx("li",{children:"• Consider infectious disease consultation"})]})]})]}),a.jsxs("div",{className:"bg-amber-50 border border-amber-200 rounded-lg p-4",children:[a.jsx("h3",{className:"font-semibold text-amber-800 mb-2",children:"⚠️ Important Clinical Notes"}),a.jsxs("ul",{className:"text-amber-700 text-sm space-y-1",children:[a.jsx("li",{children:"• Always consider patient allergies and drug interactions"}),a.jsx("li",{children:"• Adjust dosing for renal/hepatic function as needed"}),a.jsx("li",{children:"• Follow local antibiogram and guidelines"}),a.jsx("li",{children:"• Consider source control for optimal outcomes"}),((ie=s.detectedMechanisms)==null?void 0:ie.length)>0&&a.jsx("li",{children:"• Resistance mechanisms detected - follow recommendations carefully"})]})]}),a.jsxs("div",{className:"flex items-center justify-center space-x-4 pt-6 border-t border-gray-200",children:[a.jsx("button",{onClick:D,className:"px-6 py-3 bg-green-600 text-white rounded-lg hover:bg-green-700 transition-colors font-medium",children:"📋 Copy Recommendations"}),a.jsx("button",{onClick:()=>window.print(),className:"px-6 py-3 bg-blue-600 text-white rounded-lg hover:bg-blue-700 transition-colors font-medium",children:"🖨️ Print Results"})]})]})},jb={1:"Setting the Stage",2:"Initial Interpretation",3:"Resistance Mechanisms",4:"Final Recommendations"},Ab=({onBackToLanding:g})=>{const[s,l]=oe.useState("simple"),[c,d]=oe.useState(1),[m,_]=oe.useState({}),[h,v]=oe.useState(null),[y,D]=oe.useState(!1),[L]=oe.useState(()=>new cb),W=(O,U)=>{_(Z=>({...Z,...U})),d(O)},se=O=>{W(2,{organism:O.organism,infectionSite:O.infectionSite,intrinsicResistance:O.intrinsicResistance})},ie=async O=>{W(3,{micData:O.micData,interpretations:O.interpretations,warnings:O.warnings,interpretationSummary:O.interpretationSummary})},$=async O=>{var U,Z,X,T,q;D(!0);try{const C={...m,...O};console.log("🔄 Phase 3 complete, running final interpretation with data:",{organism:(U=C.organism)==null?void 0:U.id,infectionSite:C.infectionSite,micDataKeys:Object.keys(C.micData||{}),resistanceAnalysis:C.resistanceAnalysis?"Present":"Missing",detectedMechanisms:((Z=C.detectedMechanisms)==null?void 0:Z.length)||0});const E=await L.interpretAntibiogram({organism:C.organism.id,infectionSite:C.infectionSite,micData:C.micData,interpretations:C.updatedInterpretations||C.interpretations,resistanceAnalysis:C.resistanceAnalysis,detectedMechanisms:C.detectedMechanisms,patientData:{},localEpidemiology:{},mode:s});console.log("✅ Antibiogram interpretation complete:",{success:E.success,hasPhase4:!!((X=E.phases)!=null&&X.phase4),recommendations:((q=(T=E.phases)==null?void 0:T.phase4)==null?void 0:q.mode)||"Unknown"}),v(E),W(4,O)}catch(C){console.error("❌ Antibiogram interpretation failed:",C);const E={success:!1,error:C.message,phases:{phase4:{mode:s,primaryRecommendation:{agents:["Unable to generate recommendations"],rationale:`Error: ${C.message}`,totalScore:0},alternatives:[],clinicalAlerts:["System error - please review manually"],strategies:[]}}};v(E),W(4,O)}finally{D(!1)}},ne=()=>{d(1),_({}),v(null),D(!1)},w=O=>{l(O),c===4&&h&&$(m)};return a.jsxs("div",{className:"min-h-screen bg-gray-50",children:[a.jsx("div",{className:"bg-white shadow-sm border-b border-gray-200",children:a.jsx("div",{className:"max-w-7xl mx-auto px-6 py-4",children:a.jsxs("div",{className:"flex items-center justify-between",children:[a.jsxs("div",{className:"flex items-center space-x-4",children:[a.jsxs("button",{onClick:g,className:"flex items-center text-gray-600 hover:text-gray-900 transition-colors",children:[a.jsx("svg",{className:"w-5 h-5 mr-2",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M10 19l-7-7m0 0l7-7m-7 7h18"})}),"Back to Home"]}),a.jsx("div",{className:"h-6 w-px bg-gray-300"}),a.jsx("h1",{className:"text-2xl font-bold text-gray-900",children:"🧠 World-Class Antibiogram Interpretation"})]}),a.jsxs("div",{className:"flex items-center space-x-4",children:[a.jsxs("div",{className:"bg-gray-100 p-1 rounded-lg",children:[a.jsx("button",{onClick:()=>w("simple"),className:`px-4 py-2 text-sm font-medium rounded transition-colors ${s==="simple"?"bg-blue-600 text-white shadow-sm":"text-gray-700 hover:text-gray-900"}`,children:"Simple Mode"}),a.jsx("button",{onClick:()=>w("advanced"),className:`px-4 py-2 text-sm font-medium rounded transition-colors ${s==="advanced"?"bg-purple-600 text-white shadow-sm":"text-gray-700 hover:text-gray-900"}`,children:"Advanced Mode"})]}),c>1&&a.jsx("button",{onClick:ne,className:"px-4 py-2 text-sm font-medium text-gray-700 bg-white border border-gray-300 rounded hover:bg-gray-50 transition-colors",children:"Start Over"})]})]})})}),a.jsx("div",{className:"max-w-7xl mx-auto px-6 py-4",children:a.jsxs("div",{className:`p-4 rounded-lg border ${s==="simple"?"bg-blue-50 border-blue-200":"bg-purple-50 border-purple-200"}`,children:[a.jsxs("div",{className:"flex items-center",children:[a.jsx("div",{className:`w-2 h-2 rounded-full mr-2 ${s==="simple"?"bg-blue-600":"bg-purple-600"}`}),a.jsx("span",{className:`font-medium ${s==="simple"?"text-blue-800":"text-purple-800"}`,children:s==="simple"?"Simple Mode":"Advanced Mode"})]}),a.jsx("p",{className:`text-sm mt-1 ${s==="simple"?"text-blue-700":"text-purple-700"}`,children:s==="simple"?"CLSI-compliant interpretation with clear, ranked recommendations based on resistance patterns.":"Specialist-level comparative analysis with side-by-side evaluation of therapeutic strategies."})]})}),a.jsx("div",{className:"max-w-7xl mx-auto px-6 pb-6",children:a.jsx("div",{className:"bg-white rounded-lg shadow-sm border border-gray-200 p-6",children:a.jsx("div",{className:"flex items-center justify-between",children:Object.entries(jb).map(([O,U])=>{const Z=parseInt(O),X=c===Z,T=c>Z;return a.jsxs("div",{className:"flex items-center",children:[a.jsxs("div",{className:"flex items-center",children:[a.jsx("div",{className:`w-10 h-10 rounded-full flex items-center justify-center font-bold transition-colors ${T?"bg-green-600 text-white":X?(s==="simple"?"bg-blue-600":"bg-purple-600")+" text-white":"bg-gray-300 text-gray-600"}`,children:T?a.jsx("svg",{className:"w-5 h-5",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M5 13l4 4L19 7"})}):O}),a.jsxs("div",{className:"ml-3",children:[a.jsxs("h3",{className:`text-sm font-medium ${X?"text-gray-900":T?"text-green-700":"text-gray-500"}`,children:["Phase ",O]}),a.jsx("p",{className:`text-xs ${X?"text-gray-600":T?"text-green-600":"text-gray-400"}`,children:U})]})]}),Z<4&&a.jsx("div",{className:`w-16 h-1 mx-4 rounded ${c>Z?"bg-green-300":"bg-gray-200"}`})]},O)})})})}),a.jsxs("div",{className:"max-w-7xl mx-auto px-6 pb-8",children:[y&&a.jsxs("div",{className:"bg-white rounded-lg shadow-sm border border-gray-200 p-8 text-center",children:[a.jsxs("div",{className:"inline-flex items-center space-x-3",children:[a.jsxs("svg",{className:"animate-spin h-8 w-8 text-blue-600",fill:"none",viewBox:"0 0 24 24",children:[a.jsx("circle",{className:"opacity-25",cx:"12",cy:"12",r:"10",stroke:"currentColor",strokeWidth:"4"}),a.jsx("path",{className:"opacity-75",fill:"currentColor",d:"M4 12a8 8 0 018-8V0C5.373 0 0 5.373 0 12h4zm2 5.291A7.962 7.962 0 014 12H0c0 3.042 1.135 5.824 3 7.938l3-2.647z"})]}),a.jsx("span",{className:"text-lg font-medium text-gray-900",children:"Processing antibiogram with specialist-level intelligence..."})]}),a.jsxs("p",{className:"text-gray-600 mt-2",children:["Analyzing resistance patterns and generating ",s," mode recommendations"]})]}),!y&&a.jsxs(a.Fragment,{children:[c===1&&a.jsx(_b,{onComplete:se,initialData:m}),c===2&&a.jsx(bb,{organismData:m.organism,infectionSite:m.infectionSite,onComplete:ie,initialData:m}),c===3&&a.jsx(xb,{organismData:m.organism,micData:m.micData,interpretations:m.interpretations,onComplete:$,initialData:m}),c===4&&h&&a.jsx(a.Fragment,{children:s==="simple"?a.jsx(Ib,{results:h,antibiogramData:m}):a.jsx(Sb,{results:h,antibiogramData:m})})]})]})]})},_t={CNS:{label:"Sistema Nervioso Central",color:"bg-red-50 border-red-200",options:[{value:"CNS_meningitis",label:"Meningitis bacteriana",penetration:"CNS_critical",severity:3},{value:"CNS_encephalitis",label:"Encefalitis",penetration:"CNS_critical",severity:3},{value:"CNS_brain_abscess",label:"Absceso cerebral",penetration:"CNS_critical",severity:3},{value:"CNS_subdural_empyema",label:"Empiema subdural",penetration:"CNS_critical",severity:3}]},Cardiovascular:{label:"Cardiovascular",color:"bg-purple-50 border-purple-200",options:[{value:"CV_endocarditis_native",label:"Endocarditis válvula nativa",penetration:"moderate",severity:3},{value:"CV_endocarditis_prosthetic",label:"Endocarditis válvula protésica",penetration:"moderate",severity:3},{value:"CV_endocarditis_CIED",label:"Infección dispositivo cardiaco (CIED)",penetration:"moderate",severity:3},{value:"CV_pericarditis",label:"Pericarditis bacteriana",penetration:"moderate",severity:2},{value:"CV_mycotic_aneurysm",label:"Aneurisma micótico",penetration:"moderate",severity:3}]},Respiratory:{label:"Respiratorio",color:"bg-blue-50 border-blue-200",options:[{value:"RESP_CAP",label:"Neumonía adquirida en comunidad (NAC)",penetration:"good",severity:2},{value:"RESP_HAP",label:"Neumonía nosocomial (NAH)",penetration:"good",severity:2},{value:"RESP_VAP",label:"Neumonía asociada a ventilador (NAV)",penetration:"good",severity:3},{value:"RESP_empyema",label:"Empiema pleural",penetration:"good",severity:2},{value:"RESP_lung_abscess",label:"Absceso pulmonar",penetration:"good",severity:2},{value:"RESP_bronchitis_acute",label:"Bronquitis aguda",penetration:"good",severity:1}]},GU:{label:"Genitourinario",color:"bg-green-50 border-green-200",options:[{value:"GU_UTI_uncomplicated",label:"ITU no complicada (mujer)",penetration:"urinary_specific",severity:1},{value:"GU_UTI_complicated",label:"ITU complicada",penetration:"systemic",severity:2},{value:"GU_UTI_catheter",label:"ITU asociada a catéter",penetration:"systemic",severity:2},{value:"GU_pyelonephritis",label:"Pielonefritis aguda",penetration:"systemic",severity:2},{value:"GU_prostatitis_acute",label:"Prostatitis aguda",penetration:"prostate_specific",severity:2},{value:"GU_prostatitis_chronic",label:"Prostatitis crónica",penetration:"prostate_specific",severity:1}]},Skin_Soft_Tissue:{label:"Piel y Tejidos Blandos",color:"bg-yellow-50 border-yellow-200",options:[{value:"SST_cellulitis_simple",label:"Celulitis simple",penetration:"good",severity:1},{value:"SST_cellulitis_severe",label:"Celulitis severa/eritema",penetration:"good",severity:2},{value:"SST_necrotizing_fasciitis",label:"Fascitis necrotizante",penetration:"good",severity:3},{value:"SST_abscess",label:"Absceso cutáneo",penetration:"good",severity:1},{value:"SST_diabetic_foot",label:"Pie diabético infectado",penetration:"moderate",severity:2},{value:"SST_surgical_site",label:"Infección sitio quirúrgico",penetration:"good",severity:2}]},Bone_Joint:{label:"Hueso y Articulaciones",color:"bg-orange-50 border-orange-200",options:[{value:"BJ_osteomyelitis_acute",label:"Osteomielitis aguda",penetration:"bone_specific",severity:2},{value:"BJ_osteomyelitis_chronic",label:"Osteomielitis crónica",penetration:"bone_specific",severity:2},{value:"BJ_prosthetic_joint",label:"Infección prótesis articular",penetration:"bone_specific",severity:2},{value:"BJ_septic_arthritis",label:"Artritis séptica",penetration:"good",severity:2},{value:"BJ_vertebral_osteomyelitis",label:"Osteomielitis vertebral",penetration:"bone_specific",severity:2},{value:"BJ_diabetic_foot_osteo",label:"Osteomielitis pie diabético",penetration:"bone_specific",severity:2}]},Intra_Abdominal:{label:"Intraabdominal",color:"bg-indigo-50 border-indigo-200",options:[{value:"IA_peritonitis_secondary",label:"Peritonitis secundaria",penetration:"good",severity:2},{value:"IA_peritonitis_primary",label:"Peritonitis primaria/espontánea",penetration:"good",severity:2},{value:"IA_intra_abdominal",label:"Infección intraabdominal complicada",penetration:"good",severity:2},{value:"IA_cholangitis",label:"Colangitis",penetration:"good",severity:2},{value:"IA_liver_abscess",label:"Absceso hepático",penetration:"good",severity:2},{value:"IA_appendicitis",label:"Apendicitis complicada",penetration:"good",severity:2}]},Bacteremia_Sepsis:{label:"Bacteriemia y Sepsis",color:"bg-red-50 border-red-200",options:[{value:"BS_bacteremia_primary",label:"Bacteriemia primaria",penetration:"systemic",severity:2},{value:"BS_CLABSI",label:"Bacteriemia asociada a catéter central",penetration:"systemic",severity:2},{value:"BS_sepsis",label:"Sepsis",penetration:"systemic",severity:3},{value:"BS_septic_shock",label:"Shock séptico",penetration:"systemic",severity:3},{value:"BS_neutropenic_fever",label:"Fiebre neutropénica",penetration:"systemic",severity:2}]}},wb=({children:g,title:s})=>a.jsxs("div",{className:"bg-white shadow-2xl rounded-2xl overflow-hidden w-full max-w-4xl mx-auto",children:[a.jsx("div",{className:"bg-gray-800 text-white p-4 sm:p-6",children:a.jsx("h2",{className:"text-xl sm:text-2xl font-bold",children:s})}),a.jsx("div",{className:"p-4 sm:p-8 space-y-6",children:g})]}),ft=({label:g,name:s,value:l,onChange:c,type:d="number",placeholder:m,unit:_})=>a.jsxs("div",{children:[a.jsx("label",{htmlFor:s,className:"block text-sm font-medium text-gray-700 mb-1",children:g}),a.jsxs("div",{className:"flex items-center",children:[a.jsx("input",{type:d,name:s,id:s,value:l,onChange:c,placeholder:m,className:"mt-1 block w-full px-4 py-2 bg-white border border-gray-300 rounded-md shadow-sm focus:outline-none focus:ring-indigo-500 focus:border-indigo-500",min:"0",step:d==="number"?"0.01":void 0}),_&&a.jsx("span",{className:"ml-3 text-gray-500",children:_})]})]}),Tt=({label:g,name:s,value:l,onChange:c,options:d,placeholder:m,required:_})=>a.jsxs("div",{children:[a.jsx("label",{htmlFor:s,className:"block text-sm font-medium text-gray-700 mb-1",children:g}),a.jsxs("select",{name:s,id:s,value:l,onChange:c,required:_,className:"mt-1 block w-full pl-3 pr-10 py-2 text-base border-gray-300 focus:outline-none focus:ring-indigo-500 focus:border-indigo-500 sm:text-sm rounded-md",children:[a.jsx("option",{value:"",children:m}),d.map(h=>a.jsx("option",{value:h.value,children:h.label},h.value))]})]}),Rb=({current:g,total:s})=>a.jsx("div",{className:"w-full bg-gray-200 rounded-full h-2.5 mb-8",children:a.jsx("div",{className:"bg-indigo-600 h-2.5 rounded-full",style:{width:`${g/s*100}%`,transition:"width 0.5s ease-in-out"}})}),Mb=({data:g,onChange:s,calculations:l})=>a.jsxs("div",{children:[a.jsx("h3",{className:"text-xl font-semibold text-gray-800 mb-4",children:"Datos del Paciente"}),a.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[a.jsx(ft,{label:"Edad",name:"age",value:g.age,onChange:s,unit:"años",placeholder:"e.g., 55"}),a.jsx(Tt,{label:"Sexo",name:"gender",value:g.gender,onChange:s,options:[{value:"Female",label:"Femenino"},{value:"Male",label:"Masculino"}]}),a.jsx(ft,{label:"Peso",name:"weight",value:g.weight,onChange:s,unit:"kg",placeholder:"e.g., 70"}),a.jsx(ft,{label:"Talla",name:"height",value:g.height,onChange:s,unit:"cm",placeholder:"e.g., 175"})]}),g.gender==="Female"&&g.age>=15&&g.age<=50&&a.jsx("div",{className:"mt-6 border-t pt-6",children:a.jsxs("label",{className:"flex items-center space-x-3 cursor-pointer",children:[a.jsx("input",{type:"checkbox",name:"isPregnantOrFertile",checked:g.isPregnantOrFertile,onChange:s,className:"h-5 w-5 text-indigo-600 rounded focus:ring-indigo-500"}),a.jsx("span",{className:"text-gray-800 font-medium",children:"¿Paciente embarazada, en lactancia o en edad fértil?"})]})}),a.jsxs("div",{className:"mt-6 border-t pt-6",children:[a.jsx("h4",{className:"font-semibold text-gray-800",children:"Función Renal"}),a.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-6 mt-2",children:[a.jsx(ft,{label:"Creatinina Sérica",name:"creatinine",value:g.creatinine,onChange:s,unit:"mg/dL",placeholder:"e.g., 1.2"}),g.age>=18&&a.jsxs("div",{children:[a.jsxs("label",{className:"flex items-center space-x-3 cursor-pointer mt-2",children:[a.jsx("input",{type:"checkbox",name:"useCystatinC",checked:g.useCystatinC,onChange:s,className:"h-5 w-5 text-indigo-600 rounded"}),a.jsx("span",{className:"font-medium",children:"Usar Cistatina C"})]}),g.useCystatinC&&a.jsx(ft,{label:"Cistatina C",name:"cystatinC",value:g.cystatinC,onChange:s,unit:"mg/L"})]}),a.jsx(Tt,{label:"Terapia de Reemplazo Renal",name:"rrt",value:g.rrt,onChange:s,options:[{value:"None",label:"Ninguna"},{value:"HD",label:"Hemodiálisis (HD)"},{value:"CRRT",label:"CRRT"},{value:"SLED",label:"SLED"},{value:"CAPD",label:"DPAC"}],placeholder:"-- Seleccione --"})]})]}),a.jsx("div",{className:"mt-6 border-t pt-6",children:a.jsxs("label",{className:"flex items-center space-x-3 cursor-pointer",children:[a.jsx("input",{type:"checkbox",name:"hasHepaticDisease",checked:g.hasHepaticDisease,onChange:s,className:"h-5 w-5 text-indigo-600 rounded"}),a.jsx("span",{className:"font-medium",children:"¿Enfermedad Hepática?"})]})}),g.hasHepaticDisease&&a.jsxs("div",{className:"mt-4 p-4 bg-indigo-50 rounded-lg space-y-4 animate-fade-in",children:[a.jsx("h4",{className:"font-semibold text-indigo-800",children:"Cálculo de Child-Pugh"}),a.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-3 gap-4",children:[a.jsx(ft,{label:"Bilirrubina Total",name:"bilirubin",value:g.bilirubin,onChange:s,unit:"mg/dL"}),a.jsx(ft,{label:"Albúmina Sérica",name:"albumin",value:g.albumin,onChange:s,unit:"g/dL"}),a.jsx(ft,{label:"INR",name:"inr",value:g.inr,onChange:s}),a.jsx(Tt,{label:"Ascitis",name:"ascites",value:g.ascites,onChange:s,options:[{value:1,label:"Ninguna"},{value:2,label:"Leve"},{value:3,label:"Moderada/Severa"}]}),a.jsx(Tt,{label:"Encefalopatía",name:"encephalopathy",value:g.encephalopathy,onChange:s,options:[{value:1,label:"Ninguna"},{value:2,label:"Grado 1-2"},{value:3,label:"Grado 3-4"}]})]})]}),a.jsxs("div",{className:"mt-6 border-t pt-6",children:[a.jsxs("div",{className:"flex items-center justify-between",children:[a.jsx("h4",{className:"font-semibold text-gray-800",children:"Evaluación de Severidad Clínica"}),a.jsxs("button",{type:"button",onClick:()=>s({target:{name:"showSeverityAssessment",type:"checkbox",checked:!g.showSeverityAssessment}}),className:"text-sm text-indigo-600 hover:text-indigo-800 font-medium",children:[g.showSeverityAssessment?"Ocultar":"Mostrar"," evaluación avanzada"]})]}),a.jsx("div",{className:"mt-3 text-xs text-gray-600",children:a.jsxs("p",{children:[a.jsx("strong",{children:"Nota:"})," La evaluación de severidad mejora la precisión de las recomendaciones mediante criterios objetivos específicos."]})}),g.showSeverityAssessment&&a.jsx("div",{className:"mt-4 p-4 bg-yellow-50 rounded-lg space-y-4 animate-fade-in",children:a.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-4",children:[a.jsxs("div",{children:[a.jsx("label",{className:"block text-sm font-medium text-gray-700 mb-2",children:"Criterios de Severidad Objetivos"}),a.jsxs("div",{className:"space-y-2",children:[a.jsxs("label",{className:"flex items-center space-x-3 cursor-pointer",children:[a.jsx("input",{type:"checkbox",name:"isICU",checked:g.isICU||!1,onChange:s,className:"h-4 w-4 text-indigo-600 rounded focus:ring-indigo-500"}),a.jsx("span",{className:"text-sm font-medium text-gray-700",children:"UCI o cuidados intensivos"})]}),a.jsxs("label",{className:"flex items-center space-x-3 cursor-pointer",children:[a.jsx("input",{type:"checkbox",name:"isImmunocompromised",checked:g.isImmunocompromised||!1,onChange:s,className:"h-4 w-4 text-indigo-600 rounded focus:ring-indigo-500"}),a.jsx("span",{className:"text-sm font-medium text-gray-700",children:"Inmunocomprometido"})]}),a.jsxs("label",{className:"flex items-center space-x-3 cursor-pointer",children:[a.jsx("input",{type:"checkbox",name:"priorAntibiotics",checked:g.priorAntibiotics||!1,onChange:s,className:"h-4 w-4 text-indigo-600 rounded focus:ring-indigo-500"}),a.jsx("span",{className:"text-sm font-medium text-gray-700",children:"Antibióticos previos (últimos 90 días)"})]}),a.jsxs("label",{className:"flex items-center space-x-3 cursor-pointer",children:[a.jsx("input",{type:"checkbox",name:"hasOrganDysfunction",checked:g.hasOrganDysfunction||!1,onChange:s,className:"h-4 w-4 text-indigo-600 rounded focus:ring-indigo-500"}),a.jsx("span",{className:"text-sm font-medium text-gray-700",children:"Disfunción orgánica"})]}),a.jsxs("label",{className:"flex items-center space-x-3 cursor-pointer",children:[a.jsx("input",{type:"checkbox",name:"hasSepsis",checked:g.hasSepsis||!1,onChange:s,className:"h-4 w-4 text-indigo-600 rounded focus:ring-indigo-500"}),a.jsx("span",{className:"text-sm font-medium text-gray-700",children:"Sepsis o shock séptico"})]})]})]}),a.jsxs("div",{children:[a.jsx(Tt,{label:"Estado Hemodinámico",name:"hemodynamicStatus",value:g.hemodynamicStatus,onChange:s,options:[{value:"stable",label:"Estable"},{value:"hypotension",label:"Hipotensión"},{value:"shock",label:"Shock/vasopresores"}],placeholder:"-- Seleccione --"}),a.jsx("div",{className:"mt-3",children:a.jsx(Tt,{label:"Función Respiratoria",name:"respiratoryStatus",value:g.respiratoryStatus,onChange:s,options:[{value:"normal",label:"Normal"},{value:"oxygen",label:"Oxígeno suplementario"},{value:"mechanical",label:"Ventilación mecánica"}],placeholder:"-- Seleccione --"})})]})]})})]}),a.jsxs("div",{className:"mt-6 border-t pt-6",children:[a.jsxs("div",{className:"flex items-center justify-between",children:[a.jsx("h4",{className:"font-semibold text-gray-800",children:"Epidemiología Local"}),a.jsxs("button",{type:"button",onClick:()=>s({target:{name:"showEpidemiologyData",type:"checkbox",checked:!g.showEpidemiologyData}}),className:"text-sm text-indigo-600 hover:text-indigo-800 font-medium",children:[g.showEpidemiologyData?"Ocultar":"Personalizar"," datos epidemiológicos"]})]}),a.jsx("div",{className:"mt-3 text-xs text-gray-600",children:a.jsxs("p",{children:[a.jsx("strong",{children:"Nota:"})," Los datos epidemiológicos locales mejoran la precisión de las recomendaciones. Si no se especifican, se utilizarán valores por defecto basados en literatura."]})}),g.showEpidemiologyData&&a.jsx("div",{className:"mt-4 p-4 bg-blue-50 rounded-lg space-y-4 animate-fade-in",children:a.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-3 gap-4",children:[a.jsx(ft,{label:"Tasa ESBL Local (%)",name:"localESBLRate",value:g.localESBLRate,onChange:s,type:"number",placeholder:"ej. 15",unit:"%"}),a.jsx(ft,{label:"Resistencia a Carbapenémicos (%)",name:"localCarbapenemResistance",value:g.localCarbapenemResistance,onChange:s,type:"number",placeholder:"ej. 3",unit:"%"}),a.jsx(Tt,{label:"Tipo de Institución",name:"institutionType",value:g.institutionType,onChange:s,options:[{value:"community",label:"Hospital Comunitario"},{value:"academic",label:"Centro Académico"},{value:"tertiary",label:"Centro de Referencia"}],placeholder:"-- Seleccione tipo --"})]})})]}),a.jsxs("div",{className:"mt-8 p-6 bg-gray-50 rounded-lg space-y-3",children:[a.jsx("h4",{className:"text-lg font-semibold text-gray-700",children:"Valores Calculados:"}),a.jsxs("p",{children:[a.jsx("strong",{children:"TFG:"})," ",l.tfg?`${String(l.tfg.value)} mL/min/1.73m²`:"N/A"," ",a.jsxs("span",{className:"text-sm text-gray-500",children:["(",l.tfg?String(l.tfg.formula):"N/A",")"]})]}),a.jsxs("p",{children:[a.jsx("strong",{children:"IMC:"})," ",l.bmi?`${String(l.bmi)} kg/m²`:"N/A",l.bmiZScore!==null&&a.jsxs("span",{className:"text-sm text-blue-600 ml-2",children:["(Z-score: ",l.bmiZScore.toFixed(2),")"]}),a.jsx("br",{}),a.jsx("span",{className:"text-sm text-gray-600",children:String(l.obesityClass||"N/A")}),l.bmiZScore!==null&&a.jsxs(a.Fragment,{children:[a.jsx("br",{}),a.jsx("span",{className:"text-xs text-blue-500",children:"📊 Clasificación pediátrica basada en estándares WHO con z-score edad/sexo específico"})]})]}),parseFloat(g.age)<5&&parseFloat(g.age)>0&&a.jsxs("div",{className:"mt-3 p-3 bg-blue-50 rounded-md border border-blue-200",children:[a.jsx("h5",{className:"text-sm font-semibold text-blue-800 mb-2",children:"📈 Indicadores de Crecimiento WHO (menores de 5 años)"}),l.heightForAgeZScore!==null&&a.jsxs("p",{className:"text-sm text-blue-700",children:[a.jsx("strong",{children:"Talla para la edad:"})," Z-score ",l.heightForAgeZScore.toFixed(2),a.jsxs("span",{className:"ml-2 text-xs font-medium",children:["(",String(l.heightForAgeClass),")"]})]}),l.weightForAgeZScore!==null&&a.jsxs("p",{className:"text-sm text-blue-700 mt-1",children:[a.jsx("strong",{children:"Peso para la edad:"})," Z-score ",l.weightForAgeZScore.toFixed(2),a.jsxs("span",{className:"ml-2 text-xs font-medium",children:["(",String(l.weightForAgeClass),")"]})]}),a.jsxs("p",{className:"text-xs text-blue-600 mt-2",children:[a.jsx("strong",{children:"Nota:"})," Los indicadores de crecimiento ayudan a identificar desnutrición, retraso en el crecimiento, y otros factores que pueden afectar el dosaje de antibióticos."]})]}),g.hasHepaticDisease&&a.jsxs("p",{children:[a.jsx("strong",{children:"Child-Pugh Score:"})," ",l.childPugh?`${String(l.childPugh.score)} (Clase ${String(l.childPugh.class)})`:"Datos incompletos"]}),l.severityAssessment&&a.jsxs("div",{className:"p-3 bg-yellow-100 rounded-md",children:[a.jsxs("p",{children:[a.jsx("strong",{children:"Severidad Clínica:"})," ",String(l.severityAssessment.level)," (Puntuación: ",String(l.severityAssessment.score),")"]}),a.jsxs("p",{className:"text-sm text-gray-600 mt-1",children:[a.jsx("strong",{children:"Factores:"})," ",String(l.severityAssessment.factors.join(", "))]})]}),l.epidemiologyRisk&&a.jsxs("div",{className:"p-3 bg-blue-100 rounded-md",children:[a.jsxs("p",{children:[a.jsx("strong",{children:"Riesgo Epidemiológico:"})," ",String(l.epidemiologyRisk.level)]}),a.jsxs("p",{className:"text-sm text-gray-600 mt-1",children:[a.jsx("strong",{children:"Factores:"})," ",String(l.epidemiologyRisk.factors.join(", "))]})]})]})]}),Db=({data:g,onChange:s})=>{var d;const[l,c]=oe.useState(null);return oe.useEffect(()=>{if(g.location&&g.location.includes("_")){const m=Object.keys(_t).find(_=>_t[_].options.some(h=>h.value===g.location));m&&c(m)}},[g.location]),a.jsxs("div",{children:[a.jsx("h3",{className:"text-xl font-semibold text-gray-800 mb-4",children:"Síndrome Infeccioso"}),a.jsx("p",{className:"text-sm text-gray-600 mb-4",children:"Seleccione el síndrome clínico específico para optimizar la interpretación del antibiograma, requerimientos de penetración y recomendaciones de tratamiento."}),!g.location&&a.jsx("div",{className:"mb-4 p-3 bg-blue-50 border border-blue-200 rounded-lg",children:a.jsxs("p",{className:"text-sm text-blue-700",children:["💡 ",a.jsx("strong",{children:"Consejo:"})," Haga clic en cualquier categoría anatómica para ver los síndromes específicos disponibles."]})}),a.jsx("div",{className:"space-y-3",children:Object.entries(_t).map(([m,_])=>{const h=l===m,v=_.options.some(y=>y.value===g.location);return a.jsxs("div",{className:`rounded-lg border transition-all duration-200 ${v?`${_.color} border-2`:h?`${_.color}`:"bg-gray-50 border-gray-200 hover:bg-gray-100"}`,children:[a.jsxs("button",{type:"button",onClick:()=>c(h?null:m),className:"w-full p-4 text-left flex items-center justify-between focus:outline-none",children:[a.jsxs("div",{className:"flex items-center space-x-3",children:[a.jsx("h4",{className:"font-semibold text-gray-800",children:_.label}),v&&a.jsx("span",{className:"text-xs px-2 py-1 bg-indigo-100 text-indigo-700 rounded-full",children:"Seleccionado"})]}),a.jsx("svg",{className:`w-5 h-5 text-gray-500 transition-transform duration-200 ${h?"rotate-180":""}`,fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19 9l-7 7-7-7"})})]}),h&&a.jsx("div",{className:"px-4 pb-4 animate-fade-in",children:a.jsx("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-2",children:_.options.map(y=>a.jsxs("label",{className:"flex items-center space-x-3 cursor-pointer p-2 rounded hover:bg-white hover:bg-opacity-60",children:[a.jsx("input",{type:"radio",name:"location",value:y.value,checked:g.location===y.value,onChange:D=>{s(D),c(m)},className:"h-4 w-4 text-indigo-600 focus:ring-indigo-500"}),a.jsxs("div",{children:[a.jsx("span",{className:"text-sm font-medium text-gray-800",children:y.label}),a.jsxs("div",{className:"flex items-center space-x-2 mt-1",children:[a.jsxs("span",{className:`text-xs px-2 py-1 rounded ${y.severity===3?"bg-red-100 text-red-700":y.severity===2?"bg-yellow-100 text-yellow-700":"bg-green-100 text-green-700"}`,children:["Severidad: ",y.severity===3?"Alta":y.severity===2?"Moderada":"Leve"]}),a.jsxs("span",{className:"text-xs text-gray-500",children:["Penetración: ",y.penetration==="CNS_critical"?"Barrera hematoencefálica crítica":y.penetration==="bone_specific"?"Penetración ósea específica":y.penetration==="urinary_specific"?"Concentración urinaria":y.penetration==="prostate_specific"?"Penetración prostática":y.penetration==="systemic"?"Sistémica":"Buena"]})]})]})]},y.value))})})]},m)})}),g.location&&a.jsxs("div",{className:"mt-6 p-4 bg-blue-50 border border-blue-200 rounded-lg",children:[a.jsx("h4",{className:"font-semibold text-blue-800 mb-2",children:"Consideraciones Clínicas"}),a.jsx("div",{className:"text-sm text-blue-700",children:((d=_t[Object.keys(_t).find(m=>_t[m].options.some(_=>_.value===g.location))])==null?void 0:d.options.find(m=>m.value===g.location))&&(()=>{const m=_t[Object.keys(_t).find(h=>_t[h].options.some(v=>v.value===g.location))].options.find(h=>h.value===g.location);return{CNS_meningitis:"• Penetración de barrera hematoencefálica esencial • Altas dosis requeridas • Actividad bactericida preferida",CNS_brain_abscess:"• Penetración de barrera hematoencefálica esencial • Tratamiento prolongado • Considerar drenaje quirúrgico",GU_UTI_uncomplicated:"• Concentración urinaria más importante que sérica • Considerar fosfomicina, nitrofurantoína • Duración corta (3 días)",GU_UTI_complicated:"• Penetración sistémica requerida • Descartar complicaciones estructurales • Duración 7-14 días",GU_prostatitis_acute:"• Penetración prostática esencial • Fluoroquinolonas, TMP-SMX preferidos • Duración 2-4 semanas",BJ_osteomyelitis_chronic:"• Penetración ósea esencial • Tratamiento prolongado (6-12 semanas) • Considerar terapia oral secuencial",BJ_prosthetic_joint:"• Actividad anti-biofilm importante • Combinaciones sinérgicas • Evaluar retención vs remoción",RESP_VAP:"• Cobertura anti-Pseudomonas • Resistencia nosocomial alta • Considerar terapia combinada",IA_peritonitis_secondary:"• Cobertura anaeróbica esencial • Infección polimicrobiana • Control quirúrgico del foco",BS_septic_shock:"• Inicio precoz (<1 hora) • Cobertura empírica amplia • Desescalamiento basado en cultivos"}[m.value]||"• Consideraciones específicas del síndrome seleccionado aplicarán"})()})]})]})},qb=({data:g,onChange:s})=>{var se,ie,$,ne,w,O,U,Z,X,T,q,C,E,z,H,Y,ee,le,Q,k,G,ae,N,p,A,J;const[l,c]=oe.useState(""),[d,m]=oe.useState(""),[_,h]=oe.useState(""),v=ep(),y=oe.useMemo(()=>{let P=v;return l&&(P=P.filter(V=>V.name.toLowerCase().includes(l.toLowerCase())||V.searchTerms.includes(l.toLowerCase()))),d&&(P=P.filter(V=>V.gramStain.toLowerCase().includes(d.toLowerCase()))),_&&(P=P.filter(V=>V.clinicalSignificance>=parseInt(_))),P},[l,d,_,v]),D=P=>{s({target:{name:"bacteriumId",value:P}}),c("")},L=g.bacteriumId?$i()[g.bacteriumId]:null,W=({level:P})=>{const V={3:"bg-red-100 text-red-800 border-red-300",2:"bg-orange-100 text-orange-800 border-orange-300",1:"bg-yellow-100 text-yellow-800 border-yellow-300",0:"bg-gray-100 text-gray-800 border-gray-300"},te={3:"Patógeno Primario",2:"Oportunista",1:"Colonizador",0:"Contaminante"};return a.jsx("span",{className:`inline-flex items-center px-2 py-1 rounded-full text-xs font-medium border ${V[P]}`,children:te[P]})};return a.jsxs("div",{className:"space-y-6",children:[a.jsxs("div",{children:[a.jsx("h3",{className:"text-xl font-semibold text-gray-800 mb-4",children:"Identificación del Microorganismo"}),a.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-3 gap-4 mb-4",children:[a.jsx("div",{className:"relative",children:a.jsx("input",{type:"text",value:l,onChange:P=>c(P.target.value),placeholder:"Buscar por nombre, características...",className:"w-full px-4 py-2 bg-white border border-gray-300 rounded-md shadow-sm focus:outline-none focus:ring-indigo-500 focus:border-indigo-500"})}),a.jsx(Tt,{label:"",name:"gramFilter",value:d,onChange:P=>m(P.target.value),options:[{value:"",label:"Todas las bacterias"},{value:"Gram-positive",label:"Gram positivas"},{value:"Gram-negative",label:"Gram negativas"}],placeholder:"Filtrar por Gram"}),a.jsx(Tt,{label:"",name:"significanceFilter",value:_,onChange:P=>h(P.target.value),options:[{value:"",label:"Cualquier significancia"},{value:"3",label:"Solo patógenos primarios"},{value:"2",label:"Patógenos y oportunistas"},{value:"1",label:"Incluir colonizadores"}],placeholder:"Filtrar por relevancia clínica"})]}),l&&a.jsx("div",{className:"bg-white border border-gray-300 rounded-md shadow-lg max-h-80 overflow-y-auto",children:y.length>0?y.map(P=>{var V,te;return a.jsx("div",{onClick:()=>D(P.id),className:"px-4 py-3 cursor-pointer hover:bg-indigo-50 border-b border-gray-100 last:border-b-0",children:a.jsxs("div",{className:"flex items-center justify-between",children:[a.jsxs("div",{children:[a.jsx("h4",{className:"font-medium text-gray-900",children:String(P.name||"Unknown")}),a.jsxs("p",{className:"text-sm text-gray-600",children:[String(P.gramStain||"Unknown")," • ",String(P.clsiCategory||"Unknown")]}),a.jsxs("p",{className:"text-xs text-gray-500 mt-1",children:[String(((V=P.taxonomy)==null?void 0:V.genus)||"")," ",String(((te=P.taxonomy)==null?void 0:te.species)||"")]})]}),a.jsx(W,{level:P.clinicalSignificance})]})},P.id)}):a.jsx("div",{className:"px-4 py-2 text-gray-500",children:"No se encontraron resultados"})})]}),L&&a.jsxs("div",{className:"bg-white border border-gray-200 rounded-lg shadow-sm overflow-hidden",children:[a.jsx("div",{className:"bg-indigo-50 px-6 py-4 border-b border-gray-200",children:a.jsxs("div",{className:"flex items-center justify-between",children:[a.jsxs("div",{children:[a.jsx("h4",{className:"text-lg font-bold text-gray-900",children:String(((se=L.identity)==null?void 0:se.bacteriumName)||L.name||"Unknown")}),a.jsxs("p",{className:"text-sm text-gray-600 mt-1",children:[a.jsx("strong",{children:"Taxonomía:"})," ",String(((ie=L.taxonomy)==null?void 0:ie.genus)||"")," ",String((($=L.taxonomy)==null?void 0:$.species)||"")]})]}),a.jsx(W,{level:L.clinicalSignificance||2})]})}),a.jsxs("div",{className:"p-6 space-y-6",children:[a.jsxs("div",{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[a.jsxs("div",{className:"space-y-3",children:[a.jsx("h5",{className:"font-semibold text-gray-800 flex items-center",children:"🔬 Características Microscópicas"}),a.jsxs("div",{className:"bg-gray-50 p-3 rounded-md space-y-2",children:[a.jsxs("div",{className:"flex justify-between",children:[a.jsx("span",{className:"text-sm font-medium",children:"Tinción de Gram:"}),a.jsx("span",{className:"text-sm",children:((w=(ne=L.identity)==null?void 0:ne.classification)==null?void 0:w.gramStain)||"N/A"})]}),a.jsxs("div",{className:"flex justify-between",children:[a.jsx("span",{className:"text-sm font-medium",children:"Morfología:"}),a.jsx("span",{className:"text-sm",children:((U=(O=L.identity)==null?void 0:O.classification)==null?void 0:U.morphology)||"N/A"})]}),a.jsxs("div",{className:"flex justify-between",children:[a.jsx("span",{className:"text-sm font-medium",children:"Respiración:"}),a.jsx("span",{className:"text-sm",children:((X=(Z=L.identity)==null?void 0:Z.classification)==null?void 0:X.respiration)||"N/A"})]})]})]}),a.jsxs("div",{className:"space-y-3",children:[a.jsx("h5",{className:"font-semibold text-gray-800 flex items-center",children:"🧪 Pruebas Bioquímicas"}),a.jsx("div",{className:"bg-gray-50 p-3 rounded-md space-y-1",children:(T=L.identity)!=null&&T.biochemicalTests?a.jsx("div",{className:"text-sm text-gray-600",children:L.identity.biochemicalTests}):a.jsx("div",{className:"text-sm text-gray-500",children:"No disponible"})})]})]}),a.jsxs("div",{className:"space-y-3",children:[a.jsx("h5",{className:"font-semibold text-gray-800 flex items-center",children:"📋 Información Clínica"}),a.jsxs("div",{className:"bg-gray-50 p-3 rounded-md",children:[a.jsxs("div",{className:"text-sm text-gray-600",children:[a.jsx("strong",{children:"Categoría CLSI:"})," ",((q=L.identity)==null?void 0:q.clsiCategory)||"N/A"]}),a.jsxs("div",{className:"text-sm text-gray-600 mt-2",children:[a.jsx("strong",{children:"Resumen:"})," ",((C=L.clinicalProfile)==null?void 0:C.summary)||"No disponible"]})]})]}),a.jsxs("div",{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[((E=L.clinicalProfile)==null?void 0:E.clinicalSyndromes)&&a.jsxs("div",{className:"space-y-3",children:[a.jsx("h5",{className:"font-semibold text-gray-800 flex items-center",children:"🦠 Síndromes Clínicos"}),a.jsx("div",{className:"bg-blue-50 p-3 rounded-md",children:a.jsx("ul",{className:"text-sm space-y-1",children:L.clinicalProfile.clinicalSyndromes.slice(0,5).map((P,V)=>a.jsxs("li",{className:"text-blue-800",children:["• ",a.jsxs("strong",{children:[P.syndromeName,":"]})," ",P.description]},V))})})]}),((z=L.resistanceProfile)==null?void 0:z.majorMechanisms)&&a.jsxs("div",{className:"space-y-3",children:[a.jsx("h5",{className:"font-semibold text-gray-800 flex items-center",children:"🛡️ Mecanismos de Resistencia"}),a.jsx("div",{className:"bg-orange-50 p-3 rounded-md",children:a.jsx("ul",{className:"text-sm space-y-1",children:L.resistanceProfile.majorMechanisms.slice(0,3).map((P,V)=>a.jsxs("li",{className:"text-orange-800",children:["• ",a.jsxs("strong",{children:[P.mechanismName,":"]})," ",P.description]},V))})})]})]}),(((Y=(H=L.resistanceProfile)==null?void 0:H.intrinsicResistance)==null?void 0:Y.length)>0||((le=(ee=L.resistanceProfile)==null?void 0:ee.groupIntrinsicResistance)==null?void 0:le.length)>0)&&a.jsxs("div",{className:"p-3 bg-yellow-50 border-l-4 border-yellow-400 rounded-md",children:[a.jsx("h5",{className:"font-semibold text-yellow-800 mb-2",children:"⚠️ Resistencia Intrínseca"}),a.jsxs("div",{className:"space-y-3",children:[((k=(Q=L.resistanceProfile)==null?void 0:Q.groupIntrinsicResistance)==null?void 0:k.length)>0&&a.jsxs("div",{children:[a.jsx("div",{className:"text-xs font-medium text-yellow-800 mb-1",children:"Resistencia de Grupo:"}),L.resistanceProfile.groupIntrinsicResistance.map((P,V)=>a.jsxs("div",{className:"text-sm text-yellow-700 pl-2",children:[a.jsx("span",{className:"font-medium",children:P.drugOrClass}),P.notes&&a.jsxs("div",{className:"text-yellow-600 text-xs mt-1 ml-2",children:["📝 ",P.notes]})]},`group-${V}`))]}),((ae=(G=L.resistanceProfile)==null?void 0:G.intrinsicResistance)==null?void 0:ae.length)>0&&a.jsxs("div",{children:[((p=(N=L.resistanceProfile)==null?void 0:N.groupIntrinsicResistance)==null?void 0:p.length)>0&&a.jsx("div",{className:"text-xs font-medium text-yellow-800 mb-1",children:"Resistencia Específica:"}),L.resistanceProfile.intrinsicResistance.map((P,V)=>a.jsxs("div",{className:"text-sm text-yellow-700 pl-2",children:[a.jsx("span",{className:"font-medium",children:P.drugOrClass}),P.notes&&a.jsxs("div",{className:"text-yellow-600 text-xs mt-1 ml-2",children:["📝 ",P.notes]})]},`individual-${V}`))]})]})]}),((J=(A=L.clinicalProfile)==null?void 0:A.highRiskPopulations)==null?void 0:J.length)>0&&a.jsxs("div",{className:"bg-gray-50 p-3 rounded-md",children:[a.jsx("h5",{className:"font-semibold text-gray-800 mb-2",children:"👥 Poblaciones de Alto Riesgo"}),a.jsx("div",{className:"text-sm text-gray-600",children:L.clinicalProfile.highRiskPopulations.join(", ")})]})]})]})]})},Tb=({data:g,onChange:s})=>{var $,ne;const l=g.bacteriumId?$i()[g.bacteriumId]:null;if(!l)return a.jsx("div",{className:"text-center text-gray-600 p-4 bg-gray-100 rounded-md",children:"Por favor, seleccione un microorganismo en el paso anterior."});const c=(w,O)=>{var Z,X;const U={...g.micValues,[w]:O};if(s({target:{name:"micValues",value:U}}),O&&!isNaN(parseFloat(O))){const T=parseFloat(O),q=h.flatMap(E=>E.agents).find(E=>E.agentName===w),C=(X=(Z=q==null?void 0:q.breakpointSets)==null?void 0:Z[0])==null?void 0:X.mic;if(C){const E=le=>{if(!le)return NaN;const k=le.replace("≤ ","").replace("≥ ","").replace("> ","").split("/")[0];return parseFloat(k)},z=E(C.s_breakpoint),H=E(C.i_breakpoint),Y=E(C.r_breakpoint);let ee="I";if(isNaN(z)||(C.s_breakpoint.includes("≤")&&T<=z||C.s_breakpoint.includes("≥")&&T>=z)&&(ee="S"),!isNaN(Y)&&ee!=="S"&&(C.r_breakpoint.includes("≥")&&T>=Y||C.r_breakpoint.includes("≤")&&T<=Y)&&(ee="R"),!isNaN(H)&&ee==="I"&&C.i_breakpoint&&typeof C.i_breakpoint=="string")if(C.i_breakpoint.includes("–")){const[le,Q]=C.i_breakpoint.split("–").map(k=>parseFloat(k.trim()));T>=le&&T<=Q&&(ee="I")}else T===H&&(ee="I");s({target:{name:"susceptibilityResults",value:{...g.susceptibilityResults,[w]:ee}}})}}},d=(w,O)=>{const U={...g.micValues};delete U[w],s({target:{name:"micValues",value:U}}),s({target:{name:"susceptibilityResults",value:{...g.susceptibilityResults,[w]:O}}})},m=(w,O)=>{var Z,X;const U=(X=(Z=w==null?void 0:w.breakpointSets)==null?void 0:Z[0])==null?void 0:X.mic;if(!U)return"";switch(O){case"S":return U.s_breakpoint||"";case"I":return U.i_breakpoint||"";case"R":return U.r_breakpoint||"";default:return""}},_=w=>{var X;const O=(X=w==null?void 0:w.breakpointSets)==null?void 0:X[0];if(!O)return null;const U=O.comments||[],Z=O.condition||"";return U.length===0&&!Z?null:{condition:Z!=="Standard"?Z:"",comments:U}},[h,v]=oe.useState([]),[y,D]=oe.useState(!1);oe.useEffect(()=>{if(!l){v([]);return}(async()=>{var U;D(!0);try{const{getTierAntibiotics:Z,findOrganismCategory:X}=await wf(async()=>{const{getTierAntibiotics:C,findOrganismCategory:E}=await Promise.resolve().then(()=>lb);return{getTierAntibiotics:C,findOrganismCategory:E}},void 0,import.meta.url),T=((U=l.identity)==null?void 0:U.bacteriumName)||l.name;if(X(T)){const C=Z(T,"Tier 1"),E=Z(T,"Tier 2"),z=Z(T,"Tier 3"),H=(ee,le,Q)=>({tier:le,tierDescription:Q,agents:ee.map(k=>{var G,ae,N;return{agentName:k.name,breakpointSets:[{condition:k.condition||"Standard",mic:{s_breakpoint:((G=k.mic_breakpoints)==null?void 0:G.S)||"≤1",i_breakpoint:((ae=k.mic_breakpoints)==null?void 0:ae.I)||"2",r_breakpoint:((N=k.mic_breakpoints)==null?void 0:N.R)||"≥4"}}]}})}),Y=[];if(C.length>0&&Y.push(H(C,1,"Rutinas de Primera Línea")),E.length>0&&Y.push(H(E,2,"Agentes Selectivos")),z.length>0&&Y.push(H(z,3,"Agentes Especializados")),Y.length>0){v(Y),D(!1);return}}}catch(Z){console.warn("CLSI tiers not available, using fallback:",Z.message)}const O=L(l);v([{tier:1,tierDescription:"Antibióticos Básicos (CLSI no disponible)",agents:O.map(Z=>({agentName:Z,breakpointSets:[{condition:"Standard",mic:{s_breakpoint:"≤1",i_breakpoint:"2",r_breakpoint:"≥4"}}]}))}]),D(!1)})()},[l]);const L=w=>{var U;const O=(((U=w.identity)==null?void 0:U.bacteriumName)||w.name||"").toLowerCase();return O.includes("escherichia")||O.includes("e. coli")?["Ampicillin","Amoxicillin-clavulanate","Ceftriaxone","Ciprofloxacin","Trimethoprim-sulfamethoxazole","Nitrofurantoin","Gentamicin","Meropenem"]:O.includes("klebsiella")?["Amoxicillin-clavulanate","Ceftriaxone","Ceftazidime","Cefepime","Ciprofloxacin","Trimethoprim-sulfamethoxazole","Gentamicin","Meropenem"]:O.includes("staphylococcus")?["Oxacillin","Vancomycin","Clindamycin","Erythromycin","Trimethoprim-sulfamethoxazole","Linezolid","Daptomycin","Cefazolin"]:O.includes("enterococcus")?["Ampicillin","Vancomycin","Linezolid","Daptomycin","Nitrofurantoin","High-level gentamicin","High-level streptomycin"]:O.includes("pseudomonas")?["Piperacillin-tazobactam","Ceftazidime","Cefepime","Ciprofloxacin","Meropenem","Gentamicin","Amikacin","Colistin"]:["Ampicillin","Amoxicillin-clavulanate","Ceftriaxone","Ciprofloxacin","Trimethoprim-sulfamethoxazole","Gentamicin","Meropenem"]},W=w=>{if(w===1)return!0;const O=h.filter(X=>X.tier<w);let U=0,Z=0;for(const X of O)for(const T of X.agents){const q=g.susceptibilityResults[T.agentName];q&&(Z++,(q==="R"||q==="I")&&U++)}if(Z>0){const X=U/Z;if(w===2)return["Ceftriaxone","Ceftazidime","Cefepime","Gentamicin"].some(q=>g.susceptibilityResults[q]==="R")||X>=.5;if(w===3){const T=["Meropenem","Imipenem","Ertapenem"].some(C=>g.susceptibilityResults[C]==="R"),q=g.susceptibilityResults.Ceftazidime==="R"&&g.susceptibilityResults.Ceftriaxone==="R";return T||q||X>=.6}if(w===4){const T=X>=.7,q=["Meropenem","Imipenem"].every(C=>g.susceptibilityResults[C]==="R");return T||q}}return!1},ie=(()=>{var T,q,C,E;const w=((T=l.identity)==null?void 0:T.bacteriumName)||l.name,O=l.taxonomy,U=((q=l.resistanceProfile)==null?void 0:q.intrinsicResistance)||[],Z=((C=l.resistanceProfile)==null?void 0:C.resistanceMechanisms)||[],X=((E=l.clinicalSignificance)==null?void 0:E.epidemiology)||{};return{bacteriumName:w,taxonomy:O,intrinsicResistance:U,resistanceMechanisms:Z,epidemiology:X}})();return y?a.jsx("div",{className:"space-y-6",children:a.jsxs("div",{className:"text-center py-8",children:[a.jsx("div",{className:"text-blue-500 text-xl mb-2",children:"🔍"}),a.jsx("h3",{className:"text-lg font-semibold text-gray-800",children:"Cargando Panel CLSI"}),a.jsxs("p",{className:"text-sm text-gray-600",children:["Seleccionando antibióticos apropiados para ",(($=l.identity)==null?void 0:$.bacteriumName)||l.name,"..."]})]})}):a.jsxs("div",{className:"space-y-6",children:[a.jsxs("div",{children:[a.jsxs("h3",{className:"text-xl font-semibold text-gray-800 mb-2",children:["Interpretación del Antibiograma Escalonado - ",((ne=l.identity)==null?void 0:ne.bacteriumName)||l.name]}),a.jsxs("p",{className:"text-sm text-gray-600 mb-4",children:["Panel CLSI específico: ",h.reduce((w,O)=>w+O.agents.length,0)," antibióticos apropiados. Los niveles superiores se desbloquean según CLSI M100."]})]}),a.jsxs("div",{className:"bg-blue-50 rounded-lg border border-blue-200 p-6",children:[a.jsxs("h4",{className:"text-lg font-semibold text-blue-900 mb-4 flex items-center",children:[a.jsx("span",{className:"text-xl mr-2",children:"🧬"}),"Perfil de Resistencia Específico del Patógeno"]}),a.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[a.jsxs("div",{className:"bg-white p-4 rounded-lg border",children:[a.jsxs("h5",{className:"font-semibold text-gray-800 mb-3 flex items-center",children:[a.jsx("span",{className:"text-orange-500 mr-2",children:"🔒"}),"Resistencia Intrínseca"]}),ie.intrinsicResistance.length>0?a.jsxs("div",{className:"space-y-2",children:[ie.intrinsicResistance.map((w,O)=>a.jsxs("div",{className:"flex items-center",children:[a.jsx("span",{className:"w-2 h-2 bg-orange-400 rounded-full mr-2"}),a.jsx("span",{className:"text-sm text-gray-700",children:w.drugOrClass||w})]},O)),a.jsx("div",{className:"mt-3 p-2 bg-orange-50 rounded text-xs text-orange-700",children:"💡 Estos antibióticos no son efectivos independientemente del resultado del antibiograma"})]}):a.jsx("p",{className:"text-sm text-gray-500",children:"Sin resistencia intrínseca conocida"})]}),a.jsxs("div",{className:"bg-white p-4 rounded-lg border",children:[a.jsxs("h5",{className:"font-semibold text-gray-800 mb-3 flex items-center",children:[a.jsx("span",{className:"text-red-500 mr-2",children:"⚙️"}),"Mecanismos de Resistencia Comunes"]}),ie.resistanceMechanisms.length>0?a.jsxs("div",{className:"space-y-2",children:[ie.resistanceMechanisms.slice(0,3).map((w,O)=>a.jsxs("div",{className:"flex items-start",children:[a.jsx("span",{className:"w-2 h-2 bg-red-400 rounded-full mr-2 mt-1"}),a.jsxs("div",{children:[a.jsx("span",{className:"text-sm font-medium text-gray-800",children:w.mechanism}),w.description&&a.jsx("div",{className:"text-xs text-gray-600 mt-1",children:w.description})]})]},O)),a.jsx("div",{className:"mt-3 p-2 bg-red-50 rounded text-xs text-red-700",children:"🔍 Considere estas resistencias al interpretar patrones inusuales"})]}):a.jsx("p",{className:"text-sm text-gray-500",children:"Información de mecanismos no disponible"})]})]}),ie.epidemiology&&Object.keys(ie.epidemiology).length>0&&a.jsxs("div",{className:"mt-4 bg-white p-4 rounded-lg border",children:[a.jsxs("h5",{className:"font-semibold text-gray-800 mb-3 flex items-center",children:[a.jsx("span",{className:"text-teal-500 mr-2",children:"📊"}),"Contexto Epidemiológico"]}),a.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-4",children:[ie.epidemiology.prevalence&&a.jsxs("div",{className:"text-sm",children:[a.jsx("span",{className:"font-medium text-gray-700",children:"Prevalencia:"}),a.jsx("span",{className:"ml-2 text-gray-600",children:ie.epidemiology.prevalence})]}),ie.epidemiology.riskFactors&&a.jsxs("div",{className:"text-sm",children:[a.jsx("span",{className:"font-medium text-gray-700",children:"Factores de Riesgo:"}),a.jsx("span",{className:"ml-2 text-gray-600",children:ie.epidemiology.riskFactors})]})]})]})]}),a.jsxs("div",{className:"bg-purple-50 rounded-lg border border-purple-200 p-6",children:[a.jsxs("h4",{className:"text-lg font-semibold text-purple-900 mb-4 flex items-center",children:[a.jsx("span",{className:"text-xl mr-2",children:"🔗"}),"Detección de Patrones de Resistencia Cruzada"]}),a.jsxs("div",{className:"space-y-4",children:[(()=>{if(g.susceptibilityResults.Ceftriaxone==="R"||g.susceptibilityResults.Ceftazidime==="R"||g.susceptibilityResults.Cefotaxime==="R")return a.jsxs("div",{className:"bg-red-100 p-4 rounded-lg border border-red-300",children:[a.jsxs("h5",{className:"font-semibold text-red-800 mb-2 flex items-center",children:[a.jsx("span",{className:"text-red-500 mr-2",children:"🧬"}),"Patrón ESBL (Beta-lactamasa de Espectro Extendido) Detectado"]}),a.jsxs("div",{className:"text-sm text-red-700 space-y-2",children:[a.jsxs("p",{children:[a.jsx("strong",{children:"Resistencia cruzada implícita:"})," Todas las penicilinas, cefalosporinas (1ra-4ta gen), y aztreonam"]}),a.jsxs("p",{children:[a.jsx("strong",{children:"Opciones terapéuticas:"})," Carbapenémicos, cefepime (si susceptible), piperacilina-tazobactam (evaluar con precaución)"]}),a.jsxs("p",{children:[a.jsx("strong",{children:"Recomendación:"})," Reportar como resistente a todos los beta-lactámicos excepto carbapenémicos"]})]})]})})(),(()=>{if(g.susceptibilityResults.Meropenem==="R"||g.susceptibilityResults.Imipenem==="R"||g.susceptibilityResults.Ertapenem==="R")return a.jsxs("div",{className:"bg-red-100 p-4 rounded-lg border border-red-300",children:[a.jsxs("h5",{className:"font-semibold text-red-800 mb-2 flex items-center",children:[a.jsx("span",{className:"text-red-500 mr-2",children:"🚨"}),"Patrón de Resistencia a Carbapenémicos Detectado"]}),a.jsxs("div",{className:"text-sm text-red-700 space-y-2",children:[a.jsxs("p",{children:[a.jsx("strong",{children:"Resistencia cruzada implícita:"})," Todos los beta-lactámicos (penicilinas, cefalosporinas, carbapenémicos)"]}),a.jsxs("p",{children:[a.jsx("strong",{children:"Opciones terapéuticas:"})," Colistina, ceftazidima-avibactam, meropenem-vaborbactam, fosfomicina (según pruebas)"]}),a.jsxs("p",{children:[a.jsx("strong",{children:"Alerta de salud pública:"})," Reportar inmediatamente al laboratorio de referencia"]})]})]})})(),(()=>{var O,U;if((g.susceptibilityResults.Ceftriaxone==="R"||g.susceptibilityResults.Ceftazidime==="R")&&g.susceptibilityResults.Cefepime==="S"&&(((O=ie.taxonomy)==null?void 0:O.family)==="Enterobacteriaceae"||((U=ie.bacteriumName)==null?void 0:U.includes("Enterobacter"))))return a.jsxs("div",{className:"bg-orange-100 p-4 rounded-lg border border-orange-300",children:[a.jsxs("h5",{className:"font-semibold text-orange-800 mb-2 flex items-center",children:[a.jsx("span",{className:"text-orange-500 mr-2",children:"⚠️"}),"Patrón AmpC Cromosómica Detectado"]}),a.jsxs("div",{className:"text-sm text-orange-700 space-y-2",children:[a.jsxs("p",{children:[a.jsx("strong",{children:"Resistencia cruzada implícita:"})," Ampicilina, amoxicilina-clavulánico, cefalosporinas 1ra-3ra gen"]}),a.jsxs("p",{children:[a.jsx("strong",{children:"Opciones terapéuticas:"})," Cefepime, carbapenémicos, fluoroquinolonas (si susceptible)"]}),a.jsxs("p",{children:[a.jsx("strong",{children:"Precaución:"})," Puede desarrollar resistencia inducible durante el tratamiento"]})]})]})})(),(()=>{if(g.susceptibilityResults.Ciprofloxacin==="R"||g.susceptibilityResults.Levofloxacin==="R")return a.jsxs("div",{className:"bg-yellow-100 p-4 rounded-lg border border-yellow-300",children:[a.jsxs("h5",{className:"font-semibold text-yellow-800 mb-2 flex items-center",children:[a.jsx("span",{className:"text-yellow-500 mr-2",children:"🔄"}),"Resistencia Cruzada a Fluoroquinolonas"]}),a.jsxs("div",{className:"text-sm text-yellow-700 space-y-2",children:[a.jsxs("p",{children:[a.jsx("strong",{children:"Resistencia cruzada implícita:"})," Alta probabilidad para todas las fluoroquinolonas"]}),a.jsxs("p",{children:[a.jsx("strong",{children:"Recomendación:"})," No probar fluoroquinolonas adicionales"]}),a.jsxs("p",{children:[a.jsx("strong",{children:"Opciones alternativas:"})," Beta-lactámicos, aminoglucósidos, otros según patrón"]})]})]})})(),(()=>{var O;if((g.susceptibilityResults.Cefoxitin==="R"||g.susceptibilityResults.Oxacillin==="R")&&((O=ie.bacteriumName)==null?void 0:O.includes("Staphylococcus aureus")))return a.jsxs("div",{className:"bg-red-100 p-4 rounded-lg border border-red-300",children:[a.jsxs("h5",{className:"font-semibold text-red-800 mb-2 flex items-center",children:[a.jsx("span",{className:"text-red-500 mr-2",children:"🦠"}),"S. aureus Resistente a Meticilina (MRSA) Detectado"]}),a.jsxs("div",{className:"text-sm text-red-700 space-y-2",children:[a.jsxs("p",{children:[a.jsx("strong",{children:"Resistencia cruzada implícita:"})," Todos los beta-lactámicos (excepto ceftarolina)"]}),a.jsxs("p",{children:[a.jsx("strong",{children:"Opciones terapéuticas:"})," Vancomicina, daptomicina, linezolid, ceftarolina"]}),a.jsxs("p",{children:[a.jsx("strong",{children:"Recomendación:"})," Reportar como resistente a todos los beta-lactámicos"]})]})]})})(),(()=>{const w=Object.keys(g.susceptibilityResults||{}).length>0,O=g.susceptibilityResults.Ceftriaxone==="R"||g.susceptibilityResults.Ceftazidime==="R"||g.susceptibilityResults.Meropenem==="R"||g.susceptibilityResults.Ciprofloxacin==="R"||g.susceptibilityResults.Cefoxitin==="R";if(w&&!O)return a.jsxs("div",{className:"bg-green-100 p-4 rounded-lg border border-green-300",children:[a.jsxs("h5",{className:"font-semibold text-green-800 mb-2 flex items-center",children:[a.jsx("span",{className:"text-green-500 mr-2",children:"✅"}),"No se detectaron patrones de resistencia cruzada"]}),a.jsx("p",{className:"text-sm text-green-700",children:"Continue ingresando resultados. Los patrones de resistencia cruzada se detectarán automáticamente."})]});if(!w)return a.jsxs("div",{className:"bg-blue-100 p-4 rounded-lg border border-blue-300",children:[a.jsxs("h5",{className:"font-semibold text-blue-800 mb-2 flex items-center",children:[a.jsx("span",{className:"text-blue-500 mr-2",children:"📚"}),"Sistema de Detección de Resistencia Cruzada"]}),a.jsx("p",{className:"text-sm text-blue-700",children:"Este sistema detecta automáticamente patrones de resistencia cruzada como ESBL, AmpC, carbapenemasas, y MRSA. Comience ingresando los resultados del antibiograma para obtener interpretaciones inteligentes."})]})})()]})]}),h.map((w,O)=>{const U=W(w.tier);return a.jsxs("div",{className:`rounded-lg border ${U?"border-indigo-200 bg-white shadow-sm":"border-gray-300 bg-gray-50 opacity-60"} overflow-hidden`,children:[a.jsx("div",{className:`px-6 py-4 border-b ${U?"bg-indigo-50 border-indigo-200":"bg-gray-100 border-gray-300"}`,children:a.jsxs("div",{className:"flex items-center justify-between",children:[a.jsxs("div",{children:[a.jsxs("h4",{className:"text-lg font-semibold text-gray-800",children:["Tier ",w.tier," - ",w.tierDescription||"Pruebas Rutinarias"]}),a.jsxs("p",{className:"text-sm text-gray-600 mt-1",children:[w.tier===1&&"Pruebas de primera línea (siempre disponibles)",w.tier===2&&"Se desbloquea con resistencia a cefalosporinas o aminoglucósidos",w.tier===3&&"Se desbloquea con resistencia a carbapenémicos o patrón ESBL",w.tier===4&&"Se desbloquea con resistencia extrema (MDR)"]})]}),a.jsx("div",{className:"flex items-center space-x-2",children:U?a.jsx("span",{className:"inline-flex items-center px-3 py-1 rounded-full text-sm font-medium bg-green-100 text-green-800",children:"🔓 Desbloqueado"}):a.jsx("span",{className:"inline-flex items-center px-3 py-1 rounded-full text-sm font-medium bg-gray-100 text-gray-600",children:"🔒 Bloqueado"})})]})}),a.jsx("div",{className:"p-4 sm:p-6",children:U?a.jsx("div",{className:"space-y-4",children:w.agents.map((Z,X)=>{var E,z,H,Y;const T=Z.agentName,q=(E=g.susceptibilityResults)==null?void 0:E[T],C=(z=g.micValues)==null?void 0:z[T];return a.jsx("div",{className:"bg-white border border-gray-200 rounded-lg p-4 hover:border-gray-300 transition-colors",children:a.jsxs("div",{className:"flex flex-col space-y-3",children:[a.jsxs("div",{className:"flex items-start justify-between",children:[a.jsxs("div",{className:"flex-1",children:[a.jsx("h5",{className:"text-lg font-semibold text-gray-900 mb-1",children:T}),((Y=(H=Z.breakpointSets)==null?void 0:H[0])==null?void 0:Y.condition)&&Z.breakpointSets[0].condition!=="Standard"&&a.jsxs("div",{className:"text-sm text-orange-600 mb-1 flex items-center",children:[a.jsx("span",{className:"mr-1",children:"📋"}),Z.breakpointSets[0].condition]}),(()=>{const ee=_(Z);return ee&&(ee.comments.length>0||ee.condition)&&a.jsxs("div",{className:"text-sm text-blue-700 space-y-1 mb-2",children:[ee.condition&&a.jsxs("div",{className:"text-orange-600 flex items-center",children:[a.jsx("span",{className:"mr-1",children:"📋"}),ee.condition]}),ee.comments.map((le,Q)=>a.jsxs("div",{className:"text-blue-600 flex items-center",children:[a.jsx("span",{className:"mr-1",children:"💡"}),le]},Q))]})})(),(()=>{if((ie.intrinsicResistance||[]).some(Q=>{const k=Q.drugOrClass||Q;return typeof k!="string"?!1:k.toLowerCase().includes(T.toLowerCase())||T.toLowerCase().includes(k.toLowerCase().replace(/[^a-z]/g,""))}))return a.jsxs("div",{className:"text-sm text-red-600 bg-red-50 p-2 rounded border border-red-200 flex items-center",children:[a.jsx("span",{className:"mr-2",children:"🔒"}),a.jsx("span",{className:"font-medium",children:"Resistencia intrínseca - No reportar"})]})})(),q==="S"&&C&&a.jsxs("div",{className:"text-sm text-blue-600 bg-blue-50 p-2 rounded border border-blue-200 flex items-center",children:[a.jsx("span",{className:"mr-2",children:"🎯"}),a.jsx("span",{className:"font-medium",children:"PK/PD optimizable"})]})]}),q&&a.jsx("div",{className:`px-3 py-2 rounded-full text-sm font-bold border-2 ${q==="S"?"bg-green-100 text-green-800 border-green-300":q==="SDD"?"bg-blue-100 text-blue-800 border-blue-300":q==="I"?"bg-yellow-100 text-yellow-800 border-yellow-300":"bg-red-100 text-red-800 border-red-300"}`,children:q})]}),a.jsx("div",{className:"bg-gray-50 p-4 rounded-lg",children:a.jsxs("div",{className:"flex flex-col space-y-3",children:[a.jsxs("div",{children:[a.jsx("label",{className:"block text-sm font-medium text-gray-700 mb-2",children:"Valor MIC (μg/mL)"}),a.jsx("input",{type:"text",placeholder:C?"Ingrese valor MIC":q?`Rango típico: ${m(Z,q)||"Ver CLSI"}`:"Ej: ≤0.25, 4, >16",value:C||"",onChange:ee=>c(T,ee.target.value),className:"w-full px-3 py-2 text-base border border-gray-300 rounded-md focus:outline-none focus:ring-2 focus:ring-indigo-500 focus:border-indigo-500"})]}),a.jsx("div",{className:"flex items-center justify-center",children:a.jsx("span",{className:"text-sm text-gray-500 bg-white px-3 py-1 rounded-full border",children:"o seleccione interpretación directa"})}),a.jsxs("div",{children:[a.jsx("label",{className:"block text-sm font-medium text-gray-700 mb-2",children:"Interpretación Rápida"}),a.jsx("div",{className:"grid grid-cols-2 sm:grid-cols-4 gap-2",children:["S","SDD","I","R"].map(ee=>{const k=(ie.intrinsicResistance||[]).some(G=>{const ae=G.drugOrClass||G;return typeof ae!="string"?!1:ae.toLowerCase().includes(T.toLowerCase())||T.toLowerCase().includes(ae.toLowerCase().replace(/[^a-z]/g,""))})&&(ee==="S"||ee==="SDD"||ee==="I");return a.jsx("button",{onClick:()=>!k&&d(T,ee),disabled:k,className:`px-4 py-3 text-base font-semibold rounded-md transition-all duration-200 ${k?"bg-gray-200 text-gray-400 cursor-not-allowed border-2 border-gray-300":q===ee?ee==="S"?"bg-green-600 text-white border-2 border-green-600 shadow-lg":ee==="SDD"?"bg-blue-600 text-white border-2 border-blue-600 shadow-lg":ee==="I"?"bg-yellow-500 text-white border-2 border-yellow-500 shadow-lg":"bg-red-600 text-white border-2 border-red-600 shadow-lg":"bg-white text-gray-700 hover:bg-gray-50 border-2 border-gray-300 hover:border-gray-400"}`,title:k?"Resistencia intrínseca - No seleccionar":`Marcar como ${ee}`,children:a.jsxs("div",{className:"text-center",children:[a.jsx("div",{className:"font-bold",children:ee}),a.jsxs("div",{className:"text-xs mt-1",children:[ee==="S"&&"Sensible",ee==="SDD"&&"Dosis Dependiente",ee==="I"&&"Intermedio",ee==="R"&&"Resistente"]})]})},ee)})})]})]})})]})},X)})}):a.jsxs("div",{className:"text-center py-8",children:[a.jsx("div",{className:"text-gray-400 text-lg mb-2",children:"🔒"}),a.jsxs("p",{className:"text-gray-500 text-sm",children:["Complete las pruebas de Tier ",w.tier-1," para desbloquear este nivel"]})]})})]},O)})]})},Eb=({data:g,onChange:s})=>{const l=["Penicilinas","Cefalosporinas","Carbapenémicos","Quinolonas","Sulfas","Macrólidos","Glicopéptidos","Aminoglucósidos","Lincosamidas"];return a.jsxs("div",{children:[a.jsx("h3",{className:"text-xl font-semibold text-gray-800 mb-4",children:"Hipersensibilidad del Paciente"}),a.jsxs("fieldset",{className:"space-y-2",children:[a.jsx("legend",{className:"text-base font-medium text-gray-900",children:"Marque las alergias conocidas:"}),l.map(c=>a.jsxs("div",{className:"relative flex items-start",children:[a.jsx("div",{className:"flex items-center h-5",children:a.jsx("input",{id:c,name:"hypersensitivities",type:"checkbox",value:c,checked:g.hypersensitivities.includes(c),onChange:s,className:"focus:ring-indigo-500 h-4 w-4 text-indigo-600 border-gray-300 rounded"})}),a.jsx("div",{className:"ml-3 text-sm",children:a.jsx("label",{htmlFor:c,className:"font-medium text-gray-700",children:c})})]},c))]})]})},Pb=({data:g,calculations:s,recommendation:l,alternatives:c,clinicalAnalysis:d})=>{var se,ie,$,ne;const[m,_]=oe.useState(""),[h,v]=oe.useState(""),y=w=>{for(const O of Object.values(_t)){const U=O.options.find(Z=>Z.value===w);if(U)return U.label}return w||"No especificada"},D=()=>{var C;const w=g.bacteriumId?$i()[g.bacteriumId]:null,O=w?((C=w.identity)==null?void 0:C.bacteriumName)||w.name:"No especificado",U=y(g.location);let Z=[];if(g.rrt&&g.rrt!=="None"&&Z.push(`TRR: ${g.rrt}`),g.hasHepaticDisease){const E=s.childPugh?`Child-Pugh ${s.childPugh.score} (Clase ${s.childPugh.class})`:"Datos incompletos";Z.push(`Enf. Hepática: ${E}`)}if(g.isPregnantOrFertile&&Z.push("Embarazo/Fertilidad: Sí"),g.showSeverityAssessment){let E=[];g.isICU&&E.push("UCI"),g.isImmunocompromised&&E.push("Inmunocomprometido"),g.priorAntibiotics&&E.push("ATB previos"),g.hasOrganDysfunction&&E.push("Disfunción orgánica"),g.hasSepsis&&E.push("Sepsis"),g.hemodynamicStatus&&E.push(`Estado hemodinámico: ${g.hemodynamicStatus}`),g.respiratoryStatus&&E.push(`Estado respiratorio: ${g.respiratoryStatus}`),E.length>0&&Z.push(`Severidad: ${E.join(", ")}`)}if(g.showEpidemiologyData){let E=[];g.localESBLRate&&E.push(`ESBL local: ${g.localESBLRate}%`),g.localCarbapenemResistance&&E.push(`Carbapenem resist. local: ${g.localCarbapenemResistance}%`),g.institutionType&&E.push(`Institución: ${g.institutionType}`),E.length>0&&Z.push(`Epidemiología: ${E.join(", ")}`)}const X=Z.length>0?`
FACTORES CLÍNICOS:
  - ${Z.join(`
  - `)}
`:`
`,T=`** RESUMEN DE CASO CLÍNICO **
---------------------------------
PACIENTE: ${g.age||"N/A"} años, Sexo: ${g.gender==="Female"?"Femenino":"Masculino"}, ${g.weight||"N/A"} kg, ${g.height||"N/A"} cm.
CÁLCULOS:
  - TFG: ${s.tfg?`${s.tfg.value} mL/min/1.73m² (${s.tfg.formula})`:"N/A"}
  - IMC: ${s.bmi||"N/A"} (${s.obesityClass||"N/A"})${X}---------------------------------
INFECCIÓN:
  - Localización: ${U}
  - Microorganismo: ${O}
---------------------------------
RESULTADOS:
  - Alergias: ${g.hypersensitivities.length>0?g.hypersensitivities.join(", "):"Ninguna"}.
  - TRATAMIENTO RECOMENDADO: ${l.antibiotic||"Ninguno adecuado"} (${l.tier||"N/A"})
  - Alternativas viables: ${c.length>0?c.join(", "):"Ninguna"}
---------------------------------`,q=document.createElement("textarea");q.value=T,q.style.position="fixed",q.style.left="-9999px",document.body.appendChild(q),q.focus(),q.select();try{document.execCommand("copy"),_("Copiado!"),setTimeout(()=>_(""),2e3)}catch{_("Error")}document.body.removeChild(q)},L=l.antibiotic?jr[l.antibiotic]:null,W=l.dose?`${l.dose} ${l.route||"IV"} ${l.frequency||""}${l.comments?` - ${l.comments}`:""}`:L?g.age<18?L.pediatricDosage:L.adultDosage:"N/A";return a.jsxs("div",{className:"space-y-6",children:[a.jsxs("div",{className:"flex justify-between items-start",children:[a.jsx("h3",{className:"text-xl font-semibold text-gray-800",children:"Resumen y Recomendación Automática"}),a.jsxs("button",{onClick:D,className:"flex items-center gap-2 bg-gray-200 text-gray-800 font-semibold py-2 px-4 rounded-lg hover:bg-gray-300 transition duration-300",children:[a.jsx("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M8 16H6a2 2 0 01-2-2V6a2 2 0 012-2h8a2 2 0 012 2v2m-6 12h8a2 2 0 002-2v-8a2 2 0 00-2-2h-8a2 2 0 00-2 2v8a2 2 0 002 2z"})}),m||"Copiar Resumen"]})]}),a.jsxs("div",{className:"bg-blue-50 border-l-4 border-blue-500 p-4 rounded-md space-y-3",children:[a.jsx("h4",{className:"font-bold text-blue-800",children:"Resumen del Caso Completo"}),a.jsxs("p",{children:[a.jsx("strong",{children:"Paciente:"})," ",g.age||"N/A"," años, Sexo: ",g.gender==="Female"?"Femenino":"Masculino",", ",g.weight||"N/A"," kg, ",g.height||"N/A"," cm."]}),a.jsxs("p",{children:[a.jsx("strong",{children:"Valores Calculados:"})," TFG: ",s.tfg?`${s.tfg.value} mL/min/1.73m²`:"N/A"," (",s.tfg?s.tfg.formula:"N/A","), IMC: ",s.bmi||"N/A"," (",s.obesityClass||"N/A",")."]}),g.rrt&&g.rrt!=="None"&&a.jsxs("p",{children:[a.jsx("strong",{children:"Terapia de Reemplazo Renal:"})," ",g.rrt]}),g.hasHepaticDisease&&a.jsxs("p",{children:[a.jsx("strong",{children:"Enf. Hepática:"})," Child-Pugh ",s.childPugh?`${s.childPugh.score} (Clase ${s.childPugh.class})`:"Datos incompletos"]}),g.isPregnantOrFertile&&a.jsxs("p",{children:[a.jsx("strong",{children:"Embarazo/Fertilidad:"})," Consideraciones especiales requeridas"]}),g.showSeverityAssessment&&(()=>{let w=[];return g.isICU&&w.push("UCI"),g.isImmunocompromised&&w.push("Inmunocomprometido"),g.priorAntibiotics&&w.push("ATB previos"),g.hasOrganDysfunction&&w.push("Disfunción orgánica"),g.hasSepsis&&w.push("Sepsis"),g.hemodynamicStatus&&w.push(`Est. hemodinámico: ${g.hemodynamicStatus}`),g.respiratoryStatus&&w.push(`Est. respiratorio: ${g.respiratoryStatus}`),w.length>0?a.jsxs("p",{children:[a.jsx("strong",{children:"Factores de Severidad:"})," ",w.join(", ")]}):null})(),g.showEpidemiologyData&&(()=>{let w=[];return g.localESBLRate&&w.push(`ESBL local: ${g.localESBLRate}%`),g.localCarbapenemResistance&&w.push(`Carbapenem resistencia local: ${g.localCarbapenemResistance}%`),g.institutionType&&w.push(`Institución: ${g.institutionType}`),w.length>0?a.jsxs("p",{children:[a.jsx("strong",{children:"Datos Epidemiológicos:"})," ",w.join(", ")]}):null})(),a.jsxs("p",{children:[a.jsx("strong",{children:"Infección:"})," ",y(g.location),"."]}),a.jsxs("p",{children:[a.jsx("strong",{children:"Microorganismo:"})," ",g.bacteriumId?((se=$i()[g.bacteriumId].identity)==null?void 0:se.bacteriumName)||$i()[g.bacteriumId].name:"No especificado","."]}),a.jsxs("p",{children:[a.jsx("strong",{children:"Alergias:"})," ",g.hypersensitivities.length>0?g.hypersensitivities.join(", "):"Ninguna reportada","."]})]}),a.jsxs("div",{className:"p-4 rounded-lg bg-indigo-50 border border-indigo-200",children:[a.jsxs("div",{className:"flex justify-between items-start",children:[a.jsx("h4",{className:"text-lg font-semibold text-indigo-800",children:"Tratamiento Sugerido por Guía"}),l.antibiotic&&a.jsxs("button",{onClick:()=>{const w=`${l.antibiotic}
${l.tier}
${W}`;navigator.clipboard.writeText(w).then(()=>{v("¡Copiado!"),setTimeout(()=>v(""),2e3)}).catch(()=>{v("Error"),setTimeout(()=>v(""),2e3)})},className:`flex items-center gap-2 px-3 py-1.5 text-sm font-medium rounded-lg transition-colors ${h?h==="Error"?"bg-red-600 text-white":"bg-green-600 text-white":"bg-indigo-600 text-white hover:bg-indigo-700"}`,title:"Copiar tratamiento",children:[a.jsx("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M8 16H6a2 2 0 01-2-2V6a2 2 0 012-2h8a2 2 0 012 2v2m-6 12h8a2 2 0 002-2v-8a2 2 0 00-2-2h-8a2 2 0 00-2 2v8a2 2 0 002 2z"})}),h||"Copiar"]})]}),l.antibiotic?a.jsxs("div",{children:[a.jsx("p",{className:"text-2xl font-bold text-indigo-600 mt-2",children:l.antibiotic}),a.jsx("p",{className:"text-sm font-medium text-indigo-700",children:l.tier}),((ie=l.context)==null?void 0:ie.condition)&&a.jsxs("p",{className:"text-sm text-gray-700 mt-1",children:[a.jsx("span",{className:"font-semibold",children:"Contexto Clínico:"})," ",l.context.condition]}),a.jsxs("p",{className:"text-md text-gray-800 mt-2",children:[a.jsx("span",{className:"font-semibold",children:"Dosis Sugerida:"})," ",W]}),l.regimenNotes&&l.regimenNotes.length>0&&a.jsxs("div",{className:"mt-2 p-2 bg-yellow-50 border border-yellow-200 rounded",children:[a.jsx("p",{className:"text-sm font-semibold text-yellow-800",children:"Notas Importantes:"}),l.regimenNotes.map((w,O)=>a.jsxs("p",{className:"text-xs text-yellow-700 mt-1",children:["• ",w]},O))]}),a.jsx("p",{className:"text-xs text-gray-600 mt-1",children:"La duración del tratamiento es una decisión clínica."})]}):a.jsx("p",{className:"text-lg font-semibold text-red-600 mt-2",children:l.tier})]}),L&&a.jsxs("div",{className:"p-4 rounded-lg bg-gray-50 border border-gray-200 space-y-3",children:[a.jsx("h4",{className:"text-lg font-semibold text-gray-800",children:"Detalles Adicionales del Fármaco Recomendado"}),a.jsxs("div",{children:[a.jsx("strong",{children:"Ajuste Renal:"})," ",L.renalAdjustment]}),a.jsxs("div",{children:[a.jsx("strong",{children:"Ajuste Hepático:"})," ",L.hepaticAdjustment]}),g.isPregnantOrFertile&&a.jsxs("div",{children:[a.jsx("strong",{children:"Riesgo en Embarazo:"}),a.jsx("span",{className:"font-bold ml-2",children:L.pregnancyRisk})]})]}),a.jsxs("div",{className:"p-4 rounded-lg bg-gray-50 border border-gray-200",children:[a.jsx("h4",{className:"text-lg font-semibold text-gray-800",children:"Posibles Alternativas Terapéuticas"}),c.length>0?a.jsxs("p",{className:"text-gray-600 mt-2",children:["Otras opciones sensibles y sin contraindicación por alergia incluyen: ",a.jsx("span",{className:"font-semibold",children:c.join(", ")}),"."]}):a.jsx("p",{className:"text-gray-500 mt-2",children:"No se encontraron otras alternativas viables en el panel probado."})]}),g.bacteriumId&&((ne=($=$i()[g.bacteriumId])==null?void 0:$.treatment)==null?void 0:ne.generalNotes)&&a.jsxs("div",{className:"p-4 rounded-lg bg-blue-50 border border-blue-200",children:[a.jsx("h4",{className:"text-lg font-semibold text-blue-800",children:"Notas Generales de Tratamiento"}),a.jsx("div",{className:"mt-2 space-y-2",children:$i()[g.bacteriumId].treatment.generalNotes.map((w,O)=>a.jsxs("p",{className:"text-sm text-blue-700",children:["• ",w]},O))})]}),d&&a.jsxs("div",{className:"p-4 rounded-lg bg-green-50 border border-green-200",children:[a.jsx("h4",{className:"text-lg font-semibold text-green-800",children:"Análisis Clínico Inteligente"}),a.jsxs("div",{className:"mt-3 space-y-3",children:[l.clinicalRationale&&a.jsxs("div",{children:[a.jsx("p",{className:"text-sm font-semibold text-green-700",children:"Justificación Clínica:"}),a.jsx("p",{className:"text-sm text-green-600",children:l.clinicalRationale})]}),l.severityAssessment&&a.jsxs("div",{children:[a.jsx("p",{className:"text-sm font-semibold text-green-700",children:"Evaluación de Severidad:"}),a.jsxs("p",{className:"text-sm text-green-600",children:[l.severityAssessment.levelName," (Puntuación: ",l.severityAssessment.score,")"]})]}),l.resistanceAssessment&&a.jsxs("div",{children:[a.jsx("p",{className:"text-sm font-semibold text-green-700",children:"Mecanismos de Resistencia Detectados:"}),a.jsx("p",{className:"text-sm text-green-600",children:l.resistanceAssessment.summary}),(l.resistanceAssessment.esbl.suspected||l.resistanceAssessment.ampC.suspected||l.resistanceAssessment.carbapenemase.suspected)&&a.jsxs("div",{className:"mt-2 p-2 bg-yellow-50 border border-yellow-200 rounded",children:[a.jsx("p",{className:"text-xs font-semibold text-yellow-800",children:"Alertas de Resistencia:"}),l.resistanceAssessment.esbl.suspected&&a.jsxs("p",{className:"text-xs text-yellow-700",children:["• ESBL detectado - ",l.resistanceAssessment.esbl.implications]}),l.resistanceAssessment.ampC.suspected&&a.jsxs("p",{className:"text-xs text-yellow-700",children:["• AmpC detectado - ",l.resistanceAssessment.ampC.implications]}),l.resistanceAssessment.carbapenemase.suspected&&a.jsxs("p",{className:"text-xs text-yellow-700",children:["• Carbapenemasa detectada - ",l.resistanceAssessment.carbapenemase.implications]})]})]})]})]}),a.jsxs("div",{className:"p-4 rounded-lg bg-teal-50 border border-teal-200",children:[a.jsxs("h4",{className:"text-lg font-semibold text-teal-800 mb-4 flex items-center",children:[a.jsx("span",{className:"text-xl mr-2",children:"🛡️"}),"Principios de Stewardship Antimicrobiano"]}),a.jsxs("div",{className:"space-y-4",children:[a.jsxs("div",{className:"bg-white p-4 rounded-lg border",children:[a.jsxs("h5",{className:"font-semibold text-teal-700 mb-2 flex items-center",children:[a.jsx("span",{className:"text-teal-500 mr-2",children:"🎯"}),"Recomendaciones de De-escalación"]}),a.jsx("div",{className:"text-sm text-teal-600 space-y-2",children:(()=>{const w=g.susceptibilityResults.Ceftriaxone==="R"||g.susceptibilityResults.Ceftazidime==="R",O=g.susceptibilityResults.Meropenem==="R"||g.susceptibilityResults.Imipenem==="R",U=g.susceptibilityResults.Ampicillin==="S"||g.susceptibilityResults.Penicillin==="S";return O?a.jsxs("div",{className:"p-3 bg-red-50 border border-red-200 rounded",children:[a.jsx("p",{className:"text-red-700 font-medium",children:"⚠️ Resistencia a carbapenémicos detectada"}),a.jsxs("p",{className:"text-red-600 text-xs mt-1",children:["• Consultar con infectología para terapia combinada",a.jsx("br",{}),"• Considerar colistina, ceftazidima-avibactam o fosfomicina",a.jsx("br",{}),"• Evaluar necesidad de aislamiento de contacto"]})]}):w?a.jsxs("div",{className:"p-3 bg-orange-50 border border-orange-200 rounded",children:[a.jsx("p",{className:"text-orange-700 font-medium",children:"🧬 Patrón ESBL detectado"}),a.jsxs("p",{className:"text-orange-600 text-xs mt-1",children:["• Evitar cefalosporinas y piperacilina-tazobactam",a.jsx("br",{}),"• Priorizar carbapenémicos para infecciones graves",a.jsx("br",{}),"• Considerar fosfomicina o nitrofurantoína para ITU"]})]}):U?a.jsxs("div",{className:"p-3 bg-green-50 border border-green-200 rounded",children:[a.jsx("p",{className:"text-green-700 font-medium",children:"✅ Opciones de espectro estrecho disponibles"}),a.jsxs("p",{className:"text-green-600 text-xs mt-1",children:["• Priorizar agentes de espectro estrecho cuando sea posible",a.jsx("br",{}),"• Evitar uso innecesario de carbapenémicos",a.jsx("br",{}),"• Considerar cambio a vía oral cuando sea apropiado"]})]}):a.jsxs("div",{className:"p-3 bg-blue-50 border border-blue-200 rounded",children:[a.jsx("p",{className:"text-blue-700 font-medium",children:"📋 Evaluación de de-escalación"}),a.jsxs("p",{className:"text-blue-600 text-xs mt-1",children:["• Revisar resultados de susceptibilidad completamente",a.jsx("br",{}),"• Evaluar evolución clínica a las 48-72 horas",a.jsx("br",{}),"• Considerar cambio a agente más específico si es posible"]})]})})()})]}),a.jsxs("div",{className:"bg-white p-4 rounded-lg border",children:[a.jsxs("h5",{className:"font-semibold text-teal-700 mb-2 flex items-center",children:[a.jsx("span",{className:"text-teal-500 mr-2",children:"⏱️"}),"Duración y Monitoreo"]}),a.jsxs("div",{className:"text-sm text-teal-600 space-y-2",children:[a.jsxs("p",{children:["• ",a.jsx("strong",{children:"Duración:"})," Usar la menor duración efectiva según guías clínicas"]}),a.jsxs("p",{children:["• ",a.jsx("strong",{children:"Monitoreo:"})," Evaluar respuesta clínica y microbiológica"]}),a.jsxs("p",{children:["• ",a.jsx("strong",{children:"Revisión:"})," Reevaluar necesidad de antibiótico cada 48-72 horas"]}),(L==null?void 0:L.therapeuticDrugMonitoring)&&a.jsxs("p",{children:["• ",a.jsx("strong",{children:"Niveles:"})," ",L.therapeuticDrugMonitoring.monitoring," (Objetivo: ",L.therapeuticDrugMonitoring.target,")"]})]})]}),(()=>{var O,U;if(g.susceptibilityResults.Meropenem==="R"||g.susceptibilityResults.Imipenem==="R"||((O=g.location)==null?void 0:O.includes("Endocarditis"))||((U=g.location)==null?void 0:U.includes("Meningitis"))||g.isICU)return a.jsxs("div",{className:"bg-white p-4 rounded-lg border",children:[a.jsxs("h5",{className:"font-semibold text-teal-700 mb-2 flex items-center",children:[a.jsx("span",{className:"text-teal-500 mr-2",children:"🔄"}),"Consideraciones de Terapia Combinada"]}),a.jsxs("div",{className:"text-sm text-teal-600 space-y-2",children:[a.jsxs("p",{children:["• ",a.jsx("strong",{children:"Indicaciones:"})," Infección grave, resistencia extrema, o sinergia requerida"]}),a.jsxs("p",{children:["• ",a.jsx("strong",{children:"Evaluación:"})," Evaluar beneficio vs. riesgo de toxicidad"]}),a.jsxs("p",{children:["• ",a.jsx("strong",{children:"Monitoreo:"})," Seguimiento estrecho de efectos adversos"]}),a.jsxs("p",{children:["• ",a.jsx("strong",{children:"Duración:"})," Limitar al período mínimo necesario"]})]})]})})(),a.jsxs("div",{className:"bg-white p-4 rounded-lg border",children:[a.jsxs("h5",{className:"font-semibold text-teal-700 mb-2 flex items-center",children:[a.jsx("span",{className:"text-teal-500 mr-2",children:"🔒"}),"Prevención de Resistencia"]}),a.jsxs("div",{className:"text-sm text-teal-600 space-y-2",children:[a.jsxs("p",{children:["• ",a.jsx("strong",{children:"Dosis óptima:"})," Usar dosis máximas recomendadas para infecciones graves"]}),a.jsxs("p",{children:["• ",a.jsx("strong",{children:"Cumplimiento:"})," Asegurar adherencia completa al tratamiento"]}),a.jsxs("p",{children:["• ",a.jsx("strong",{children:"Combinaciones:"})," Evitar monoterapia en infecciones por P. aeruginosa grave"]}),a.jsxs("p",{children:["• ",a.jsx("strong",{children:"Rotación:"})," Considerar políticas de rotación de antibióticos institucionales"]})]})]})]})]})]})},Lb=({onBackToLanding:g})=>{const[s,l]=oe.useState("selection"),[c,d]=oe.useState({age:"",weight:"",height:"",creatinine:"",gender:"Female",useCystatinC:!1,cystatinC:"",isPregnantOrFertile:!1,hasHepaticDisease:!1,bilirubin:"",albumin:"",inr:"1",ascites:"1",encephalopathy:"1",location:"",rrt:"None",bacteriumId:"",susceptibilityResults:{},micValues:{},hypersensitivities:[],showSeverityAssessment:!1,isICU:!1,isImmunocompromised:!1,priorAntibiotics:!1,hasOrganDysfunction:!1,hasSepsis:!1,hemodynamicStatus:"",respiratoryStatus:"",showEpidemiologyData:!1,localESBLRate:"",localCarbapenemResistance:"",institutionType:""}),[m,_]=oe.useState(1),h=6,v=()=>_(C=>Math.min(C+1,h)),y=()=>_(C=>Math.max(C-1,1)),D=()=>{d({age:"",weight:"",height:"",creatinine:"",gender:"Female",useCystatinC:!1,cystatinC:"",isPregnantOrFertile:!1,hasHepaticDisease:!1,bilirubin:"",albumin:"",inr:"1",ascites:"1",encephalopathy:"1",location:"",rrt:"None",bacteriumId:"",susceptibilityResults:{},micValues:{},hypersensitivities:[],showSeverityAssessment:!1,isICU:!1,isImmunocompromised:!1,priorAntibiotics:!1,hasOrganDysfunction:!1,hasSepsis:!1,hemodynamicStatus:"",respiratoryStatus:"",showEpidemiologyData:!1,localESBLRate:"",localCarbapenemResistance:"",institutionType:""}),_(1)},L=C=>{const{name:E,value:z,type:H,checked:Y}=C.target;if(E==="susceptibilityResults"||E==="micValues"||E==="bacteriumId")d(ee=>({...ee,[E]:z}));else if(E==="hypersensitivities")d(ee=>({...ee,hypersensitivities:Y?[...ee.hypersensitivities,z]:ee.hypersensitivities.filter(le=>le!==z)}));else{const ee=H==="checkbox"?Y:z;d(le=>({...le,[E]:ee}))}},W=(C,E,z)=>{if(E<24||E>228)return null;const H={Male:{24:{L:1,M:16,S:.11},60:{L:1,M:15.5,S:.13},120:{L:1,M:16.8,S:.15},180:{L:1,M:20.2,S:.14},216:{L:1,M:21.9,S:.13}},Female:{24:{L:1,M:15.8,S:.11},60:{L:1,M:15.2,S:.14},120:{L:1,M:16.9,S:.16},180:{L:1,M:20.7,S:.13},216:{L:1,M:21.4,S:.12}}},Y=H[z]||H.Male;let le=Object.keys(Y).map(Number).sort((ae,N)=>ae-N).reduce((ae,N)=>Math.abs(N-E)<Math.abs(ae-E)?N:ae);const{L:Q,M:k,S:G}=Y[le];return Q!==0?(Math.pow(C/k,Q)-1)/(Q*G):Math.log(C/k)/G},se=C=>C<-3?"Desnutrición severa (z-score < -3)":C<-2?"Desnutrición moderada (z-score -3 a -2)":C<-1?"Bajo peso (z-score -2 a -1)":C<=1?"Normal (z-score -1 a +1)":C<=2?"Sobrepeso (z-score +1 a +2)":C<=3?"Obesidad (z-score +2 a +3)":"Obesidad severa (z-score > +3)",ie=(C,E,z)=>{if(E<24||E>60)return null;const H={Male:{24:{L:1,M:87.1,S:.04},36:{L:1,M:96.1,S:.04},48:{L:1,M:103.3,S:.04},60:{L:1,M:110,S:.04}},Female:{24:{L:1,M:86.4,S:.04},36:{L:1,M:95.1,S:.04},48:{L:1,M:102.7,S:.04},60:{L:1,M:109.4,S:.04}}},Y=H[z]||H.Male;let le=Object.keys(Y).map(Number).sort((ae,N)=>ae-N).reduce((ae,N)=>Math.abs(N-E)<Math.abs(ae-E)?N:ae);const{L:Q,M:k,S:G}=Y[le];return Q!==0?(Math.pow(C/k,Q)-1)/(Q*G):Math.log(C/k)/G},$=(C,E,z)=>{if(E<24||E>60)return null;const H={Male:{24:{L:1,M:12.2,S:.15},36:{L:1,M:14.3,S:.15},48:{L:1,M:16.3,S:.14},60:{L:1,M:18.3,S:.14}},Female:{24:{L:1,M:11.5,S:.15},36:{L:1,M:13.9,S:.15},48:{L:1,M:15.7,S:.14},60:{L:1,M:17.7,S:.14}}},Y=H[z]||H.Male;let le=Object.keys(Y).map(Number).sort((ae,N)=>ae-N).reduce((ae,N)=>Math.abs(N-E)<Math.abs(ae-E)?N:ae);const{L:Q,M:k,S:G}=Y[le];return Q!==0?(Math.pow(C/k,Q)-1)/(Q*G):Math.log(C/k)/G},ne=C=>C<-3?"Talla baja severa (stunting severo)":C<-2?"Talla baja (stunting)":C<=2?"Talla normal":"Talla alta",w=C=>C<-3?"Bajo peso severo":C<-2?"Bajo peso":C<=2?"Peso normal":"Peso alto",O=oe.useMemo(()=>{const C=parseFloat(c.age),E=parseFloat(c.height),z=parseFloat(c.creatinine),H=parseFloat(c.cystatinC),Y=parseFloat(c.weight);let ee=null;if(C>0&&E>0){if(C<18)z>0&&(ee={value:(.413*E/z).toFixed(2),formula:"Schwartz (Bedside)"});else if(c.useCystatinC&&H>0){let V;const re=H/.8<1?-.219:-.544;V=135*Math.pow(Math.min(H/.8,1),re)*Math.pow(Math.max(H/.8,1),-.544)*Math.pow(.9961,C),c.gender==="Female"&&(V*=.963),ee={value:V.toFixed(2),formula:"CKD-EPI (Cistatina C)"}}else if(z>0){const V=c.gender==="Female"?.7:.9,te=c.gender==="Female"?-.241:-.302,re=c.gender==="Female"?1.012:1;ee={value:(142*Math.pow(Math.min(z/V,1),te)*Math.pow(Math.max(z/V,1),-1.2)*Math.pow(.9938,C)*re).toFixed(2),formula:"CKD-EPI (Creatinina)"}}}let le=null,Q="",k=null,G=null,ae="",N=null,p="";if(Y>0&&E>0)if(le=(Y/(E/100)**2).toFixed(2),C<18){const V=C*12;k=W(parseFloat(le),V,c.gender),k!==null?Q=se(k):Q="Z-score no disponible (requiere datos WHO)",C<5&&(G=ie(E,V,c.gender),G!==null&&(ae=ne(G)),N=$(Y,V,c.gender),N!==null&&(p=w(N)))}else le<18.5?Q="Bajo Peso":le<25?Q="Normal":le<30?Q="Sobrepeso":le<35?Q="Obesidad Grado I":le<40?Q="Obesidad Grado II":Q="Obesidad Grado III";let A=null;if(c.hasHepaticDisease){const V=parseFloat(c.bilirubin),te=parseFloat(c.albumin),re=parseFloat(c.inr);if(V>0&&te>0&&re>0){let ue=0;V<2?ue+=1:V<=3?ue+=2:ue+=3,te>3.5?ue+=1:te>=2.8?ue+=2:ue+=3,re<1.7?ue+=1:re<=2.3?ue+=2:ue+=3,ue+=parseInt(c.ascites),ue+=parseInt(c.encephalopathy);let he="";ue<=6?he="A":ue<=9?he="B":he="C",A={score:ue,class:he}}}let J=null;if(c.showSeverityAssessment){let V=0;const te=[],ue={CNS_meningitis:3,CNS_encephalitis:3,CNS_brain_abscess:3,CNS_subdural_empyema:3,CV_endocarditis_native:3,CV_endocarditis_prosthetic:3,CV_endocarditis_CIED:3,CV_mycotic_aneurysm:3,CV_pericarditis:2,RESP_CAP:2,RESP_HAP:2,RESP_VAP:3,RESP_empyema:2,RESP_lung_abscess:2,RESP_bronchitis_acute:1,GU_UTI_uncomplicated:1,GU_UTI_complicated:2,GU_UTI_catheter:2,GU_pyelonephritis:2,GU_prostatitis_acute:2,GU_prostatitis_chronic:1,SST_cellulitis_simple:1,SST_cellulitis_severe:2,SST_necrotizing_fasciitis:3,SST_abscess:1,SST_diabetic_foot:2,SST_surgical_site:2,BJ_osteomyelitis_acute:2,BJ_osteomyelitis_chronic:2,BJ_prosthetic_joint:2,BJ_septic_arthritis:2,BJ_vertebral_osteomyelitis:2,BJ_diabetic_foot_osteo:2,IA_peritonitis_secondary:2,IA_peritonitis_primary:2,IA_intra_abdominal:2,IA_cholangitis:2,IA_liver_abscess:2,IA_appendicitis:2,BS_bacteremia_primary:2,BS_CLABSI:2,BS_sepsis:3,BS_septic_shock:3,BS_neutropenic_fever:2,"Skin and soft tissues":1,Genitourinary:1,Respiratory:2,Gastrointestinal:2,"Bone tissue":2,Cardiovascular:3,"Central nervous system":3,"Bacteremia/Sepsis":3}[c.location]||0;if(ue>0){V+=ue;const li=c.location.includes("_")?"Síndrome específico":c.location;te.push(`${li} (+${ue})`)}parseFloat(c.age)>65&&(V+=1,te.push("Edad >65 años (+1)")),c.isICU&&(V+=3,te.push("UCI (+3)")),c.isImmunocompromised&&(V+=2,te.push("Inmunocomprometido (+2)")),c.priorAntibiotics&&(V+=1,te.push("Antibióticos previos (+1)")),c.hasOrganDysfunction&&(V+=2,te.push("Disfunción orgánica (+2)")),c.hasSepsis&&(V+=3,te.push("Sepsis/shock séptico (+3)")),c.hemodynamicStatus==="shock"?(V+=3,te.push("Shock hemodinámico (+3)")):c.hemodynamicStatus==="hypotension"&&(V+=2,te.push("Hipotensión (+2)")),c.respiratoryStatus==="mechanical"?(V+=2,te.push("Ventilación mecánica (+2)")):c.respiratoryStatus==="oxygen"&&(V+=1,te.push("Oxígeno suplementario (+1)"));let Te;V<=2?Te="LEVE":V<=5?Te="MODERADO":V<=8?Te="GRAVE":Te="CRÍTICO",J={score:V,level:Te,factors:te}}let P=null;if(c.showEpidemiologyData){const V=parseFloat(c.localESBLRate),te=parseFloat(c.localCarbapenemResistance);let re="BAJO";const ue=[];V>30?(re="ALTO",ue.push(`ESBL alta (${V}%)`)):V>15?(re="MODERADO",ue.push(`ESBL moderada (${V}%)`)):V>0&&ue.push(`ESBL baja (${V}%)`),te>15?(re="ALTO",ue.push(`Carbapenem alta (${te}%)`)):te>5?(re==="BAJO"&&(re="MODERADO"),ue.push(`Carbapenem moderada (${te}%)`)):te>0&&ue.push(`Carbapenem baja (${te}%)`),c.institutionType==="tertiary"?(re==="BAJO"&&(re="MODERADO"),ue.push("Centro de referencia")):c.institutionType==="academic"?ue.push("Centro académico"):c.institutionType==="community"&&ue.push("Hospital comunitario"),P={level:re,factors:ue.length>0?ue:["Datos por defecto"]}}return{tfg:ee,bmi:le,obesityClass:Q,bmiZScore:k,heightForAgeZScore:G,heightForAgeClass:ae,weightForAgeZScore:N,weightForAgeClass:p,childPugh:A,severityAssessment:J,epidemiologyRisk:P}},[c]),{recommendation:U,alternatives:Z,clinicalAnalysis:X}=oe.useMemo(()=>{var H,Y,ee;const{bacteriumId:C,location:E}=c,z=C?$i()[C]:null;if(!z||!E)return{recommendation:{antibiotic:null,tier:"Información incompleta (bacteria o localización)."},alternatives:[],clinicalAnalysis:null};try{const le={esblRate:{enterobacterales:c.localESBLRate?parseFloat(c.localESBLRate)/100:.12,klebsiella:.18,escherichia:.08,enterobacter:.25},carbapenemResistance:{enterobacterales:c.localCarbapenemResistance?parseFloat(c.localCarbapenemResistance)/100:.03,klebsiella:.05,acinetobacter:.25,pseudomonas:.15},mrsaRate:.35,vreRate:.15},Q=Th(c,z,le),k=Q.regimen;if(!k.regimen||!k.suitableOptions||k.suitableOptions.length===0)return{recommendation:{antibiotic:null,tier:k.note||"No se encontró opción adecuada con los datos actuales."},alternatives:[],clinicalAnalysis:Q};const G=k.suitableOptions[0],ae=k.regimen,N={antibiotic:G.drugName,tier:((H=ae.context)==null?void 0:H.condition)||"Recomendación inteligente",dose:G.dose,route:G.route,frequency:G.frequency,comments:G.comments,context:ae.context,regimenNotes:((ee=(Y=ae.recommendations)==null?void 0:Y[0])==null?void 0:ee.notes)||[],clinicalRationale:Q.rationale.summary,severityAssessment:Q.severity,resistanceAssessment:Q.mechanisms},p=k.suitableOptions.slice(1).map(A=>A.drugName);return{recommendation:N,alternatives:p,clinicalAnalysis:Q}}catch(le){return console.error("Error in intelligent recommendation:",le),{recommendation:{antibiotic:null,tier:"Error en el análisis clínico. Consulte con especialista en infectología."},alternatives:[],clinicalAnalysis:null}}},[c]),T=["Datos del Paciente","Localización de Infección","Selección de Microorganismo","Panel de Sensibilidad","Hipersensibilidad","Resumen y Recomendación"],q=()=>{switch(m){case 1:return a.jsx(Mb,{data:c,onChange:L,calculations:O});case 2:return a.jsx(Db,{data:c,onChange:L});case 3:return a.jsx(qb,{data:c,onChange:L});case 4:return a.jsx(Tb,{data:c,onChange:L});case 5:return a.jsx(Eb,{data:c,onChange:L});case 6:return a.jsx(Pb,{data:c,calculations:O,recommendation:U,alternatives:Z,clinicalAnalysis:X});default:return a.jsx("div",{children:"Paso desconocido"})}};return s==="worldclass"?a.jsx(Ab,{onBackToLanding:()=>l("selection")}):s==="selection"?a.jsxs("div",{className:"min-h-screen bg-gradient-to-br from-blue-50 to-indigo-100",children:[a.jsx("div",{className:"bg-white shadow-sm border-b border-gray-200",children:a.jsxs("div",{className:"max-w-6xl mx-auto px-6 py-4 flex items-center justify-between",children:[a.jsxs("button",{onClick:g,className:"flex items-center text-gray-600 hover:text-gray-800 transition-colors",children:[a.jsx("span",{className:"mr-2",children:"←"}),a.jsx("span",{className:"text-sm",children:"Back to Home"})]}),a.jsxs("div",{className:"text-center",children:[a.jsx("h1",{className:"text-3xl font-bold text-gray-800",children:"Antibiogram Analysis"}),a.jsx("p",{className:"text-sm text-gray-600",children:"Choose your analysis method"})]}),a.jsx("div",{className:"w-24"})]})}),a.jsxs("div",{className:"max-w-4xl mx-auto px-6 py-12",children:[a.jsxs("div",{className:"text-center mb-12",children:[a.jsx("h2",{className:"text-2xl font-bold text-gray-900 mb-4",children:"Select Analysis Method"}),a.jsx("p",{className:"text-lg text-gray-600 max-w-3xl mx-auto",children:"Choose between our traditional form-based approach or our new world-class specialist-level antibiogram interpretation system."})]}),a.jsxs("div",{className:"grid grid-cols-1 lg:grid-cols-2 gap-8",children:[a.jsxs("div",{className:"bg-white rounded-xl shadow-lg border border-gray-200 overflow-hidden hover:shadow-xl transition-shadow",children:[a.jsxs("div",{className:"bg-gradient-to-r from-purple-600 to-blue-600 p-6",children:[a.jsxs("div",{className:"flex items-center space-x-3 mb-4",children:[a.jsx("div",{className:"text-3xl",children:"🧠"}),a.jsx("h3",{className:"text-xl font-bold text-white",children:"World-Class Analysis"})]}),a.jsx("p",{className:"text-purple-100",children:"NEW: Specialist-level 4-phase antibiogram interpretation with resistance pattern detection"})]}),a.jsxs("div",{className:"p-6",children:[a.jsxs("div",{className:"space-y-3 mb-6",children:[a.jsxs("div",{className:"flex items-center text-sm text-gray-700",children:[a.jsx("span",{className:"text-green-500 mr-2",children:"✓"}),"CLSI M100-Ed34 compliant breakpoint interpretation"]}),a.jsxs("div",{className:"flex items-center text-sm text-gray-700",children:[a.jsx("span",{className:"text-green-500 mr-2",children:"✓"}),"Advanced resistance mechanism detection (ESBL, AmpC, MRSA, VRE)"]}),a.jsxs("div",{className:"flex items-center text-sm text-gray-700",children:[a.jsx("span",{className:"text-green-500 mr-2",children:"✓"}),"Intelligent S/I/R overrides based on detected mechanisms"]}),a.jsxs("div",{className:"flex items-center text-sm text-gray-700",children:[a.jsx("span",{className:"text-green-500 mr-2",children:"✓"}),"Simple & Advanced mode therapeutic comparisons"]}),a.jsxs("div",{className:"flex items-center text-sm text-gray-700",children:[a.jsx("span",{className:"text-green-500 mr-2",children:"✓"}),"Educational insights and clinical reasoning"]})]}),a.jsx("button",{onClick:()=>l("worldclass"),className:"w-full bg-gradient-to-r from-purple-600 to-blue-600 text-white py-3 px-4 rounded-lg font-medium hover:from-purple-700 hover:to-blue-700 transition-colors",children:"Start World-Class Analysis"})]})]}),a.jsxs("div",{className:"bg-white rounded-xl shadow-lg border border-gray-200 overflow-hidden hover:shadow-xl transition-shadow",children:[a.jsxs("div",{className:"bg-gradient-to-r from-green-600 to-teal-600 p-6",children:[a.jsxs("div",{className:"flex items-center space-x-3 mb-4",children:[a.jsx("div",{className:"text-3xl",children:"📋"}),a.jsx("h3",{className:"text-xl font-bold text-white",children:"Traditional Analysis"})]}),a.jsx("p",{className:"text-green-100",children:"Original comprehensive form-based antibiogram analysis with patient data integration"})]}),a.jsxs("div",{className:"p-6",children:[a.jsxs("div",{className:"space-y-3 mb-6",children:[a.jsxs("div",{className:"flex items-center text-sm text-gray-700",children:[a.jsx("span",{className:"text-green-500 mr-2",children:"✓"}),"Comprehensive patient demographics and clinical data"]}),a.jsxs("div",{className:"flex items-center text-sm text-gray-700",children:[a.jsx("span",{className:"text-green-500 mr-2",children:"✓"}),"Detailed allergy and hypersensitivity assessment"]}),a.jsxs("div",{className:"flex items-center text-sm text-gray-700",children:[a.jsx("span",{className:"text-green-500 mr-2",children:"✓"}),"Renal and hepatic function calculations"]}),a.jsxs("div",{className:"flex items-center text-sm text-gray-700",children:[a.jsx("span",{className:"text-green-500 mr-2",children:"✓"}),"Step-by-step guided workflow"]}),a.jsxs("div",{className:"flex items-center text-sm text-gray-700",children:[a.jsx("span",{className:"text-green-500 mr-2",children:"✓"}),"Established clinical decision support"]})]}),a.jsx("button",{onClick:()=>l("original"),className:"w-full bg-gradient-to-r from-green-600 to-teal-600 text-white py-3 px-4 rounded-lg font-medium hover:from-green-700 hover:to-teal-700 transition-colors",children:"Use Traditional Method"})]})]})]}),a.jsxs("div",{className:"mt-12 bg-blue-50 border border-blue-200 rounded-lg p-6",children:[a.jsx("h4",{className:"font-semibold text-blue-800 mb-2",children:"💡 Which should you choose?"}),a.jsxs("div",{className:"text-blue-700 text-sm space-y-2",children:[a.jsxs("p",{children:[a.jsx("strong",{children:"World-Class Analysis"})," is recommended for:"]}),a.jsxs("ul",{className:"list-disc list-inside ml-4 space-y-1",children:[a.jsx("li",{children:"Complex resistance patterns or unusual organisms"}),a.jsx("li",{children:"Educational purposes and understanding resistance mechanisms"}),a.jsx("li",{children:"When you want specialist-level interpretation confidence"}),a.jsx("li",{children:"Advanced therapeutic strategy comparison"})]}),a.jsxs("p",{className:"mt-3",children:[a.jsx("strong",{children:"Traditional Analysis"})," is recommended for:"]}),a.jsxs("ul",{className:"list-disc list-inside ml-4 space-y-1",children:[a.jsx("li",{children:"Routine clinical cases with detailed patient data"}),a.jsx("li",{children:"When comprehensive allergy assessment is needed"}),a.jsx("li",{children:"Cases requiring precise renal/hepatic dosing calculations"})]})]})]})]})]}):a.jsxs("div",{className:"bg-gray-100 font-sans",style:{minHeight:"100vh",paddingBottom:"2rem"},children:[a.jsx("div",{className:"bg-white shadow-sm border-b border-gray-200 sticky top-0 z-10",children:a.jsxs("div",{className:"max-w-4xl mx-auto px-4 sm:px-8 py-4 flex items-center justify-between",children:[a.jsxs("button",{onClick:()=>l("selection"),className:"flex items-center text-gray-600 hover:text-gray-800 transition-colors",children:[a.jsx("span",{className:"mr-2",children:"←"}),a.jsx("span",{className:"text-sm",children:"Back to Selection"})]}),a.jsxs("div",{className:"text-center",children:[a.jsx("h1",{className:"text-2xl font-bold text-gray-800",children:"Traditional Antibiogram Analysis"}),a.jsx("p",{className:"text-sm text-gray-600",children:"Comprehensive Patient-Centered Approach"})]}),a.jsx("div",{className:"w-24"})]})}),a.jsx("div",{className:"p-2 sm:p-4 lg:p-8 flex flex-col items-center",style:{minHeight:"calc(100vh - 100px)"},children:a.jsxs("div",{className:"w-full max-w-4xl pb-8",children:[a.jsx(Rb,{current:m,total:h}),a.jsxs(wb,{title:T[m-1],children:[a.jsx("form",{onSubmit:C=>C.preventDefault(),children:q()}),a.jsxs("div",{className:"mt-8 pt-6 border-t border-gray-200 flex justify-between items-center",children:[a.jsx("button",{onClick:y,disabled:m===1,className:"bg-gray-600 hover:bg-gray-700 text-white font-bold py-2 px-6 rounded-lg transition duration-300 disabled:opacity-50 disabled:cursor-not-allowed",children:"Anterior"}),m===h?a.jsx("button",{onClick:D,className:"bg-green-600 hover:bg-green-700 text-white font-bold py-2 px-6 rounded-lg transition duration-300",children:"Finalizar y Reiniciar"}):a.jsx("button",{onClick:v,className:"bg-indigo-600 hover:bg-indigo-700 text-white font-bold py-2 px-6 rounded-lg transition duration-300",children:"Siguiente"})]})]})]})})]})},zb=({onBackToLanding:g})=>{var k,G,ae;const[s,l]=oe.useState("browse"),[c,d]=oe.useState(null),[m,_]=oe.useState(""),[h,v]=oe.useState([]),[y,D]=oe.useState([]),[L,W]=oe.useState(!0),[se,ie]=oe.useState(null),[$,ne]=oe.useState(null),[w,O]=oe.useState({}),[U,Z]=oe.useState(new Set),[X,T]=oe.useState([]),q=N=>{const p={};return N.forEach(A=>{if(!A.filePath)return;const J=A.filePath.replace("./syndromes_json/","").split("/").filter(V=>V&&!V.endsWith(".json"));let P=p;if(J.forEach((V,te)=>{P[V]||(P[V]={folders:{},files:[],path:J.slice(0,te+1),displayName:uo(V)}),te===J.length-1&&P[V].files.push(A),P=P[V].folders}),J.length===1){const V=J[0];p[V]||(p[V]={folders:{},files:[],path:[V],displayName:uo(V)}),p[V].files.push(A)}}),p};oe.useEffect(()=>{async function N(){try{const p=await mb(),A=Object.values(p).filter(P=>P.title);D(A);const J=q(A);O(J),Z(new Set)}catch(p){console.error("Failed to load syndromes:",p)}finally{W(!1)}}N()},[]);const C=oe.useCallback(N=>{if(N.trim().length===0){v([]);return}const p=N.toLowerCase(),A=y.filter(J=>{var te;const P=((te=J.title)==null?void 0:te.toLowerCase())||"",V=uo(J.category).toLowerCase();return P.includes(p)||V.includes(p)}).slice(0,15);v(A)},[y]);oe.useEffect(()=>{C(m)},[m,C]);const E=N=>{d(N),l("syndrome")},z=N=>{const p=new Set(U);p.has(N)?p.delete(N):p.add(N),Z(p)},H=()=>{_(""),v([])},Y=async(N,p)=>{try{await navigator.clipboard.writeText(N),ie(p),$&&clearTimeout($);const A=setTimeout(()=>{ie(null)},2e3);ne(A)}catch(A){console.error("Failed to copy text: ",A)}},ee=N=>{var p,A,J,P,V,te,re,ue,he,Te,li,mi,Ai,wi,Ri,Ji,Qi,Xe,Wi,Bi,Ui,bi,Zi,Fi,et,it,pi,Ve,Ce,$e,sa,la,ca,tt,at,yi,nt,Gi,da,Et;switch(N.type){case"header":return`${N.text}
${"=".repeat(N.text.length)}
`;case"list":return N.items.map(pe=>`• ${pe}`).join(`
`)+`
`;case"paragraph":return`${N.text}
`;case"regimen":let Ze=`Treatment Regimen:
`;return(p=N.regimenData)!=null&&p.strengthOfRecommendation&&(Ze+=`Recommendation: ${N.regimenData.strengthOfRecommendation}
`),(J=(A=N.regimenData)==null?void 0:A.appliesTo)!=null&&J.description&&(Ze+=`Applies to: ${N.regimenData.appliesTo.description}
`),(P=N.regimenData)!=null&&P.condition&&(Ze+=`Condition: ${N.regimenData.condition}
`),(te=(V=N.regimenData)==null?void 0:V.components)==null||te.forEach((pe,Ue)=>{pe.connector&&Ue>0&&(Ze+=`${pe.connector.toUpperCase()} `),Ze+=`${pe.drug}`,pe.dose&&(Ze+=` ${pe.dose}`),pe.route&&(Ze+=` ${pe.route}`),pe.frequency&&(Ze+=` ${pe.frequency}`),Ze+=`
`}),(ue=(re=N.regimenData)==null?void 0:re.durationDetail)!=null&&ue.fixedDuration&&(Ze+=`Duration: ${N.regimenData.durationDetail.fixedDuration}
`),(he=N.regimenData)!=null&&he.notes&&(Ze+=`Notes: ${N.regimenData.notes}
`),Ze;case"drugRegimen":let Je=`Drug Regimen:
`;return(Te=N.regimenData)!=null&&Te.strengthOfRecommendation&&(Je+=`Recommendation: ${N.regimenData.strengthOfRecommendation}
`),(mi=(li=N.regimenData)==null?void 0:li.appliesTo)!=null&&mi.description&&(Je+=`Applies to: ${N.regimenData.appliesTo.description}
`),(Ai=N.regimenData)!=null&&Ai.condition&&(Je+=`Condition: ${N.regimenData.condition}
`),(Ri=(wi=N.regimenData)==null?void 0:wi.components)==null||Ri.forEach((pe,Ue)=>{pe.connector&&Ue>0&&(Je+=`${pe.connector.toUpperCase()} `),Je+=`${pe.drug}`,pe.dose&&(Je+=` ${pe.dose}`),pe.route&&(Je+=` ${pe.route}`),pe.frequency&&(Je+=` ${pe.frequency}`),Je+=`
`}),(Qi=(Ji=N.regimenData)==null?void 0:Ji.durationDetail)!=null&&Qi.fixedDuration&&(Je+=`Duration: ${N.regimenData.durationDetail.fixedDuration}
`),(Xe=N.regimenData)!=null&&Xe.notes&&(Je+=`Notes: ${N.regimenData.notes}
`),Je;case"table":let vi="";return N.headers&&(vi+=N.headers.join(" | ")+`
`,vi+=N.headers.map(()=>"---").join(" | ")+`
`),(Wi=N.rows)==null||Wi.forEach(pe=>{vi+=pe.join(" | ")+`
`}),vi;case"keyValuePairs":let ma=`Clinical Information:
`;return(Bi=N.pairs)==null||Bi.forEach(pe=>{ma+=`${pe.key}: ${pe.value}

`}),ma;case"nestedContent":let Pt=`${N.title||"Detailed Information"}:
`;return N.content&&N.content.forEach(pe=>{Pt+=ee(pe)+`
`}),Pt;case"differentialDiagnosis":let ot=`Differential Diagnosis:
`;return(bi=(Ui=N.differentialData)==null?void 0:Ui.conditions)==null||bi.forEach(pe=>{ot+=`• ${pe.conditionName}`,pe.differentiatingFeatures&&(ot+=`: ${pe.differentiatingFeatures}`),ot+=`
`}),ot;case"partnerManagement":let rt=`Partner Management:
`;return(Zi=N.partnerManagementData)!=null&&Zi.lookBackPeriod&&(rt+=`Look-back Period: ${N.partnerManagementData.lookBackPeriod}
`),(Fi=N.partnerManagementData)!=null&&Fi.action&&(rt+=`Action: ${N.partnerManagementData.action}
`),rt;case"publicHealthStrategy":let ht=`Public Health Strategy: ${((et=N.publicHealthData)==null?void 0:et.name)||""}
`;return(pi=(it=N.publicHealthData)==null?void 0:it.components)==null||pi.forEach(pe=>{ht+=`${pe.componentName}: ${pe.description}
`}),ht;case"procedure":let st=`${((Ve=N.procedureData)==null?void 0:Ve.name)||"Medical Procedure"}:
`;return(Ce=N.procedureData)!=null&&Ce.indication&&(st+=`Indication: ${N.procedureData.indication}
`),($e=N.procedureData)!=null&&$e.timing&&(st+=`Timing: ${N.procedureData.timing}
`),(sa=N.procedureData)!=null&&sa.notes&&(st+=`Notes: ${N.procedureData.notes}
`),st;case"image":let Lt=`Clinical Image:
`;return(la=N.imageData)!=null&&la.caption&&(Lt+=`Caption: ${N.imageData.caption}
`),(ca=N.imageData)!=null&&ca.src&&(Lt+=`Source: ${N.imageData.src}
`),Lt;case"crossReference":return`${((tt=N.referenceData)==null?void 0:tt.text)||"See also"}: ${(at=N.referenceData)==null?void 0:at.targetIdentifier}
`;case"diagnosticTest":let ni=`Diagnostic Test: ${((yi=N.diagnosticTestData)==null?void 0:yi.name)||""}
`;return(nt=N.diagnosticTestData)!=null&&nt.analyte&&(ni+=`Analyte: ${N.diagnosticTestData.analyte}
`),(Gi=N.diagnosticTestData)!=null&&Gi.sampleType&&(ni+=`Sample Type: ${N.diagnosticTestData.sampleType}
`),(da=N.diagnosticTestData)!=null&&da.interpretation&&(ni+=`Interpretation: ${N.diagnosticTestData.interpretation}
`),(Et=N.diagnosticTestData)!=null&&Et.notes&&(ni+=`Notes: ${N.diagnosticTestData.notes}
`),ni;default:return JSON.stringify(N,null,2)}};oe.useEffect(()=>()=>{$&&clearTimeout($)},[$]);const le=(N,p=0)=>Object.entries(N).map(([A,J])=>{const P=J.path.join("/"),V=U.has(P),te=Object.keys(J.folders).length>0,re=J.files.length,ue=re+Object.values(J.folders).reduce((he,Te)=>he+Te.files.length+Object.values(Te.folders).reduce((li,mi)=>li+mi.files.length,0),0);return a.jsxs("div",{children:[a.jsxs("div",{className:`flex items-center py-0.5 px-1 hover:bg-gray-100 cursor-pointer text-xs ${p>0?`ml-${p*3}`:""}`,onClick:()=>z(P),children:[a.jsx("div",{className:"w-3 h-3 flex items-center justify-center mr-1 flex-shrink-0",children:te?a.jsx("svg",{className:`w-2 h-2 text-gray-500 transition-transform ${V?"rotate-90":""}`,fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:3,d:"M9 5l7 7-7 7"})}):a.jsx("div",{className:"w-1 h-1 bg-blue-500 rounded-full"})}),a.jsx("svg",{className:"w-3 h-3 text-blue-600 mr-1 flex-shrink-0",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M3 7v10a2 2 0 002 2h14a2 2 0 002-2V9a2 2 0 00-2-2h-5l-2-2H5a2 2 0 00-2 2z"})}),a.jsx("span",{className:"text-gray-700 truncate flex-1 text-xs font-medium",children:J.displayName}),a.jsx("span",{className:"text-gray-400 text-xs ml-1 bg-gray-100 px-1 rounded-sm font-mono",children:ue})]}),V&&re>0&&a.jsx("div",{className:`${p>0?`ml-${p*3+3}`:"ml-3"}`,children:J.files.map(he=>a.jsxs("button",{onClick:()=>E(he),className:"flex items-center w-full py-0.5 px-1 hover:bg-blue-50 text-left text-xs group rounded-sm",children:[a.jsx("div",{className:"w-1 h-1 bg-green-500 rounded-full mr-2 flex-shrink-0"}),a.jsx("span",{className:"text-gray-600 group-hover:text-blue-700 truncate text-xs",children:he.title})]},he.id))}),V&&te&&a.jsx("div",{children:le(J.folders,p+1)})]},P)}),Q=N=>!N||!Array.isArray(N)?null:N.map((p,A)=>{var re,ue,he,Te,li,mi,Ai,wi,Ri,Ji,Qi,Xe,Wi,Bi,Ui,bi,Zi,Fi,et,it,pi,Ve,Ce,$e,sa,la,ca,tt,at,yi,nt,Gi,da,Et,Ze,Je,vi,ma,Pt,ot,rt,ht,st,Lt,ni,pe,Ue,bt;const J=`section-${A}`,P=se===J,V=ee(p),te=()=>a.jsx("button",{onClick:lt=>{lt.stopPropagation(),Y(V,J)},className:`opacity-0 group-hover:opacity-100 transition-all duration-200 p-1.5 rounded-md text-xs font-medium ${P?"bg-green-100 text-green-700 border border-green-300":"bg-gray-100 hover:bg-gray-200 text-gray-600 hover:text-gray-800 border border-gray-300"}`,title:P?"Copied!":"Copy to clipboard",children:P?a.jsx("svg",{className:"w-3 h-3",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M5 13l4 4L19 7"})}):a.jsx("svg",{className:"w-3 h-3",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M8 16H6a2 2 0 01-2-2V6a2 2 0 012-2h8a2 2 0 012 2v2m-6 12h8a2 2 0 002-2v-8a2 2 0 00-2-2h-8a2 2 0 00-2 2v8a2 2 0 002 2z"})})});try{switch(p.type){case"header":const lt=`h${Math.min(p.level+1,6)}`,Ar=p.level===1?"text-2xl font-bold text-slate-900 border-b-2 border-blue-500 pb-2":p.level===2?"text-xl font-semibold text-slate-800 border-b border-gray-300 pb-1":"text-lg font-medium text-slate-700";return a.jsx("div",{className:"group relative mb-6 mt-8 first:mt-0",children:a.jsxs("div",{className:"flex items-center justify-between",children:[a.jsx(lt,{className:Ar,children:p.text}),a.jsx(te,{})]})},A);case"list":return a.jsxs("div",{className:"group relative mb-6 p-4 bg-white border border-gray-200 rounded-xl shadow-sm hover:shadow-md transition-shadow",children:[a.jsx("div",{className:"absolute top-3 right-3",children:a.jsx(te,{})}),a.jsx("ul",{className:"space-y-2",children:p.items.map((de,je)=>a.jsxs("li",{className:"flex items-start",children:[a.jsx("span",{className:"inline-block w-2 h-2 bg-blue-500 rounded-full mt-2 mr-3 flex-shrink-0"}),a.jsx("span",{className:"text-gray-700 leading-relaxed",children:de})]},je))})]},A);case"paragraph":return a.jsxs("div",{className:"group relative mb-6 p-4 bg-white border border-gray-200 rounded-xl shadow-sm hover:shadow-md transition-shadow",children:[a.jsx("div",{className:"absolute top-3 right-3",children:a.jsx(te,{})}),a.jsx("p",{className:"text-gray-700 leading-relaxed",children:p.text})]},A);case"regimen":return a.jsxs("div",{className:"group relative mb-6 p-5 bg-gradient-to-br from-blue-50 to-blue-100 border-l-4 border-blue-500 rounded-xl shadow-sm hover:shadow-md transition-shadow",children:[a.jsx("div",{className:"absolute top-4 right-4",children:a.jsx(te,{})}),a.jsxs("div",{className:"flex items-center mb-4",children:[a.jsx("div",{className:"w-8 h-8 bg-blue-500 rounded-full flex items-center justify-center mr-3",children:a.jsx("svg",{className:"w-4 h-4 text-white",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19.428 15.428a2 2 0 00-1.022-.547l-2.387-.477a6 6 0 00-3.86.517l-.318.158a6 6 0 01-3.86.517L6.05 15.21a2 2 0 00-1.806.547M8 4h8l-1 1v5.172a2 2 0 00.586 1.414l5 5c1.26 1.26.367 3.414-1.415 3.414H4.828c-1.782 0-2.674-2.154-1.415-3.414l5-5A2 2 0 009 8.172V5L8 4z"})})}),a.jsxs("div",{className:"flex-1",children:[a.jsx("h4",{className:"text-lg font-semibold text-blue-900",children:"Treatment Regimen"}),((re=p.regimenData)==null?void 0:re.strengthOfRecommendation)&&a.jsx("span",{className:`text-sm px-2 py-1 rounded-full ${p.regimenData.strengthOfRecommendation==="Recommended"?"bg-green-100 text-green-800":"bg-yellow-100 text-yellow-800"}`,children:p.regimenData.strengthOfRecommendation})]})]}),((ue=p.regimenData)==null?void 0:ue.appliesTo)&&a.jsxs("div",{className:"mb-3 p-3 bg-blue-100 rounded-lg",children:[a.jsx("span",{className:"font-medium text-blue-900",children:"Applies to: "}),a.jsx("span",{className:"text-blue-800",children:p.regimenData.appliesTo.description})]}),((he=p.regimenData)==null?void 0:he.condition)&&a.jsxs("div",{className:"mb-3 p-3 bg-blue-100 rounded-lg",children:[a.jsx("span",{className:"font-medium text-blue-900",children:"Condition: "}),a.jsx("span",{className:"text-blue-800",children:p.regimenData.condition})]}),(Te=p.regimenData)!=null&&Te.components&&p.regimenData.components.length>0?a.jsx("div",{className:"space-y-3",children:p.regimenData.components.map((de,je)=>a.jsx("div",{className:"bg-white/70 rounded-lg p-3 border border-blue-200",children:a.jsxs("div",{className:"flex flex-wrap items-center gap-2",children:[de.connector&&je>0&&a.jsx("span",{className:"px-2 py-1 text-xs font-bold text-blue-700 bg-blue-200 rounded-full",children:de.connector.toUpperCase()}),a.jsx("span",{className:"font-semibold text-blue-900 text-base",children:de.drug}),de.dose&&a.jsx("span",{className:"px-2 py-1 text-sm bg-gray-100 rounded-md text-gray-700",children:de.dose}),de.route&&a.jsx("span",{className:"px-2 py-1 text-sm bg-gray-100 rounded-md text-gray-600",children:de.route}),de.frequency&&a.jsx("span",{className:"px-2 py-1 text-sm bg-gray-100 rounded-md text-gray-600",children:de.frequency})]})},je))}):a.jsx("div",{className:"bg-white/70 rounded-lg p-3 border border-blue-200",children:a.jsx("span",{className:"text-blue-800 italic",children:"Regimen details as referenced above"})}),((li=p.regimenData)==null?void 0:li.durationDetail)&&a.jsxs("div",{className:"mt-4 p-3 bg-white/70 rounded-lg border border-blue-200",children:[a.jsx("span",{className:"font-medium text-blue-900",children:"Duration: "}),p.regimenData.durationDetail.fixedDuration&&a.jsx("span",{className:"text-blue-800",children:p.regimenData.durationDetail.fixedDuration}),p.regimenData.durationDetail.criteriaBasedDuration&&a.jsx("span",{className:"text-blue-800",children:p.regimenData.durationDetail.criteriaBasedDuration.description}),p.regimenData.durationDetail.comparativeDurations&&a.jsx("div",{className:"space-y-1 mt-2",children:p.regimenData.durationDetail.comparativeDurations.map((de,je)=>a.jsxs("div",{className:"text-blue-800",children:[de.duration," ",de.comparator&&`(${de.comparator})`]},je))})]}),((mi=p.regimenData)==null?void 0:mi.evidence)&&a.jsxs("div",{className:"mt-4 p-3 bg-white/70 rounded-lg border border-blue-200",children:[a.jsx("span",{className:"font-medium text-blue-900",children:"Evidence: "}),a.jsxs("span",{className:"text-blue-800",children:[p.regimenData.evidence.studyCount&&`${p.regimenData.evidence.studyCount} `,p.regimenData.evidence.studyType,p.regimenData.evidence.outcomeSummary&&` - ${p.regimenData.evidence.outcomeSummary}`]})]}),((Ai=p.regimenData)==null?void 0:Ai.efficacy)&&a.jsxs("div",{className:"mt-4 p-3 bg-white/70 rounded-lg border border-blue-200",children:[a.jsx("span",{className:"font-medium text-blue-900",children:"Efficacy: "}),a.jsx("span",{className:"text-blue-800",children:p.regimenData.efficacy})]}),((wi=p.regimenData)==null?void 0:wi.notes)&&a.jsxs("div",{className:"mt-4 p-3 bg-white/70 rounded-lg border border-blue-200",children:[a.jsx("span",{className:"font-medium text-blue-900",children:"Notes: "}),a.jsx("span",{className:"text-blue-800",children:p.regimenData.notes})]})]},A);case"drugRegimen":return a.jsxs("div",{className:"group relative mb-6 p-5 bg-gradient-to-br from-emerald-50 to-emerald-100 border-l-4 border-emerald-500 rounded-xl shadow-sm hover:shadow-md transition-shadow",children:[a.jsx("div",{className:"absolute top-4 right-4",children:a.jsx(te,{})}),a.jsxs("div",{className:"flex items-center mb-4",children:[a.jsx("div",{className:"w-8 h-8 bg-emerald-500 rounded-full flex items-center justify-center mr-3",children:a.jsx("svg",{className:"w-4 h-4 text-white",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19.428 15.428a2 2 0 00-1.022-.547l-2.387-.477a6 6 0 00-3.86.517l-.318.158a6 6 0 01-3.86.517L6.05 15.21a2 2 0 00-1.806.547M8 4h8l-1 1v5.172a2 2 0 00.586 1.414l5 5c1.26 1.26.367 3.414-1.415 3.414H4.828c-1.782 0-2.674-2.154-1.415-3.414l5-5A2 2 0 009 8.172V5L8 4z"})})}),a.jsxs("div",{className:"flex-1",children:[a.jsx("h4",{className:"text-lg font-semibold text-emerald-900",children:"Drug Regimen"}),((Ri=p.regimenData)==null?void 0:Ri.strengthOfRecommendation)&&a.jsx("span",{className:`text-sm px-2 py-1 rounded-full ${p.regimenData.strengthOfRecommendation==="Recommended"?"bg-green-100 text-green-800":"bg-yellow-100 text-yellow-800"}`,children:p.regimenData.strengthOfRecommendation})]})]}),((Ji=p.regimenData)==null?void 0:Ji.appliesTo)&&a.jsxs("div",{className:"mb-3 p-3 bg-emerald-100 rounded-lg",children:[a.jsx("span",{className:"font-medium text-emerald-900",children:"Applies to: "}),a.jsx("span",{className:"text-emerald-800",children:p.regimenData.appliesTo.description})]}),((Qi=p.regimenData)==null?void 0:Qi.condition)&&a.jsxs("div",{className:"mb-3 p-3 bg-emerald-100 rounded-lg",children:[a.jsx("span",{className:"font-medium text-emerald-900",children:"Condition: "}),a.jsx("span",{className:"text-emerald-800",children:p.regimenData.condition})]}),(Xe=p.regimenData)!=null&&Xe.components&&p.regimenData.components.length>0?a.jsx("div",{className:"space-y-3",children:p.regimenData.components.map((de,je)=>a.jsx("div",{className:"bg-white/70 rounded-lg p-3 border border-emerald-200",children:a.jsxs("div",{className:"flex flex-wrap items-center gap-2",children:[de.connector&&je>0&&a.jsx("span",{className:"px-2 py-1 text-xs font-bold text-emerald-700 bg-emerald-200 rounded-full",children:de.connector.toUpperCase()}),a.jsx("span",{className:"font-semibold text-emerald-900 text-base",children:de.drug}),de.dose&&a.jsx("span",{className:"px-2 py-1 text-sm bg-gray-100 rounded-md text-gray-700",children:de.dose}),de.route&&a.jsx("span",{className:"px-2 py-1 text-sm bg-gray-100 rounded-md text-gray-600",children:de.route}),de.frequency&&a.jsx("span",{className:"px-2 py-1 text-sm bg-gray-100 rounded-md text-gray-600",children:de.frequency})]})},je))}):a.jsx("div",{className:"bg-white/70 rounded-lg p-3 border border-emerald-200",children:a.jsx("span",{className:"text-emerald-800 italic",children:"Regimen details as referenced above"})}),((Wi=p.regimenData)==null?void 0:Wi.durationDetail)&&a.jsxs("div",{className:"mt-4 p-3 bg-white/70 rounded-lg border border-emerald-200",children:[a.jsx("span",{className:"font-medium text-emerald-900",children:"Duration: "}),p.regimenData.durationDetail.fixedDuration&&a.jsx("span",{className:"text-emerald-800",children:p.regimenData.durationDetail.fixedDuration}),p.regimenData.durationDetail.criteriaBasedDuration&&a.jsx("span",{className:"text-emerald-800",children:p.regimenData.durationDetail.criteriaBasedDuration.description}),p.regimenData.durationDetail.comparativeDurations&&a.jsx("div",{className:"space-y-1 mt-2",children:p.regimenData.durationDetail.comparativeDurations.map((de,je)=>a.jsxs("div",{className:"text-emerald-800",children:[de.duration," ",de.comparator&&`(${de.comparator})`]},je))})]}),((Bi=p.regimenData)==null?void 0:Bi.evidence)&&a.jsxs("div",{className:"mt-4 p-3 bg-white/70 rounded-lg border border-emerald-200",children:[a.jsx("span",{className:"font-medium text-emerald-900",children:"Evidence: "}),a.jsxs("span",{className:"text-emerald-800",children:[p.regimenData.evidence.studyCount&&`${p.regimenData.evidence.studyCount} `,p.regimenData.evidence.studyType,p.regimenData.evidence.outcomeSummary&&` - ${p.regimenData.evidence.outcomeSummary}`]})]}),((Ui=p.regimenData)==null?void 0:Ui.efficacy)&&a.jsxs("div",{className:"mt-4 p-3 bg-white/70 rounded-lg border border-emerald-200",children:[a.jsx("span",{className:"font-medium text-emerald-900",children:"Efficacy: "}),a.jsx("span",{className:"text-emerald-800",children:p.regimenData.efficacy})]}),((bi=p.regimenData)==null?void 0:bi.notes)&&a.jsxs("div",{className:"mt-4 p-3 bg-white/70 rounded-lg border border-emerald-200",children:[a.jsx("span",{className:"font-medium text-emerald-900",children:"Notes: "}),a.jsx("span",{className:"text-emerald-800",children:p.regimenData.notes})]})]},A);case"table":return a.jsxs("div",{className:"group relative mb-6 bg-white border border-gray-200 rounded-xl shadow-sm hover:shadow-md transition-shadow overflow-hidden",children:[a.jsx("div",{className:"absolute top-4 right-4 z-10",children:a.jsx(te,{})}),a.jsx("div",{className:"overflow-x-auto",children:a.jsxs("table",{className:"min-w-full",children:[p.headers&&a.jsx("thead",{children:a.jsx("tr",{className:"bg-gradient-to-r from-gray-50 to-gray-100 border-b border-gray-200",children:p.headers.map((de,je)=>a.jsx("th",{className:"px-4 py-3 text-left text-sm font-semibold text-gray-900 border-r border-gray-200 last:border-r-0",children:de},je))})}),a.jsx("tbody",{children:(Zi=p.rows)==null?void 0:Zi.map((de,je)=>a.jsx("tr",{className:"border-b border-gray-100 hover:bg-gray-50",children:de.map((fn,zt)=>a.jsx("td",{className:"px-4 py-3 text-sm text-gray-700 border-r border-gray-100 last:border-r-0",children:fn},zt))},je))})]})})]},A);case"diagnosticTest":const ua=p.diagnosticTestData||{};return a.jsxs("div",{className:"group relative mb-6 p-5 bg-gradient-to-br from-indigo-50 to-indigo-100 border-l-4 border-indigo-500 rounded-xl shadow-sm hover:shadow-md transition-shadow",children:[a.jsx("div",{className:"absolute top-3 right-3",children:a.jsx(te,{})}),a.jsxs("div",{className:"flex items-start",children:[a.jsx("div",{className:"w-6 h-6 bg-indigo-500 rounded-full flex items-center justify-center mr-3 mt-1 flex-shrink-0",children:a.jsx("svg",{className:"w-3 h-3 text-white",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"})})}),a.jsxs("div",{className:"flex-1",children:[a.jsx("h4",{className:"text-lg font-semibold text-indigo-800 mb-2",children:ua.name||"Diagnostic Test"}),ua.description&&a.jsx("p",{className:"text-gray-700 leading-relaxed mb-2",children:ua.description}),ua.notes&&a.jsxs("div",{className:"mt-3 p-3 bg-indigo-100 rounded-lg border border-indigo-200",children:[a.jsx("p",{className:"text-sm text-indigo-700 font-medium",children:"Notes:"}),a.jsx("p",{className:"text-sm text-indigo-600 mt-1",children:ua.notes})]})]})]})]},A);case"crossReference":return a.jsxs("div",{className:"group relative mb-6 p-4 bg-gradient-to-r from-amber-50 to-amber-100 border-l-4 border-amber-400 rounded-xl shadow-sm hover:shadow-md transition-shadow",children:[a.jsx("div",{className:"absolute top-3 right-3",children:a.jsx(te,{})}),a.jsxs("div",{className:"flex items-center",children:[a.jsx("div",{className:"w-6 h-6 bg-amber-400 rounded-full flex items-center justify-center mr-3",children:a.jsx("svg",{className:"w-3 h-3 text-white",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M13.828 10.172a4 4 0 00-5.656 0l-4 4a4 4 0 105.656 5.656l1.102-1.101m-.758-4.899a4 4 0 005.656 0l4-4a4 4 0 00-5.656-5.656l-1.1 1.1"})})}),a.jsxs("div",{className:"flex-1",children:[a.jsx("span",{className:"text-sm text-amber-900",children:a.jsx("strong",{children:((Fi=p.referenceData)==null?void 0:Fi.text)||"See also:"})}),((et=p.referenceData)==null?void 0:et.targetType)==="externalURL"?a.jsx("a",{href:p.referenceData.targetIdentifier,target:"_blank",rel:"noopener noreferrer",className:"text-amber-700 hover:text-amber-900 underline ml-2",children:p.referenceData.targetIdentifier}):a.jsx("span",{className:"text-amber-800 ml-2",children:(it=p.referenceData)==null?void 0:it.targetIdentifier})]})]})]},A);case"diagnosticTest":return a.jsxs("div",{className:"group relative mb-6 p-5 bg-gradient-to-br from-purple-50 to-purple-100 border-l-4 border-purple-500 rounded-xl shadow-sm hover:shadow-md transition-shadow",children:[a.jsx("div",{className:"absolute top-4 right-4",children:a.jsx(te,{})}),a.jsxs("div",{className:"flex items-center mb-3",children:[a.jsx("div",{className:"w-8 h-8 bg-purple-500 rounded-full flex items-center justify-center mr-3",children:a.jsx("svg",{className:"w-4 h-4 text-white",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M9 5H7a2 2 0 00-2 2v10a2 2 0 002 2h8a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2m-6 9l2 2 4-4"})})}),a.jsxs("div",{className:"flex-1",children:[a.jsx("h5",{className:"text-lg font-semibold text-purple-900",children:((pi=p.diagnosticTestData)==null?void 0:pi.name)||"Diagnostic Test"}),((Ve=p.diagnosticTestData)==null?void 0:Ve.strengthOfRecommendation)&&a.jsx("span",{className:"text-sm px-2 py-1 bg-purple-100 text-purple-800 rounded-full",children:p.diagnosticTestData.strengthOfRecommendation})]})]}),((Ce=p.diagnosticTestData)==null?void 0:Ce.appliesTo)&&a.jsxs("div",{className:"mb-3 p-3 bg-purple-100 rounded-lg",children:[a.jsx("span",{className:"font-medium text-purple-900",children:"Applies to: "}),a.jsx("span",{className:"text-purple-800",children:p.diagnosticTestData.appliesTo.description})]}),a.jsxs("div",{className:"space-y-3",children:[(($e=p.diagnosticTestData)==null?void 0:$e.analyte)&&a.jsxs("div",{className:"bg-white/70 rounded-lg p-3 border border-purple-200",children:[a.jsx("span",{className:"font-medium text-purple-900",children:"Analyte: "}),a.jsx("span",{className:"text-gray-700",children:p.diagnosticTestData.analyte})]}),((sa=p.diagnosticTestData)==null?void 0:sa.sampleType)&&a.jsxs("div",{className:"bg-white/70 rounded-lg p-3 border border-purple-200",children:[a.jsx("span",{className:"font-medium text-purple-900",children:"Sample Type: "}),a.jsx("span",{className:"text-gray-700",children:p.diagnosticTestData.sampleType})]}),((la=p.diagnosticTestData)==null?void 0:la.interpretation)&&a.jsxs("div",{className:"bg-white/70 rounded-lg p-3 border border-purple-200",children:[a.jsx("span",{className:"font-medium text-purple-900",children:"Interpretation: "}),a.jsx("span",{className:"text-gray-700",children:p.diagnosticTestData.interpretation})]}),(((ca=p.diagnosticTestData)==null?void 0:ca.sensitivity)||((tt=p.diagnosticTestData)==null?void 0:tt.specificity))&&a.jsxs("div",{className:"bg-white/70 rounded-lg p-3 border border-purple-200",children:[p.diagnosticTestData.sensitivity&&a.jsxs("div",{children:[a.jsx("span",{className:"font-medium text-purple-900",children:"Sensitivity: "}),a.jsxs("span",{className:"text-gray-700",children:[(p.diagnosticTestData.sensitivity*100).toFixed(1),"%"]})]}),p.diagnosticTestData.specificity&&a.jsxs("div",{children:[a.jsx("span",{className:"font-medium text-purple-900",children:"Specificity: "}),a.jsxs("span",{className:"text-gray-700",children:[(p.diagnosticTestData.specificity*100).toFixed(1),"%"]})]})]}),((at=p.diagnosticTestData)==null?void 0:at.notes)&&a.jsxs("div",{className:"bg-white/70 rounded-lg p-3 border border-purple-200",children:[a.jsx("span",{className:"font-medium text-purple-900",children:"Notes: "}),a.jsx("span",{className:"text-gray-700",children:p.diagnosticTestData.notes})]})]})]},A);case"keyValuePairs":return a.jsxs("div",{className:"group relative mb-6 p-5 bg-gradient-to-br from-indigo-50 to-indigo-100 border-l-4 border-indigo-500 rounded-xl shadow-sm hover:shadow-md transition-shadow",children:[a.jsx("div",{className:"absolute top-4 right-4",children:a.jsx(te,{})}),a.jsxs("div",{className:"flex items-center mb-4",children:[a.jsx("div",{className:"w-8 h-8 bg-indigo-500 rounded-full flex items-center justify-center mr-3",children:a.jsx("svg",{className:"w-4 h-4 text-white",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M9 5H7a2 2 0 00-2 2v10a2 2 0 002 2h8a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2m-3 10v-6a3 3 0 116 0v6m-9 4h12a2 2 0 002-2v-6a2 2 0 00-2-2H6a2 2 0 00-2 2v6a2 2 0 002 2z"})})}),a.jsx("h4",{className:"text-lg font-semibold text-indigo-900",children:"Clinical Information"})]}),a.jsx("div",{className:"space-y-3",children:(yi=p.pairs)==null?void 0:yi.map((de,je)=>a.jsx("div",{className:"bg-white/70 rounded-lg p-4 border border-indigo-200",children:a.jsxs("div",{className:"flex items-start space-x-3",children:[a.jsx("div",{className:"w-2 h-2 bg-indigo-500 rounded-full mt-2 flex-shrink-0"}),a.jsxs("div",{className:"flex-1",children:[a.jsx("h6",{className:"font-semibold text-indigo-900 mb-2",children:de.key}),a.jsx("p",{className:"text-gray-700 leading-relaxed",children:de.value})]})]})},je))})]},A);case"nestedContent":return a.jsxs("div",{className:"group relative mb-6 p-5 bg-gradient-to-br from-teal-50 to-teal-100 border-l-4 border-teal-500 rounded-xl shadow-sm hover:shadow-md transition-shadow",children:[a.jsx("div",{className:"absolute top-4 right-4",children:a.jsx(te,{})}),a.jsxs("div",{className:"flex items-center mb-4",children:[a.jsx("div",{className:"w-8 h-8 bg-teal-500 rounded-full flex items-center justify-center mr-3",children:a.jsx("svg",{className:"w-4 h-4 text-white",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19 11H5m14-4H5m14 8H5m14 4H5"})})}),a.jsx("h4",{className:"text-lg font-semibold text-teal-900",children:p.title||"Detailed Information"})]}),a.jsx("div",{className:"pl-4 border-l-2 border-teal-300",children:p.content&&Q(p.content)})]},A);case"differentialDiagnosis":return a.jsxs("div",{className:"group relative mb-6 p-5 bg-gradient-to-br from-orange-50 to-orange-100 border-l-4 border-orange-500 rounded-xl shadow-sm hover:shadow-md transition-shadow",children:[a.jsx("div",{className:"absolute top-4 right-4",children:a.jsx(te,{})}),a.jsxs("div",{className:"flex items-center mb-4",children:[a.jsx("div",{className:"w-8 h-8 bg-orange-500 rounded-full flex items-center justify-center mr-3",children:a.jsx("svg",{className:"w-4 h-4 text-white",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M8.228 9c.549-1.165 2.03-2 3.772-2 2.21 0 4 1.343 4 3 0 1.4-1.278 2.575-3.006 2.907-.542.104-.994.54-.994 1.093m0 3h.01M21 12a9 9 0 11-18 0 9 9 0 0118 0z"})})}),a.jsx("h4",{className:"text-lg font-semibold text-orange-900",children:"Differential Diagnosis"})]}),(Gi=(nt=p.differentialData)==null?void 0:nt.conditions)==null?void 0:Gi.map((de,je)=>a.jsx("div",{className:"bg-white/70 rounded-lg p-3 border border-orange-200 mb-3",children:a.jsxs("div",{className:"flex items-start space-x-3",children:[a.jsx("div",{className:"w-2 h-2 bg-orange-500 rounded-full mt-2 flex-shrink-0"}),a.jsxs("div",{className:"flex-1",children:[a.jsx("h6",{className:"font-medium text-orange-900 mb-1",children:de.conditionName}),de.differentiatingFeatures&&a.jsx("p",{className:"text-gray-700 text-sm",children:de.differentiatingFeatures})]})]})},je))]},A);case"partnerManagement":return a.jsxs("div",{className:"group relative mb-6 p-5 bg-gradient-to-br from-pink-50 to-pink-100 border-l-4 border-pink-500 rounded-xl shadow-sm hover:shadow-md transition-shadow",children:[a.jsx("div",{className:"absolute top-4 right-4",children:a.jsx(te,{})}),a.jsxs("div",{className:"flex items-center mb-4",children:[a.jsx("div",{className:"w-8 h-8 bg-pink-500 rounded-full flex items-center justify-center mr-3",children:a.jsx("svg",{className:"w-4 h-4 text-white",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M17 20h5v-2a3 3 0 00-5.356-1.857M17 20H7m10 0v-2c0-.656-.126-1.283-.356-1.857M7 20H2v-2a3 3 0 015.356-1.857M7 20v-2c0-.656.126-1.283.356-1.857m0 0a5.002 5.002 0 019.288 0M15 7a3 3 0 11-6 0 3 3 0 016 0zm6 3a2 2 0 11-4 0 2 2 0 014 0zM7 10a2 2 0 11-4 0 2 2 0 014 0z"})})}),a.jsx("h4",{className:"text-lg font-semibold text-pink-900",children:"Partner Management"})]}),a.jsxs("div",{className:"space-y-3",children:[((da=p.partnerManagementData)==null?void 0:da.lookBackPeriod)&&a.jsxs("div",{className:"bg-white/70 rounded-lg p-3 border border-pink-200",children:[a.jsx("span",{className:"font-medium text-pink-900",children:"Look-back Period: "}),a.jsx("span",{className:"text-gray-700",children:p.partnerManagementData.lookBackPeriod})]}),((Et=p.partnerManagementData)==null?void 0:Et.action)&&a.jsxs("div",{className:"bg-white/70 rounded-lg p-3 border border-pink-200",children:[a.jsx("span",{className:"font-medium text-pink-900",children:"Action: "}),a.jsx("span",{className:"text-gray-700",children:p.partnerManagementData.action})]}),((Ze=p.partnerManagementData)==null?void 0:Ze.partnerRegimen)&&a.jsxs("div",{className:"bg-white/70 rounded-lg p-3 border border-pink-200",children:[a.jsx("span",{className:"font-medium text-pink-900 block mb-2",children:"Partner Regimen:"}),a.jsx("div",{className:"space-y-2",children:(Je=p.partnerManagementData.partnerRegimen.components)==null?void 0:Je.map((de,je)=>a.jsxs("div",{className:"text-gray-700",children:[a.jsx("span",{className:"font-medium",children:de.drug}),de.dose&&` ${de.dose}`,de.route&&` ${de.route}`,de.frequency&&` ${de.frequency}`]},je))})]})]})]},A);case"publicHealthStrategy":return a.jsxs("div",{className:"group relative mb-6 p-5 bg-gradient-to-br from-cyan-50 to-cyan-100 border-l-4 border-cyan-500 rounded-xl shadow-sm hover:shadow-md transition-shadow",children:[a.jsx("div",{className:"absolute top-4 right-4",children:a.jsx(te,{})}),a.jsxs("div",{className:"flex items-center mb-4",children:[a.jsx("div",{className:"w-8 h-8 bg-cyan-500 rounded-full flex items-center justify-center mr-3",children:a.jsx("svg",{className:"w-4 h-4 text-white",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M3.055 11H5a2 2 0 012 2v1a2 2 0 002 2 2 2 0 012 2v2.945M8 3.935V5.5A2.5 2.5 0 0010.5 8h.5a2 2 0 012 2 2 2 0 104 0 2 2 0 012-2h1.064M15 20.488V18a2 2 0 012-2h3.064M21 12a9 9 0 11-18 0 9 9 0 0118 0z"})})}),a.jsx("h4",{className:"text-lg font-semibold text-cyan-900",children:((vi=p.publicHealthData)==null?void 0:vi.name)||"Public Health Strategy"})]}),a.jsx("div",{className:"space-y-3",children:(Pt=(ma=p.publicHealthData)==null?void 0:ma.components)==null?void 0:Pt.map((de,je)=>a.jsxs("div",{className:"bg-white/70 rounded-lg p-3 border border-cyan-200",children:[a.jsx("h6",{className:"font-medium text-cyan-900 mb-2",children:de.componentName}),a.jsx("p",{className:"text-gray-700 text-sm",children:de.description})]},je))})]},A);case"procedure":return a.jsxs("div",{className:"group relative mb-6 p-5 bg-gradient-to-br from-violet-50 to-violet-100 border-l-4 border-violet-500 rounded-xl shadow-sm hover:shadow-md transition-shadow",children:[a.jsx("div",{className:"absolute top-4 right-4",children:a.jsx(te,{})}),a.jsxs("div",{className:"flex items-center mb-4",children:[a.jsx("div",{className:"w-8 h-8 bg-violet-500 rounded-full flex items-center justify-center mr-3",children:a.jsx("svg",{className:"w-4 h-4 text-white",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M9 5H7a2 2 0 00-2 2v10a2 2 0 002 2h8a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2m-6 9l2 2 4-4"})})}),a.jsxs("div",{className:"flex-1",children:[a.jsx("h4",{className:"text-lg font-semibold text-violet-900",children:((ot=p.procedureData)==null?void 0:ot.name)||"Medical Procedure"}),((rt=p.procedureData)==null?void 0:rt.strengthOfRecommendation)&&a.jsx("span",{className:"text-sm px-2 py-1 bg-violet-100 text-violet-800 rounded-full",children:p.procedureData.strengthOfRecommendation})]})]}),((ht=p.procedureData)==null?void 0:ht.appliesTo)&&a.jsxs("div",{className:"mb-3 p-3 bg-violet-100 rounded-lg",children:[a.jsx("span",{className:"font-medium text-violet-900",children:"Applies to: "}),a.jsx("span",{className:"text-violet-800",children:p.procedureData.appliesTo.description})]}),a.jsxs("div",{className:"space-y-3",children:[((st=p.procedureData)==null?void 0:st.indication)&&a.jsxs("div",{className:"bg-white/70 rounded-lg p-3 border border-violet-200",children:[a.jsx("span",{className:"font-medium text-violet-900",children:"Indication: "}),a.jsx("span",{className:"text-gray-700",children:p.procedureData.indication})]}),((Lt=p.procedureData)==null?void 0:Lt.timing)&&a.jsxs("div",{className:"bg-white/70 rounded-lg p-3 border border-violet-200",children:[a.jsx("span",{className:"font-medium text-violet-900",children:"Timing: "}),a.jsx("span",{className:"text-gray-700",children:p.procedureData.timing})]}),((ni=p.procedureData)==null?void 0:ni.notes)&&a.jsxs("div",{className:"bg-white/70 rounded-lg p-3 border border-violet-200",children:[a.jsx("span",{className:"font-medium text-violet-900",children:"Notes: "}),a.jsx("span",{className:"text-gray-700",children:p.procedureData.notes})]})]})]},A);case"image":return a.jsxs("div",{className:"group relative mb-6 p-5 bg-gradient-to-br from-slate-50 to-slate-100 border-l-4 border-slate-500 rounded-xl shadow-sm hover:shadow-md transition-shadow",children:[a.jsx("div",{className:"absolute top-4 right-4",children:a.jsx(te,{})}),a.jsxs("div",{className:"flex items-center mb-4",children:[a.jsx("div",{className:"w-8 h-8 bg-slate-500 rounded-full flex items-center justify-center mr-3",children:a.jsx("svg",{className:"w-4 h-4 text-white",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M4 16l4.586-4.586a2 2 0 012.828 0L16 16m-2-2l1.586-1.586a2 2 0 012.828 0L20 14m-6-6h.01M6 20h12a2 2 0 002-2V6a2 2 0 00-2-2H6a2 2 0 00-2 2v12a2 2 0 002 2z"})})}),a.jsx("h4",{className:"text-lg font-semibold text-slate-900",children:"Clinical Image"})]}),a.jsxs("div",{className:"bg-white/70 rounded-lg p-4 border border-slate-200",children:[((pe=p.imageData)==null?void 0:pe.caption)&&a.jsx("p",{className:"text-gray-700 mb-3",children:p.imageData.caption}),a.jsxs("div",{className:"bg-gray-100 rounded-lg p-4 text-center",children:[(Ue=p.imageData)!=null&&Ue.src?a.jsx("img",{src:p.imageData.src,alt:p.imageData.caption||"Clinical image",className:"max-w-full h-auto rounded-lg mx-auto",onError:de=>{de.target.style.display="none",de.target.nextSibling.style.display="block"}}):null,a.jsxs("div",{className:"text-center",style:{display:(bt=p.imageData)!=null&&bt.src?"none":"block"},children:[a.jsx("svg",{className:"w-16 h-16 text-gray-400 mx-auto mb-2",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M4 16l4.586-4.586a2 2 0 012.828 0L16 16m-2-2l1.586-1.586a2 2 0 012.828 0L20 14m-6-6h.01M6 20h12a2 2 0 002-2V6a2 2 0 00-2-2H6a2 2 0 00-2 2v12a2 2 0 002 2z"})}),a.jsx("p",{className:"text-gray-500 text-sm",children:"Clinical image reference"})]})]})]})]},A);default:return a.jsxs("div",{className:"group relative mb-6 p-4 bg-gray-50 border border-gray-300 rounded-xl shadow-sm",children:[a.jsx("div",{className:"absolute top-3 right-3",children:a.jsx(te,{})}),a.jsxs("div",{className:"flex items-center mb-3",children:[a.jsx("div",{className:"w-6 h-6 bg-gray-400 rounded-full flex items-center justify-center mr-3",children:a.jsx("svg",{className:"w-3 h-3 text-white",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M13 16h-1v-4h-1m1-4h.01M21 12a9 9 0 11-18 0 9 9 0 0118 0z"})})}),a.jsxs("span",{className:"text-sm font-medium text-gray-600",children:["Content type: ",p.type]})]}),a.jsx("pre",{className:"text-sm text-gray-700 overflow-x-auto bg-white rounded-lg p-3 border",children:JSON.stringify(p,null,2)})]},A)}}catch(lt){return console.error("Error rendering section:",lt,p),a.jsx("div",{className:"group relative mb-6 p-4 bg-red-50 border border-red-300 rounded-xl shadow-sm",children:a.jsxs("div",{className:"text-red-700",children:[a.jsx("strong",{children:"Error rendering section:"})," ",lt.message,a.jsx("br",{}),a.jsx("strong",{children:"Section type:"})," ",p.type]})},A)}});return L?a.jsx("div",{className:"min-h-screen bg-gradient-to-br from-blue-50 via-white to-blue-50 flex items-center justify-center",children:a.jsxs("div",{className:"text-center p-8 bg-white rounded-2xl shadow-lg border border-blue-100",children:[a.jsxs("div",{className:"relative",children:[a.jsx("div",{className:"animate-spin w-12 h-12 border-4 border-blue-500 border-t-transparent rounded-full mx-auto mb-4"}),a.jsx("div",{className:"absolute top-3 left-1/2 transform -translate-x-1/2",children:a.jsx("svg",{className:"w-6 h-6 text-blue-500",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19.428 15.428a2 2 0 00-1.022-.547l-2.387-.477a6 6 0 00-3.86.517l-.318.158a6 6 0 01-3.86.517L6.05 15.21a2 2 0 00-1.806.547M8 4h8l-1 1v5.172a2 2 0 00.586 1.414l5 5c1.26 1.26.367 3.414-1.415 3.414H4.828c-1.782 0-2.674-2.154-1.415-3.414l5-5A2 2 0 009 8.172V5L8 4z"})})})]}),a.jsx("h3",{className:"text-lg font-semibold text-gray-900 mb-2",children:"Loading Clinical Database"}),a.jsx("p",{className:"text-gray-600",children:"Preparing 453 syndrome protocols..."})]})}):a.jsxs("div",{className:"min-h-screen bg-gradient-to-br from-slate-50 via-white to-blue-50",children:[a.jsx("div",{className:"bg-white/90 backdrop-blur-sm border-b border-gray-200 sticky top-0 z-20 shadow-sm",children:a.jsx("div",{className:"max-w-7xl mx-auto",children:a.jsxs("div",{className:"flex items-center justify-between px-6 py-4",children:[a.jsxs("button",{onClick:g,className:"flex items-center space-x-2 text-gray-600 hover:text-blue-600 transition-colors duration-200 group",children:[a.jsx("div",{className:"w-8 h-8 rounded-full bg-gray-100 group-hover:bg-blue-100 flex items-center justify-center transition-colors",children:a.jsx("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M15 19l-7-7 7-7"})})}),a.jsx("span",{className:"font-medium",children:"Dashboard"})]}),a.jsxs("div",{className:"flex items-center space-x-3",children:[a.jsx("div",{className:"w-8 h-8 bg-blue-500 rounded-full flex items-center justify-center",children:a.jsx("svg",{className:"w-4 h-4 text-white",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19.428 15.428a2 2 0 00-1.022-.547l-2.387-.477a6 6 0 00-3.86.517l-.318.158a6 6 0 01-3.86.517L6.05 15.21a2 2 0 00-1.806.547M8 4h8l-1 1v5.172a2 2 0 00.586 1.414l5 5c1.26 1.26.367 3.414-1.415 3.414H4.828c-1.782 0-2.674-2.154-1.415-3.414l5-5A2 2 0 009 8.172V5L8 4z"})})}),a.jsxs("div",{children:[a.jsx("h1",{className:"text-xl font-bold text-gray-900",children:"Clinical Syndromes"}),a.jsx("p",{className:"text-xs text-gray-500",children:"Evidence-Based Treatment Protocols"})]})]}),c&&a.jsxs("button",{onClick:()=>{d(null),l("browse")},className:"flex items-center space-x-2 px-4 py-2 bg-blue-50 hover:bg-blue-100 text-blue-700 rounded-lg transition-colors duration-200 border border-blue-200",children:[a.jsx("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"})}),a.jsx("span",{className:"font-medium",children:"Back to Browse"})]}),!c&&a.jsx("div",{className:"w-32"})]})})}),s!=="syndrome"&&a.jsxs("div",{className:"max-w-7xl mx-auto px-6 py-8",children:[a.jsxs("div",{className:"text-center mb-6",children:[a.jsx("h2",{className:"text-3xl font-bold text-gray-900 mb-2",children:"Clinical Protocols Database"}),a.jsx("p",{className:"text-gray-600 max-w-2xl mx-auto",children:"Browse by category or search across 453 evidence-based treatment protocols"})]}),a.jsx("div",{className:"max-w-lg mx-auto mb-6",children:a.jsxs("div",{className:"relative",children:[a.jsx("div",{className:"absolute inset-y-0 left-0 pl-3 flex items-center pointer-events-none",children:a.jsx("svg",{className:"h-4 w-4 text-gray-400",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M21 21l-6-6m2-5a7 7 0 11-14 0 7 7 0 0114 0z"})})}),a.jsx("input",{type:"text",placeholder:"Quick search protocols...",value:m,onChange:N=>_(N.target.value),className:"w-full pl-10 pr-10 py-3 text-sm border border-gray-300 rounded-lg focus:ring-2 focus:ring-blue-500 focus:border-blue-500 bg-white shadow-sm transition-all duration-200"}),m&&a.jsx("button",{onClick:H,className:"absolute inset-y-0 right-0 pr-3 flex items-center text-gray-400 hover:text-gray-600 transition-colors",children:a.jsx("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M6 18L18 6M6 6l12 12"})})})]})}),a.jsx("div",{className:"max-w-4xl mx-auto",children:a.jsxs("div",{className:"bg-white rounded-xl border border-gray-200 shadow-sm",children:[a.jsx("div",{className:"px-4 py-3 border-b border-gray-200 bg-gray-50 rounded-t-xl",children:a.jsxs("div",{className:"flex items-center justify-between",children:[a.jsxs("div",{className:"flex items-center space-x-2 text-sm font-medium text-gray-700",children:[a.jsx("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M3 7v10a2 2 0 002 2h14a2 2 0 002-2V9a2 2 0 00-2-2h-5l-2-2H5a2 2 0 00-2 2z"})}),a.jsx("span",{children:"Browse by Clinical Category"})]}),a.jsxs("div",{className:"flex items-center space-x-2 text-xs text-gray-500",children:[m&&a.jsxs("span",{className:"bg-blue-100 text-blue-700 px-2 py-1 rounded",children:[h.length,' found for "',m,'"']}),a.jsxs("span",{children:[y.length," total protocols"]})]})]})}),a.jsxs("div",{className:"p-2 max-h-96 overflow-y-auto",children:[m&&h.length>0&&a.jsx("div",{className:"mb-4 pb-4 border-b border-gray-200",children:a.jsx("div",{className:"space-y-1",children:h.map(N=>a.jsxs("button",{onClick:()=>E(N),className:"w-full flex items-center py-2 px-3 hover:bg-blue-50 text-left text-sm group rounded-md transition-colors",children:[a.jsx("div",{className:"w-2 h-2 bg-blue-500 rounded-full mr-3 flex-shrink-0"}),a.jsxs("div",{className:"flex-1 min-w-0",children:[a.jsx("div",{className:"font-medium text-gray-900 group-hover:text-blue-700 truncate",children:N.title}),a.jsx("div",{className:"text-xs text-gray-500 truncate",children:uo(N.category)})]}),a.jsx("svg",{className:"w-4 h-4 text-gray-400 group-hover:text-blue-500 ml-2 flex-shrink-0",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M9 5l7 7-7 7"})})]},N.id))})}),m&&h.length===0&&a.jsx("div",{className:"mb-4 pb-4 border-b border-gray-200",children:a.jsxs("div",{className:"text-center py-4 text-gray-500",children:[a.jsx("svg",{className:"w-8 h-8 text-gray-400 mx-auto mb-2",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M9.172 16.172a4 4 0 015.656 0M9 12h6m-6-4h6m2 5.291A7.962 7.962 0 0112 15c-2.34 0-4.47-.881-6.08-2.33"})}),a.jsxs("p",{className:"text-sm",children:['No protocols found for "',m,'"']})]})}),Object.keys(w).length>0?le(w):a.jsxs("div",{className:"text-center py-8 text-gray-500",children:[a.jsx("div",{className:"w-12 h-12 bg-gray-100 rounded-full flex items-center justify-center mx-auto mb-3",children:a.jsx("svg",{className:"w-6 h-6 text-gray-400",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M3 7v10a2 2 0 002 2h14a2 2 0 002-2V9a2 2 0 00-2-2h-5l-2-2H5a2 2 0 00-2 2z"})})}),a.jsx("p",{className:"text-sm",children:"Building folder structure..."})]})]})]})})]}),s==="syndrome"&&c&&a.jsxs("div",{className:"max-w-7xl mx-auto px-6 py-8",children:[a.jsxs("div",{className:"bg-white rounded-2xl shadow-lg border border-gray-200 p-8 mb-8",children:[a.jsxs("div",{className:"flex items-start justify-between mb-6",children:[a.jsxs("div",{className:"flex items-start space-x-4",children:[a.jsx("div",{className:"w-16 h-16 bg-gradient-to-br from-blue-500 to-blue-600 rounded-xl flex items-center justify-center flex-shrink-0",children:a.jsx("svg",{className:"w-8 h-8 text-white",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19.428 15.428a2 2 0 00-1.022-.547l-2.387-.477a6 6 0 00-3.86.517l-.318.158a6 6 0 01-3.86.517L6.05 15.21a2 2 0 00-1.806.547M8 4h8l-1 1v5.172a2 2 0 00.586 1.414l5 5c1.26 1.26.367 3.414-1.415 3.414H4.828c-1.782 0-2.674-2.154-1.415-3.414l5-5A2 2 0 009 8.172V5L8 4z"})})}),a.jsxs("div",{children:[a.jsx("h1",{className:"text-3xl font-bold text-gray-900 mb-2",children:c.title||"Untitled Protocol"}),a.jsxs("div",{className:"flex items-center space-x-4 text-sm text-gray-600",children:[a.jsxs("span",{className:"flex items-center space-x-1",children:[a.jsx("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M7 7h.01M7 3h5c.512 0 1.024.195 1.414.586l7 7a2 2 0 010 2.828l-7 7a2 2 0 01-2.828 0l-7-7A1.994 1.994 0 013 12V7a4 4 0 014-4z"})}),a.jsx("span",{children:uo(c.category)})]}),((G=(k=c.data)==null?void 0:k.documentMetadata)==null?void 0:G.lastUpdated)&&a.jsxs("span",{className:"flex items-center space-x-1",children:[a.jsx("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M12 8v4l3 3m6-3a9 9 0 11-18 0 9 9 0 0118 0z"})}),a.jsxs("span",{children:["Updated ",c.data.documentMetadata.lastUpdated]})]})]})]})]}),a.jsx("div",{className:"flex items-center space-x-3",children:a.jsxs("button",{onClick:()=>{var p,A;const N=((A=(p=c.data)==null?void 0:p.content)==null?void 0:A.map(J=>ee(J)).join(`

`))||"";Y(`${c.title}
${"=".repeat(c.title.length)}

${N}`,"full-protocol")},className:"flex items-center space-x-2 px-4 py-2 bg-blue-600 hover:bg-blue-700 text-white rounded-lg transition-colors duration-200",children:[a.jsx("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:a.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M8 16H6a2 2 0 01-2-2V6a2 2 0 012-2h8a2 2 0 012 2v2m-6 12h8a2 2 0 002-2v-8a2 2 0 00-2-2h-8a2 2 0 00-2 2v8a2 2 0 002 2z"})}),a.jsx("span",{children:"Copy Full Protocol"})]})})]}),a.jsx("div",{className:"bg-blue-50 rounded-xl p-4 border border-blue-200",children:a.jsxs("p",{className:"text-blue-800 text-sm leading-relaxed",children:[a.jsx("strong",{children:"Clinical Decision Support:"})," This evidence-based protocol provides standardized treatment guidelines. Always consider patient-specific factors, local resistance patterns, and institutional guidelines when making treatment decisions."]})})]}),a.jsx("div",{className:"space-y-6",children:Q((ae=c.data)==null?void 0:ae.content)})]})]})},Vb=()=>{const[g,s]=oe.useState("landing"),l=m=>{m==="antibiogram"?s("antibiogram"):m==="syndromes"&&s("syndromes")},c=()=>{s("landing")};return(()=>{switch(g){case"antibiogram":return a.jsx(Lb,{onBackToLanding:c});case"syndromes":return a.jsx(zb,{onBackToLanding:c});case"landing":default:return a.jsx(If,{onSelectSection:l})}})()};Sf.createRoot(document.getElementById("root")).render(a.jsx(oe.StrictMode,{children:a.jsx(Vb,{})}));
